-DOCSTART- -X- -X- O
   
Reactive NN NN O
oxygen NN NN O
intermediate NN NN O
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
requires NN NN O
5 NN NN B-Protein
- NN NN I-Protein
lipoxygenase NN NN I-Protein
or NN NN O
NADPH NN NN O
oxidase NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
that NN NN O
the NN NN O
role NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
( NN NN O
ROIs NN NN O
) NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
proinflammatory NN NN O
cytokines NN NN O
was NN NN O
cell NN NN O
specific NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
sources NN NN O
for NN NN O
ROIs NN NN O
in NN NN O
various NN NN O
cell NN NN O
types NN NN O
are NN NN O
yet NN NN O
to NN NN O
be NN NN O
determined NN NN O
and NN NN O
might NN NN O
include NN NN O
5 NN NN B-Protein
- NN NN I-Protein
lipoxygenase NN NN I-Protein
( NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
) NN NN O
and NN NN O
NADPH NN NN O
oxidase NN NN O
. NN NN O
   
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
and NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
activating NN NN O
protein NN NN O
( NN NN O
FLAP NN NN B-Protein
) NN NN O
are NN NN O
coexpressed NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
monocytic NN NN O
or NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
lymphoid NN NN O
cells NN NN O
with NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
led NN NN O
to NN NN O
ROI NN NN O
production NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
which NN NN O
could NN NN O
both NN NN O
be NN NN O
blocked NN NN O
by NN NN O
antioxidants NN NN O
or NN NN O
FLAP NN NN B-Protein
inhibitors NN NN O
, NN NN O
confirming NN NN O
that NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
was NN NN O
the NN NN O
source NN NN O
of NN NN O
ROIs NN NN O
and NN NN O
was NN NN O
required NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
stimulation NN NN O
of NN NN O
epithelial NN NN O
cells NN NN O
did NN NN O
not NN NN O
generate NN NN O
any NN NN O
ROIs NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
induction NN NN O
was NN NN O
not NN NN O
influenced NN NN O
by NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
inhibitors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
reintroduction NN NN O
of NN NN O
a NN NN O
functional NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
system NN NN O
in NN NN O
these NN NN O
cells NN NN O
allowed NN NN O
ROI NN NN O
production NN NN O
and NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
treatment NN NN O
led NN NN O
to NN NN O
a NN NN O
production NN NN O
of NN NN O
ROIs NN NN O
which NN NN O
is NN NN O
independent NN NN O
of NN NN O
the NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
enzyme NN NN O
but NN NN O
requires NN NN O
the NN NN O
NADPH NN NN O
oxidase NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
pathway NN NN O
involves NN NN O
the NN NN O
Rac1 NN NN B-Protein
and NN NN O
Cdc42 NN NN B-Protein
GTPases NN NN O
, NN NN O
two NN NN O
enzymes NN NN O
which NN NN O
are NN NN O
not NN NN O
required NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
in NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
three NN NN O
different NN NN O
cell NN NN O
- NN NN O
specific NN NN O
pathways NN NN O
lead NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
: NN NN O
a NN NN O
pathway NN NN O
dependent NN NN O
on NN NN O
ROI NN NN O
production NN NN O
by NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
in NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
an NN NN O
ROI NN NN O
- NN NN O
and NN NN O
5 NN NN B-Protein
- NN NN I-Protein
LOX NN NN I-Protein
- NN NN O
independent NN NN O
pathway NN NN O
in NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
a NN NN O
pathway NN NN O
requiring NN NN O
ROI NN NN O
production NN NN O
by NN NN O
NADPH NN NN O
oxidase NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
Fas NN NN B-Protein
promoter NN NN O
requires NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
recruitment NN NN O
. NN NN O
   
Fas NN NN B-Protein
( NN NN O
CD95 NN NN B-Protein
) NN NN O
and NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
CD95L NN NN B-Protein
) NN NN O
are NN NN O
an NN NN O
interacting NN NN O
receptor NN NN O
- NN NN O
ligand NN NN O
pair NN NN O
required NN NN O
for NN NN O
immune NN NN O
homeostasis NN NN O
. NN NN O
   
Lymphocyte NN NN O
activation NN NN O
results NN NN O
in NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
Fas NN NN B-Protein
expression NN NN O
and NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
sensitivity NN NN O
to NN NN O
FasL NN NN B-Protein
- NN NN O
mediated NN NN O
apoptosis NN NN O
. NN NN O
   
Although NN NN O
Fas NN NN B-Protein
upregulation NN NN O
is NN NN O
central NN NN O
to NN NN O
the NN NN O
preservation NN NN O
of NN NN O
immunologic NN NN O
tolerance NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
molecular NN NN O
machinery NN NN O
underlying NN NN O
this NN NN O
process NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
events NN NN O
involved NN NN O
in NN NN O
activation NN NN O
- NN NN O
induced NN NN O
Fas NN NN B-Protein
upregulation NN NN O
, NN NN O
we NN NN O
have NN NN O
examined NN NN O
mRNA NN NN O
accumulation NN NN O
, NN NN O
fas NN NN B-Protein
promoter NN NN O
activity NN NN O
, NN NN O
and NN NN O
protein NN NN O
expression NN NN O
in NN NN O
the NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
treated NN NN O
with NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
and NN NN O
ionomycin NN NN O
( NN NN O
P NN NN O
/ NN NN O
I NN NN O
) NN NN O
, NN NN O
pharmacological NN NN O
mimics NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
activation NN NN O
. NN NN O
   
Although NN NN O
resting NN NN O
Jurkat NN NN O
cells NN NN O
express NN NN O
Fas NN NN B-Protein
, NN NN O
Fas NN NN B-Protein
mRNA NN NN O
was NN NN O
induced NN NN O
approximately NN NN O
10 NN NN O
- NN NN O
fold NN NN O
in NN NN O
2 NN NN O
h NN NN O
upon NN NN O
P NN NN O
/ NN NN O
I NN NN O
stimulation NN NN O
. NN NN O
   
Using NN NN O
sequential NN NN O
deletion NN NN O
mutants NN NN O
of NN NN O
the NN NN O
human NN NN O
fas NN NN B-Protein
promoter NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
47 NN NN O
- NN NN O
bp NN NN O
sequence NN NN O
( NN NN O
positions NN NN O
- NN NN O
306 NN NN O
to NN NN O
- NN NN O
260 NN NN O
relative NN NN O
to NN NN O
the NN NN O
ATG NN NN O
) NN NN O
required NN NN O
for NN NN O
activation NN NN O
- NN NN O
driven NN NN O
fas NN NN B-Protein
upregulation NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
composite NN NN O
binding NN NN O
site NN NN O
for NN NN O
both NN NN O
the NN NN O
Sp1 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factors NN NN O
at NN NN O
positions NN NN O
- NN NN O
295 NN NN O
to NN NN O
- NN NN O
286 NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
and NN NN O
supershift NN NN O
analyses NN NN O
of NN NN O
this NN NN O
region NN NN O
documented NN NN O
constitutive NN NN O
binding NN NN O
of NN NN O
Sp1 NN NN B-Protein
in NN NN O
unactivated NN NN O
nuclear NN NN O
extracts NN NN O
and NN NN O
inducible NN NN O
binding NN NN O
of NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappaB NN NN O
heterodimers NN NN O
after NN NN O
P NN NN O
/ NN NN O
I NN NN O
activation NN NN O
. NN NN O
   
Sp1 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
mutually NN NN O
exclusive NN NN O
by NN NN O
EMSA NN NN O
displacement NN NN O
studies NN NN O
with NN NN O
purified NN NN O
recombinant NN NN O
Sp1 NN NN B-Protein
and NN NN O
recombinant NN NN O
p50 NN NN B-Protein
. NN NN O
   
The NN NN O
functional NN NN O
contribution NN NN O
of NN NN O
the NN NN O
kappaB NN NN O
- NN NN O
Sp1 NN NN B-Protein
composite NN NN O
site NN NN O
in NN NN O
P NN NN O
/ NN NN O
I NN NN O
- NN NN O
inducible NN NN O
fas NN NN B-Protein
promoter NN NN O
activation NN NN O
was NN NN O
verified NN NN O
by NN NN O
using NN NN O
kappaB NN NN O
- NN NN O
Sp1 NN NN B-Protein
concatamers NN NN O
( NN NN O
- NN NN O
295 NN NN O
to NN NN O
- NN NN O
286 NN NN O
) NN NN O
in NN NN O
a NN NN O
thymidine NN NN O
kinase NN NN O
promoter NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
construct NN NN O
and NN NN O
native NN NN O
promoter NN NN O
constructs NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
overexpressing NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
critical NN NN O
guanine NN NN O
nucleotides NN NN O
in NN NN O
the NN NN O
kappaB NN NN O
- NN NN O
Sp1 NN NN B-Protein
element NN NN O
documented NN NN O
the NN NN O
essential NN NN O
role NN NN O
of NN NN O
this NN NN O
site NN NN O
in NN NN O
activation NN NN O
- NN NN O
dependent NN NN O
fas NN NN B-Protein
promoter NN NN O
induction NN NN O
. NN NN O
   
RFLAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
: NN NN O
a NN NN O
new NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
activates NN NN O
RANTES NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
RANTES NN NN B-Protein
( NN NN O
Regulated NN NN B-Protein
upon NN NN I-Protein
Activation NN NN I-Protein
, NN NN I-Protein
Normal NN NN I-Protein
T NN NN I-Protein
cell NN NN I-Protein
Expressed NN NN I-Protein
and NN NN I-Protein
Secreted NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
chemoattractant NN NN O
cytokine NN NN O
( NN NN O
chemokine NN NN O
) NN NN O
important NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
inflammatory NN NN O
infiltrate NN NN O
and NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
entry NN NN O
into NN NN O
immune NN NN O
cells NN NN O
. NN NN O
   
RANTES NN NN B-Protein
is NN NN O
expressed NN NN O
late NN NN O
( NN NN O
3 NN NN O
- NN NN O
5 NN NN O
days NN NN O
) NN NN O
after NN NN O
activation NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Using NN NN O
expression NN NN O
cloning NN NN O
, NN NN O
we NN NN O
identified NN NN O
the NN NN O
first NN NN O
"""""""" NN NN O
late NN NN O
"""""""" NN NN O
T NN NN O
lymphocyte NN NN O
associated NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
named NN NN O
it NN NN O
"""""""" NN NN O
RANTES NN NN B-Protein
Factor NN NN I-Protein
of NN NN I-Protein
Late NN NN I-Protein
Activated NN NN I-Protein
T NN NN I-Protein
Lymphocytes NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
"""""""" NN NN O
( NN NN O
RFLAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
RFLAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
novel NN NN O
, NN NN O
phosphorylated NN NN O
, NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
is NN NN O
expressed NN NN O
in NN NN O
T NN NN O
cells NN NN O
3 NN NN O
days NN NN O
after NN NN O
activation NN NN O
, NN NN O
coincident NN NN O
with NN NN O
RANTES NN NN B-Protein
expression NN NN O
. NN NN O
   
While NN NN O
Rel NN NN O
proteins NN NN O
play NN NN O
the NN NN O
dominant NN NN O
role NN NN O
in NN NN O
RANTES NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
fibroblasts NN NN O
, NN NN O
RFLAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
strong NN NN O
transactivator NN NN O
for NN NN O
RANTES NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibits NN NN O
expression NN NN O
of NN NN O
both NN NN O
interferon NN NN O
alpha NN NN O
- NN NN O
and NN NN O
interferon NN NN B-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
genes NN NN O
by NN NN O
suppressing NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
helps NN NN O
maintain NN NN O
polarized NN NN O
T NN NN O
- NN NN O
helper NN NN O
cells NN NN O
in NN NN O
a NN NN O
T NN NN O
- NN NN O
helper NN NN O
lymphocyte NN NN O
2 NN NN O
( NN NN O
Th2 NN NN O
) NN NN O
phenotype NN NN O
. NN NN O
   
Part NN NN O
of NN NN O
this NN NN O
process NN NN O
involves NN NN O
the NN NN O
prevention NN NN O
of NN NN O
the NN NN O
development NN NN O
of NN NN O
Th1 NN NN O
cells NN NN O
, NN NN O
which NN NN O
are NN NN O
a NN NN O
primary NN NN O
source NN NN O
of NN NN O
interferon NN NN B-Protein
gamma NN NN I-Protein
( NN NN O
IFNgamma NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
activator NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
Th2 NN NN O
proliferation NN NN O
. NN NN O
   
Because NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
are NN NN O
important NN NN O
mediators NN NN O
of NN NN O
Th1 NN NN O
- NN NN O
type NN NN O
responses NN NN O
, NN NN O
such NN NN O
as NN NN O
delayed NN NN O
- NN NN O
type NN NN O
hypersensitivity NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
determine NN NN O
if NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
could NN NN O
directly NN NN O
mediate NN NN O
inhibition NN NN O
of NN NN O
IFNgamma NN NN B-Protein
- NN NN O
and NN NN O
IFNalpha NN NN O
- NN NN O
induced NN NN O
gene NN NN O
expression NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Highly NN NN O
purified NN NN O
monocytes NN NN O
were NN NN O
incubated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
for NN NN O
60 NN NN O
to NN NN O
90 NN NN O
minutes NN NN O
before NN NN O
the NN NN O
addition NN NN O
of NN NN O
IFNgamma NN NN B-Protein
or NN NN O
IFNalpha NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
preincubation NN NN O
resulted NN NN O
in NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
gene NN NN O
expression NN NN O
for NN NN O
several NN NN O
IFN NN NN O
- NN NN O
induced NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
ISG54 NN NN B-Protein
, NN NN O
and NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
reduction NN NN O
in NN NN O
gene NN NN O
expression NN NN O
resulted NN NN O
from NN NN O
the NN NN O
ability NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
to NN NN O
suppress NN NN O
IFN NN NN O
- NN NN O
induced NN NN O
assembly NN NN O
of NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
factors NN NN O
to NN NN O
specific NN NN O
promoter NN NN O
motifs NN NN O
on NN NN O
IFNalpha NN NN O
- NN NN O
and NN NN O
IFNgamma NN NN B-Protein
- NN NN O
inducible NN NN O
genes NN NN O
. NN NN O
   
This NN NN O
was NN NN O
accomplished NN NN O
by NN NN O
preventing NN NN O
the NN NN O
IFN NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
a NN NN O
component NN NN O
of NN NN O
both NN NN O
IFNalpha NN NN O
- NN NN O
and NN NN O
IFNgamma NN NN B-Protein
- NN NN O
induced NN NN O
DNA NN NN O
binding NN NN O
complexes NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
can NN NN O
directly NN NN O
inhibit NN NN O
STAT NN NN O
- NN NN O
dependent NN NN O
early NN NN O
response NN NN O
gene NN NN O
expression NN NN O
induced NN NN O
by NN NN O
both NN NN O
IFNalpha NN NN O
and NN NN O
IFNgamma NN NN B-Protein
in NN NN O
monocytes NN NN O
by NN NN O
suppressing NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
. NN NN O
   
This NN NN O
may NN NN O
occur NN NN O
through NN NN O
the NN NN O
ability NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
to NN NN O
induce NN NN O
expression NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
suppressor NN NN B-Protein
of NN NN I-Protein
cytokine NN NN I-Protein
signaling NN NN I-Protein
3 NN NN I-Protein
( NN NN O
SOCS3 NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
Megakaryocyte NN NN O
/ NN NN O
Platelet NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
alpha2beta1 NN NN O
integrin NN NN O
gene NN NN O
: NN NN O
two NN NN O
tandem NN NN O
AP1 NN NN O
sites NN NN O
and NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
signaling NN NN O
cascade NN NN O
. NN NN O
   
The NN NN O
alpha2beta1 NN NN O
integrin NN NN O
, NN NN O
a NN NN O
collagen NN NN O
receptor NN NN O
on NN NN O
platelets NN NN O
and NN NN O
megakaryocytes NN NN O
, NN NN O
is NN NN O
required NN NN O
for NN NN O
normal NN NN O
platelet NN NN O
function NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
gene NN NN O
in NN NN O
cells NN NN O
undergoing NN NN O
megakaryocytic NN NN O
differentiation NN NN O
requires NN NN O
a NN NN O
core NN NN O
promoter NN NN O
between NN NN O
bp NN NN O
- NN NN O
30 NN NN O
and NN NN O
- NN NN O
92 NN NN O
, NN NN O
a NN NN O
silencer NN NN O
between NN NN O
bp NN NN O
- NN NN O
92 NN NN O
and NN NN O
- NN NN O
351 NN NN O
, NN NN O
and NN NN O
megakaryocytic NN NN O
enhancers NN NN O
in NN NN O
the NN NN O
distal NN NN O
5 NN NN O
' NN NN O
flank NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
identified NN NN O
a NN NN O
229 NN NN O
- NN NN O
bp NN NN O
region NN NN O
of NN NN O
the NN NN O
distal NN NN O
5 NN NN O
' NN NN O
flank NN NN O
of NN NN O
the NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
gene NN NN O
required NN NN O
for NN NN O
high NN NN O
- NN NN O
level NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
cells NN NN O
with NN NN O
megakaryocytic NN NN O
features NN NN O
. NN NN O
   
Two NN NN O
tandem NN NN O
AP1 NN NN O
binding NN NN O
sites NN NN O
with NN NN O
dyad NN NN O
symmetry NN NN O
are NN NN O
required NN NN O
for NN NN O
enhancer NN NN O
activity NN NN O
and NN NN O
for NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complex NN NN O
formation NN NN O
with NN NN O
members NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
family NN NN O
. NN NN O
   
The NN NN O
requirement NN NN O
for NN NN O
AP1 NN NN O
activation NN NN O
suggested NN NN O
a NN NN O
role NN NN O
for NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
signaling NN NN O
pathway NN NN O
in NN NN O
regulating NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
the NN NN O
MAP NN NN O
kinase NN NN O
cascade NN NN O
with NN NN O
PD98059 NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
MAPK NN NN B-Protein
kinase NN NN I-Protein
1 NN NN I-Protein
, NN NN O
prevented NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
subunit NN NN O
in NN NN O
cells NN NN O
induced NN NN O
to NN NN O
become NN NN O
megakaryocytic NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
a NN NN O
model NN NN O
of NN NN O
megakaryocytic NN NN O
differentiation NN NN O
in NN NN O
which NN NN O
expression NN NN O
of NN NN O
the NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
gene NN NN O
requires NN NN O
signaling NN NN O
via NN NN O
the NN NN O
MAP NN NN O
kinase NN NN O
pathway NN NN O
to NN NN O
activate NN NN O
two NN NN O
tandem NN NN O
AP1 NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
alpha2 NN NN B-Protein
integrin NN NN I-Protein
enhancer NN NN O
. NN NN O
   
Differential NN NN O
expression NN NN O
and NN NN O
phosphorylation NN NN O
of NN NN O
CTCF NN NN B-Protein
, NN NN O
a NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
transcriptional NN NN O
regulator NN NN O
, NN NN O
during NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
CTCF NN NN B-Protein
is NN NN O
a NN NN O
transcriptional NN NN O
repressor NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
gene NN NN O
. NN NN O
   
Although NN NN O
CTCF NN NN B-Protein
has NN NN O
been NN NN O
characterized NN NN O
in NN NN O
some NN NN O
detail NN NN O
, NN NN O
there NN NN O
is NN NN O
very NN NN O
little NN NN O
information NN NN O
about NN NN O
the NN NN O
regulation NN NN O
of NN NN O
CTCF NN NN B-Protein
activity NN NN O
. NN NN O
   
Therefore NN NN O
we NN NN O
investigated NN NN O
CTCF NN NN B-Protein
expression NN NN O
and NN NN O
phosphorylation NN NN O
during NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
: NN NN O
( NN NN O
i NN NN O
) NN NN O
both NN NN O
CTCF NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
are NN NN O
down NN NN O
- NN NN O
regulated NN NN O
during NN NN O
terminal NN NN O
differentiation NN NN O
in NN NN O
most NN NN O
cell NN NN O
lines NN NN O
tested NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
CTCF NN NN B-Protein
down NN NN O
- NN NN O
regulation NN NN O
is NN NN O
retarded NN NN O
and NN NN O
less NN NN O
pronounced NN NN O
than NN NN O
that NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
; NN NN O
( NN NN O
iii NN NN O
) NN NN O
CTCF NN NN B-Protein
protein NN NN O
is NN NN O
differentially NN NN O
phosphorylated NN NN O
and NN NN O
the NN NN O
phosphorylation NN NN O
profiles NN NN O
depend NN NN O
on NN NN O
the NN NN O
differentiation NN NN O
pathway NN NN O
. NN NN O
   
We NN NN O
concluded NN NN O
that NN NN O
CTCF NN NN B-Protein
expression NN NN O
and NN NN O
activity NN NN O
is NN NN O
controlled NN NN O
at NN NN O
transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
levels NN NN O
. NN NN O
   
T NN NN O
- NN NN O
cell NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
is NN NN O
regulated NN NN O
by NN NN O
a NN NN O
non NN NN O
- NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
silencer NN NN O
. NN NN O
   
The NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
transcription NN NN O
factor NN NN O
is NN NN O
required NN NN O
for NN NN O
development NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
lineage NN NN O
and NN NN O
Th2 NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
in NN NN O
CD4 NN NN B-Protein
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
mapped NN NN O
the NN NN O
DNase NN NN O
- NN NN O
I NN NN O
- NN NN O
hypersensitive NN NN O
( NN NN O
HS NN NN O
) NN NN O
regions NN NN O
of NN NN O
the NN NN O
human NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
non NN NN O
- NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
studied NN NN O
their NN NN O
transcriptional NN NN O
activities NN NN O
. NN NN O
   
HS NN NN O
I NN NN O
- NN NN O
III NN NN O
, NN NN O
located NN NN O
5 NN NN O
' NN NN O
from NN NN O
the NN NN O
transcriptional NN NN O
initiation NN NN O
site NN NN O
, NN NN O
were NN NN O
found NN NN O
in NN NN O
hematopoietic NN NN O
and NN NN O
non NN NN O
- NN NN O
hematopoietic NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
HS NN NN O
IV NN NN O
- NN NN O
VII NN NN O
, NN NN O
located NN NN O
3 NN NN O
' NN NN O
from NN NN O
the NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
, NN NN O
were NN NN O
exclusively NN NN O
observed NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
hypersensitive NN NN O
sites NN NN O
, NN NN O
two NN NN O
transcriptional NN NN O
control NN NN O
elements NN NN O
were NN NN O
found NN NN O
, NN NN O
one NN NN O
in NN NN O
the NN NN O
first NN NN O
intron NN NN O
of NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
and NN NN O
the NN NN O
other NN NN O
between NN NN O
8 NN NN O
. NN NN O
3 NN NN O
and NN NN O
5 NN NN O
. NN NN O
9 NN NN O
kilobases NN NN O
5 NN NN O
' NN NN O
from NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
transcriptional NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
The NN NN O
first NN NN O
intron NN NN O
acted NN NN O
as NN NN O
a NN NN O
strong NN NN O
transcriptional NN NN O
activator NN NN O
in NN NN O
a NN NN O
position NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
and NN NN O
with NN NN O
no NN NN O
cell NN NN O
- NN NN O
type NN NN O
specificity NN NN O
. NN NN O
   
The NN NN O
upstream NN NN O
regulatory NN NN O
element NN NN O
could NN NN O
confer NN NN O
T NN NN O
- NN NN O
cell NN NN O
specificity NN NN O
to NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
and NN NN O
analysis NN NN O
of NN NN O
this NN NN O
region NN NN O
revealed NN NN O
a NN NN O
707 NN NN O
- NN NN O
base NN NN O
pair NN NN O
silencer NN NN O
that NN NN O
drastically NN NN O
inhibited NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
non NN NN O
- NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
CAGGTG NN NN O
E NN NN O
- NN NN O
boxes NN NN O
, NN NN O
located NN NN O
at NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
and NN NN O
3 NN NN O
' NN NN O
- NN NN O
ends NN NN O
of NN NN O
the NN NN O
silencer NN NN O
, NN NN O
were NN NN O
necessary NN NN O
for NN NN O
this NN NN O
silencer NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
3 NN NN O
' NN NN O
- NN NN O
CAGGTG NN NN O
E NN NN O
- NN NN O
box NN NN O
could NN NN O
bind NN NN O
USF NN NN O
proteins NN NN O
, NN NN O
the NN NN O
ubiquitous NN NN O
repressor NN NN O
ZEB NN NN B-Protein
, NN NN O
or NN NN O
the NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
E2A NN NN B-Protein
and NN NN O
HEB NN NN B-Protein
, NN NN O
and NN NN O
we NN NN O
showed NN NN O
that NN NN O
a NN NN O
competition NN NN O
between NN NN O
ZEB NN NN B-Protein
and NN NN O
E2A NN NN B-Protein
/ NN NN O
HEB NN NN B-Protein
proteins NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
silencer NN NN O
activity NN NN O
. NN NN O
   
AML NN NN O
and NN NN O
Ets NN NN O
proteins NN NN O
regulate NN NN O
the NN NN O
I NN NN O
alpha1 NN NN O
germ NN NN O
- NN NN O
line NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
( NN NN O
IgH NN NN O
) NN NN O
class NN NN O
switch NN NN O
recombination NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
preferentially NN NN O
targets NN NN O
unrearranged NN NN O
IgH NN NN O
genes NN NN O
that NN NN O
have NN NN O
already NN NN O
been NN NN O
rendered NN NN O
transcriptionally NN NN O
active NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
the NN NN O
germ NN NN O
- NN NN O
line NN NN O
IgH NN NN O
genes NN NN O
is NN NN O
controlled NN NN O
by NN NN O
intervening NN NN O
( NN NN O
I NN NN O
) NN NN O
regions NN NN O
upstream NN NN O
of NN NN O
their NN NN O
switch NN NN O
regions NN NN O
. NN NN O
   
The NN NN O
I NN NN O
alpha1 NN NN O
promoter NN NN O
activates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
germ NN NN O
- NN NN O
line NN NN O
C NN NN O
alpha1 NN NN O
gene NN NN O
for NN NN O
IgA1 NN NN O
and NN NN O
mediates NN NN O
the NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TGF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
responsiveness NN NN O
of NN NN O
this NN NN O
locus NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
I NN NN O
alpha1 NN NN O
promoter NN NN O
contains NN NN O
several NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
AML NN NN O
/ NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
that NN NN O
AML NN NN O
and NN NN O
Ets NN NN O
proteins NN NN O
are NN NN O
major NN NN O
regulators NN NN O
of NN NN O
the NN NN O
basal NN NN O
and NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
- NN NN O
inducible NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
constitute NN NN O
a NN NN O
starting NN NN O
point NN NN O
for NN NN O
studies NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
regulates NN NN O
IgA NN NN O
production NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
patients NN NN O
with NN NN O
diabetic NN NN O
nephropathy NN NN O
show NN NN O
increased NN NN O
activation NN NN O
of NN NN O
the NN NN O
oxidative NN NN O
- NN NN O
stress NN NN O
sensitive NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Increased NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
subsequent NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
late NN NN O
diabetic NN NN O
complications NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
oxidative NN NN O
stress NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
evident NN NN O
in NN NN O
patients NN NN O
with NN NN O
diabetic NN NN O
nephropathy NN NN O
we NN NN O
used NN NN O
an NN NN O
Electrophoretic NN NN O
Mobility NN NN O
Shift NN NN O
Assay NN NN O
based NN NN O
semiquantitative NN NN O
detection NN NN O
system NN NN O
which NN NN O
enabled NN NN O
us NN NN O
to NN NN O
determine NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
ex NN NN O
vivo NN NN O
isolated NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
33 NN NN O
patients NN NN O
with NN NN O
diabetes NN NN O
mellitus NN NN O
( NN NN O
Type NN NN O
I NN NN O
and NN NN O
Type NN NN O
II NN NN O
) NN NN O
. NN NN O
   
Patients NN NN O
with NN NN O
diabetic NN NN O
nephropathy NN NN O
showed NN NN O
higher NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
in NN NN O
Electrophoretic NN NN O
Mobility NN NN O
Shift NN NN O
Assays NN NN O
and NN NN O
stronger NN NN O
immunohistological NN NN O
staining NN NN O
for NN NN O
activated NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaBp65 NN NN I-Protein
than NN NN O
patients NN NN O
without NN NN O
renal NN NN O
complications NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
correlated NN NN O
with NN NN O
the NN NN O
degree NN NN O
of NN NN O
albuminuria NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
316 NN NN O
) NN NN O
and NN NN O
with NN NN O
thrombomodulin NN NN B-Protein
plasma NN NN O
concentrations NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
33 NN NN O
) NN NN O
, NN NN O
indicative NN NN O
for NN NN O
albuminuria NN NN O
associated NN NN O
endothelial NN NN O
dysfunction NN NN O
. NN NN O
   
In NN NN O
a NN NN O
3 NN NN O
day NN NN O
intervention NN NN O
study NN NN O
in NN NN O
which NN NN O
600 NN NN O
mg NN NN O
of NN NN O
the NN NN O
antioxidant NN NN O
thioctic NN NN O
acid NN NN O
( NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
) NN NN O
per NN NN O
day NN NN O
were NN NN O
given NN NN O
to NN NN O
nine NN NN O
patients NN NN O
with NN NN O
diabetic NN NN O
nephropathy NN NN O
oxidative NN NN O
stress NN NN O
in NN NN O
plasma NN NN O
samples NN NN O
was NN NN O
decreased NN NN O
by NN NN O
48 NN NN O
% NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
in NN NN O
ex NN NN O
vivo NN NN O
isolated NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
by NN NN O
38 NN NN O
% NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
ex NN NN O
vivo NN NN O
isolated NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
of NN NN O
patients NN NN O
with NN NN O
diabetes NN NN O
mellitus NN NN O
correlates NN NN O
with NN NN O
the NN NN O
degree NN NN O
of NN NN O
diabetic NN NN O
nephropathy NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
dependent NN NN O
on NN NN O
oxidative NN NN O
stress NN NN O
since NN NN O
thioctic NN NN O
acid NN NN O
( NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
) NN NN O
reduced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
expression NN NN O
by NN NN O
Gardnerella NN NN O
vaginalis NN NN O
. NN NN O
   
Bacterial NN NN O
vaginosis NN NN O
( NN NN O
BV NN NN O
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
rate NN NN O
of NN NN O
sexual NN NN O
transmission NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
type NN NN O
1 NN NN O
, NN NN O
and NN NN O
Gardnerella NN NN O
vaginalis NN NN O
is NN NN O
frequently NN NN O
isolated NN NN O
from NN NN O
the NN NN O
genital NN NN O
tracts NN NN O
of NN NN O
women NN NN O
with NN NN O
BV NN NN O
. NN NN O
   
G NN NN O
. NN NN O
vaginalis NN NN O
lysates NN NN O
were NN NN O
found NN NN O
to NN NN O
significantly NN NN O
stimulate NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
monocytoid NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
when NN NN O
lysates NN NN O
were NN NN O
heated NN NN O
at NN NN O
100 NN NN O
degrees NN NN O
C NN NN O
for NN NN O
5 NN NN O
min NN NN O
but NN NN O
was NN NN O
reduced NN NN O
by NN NN O
treatment NN NN O
with NN NN O
lysozyme NN NN O
or NN NN O
protease NN NN O
. NN NN O
   
G NN NN O
. NN NN O
vaginalis NN NN O
lysates NN NN O
also NN NN O
activated NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
certain NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
G NN NN O
. NN NN O
vaginalis NN NN O
lysates NN NN O
activated NN NN O
HIV NN NN O
long NN NN O
- NN NN O
terminal NN NN O
repeat NN NN O
transcription NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
cells NN NN O
and NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
, NN NN O
indicating NN NN O
an NN NN O
effect NN NN O
by NN NN O
G NN NN O
. NN NN O
vaginalis NN NN O
on NN NN O
HIV NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
production NN NN O
by NN NN O
G NN NN O
. NN NN O
vaginalis NN NN O
suggests NN NN O
that NN NN O
genital NN NN O
tract NN NN O
infection NN NN O
with NN NN O
G NN NN O
. NN NN O
vaginalis NN NN O
increases NN NN O
the NN NN O
risk NN NN O
of NN NN O
HIV NN NN O
transmission NN NN O
by NN NN O
increasing NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
the NN NN O
genital NN NN O
tract NN NN O
. NN NN O
   
This NN NN O
may NN NN O
explain NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
the NN NN O
increased NN NN O
rate NN NN O
of NN NN O
HIV NN NN O
transmission NN NN O
in NN NN O
women NN NN O
with NN NN O
BV NN NN O
. NN NN O
   
Interferon NN NN O
- NN NN O
alpha NN NN O
activates NN NN O
multiple NN NN O
STAT NN NN O
proteins NN NN O
and NN NN O
upregulates NN NN O
proliferation NN NN O
- NN NN O
associated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
and NN NN O
pim NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Interferon NN NN O
- NN NN O
alpha NN NN O
( NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
) NN NN O
is NN NN O
a NN NN O
pleiotropic NN NN O
cytokine NN NN O
that NN NN O
has NN NN O
antiviral NN NN O
, NN NN O
antiproliferative NN NN O
, NN NN O
and NN NN O
immunoregulatory NN NN O
functions NN NN O
. NN NN O
   
There NN NN O
is NN NN O
increasing NN NN O
evidence NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
has NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
biology NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
and NN NN O
pim NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
activated NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
is NN NN O
associated NN NN O
with NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
T NN NN O
- NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
with NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
upregulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
and NN NN O
pim NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
IFN NN NN O
- NN NN O
alpha NN NN O
also NN NN O
sensitized NN NN O
T NN NN O
cells NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
proliferation NN NN O
, NN NN O
further NN NN O
suggesting NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogenesis NN NN O
. NN NN O
   
When NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
nature NN NN O
of NN NN O
STAT NN NN O
proteins NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
, NN NN O
pim NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
GAS NN NN O
elements NN NN O
after NN NN O
cytokine NN NN O
stimulation NN NN O
, NN NN O
we NN NN O
observed NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
induced NN NN O
binding NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
, NN NN O
and NN NN O
STAT4 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
STAT5 NN NN O
to NN NN O
all NN NN O
of NN NN O
these NN NN O
elements NN NN O
. NN NN O
   
Yet NN NN O
, NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
was NN NN O
able NN NN O
to NN NN O
activate NN NN O
binding NN NN O
of NN NN O
STAT5 NN NN O
to NN NN O
the NN NN O
high NN NN O
- NN NN O
affinity NN NN O
IFP53 NN NN B-Protein
GAS NN NN O
site NN NN O
. NN NN O
   
IFN NN NN O
- NN NN O
alpha NN NN O
enhanced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
STAT3 NN NN B-Protein
, NN NN O
STAT4 NN NN B-Protein
, NN NN O
STAT5a NN NN B-Protein
, NN NN O
and NN NN O
STAT5b NN NN B-Protein
. NN NN O
   
IL NN NN O
- NN NN O
12 NN NN O
induced NN NN O
STAT4 NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
induced NN NN O
STAT5 NN NN O
binding NN NN O
to NN NN O
the NN NN O
GAS NN NN O
elements NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
have NN NN O
overlapping NN NN O
activities NN NN O
on NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
thus NN NN O
emphasize NN NN O
the NN NN O
importance NN NN O
of NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
as NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
regulatory NN NN O
cytokine NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
rheumatic NN NN O
compound NN NN O
aurothioglucose NN NN O
inhibits NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
latently NN NN O
infected NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
and NN NN O
Ach2 NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
a NN NN O
potent NN NN O
cellular NN NN O
activator NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
known NN NN O
to NN NN O
inhibit NN NN O
HIV NN NN O
replication NN NN O
from NN NN O
the NN NN O
latently NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Gold NN NN O
compounds NN NN O
have NN NN O
been NN NN O
effectively NN NN O
used NN NN O
for NN NN O
many NN NN O
decades NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
rheumatoid NN NN O
arthritis NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
that NN NN O
gold NN NN O
compounds NN NN O
, NN NN O
especially NN NN O
aurothioglucose NN NN O
( NN NN O
AuTG NN NN O
) NN NN O
containing NN NN O
monovalent NN NN O
gold NN NN O
ion NN NN O
, NN NN O
inhibited NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
gold NN NN O
compound NN NN O
AuTG NN NN O
as NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
latently NN NN O
infected NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
and NN NN O
Ach2 NN NN O
cells NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
or NN NN O
Ach2 NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
non NN NN O
- NN NN O
cytotoxic NN NN O
doses NN NN O
of NN NN O
AuTG NN NN O
( NN NN O
> NN NN O
10 NN NN O
microM NN NN O
in NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
and NN NN O
> NN NN O
25 NN NN O
F NN NN O
. NN NN O
M NN NN O
in NN NN O
Ach2 NN NN O
cells NN NN O
) NN NN O
, NN NN O
while NN NN O
25 NN NN O
microM NN NN O
of NN NN O
the NN NN O
counter NN NN O
- NN NN O
anion NN NN O
thioglucose NN NN O
( NN NN O
TG NN NN O
) NN NN O
or NN NN O
gold NN NN O
compound NN NN O
containing NN NN O
divalent NN NN O
gold NN NN O
ion NN NN O
, NN NN O
HAuCl3 NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
AuTG NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
a NN NN O
transient NN NN O
CAT NN NN B-Protein
assay NN NN O
. NN NN O
   
Specific NN NN O
staining NN NN O
as NN NN O
well NN NN O
as NN NN O
electron NN NN O
microscopic NN NN O
examinations NN NN O
revealed NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
metal NN NN O
gold NN NN O
in NN NN O
the NN NN O
cells NN NN O
, NN NN O
supporting NN NN O
our NN NN O
previous NN NN O
hypothesis NN NN O
that NN NN O
gold NN NN O
ions NN NN O
could NN NN O
block NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
a NN NN O
redox NN NN O
mechanism NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
the NN NN O
monovalent NN NN O
gold NN NN O
compound NN NN O
AuTG NN NN O
is NN NN O
a NN NN O
potentially NN NN O
useful NN NN O
drug NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
suppressed NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NFAT1 NN NN B-Protein
at NN NN O
its NN NN O
proximal NN NN O
binding NN NN O
element NN NN O
P0 NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
of NN NN O
atopic NN NN O
patients NN NN O
. NN NN O
   
Allergen NN NN O
- NN NN O
specific NN NN O
T NN NN O
cells NN NN O
in NN NN O
atopic NN NN O
patients NN NN O
are NN NN O
polarized NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
producing NN NN O
Th2 NN NN O
cells NN NN O
, NN NN O
promoting NN NN O
IgE NN NN B-Protein
synthesis NN NN O
by NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
atopy NN NN O
is NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
regulation NN NN O
in NN NN O
general NN NN O
involves NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
of NN NN O
which NN NN O
NFAT1 NN NN B-Protein
and NN NN O
NFAT2 NN NN B-Protein
are NN NN O
most NN NN O
prominent NN NN O
in NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
a NN NN O
unique NN NN O
inhibitory NN NN O
role NN NN O
of NN NN O
NFAT1 NN NN B-Protein
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
control NN NN O
was NN NN O
shown NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O
   
In NN NN O
a NN NN O
series NN NN O
of NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
with NN NN O
protein NN NN O
extracts NN NN O
of NN NN O
highly NN NN O
polarized NN NN O
Th2 NN NN O
clones NN NN O
from NN NN O
atopics NN NN O
and NN NN O
Th1 NN NN O
clones NN NN O
from NN NN O
controls NN NN O
we NN NN O
compared NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
at NN NN O
the NN NN O
two NN NN O
NFAT NN NN O
- NN NN O
binding NN NN O
elements NN NN O
P0 NN NN O
and NN NN O
P1 NN NN O
of NN NN O
the NN NN O
crucial NN NN O
proximal NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
At NN NN O
the NN NN O
most NN NN O
proximal NN NN O
P0 NN NN O
site NN NN O
, NN NN O
NFAT NN NN O
- NN NN O
containing NN NN O
complexes NN NN O
devoid NN NN O
of NN NN O
NFAT2 NN NN B-Protein
were NN NN O
readily NN NN O
inducible NN NN O
in NN NN O
the NN NN O
Th1 NN NN O
clones NN NN O
, NN NN O
but NN NN O
hardly NN NN O
or NN NN O
not NN NN O
in NN NN O
the NN NN O
Th2 NN NN O
clones NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
both NN NN O
in NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
clones NN NN O
NFAT NN NN O
- NN NN O
containing NN NN O
complexes NN NN O
were NN NN O
strongly NN NN O
inducible NN NN O
at NN NN O
the NN NN O
P1 NN NN O
site NN NN O
, NN NN O
consisting NN NN O
of NN NN O
NFAT2 NN NN B-Protein
and NN NN O
a NN NN O
P0 NN NN O
- NN NN O
compatible NN NN O
NFAT NN NN O
activity NN NN O
, NN NN O
without NN NN O
apparent NN NN O
differences NN NN O
between NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
clones NN NN O
. NN NN O
   
Like NN NN O
in NN NN O
Th2 NN NN O
clones NN NN O
, NN NN O
suppressed NN NN O
NFAT NN NN O
- NN NN O
P0 NN NN O
complex NN NN O
formation NN NN O
was NN NN O
observed NN NN O
also NN NN O
at NN NN O
the NN NN O
polyclonal NN NN O
level NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
of NN NN O
three NN NN O
of NN NN O
five NN NN O
severe NN NN O
atopic NN NN O
dermatitis NN NN O
patients NN NN O
with NN NN O
strongly NN NN O
elevated NN NN O
serum NN NN O
IgE NN NN B-Protein
levels NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
control NN NN O
PBMC NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
high NN NN O
- NN NN O
level NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
production NN NN O
in NN NN O
atopic NN NN O
Th2 NN NN O
cells NN NN O
is NN NN O
associated NN NN O
with NN NN O
selective NN NN O
reduction NN NN O
of NN NN O
suppressive NN NN O
NFAT1 NN NN B-Protein
activity NN NN O
at NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
P0 NN NN O
element NN NN O
and NN NN O
that NN NN O
some NN NN O
patients NN NN O
with NN NN O
this NN NN O
multifactorial NN NN O
disease NN NN O
may NN NN O
have NN NN O
a NN NN O
putative NN NN O
systemic NN NN O
disorder NN NN O
at NN NN O
this NN NN O
level NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
rheumatic NN NN O
diseases NN NN O
: NN NN O
a NN NN O
preliminary NN NN O
report NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
regulates NN NN O
the NN NN O
expression NN NN O
of NN NN O
many NN NN O
genes NN NN O
involved NN NN O
in NN NN O
the NN NN O
immune NN NN O
or NN NN O
inflammatory NN NN O
response NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
distinctive NN NN O
patterns NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
are NN NN O
seen NN NN O
in NN NN O
different NN NN O
forms NN NN O
of NN NN O
joint NN NN O
disease NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
The NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
these NN NN O
nucleoproteins NN NN O
was NN NN O
examined NN NN O
in NN NN O
purified NN NN O
synovial NN NN O
and NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
various NN NN O
chronic NN NN O
rheumatic NN NN O
diseases NN NN O
( NN NN O
12 NN NN O
: NN NN O
four NN NN O
with NN NN O
rheumatoid NN NN O
arthritis NN NN O
; NN NN O
five NN NN O
with NN NN O
spondyloarthropathies NN NN O
; NN NN O
and NN NN O
three NN NN O
with NN NN O
osteoarthritis NN NN O
) NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
disclosed NN NN O
two NN NN O
specific NN NN O
complexes NN NN O
bound NN NN O
to NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
specific NN NN O
32P NN NN O
- NN NN O
labelled NN NN O
oligonucleotide NN NN O
in NN NN O
nucleoproteins NN NN O
extracted NN NN O
from NN NN O
purified NN NN O
T NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
synovial NN NN O
fluid NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
patients NN NN O
with NN NN O
rheumatoid NN NN O
arthritis NN NN O
. NN NN O
   
The NN NN O
complexes NN NN O
consisted NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
homodimers NN NN O
and NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
. NN NN O
   
Increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
in NN NN O
synovial NN NN O
T NN NN O
cells NN NN O
was NN NN O
observed NN NN O
relative NN NN O
to NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
non NN NN O
- NN NN O
rheumatoid NN NN O
arthritis NN NN O
, NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
synovial NN NN O
T NN NN O
cells NN NN O
was NN NN O
exclusively NN NN O
mediated NN NN O
by NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Overall NN NN O
, NN NN O
the NN NN O
results NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
play NN NN O
a NN NN O
central NN NN O
part NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
infiltrating NN NN O
T NN NN O
cells NN NN O
in NN NN O
chronic NN NN O
rheumatoid NN NN O
arthritis NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
this NN NN O
nuclear NN NN O
factor NN NN O
is NN NN O
qualitatively NN NN O
different NN NN O
in NN NN O
rheumatoid NN NN O
synovial NN NN O
T NN NN O
cells NN NN O
to NN NN O
that NN NN O
in NN NN O
other NN NN O
forms NN NN O
of NN NN O
non NN NN O
- NN NN O
rheumatoid NN NN O
arthritis NN NN O
( NN NN O
for NN NN O
example NN NN O
, NN NN O
osteoarthritis NN NN O
, NN NN O
spondyloarthropathies NN NN O
) NN NN O
. NN NN O
   
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
inhibits NN NN O
primary NN NN O
human NN NN O
T NN NN O
cell NN NN O
responses NN NN O
at NN NN O
the NN NN O
dendritic NN NN O
cell NN NN O
level NN NN O
: NN NN O
association NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibition NN NN O
. NN NN O
   
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
is NN NN O
an NN NN O
antioxidant NN NN O
molecule NN NN O
endowed NN NN O
with NN NN O
immunomodulatory NN NN O
properties NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
effect NN NN O
of NN NN O
NAC NN NN O
on NN NN O
the NN NN O
induction NN NN O
phase NN NN O
of NN NN O
T NN NN O
cell NN NN O
responses NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
its NN NN O
action NN NN O
on NN NN O
human NN NN O
dendritic NN NN O
cells NN NN O
( NN NN O
DC NN NN O
) NN NN O
derived NN NN O
from NN NN O
adherent NN NN O
PBMC NN NN O
cultured NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
We NN NN O
first NN NN O
found NN NN O
that NN NN O
NAC NN NN O
inhibited NN NN O
the NN NN O
constitutive NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
, NN NN O
NAC NN NN O
was NN NN O
shown NN NN O
to NN NN O
down NN NN O
- NN NN O
regulate NN NN O
the NN NN O
production NN NN O
of NN NN O
cytokines NN NN O
by NN NN O
DC NN NN O
as NN NN O
well NN NN O
as NN NN O
their NN NN O
surface NN NN O
expression NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
, NN NN O
CD86 NN NN B-Protein
( NN NN O
B7 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
CD40 NN NN B-Protein
molecules NN NN O
both NN NN O
at NN NN O
the NN NN O
basal NN NN O
state NN NN O
and NN NN O
upon NN NN O
LPS NN NN O
activation NN NN O
. NN NN O
   
NAC NN NN O
also NN NN O
inhibited NN NN O
DC NN NN O
responses NN NN O
induced NN NN O
by NN NN O
CD40 NN NN B-Protein
engagement NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
NAC NN NN O
were NN NN O
not NN NN O
due NN NN O
to NN NN O
nonspecific NN NN O
toxicity NN NN O
as NN NN O
neither NN NN O
the NN NN O
viability NN NN O
of NN NN O
DC NN NN O
nor NN NN O
their NN NN O
mannose NN NN B-Protein
receptor NN NN I-Protein
- NN NN O
mediated NN NN O
endocytosis NN NN O
were NN NN O
modified NN NN O
by NN NN O
NAC NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
addition NN NN O
of NN NN O
NAC NN NN O
to NN NN O
MLR NN NN O
between NN NN O
naive NN NN O
T NN NN O
cells NN NN O
and NN NN O
allogeneic NN NN O
DC NN NN O
resulted NN NN O
in NN NN O
a NN NN O
profound NN NN O
inhibition NN NN O
of NN NN O
alloreactive NN NN O
responses NN NN O
, NN NN O
which NN NN O
could NN NN O
be NN NN O
attributed NN NN O
to NN NN O
a NN NN O
defect NN NN O
of NN NN O
DC NN NN O
as NN NN O
APC NN NN O
- NN NN O
independent NN NN O
T NN NN O
cell NN NN O
responses NN NN O
were NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
NAC NN NN O
. NN NN O
   
Altogether NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
NAC NN NN O
might NN NN O
impair NN NN O
the NN NN O
generation NN NN O
of NN NN O
primary NN NN O
immune NN NN O
responses NN NN O
in NN NN O
humans NN NN O
through NN NN O
its NN NN O
inhibitory NN NN O
action NN NN O
on NN NN O
DC NN NN O
. NN NN O
   
Bacterial NN NN O
lipopolysaccharide NN NN O
activates NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
signaling NN NN O
mediators NN NN O
in NN NN O
cultured NN NN O
human NN NN O
dermal NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
mononuclear NN NN O
phagocytes NN NN O
. NN NN O
   
Bacterial NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
responses NN NN O
, NN NN O
including NN NN O
activation NN NN O
of NN NN O
monocytes NN NN O
, NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Gram NN NN O
- NN NN O
negative NN NN O
bacteria NN NN O
- NN NN O
induced NN NN O
sepsis NN NN O
syndrome NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
cytokine NN NN O
release NN NN O
from NN NN O
LPS NN NN O
- NN NN O
responsive NN NN O
cells NN NN O
, NN NN O
a NN NN O
critical NN NN O
step NN NN O
for NN NN O
endotoxic NN NN O
effects NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
investigated NN NN O
the NN NN O
role NN NN O
and NN NN O
involvement NN NN O
of NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
signal NN NN O
transducer NN NN O
molecules NN NN O
in NN NN O
LPS NN NN O
signaling NN NN O
in NN NN O
human NN NN O
dermal NN NN O
microvessel NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HDMEC NN NN O
) NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
LPS NN NN O
stimulation NN NN O
of NN NN O
HDMEC NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
initiated NN NN O
an NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
- NN NN O
like NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
signaling NN NN O
cascade NN NN O
. NN NN O
   
In NN NN O
transient NN NN O
cotransfection NN NN O
experiments NN NN O
, NN NN O
dominant NN NN O
negative NN NN O
mutants NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
signaling NN NN O
pathway NN NN O
, NN NN O
including NN NN O
MyD88 NN NN B-Protein
, NN NN O
IRAK NN NN B-Protein
, NN NN O
IRAK2 NN NN B-Protein
, NN NN O
and NN NN O
TRAF6 NN NN B-Protein
inhibited NN NN O
both NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
luciferase NN NN O
activity NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
was NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
mutant NN NN O
of NN NN O
TRAF2 NN NN B-Protein
that NN NN O
is NN NN O
involved NN NN O
in NN NN O
TNF NN NN O
signaling NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
responsive NN NN O
reporter NN NN O
gene NN NN O
was NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
TLR2 NN NN B-Protein
and NN NN O
TLR4 NN NN B-Protein
were NN NN O
expressed NN NN O
on NN NN O
the NN NN O
cell NN NN O
surface NN NN O
of NN NN O
HDMEC NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
a NN NN O
signal NN NN O
transduction NN NN O
molecule NN NN O
in NN NN O
the NN NN O
LPS NN NN O
receptor NN NN O
complex NN NN O
may NN NN O
belong NN NN O
to NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
/ NN NN O
toll NN NN O
- NN NN O
like NN NN O
receptor NN NN O
( NN NN O
TLR NN NN O
) NN NN O
super NN NN O
family NN NN O
, NN NN O
and NN NN O
the NN NN O
LPS NN NN O
signaling NN NN O
cascade NN NN O
uses NN NN O
an NN NN O
analogous NN NN O
molecular NN NN O
framework NN NN O
for NN NN O
signaling NN NN O
as NN NN O
IL NN NN O
- NN NN O
1 NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Selective NN NN O
activation NN NN O
and NN NN O
functional NN NN O
significance NN NN O
of NN NN O
p38alpha NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
in NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
neutrophils NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
leukocytes NN NN O
by NN NN O
proinflammatory NN NN O
stimuli NN NN O
selectively NN NN O
initiates NN NN O
intracellular NN NN O
signal NN NN O
transduction NN NN O
via NN NN O
sequential NN NN O
phosphorylation NN NN O
of NN NN O
kinases NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
neutrophils NN NN O
is NN NN O
known NN NN O
to NN NN O
result NN NN O
in NN NN O
activation NN NN O
of NN NN O
p38 NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPk NN NN O
) NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
upstream NN NN O
activator NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
p38 NN NN O
MAPk NN NN O
is NN NN O
unknown NN NN O
, NN NN O
and NN NN O
consequences NN NN O
of NN NN O
p38 NN NN O
MAPk NN NN O
activation NN NN O
remain NN NN O
largely NN NN O
undefined NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
MAPk NN NN O
kinase NN NN O
( NN NN O
MKK NN NN O
) NN NN O
that NN NN O
activates NN NN O
p38 NN NN O
MAPk NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
, NN NN O
the NN NN O
p38 NN NN O
MAPk NN NN O
isoforms NN NN O
that NN NN O
are NN NN O
activated NN NN O
as NN NN O
part NN NN O
of NN NN O
this NN NN O
pathway NN NN O
, NN NN O
and NN NN O
the NN NN O
functional NN NN O
responses NN NN O
affected NN NN O
by NN NN O
p38 NN NN O
MAPk NN NN O
activation NN NN O
. NN NN O
   
Although NN NN O
MKK3 NN NN B-Protein
, NN NN O
MKK4 NN NN B-Protein
, NN NN O
and NN NN O
MKK6 NN NN B-Protein
all NN NN O
activated NN NN O
p38 NN NN O
MAPk NN NN O
in NN NN O
experimental NN NN O
models NN NN O
, NN NN O
only NN NN O
MKK3 NN NN B-Protein
was NN NN O
found NN NN O
to NN NN O
activate NN NN O
recombinant NN NN O
p38 NN NN O
MAPk NN NN O
in NN NN O
LPS NN NN O
- NN NN O
treated NN NN O
neutrophils NN NN O
. NN NN O
   
Of NN NN O
p38 NN NN O
MAPk NN NN O
isoforms NN NN O
studied NN NN O
, NN NN O
only NN NN O
p38alpha NN NN B-Protein
and NN NN O
p38delta NN NN B-Protein
were NN NN O
detected NN NN O
in NN NN O
neutrophils NN NN O
. NN NN O
   
LPS NN NN O
stimulation NN NN O
selectively NN NN O
activated NN NN O
p38alpha NN NN B-Protein
. NN NN O
   
Specific NN NN O
inhibitors NN NN O
of NN NN O
p38alpha NN NN B-Protein
MAPk NN NN I-Protein
blocked NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
adhesion NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
activation NN NN O
, NN NN O
and NN NN O
synthesis NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
p38alpha NN NN B-Protein
MAPk NN NN I-Protein
resulted NN NN O
in NN NN O
a NN NN O
transient NN NN O
decrease NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
but NN NN O
persistent NN NN O
loss NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
support NN NN O
a NN NN O
pathway NN NN O
by NN NN O
which NN NN O
LPS NN NN O
stimulation NN NN O
of NN NN O
neutrophils NN NN O
results NN NN O
in NN NN O
activation NN NN O
of NN NN O
MKK3 NN NN B-Protein
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
activates NN NN O
p38alpha NN NN B-Protein
MAPk NN NN I-Protein
, NN NN O
ultimately NN NN O
regulating NN NN O
adhesion NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
enhanced NN NN O
gene NN NN O
expression NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
and NN NN O
regulation NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
by NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
interferons NN NN O
. NN NN O
   
The NN NN O
Th2 NN NN O
- NN NN O
type NN NN O
cytokines NN NN O
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
) NN NN O
, NN NN O
induce NN NN O
expression NN NN O
of NN NN O
a NN NN O
distinct NN NN O
subset NN NN O
of NN NN O
genes NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
including NN NN O
FcepsilonRIIb NN NN B-Protein
( NN NN O
CD23 NN NN B-Protein
) NN NN O
, NN NN O
15 NN NN B-Protein
- NN NN I-Protein
lipoxygenase NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1ra NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptors NN NN O
( NN NN O
IL NN NN O
- NN NN O
1R NN NN O
) NN NN O
. NN NN O
   
Type NN NN O
I NN NN O
interferons NN NN O
( NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
) NN NN O
and NN NN O
type NN NN O
II NN NN O
interferon NN NN O
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
inhibit NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
IFNs NN NN O
mediate NN NN O
this NN NN O
inhibition NN NN O
has NN NN O
not NN NN O
been NN NN O
defined NN NN O
. NN NN O
   
In NN NN O
this NN NN O
overview NN NN O
, NN NN O
we NN NN O
discuss NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
STAT6 NN NN B-Protein
( NN NN O
signal NN NN B-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
in NN NN O
mediating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
induced NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
also NN NN O
discuss NN NN O
our NN NN O
recent NN NN O
findings NN NN O
that NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
IFNs NN NN O
suppress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
by NN NN O
inhibiting NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
STAT6 NN NN B-Protein
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
IFNs NN NN O
to NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
induced NN NN O
STAT6 NN NN B-Protein
activity NN NN O
is NN NN O
dose NN NN O
- NN NN O
and NN NN O
time NN NN O
- NN NN O
dependent NN NN O
, NN NN O
and NN NN O
is NN NN O
not NN NN O
unique NN NN O
to NN NN O
monocytes NN NN O
because NN NN O
IFNs NN NN O
induce NN NN O
the NN NN O
same NN NN O
effects NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
STAT6 NN NN B-Protein
activity NN NN O
is NN NN O
not NN NN O
evident NN NN O
unless NN NN O
cells NN NN O
are NN NN O
preincubated NN NN O
with NN NN O
IFN NN NN O
for NN NN O
at NN NN O
least NN NN O
1 NN NN O
h NN NN O
before NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
inhibition NN NN O
can NN NN O
be NN NN O
blocked NN NN O
by NN NN O
actinomycin NN NN O
D NN NN O
, NN NN O
indicating NN NN O
a NN NN O
requirement NN NN O
for NN NN O
de NN NN O
novo NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
a NN NN O
model NN NN O
in NN NN O
which NN NN O
stimulation NN NN O
of NN NN O
monocytes NN NN O
by NN NN O
IFN NN NN O
activates NN NN O
de NN NN O
novo NN NN O
synthesis NN NN O
of NN NN O
an NN NN O
inhibitory NN NN O
factor NN NN O
, NN NN O
possibly NN NN O
one NN NN O
or NN NN O
more NN NN O
members NN NN O
of NN NN O
the NN NN O
SOCS NN NN O
/ NN NN O
SSI NN NN O
/ NN NN O
CIS NN NN O
gene NN NN O
family NN NN O
, NN NN O
capable NN NN O
of NN NN O
suppressing NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
. NN NN O
   
Because NN NN O
STAT6 NN NN B-Protein
activation NN NN O
plays NN NN O
an NN NN O
essential NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
induced NN NN O
gene NN NN O
expression NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
to NN NN O
inhibit NN NN O
STAT6 NN NN B-Protein
activity NN NN O
provides NN NN O
an NN NN O
explanation NN NN O
for NN NN O
how NN NN O
IFNs NN NN O
can NN NN O
suppress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
- NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimer NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
pro NN NN B-Protein
- NN NN I-Protein
interleukin NN NN I-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
at NN NN O
two NN NN O
subregions NN NN O
of NN NN O
the NN NN O
upstream NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
A NN NN O
region NN NN O
between NN NN O
- NN NN O
3134 NN NN O
and NN NN O
- NN NN O
2729 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
transcription NN NN O
site NN NN O
of NN NN O
the NN NN O
human NN NN O
pro NN NN B-Protein
- NN NN I-Protein
interleukin NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
gene NN NN O
was NN NN O
identified NN NN O
as NN NN O
an NN NN O
LPS NN NN O
- NN NN O
responsive NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
influence NN NN O
of NN NN O
the NN NN O
sequences NN NN O
located NN NN O
between NN NN O
- NN NN O
3134 NN NN O
and NN NN O
- NN NN O
2987 NN NN O
on NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
in NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
Raw NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
was NN NN O
examined NN NN O
in NN NN O
detail NN NN O
. NN NN O
   
The NN NN O
results NN NN O
obtained NN NN O
by NN NN O
transient NN NN O
transfection NN NN O
of NN NN O
fos NN NN B-Protein
- NN NN O
CAT NN NN B-Protein
constructs NN NN O
that NN NN O
contained NN NN O
serial NN NN O
5 NN NN O
' NN NN O
- NN NN O
deletion NN NN O
mutations NN NN O
showed NN NN O
that NN NN O
the NN NN O
region NN NN O
between NN NN O
- NN NN O
3134 NN NN O
and NN NN O
- NN NN O
3059 NN NN O
appears NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
by NN NN O
LPS NN NN O
. NN NN O
   
Gel NN NN O
shift NN NN O
assay NN NN O
studies NN NN O
with NN NN O
synthetic NN NN O
oligonucleotides NN NN O
corresponding NN NN O
to NN NN O
partial NN NN O
sequences NN NN O
of NN NN O
the NN NN O
latter NN NN O
region NN NN O
and NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
stimulated NN NN O
cells NN NN O
revealed NN NN O
specific NN NN O
protein NN NN O
binding NN NN O
sites NN NN O
between NN NN O
- NN NN O
3110 NN NN O
and NN NN O
- NN NN O
3090 NN NN O
and NN NN O
between NN NN O
- NN NN O
3079 NN NN O
and NN NN O
- NN NN O
3059 NN NN O
. NN NN O
   
These NN NN O
specific NN NN O
bindings NN NN O
were NN NN O
time NN NN O
and NN NN O
LPS NN NN O
dose NN NN O
dependent NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
supershift NN NN O
analysis NN NN O
using NN NN O
specific NN NN O
antibodies NN NN O
against NN NN O
transcription NN NN O
factors NN NN O
suggested NN NN O
that NN NN O
both NN NN O
binding NN NN O
complexes NN NN O
contained NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
components NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
did NN NN O
not NN NN O
contain NN NN O
other NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
( NN NN O
p52 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
Rel NN NN B-Protein
B NN NN I-Protein
) NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
proteins NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
C NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
) NN NN O
, NN NN O
CREB NN NN O
or NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
) NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
either NN NN O
of NN NN O
the NN NN O
putative NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
enhancer NN NN O
element NN NN O
decreased NN NN O
the NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicated NN NN O
that NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
which NN NN O
are NN NN O
located NN NN O
between NN NN O
- NN NN O
3134 NN NN O
and NN NN O
- NN NN O
3059 NN NN O
, NN NN O
are NN NN O
critical NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Phosphorylation NN NN O
of NN NN O
TRAF2 NN NN B-Protein
inhibits NN NN O
binding NN NN O
to NN NN O
the NN NN O
CD40 NN NN B-Protein
cytoplasmic NN NN O
domain NN NN O
. NN NN O
   
TRAF2 NN NN B-Protein
is NN NN O
a NN NN O
signal NN NN O
transducing NN NN O
adaptor NN NN O
molecule NN NN O
which NN NN O
binds NN NN O
to NN NN O
the NN NN O
CD40 NN NN B-Protein
cytoplasmic NN NN O
domain NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
it NN NN O
is NN NN O
phosphorylated NN NN O
, NN NN O
predominantly NN NN O
on NN NN O
serine NN NN O
residues NN NN O
, NN NN O
when NN NN O
transiently NN NN O
overexpressed NN NN O
in NN NN O
293 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
phosphorylation NN NN O
appears NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
signaling NN NN O
events NN NN O
that NN NN O
are NN NN O
activated NN NN O
by NN NN O
TRAF2 NN NN B-Protein
under NN NN O
these NN NN O
circumstances NN NN O
, NN NN O
since NN NN O
two NN NN O
nonfunctional NN NN O
mutants NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
phosphorylated NN NN O
significantly NN NN O
less NN NN O
than NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
protein NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
phosphorylation NN NN O
status NN NN O
of NN NN O
TRAF2 NN NN B-Protein
had NN NN O
significant NN NN O
effects NN NN O
on NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
protein NN NN O
to NN NN O
bind NN NN O
to NN NN O
CD40 NN NN B-Protein
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
our NN NN O
observations NN NN O
that NN NN O
the NN NN O
CD40 NN NN B-Protein
cytoplasmic NN NN O
domain NN NN O
interacted NN NN O
preferentially NN NN O
with NN NN O
underphosphorylated NN NN O
TRAF2 NN NN B-Protein
and NN NN O
that NN NN O
phosphatase NN NN O
treatment NN NN O
significantly NN NN O
enhanced NN NN O
the NN NN O
binding NN NN O
of NN NN O
TRAF2 NN NN B-Protein
to NN NN O
CD40 NN NN B-Protein
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
studies NN NN O
that NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
TRAF2 NN NN B-Protein
is NN NN O
likely NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulating NN NN O
signaling NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
ability NN NN O
to NN NN O
influence NN NN O
the NN NN O
CD40 NN NN B-Protein
- NN NN O
TRAF2 NN NN B-Protein
interaction NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Cobalt NN NN O
chloride NN NN O
- NN NN O
induced NN NN O
signaling NN NN O
in NN NN O
endothelium NN NN O
leading NN NN O
to NN NN O
the NN NN O
augmented NN NN O
adherence NN NN O
of NN NN O
sickle NN NN O
red NN NN O
blood NN NN O
cells NN NN O
and NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
is NN NN O
blocked NN NN O
by NN NN O
PAF NN NN B-Protein
- NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN O
. NN NN O
   
In NN NN O
response NN NN O
to NN NN O
hypoxia NN NN O
, NN NN O
sickle NN NN O
red NN NN O
blood NN NN O
cells NN NN O
( NN NN O
SS NN NN O
RBC NN NN O
) NN NN O
and NN NN O
leukocytes NN NN O
exhibit NN NN O
increased NN NN O
adherence NN NN O
to NN NN O
the NN NN O
vascular NN NN O
endothelium NN NN O
, NN NN O
while NN NN O
diapedesis NN NN O
of NN NN O
leukocytes NN NN O
through NN NN O
the NN NN O
blood NN NN O
vessel NN NN O
increases NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
cellular NN NN O
signaling NN NN O
pathway NN NN O
( NN NN O
s NN NN O
) NN NN O
caused NN NN O
by NN NN O
hypoxia NN NN O
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
utilized NN NN O
CoCl2 NN NN O
as NN NN O
a NN NN O
mimetic NN NN O
molecule NN NN O
for NN NN O
hypoxia NN NN O
to NN NN O
study NN NN O
cellular NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
in NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVEC NN NN O
) NN NN O
, NN NN O
CoCl2 NN NN O
at NN NN O
2 NN NN O
mM NN NN O
concentration NN NN O
induced NN NN O
the NN NN O
surface NN NN O
expression NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
CAMs NN NN O
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
HUVEC NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
CoCl2 NN NN O
also NN NN O
caused NN NN O
time NN NN O
- NN NN O
dependent NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
( NN NN O
MAP NN NN O
) NN NN O
kinase NN NN O
isoform NN NN O
ERK2 NN NN B-Protein
without NN NN O
significantly NN NN O
affecting NN NN O
ERK1 NN NN B-Protein
, NN NN O
indicating NN NN O
ERK2 NN NN B-Protein
is NN NN O
the NN NN O
preferred NN NN O
substrate NN NN O
for NN NN O
upstream NN NN O
kinase NN NN O
of NN NN O
the NN NN O
MAPK NN NN O
pathway NN NN O
. NN NN O
   
Inhibitors NN NN O
of NN NN O
MAP NN NN O
kinase NN NN O
( NN NN O
PD98059 NN NN O
) NN NN O
or NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
( NN NN O
PAF NN NN O
) NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
( NN NN O
CV3988 NN NN O
) NN NN O
inhibited NN NN O
the NN NN O
CoCl2 NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Augmented NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
led NN NN O
to NN NN O
increased NN NN O
SS NN NN O
RBC NN NN O
adhesion NN NN O
, NN NN O
inhibitable NN NN O
by NN NN O
a NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
antibody NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
CoCl2 NN NN O
caused NN NN O
a NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
increase NN NN O
in NN NN O
the NN NN O
rate NN NN O
of NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
and NN NN O
a NN NN O
twentyfold NN NN O
increase NN NN O
in NN NN O
phosphorylation NN NN O
of NN NN O
platelet NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
( NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocytes NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
an NN NN O
antibody NN NN O
to NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Both NN NN O
phosphorylation NN NN O
of NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocytes NN NN O
in NN NN O
response NN NN O
to NN NN O
CoCl2 NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
inhibitor NN NN O
( NN NN O
GF109203X NN NN O
) NN NN O
and NN NN O
augmented NN NN O
by NN NN O
protein NN NN O
phosphatase NN NN O
inhibitor NN NN O
( NN NN O
Calyculin NN NN O
A NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggests NN NN O
that NN NN O
CoCl2 NN NN O
- NN NN O
induced NN NN O
cellular NN NN O
signals NN NN O
directing NN NN O
increased NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
HUVEC NN NN O
involve NN NN O
downstream NN NN O
activation NN NN O
of NN NN O
MAP NN NN O
kinase NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
while NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
occurs NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
activation NN NN O
of NN NN O
PKC NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
PAF NN NN O
- NN NN O
receptor NN NN O
antagonist NN NN O
inhibits NN NN O
the NN NN O
CoCl2 NN NN O
- NN NN O
or NN NN O
hypoxia NN NN O
- NN NN O
induced NN NN O
increase NN NN O
in NN NN O
the NN NN O
adhesion NN NN O
of NN NN O
SS NN NN O
RBC NN NN O
, NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
phosphorylation NN NN O
, NN NN O
and NN NN O
the NN NN O
concomitant NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocytes NN NN O
. NN NN O
   
Molecular NN NN O
mechanisms NN NN O
of NN NN O
neutrophil NN NN O
- NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
induced NN NN O
by NN NN O
redox NN NN O
imbalance NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
implicated NN NN O
a NN NN O
role NN NN O
for NN NN O
intracellular NN NN O
thiols NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
determine NN NN O
whether NN NN O
changes NN NN O
in NN NN O
endothelial NN NN O
cell NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
or NN NN O
oxidized NN NN O
glutathione NN NN O
( NN NN O
GSSG NN NN O
) NN NN O
can NN NN O
alter NN NN O
neutrophil NN NN O
adhesivity NN NN O
and NN NN O
to NN NN O
define NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
that NN NN O
underlies NN NN O
this NN NN O
GSSG NN NN O
/ NN NN O
GSH NN NN O
- NN NN O
induced NN NN O
adhesion NN NN O
response NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cell NN NN O
( NN NN O
HUVEC NN NN O
) NN NN O
monolayers NN NN O
for NN NN O
6 NN NN O
hours NN NN O
with NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
diamide NN NN O
and NN NN O
1 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
buthionine NN NN O
sulfoximine NN NN O
( NN NN O
BSO NN NN O
) NN NN O
decreased NN NN O
GSH NN NN O
levels NN NN O
and NN NN O
increased NN NN O
the NN NN O
ratio NN NN O
of NN NN O
GSSG NN NN O
to NN NN O
GSH NN NN O
without NN NN O
cell NN NN O
toxicity NN NN O
. NN NN O
   
These NN NN O
redox NN NN O
changes NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
with NN NN O
anoxia NN NN O
/ NN NN O
reoxygenation NN NN O
. NN NN O
   
Diamide NN NN O
plus NN NN O
BSO NN NN O
- NN NN O
induced NN NN O
thiol NN NN O
/ NN NN O
disulfide NN NN O
imbalance NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
biphasic NN NN O
increase NN NN O
in NN NN O
neutrophil NN NN O
adhesion NN NN O
to NN NN O
HUVECs NN NN O
with NN NN O
peak NN NN O
responses NN NN O
observed NN NN O
at NN NN O
15 NN NN O
minutes NN NN O
( NN NN O
phase NN NN O
1 NN NN O
) NN NN O
and NN NN O
240 NN NN O
minutes NN NN O
( NN NN O
phase NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
N NN NN O
- NN NN O
Acetylcysteine NN NN O
treatment NN NN O
attenuated NN NN O
neutrophil NN NN O
adhesion NN NN O
in NN NN O
both NN NN O
phases NN NN O
, NN NN O
which NN NN O
indicated NN NN O
a NN NN O
role NN NN O
for NN NN O
GSH NN NN O
in NN NN O
the NN NN O
adhesion NN NN O
responses NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
phase NN NN O
1 NN NN O
adhesion NN NN O
was NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
GSH NN NN O
levels NN NN O
but NN NN O
not NN NN O
with NN NN O
the NN NN O
GSSG NN NN O
/ NN NN O
GSH NN NN O
ratio NN NN O
, NN NN O
whereas NN NN O
phase NN NN O
2 NN NN O
neutrophil NN NN O
adhesion NN NN O
was NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
GSSG NN NN O
/ NN NN O
GSH NN NN O
ratio NN NN O
but NN NN O
not NN NN O
with NN NN O
GSH NN NN O
levels NN NN O
. NN NN O
   
Intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
- NN NN O
specific NN NN O
monoclonal NN NN O
antibodies NN NN O
attenuated NN NN O
the NN NN O
increased NN NN O
neutrophil NN NN O
adhesion NN NN O
during NN NN O
both NN NN O
phases NN NN O
, NN NN O
whereas NN NN O
an NN NN O
anti NN NN O
- NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
monoclonal NN NN O
antibody NN NN O
also NN NN O
attenuated NN NN O
the NN NN O
phase NN NN O
2 NN NN O
response NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
actinomycin NN NN O
D NN NN O
and NN NN O
cycloheximide NN NN O
or NN NN O
with NN NN O
competing NN NN O
ds NN NN O
- NN NN O
oligonucleotides NN NN O
that NN NN O
contained NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
or NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
cognate NN NN O
DNA NN NN O
sequences NN NN O
significantly NN NN O
attenuated NN NN O
the NN NN O
phase NN NN O
2 NN NN O
response NN NN O
, NN NN O
which NN NN O
implicated NN NN O
a NN NN O
role NN NN O
for NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Surface NN NN O
expression NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
on NN NN O
HUVECs NN NN O
correlated NN NN O
with NN NN O
the NN NN O
phase NN NN O
1 NN NN O
and NN NN O
2 NN NN O
neutrophil NN NN O
adhesion NN NN O
responses NN NN O
. NN NN O
   
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
changes NN NN O
in NN NN O
endothelial NN NN O
cell NN NN O
GSSG NN NN O
/ NN NN O
GSH NN NN O
cause NN NN O
transcription NN NN O
- NN NN O
independent NN NN O
and NN NN O
transcription NN NN O
- NN NN O
dependent NN NN O
surface NN NN O
expression NN NN O
of NN NN O
different NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
a NN NN O
2 NN NN O
- NN NN O
phase NN NN O
neutrophil NN NN O
- NN NN O
endothelial NN NN O
adhesion NN NN O
response NN NN O
. NN NN O
   
Decreased NN NN O
proteasome NN NN O
- NN NN O
mediated NN NN O
degradation NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
the NN NN O
elderly NN NN O
: NN NN O
A NN NN O
role NN NN O
in NN NN O
immune NN NN O
senescence NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
NFkappaB NN NN O
is NN NN O
a NN NN O
highly NN NN O
regulated NN NN O
process NN NN O
requiring NN NN O
phosphorylation NN NN O
, NN NN O
ubiquitination NN NN O
, NN NN O
and NN NN O
proteasome NN NN O
- NN NN O
mediated NN NN O
degradation NN NN O
of NN NN O
the NN NN O
cytosolic NN NN O
inhibitor NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
Analyses NN NN O
of NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
treated NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
young NN NN O
and NN NN O
elderly NN NN O
donors NN NN O
revealed NN NN O
severely NN NN O
compromised NN NN O
degradation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
Examination NN NN O
of NN NN O
activation NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
and NN NN O
ubiquitination NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
did NN NN O
not NN NN O
demonstrate NN NN O
any NN NN O
significant NN NN O
age NN NN O
- NN NN O
related NN NN O
alterations NN NN O
. NN NN O
   
However NN NN O
, NN NN O
examination NN NN O
of NN NN O
proteasome NN NN O
activity NN NN O
in NN NN O
these NN NN O
T NN NN O
cells NN NN O
using NN NN O
fluorogenic NN NN O
peptide NN NN O
assays NN NN O
revealed NN NN O
a NN NN O
significant NN NN O
age NN NN O
- NN NN O
related NN NN O
decline NN NN O
in NN NN O
chymotryptic NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
decline NN NN O
in NN NN O
proteasome NN NN O
activity NN NN O
results NN NN O
in NN NN O
a NN NN O
failure NN NN O
to NN NN O
fully NN NN O
degrade NN NN O
IkappaBalpha NN NN B-Protein
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
This NN NN O
failure NN NN O
to NN NN O
degrade NN NN O
IkappaBalpha NN NN B-Protein
may NN NN O
underlie NN NN O
both NN NN O
the NN NN O
observed NN NN O
decrease NN NN O
in NN NN O
NFkappaB NN NN O
induction NN NN O
and NN NN O
the NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
in NN NN O
TNF NN NN O
- NN NN O
treated NN NN O
T NN NN O
cells NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
decreased NN NN O
proteasome NN NN O
- NN NN O
mediated NN NN O
degradation NN NN O
may NN NN O
be NN NN O
central NN NN O
to NN NN O
immune NN NN O
dysfunction NN NN O
that NN NN O
accompanies NN NN O
aging NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
upstream NN NN O
regulatory NN NN O
elements NN NN O
that NN NN O
repress NN NN O
expression NN NN O
of NN NN O
adult NN NN O
beta NN NN O
- NN NN O
like NN NN O
globin NN NN O
genes NN NN O
in NN NN O
a NN NN O
primitive NN NN O
erythroid NN NN O
environment NN NN O
. NN NN O
   
Our NN NN O
investigations NN NN O
have NN NN O
focused NN NN O
on NN NN O
localizing NN NN O
cis NN NN O
- NN NN O
elements NN NN O
responsible NN NN O
for NN NN O
the NN NN O
down NN NN O
regulation NN NN O
of NN NN O
the NN NN O
adult NN NN O
beta NN NN O
- NN NN O
like NN NN O
globin NN NN O
genes NN NN O
( NN NN O
delta NN NN B-Protein
and NN NN O
beta NN NN B-Protein
) NN NN O
in NN NN O
immature NN NN O
, NN NN O
or NN NN O
primitive NN NN O
erythroid NN NN O
tissues NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
their NN NN O
activity NN NN O
after NN NN O
transfection NN NN O
into NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
an NN NN O
erythroleukemia NN NN O
cell NN NN O
line NN NN O
with NN NN O
an NN NN O
embryonic NN NN O
- NN NN O
fetal NN NN O
phenotype NN NN O
. NN NN O
   
Analyzed NN NN O
DNA NN NN O
sequences NN NN O
included NN NN O
delta NN NN B-Protein
and NN NN O
beta NN NN B-Protein
5 NN NN O
' NN NN O
flanking NN NN O
regions NN NN O
extending NN NN O
from NN NN O
approximately NN NN O
- NN NN O
500 NN NN O
to NN NN O
+ NN NN O
50bp NN NN O
( NN NN O
promoter NN NN O
regions NN NN O
) NN NN O
, NN NN O
truncated NN NN O
delta NN NN B-Protein
and NN NN O
beta NN NN B-Protein
5 NN NN O
' NN NN O
flanking NN NN O
regions NN NN O
extending NN NN O
from NN NN O
approximately NN NN O
- NN NN O
250 NN NN O
to NN NN O
+ NN NN O
50 NN NN O
bp NN NN O
, NN NN O
and NN NN O
chimeric NN NN O
promoter NN NN O
constructions NN NN O
, NN NN O
which NN NN O
consisted NN NN O
of NN NN O
a NN NN O
distal NN NN O
delta NN NN B-Protein
or NN NN O
beta NN NN B-Protein
fragment NN NN O
fused NN NN O
to NN NN O
a NN NN O
proximal NN NN O
beta NN NN B-Protein
or NN NN O
delta NN NN B-Protein
sequence NN NN O
. NN NN O
   
In NN NN O
CAT NN NN B-Protein
reporter NN NN O
constructions NN NN O
no NN NN O
appreciable NN NN O
level NN NN O
of NN NN O
CAT NN NN B-Protein
activity NN NN O
was NN NN O
supported NN NN O
by NN NN O
the NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
promoter NN NN O
, NN NN O
and NN NN O
only NN NN O
low NN NN O
level NN NN O
activity NN NN O
by NN NN O
the NN NN O
delta NN NN B-Protein
promoter NN NN O
. NN NN O
   
Truncation NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
promoter NN NN O
led NN NN O
to NN NN O
a NN NN O
2 NN NN O
- NN NN O
3 NN NN O
fold NN NN O
increase NN NN O
in NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
deletion NN NN O
of NN NN O
the NN NN O
upstream NN NN O
portion NN NN O
of NN NN O
the NN NN O
delta NN NN B-Protein
promoter NN NN O
led NN NN O
to NN NN O
a NN NN O
10 NN NN O
fold NN NN O
decrease NN NN O
in NN NN O
expression NN NN O
. NN NN O
   
Coupling NN NN O
of NN NN O
the NN NN O
upstream NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
sequence NN NN O
from NN NN O
approximately NN NN O
- NN NN O
500 NN NN O
to NN NN O
- NN NN O
250 NN NN O
bp NN NN O
to NN NN O
the NN NN O
truncated NN NN O
delta NN NN B-Protein
promoter NN NN O
fragment NN NN O
led NN NN O
to NN NN O
complete NN NN O
extinction NN NN O
of NN NN O
transcription NN NN O
activity NN NN O
, NN NN O
consistent NN NN O
with NN NN O
a NN NN O
negative NN NN O
regulatory NN NN O
effect NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
gene NN NN O
upstream NN NN O
element NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
Fusion NN NN O
of NN NN O
the NN NN O
upstream NN NN O
portion NN NN O
of NN NN O
the NN NN O
delta NN NN B-Protein
promoter NN NN O
to NN NN O
the NN NN O
truncated NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
promoter NN NN O
yielded NN NN O
a NN NN O
modest NN NN O
increase NN NN O
in NN NN O
promoter NN NN O
strength NN NN O
relative NN NN O
to NN NN O
the NN NN O
truncated NN NN O
beta NN NN B-Protein
gene NN NN O
promoter NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
positive NN NN O
transcriptional NN NN O
element NN NN O
( NN NN O
s NN NN O
) NN NN O
in NN NN O
the NN NN O
upstream NN NN O
delta NN NN B-Protein
globin NN NN I-Protein
regulatory NN NN O
region NN NN O
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
of NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
repressor NN NN O
proteins NN NN O
BP1 NN NN B-Protein
and NN NN O
BP2 NN NN B-Protein
in NN NN O
the NN NN O
upstream NN NN O
portion NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
gene NN NN O
flanking NN NN O
region NN NN O
led NN NN O
to NN NN O
a NN NN O
4 NN NN O
- NN NN O
6 NN NN O
fold NN NN O
increase NN NN O
in NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
DNase NN NN B-Protein
I NN NN I-Protein
footprinting NN NN O
of NN NN O
the NN NN O
upstream NN NN O
delta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
region NN NN O
revealed NN NN O
protected NN NN O
sequences NN NN O
corresponding NN NN O
to NN NN O
consensus NN NN O
binding NN NN O
sites NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
BP2 NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
confirm NN NN O
that NN NN O
sequences NN NN O
in NN NN O
the NN NN O
upstream NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
adult NN NN O
beta NN NN B-Protein
globin NN NN I-Protein
gene NN NN O
contribute NN NN O
to NN NN O
its NN NN O
factor NN NN O
- NN NN O
mediated NN NN O
suppression NN NN O
early NN NN O
in NN NN O
development NN NN O
and NN NN O
then NN NN O
may NN NN O
modulate NN NN O
its NN NN O
expression NN NN O
at NN NN O
a NN NN O
later NN NN O
stage NN NN O
. NN NN O
   
Reduction NN NN O
of NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
and NN NN O
signalling NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
thalassaemia NN NN O
or NN NN O
sickle NN NN O
cell NN NN O
anaemia NN NN O
upon NN NN O
treatment NN NN O
with NN NN O
desferrioxamine NN NN O
. NN NN O
   
Recent NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
the NN NN O
rate NN NN O
of NN NN O
progression NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
disease NN NN O
is NN NN O
significantly NN NN O
reduced NN NN O
in NN NN O
thalassaemia NN NN O
major NN NN O
patients NN NN O
upon NN NN O
treatment NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
desferrioxamine NN NN O
( NN NN O
DFX NN NN O
) NN NN O
. NN NN O
   
The NN NN O
authors NN NN O
have NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
in NN NN O
vitro NN NN O
exposure NN NN O
of NN NN O
mononuclear NN NN O
cells NN NN O
to NN NN O
DFX NN NN O
decreases NN NN O
the NN NN O
bioavailability NN NN O
of NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
which NN NN O
has NN NN O
a NN NN O
stimulatory NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
therefore NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
bioavailability NN NN O
from NN NN O
mononuclear NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
10 NN NN O
patients NN NN O
with NN NN O
thalassaemia NN NN O
or NN NN O
sickle NN NN O
cell NN NN O
anaemia NN NN O
given NN NN O
DFX NN NN O
as NN NN O
compared NN NN O
to NN NN O
10 NN NN O
untreated NN NN O
subjects NN NN O
has NN NN O
been NN NN O
evaluated NN NN O
. NN NN O
   
Evidence NN NN O
is NN NN O
presented NN NN O
showing NN NN O
that NN NN O
DFX NN NN O
treatment NN NN O
reduces NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
bioavailability NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
by NN NN O
inhibiting NN NN O
its NN NN O
steady NN NN O
state NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
and NN NN O
by NN NN O
enhancing NN NN O
its NN NN O
inactivation NN NN O
through NN NN O
binding NN NN O
to NN NN O
soluble NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
receptor NN NN I-Protein
type NN NN I-Protein
II NN NN I-Protein
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
DFX NN NN O
treatment NN NN O
limits NN NN O
the NN NN O
in NN NN O
vivo NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
both NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
signalling NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
005 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
bioavailability NN NN O
and NN NN O
signalling NN NN O
are NN NN O
impaired NN NN O
in NN NN O
patients NN NN O
upon NN NN O
DFX NN NN O
treatment NN NN O
. NN NN O
   
This NN NN O
mechanism NN NN O
may NN NN O
contribute NN NN O
to NN NN O
delayed NN NN O
progression NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
cyclooxygenase NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
4 NN NN O
- NN NN O
trifluoromethyl NN NN O
derivatives NN NN O
of NN NN O
salicylate NN NN O
, NN NN O
triflusal NN NN O
, NN NN O
and NN NN O
its NN NN O
deacetylated NN NN O
metabolite NN NN O
, NN NN O
2 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
trifluoromethylbenzoic NN NN O
acid NN NN O
. NN NN O
   
The NN NN O
therapeutic NN NN O
potential NN NN O
of NN NN O
drugs NN NN O
that NN NN O
block NN NN O
the NN NN O
induction NN NN O
of NN NN O
cyclooxygenase NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
has NN NN O
been NN NN O
emphasized NN NN O
. NN NN O
   
When NN NN O
two NN NN O
4 NN NN O
- NN NN O
trifluoromethyl NN NN O
salicylate NN NN O
derivatives NN NN O
[ NN NN O
2 NN NN O
- NN NN O
acetoxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
trifluoromethyl NN NN O
- NN NN O
benzoic NN NN O
acid NN NN O
( NN NN O
triflusal NN NN O
) NN NN O
and NN NN O
its NN NN O
deacetylated NN NN O
metabolite NN NN O
2 NN NN O
- NN NN O
hydroxy NN NN O
- NN NN O
4 NN NN O
- NN NN O
trifluoromethylbenzoic NN NN O
acid NN NN O
( NN NN O
HTB NN NN O
) NN NN O
] NN NN O
were NN NN O
compared NN NN O
with NN NN O
aspirin NN NN O
and NN NN O
sodium NN NN O
salicylate NN NN O
as NN NN O
cyclooxygenase NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
inhibitors NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
in NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
- NN NN O
activated NN NN O
human NN NN O
blood NN NN O
, NN NN O
triflusal NN NN O
, NN NN O
aspirin NN NN O
, NN NN O
and NN NN O
HTB NN NN O
, NN NN O
but NN NN O
not NN NN O
sodium NN NN O
salicylate NN NN O
, NN NN O
inhibited NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mediated NN NN O
prostaglandin NN NN O
E2 NN NN O
( NN NN O
PGE2 NN NN O
) NN NN O
production NN NN O
( NN NN O
IC50 NN NN O
= NN NN O
0 NN NN O
. NN NN O
16 NN NN O
, NN NN O
0 NN NN O
. NN NN O
18 NN NN O
, NN NN O
0 NN NN O
. NN NN O
39 NN NN O
, NN NN O
and NN NN O
> NN NN O
10 NN NN O
mM NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
triflusal NN NN O
and NN NN O
aspirin NN NN O
inhibited NN NN O
purified NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enzyme NN NN O
. NN NN O
   
To NN NN O
test NN NN O
this NN NN O
apparent NN NN O
discrepancy NN NN O
, NN NN O
we NN NN O
realized NN NN O
that NN NN O
HTB NN NN O
and NN NN O
triflusal NN NN O
( NN NN O
but NN NN O
neither NN NN O
aspirin NN NN O
nor NN NN O
salicylate NN NN O
) NN NN O
produced NN NN O
a NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
expression NN NN O
in NN NN O
peripheral NN NN O
human NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
was NN NN O
further NN NN O
confirmed NN NN O
in NN NN O
a NN NN O
rat NN NN O
air NN NN O
pouch NN NN O
model NN NN O
in NN NN O
vivo NN NN O
, NN NN O
in NN NN O
which NN NN O
both NN NN O
aspirin NN NN O
and NN NN O
triflusal NN NN O
inhibited NN NN O
PGE2 NN NN O
production NN NN O
( NN NN O
ID50 NN NN O
= NN NN O
18 NN NN O
. NN NN O
9 NN NN O
and NN NN O
11 NN NN O
. NN NN O
4 NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
p NN NN O
. NN NN O
o NN NN O
. NN NN O
, NN NN O
respectively NN NN O
) NN NN O
but NN NN O
only NN NN O
triflusal NN NN O
- NN NN O
treated NN NN O
animals NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
This NN NN O
different NN NN O
behavior NN NN O
may NN NN O
be NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
due NN NN O
to NN NN O
the NN NN O
ability NN NN O
of NN NN O
HTB NN NN O
and NN NN O
triflusal NN NN O
to NN NN O
block NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
to NN NN O
a NN NN O
higher NN NN O
extent NN NN O
than NN NN O
aspirin NN NN O
and NN NN O
sodium NN NN O
salicylate NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
inhibiting NN NN O
the NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
activity NN NN O
at NN NN O
therapeutic NN NN O
concentrations NN NN O
, NN NN O
triflusal NN NN O
is NN NN O
able NN NN O
to NN NN O
block NN NN O
through NN NN O
its NN NN O
metabolite NN NN O
HTB NN NN O
the NN NN O
expression NN NN O
of NN NN O
new NN NN O
enzyme NN NN O
, NN NN O
and NN NN O
hence NN NN O
the NN NN O
resumption NN NN O
of NN NN O
PGE2 NN NN O
synthesis NN NN O
. NN NN O
   
Triflusal NN NN O
and NN NN O
HTB NN NN O
may NN NN O
exert NN NN O
beneficial NN NN O
effects NN NN O
in NN NN O
processes NN NN O
in NN NN O
which NN NN O
de NN NN O
novo NN NN O
COX NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
is NN NN O
involved NN NN O
and NN NN O
, NN NN O
in NN NN O
a NN NN O
broader NN NN O
sense NN NN O
, NN NN O
in NN NN O
pathological NN NN O
situations NN NN O
in NN NN O
which NN NN O
genes NN NN O
under NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
control NN NN O
are NN NN O
up NN NN O
- NN NN O
regulated NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
According NN NN O
to NN NN O
current NN NN O
models NN NN O
the NN NN O
inhibitory NN NN O
capacity NN NN O
of NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
would NN NN O
be NN NN O
mediated NN NN O
through NN NN O
the NN NN O
retention NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
. NN NN O
   
However NN NN O
, NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
has NN NN O
also NN NN O
been NN NN O
detected NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
cell NN NN O
lines NN NN O
and NN NN O
when NN NN O
overexpressed NN NN O
by NN NN O
transient NN NN O
transfection NN NN O
. NN NN O
   
To NN NN O
gain NN NN O
better NN NN O
insight NN NN O
into NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
nuclear NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
in NN NN O
a NN NN O
physiological NN NN O
context NN NN O
we NN NN O
have NN NN O
analysed NN NN O
its NN NN O
presence NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
in NN NN O
PBL NN NN O
by NN NN O
different NN NN O
techniques NN NN O
: NN NN O
Western NN NN O
blot NN NN O
, NN NN O
indirect NN NN O
immunofluorescence NN NN O
and NN NN O
electron NN NN O
microscopy NN NN O
. NN NN O
   
Low NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
were NN NN O
detected NN NN O
in NN NN O
resting NN NN O
cells NN NN O
whereas NN NN O
a NN NN O
superinduction NN NN O
was NN NN O
obtained NN NN O
after NN NN O
PMA NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
pool NN NN O
of NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
showed NN NN O
a NN NN O
higher NN NN O
stability NN NN O
than NN NN O
cytosolic NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
and NN NN O
was NN NN O
partially NN NN O
independent NN NN O
of NN NN O
the NN NN O
resynthesis NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
nuclear NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
did NN NN O
not NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
and NN NN O
this NN NN O
phenomenon NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
the NN NN O
presence NN NN O
of NN NN O
IkappaBbeta NN NN B-Protein
at NN NN O
the NN NN O
nuclear NN NN O
level NN NN O
. NN NN O
   
Immunoprecipitation NN NN O
experiments NN NN O
failed NN NN O
to NN NN O
demonstrate NN NN O
an NN NN O
association NN NN O
between NN NN O
nuclear NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
resting NN NN O
and NN NN O
PMA NN NN O
- NN NN O
activated NN NN O
human NN NN O
PBL NN NN O
, NN NN O
I NN NN B-Protein
( NN NN I-Protein
kappa NN NN I-Protein
) NN NN I-Protein
B NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
is NN NN O
present NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
an NN NN O
apparently NN NN O
inactive NN NN O
form NN NN O
unable NN NN O
to NN NN O
disrupt NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
from NN NN O
DNA NN NN O
. NN NN O
   
PGG NN NN O
- NN NN O
glucan NN NN O
, NN NN O
a NN NN O
soluble NN NN O
beta NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
3 NN NN O
) NN NN O
- NN NN O
glucan NN NN O
, NN NN O
enhances NN NN O
the NN NN O
oxidative NN NN O
burst NN NN O
response NN NN O
, NN NN O
microbicidal NN NN O
activity NN NN O
, NN NN O
and NN NN O
activates NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
factor NN NN O
in NN NN O
human NN NN O
PMN NN NN O
: NN NN O
evidence NN NN O
for NN NN O
a NN NN O
glycosphingolipid NN NN O
beta NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
3 NN NN O
) NN NN O
- NN NN O
glucan NN NN O
receptor NN NN O
. NN NN O
   
PGG NN NN O
- NN NN O
Glucan NN NN O
, NN NN O
a NN NN O
soluble NN NN O
beta NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
6 NN NN O
) NN NN O
- NN NN O
branched NN NN O
beta NN NN O
- NN NN O
( NN NN O
1 NN NN O
, NN NN O
3 NN NN O
) NN NN O
- NN NN O
linked NN NN O
glucose NN NN O
homopolymer NN NN O
derived NN NN O
from NN NN O
the NN NN O
cell NN NN O
wall NN NN O
of NN NN O
the NN NN O
yeast NN NN O
Saccharomyces NN NN O
cerevisiae NN NN O
, NN NN O
is NN NN O
an NN NN O
immunomodulator NN NN O
which NN NN O
enhances NN NN O
leukocyte NN NN O
anti NN NN O
- NN NN O
infective NN NN O
activity NN NN O
and NN NN O
enhances NN NN O
myeloid NN NN O
and NN NN O
megakaryocyte NN NN O
progenitor NN NN O
proliferation NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
human NN NN O
whole NN NN O
blood NN NN O
with NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
significantly NN NN O
enhanced NN NN O
the NN NN O
oxidative NN NN O
burst NN NN O
response NN NN O
of NN NN O
subsequently NN NN O
isolated NN NN O
blood NN NN O
leukocytes NN NN O
to NN NN O
both NN NN O
soluble NN NN O
and NN NN O
particulate NN NN O
activators NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
and NN NN O
increased NN NN O
leukocyte NN NN O
microbicidal NN NN O
activity NN NN O
. NN NN O
   
No NN NN O
evidence NN NN O
for NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
was NN NN O
obtained NN NN O
under NN NN O
these NN NN O
conditions NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrated NN NN O
that NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
induced NN NN O
the NN NN O
activation NN NN O
of NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
like NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
purified NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
3H NN NN O
- NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
to NN NN O
human NN NN O
leukocyte NN NN O
membranes NN NN O
was NN NN O
specific NN NN O
, NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
, NN NN O
saturable NN NN O
, NN NN O
and NN NN O
high NN NN O
affinity NN NN O
( NN NN O
Kd NN NN O
approximately NN NN O
6 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
A NN NN O
monoclonal NN NN O
antibody NN NN O
specific NN NN O
to NN NN O
the NN NN O
glycosphingolipid NN NN O
lactosylceramide NN NN O
was NN NN O
able NN NN O
to NN NN O
inhibit NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
like NN NN O
factor NN NN O
by NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
, NN NN O
and NN NN O
ligand NN NN O
binding NN NN O
data NN NN O
, NN NN O
including NN NN O
polysaccharide NN NN O
specificity NN NN O
, NN NN O
suggested NN NN O
that NN NN O
the NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
binding NN NN O
moiety NN NN O
was NN NN O
lactosylceramide NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
PGG NN NN O
- NN NN O
Glucan NN NN O
enhances NN NN O
neutrophil NN NN O
anti NN NN O
- NN NN O
microbial NN NN O
functions NN NN O
and NN NN O
that NN NN O
interaction NN NN O
between NN NN O
this NN NN O
beta NN NN O
- NN NN O
glucan NN NN O
and NN NN O
human NN NN O
neutrophils NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
glycosphingolipid NN NN O
lactosylceramide NN NN O
present NN NN O
at NN NN O
the NN NN O
cell NN NN O
surface NN NN O
. NN NN O
   
[ NN NN O
Corticoids NN NN O
and NN NN O
allergy NN NN O
] NN NN O
   
Inflammation NN NN O
is NN NN O
constantly NN NN O
observed NN NN O
in NN NN O
allergic NN NN O
reactions NN NN O
. NN NN O
   
Corticosteroids NN NN O
are NN NN O
most NN NN O
effective NN NN O
in NN NN O
preventing NN NN O
the NN NN O
late NN NN O
phase NN NN O
of NN NN O
allergic NN NN O
reaction NN NN O
. NN NN O
   
The NN NN O
action NN NN O
of NN NN O
glucocorticosteroids NN NN O
is NN NN O
mediated NN NN O
through NN NN O
glucocorticoid NN NN O
receptors NN NN O
present NN NN O
in NN NN O
the NN NN O
cellular NN NN O
cytoplasm NN NN O
. NN NN O
   
When NN NN O
activated NN NN O
, NN NN O
glucocorticoid NN NN O
receptors NN NN O
form NN NN O
a NN NN O
dimer NN NN O
and NN NN O
bind NN NN O
to NN NN O
DNA NN NN O
after NN NN O
migration NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Interaction NN NN O
to NN NN O
DNA NN NN O
induces NN NN O
changes NN NN O
in NN NN O
the NN NN O
transcription NN NN O
rate NN NN O
, NN NN O
leading NN NN O
to NN NN O
either NN NN O
gene NN NN O
induction NN NN O
or NN NN O
gene NN NN O
repression NN NN O
. NN NN O
   
Glucocorticoid NN NN O
receptors NN NN O
are NN NN O
also NN NN O
able NN NN O
to NN NN O
interact NN NN O
with NN NN O
transcriptional NN NN O
factors NN NN O
such NN NN O
as NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
) NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Through NN NN O
these NN NN O
actions NN NN O
glucocorticosteroids NN NN O
are NN NN O
susceptible NN NN O
to NN NN O
modify NN NN O
functions NN NN O
of NN NN O
cells NN NN O
involved NN NN O
in NN NN O
the NN NN O
allergic NN NN O
inflammatory NN NN O
response NN NN O
. NN NN O
   
They NN NN O
are NN NN O
in NN NN O
particular NN NN O
able NN NN O
to NN NN O
inhibit NN NN O
most NN NN O
of NN NN O
the NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
functions NN NN O
of NN NN O
the NN NN O
eosinophils NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
Mycobacterium NN NN O
tuberculosis NN NN O
- NN NN O
induced NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
. NN NN O
   
Soluble NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
) NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
increased NN NN O
in NN NN O
the NN NN O
sera NN NN O
of NN NN O
patients NN NN O
with NN NN O
advanced NN NN O
tuberculosis NN NN O
, NN NN O
and NN NN O
levels NN NN O
decline NN NN O
after NN NN O
therapy NN NN O
in NN NN O
accordance NN NN O
with NN NN O
improvement NN NN O
of NN NN O
radiologic NN NN O
findings NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
in NN NN O
bronchoalveolar NN NN O
lavage NN NN O
( NN NN O
BAL NN NN O
) NN NN O
cells NN NN O
in NN NN O
active NN NN O
pulmonary NN NN O
tuberculosis NN NN O
, NN NN O
and NN NN O
evaluated NN NN O
the NN NN O
mechanism NN NN O
Mycobacterium NN NN O
tuberculosis NN NN O
induces NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
using NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
mononuclear NN NN O
phagocyte NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
We NN NN O
found NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
expression NN NN O
to NN NN O
be NN NN O
increased NN NN O
in NN NN O
BAL NN NN O
cells NN NN O
from NN NN O
involved NN NN O
sites NN NN O
of NN NN O
active NN NN O
pulmonary NN NN O
tuberculosis NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
alpha NN NN O
- NN NN O
chain NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
on NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
( NN NN O
PBM NN NN O
) NN NN O
was NN NN O
induced NN NN O
by NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
evaluation NN NN O
. NN NN O
   
Northern NN NN O
analysis NN NN O
demonstrated NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
gene NN NN O
expression NN NN O
after NN NN O
stimulation NN NN O
with NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
which NN NN O
was NN NN O
further NN NN O
induced NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
promoter NN NN O
containing NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
site NN NN O
was NN NN O
transcriptionally NN NN O
induced NN NN O
by NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
and NN NN O
this NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
could NN NN O
confer NN NN O
inducibility NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
herpes NN NN O
thymidine NN NN O
kinase NN NN O
( NN NN O
TK NN NN O
) NN NN O
promoter NN NN O
by NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
revealed NN NN O
specific NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
protein NN NN O
to NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
upon NN NN O
induction NN NN O
with NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
. NN NN O
   
Using NN NN O
antibodies NN NN O
against NN NN O
the NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
subunits NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
EMSAs NN NN O
, NN NN O
the NN NN O
involvement NN NN O
of NN NN O
both NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
proteins NN NN O
was NN NN O
further NN NN O
demonstrated NN NN O
. NN NN O
   
Functional NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Ralpha NN NN I-Protein
on NN NN O
mononuclear NN NN O
phagocytes NN NN O
in NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
infection NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
immunomodulatory NN NN O
role NN NN O
in NN NN O
the NN NN O
host NN NN O
response NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
megakaryocytic NN NN O
glycoprotein NN NN B-Protein
IX NN NN I-Protein
promoter NN NN O
by NN NN O
the NN NN O
oncogenic NN NN O
Ets NN NN O
transcription NN NN O
factor NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Glycoprotein NN NN B-Protein
( NN NN I-Protein
GP NN NN I-Protein
) NN NN I-Protein
IX NN NN I-Protein
is NN NN O
a NN NN O
subunit NN NN O
of NN NN O
the NN NN O
von NN NN O
Willebrand NN NN O
receptor NN NN O
, NN NN O
GPIb NN NN O
- NN NN O
V NN NN O
- NN NN O
IX NN NN O
, NN NN O
which NN NN O
mediates NN NN O
adhesion NN NN O
of NN NN O
platelets NN NN O
to NN NN O
the NN NN O
subendothelium NN NN O
of NN NN O
damaged NN NN O
blood NN NN O
vessels NN NN O
. NN NN O
   
Previous NN NN O
characterization NN NN O
of NN NN O
the NN NN O
GPIX NN NN B-Protein
promoter NN NN O
identified NN NN O
a NN NN O
functional NN NN O
Ets NN NN O
site NN NN O
that NN NN O
, NN NN O
when NN NN O
disrupted NN NN O
, NN NN O
reduced NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
Ets NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
that NN NN O
regulated NN NN O
GPIX NN NN B-Protein
promoter NN NN O
expression NN NN O
was NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
transient NN NN O
cotransfection NN NN O
of NN NN O
several NN NN O
GPIX NN NN B-Protein
promoter NN NN O
/ NN NN O
reporter NN NN O
constructs NN NN O
into NN NN O
293T NN NN O
kidney NN NN O
fibroblasts NN NN O
with NN NN O
a NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
vector NN NN O
shows NN NN O
that NN NN O
the NN NN O
oncogenic NN NN O
protein NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
can NN NN O
transactivate NN NN O
the NN NN O
GPIX NN NN B-Protein
promoter NN NN O
when NN NN O
an NN NN O
intact NN NN O
GPIX NN NN B-Protein
Ets NN NN O
site NN NN O
is NN NN O
present NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
of NN NN O
the NN NN O
GPIX NN NN B-Protein
Ets NN NN O
site NN NN O
was NN NN O
identified NN NN O
in NN NN O
antibody NN NN O
supershift NN NN O
experiments NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
derived NN NN O
from NN NN O
hematopoietic NN NN O
human NN NN O
erythroleukemia NN NN O
cells NN NN O
. NN NN O
   
Comparative NN NN O
studies NN NN O
showed NN NN O
that NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
also NN NN O
able NN NN O
to NN NN O
transactivate NN NN O
the NN NN O
GPIbalpha NN NN B-Protein
and NN NN O
, NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
the NN NN O
GPIIb NN NN B-Protein
promoter NN NN O
. NN NN O
   
Immunoblot NN NN O
analysis NN NN O
identified NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
in NN NN O
lysates NN NN O
derived NN NN O
from NN NN O
platelets NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
expression NN NN O
of NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
identified NN NN O
immunohistochemically NN NN O
in NN NN O
megakaryocytes NN NN O
derived NN NN O
from NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
cells NN NN O
treated NN NN O
with NN NN O
the NN NN O
megakaryocyte NN NN O
differentiation NN NN O
and NN NN O
proliferation NN NN O
factor NN NN O
, NN NN O
thrombopoietin NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
likely NN NN O
to NN NN O
regulate NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
genes NN NN O
during NN NN O
megakaryocytopoiesis NN NN O
. NN NN O
   
Studies NN NN O
into NN NN O
the NN NN O
effect NN NN O
of NN NN O
tyrosine NN NN O
phosphatase NN NN O
inhibitor NN NN O
phenylarsine NN NN O
oxide NN NN O
on NN NN O
NFkappaB NN NN O
activation NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
during NN NN O
aging NN NN O
: NN NN O
evidence NN NN O
for NN NN O
altered NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
and NN NN O
degradation NN NN O
. NN NN O
   
Nuclear NN NN O
Factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
is NN NN O
a NN NN O
critical NN NN O
regulator NN NN O
of NN NN O
several NN NN O
genes NN NN O
involved NN NN O
in NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
leads NN NN O
to NN NN O
the NN NN O
translocation NN NN O
of NN NN O
the NN NN O
active NN NN O
p65 NN NN O
- NN NN O
50 NN NN O
heterodimer NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
albeit NN NN O
at NN NN O
a NN NN O
lower NN NN O
level NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
pretreatment NN NN O
with NN NN O
PAO NN NN O
results NN NN O
in NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
NFkappaB NN NN O
induction NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
treated NN NN O
T NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
PAO NN NN O
- NN NN O
sensitive NN NN O
phosphatase NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
NFkappaB NN NN O
via NN NN O
this NN NN O
pathway NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
demonstrates NN NN O
that NN NN O
aging NN NN O
does NN NN O
not NN NN O
influence NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
this NN NN O
phosphatase NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
DMP NN NN O
prior NN NN O
to NN NN O
treatment NN NN O
with NN NN O
PAO NN NN O
and NN NN O
TNF NN NN O
abolishes NN NN O
the NN NN O
inhibition NN NN O
induced NN NN O
by NN NN O
PAO NN NN O
, NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
both NN NN O
young NN NN O
and NN NN O
old NN NN O
donors NN NN O
, NN NN O
alike NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
failure NN NN O
to NN NN O
degrade NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
cytosols NN NN O
of NN NN O
TNF NN NN O
- NN NN O
treated NN NN O
T NN NN O
cells NN NN O
pretreated NN NN O
with NN NN O
PAO NN NN O
is NN NN O
due NN NN O
to NN NN O
its NN NN O
interference NN NN O
with NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
not NN NN O
due NN NN O
to NN NN O
its NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
proteasomal NN NN O
degradation NN NN O
. NN NN O
   
These NN NN O
data NN NN O
collectively NN NN O
suggest NN NN O
that NN NN O
PAO NN NN O
interferes NN NN O
with NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
the NN NN O
regulated NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
induced NN NN O
by NN NN O
TNF NN NN O
, NN NN O
without NN NN O
affecting NN NN O
the NN NN O
chymotryptic NN NN O
activity NN NN O
of NN NN O
the NN NN O
proteasome NN NN O
, NN NN O
independent NN NN O
of NN NN O
age NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
transcription NN NN O
factor NN NN O
regulating NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
: NN NN O
molecular NN NN O
cloning NN NN O
, NN NN O
sequencing NN NN O
, NN NN O
characterization NN NN O
, NN NN O
and NN NN O
chromosomal NN NN O
assignment NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
is NN NN O
a NN NN O
potent NN NN O
stimulator NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
, NN NN O
causing NN NN O
secretion NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
other NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
deleterious NN NN O
effects NN NN O
to NN NN O
the NN NN O
host NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
it NN NN O
has NN NN O
been NN NN O
postulated NN NN O
that NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
must NN NN O
be NN NN O
tightly NN NN O
regulated NN NN O
. NN NN O
   
The NN NN O
nature NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
that NN NN O
control NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
humans NN NN O
remains NN NN O
obscure NN NN O
, NN NN O
although NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
has NN NN O
been NN NN O
suggested NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
studies NN NN O
pertaining NN NN O
to NN NN O
macrophage NN NN O
response NN NN O
to NN NN O
LPS NN NN O
identified NN NN O
a NN NN O
novel NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
located NN NN O
from NN NN O
- NN NN O
550 NN NN O
to NN NN O
- NN NN O
487 NN NN O
in NN NN O
the NN NN O
human NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
that NN NN O
contains NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
but NN NN O
lacks NN NN O
any NN NN O
known NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
this NN NN O
DNA NN NN O
fragment NN NN O
to NN NN O
isolate NN NN O
and NN NN O
purify NN NN O
a NN NN O
60 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
binding NN NN O
to NN NN O
this NN NN O
fragment NN NN O
and NN NN O
obtained NN NN O
its NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
sequence NN NN O
, NN NN O
which NN NN O
was NN NN O
used NN NN O
to NN NN O
design NN NN O
degenerate NN NN O
probes NN NN O
to NN NN O
screen NN NN O
a NN NN O
cDNA NN NN O
library NN NN O
from NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
cDNA NN NN O
clone NN NN O
( NN NN O
1 NN NN O
. NN NN O
8 NN NN O
kb NN NN O
) NN NN O
was NN NN O
isolated NN NN O
and NN NN O
fully NN NN O
sequenced NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
this NN NN O
cDNA NN NN O
clone NN NN O
revealed NN NN O
that NN NN O
its NN NN O
induction NN NN O
was NN NN O
dependent NN NN O
on NN NN O
LPS NN NN O
activation NN NN O
of NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
; NN NN O
hence NN NN O
, NN NN O
the NN NN O
name NN NN O
LPS NN NN B-Protein
- NN NN I-Protein
induced NN NN I-Protein
TNF NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
factor NN NN I-Protein
( NN NN O
LITAF NN NN B-Protein
) NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
LITAF NN NN B-Protein
mRNA NN NN O
expression NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
a NN NN O
reduction NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
transcripts NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
high NN NN O
level NN NN O
of NN NN O
expression NN NN O
of NN NN O
LITAF NN NN B-Protein
mRNA NN NN O
was NN NN O
observed NN NN O
predominantly NN NN O
in NN NN O
the NN NN O
placenta NN NN O
, NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
, NN NN O
lymph NN NN O
nodes NN NN O
, NN NN O
and NN NN O
the NN NN O
spleen NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
chromosomal NN NN O
localization NN NN O
using NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
revealed NN NN O
that NN NN O
LITAF NN NN B-Protein
mapped NN NN O
to NN NN O
chromosome NN NN O
16p12 NN NN O
- NN NN O
16p13 NN NN O
. NN NN O
3 NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
LITAF NN NN B-Protein
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
and NN NN O
proposes NN NN O
a NN NN O
new NN NN O
mechanism NN NN O
to NN NN O
control NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Engagement NN NN O
of NN NN O
natural NN NN O
cytotoxicity NN NN O
programs NN NN O
regulates NN NN O
AP NN NN O
- NN NN O
1 NN NN O
expression NN NN O
in NN NN O
the NN NN O
NKL NN NN O
human NN NN O
NK NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
NK NN NN O
cell NN NN O
cytotoxicity NN NN O
is NN NN O
a NN NN O
fast NN NN O
and NN NN O
efficient NN NN O
mechanism NN NN O
of NN NN O
target NN NN O
cell NN NN O
lysis NN NN O
. NN NN O
   
Using NN NN O
transcription NN NN O
analysis NN NN O
, NN NN O
such NN NN O
as NN NN O
multiplex NN NN O
messenger NN NN O
assays NN NN O
, NN NN O
we NN NN O
show NN NN O
here NN NN O
that NN NN O
natural NN NN O
cytotoxicity NN NN O
exerted NN NN O
by NN NN O
the NN NN O
human NN NN O
NKL NN NN O
cell NN NN O
line NN NN O
correlates NN NN O
with NN NN O
mRNA NN NN O
accumulation NN NN O
of NN NN O
very NN NN O
early NN NN O
activator NN NN O
protein NN NN O
( NN NN O
AP NN NN O
) NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
genes NN NN O
such NN NN O
as NN NN O
JunB NN NN B-Protein
, NN NN O
FosB NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
of NN NN O
Jun NN NN O
- NN NN O
Fos NN NN O
heterodimers NN NN O
were NN NN O
observed NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
during NN NN O
the NN NN O
course NN NN O
of NN NN O
natural NN NN O
cytotoxicity NN NN O
. NN NN O
   
Interaction NN NN O
between NN NN O
immunoglobulin NN NN B-Protein
- NN NN I-Protein
like NN NN I-Protein
transcript NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
/ NN NN O
leukocyte NN NN B-Protein
Ig NN NN I-Protein
- NN NN I-Protein
like NN NN I-Protein
receptor NN NN I-Protein
1 NN NN I-Protein
on NN NN O
NKL NN NN O
cells NN NN O
and NN NN O
HLA NN NN B-Protein
- NN NN I-Protein
B27 NN NN I-Protein
on NN NN O
target NN NN O
cells NN NN O
leads NN NN O
to NN NN O
an NN NN O
impairment NN NN O
of NN NN O
NKL NN NN O
natural NN NN O
cytotoxicity NN NN O
, NN NN O
which NN NN O
correlates NN NN O
with NN NN O
an NN NN O
absence NN NN O
of NN NN O
JunB NN NN B-Protein
, NN NN O
FosB NN NN B-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
transcription NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN O
absence NN NN O
of NN NN O
their NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
thus NN NN O
indicate NN NN O
that NN NN O
, NN NN O
despite NN NN O
the NN NN O
rapidity NN NN O
of NN NN O
NK NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
lysis NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
is NN NN O
activated NN NN O
during NN NN O
the NN NN O
early NN NN O
stage NN NN O
of NN NN O
NK NN NN O
cell NN NN O
cytolytic NN NN O
programs NN NN O
and NN NN O
that NN NN O
engagement NN NN O
of NN NN O
NK NN NN O
cell NN NN O
inhibitory NN NN O
receptors NN NN O
for NN NN O
MHC NN NN O
class NN NN O
I NN NN O
molecules NN NN O
impairs NN NN O
the NN NN O
very NN NN O
early NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Human NN NN O
cytomegalovirus NN NN O
binding NN NN O
to NN NN O
human NN NN O
monocytes NN NN O
induces NN NN O
immunoregulatory NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
To NN NN O
continue NN NN O
our NN NN O
investigation NN NN O
of NN NN O
the NN NN O
cellular NN NN O
events NN NN O
that NN NN O
occur NN NN O
following NN NN O
human NN NN O
CMV NN NN O
( NN NN O
HCMV NN NN O
) NN NN O
infection NN NN O
, NN NN O
we NN NN O
focused NN NN O
on NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cellular NN NN O
activation NN NN O
following NN NN O
viral NN NN O
binding NN NN O
to NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
First NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
viral NN NN O
binding NN NN O
induced NN NN O
a NN NN O
number NN NN O
of NN NN O
immunoregulatory NN NN O
genes NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
A20 NN NN B-Protein
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
p105 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
, NN NN O
and NN NN O
IkappaBalpha NN NN B-Protein
) NN NN O
in NN NN O
unactivated NN NN O
monocytes NN NN O
and NN NN O
that NN NN O
neutralizing NN NN O
Abs NN NN O
to NN NN O
the NN NN O
major NN NN O
HCMV NN NN O
glycoproteins NN NN O
, NN NN O
gB NN NN O
( NN NN O
UL55 NN NN O
) NN NN O
and NN NN O
gH NN NN O
( NN NN O
UL75 NN NN O
) NN NN O
, NN NN O
inhibited NN NN O
the NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
Next NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
these NN NN O
viral NN NN O
ligands NN NN O
directly NN NN O
up NN NN O
- NN NN O
regulated NN NN O
monocyte NN NN O
gene NN NN O
expression NN NN O
upon NN NN O
their NN NN O
binding NN NN O
to NN NN O
their NN NN O
appropriate NN NN O
cellular NN NN O
receptors NN NN O
. NN NN O
   
We NN NN O
then NN NN O
investigated NN NN O
if NN NN O
HCMV NN NN O
binding NN NN O
also NN NN O
resulted NN NN O
in NN NN O
the NN NN O
translation NN NN O
and NN NN O
secretion NN NN O
of NN NN O
cytokines NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
showed NN NN O
that NN NN O
HCMV NN NN O
binding NN NN O
to NN NN O
monocytes NN NN O
resulted NN NN O
in NN NN O
the NN NN O
production NN NN O
and NN NN O
release NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
protein NN NN O
. NN NN O
   
Because NN NN O
these NN NN O
induced NN NN O
gene NN NN O
products NN NN O
have NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
sites NN NN O
in NN NN O
their NN NN O
promoter NN NN O
regions NN NN O
, NN NN O
we NN NN O
next NN NN O
examined NN NN O
whether NN NN O
there NN NN O
was NN NN O
an NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
levels NN NN O
. NN NN O
   
These NN NN O
experiments NN NN O
showed NN NN O
that NN NN O
, NN NN O
in NN NN O
fact NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
was NN NN O
translocated NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
following NN NN O
viral NN NN O
binding NN NN O
or NN NN O
purified NN NN O
viral NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
Changes NN NN O
in NN NN O
IkappaBalpha NN NN B-Protein
levels NN NN O
correlated NN NN O
with NN NN O
the NN NN O
changes NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
translocation NN NN O
. NN NN O
   
Lastly NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
p38 NN NN O
kinase NN NN O
activity NN NN O
played NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
production NN NN O
and NN NN O
that NN NN O
it NN NN O
was NN NN O
rapidly NN NN O
up NN NN O
- NN NN O
regulated NN NN O
following NN NN O
infection NN NN O
. NN NN O
   
These NN NN O
results NN NN O
support NN NN O
our NN NN O
hypothesis NN NN O
that NN NN O
HCMV NN NN O
initiates NN NN O
a NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
that NN NN O
leads NN NN O
to NN NN O
monocyte NN NN O
activation NN NN O
and NN NN O
pinpoints NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
whereby NN NN O
HCMV NN NN O
infection NN NN O
of NN NN O
monocytes NN NN O
can NN NN O
result NN NN O
in NN NN O
profound NN NN O
pathogenesis NN NN O
, NN NN O
especially NN NN O
in NN NN O
chronic NN NN O
inflammatory NN NN O
- NN NN O
type NN NN O
conditions NN NN O
. NN NN O
   
Signal NN NN O
transduction NN NN O
pathways NN NN O
activated NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
following NN NN O
infection NN NN O
with NN NN O
Chlamydia NN NN O
pneumoniae NN NN O
. NN NN O
   
Chlamydia NN NN O
pneumoniae NN NN O
is NN NN O
an NN NN O
important NN NN O
respiratory NN NN O
pathogen NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
its NN NN O
presence NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
in NN NN O
atherosclerotic NN NN O
lesions NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
characterized NN NN O
C NN NN O
. NN NN O
pneumoniae NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
demonstrated NN NN O
an NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
endothelial NN NN O
adhesion NN NN O
molecules NN NN O
followed NN NN O
by NN NN O
subsequent NN NN O
rolling NN NN O
, NN NN O
adhesion NN NN O
, NN NN O
and NN NN O
transmigration NN NN O
of NN NN O
leukocytes NN NN O
( NN NN O
monocytes NN NN O
, NN NN O
granulocytes NN NN O
) NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
were NN NN O
blocked NN NN O
by NN NN O
mAbs NN NN O
against NN NN O
endothelial NN NN O
and NN NN O
/ NN NN O
or NN NN O
leukocyte NN NN O
adhesion NN NN O
molecules NN NN O
( NN NN O
beta1 NN NN B-Protein
and NN NN O
beta2 NN NN B-Protein
integrins NN NN I-Protein
) NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
activation NN NN O
of NN NN O
different NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
in NN NN O
C NN NN O
. NN NN O
pneumoniae NN NN O
- NN NN O
infected NN NN O
endothelial NN NN O
cells NN NN O
was NN NN O
shown NN NN O
: NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
phosphorylated NN NN O
p42 NN NN B-Protein
/ NN NN O
p44 NN NN B-Protein
mitogen NN NN I-Protein
- NN NN I-Protein
activated NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
/ NN NN O
translocation NN NN O
occurred NN NN O
within NN NN O
10 NN NN O
- NN NN O
15 NN NN O
min NN NN O
. NN NN O
   
Increased NN NN O
mRNA NN NN O
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
were NN NN O
noted NN NN O
within NN NN O
hours NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
C NN NN O
. NN NN O
pneumoniae NN NN O
triggers NN NN O
a NN NN O
cascade NN NN O
of NN NN O
events NN NN O
that NN NN O
could NN NN O
lead NN NN O
to NN NN O
endothelial NN NN O
activation NN NN O
, NN NN O
inflammation NN NN O
, NN NN O
and NN NN O
thrombosis NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
may NN NN O
result NN NN O
in NN NN O
or NN NN O
may NN NN O
promote NN NN O
atherosclerosis NN NN O
. NN NN O
   
Extracellular NN NN B-Protein
- NN NN I-Protein
regulated NN NN I-Protein
kinase NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
2 NN NN B-Protein
, NN NN O
Jun NN NN B-Protein
N NN NN I-Protein
- NN NN I-Protein
terminal NN NN I-Protein
kinase NN NN I-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
are NN NN O
involved NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
investigated NN NN O
the NN NN O
possible NN NN O
involvement NN NN O
of NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
family NN NN O
members NN NN O
extracellular NN NN B-Protein
- NN NN I-Protein
regulated NN NN I-Protein
kinase NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
2 NN NN B-Protein
( NN NN O
ERK1 NN NN B-Protein
/ NN NN O
2 NN NN B-Protein
) NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
N NN NN I-Protein
- NN NN I-Protein
terminal NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
JNK NN NN B-Protein
) NN NN O
in NN NN O
mediating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
in NN NN O
particular NN NN O
their NN NN O
role NN NN O
in NN NN O
enhancing NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
. NN NN O
   
Freshly NN NN O
isolated NN NN O
monocytes NN NN O
treated NN NN O
with NN NN O
the NN NN O
protein NN NN O
phosphatase NN NN O
inhibitor NN NN O
okadaic NN NN O
acid NN NN O
secreted NN NN O
high NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
, NN NN O
which NN NN O
coincided NN NN O
with NN NN O
enhanced NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
the NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
and NN NN O
JNK NN NN B-Protein
proteins NN NN O
. NN NN O
   
The NN NN O
ERK NN NN O
pathway NN NN O
- NN NN O
specific NN NN O
inhibitor NN NN O
PD98059 NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
secretion NN NN O
from NN NN O
monocytes NN NN O
. NN NN O
   
Transient NN NN O
overexpression NN NN O
of NN NN O
inactive NN NN O
mutants NN NN O
of NN NN O
either NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
JNK1 NN NN B-Protein
showed NN NN O
that NN NN O
both NN NN O
pathways NN NN O
were NN NN O
involved NN NN O
in NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
By NN NN O
using NN NN O
PD98059 NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
Raf1 NN NN B-Protein
/ NN NN O
MEK1 NN NN B-Protein
/ NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
pathway NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
but NN NN O
, NN NN O
rather NN NN O
, NN NN O
acted NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
it NN NN O
was NN NN O
shown NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
both NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
promoter NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
its NN NN O
own NN NN O
, NN NN O
was NN NN O
dependent NN NN O
on NN NN O
both NN NN O
serine NN NN O
kinase NN NN O
activity NN NN O
and NN NN O
interaction NN NN O
with NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
expression NN NN O
is NN NN O
at NN NN O
least NN NN O
partly NN NN O
mediated NN NN O
through NN NN O
the NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
and NN NN O
JNK NN NN O
pathway NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcriptional NN NN O
capacity NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
JNK NN NN B-Protein
pathway NN NN O
may NN NN O
regulate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
transcription NN NN O
through NN NN O
its NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
. NN NN O
   
Differential NN NN O
induction NN NN O
of NN NN O
interferon NN NN B-Protein
( NN NN I-Protein
IFN NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
inducible NN NN I-Protein
protein NN NN I-Protein
10 NN NN I-Protein
following NN NN O
differentiation NN NN O
of NN NN O
a NN NN O
monocyte NN NN O
, NN NN O
macrophage NN NN O
cell NN NN O
lineage NN NN O
is NN NN O
related NN NN O
to NN NN O
the NN NN O
changes NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
bound NN NN O
to NN NN O
IFN NN NN O
stimulus NN NN O
response NN NN O
element NN NN O
and NN NN O
kappaB NN NN O
sites NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
chemokine NN NN O
gene NN NN O
expression NN NN O
following NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
a NN NN O
monocyte NN NN O
, NN NN O
macrophage NN NN O
cell NN NN O
lineage NN NN O
. NN NN O
   
The NN NN O
human NN NN O
monoblastic NN NN O
cell NN NN O
line NN NN O
, NN NN O
U937 NN NN O
was NN NN O
differentiated NN NN O
to NN NN O
macrophages NN NN O
by NN NN O
the NN NN O
treatment NN NN O
with NN NN O
either NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
, NN NN O
or NN NN O
vitamin NN NN O
D3 NN NN O
( NN NN O
VitD3 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
gene NN NN O
expression NN NN O
of NN NN O
interferon NN NN B-Protein
( NN NN I-Protein
IFN NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
inducible NN NN I-Protein
protein NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
( NN NN O
a NN NN O
CXC NN NN O
chemokine NN NN O
) NN NN O
was NN NN O
markedly NN NN O
augmented NN NN O
by NN NN O
the NN NN O
IFNgamma NN NN B-Protein
treatment NN NN O
in NN NN O
PMA NN NN O
- NN NN O
or NN NN O
RA NN NN O
- NN NN O
differentiated NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
but NN NN O
only NN NN O
marginally NN NN O
in NN NN O
undifferentiated NN NN O
or NN NN O
VitD3 NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
another NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
of NN NN O
monocyte NN NN B-Protein
chemotactic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
a NN NN O
CC NN NN O
chemokine NN NN O
) NN NN O
and NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
factor NN NN O
( NN NN O
FcRFgamma NN NN O
) NN NN O
bound NN NN O
to NN NN O
the NN NN O
gamma NN NN O
response NN NN O
region NN NN O
were NN NN O
similarly NN NN O
or NN NN O
less NN NN O
abundantly NN NN O
induced NN NN O
by NN NN O
IFNgamma NN NN B-Protein
treatment NN NN O
in NN NN O
PMA NN NN O
- NN NN O
or NN NN O
RA NN NN O
- NN NN O
differentiated NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
that NN NN O
increased NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
mRNA NN NN O
induction NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
the NN NN O
augmented NN NN O
ability NN NN O
of NN NN O
the NN NN O
cells NN NN O
to NN NN O
respond NN NN O
to NN NN O
the NN NN O
presence NN NN O
of NN NN O
IFNgamma NN NN B-Protein
. NN NN O
   
Increased NN NN O
expression NN NN O
of NN NN O
IFNgamma NN NN B-Protein
- NN NN O
induced NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
mRNA NN NN O
following NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
was NN NN O
mediated NN NN O
largely NN NN O
by NN NN O
augmented NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
was NN NN O
related NN NN O
to NN NN O
differentiation NN NN O
- NN NN O
dependent NN NN O
changes NN NN O
of NN NN O
the NN NN O
proteins NN NN O
bound NN NN O
to NN NN O
IFN NN NN O
stimulus NN NN O
response NN NN O
element NN NN O
( NN NN O
ISRE NN NN O
) NN NN O
and NN NN O
kB NN NN O
sites NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
nuclear NN NN O
proteins NN NN O
may NN NN O
determine NN NN O
the NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
mRNA NN NN O
inducibility NN NN O
by NN NN O
IFNgamma NN NN B-Protein
. NN NN O
   
Fludarabine NN NN O
- NN NN O
induced NN NN O
immunosuppression NN NN O
is NN NN O
associated NN NN O
with NN NN O
inhibition NN NN O
of NN NN O
STAT1 NN NN B-Protein
signaling NN NN O
. NN NN O
   
Fludarabine NN NN O
is NN NN O
a NN NN O
nucleoside NN NN O
analog NN NN O
used NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
hematologic NN NN O
malignancies NN NN O
that NN NN O
can NN NN O
induce NN NN O
severe NN NN O
and NN NN O
prolonged NN NN O
immunosuppression NN NN O
. NN NN O
   
Although NN NN O
it NN NN O
can NN NN O
be NN NN O
incorporated NN NN O
into NN NN O
the NN NN O
DNA NN NN O
of NN NN O
dividing NN NN O
cells NN NN O
, NN NN O
fludarabine NN NN O
is NN NN O
also NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
cells NN NN O
with NN NN O
a NN NN O
low NN NN O
growth NN NN O
fraction NN NN O
, NN NN O
thus NN NN O
it NN NN O
must NN NN O
have NN NN O
other NN NN O
mechanisms NN NN O
of NN NN O
action NN NN O
. NN NN O
   
STAT1 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
activated NN NN O
in NN NN O
response NN NN O
to NN NN O
many NN NN O
lymphocyte NN NN O
- NN NN O
activating NN NN O
cytokines NN NN O
including NN NN O
the NN NN O
interferons NN NN O
, NN NN O
is NN NN O
essential NN NN O
for NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immunity NN NN O
, NN NN O
as NN NN O
the NN NN O
absence NN NN O
of NN NN O
this NN NN O
protein NN NN O
is NN NN O
associated NN NN O
with NN NN O
prominent NN NN O
defects NN NN O
in NN NN O
the NN NN O
ability NN NN O
to NN NN O
control NN NN O
viral NN NN O
infections NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
fludarabine NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
immunosuppressant NN NN O
cyclosporine NN NN O
A NN NN O
, NN NN O
inhibits NN NN O
the NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
STAT1 NN NN B-Protein
- NN NN O
dependent NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
normal NN NN O
resting NN NN O
or NN NN O
activated NN NN O
lymphocytes NN NN O
. NN NN O
   
Fludarabine NN NN O
caused NN NN O
a NN NN O
specific NN NN O
depletion NN NN O
of NN NN O
STAT1 NN NN B-Protein
protein NN NN O
( NN NN O
and NN NN O
mRNA NN NN O
) NN NN O
but NN NN O
not NN NN O
of NN NN O
other NN NN O
STATs NN NN O
. NN NN O
   
This NN NN O
loss NN NN O
of NN NN O
STAT1 NN NN B-Protein
was NN NN O
also NN NN O
seen NN NN O
in NN NN O
cells NN NN O
from NN NN O
patients NN NN O
treated NN NN O
with NN NN O
fludarabine NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Brief NN NN O
exposure NN NN O
to NN NN O
fludarabine NN NN O
led NN NN O
to NN NN O
a NN NN O
sustained NN NN O
loss NN NN O
of NN NN O
STAT1 NN NN B-Protein
, NN NN O
analogous NN NN O
to NN NN O
the NN NN O
prolonged NN NN O
period NN NN O
of NN NN O
immunosuppression NN NN O
induced NN NN O
by NN NN O
exposure NN NN O
to NN NN O
the NN NN O
drug NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
STAT1 NN NN B-Protein
may NN NN O
be NN NN O
a NN NN O
useful NN NN O
target NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
new NN NN O
immunosuppressive NN NN O
and NN NN O
antineoplastic NN NN O
agents NN NN O
. NN NN O
   
Suppressive NN NN O
effects NN NN O
of NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
on NN NN O
human NN NN O
endothelial NN NN O
cell NN NN O
activation NN NN O
and NN NN O
induction NN NN O
of NN NN O
heat NN NN O
shock NN NN O
proteins NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Studies NN NN O
from NN NN O
our NN NN O
laboratory NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
earliest NN NN O
stages NN NN O
of NN NN O
atherosclerosis NN NN O
may NN NN O
be NN NN O
mediated NN NN O
by NN NN O
an NN NN O
autoimmune NN NN O
reaction NN NN O
against NN NN O
heat NN NN B-Protein
shock NN NN I-Protein
protein NN NN I-Protein
60 NN NN I-Protein
( NN NN O
Hsp60 NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
interactions NN NN O
of NN NN O
Hsp60 NN NN B-Protein
- NN NN O
specific NN NN O
T NN NN O
cells NN NN O
with NN NN O
arterial NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
EC NN NN O
) NN NN O
require NN NN O
expression NN NN O
of NN NN O
both NN NN O
Hsp60 NN NN B-Protein
and NN NN O
certain NN NN O
adhesion NN NN O
molecules NN NN O
shown NN NN O
to NN NN O
be NN NN O
induced NN NN O
simultaneously NN NN O
in NN NN O
EC NN NN O
by NN NN O
mechanical NN NN O
and NN NN O
other NN NN O
types NN NN O
of NN NN O
stress NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
it NN NN O
was NN NN O
shown NN NN O
that NN NN O
suppression NN NN O
of NN NN O
T NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
responses NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CyA NN NN O
) NN NN O
enhanced NN NN O
atherosclerotic NN NN O
lesion NN NN O
formation NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
aspirin NN NN O
was NN NN O
found NN NN O
to NN NN O
lower NN NN O
the NN NN O
risk NN NN O
of NN NN O
myocardial NN NN O
infarction NN NN O
in NN NN O
men NN NN O
. NN NN O
   
These NN NN O
conflicting NN NN O
observations NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
different NN NN O
effects NN NN O
of NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
on NN NN O
adhesion NN NN O
molecule NN NN O
and NN NN O
Hsp NN NN O
expression NN NN O
in NN NN O
EC NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
MATERIAL NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
effects NN NN O
of NN NN O
CyA NN NN O
, NN NN O
aspirin NN NN O
, NN NN O
and NN NN O
indomethacin NN NN O
on NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
using NN NN O
a NN NN O
proliferation NN NN O
assay NN NN O
. NN NN O
   
To NN NN O
explore NN NN O
the NN NN O
expression NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
, NN NN O
monocyte NN NN B-Protein
chemoattractant NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
Hsp60 NN NN B-Protein
in NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
, NN NN O
Northern NN NN O
blot NN NN O
analyses NN NN O
were NN NN O
used NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
activation NN NN O
status NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
and NN NN O
heat NN NN B-Protein
shock NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
HSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
With NN NN O
the NN NN O
exception NN NN O
of NN NN O
indomethacin NN NN O
, NN NN O
the NN NN O
used NN NN O
immunosuppressive NN NN O
and NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
agents NN NN O
significantly NN NN O
inhibited NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
response NN NN O
to NN NN O
influenza NN NN O
virus NN NN O
antigen NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
CyA NN NN O
and NN NN O
indomethacin NN NN O
did NN NN O
not NN NN O
suppress NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
on NN NN O
HUVECs NN NN O
, NN NN O
whereas NN NN O
aspirin NN NN O
had NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
correlated NN NN O
with NN NN O
the NN NN O
modulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
EC NN NN O
. NN NN O
   
All NN NN O
agents NN NN O
tested NN NN O
induced NN NN O
expression NN NN O
of NN NN O
Hsp60 NN NN B-Protein
6 NN NN O
hr NN NN O
after NN NN O
application NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
aspirin NN NN O
and NN NN O
indomethacin NN NN O
, NN NN O
but NN NN O
not NN NN O
CyA NN NN O
, NN NN O
induced NN NN O
Hsp70 NN NN B-Protein
expression NN NN O
in NN NN O
HUVECs NN NN O
that NN NN O
correlated NN NN O
with NN NN O
induction NN NN O
of NN NN O
HSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Our NN NN O
results NN NN O
show NN NN O
that NN NN O
the NN NN O
tested NN NN O
agents NN NN O
( NN NN O
except NN NN O
indomethacin NN NN O
) NN NN O
are NN NN O
inhibitors NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
response NN NN O
, NN NN O
as NN NN O
expected NN NN O
, NN NN O
that NN NN O
aspirin NN NN O
is NN NN O
an NN NN O
effective NN NN O
suppressor NN NN O
of NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
, NN NN O
and NN NN O
that NN NN O
all NN NN O
three NN NN O
agents NN NN O
can NN NN O
induce NN NN O
Hsp60 NN NN B-Protein
in NN NN O
HUVECs NN NN O
. NN NN O
   
These NN NN O
data NN NN O
provide NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
notion NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
part NN NN O
of NN NN O
the NN NN O
anti NN NN O
- NN NN O
atherogenic NN NN O
effect NN NN O
of NN NN O
aspirin NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
the NN NN O
prevention NN NN O
of NN NN O
the NN NN O
adhesion NN NN O
of NN NN O
sensitized NN NN O
T NN NN O
cells NN NN O
to NN NN O
stressed NN NN O
EC NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
that NN NN O
part NN NN O
of NN NN O
the NN NN O
atherosclerosis NN NN O
- NN NN O
promoting NN NN O
effect NN NN O
of NN NN O
CyA NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
its NN NN O
potential NN NN O
as NN NN O
an NN NN O
inducer NN NN O
of NN NN O
Hsp60 NN NN B-Protein
expression NN NN O
and NN NN O
its NN NN O
inability NN NN O
to NN NN O
down NN NN O
- NN NN O
regulate NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
on NN NN O
EC NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
that NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
by NN NN O
aspirin NN NN O
may NN NN O
result NN NN O
in NN NN O
decreased NN NN O
recruitment NN NN O
of NN NN O
monocytes NN NN O
into NN NN O
the NN NN O
arterial NN NN O
intima NN NN O
beneath NN NN O
stressed NN NN O
EC NN NN O
. NN NN O
   
Amelioration NN NN O
of NN NN O
rat NN NN O
cerulein NN NN O
pancreatitis NN NN O
by NN NN O
guamerin NN NN O
- NN NN O
derived NN NN O
peptide NN NN O
, NN NN O
a NN NN O
novel NN NN O
elastase NN NN O
inhibitor NN NN O
. NN NN O
   
Increased NN NN O
activity NN NN O
of NN NN O
various NN NN O
proteases NN NN O
is NN NN O
observed NN NN O
in NN NN O
both NN NN O
human NN NN O
and NN NN O
experimental NN NN O
pancreatitis NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
information NN NN O
on NN NN O
the NN NN O
effects NN NN O
of NN NN O
specific NN NN O
protease NN NN O
inhibitors NN NN O
on NN NN O
the NN NN O
disease NN NN O
is NN NN O
limited NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
show NN NN O
that NN NN O
a NN NN O
novel NN NN O
elastase NN NN O
inhibitor NN NN O
, NN NN O
guamerin NN NN O
- NN NN O
derived NN NN O
synthetic NN NN O
peptide NN NN O
( NN NN O
GDSP NN NN O
) NN NN O
, NN NN O
improves NN NN O
the NN NN O
parameters NN NN O
of NN NN O
cerulein NN NN O
- NN NN O
induced NN NN O
acute NN NN O
pancreatitis NN NN O
in NN NN O
the NN NN O
rat NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
GDSP NN NN O
on NN NN O
pancreatic NN NN O
weight NN NN O
, NN NN O
serum NN NN O
amylase NN NN O
and NN NN O
lipase NN NN O
, NN NN O
morphologic NN NN O
changes NN NN O
in NN NN O
the NN NN O
pancreas NN NN O
, NN NN O
neutrophil NN NN O
infiltration NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
KB NN NN O
( NN NN O
NF NN NN O
- NN NN O
KB NN NN O
) NN NN O
activation NN NN O
were NN NN O
measured NN NN O
in NN NN O
rats NN NN O
infused NN NN O
with NN NN O
supramaximal NN NN O
dose NN NN O
of NN NN O
cerulein NN NN O
( NN NN O
5 NN NN O
( NN NN O
g NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
h NN NN O
) NN NN O
for NN NN O
6 NN NN O
h NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
GDSP NN NN O
were NN NN O
also NN NN O
measured NN NN O
on NN NN O
superoxide NN NN O
formation NN NN O
by NN NN O
activated NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
GDSP NN NN O
were NN NN O
compared NN NN O
with NN NN O
those NN NN O
of NN NN O
another NN NN O
elastase NN NN O
inhibitor NN NN O
, NN NN O
elastatinal NN NN O
. NN NN O
   
GDSP NN NN O
significantly NN NN O
inhibited NN NN O
edema NN NN O
formation NN NN O
, NN NN O
neutrophil NN NN O
infiltration NN NN O
, NN NN O
acinar NN NN O
cell NN NN O
damage NN NN O
, NN NN O
and NN NN O
plasma NN NN O
lipase NN NN O
and NN NN O
amylase NN NN O
increases NN NN O
caused NN NN O
by NN NN O
cerulein NN NN O
. NN NN O
   
GDSP NN NN O
also NN NN O
completely NN NN O
inhibited NN NN O
superoxide NN NN O
formation NN NN O
in NN NN O
the NN NN O
human NN NN O
neutrophils NN NN O
stimulated NN NN O
by NN NN O
N NN NN O
- NN NN O
formyl NN NN O
- NN NN O
methionine NN NN O
- NN NN O
leucine NN NN O
- NN NN O
phenyl NN NN O
- NN NN O
alanine NN NN O
( NN NN O
fMLP NN NN O
) NN NN O
or NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
. NN NN O
   
Elastatinal NN NN O
had NN NN O
some NN NN O
of NN NN O
the NN NN O
same NN NN O
effects NN NN O
as NN NN O
GDSP NN NN O
but NN NN O
was NN NN O
less NN NN O
potent NN NN O
and NN NN O
effective NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
a NN NN O
beneficial NN NN O
effect NN NN O
of NN NN O
GDSP NN NN O
, NN NN O
a NN NN O
novel NN NN O
specific NN NN O
elastase NN NN O
inhibitor NN NN O
, NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
rat NN NN O
cerulein NN NN O
pancreatitis NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
T NN NN O
cell NN NN O
signaling NN NN O
by NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
- NN NN O
targeted NN NN O
hematopoietic NN NN B-Protein
tyrosine NN NN I-Protein
phosphatase NN NN I-Protein
( NN NN O
HePTP NN NN B-Protein
) NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
to NN NN O
produce NN NN O
cytokines NN NN O
is NN NN O
regulated NN NN O
by NN NN O
the NN NN O
counterbalance NN NN O
of NN NN O
protein NN NN O
- NN NN O
tyrosine NN NN O
kinases NN NN O
and NN NN O
protein NN NN O
- NN NN O
tyrosine NN NN O
phosphatases NN NN O
, NN NN O
many NN NN O
of NN NN O
which NN NN O
have NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
substrate NN NN O
specificity NN NN O
because NN NN O
of NN NN O
physical NN NN O
association NN NN O
with NN NN O
their NN NN O
targets NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
hematopoietic NN NN B-Protein
protein NN NN I-Protein
- NN NN I-Protein
tyrosine NN NN I-Protein
phosphatase NN NN I-Protein
( NN NN O
HePTP NN NN B-Protein
) NN NN O
results NN NN O
in NN NN O
suppression NN NN O
of NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
as NN NN O
measured NN NN O
by NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
binding NN NN O
to NN NN O
the NN NN O
5 NN NN O
' NN NN O
promoter NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Efforts NN NN O
to NN NN O
pinpoint NN NN O
the NN NN O
exact NN NN O
site NN NN O
of NN NN O
action NN NN O
and NN NN O
specificity NN NN O
of NN NN O
HePTP NN NN B-Protein
in NN NN O
the NN NN O
signaling NN NN O
cascade NN NN O
revealed NN NN O
that NN NN O
HePTP NN NN B-Protein
acts NN NN O
directly NN NN O
on NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
( NN NN O
MAP NN NN O
) NN NN O
kinases NN NN O
Erk1 NN NN B-Protein
and NN NN O
2 NN NN B-Protein
and NN NN O
consequently NN NN O
reduces NN NN O
the NN NN O
magnitude NN NN O
and NN NN O
duration NN NN O
of NN NN O
their NN NN O
catalytic NN NN O
activation NN NN O
in NN NN O
intact NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
HePTP NN NN B-Protein
had NN NN O
no NN NN O
effects NN NN O
on NN NN O
N NN NN O
- NN NN O
terminal NN NN O
c NN NN O
- NN NN O
Jun NN NN O
kinase NN NN O
or NN NN O
on NN NN O
events NN NN O
upstream NN NN O
of NN NN O
the NN NN O
MAP NN NN O
kinases NN NN O
. NN NN O
   
The NN NN O
specificity NN NN O
of NN NN O
HePTP NN NN B-Protein
correlated NN NN O
with NN NN O
its NN NN O
physical NN NN O
association NN NN O
through NN NN O
its NN NN O
noncatalytic NN NN O
N NN NN O
terminus NN NN O
with NN NN O
Erk NN NN O
and NN NN O
another NN NN O
MAP NN NN O
kinase NN NN O
, NN NN O
p38 NN NN O
, NN NN O
but NN NN O
not NN NN O
Jnk NN NN O
or NN NN O
other NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
HePTP NN NN B-Protein
plays NN NN O
a NN NN O
negative NN NN O
role NN NN O
in NN NN O
antigen NN NN O
receptor NN NN O
signaling NN NN O
by NN NN O
specifically NN NN O
regulating NN NN O
MAP NN NN O
kinases NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
at NN NN O
early NN NN O
time NN NN O
points NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
before NN NN O
the NN NN O
activation NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
nuclear NN NN O
dual NN NN O
- NN NN O
specific NN NN O
MAP NN NN O
kinase NN NN O
phosphatases NN NN O
. NN NN O
   
Angiotensin NN NN O
II NN NN O
activates NN NN O
the NN NN O
proinflammatory NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
renin NN NN O
- NN NN O
angiotensin NN NN O
system NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
atherosclerosis NN NN O
. NN NN O
   
A NN NN O
common NN NN O
feature NN NN O
of NN NN O
all NN NN O
stages NN NN O
of NN NN O
atherosclerosis NN NN O
is NN NN O
inflammation NN NN O
of NN NN O
the NN NN O
vessel NN NN O
wall NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
participates NN NN O
in NN NN O
most NN NN O
signaling NN NN O
pathways NN NN O
involved NN NN O
in NN NN O
inflammation NN NN O
. NN NN O
   
This NN NN O
study NN NN O
therefore NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
angiotensin NN NN O
( NN NN O
ANG NN NN O
) NN NN O
II NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
a NN NN O
major NN NN O
cellular NN NN O
component NN NN O
of NN NN O
human NN NN O
atheroma NN NN O
, NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
ANG NN NN O
II NN NN O
, NN NN O
like NN NN O
TNFalpha NN NN B-Protein
, NN NN O
caused NN NN O
rapid NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
human NN NN O
mononuclear NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
by NN NN O
Ficoll NN NN O
density NN NN O
gradient NN NN O
. NN NN O
   
This NN NN O
ANG NN NN O
II NN NN O
effect NN NN O
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
angiotensin NN NN B-Protein
AT1 NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN O
losartan NN NN O
. NN NN O
   
Specificity NN NN O
of NN NN O
ANG NN NN O
II NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
was NN NN O
ascertained NN NN O
by NN NN O
supershift NN NN O
and NN NN O
competition NN NN O
experiments NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
ANG NN NN O
II NN NN O
stimulated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
the NN NN O
same NN NN O
preparation NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
the NN NN O
data NN NN O
demonstrate NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
vasoactive NN NN O
peptide NN NN O
ANG NN NN O
II NN NN O
to NN NN O
activate NN NN O
inflammatory NN NN O
pathways NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
SHP2 NN NN B-Protein
- NN NN I-Protein
interacting NN NN I-Protein
transmembrane NN NN I-Protein
adaptor NN NN I-Protein
protein NN NN I-Protein
( NN NN O
SIT NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
novel NN NN O
disulfide NN NN O
- NN NN O
linked NN NN O
dimer NN NN O
regulating NN NN O
human NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
T NN NN O
lymphocytes NN NN O
express NN NN O
several NN NN O
low NN NN O
molecular NN NN O
weight NN NN O
transmembrane NN NN O
adaptor NN NN O
proteins NN NN O
that NN NN O
recruit NN NN O
src NN NN O
homology NN NN O
( NN NN O
SH NN NN O
) NN NN O
2 NN NN O
domain NN NN O
- NN NN O
containing NN NN O
intracellular NN NN O
molecules NN NN O
to NN NN O
the NN NN O
cell NN NN O
membrane NN NN O
via NN NN O
tyrosine NN NN O
- NN NN O
based NN NN O
signaling NN NN O
motifs NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
here NN NN O
a NN NN O
novel NN NN O
molecule NN NN O
of NN NN O
this NN NN O
group NN NN O
termed NN NN O
SIT NN NN B-Protein
( NN NN O
SHP2 NN NN B-Protein
interacting NN NN I-Protein
transmembrane NN NN I-Protein
adaptor NN NN I-Protein
protein NN NN I-Protein
) NN NN O
. NN NN O
   
SIT NN NN B-Protein
is NN NN O
a NN NN O
disulfide NN NN O
- NN NN O
linked NN NN O
homodimeric NN NN O
glycoprotein NN NN O
that NN NN O
is NN NN O
expressed NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O
   
After NN NN O
tyrosine NN NN O
phosphorylation NN NN O
by NN NN O
src NN NN B-Protein
and NN NN O
possibly NN NN O
syk NN NN B-Protein
protein NN NN O
tyrosine NN NN O
kinases NN NN O
SIT NN NN B-Protein
recruits NN NN O
the NN NN O
SH2 NN NN O
domain NN NN O
- NN NN O
containing NN NN O
tyrosine NN NN O
phosphatase NN NN O
SHP2 NN NN B-Protein
via NN NN O
an NN NN O
immunoreceptor NN NN O
tyrosine NN NN O
- NN NN O
based NN NN O
inhibition NN NN O
motif NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
SIT NN NN B-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
downmodulates NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
- NN NN O
and NN NN O
phytohemagglutinin NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
by NN NN O
interfering NN NN O
with NN NN O
signaling NN NN O
processes NN NN O
that NN NN O
are NN NN O
probably NN NN O
located NN NN O
upstream NN NN O
of NN NN O
activation NN NN O
of NN NN O
phospholipase NN NN O
C NN NN O
. NN NN O
   
However NN NN O
, NN NN O
binding NN NN O
of NN NN O
SHP2 NN NN B-Protein
to NN NN O
SIT NN NN B-Protein
is NN NN O
not NN NN O
required NN NN O
for NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
induction NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
SIT NN NN B-Protein
not NN NN O
only NN NN O
regulates NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activity NN NN O
but NN NN O
also NN NN O
controls NN NN O
NF NN NN O
- NN NN O
AT NN NN O
unrelated NN NN O
pathways NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
involving NN NN O
SHP2 NN NN B-Protein
. NN NN O
   
GrpL NN NN B-Protein
, NN NN O
a NN NN O
Grb2 NN NN B-Protein
- NN NN O
related NN NN O
adaptor NN NN O
protein NN NN O
, NN NN O
interacts NN NN O
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
to NN NN O
regulate NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Propagation NN NN O
of NN NN O
signals NN NN O
from NN NN O
the NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
involves NN NN O
a NN NN O
number NN NN O
of NN NN O
adaptor NN NN O
molecules NN NN O
. NN NN O
   
SH2 NN NN B-Protein
domain NN NN I-Protein
- NN NN I-Protein
containing NN NN I-Protein
protein NN NN I-Protein
76 NN NN I-Protein
( NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
) NN NN O
interacts NN NN O
with NN NN O
the NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
factor NN NN O
Vav NN NN B-Protein
to NN NN O
activate NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
, NN NN O
and NN NN O
its NN NN O
expression NN NN O
is NN NN O
required NN NN O
for NN NN O
normal NN NN O
T NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
a NN NN O
novel NN NN O
Grb2 NN NN B-Protein
- NN NN O
like NN NN O
adaptor NN NN O
molecule NN NN O
designated NN NN O
as NN NN O
Grb2 NN NN B-Protein
- NN NN I-Protein
related NN NN I-Protein
protein NN NN I-Protein
of NN NN I-Protein
the NN NN I-Protein
lymphoid NN NN I-Protein
system NN NN I-Protein
( NN NN O
GrpL NN NN B-Protein
) NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
GrpL NN NN B-Protein
is NN NN O
restricted NN NN O
to NN NN O
hematopoietic NN NN O
tissues NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
distinguished NN NN O
from NN NN O
Grb2 NN NN B-Protein
by NN NN O
having NN NN O
a NN NN O
proline NN NN O
- NN NN O
rich NN NN O
region NN NN O
. NN NN O
   
GrpL NN NN B-Protein
can NN NN O
be NN NN O
coimmunoprecipitated NN NN O
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
but NN NN O
not NN NN O
with NN NN O
Sos1 NN NN B-Protein
or NN NN O
Sos2 NN NN B-Protein
from NN NN O
Jurkat NN NN O
cell NN NN O
lysates NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
Grb2 NN NN B-Protein
can NN NN O
be NN NN O
coimmunoprecipitated NN NN O
with NN NN O
Sos1 NN NN B-Protein
and NN NN O
Sos2 NN NN B-Protein
but NN NN O
not NN NN O
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
LAT NN NN B-Protein
/ NN NN O
pp36 NN NN B-Protein
/ NN NN I-Protein
38 NN NN I-Protein
in NN NN O
detergent NN NN O
lysates NN NN O
prepared NN NN O
from NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
associated NN NN O
with NN NN O
Grb2 NN NN B-Protein
but NN NN O
not NN NN O
GrpL NN NN B-Protein
. NN NN O
   
These NN NN O
data NN NN O
reveal NN NN O
the NN NN O
presence NN NN O
of NN NN O
distinct NN NN O
complexes NN NN O
involving NN NN O
GrpL NN NN B-Protein
and NN NN O
Grb2 NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
functional NN NN O
role NN NN O
of NN NN O
the NN NN O
GrpL NN NN B-Protein
- NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
complex NN NN O
is NN NN O
suggested NN NN O
by NN NN O
the NN NN O
ability NN NN O
of NN NN O
GrpL NN NN B-Protein
to NN NN O
act NN NN O
alone NN NN O
or NN NN O
in NN NN O
concert NN NN O
with NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
to NN NN O
augment NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Unexpected NN NN O
and NN NN O
coordinated NN NN O
expression NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
megakaryocytic NN NN O
genes NN NN O
in NN NN O
four NN NN O
Epo NN NN B-Protein
- NN NN O
dependent NN NN O
cell NN NN O
lines NN NN O
established NN NN O
from NN NN O
transgenic NN NN O
mice NN NN O
displaying NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
a NN NN O
thermosensitive NN NN O
SV40 NN NN O
T NN NN O
antigen NN NN O
. NN NN O
   
Most NN NN O
erythroleukemic NN NN O
cell NN NN O
lines NN NN O
established NN NN O
in NN NN O
vitro NN NN O
coexpress NN NN O
erythrocytic NN NN O
and NN NN O
megakaryocytic NN NN O
markers NN NN O
that NN NN O
often NN NN O
are NN NN O
associated NN NN O
with NN NN O
expression NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
/ NN NN O
or NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factors NN NN O
known NN NN O
as NN NN O
transactivators NN NN O
of NN NN O
megakaryocyte NN NN O
- NN NN O
specific NN NN O
promoters NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
possibility NN NN O
of NN NN O
establishing NN NN O
new NN NN O
cell NN NN O
lines NN NN O
keeping NN NN O
strictly NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
properties NN NN O
in NN NN O
vitro NN NN O
through NN NN O
the NN NN O
targeted NN NN O
and NN NN O
conditional NN NN O
immortalization NN NN O
of NN NN O
erythrocytic NN NN O
progenitors NN NN O
. NN NN O
   
For NN NN O
that NN NN O
purpose NN NN O
, NN NN O
we NN NN O
established NN NN O
several NN NN O
lines NN NN O
of NN NN O
transgenic NN NN O
mice NN NN O
displaying NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
a NN NN O
thermosensitive NN NN O
SV40 NN NN O
T NN NN O
antigen NN NN O
. NN NN O
   
As NN NN O
expected NN NN O
, NN NN O
these NN NN O
transgenic NN NN O
mice NN NN O
developed NN NN O
splenomegaly NN NN O
due NN NN O
to NN NN O
the NN NN O
massive NN NN O
amplification NN NN O
of NN NN O
Ter NN NN O
119 NN NN O
positive NN NN O
erythroid NN NN O
nucleated NN NN O
cells NN NN O
expressing NN NN O
T NN NN O
antigen NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
drastic NN NN O
effect NN NN O
in NN NN O
vivo NN NN O
, NN NN O
the NN NN O
in NN NN O
vitro NN NN O
immortalization NN NN O
of NN NN O
erythropoietin NN NN B-Protein
- NN NN O
dependent NN NN O
erythroid NN NN O
progenitors NN NN O
unexpectedly NN NN O
occurred NN NN O
at NN NN O
low NN NN O
frequency NN NN O
, NN NN O
and NN NN O
all NN NN O
four NN NN O
cell NN NN O
lines NN NN O
established NN NN O
expressed NN NN O
both NN NN O
erythrocytic NN NN O
( NN NN O
globins NN NN O
) NN NN O
and NN NN O
megakaryocytic NN NN O
markers NN NN O
( NN NN O
glycoprotein NN NN B-Protein
IIb NN NN I-Protein
, NN NN O
platelet NN NN B-Protein
factor NN NN I-Protein
4 NN NN I-Protein
) NN NN O
as NN NN O
well NN NN O
as NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcripts NN NN O
at NN NN O
permissive NN NN O
temperature NN NN O
. NN NN O
   
Switching NN NN O
the NN NN O
cells NN NN O
to NN NN O
the NN NN O
nonpermissive NN NN O
temperature NN NN O
led NN NN O
to NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
globin NN NN O
gene NN NN O
expression NN NN O
and NN NN O
concomitant NN NN O
decrease NN NN O
in NN NN O
expression NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
megakaryocytic NN NN O
genes NN NN O
in NN NN O
an NN NN O
erythropoietin NN NN B-Protein
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
already NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
Ter NN NN O
119 NN NN O
positive NN NN O
cell NN NN O
population NN NN O
of NN NN O
transgenic NN NN O
mice NN NN O
spleen NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
However NN NN O
, NN NN O
like NN NN O
normal NN NN O
Ter NN NN O
119 NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
these NN NN O
Ter NN NN O
119 NN NN O
positive NN NN O
cells NN NN O
from NN NN O
transgenic NN NN O
mice NN NN O
still NN NN O
expressed NN NN O
high NN NN O
levels NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
and NN NN O
very NN NN O
low NN NN O
or NN NN O
undetectable NN NN O
glycoprotein NN NN B-Protein
IIb NN NN I-Protein
and NN NN O
platelet NN NN B-Protein
factor NN NN I-Protein
4 NN NN I-Protein
megakaryocytic NN NN O
transcripts NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
unexpected NN NN O
expression NN NN O
of NN NN O
megakaryocytic NN NN O
genes NN NN O
is NN NN O
a NN NN O
specific NN NN O
property NN NN O
of NN NN O
immortalized NN NN O
cells NN NN O
that NN NN O
cannot NN NN O
be NN NN O
explained NN NN O
only NN NN O
by NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
/ NN NN O
or NN NN O
Fli NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
Induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
are NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
dependent NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
independent NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
important NN NN O
mediator NN NN O
of NN NN O
septic NN NN O
shock NN NN O
. NN NN O
   
Endotoxin NN NN O
( NN NN O
LPS NN NN O
) NN NN O
signal NN NN O
transduction NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
leads NN NN O
to NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
implicated NN NN O
activation NN NN O
of NN NN O
both NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
and NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
( NN NN O
PTK NN NN O
) NN NN O
in NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
either NN NN O
PKC NN NN O
or NN NN O
PTK NN NN O
would NN NN O
decrease NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
MATERIALS NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
Human NN NN O
monocytes NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
PMA NN NN O
( NN NN O
50 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
alone NN NN O
or NN NN O
LPS NN NN O
( NN NN O
100 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
with NN NN O
and NN NN O
without NN NN O
a NN NN O
nonspecific NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
protein NN NN O
kinase NN NN O
inhibitor NN NN O
staurosporine NN NN O
( NN NN O
Stauro NN NN O
) NN NN O
, NN NN O
a NN NN O
specific NN NN O
pan NN NN O
- NN NN O
PKC NN NN O
inhibitor NN NN O
bisindolylmaleimide NN NN O
( NN NN O
Bis NN NN O
) NN NN O
, NN NN O
or NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
PTK NN NN O
genistein NN NN O
( NN NN O
Gen NN NN O
) NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
culture NN NN O
supernatants NN NN O
was NN NN O
measured NN NN O
by NN NN O
an NN NN O
ELISA NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
LPS NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Nonspecific NN NN O
protein NN NN O
kinase NN NN O
inhibition NN NN O
inhibited NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
, NN NN O
while NN NN O
specific NN NN O
PKC NN NN O
inhibition NN NN O
with NN NN O
Bis NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
or NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
. NN NN O
   
PTK NN NN O
inhibition NN NN O
with NN NN O
Gen NN NN O
attenuated NN NN O
both NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Direct NN NN O
activation NN NN O
of NN NN O
PKC NN NN O
with NN NN O
PMA NN NN O
induced NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
are NN NN O
independent NN NN O
of NN NN O
PKC NN NN O
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
our NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
PTK NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
thus NN NN O
could NN NN O
be NN NN O
a NN NN O
potential NN NN O
therapeutic NN NN O
target NN NN O
in NN NN O
inflammatory NN NN O
states NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Cellular NN NN O
disposition NN NN O
of NN NN O
sulphamethoxazole NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
: NN NN O
implications NN NN O
for NN NN O
hypersensitivity NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Bioactivation NN NN O
of NN NN O
sulphamethoxazole NN NN O
( NN NN O
SMX NN NN O
) NN NN O
to NN NN O
chemically NN NN O
- NN NN O
reactive NN NN O
metabolites NN NN O
and NN NN O
subsequent NN NN O
protein NN NN O
conjugation NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
SMX NN NN O
hypersensitivity NN NN O
. NN NN O
   
We NN NN O
have NN NN O
therefore NN NN O
examined NN NN O
the NN NN O
cellular NN NN O
metabolism NN NN O
, NN NN O
disposition NN NN O
and NN NN O
conjugation NN NN O
of NN NN O
SMX NN NN O
and NN NN O
its NN NN O
metabolites NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Flow NN NN O
cytometry NN NN O
revealed NN NN O
binding NN NN O
of NN NN O
N NN NN O
- NN NN O
hydroxy NN NN O
( NN NN O
SMX NN NN O
- NN NN O
NHOH NN NN O
) NN NN O
and NN NN O
nitroso NN NN O
( NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
) NN NN O
metabolites NN NN O
of NN NN O
SMX NN NN O
, NN NN O
but NN NN O
not NN NN O
of NN NN O
SMX NN NN O
itself NN NN O
, NN NN O
to NN NN O
the NN NN O
surface NN NN O
of NN NN O
viable NN NN O
white NN NN O
blood NN NN O
cells NN NN O
. NN NN O
   
Cellular NN NN O
haptenation NN NN O
by NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
was NN NN O
reduced NN NN O
by NN NN O
exogenous NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
SMX NN NN O
- NN NN O
NHOH NN NN O
and NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
were NN NN O
rapidly NN NN O
reduced NN NN O
back NN NN O
to NN NN O
the NN NN O
parent NN NN O
compound NN NN O
by NN NN O
cysteine NN NN O
( NN NN O
CYS NN NN O
) NN NN O
, NN NN O
GSH NN NN O
, NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
and NN NN O
plasma NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
is NN NN O
an NN NN O
important NN NN O
and NN NN O
ubiquitous NN NN O
bioinactivation NN NN O
mechanism NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Fluorescence NN NN O
HPLC NN NN O
showed NN NN O
that NN NN O
SMX NN NN O
- NN NN O
NHOH NN NN O
and NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
depleted NN NN O
CYS NN NN O
and NN NN O
GSH NN NN O
in NN NN O
buffer NN NN O
, NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
in NN NN O
cells NN NN O
and NN NN O
plasma NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
Neutrophil NN NN O
apoptosis NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
neutrophil NN NN O
function NN NN O
were NN NN O
induced NN NN O
at NN NN O
lower NN NN O
concentrations NN NN O
of NN NN O
SMX NN NN O
- NN NN O
NHOH NN NN O
and NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
than NN NN O
those NN NN O
inducing NN NN O
loss NN NN O
of NN NN O
membrane NN NN O
viability NN NN O
, NN NN O
with NN NN O
SMX NN NN O
having NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Lymphocytes NN NN O
were NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
direct NN NN O
cytotoxic NN NN O
effects NN NN O
of NN NN O
SMX NN NN O
- NN NN O
NO NN NN O
than NN NN O
neutrophils NN NN O
. NN NN O
   
6 NN NN O
. NN NN O
   
Partitioning NN NN O
of NN NN O
SMX NN NN O
- NN NN O
NHOH NN NN O
into NN NN O
red NN NN O
blood NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
lower NN NN O
than NN NN O
with NN NN O
the NN NN O
hydroxylamine NN NN O
of NN NN O
dapsone NN NN O
. NN NN O
   
7 NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
balance NN NN O
between NN NN O
oxidation NN NN O
of NN NN O
SMX NN NN O
to NN NN O
its NN NN O
toxic NN NN O
metabolites NN NN O
and NN NN O
their NN NN O
reduction NN NN O
is NN NN O
an NN NN O
important NN NN O
protective NN NN O
cellular NN NN O
mechanism NN NN O
. NN NN O
   
If NN NN O
an NN NN O
imbalance NN NN O
exists NN NN O
, NN NN O
haptenation NN NN O
of NN NN O
the NN NN O
toxic NN NN O
metabolites NN NN O
to NN NN O
bodily NN NN O
proteins NN NN O
including NN NN O
the NN NN O
surface NN NN O
of NN NN O
viable NN NN O
cells NN NN O
can NN NN O
occur NN NN O
, NN NN O
and NN NN O
may NN NN O
result NN NN O
in NN NN O
drug NN NN O
hypersensitivity NN NN O
. NN NN O
   
Tcf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
transcription NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
: NN NN O
differential NN NN O
role NN NN O
for NN NN O
glycogen NN NN B-Protein
synthase NN NN I-Protein
kinase NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
fibroblasts NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
is NN NN O
the NN NN O
vertebrate NN NN O
homolog NN NN O
of NN NN O
the NN NN O
Drosophila NN NN O
segment NN NN O
polarity NN NN O
gene NN NN O
Armadillo NN NN O
and NN NN O
plays NN NN O
roles NN NN O
in NN NN O
both NN NN O
cell NN NN O
- NN NN O
cell NN NN O
adhesion NN NN O
and NN NN O
transduction NN NN O
of NN NN O
the NN NN O
Wnt NN NN O
signaling NN NN O
cascade NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
members NN NN O
of NN NN O
the NN NN O
Lef NN NN O
/ NN NN O
Tcf NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
have NN NN O
been NN NN O
identified NN NN O
as NN NN O
protein NN NN O
partners NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
, NN NN O
explaining NN NN O
how NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
alters NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
Tcf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
also NN NN O
becomes NN NN O
transcriptionally NN NN O
active NN NN O
through NN NN O
interaction NN NN O
with NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
Wnt NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
is NN NN O
operational NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
as NN NN O
well NN NN O
. NN NN O
   
However NN NN O
, NN NN O
although NN NN O
Wnt NN NN O
signals NN NN O
are NN NN O
known NN NN O
to NN NN O
inhibit NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
negative NN NN O
regulatory NN NN O
protein NN NN O
kinase NN NN O
glycogen NN NN B-Protein
synthase NN NN I-Protein
kinase NN NN I-Protein
- NN NN I-Protein
3beta NN NN I-Protein
( NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
) NN NN O
, NN NN O
resulting NN NN O
in NN NN O
increased NN NN O
levels NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
, NN NN O
we NN NN O
find NN NN O
no NN NN O
evidence NN NN O
for NN NN O
involvement NN NN O
of NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
in NN NN O
Tcf NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
That NN NN O
is NN NN O
, NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
does NN NN O
not NN NN O
specifically NN NN O
activate NN NN O
Tcf NN NN O
transcription NN NN O
and NN NN O
stimuli NN NN O
( NN NN O
lithium NN NN O
or NN NN O
phytohemagglutinin NN NN B-Protein
) NN NN O
that NN NN O
inhibit NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
activity NN NN O
also NN NN O
do NN NN O
not NN NN O
activate NN NN O
Tcf NN NN O
reporter NN NN O
genes NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
is NN NN O
insufficient NN NN O
to NN NN O
activate NN NN O
Tcf NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
C57MG NN NN O
fibroblast NN NN O
cells NN NN O
, NN NN O
lithium NN NN O
inactivates NN NN O
GSK NN NN B-Protein
- NN NN I-Protein
3beta NN NN I-Protein
and NN NN O
induces NN NN O
Tcf NN NN B-Protein
- NN NN O
controlled NN NN O
transcription NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
that NN NN O
lithium NN NN O
can NN NN O
alter NN NN O
gene NN NN O
expression NN NN O
of NN NN O
Tcf NN NN O
- NN NN O
responsive NN NN O
genes NN NN O
, NN NN O
and NN NN O
points NN NN O
to NN NN O
a NN NN O
difference NN NN O
in NN NN O
regulation NN NN O
of NN NN O
Wnt NN NN O
signaling NN NN O
between NN NN O
fibroblasts NN NN O
and NN NN O
lymphocytes NN NN O
. NN NN O
   
CIITA NN NN B-Protein
- NN NN O
induced NN NN O
occupation NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
promoters NN NN O
is NN NN O
independent NN NN O
of NN NN O
the NN NN O
cooperative NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
promoter NN NN O
- NN NN O
bound NN NN O
multi NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
. NN NN O
   
Precise NN NN O
regulation NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
expression NN NN O
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
The NN NN O
transactivator NN NN O
CIITA NN NN B-Protein
behaves NN NN O
as NN NN O
a NN NN O
master NN NN O
controller NN NN O
of NN NN O
constitutive NN NN O
and NN NN O
inducible NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
activation NN NN O
, NN NN O
but NN NN O
its NN NN O
exact NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
promoters NN NN O
requires NN NN O
binding NN NN O
of NN NN O
at NN NN O
least NN NN O
three NN NN O
distinct NN NN O
multi NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
( NN NN O
RFX NN NN O
, NN NN O
X2BP NN NN O
and NN NN O
NF NN NN O
- NN NN O
Y NN NN O
) NN NN O
. NN NN O
   
It NN NN O
is NN NN O
known NN NN O
that NN NN O
the NN NN O
stability NN NN O
of NN NN O
this NN NN O
binding NN NN O
results NN NN O
from NN NN O
cooperative NN NN O
interactions NN NN O
between NN NN O
these NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
expression NN NN O
of NN NN O
CIITA NN NN B-Protein
in NN NN O
MHC NN NN O
class NN NN O
II NN NN O
- NN NN O
cells NN NN O
triggers NN NN O
occupation NN NN O
of NN NN O
the NN NN O
promoters NN NN O
by NN NN O
these NN NN O
complexes NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
raised NN NN O
the NN NN O
possibility NN NN O
that NN NN O
the NN NN O
effect NN NN O
of NN NN O
CIITA NN NN B-Protein
on NN NN O
promoter NN NN O
occupation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
an NN NN O
effect NN NN O
on NN NN O
the NN NN O
cooperative NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
bound NN NN O
multi NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
. NN NN O
   
We NN NN O
show NN NN O
, NN NN O
however NN NN O
, NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
CIITA NN NN B-Protein
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
stability NN NN O
of NN NN O
the NN NN O
higher NN NN O
- NN NN O
order NN NN O
protein NN NN O
complex NN NN O
formed NN NN O
on NN NN O
DNA NN NN O
by NN NN O
RFX NN NN O
, NN NN O
X2BP NN NN O
and NN NN O
NF NN NN O
- NN NN O
Y NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
other NN NN O
mechanisms NN NN O
for NN NN O
CIITA NN NN B-Protein
- NN NN O
induced NN NN O
promoter NN NN O
occupancy NN NN O
, NN NN O
such NN NN O
as NN NN O
an NN NN O
effect NN NN O
on NN NN O
chromatin NN NN O
structure NN NN O
leading NN NN O
to NN NN O
increased NN NN O
accessibility NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
promoters NN NN O
. NN NN O
   
This NN NN O
ability NN NN O
of NN NN O
CIITA NN NN B-Protein
to NN NN O
facilitate NN NN O
promoter NN NN O
occupation NN NN O
is NN NN O
undissociable NN NN O
from NN NN O
its NN NN O
transactivation NN NN O
potential NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
this NN NN O
effect NN NN O
of NN NN O
CIITA NN NN B-Protein
is NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
, NN NN O
since NN NN O
expression NN NN O
of NN NN O
CIITA NN NN B-Protein
is NN NN O
not NN NN O
required NN NN O
for NN NN O
normal NN NN O
occupation NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
promoters NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Immunosuppressant NN NN O
PG490 NN NN O
( NN NN O
triptolide NN NN O
) NN NN O
inhibits NN NN O
T NN NN O
- NN NN O
cell NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
purine NN NN O
- NN NN O
box NN NN O
/ NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
PG490 NN NN O
( NN NN O
triptolide NN NN O
) NN NN O
is NN NN O
a NN NN O
diterpene NN NN O
triepoxide NN NN O
with NN NN O
potent NN NN O
immunosuppressive NN NN O
and NN NN O
antiinflammatory NN NN O
properties NN NN O
. NN NN O
   
PG490 NN NN O
inhibits NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
normal NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
antibody NN NN O
to NN NN O
CD3 NN NN O
( NN NN O
IC50 NN NN O
of NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
and NN NN O
with NN NN O
PMA NN NN O
and NN NN O
ionomycin NN NN O
( NN NN O
Iono NN NN O
, NN NN O
IC50 NN NN O
of NN NN O
40 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
PG490 NN NN O
inhibits NN NN O
PMA NN NN O
/ NN NN O
Iono NN NN O
- NN NN O
stimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
. NN NN O
   
PG490 NN NN O
inhibits NN NN O
the NN NN O
induction NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
at NN NN O
the NN NN O
purine NN NN O
- NN NN O
box NN NN O
/ NN NN O
antigen NN NN O
receptor NN NN O
response NN NN O
element NN NN O
( NN NN O
ARRE NN NN O
) NN NN O
/ NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
- NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
target NN NN O
sequence NN NN O
but NN NN O
not NN NN O
at NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
. NN NN O
   
PG490 NN NN O
can NN NN O
completely NN NN O
inhibit NN NN O
transcriptional NN NN O
activation NN NN O
at NN NN O
the NN NN O
purine NN NN O
- NN NN O
box NN NN O
/ NN NN O
ARRE NN NN O
/ NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
target NN NN O
DNA NN NN O
sequences NN NN O
triggered NN NN O
by NN NN O
all NN NN O
stimuli NN NN O
examined NN NN O
( NN NN O
PMA NN NN O
, NN NN O
PMA NN NN O
/ NN NN O
Iono NN NN O
, NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
PG490 NN NN O
also NN NN O
inhibits NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
activation NN NN O
of NN NN O
a NN NN O
chimeric NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
which NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
TA1 NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
p65 NN NN B-Protein
is NN NN O
fused NN NN O
to NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
of NN NN O
GAL4 NN NN B-Protein
. NN NN O
   
In NN NN O
16HBE NN NN O
human NN NN O
bronchial NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
is NN NN O
regulated NN NN O
predominantly NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
and NN NN O
PG490 NN NN O
but NN NN O
not NN NN O
cyclosporin NN NN O
A NN NN O
can NN NN O
completely NN NN O
inhibit NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
PG490 NN NN O
inhibition NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
differs NN NN O
from NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
involves NN NN O
nuclear NN NN O
inhibition NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
the NN NN O
purine NN NN O
- NN NN O
box NN NN O
regulator NN NN O
operating NN NN O
at NN NN O
the NN NN O
ARRE NN NN O
/ NN NN O
NF NN NN O
- NN NN O
AT NN NN O
site NN NN O
at NN NN O
a NN NN O
step NN NN O
after NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
lipopolysaccharide NN NN O
in NN NN O
mononuclear NN NN O
leukocytes NN NN O
is NN NN O
prevented NN NN O
by NN NN O
inhibitors NN NN O
of NN NN O
cytosolic NN NN O
phospholipase NN NN O
A2 NN NN O
. NN NN O
   
In NN NN O
monocytes NN NN O
, NN NN O
lipopolysaccharide NN NN O
induces NN NN O
synthesis NN NN O
and NN NN O
activity NN NN O
of NN NN O
the NN NN O
85 NN NN O
- NN NN O
kDa NN NN O
cytosolic NN NN O
phospholipase NN NN O
A2 NN NN O
. NN NN O
   
This NN NN O
enzyme NN NN O
releases NN NN O
arachidonic NN NN O
acid NN NN O
and NN NN O
lyso NN NN O
- NN NN O
phospholipids NN NN O
from NN NN O
membranes NN NN O
which NN NN O
are NN NN O
metabolized NN NN O
to NN NN O
eicosanoids NN NN O
and NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
- NN NN O
factor NN NN O
. NN NN O
   
These NN NN O
lipid NN NN O
mediators NN NN O
increase NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
indicating NN NN O
a NN NN O
function NN NN O
for NN NN O
cytosolic NN NN O
phospholipase NN NN O
A2 NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
and NN NN O
inflammation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
shown NN NN O
previously NN NN O
that NN NN O
trifluoromethylketone NN NN O
inhibitors NN NN O
of NN NN O
cytosolic NN NN O
phospholipase NN NN O
A2 NN NN O
suppressed NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
protein NN NN O
and NN NN O
steady NN NN O
- NN NN O
state NN NN O
mRNA NN NN O
levels NN NN O
in NN NN O
human NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
leukocytes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
subcellular NN NN O
mechanisms NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
which NN NN O
trifluoromethylketones NN NN O
interfere NN NN O
with NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
they NN NN O
reduced NN NN O
the NN NN O
initial NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
mRNA NN NN O
transcription NN NN O
rate NN NN O
through NN NN O
prevention NN NN O
of NN NN O
degradation NN NN O
of NN NN O
inhibitor NN NN B-Protein
- NN NN I-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Consequently NN NN O
, NN NN O
cytosolic NN NN O
activation NN NN O
, NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
were NN NN O
decreased NN NN O
. NN NN O
   
Trifluoromethylketones NN NN O
ameliorate NN NN O
chronic NN NN O
inflammation NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
this NN NN O
therapeutic NN NN O
potency NN NN O
may NN NN O
reside NN NN O
in NN NN O
retention NN NN O
of NN NN O
inactive NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
thereby NN NN O
abrogating NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Molecular NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Cytokine NN NN O
expression NN NN O
by NN NN O
immune NN NN O
system NN NN O
cells NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
On NN NN O
first NN NN O
encounter NN NN O
with NN NN O
antigen NN NN O
, NN NN O
naive NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
helper NN NN O
( NN NN O
Th NN NN O
) NN NN O
cells NN NN O
differentiate NN NN O
into NN NN O
cytokine NN NN O
- NN NN O
producing NN NN O
effector NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
types NN NN O
of NN NN O
effector NN NN O
cells NN NN O
characterized NN NN O
by NN NN O
their NN NN O
distinct NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
profiles NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O
   
Th1 NN NN O
cells NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
whereas NN NN O
Th2 NN NN O
cells NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
. NN NN O
   
In NN NN O
many NN NN O
pathological NN NN O
situations NN NN O
, NN NN O
the NN NN O
balance NN NN O
between NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
immune NN NN O
responses NN NN O
determines NN NN O
the NN NN O
outcome NN NN O
of NN NN O
diverse NN NN O
immunologically NN NN O
mediated NN NN O
clinical NN NN O
syndromes NN NN O
including NN NN O
infectious NN NN O
, NN NN O
autoimmune NN NN O
, NN NN O
and NN NN O
allergic NN NN O
diseases NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
Th1 NN NN O
/ NN NN O
Th2 NN NN O
- NN NN O
like NN NN O
cytokines NN NN O
has NN NN O
remained NN NN O
elusive NN NN O
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
we NN NN O
evaluate NN NN O
the NN NN O
possible NN NN O
in NN NN O
vivo NN NN O
role NN NN O
of NN NN O
different NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
transcriptional NN NN O
mechanisms NN NN O
in NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
The NN NN O
evolutionarily NN NN O
conserved NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
human NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
S NN NN O
gamma NN NN O
3 NN NN O
region NN NN O
is NN NN O
an NN NN O
inducible NN NN O
promoter NN NN O
: NN NN O
synergistic NN NN O
activation NN NN O
by NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
via NN NN O
cooperative NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
binding NN NN O
sites NN NN O
. NN NN O
   
Germline NN NN O
C NN NN O
gamma NN NN O
gene NN NN O
transcription NN NN O
is NN NN O
a NN NN O
crucial NN NN O
event NN NN O
in NN NN O
the NN NN O
process NN NN O
that NN NN O
leads NN NN O
to NN NN O
switch NN NN O
DNA NN NN O
recombination NN NN O
to NN NN O
IgG NN NN O
, NN NN O
but NN NN O
its NN NN O
regulation NN NN O
in NN NN O
the NN NN O
human NN NN O
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
took NN NN O
advantage NN NN O
of NN NN O
our NN NN O
monoclonal NN NN O
model NN NN O
of NN NN O
germinal NN NN O
center NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
IgM NN NN O
+ NN NN O
IgD NN NN O
+ NN NN O
CL NN NN O
- NN NN O
01 NN NN O
cells NN NN O
, NN NN O
to NN NN O
define NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
3 NN NN I-Protein
evolutionarily NN NN O
conserved NN NN O
sequence NN NN O
( NN NN O
ECS NN NN O
) NN NN O
in NN NN O
the NN NN O
germline NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
C NN NN B-Protein
gamma NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
3 NN NN I-Protein
ECS NN NN O
lies NN NN O
upstream NN NN O
of NN NN O
the NN NN O
major NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
3 NN NN I-Protein
transcription NN NN O
initiation NN NN O
site NN NN O
and NN NN O
displays NN NN O
more NN NN O
than NN NN O
90 NN NN O
% NN NN O
identity NN NN O
with NN NN O
the NN NN O
corresponding NN NN O
human NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
1 NN NN I-Protein
, NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
I NN NN B-Protein
gamma NN NN I-Protein
4 NN NN I-Protein
regions NN NN O
. NN NN O
   
Reporter NN NN O
luciferase NN NN O
gene NN NN O
vectors NN NN O
containing NN NN O
the NN NN O
human NN NN O
gamma NN NN O
3 NN NN O
ECS NN NN O
were NN NN O
used NN NN O
to NN NN O
transfect NN NN O
CL NN NN O
- NN NN O
01 NN NN O
cells NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
undergo NN NN O
Smu NN NN O
- NN NN O
- NN NN O
> NN NN O
S NN NN O
gamma NN NN O
3 NN NN O
DNA NN NN O
recombination NN NN O
, NN NN O
upon NN NN O
engagement NN NN O
of NN NN O
CD40 NN NN B-Protein
by NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
CD40L NN NN B-Protein
) NN NN O
and NN NN O
exposure NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
In NN NN O
these NN NN O
transfected NN NN O
CL NN NN O
- NN NN O
01 NN NN O
cells NN NN O
, NN NN O
CD40 NN NN B-Protein
: NN NN O
CD40L NN NN B-Protein
engagement NN NN O
and NN NN O
exposure NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
synergistically NN NN O
induced NN NN O
gamma NN NN O
3 NN NN O
ECS NN NN O
- NN NN O
dependent NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
Targeted NN NN O
mutational NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
a NN NN O
tandem NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
binding NN NN O
motif NN NN O
is NN NN O
critical NN NN O
for NN NN O
the NN NN O
gamma NN NN O
3 NN NN O
ECS NN NN O
responsiveness NN NN O
to NN NN O
both NN NN O
CD40L NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
while NN NN O
a NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
is NN NN O
additionally NN NN O
required NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inducibility NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
are NN NN O
effectively NN NN O
induced NN NN O
by NN NN O
CD40L NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
bind NN NN O
to NN NN O
specific NN NN O
DNA NN NN O
motifs NN NN O
within NN NN O
the NN NN O
ECS NN NN O
. NN NN O
   
These NN NN O
partially NN NN O
overlapping NN NN O
CD40L NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
responsive NN NN O
elements NN NN O
are NN NN O
functionally NN NN O
cooperative NN NN O
as NN NN O
the NN NN O
disruption NN NN O
of NN NN O
one NN NN O
of NN NN O
them NN NN O
prevents NN NN O
synergistic NN NN O
promoter NN NN O
activation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
gamma NN NN O
3 NN NN O
ECS NN NN O
is NN NN O
an NN NN O
inducible NN NN O
promoter NN NN O
containing NN NN O
cis NN NN O
elements NN NN O
that NN NN O
critically NN NN O
mediate NN NN O
CD40L NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
triggered NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
C NN NN O
gamma NN NN O
3 NN NN O
gene NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
- NN NN O
induced NN NN O
p65 NN NN B-Protein
homodimer NN NN O
binding NN NN O
to NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
of NN NN O
the NN NN O
promoter NN NN O
mediates NN NN O
endothelial NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
neutrophil NN NN O
adhesion NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
proinflammatory NN NN O
mediator NN NN O
, NN NN O
thrombin NN NN B-Protein
, NN NN O
released NN NN O
during NN NN O
intravascular NN NN O
coagulation NN NN O
and NN NN O
tissue NN NN O
injury NN NN O
, NN NN O
induces NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
CD54 NN NN B-Protein
) NN NN O
expression NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
HUVEC NN NN O
with NN NN O
thrombin NN NN B-Protein
resulted NN NN O
in NN NN O
dose NN NN O
- NN NN O
and NN NN O
time NN NN O
- NN NN O
dependent NN NN O
increases NN NN O
in NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
and NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
and NN NN O
in NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
endothelial NN NN O
adhesivity NN NN O
toward NN NN O
polymorphonuclear NN NN O
leukocytes NN NN O
. NN NN O
   
Transient NN NN O
transfection NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
with NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
( NN NN O
ICAM NN NN O
- NN NN O
1LUC NN NN O
) NN NN O
constructs NN NN O
indicated NN NN O
that NN NN O
deletion NN NN O
of NN NN O
upstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
( NN NN O
- NN NN O
533 NN NN O
bases NN NN O
from NN NN O
translation NN NN O
start NN NN O
site NN NN O
) NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
thrombin NN NN B-Protein
responsiveness NN NN O
, NN NN O
whereas NN NN O
mutation NN NN O
/ NN NN O
deletion NN NN O
of NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
( NN NN O
- NN NN O
223 NN NN O
bases NN NN O
from NN NN O
the NN NN O
translation NN NN O
start NN NN O
site NN NN O
) NN NN O
prevented NN NN O
the NN NN O
activation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
is NN NN O
critical NN NN O
for NN NN O
thrombin NN NN B-Protein
inducibility NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
directed NN NN O
luciferase NN NN O
activity NN NN O
increased NN NN O
approximately NN NN O
3 NN NN O
- NN NN O
fold NN NN O
when NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
the NN NN O
plasmid NN NN O
pNF NN NN O
- NN NN O
kappa NN NN O
BLUC NN NN O
containing NN NN O
five NN NN O
copies NN NN O
of NN NN O
consensus NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
linked NN NN O
to NN NN O
a NN NN O
minimal NN NN O
adenovirus NN NN O
E1B NN NN B-Protein
promoter NN NN O
- NN NN O
luciferase NN NN O
gene NN NN O
were NN NN O
exposed NN NN O
to NN NN O
thrombin NN NN B-Protein
, NN NN O
indicating NN NN O
that NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
essential NN NN O
for NN NN O
thrombin NN NN B-Protein
response NN NN O
. NN NN O
   
Gel NN NN O
supershift NN NN O
assays NN NN O
demonstrated NN NN O
that NN NN O
thrombin NN NN B-Protein
induced NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
Bp65 NN NN B-Protein
( NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
) NN NN O
to NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
of NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
receptor NN NN I-Protein
activation NN NN O
peptide NN NN O
, NN NN O
a NN NN O
14 NN NN O
- NN NN O
amino NN NN O
- NN NN O
acid NN NN O
peptide NN NN O
representing NN NN O
the NN NN O
new NN NN O
NH2 NN NN O
terminus NN NN O
of NN NN O
proteolytically NN NN B-Protein
activated NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
mimicked NN NN O
thrombin NN NN B-Protein
' NN NN O
s NN NN O
action NN NN O
in NN NN O
inducing NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
thrombin NN NN B-Protein
activates NN NN O
endothelial NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
polymorphonuclear NN NN O
leukocyte NN NN O
adhesion NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
Bp65 NN NN B-Protein
binding NN NN O
to NN NN O
the NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
after NN NN O
proteolytically NN NN B-Protein
activated NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
activation NN NN O
. NN NN O
   
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
Mediated NN NN O
inhibition NN NN O
of NN NN O
early NN NN O
events NN NN O
of NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
engagement NN NN O
by NN NN O
mAbs NN NN O
inhibits NN NN O
, NN NN O
while NN NN O
CD28 NN NN B-Protein
enhances NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
and NN NN O
proliferation NN NN O
upon NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
of NN NN O
naive NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
using NN NN O
Ab NN NN O
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
ligation NN NN O
inhibited NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN B-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
by NN NN O
inhibiting NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
, NN NN O
which NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
in NN NN O
part NN NN O
through NN NN O
decreasing NN NN O
NF NN NN O
- NN NN O
AT NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
. NN NN O
   
However NN NN O
, NN NN O
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
ligation NN NN O
did NN NN O
not NN NN O
appear NN NN O
to NN NN O
affect NN NN O
the NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
stabilization NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
engagement NN NN O
inhibited NN NN O
progression NN NN O
through NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
production NN NN O
of NN NN O
cyclin NN NN B-Protein
D3 NN NN I-Protein
, NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
( NN NN B-Protein
cdk NN NN I-Protein
) NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
cdk6 NN NN B-Protein
when NN NN O
the NN NN O
T NN NN O
cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN O
and NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
alone NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
signaling NN NN O
inhibits NN NN O
events NN NN O
early NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
both NN NN O
at NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
and NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
events NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
and NN NN O
does NN NN O
not NN NN O
simply NN NN O
oppose NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
costimulation NN NN O
. NN NN O
   
Fibroblast NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
enhances NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
FGF NN NN O
receptor NN NN O
- NN NN O
bearing NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Fibroblast NN NN O
growth NN NN O
factors NN NN O
( NN NN O
FGFs NN NN O
) NN NN O
are NN NN O
heparin NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
crucial NN NN O
to NN NN O
embryogenesis NN NN O
, NN NN O
angiogenesis NN NN O
, NN NN O
and NN NN O
wound NN NN O
healing NN NN O
. NN NN O
   
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
the NN NN O
synovium NN NN O
in NN NN O
rheumatoid NN NN O
arthritis NN NN O
and NN NN O
in NN NN O
rejecting NN NN O
allografts NN NN O
, NN NN O
sites NN NN O
of NN NN O
chronic NN NN O
immune NN NN O
- NN NN O
mediated NN NN O
inflammation NN NN O
. NN NN O
   
The NN NN O
frequency NN NN O
of NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
responsive NN NN O
T NN NN O
cells NN NN O
is NN NN O
increased NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
these NN NN O
disorders NN NN O
, NN NN O
and NN NN O
a NN NN O
high NN NN O
percentage NN NN O
of NN NN O
infiltrating NN NN O
T NN NN O
cells NN NN O
in NN NN O
rheumatoid NN NN O
arthritis NN NN O
synovium NN NN O
express NN NN O
receptors NN NN O
for NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
action NN NN O
of NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
studies NN NN O
were NN NN O
initiated NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
that NN NN O
express NN NN O
the NN NN O
signaling NN NN O
isoform NN NN O
of NN NN O
FGF NN NN B-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
These NN NN O
experiments NN NN O
show NN NN O
that NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
stimulation NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
provides NN NN O
a NN NN O
second NN NN O
signal NN NN O
that NN NN O
augments NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Analogous NN NN O
to NN NN O
costimulation NN NN O
via NN NN O
CD28 NN NN B-Protein
, NN NN O
this NN NN O
activity NN NN O
is NN NN O
mediated NN NN O
through NN NN O
activation NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
kappaB NN NN O
, NN NN O
a NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
known NN NN O
to NN NN O
regulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
other NN NN O
activation NN NN O
- NN NN O
inducible NN NN O
proteins NN NN O
. NN NN O
   
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alone NN NN O
induces NN NN O
modest NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
and NN NN O
this NN NN O
translocation NN NN O
is NN NN O
enhanced NN NN O
by NN NN O
the NN NN O
combination NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
This NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
complex NN NN O
is NN NN O
composed NN NN O
of NN NN O
transcriptionally NN NN O
active NN NN O
p65 NN NN B-Protein
( NN NN O
RelA NN NN B-Protein
) NN NN O
/ NN NN O
p50 NN NN B-Protein
heterodimers NN NN O
and NN NN O
results NN NN O
primarily NN NN O
from NN NN O
the NN NN O
targeted NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
an NN NN O
inhibitor NN NN O
that NN NN O
sequesters NN NN O
Rel NN NN O
/ NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
These NN NN O
data NN NN O
are NN NN O
the NN NN O
first NN NN O
to NN NN O
show NN NN O
a NN NN O
connection NN NN O
between NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
signaling NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
outside NN NN O
of NN NN O
embryonic NN NN O
development NN NN O
. NN NN O
   
The NN NN O
signaling NN NN O
events NN NN O
that NN NN O
link NN NN O
FGF NN NN B-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
engagement NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
are NN NN O
probably NN NN O
distinct NN NN O
from NN NN O
the NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
pathway NN NN O
, NN NN O
since NN NN O
FGF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
induced NN NN O
Rel NN NN O
/ NN NN O
kappaB NN NN O
binding NN NN O
proteins NN NN O
do NN NN O
not NN NN O
contain NN NN O
significant NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
are NN NN O
not NN NN O
identical NN NN O
with NN NN O
the NN NN O
CD28 NN NN B-Protein
response NN NN O
complex NN NN O
. NN NN O
   
Signaling NN NN O
through NN NN O
the NN NN O
lymphotoxin NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
receptor NN NN I-Protein
stimulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
alone NN NN O
and NN NN O
in NN NN O
cooperation NN NN O
with NN NN O
soluble NN NN O
or NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
ongoing NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
within NN NN O
an NN NN O
individual NN NN O
is NN NN O
critical NN NN O
to NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
pathogenesis NN NN O
. NN NN O
   
Among NN NN O
host NN NN O
immune NN NN O
factors NN NN O
, NN NN O
the NN NN O
cytokine NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
has NN NN O
previously NN NN O
been NN NN O
shown NN NN O
to NN NN O
increase NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
various NN NN O
monocyte NN NN O
and NN NN O
T NN NN O
cell NN NN O
model NN NN O
systems NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
signaling NN NN O
through NN NN O
the NN NN O
TNF NN NN O
receptor NN NN O
family NN NN O
member NN NN O
, NN NN O
the NN NN O
lymphotoxin NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
( NN NN I-Protein
LT NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
LT NN NN B-Protein
- NN NN I-Protein
betaR NN NN I-Protein
) NN NN O
, NN NN O
also NN NN O
regulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
is NN NN O
cooperatively NN NN O
stimulated NN NN O
when NN NN O
the NN NN O
distinct NN NN O
LT NN NN B-Protein
- NN NN I-Protein
betaR NN NN I-Protein
and NN NN O
TNF NN NN O
receptor NN NN O
systems NN NN O
are NN NN O
simultaneously NN NN O
engaged NN NN O
by NN NN O
their NN NN O
specific NN NN O
ligands NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
in NN NN O
a NN NN O
physiological NN NN O
coculture NN NN O
cellular NN NN O
assay NN NN O
system NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
LT NN NN O
- NN NN O
alpha1beta2 NN NN O
act NN NN O
virtually NN NN O
identically NN NN O
to NN NN O
their NN NN O
soluble NN NN O
forms NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
cosignaling NN NN O
via NN NN O
the NN NN O
LT NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
receptors NN NN I-Protein
is NN NN O
probably NN NN O
involved NN NN O
in NN NN O
the NN NN O
modulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
the NN NN O
subsequent NN NN O
determination NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
viral NN NN O
burden NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Intriguingly NN NN O
, NN NN O
surface NN NN O
expression NN NN O
of NN NN O
LT NN NN O
- NN NN O
alpha1beta2 NN NN O
is NN NN O
up NN NN O
- NN NN O
regulated NN NN O
on NN NN O
a NN NN O
T NN NN O
cell NN NN O
line NN NN O
acutely NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
positive NN NN O
feedback NN NN O
loop NN NN O
between NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
, NN NN O
LT NN NN O
- NN NN O
alpha1beta2 NN NN O
expression NN NN O
, NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
critical NN NN O
role NN NN O
that NN NN O
LT NN NN O
- NN NN O
alpha1beta2 NN NN O
plays NN NN O
in NN NN O
lymphoid NN NN O
architecture NN NN O
, NN NN O
we NN NN O
speculate NN NN O
that NN NN O
LT NN NN O
- NN NN O
alpha1beta2 NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
HIV NN NN O
- NN NN O
associated NN NN O
abnormalities NN NN O
of NN NN O
the NN NN O
lymphoid NN NN O
organs NN NN O
. NN NN O
   
Resistance NN NN O
to NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
vitro NN NN O
correlates NN NN O
with NN NN O
high NN NN O
metastatic NN NN O
capacity NN NN O
of NN NN O
cells NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
TNF NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
cytokines NN NN O
secreted NN NN O
by NN NN O
the NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
those NN NN O
cell NN NN O
lines NN NN O
lacking NN NN O
capability NN NN O
to NN NN O
form NN NN O
metastatic NN NN O
tumors NN NN O
in NN NN O
vivo NN NN O
are NN NN O
susceptible NN NN O
to NN NN O
TNF NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
However NN NN O
, NN NN O
cell NN NN O
lines NN NN O
with NN NN O
high NN NN O
metastatic NN NN O
potential NN NN O
are NN NN O
resistant NN NN O
to NN NN O
TNF NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
same NN NN O
cell NN NN O
lines NN NN O
were NN NN O
resistant NN NN O
to NN NN O
cytolytic NN NN O
action NN NN O
of NN NN O
other NN NN O
cytotoxic NN NN O
proteins NN NN O
secreted NN NN O
by NN NN O
LAK NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
showed NN NN O
that NN NN O
TNF NN NN O
resistance NN NN O
in NN NN O
vitro NN NN O
correlates NN NN O
with NN NN O
the NN NN O
increased NN NN O
level NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
This NN NN O
finding NN NN O
may NN NN O
provide NN NN O
a NN NN O
tool NN NN O
to NN NN O
improve NN NN O
current NN NN O
protocols NN NN O
of NN NN O
immunotherapy NN NN O
and NN NN O
insights NN NN O
to NN NN O
how NN NN O
tumor NN NN O
cells NN NN O
are NN NN O
or NN NN O
are NN NN O
not NN NN O
killed NN NN O
by NN NN O
LAK NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
required NN NN O
for NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
C5a NN NN O
, NN NN O
a NN NN O
potent NN NN O
peptide NN NN O
chemoattractant NN NN O
, NN NN O
stimulates NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
secretion NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
. NN NN O
   
Experiments NN NN O
were NN NN O
conducted NN NN O
to NN NN O
understand NN NN O
the NN NN O
mechanisms NN NN O
for NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
, NN NN O
which NN NN O
was NN NN O
14 NN NN O
- NN NN O
fold NN NN O
greater NN NN O
than NN NN O
that NN NN O
in NN NN O
unstimulated NN NN O
cells NN NN O
by NN NN O
2 NN NN O
hours NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
secretion NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
accumulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
mRNA NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
by NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
a NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
within NN NN O
30 NN NN O
minutes NN NN O
. NN NN O
   
AP NN NN O
- NN NN O
1 NN NN O
but NN NN O
not NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
C5a NN NN O
- NN NN O
stimulated NN NN O
PBMC NN NN O
; NN NN O
however NN NN O
, NN NN O
its NN NN O
delayed NN NN O
expression NN NN O
( NN NN O
maximal NN NN O
at NN NN O
4 NN NN O
hours NN NN O
) NN NN O
suggested NN NN O
a NN NN O
less NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
rapid NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
The NN NN O
correlation NN NN O
between NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
was NN NN O
examined NN NN O
in NN NN O
the NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
macrophage NN NN O
cells NN NN O
using NN NN O
reporter NN NN O
genes NN NN O
directed NN NN O
by NN NN O
the NN NN O
kappaB NN NN O
sequence NN NN O
from NN NN O
IkappaBalpha NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
promoter NN NN O
regions NN NN O
. NN NN O
   
C5a NN NN O
- NN NN O
induced NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
was NN NN O
abolished NN NN O
by NN NN O
introducing NN NN O
mutations NN NN O
into NN NN O
the NN NN O
kappaB NN NN O
sites NN NN O
and NN NN O
by NN NN O
coexpression NN NN O
of NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
IkappaBalpha NN NN B-Protein
construct NN NN O
resistant NN NN O
to NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
. NN NN O
   
Pertussis NN NN O
toxin NN NN O
, NN NN O
which NN NN O
ADP NN NN O
- NN NN O
ribosylates NN NN O
the NN NN O
Gi NN NN O
proteins NN NN O
known NN NN O
to NN NN O
couple NN NN O
to NN NN O
the NN NN O
C5a NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
produced NN NN O
minimal NN NN O
inhibition NN NN O
of NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
and NN NN O
had NN NN O
little NN NN O
effect NN NN O
on NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
calcium NN NN O
mobilization NN NN O
in NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
required NN NN O
for NN NN O
C5a NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
and NN NN O
that NN NN O
this NN NN O
response NN NN O
is NN NN O
mediated NN NN O
primarily NN NN O
through NN NN O
a NN NN O
pertussis NN NN O
toxin NN NN O
- NN NN O
insensitive NN NN O
pathway NN NN O
. NN NN O
   
Transcriptional NN NN O
targeting NN NN O
of NN NN O
retroviral NN NN O
vectors NN NN O
to NN NN O
the NN NN O
erythroblastic NN NN O
progeny NN NN O
of NN NN O
transduced NN NN O
hematopoietic NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
Targeted NN NN O
expression NN NN O
to NN NN O
specific NN NN O
tissues NN NN O
or NN NN O
cell NN NN O
lineages NN NN O
is NN NN O
a NN NN O
necessary NN NN O
feature NN NN O
of NN NN O
a NN NN O
gene NN NN O
therapy NN NN O
vector NN NN O
for NN NN O
many NN NN O
clinical NN NN O
applications NN NN O
, NN NN O
such NN NN O
as NN NN O
correction NN NN O
of NN NN O
hemoglobinopathies NN NN O
or NN NN O
thalassemias NN NN O
by NN NN O
transplantation NN NN O
of NN NN O
genetically NN NN O
modified NN NN O
hematopoietic NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
developed NN NN O
retroviral NN NN O
vectors NN NN O
in NN NN O
which NN NN O
the NN NN O
constitutive NN NN O
viral NN NN O
enhancer NN NN O
in NN NN O
the NN NN O
U3 NN NN O
region NN NN O
of NN NN O
the NN NN O
3 NN NN O
' NN NN O
LTR NN NN O
is NN NN O
replaced NN NN O
by NN NN O
an NN NN O
autoregulatory NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factor NN NN O
gene NN NN O
. NN NN O
   
The NN NN O
replaced NN NN O
enhancer NN NN O
is NN NN O
propagated NN NN O
to NN NN O
the NN NN O
5 NN NN O
' NN NN O
LTR NN NN O
upon NN NN O
integration NN NN O
into NN NN O
the NN NN O
target NN NN O
cell NN NN O
genome NN NN O
. NN NN O
   
The NN NN O
modified NN NN O
vectors NN NN O
were NN NN O
used NN NN O
to NN NN O
transduce NN NN O
human NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
, NN NN O
cord NN NN O
blood NN NN O
- NN NN O
derived NN NN O
CD34 NN NN O
( NN NN O
+ NN NN O
) NN NN O
stem NN NN O
/ NN NN O
progenitor NN NN O
cells NN NN O
, NN NN O
and NN NN O
murine NN NN O
bone NN NN O
marrow NN NN O
repopulating NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
appropriate NN NN O
reporter NN NN O
genes NN NN O
( NN NN O
triangle NN NN O
upLNGFR NN NN O
, NN NN O
EGFP NN NN B-Protein
) NN NN O
was NN NN O
analyzed NN NN O
in NN NN O
the NN NN O
differentiated NN NN O
progeny NN NN O
of NN NN O
transduced NN NN O
stem NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
, NN NN O
in NN NN O
liquid NN NN O
culture NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
clonogenic NN NN O
assay NN NN O
, NN NN O
and NN NN O
in NN NN O
vivo NN NN O
, NN NN O
after NN NN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
in NN NN O
lethally NN NN O
irradiated NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
autoregulatory NN NN O
enhancer NN NN O
effectively NN NN O
restricts NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
proviral NN NN O
transcription NN NN O
unit NN NN O
to NN NN O
the NN NN O
erythroblastic NN NN O
progeny NN NN O
of NN NN O
both NN NN O
human NN NN O
progenitors NN NN O
and NN NN O
mouse NN NN O
- NN NN O
repopulating NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
Packaging NN NN O
of NN NN O
viral NN NN O
particles NN NN O
, NN NN O
integration NN NN O
into NN NN O
the NN NN O
target NN NN O
genome NN NN O
, NN NN O
and NN NN O
stability NN NN O
of NN NN O
the NN NN O
integrated NN NN O
provirus NN NN O
are NN NN O
not NN NN O
affected NN NN O
by NN NN O
the NN NN O
LTR NN NN O
modification NN NN O
. NN NN O
   
Enhancer NN NN O
replacement NN NN O
is NN NN O
therefore NN NN O
an NN NN O
effective NN NN O
strategy NN NN O
to NN NN O
target NN NN O
expression NN NN O
of NN NN O
a NN NN O
retroviral NN NN O
transgene NN NN O
to NN NN O
a NN NN O
specific NN NN O
progeny NN NN O
of NN NN O
transduced NN NN O
hematopoietic NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
essential NN NN O
role NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
human NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
bone NN NN O
marrow NN NN O
cell NN NN O
survival NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
is NN NN O
important NN NN O
for NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
B NN NN O
- NN NN O
cell NN NN O
maturation NN NN O
, NN NN O
and NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
transcription NN NN O
and NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
alternatively NN NN O
mediating NN NN O
and NN NN O
protecting NN NN O
against NN NN O
apoptosis NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
role NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
human NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
has NN NN O
not NN NN O
been NN NN O
described NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
evidence NN NN O
here NN NN O
that NN NN O
virtually NN NN O
all NN NN O
human NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
express NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
that NN NN O
can NN NN O
be NN NN O
activated NN NN O
by NN NN O
exposure NN NN O
to NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
and NN NN O
a NN NN O
variety NN NN O
of NN NN O
cytokines NN NN O
, NN NN O
eg NN NN O
, NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
may NN NN O
be NN NN O
required NN NN O
for NN NN O
human NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
bone NN NN O
marrow NN NN O
cell NN NN O
clonogenic NN NN O
function NN NN O
and NN NN O
survival NN NN O
. NN NN O
   
These NN NN O
results NN NN O
offer NN NN O
insight NN NN O
into NN NN O
a NN NN O
new NN NN O
role NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
maintaining NN NN O
survival NN NN O
and NN NN O
function NN NN O
in NN NN O
hematopoietic NN NN O
stem NN NN O
and NN NN O
progenitor NN NN O
cells NN NN O
and NN NN O
suggest NN NN O
that NN NN O
proposed NN NN O
strategies NN NN O
involving NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
as NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
cancer NN NN O
chemotherapy NN NN O
should NN NN O
be NN NN O
approached NN NN O
with NN NN O
caution NN NN O
. NN NN O
   
Unicellular NN NN O
- NN NN O
unilineage NN NN O
erythropoietic NN NN O
cultures NN NN O
: NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
regulatory NN NN O
gene NN NN O
expression NN NN O
at NN NN O
sibling NN NN O
cell NN NN O
level NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
studies NN NN O
on NN NN O
hematopoietic NN NN O
control NN NN O
mechanisms NN NN O
have NN NN O
been NN NN O
hampered NN NN O
by NN NN O
the NN NN O
heterogeneity NN NN O
of NN NN O
the NN NN O
analyzed NN NN O
cell NN NN O
populations NN NN O
, NN NN O
ie NN NN O
, NN NN O
lack NN NN O
of NN NN O
lineage NN NN O
specificity NN NN O
and NN NN O
developmental NN NN O
stage NN NN O
homogeneity NN NN O
of NN NN O
progenitor NN NN O
/ NN NN O
precursor NN NN O
cells NN NN O
growing NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
We NN NN O
developed NN NN O
unicellular NN NN O
culture NN NN O
systems NN NN O
for NN NN O
unilineage NN NN O
differentiation NN NN O
of NN NN O
purified NN NN O
hematopoietic NN NN O
progenitor NN NN O
cells NN NN O
followed NN NN O
by NN NN O
daughter NN NN O
cell NN NN O
analysis NN NN O
at NN NN O
cellular NN NN O
and NN NN O
molecular NN NN O
level NN NN O
. NN NN O
   
In NN NN O
the NN NN O
culture NN NN O
system NN NN O
reported NN NN O
here NN NN O
, NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
growth NN NN O
factor NN NN O
( NN NN O
GF NN NN O
) NN NN O
stimulus NN NN O
induces NN NN O
cord NN NN O
blood NN NN O
( NN NN O
CB NN NN O
) NN NN O
progenitor NN NN O
cells NN NN O
to NN NN O
proliferate NN NN O
and NN NN O
differentiate NN NN O
/ NN NN O
mature NN NN O
exclusively NN NN O
along NN NN O
the NN NN O
erythroid NN NN O
lineage NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
this NN NN O
erythropoietic NN NN O
wave NN NN O
is NN NN O
characterized NN NN O
by NN NN O
less NN NN O
than NN NN O
4 NN NN O
% NN NN O
apoptotic NN NN O
cells NN NN O
; NN NN O
( NN NN O
3 NN NN O
) NN NN O
asymmetric NN NN O
divisions NN NN O
are NN NN O
virtually NN NN O
absent NN NN O
, NN NN O
ie NN NN O
, NN NN O
nonresponsive NN NN O
hematopoietic NN NN O
progenitors NN NN O
with NN NN O
no NN NN O
erythropoietic NN NN O
potential NN NN O
are NN NN O
forced NN NN O
into NN NN O
apoptosis NN NN O
; NN NN O
( NN NN O
4 NN NN O
) NN NN O
the NN NN O
system NN NN O
is NN NN O
cell NN NN O
division NN NN O
controlled NN NN O
( NN NN O
cdc NN NN O
) NN NN O
, NN NN O
ie NN NN O
, NN NN O
the NN NN O
number NN NN O
of NN NN O
divisions NN NN O
performed NN NN O
by NN NN O
each NN NN O
cell NN NN O
is NN NN O
monitored NN NN O
. NN NN O
   
Single NN NN O
- NN NN O
cell NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
analysis NN NN O
was NN NN O
applied NN NN O
to NN NN O
this NN NN O
culture NN NN O
system NN NN O
to NN NN O
investigate NN NN O
gene NN NN O
expression NN NN O
of NN NN O
diverse NN NN O
receptors NN NN O
, NN NN O
markers NN NN O
of NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
transcription NN NN O
factors NN NN O
( NN NN O
EKLF NN NN B-Protein
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
p45 NN NN B-Protein
NF NN NN I-Protein
- NN NN I-Protein
E2 NN NN I-Protein
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
SCL NN NN B-Protein
/ NN NN O
Tal1 NN NN B-Protein
) NN NN O
at NN NN O
discrete NN NN O
stages NN NN O
of NN NN O
erythropoietic NN NN O
development NN NN O
. NN NN O
   
Freshly NN NN O
isolated NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
cells NN NN O
expressed NN NN O
CD34 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
kit NN NN I-Protein
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
but NN NN O
did NN NN O
not NN NN O
express NN NN O
CD36 NN NN B-Protein
, NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
EpoR NN NN B-Protein
) NN NN O
, NN NN O
SCL NN NN B-Protein
/ NN NN O
Tal1 NN NN B-Protein
, NN NN O
EKLF NN NN B-Protein
, NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
or NN NN O
glyocophorin NN NN B-Protein
A NN NN I-Protein
( NN NN O
GPA NN NN B-Protein
) NN NN O
. NN NN O
   
In NN NN O
early NN NN O
to NN NN O
intermediate NN NN O
stages NN NN O
of NN NN O
erythroid NN NN O
differentiation NN NN O
we NN NN O
monitored NN NN O
the NN NN O
induction NN NN O
of NN NN O
CD36 NN NN B-Protein
, NN NN O
Tal1 NN NN B-Protein
, NN NN O
EKLF NN NN B-Protein
, NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
that NN NN O
preceeded NN NN O
expression NN NN O
of NN NN O
EpoR NN NN B-Protein
. NN NN O
   
In NN NN O
late NN NN O
stages NN NN O
of NN NN O
erythroid NN NN O
maturation NN NN O
, NN NN O
GPA NN NN B-Protein
was NN NN O
upregulated NN NN O
, NN NN O
whereas NN NN O
CD34 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
kit NN NN I-Protein
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
were NN NN O
barely NN NN O
or NN NN O
not NN NN O
detected NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
competitive NN NN O
single NN NN O
- NN NN O
cell NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
was NN NN O
used NN NN O
to NN NN O
assay NN NN O
CD34 NN NN B-Protein
mRNA NN NN O
transcripts NN NN O
in NN NN O
sibling NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD38 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
cells NN NN O
differentiating NN NN O
in NN NN O
unilineage NN NN O
erythroid NN NN O
cultures NN NN O
: NN NN O
this NN NN O
analysis NN NN O
allowed NN NN O
us NN NN O
to NN NN O
semiquantitate NN NN O
the NN NN O
gradual NN NN O
downmodulation NN NN O
of NN NN O
CD34 NN NN B-Protein
mRNA NN NN O
from NN NN O
progenitor NN NN O
cells NN NN O
through NN NN O
their NN NN O
differentiating NN NN O
erythroid NN NN O
progeny NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
this NN NN O
novel NN NN O
culture NN NN O
system NN NN O
, NN NN O
coupled NN NN O
with NN NN O
single NN NN O
- NN NN O
cell NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
analysis NN NN O
, NN NN O
may NN NN O
eliminate NN NN O
the NN NN O
ambiguities NN NN O
intrinsic NN NN O
to NN NN O
molecular NN NN O
studies NN NN O
on NN NN O
heterogeneous NN NN O
populations NN NN O
of NN NN O
hematopoietic NN NN O
progenitors NN NN O
/ NN NN O
precursors NN NN O
growing NN NN O
in NN NN O
culture NN NN O
, NN NN O
particularly NN NN O
in NN NN O
the NN NN O
initial NN NN O
stages NN NN O
of NN NN O
development NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
cell NN NN O
cycle NN NN O
entry NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
infected NN NN O
by NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
. NN NN O
   
Infection NN NN O
of NN NN O
human NN NN O
B NN NN O
cells NN NN O
with NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
results NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
and NN NN O
cell NN NN O
growth NN NN O
. NN NN O
   
To NN NN O
interpret NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
EBV NN NN O
activates NN NN O
the NN NN O
cell NN NN O
, NN NN O
we NN NN O
have NN NN O
assayed NN NN O
many NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
control NN NN O
of NN NN O
the NN NN O
G0 NN NN O
and NN NN O
G1 NN NN O
phases NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
and NN NN O
regulation NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
In NN NN O
EBV NN NN O
infection NN NN O
most NN NN O
of NN NN O
the NN NN O
changes NN NN O
, NN NN O
including NN NN O
the NN NN O
early NN NN O
induction NN NN O
of NN NN O
cyclin NN NN B-Protein
D2 NN NN I-Protein
, NN NN O
are NN NN O
dependent NN NN O
on NN NN O
expression NN NN O
of NN NN O
EBV NN NN O
genes NN NN O
, NN NN O
but NN NN O
an NN NN O
alteration NN NN O
in NN NN O
the NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
profile NN NN O
was NN NN O
partly NN NN O
independent NN NN O
of NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
, NN NN O
presumably NN NN O
occurring NN NN O
in NN NN O
response NN NN O
to NN NN O
signal NN NN O
transduction NN NN O
activated NN NN O
when NN NN O
the NN NN O
virus NN NN O
binds NN NN O
to NN NN O
its NN NN O
receptor NN NN O
, NN NN O
CD21 NN NN B-Protein
. NN NN O
   
By NN NN O
comparing NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
controlling NN NN O
apoptosis NN NN O
, NN NN O
including NN NN O
those NN NN O
encoding NN NN O
several NN NN O
members NN NN O
of NN NN O
the NN NN O
BCL NN NN O
- NN NN O
2 NN NN O
family NN NN O
of NN NN O
proteins NN NN O
, NN NN O
the NN NN O
known NN NN O
relative NN NN O
resistance NN NN O
of NN NN O
EBV NN NN O
- NN NN O
immortalized NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
to NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
low NN NN O
serum NN NN O
was NN NN O
found NN NN O
to NN NN O
correlate NN NN O
with NN NN O
expression NN NN O
of NN NN O
both NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
A20 NN NN B-Protein
. NN NN O
   
A20 NN NN B-Protein
can NN NN O
be NN NN O
regulated NN NN O
by NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
which NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
activated NN NN O
by NN NN O
the NN NN O
EBV NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
. NN NN O
   
Quantitative NN NN O
assays NN NN O
demonstrated NN NN O
a NN NN O
direct NN NN O
temporal NN NN O
relationship NN NN O
between NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
levels NN NN O
and NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
during NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
infection NN NN O
. NN NN O
   
Immortalization NN NN O
of NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
and NN NN O
CD8 NN NN O
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
mutants NN NN O
expressed NN NN O
in NN NN O
a NN NN O
functional NN NN O
molecular NN NN O
clone NN NN O
. NN NN O
   
The NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
transcriptional NN NN O
trans NN NN O
- NN NN O
activator NN NN O
Tax NN NN B-Protein
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
have NN NN O
transforming NN NN O
activity NN NN O
in NN NN O
multiple NN NN O
cell NN NN O
culture NN NN O
and NN NN O
transgenic NN NN O
- NN NN O
mouse NN NN O
models NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
activating NN NN O
transcription NN NN O
from NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
through NN NN O
the NN NN O
cyclic NN NN O
AMP NN NN O
response NN NN O
element NN NN O
binding NN NN O
protein NN NN O
/ NN NN O
activating NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
) NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
Tax NN NN B-Protein
activates NN NN O
the NN NN O
expression NN NN O
of NN NN O
multiple NN NN O
cellular NN NN O
promoters NN NN O
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
Tax NN NN B-Protein
mutants NN NN O
M22 NN NN O
and NN NN O
M47 NN NN O
have NN NN O
previously NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
selectively NN NN O
abrogate NN NN O
the NN NN O
ability NN NN O
of NN NN O
Tax NN NN B-Protein
to NN NN O
activate NN NN O
transcription NN NN O
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
or NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
pathway NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
These NN NN O
mutations NN NN O
were NN NN O
introduced NN NN O
in NN NN O
the NN NN O
tax NN NN B-Protein
gene NN NN O
of NN NN O
the NN NN O
ACH NN NN O
functional NN NN O
molecular NN NN O
clone NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
virus NN NN O
produced NN NN O
from NN NN O
the NN NN O
mutant NN NN O
ACH NN NN O
clones NN NN O
was NN NN O
examined NN NN O
for NN NN O
the NN NN O
ability NN NN O
to NN NN O
replicate NN NN O
and NN NN O
immortalize NN NN O
primary NN NN O
human NN NN O
lymphocytes NN NN O
. NN NN O
   
While NN NN O
virus NN NN O
derived NN NN O
from NN NN O
the NN NN O
clone NN NN O
containing NN NN O
the NN NN O
M47 NN NN O
mutation NN NN O
retained NN NN O
the NN NN O
ability NN NN O
to NN NN O
immortalize NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
M22 NN NN O
mutant NN NN O
lost NN NN O
the NN NN O
ability NN NN O
to NN NN O
immortalize NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
activation NN NN O
of NN NN O
the NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
pathway NN NN O
by NN NN O
Tax NN NN B-Protein
is NN NN O
dispensable NN NN O
for NN NN O
the NN NN O
immortalization NN NN O
of NN NN O
T NN NN O
cells NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
, NN NN O
whereas NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
may NN NN O
be NN NN O
critical NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
reactivation NN NN O
in NN NN O
resting NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
of NN NN O
infected NN NN O
adults NN NN O
upon NN NN O
in NN NN O
vitro NN NN O
CD4 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
by NN NN O
ligands NN NN O
of NN NN O
the NN NN O
CDR2 NN NN O
- NN NN O
loop NN NN O
in NN NN O
extracellular NN NN O
domain NN NN O
1 NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
infects NN NN O
resting NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMCs NN NN O
) NN NN O
but NN NN O
remains NN NN O
inactive NN NN O
state NN NN O
until NN NN O
subsequent NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
cell NN NN O
surface NN NN O
CD4 NN NN B-Protein
by NN NN O
gp120 NN NN O
- NN NN O
anti NN NN O
- NN NN O
gp120 NN NN O
immune NN NN O
complexes NN NN O
or NN NN O
heat NN NN O
- NN NN O
inactivated NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
( NN NN O
iHIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
trigger NN NN O
activation NN NN O
signals NN NN O
leading NN NN O
to NN NN O
virus NN NN O
reactivation NN NN O
( NN NN O
9 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
stimulation NN NN O
of NN NN O
virus NN NN O
production NN NN O
by NN NN O
iHIV NN NN O
- NN NN O
1 NN NN O
were NN NN O
strictly NN NN O
linked NN NN O
to NN NN O
the NN NN O
concentrations NN NN O
of NN NN O
viral NN NN O
proteins NN NN O
used NN NN O
as NN NN O
exogenous NN NN O
stimuli NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
further NN NN O
investigated NN NN O
the NN NN O
physiologic NN NN O
relevance NN NN O
of NN NN O
these NN NN O
observations NN NN O
. NN NN O
   
When NN NN O
submitted NN NN O
to NN NN O
an NN NN O
in NN NN O
vitro NN NN O
CD4 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
by NN NN O
iHIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
PBMCs NN NN O
from NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
patients NN NN O
were NN NN O
found NN NN O
to NN NN O
produce NN NN O
virus NN NN O
. NN NN O
   
This NN NN O
viral NN NN O
reactivation NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
in NN NN O
patients NN NN O
' NN NN O
PBMCs NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
virus NN NN O
reactivation NN NN O
in NN NN O
resting NN NN O
PBMCs NN NN O
infected NN NN O
in NN NN O
vitro NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
specifically NN NN O
induced NN NN O
by NN NN O
ligands NN NN O
of NN NN O
the NN NN O
CDR2 NN NN O
- NN NN O
loop NN NN O
in NN NN O
domain NN NN O
1 NN NN O
( NN NN O
D1 NN NN O
) NN NN O
of NN NN O
CD4 NN NN B-Protein
( NN NN O
virus NN NN O
envelope NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD4 NN NN B-Protein
monoclonal NN NN O
antibodies NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
virus NN NN O
reactivation NN NN O
was NN NN O
not NN NN O
observed NN NN O
following NN NN O
CD4 NN NN B-Protein
oligomerization NN NN O
by NN NN O
antibodies NN NN O
that NN NN O
bind NN NN O
other NN NN O
epitopes NN NN O
in NN NN O
D1 NN NN O
, NN NN O
including NN NN O
the NN NN O
D1 NN NN O
/ NN NN O
CDR3 NN NN O
- NN NN O
loop NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
soluble NN NN O
CD4 NN NN B-Protein
( NN NN O
sCD4 NN NN O
) NN NN O
prevented NN NN O
virus NN NN O
reactivation NN NN O
by NN NN O
D1 NN NN O
/ NN NN O
CDR2 NN NN O
- NN NN O
loop NN NN O
ligands NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
signaling NN NN O
events NN NN O
initiated NN NN O
in NN NN O
PBMCs NN NN O
by NN NN O
oligomerization NN NN O
of NN NN O
CD4 NN NN B-Protein
at NN NN O
the NN NN O
D1 NN NN O
/ NN NN O
CDR2 NN NN O
- NN NN O
loop NN NN O
can NN NN O
trigger NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
upregulation NN NN O
in NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
Defining NN NN O
therapeutic NN NN O
targets NN NN O
by NN NN O
using NN NN O
adenovirus NN NN O
: NN NN O
blocking NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibits NN NN O
both NN NN O
inflammatory NN NN O
and NN NN O
destructive NN NN O
mechanisms NN NN O
in NN NN O
rheumatoid NN NN O
synovium NN NN O
but NN NN O
spares NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
rheumatoid NN NN O
arthritis NN NN O
has NN NN O
long NN NN O
been NN NN O
a NN NN O
subject NN NN O
of NN NN O
controversy NN NN O
. NN NN O
   
We NN NN O
used NN NN O
an NN NN O
adenoviral NN NN O
technique NN NN O
of NN NN O
blocking NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
subunit NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
which NN NN O
has NN NN O
the NN NN O
advantage NN NN O
that NN NN O
it NN NN O
can NN NN O
be NN NN O
used NN NN O
in NN NN O
the NN NN O
diseased NN NN O
tissue NN NN O
itself NN NN O
, NN NN O
with NN NN O
> NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
synovial NN NN O
macrophages NN NN O
, NN NN O
fibroblasts NN NN O
, NN NN O
and NN NN O
T NN NN O
cells NN NN O
infected NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
the NN NN O
spontaneous NN NN O
production NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
other NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
cytokines NN NN O
is NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
in NN NN O
rheumatoid NN NN O
synovial NN NN O
tissue NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
main NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
mediators NN NN O
, NN NN O
like NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
- NN NN B-Protein
11 NN NN I-Protein
, NN NN O
and NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
antagonist NN NN O
. NN NN O
   
Of NN NN O
even NN NN O
more NN NN O
interest NN NN O
, NN NN O
IkappaBalpha NN NN B-Protein
overexpression NN NN O
inhibited NN NN O
the NN NN O
production NN NN O
of NN NN O
matrix NN NN B-Protein
metalloproteinases NN NN I-Protein
1 NN NN I-Protein
and NN NN O
3 NN NN B-Protein
while NN NN O
not NN NN O
affecting NN NN O
their NN NN O
tissue NN NN O
inhibitor NN NN O
. NN NN O
   
Blocking NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
rheumatoid NN NN O
joint NN NN O
thus NN NN O
has NN NN O
a NN NN O
very NN NN O
beneficial NN NN O
profile NN NN O
, NN NN O
reducing NN NN O
both NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
and NN NN O
the NN NN O
tissue NN NN O
destruction NN NN O
. NN NN O
   
The NN NN O
adenoviral NN NN O
technique NN NN O
described NN NN O
here NN NN O
has NN NN O
widespread NN NN O
applicability NN NN O
, NN NN O
allowing NN NN O
rapid NN NN O
testing NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
blocking NN NN O
a NN NN O
potential NN NN O
therapeutic NN NN O
target NN NN O
in NN NN O
either NN NN O
cultures NN NN O
of NN NN O
normal NN NN O
cells NN NN O
or NN NN O
in NN NN O
the NN NN O
diseased NN NN O
tissue NN NN O
itself NN NN O
. NN NN O
   
Cell NN NN O
growth NN NN O
- NN NN O
regulated NN NN O
expression NN NN O
of NN NN O
mammalian NN NN O
MCM5 NN NN B-Protein
and NN NN O
MCM6 NN NN B-Protein
genes NN NN O
mediated NN NN O
by NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
E2F NN NN O
. NN NN O
   
Initiation NN NN O
of NN NN O
DNA NN NN O
replication NN NN O
requires NN NN O
the NN NN O
function NN NN O
of NN NN O
MCM NN NN O
gene NN NN O
products NN NN O
, NN NN O
which NN NN O
participate NN NN O
in NN NN O
ensuring NN NN O
that NN NN O
DNA NN NN O
replication NN NN O
occurs NN NN O
only NN NN O
once NN NN O
in NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
all NN NN O
mammalian NN NN O
genes NN NN O
of NN NN O
the NN NN O
MCM NN NN O
family NN NN O
is NN NN O
induced NN NN O
by NN NN O
growth NN NN O
stimulation NN NN O
, NN NN O
unlike NN NN O
yeast NN NN O
, NN NN O
and NN NN O
the NN NN O
mRNA NN NN O
levels NN NN O
peak NN NN O
at NN NN O
G1 NN NN O
/ NN NN O
S NN NN O
boundary NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
isolated NN NN O
human NN NN O
MCM NN NN O
gene NN NN O
promoters NN NN O
. NN NN O
   
Human NN NN O
MCM5 NN NN B-Protein
and NN NN O
MCM6 NN NN B-Protein
promoters NN NN O
with NN NN O
mutation NN NN O
in NN NN O
the NN NN O
E2F NN NN O
sites NN NN O
failed NN NN O
in NN NN O
promoter NN NN O
regulation NN NN O
following NN NN O
serum NN NN O
stimulation NN NN O
and NN NN O
exogenous NN NN O
E2F NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
novel NN NN O
E2F NN NN O
- NN NN O
like NN NN O
sequence NN NN O
in NN NN O
human NN NN O
MCM6 NN NN B-Protein
promoter NN NN O
which NN NN O
cooperates NN NN O
with NN NN O
the NN NN O
authentic NN NN O
E2F NN NN O
sites NN NN O
in NN NN O
E2F NN NN O
- NN NN O
dependent NN NN O
regulation NN NN O
. NN NN O
   
Forced NN NN O
expression NN NN O
of NN NN O
E2F1 NN NN B-Protein
could NN NN O
induce NN NN O
expression NN NN O
of NN NN O
all NN NN O
members NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
MCM NN NN O
genes NN NN O
in NN NN O
rat NN NN O
embryonal NN NN O
fibroblast NN NN O
REF52 NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
growth NN NN O
- NN NN O
regulated NN NN O
expression NN NN O
of NN NN O
mammalian NN NN O
MCM5 NN NN B-Protein
and NN NN O
MCM6 NN NN B-Protein
genes NN NN O
, NN NN O
and NN NN O
presumably NN NN O
other NN NN O
MCM NN NN O
members NN NN O
, NN NN O
is NN NN O
primarily NN NN O
regulated NN NN O
by NN NN O
E2F NN NN O
through NN NN O
binding NN NN O
to NN NN O
multiple NN NN O
E2F NN NN O
sites NN NN O
in NN NN O
the NN NN O
promoters NN NN O
. NN NN O
   
Non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
inhibit NN NN O
the NN NN O
expression NN NN O
of NN NN O
cytokines NN NN O
and NN NN O
induce NN NN O
HSP70 NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
non NN NN O
- NN NN O
steroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
activate NN NN O
heat NN NN O
shock NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
HSF1 NN NN B-Protein
) NN NN O
from NN NN O
a NN NN O
latent NN NN O
cytoplasmic NN NN O
form NN NN O
to NN NN O
a NN NN O
nuclear NN NN O
, NN NN O
DNA NN NN O
binding NN NN O
state NN NN O
. NN NN O
   
As NN NN O
HSF1 NN NN B-Protein
can NN NN O
function NN NN O
as NN NN O
both NN NN O
an NN NN O
activator NN NN O
of NN NN O
heat NN NN O
shock NN NN O
genes NN NN O
and NN NN O
a NN NN O
repressor NN NN O
of NN NN O
non NN NN O
- NN NN O
heat NN NN O
shock NN NN O
genes NN NN O
such NN NN O
as NN NN O
IL1B NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
HSF1 NN NN B-Protein
in NN NN O
the NN NN O
effects NN NN O
of NN NN O
NSAIDs NN NN O
on NN NN O
gene NN NN O
expression NN NN O
in NN NN O
a NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
two NN NN O
members NN NN O
of NN NN O
the NN NN O
NSAIDs NN NN O
, NN NN O
sodium NN NN O
salicylate NN NN O
and NN NN O
sulindac NN NN O
repress NN NN O
the NN NN O
IL1B NN NN B-Protein
promoter NN NN O
to NN NN O
similar NN NN O
degree NN NN O
to NN NN O
heat NN NN O
shock NN NN O
or NN NN O
HSF1 NN NN B-Protein
overexpression NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
sodium NN NN O
salicylate NN NN O
and NN NN O
additional NN NN O
NSAIDs NN NN O
used NN NN O
at NN NN O
concentrations NN NN O
that NN NN O
activate NN NN O
HSF1 NN NN B-Protein
also NN NN O
inhibited NN NN O
the NN NN O
expression NN NN O
of NN NN O
other NN NN O
monocytic NN NN O
genes NN NN O
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
activated NN NN O
by NN NN O
exposure NN NN O
to NN NN O
a NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
stimulus NN NN O
( NN NN O
lipopolysaccharide NN NN O
, NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
At NN NN O
least NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
the NN NN O
IL1B NN NN B-Protein
promoter NN NN O
, NN NN O
repression NN NN O
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
involve NN NN O
another NN NN O
factor NN NN O
whose NN NN O
activity NN NN O
is NN NN O
affected NN NN O
by NN NN O
the NN NN O
NSAIDs NN NN O
, NN NN O
NFkappaB NN NN O
as NN NN O
the NN NN O
IL1B NN NN B-Protein
promoter NN NN O
fragment NN NN O
used NN NN O
in NN NN O
our NN NN O
studies NN NN O
is NN NN O
not NN NN O
NFkappaB NN NN O
responsive NN NN O
and NN NN O
binds NN NN O
specifically NN NN O
to NN NN O
HSF1 NN NN B-Protein
. NN NN O
   
Exposure NN NN O
to NN NN O
NSAIDs NN NN O
had NN NN O
a NN NN O
complex NN NN O
effect NN NN O
on NN NN O
HSP NN NN O
gene NN NN O
expression NN NN O
and NN NN O
while NN NN O
sulindac NN NN O
activated NN NN O
the NN NN O
stress NN NN O
responsive NN NN O
HSP70B NN NN B-Protein
promoter NN NN O
, NN NN O
sodium NN NN O
salicylate NN NN O
did NN NN O
not NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
only NN NN O
a NN NN O
subset NN NN O
of NN NN O
the NN NN O
NSAIDs NN NN O
induced NN NN O
HSP70 NN NN B-Protein
mRNA NN NN O
species NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
reflect NN NN O
the NN NN O
properties NN NN O
of NN NN O
HSF1 NN NN B-Protein
which NN NN O
can NN NN O
be NN NN O
activated NN NN O
to NN NN O
at NN NN O
least NN NN O
two NN NN O
DNA NN NN O
binding NN NN O
forms NN NN O
only NN NN O
one NN NN O
of NN NN O
which NN NN O
activates NN NN O
heat NN NN O
shock NN NN O
promoters NN NN O
and NN NN O
suggest NN NN O
that NN NN O
individual NN NN O
NSAID NN NN O
family NN NN O
members NN NN O
may NN NN O
differentially NN NN O
induce NN NN O
one NN NN O
or NN NN O
other NN NN O
of NN NN O
these NN NN O
forms NN NN O
. NN NN O
   
Overall NN NN O
therefore NN NN O
, NN NN O
exposure NN NN O
to NN NN O
NSAIDs NN NN O
leads NN NN O
to NN NN O
a NN NN O
profound NN NN O
switch NN NN O
in NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
with NN NN O
suppression NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
macrophage NN NN O
activation NN NN O
and NN NN O
induction NN NN O
of NN NN O
stress NN NN O
genes NN NN O
and NN NN O
HSF1 NN NN B-Protein
appears NN NN O
to NN NN O
play NN NN O
a NN NN O
regulatory NN NN O
role NN NN O
in NN NN O
these NN NN O
effects NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Disruption NN NN O
of NN NN O
alpha NN NN O
beta NN NN O
but NN NN O
not NN NN O
of NN NN O
gamma NN NN O
delta NN NN O
T NN NN O
cell NN NN O
development NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
protein NN NN O
Id3 NN NN B-Protein
in NN NN O
committed NN NN O
T NN NN O
cell NN NN O
progenitors NN NN O
. NN NN O
   
Enforced NN NN O
expression NN NN O
of NN NN O
Id3 NN NN B-Protein
, NN NN O
which NN NN O
has NN NN O
the NN NN O
capacity NN NN O
to NN NN O
inhibit NN NN O
many NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
( NN NN O
bHLH NN NN O
) NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
in NN NN O
human NN NN O
CD34 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
hematopoietic NN NN O
progenitor NN NN O
cells NN NN O
that NN NN O
have NN NN O
not NN NN O
undergone NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
gene NN NN O
rearrangements NN NN O
inhibits NN NN O
development NN NN O
of NN NN O
the NN NN O
transduced NN NN O
cells NN NN O
into NN NN O
TCRalpha NN NN O
beta NN NN O
and NN NN O
gamma NN NN O
delta NN NN O
cells NN NN O
in NN NN O
a NN NN O
fetal NN NN O
thymic NN NN O
organ NN NN O
culture NN NN O
( NN NN O
FTOC NN NN O
) NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
document NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
Id3 NN NN B-Protein
, NN NN O
in NN NN O
progenitors NN NN O
that NN NN O
have NN NN O
initiated NN NN O
TCR NN NN O
gene NN NN O
rearrangements NN NN O
( NN NN O
pre NN NN O
- NN NN O
T NN NN O
cells NN NN O
) NN NN O
, NN NN O
inhibits NN NN O
development NN NN O
into NN NN O
TCRalpha NN NN O
beta NN NN O
but NN NN O
not NN NN O
into NN NN O
TCRgamma NN NN O
delta NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
Id3 NN NN B-Protein
impedes NN NN O
expression NN NN O
of NN NN O
recombination NN NN O
activating NN NN O
genes NN NN O
and NN NN O
downregulates NN NN O
pre NN NN O
- NN NN O
Talpha NN NN O
mRNA NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
possible NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
Id3 NN NN B-Protein
overexpression NN NN O
can NN NN O
differentially NN NN O
affect NN NN O
development NN NN O
of NN NN O
pre NN NN O
- NN NN O
T NN NN O
cells NN NN O
into NN NN O
TCRalpha NN NN O
beta NN NN O
and NN NN O
gamma NN NN O
delta NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
also NN NN O
observed NN NN O
that NN NN O
cell NN NN O
surface NN NN O
CD4 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
- NN NN O
) NN NN O
cells NN NN O
with NN NN O
rearranged NN NN O
TCR NN NN O
genes NN NN O
developed NN NN O
from NN NN O
Id3 NN NN B-Protein
- NN NN O
transduced NN NN O
but NN NN O
not NN NN O
from NN NN O
control NN NN O
- NN NN O
transduced NN NN O
pre NN NN O
- NN NN O
T NN NN O
cells NN NN O
in NN NN O
an NN NN O
FTOC NN NN O
. NN NN O
   
These NN NN O
cells NN NN O
had NN NN O
properties NN NN O
of NN NN O
both NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
and NN NN O
pre NN NN O
- NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
bHLH NN NN O
factors NN NN O
are NN NN O
required NN NN O
to NN NN O
control NN NN O
T NN NN O
cell NN NN O
development NN NN O
after NN NN O
the NN NN O
T NN NN O
/ NN NN O
NK NN NN O
developmental NN NN O
checkpoint NN NN O
. NN NN O
   
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
can NN NN O
trigger NN NN O
the NN NN O
Notch NN NN O
signaling NN NN O
pathway NN NN O
by NN NN O
inducing NN NN O
the NN NN O
expression NN NN O
of NN NN O
Jagged1 NN NN B-Protein
, NN NN O
a NN NN O
ligand NN NN O
for NN NN O
Notch NN NN O
receptors NN NN O
. NN NN O
   
Jagged1 NN NN B-Protein
belongs NN NN O
to NN NN O
the NN NN O
DSL NN NN O
family NN NN O
of NN NN O
ligands NN NN O
for NN NN O
Notch NN NN O
receptors NN NN O
that NN NN O
control NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
various NN NN O
cell NN NN O
lineages NN NN O
. NN NN O
   
However NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
its NN NN O
expression NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
Jagged1 NN NN B-Protein
is NN NN O
a NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
responsive NN NN O
gene NN NN O
. NN NN O
   
Both NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
RelA NN NN B-Protein
induced NN NN O
jagged1 NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
whereas NN NN O
a NN NN O
mutant NN NN O
defective NN NN O
for NN NN O
transactivation NN NN O
did NN NN O
not NN NN O
. NN NN O
   
Importantly NN NN O
, NN NN O
jagged1 NN NN B-Protein
transcripts NN NN O
were NN NN O
also NN NN O
upregulated NN NN O
by NN NN O
endogenous NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
this NN NN O
effect NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
dominant NN NN O
mutant NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
a NN NN O
physiological NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Cell NN NN O
surface NN NN O
expression NN NN O
of NN NN O
Jagged1 NN NN B-Protein
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
- NN NN O
expressing NN NN O
cell NN NN O
monolayers NN NN O
led NN NN O
to NN NN O
a NN NN O
functional NN NN O
interaction NN NN O
with NN NN O
lymphocytes NN NN O
expressing NN NN O
the NN NN O
Notch1 NN NN B-Protein
/ NN NN O
TAN NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN O
. NN NN O
   
This NN NN O
correlated NN NN O
with NN NN O
the NN NN O
initiation NN NN O
of NN NN O
signaling NN NN O
downstream NN NN O
of NN NN O
Notch NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
increased NN NN O
levels NN NN O
of NN NN O
HES NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcripts NN NN O
in NN NN O
co NN NN O
- NN NN O
cultivated NN NN O
T NN NN O
cells NN NN O
and NN NN O
of NN NN O
CD23 NN NN B-Protein
transcripts NN NN O
in NN NN O
co NN NN O
- NN NN O
cultivated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
its NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
induction NN NN O
, NN NN O
Jagged1 NN NN B-Protein
was NN NN O
found NN NN O
to NN NN O
be NN NN O
highly NN NN O
expressed NN NN O
in NN NN O
splenic NN NN O
B NN NN O
cells NN NN O
where NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
is NN NN O
expressed NN NN O
constitutively NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
can NN NN O
trigger NN NN O
the NN NN O
Notch NN NN O
signaling NN NN O
pathway NN NN O
in NN NN O
neighboring NN NN O
cells NN NN O
by NN NN O
inducing NN NN O
jagged1 NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
Jagged1 NN NN B-Protein
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
differentiation NN NN O
or NN NN O
function NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
also NN NN O
highlight NN NN O
the NN NN O
potential NN NN O
for NN NN O
an NN NN O
interplay NN NN O
between NN NN O
the NN NN O
Notch NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
signaling NN NN O
pathways NN NN O
in NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Transcriptional NN NN O
control NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
by NN NN O
human NN NN O
helper NN NN O
T NN NN O
cells NN NN O
: NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
is NN NN O
regulated NN NN O
independently NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
synthesis NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
is NN NN O
fundamentally NN NN O
involved NN NN O
in NN NN O
eosinophilic NN NN O
inflammation NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
production NN NN O
may NN NN O
be NN NN O
effective NN NN O
for NN NN O
the NN NN O
management NN NN O
of NN NN O
allergic NN NN O
diseases NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
aimed NN NN O
to NN NN O
find NN NN O
the NN NN O
transcriptional NN NN O
mechanisms NN NN O
that NN NN O
regulate NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
to NN NN O
selectively NN NN O
control NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Allergen NN NN O
- NN NN O
specific NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
hybridomas NN NN O
were NN NN O
established NN NN O
from NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
of NN NN O
patients NN NN O
with NN NN O
asthma NN NN O
, NN NN O
and NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
was NN NN O
investigated NN NN O
with NN NN O
transient NN NN O
transfection NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
A NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
luciferase NN NN B-Protein
gene NN NN O
construct NN NN O
, NN NN O
pIL NN NN O
- NN NN O
5 NN NN O
( NN NN O
- NN NN O
511 NN NN O
) NN NN O
Luc NN NN O
, NN NN O
was NN NN O
transcribed NN NN O
on NN NN O
activation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
producing NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
, NN NN O
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
nonproducing NN NN O
clones NN NN O
. NN NN O
   
pIL NN NN O
- NN NN O
5 NN NN O
( NN NN O
- NN NN O
511 NN NN O
) NN NN O
Luc NN NN O
was NN NN O
transcribed NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
hybridomas NN NN O
derived NN NN O
from NN NN O
fusion NN NN O
between NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
producing NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
and NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
- NN NN O
nonexpressing NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
hybridomas NN NN O
derived NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
nonproducing NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
was NN NN O
not NN NN O
only NN NN O
induced NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
stimulation NN NN O
but NN NN O
also NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
stimulation NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
induced NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TcR NN NN O
) NN NN O
stimulation NN NN O
, NN NN O
although NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
upregulation NN NN O
of NN NN O
binding NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
by NN NN O
human NN NN O
helper NN NN O
T NN NN O
cells NN NN O
is NN NN O
regulated NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
A NN NN O
unique NN NN O
transcriptional NN NN O
mechanism NN NN O
distinct NN NN O
from NN NN O
those NN NN O
regulating NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
genes NN NN O
seems NN NN O
to NN NN O
control NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
. NN NN O
   
Selective NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
transcription NN NN O
may NN NN O
be NN NN O
useful NN NN O
for NN NN O
treating NN NN O
eosinophlic NN NN O
inflammation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
low NN NN O
shear NN NN O
flow NN NN O
- NN NN O
induced NN NN O
HAEC NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
monocyte NN NN O
adhesion NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
reported NN NN O
that NN NN O
prolonged NN NN O
exposure NN NN O
of NN NN O
human NN NN O
aortic NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HAEC NN NN O
) NN NN O
to NN NN O
low NN NN O
shear NN NN O
stress NN NN O
flow NN NN O
patterns NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
sustained NN NN O
increase NN NN O
in NN NN O
the NN NN O
activated NN NN O
form NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
regulator NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
investigate NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
low NN NN O
shear NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
responsible NN NN O
for NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
resulting NN NN O
in NN NN O
augmented NN NN O
endothelial NN NN O
cell NN NN O
- NN NN O
monocyte NN NN O
( NN NN O
EC NN NN O
- NN NN O
Mn NN NN O
) NN NN O
adhesion NN NN O
and NN NN O
that NN NN O
this NN NN O
activation NN NN O
is NN NN O
dependent NN NN O
on NN NN O
intracellular NN NN O
oxidant NN NN O
activity NN NN O
. NN NN O
   
Before NN NN O
exposure NN NN O
to NN NN O
low NN NN O
shear NN NN O
( NN NN O
2 NN NN O
dyn NN NN O
/ NN NN O
cm2 NN NN O
) NN NN O
for NN NN O
6 NN NN O
h NN NN O
, NN NN O
HAEC NN NN O
were NN NN O
preincubated NN NN O
with NN NN O
or NN NN O
without NN NN O
the NN NN O
antioxidants NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
or NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
. NN NN O
   
PDTC NN NN O
strongly NN NN O
inhibited NN NN O
low NN NN O
shear NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
EC NN NN O
- NN NN O
Mn NN NN O
adhesion NN NN O
. NN NN O
   
Paradoxically NN NN O
, NN NN O
NAC NN NN O
exerted NN NN O
a NN NN O
positive NN NN O
effect NN NN O
on NN NN O
low NN NN O
shear NN NN O
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
EC NN NN O
- NN NN O
Mn NN NN O
adhesion NN NN O
and NN NN O
only NN NN O
slightly NN NN O
downregulated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
are NN NN O
blocked NN NN O
by NN NN O
both NN NN O
PDTC NN NN O
and NN NN O
NAC NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
low NN NN O
shear NN NN O
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
that NN NN O
pathways NN NN O
mediating NN NN O
low NN NN O
shear NN NN O
- NN NN O
and NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
EC NN NN O
- NN NN O
Mn NN NN O
adhesion NN NN O
may NN NN O
be NN NN O
differentially NN NN O
regulated NN NN O
. NN NN O
   
Nuclear NN NN O
localization NN NN O
and NN NN O
formation NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
- NN NN O
lymphoid NN NN B-Protein
enhancer NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
complexes NN NN O
are NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
activation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
response NN NN O
to NN NN O
activation NN NN O
of NN NN O
the NN NN O
Wnt NN NN O
signaling NN NN O
pathway NN NN O
, NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
accumulates NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
where NN NN O
it NN NN O
cooperates NN NN O
with NN NN O
LEF NN NN O
/ NN NN O
TCF NN NN O
( NN NN O
for NN NN O
lymphoid NN NN O
enhancer NN NN O
factor NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
factor NN NN O
) NN NN O
transcription NN NN O
factors NN NN O
to NN NN O
activate NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
undergoes NN NN O
this NN NN O
shift NN NN O
in NN NN O
location NN NN O
and NN NN O
participates NN NN O
in NN NN O
activation NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
can NN NN O
be NN NN O
imported NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
independently NN NN O
of NN NN O
LEF NN NN O
/ NN NN O
TCF NN NN O
binding NN NN O
, NN NN O
and NN NN O
it NN NN O
may NN NN O
also NN NN O
be NN NN O
exported NN NN O
from NN NN O
nuclei NN NN O
. NN NN O
   
We NN NN O
have NN NN O
introduced NN NN O
a NN NN O
small NN NN O
deletion NN NN O
within NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
( NN NN O
Delta19 NN NN O
) NN NN O
that NN NN O
disrupts NN NN O
binding NN NN O
to NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
E NN NN B-Protein
- NN NN I-Protein
cadherin NN NN I-Protein
, NN NN O
and NN NN O
APC NN NN B-Protein
but NN NN O
not NN NN O
axin NN NN B-Protein
. NN NN O
   
This NN NN O
Delta19 NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
mutant NN NN O
localizes NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
because NN NN O
it NN NN O
may NN NN O
not NN NN O
be NN NN O
efficiently NN NN O
sequestered NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
Delta19 NN NN O
definitively NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
localizes NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
are NN NN O
completely NN NN O
independent NN NN O
of NN NN O
LEF NN NN O
/ NN NN O
TCF NN NN O
factors NN NN O
. NN NN O
   
beta NN NN B-Protein
- NN NN I-Protein
Catenin NN NN I-Protein
and NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
complexes NN NN O
can NN NN O
activate NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
in NN NN O
a NN NN O
transformed NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
line NN NN O
( NN NN O
Jurkat NN NN O
) NN NN O
but NN NN O
not NN NN O
in NN NN O
normal NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
even NN NN O
though NN NN O
both NN NN O
factors NN NN O
are NN NN O
nuclear NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
localization NN NN O
of NN NN O
both NN NN O
factors NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
activation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Excess NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
can NN NN O
squelch NN NN O
reporter NN NN O
gene NN NN O
activation NN NN O
by NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
beta NN NN B-Protein
- NN NN I-Protein
catenin NN NN I-Protein
complexes NN NN O
but NN NN O
not NN NN O
activation NN NN O
by NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
VP16 NN NN B-Protein
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
a NN NN O
third NN NN O
component NN NN O
is NN NN O
necessary NN NN O
for NN NN O
gene NN NN O
activation NN NN O
and NN NN O
that NN NN O
this NN NN O
third NN NN O
component NN NN O
may NN NN O
vary NN NN O
with NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
Paradoxical NN NN O
priming NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
cytokine NN NN O
production NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
is NN NN O
a NN NN O
well NN NN O
- NN NN O
known NN NN O
immunosuppressive NN NN O
and NN NN O
/ NN NN O
or NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
cytokine NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
report NN NN O
in NN NN O
vitro NN NN O
experimental NN NN O
studies NN NN O
in NN NN O
which NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
primed NN NN O
leukocytes NN NN O
and NN NN O
led NN NN O
to NN NN O
an NN NN O
enhanced NN NN O
production NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
upon NN NN O
further NN NN O
stimulation NN NN O
by NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
Monocytes NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
prepared NN NN O
from NN NN O
whole NN NN O
blood NN NN O
maintained NN NN O
for NN NN O
20 NN NN O
h NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
recombinant NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
had NN NN O
an NN NN O
enhanced NN NN O
capacity NN NN O
to NN NN O
produce NN NN O
TNF NN NN B-Protein
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
TNF NN NN B-Protein
, NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
spontaneous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1ra NN NN I-Protein
production NN NN O
were NN NN O
also NN NN O
enhanced NN NN O
. NN NN O
   
When NN NN O
isolated NN NN O
PBMC NN NN O
were NN NN O
first NN NN O
cultured NN NN O
for NN NN O
20 NN NN O
h NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
Teflon NN NN O
to NN NN O
prevent NN NN O
adherence NN NN O
, NN NN O
washed NN NN O
to NN NN O
remove NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
then NN NN O
further NN NN O
cultured NN NN O
in NN NN O
plastic NN NN O
dishes NN NN O
for NN NN O
an NN NN O
additional NN NN O
20 NN NN O
h NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
LPS NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
an NN NN O
enhanced NN NN O
release NN NN O
of NN NN O
TNF NN NN B-Protein
was NN NN O
observed NN NN O
. NN NN O
   
This NN NN O
was NN NN O
not NN NN O
the NN NN O
case NN NN O
when NN NN O
PBMC NN NN O
were NN NN O
pre NN NN O
- NN NN O
cultured NN NN O
in NN NN O
plastic NN NN O
multidishes NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
. NN NN O
   
TNF NN NN O
mRNA NN NN O
expression NN NN O
induced NN NN O
by NN NN O
LPS NN NN O
was NN NN O
decreased NN NN O
when NN NN O
the NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
of NN NN O
PBMC NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
performed NN NN O
on NN NN O
plastic NN NN O
, NN NN O
whereas NN NN O
this NN NN O
was NN NN O
not NN NN O
the NN NN O
case NN NN O
when NN NN O
cells NN NN O
were NN NN O
pre NN NN O
- NN NN O
cultured NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
Teflon NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
NFkappaB NN NN O
translocation NN NN O
following NN NN O
LPS NN NN O
activation NN NN O
was NN NN O
higher NN NN O
after NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
pre NN NN O
- NN NN O
treatment NN NN O
on NN NN O
Teflon NN NN O
than NN NN O
on NN NN O
plastic NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
an NN NN O
enhanced NN NN O
frequency NN NN O
of NN NN O
CD16 NN NN B-Protein
and NN NN O
CD68 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
cells NN NN O
among NN NN O
the NN NN O
CD14 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
cells NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
independently NN NN O
of NN NN O
the NN NN O
pre NN NN O
- NN NN O
culture NN NN O
conditions NN NN O
of NN NN O
the NN NN O
PBMC NN NN O
. NN NN O
   
Altogether NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
depends NN NN O
on NN NN O
the NN NN O
prevention NN NN O
of NN NN O
monocyte NN NN O
adherence NN NN O
by NN NN O
red NN NN O
cells NN NN O
in NN NN O
the NN NN O
whole NN NN O
blood NN NN O
assays NN NN O
or NN NN O
by NN NN O
cultures NN NN O
of NN NN O
PBMC NN NN O
on NN NN O
Teflon NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
adherence NN NN O
parameter NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
induced NN NN O
modulation NN NN O
of NN NN O
some NN NN O
monocyte NN NN O
surface NN NN O
markers NN NN O
. NN NN O
   
Different NN NN O
sequence NN NN O
requirements NN NN O
for NN NN O
expression NN NN O
in NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
cells NN NN O
within NN NN O
a NN NN O
regulatory NN NN O
element NN NN O
upstream NN NN O
of NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
lineage NN NN O
- NN NN O
restricted NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
differentiation NN NN O
of NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
localized NN NN O
a NN NN O
317 NN NN O
base NN NN O
pair NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
element NN NN O
, NN NN O
HS NN NN O
I NN NN O
, NN NN O
associated NN NN O
with NN NN O
a NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
DNase NN NN O
I NN NN O
hypersensitive NN NN O
site NN NN O
, NN NN O
which NN NN O
lies NN NN O
approx NN NN O
. NN NN O
3 NN NN O
. NN NN O
7 NN NN O
kilobases NN NN O
upstream NN NN O
of NN NN O
the NN NN O
murine NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
IE NN NN O
promoter NN NN O
. NN NN O
   
HS NN NN O
I NN NN O
directs NN NN O
high NN NN O
- NN NN O
level NN NN O
expression NN NN O
of NN NN O
reporter NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
lacZ NN NN B-Protein
genes NN NN O
to NN NN O
primitive NN NN O
and NN NN O
definitive NN NN O
erythroid NN NN O
cells NN NN O
and NN NN O
megakaryocytes NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
Comparative NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
HS NN NN O
I NN NN O
between NN NN O
human NN NN O
and NN NN O
mouse NN NN O
shows NN NN O
approx NN NN O
. NN NN O
63 NN NN O
% NN NN O
nucleotide NN NN O
identity NN NN O
with NN NN O
a NN NN O
more NN NN O
conserved NN NN O
core NN NN O
of NN NN O
169 NN NN O
base NN NN O
pairs NN NN O
( NN NN O
86 NN NN O
% NN NN O
identity NN NN O
) NN NN O
. NN NN O
   
This NN NN O
core NN NN O
contains NN NN O
a NN NN O
GATA NN NN O
site NN NN O
separated NN NN O
by NN NN O
10 NN NN O
base NN NN O
pairs NN NN O
from NN NN O
an NN NN O
E NN NN O
- NN NN O
box NN NN O
motif NN NN O
. NN NN O
   
The NN NN O
composite NN NN O
motif NN NN O
binds NN NN O
a NN NN O
multi NN NN O
- NN NN O
protein NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
complex NN NN O
which NN NN O
includes NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
SCL NN NN B-Protein
/ NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
E2A NN NN B-Protein
, NN NN O
Lmo2 NN NN B-Protein
and NN NN O
Ldb NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Point NN NN O
mutations NN NN O
of NN NN O
the NN NN O
GATA NN NN O
site NN NN O
abolishes NN NN O
HS NN NN O
I NN NN O
function NN NN O
, NN NN O
whereas NN NN O
mutation NN NN O
of NN NN O
the NN NN O
E NN NN O
- NN NN O
box NN NN O
motif NN NN O
still NN NN O
allows NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
in NN NN O
both NN NN O
lineages NN NN O
. NN NN O
   
Strict NN NN O
dependence NN NN O
of NN NN O
HS NN NN O
I NN NN O
activity NN NN O
on NN NN O
a NN NN O
GATA NN NN O
site NN NN O
implies NN NN O
that NN NN O
assembly NN NN O
of NN NN O
a NN NN O
protein NN NN O
complex NN NN O
containing NN NN O
a NN NN O
GATA NN NN O
- NN NN O
factor NN NN O
, NN NN O
presumably NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
is NN NN O
critical NN NN O
to NN NN O
activating NN NN O
or NN NN O
maintaining NN NN O
its NN NN O
function NN NN O
. NN NN O
   
Further NN NN O
dissection NN NN O
of NN NN O
the NN NN O
317 NN NN O
base NN NN O
pair NN NN O
region NN NN O
demonstrates NN NN O
that NN NN O
, NN NN O
whereas NN NN O
all NN NN O
317 NN NN O
base NN NN O
pairs NN NN O
are NN NN O
required NN NN O
for NN NN O
expression NN NN O
in NN NN O
megakaryocytes NN NN O
, NN NN O
only NN NN O
the NN NN O
5 NN NN O
' NN NN O
62 NN NN O
base NN NN O
pairs NN NN O
are NN NN O
needed NN NN O
for NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
reporter NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
differential NN NN O
lineage NN NN O
requirements NN NN O
for NN NN O
expression NN NN O
within NN NN O
the NN NN O
HS NN NN O
I NN NN O
element NN NN O
. NN NN O
   
Monocyte NN NN O
arrest NN NN O
and NN NN O
transmigration NN NN O
on NN NN O
inflamed NN NN O
endothelium NN NN O
in NN NN O
shear NN NN O
flow NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
adenovirus NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
transfer NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Mobilization NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
activates NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
endothelial NN NN O
adhesion NN NN O
molecules NN NN O
and NN NN O
chemokines NN NN O
that NN NN O
contribute NN NN O
to NN NN O
monocyte NN NN O
infiltration NN NN O
critical NN NN O
in NN NN O
atherogenesis NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
has NN NN O
been NN NN O
achieved NN NN O
by NN NN O
pharmacological NN NN O
and NN NN O
genetic NN NN O
approaches NN NN O
; NN NN O
however NN NN O
, NN NN O
monocyte NN NN O
interactions NN NN O
with NN NN O
activated NN NN O
endothelium NN NN O
in NN NN O
shear NN NN O
flow NN NN O
following NN NN O
gene NN NN O
transfer NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitor NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
have NN NN O
not NN NN O
been NN NN O
studied NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
endothelial NN NN O
cells NN NN O
using NN NN O
a NN NN O
recombinant NN NN O
adenovirus NN NN O
prevented NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
suppressed NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mRNA NN NN O
and NN NN O
surface NN NN O
protein NN NN O
expression NN NN O
and NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
transcripts NN NN O
for NN NN O
the NN NN O
chemokines NN NN O
monocyte NN NN B-Protein
chemoattractant NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
growth NN NN B-Protein
- NN NN I-Protein
related NN NN I-Protein
activity NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
GRO NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
This NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
reduction NN NN O
in NN NN O
endothelial NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
secretion NN NN O
and NN NN O
GRO NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
immobilization NN NN O
. NN NN O
   
Adhesion NN NN O
assays NN NN O
under NN NN O
physiological NN NN O
shear NN NN O
flow NN NN O
conditions NN NN O
showed NN NN O
that NN NN O
firm NN NN O
arrest NN NN O
, NN NN O
spreading NN NN O
, NN NN O
and NN NN O
transmigration NN NN O
of NN NN O
monocytes NN NN O
on NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
activated NN NN O
endothelium NN NN O
was NN NN O
markedly NN NN O
inhibited NN NN O
by NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
overexpression NN NN O
. NN NN O
   
Inhibition NN NN O
with NN NN O
monoclonal NN NN O
antibodies NN NN O
and NN NN O
peptide NN NN O
antagonists NN NN O
inferred NN NN O
that NN NN O
this NN NN O
was NN NN O
due NN NN O
to NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
Ig NN NN O
integrin NN NN O
ligand NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
chemokines NN NN O
specifically NN NN O
involved NN NN O
in NN NN O
these NN NN O
events NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
rolling NN NN O
of NN NN O
monocytes NN NN O
was NN NN O
increased NN NN O
by NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
transfer NN NN O
and NN NN O
was NN NN O
partly NN NN O
mediated NN NN O
by NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
; NN NN O
however NN NN O
, NN NN O
it NN NN O
appeared NN NN O
to NN NN O
be NN NN O
unaffected NN NN O
by NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
induction NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
data NN NN O
provide NN NN O
novel NN NN O
evidence NN NN O
that NN NN O
selective NN NN O
modulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
adenoviral NN NN O
transfer NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
impairs NN NN O
the NN NN O
expression NN NN O
of NN NN O
multiple NN NN O
endothelial NN NN O
gene NN NN O
products NN NN O
required NN NN O
for NN NN O
subsequent NN NN O
monocyte NN NN O
arrest NN NN O
and NN NN O
emigration NN NN O
in NN NN O
shear NN NN O
flow NN NN O
and NN NN O
thus NN NN O
for NN NN O
monocyte NN NN O
infiltration NN NN O
in NN NN O
atherosclerotic NN NN O
plaques NN NN O
. NN NN O
   
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
function NN NN O
in NN NN O
separate NN NN O
, NN NN O
but NN NN O
overlapping NN NN O
pathways NN NN O
to NN NN O
augment NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
, NN NN O
two NN NN O
hematopoietic NN NN O
cell NN NN O
specific NN NN O
molecules NN NN O
, NN NN O
are NN NN O
critical NN NN O
for NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
activation NN NN O
. NN NN O
   
Following NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
stimulation NN NN O
, NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
both NN NN O
undergo NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
associate NN NN O
with NN NN O
each NN NN O
other NN NN O
via NN NN O
the NN NN O
SH2 NN NN O
domain NN NN O
of NN NN O
Vav NN NN B-Protein
and NN NN O
phosphorylated NN NN O
tyrosines NN NN O
of NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
have NN NN O
a NN NN O
synergistic NN NN O
effect NN NN O
on NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
two NN NN O
tyrosines NN NN O
, NN NN O
Tyr NN NN O
- NN NN O
113 NN NN O
and NN NN O
Tyr NN NN O
- NN NN O
128 NN NN O
, NN NN O
of NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
are NN NN O
required NN NN O
for NN NN O
its NN NN O
binding NN NN O
to NN NN O
Vav NN NN B-Protein
, NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
intact NN NN O
cells NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
we NN NN O
find NN NN O
also NN NN O
that NN NN O
the NN NN O
interaction NN NN O
between NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
is NN NN O
not NN NN O
required NN NN O
for NN NN O
their NN NN O
cooperation NN NN O
in NN NN O
augmenting NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
as NN NN O
the NN NN O
two NN NN O
molecules NN NN O
appear NN NN O
to NN NN O
function NN NN O
in NN NN O
different NN NN O
signaling NN NN O
pathways NN NN O
upstream NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
in NN NN O
the NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
line NN NN O
potentiates NN NN O
the NN NN O
activities NN NN O
of NN NN O
both NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
overexpression NN NN O
of NN NN O
Vav NN NN B-Protein
leads NN NN O
to NN NN O
enhanced NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
activity NN NN O
without NN NN O
affecting NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
overexpression NN NN O
of NN NN O
Vav NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
, NN NN O
augments NN NN O
CD28 NN NN B-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
synergy NN NN O
between NN NN O
SLP NN NN B-Protein
- NN NN I-Protein
76 NN NN I-Protein
and NN NN O
Vav NN NN B-Protein
in NN NN O
regulating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
reflects NN NN O
the NN NN O
cooperation NN NN O
between NN NN O
different NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
Targeted NN NN O
remodeling NN NN O
of NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
chromatin NN NN O
structure NN NN O
produces NN NN O
increased NN NN O
expression NN NN O
and NN NN O
decreased NN NN O
silencing NN NN O
. NN NN O
   
The NN NN O
chromatin NN NN O
structure NN NN O
of NN NN O
the NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
locus NN NN O
assumes NN NN O
a NN NN O
transcriptionally NN NN O
- NN NN O
active NN NN O
conformation NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
One NN NN O
feature NN NN O
of NN NN O
this NN NN O
chromatin NN NN O
reorganization NN NN O
is NN NN O
the NN NN O
formation NN NN O
of NN NN O
DNase NN NN O
1 NN NN O
hypersensitive NN NN O
sites NN NN O
in NN NN O
the NN NN O
regions NN NN O
of NN NN O
active NN NN O
globin NN NN O
gene NN NN O
promoters NN NN O
. NN NN O
   
This NN NN O
reorganization NN NN O
requires NN NN O
the NN NN O
globin NN NN O
locus NN NN O
control NN NN O
region NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
normal NN NN O
expression NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
like NN NN O
globin NN NN O
genes NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
it NN NN O
is NN NN O
possible NN NN O
to NN NN O
artificially NN NN O
enhance NN NN O
the NN NN O
opening NN NN O
of NN NN O
the NN NN O
chromatin NN NN O
structure NN NN O
of NN NN O
a NN NN O
minimal NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
, NN NN O
we NN NN O
placed NN NN O
a NN NN O
101bp NN NN O
, NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
DNase NN NN O
1 NN NN O
hypersensitive NN NN O
site NN NN O
- NN NN O
forming NN NN O
element NN NN O
( NN NN O
HSFE NN NN O
) NN NN O
immediately NN NN O
upstream NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
and NN NN O
gene NN NN O
. NN NN O
   
This NN NN O
element NN NN O
includes NN NN O
binding NN NN O
sites NN NN O
for NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Sp NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Constructs NN NN O
were NN NN O
stably NN NN O
transfected NN NN O
into NN NN O
murine NN NN O
erythroleukemia NN NN O
cells NN NN O
and NN NN O
promoter NN NN O
chromatin NN NN O
structure NN NN O
and NN NN O
gene NN NN O
expression NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
The NN NN O
HSFE NN NN O
induced NN NN O
an NN NN O
area NN NN O
of NN NN O
enhanced NN NN O
DNase NN NN B-Protein
1 NN NN I-Protein
hypersensitivity NN NN O
extending NN NN O
from NN NN O
the NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
to NN NN O
- NN NN O
300bp NN NN O
of NN NN O
the NN NN O
artificial NN NN O
promoter NN NN O
and NN NN O
significantly NN NN O
increased NN NN O
the NN NN O
proportion NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoters NN NN O
in NN NN O
an NN NN O
open NN NN O
chromatin NN NN O
configuration NN NN O
. NN NN O
   
This NN NN O
remodeling NN NN O
of NN NN O
promoter NN NN O
chromatin NN NN O
structure NN NN O
resulted NN NN O
in NN NN O
3 NN NN O
- NN NN O
fold NN NN O
increases NN NN O
in NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
induction NN NN O
, NN NN O
and NN NN O
inhibited NN NN O
long NN NN O
- NN NN O
term NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
silencing NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
a NN NN O
relatively NN NN O
small NN NN O
cis NN NN O
- NN NN O
acting NN NN O
element NN NN O
is NN NN O
able NN NN O
to NN NN O
enhance NN NN O
remodeling NN NN O
of NN NN O
promoter NN NN O
chromatin NN NN O
structure NN NN O
resulting NN NN O
in NN NN O
increased NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
T NN NN O
- NN NN O
lineage NN NN O
cells NN NN O
leads NN NN O
to NN NN O
a NN NN O
dramatic NN NN O
decrease NN NN O
in NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
to NN NN O
increased NN NN O
cell NN NN O
apoptosis NN NN O
in NN NN O
response NN NN O
to NN NN O
mitogenic NN NN O
stimuli NN NN O
, NN NN O
but NN NN O
not NN NN O
to NN NN O
abnormal NN NN O
thymopoiesis NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
role NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complexes NN NN O
in NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
activation NN NN O
, NN NN O
we NN NN O
have NN NN O
generated NN NN O
transgenic NN NN O
mice NN NN O
in NN NN O
which NN NN O
RelA NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
complexes NN NN O
were NN NN O
selectively NN NN O
inhibited NN NN O
in NN NN O
the NN NN O
T NN NN O
- NN NN O
lineage NN NN O
cells NN NN O
by NN NN O
specific NN NN O
expression NN NN O
of NN NN O
a NN NN O
trans NN NN O
- NN NN O
dominant NN NN O
form NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Transgene NN NN O
expression NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
thymic NN NN O
development NN NN O
, NN NN O
but NN NN O
led NN NN O
to NN NN O
lowered NN NN O
numbers NN NN O
of NN NN O
splenic NN NN O
T NN NN O
cells NN NN O
and NN NN O
to NN NN O
a NN NN O
dramatic NN NN O
decrease NN NN O
in NN NN O
the NN NN O
ex NN NN O
vivo NN NN O
proliferative NN NN O
response NN NN O
of NN NN O
splenic NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
perturbation NN NN O
of NN NN O
the NN NN O
proliferation NN NN O
response NN NN O
was NN NN O
not NN NN O
attributable NN NN O
to NN NN O
an NN NN O
abnormal NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
was NN NN O
strongly NN NN O
inhibited NN NN O
in NN NN O
the NN NN O
transgenic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
proliferative NN NN O
deficiency NN NN O
of NN NN O
the NN NN O
transgenic NN NN O
T NN NN O
cells NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
apoptosis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
point NN NN O
out NN NN O
the NN NN O
involvement NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
proteins NN NN O
in NN NN O
growth NN NN O
signaling NN NN O
pathways NN NN O
by NN NN O
either NN NN O
regulating NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
signaling NN NN O
or NN NN O
by NN NN O
functionally NN NN O
interfering NN NN O
with NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
CD28 NN NN B-Protein
costimulation NN NN O
augments NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
of NN NN O
activated NN NN O
lamina NN NN O
propria NN NN O
T NN NN O
cells NN NN O
by NN NN O
increasing NN NN O
mRNA NN NN O
stability NN NN O
without NN NN O
enhancing NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transactivation NN NN O
. NN NN O
   
The NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
activation NN NN O
in NN NN O
lamina NN NN O
propria NN NN O
( NN NN O
LP NN NN O
) NN NN O
T NN NN O
cells NN NN O
are NN NN O
different NN NN O
from NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
LP NN NN O
T NN NN O
cells NN NN O
exhibit NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
when NN NN O
activated NN NN O
through NN NN O
the NN NN O
CD2 NN NN O
pathway NN NN O
. NN NN O
   
Coligation NN NN O
of NN NN O
CD28 NN NN B-Protein
leads NN NN O
to NN NN O
synergistic NN NN O
enhancement NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
characterized NN NN O
the NN NN O
CD28 NN NN B-Protein
augmentation NN NN O
of NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
through NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
CD28 NN NN B-Protein
response NN NN O
element NN NN O
( NN NN O
CD28RE NN NN O
) NN NN O
, NN NN O
along NN NN O
with NN NN O
enhanced NN NN O
mRNA NN NN O
stability NN NN O
. NN NN O
   
This NN NN O
study NN NN O
characterized NN NN O
molecular NN NN O
events NN NN O
involved NN NN O
in NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
LP NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
LPMC NN NN O
) NN NN O
. NN NN O
   
LPMC NN NN O
exhibited NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
response NN NN O
to NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
, NN NN O
compared NN NN O
with NN NN O
cells NN NN O
activated NN NN O
through NN NN O
CD2 NN NN O
alone NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
was NN NN O
paralleled NN NN O
by NN NN O
increased NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
, NN NN O
resulting NN NN O
from NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
stability NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
PBMC NN NN O
, NN NN O
EMSA NN NN O
revealed NN NN O
that NN NN O
CD28 NN NN B-Protein
coligation NN NN O
of NN NN O
CD2 NN NN O
- NN NN O
activated NN NN O
LPMC NN NN O
does NN NN O
not NN NN O
result NN NN O
in NN NN O
increased NN NN O
binding NN NN O
of NN NN O
trans NN NN O
- NN NN O
factors NN NN O
to NN NN O
the NN NN O
CD28RE NN NN O
, NN NN O
nor NN NN O
did NN NN O
Western NN NN O
blots NN NN O
detect NN NN O
changes NN NN O
in NN NN O
I NN NN B-Protein
- NN NN I-Protein
kappaBalpha NN NN I-Protein
or NN NN O
I NN NN B-Protein
- NN NN I-Protein
kappaBbeta NN NN I-Protein
levels NN NN O
following NN NN O
CD28 NN NN B-Protein
coligation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
CD28 NN NN B-Protein
coligation NN NN O
fails NN NN O
to NN NN O
enhance NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
- NN NN O
reporter NN NN O
or NN NN O
RE NN NN O
/ NN NN O
AP NN NN O
construct NN NN O
expression NN NN O
in NN NN O
CD2 NN NN O
- NN NN O
activated NN NN O
LPMC NN NN O
. NN NN O
   
The NN NN O
results NN NN O
reported NN NN O
herein NN NN O
indicate NN NN O
that NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
CD28 NN NN B-Protein
cosignaling NN NN O
and NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
in NN NN O
LP NN NN O
T NN NN O
cells NN NN O
are NN NN O
unique NN NN O
to NN NN O
that NN NN O
compartment NN NN O
and NN NN O
differ NN NN O
from NN NN O
those NN NN O
seen NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
a NN NN O
biological NN NN O
significance NN NN O
for NN NN O
different NN NN O
mechanisms NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
activation NN NN O
in NN NN O
initiation NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
the NN NN O
cytokine NN NN O
repertoire NN NN O
found NN NN O
in NN NN O
the NN NN O
mucosa NN NN O
. NN NN O
   
Repression NN NN O
by NN NN O
Ikaros NN NN B-Protein
and NN NN O
Aiolos NN NN B-Protein
is NN NN O
mediated NN NN O
through NN NN O
histone NN NN O
deacetylase NN NN O
complexes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
lymphoid NN NN O
lineage NN NN O
- NN NN O
determining NN NN O
factors NN NN O
Ikaros NN NN B-Protein
and NN NN O
Aiolos NN NN B-Protein
can NN NN O
function NN NN O
as NN NN O
strong NN NN O
transcriptional NN NN O
repressors NN NN O
. NN NN O
   
This NN NN O
function NN NN O
is NN NN O
mediated NN NN O
through NN NN O
two NN NN O
repression NN NN O
domains NN NN O
and NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
promoter NN NN O
context NN NN O
and NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
Repression NN NN O
by NN NN O
Ikaros NN NN B-Protein
proteins NN NN O
correlates NN NN O
with NN NN O
hypo NN NN O
- NN NN O
acetylation NN NN O
of NN NN O
core NN NN O
histones NN NN O
at NN NN O
promoter NN NN O
sites NN NN O
and NN NN O
is NN NN O
relieved NN NN O
by NN NN O
histone NN NN O
deacetylase NN NN O
inhibitors NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
findings NN NN O
, NN NN O
Ikaros NN NN B-Protein
and NN NN O
its NN NN O
repression NN NN O
domains NN NN O
can NN NN O
interact NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
with NN NN O
the NN NN O
mSin3 NN NN O
family NN NN O
of NN NN O
co NN NN O
- NN NN O
repressors NN NN O
which NN NN O
bind NN NN O
to NN NN O
histone NN NN O
deacetylases NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
and NN NN O
our NN NN O
recent NN NN O
findings NN NN O
of NN NN O
associations NN NN O
between NN NN O
Ikaros NN NN B-Protein
and NN NN O
Mi NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN I-Protein
HDAC NN NN I-Protein
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
Ikaros NN NN B-Protein
family NN NN O
members NN NN O
modulate NN NN O
gene NN NN O
expression NN NN O
during NN NN O
lymphocyte NN NN O
development NN NN O
by NN NN O
recruiting NN NN O
distinct NN NN O
histone NN NN O
deacetylase NN NN O
complexes NN NN O
to NN NN O
specific NN NN O
promoters NN NN O
. NN NN O
   
New NN NN O
immunosuppressive NN NN O
drug NN NN O
PNU156804 NN NN O
blocks NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
proliferation NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
had NN NN O
previously NN NN O
shown NN NN O
that NN NN O
the NN NN O
drug NN NN O
undecylprodigiosin NN NN O
( NN NN O
UP NN NN O
) NN NN O
blocks NN NN O
human NN NN O
lymphocyte NN NN O
proliferation NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
investigated NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
a NN NN O
new NN NN O
analogue NN NN O
of NN NN O
UP NN NN O
, NN NN O
PNU156804 NN NN O
, NN NN O
which NN NN O
shows NN NN O
a NN NN O
more NN NN O
favorable NN NN O
activity NN NN O
profile NN NN O
than NN NN O
UP NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
the NN NN O
biological NN NN O
effect NN NN O
of NN NN O
PNU156804 NN NN O
in NN NN O
vitro NN NN O
is NN NN O
indistinguishable NN NN O
from NN NN O
UP NN NN O
: NN NN O
PNU156804 NN NN O
blocks NN NN O
human NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
mid NN NN O
- NN NN O
late NN NN O
G1 NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
cell NN NN O
cycle NN NN O
analysis NN NN O
, NN NN O
expression NN NN O
of NN NN O
cyclins NN NN O
, NN NN O
and NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinases NN NN O
and NN NN O
retinoblastoma NN NN O
phosphorylation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
PNU156804 NN NN O
does NN NN O
not NN NN O
block NN NN O
significantly NN NN O
the NN NN O
induction NN NN O
of NN NN O
either NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
IL NN NN O
- NN NN O
2R NN NN O
alpha NN NN O
- NN NN O
and NN NN O
gamma NN NN O
- NN NN O
chains NN NN O
but NN NN O
inhibits NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
several NN NN O
molecular NN NN O
pathways NN NN O
that NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
activated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
PNU156804 NN NN O
does NN NN O
not NN NN O
inhibit NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
and NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
induction NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
PNU156804 NN NN O
efficiently NN NN O
inhibits NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
PNU156804 NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
is NN NN O
due NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
PNU156804 NN NN O
action NN NN O
is NN NN O
restricted NN NN O
to NN NN O
some NN NN O
signaling NN NN O
pathways NN NN O
; NN NN O
it NN NN O
does NN NN O
not NN NN O
affect NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
PMA NN NN O
in NN NN O
T NN NN O
cells NN NN O
but NN NN O
blocks NN NN O
that NN NN O
induced NN NN O
by NN NN O
CD40 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
prodigiosin NN NN O
family NN NN O
of NN NN O
immunosuppressants NN NN O
is NN NN O
a NN NN O
new NN NN O
family NN NN O
of NN NN O
molecules NN NN O
that NN NN O
show NN NN O
a NN NN O
novel NN NN O
target NN NN O
specificity NN NN O
clearly NN NN O
distinct NN NN O
from NN NN O
that NN NN O
of NN NN O
other NN NN O
immunosuppressive NN NN O
drugs NN NN O
such NN NN O
as NN NN O
cyclosporin NN NN O
A NN NN O
, NN NN O
FK506 NN NN O
, NN NN O
and NN NN O
rapamycin NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
12 NN NN O
induces NN NN O
IFN NN NN B-Protein
regulating NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
NK NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
12 NN NN O
is NN NN O
a NN NN O
critical NN NN O
immunoregulatory NN NN O
cytokine NN NN O
that NN NN O
promotes NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
responses NN NN O
and NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
naive NN NN O
CD4 NN NN B-Protein
+ NN NN O
cells NN NN O
to NN NN O
Th1 NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
relatively NN NN O
few NN NN O
IL NN NN O
- NN NN O
12 NN NN O
target NN NN O
genes NN NN O
have NN NN O
been NN NN O
identified NN NN O
. NN NN O
   
To NN NN O
better NN NN O
clarify NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
IL NN NN O
- NN NN O
12 NN NN O
action NN NN O
, NN NN O
we NN NN O
set NN NN O
out NN NN O
to NN NN O
characterize NN NN O
genes NN NN O
up NN NN O
- NN NN O
regulated NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
first NN NN O
by NN NN O
contrasting NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
and NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
inducible NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
several NN NN O
genes NN NN O
up NN NN O
- NN NN O
regulated NN NN O
by NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
namely NN NN O
, NN NN O
MIP NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
, NN NN O
MIP NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RA NN NN I-Protein
, NN NN O
and NN NN O
IFN NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
regulated NN NN O
by NN NN O
IFNs NN NN O
that NN NN O
is NN NN O
also NN NN O
essential NN NN O
for NN NN O
Th1 NN NN O
responses NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
that NN NN O
IL NN NN O
- NN NN O
12 NN NN O
directly NN NN O
up NN NN O
- NN NN O
regulates NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
the NN NN O
same NN NN O
extent NN NN O
as NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
in NN NN O
normal NN NN O
human NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
showed NN NN O
that NN NN O
IL NN NN O
- NN NN O
12 NN NN O
had NN NN O
a NN NN O
direct NN NN O
effect NN NN O
on NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
an NN NN O
effect NN NN O
not NN NN O
mediated NN NN O
indirectly NN NN O
by NN NN O
the NN NN O
induction NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
IL NN NN O
- NN NN O
2 NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
synergistically NN NN O
induced NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
whereas NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
did NN NN O
not NN NN O
. NN NN O
   
The NN NN O
participation NN NN O
of NN NN O
STAT4 NN NN B-Protein
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
demonstrated NN NN O
in NN NN O
two NN NN O
ways NN NN O
. NN NN O
   
First NN NN O
, NN NN O
STAT4 NN NN B-Protein
was NN NN O
required NN NN O
for NN NN O
the NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
dependent NN NN O
transactivation NN NN O
of NN NN O
an NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
reporter NN NN O
construct NN NN O
, NN NN O
and NN NN O
second NN NN O
, NN NN O
STAT4 NN NN B-Protein
binding NN NN O
to NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
was NN NN O
shown NN NN O
using NN NN O
EMSA NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
no NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
found NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
stimulated NN NN O
cells NN NN O
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
did NN NN O
not NN NN O
block NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
dependent NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Therefore NN NN O
, NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
may NN NN O
be NN NN O
an NN NN O
important NN NN O
contributor NN NN O
to NN NN O
IL NN NN O
- NN NN O
12 NN NN O
signaling NN NN O
, NN NN O
and NN NN O
we NN NN O
speculate NN NN O
that NN NN O
the NN NN O
defective NN NN O
IL NN NN O
- NN NN O
12 NN NN O
responses NN NN O
seen NN NN O
in NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
might NN NN O
be NN NN O
attributable NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
the NN NN O
absence NN NN O
of NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
T NN NN O
lymphocyte NN NN O
development NN NN O
and NN NN O
function NN NN O
. NN NN O
   
The NN NN O
development NN NN O
and NN NN O
function NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
are NN NN O
regulated NN NN O
tightly NN NN O
by NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
that NN NN O
include NN NN O
specific NN NN O
cell NN NN O
- NN NN O
surface NN NN O
receptors NN NN O
, NN NN O
intracellular NN NN O
signaling NN NN O
molecules NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Since NN NN O
1988 NN NN O
, NN NN O
several NN NN O
families NN NN O
of NN NN O
functionally NN NN O
important NN NN O
T NN NN O
cell NN NN O
transcription NN NN O
factors NN NN O
have NN NN O
been NN NN O
identified NN NN O
. NN NN O
   
These NN NN O
include NN NN O
the NN NN O
Ikaros NN NN B-Protein
, NN NN O
LKLF NN NN B-Protein
, NN NN O
and NN NN O
GATA3 NN NN B-Protein
zinc NN NN O
- NN NN O
finger NN NN O
proteins NN NN O
; NN NN O
the NN NN O
Ets NN NN O
, NN NN O
CREB NN NN B-Protein
/ NN NN O
ATF NN NN B-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
/ NN NN O
NFAT NN NN O
transcription NN NN O
factors NN NN O
; NN NN O
the NN NN O
Stat NN NN O
proteins NN NN O
; NN NN O
and NN NN O
HMG NN NN O
box NN NN O
transcription NN NN O
factors NN NN O
such NN NN O
as NN NN O
LEF1 NN NN B-Protein
, NN NN O
TCF1 NN NN B-Protein
, NN NN O
and NN NN O
Sox4 NN NN B-Protein
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
, NN NN O
we NN NN O
summarize NN NN O
our NN NN O
current NN NN O
understanding NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
function NN NN O
with NN NN O
particular NN NN O
emphasis NN NN O
on NN NN O
the NN NN O
results NN NN O
of NN NN O
recent NN NN O
gene NN NN O
targeting NN NN O
and NN NN O
transgenic NN NN O
experiments NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
increasing NN NN O
our NN NN O
understanding NN NN O
of NN NN O
the NN NN O
molecular NN NN O
pathways NN NN O
that NN NN O
regulate NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
function NN NN O
, NN NN O
these NN NN O
results NN NN O
have NN NN O
suggested NN NN O
novel NN NN O
targets NN NN O
for NN NN O
genetic NN NN O
and NN NN O
pharmacological NN NN O
manipulation NN NN O
of NN NN O
T NN NN O
cell NN NN O
immunity NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
YY1 NN NN B-Protein
and NN NN O
Oct1 NN NN B-Protein
to NN NN O
a NN NN O
novel NN NN O
element NN NN O
that NN NN O
downregulates NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
controls NN NN O
development NN NN O
of NN NN O
eosinophilia NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
allergic NN NN O
diseases NN NN O
. NN NN O
   
In NN NN O
both NN NN O
atopic NN NN O
and NN NN O
nonatopic NN NN O
asthma NN NN O
, NN NN O
elevated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
and NN NN O
the NN NN O
airways NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
is NN NN O
produced NN NN O
mainly NN NN O
by NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
its NN NN O
expression NN NN O
is NN NN O
regulated NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
This NN NN O
study NN NN O
focuses NN NN O
on NN NN O
the NN NN O
functional NN NN O
analysis NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
( NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
) NN NN O
promoter NN NN O
and NN NN O
characterization NN NN O
of NN NN O
cis NN NN O
- NN NN O
regulatory NN NN O
elements NN NN O
and NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
the NN NN O
suppression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Methods NN NN O
used NN NN O
in NN NN O
this NN NN O
study NN NN O
include NN NN O
DNase NN NN O
I NN NN O
footprint NN NN O
assays NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
and NN NN O
functional NN NN O
analysis NN NN O
by NN NN O
mammalian NN NN O
cell NN NN O
transfection NN NN O
involving NN NN O
deletion NN NN O
analysis NN NN O
and NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
We NN NN O
identified NN NN O
5 NN NN O
protein NN NN O
binding NN NN O
regions NN NN O
( NN NN O
BRs NN NN O
) NN NN O
located NN NN O
within NN NN O
the NN NN O
proximal NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Functional NN NN O
analysis NN NN O
indicates NN NN O
that NN NN O
the NN NN O
BRs NN NN O
are NN NN O
involved NN NN O
in NN NN O
control NN NN O
of NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Two NN NN O
of NN NN O
these NN NN O
regions NN NN O
, NN NN O
BR3 NN NN O
and NN NN O
BR4 NN NN O
located NN NN O
at NN NN O
positions NN NN O
- NN NN O
102 NN NN O
to NN NN O
- NN NN O
73 NN NN O
, NN NN O
have NN NN O
not NN NN O
previously NN NN O
been NN NN O
described NN NN O
as NN NN O
regulators NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
BR3 NN NN O
sequence NN NN O
contains NN NN O
a NN NN O
novel NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
located NN NN O
at NN NN O
positions NN NN O
- NN NN O
90 NN NN O
to NN NN O
- NN NN O
79 NN NN O
of NN NN O
the NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
, NN NN O
which NN NN O
binds NN NN O
Oct1 NN NN B-Protein
, NN NN O
octamer NN NN O
- NN NN O
like NN NN O
, NN NN O
and NN NN O
YY1 NN NN B-Protein
nuclear NN NN O
factors NN NN O
. NN NN O
   
Substitution NN NN O
mutations NN NN O
, NN NN O
which NN NN O
abolished NN NN O
binding NN NN O
of NN NN O
these NN NN O
proteins NN NN O
to NN NN O
the NN NN O
BR3 NN NN O
sequence NN NN O
, NN NN O
significantly NN NN O
increased NN NN O
hIL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
We NN NN O
suggest NN NN O
that NN NN O
Oct1 NN NN B-Protein
, NN NN O
YY1 NN NN B-Protein
, NN NN O
and NN NN O
octamer NN NN O
- NN NN O
like NN NN O
factors NN NN O
binding NN NN O
to NN NN O
the NN NN O
- NN NN O
90 NN NN O
/ NN NN O
- NN NN O
79 NN NN O
sequence NN NN O
within NN NN O
the NN NN O
proximal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
are NN NN O
involved NN NN O
in NN NN O
suppression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Direct NN NN O
interaction NN NN O
of NN NN O
hematopoietic NN NN O
transcription NN NN O
factors NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
: NN NN O
functional NN NN O
antagonism NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
Malignant NN NN O
transformation NN NN O
usually NN NN O
inhibits NN NN O
terminal NN NN O
cell NN NN O
differentiation NN NN O
but NN NN O
the NN NN O
precise NN NN O
mechanisms NN NN O
involved NN NN O
are NN NN O
not NN NN O
understood NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
Ets NN NN O
family NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
development NN NN O
of NN NN O
some NN NN O
lymphoid NN NN O
and NN NN O
myeloid NN NN O
lineages NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
can NN NN O
also NN NN O
act NN NN O
as NN NN O
an NN NN O
oncoprotein NN NN O
as NN NN O
activation NN NN O
of NN NN O
its NN NN O
expression NN NN O
in NN NN O
erythroid NN NN O
precursors NN NN O
by NN NN O
proviral NN NN O
insertion NN NN O
or NN NN O
transgenesis NN NN O
causes NN NN O
erythroleukemias NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
Restoration NN NN O
of NN NN O
terminal NN NN O
differentiation NN NN O
in NN NN O
the NN NN O
mouse NN NN O
erythroleukemia NN NN O
( NN NN O
MEL NN NN O
) NN NN O
cells NN NN O
requires NN NN O
a NN NN O
decline NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
indicating NN NN O
that NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
can NN NN O
block NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
investigate NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
interferes NN NN O
with NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
find NN NN O
that NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
interacts NN NN O
directly NN NN O
with NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
required NN NN O
for NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Interaction NN NN O
between NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
requires NN NN O
intact NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domains NN NN O
in NN NN O
both NN NN O
proteins NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
represses NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
transactivation NN NN O
domains NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
are NN NN O
required NN NN O
for NN NN O
repression NN NN O
and NN NN O
both NN NN O
domains NN NN O
are NN NN O
also NN NN O
needed NN NN O
to NN NN O
block NN NN O
terminal NN NN O
differentiation NN NN O
in NN NN O
MEL NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
in NN NN O
Xenopus NN NN O
embryos NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
block NN NN O
erythropoiesis NN NN O
during NN NN O
normal NN NN O
development NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
introduction NN NN O
of NN NN O
exogenous NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
both NN NN O
MEL NN NN O
cells NN NN O
and NN NN O
Xenopus NN NN O
embryos NN NN O
and NN NN O
explants NN NN O
relieves NN NN O
the NN NN O
block NN NN O
to NN NN O
erythroid NN NN O
differentiation NN NN O
imposed NN NN O
by NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
stoichiometry NN NN O
of NN NN O
directly NN NN O
interacting NN NN O
but NN NN O
opposing NN NN O
transcription NN NN O
factors NN NN O
may NN NN O
be NN NN O
a NN NN O
crucial NN NN O
determinant NN NN O
governing NN NN O
processes NN NN O
of NN NN O
normal NN NN O
differentiation NN NN O
and NN NN O
malignant NN NN O
transformation NN NN O
. NN NN O
   
Potent NN NN O
and NN NN O
stable NN NN O
attenuation NN NN O
of NN NN O
live NN NN O
- NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
by NN NN O
gain NN NN O
of NN NN O
a NN NN O
proteolysis NN NN O
- NN NN O
resistant NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alphaS32 NN NN I-Protein
/ NN NN O
36A NN NN O
) NN NN O
and NN NN O
the NN NN O
implications NN NN O
for NN NN O
vaccine NN NN O
development NN NN O
. NN NN O
   
Live NN NN O
- NN NN O
attenuated NN NN O
human NN NN O
immunodeficiency NN NN O
viruses NN NN O
( NN NN O
HIVs NN NN O
) NN NN O
are NN NN O
candidates NN NN O
for NN NN O
Acquired NN NN O
Immunodeficiency NN NN O
Syndrome NN NN O
( NN NN O
AIDS NN NN O
) NN NN O
vaccine NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
the NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
SIV NN NN O
) NN NN O
model NN NN O
for NN NN O
AIDS NN NN O
, NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
deletion NN NN O
of NN NN O
accessory NN NN O
genes NN NN O
such NN NN O
as NN NN O
nef NN NN B-Protein
) NN NN O
has NN NN O
been NN NN O
forwarded NN NN O
as NN NN O
a NN NN O
primary NN NN O
approach NN NN O
for NN NN O
creating NN NN O
enfeebled NN NN O
, NN NN O
but NN NN O
replication NN NN O
- NN NN O
competent NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
/ NN NN O
SIV NN NN O
. NN NN O
   
Regrettably NN NN O
, NN NN O
recent NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
alone NN NN O
is NN NN O
not NN NN O
always NN NN O
sufficient NN NN O
to NN NN O
prevent NN NN O
the NN NN O
emergence NN NN O
of NN NN O
virulent NN NN O
mutants NN NN O
. NN NN O
   
New NN NN O
strategies NN NN O
that NN NN O
attenuate NN NN O
via NN NN O
mechanisms NN NN O
distinct NN NN O
from NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
are NN NN O
needed NN NN O
for NN NN O
enhancing NN NN O
the NN NN O
safety NN NN O
phenotype NN NN O
of NN NN O
viral NN NN O
genome NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
propose NN NN O
gain NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
to NN NN O
be NN NN O
used NN NN O
simultaneously NN NN O
with NN NN O
loss NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
as NN NN O
a NN NN O
novel NN NN O
approach NN NN O
for NN NN O
attenuating NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
We NN NN O
have NN NN O
constructed NN NN O
an NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
genome NN NN O
carrying NN NN O
the NN NN O
cDNA NN NN O
of NN NN O
a NN NN O
proteolysis NN NN O
- NN NN O
resistant NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
inhibitor NN NN O
( NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alphaS32 NN NN I-Protein
/ NN NN O
36A NN NN O
) NN NN O
in NN NN O
the NN NN O
nef NN NN B-Protein
region NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
expressing NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alphaS32 NN NN I-Protein
/ NN NN O
36A NN NN O
down NN NN O
- NN NN O
regulates NN NN O
viral NN NN O
expression NN NN O
and NN NN O
is NN NN O
highly NN NN O
attenuated NN NN O
in NN NN O
both NN NN O
Jurkat NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
formal NN NN O
proof NN NN O
that NN NN O
the NN NN O
phenotypic NN NN O
and NN NN O
attenuating NN NN O
characteristics NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alphaS32 NN NN I-Protein
/ NN NN O
36A NN NN O
permit NN NN O
its NN NN O
stable NN NN O
maintenance NN NN O
in NN NN O
a NN NN O
live NN NN O
, NN NN O
replicating NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
despite NN NN O
180 NN NN O
days NN NN O
of NN NN O
forced NN NN O
ex NN NN O
vivo NN NN O
passaging NN NN O
in NN NN O
tissue NN NN O
culture NN NN O
. NN NN O
   
As NN NN O
compared NN NN O
with NN NN O
other NN NN O
open NN NN O
- NN NN O
reading NN NN O
frames NN NN O
embedded NN NN O
into NN NN O
HIV NN NN O
/ NN NN O
SIV NN NN O
genome NN NN O
, NN NN O
this NN NN O
degree NN NN O
of NN NN O
stability NN NN O
is NN NN O
unprecedented NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alphaS32 NN NN I-Protein
/ NN NN O
36A NN NN O
offers NN NN O
proof NN NN O
- NN NN O
of NN NN O
- NN NN O
principle NN NN O
that NN NN O
artifactually NN NN O
gained NN NN O
functions NN NN O
, NN NN O
when NN NN O
used NN NN O
to NN NN O
attenuate NN NN O
the NN NN O
replication NN NN O
of NN NN O
live NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
can NN NN O
be NN NN O
stable NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
illustrate NN NN O
gain NN NN O
- NN NN O
of NN NN O
- NN NN O
function NN NN O
as NN NN O
a NN NN O
feasible NN NN O
strategy NN NN O
for NN NN O
developing NN NN O
safer NN NN O
live NN NN O
- NN NN O
attenuated NN NN O
HIVs NN NN O
to NN NN O
be NN NN O
tested NN NN O
as NN NN O
candidates NN NN O
for NN NN O
AIDS NN NN O
vaccine NN NN O
. NN NN O
   
Human NN NN O
alveolar NN NN O
macrophages NN NN O
are NN NN O
markedly NN NN O
deficient NN NN O
in NN NN O
REF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Although NN NN O
many NN NN O
functions NN NN O
of NN NN O
human NN NN O
alveolar NN NN O
macrophages NN NN O
are NN NN O
altered NN NN O
compared NN NN O
with NN NN O
their NN NN O
precursor NN NN O
cell NN NN O
, NN NN O
the NN NN O
blood NN NN O
monocyte NN NN O
( NN NN O
monocyte NN NN O
) NN NN O
, NN NN O
the NN NN O
reason NN NN O
( NN NN O
s NN NN O
) NN NN O
for NN NN O
these NN NN O
functional NN NN O
changes NN NN O
have NN NN O
not NN NN O
been NN NN O
determined NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
reported NN NN O
that NN NN O
human NN NN O
alveolar NN NN O
macrophages NN NN O
do NN NN O
not NN NN O
express NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
( NN NN O
Monick NN NN O
, NN NN O
M NN NN O
. NN NN O
M NN NN O
. NN NN O
, NN NN O
Carter NN NN O
, NN NN O
A NN NN O
. NN NN O
B NN NN O
. NN NN O
, NN NN O
Gudmundsson NN NN O
, NN NN O
G NN NN O
. NN NN O
, NN NN O
Geist NN NN O
, NN NN O
L NN NN O
. NN NN O
J NN NN O
. NN NN O
, NN NN O
and NN NN O
Hunninghake NN NN O
, NN NN O
G NN NN O
. NN NN O
W NN NN O
. NN NN O
( NN NN O
1998 NN NN O
) NN NN O
Am NN NN O
. NN NN O
J NN NN O
. NN NN O
Physiol NN NN O
. NN NN O
275 NN NN O
, NN NN O
L389 NN NN O
- NN NN O
L397 NN NN O
) NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
why NN NN O
alveolar NN NN O
macrophages NN NN O
do NN NN O
not NN NN O
express NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
, NN NN O
we NN NN O
first NN NN O
showed NN NN O
that NN NN O
there NN NN O
was NN NN O
not NN NN O
a NN NN O
decrease NN NN O
in NN NN O
expression NN NN O
of NN NN O
the NN NN O
FOS NN NN O
and NN NN O
JUN NN NN O
proteins NN NN O
that NN NN O
make NN NN O
up NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
. NN NN O
   
There NN NN O
was NN NN O
, NN NN O
however NN NN O
, NN NN O
a NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
amounts NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
protein NN NN O
, NN NN O
REF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
which NN NN O
regulates NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
altering NN NN O
the NN NN O
redox NN NN O
status NN NN O
of NN NN O
FOS NN NN O
and NN NN O
JUN NN NN O
proteins NN NN O
) NN NN O
, NN NN O
in NN NN O
alveolar NN NN O
macrophages NN NN O
compared NN NN O
with NN NN O
monocytes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
in NN NN O
vitro NN NN O
differentiation NN NN O
of NN NN O
monocytes NN NN O
to NN NN O
a NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cell NN NN O
resulted NN NN O
in NN NN O
decreased NN NN O
amounts NN NN O
of NN NN O
REF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Finally NN NN O
, NN NN O
addition NN NN O
of NN NN O
REF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
from NN NN O
activated NN NN O
monocytes NN NN O
to NN NN O
alveolar NN NN O
macrophage NN NN O
nuclear NN NN O
proteins NN NN O
resulted NN NN O
in NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
the NN NN O
process NN NN O
of NN NN O
differentiation NN NN O
of NN NN O
monocytes NN NN O
into NN NN O
alveolar NN NN O
macrophages NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
loss NN NN O
of NN NN O
REF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
may NN NN O
explain NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
some NN NN O
of NN NN O
the NN NN O
functional NN NN O
differences NN NN O
observed NN NN O
for NN NN O
alveolar NN NN O
macrophages NN NN O
compared NN NN O
with NN NN O
monocytes NN NN O
. NN NN O
   
A NN NN O
polymorphism NN NN O
that NN NN O
affects NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
to NN NN O
the NN NN O
TNF NN NN B-Protein
promoter NN NN O
region NN NN O
is NN NN O
associated NN NN O
with NN NN O
severe NN NN O
malaria NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
Genetic NN NN O
variation NN NN O
in NN NN O
cytokine NN NN O
promoter NN NN O
regions NN NN O
is NN NN O
postulated NN NN O
to NN NN O
influence NN NN O
susceptibility NN NN O
to NN NN O
infection NN NN O
, NN NN O
but NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
such NN NN O
polymorphisms NN NN O
might NN NN O
affect NN NN O
gene NN NN O
regulation NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
Through NN NN O
systematic NN NN O
DNA NN NN O
footprinting NN NN O
of NN NN O
the NN NN O
TNF NN NN B-Protein
( NN NN O
encoding NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
, NN NN O
TNF NN NN B-Protein
) NN NN O
promoter NN NN O
region NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
polymorphism NN NN O
( NN NN O
SNP NN NN O
) NN NN O
that NN NN O
causes NN NN O
the NN NN O
helix NN NN O
- NN NN O
turn NN NN O
- NN NN O
helix NN NN O
transcription NN NN O
factor NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
bind NN NN O
to NN NN O
a NN NN O
novel NN NN O
region NN NN O
of NN NN O
complex NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
interactions NN NN O
and NN NN O
alters NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
genotype NN NN O
, NN NN O
found NN NN O
in NN NN O
approximately NN NN O
5 NN NN O
% NN NN O
of NN NN O
Africans NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
fourfold NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
cerebral NN NN O
malaria NN NN O
in NN NN O
large NN NN O
case NN NN O
- NN NN O
control NN NN O
studies NN NN O
of NN NN O
West NN NN O
African NN NN O
and NN NN O
East NN NN O
African NN NN O
populations NN NN O
, NN NN O
after NN NN O
correction NN NN O
for NN NN O
other NN NN O
known NN NN O
TNF NN NN B-Protein
polymorphisms NN NN O
and NN NN O
linked NN NN O
HLA NN NN O
alleles NN NN O
. NN NN O
   
Novel NN NN O
therapies NN NN O
for NN NN O
inflammatory NN NN O
bowel NN NN O
disease NN NN O
. NN NN O
   
Looking NN NN O
back NN NN O
at NN NN O
successes NN NN O
and NN NN O
failures NN NN O
in NN NN O
newer NN NN O
approaches NN NN O
to NN NN O
treating NN NN O
IBD NN NN O
, NN NN O
it NN NN O
is NN NN O
tempting NN NN O
- NN NN O
- NN NN O
although NN NN O
still NN NN O
difficult NN NN O
- NN NN O
- NN NN O
to NN NN O
draw NN NN O
conclusions NN NN O
about NN NN O
pathogenesis NN NN O
. NN NN O
   
When NN NN O
a NN NN O
therapy NN NN O
proves NN NN O
effective NN NN O
, NN NN O
do NN NN O
clinicians NN NN O
truly NN NN O
know NN NN O
how NN NN O
it NN NN O
works NN NN O
? NN NN O
   
Even NN NN O
with NN NN O
a NN NN O
therapy NN NN O
as NN NN O
specific NN NN O
as NN NN O
anti NN NN O
- NN NN O
TNF NN NN O
antibody NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
if NN NN O
the NN NN O
benefit NN NN O
is NN NN O
attributable NN NN O
to NN NN O
simple NN NN O
binding NN NN O
and NN NN O
clearance NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
or NN NN O
to NN NN O
binding NN NN O
on NN NN O
the NN NN O
cell NN NN O
surface NN NN O
and NN NN O
subsequent NN NN O
deletion NN NN O
of NN NN O
the NN NN O
activated NN NN O
macrophage NN NN O
. NN NN O
   
When NN NN O
a NN NN O
drug NN NN O
appears NN NN O
to NN NN O
be NN NN O
less NN NN O
effective NN NN O
than NN NN O
preclinical NN NN O
models NN NN O
suggest NN NN O
, NN NN O
can NN NN O
failures NN NN O
in NN NN O
effectiveness NN NN O
from NN NN O
delivery NN NN O
or NN NN O
dosing NN NN O
be NN NN O
differentiated NN NN O
? NN NN O
   
The NN NN O
disappointing NN NN O
results NN NN O
of NN NN O
clinical NN NN O
trials NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
- NN NN O
- NN NN O
so NN NN O
at NN NN O
odds NN NN O
with NN NN O
the NN NN O
prediction NN NN O
of NN NN O
benefit NN NN O
from NN NN O
animal NN NN O
models NN NN O
- NN NN O
- NN NN O
bring NN NN O
into NN NN O
question NN NN O
the NN NN O
validity NN NN O
of NN NN O
those NN NN O
models NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
soundness NN NN O
of NN NN O
design NN NN O
of NN NN O
the NN NN O
clinical NN NN O
trials NN NN O
on NN NN O
which NN NN O
efficacy NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
is NN NN O
judged NN NN O
. NN NN O
   
The NN NN O
variability NN NN O
of NN NN O
response NN NN O
even NN NN O
to NN NN O
the NN NN O
most NN NN O
narrowly NN NN O
targeted NN NN O
agents NN NN O
suggests NN NN O
that NN NN O
these NN NN O
diseases NN NN O
are NN NN O
far NN NN O
more NN NN O
heterogeneous NN NN O
in NN NN O
humans NN NN O
than NN NN O
in NN NN O
their NN NN O
murine NN NN O
counterparts NN NN O
. NN NN O
   
Clinicians NN NN O
are NN NN O
only NN NN O
just NN NN O
beginning NN NN O
to NN NN O
recognize NN NN O
subclinical NN NN O
markers NN NN O
of NN NN O
response NN NN O
, NN NN O
and NN NN O
it NN NN O
may NN NN O
soon NN NN O
be NN NN O
possible NN NN O
to NN NN O
predict NN NN O
response NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
genetic NN NN O
composition NN NN O
. NN NN O
   
For NN NN O
the NN NN O
moment NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
field NN NN O
of NN NN O
pharmacogenetics NN NN O
is NN NN O
embryonic NN NN O
. NN NN O
   
Challenges NN NN O
in NN NN O
developing NN NN O
new NN NN O
therapeutic NN NN O
strategies NN NN O
include NN NN O
not NN NN O
only NN NN O
identifying NN NN O
novel NN NN O
agents NN NN O
, NN NN O
but NN NN O
also NN NN O
improving NN NN O
the NN NN O
definitions NN NN O
of NN NN O
clinical NN NN O
endpoints NN NN O
and NN NN O
defining NN NN O
efficacy NN NN O
at NN NN O
the NN NN O
biologic NN NN O
level NN NN O
. NN NN O
   
Only NN NN O
through NN NN O
considered NN NN O
evaluation NN NN O
of NN NN O
clinical NN NN O
evidence NN NN O
may NN NN O
clinicians NN NN O
determine NN NN O
which NN NN O
therapies NN NN O
should NN NN O
remain NN NN O
novelties NN NN O
and NN NN O
which NN NN O
should NN NN O
become NN NN O
an NN NN O
accepted NN NN O
part NN NN O
of NN NN O
the NN NN O
armamentarium NN NN O
. NN NN O
   
PPARalpha NN NN O
activators NN NN O
inhibit NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Adhesion NN NN O
molecule NN NN O
expression NN NN O
on NN NN O
the NN NN O
endothelial NN NN O
cell NN NN O
( NN NN O
EC NN NN O
) NN NN O
surface NN NN O
is NN NN O
critical NN NN O
for NN NN O
leukocyte NN NN O
recruitment NN NN O
to NN NN O
atherosclerotic NN NN O
lesions NN NN O
. NN NN O
   
Better NN NN O
understanding NN NN O
of NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
in NN NN O
ECs NN NN O
may NN NN O
provide NN NN O
important NN NN O
insight NN NN O
into NN NN O
plaque NN NN O
formation NN NN O
. NN NN O
   
Peroxisome NN NN B-Protein
proliferator NN NN I-Protein
- NN NN I-Protein
activated NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
PPARalpha NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
receptor NN NN O
family NN NN O
, NN NN O
regulates NN NN O
gene NN NN O
expression NN NN O
in NN NN O
response NN NN O
to NN NN O
certain NN NN O
fatty NN NN O
acids NN NN O
and NN NN O
fibric NN NN O
acid NN NN O
derivatives NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
investigated NN NN O
PPARalpha NN NN B-Protein
expression NN NN O
in NN NN O
human NN NN O
ECs NN NN O
and NN NN O
their NN NN O
regulation NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Immunohistochemistry NN NN O
revealed NN NN O
that NN NN O
human NN NN O
carotid NN NN O
artery NN NN O
ECs NN NN O
express NN NN O
PPARalpha NN NN B-Protein
. NN NN O
   
Pretreatment NN NN O
of NN NN O
cultured NN NN O
human NN NN O
ECs NN NN O
with NN NN O
the NN NN O
PPARalpha NN NN B-Protein
activators NN NN O
fenofibrate NN NN O
or NN NN O
WY14643 NN NN O
inhibited NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
a NN NN O
time NN NN O
- NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
an NN NN O
effect NN NN O
not NN NN O
seen NN NN O
with NN NN O
PPARgamma NN NN B-Protein
activators NN NN O
. NN NN O
   
Both NN NN O
PPARalpha NN NN B-Protein
activators NN NN O
decreased NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
expression NN NN O
without NN NN O
altering NN NN O
its NN NN O
mRNA NN NN O
half NN NN O
- NN NN O
life NN NN O
. NN NN O
   
Transient NN NN O
transfection NN NN O
of NN NN O
deletional NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
constructs NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
suggest NN NN O
that NN NN O
fenofibrate NN NN O
inhibits NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
in NN NN O
part NN NN O
by NN NN O
inhibiting NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
PPARalpha NN NN B-Protein
activators NN NN O
significantly NN NN O
reduced NN NN O
adhesion NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
to NN NN O
cultured NN NN O
human NN NN O
ECs NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Human NN NN O
ECs NN NN O
express NN NN O
PPARalpha NN NN B-Protein
, NN NN O
a NN NN O
potentially NN NN O
important NN NN O
regulator NN NN O
of NN NN O
atherogenesis NN NN O
through NN NN O
its NN NN O
transcriptional NN NN O
control NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Such NN NN O
findings NN NN O
also NN NN O
have NN NN O
implications NN NN O
regarding NN NN O
the NN NN O
clinical NN NN O
use NN NN O
of NN NN O
lipid NN NN O
- NN NN O
lowering NN NN O
agents NN NN O
, NN NN O
like NN NN O
fibric NN NN O
acids NN NN O
, NN NN O
which NN NN O
can NN NN O
activate NN NN O
PPARalpha NN NN B-Protein
. NN NN O
   
The NN NN O
intracellular NN NN O
parasite NN NN O
Theileria NN NN O
parva NN NN O
protects NN NN O
infected NN NN O
T NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
Parasites NN NN O
have NN NN O
evolved NN NN O
a NN NN O
plethora NN NN O
of NN NN O
strategies NN NN O
to NN NN O
ensure NN NN O
their NN NN O
survival NN NN O
. NN NN O
   
The NN NN O
intracellular NN NN O
parasite NN NN O
Theileria NN NN O
parva NN NN O
secures NN NN O
its NN NN O
propagation NN NN O
and NN NN O
spreads NN NN O
through NN NN O
the NN NN O
infected NN NN O
animal NN NN O
by NN NN O
infecting NN NN O
and NN NN O
transforming NN NN O
T NN NN O
cells NN NN O
, NN NN O
inducing NN NN O
their NN NN O
continuous NN NN O
proliferation NN NN O
and NN NN O
rendering NN NN O
them NN NN O
metastatic NN NN O
. NN NN O
   
In NN NN O
previous NN NN O
work NN NN O
, NN NN O
we NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
parasite NN NN O
induces NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
by NN NN O
inducing NN NN O
the NN NN O
constitutive NN NN O
degradation NN NN O
of NN NN O
its NN NN O
cytoplasmic NN NN O
inhibitors NN NN O
. NN NN O
   
The NN NN O
biological NN NN O
significance NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
T NN NN O
. NN NN O
parva NN NN O
- NN NN O
infected NN NN O
cells NN NN O
, NN NN O
however NN NN O
, NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
defined NN NN O
. NN NN O
   
Cells NN NN O
that NN NN O
have NN NN O
been NN NN O
transformed NN NN O
by NN NN O
viruses NN NN O
or NN NN O
oncogenes NN NN O
can NN NN O
persist NN NN O
only NN NN O
if NN NN O
they NN NN O
manage NN NN O
to NN NN O
avoid NN NN O
destruction NN NN O
by NN NN O
the NN NN O
apoptotic NN NN O
mechanisms NN NN O
that NN NN O
are NN NN O
activated NN NN O
on NN NN O
transformation NN NN O
and NN NN O
that NN NN O
contribute NN NN O
to NN NN O
maintain NN NN O
cellular NN NN O
homeostasis NN NN O
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
parasite NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
survival NN NN O
of NN NN O
T NN NN O
. NN NN O
parva NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
by NN NN O
conveying NN NN O
protection NN NN O
against NN NN O
an NN NN O
apoptotic NN NN O
signal NN NN O
that NN NN O
accompanies NN NN O
parasite NN NN O
- NN NN O
mediated NN NN O
transformation NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
dominant NN NN O
negative NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
components NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
pathway NN NN O
, NN NN O
such NN NN O
as NN NN O
IkappaBalpha NN NN B-Protein
or NN NN O
p65 NN NN B-Protein
, NN NN O
prompt NN NN O
rapid NN NN O
apoptosis NN NN O
of NN NN O
T NN NN O
. NN NN O
parva NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
offer NN NN O
important NN NN O
insights NN NN O
into NN NN O
parasite NN NN O
survival NN NN O
strategies NN NN O
and NN NN O
demonstrate NN NN O
that NN NN O
parasite NN NN O
- NN NN O
induced NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
an NN NN O
essential NN NN O
step NN NN O
in NN NN O
maintaining NN NN O
the NN NN O
transformed NN NN O
phenotype NN NN O
of NN NN O
the NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Downregulation NN NN O
of NN NN O
Wilms NN NN O
' NN NN O
tumor NN NN O
gene NN NN O
( NN NN O
WT1 NN NN B-Protein
) NN NN O
is NN NN O
not NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
erythroid NN NN O
or NN NN O
megakaryocytic NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
. NN NN O
   
The NN NN O
Wilms NN NN O
' NN NN O
tumor NN NN O
gene NN NN O
( NN NN O
WT1 NN NN B-Protein
) NN NN O
encodes NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
of NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
type NN NN O
. NN NN O
   
A NN NN O
high NN NN O
expression NN NN O
of NN NN O
WT1 NN NN B-Protein
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
a NN NN O
range NN NN O
of NN NN O
acute NN NN O
leukemias NN NN O
, NN NN O
and NN NN O
WT1 NN NN B-Protein
is NN NN O
downregulated NN NN O
during NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
some NN NN O
leukemic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
WT1 NN NN B-Protein
in NN NN O
some NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
confers NN NN O
resistance NN NN O
to NN NN O
differentiation NN NN O
induction NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
a NN NN O
high NN NN O
WT1 NN NN B-Protein
expression NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
is NN NN O
incompatible NN NN O
with NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
each NN NN O
of NN NN O
the NN NN O
four NN NN O
different NN NN O
isoforms NN NN O
of NN NN O
WT1 NN NN B-Protein
was NN NN O
constitutively NN NN O
overexpressed NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
. NN NN O
   
K562 NN NN O
cells NN NN O
express NN NN O
endogenous NN NN O
WT1 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
downregulated NN NN O
as NN NN O
a NN NN O
response NN NN O
to NN NN O
induced NN NN O
differentiation NN NN O
along NN NN O
the NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
pathways NN NN O
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
forced NN NN O
exogenous NN NN O
expression NN NN O
of NN NN O
the NN NN O
four NN NN O
different NN NN O
isoforms NN NN O
of NN NN O
WT1 NN NN B-Protein
in NN NN O
K562 NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
differentiation NN NN O
response NN NN O
, NN NN O
as NN NN O
judged NN NN O
by NN NN O
accumulation NN NN O
of NN NN O
hemoglobin NN NN O
in NN NN O
response NN NN O
to NN NN O
hemin NN NN O
or NN NN O
the NN NN O
expression NN NN O
of NN NN O
megakaryocytic NN NN O
cell NN NN O
surface NN NN O
markers NN NN O
in NN NN O
response NN NN O
to NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
downregulation NN NN O
of NN NN O
WT1 NN NN B-Protein
during NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
K562 NN NN O
cells NN NN O
is NN NN O
not NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
erythroid NN NN O
or NN NN O
megakaryocytic NN NN O
differentiation NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
erythropoietin NN NN B-Protein
cooperate NN NN O
to NN NN O
promote NN NN O
erythroid NN NN O
cell NN NN O
survival NN NN O
by NN NN O
regulating NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
expression NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
erythropoiesis NN NN O
. NN NN O
   
By NN NN O
examining NN NN O
in NN NN O
vitro NN NN O
- NN NN O
differentiated NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
, NN NN O
we NN NN O
showed NN NN O
previously NN NN O
that NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
committed NN NN O
erythroid NN NN O
precursors NN NN O
fail NN NN O
to NN NN O
complete NN NN O
maturation NN NN O
and NN NN O
instead NN NN O
undergo NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
controls NN NN O
cell NN NN O
survival NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
strongly NN NN O
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
anti NN NN O
- NN NN O
apoptotic NN NN O
protein NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
the NN NN O
related NN NN O
proteins NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
mcl NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
in NN NN O
mediating NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
induced NN NN O
erythroid NN NN O
cell NN NN O
survival NN NN O
, NN NN O
in NN NN O
vitro NN NN O
- NN NN O
differentiated NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
- NN NN O
/ NN NN O
- NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
fail NN NN O
to NN NN O
generate NN NN O
viable NN NN O
mature NN NN O
definitive NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
a NN NN O
phenotype NN NN O
resembling NN NN O
that NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
disruption NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
erythropoietin NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
also NN NN O
required NN NN O
for NN NN O
erythroid NN NN O
cell NN NN O
survival NN NN O
, NN NN O
cooperates NN NN O
with NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
stimulate NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
gene NN NN O
expression NN NN O
and NN NN O
to NN NN O
maintain NN NN O
erythroid NN NN O
cell NN NN O
viability NN NN O
during NN NN O
terminal NN NN O
maturation NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
our NN NN O
data NN NN O
show NN NN O
that NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
erythroid NN NN O
development NN NN O
and NN NN O
suggest NN NN O
a NN NN O
regulatory NN NN O
hierarchy NN NN O
in NN NN O
which NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
is NN NN O
a NN NN O
critical NN NN O
downstream NN NN O
effector NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
erythropoietin NN NN B-Protein
- NN NN O
mediated NN NN O
signals NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
functions NN NN O
as NN NN O
both NN NN O
a NN NN O
proapoptotic NN NN O
and NN NN O
antiapoptotic NN NN O
regulatory NN NN O
factor NN NN O
within NN NN O
a NN NN O
single NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
Recently NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
have NN NN O
both NN NN O
proapoptotic NN NN O
and NN NN O
antiapoptotic NN NN O
functions NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cell NN NN O
hybridomas NN NN O
, NN NN O
both NN NN O
T NN NN O
cell NN NN O
activators NN NN O
and NN NN O
glucocorticoids NN NN O
induce NN NN O
apoptosis NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
blockade NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
, NN NN O
using NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
has NN NN O
opposite NN NN O
effects NN NN O
on NN NN O
these NN NN O
two NN NN O
apoptotic NN NN O
signals NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
PMA NN NN O
plus NN NN O
ionomycin NN NN O
( NN NN O
P NN NN O
/ NN NN O
I NN NN O
) NN NN O
results NN NN O
in NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
Fas NN NN B-Protein
Ligand NN NN I-Protein
( NN NN O
FasL NN NN B-Protein
) NN NN O
and NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
inhibits NN NN O
the NN NN O
P NN NN O
/ NN NN O
I NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
FasL NN NN B-Protein
mRNA NN NN O
and NN NN O
decreases NN NN O
the NN NN O
level NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
these NN NN O
cultures NN NN O
, NN NN O
thus NN NN O
establishing NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
as NN NN O
a NN NN O
proapoptotic NN NN O
factor NN NN O
in NN NN O
this NN NN O
context NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
confers NN NN O
a NN NN O
tenfold NN NN O
increase NN NN O
in NN NN O
glucocorticoid NN NN O
mediated NN NN O
apoptosis NN NN O
, NN NN O
establishing NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
also NN NN O
functions NN NN O
as NN NN O
an NN NN O
antiapoptotic NN NN O
factor NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
a NN NN O
context NN NN O
- NN NN O
dependent NN NN O
apoptosis NN NN O
regulator NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggests NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
may NN NN O
function NN NN O
as NN NN O
an NN NN O
antiapoptotic NN NN O
factor NN NN O
in NN NN O
thymocytes NN NN O
while NN NN O
functioning NN NN O
as NN NN O
a NN NN O
proapoptotic NN NN O
factor NN NN O
in NN NN O
mature NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
3 NN NN O
- NN NN O
deazaadenosine NN NN O
, NN NN O
a NN NN O
S NN NN B-Protein
- NN NN I-Protein
adenosylhomocysteine NN NN I-Protein
hydrolase NN NN I-Protein
inhibitor NN NN O
, NN NN O
has NN NN O
dual NN NN O
effects NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
regulation NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcriptional NN NN O
activity NN NN O
and NN NN O
promotion NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
degradation NN NN O
. NN NN O
   
Previously NN NN O
we NN NN O
reported NN NN O
that NN NN O
3 NN NN O
- NN NN O
deazaadenosine NN NN O
( NN NN O
DZA NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
and NN NN O
substrate NN NN O
for NN NN O
S NN NN B-Protein
- NN NN I-Protein
adenosylhomocysteine NN NN I-Protein
hydrolase NN NN I-Protein
inhibits NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
transcription NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
in NN NN O
mouse NN NN O
macrophage NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
the NN NN O
effects NN NN O
of NN NN O
DZA NN NN O
on NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
regulation NN NN O
. NN NN O
   
DZA NN NN O
inhibits NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
the NN NN O
hindrance NN NN O
of NN NN O
p65 NN NN B-Protein
( NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
) NN NN O
phosphorylation NN NN O
without NN NN O
reduction NN NN O
of NN NN O
its NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
DZA NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcriptional NN NN O
activity NN NN O
is NN NN O
potentiated NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
homocysteine NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
DZA NN NN O
promotes NN NN O
the NN NN O
proteolytic NN NN O
degradation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
IkappaBbeta NN NN B-Protein
, NN NN O
resulting NN NN O
in NN NN O
an NN NN O
increase NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
its NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
by NN NN O
DZA NN NN O
is NN NN O
neither NN NN O
involved NN NN O
in NN NN O
IkappaB NN NN O
kinase NN NN O
complex NN NN O
activation NN NN O
nor NN NN O
modulated NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
homocysteine NN NN O
. NN NN O
   
This NN NN O
study NN NN O
strongly NN NN O
suggests NN NN O
that NN NN O
DZA NN NN O
may NN NN O
be NN NN O
a NN NN O
potent NN NN O
drug NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
diseases NN NN O
in NN NN O
which NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
plays NN NN O
a NN NN O
central NN NN O
pathogenic NN NN O
role NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
useful NN NN O
tool NN NN O
for NN NN O
studying NN NN O
the NN NN O
regulation NN NN O
and NN NN O
physiological NN NN O
functions NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
STAT1 NN NN B-Protein
activation NN NN O
during NN NN O
monocyte NN NN O
to NN NN O
macrophage NN NN O
maturation NN NN O
: NN NN O
role NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
Human NN NN O
monocytes NN NN O
isolated NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
healthy NN NN O
donors NN NN O
show NN NN O
a NN NN O
time NN NN O
- NN NN O
dependent NN NN O
differentiation NN NN O
into NN NN O
macrophages NN NN O
upon NN NN O
in NN NN O
vitro NN NN O
cultivation NN NN O
, NN NN O
closely NN NN O
mimicking NN NN O
their NN NN O
in NN NN O
vivo NN NN O
migration NN NN O
and NN NN O
maturation NN NN O
into NN NN O
extravascular NN NN O
tissues NN NN O
. NN NN O
   
The NN NN O
mediator NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
this NN NN O
maturation NN NN O
process NN NN O
has NN NN O
not NN NN O
been NN NN O
yet NN NN O
defined NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
involvement NN NN O
of NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
factors NN NN O
in NN NN O
this NN NN O
phenomenon NN NN O
and NN NN O
reported NN NN O
the NN NN O
specific NN NN O
, NN NN O
time NN NN O
- NN NN O
dependent NN NN O
, NN NN O
activation NN NN O
of NN NN O
STAT1 NN NN B-Protein
protein NN NN O
starting NN NN O
at NN NN O
day NN NN O
0 NN NN O
/ NN NN O
1 NN NN O
of NN NN O
cultivation NN NN O
and NN NN O
maximally NN NN O
expressed NN NN O
at NN NN O
day NN NN O
5 NN NN O
. NN NN O
   
STAT1 NN NN B-Protein
activity NN NN O
was NN NN O
evident NN NN O
on NN NN O
the NN NN O
STAT NN NN O
binding NN NN O
sequences NN NN O
( NN NN O
SBE NN NN O
) NN NN O
present NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
genes NN NN O
which NN NN O
are NN NN O
up NN NN O
- NN NN O
regulated NN NN O
during NN NN O
monocyte NN NN O
to NN NN O
macrophage NN NN O
maturation NN NN O
such NN NN O
as NN NN O
FcgammaRI NN NN B-Protein
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
IFN NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
fibronectin NN NN B-Protein
or NN NN O
laminin NN NN O
was NN NN O
studied NN NN O
to NN NN O
investigate NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
STAT1 NN NN B-Protein
activation NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
monocytes NN NN O
adherent NN NN O
on NN NN O
plastic NN NN O
surfaces NN NN O
, NN NN O
freshly NN NN O
isolated NN NN O
cells NN NN O
allowed NN NN O
to NN NN O
adhere NN NN O
either NN NN O
to NN NN O
fibronectin NN NN B-Protein
- NN NN O
or NN NN O
laminin NN NN O
- NN NN O
coated NN NN O
flasks NN NN O
exhibited NN NN O
an NN NN O
increased NN NN O
STAT1 NN NN B-Protein
binding NN NN O
activity NN NN O
both NN NN O
in NN NN O
control NN NN O
and NN NN O
in NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
events NN NN O
leading NN NN O
to NN NN O
enhanced NN NN O
STAT1 NN NN B-Protein
activation NN NN O
and NN NN O
cytokine NN NN O
responsiveness NN NN O
concerned NN NN O
both NN NN O
Y701 NN NN O
and NN NN O
S727 NN NN O
STAT1 NN NN B-Protein
phosphorylation NN NN O
. NN NN O
   
Exogenous NN NN O
addition NN NN O
of NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
, NN NN O
which NN NN O
exerts NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
some NN NN O
monocytic NN NN O
differentiation NN NN O
markers NN NN O
, NN NN O
inhibited NN NN O
macrophage NN NN O
maturation NN NN O
, NN NN O
integrin NN NN O
expression NN NN O
and NN NN O
STAT1 NN NN B-Protein
binding NN NN O
activity NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
STAT1 NN NN B-Protein
plays NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
the NN NN O
differentiation NN NN O
/ NN NN O
maturation NN NN O
process NN NN O
of NN NN O
monocytes NN NN O
as NN NN O
an NN NN O
early NN NN O
transcription NN NN O
factor NN NN O
initially NN NN O
activated NN NN O
by NN NN O
adherence NN NN O
and NN NN O
then NN NN O
able NN NN O
to NN NN O
modulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
functional NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
FcgammaRI NN NN B-Protein
. NN NN O
   
Stimulation NN NN O
of NN NN O
neutrophil NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
by NN NN O
eosinophil NN NN B-Protein
granule NN NN I-Protein
major NN NN I-Protein
basic NN NN I-Protein
protein NN NN I-Protein
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
ability NN NN O
of NN NN O
eosinophil NN NN B-Protein
granule NN NN I-Protein
major NN NN I-Protein
basic NN NN I-Protein
protein NN NN I-Protein
( NN NN O
MBP NN NN B-Protein
) NN NN O
to NN NN O
stimulate NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
by NN NN O
neutrophils NN NN O
. NN NN O
   
MBP NN NN B-Protein
over NN NN O
the NN NN O
concentration NN NN O
range NN NN O
of NN NN O
0 NN NN O
. NN NN O
1 NN NN O
to NN NN O
10 NN NN O
microM NN NN O
stimulated NN NN O
the NN NN O
release NN NN O
of NN NN O
up NN NN O
to NN NN O
approximately NN NN O
8 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
Incubation NN NN O
with NN NN O
2 NN NN O
microM NN NN O
MBP NN NN B-Protein
showed NN NN O
that NN NN O
, NN NN O
after NN NN O
a NN NN O
1 NN NN O
h NN NN O
lag NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
release NN NN O
increased NN NN O
with NN NN O
time NN NN O
for NN NN O
approximately NN NN O
10 NN NN O
h NN NN O
. NN NN O
   
At NN NN O
the NN NN O
2 NN NN O
microM NN NN O
concentration NN NN O
, NN NN O
eosinophil NN NN B-Protein
cationic NN NN I-Protein
protein NN NN I-Protein
, NN NN O
eosinophil NN NN O
- NN NN O
derived NN NN O
neurotoxin NN NN O
, NN NN O
and NN NN O
eosinophil NN NN B-Protein
peroxidase NN NN I-Protein
did NN NN O
not NN NN O
stimulate NN NN O
significant NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
. NN NN O
   
MBP NN NN B-Protein
stimulated NN NN O
2 NN NN O
- NN NN O
fold NN NN O
increases NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
messenger NN NN O
RNA NN NN O
( NN NN O
mRNA NN NN O
) NN NN O
after NN NN O
1 NN NN O
and NN NN O
3 NN NN O
h NN NN O
of NN NN O
incubation NN NN O
, NN NN O
which NN NN O
were NN NN O
blocked NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
actinomycin NN NN O
D NN NN O
. NN NN O
   
However NN NN O
, NN NN O
stimulation NN NN O
with NN NN O
MBP NN NN B-Protein
did NN NN O
not NN NN O
produce NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
binding NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
or NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
No NN NN O
NF NN NN O
- NN NN O
IL NN NN O
- NN NN O
6 NN NN O
binding NN NN O
activity NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
same NN NN O
nuclear NN NN O
extracts NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
stimulation NN NN O
with NN NN O
MBP NN NN B-Protein
prolonged NN NN O
the NN NN O
stability NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
MBP NN NN B-Protein
also NN NN O
induced NN NN O
transient NN NN O
increases NN NN O
in NN NN O
mRNA NN NN O
for NN NN O
macrophage NN NN B-Protein
inflammatory NN NN I-Protein
protein NN NN I-Protein
( NN NN I-Protein
MIP NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
and NN NN O
MIP NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
but NN NN O
did NN NN O
not NN NN O
stimulate NN NN O
the NN NN O
release NN NN O
of NN NN O
either NN NN O
chemokine NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
MBP NN NN B-Protein
is NN NN O
selective NN NN O
among NN NN O
the NN NN O
eosinophil NN NN O
granule NN NN O
proteins NN NN O
as NN NN O
a NN NN O
stimulus NN NN O
for NN NN O
neutrophil NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
release NN NN O
and NN NN O
, NN NN O
further NN NN O
, NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
neutrophil NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
release NN NN O
by NN NN O
MBP NN NN B-Protein
involves NN NN O
both NN NN O
transcriptional NN NN O
and NN NN O
posttranscriptional NN NN O
regulation NN NN O
. NN NN O
   
We NN NN O
postulate NN NN O
that NN NN O
MBP NN NN B-Protein
- NN NN O
induced NN NN O
release NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
by NN NN O
neutrophils NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
acute NN NN O
asthma NN NN O
and NN NN O
other NN NN O
inflammatory NN NN O
lung NN NN O
diseases NN NN O
. NN NN O
   
PPARgamma NN NN B-Protein
activation NN NN O
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
adipocyte NN NN B-Protein
fatty NN NN I-Protein
acid NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
gene NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
peroxisome NN NN B-Protein
- NN NN I-Protein
proliferator NN NN I-Protein
activated NN NN I-Protein
receptor NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
PPARgamma NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
receptor NN NN O
superfamily NN NN O
of NN NN O
ligand NN NN O
activated NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
anti NN NN O
- NN NN O
diabetic NN NN O
actions NN NN O
of NN NN O
the NN NN O
thiazolidinediones NN NN O
( NN NN O
TZDs NN NN O
) NN NN O
. NN NN O
   
PPARgamma NN NN B-Protein
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
many NN NN O
genes NN NN O
involved NN NN O
in NN NN O
lipid NN NN O
anabolism NN NN O
, NN NN O
including NN NN O
the NN NN O
adipocyte NN NN B-Protein
fatty NN NN I-Protein
acid NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
( NN NN O
aP2 NN NN B-Protein
) NN NN O
, NN NN O
and NN NN O
is NN NN O
a NN NN O
key NN NN O
regulator NN NN O
of NN NN O
adipocyte NN NN O
differentiation NN NN O
. NN NN O
   
PPARgamma NN NN B-Protein
is NN NN O
also NN NN O
expressed NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
and NN NN O
is NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
activated NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
PPARgamma NN NN B-Protein
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
differentiation NN NN O
of NN NN O
macrophages NN NN O
to NN NN O
foam NN NN O
cells NN NN O
that NN NN O
are NN NN O
associated NN NN O
with NN NN O
atherosclerotic NN NN O
lesions NN NN O
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
both NN NN O
natural NN NN O
and NN NN O
synthetic NN NN O
PPARgamma NN NN O
agonists NN NN O
induce NN NN O
time NN NN O
- NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increases NN NN O
in NN NN O
aP2 NN NN B-Protein
mRNA NN NN O
in NN NN O
both NN NN O
primary NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
PPARgamma NN NN B-Protein
activation NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
monocyte NN NN O
differentiation NN NN O
and NN NN O
function NN NN O
analogous NN NN O
to NN NN O
its NN NN O
well NN NN O
- NN NN O
characterized NN NN O
role NN NN O
in NN NN O
adipocytes NN NN O
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
intermediate NN NN O
- NN NN O
release NN NN O
of NN NN O
fibre NN NN O
- NN NN O
exposed NN NN O
monocytes NN NN O
increases NN NN O
inflammatory NN NN O
cytokine NN NN O
- NN NN O
mRNA NN NN O
level NN NN O
, NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
co NN NN O
- NN NN O
cultured NN NN O
bronchial NN NN O
epithelial NN NN O
cells NN NN O
( NN NN O
BEAS NN NN O
- NN NN O
2B NN NN O
) NN NN O
. NN NN O
   
Some NN NN O
pulmonary NN NN O
diseases NN NN O
like NN NN O
bronchitis NN NN O
or NN NN O
asthma NN NN O
bronchiale NN NN O
are NN NN O
mediated NN NN O
by NN NN O
inflammatory NN NN O
mechanisms NN NN O
in NN NN O
bronchial NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
Alveolar NN NN O
macrophages NN NN O
are NN NN O
located NN NN O
directly NN NN O
in NN NN O
the NN NN O
surrounding NN NN O
of NN NN O
these NN NN O
cells NN NN O
, NN NN O
so NN NN O
that NN NN O
we NN NN O
suppose NN NN O
an NN NN O
interaction NN NN O
between NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
macrophages NN NN O
regarding NN NN O
to NN NN O
the NN NN O
release NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O
   
For NN NN O
measuring NN NN O
the NN NN O
contribution NN NN O
of NN NN O
macrophages NN NN O
to NN NN O
the NN NN O
release NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
by NN NN O
bronchial NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
we NN NN O
established NN NN O
an NN NN O
in NN NN O
vitro NN NN O
model NN NN O
of NN NN O
co NN NN O
- NN NN O
cultured NN NN O
blood NN NN O
monocytes NN NN O
( NN NN O
BM NN NN O
) NN NN O
and NN NN O
BEAS NN NN O
- NN NN O
2B NN NN O
cells NN NN O
in NN NN O
a NN NN O
transwell NN NN O
system NN NN O
( NN NN O
Costar NN NN O
) NN NN O
. NN NN O
   
BM NN NN O
were NN NN O
exposed NN NN O
to NN NN O
Chrysotile NN NN O
B NN NN O
and NN NN O
soot NN NN O
particle NN NN O
FR NN NN O
101 NN NN O
in NN NN O
a NN NN O
concentration NN NN O
of NN NN O
100 NN NN O
microg NN NN O
/ NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
After NN NN O
up NN NN O
to NN NN O
90 NN NN O
min NN NN O
exposure NN NN O
time NN NN O
ELISA NN NN O
, NN NN O
EMSA NN NN O
( NN NN O
electromobility NN NN O
shift NN NN O
assay NN NN O
) NN NN O
and NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
were NN NN O
used NN NN O
to NN NN O
measure NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
protein NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
cytokine NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
specific NN NN O
mRNA NN NN O
levels NN NN O
in NN NN O
BEAS NN NN O
- NN NN O
2B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
an NN NN O
increase NN NN O
in NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
( NN NN O
up NN NN O
to NN NN O
1 NN NN O
. NN NN O
8 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
) NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
protein NN NN O
activity NN NN O
in NN NN O
BEAS NN NN O
- NN NN O
2B NN NN O
cells NN NN O
after NN NN O
particle NN NN O
or NN NN O
fibre NN NN O
exposure NN NN O
of NN NN O
co NN NN O
- NN NN O
cultured NN NN O
BM NN NN O
. NN NN O
   
Consecutive NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
- NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
- NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mRNA NN NN O
were NN NN O
elevated NN NN O
( NN NN O
up NN NN O
to NN NN O
1 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
58 NN NN O
- NN NN O
fold NN NN O
) NN NN O
. NN NN O
   
Protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
, NN NN O
and NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
cytokine NN NN O
- NN NN O
specific NN NN O
mRNA NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
antioxidants NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
ROI NN NN O
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
mediated NN NN O
transcription NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
in NN NN O
bronchial NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
Host NN NN O
defense NN NN O
mechanisms NN NN O
triggered NN NN O
by NN NN O
microbial NN NN O
lipoproteins NN NN O
through NN NN O
toll NN NN O
- NN NN O
like NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
generation NN NN O
of NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immunity NN NN O
against NN NN O
many NN NN O
infectious NN NN O
pathogens NN NN O
involves NN NN O
the NN NN O
production NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
12 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
key NN NN O
signal NN NN O
of NN NN O
the NN NN O
innate NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Yet NN NN O
, NN NN O
for NN NN O
many NN NN O
pathogens NN NN O
, NN NN O
the NN NN O
molecules NN NN O
that NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12 NN NN I-Protein
production NN NN O
by NN NN O
macrophages NN NN O
and NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
they NN NN O
do NN NN O
so NN NN O
remain NN NN O
undefined NN NN O
. NN NN O
   
Here NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
microbial NN NN O
lipoproteins NN NN O
are NN NN O
potent NN NN O
stimulators NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
12 NN NN I-Protein
production NN NN O
by NN NN O
human NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
that NN NN O
induction NN NN O
is NN NN O
mediated NN NN O
by NN NN O
Toll NN NN O
- NN NN O
like NN NN O
receptors NN NN O
( NN NN O
TLRs NN NN O
) NN NN O
. NN NN O
   
Several NN NN O
lipoproteins NN NN O
stimulated NN NN O
TLR NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
of NN NN O
inducible NN NN O
nitric NN NN B-Protein
oxide NN NN I-Protein
synthase NN NN I-Protein
and NN NN O
the NN NN O
production NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
, NN NN O
a NN NN O
powerful NN NN O
microbicidal NN NN O
pathway NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
TLRs NN NN O
by NN NN O
microbial NN NN O
lipoproteins NN NN O
may NN NN O
initiate NN NN O
innate NN NN O
defense NN NN O
mechanisms NN NN O
against NN NN O
infectious NN NN O
pathogens NN NN O
. NN NN O
   
Cell NN NN O
activation NN NN O
and NN NN O
apoptosis NN NN O
by NN NN O
bacterial NN NN O
lipoproteins NN NN O
through NN NN O
toll NN NN B-Protein
- NN NN I-Protein
like NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Apoptosis NN NN O
is NN NN O
implicated NN NN O
in NN NN O
the NN NN O
generation NN NN O
and NN NN O
resolution NN NN O
of NN NN O
inflammation NN NN O
in NN NN O
response NN NN O
to NN NN O
bacterial NN NN O
pathogens NN NN O
. NN NN O
   
All NN NN O
bacterial NN NN O
pathogens NN NN O
produce NN NN O
lipoproteins NN NN O
( NN NN O
BLPs NN NN O
) NN NN O
, NN NN O
which NN NN O
trigger NN NN O
the NN NN O
innate NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
BLPs NN NN O
were NN NN O
found NN NN O
to NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocytic NN NN O
cells NN NN O
through NN NN O
human NN NN B-Protein
Toll NN NN I-Protein
- NN NN I-Protein
like NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
hTLR2 NN NN B-Protein
) NN NN O
. NN NN O
   
BLPs NN NN O
also NN NN O
initiated NN NN O
apoptosis NN NN O
in NN NN O
an NN NN O
epithelial NN NN O
cell NN NN O
line NN NN O
transfected NN NN O
with NN NN O
hTLR2 NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
BLPs NN NN O
stimulated NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
of NN NN O
multiple NN NN O
host NN NN O
defense NN NN O
genes NN NN O
, NN NN O
and NN NN O
activated NN NN O
the NN NN O
respiratory NN NN O
burst NN NN O
through NN NN O
hTLR2 NN NN B-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
hTLR2 NN NN B-Protein
is NN NN O
a NN NN O
molecular NN NN O
link NN NN O
between NN NN O
microbial NN NN O
products NN NN O
, NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
host NN NN O
defense NN NN O
mechanisms NN NN O
. NN NN O
   
Tissue NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
the NN NN O
ecto NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
' NN NN I-Protein
- NN NN I-Protein
nucleotidase NN NN I-Protein
promoter NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
the NN NN O
camp NN NN O
response NN NN O
element NN NN O
site NN NN O
in NN NN O
mediating NN NN O
repression NN NN O
by NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
region NN NN O
. NN NN O
   
We NN NN O
have NN NN O
isolated NN NN O
the NN NN O
5 NN NN O
' NN NN O
region NN NN O
of NN NN O
the NN NN O
ecto NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
' NN NN I-Protein
- NN NN I-Protein
nucleotidase NN NN I-Protein
( NN NN O
low NN NN O
K NN NN O
( NN NN O
m NN NN O
) NN NN O
5 NN NN B-Protein
' NN NN I-Protein
- NN NN I-Protein
NT NN NN I-Protein
) NN NN O
gene NN NN O
and NN NN O
established NN NN O
that NN NN O
a NN NN O
969 NN NN O
- NN NN O
base NN NN O
pair NN NN O
( NN NN O
bp NN NN O
) NN NN O
fragment NN NN O
confers NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
a NN NN O
CAT NN NN B-Protein
reporter NN NN O
gene NN NN O
that NN NN O
correlates NN NN O
with NN NN O
the NN NN O
expression NN NN O
of NN NN O
endogenous NN NN O
ecto NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
' NN NN I-Protein
- NN NN I-Protein
NT NN NN I-Protein
mRNA NN NN O
and NN NN O
enzymatic NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
768 NN NN O
- NN NN O
bp NN NN O
upstream NN NN O
negative NN NN O
regulatory NN NN O
region NN NN O
has NN NN O
been NN NN O
identified NN NN O
that NN NN O
conferred NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
negative NN NN O
regulation NN NN O
in NN NN O
a NN NN O
heterologous NN NN O
system NN NN O
with NN NN O
a NN NN O
244 NN NN O
- NN NN O
bp NN NN O
deoxycytidine NN NN O
kinase NN NN O
core NN NN O
promoter NN NN O
. NN NN O
   
DNase NN NN B-Protein
I NN NN I-Protein
footprinting NN NN O
identified NN NN O
several NN NN O
protected NN NN O
areas NN NN O
including NN NN O
Sp1 NN NN B-Protein
, NN NN O
Sp1 NN NN B-Protein
/ NN NN O
AP NN NN O
- NN NN O
2 NN NN O
, NN NN O
and NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
( NN NN O
CRE NN NN O
) NN NN O
binding NN NN O
sites NN NN O
within NN NN O
the NN NN O
201 NN NN O
- NN NN O
bp NN NN O
core NN NN O
promoter NN NN O
region NN NN O
and NN NN O
Sp1 NN NN B-Protein
, NN NN O
NRE NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
/ NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
region NN NN O
. NN NN O
   
Whereas NN NN O
the NN NN O
CRE NN NN O
site NN NN O
was NN NN O
essential NN NN O
in NN NN O
mediating NN NN O
the NN NN O
negative NN NN O
activity NN NN O
of NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
region NN NN O
in NN NN O
Jurkat NN NN O
but NN NN O
not NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
mutation NN NN O
of NN NN O
the NN NN O
Sp1 NN NN B-Protein
/ NN NN O
AP NN NN O
- NN NN O
2 NN NN O
site NN NN O
decreased NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
both NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
analysis NN NN O
of NN NN O
proteins NN NN O
binding NN NN O
to NN NN O
the NN NN O
CRE NN NN O
site NN NN O
identified NN NN O
both NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
increased NN NN O
the NN NN O
activity NN NN O
of NN NN O
both NN NN O
the NN NN O
core NN NN O
and NN NN O
the NN NN O
969 NN NN O
- NN NN O
bp NN NN O
promoter NN NN O
fragments NN NN O
, NN NN O
and NN NN O
this NN NN O
increase NN NN O
was NN NN O
abrogated NN NN O
by NN NN O
mutations NN NN O
at NN NN O
the NN NN O
CRE NN NN O
site NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
regulatory NN NN O
region NN NN O
5 NN NN O
' NN NN O
of NN NN O
the NN NN O
ecto NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
' NN NN I-Protein
- NN NN I-Protein
NT NN NN I-Protein
core NN NN O
promoter NN NN O
that NN NN O
requires NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
functional NN NN O
CRE NN NN O
site NN NN O
within NN NN O
the NN NN O
basal NN NN O
promoter NN NN O
for NN NN O
its NN NN O
suppressive NN NN O
activity NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
mediated NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
and NN NN O
Bfl NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN I-Protein
A1 NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
CD40 NN NN B-Protein
survival NN NN O
signaling NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
CD40 NN NN B-Protein
is NN NN O
essential NN NN O
for NN NN O
thymus NN NN O
- NN NN O
dependent NN NN O
humoral NN NN O
immune NN NN O
responses NN NN O
and NN NN O
rescuing NN NN O
B NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
Many NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
CD40 NN NN B-Protein
are NN NN O
believed NN NN O
to NN NN O
be NN NN O
achieved NN NN O
through NN NN O
altered NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
, NN NN O
a NN NN O
known NN NN O
CD40 NN NN B-Protein
- NN NN O
regulated NN NN O
antiapoptotic NN NN O
molecule NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
related NN NN O
antiapoptotic NN NN O
molecule NN NN O
, NN NN O
A1 NN NN B-Protein
/ NN NN I-Protein
Bfl NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
as NN NN O
a NN NN O
CD40 NN NN B-Protein
- NN NN O
inducible NN NN O
gene NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
a NN NN O
dominant NN NN O
- NN NN O
active NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
abolished NN NN O
CD40 NN NN B-Protein
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
both NN NN O
the NN NN O
Bfl NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
genes NN NN O
and NN NN O
also NN NN O
eliminated NN NN O
the NN NN O
ability NN NN O
of NN NN O
CD40 NN NN B-Protein
to NN NN O
rescue NN NN O
Fas NN NN B-Protein
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
upstream NN NN O
promoter NN NN O
region NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
, NN NN O
a NN NN O
potential NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
sequence NN NN O
was NN NN O
found NN NN O
to NN NN O
support NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
expression NN NN O
of NN NN O
physiological NN NN O
levels NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
protected NN NN O
B NN NN O
cells NN NN O
from NN NN O
Fas NN NN B-Protein
- NN NN O
mediated NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
signaling NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
cell NN NN O
survival NN NN O
proceeds NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
members NN NN O
. NN NN O
   
Distinctive NN NN O
gene NN NN O
expression NN NN O
patterns NN NN O
in NN NN O
human NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
breast NN NN O
cancers NN NN O
. NN NN O
   
cDNA NN NN O
microarrays NN NN O
and NN NN O
a NN NN O
clustering NN NN O
algorithm NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
patterns NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
growing NN NN O
in NN NN O
culture NN NN O
and NN NN O
in NN NN O
primary NN NN O
human NN NN O
breast NN NN O
tumors NN NN O
. NN NN O
   
Clusters NN NN O
of NN NN O
coexpressed NN NN O
genes NN NN O
identified NN NN O
through NN NN O
manipulations NN NN O
of NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
also NN NN O
showed NN NN O
consistent NN NN O
patterns NN NN O
of NN NN O
variation NN NN O
in NN NN O
expression NN NN O
among NN NN O
breast NN NN O
tumor NN NN O
samples NN NN O
. NN NN O
   
By NN NN O
using NN NN O
immunohistochemistry NN NN O
with NN NN O
antibodies NN NN O
against NN NN O
proteins NN NN O
encoded NN NN O
by NN NN O
a NN NN O
particular NN NN O
gene NN NN O
in NN NN O
a NN NN O
cluster NN NN O
, NN NN O
the NN NN O
identity NN NN O
of NN NN O
the NN NN O
cell NN NN O
type NN NN O
within NN NN O
the NN NN O
tumor NN NN O
specimen NN NN O
that NN NN O
contributed NN NN O
the NN NN O
observed NN NN O
gene NN NN O
expression NN NN O
pattern NN NN O
could NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
Clusters NN NN O
of NN NN O
genes NN NN O
with NN NN O
coherent NN NN O
expression NN NN O
patterns NN NN O
in NN NN O
cultured NN NN O
cells NN NN O
and NN NN O
in NN NN O
the NN NN O
breast NN NN O
tumors NN NN O
samples NN NN O
could NN NN O
be NN NN O
related NN NN O
to NN NN O
specific NN NN O
features NN NN O
of NN NN O
biological NN NN O
variation NN NN O
among NN NN O
the NN NN O
samples NN NN O
. NN NN O
   
Two NN NN O
such NN NN O
clusters NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
patterns NN NN O
that NN NN O
correlated NN NN O
with NN NN O
variation NN NN O
in NN NN O
cell NN NN O
proliferation NN NN O
rates NN NN O
and NN NN O
with NN NN O
activation NN NN O
of NN NN O
the NN NN O
IFN NN NN O
- NN NN O
regulated NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Clusters NN NN O
of NN NN O
genes NN NN O
expressed NN NN O
by NN NN O
stromal NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
in NN NN O
the NN NN O
breast NN NN O
tumors NN NN O
also NN NN O
were NN NN O
identified NN NN O
in NN NN O
this NN NN O
analysis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
support NN NN O
the NN NN O
feasibility NN NN O
and NN NN O
usefulness NN NN O
of NN NN O
this NN NN O
systematic NN NN O
approach NN NN O
to NN NN O
studying NN NN O
variation NN NN O
in NN NN O
gene NN NN O
expression NN NN O
patterns NN NN O
in NN NN O
human NN NN O
cancers NN NN O
as NN NN O
a NN NN O
means NN NN O
to NN NN O
dissect NN NN O
and NN NN O
classify NN NN O
solid NN NN O
tumors NN NN O
. NN NN O
   
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mediated NN NN O
drug NN NN O
resistance NN NN O
: NN NN O
inhibition NN NN O
of NN NN O
apoptosis NN NN O
by NN NN O
blocking NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
- NN NN O
induced NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
transcription NN NN O
. NN NN O
   
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
inhibits NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
a NN NN O
variety NN NN O
of NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
chemotherapy NN NN O
drugs NN NN O
and NN NN O
glucocorticoids NN NN O
. NN NN O
   
It NN NN O
is NN NN O
generally NN NN O
accepted NN NN O
that NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
exerts NN NN O
its NN NN O
antiapoptotic NN NN O
effects NN NN O
mainly NN NN O
by NN NN O
dimerizing NN NN O
with NN NN O
proapoptotic NN NN O
members NN NN O
of NN NN O
the NN NN O
Bcl NN NN O
- NN NN O
2 NN NN O
family NN NN O
such NN NN O
as NN NN O
Bax NN NN B-Protein
and NN NN O
Bad NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
antiapoptotic NN NN O
effects NN NN O
is NN NN O
unclear NN NN O
. NN NN O
   
Paclitaxel NN NN O
and NN NN O
other NN NN O
drugs NN NN O
that NN NN O
disturb NN NN O
microtubule NN NN O
dynamics NN NN O
kill NN NN O
cells NN NN O
in NN NN O
a NN NN O
Fas NN NN B-Protein
/ NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
FasL NN NN B-Protein
) NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
; NN NN O
antibody NN NN O
to NN NN O
FasL NN NN B-Protein
inhibits NN NN O
paclitaxel NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
overexpression NN NN O
leads NN NN O
to NN NN O
the NN NN O
prevention NN NN O
of NN NN O
chemotherapy NN NN O
( NN NN O
paclitaxel NN NN O
) NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
FasL NN NN B-Protein
and NN NN O
blocks NN NN O
paclitaxel NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
this NN NN O
effect NN NN O
is NN NN O
that NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
prevents NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
activated NN NN O
by NN NN O
microtubule NN NN O
damage NN NN O
) NN NN O
by NN NN O
binding NN NN O
and NN NN O
sequestering NN NN O
calcineurin NN NN O
, NN NN O
a NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
phosphatase NN NN O
that NN NN O
must NN NN O
dephosphorylate NN NN O
NFAT NN NN O
to NN NN O
move NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Without NN NN O
NFAT NN NN O
nuclear NN NN O
translocation NN NN O
, NN NN O
the NN NN O
FasL NN NN B-Protein
gene NN NN O
is NN NN O
not NN NN O
transcribed NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
it NN NN O
appears NN NN O
that NN NN O
paclitaxel NN NN O
and NN NN O
other NN NN O
drugs NN NN O
that NN NN O
disturb NN NN O
microtubule NN NN O
function NN NN O
kill NN NN O
cells NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
through NN NN O
the NN NN O
induction NN NN O
of NN NN O
FasL NN NN B-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
antagonizes NN NN O
drug NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
by NN NN O
inhibiting NN NN O
calcineurin NN NN O
activation NN NN O
, NN NN O
blocking NN NN O
NFAT NN NN O
nuclear NN NN O
translocation NN NN O
, NN NN O
and NN NN O
preventing NN NN O
FasL NN NN B-Protein
expression NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
can NN NN O
be NN NN O
overcome NN NN O
, NN NN O
at NN NN O
least NN NN O
partially NN NN O
, NN NN O
through NN NN O
phosphorylation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Phosphorylated NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
cannot NN NN O
bind NN NN O
calcineurin NN NN B-Protein
, NN NN O
and NN NN O
NFAT NN NN O
activation NN NN O
, NN NN O
FasL NN NN B-Protein
expression NN NN O
, NN NN O
and NN NN O
apoptosis NN NN O
can NN NN O
occur NN NN O
after NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
phosphorylation NN NN O
. NN NN O
   
Retinoblastoma NN NN B-Protein
protein NN NN O
expression NN NN O
leads NN NN O
to NN NN O
reduced NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
enhances NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
. NN NN O
   
Tumor NN NN O
cell NN NN O
lines NN NN O
with NN NN O
a NN NN O
defective NN NN O
retinoblastoma NN NN B-Protein
gene NN NN O
are NN NN O
unable NN NN O
to NN NN O
transcribe NN NN O
the NN NN O
HLA NN NN O
class NN NN O
II NN NN O
genes NN NN O
in NN NN O
response NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
treatment NN NN O
, NN NN O
and NN NN O
reconstitution NN NN O
of NN NN O
functional NN NN O
Rb NN NN B-Protein
rescues NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
Rb NN NN B-Protein
rescue NN NN O
of NN NN O
the NN NN O
class NN NN O
II NN NN O
genes NN NN O
is NN NN O
unknown NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
Rb NN NN B-Protein
expression NN NN O
on NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
promoter NN NN O
for NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
, NN NN O
the NN NN O
prototype NN NN O
class NN NN O
II NN NN O
gene NN NN O
. NN NN O
   
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
POU NN NN O
domain NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
repressor NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
the NN NN O
Rb NN NN B-Protein
- NN NN O
defective NN NN O
cells NN NN O
. NN NN O
   
Rb NN NN B-Protein
expression NN NN O
led NN NN O
to NN NN O
phosphorylation NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
thus NN NN O
relieving NN NN O
its NN NN O
repressive NN NN O
effect NN NN O
. NN NN O
   
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
has NN NN O
also NN NN O
been NN NN O
shown NN NN O
to NN NN O
repress NN NN O
interleukin NN NN B-Protein
8 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
reduced NN NN O
levels NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
in NN NN O
the NN NN O
Rb NN NN B-Protein
- NN NN O
transformed NN NN O
cell NN NN O
lines NN NN O
, NN NN O
interleukin NN NN B-Protein
8 NN NN I-Protein
expression NN NN O
is NN NN O
higher NN NN O
in NN NN O
these NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
and NN NN O
calcineurin NN NN O
synergize NN NN O
to NN NN O
activate NN NN O
IkappaB NN NN O
kinase NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
is NN NN O
key NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
and NN NN O
inflammation NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
cross NN NN O
- NN NN O
linking NN NN O
is NN NN O
in NN NN O
part NN NN O
required NN NN O
for NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
which NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
By NN NN O
using NN NN O
Jurkat NN NN O
and NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
simultaneous NN NN O
activation NN NN O
of NN NN O
two NN NN O
second NN NN O
messengers NN NN O
of NN NN O
the NN NN O
TCR NN NN O
- NN NN O
initiated NN NN O
signal NN NN O
transduction NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
and NN NN O
calcineurin NN NN O
, NN NN O
results NN NN O
in NN NN O
the NN NN O
synergistic NN NN O
activation NN NN O
of NN NN O
the NN NN O
IkappaBalpha NN NN O
kinase NN NN O
( NN NN O
IKK NN NN O
) NN NN O
complex NN NN O
but NN NN O
not NN NN O
of NN NN O
another NN NN O
putative NN NN O
IkappaBalpha NN NN B-Protein
kinase NN NN I-Protein
, NN NN O
p90 NN NN B-Protein
( NN NN I-Protein
rsk NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
We NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
IKK NN NN O
complex NN NN O
, NN NN O
but NN NN O
not NN NN O
p90 NN NN B-Protein
( NN NN I-Protein
rsk NN NN I-Protein
) NN NN I-Protein
, NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
in NN NN O
vivo NN NN O
phosphorylation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
mediated NN NN O
by NN NN O
the NN NN O
co NN NN O
- NN NN O
activation NN NN O
of NN NN O
PKC NN NN O
and NN NN O
calcineurin NN NN O
. NN NN O
   
Each NN NN O
second NN NN O
messenger NN NN O
is NN NN O
necessary NN NN O
, NN NN O
as NN NN O
inhibition NN NN O
of NN NN O
either NN NN O
one NN NN O
reverses NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IKK NN NN O
complex NN NN O
and NN NN O
IkappaBalpha NN NN B-Protein
phosphorylation NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
dominant NN NN O
negative NN NN O
forms NN NN O
of NN NN O
IKKalpha NN NN B-Protein
and NN NN O
- NN NN B-Protein
beta NN NN I-Protein
demonstrates NN NN O
that NN NN O
only NN NN O
IKKbeta NN NN B-Protein
is NN NN O
the NN NN O
target NN NN O
for NN NN O
PKC NN NN O
and NN NN O
calcineurin NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
within NN NN O
the NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
both NN NN O
PKC NN NN O
and NN NN O
calcineurin NN NN O
are NN NN O
required NN NN O
for NN NN O
the NN NN O
effective NN NN O
activation NN NN O
of NN NN O
the NN NN O
IKK NN NN O
complex NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
synergistically NN NN O
regulate NN NN O
activity NN NN O
of NN NN O
the NN NN O
eosinophil NN NN B-Protein
granule NN NN I-Protein
major NN NN I-Protein
basic NN NN I-Protein
protein NN NN I-Protein
promoter NN NN O
: NN NN O
implication NN NN O
for NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
activity NN NN O
in NN NN O
eosinophil NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Eosinophil NN NN B-Protein
granule NN NN I-Protein
major NN NN I-Protein
basic NN NN I-Protein
protein NN NN I-Protein
( NN NN O
MBP NN NN B-Protein
) NN NN O
is NN NN O
expressed NN NN O
exclusively NN NN O
in NN NN O
eosinophils NN NN O
and NN NN O
basophils NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
our NN NN O
previous NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
a NN NN O
major NN NN O
positive NN NN O
regulatory NN NN O
role NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
a NN NN O
negative NN NN O
regulatory NN NN O
role NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
MBP NN NN B-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
of NN NN O
the NN NN O
MBP NN NN B-Protein
promoter NN NN O
region NN NN O
identified NN NN O
a NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
( NN NN O
CCAAT NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
) NN NN O
consensus NN NN O
binding NN NN O
site NN NN O
6 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
functional NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
MBP NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
the NN NN O
cell NN NN O
line NN NN O
HT93A NN NN O
, NN NN O
which NN NN O
is NN NN O
capable NN NN O
of NN NN O
differentiating NN NN O
towards NN NN O
both NN NN O
the NN NN O
eosinophil NN NN O
and NN NN O
neutrophil NN NN O
lineages NN NN O
in NN NN O
response NN NN O
to NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
, NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPalpha NN NN I-Protein
mRNA NN NN O
expression NN NN O
decreased NN NN O
significantly NN NN O
concomitant NN NN O
with NN NN O
eosinophilic NN NN O
and NN NN O
neutrophilic NN NN O
differentiation NN NN O
, NN NN O
whereas NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
expression NN NN O
was NN NN O
markedly NN NN O
increased NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
showed NN NN O
that NN NN O
recombinant NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
protein NN NN O
could NN NN O
bind NN NN O
to NN NN O
the NN NN O
potential NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
- NN NN O
binding NN NN O
site NN NN O
( NN NN O
bp NN NN O
- NN NN O
90 NN NN O
to NN NN O
- NN NN O
82 NN NN O
) NN NN O
in NN NN O
the NN NN O
MBP NN NN B-Protein
promoter NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
can NN NN O
bind NN NN O
simultaneously NN NN O
to NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
- NN NN O
and NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
MBP NN NN B-Protein
promoter NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
functionality NN NN O
of NN NN O
both NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
- NN NN O
and NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
whether NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
can NN NN O
stimulate NN NN O
the NN NN O
MBP NN NN B-Protein
promoter NN NN O
in NN NN O
the NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
negative NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Cotransfection NN NN O
with NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
vectors NN NN O
produced NN NN O
a NN NN O
5 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
compared NN NN O
with NN NN O
cotransfection NN NN O
with NN NN O
the NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
or NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
vectors NN NN O
individually NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
GST NN NN O
pull NN NN O
- NN NN O
down NN NN O
experiments NN NN O
demonstrated NN NN O
a NN NN O
physical NN NN O
interaction NN NN O
between NN NN O
human NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
. NN NN O
   
Expression NN NN O
of NN NN O
FOG NN NN O
( NN NN O
riend NN NN O
ATA NN NN O
) NN NN O
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
acts NN NN O
as NN NN O
a NN NN O
cofactor NN NN O
for NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
decreased NN NN O
transactivation NN NN O
activity NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
for NN NN O
the NN NN O
MBP NN NN B-Protein
promoter NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
provide NN NN O
the NN NN O
first NN NN O
evidence NN NN O
that NN NN O
both NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
synergistically NN NN O
transactivate NN NN O
the NN NN O
promoter NN NN O
of NN NN O
an NN NN O
eosinophil NN NN O
- NN NN O
specific NN NN O
granule NN NN O
protein NN NN O
gene NN NN O
and NN NN O
that NN NN O
FOG NN NN O
may NN NN O
act NN NN O
as NN NN O
a NN NN O
negative NN NN O
cofactor NN NN O
for NN NN O
the NN NN O
eosinophil NN NN O
lineage NN NN O
, NN NN O
unlike NN NN O
its NN NN O
positively NN NN O
regulatory NN NN O
function NN NN O
for NN NN O
the NN NN O
erythroid NN NN O
and NN NN O
megakaryocyte NN NN O
lineages NN NN O
. NN NN O
   
Thymocyte NN NN O
- NN NN O
thymic NN NN O
epithelial NN NN O
cell NN NN O
interaction NN NN O
leads NN NN O
to NN NN O
high NN NN O
- NN NN O
level NN NN O
replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
exclusively NN NN O
in NN NN O
mature NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
+ NN NN O
) NN NN O
thymocytes NN NN O
: NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
. NN NN O
   
This NN NN O
work NN NN O
aims NN NN O
at NN NN O
identifying NN NN O
the NN NN O
thymocyte NN NN O
subpopulation NN NN O
able NN NN O
to NN NN O
support NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
replication NN NN O
under NN NN O
the NN NN O
biological NN NN O
stimuli NN NN O
of NN NN O
the NN NN O
thymic NN NN O
microenvironment NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
interaction NN NN O
with NN NN O
thymic NN NN O
epithelial NN NN O
cells NN NN O
( NN NN O
TEC NN NN O
) NN NN O
induces NN NN O
a NN NN O
high NN NN O
- NN NN O
level NN NN O
replication NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
tropic NN NN O
primary NN NN O
isolate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
( NN NN O
B NN NN O
- NN NN O
LAIp NN NN O
) NN NN O
exclusively NN NN O
in NN NN O
the NN NN O
mature NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
+ NN NN O
) NN NN O
thymocytes NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
) NN NN O
, NN NN O
secreted NN NN O
during NN NN O
this NN NN O
interaction NN NN O
, NN NN O
are NN NN O
critical NN NN O
cytokines NN NN O
for NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
transactivation NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
. NN NN O
   
TNF NN NN B-Protein
is NN NN O
the NN NN O
major NN NN O
inducer NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
particularly NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
complex NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
acts NN NN O
as NN NN O
a NN NN O
cofactor NN NN O
by NN NN O
sustaining NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
p75 NN NN B-Protein
TNF NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
The NN NN O
requirement NN NN O
for NN NN O
TNF NN NN B-Protein
is NN NN O
further NN NN O
confirmed NN NN O
by NN NN O
the NN NN O
observation NN NN O
that NN NN O
the NN NN O
inability NN NN O
of NN NN O
the NN NN O
intermediate NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
- NN NN O
) NN NN O
thymocytes NN NN O
to NN NN O
replicate NN NN O
the NN NN O
virus NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
defect NN NN O
in NN NN O
TNF NN NN B-Protein
production NN NN O
during NN NN O
their NN NN O
interaction NN NN O
with NN NN O
TEC NN NN O
and NN NN O
correlates NN NN O
with NN NN O
the NN NN O
absence NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
these NN NN O
freshly NN NN O
isolated NN NN O
thymocytes NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
exogenous NN NN O
TNF NN NN B-Protein
to NN NN O
the NN NN O
intermediate NN NN O
thymocyte NN NN O
cultures NN NN O
induces NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
and NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
promote NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
the NN NN O
cocultures NN NN O
with NN NN O
TEC NN NN O
. NN NN O
   
The NN NN O
other NN NN O
major NN NN O
subpopulation NN NN O
expressing NN NN O
the NN NN O
CD4 NN NN B-Protein
receptor NN NN O
, NN NN O
namely NN NN O
, NN NN O
the NN NN O
double NN NN O
- NN NN O
positive NN NN O
( NN NN O
DP NN NN O
) NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
+ NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
thymocytes NN NN O
, NN NN O
despite NN NN O
the NN NN O
entry NN NN O
of NN NN O
the NN NN O
virus NN NN O
, NN NN O
do NN NN O
not NN NN O
produce NN NN O
a NN NN O
significant NN NN O
level NN NN O
of NN NN O
virus NN NN O
, NN NN O
presumably NN NN O
because NN NN O
they NN NN O
are NN NN O
unresponsive NN NN O
to NN NN O
TNF NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
in NN NN O
vivo NN NN O
, NN NN O
despite NN NN O
an NN NN O
efficient NN NN O
entry NN NN O
of NN NN O
the NN NN O
virus NN NN O
in NN NN O
all NN NN O
the NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
subpopulations NN NN O
, NN NN O
a NN NN O
high NN NN O
viral NN NN O
load NN NN O
may NN NN O
be NN NN O
generated NN NN O
exclusively NN NN O
within NN NN O
the NN NN O
mature NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
CD3 NN NN O
( NN NN O
+ NN NN O
) NN NN O
subset NN NN O
of NN NN O
thymocytes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
under NN NN O
conditions NN NN O
of NN NN O
inflammatory NN NN O
response NN NN O
after NN NN O
infection NN NN O
, NN NN O
TNF NN NN B-Protein
might NN NN O
also NN NN O
be NN NN O
present NN NN O
in NN NN O
the NN NN O
intermediate NN NN O
thymocyte NN NN O
compartment NN NN O
, NN NN O
leading NN NN O
to NN NN O
efficient NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
activation NN NN O
and NN NN O
proliferation NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
induced NN NN O
by NN NN O
CD28 NN NN B-Protein
. NN NN O
   
Although NN NN O
the NN NN O
role NN NN O
of NN NN O
CD28 NN NN B-Protein
in NN NN O
T NN NN O
cell NN NN O
costimulation NN NN O
is NN NN O
firmly NN NN O
established NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
it NN NN O
exerts NN NN O
its NN NN O
costimulatory NN NN O
actions NN NN O
are NN NN O
less NN NN O
clear NN NN O
. NN NN O
   
In NN NN O
many NN NN O
circumstances NN NN O
it NN NN O
is NN NN O
difficult NN NN O
to NN NN O
distinguish NN NN O
the NN NN O
effects NN NN O
of NN NN O
CD28 NN NN B-Protein
from NN NN O
subsequent NN NN O
actions NN NN O
of NN NN O
cytokines NN NN O
, NN NN O
such NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
on NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
a NN NN O
model NN NN O
of NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
using NN NN O
PMA NN NN O
plus NN NN O
the NN NN O
natural NN NN O
ligand NN NN O
CD80 NN NN B-Protein
that NN NN O
resulted NN NN O
in NN NN O
very NN NN O
limited NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
both NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
stimulation NN NN O
. NN NN O
   
Promoter NN NN O
assays NN NN O
revealed NN NN O
CD28 NN NN B-Protein
- NN NN O
dependent NN NN O
effects NN NN O
on NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
but NN NN O
not NN NN O
on NN NN O
NF NN NN O
- NN NN O
AT NN NN O
or NN NN O
the NN NN O
intact NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
was NN NN O
completely NN NN O
resistant NN NN O
to NN NN O
the NN NN O
actions NN NN O
of NN NN O
the NN NN O
immunosuppressant NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
. NN NN O
   
Moreover NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
blocking NN NN O
Abs NN NN O
to NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
the NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
this NN NN O
form NN NN O
of NN NN O
costimulation NN NN O
by NN NN O
CD28 NN NN B-Protein
was NN NN O
independent NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
We NN NN O
also NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
stimulating NN NN O
T NN NN O
cell NN NN O
blasts NN NN O
with NN NN O
CD80 NN NN B-Protein
alone NN NN O
and NN NN O
found NN NN O
that NN NN O
there NN NN O
was NN NN O
a NN NN O
limited NN NN O
requirement NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
this NN NN O
system NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
can NN NN O
cause NN NN O
substantial NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
driven NN NN O
by NN NN O
a NN NN O
soluble NN NN O
factor NN NN O
independent NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
transactivation NN NN O
. NN NN O
   
Suppression NN NN O
of NN NN O
TNFalpha NN NN B-Protein
- NN NN O
mediated NN NN O
NFkappaB NN NN O
activity NN NN O
by NN NN O
myricetin NN NN O
and NN NN O
other NN NN O
flavonoids NN NN O
through NN NN O
downregulating NN NN O
the NN NN O
activity NN NN O
of NN NN O
IKK NN NN O
in NN NN O
ECV304 NN NN O
cells NN NN O
. NN NN O
   
Flavonoids NN NN O
are NN NN O
a NN NN O
group NN NN O
of NN NN O
naturally NN NN O
- NN NN O
occurring NN NN O
phenolic NN NN O
compounds NN NN O
in NN NN O
the NN NN O
plant NN NN O
kingdom NN NN O
, NN NN O
and NN NN O
many NN NN O
flavonoids NN NN O
are NN NN O
found NN NN O
with NN NN O
vascular NN NN O
protective NN NN O
properties NN NN O
. NN NN O
   
Nevertheless NN NN O
how NN NN O
the NN NN O
protective NN NN O
response NN NN O
is NN NN O
exerted NN NN O
by NN NN O
flavonoids NN NN O
is NN NN O
not NN NN O
well NN NN O
characterized NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
may NN NN O
play NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
atherosclerosis NN NN O
, NN NN O
prevention NN NN O
of NN NN O
the NN NN O
activation NN NN O
of NN NN O
NFkappaB NN NN O
represents NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
protecting NN NN O
vascular NN NN O
injury NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
flavonoids NN NN O
on NN NN O
NFkappaB NN NN O
/ NN NN O
inhibitor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
IkappaB NN NN O
) NN NN O
system NN NN O
in NN NN O
ECV304 NN NN O
cells NN NN O
activated NN NN O
with NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
) NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
inhibitory NN NN O
action NN NN O
of NN NN O
six NN NN O
flavonoids NN NN O
on NN NN O
IkappaB NN NN O
kinase NN NN O
( NN NN O
IKK NN NN O
) NN NN O
activity NN NN O
, NN NN O
an NN NN O
enzyme NN NN O
recently NN NN O
found NN NN O
to NN NN O
phosphorylate NN NN O
critical NN NN O
serine NN NN O
residues NN NN O
of NN NN O
IkappaB NN NN O
for NN NN O
degradation NN NN O
. NN NN O
   
Of NN NN O
six NN NN O
flavonoids NN NN O
tested NN NN O
, NN NN O
myricetin NN NN O
was NN NN O
found NN NN O
to NN NN O
strongly NN NN O
inhibit NN NN O
IKK NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
and NN NN O
prevent NN NN O
the NN NN O
degradation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
and NN NN O
IkappaBbeta NN NN B-Protein
in NN NN O
activated NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
myricetin NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
inhibit NN NN O
NFkappaB NN NN O
activity NN NN O
correlated NN NN O
with NN NN O
suppression NN NN O
of NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
ECV304 NN NN O
cells NN NN O
. NN NN O
   
Therefore NN NN O
we NN NN O
conclude NN NN O
that NN NN O
flavonoids NN NN O
may NN NN O
be NN NN O
of NN NN O
therapeutic NN NN O
value NN NN O
for NN NN O
vascular NN NN O
disease NN NN O
through NN NN O
down NN NN O
regulation NN NN O
of NN NN O
NFkappaB NN NN O
/ NN NN O
IkappaB NN NN O
system NN NN O
. NN NN O
   
Copyright NN NN O
1999 NN NN O
Wiley NN NN O
- NN NN O
Liss NN NN O
, NN NN O
Inc NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
a NN NN O
functional NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
in NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
M2 NN NN O
- NN NN O
type NN NN O
leukemic NN NN O
blast NN NN O
cells NN NN O
. NN NN O
   
Different NN NN O
types NN NN O
of NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
blast NN NN O
cells NN NN O
were NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
in NN NN O
vitro NN NN O
with NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
and NN NN O
vitamin NN NN O
D3 NN NN O
( NN NN O
VD NN NN O
) NN NN O
. NN NN O
   
M0 NN NN O
/ NN NN O
M1 NN NN O
leukemic NN NN O
cells NN NN O
are NN NN O
not NN NN O
sensitive NN NN O
to NN NN O
differentiating NN NN O
agents NN NN O
, NN NN O
whereas NN NN O
M3 NN NN O
leukemic NN NN O
cells NN NN O
are NN NN O
induced NN NN O
to NN NN O
undergo NN NN O
granulocytic NN NN O
differentiation NN NN O
after NN NN O
ATRA NN NN O
treatment NN NN O
but NN NN O
are NN NN O
not NN NN O
sensitive NN NN O
to NN NN O
VD NN NN O
. NN NN O
   
M2 NN NN O
leukemic NN NN O
blast NN NN O
cells NN NN O
behave NN NN O
differently NN NN O
because NN NN O
they NN NN O
undergo NN NN O
monocytic NN NN O
differentiation NN NN O
with NN NN O
both NN NN O
the NN NN O
differentiation NN NN O
inducers NN NN O
. NN NN O
   
To NN NN O
gain NN NN O
some NN NN O
insight NN NN O
into NN NN O
the NN NN O
maturation NN NN O
of NN NN O
M2 NN NN O
- NN NN O
type NN NN O
leukemic NN NN O
cells NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
monocytic NN NN O
differentiation NN NN O
induced NN NN O
by NN NN O
ATRA NN NN O
and NN NN O
VD NN NN O
in NN NN O
spontaneous NN NN O
M2 NN NN O
blast NN NN O
cells NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
Kasumi NN NN O
- NN NN O
1 NN NN O
cells NN NN O
( NN NN O
an NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
M2 NN NN O
- NN NN O
type NN NN O
cell NN NN O
line NN NN O
) NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
ATRA NN NN O
as NN NN O
well NN NN O
as NN NN O
VD NN NN O
efficiently NN NN O
increases NN NN O
the NN NN O
nuclear NN NN O
abundance NN NN O
of NN NN O
VD NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
and NN NN O
promotes NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
VDR NN NN B-Protein
is NN NN O
functionally NN NN O
active NN NN O
in NN NN O
ATRA NN NN O
- NN NN O
treated NN NN O
Kasumi NN NN O
- NN NN O
1 NN NN O
cells NN NN O
because NN NN O
it NN NN O
efficiently NN NN O
heterodimerizes NN NN O
with NN NN O
retinoid NN NN B-Protein
X NN NN I-Protein
receptor NN NN I-Protein
, NN NN O
binds NN NN O
to NN NN O
a NN NN O
DR3 NN NN O
- NN NN O
type NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
responsive NN NN O
element NN NN O
, NN NN O
and NN NN O
activates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
a NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
responsive NN NN O
element NN NN O
- NN NN O
regulated NN NN O
reporter NN NN O
gene NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
findings NN NN O
, NN NN O
VD NN NN O
- NN NN O
responsive NN NN O
genes NN NN O
are NN NN O
induced NN NN O
by NN NN O
ATRA NN NN O
treatment NN NN O
of NN NN O
Kasumi NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
genetic NN NN O
program NN NN O
underlying NN NN O
monocytic NN NN O
differentiation NN NN O
is NN NN O
activated NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
ATRA NN NN O
increases NN NN O
the NN NN O
nuclear NN NN O
abundance NN NN O
of NN NN O
a NN NN O
functional NN NN O
VDR NN NN B-Protein
is NN NN O
still NN NN O
unknown NN NN O
, NN NN O
but NN NN O
our NN NN O
data NN NN O
clearly NN NN O
indicate NN NN O
that NN NN O
the NN NN O
M2 NN NN O
leukemic NN NN O
cell NN NN O
context NN NN O
is NN NN O
only NN NN O
permissive NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Signal NN NN O
transduction NN NN O
pathways NN NN O
triggered NN NN O
by NN NN O
the NN NN O
FcepsilonRIIb NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
CD23 NN NN B-Protein
) NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
lead NN NN O
to NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Alveolar NN NN O
macrophages NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
reaction NN NN O
of NN NN O
allergic NN NN O
asthma NN NN O
. NN NN O
   
Alveolar NN NN O
macrophages NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
are NN NN O
activated NN NN O
when NN NN O
IgE NN NN O
/ NN NN O
allergen NN NN O
immune NN NN O
complexes NN NN O
bind NN NN O
to NN NN O
the NN NN O
CD23 NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
the NN NN O
production NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
sought NN NN O
to NN NN O
investigate NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
regulating NN NN O
this NN NN O
early NN NN O
inflammatory NN NN O
response NN NN O
. NN NN O
   
We NN NN O
have NN NN O
focused NN NN O
on NN NN O
the NN NN O
study NN NN O
of NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
triggered NN NN O
by NN NN O
CD23 NN NN B-Protein
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
the NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
CD23 NN NN B-Protein
was NN NN O
cross NN NN O
- NN NN O
linked NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
U937 NN NN O
cells NN NN O
with NN NN O
IgE NN NN O
immune NN NN O
complexes NN NN O
. NN NN O
   
Surface NN NN O
expression NN NN O
of NN NN O
CD23 NN NN B-Protein
was NN NN O
determined NN NN O
by NN NN O
FACS NN NN O
analysis NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
activation NN NN O
and NN NN O
gene NN NN O
transcription NN NN O
were NN NN O
studied NN NN O
by NN NN O
gel NN NN O
- NN NN O
shift NN NN O
assays NN NN O
and NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
IkappaBalpha NN NN B-Protein
phosphorylation NN NN O
and NN NN O
degradation NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
Western NN NN O
blot NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
the NN NN O
main NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
the NN NN O
gene NN NN O
activation NN NN O
that NN NN O
follows NN NN O
CD23 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
CD23 NN NN B-Protein
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
a NN NN O
heterodimer NN NN O
composed NN NN O
of NN NN O
p65 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
subunits NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
is NN NN O
secondary NN NN O
to NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
subsequent NN NN O
degradation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitory NN NN O
molecule NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
Tyrosine NN NN O
kinase NN NN O
- NN NN O
dependent NN NN O
, NN NN O
and NN NN O
not NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
dependent NN NN O
, NN NN O
pathways NN NN O
mediate NN NN O
CD23 NN NN B-Protein
- NN NN O
triggered NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
but NN NN O
do NN NN O
not NN NN O
participate NN NN O
in NN NN O
the NN NN O
direct NN NN O
phosphorylation NN NN O
of NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
IkappaBalpha NN NN B-Protein
degradation NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
correlate NN NN O
with NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
cytokines NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
the NN NN O
main NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
of NN NN O
CD23 NN NN B-Protein
in NN NN O
monocytes NN NN O
. NN NN O
   
Dopamine NN NN O
stimulates NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
reported NN NN O
that NN NN O
lymphocytes NN NN O
produce NN NN O
, NN NN O
transport NN NN O
and NN NN O
bind NN NN O
dopamine NN NN O
present NN NN O
in NN NN O
plasma NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
action NN NN O
of NN NN O
dopamine NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
examined NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
by NN NN O
dopamine NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
primary NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
was NN NN O
increased NN NN O
by NN NN O
dopamine NN NN O
, NN NN O
which NN NN O
correlated NN NN O
with NN NN O
the NN NN O
increased NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transactivation NN NN O
. NN NN O
   
Our NN NN O
transient NN NN O
expression NN NN O
data NN NN O
revealed NN NN O
that NN NN O
dopamine NN NN O
stimulated NN NN O
transcription NN NN O
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
element NN NN O
present NN NN O
in NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
sites NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
using NN NN O
vectors NN NN O
containing NN NN O
wild NN NN O
- NN NN O
type NN NN O
or NN NN O
mutant NN NN O
kappaB NN NN O
sites NN NN O
in NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
the NN NN O
role NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
mediating NN NN O
dopamine NN NN O
responsiveness NN NN O
, NN NN O
the NN NN O
proteasome NN NN O
inhibitor NN NN O
MG132 NN NN O
abolished NN NN O
dopamine NN NN O
- NN NN O
induced NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
further NN NN O
explored NN NN O
the NN NN O
effect NN NN O
of NN NN O
dopamine NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
phorbol NN NN O
esters NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
known NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
combination NN NN O
of NN NN O
dopamine NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
led NN NN O
to NN NN O
a NN NN O
stimulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
and NN NN O
replication NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
contrast NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
dopamine NN NN O
treatment NN NN O
did NN NN O
not NN NN O
affect NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
nor NN NN O
the NN NN O
concentrations NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
and NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
proteins NN NN O
, NN NN O
which NN NN O
suggests NN NN O
a NN NN O
distinct NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
mechanism NN NN O
. NN NN O
   
These NN NN O
results NN NN O
reveal NN NN O
a NN NN O
new NN NN O
link NN NN O
between NN NN O
the NN NN O
dopamine NN NN O
system NN NN O
, NN NN O
cytokine NN NN O
signaling NN NN O
pathway NN NN O
and NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
via NN NN O
the NN NN O
involvement NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
PBMC NN NN O
. NN NN O
   
AML1 NN NN B-Protein
( NN NN O
CBFalpha2 NN NN B-Protein
) NN NN O
cooperates NN NN O
with NN NN O
B NN NN B-Protein
cell NN NN I-Protein
- NN NN I-Protein
specific NN NN I-Protein
activating NN NN I-Protein
protein NN NN I-Protein
( NN NN O
BSAP NN NN B-Protein
/ NN NN O
PAX5 NN NN B-Protein
) NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
BLK NN NN B-Protein
gene NN NN O
promoter NN NN O
. NN NN O
   
AML1 NN NN B-Protein
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
during NN NN O
hematopoiesis NN NN O
and NN NN O
chromosomal NN NN O
translocations NN NN O
involving NN NN O
AML1 NN NN B-Protein
are NN NN O
commonly NN NN O
associated NN NN O
with NN NN O
different NN NN O
forms NN NN O
of NN NN O
leukemia NN NN O
, NN NN O
including NN NN O
pre NN NN O
- NN NN O
B NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
function NN NN O
of NN NN O
AML1 NN NN B-Protein
during NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
for NN NN O
potential NN NN O
AML1 NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
and NN NN O
have NN NN O
identified NN NN O
a NN NN O
putative NN NN O
AML1 NN NN B-Protein
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
B NN NN B-Protein
cell NN NN I-Protein
- NN NN I-Protein
specific NN NN I-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
gene NN NN O
, NN NN O
blk NN NN B-Protein
. NN NN O
   
Gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
demonstrate NN NN O
that NN NN O
AML1 NN NN B-Protein
binds NN NN O
specifically NN NN O
to NN NN O
this NN NN O
site NN NN O
in NN NN O
the NN NN O
blk NN NN B-Protein
promoter NN NN O
and NN NN O
this NN NN O
binding NN NN O
site NN NN O
is NN NN O
important NN NN O
for NN NN O
blk NN NN B-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
in NN NN O
vitro NN NN O
binding NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
AML1 NN NN B-Protein
runt NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
physically NN NN O
interacts NN NN O
with NN NN O
the NN NN O
paired NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
BSAP NN NN B-Protein
, NN NN O
a NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
BSAP NN NN B-Protein
has NN NN O
been NN NN O
shown NN NN O
previously NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
the NN NN O
blk NN NN B-Protein
gene NN NN O
. NN NN O
   
Physical NN NN O
interaction NN NN O
of NN NN O
AML1 NN NN B-Protein
with NN NN O
BSAP NN NN B-Protein
correlates NN NN O
with NN NN O
functional NN NN O
cooperativity NN NN O
in NN NN O
transfection NN NN O
studies NN NN O
where NN NN O
AML1 NN NN B-Protein
and NN NN O
BSAP NN NN B-Protein
synergistically NN NN O
activate NN NN O
blk NN NN B-Protein
promoter NN NN O
transcription NN NN O
by NN NN O
more NN NN O
than NN NN O
50 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
physical NN NN O
and NN NN O
functional NN NN O
interactions NN NN O
between NN NN O
AML1 NN NN B-Protein
and NN NN O
BSAP NN NN B-Protein
and NN NN O
suggest NN NN O
that NN NN O
AML1 NN NN B-Protein
is NN NN O
an NN NN O
important NN NN O
factor NN NN O
for NN NN O
regulating NN NN O
a NN NN O
critical NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
gene NN NN O
, NN NN O
blk NN NN B-Protein
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
induces NN NN O
monocytic NN NN O
differentiation NN NN O
and NN NN O
apoptosis NN NN O
in NN NN O
bipotent NN NN O
myeloid NN NN O
progenitors NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
mechanisms NN NN O
that NN NN O
drive NN NN O
colony NN NN O
- NN NN O
forming NN NN O
unit NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
( NN NN O
CFU NN NN O
- NN NN O
GM NN NN O
) NN NN O
myeloid NN NN O
progenitors NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
cells NN NN O
of NN NN O
either NN NN O
the NN NN O
granulocytic NN NN O
or NN NN O
monocytic NN NN O
lineage NN NN O
are NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
have NN NN O
shown NN NN O
that NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
transcription NN NN O
factors NN NN O
physically NN NN O
interact NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
to NN NN O
form NN NN O
inhibitory NN NN O
complexes NN NN O
that NN NN O
hinder NN NN O
transactivation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
target NN NN O
genes NN NN O
through NN NN O
direct NN NN O
binding NN NN O
to NN NN O
Myb NN NN O
consensus NN NN O
sites NN NN O
. NN NN O
   
These NN NN O
complexes NN NN O
arise NN NN O
in NN NN O
a NN NN O
developmentally NN NN O
regulated NN NN O
pattern NN NN O
, NN NN O
peaking NN NN O
at NN NN O
the NN NN O
promyelocyte NN NN O
stage NN NN O
, NN NN O
or NN NN O
in NN NN O
cell NN NN O
model NN NN O
systems NN NN O
, NN NN O
appearing NN NN O
soon NN NN O
after NN NN O
the NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
wished NN NN O
to NN NN O
determine NN NN O
if NN NN O
this NN NN O
developmentally NN NN O
related NN NN O
interaction NN NN O
is NN NN O
a NN NN O
consequence NN NN O
of NN NN O
myeloid NN NN O
differentiation NN NN O
or NN NN O
an NN NN O
intrinsic NN NN O
differentiating NN NN O
stimulus NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
elevated NN NN O
Myb NN NN O
: NN NN O
Maf NN NN O
status NN NN O
seen NN NN O
in NN NN O
differentiating NN NN O
cells NN NN O
can NN NN O
be NN NN O
recapitulated NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
in NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
we NN NN O
inducibly NN NN O
expressed NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
cDNA NN NN O
in NN NN O
2 NN NN O
bipotent NN NN O
human NN NN O
myeloid NN NN O
progenitor NN NN O
cells NN NN O
. NN NN O
   
Elevated NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
protein NN NN O
led NN NN O
to NN NN O
marked NN NN O
increases NN NN O
in NN NN O
Myb NN NN O
: NN NN O
Maf NN NN O
complexes NN NN O
and NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cells NN NN O
, NN NN O
followed NN NN O
by NN NN O
eventual NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
targets NN NN O
that NN NN O
could NN NN O
mediate NN NN O
these NN NN O
phenotypic NN NN O
changes NN NN O
indicated NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Maf NN NN I-Protein
likely NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
myeloid NN NN O
cell NN NN O
development NN NN O
through NN NN O
dual NN NN O
mechanisms NN NN O
; NN NN O
inhibition NN NN O
of NN NN O
a NN NN O
select NN NN O
set NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
regulated NN NN O
targets NN NN O
, NN NN O
such NN NN O
as NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
CD13 NN NN B-Protein
/ NN NN O
APN NN NN B-Protein
, NN NN O
coupled NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
as NN NN O
yet NN NN O
undefined NN NN O
differentiation NN NN O
- NN NN O
promoting NN NN O
genes NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
: NN NN O
evidence NN NN O
for NN NN O
an NN NN O
antioxidant NN NN O
sensitive NN NN O
activating NN NN O
pathway NN NN O
distinct NN NN O
from NN NN O
nuclear NN NN O
translocation NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
pluripotent NN NN O
activator NN NN O
of NN NN O
inflammation NN NN O
by NN NN O
inducing NN NN O
a NN NN O
proinflammatory NN NN O
cytokine NN NN O
cascade NN NN O
. NN NN O
   
This NN NN O
phenomenon NN NN O
is NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
through NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
the NN NN O
CXC NN NN O
chemokine NN NN O
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
TNFalpha NN NN B-Protein
- NN NN O
inducible NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
by NN NN O
"""""""" NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
"""""""" NN NN O
U937 NN NN O
histiocytic NN NN O
lymphoma NN NN O
cells NN NN O
. NN NN O
   
TNFalpha NN NN B-Protein
is NN NN O
a NN NN O
rapid NN NN O
activator NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
U937 NN NN O
, NN NN O
producing NN NN O
a NN NN O
50 NN NN O
- NN NN O
fold NN NN O
induction NN NN O
of NN NN O
mRNA NN NN O
within NN NN O
1 NN NN O
hour NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
gene NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
TNFalpha NN NN B-Protein
requires NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
inducible NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
( NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
) NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
promoter NN NN O
. NN NN O
   
TNFalpha NN NN B-Protein
treatment NN NN O
induces NN NN O
a NN NN O
rapid NN NN O
translocation NN NN O
of NN NN O
the NN NN O
65 NN NN O
kD NN NN O
transcriptional NN NN O
activator NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunit NN NN O
, NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
, NN NN O
whose NN NN O
binding NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
occurs NN NN O
before NN NN O
changes NN NN O
in NN NN O
intracellular NN NN O
ROS NN NN O
. NN NN O
   
Pretreatment NN NN O
( NN NN O
or NN NN O
up NN NN O
to NN NN O
15 NN NN O
minutes NN NN O
posttreatment NN NN O
) NN NN O
relative NN NN O
to NN NN O
TNFalpha NN NN B-Protein
with NN NN O
the NN NN O
antioxidant NN NN O
dimethyl NN NN O
sulfoxide NN NN O
( NN NN O
DMSO NN NN O
) NN NN O
( NN NN O
2 NN NN O
% NN NN O
[ NN NN O
vol NN NN O
/ NN NN O
vol NN NN O
] NN NN O
) NN NN O
blocks NN NN O
80 NN NN O
% NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
however NN NN O
, NN NN O
DMSO NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
inducible NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
binding NN NN O
. NN NN O
   
Similar NN NN O
selective NN NN O
effects NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
are NN NN O
seen NN NN O
with NN NN O
the NN NN O
unrelated NN NN O
antioxidants NN NN O
, NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
and NN NN O
vitamin NN NN O
C NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
TNFalpha NN NN B-Protein
induces NN NN O
a NN NN O
delayed NN NN O
ROS NN NN O
- NN NN O
dependent NN NN O
signalling NN NN O
pathway NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcriptional NN NN O
activation NN NN O
and NN NN O
is NN NN O
separable NN NN O
from NN NN O
that NN NN O
required NN NN O
for NN NN O
its NN NN O
nuclear NN NN O
translocation NN NN O
. NN NN O
   
Further NN NN O
definition NN NN O
of NN NN O
this NN NN O
pathway NN NN O
will NN NN O
yield NN NN O
new NN NN O
insights NN NN O
into NN NN O
inflammation NN NN O
initiated NN NN O
by NN NN O
TNFalpha NN NN B-Protein
signalling NN NN O
. NN NN O
   
Neutrophil NN NN O
maturation NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
. NN NN O
   
Neutrophil NN NN O
maturation NN NN O
occurs NN NN O
in NN NN O
well NN NN O
defined NN NN O
morphological NN NN O
stages NN NN O
that NN NN O
correlate NN NN O
with NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
molecular NN NN O
markers NN NN O
associated NN NN O
with NN NN O
neutrophil NN NN O
function NN NN O
. NN NN O
   
A NN NN O
variety NN NN O
of NN NN O
factors NN NN O
are NN NN O
known NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
terminal NN NN O
neutrophil NN NN O
maturation NN NN O
, NN NN O
including NN NN O
the NN NN O
vitamin NN NN O
A NN NN O
derivative NN NN O
, NN NN O
retinoic NN NN O
acid NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
can NN NN O
directly NN NN O
modulate NN NN O
gene NN NN O
expression NN NN O
via NN NN O
binding NN NN O
to NN NN O
its NN NN O
nuclear NN NN O
receptors NN NN O
, NN NN O
which NN NN O
can NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
A NN NN O
role NN NN O
for NN NN O
retinoic NN NN O
acid NN NN O
during NN NN O
neutrophil NN NN O
maturation NN NN O
has NN NN O
been NN NN O
suggested NN NN O
from NN NN O
a NN NN O
variety NN NN O
of NN NN O
sources NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
present NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
receptor NN NN O
action NN NN O
and NN NN O
the NN NN O
major NN NN O
evidence NN NN O
showing NN NN O
that NN NN O
normal NN NN O
retinoid NN NN O
signaling NN NN O
is NN NN O
required NN NN O
for NN NN O
neutrophil NN NN O
maturation NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
( NN NN I-Protein
L NN NN I-Protein
) NN NN I-Protein
expression NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
through NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
apoptosis NN NN O
- NN NN O
resistant NN NN O
T NN NN O
- NN NN O
cell NN NN O
transfectants NN NN O
with NN NN O
Tax NN NN B-Protein
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tax NN NN B-Protein
is NN NN O
thought NN NN O
to NN NN O
play NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
immortalization NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
shown NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
Tax NN NN B-Protein
protected NN NN O
the NN NN O
mouse NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
against NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
deprivation NN NN O
and NN NN O
converted NN NN O
its NN NN O
growth NN NN O
from NN NN O
being NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
dependent NN NN O
to NN NN O
being NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
independent NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xl NN NN I-Protein
but NN NN O
not NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
xs NN NN I-Protein
, NN NN O
bak NN NN B-Protein
, NN NN O
bad NN NN B-Protein
, NN NN O
or NN NN O
bax NN NN B-Protein
was NN NN O
associated NN NN O
with NN NN O
apoptosis NN NN O
resistance NN NN O
after NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
in NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
cells NN NN O
that NN NN O
expressed NN NN O
Tax NN NN B-Protein
. NN NN O
   
Transient NN NN O
- NN NN O
transfection NN NN O
assays NN NN O
showed NN NN O
that NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
promoter NN NN O
was NN NN O
transactivated NN NN O
by NN NN O
wild NN NN O
- NN NN O
type NN NN O
Tax NN NN B-Protein
. NN NN O
   
Similar NN NN O
effects NN NN O
were NN NN O
observed NN NN O
in NN NN O
mutant NN NN O
Tax NN NN B-Protein
retaining NN NN O
transactivating NN NN O
ability NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Deletion NN NN O
or NN NN O
substitution NN NN O
of NN NN O
a NN NN O
putative NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
site NN NN O
identified NN NN O
in NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
promoter NN NN O
significantly NN NN O
decreased NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
transactivation NN NN O
. NN NN O
   
This NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
like NN NN O
element NN NN O
was NN NN O
able NN NN O
to NN NN O
form NN NN O
a NN NN O
complex NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
proteins NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
promoter NN NN O
was NN NN O
also NN NN O
diminished NN NN O
by NN NN O
the NN NN O
mutant NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
which NN NN O
specifically NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
x NN NN I-Protein
( NN NN I-Protein
L NN NN I-Protein
) NN NN I-Protein
induced NN NN O
by NN NN O
Tax NN NN B-Protein
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
contributes NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
cells NN NN O
after NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
. NN NN O
   
Interferons NN NN O
inhibit NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
by NN NN O
interleukin NN NN B-Protein
4 NN NN I-Protein
in NN NN O
human NN NN O
monocytes NN NN O
by NN NN O
inducing NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Interferons NN NN O
( NN NN O
IFNs NN NN O
) NN NN O
inhibit NN NN O
induction NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
of NN NN O
multiple NN NN O
genes NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
IFNs NN NN O
mediate NN NN O
this NN NN O
inhibition NN NN O
has NN NN O
not NN NN O
been NN NN O
defined NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
activates NN NN O
gene NN NN O
expression NN NN O
by NN NN O
inducing NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
homodimerization NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
latent NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
STAT6 NN NN B-Protein
( NN NN O
signal NN NN B-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
. NN NN O
   
STAT6 NN NN B-Protein
- NN NN O
responsive NN NN O
elements NN NN O
are NN NN O
characteristically NN NN O
present NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
inducible NN NN O
genes NN NN O
. NN NN O
   
Because NN NN O
STAT6 NN NN B-Protein
activation NN NN O
is NN NN O
essential NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
gene NN NN O
expression NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
ability NN NN O
of NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
IFNs NN NN O
to NN NN O
regulate NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
primary NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
monocytes NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
or NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
macrophage NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
, NN NN O
granulocyte NN NN O
/ NN NN O
macrophage NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
or NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
beta NN NN I-Protein
suppressed NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
This NN NN O
inhibition NN NN O
was NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
STAT6 NN NN B-Protein
and NN NN O
was NN NN O
not NN NN O
evident NN NN O
unless NN NN O
the NN NN O
cells NN NN O
were NN NN O
preincubated NN NN O
with NN NN O
IFN NN NN O
for NN NN O
at NN NN O
least NN NN O
1 NN NN O
hr NN NN O
before NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
inhibition NN NN O
by NN NN O
IFN NN NN O
could NN NN O
be NN NN O
blocked NN NN O
by NN NN O
cotreatment NN NN O
with NN NN O
actinomycin NN NN O
D NN NN O
and NN NN O
correlated NN NN O
temporally NN NN O
with NN NN O
induction NN NN O
of NN NN O
the NN NN O
JAK NN NN O
/ NN NN O
STAT NN NN O
inhibitory NN NN O
gene NN NN O
, NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Forced NN NN O
expression NN NN O
of NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
a NN NN O
macrophage NN NN O
cell NN NN O
line NN NN O
, NN NN O
RAW264 NN NN O
, NN NN O
markedly NN NN O
suppressed NN NN O
trans NN NN O
- NN NN O
activation NN NN O
of NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
inducible NN NN O
reporter NN NN O
as NN NN O
well NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
- NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
IFNs NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
STAT6 NN NN B-Protein
and NN NN O
STAT6 NN NN B-Protein
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
inducing NN NN O
expression NN NN O
of NN NN O
SOCS NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Increased NN NN O
IkappaB NN NN O
expression NN NN O
and NN NN O
diminished NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
human NN NN O
mononuclear NN NN O
cells NN NN O
following NN NN O
hydrocortisone NN NN O
injection NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
demonstrated NN NN O
that NN NN O
hydrocortisone NN NN O
and NN NN O
other NN NN O
glucocorticoids NN NN O
inhibit NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
generation NN NN O
by NN NN O
mononuclear NN NN O
( NN NN O
MNC NN NN O
) NN NN O
and NN NN O
polymorphonuclear NN NN O
leucocytes NN NN O
( NN NN O
PMNL NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
IkappaB NN NN O
system NN NN O
regulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
proinflammatory NN NN O
genes NN NN O
, NN NN O
including NN NN O
those NN NN O
responsible NN NN O
for NN NN O
ROS NN NN O
generation NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
hydrocortisone NN NN O
may NN NN O
stimulate NN NN O
IkappaB NN NN O
production NN NN O
thus NN NN O
inhibiting NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
translocation NN NN O
from NN NN O
the NN NN O
cytosol NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
MNC NN NN O
, NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
One NN NN O
hundred NN NN O
milligram NN NN O
of NN NN O
hydrocortisone NN NN O
was NN NN O
injected NN NN O
intravenously NN NN O
into NN NN O
4 NN NN O
normal NN NN O
subjects NN NN O
. NN NN O
   
Blood NN NN O
samples NN NN O
were NN NN O
obtained NN NN O
prior NN NN O
to NN NN O
the NN NN O
injection NN NN O
and NN NN O
at NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
4 NN NN O
, NN NN O
8 NN NN O
and NN NN O
24 NN NN O
hr NN NN O
after NN NN O
the NN NN O
injection NN NN O
. NN NN O
   
Nuclear NN NN O
extracts NN NN O
and NN NN O
total NN NN O
cell NN NN O
lysates NN NN O
were NN NN O
prepared NN NN O
from NN NN O
MNC NN NN O
by NN NN O
standard NN NN O
techniques NN NN O
. NN NN O
   
IkappaB NN NN O
levels NN NN O
in NN NN O
MNC NN NN O
homogenates NN NN O
increased NN NN O
at NN NN O
1 NN NN O
hr NN NN O
, NN NN O
peaked NN NN O
at NN NN O
2 NN NN O
- NN NN O
4 NN NN O
hr NN NN O
, NN NN O
started NN NN O
to NN NN O
decrease NN NN O
at NN NN O
8 NN NN O
hr NN NN O
, NN NN O
and NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
levels NN NN O
at NN NN O
24 NN NN O
hr NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
MNC NN NN O
nuclear NN NN O
extracts NN NN O
decreased NN NN O
at NN NN O
1 NN NN O
hr NN NN O
, NN NN O
reached NN NN O
a NN NN O
nadir NN NN O
at NN NN O
4 NN NN O
hr NN NN O
, NN NN O
gradually NN NN O
increased NN NN O
at NN NN O
8 NN NN O
hr NN NN O
and NN NN O
returned NN NN O
back NN NN O
to NN NN O
baseline NN NN O
levels NN NN O
at NN NN O
24 NN NN O
hr NN NN O
. NN NN O
   
The NN NN O
total NN NN O
protein NN NN O
content NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunit NN NN O
( NN NN O
P65 NN NN B-Protein
) NN NN O
in NN NN O
MNC NN NN O
lysates NN NN O
also NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
following NN NN O
hydrocortisone NN NN O
injection NN NN O
. NN NN O
   
This NN NN O
decrease NN NN O
was NN NN O
observed NN NN O
at NN NN O
2 NN NN O
hr NN NN O
, NN NN O
reached NN NN O
a NN NN O
nadir NN NN O
at NN NN O
4 NN NN O
hr NN NN O
, NN NN O
and NN NN O
returned NN NN O
to NN NN O
baseline NN NN O
levels NN NN O
at NN NN O
24 NN NN O
hr NN NN O
. NN NN O
   
ROS NN NN O
generation NN NN O
inhibition NN NN O
paralleled NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
levels NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
It NN NN O
was NN NN O
inhibited NN NN O
at NN NN O
1 NN NN O
hr NN NN O
, NN NN O
reached NN NN O
a NN NN O
nadir NN NN O
at NN NN O
2 NN NN O
- NN NN O
4 NN NN O
hr NN NN O
, NN NN O
started NN NN O
to NN NN O
increase NN NN O
at NN NN O
8 NN NN O
hr NN NN O
, NN NN O
and NN NN O
returned NN NN O
to NN NN O
basal NN NN O
levels NN NN O
at NN NN O
24 NN NN O
hr NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
hydrocortisone NN NN O
induces NN NN O
IkappaB NN NN O
and NN NN O
suppresses NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
expression NN NN O
in NN NN O
MNC NN NN O
in NN NN O
parallel NN NN O
. NN NN O
   
IkappaB NN NN O
further NN NN O
reduces NN NN O
the NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
thus NN NN O
preventing NN NN O
the NN NN O
expression NN NN O
of NN NN O
proinflammatory NN NN O
genes NN NN O
. NN NN O
   
Renal NN NN O
cell NN NN O
carcinoma NN NN O
- NN NN O
derived NN NN O
gangliosides NN NN O
suppress NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
is NN NN O
impaired NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
renal NN NN O
cell NN NN O
carcinomas NN NN O
( NN NN O
RCCs NN NN O
) NN NN O
. NN NN O
   
In NN NN O
circulating NN NN O
T NN NN O
cells NN NN O
from NN NN O
a NN NN O
subset NN NN O
of NN NN O
patients NN NN O
with NN NN O
RCCs NN NN O
, NN NN O
the NN NN O
suppression NN NN O
of NN NN O
NFkappaB NN NN O
binding NN NN O
activity NN NN O
is NN NN O
downstream NN NN O
from NN NN O
the NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
degradation NN NN O
of NN NN O
the NN NN O
cytoplasmic NN NN O
factor NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
Tumor NN NN O
- NN NN O
derived NN NN O
soluble NN NN O
products NN NN O
from NN NN O
cultured NN NN O
RCC NN NN O
explants NN NN O
inhibit NN NN O
NFkappaB NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
healthy NN NN O
volunteers NN NN O
, NN NN O
despite NN NN O
a NN NN O
normal NN NN O
level NN NN O
of NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
IkappaBalpha NN NN B-Protein
degradation NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
agent NN NN O
has NN NN O
several NN NN O
features NN NN O
characteristic NN NN O
of NN NN O
a NN NN O
ganglioside NN NN O
, NN NN O
including NN NN O
sensitivity NN NN O
to NN NN O
neuraminidase NN NN O
but NN NN O
not NN NN O
protease NN NN O
treatment NN NN O
; NN NN O
hydrophobicity NN NN O
; NN NN O
and NN NN O
molecular NN NN O
weight NN NN O
less NN NN O
than NN NN O
3 NN NN O
kDa NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
we NN NN O
detected NN NN O
gangliosides NN NN O
in NN NN O
supernatants NN NN O
from NN NN O
RCC NN NN O
explants NN NN O
and NN NN O
not NN NN O
from NN NN O
adjacent NN NN O
normal NN NN O
kidney NN NN O
tissue NN NN O
. NN NN O
   
Gangliosides NN NN O
prepared NN NN O
from NN NN O
RCC NN NN O
supernatants NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
purified NN NN O
bovine NN NN O
gangliosides NN NN O
G NN NN O
( NN NN O
m1 NN NN O
) NN NN O
and NN NN O
G NN NN O
( NN NN O
d1a NN NN O
) NN NN O
, NN NN O
suppressed NN NN O
NFkappaB NN NN O
binding NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
the NN NN O
cytokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
tumor NN NN O
- NN NN O
derived NN NN O
gangliosides NN NN O
may NN NN O
blunt NN NN O
antitumor NN NN O
immune NN NN O
responses NN NN O
in NN NN O
patients NN NN O
with NN NN O
RCCs NN NN O
. NN NN O
   
Affinity NN NN O
- NN NN O
driven NN NN O
peptide NN NN O
selection NN NN O
of NN NN O
an NN NN O
NFAT NN NN O
inhibitor NN NN O
more NN NN O
selective NN NN O
than NN NN O
cyclosporin NN NN O
A NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
The NN NN O
flow NN NN O
of NN NN O
information NN NN O
from NN NN O
calcium NN NN O
- NN NN O
mobilizing NN NN O
receptors NN NN O
to NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
- NN NN O
dependent NN NN O
genes NN NN O
is NN NN O
critically NN NN O
dependent NN NN O
on NN NN O
interaction NN NN O
between NN NN O
the NN NN O
phosphatase NN NN O
calcineurin NN NN O
and NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NFAT NN NN O
. NN NN O
   
A NN NN O
high NN NN O
- NN NN O
affinity NN NN O
calcineurin NN NN O
- NN NN O
binding NN NN O
peptide NN NN O
was NN NN O
selected NN NN O
from NN NN O
combinatorial NN NN O
peptide NN NN O
libraries NN NN O
based NN NN O
on NN NN O
the NN NN O
calcineurin NN NN O
docking NN NN O
motif NN NN O
of NN NN O
NFAT NN NN O
. NN NN O
   
This NN NN O
peptide NN NN O
potently NN NN O
inhibited NN NN O
NFAT NN NN O
activation NN NN O
and NN NN O
NFAT NN NN O
- NN NN O
dependent NN NN O
expression NN NN O
of NN NN O
endogenous NN NN O
cytokine NN NN O
genes NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
without NN NN O
affecting NN NN O
the NN NN O
expression NN NN O
of NN NN O
other NN NN O
cytokines NN NN O
that NN NN O
require NN NN O
calcineurin NN NN O
but NN NN O
not NN NN O
NFAT NN NN O
. NN NN O
   
Substitution NN NN O
of NN NN O
the NN NN O
optimized NN NN O
peptide NN NN O
sequence NN NN O
into NN NN O
the NN NN O
natural NN NN O
calcineurin NN NN O
docking NN NN O
site NN NN O
increased NN NN O
the NN NN O
calcineurin NN NN O
responsiveness NN NN O
of NN NN O
NFAT NN NN O
. NN NN O
   
Compounds NN NN O
that NN NN O
interfere NN NN O
selectively NN NN O
with NN NN O
the NN NN O
calcineurin NN NN O
- NN NN O
NFAT NN NN O
interaction NN NN O
without NN NN O
affecting NN NN O
calcineurin NN NN O
phosphatase NN NN O
activity NN NN O
may NN NN O
be NN NN O
useful NN NN O
as NN NN O
therapeutic NN NN O
agents NN NN O
that NN NN O
are NN NN O
less NN NN O
toxic NN NN O
than NN NN O
current NN NN O
drugs NN NN O
. NN NN O
   
Leukotriene NN NN O
B4 NN NN O
stimulates NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
leukotriene NN NN O
B4 NN NN O
( NN NN O
LTB4 NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
lipid NN NN O
proinflammatory NN NN O
mediator NN NN O
, NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
looked NN NN O
at NN NN O
the NN NN O
modulation NN NN O
of NN NN O
nuclear NN NN O
factors NN NN O
binding NN NN O
specifically NN NN O
to NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
element NN NN O
after NN NN O
LTB4 NN NN O
stimulation NN NN O
. NN NN O
   
LTB4 NN NN O
increased NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
gene NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
, NN NN O
which NN NN O
is NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
- NN NN O
blood NN NN O
monocytes NN NN O
at NN NN O
relatively NN NN O
high NN NN O
levels NN NN O
, NN NN O
was NN NN O
also NN NN O
slightly NN NN O
augmented NN NN O
by NN NN O
LTB4 NN NN O
, NN NN O
although NN NN O
to NN NN O
a NN NN O
much NN NN O
lower NN NN O
extent NN NN O
than NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
. NN NN O
   
The NN NN O
kinetics NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
two NN NN O
genes NN NN O
were NN NN O
also NN NN O
slightly NN NN O
different NN NN O
, NN NN O
with NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
reaching NN NN O
a NN NN O
peak NN NN O
at NN NN O
15 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
at NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
Both NN NN O
messages NN NN O
rapidly NN NN O
declined NN NN O
thereafter NN NN O
. NN NN O
   
Stability NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
was NN NN O
not NN NN O
affected NN NN O
by NN NN O
LTB4 NN NN O
, NN NN O
as NN NN O
assessed NN NN O
after NN NN O
actinomycin NN NN O
D NN NN O
treatment NN NN O
. NN NN O
   
Nuclear NN NN O
transcription NN NN O
studies NN NN O
in NN NN O
vitro NN NN O
showed NN NN O
that NN NN O
LTB4 NN NN O
increased NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
gene NN NN O
7 NN NN O
- NN NN O
fold NN NN O
and NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
1 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
Resting NN NN O
monocytes NN NN O
contained NN NN O
nuclear NN NN O
factors NN NN O
binding NN NN O
to NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
element NN NN O
, NN NN O
but NN NN O
stimulation NN NN O
of NN NN O
monocytes NN NN O
with NN NN O
LTB4 NN NN O
induced NN NN O
greater NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
LTB4 NN NN O
may NN NN O
regulate NN NN O
the NN NN O
production NN NN O
of NN NN O
different NN NN O
cytokines NN NN O
by NN NN O
modulating NN NN O
the NN NN O
yield NN NN O
and NN NN O
/ NN NN O
or NN NN O
the NN NN O
function NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
such NN NN O
as NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
products NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
activation NN NN O
and NN NN O
functional NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
expression NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
transcription NN NN O
factors NN NN O
: NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
formation NN NN O
of NN NN O
AP1 NN NN O
transcriptional NN NN O
complex NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
lipopolysaccharide NN NN O
induced NN NN O
strongly NN NN O
both NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
as NN NN O
well NN NN O
as NN NN O
AP1 NN NN O
formation NN NN O
. NN NN O
   
Interferon NN NN B-Protein
gamma NN NN I-Protein
activated NN NN O
strongly NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
weakly NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
AP1 NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
induced NN NN O
slightly NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
had NN NN O
almost NN NN O
no NN NN O
effect NN NN O
on NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
AP1 NN NN O
. NN NN O
   
The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
differences NN NN O
in NN NN O
functional NN NN O
responses NN NN O
elicited NN NN O
in NN NN O
monocytes NN NN O
by NN NN O
all NN NN O
three NN NN O
factors NN NN O
may NN NN O
be NN NN O
dependent NN NN O
on NN NN O
different NN NN O
routes NN NN O
on NN NN O
nuclear NN NN O
signalling NN NN O
employed NN NN O
by NN NN O
the NN NN O
factors NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
potentiates NN NN O
the NN NN O
antiviral NN NN O
activity NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
interferon NN NN O
- NN NN O
stimulated NN NN O
genes NN NN O
induced NN NN O
by NN NN O
interferon NN NN O
- NN NN O
alpha NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
type NN NN O
I NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
) NN NN O
to NN NN O
specific NN NN O
receptors NN NN O
results NN NN O
in NN NN O
the NN NN O
rapid NN NN O
transcriptional NN NN O
activation NN NN O
, NN NN O
independent NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
, NN NN O
of NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
stimulated NN NN O
genes NN NN O
( NN NN O
ISGs NN NN O
) NN NN O
in NN NN O
human NN NN O
fibroblasts NN NN O
and NN NN O
HeLa NN NN O
and NN NN O
Daudi NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
ISGF3 NN NN O
( NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
gene NN NN O
factor NN NN O
3 NN NN O
) NN NN O
to NN NN O
the NN NN O
conserved NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
response NN NN O
element NN NN O
( NN NN O
ISRE NN NN O
) NN NN O
results NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
is NN NN O
composed NN NN O
of NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
ISGF3 NN NN B-Protein
gamma NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
normally NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
, NN NN O
and NN NN O
other NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
activated NN NN O
proteins NN NN O
which NN NN O
preexist NN NN O
as NN NN O
latent NN NN O
cytoplasmic NN NN O
precursors NN NN O
( NN NN O
ISGF3 NN NN O
alpha NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
ISG NN NN O
expression NN NN O
in NN NN O
the NN NN O
monocytic NN NN O
U937 NN NN O
cell NN NN O
line NN NN O
differs NN NN O
from NN NN O
most NN NN O
cell NN NN O
lines NN NN O
previously NN NN O
examined NN NN O
. NN NN O
   
U937 NN NN O
cells NN NN O
express NN NN O
both NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
IFN NN NN O
receptors NN NN O
, NN NN O
but NN NN O
only NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
is NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
antiviral NN NN O
protection NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
potentiates NN NN O
the NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
- NN NN O
induced NN NN O
protection NN NN O
, NN NN O
but NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
alone NN NN O
does NN NN O
not NN NN O
have NN NN O
any NN NN O
antiviral NN NN O
activity NN NN O
. NN NN O
   
ISG15 NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
is NN NN O
not NN NN O
detectable NN NN O
before NN NN O
6 NN NN O
h NN NN O
of NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
treatment NN NN O
, NN NN O
peaks NN NN O
at NN NN O
24 NN NN O
h NN NN O
, NN NN O
and NN NN O
requires NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Although NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
alone NN NN O
does NN NN O
not NN NN O
induce NN NN O
ISG NN NN O
expression NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
pretreatment NN NN O
markedly NN NN O
increases NN NN O
and NN NN O
hastens NN NN O
ISG NN NN O
expression NN NN O
and NN NN O
transcriptional NN NN O
induction NN NN O
. NN NN O
   
Nuclear NN NN O
extracts NN NN O
assayed NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
ISRE NN NN O
binding NN NN O
factors NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
show NN NN O
that NN NN O
ISGF3 NN NN O
is NN NN O
induced NN NN O
by NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
within NN NN O
6 NN NN O
h NN NN O
from NN NN O
undetectable NN NN O
basal NN NN O
levels NN NN O
in NN NN O
untreated NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
ISGF3 NN NN O
alpha NN NN O
, NN NN O
the NN NN O
latent NN NN O
component NN NN O
of NN NN O
ISGF3 NN NN O
, NN NN O
occurs NN NN O
rapidly NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
ISGF3 NN NN O
activity NN NN O
ultimately NN NN O
correlates NN NN O
with NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
ISGF3 NN NN B-Protein
gamma NN NN I-Protein
induced NN NN O
by NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
or NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
A NN NN O
lymphoid NN NN O
cell NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
containing NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
- NN NN O
like NN NN O
proteins NN NN O
preferentially NN NN O
interacts NN NN O
with NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
motifs NN NN O
whose NN NN O
activities NN NN O
are NN NN O
repressed NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
proto NN NN O
- NN NN O
oncoprotein NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
, NN NN O
which NN NN O
includes NN NN O
the NN NN O
p50 NN NN O
and NN NN O
p65 NN NN O
subunits NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
binds NN NN O
to NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
as NN NN O
homodimers NN NN O
as NN NN O
well NN NN O
as NN NN O
heterodimers NN NN O
with NN NN O
p50 NN NN B-Protein
. NN NN O
   
These NN NN O
homodimers NN NN O
and NN NN O
heterodimers NN NN O
show NN NN O
distinct NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
specificities NN NN O
and NN NN O
affinities NN NN O
for NN NN O
various NN NN O
kappa NN NN O
B NN NN O
motifs NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
homodimer NN NN O
has NN NN O
a NN NN O
high NN NN O
affinity NN NN O
for NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
and NN NN O
beta NN NN B-Protein
interferon NN NN I-Protein
kappa NN NN O
B NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
spite NN NN O
of NN NN O
its NN NN O
association NN NN O
with NN NN O
p50 NN NN B-Protein
in NN NN O
vitro NN NN O
, NN NN O
however NN NN O
, NN NN O
we NN NN O
found NN NN O
a NN NN O
lymphoid NN NN O
cell NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
in NN NN O
vivo NN NN O
that NN NN O
contains NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
but NN NN O
not NN NN O
p50 NN NN B-Protein
epitopes NN NN O
; NN NN O
this NN NN O
factor NN NN O
, NN NN O
termed NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
binding NN NN O
factor NN NN O
II NN NN O
, NN NN O
appears NN NN O
to NN NN O
contain NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
homodimer NN NN O
and NN NN O
preferentially NN NN O
recognizes NN NN O
several NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
kappa NN NN O
B NN NN O
motifs NN NN O
. NN NN O
   
Although NN NN O
it NN NN O
has NN NN O
been NN NN O
previously NN NN O
shown NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
motif NN NN O
functions NN NN O
as NN NN O
a NN NN O
potent NN NN O
IL NN NN O
- NN NN O
1 NN NN O
/ NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN O
responsive NN NN O
element NN NN O
in NN NN O
nonlymphoid NN NN O
cells NN NN O
, NN NN O
its NN NN O
activity NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
repressed NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
such NN NN O
as NN NN O
a NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
We NN NN O
also NN NN O
present NN NN O
evidence NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
binding NN NN O
factor NN NN O
II NN NN O
functions NN NN O
as NN NN O
a NN NN O
repressor NN NN O
specific NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
kappa NN NN O
B NN NN O
motifs NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
of NN NN O
the NN NN O
CD19 NN NN B-Protein
gene NN NN O
is NN NN O
a NN NN O
target NN NN O
for NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
BSAP NN NN B-Protein
. NN NN O
   
The NN NN O
CD19 NN NN B-Protein
protein NN NN O
is NN NN O
expressed NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
all NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
terminally NN NN O
differentiated NN NN O
plasma NN NN O
cells NN NN O
and NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
a NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
receptor NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
complete NN NN O
correlation NN NN O
between NN NN O
the NN NN O
expression NN NN O
pattern NN NN O
of NN NN O
the NN NN O
CD19 NN NN B-Protein
gene NN NN O
and NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
BSAP NN NN B-Protein
in NN NN O
a NN NN O
large NN NN O
panel NN NN O
of NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
human NN NN O
CD19 NN NN B-Protein
gene NN NN O
has NN NN O
been NN NN O
cloned NN NN O
, NN NN O
and NN NN O
several NN NN O
BSAP NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
have NN NN O
been NN NN O
mapped NN NN O
by NN NN O
in NN NN O
vitro NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
studies NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
a NN NN O
high NN NN O
- NN NN O
affinity NN NN O
BSAP NN NN B-Protein
- NN NN O
binding NN NN O
site NN NN O
instead NN NN O
of NN NN O
a NN NN O
TATA NN NN O
sequence NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
- NN NN O
30 NN NN O
promoter NN NN O
region NN NN O
upstream NN NN O
of NN NN O
a NN NN O
cluster NN NN O
of NN NN O
heterogeneous NN NN O
transcription NN NN O
start NN NN O
sites NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
this NN NN O
site NN NN O
is NN NN O
occupied NN NN O
by NN NN O
BSAP NN NN B-Protein
in NN NN O
vivo NN NN O
in NN NN O
a NN NN O
CD19 NN NN B-Protein
- NN NN O
expressing NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
but NN NN O
not NN NN O
in NN NN O
plasma NN NN O
or NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
high NN NN O
- NN NN O
affinity NN NN O
site NN NN O
has NN NN O
been NN NN O
conserved NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
both NN NN O
human NN NN O
and NN NN O
mouse NN NN O
CD19 NN NN B-Protein
genes NN NN O
and NN NN O
was NN NN O
furthermore NN NN O
shown NN NN O
to NN NN O
confer NN NN O
B NN NN O
- NN NN O
cell NN NN O
specificity NN NN O
to NN NN O
a NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
reporter NN NN I-Protein
gene NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
BSAP NN NN B-Protein
was NN NN O
found NN NN O
to NN NN O
be NN NN O
the NN NN O
only NN NN O
abundant NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
that NN NN O
interacts NN NN O
with NN NN O
the NN NN O
CD19 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
this NN NN O
evidence NN NN O
strongly NN NN O
implicates NN NN O
BSAP NN NN B-Protein
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
CD19 NN NN B-Protein
gene NN NN O
. NN NN O
   
SRC NN NN O
- NN NN O
related NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
and NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
cells NN NN O
: NN NN O
modulation NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
FK506 NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
induces NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
for NN NN O
lymphokines NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
is NN NN O
controlled NN NN O
transcriptionally NN NN O
by NN NN O
the NN NN O
cooperative NN NN O
activity NN NN O
of NN NN O
specific NN NN O
trans NN NN O
- NN NN O
activating NN NN O
factors NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
and NN NN O
FK506 NN NN O
inhibit NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
T NN NN O
lymphocytes NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
A NN NN O
member NN NN O
of NN NN O
the NN NN O
src NN NN O
gene NN NN O
family NN NN O
, NN NN O
the NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
, NN NN O
p56lck NN NN B-Protein
, NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
CsA NN NN O
was NN NN O
found NN NN O
not NN NN O
to NN NN O
inhibit NN NN O
lck NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
nor NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
lck NN NN B-Protein
gene NN NN O
product NN NN O
. NN NN O
   
However NN NN O
, NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
inhibit NN NN O
the NN NN O
appearance NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
factors NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
induced NN NN O
by NN NN O
the NN NN O
same NN NN O
stimuli NN NN O
that NN NN O
stimulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
immunosuppressant NN NN O
action NN NN O
of NN NN O
CsA NN NN O
and NN NN O
FK506 NN NN O
is NN NN O
exerted NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
these NN NN O
trans NN NN O
- NN NN O
activating NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
functionally NN NN O
responsive NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
work NN NN O
reviewed NN NN O
in NN NN O
this NN NN O
article NN NN O
separates NN NN O
T NN NN O
cell NN NN O
development NN NN O
into NN NN O
four NN NN O
phases NN NN O
. NN NN O
   
First NN NN O
is NN NN O
an NN NN O
expansion NN NN O
phase NN NN O
prior NN NN O
to NN NN O
TCR NN NN O
rearrangement NN NN O
, NN NN O
which NN NN O
appears NN NN O
to NN NN O
be NN NN O
correlated NN NN O
with NN NN O
programming NN NN O
of NN NN O
at NN NN O
least NN NN O
some NN NN O
response NN NN O
genes NN NN O
for NN NN O
inducibility NN NN O
. NN NN O
   
This NN NN O
phase NN NN O
can NN NN O
occur NN NN O
to NN NN O
some NN NN O
extent NN NN O
outside NN NN O
of NN NN O
the NN NN O
thymus NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
profound NN NN O
T NN NN O
cell NN NN O
deficit NN NN O
of NN NN O
nude NN NN O
mice NN NN O
indicates NN NN O
that NN NN O
the NN NN O
thymus NN NN O
is NN NN O
by NN NN O
far NN NN O
the NN NN O
most NN NN O
potent NN NN O
site NN NN O
for NN NN O
inducing NN NN O
the NN NN O
expansion NN NN O
per NN NN O
se NN NN O
, NN NN O
even NN NN O
if NN NN O
other NN NN O
sites NN NN O
can NN NN O
induce NN NN O
some NN NN O
response NN NN O
acquisition NN NN O
. NN NN O
   
Second NN NN O
is NN NN O
a NN NN O
controlled NN NN O
phase NN NN O
of NN NN O
TCR NN NN O
gene NN NN O
rearrangement NN NN O
. NN NN O
   
The NN NN O
details NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
mechanism NN NN O
that NN NN O
selects NN NN O
particular NN NN O
loci NN NN O
for NN NN O
rearrangement NN NN O
are NN NN O
still NN NN O
not NN NN O
known NN NN O
. NN NN O
   
It NN NN O
seems NN NN O
that NN NN O
the NN NN O
rearrangement NN NN O
of NN NN O
the NN NN O
TCR NN NN O
gamma NN NN O
loci NN NN O
in NN NN O
the NN NN O
gamma NN NN O
delta NN NN O
lineage NN NN O
may NN NN O
not NN NN O
always NN NN O
take NN NN O
place NN NN O
at NN NN O
a NN NN O
developmental NN NN O
stage NN NN O
strictly NN NN O
equivalent NN NN O
to NN NN O
the NN NN O
rearrangement NN NN O
of NN NN O
TCR NN NN O
beta NN NN O
in NN NN O
the NN NN O
alpha NN NN O
beta NN NN O
lineage NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
just NN NN O
how NN NN O
early NN NN O
the NN NN O
two NN NN O
lineages NN NN O
diverge NN NN O
. NN NN O
   
In NN NN O
the NN NN O
TCR NN NN O
alpha NN NN O
beta NN NN O
lineage NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
final NN NN O
gene NN NN O
rearrangement NN NN O
events NN NN O
are NN NN O
accompanied NN NN O
by NN NN O
rapid NN NN O
proliferation NN NN O
and NN NN O
an NN NN O
interruption NN NN O
in NN NN O
cellular NN NN O
response NN NN O
gene NN NN O
inducibility NN NN O
. NN NN O
   
The NN NN O
loss NN NN O
of NN NN O
conventional NN NN O
responsiveness NN NN O
is NN NN O
probably NN NN O
caused NN NN O
by NN NN O
alterations NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
signaling NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
a NN NN O
manifestation NN NN O
of NN NN O
the NN NN O
physiological NN NN O
state NN NN O
that NN NN O
is NN NN O
a NN NN O
precondition NN NN O
for NN NN O
selection NN NN O
. NN NN O
   
Third NN NN O
is NN NN O
the NN NN O
complex NN NN O
process NN NN O
of NN NN O
selection NN NN O
. NN NN O
   
Whereas NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
can NN NN O
undergo NN NN O
forms NN NN O
of NN NN O
positive NN NN O
selection NN NN O
( NN NN O
by NN NN O
antigen NN NN O
- NN NN O
driven NN NN O
clonal NN NN O
expansion NN NN O
) NN NN O
and NN NN O
negative NN NN O
selection NN NN O
( NN NN O
by NN NN O
abortive NN NN O
stimulation NN NN O
leading NN NN O
to NN NN O
anergy NN NN O
or NN NN O
death NN NN O
) NN NN O
, NN NN O
neither NN NN O
is NN NN O
exactly NN NN O
the NN NN O
same NN NN O
phenomenon NN NN O
that NN NN O
occurs NN NN O
in NN NN O
the NN NN O
thymic NN NN O
cortex NN NN O
. NN NN O
   
Negative NN NN O
selection NN NN O
in NN NN O
the NN NN O
cortex NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
suicidal NN NN O
inversion NN NN O
of NN NN O
antigen NN NN O
responsiveness NN NN O
: NN NN O
instead NN NN O
of NN NN O
turning NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
, NN NN O
the NN NN O
activated NN NN O
cell NN NN O
destroys NN NN O
its NN NN O
own NN NN O
chromatin NN NN O
. NN NN O
   
The NN NN O
genes NN NN O
that NN NN O
need NN NN O
to NN NN O
be NN NN O
induced NN NN O
for NN NN O
this NN NN O
response NN NN O
are NN NN O
not NN NN O
yet NN NN O
identified NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
unquestionably NN NN O
a NN NN O
form NN NN O
of NN NN O
activation NN NN O
. NN NN O
   
It NN NN O
is NN NN O
interesting NN NN O
that NN NN O
in NN NN O
humans NN NN O
and NN NN O
rats NN NN O
, NN NN O
cortical NN NN O
thymocytes NN NN O
undergoing NN NN O
negative NN NN O
selection NN NN O
can NN NN O
still NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
and NN NN O
even NN NN O
be NN NN O
rescued NN NN O
in NN NN O
vitro NN NN O
, NN NN O
if NN NN O
exogenous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
provided NN NN O
. NN NN O
   
Perhaps NN NN O
murine NN NN O
thymocytes NN NN O
are NN NN O
denied NN NN O
this NN NN O
form NN NN O
of NN NN O
rescue NN NN O
because NN NN O
they NN NN O
shut NN NN O
off NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
chain NN NN I-Protein
expression NN NN O
at NN NN O
an NN NN O
earlier NN NN O
stage NN NN O
or NN NN O
because NN NN O
they NN NN O
may NN NN O
be NN NN O
uncommonly NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deficient NN NN O
( NN NN O
cf NN NN O
. NN NN O
Sentman NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
1991 NN NN O
; NN NN O
Strasser NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
1991 NN NN O
) NN NN O
. NN NN O
   
Even NN NN O
so NN NN O
, NN NN O
medullary NN NN O
thymocytes NN NN O
remain NN NN O
at NN NN O
least NN NN O
partially NN NN O
susceptible NN NN O
to NN NN O
negative NN NN O
selection NN NN O
even NN NN O
as NN NN O
they NN NN O
continue NN NN O
to NN NN O
mature NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
during NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
. NN NN O
   
The NN NN O
present NN NN O
work NN NN O
has NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
type NN NN B-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
protein NN NN I-Protein
phosphatases NN NN I-Protein
, NN NN O
on NN NN O
the NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
okadaic NN NN O
acid NN NN O
treatment NN NN O
is NN NN O
associated NN NN O
with NN NN O
induction NN NN O
of NN NN O
a NN NN O
differentiated NN NN O
monocyte NN NN O
phenotype NN NN O
characterized NN NN O
by NN NN O
: NN NN O
( NN NN O
a NN NN O
) NN NN O
growth NN NN O
arrest NN NN O
; NN NN O
( NN NN O
b NN NN O
) NN NN O
increases NN NN O
in NN NN O
Mac NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
cell NN NN I-Protein
surface NN NN I-Protein
antigen NN NN I-Protein
expression NN NN O
; NN NN O
( NN NN O
c NN NN O
) NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
transcripts NN NN O
; NN NN O
and NN NN O
( NN NN O
d NN NN O
) NN NN O
induction NN NN O
of NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
was NN NN O
associated NN NN O
with NN NN O
transient NN NN O
increases NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
levels NN NN O
, NN NN O
which NN NN O
were NN NN O
maximal NN NN O
at NN NN O
6 NN NN O
h NN NN O
. NN NN O
   
Similar NN NN O
effects NN NN O
were NN NN O
obtained NN NN O
for NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
gene NN NN O
. NN NN O
   
Run NN NN O
- NN NN O
on NN NN O
analysis NN NN O
demonstrated NN NN O
detectable NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcription NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
and NN NN O
that NN NN O
this NN NN O
rate NN NN O
is NN NN O
increased NN NN O
approximately NN NN O
40 NN NN O
- NN NN O
fold NN NN O
following NN NN O
okadaic NN NN O
acid NN NN O
exposure NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
superinduced NN NN O
in NN NN O
cells NN NN O
treated NN NN O
with NN NN O
both NN NN O
okadaic NN NN O
acid NN NN O
and NN NN O
cycloheximide NN NN O
, NN NN O
whereas NN NN O
inhibition NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
had NN NN O
little NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
effect NN NN O
on NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcription NN NN O
. NN NN O
   
The NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
was NN NN O
similar NN NN O
( NN NN O
45 NN NN O
- NN NN O
50 NN NN O
min NN NN O
) NN NN O
in NN NN O
both NN NN O
untreated NN NN O
and NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
treatment NN NN O
with NN NN O
both NN NN O
okadaic NN NN O
acid NN NN O
and NN NN O
cycloheximide NN NN O
was NN NN O
associated NN NN O
with NN NN O
stabilization NN NN O
( NN NN O
t NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
= NN NN O
90 NN NN O
min NN NN O
) NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcripts NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcription NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
is NN NN O
controlled NN NN O
primarily NN NN O
by NN NN O
a NN NN O
transcriptional NN NN O
mechanism NN NN O
. NN NN O
   
Since NN NN O
previous NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
is NN NN O
autoinduced NN NN O
by NN NN O
Jun NN NN O
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
we NN NN O
also NN NN O
studied NN NN O
transcription NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
promoter NN NN O
( NN NN O
positions NN NN O
- NN NN O
132 NN NN O
/ NN NN O
+ NN NN O
170 NN NN O
) NN NN O
- NN NN O
reporter NN NN O
gene NN NN O
constructs NN NN O
with NN NN O
and NN NN O
without NN NN O
a NN NN O
mutated NN NN O
AP NN NN O
- NN NN O
1 NN NN O
element NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
in NN NN O
human NN NN O
blood NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
acts NN NN O
on NN NN O
human NN NN O
blood NN NN O
monocytes NN NN O
by NN NN O
enhancing NN NN O
binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
its NN NN O
consensus NN NN O
sequence NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
regulatory NN NN O
enhancer NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
( NN NN O
p55 NN NN B-Protein
) NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
U NN NN O
937 NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
resting NN NN O
human NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
detectable NN NN O
within NN NN O
15 NN NN O
min NN NN O
and NN NN O
peaks NN NN O
1 NN NN O
h NN NN O
after NN NN O
exposure NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
is NN NN O
followed NN NN O
by NN NN O
functional NN NN O
activation NN NN O
in NN NN O
that NN NN O
inducibility NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
is NN NN O
mediated NN NN O
by NN NN O
enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
and NN NN O
that NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
containing NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
consensus NN NN O
sequence NN NN O
( NN NN O
- NN NN O
291 NN NN O
to NN NN O
- NN NN O
245 NN NN O
) NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
is NN NN O
activated NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
capable NN NN O
of NN NN O
increasing NN NN O
transcript NN NN O
levels NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
gene NN NN O
coding NN NN O
for NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
whereas NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
gene NN NN O
remained NN NN O
unchanged NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
region NN NN O
in NN NN O
macrophage NN NN O
, NN NN O
T NN NN O
cell NN NN O
, NN NN O
and NN NN O
B NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
1311 NN NN O
- NN NN O
base NN NN O
pair NN NN O
human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
region NN NN O
was NN NN O
fused NN NN O
to NN NN O
the NN NN O
luciferase NN NN O
( NN NN O
Luc NN NN O
) NN NN O
reporter NN NN O
gene NN NN O
and NN NN O
studied NN NN O
in NN NN O
a NN NN O
transient NN NN O
transfection NN NN O
system NN NN O
in NN NN O
three NN NN O
TNF NN NN O
producing NN NN O
cell NN NN O
lines NN NN O
, NN NN O
the NN NN O
U937 NN NN O
macrophage NN NN O
cell NN NN O
line NN NN O
, NN NN O
the NN NN O
MLA NN NN O
144 NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
and NN NN O
the NN NN O
729 NN NN O
- NN NN O
6 NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
This NN NN O
full NN NN O
length NN NN O
promoter NN NN O
construct NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
13 NN NN O
- NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
in NN NN O
each NN NN O
of NN NN O
these NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
a NN NN O
series NN NN O
of NN NN O
5 NN NN O
' NN NN O
- NN NN O
truncations NN NN O
showed NN NN O
several NN NN O
peaks NN NN O
of NN NN O
basal NN NN O
and NN NN O
PMA NN NN O
induced NN NN O
activity NN NN O
suggesting NN NN O
the NN NN O
presence NN NN O
of NN NN O
several NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
A NN NN O
PMA NN NN O
responsive NN NN O
element NN NN O
was NN NN O
localized NN NN O
to NN NN O
a NN NN O
region NN NN O
between NN NN O
- NN NN O
95 NN NN O
and NN NN O
- NN NN O
36 NN NN O
bp NN NN O
relative NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
Within NN NN O
this NN NN O
region NN NN O
, NN NN O
single NN NN O
AP NN NN O
- NN NN O
2 NN NN O
- NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
like NN NN O
consensus NN NN O
sequences NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
These NN NN O
AP NN NN O
- NN NN O
2 NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
were NN NN O
each NN NN O
modified NN NN O
with NN NN O
a NN NN O
double NN NN O
point NN NN O
mutation NN NN O
. NN NN O
   
A NN NN O
modest NN NN O
( NN NN O
20 NN NN O
- NN NN O
50 NN NN O
% NN NN O
) NN NN O
reduction NN NN O
in NN NN O
TNF NN NN B-Protein
promoter NN NN O
activity NN NN O
was NN NN O
observed NN NN O
with NN NN O
the NN NN O
AP NN NN O
- NN NN O
2 NN NN O
site NN NN O
mutation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
mutation NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
markedly NN NN O
diminished NN NN O
both NN NN O
the NN NN O
basal NN NN O
and NN NN O
PMA NN NN O
- NN NN O
activated NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Also NN NN O
co NN NN O
- NN NN O
transfections NN NN O
of NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
promoter NN NN O
construct NN NN O
with NN NN O
an NN NN O
AP NN NN O
- NN NN O
1 NN NN O
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
vector NN NN O
resulted NN NN O
in NN NN O
augmented NN NN O
basal NN NN O
and NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Redox NN NN O
status NN NN O
of NN NN O
cells NN NN O
influences NN NN O
constitutive NN NN O
or NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
and NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
activity NN NN O
in NN NN O
human NN NN O
T NN NN O
and NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
have NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
cellular NN NN O
activation NN NN O
events NN NN O
occurring NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
monocytes NN NN O
and NN NN O
mediated NN NN O
through NN NN O
translocation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
are NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
constitutive NN NN O
redox NN NN O
status NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
used NN NN O
phenolic NN NN O
, NN NN O
lipid NN NN O
- NN NN O
soluble NN NN O
, NN NN O
chain NN NN O
- NN NN O
breaking NN NN O
antioxidants NN NN O
( NN NN O
butylated NN NN O
hydroxyanisole NN NN O
( NN NN O
BHA NN NN O
) NN NN O
, NN NN O
nordihydroquairetic NN NN O
acid NN NN O
, NN NN O
or NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
( NN NN O
vitamin NN NN O
E NN NN O
) NN NN O
to NN NN O
show NN NN O
that NN NN O
peroxyl NN NN O
radical NN NN O
scavenging NN NN O
in NN NN O
unstimulated NN NN O
and NN NN O
PMA NN NN O
- NN NN O
or NN NN O
TNF NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
blocks NN NN O
the NN NN O
functions NN NN O
depending NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
BHA NN NN O
was NN NN O
found NN NN O
to NN NN O
suppress NN NN O
not NN NN O
only NN NN O
PMA NN NN O
- NN NN O
or NN NN O
TNF NN NN O
- NN NN O
induced NN NN O
, NN NN O
but NN NN O
also NN NN O
constitutive NN NN O
, NN NN O
HIV NN NN O
- NN NN O
enhancer NN NN O
activity NN NN O
concomitant NN NN O
to NN NN O
an NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
in NN NN O
both NN NN O
lymphoblastoid NN NN O
T NN NN O
( NN NN O
J NN NN O
. NN NN O
Jhan NN NN O
) NN NN O
and NN NN O
monocytic NN NN O
( NN NN O
U937 NN NN O
) NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
This NN NN O
was NN NN O
also NN NN O
true NN NN O
for NN NN O
KBF NN NN O
( NN NN O
p50 NN NN B-Protein
homodimer NN NN O
) NN NN O
binding NN NN O
activity NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Secretion NN NN O
of NN NN O
TNF NN NN O
, NN NN O
the NN NN O
product NN NN O
of NN NN O
another NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
, NN NN O
was NN NN O
abolished NN NN O
by NN NN O
BHA NN NN O
in NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
anti NN NN O
- NN NN O
oxidative NN NN O
effect NN NN O
of NN NN O
BHA NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
thiol NN NN O
, NN NN O
but NN NN O
not NN NN O
glutathione NN NN O
, NN NN O
content NN NN O
in NN NN O
stimulated NN NN O
and NN NN O
unstimulated NN NN O
T NN NN O
cell NN NN O
, NN NN O
whereas NN NN O
TNF NN NN O
stimulation NN NN O
itself NN NN O
barely NN NN O
modified NN NN O
the NN NN O
cellular NN NN O
thiol NN NN O
level NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
obtained NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
H2O2 NN NN O
to NN NN O
the NN NN O
culture NN NN O
medium NN NN O
of NN NN O
J NN NN O
. NN NN O
Jhan NN NN O
or NN NN O
U937 NN NN O
cells NN NN O
could NN NN O
not NN NN O
by NN NN O
itself NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
TNF NN NN O
and NN NN O
PMA NN NN O
do NN NN O
not NN NN O
lead NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
through NN NN O
induction NN NN O
of NN NN O
changes NN NN O
in NN NN O
the NN NN O
cell NN NN O
redox NN NN O
status NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
TNF NN NN O
and NN NN O
PMA NN NN O
can NN NN O
exert NN NN O
their NN NN O
effect NN NN O
only NN NN O
if NN NN O
cells NN NN O
are NN NN O
in NN NN O
an NN NN O
appropriate NN NN O
redox NN NN O
status NN NN O
, NN NN O
because NN NN O
prior NN NN O
modification NN NN O
toward NN NN O
reduction NN NN O
with NN NN O
BHA NN NN O
treatment NN NN O
prevents NN NN O
this NN NN O
activation NN NN O
. NN NN O
   
It NN NN O
appears NN NN O
that NN NN O
a NN NN O
basal NN NN O
redox NN NN O
equilibrium NN NN O
tending NN NN O
toward NN NN O
oxidation NN NN O
is NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
full NN NN O
activation NN NN O
of NN NN O
transduction NN NN O
pathways NN NN O
regulating NN NN O
the NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
genes NN NN O
. NN NN O
   
Natural NN NN O
variants NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
: NN NN O
analysis NN NN O
of NN NN O
promoters NN NN O
with NN NN O
duplicated NN NN O
DNA NN NN O
regulatory NN NN O
motifs NN NN O
. NN NN O
   
Sequence NN NN O
variation NN NN O
in NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
region NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
was NN NN O
analyzed NN NN O
in NN NN O
viral NN NN O
isolates NN NN O
of NN NN O
17 NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
Two NN NN O
classes NN NN O
of NN NN O
LTR NN NN O
size NN NN O
variants NN NN O
were NN NN O
found NN NN O
. NN NN O
   
One NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
variant NN NN O
was NN NN O
detected NN NN O
containing NN NN O
an NN NN O
additional NN NN O
binding NN NN O
site NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
Another NN NN O
LTR NN NN O
size NN NN O
variation NN NN O
was NN NN O
observed NN NN O
in NN NN O
four NN NN O
patients NN NN O
in NN NN O
a NN NN O
region NN NN O
just NN NN O
upstream NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
. NN NN O
   
This NN NN O
variation NN NN O
was NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
duplication NN NN O
of NN NN O
a NN NN O
short NN NN O
DNA NN NN O
sequence NN NN O
( NN NN O
CTG NN NN O
- NN NN O
motif NN NN O
) NN NN O
. NN NN O
   
Cell NN NN O
culture NN NN O
experiments NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
natural NN NN O
variant NN NN O
with NN NN O
four NN NN O
Sp1 NN NN B-Protein
sites NN NN O
had NN NN O
a NN NN O
slightly NN NN O
higher NN NN O
promoter NN NN O
activity NN NN O
and NN NN O
viral NN NN O
replication NN NN O
rate NN NN O
than NN NN O
the NN NN O
isogenic NN NN O
control NN NN O
LTR NN NN O
with NN NN O
three NN NN O
Sp1 NN NN B-Protein
sites NN NN O
. NN NN O
   
No NN NN O
positive NN NN O
effect NN NN O
of NN NN O
the NN NN O
duplicated NN NN O
CTG NN NN O
- NN NN O
motif NN NN O
could NN NN O
be NN NN O
detected NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
measure NN NN O
small NN NN O
differences NN NN O
in NN NN O
virus NN NN O
production NN NN O
more NN NN O
accurately NN NN O
, NN NN O
equal NN NN O
amounts NN NN O
of NN NN O
a NN NN O
size NN NN O
variant NN NN O
and NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
plasmid NN NN O
were NN NN O
cotransfected NN NN O
into NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
virus NN NN O
with NN NN O
four NN NN O
Sp1 NN NN B-Protein
sites NN NN O
did NN NN O
outgrow NN NN O
the NN NN O
three NN NN O
Sp1 NN NN B-Protein
virus NN NN O
in NN NN O
35 NN NN O
days NN NN O
of NN NN O
culture NN NN O
and NN NN O
CTG NN NN O
- NN NN O
monomer NN NN O
virus NN NN O
outcompeted NN NN O
the NN NN O
CTG NN NN O
- NN NN O
dimer NN NN O
virus NN NN O
in NN NN O
42 NN NN O
days NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
results NN NN O
we NN NN O
estimate NN NN O
a NN NN O
5 NN NN O
- NN NN O
10 NN NN O
% NN NN O
difference NN NN O
in NN NN O
virus NN NN O
production NN NN O
of NN NN O
the NN NN O
LTR NN NN O
variants NN NN O
when NN NN O
compared NN NN O
to NN NN O
that NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
the NN NN O
hypersensitive NN NN O
site NN NN O
HS2 NN NN O
enhancer NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
human NN NN O
genome NN NN O
, NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
hypersensitive NN NN O
site NN NN O
HS2 NN NN O
enhancer NN NN O
regulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
downstream NN NN O
beta NN NN B-Protein
- NN NN I-Protein
like NN NN I-Protein
globin NN NN I-Protein
genes NN NN O
10 NN NN O
- NN NN O
50 NN NN O
kilobases NN NN O
away NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
HS2 NN NN O
enhancer NN NN O
function NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
employs NN NN O
RNA NN NN O
protection NN NN O
assays NN NN O
to NN NN O
analyze NN NN O
the NN NN O
transcriptional NN NN O
status NN NN O
of NN NN O
the NN NN O
HS2 NN NN O
enhancer NN NN O
in NN NN O
transfected NN NN O
recombinant NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
plasmids NN NN O
. NN NN O
   
In NN NN O
erythroid NN NN O
K562 NN NN O
cells NN NN O
in NN NN O
which NN NN O
the NN NN O
HS2 NN NN O
enhancer NN NN O
is NN NN O
active NN NN O
, NN NN O
the NN NN O
HS2 NN NN O
sequence NN NN O
directs NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
long NN NN O
enhancer NN NN O
transcripts NN NN O
that NN NN O
are NN NN O
initiated NN NN O
apparently NN NN O
from NN NN O
within NN NN O
the NN NN O
enhancer NN NN O
and NN NN O
elongated NN NN O
through NN NN O
the NN NN O
intervening NN NN O
DNA NN NN O
into NN NN O
the NN NN O
cis NN NN O
- NN NN O
linked NN NN O
CAT NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
nonerythroid NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
in NN NN O
which NN NN O
the NN NN O
HS2 NN NN O
enhancer NN NN O
is NN NN O
inactive NN NN O
, NN NN O
long NN NN O
enhancer NN NN O
transcripts NN NN O
are NN NN O
not NN NN O
detectable NN NN O
. NN NN O
   
Splitting NN NN O
the NN NN O
HS2 NN NN O
enhancer NN NN O
between NN NN O
two NN NN O
tandem NN NN O
Ap1 NN NN O
sites NN NN O
abolishes NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
group NN NN O
of NN NN O
long NN NN O
enhancer NN NN O
transcripts NN NN O
and NN NN O
results NN NN O
in NN NN O
loss NN NN O
of NN NN O
enhancer NN NN O
function NN NN O
and NN NN O
transcriptional NN NN O
silencing NN NN O
of NN NN O
the NN NN O
cis NN NN O
- NN NN O
linked NN NN O
CAT NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
directing NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
RNA NN NN O
through NN NN O
the NN NN O
intervening NN NN O
DNA NN NN O
and NN NN O
the NN NN O
gene NN NN O
by NN NN O
a NN NN O
tracking NN NN O
and NN NN O
transcription NN NN O
mechanism NN NN O
, NN NN O
the NN NN O
HS2 NN NN O
enhancer NN NN O
may NN NN O
( NN NN O
i NN NN O
) NN NN O
open NN NN O
up NN NN O
the NN NN O
chromatin NN NN O
structure NN NN O
of NN NN O
a NN NN O
gene NN NN O
domain NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
deliver NN NN O
enhancer NN NN O
binding NN NN O
proteins NN NN O
to NN NN O
the NN NN O
promoter NN NN O
sequence NN NN O
where NN NN O
they NN NN O
may NN NN O
stimulate NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
gene NN NN O
at NN NN O
the NN NN O
cap NN NN O
site NN NN O
. NN NN O
   
Phorbol NN NN O
ester NN NN O
reduces NN NN O
constitutive NN NN O
nuclear NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
inhibits NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
in NN NN O
mature NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
potent NN NN O
mediator NN NN O
of NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
transcription NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
genome NN NN O
in NN NN O
promonocytic NN NN O
leukemias NN NN O
. NN NN O
   
There NN NN O
is NN NN O
little NN NN O
information NN NN O
available NN NN O
on NN NN O
the NN NN O
response NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
to NN NN O
cytokines NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
a NN NN O
32P NN NN O
- NN NN O
labeled NN NN O
oligonucleotide NN NN O
derived NN NN O
from NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
, NN NN O
which NN NN O
contains NN NN O
a NN NN O
tandem NN NN O
repeat NN NN O
of NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sequence NN NN O
, NN NN O
as NN NN O
a NN NN O
probe NN NN O
in NN NN O
a NN NN O
gel NN NN O
retardation NN NN O
assay NN NN O
to NN NN O
study NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Using NN NN O
this NN NN O
assay NN NN O
, NN NN O
we NN NN O
have NN NN O
detected NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
in NN NN O
extracts NN NN O
of NN NN O
nuclei NN NN O
from NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
normal NN NN O
monocytes NN NN O
with NN NN O
12 NN NN O
- NN NN O
0 NN NN O
- NN NN O
tetradecanoyl NN NN O
phorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
for NN NN O
4 NN NN O
- NN NN O
24 NN NN O
h NN NN O
caused NN NN O
the NN NN O
complete NN NN O
disappearance NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
from NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
monocytes NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
result NN NN O
was NN NN O
obtained NN NN O
with NN NN O
the NN NN O
mature NN NN O
monocytic NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
constitutive NN NN O
transcription NN NN O
factor NN NN O
SP1 NN NN B-Protein
was NN NN O
unaffected NN NN O
by NN NN O
addition NN NN O
of NN NN O
TPA NN NN O
. NN NN O
   
The NN NN O
disappearance NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
from NN NN O
the NN NN O
nucleus NN NN O
was NN NN O
concentration NN NN O
dependent NN NN O
between NN NN O
10 NN NN O
and NN NN O
50 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
of NN NN O
phorbol NN NN O
ester NN NN O
. NN NN O
   
In NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
TPA NN NN O
also NN NN O
induced NN NN O
a NN NN O
new NN NN O
, NN NN O
faster NN NN O
- NN NN O
migrating NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
species NN NN O
not NN NN O
induced NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
inhibitor NN NN O
staurosporine NN NN O
, NN NN O
but NN NN O
not NN NN O
cyclic NN NN O
nucleotide NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
inhibitor NN NN O
HA NN NN O
- NN NN O
1004 NN NN O
, NN NN O
also NN NN O
dramatically NN NN O
reduced NN NN O
constitutive NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
TPA NN NN O
addition NN NN O
to NN NN O
monocytes NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
reverse NN NN O
transcriptase NN NN O
assays NN NN O
, NN NN O
in NN NN O
a NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
in NN NN O
striking NN NN O
contrast NN NN O
to NN NN O
the NN NN O
increase NN NN O
in NN NN O
nuclear NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
in NN NN O
promonocytic NN NN O
leukemia NN NN O
cells NN NN O
U937 NN NN O
and NN NN O
HL NN NN O
- NN NN O
60 NN NN O
, NN NN O
and NN NN O
emphasize NN NN O
the NN NN O
importance NN NN O
of NN NN O
studying NN NN O
cytokine NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
normal NN NN O
monocytes NN NN O
. NN NN O
   
Targeted NN NN O
degradation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
v NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
by NN NN O
a NN NN O
phosphorylation NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
on NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
. NN NN O
   
The NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
products NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
heterodimerize NN NN O
through NN NN O
their NN NN O
leucine NN NN O
zippers NN NN O
to NN NN O
form NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
heterodimer NN NN O
is NN NN O
regulated NN NN O
by NN NN O
signal NN NN O
- NN NN O
dependent NN NN O
phosphorylation NN NN O
and NN NN O
dephosphorylation NN NN O
events NN NN O
. NN NN O
   
The NN NN O
stability NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
was NN NN O
found NN NN O
to NN NN O
also NN NN O
be NN NN O
controlled NN NN O
by NN NN O
intracellular NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
In NN NN O
transient NN NN O
expression NN NN O
and NN NN O
in NN NN O
vitro NN NN O
degradation NN NN O
experiments NN NN O
, NN NN O
the NN NN O
stability NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
was NN NN O
decreased NN NN O
when NN NN O
the NN NN O
protein NN NN O
was NN NN O
dimerized NN NN O
with NN NN O
phosphorylated NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
isolated NN NN O
from NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
induced NN NN O
cells NN NN O
did NN NN O
not NN NN O
target NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
for NN NN O
degradation NN NN O
, NN NN O
which NN NN O
suggests NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
is NN NN O
transiently NN NN O
stabilized NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
cell NN NN O
growth NN NN O
. NN NN O
   
v NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
protein NN NN O
, NN NN O
the NN NN O
retroviral NN NN O
counterpart NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
was NN NN O
not NN NN O
susceptible NN NN O
to NN NN O
degradation NN NN O
targeted NN NN O
by NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
. NN NN O
   
Alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
is NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Acquired NN NN O
immunodeficiency NN NN O
syndrome NN NN O
( NN NN O
AIDS NN NN O
) NN NN O
results NN NN O
from NN NN O
infection NN NN O
with NN NN O
a NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
. NN NN O
   
The NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
region NN NN O
of NN NN O
HIV NN NN O
proviral NN NN O
DNA NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
and NN NN O
this NN NN O
transcriptional NN NN O
activator NN NN O
appears NN NN O
to NN NN O
regulate NN NN O
HIV NN NN O
activation NN NN O
. NN NN O
   
Recent NN NN O
findings NN NN O
suggest NN NN O
an NN NN O
involvement NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
was NN NN O
based NN NN O
on NN NN O
reports NN NN O
that NN NN O
antioxidants NN NN O
which NN NN O
eliminate NN NN O
ROS NN NN O
should NN NN O
block NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
subsequently NN NN O
HIV NN NN O
transcription NN NN O
, NN NN O
and NN NN O
thus NN NN O
antioxidants NN NN O
can NN NN O
be NN NN O
used NN NN O
as NN NN O
therapeutic NN NN O
agents NN NN O
for NN NN O
AIDS NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
( NN NN O
1 NN NN O
x NN NN O
10 NN NN O
( NN NN O
6 NN NN O
) NN NN O
cells NN NN O
/ NN NN O
ml NN NN O
) NN NN O
with NN NN O
a NN NN O
natural NN NN O
thiol NN NN O
antioxidant NN NN O
, NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
, NN NN O
prior NN NN O
to NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
cells NN NN O
was NN NN O
found NN NN O
to NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
induced NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
25 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
or NN NN O
by NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
50 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
action NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
very NN NN O
potent NN NN O
as NN NN O
only NN NN O
4 NN NN O
mM NN NN O
was NN NN O
needed NN NN O
for NN NN O
a NN NN O
complete NN NN O
inhibition NN NN O
, NN NN O
whereas NN NN O
20 NN NN O
mM NN NN O
was NN NN O
required NN NN O
for NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
may NN NN O
be NN NN O
effective NN NN O
in NN NN O
AIDS NN NN O
therapeutics NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
lymphokine NN NN O
genes NN NN O
in NN NN O
T NN NN O
cells NN NN O
: NN NN O
role NN NN O
of NN NN O
cis NN NN O
- NN NN O
acting NN NN O
DNA NN NN O
elements NN NN O
that NN NN O
respond NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
is NN NN O
initiated NN NN O
by NN NN O
the NN NN O
recognition NN NN O
of NN NN O
antigen NN NN O
on NN NN O
antigen NN NN O
presenting NN NN O
cells NN NN O
to NN NN O
exert NN NN O
the NN NN O
effector NN NN O
functions NN NN O
in NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
Two NN NN O
types NN NN O
of NN NN O
helper NN NN O
T NN NN O
cell NN NN O
( NN NN O
Th NN NN O
) NN NN O
clones NN NN O
( NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
) NN NN O
are NN NN O
defined NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
different NN NN O
patterns NN NN O
of NN NN O
cytokine NN NN O
( NN NN O
lymphokine NN NN O
) NN NN O
secretion NN NN O
. NN NN O
   
They NN NN O
determine NN NN O
the NN NN O
outcome NN NN O
of NN NN O
an NN NN O
antigenic NN NN O
response NN NN O
toward NN NN O
humoral NN NN O
or NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immunity NN NN O
. NN NN O
   
Although NN NN O
lymphokine NN NN O
genes NN NN O
are NN NN O
coordinately NN NN O
regulated NN NN O
upon NN NN O
antigen NN NN O
stimulation NN NN O
, NN NN O
they NN NN O
are NN NN O
regulated NN NN O
by NN NN O
the NN NN O
mechanisms NN NN O
common NN NN O
to NN NN O
all NN NN O
as NN NN O
well NN NN O
as NN NN O
those NN NN O
which NN NN O
are NN NN O
unique NN NN O
to NN NN O
each NN NN O
gene NN NN O
. NN NN O
   
For NN NN O
most NN NN O
lymphokine NN NN O
genes NN NN O
, NN NN O
a NN NN O
combination NN NN O
of NN NN O
phorbol NN NN O
esters NN NN O
( NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
acetate NN NN O
, NN NN O
PMA NN NN O
) NN NN O
and NN NN O
calcium NN NN O
ionophores NN NN O
( NN NN O
A23187 NN NN O
) NN NN O
is NN NN O
required NN NN O
for NN NN O
their NN NN O
maximal NN NN O
induction NN NN O
. NN NN O
   
Yet NN NN O
phorbol NN NN O
ester NN NN O
alone NN NN O
or NN NN O
calcium NN NN O
ionophore NN NN O
alone NN NN O
produce NN NN O
several NN NN O
lymphokines NN NN O
. NN NN O
   
The NN NN O
production NN NN O
of NN NN O
the NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
is NN NN O
completely NN NN O
dependent NN NN O
on NN NN O
the NN NN O
two NN NN O
signals NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
found NN NN O
a NN NN O
cis NN NN O
- NN NN O
acting NN NN O
region NN NN O
spanning NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
region NN NN O
( NN NN O
positions NN NN O
- NN NN O
95 NN NN O
to NN NN O
+ NN NN O
27 NN NN O
) NN NN O
that NN NN O
confers NN NN O
inducibility NN NN O
to NN NN O
reporter NN NN O
genes NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
identified NN NN O
three NN NN O
elements NN NN O
required NN NN O
for NN NN O
efficient NN NN O
induction NN NN O
, NN NN O
referred NN NN O
to NN NN O
as NN NN O
GM2 NN NN O
, NN NN O
GC NN NN O
- NN NN O
box NN NN O
and NN NN O
conserved NN NN O
lymphokine NN NN O
element NN NN O
( NN NN O
CLE0 NN NN O
) NN NN O
. NN NN O
   
GM2 NN NN O
defines NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
whose NN NN O
binding NN NN O
is NN NN O
inducible NN NN O
by NN NN O
PMA NN NN O
. NN NN O
   
One NN NN O
protein NN NN O
, NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
is NN NN O
similar NN NN O
to NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kB NN NN O
. NN NN O
   
GC NN NN O
- NN NN O
box NN NN O
is NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
constitutively NN NN O
bound NN NN O
proteins NN NN O
. NN NN O
   
CLEO NN NN O
defines NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
whose NN NN O
optimum NN NN O
binding NN NN O
is NN NN O
stimulated NN NN O
by NN NN O
PMA NN NN O
and NN NN O
A23187 NN NN O
. NN NN O
   
Viral NN NN O
trans NN NN O
- NN NN O
activators NN NN O
such NN NN O
as NN NN O
Tax NN NN B-Protein
( NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
- NN NN O
1 NN NN O
, NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
E2 NN NN B-Protein
( NN NN O
bovine NN NN O
papilloma NN NN O
virus NN NN O
, NN NN O
BPV NN NN O
) NN NN O
proteins NN NN O
are NN NN O
other NN NN O
agents NN NN O
which NN NN O
activate NN NN O
lymphokine NN NN O
gene NN NN O
expression NN NN O
by NN NN O
bypassing NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
mediated NN NN O
signaling NN NN O
. NN NN O
   
The NN NN O
trans NN NN O
- NN NN O
activation NN NN O
domain NN NN O
of NN NN O
E2 NN NN B-Protein
and NN NN O
Tax NN NN B-Protein
is NN NN O
interchangeable NN NN O
although NN NN O
they NN NN O
have NN NN O
no NN NN O
obvious NN NN O
sequence NN NN O
homology NN NN O
between NN NN O
them NN NN O
. NN NN O
   
The NN NN O
viral NN NN O
trans NN NN O
- NN NN O
activators NN NN O
appear NN NN O
to NN NN O
target NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
such NN NN O
as NN NN O
NF NN NN O
- NN NN O
kB NN NN O
and NN NN O
Sp1 NN NN B-Protein
to NN NN O
cis NN NN O
- NN NN O
acting NN NN O
DNA NN NN O
site NN NN O
and NN NN O
promote NN NN O
lymphokine NN NN O
gene NN NN O
expression NN NN O
without NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
stimulation NN NN O
. NN NN O
   
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
masks NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
signal NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
and NN NN O
requires NN NN O
the NN NN O
transactivation NN NN O
domain NN NN O
to NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
DNA NN NN O
binding NN NN O
. NN NN O
   
The NN NN O
active NN NN O
nuclear NN NN O
form NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
complex NN NN O
is NN NN O
composed NN NN O
of NN NN O
two NN NN O
DNA NN NN O
binding NN NN O
subunits NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
, NN NN O
both NN NN O
of NN NN O
which NN NN O
share NN NN O
extensive NN NN O
N NN NN O
- NN NN O
terminal NN NN O
sequence NN NN O
homology NN NN O
with NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
oncogene NN NN O
product NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
subunit NN NN O
provides NN NN O
the NN NN O
transactivation NN NN O
activity NN NN O
in NN NN O
this NN NN O
complex NN NN O
and NN NN O
serves NN NN O
as NN NN O
an NN NN O
intracellular NN NN O
receptor NN NN O
for NN NN O
a NN NN O
cytoplasmic NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
termed NN NN O
I NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
alone NN NN O
fails NN NN O
to NN NN O
stimulate NN NN O
kappa NN NN O
B NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
, NN NN O
and NN NN O
based NN NN O
on NN NN O
prior NN NN O
in NN NN O
vitro NN NN O
studies NN NN O
, NN NN O
is NN NN O
not NN NN O
directly NN NN O
regulated NN NN O
by NN NN O
I NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
critical NN NN O
regulatory NN NN O
interaction NN NN O
between NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
a NN NN O
series NN NN O
of NN NN O
human NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
mutants NN NN O
was NN NN O
identified NN NN O
that NN NN O
functionally NN NN O
segregated NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
, NN NN O
and NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
induced NN NN O
nuclear NN NN O
exclusion NN NN O
of NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Results NN NN O
from NN NN O
in NN NN O
vivo NN NN O
expression NN NN O
studies NN NN O
performed NN NN O
with NN NN O
these NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
mutants NN NN O
revealed NN NN O
the NN NN O
following NN NN O
: NN NN O
1 NN NN O
) NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
completely NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
- NN NN O
dependent NN NN O
transcriptional NN NN O
activation NN NN O
mediated NN NN O
through NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
2 NN NN O
) NN NN O
the NN NN O
binding NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
is NN NN O
sufficient NN NN O
to NN NN O
retarget NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
from NN NN O
the NN NN O
nucleus NN NN O
to NN NN O
the NN NN O
cytoplasm NN NN O
, NN NN O
3 NN NN O
) NN NN O
selective NN NN O
deletion NN NN O
of NN NN O
the NN NN O
functional NN NN O
nuclear NN NN O
localization NN NN O
signal NN NN O
present NN NN O
in NN NN O
the NN NN O
Rel NN NN O
homology NN NN O
domain NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
disrupts NN NN O
its NN NN O
ability NN NN O
to NN NN O
engage NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
4 NN NN O
) NN NN O
the NN NN O
unique NN NN O
C NN NN O
- NN NN O
terminus NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
attenuates NN NN O
its NN NN O
own NN NN O
nuclear NN NN O
localization NN NN O
and NN NN O
contains NN NN O
sequences NN NN O
that NN NN O
are NN NN O
required NN NN O
for NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
signal NN NN O
and NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
constitute NN NN O
a NN NN O
bipartite NN NN O
system NN NN O
that NN NN O
is NN NN O
critically NN NN O
involved NN NN O
in NN NN O
the NN NN O
inhibitory NN NN O
function NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
our NN NN O
in NN NN O
vivo NN NN O
studies NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
I NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
binds NN NN O
directly NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
. NN NN O
   
This NN NN O
interaction NN NN O
is NN NN O
functional NN NN O
as NN NN O
it NN NN O
leads NN NN O
to NN NN O
retargeting NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
from NN NN O
the NN NN O
nucleus NN NN O
to NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
loss NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
is NN NN O
observed NN NN O
, NN NN O
presumably NN NN O
reflecting NN NN O
the NN NN O
unique NN NN O
C NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
that NN NN O
is NN NN O
distinct NN NN O
from NN NN O
that NN NN O
present NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
. NN NN O
   
Simple NN NN O
derivation NN NN O
of NN NN O
TFIID NN NN O
- NN NN O
dependent NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
transcription NN NN O
systems NN NN O
from NN NN O
Schizosaccharomyces NN NN O
pombe NN NN O
and NN NN O
other NN NN O
organisms NN NN O
, NN NN O
and NN NN O
factors NN NN O
required NN NN O
for NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
Resolution NN NN O
of NN NN O
whole NN NN O
cell NN NN O
extract NN NN O
through NN NN O
two NN NN O
chromatographic NN NN O
steps NN NN O
yields NN NN O
a NN NN O
single NN NN O
protein NN NN O
fraction NN NN O
requiring NN NN O
only NN NN O
the NN NN O
addition NN NN O
of NN NN O
TFIID NN NN O
for NN NN O
the NN NN O
initiation NN NN O
of NN NN O
transcription NN NN O
at NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
promoters NN NN O
. NN NN O
   
This NN NN O
approach NN NN O
allows NN NN O
the NN NN O
convenient NN NN O
generation NN NN O
of NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
transcription NN NN O
systems NN NN O
from NN NN O
Saccharomyces NN NN O
cerevisiae NN NN O
, NN NN O
human NN NN O
lymphocytes NN NN O
, NN NN O
and NN NN O
Schizosaccharomyces NN NN O
pombe NN NN O
. NN NN O
   
TFIIDs NN NN O
from NN NN O
all NN NN O
three NN NN O
organisms NN NN O
are NN NN O
interchangeable NN NN O
among NN NN O
all NN NN O
three NN NN O
systems NN NN O
. NN NN O
   
The NN NN O
S NN NN O
. NN NN O
cerevisiae NN NN O
and NN NN O
Sch NN NN O
. NN NN O
pombe NN NN O
systems NN NN O
support NN NN O
effects NN NN O
of NN NN O
acidic NN NN O
activator NN NN O
proteins NN NN O
, NN NN O
provided NN NN O
a NN NN O
further NN NN O
protein NN NN O
fraction NN NN O
from NN NN O
S NN NN O
. NN NN O
cerevisiae NN NN O
is NN NN O
supplied NN NN O
. NN NN O
   
This NN NN O
further NN NN O
fraction NN NN O
is NN NN O
distinct NN NN O
from NN NN O
the NN NN O
mediator NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
described NN NN O
previously NN NN O
and NN NN O
represents NN NN O
a NN NN O
second NN NN O
component NN NN O
in NN NN O
addition NN NN O
to NN NN O
general NN NN O
initiation NN NN O
factors NN NN O
that NN NN O
may NN NN O
facilitate NN NN O
a NN NN O
response NN NN O
to NN NN O
acidic NN NN O
activators NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
subunit NN NN O
gene NN NN O
promoter NN NN O
underlies NN NN O
self NN NN O
- NN NN O
perpetuation NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
transcription NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
sustained NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
observed NN NN O
in NN NN O
U937 NN NN O
monocytic NN NN O
cells NN NN O
chronically NN NN O
infected NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
the NN NN O
promoter NN NN O
regulating NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
p105 NN NN B-Protein
precursor NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
subunit NN NN O
was NN NN O
enhanced NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Deletions NN NN O
in NN NN O
this NN NN O
promoter NN NN O
indicated NN NN O
that NN NN O
this NN NN O
upregulation NN NN O
was NN NN O
mediated NN NN O
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
but NN NN O
not NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
motif NN NN O
, NN NN O
by NN NN O
bona NN NN O
fide NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
cytosolic NN NN O
extracts NN NN O
indicated NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
levels NN NN O
were NN NN O
increased NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
transient NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
the NN NN O
permanent NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
induced NN NN O
by NN NN O
HIV NN NN O
infection NN NN O
was NN NN O
not NN NN O
dependent NN NN O
on NN NN O
PKC NN NN B-Protein
isoenzymes NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
beta NN NN B-Protein
as NN NN O
shown NN NN O
by NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
( NN NN O
GF NN NN O
109203X NN NN O
) NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
during NN NN O
chronic NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
continuous NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
translocation NN NN O
results NN NN O
in NN NN O
p105 NN NN B-Protein
promoter NN NN O
upregulation NN NN O
with NN NN O
subsequent NN NN O
cytosolic NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
accumulation NN NN O
, NN NN O
ready NN NN O
for NN NN O
further NN NN O
translocation NN NN O
. NN NN O
   
This NN NN O
HIV NN NN O
- NN NN O
mediated NN NN O
mechanism NN NN O
results NN NN O
in NN NN O
a NN NN O
self NN NN O
- NN NN O
perpetuating NN NN O
loop NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
production NN NN O
. NN NN O
   
TAR NN NN O
- NN NN O
independent NN NN O
transactivation NN NN O
by NN NN O
Tat NN NN B-Protein
in NN NN O
cells NN NN O
derived NN NN O
from NN NN O
the NN NN O
CNS NN NN O
: NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
The NN NN O
Tat NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
essential NN NN O
for NN NN O
productive NN NN O
infection NN NN O
and NN NN O
is NN NN O
a NN NN O
potential NN NN O
target NN NN O
for NN NN O
antiviral NN NN O
therapy NN NN O
. NN NN O
   
Tat NN NN B-Protein
, NN NN O
a NN NN O
potent NN NN O
activator NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
, NN NN O
serves NN NN O
to NN NN O
greatly NN NN O
increase NN NN O
the NN NN O
rate NN NN O
of NN NN O
transcription NN NN O
directed NN NN O
by NN NN O
the NN NN O
viral NN NN O
promoter NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
, NN NN O
which NN NN O
seems NN NN O
to NN NN O
be NN NN O
an NN NN O
important NN NN O
component NN NN O
in NN NN O
the NN NN O
progression NN NN O
of NN NN O
acquired NN NN O
immune NN NN O
deficiency NN NN O
syndrome NN NN O
( NN NN O
AIDS NN NN O
) NN NN O
, NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
increased NN NN O
transcriptional NN NN O
initiation NN NN O
, NN NN O
increased NN NN O
transcriptional NN NN O
elongation NN NN O
, NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
these NN NN O
processes NN NN O
. NN NN O
   
Much NN NN O
attention NN NN O
has NN NN O
been NN NN O
focused NN NN O
on NN NN O
the NN NN O
interaction NN NN O
of NN NN O
Tat NN NN B-Protein
with NN NN O
a NN NN O
specific NN NN O
RNA NN NN O
target NN NN O
termed NN NN O
TAR NN NN O
( NN NN O
transactivation NN NN O
responsive NN NN O
) NN NN O
which NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
leader NN NN O
sequence NN NN O
of NN NN O
all NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
mRNAs NN NN O
. NN NN O
   
This NN NN O
interaction NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
an NN NN O
important NN NN O
component NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
transactivation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
certain NN NN O
CNS NN NN O
- NN NN O
derived NN NN O
cells NN NN O
Tat NN NN B-Protein
is NN NN O
capable NN NN O
of NN NN O
activating NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
through NN NN O
a NN NN O
TAR NN NN O
- NN NN O
independent NN NN O
pathway NN NN O
. NN NN O
   
A NN NN O
Tat NN NN B-Protein
- NN NN O
responsive NN NN O
element NN NN O
is NN NN O
found NN NN O
upstream NN NN O
within NN NN O
the NN NN O
viral NN NN O
promoter NN NN O
that NN NN O
in NN NN O
glial NN NN O
- NN NN O
derived NN NN O
cell NN NN O
lines NN NN O
allows NN NN O
transactivation NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
TAR NN NN O
. NN NN O
   
Deletion NN NN O
mapping NN NN O
and NN NN O
hybrid NN NN O
promoter NN NN O
constructs NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
newly NN NN O
identified NN NN O
Tat NN NN B-Protein
- NN NN O
responsive NN NN O
element NN NN O
corresponds NN NN O
to NN NN O
a NN NN O
sequence NN NN O
within NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
previously NN NN O
identified NN NN O
as NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
, NN NN O
or NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
domain NN NN O
. NN NN O
   
DNA NN NN O
band NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
reveals NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
in NN NN O
glial NN NN O
cells NN NN O
that NN NN O
differs NN NN O
from NN NN O
that NN NN O
present NN NN O
in NN NN O
T NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
we NN NN O
observe NN NN O
that NN NN O
TAR NN NN O
- NN NN O
deleted NN NN O
mutants NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
demonstrate NN NN O
normal NN NN O
late NN NN O
gene NN NN O
expression NN NN O
in NN NN O
glial NN NN O
cells NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
syncytia NN NN O
formation NN NN O
and NN NN O
production NN NN O
of NN NN O
viral NN NN O
p24 NN NN B-Protein
antigen NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Mitogen NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
increases NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
levels NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analysed NN NN O
the NN NN O
effect NN NN O
of NN NN O
mitogenic NN NN O
lectins NN NN O
on NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
levels NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
binding NN NN O
and NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Both NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
levels NN NN O
were NN NN O
increased NN NN O
after NN NN O
Con NN NN B-Protein
A NN NN I-Protein
and NN NN O
PHA NN NN O
stimulation NN NN O
. NN NN O
   
Since NN NN O
T NN NN O
- NN NN O
cell NN NN O
stimulation NN NN O
increases NN NN O
both NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
and NN NN O
cAMP NN NN O
levels NN NN O
and NN NN O
activates NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
, NN NN O
the NN NN O
possible NN NN O
involvement NN NN O
of NN NN O
these NN NN O
intracellular NN NN O
messengers NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
induction NN NN O
was NN NN O
tested NN NN O
. NN NN O
   
PMA NN NN O
, NN NN O
which NN NN O
directly NN NN O
activates NN NN O
PKC NN NN B-Protein
, NN NN O
mimicked NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
lectins NN NN O
on NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
but NN NN O
elevation NN NN O
of NN NN O
either NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
or NN NN O
cAMP NN NN O
levels NN NN O
had NN NN O
little NN NN O
or NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
mitogen NN NN O
- NN NN O
induced NN NN O
increase NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
immunoreactivity NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
H NN NN O
- NN NN O
7 NN NN O
, NN NN O
a NN NN O
kinase NN NN O
inhibitor NN NN O
with NN NN O
relatively NN NN O
high NN NN O
specificity NN NN O
for NN NN O
PKC NN NN B-Protein
, NN NN O
and NN NN O
less NN NN O
efficiently NN NN O
by NN NN O
H NN NN O
- NN NN O
8 NN NN O
, NN NN O
a NN NN O
structurally NN NN O
related NN NN O
kinase NN NN O
inhibitor NN NN O
less NN NN O
active NN NN O
on NN NN O
PKC NN NN B-Protein
, NN NN O
but NN NN O
more NN NN O
active NN NN O
on NN NN O
cyclic NN NN O
nucleotide NN NN O
- NN NN O
dependent NN NN O
kinases NN NN O
. NN NN O
   
Con NN NN B-Protein
A NN NN I-Protein
stimulation NN NN O
was NN NN O
found NN NN O
to NN NN O
increase NN NN O
both NN NN O
binding NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
to NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
consensus NN NN O
sequence NN NN O
, NN NN O
TRE NN NN O
, NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
activity NN NN O
, NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
PMA NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
increase NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
activity NN NN O
, NN NN O
whereas NN NN O
elevation NN NN O
of NN NN O
Ca2 NN NN O
+ NN NN O
or NN NN O
cAMP NN NN O
had NN NN O
only NN NN O
minor NN NN O
effects NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
stimulation NN NN O
with NN NN O
mitogenic NN NN O
lectins NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
increase NN NN O
both NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
protein NN NN O
levels NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
and NN NN O
that NN NN O
they NN NN O
act NN NN O
via NN NN O
mechanisms NN NN O
that NN NN O
could NN NN O
involve NN NN O
the NN NN O
activation NN NN O
of NN NN O
PKC NN NN B-Protein
. NN NN O
   
Okadaic NN NN O
acid NN NN O
is NN NN O
a NN NN O
potent NN NN O
inducer NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
with NN NN O
an NN NN O
optimal NN NN O
concentration NN NN O
of NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
phosphatases NN NN B-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
, NN NN O
resulted NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
levels NN NN O
of NN NN O
the NN NN O
octamer NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
were NN NN O
found NN NN O
. NN NN O
   
Since NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
we NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
okadaic NN NN O
acid NN NN O
on NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
okadaic NN NN O
acid NN NN O
resulted NN NN O
in NN NN O
a NN NN O
striking NN NN O
increase NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
transcripts NN NN O
within NN NN O
1 NN NN O
h NN NN O
of NN NN O
stimulation NN NN O
and NN NN O
large NN NN O
amounts NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
were NN NN O
released NN NN O
into NN NN O
the NN NN O
culture NN NN O
media NN NN O
. NN NN O
   
Although NN NN O
okadaic NN NN O
acid NN NN O
provides NN NN O
a NN NN O
potent NN NN O
inductive NN NN O
signal NN NN O
for NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
it NN NN O
did NN NN O
not NN NN O
induce NN NN O
either NN NN O
B NN NN O
cell NN NN O
proliferation NN NN O
or NN NN O
immunoglobulin NN NN O
secretion NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
Ets NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
binds NN NN O
to NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
2 NN NN O
regulatory NN NN O
elements NN NN O
that NN NN O
are NN NN O
required NN NN O
for NN NN O
inducible NN NN O
trans NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
are NN NN O
structurally NN NN O
related NN NN O
retroviruses NN NN O
which NN NN O
both NN NN O
cause NN NN O
AIDS NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
Although NN NN O
both NN NN O
viruses NN NN O
establish NN NN O
latency NN NN O
in NN NN O
quiescent NN NN O
human NN NN O
- NN NN O
peripheral NN NN O
- NN NN O
blood NN NN O
T NN NN O
cells NN NN O
, NN NN O
the NN NN O
asymptomatic NN NN O
phase NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
infection NN NN O
may NN NN O
be NN NN O
more NN NN O
prolonged NN NN O
than NN NN O
that NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
latent NN NN O
phases NN NN O
of NN NN O
both NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
infection NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
disrupted NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
a NN NN O
process NN NN O
that NN NN O
requires NN NN O
host NN NN O
cell NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
the NN NN O
case NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
sufficient NN NN O
for NN NN O
inducible NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
factors NN NN O
in NN NN O
addition NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
are NN NN O
required NN NN O
to NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
transcription NN NN O
in NN NN O
infected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
novel NN NN O
Ets NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
binds NN NN O
specifically NN NN O
to NN NN O
two NN NN O
purine NN NN O
- NN NN O
rich NN NN O
motifs NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
. NN NN O
   
Mutagenesis NN NN O
experiments NN NN O
demonstrated NN NN O
that NN NN O
these NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
sites NN NN O
are NN NN O
required NN NN O
for NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
transcription NN NN O
following NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
the NN NN O
only NN NN O
factor NN NN O
present NN NN O
in NN NN O
activated NN NN O
T NN NN O
- NN NN O
cell NN NN O
nuclear NN NN O
extracts NN NN O
that NN NN O
binds NN NN O
to NN NN O
these NN NN O
sites NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
novel NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
appears NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
trans NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
results NN NN O
may NN NN O
explain NN NN O
differences NN NN O
in NN NN O
the NN NN O
clinical NN NN O
spectra NN NN O
of NN NN O
diseases NN NN O
caused NN NN O
by NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
and NN NN O
may NN NN O
also NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
design NN NN O
of NN NN O
therapeutic NN NN O
approaches NN NN O
to NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
infection NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Nef NN NN B-Protein
protein NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
can NN NN O
establish NN NN O
a NN NN O
persistent NN NN O
and NN NN O
latent NN NN O
infection NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
lymphocytes NN NN O
( NN NN O
W NN NN O
. NN NN O
C NN NN O
. NN NN O
Greene NN NN O
, NN NN O
N NN NN O
. NN NN O
Engl NN NN O
. NN NN O
J NN NN O
. NN NN O
Med NN NN O
. NN NN O
324 NN NN O
: NN NN O
308 NN NN O
- NN NN O
317 NN NN O
, NN NN O
1991 NN NN O
; NN NN O
S NN NN O
. NN NN O
M NN NN O
. NN NN O
Schnittman NN NN O
, NN NN O
M NN NN O
. NN NN O
C NN NN O
. NN NN O
Psallidopoulos NN NN O
, NN NN O
H NN NN O
. NN NN O
C NN NN O
. NN NN O
Lane NN NN O
, NN NN O
L NN NN O
. NN NN O
Thompson NN NN O
, NN NN O
M NN NN O
. NN NN O
Baseler NN NN O
, NN NN O
F NN NN O
. NN NN O
Massari NN NN O
, NN NN O
C NN NN O
. NN NN O
H NN NN O
. NN NN O
Fox NN NN O
, NN NN O
N NN NN O
. NN NN O
P NN NN O
. NN NN O
Salzman NN NN O
, NN NN O
and NN NN O
A NN NN O
. NN NN O
S NN NN O
. NN NN O
Fauci NN NN O
, NN NN O
Science NN NN O
245 NN NN O
: NN NN O
305 NN NN O
- NN NN O
308 NN NN O
, NN NN O
1989 NN NN O
) NN NN O
. NN NN O
   
Production NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
from NN NN O
latently NN NN O
infected NN NN O
cells NN NN O
requires NN NN O
host NN NN O
cell NN NN O
activation NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogens NN NN O
( NN NN O
T NN NN O
. NN NN O
Folks NN NN O
, NN NN O
D NN NN O
. NN NN O
M NN NN O
. NN NN O
Powell NN NN O
, NN NN O
M NN NN O
. NN NN O
M NN NN O
. NN NN O
Lightfoote NN NN O
, NN NN O
S NN NN O
. NN NN O
Benn NN NN O
, NN NN O
M NN NN O
. NN NN O
A NN NN O
. NN NN O
Martin NN NN O
, NN NN O
and NN NN O
A NN NN O
. NN NN O
S NN NN O
. NN NN O
Fauci NN NN O
, NN NN O
Science NN NN O
231 NN NN O
: NN NN O
600 NN NN O
- NN NN O
602 NN NN O
, NN NN O
1986 NN NN O
; NN NN O
D NN NN O
. NN NN O
Zagury NN NN O
, NN NN O
J NN NN O
. NN NN O
Bernard NN NN O
, NN NN O
R NN NN O
. NN NN O
Leonard NN NN O
, NN NN O
R NN NN O
. NN NN O
Cheynier NN NN O
, NN NN O
M NN NN O
. NN NN O
Feldman NN NN O
, NN NN O
P NN NN O
. NN NN O
S NN NN O
. NN NN O
Sarin NN NN O
, NN NN O
and NN NN O
R NN NN O
. NN NN O
C NN NN O
. NN NN O
Gallo NN NN O
, NN NN O
Science NN NN O
231 NN NN O
: NN NN O
850 NN NN O
- NN NN O
853 NN NN O
, NN NN O
1986 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
activation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
host NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
[ NN NN O
G NN NN O
. NN NN O
Nabel NN NN O
and NN NN O
D NN NN O
. NN NN O
Baltimore NN NN O
, NN NN O
Nature NN NN O
( NN NN O
London NN NN O
) NN NN O
326 NN NN O
: NN NN O
711 NN NN O
- NN NN O
717 NN NN O
, NN NN O
1987 NN NN O
] NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
encoded NN NN O
Nef NN NN B-Protein
protein NN NN O
inhibits NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogens NN NN O
. NN NN O
   
However NN NN O
, NN NN O
Nef NN NN B-Protein
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
implicated NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
regulation NN NN O
, NN NN O
including NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
USF NN NN O
, NN NN O
URS NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
Nef NN NN B-Protein
inhibits NN NN O
the NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
- NN NN O
directed NN NN O
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
the NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
depends NN NN O
on NN NN O
an NN NN O
intact NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
defective NN NN O
recruitment NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
underlie NN NN O
Nef NN NN B-Protein
' NN NN O
s NN NN O
negative NN NN O
transcriptional NN NN O
effects NN NN O
on NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
promoters NN NN O
. NN NN O
   
Further NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
Nef NN NN B-Protein
inhibits NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
by NN NN O
interfering NN NN O
with NN NN O
a NN NN O
signal NN NN O
derived NN NN O
from NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
complex NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
gene NN NN O
product NN NN O
related NN NN O
to NN NN O
p50 NN NN B-Protein
/ NN NN O
p105 NN NN B-Protein
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
participates NN NN O
in NN NN O
transactivation NN NN O
through NN NN O
a NN NN O
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
A NN NN O
Rel NN NN O
- NN NN O
related NN NN O
, NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
, NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
protein NN NN O
has NN NN O
been NN NN O
cloned NN NN O
as NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
activation NN NN O
gene NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
has NN NN O
an NN NN O
open NN NN O
reading NN NN O
frame NN NN O
of NN NN O
900 NN NN O
amino NN NN O
acids NN NN O
capable NN NN O
of NN NN O
encoding NN NN O
a NN NN O
97 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
is NN NN O
most NN NN O
similar NN NN O
to NN NN O
the NN NN O
105 NN NN O
- NN NN O
kDa NN NN O
precursor NN NN O
polypeptide NN NN O
of NN NN O
p50 NN NN B-Protein
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Like NN NN O
the NN NN O
105 NN NN O
- NN NN O
kDa NN NN O
precursor NN NN O
, NN NN O
it NN NN O
contains NN NN O
an NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
Rel NN NN O
- NN NN O
related NN NN O
domain NN NN O
of NN NN O
about NN NN O
300 NN NN O
amino NN NN O
acids NN NN O
and NN NN O
a NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
containing NN NN O
six NN NN O
full NN NN O
cell NN NN O
cycle NN NN O
or NN NN O
ankyrin NN NN O
repeats NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
- NN NN O
translated NN NN O
proteins NN NN O
, NN NN O
truncated NN NN O
downstream NN NN O
of NN NN O
the NN NN O
Rel NN NN O
domain NN NN O
and NN NN O
excluding NN NN O
the NN NN O
repeats NN NN O
, NN NN O
bind NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
. NN NN O
   
We NN NN O
refer NN NN O
to NN NN O
the NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
, NN NN O
truncated NN NN O
protein NN NN O
as NN NN O
p50B NN NN B-Protein
by NN NN O
analogy NN NN O
with NN NN O
p50 NN NN B-Protein
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
to NN NN O
the NN NN O
full NN NN O
- NN NN O
length NN NN O
protein NN NN O
as NN NN O
p97 NN NN B-Protein
. NN NN O
   
p50B NN NN B-Protein
is NN NN O
able NN NN O
to NN NN O
form NN NN O
heteromeric NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
with NN NN O
RelB NN NN B-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
, NN NN O
the NN NN O
two NN NN O
subunits NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Transient NN NN O
- NN NN O
transfection NN NN O
experiments NN NN O
in NN NN O
embryonal NN NN O
carcinoma NN NN O
cells NN NN O
demonstrate NN NN O
a NN NN O
functional NN NN O
cooperation NN NN O
between NN NN O
p50B NN NN B-Protein
and NN NN O
RelB NN NN B-Protein
or NN NN O
p65 NN NN B-Protein
in NN NN O
transactivation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
plasmid NN NN O
dependent NN NN O
on NN NN O
a NN NN O
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
The NN NN O
data NN NN O
imply NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
complex NN NN O
family NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
development NN NN O
: NN NN O
the NN NN O
alpha NN NN B-Protein
TCR NN NN I-Protein
gene NN NN O
as NN NN O
a NN NN O
molecular NN NN O
model NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
during NN NN O
lymphocyte NN NN O
differentiation NN NN O
is NN NN O
a NN NN O
complex NN NN O
process NN NN O
involving NN NN O
interactions NN NN O
between NN NN O
multiple NN NN O
positive NN NN O
and NN NN O
negative NN NN O
transcriptional NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
In NN NN O
this NN NN O
article NN NN O
, NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
archetypal NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
gene NN NN O
, NN NN O
alpha NN NN B-Protein
TCR NN NN I-Protein
, NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Major NN NN O
recent NN NN O
developments NN NN O
, NN NN O
including NN NN O
the NN NN O
identification NN NN O
of NN NN O
novel NN NN O
families NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
multiple NN NN O
T NN NN O
- NN NN O
cell NN NN O
genes NN NN O
during NN NN O
thymocyte NN NN O
ontogeny NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
are NN NN O
described NN NN O
. NN NN O
   
An NN NN O
11 NN NN O
- NN NN O
base NN NN O
- NN NN O
pair NN NN O
DNA NN NN O
sequence NN NN O
motif NN NN O
apparently NN NN O
unique NN NN O
to NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
4 NN NN I-Protein
gene NN NN O
confers NN NN O
responsiveness NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
DNA NN NN O
segment NN NN O
that NN NN O
confers NN NN O
responsiveness NN NN O
to NN NN O
antigen NN NN O
stimulation NN NN O
signals NN NN O
on NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
, NN NN O
of NN NN O
10 NN NN O
kilobases NN NN O
, NN NN O
is NN NN O
composed NN NN O
of NN NN O
four NN NN O
exons NN NN O
and NN NN O
three NN NN O
introns NN NN O
. NN NN O
   
A NN NN O
cis NN NN O
- NN NN O
acting NN NN O
element NN NN O
( NN NN O
P NN NN O
sequence NN NN O
) NN NN O
resides NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
region NN NN O
; NN NN O
no NN NN O
additional NN NN O
DNA NN NN O
segments NN NN O
with NN NN O
enhancer NN NN O
activity NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
. NN NN O
   
For NN NN O
further NN NN O
mapping NN NN O
purposes NN NN O
, NN NN O
a NN NN O
fusion NN NN O
promoter NN NN O
was NN NN O
constructed NN NN O
with NN NN O
the NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
basic NN NN O
promoter NN NN O
containing NN NN O
60 NN NN O
base NN NN O
pairs NN NN O
of NN NN O
sequence NN NN O
upstream NN NN O
from NN NN O
the NN NN O
cap NN NN O
site NN NN O
of NN NN O
the NN NN O
mouse NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
gene NN NN O
and NN NN O
various NN NN O
lengths NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
P NN NN O
sequence NN NN O
was NN NN O
located NN NN O
between NN NN O
positions NN NN O
- NN NN O
79 NN NN O
and NN NN O
- NN NN O
69 NN NN O
relative NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
, NN NN O
and NN NN O
this NN NN O
location NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
base NN NN O
- NN NN O
substitution NN NN O
mutations NN NN O
. NN NN O
   
The NN NN O
plasmids NN NN O
carrying NN NN O
multiple NN NN O
copies NN NN O
of NN NN O
the NN NN O
P NN NN O
sequence NN NN O
showed NN NN O
higher NN NN O
responsiveness NN NN O
to NN NN O
the NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
that NN NN O
recognize NN NN O
the NN NN O
P NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
were NN NN O
identified NN NN O
by NN NN O
DNA NN NN O
- NN NN O
mobility NN NN O
- NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
( NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
that NN NN O
specifically NN NN O
recognizes NN NN O
the NN NN O
P NN NN O
sequence NN NN O
) NN NN O
to NN NN O
the NN NN O
P NN NN O
sequence NN NN O
was NN NN O
abolished NN NN O
when NN NN O
oligonucleotides NN NN O
carrying NN NN O
base NN NN O
substitutions NN NN O
were NN NN O
used NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
interaction NN NN O
is NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
and NN NN O
that NN NN O
binding NN NN O
specificity NN NN O
of NN NN O
the NN NN O
protein NN NN O
paralleled NN NN O
the NN NN O
sequence NN NN O
requirements NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
expression NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
The NN NN O
P NN NN O
sequence NN NN O
does NN NN O
not NN NN O
share NN NN O
homology NN NN O
with NN NN O
the NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
, NN NN O
even NN NN O
though NN NN O
surrounding NN NN O
sequences NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
share NN NN O
high NN NN O
homology NN NN O
with NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
a NN NN O
different NN NN O
set NN NN O
of NN NN O
proteins NN NN O
recognize NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
genes NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
enhancer NN NN O
is NN NN O
not NN NN O
dependent NN NN O
on NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
function NN NN O
of NN NN O
a NN NN O
putative NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
in NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
enhancer NN NN O
has NN NN O
been NN NN O
analyzed NN NN O
. NN NN O
   
Activation NN NN O
by NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
is NN NN O
minimal NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
and NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
putative NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
region NN NN O
is NN NN O
not NN NN O
required NN NN O
for NN NN O
the NN NN O
response NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
or NN NN O
to NN NN O
mitogens NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
, NN NN O
B NN NN O
- NN NN O
cell NN NN O
, NN NN O
or NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
leukemia NN NN O
lines NN NN O
, NN NN O
nor NN NN O
is NN NN O
it NN NN O
a NN NN O
cis NN NN O
- NN NN O
acting NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
6 NN NN I-Protein
- NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
a NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
into NN NN O
IgM NN NN O
- NN NN O
secreting NN NN O
plasma NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
the NN NN O
protooncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
in NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
6 NN NN I-Protein
- NN NN O
induced NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
was NN NN O
assessed NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
SKW NN NN O
6 NN NN O
. NN NN O
4 NN NN O
cells NN NN O
with NN NN O
IL NN NN B-Protein
6 NN NN I-Protein
induced NN NN O
a NN NN O
transient NN NN O
and NN NN O
early NN NN O
stimulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
sense NN NN O
mRNA NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
appeared NN NN O
within NN NN O
30 NN NN O
min NN NN O
and NN NN O
returned NN NN O
to NN NN O
basal NN NN O
levels NN NN O
after NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
antisense NN NN O
oligonucleotides NN NN O
to NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
significantly NN NN O
inhibited NN NN O
IL NN NN B-Protein
6 NN NN I-Protein
- NN NN O
induced NN NN O
IgM NN NN O
production NN NN O
by NN NN O
SKW NN NN O
6 NN NN O
. NN NN O
4 NN NN O
cells NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
control NN NN O
oligonucleotides NN NN O
had NN NN O
no NN NN O
inhibitory NN NN O
effect NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
is NN NN O
involved NN NN O
in NN NN O
IL NN NN B-Protein
6 NN NN I-Protein
- NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
SKW NN NN O
6 NN NN O
. NN NN O
4 NN NN O
cells NN NN O
into NN NN O
IgM NN NN O
- NN NN O
secreting NN NN O
cells NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
erythroid NN NN O
and NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
nuclear NN NN O
proteins NN NN O
to NN NN O
the NN NN O
silencer NN NN O
of NN NN O
the NN NN O
human NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
- NN NN O
encoding NN NN O
gene NN NN O
. NN NN O
   
To NN NN O
clarify NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
the NN NN O
developmental NN NN O
control NN NN O
of NN NN O
hemoglobin NN NN O
- NN NN O
encoding NN NN O
genes NN NN O
we NN NN O
have NN NN O
been NN NN O
studying NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
in NN NN O
human NN NN O
cells NN NN O
in NN NN O
continuous NN NN O
culture NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
reported NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
transcriptional NN NN O
control NN NN O
element NN NN O
with NN NN O
the NN NN O
properties NN NN O
of NN NN O
a NN NN O
silencer NN NN O
extending NN NN O
from NN NN O
- NN NN O
392 NN NN O
to NN NN O
- NN NN O
177 NN NN O
bp NN NN O
relative NN NN O
to NN NN O
the NN NN O
cap NN NN O
site NN NN O
of NN NN O
the NN NN O
human NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
- NN NN O
encoding NN NN O
gene NN NN O
[ NN NN O
Cao NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
Proc NN NN O
. NN NN O
Natl NN NN O
. NN NN O
Acad NN NN O
. NN NN O
Sci NN NN O
. NN NN O
USA NN NN O
86 NN NN O
( NN NN O
1989 NN NN O
) NN NN O
5306 NN NN O
- NN NN O
5309 NN NN O
] NN NN O
. NN NN O
   
We NN NN O
also NN NN O
showed NN NN O
that NN NN O
this NN NN O
silencer NN NN O
has NN NN O
stronger NN NN O
inhibitory NN NN O
activity NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
as NN NN O
compared NN NN O
to NN NN O
K562 NN NN O
human NN NN O
erythroleukemia NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
deletion NN NN O
mutants NN NN O
and NN NN O
cis NN NN O
- NN NN O
cloned NN NN O
synthetic NN NN O
oligodeoxyribonucleotides NN NN O
in NN NN O
transient NN NN O
expression NN NN O
assays NN NN O
, NN NN O
nucleotide NN NN O
sequences NN NN O
responsible NN NN O
for NN NN O
this NN NN O
effect NN NN O
have NN NN O
now NN NN O
been NN NN O
further NN NN O
delimited NN NN O
to NN NN O
44 NN NN O
bp NN NN O
located NN NN O
from NN NN O
- NN NN O
294 NN NN O
to NN NN O
- NN NN O
251 NN NN O
bp NN NN O
. NN NN O
   
Gel NN NN O
electrophoresis NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
DNaseI NN NN B-Protein
footprinting NN NN O
assays NN NN O
demonstrate NN NN O
that NN NN O
these NN NN O
negative NN NN O
regulatory NN NN O
sequences NN NN O
are NN NN O
recognized NN NN O
differently NN NN O
by NN NN O
proteins NN NN O
present NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
obtained NN NN O
from NN NN O
HeLa NN NN O
and NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
detected NN NN O
in NN NN O
K562 NN NN O
nuclear NN NN O
extracts NN NN O
, NN NN O
while NN NN O
only NN NN O
one NN NN O
is NN NN O
found NN NN O
in NN NN O
extracts NN NN O
from NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Possible NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
these NN NN O
proteins NN NN O
may NN NN O
regulate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
- NN NN O
encoding NN NN O
gene NN NN O
in NN NN O
erythroid NN NN O
and NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cells NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
cytokine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
secreted NN NN O
by NN NN O
activated NN NN O
T NN NN O
cells NN NN O
is NN NN O
a NN NN O
pleiotropic NN NN O
cytokine NN NN O
affecting NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
diverse NN NN O
cell NN NN O
types NN NN O
such NN NN O
as NN NN O
T NN NN O
cells NN NN O
, NN NN O
B NN NN O
cells NN NN O
, NN NN O
and NN NN O
mast NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
elements NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
( NN NN O
NRE NN NN O
) NN NN O
composed NN NN O
of NN NN O
two NN NN O
protein NN NN O
- NN NN O
binding NN NN O
sites NN NN O
were NN NN O
mapped NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
: NN NN O
- NN NN O
311CTCCCTTCT NN NN O
- NN NN O
303 NN NN O
( NN NN O
NRE NN NN O
- NN NN O
I NN NN O
) NN NN O
and NN NN O
- NN NN O
288CTTTTTGCTT NN NN O
- NN NN O
TGC NN NN O
- NN NN O
300 NN NN O
( NN NN O
NRE NN NN O
- NN NN O
II NN NN O
) NN NN O
. NN NN O
   
A NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
protein NN NN O
Neg NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
a NN NN O
ubiquitous NN NN O
protein NN NN O
Neg NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
to NN NN O
NRE NN NN O
- NN NN O
I NN NN O
and NN NN O
NRE NN NN O
- NN NN O
II NN NN O
, NN NN O
respectively NN NN O
, NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
was NN NN O
found NN NN O
45 NN NN O
bp NN NN O
downstream NN NN O
of NN NN O
the NN NN O
NRE NN NN O
. NN NN O
   
The NN NN O
enhancer NN NN O
activity NN NN O
of NN NN O
the NN NN O
PRE NN NN O
was NN NN O
completely NN NN O
suppressed NN NN O
when NN NN O
the NN NN O
NRE NN NN O
was NN NN O
present NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activity NN NN O
is NN NN O
normally NN NN O
down NN NN O
- NN NN O
regulated NN NN O
by NN NN O
an NN NN O
NRE NN NN O
via NN NN O
repression NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
These NN NN O
data NN NN O
may NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
stringent NN NN O
control NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
cell NN NN O
activation NN NN O
through NN NN O
the NN NN O
activation NN NN B-Protein
- NN NN I-Protein
inducer NN NN I-Protein
molecule NN NN I-Protein
/ NN NN O
CD69 NN NN B-Protein
enhances NN NN O
the NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
has NN NN O
been NN NN O
ascribed NN NN O
to NN NN O
the NN NN O
early NN NN O
events NN NN O
leading NN NN O
to NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
regulation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
stimulated NN NN O
through NN NN O
the NN NN O
activation NN NN B-Protein
inducer NN NN I-Protein
molecule NN NN I-Protein
( NN NN O
AIM NN NN B-Protein
) NN NN O
/ NN NN O
CD69 NN NN B-Protein
activation NN NN O
pathway NN NN O
. NN NN O
   
Phorbol NN NN O
esters NN NN O
are NN NN O
required NN NN O
to NN NN O
induce NN NN O
AIM NN NN B-Protein
/ NN NN O
CD69 NN NN B-Protein
cell NN NN O
- NN NN O
surface NN NN O
expression NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
triggering NN NN O
the NN NN O
proliferation NN NN O
of NN NN O
T NN NN O
cells NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
anti NN NN O
- NN NN O
AIM NN NN B-Protein
mAb NN NN O
. NN NN O
   
Mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
AIM NN NN B-Protein
mAb NN NN O
to NN NN O
PMA NN NN O
- NN NN O
treated NN NN O
T NN NN O
lymphocytes NN NN O
markedly NN NN O
enhanced NN NN O
the NN NN O
binding NN NN O
activity NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
to NN NN O
its NN NN O
cognate NN NN O
sequence NN NN O
, NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
response NN NN O
element NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
anti NN NN O
- NN NN O
AIM NN NN B-Protein
mAb NN NN O
did NN NN O
not NN NN O
induce NN NN O
any NN NN O
change NN NN O
in NN NN O
the NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
whose NN NN O
activity NN NN O
is NN NN O
also NN NN O
regulated NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
the NN NN O
marked NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
but NN NN O
not NN NN O
that NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
. NN NN O
   
Blockade NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
with NN NN O
an NN NN O
anti NN NN O
- NN NN O
Fos NN NN B-Protein
mAb NN NN O
demonstrated NN NN O
a NN NN O
direct NN NN O
participation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
in NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complexes NN NN O
induced NN NN O
by NN NN O
anti NN NN O
- NN NN O
AIM NN NN B-Protein
mAb NN NN O
. NN NN O
   
Most NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
could NN NN O
be NN NN O
eliminated NN NN O
when NN NN O
the NN NN O
anti NN NN O
- NN NN O
AIM NN NN B-Protein
mAb NN NN O
was NN NN O
added NN NN O
to NN NN O
the NN NN O
culture NN NN O
medium NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
cycloheximide NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
is NN NN O
crucial NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
data NN NN O
provide NN NN O
the NN NN O
evidence NN NN O
that NN NN O
activation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
through NN NN O
the NN NN O
AIM NN NN B-Protein
activation NN NN O
pathway NN NN O
regulate NN NN O
the NN NN O
activity NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
this NN NN O
pathway NN NN O
appears NN NN O
as NN NN O
a NN NN O
crucial NN NN O
step NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
early NN NN O
T NN NN O
cell NN NN O
activation NN NN O
events NN NN O
. NN NN O
   
The NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
positively NN NN O
regulates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
class NN NN O
II NN NN O
transplantation NN NN O
gene NN NN O
, NN NN O
DRA NN NN B-Protein
. NN NN O
   
The NN NN O
promoter NN NN O
of NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
class NN NN O
II NN NN O
gene NN NN O
DRA NN NN B-Protein
contains NN NN O
an NN NN O
octamer NN NN O
element NN NN O
( NN NN O
ATTTGCAT NN NN O
) NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
efficient NN NN O
DRA NN NN B-Protein
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Several NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
known NN NN O
to NN NN O
bind NN NN O
this NN NN O
sequence NN NN O
. NN NN O
   
The NN NN O
best NN NN O
characterized NN NN O
are NN NN O
the NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
the NN NN O
ubiquitous NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
This NN NN O
report NN NN O
directly NN NN O
demonstrates NN NN O
that NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
but NN NN O
not NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
regulates NN NN O
the NN NN O
DRA NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
transcription NN NN O
analysis NN NN O
using NN NN O
protein NN NN O
fractions NN NN O
enriched NN NN O
for NN NN O
the NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
demonstrate NN NN O
a NN NN O
positive NN NN O
functional NN NN O
role NN NN O
for NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
DRA NN NN B-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
enriched NN NN O
protein NN NN O
fractions NN NN O
did NN NN O
not NN NN O
affect NN NN O
DRA NN NN B-Protein
gene NN NN O
transcription NN NN O
although NN NN O
it NN NN O
functionally NN NN O
enhanced NN NN O
the NN NN O
transcription NN NN O
of NN NN O
another NN NN O
gene NN NN O
. NN NN O
   
Recombinant NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
produced NN NN O
by NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
/ NN NN O
translation NN NN O
could NN NN O
also NN NN O
enhance NN NN O
DRA NN NN B-Protein
gene NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
transient NN NN O
transfection NN NN O
studies NN NN O
utilizing NN NN O
an NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
vector NN NN O
resulted NN NN O
in NN NN O
similar NN NN O
findings NN NN O
: NN NN O
that NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
enhanced NN NN O
DRA NN NN B-Protein
gene NN NN O
transcription NN NN O
, NN NN O
and NN NN O
that NN NN O
this NN NN O
effect NN NN O
requires NN NN O
an NN NN O
intact NN NN O
octamer NN NN O
element NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
results NN NN O
constitute NN NN O
the NN NN O
first NN NN O
direct NN NN O
evidence NN NN O
of NN NN O
a NN NN O
positive NN NN O
role NN NN O
for NN NN O
the NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
factor NN NN O
in NN NN O
DRA NN NN B-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Specific NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
Tat NN NN B-Protein
to NN NN O
stimulate NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
transcription NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
protein NN NN O
complex NN NN O
which NN NN O
functions NN NN O
in NN NN O
concert NN NN O
with NN NN O
the NN NN O
tat NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
gene NN NN O
product NN NN O
to NN NN O
stimulate NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
transcription NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
specific NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
contribute NN NN O
to NN NN O
this NN NN O
effect NN NN O
, NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
abilities NN NN O
of NN NN O
different NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
to NN NN O
act NN NN O
with NN NN O
Tat NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
to NN NN O
stimulate NN NN O
transcription NN NN O
of NN NN O
HIV NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
the NN NN O
p49 NN NN B-Protein
( NN NN I-Protein
100 NN NN I-Protein
) NN NN I-Protein
DNA NN NN O
binding NN NN O
subunit NN NN O
, NN NN O
together NN NN O
with NN NN O
p65 NN NN B-Protein
, NN NN O
can NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
Tat NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
to NN NN O
stimulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
HIV NN NN O
- NN NN O
CAT NN NN B-Protein
plasmid NN NN O
. NN NN O
   
Little NN NN O
effect NN NN O
was NN NN O
observed NN NN O
with NN NN O
50 NN NN O
- NN NN O
kDa NN NN O
forms NN NN O
of NN NN O
p105 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
rel NN NN B-Protein
, NN NN O
in NN NN O
combination NN NN O
with NN NN O
p65 NN NN B-Protein
or NN NN O
full NN NN O
- NN NN O
length NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
which NN NN O
do NN NN O
not NN NN O
stimulate NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
combination NN NN O
of NN NN O
p49 NN NN B-Protein
( NN NN I-Protein
100 NN NN I-Protein
) NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
the NN NN O
tat NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
gene NN NN O
product NN NN O
to NN NN O
stimulate NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
HIV NN NN O
RNA NN NN O
. NN NN O
   
Heterodimerization NN NN O
and NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
vitro NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
of NN NN O
transcription NN NN O
proteins NN NN O
represents NN NN O
multiple NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
rel NN NN B-Protein
related NN NN O
polypeptides NN NN O
that NN NN O
contribute NN NN O
to NN NN O
regulation NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
immune NN NN O
responsiveness NN NN O
and NN NN O
inflammation NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
multiple NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
related NN NN O
polypeptides NN NN O
ranging NN NN O
from NN NN O
85 NN NN O
to NN NN O
45 NN NN O
kDa NN NN O
were NN NN O
examined NN NN O
for NN NN O
their NN NN O
capacity NN NN O
to NN NN O
interact NN NN O
with NN NN O
the NN NN O
PRDII NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
interferon NN NN O
beta NN NN O
and NN NN O
were NN NN O
shown NN NN O
to NN NN O
possess NN NN O
distinct NN NN O
intrinsic NN NN O
DNA NN NN O
binding NN NN O
affinities NN NN O
for NN NN O
this NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
and NN NN O
form NN NN O
multiple NN NN O
DNA NN NN O
binding NN NN O
homo NN NN O
- NN NN O
and NN NN O
heterodimer NN NN O
complexes NN NN O
in NN NN O
co NN NN O
- NN NN O
renaturation NN NN O
experiments NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
using NN NN O
DNA NN NN O
templates NN NN O
containing NN NN O
two NN NN O
copies NN NN O
of NN NN O
the NN NN O
PRDII NN NN O
domain NN NN O
linked NN NN O
to NN NN O
the NN NN O
rabbit NN NN O
beta NN NN O
globin NN NN O
gene NN NN O
, NN NN O
the NN NN O
purified NN NN O
polypeptides NN NN O
specifically NN NN O
stimulated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
dependent NN NN O
transcription NN NN O
in NN NN O
an NN NN O
in NN NN O
vitro NN NN O
reconstitution NN NN O
assay NN NN O
as NN NN O
heterodimers NN NN O
but NN NN O
not NN NN O
as NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
These NN NN O
experiments NN NN O
emphasize NN NN O
the NN NN O
role NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
dimerization NN NN O
as NN NN O
a NN NN O
distinct NN NN O
level NN NN O
of NN NN O
transcriptional NN NN O
control NN NN O
that NN NN O
may NN NN O
permit NN NN O
functional NN NN O
diversification NN NN O
of NN NN O
a NN NN O
limited NN NN O
number NN NN O
of NN NN O
regulatory NN NN O
proteins NN NN O
. NN NN O
   
Oct2 NN NN B-Protein
transactivation NN NN O
from NN NN O
a NN NN O
remote NN NN O
enhancer NN NN O
position NN NN O
requires NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
restricted NN NN O
activity NN NN O
. NN NN O
   
Previous NN NN O
cotransfection NN NN O
experiments NN NN O
had NN NN O
demonstrated NN NN O
that NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
the NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
Oct2 NN NN B-Protein
could NN NN O
efficiently NN NN O
activate NN NN O
a NN NN O
promoter NN NN O
containing NN NN O
an NN NN O
octamer NN NN O
motif NN NN O
. NN NN O
   
Oct2 NN NN B-Protein
expression NN NN O
was NN NN O
unable NN NN O
to NN NN O
stimulate NN NN O
a NN NN O
multimerized NN NN O
octamer NN NN O
enhancer NN NN O
element NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
however NN NN O
. NN NN O
   
We NN NN O
have NN NN O
tested NN NN O
a NN NN O
variety NN NN O
of NN NN O
Oct2 NN NN B-Protein
isoforms NN NN O
generated NN NN O
by NN NN O
alternative NN NN O
splicing NN NN O
for NN NN O
the NN NN O
capability NN NN O
to NN NN O
activate NN NN O
an NN NN O
octamer NN NN O
enhancer NN NN O
in NN NN O
nonlymphoid NN NN O
cells NN NN O
and NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Our NN NN O
analyses NN NN O
show NN NN O
that NN NN O
several NN NN O
Oct2 NN NN B-Protein
isoforms NN NN O
can NN NN O
stimulate NN NN O
from NN NN O
a NN NN O
remote NN NN O
position NN NN O
but NN NN O
that NN NN O
this NN NN O
stimulation NN NN O
is NN NN O
restricted NN NN O
to NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
result NN NN O
indicates NN NN O
the NN NN O
involvement NN NN O
of NN NN O
either NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
cofactor NN NN O
or NN NN O
a NN NN O
specific NN NN O
modification NN NN O
of NN NN O
a NN NN O
cofactor NN NN O
or NN NN O
the NN NN O
Oct2 NN NN B-Protein
protein NN NN O
in NN NN O
Oct2 NN NN B-Protein
- NN NN O
mediated NN NN O
enhancer NN NN O
activation NN NN O
. NN NN O
   
Mutational NN NN O
analyses NN NN O
indicate NN NN O
that NN NN O
the NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
of NN NN O
Oct2 NN NN B-Protein
is NN NN O
critical NN NN O
for NN NN O
enhancer NN NN O
activation NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
this NN NN O
domain NN NN O
conferred NN NN O
enhancing NN NN O
activity NN NN O
when NN NN O
fused NN NN O
to NN NN O
the NN NN O
Oct1 NN NN B-Protein
protein NN NN O
, NN NN O
which NN NN O
by NN NN O
itself NN NN O
was NN NN O
unable NN NN O
to NN NN O
stimulate NN NN O
from NN NN O
a NN NN O
remote NN NN O
position NN NN O
. NN NN O
   
The NN NN O
glutamine NN NN O
- NN NN O
rich NN NN O
activation NN NN O
domain NN NN O
present NN NN O
in NN NN O
the NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
portion NN NN O
of NN NN O
Oct2 NN NN B-Protein
and NN NN O
the NN NN O
POU NN NN O
domain NN NN O
contribute NN NN O
only NN NN O
marginally NN NN O
to NN NN O
the NN NN O
transactivation NN NN O
function NN NN O
from NN NN O
a NN NN O
distal NN NN O
position NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
2 NN NN O
activates NN NN O
gene NN NN O
expression NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
The NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
LTR NN NN O
contains NN NN O
three NN NN O
conserved NN NN O
regulatory NN NN O
elements NN NN O
known NN NN O
as NN NN O
21 NN NN O
base NN NN O
pair NN NN O
repeats NN NN O
which NN NN O
are NN NN O
required NN NN O
for NN NN O
stimulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
by NN NN O
the NN NN O
transactivator NN NN O
protein NN NN O
tax NN NN B-Protein
. NN NN O
   
Mutagenesis NN NN O
indicates NN NN O
that NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
can NN NN O
be NN NN O
subdivided NN NN O
into NN NN O
three NN NN O
motifs NN NN O
, NN NN O
A NN NN O
, NN NN O
B NN NN O
and NN NN O
C NN NN O
, NN NN O
each NN NN O
of NN NN O
which NN NN O
influences NN NN O
the NN NN O
level NN NN O
of NN NN O
tax NN NN B-Protein
activation NN NN O
. NN NN O
   
The NN NN O
A NN NN O
site NN NN O
in NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeat NN NN O
has NN NN O
strong NN NN O
homology NN NN O
with NN NN O
previously NN NN O
described NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
that NN NN O
AP NN NN O
- NN NN O
2 NN NN O
mRNA NN NN O
was NN NN O
present NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
and NN NN O
that NN NN O
cellular NN NN O
factors NN NN O
from NN NN O
both NN NN O
non NN NN O
- NN NN O
transformed NN NN O
and NN NN O
transformed NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
specifically NN NN O
bound NN NN O
to NN NN O
the NN NN O
consensus NN NN O
motif NN NN O
for NN NN O
AP NN NN O
- NN NN O
2 NN NN O
in NN NN O
each NN NN O
21 NN NN O
bp NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
role NN NN O
of NN NN O
AP NN NN O
- NN NN O
2 NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
LTR NN NN O
gene NN NN O
expression NN NN O
, NN NN O
we NN NN O
used NN NN O
an NN NN O
AP NN NN O
- NN NN O
2 NN NN O
cDNA NN NN O
in NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
transient NN NN O
expression NN NN O
assays NN NN O
. NN NN O
   
Gel NN NN O
retardation NN NN O
and NN NN O
methylation NN NN O
interference NN NN O
studies NN NN O
revealed NN NN O
that NN NN O
bacterially NN NN O
produced NN NN O
AP NN NN O
- NN NN O
2 NN NN O
bound NN NN O
specifically NN NN O
and NN NN O
with NN NN O
high NN NN O
affinity NN NN O
to NN NN O
all NN NN O
three NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
, NN NN O
and NN NN O
that NN NN O
it NN NN O
required NN NN O
the NN NN O
core NN NN O
sequence NN NN O
AGGC NN NN O
for NN NN O
specific NN NN O
binding NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
AP NN NN O
- NN NN O
2 NN NN O
prevented NN NN O
the NN NN O
subsequent NN NN O
binding NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
family NN NN O
to NN NN O
an NN NN O
adjacent NN NN O
regulatory NN NN O
motif NN NN O
in NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeat NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
an NN NN O
AP NN NN O
- NN NN O
2 NN NN O
expression NN NN O
construct NN NN O
into NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
activated NN NN O
gene NN NN O
expression NN NN O
from NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
LTR NN NN O
. NN NN O
   
At NN NN O
least NN NN O
two NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
were NN NN O
required NN NN O
for NN NN O
high NN NN O
levels NN NN O
of NN NN O
AP NN NN O
- NN NN O
2 NN NN O
activation NN NN O
and NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
2 NN NN O
consensus NN NN O
binding NN NN O
sequences NN NN O
in NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
eliminate NN NN O
this NN NN O
activation NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
The NN NN O
human NN NN O
myelomonocytic NN NN O
cell NN NN O
line NN NN O
U NN NN O
- NN NN O
937 NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
studying NN NN O
alterations NN NN O
in NN NN O
steroid NN NN O
- NN NN O
induced NN NN O
monokine NN NN O
gene NN NN O
expression NN NN O
: NN NN O
marked NN NN O
enhancement NN NN O
of NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
messenger NN NN O
RNA NN NN O
levels NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
. NN NN O
   
The NN NN O
active NN NN O
metabolite NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
, NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
[ NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
] NN NN O
, NN NN O
is NN NN O
a NN NN O
potent NN NN O
regulator NN NN O
of NN NN O
human NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
function NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
To NN NN O
establish NN NN O
a NN NN O
model NN NN O
for NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
regulation NN NN O
of NN NN O
human NN NN O
monocyte NN NN O
monokine NN NN O
synthesis NN NN O
, NN NN O
three NN NN O
human NN NN O
cell NN NN O
lines NN NN O
( NN NN O
U NN NN O
- NN NN O
937 NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
HL NN NN O
- NN NN O
60 NN NN O
) NN NN O
were NN NN O
examined NN NN O
for NN NN O
: NN NN O
1 NN NN O
) NN NN O
the NN NN O
presence NN NN O
of NN NN O
functional NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
receptors NN NN O
; NN NN O
2 NN NN O
) NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
) NN NN O
mRNA NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
protein NN NN O
in NN NN O
response NN NN O
to NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
; NN NN O
and NN NN O
3 NN NN O
) NN NN O
the NN NN O
regulation NN NN O
of NN NN O
this NN NN O
response NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
All NN NN O
three NN NN O
cell NN NN O
lines NN NN O
expressed NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
and NN NN O
had NN NN O
increased NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
Preincubation NN NN O
of NN NN O
cells NN NN O
with NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
augmented NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
levels NN NN O
only NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
and NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
these NN NN O
data NN NN O
, NN NN O
and NN NN O
taking NN NN O
into NN NN O
consideration NN NN O
their NN NN O
state NN NN O
of NN NN O
differentiation NN NN O
and NN NN O
relative NN NN O
ease NN NN O
of NN NN O
culture NN NN O
, NN NN O
U NN NN O
- NN NN O
937 NN NN O
was NN NN O
chosen NN NN O
over NN NN O
HL NN NN O
- NN NN O
60 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
as NN NN O
the NN NN O
cell NN NN O
line NN NN O
we NN NN O
further NN NN O
characterized NN NN O
. NN NN O
   
In NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
, NN NN O
optimum NN NN O
time NN NN O
and NN NN O
dose NN NN O
of NN NN O
pretreatment NN NN O
with NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
were NN NN O
determined NN NN O
to NN NN O
be NN NN O
12 NN NN O
- NN NN O
24 NN NN O
h NN NN O
at NN NN O
a NN NN O
receptor NN NN O
saturating NN NN O
concentration NN NN O
of NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
( NN NN O
10 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
Preincubation NN NN O
of NN NN O
cells NN NN O
with NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
appearance NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
However NN NN O
, NN NN O
exposure NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
to NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
increased NN NN O
by NN NN O
200 NN NN O
% NN NN O
the NN NN O
level NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
detected NN NN O
and NN NN O
decreased NN NN O
by NN NN O
three NN NN O
orders NN NN O
of NN NN O
magnitude NN NN O
the NN NN O
concentration NN NN O
of NN NN O
LPS NN NN O
required NN NN O
to NN NN O
achieve NN NN O
steady NN NN O
state NN NN O
mRNA NN NN O
levels NN NN O
equivalent NN NN O
to NN NN O
those NN NN O
observed NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
not NN NN O
preincubated NN NN O
with NN NN O
the NN NN O
hormone NN NN O
. NN NN O
2 NN NN O
+ NN NN O
o NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
the NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
line NN NN O
is NN NN O
independent NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
regulated NN NN O
kinases NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
regulatory NN NN O
factor NN NN O
able NN NN O
to NN NN O
control NN NN O
transcription NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
genes NN NN O
, NN NN O
including NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cells NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
activated NN NN O
upon NN NN O
cellular NN NN O
treatment NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
and NN NN O
the NN NN O
cytokine NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
work NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
molecular NN NN O
events NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
a NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
( NN NN O
Jurkat NN NN O
) NN NN O
and NN NN O
its NN NN O
subclone NN NN O
JCT6 NN NN O
, NN NN O
which NN NN O
presents NN NN O
a NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
PKA NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
in NN NN O
both NN NN O
cell NN NN O
lines NN NN O
, NN NN O
both NN NN O
phorbol NN NN O
ester NN NN O
and NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
were NN NN O
able NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Phorbol NN NN O
activation NN NN O
was NN NN O
positively NN NN O
modulated NN NN O
by NN NN O
Ca2 NN NN O
+ NN NN O
influx NN NN O
while NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
activation NN NN O
was NN NN O
not NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
while NN NN O
PMA NN NN O
activation NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
PKC NN NN O
inhibitor NN NN O
staurosporin NN NN O
, NN NN O
the NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
effect NN NN O
was NN NN O
unchanged NN NN O
. NN NN O
   
TNF NN NN B-Protein
alpha NN NN I-Protein
did NN NN O
not NN NN O
activate NN NN O
cAMP NN NN O
production NN NN O
and NN NN O
its NN NN O
signal NN NN O
was NN NN O
not NN NN O
modulated NN NN O
by NN NN O
cAMP NN NN O
activators NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
cAMP NN NN O
activators NN NN O
did NN NN O
not NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
none NN NN O
of NN NN O
the NN NN O
major NN NN O
signal NN NN O
- NN NN O
mediating NN NN O
kinases NN NN O
such NN NN O
as NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
, NN NN O
or NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
regulated NN NN O
kinases NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
cytoplasmic NN NN O
acidification NN NN O
facilitated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
both NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
PKC NN NN O
, NN NN O
by NN NN O
a NN NN O
mechanism NN NN O
that NN NN O
increases NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
I NN NN O
kappa NN NN O
B NN NN O
dissociation NN NN O
without NN NN O
affecting NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
step NN NN O
. NN NN O
   
USF NN NN B-Protein
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
, NN NN O
stimulates NN NN O
transcription NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
a NN NN O
region NN NN O
about NN NN O
60 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
was NN NN O
purified NN NN O
from NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
had NN NN O
a NN NN O
molecular NN NN O
weight NN NN O
of NN NN O
39 NN NN O
, NN NN O
000 NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
to NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
HIV NN NN O
LTR NN NN O
was NN NN O
similar NN NN O
to NN NN O
the NN NN O
site NN NN O
recognized NN NN O
by NN NN O
upstream NN NN B-Protein
stimulatory NN NN I-Protein
factor NN NN I-Protein
( NN NN O
USF NN NN B-Protein
) NN NN O
in NN NN O
the NN NN O
adenovirus NN NN O
major NN NN O
late NN NN O
promoter NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
binding NN NN O
properties NN NN O
of NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
suggested NN NN O
that NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
might NN NN O
be NN NN O
identical NN NN O
or NN NN O
related NN NN O
to NN NN O
USF NN NN B-Protein
. NN NN O
   
Interestingly NN NN O
, NN NN O
treatment NN NN O
of NN NN O
purified NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
by NN NN O
phosphatase NN NN O
greatly NN NN O
reduced NN NN O
its NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
phosphorylation NN NN O
of NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
was NN NN O
essential NN NN O
for NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
The NN NN O
disruption NN NN O
of NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
induced NN NN O
a NN NN O
60 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
from NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
TF1 NN NN I-Protein
is NN NN O
involved NN NN O
in NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Nuclear NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
bind NN NN O
to NN NN O
elements NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Induction NN NN O
requirements NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Prior NN NN O
studies NN NN O
have NN NN O
identified NN NN O
several NN NN O
elements NN NN O
that NN NN O
contribute NN NN O
to NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
the NN NN O
stimulated NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
Jurkat NN NN O
. NN NN O
   
The NN NN O
sites NN NN O
and NN NN O
their NN NN O
corresponding NN NN O
nuclear NN NN O
binding NN NN O
factors NN NN O
include NN NN O
: NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
AP NN NN O
- NN NN O
3 NN NN O
, NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
"""""""" NN NN O
nuclear NN NN O
factor NN NN O
for NN NN O
activated NN NN O
T NN NN O
cells NN NN O
"""""""" NN NN O
likely NN NN O
contributes NN NN O
to NN NN O
the NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
primary NN NN O
T NN NN O
cells NN NN O
from NN NN O
human NN NN O
blood NN NN O
to NN NN O
verify NN NN O
their NN NN O
presence NN NN O
in NN NN O
a NN NN O
physiologic NN NN O
setting NN NN O
and NN NN O
to NN NN O
identify NN NN O
the NN NN O
signals NN NN O
that NN NN O
stimulate NN NN O
factor NN NN O
activity NN NN O
. NN NN O
   
All NN NN O
factors NN NN O
are NN NN O
induced NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
T NN NN O
cells NN NN O
upon NN NN O
activation NN NN O
with NN NN O
mitogens NN NN O
but NN NN O
not NN NN O
with NN NN O
exogenous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
growth NN NN O
factor NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
signaling NN NN O
requirements NN NN O
and NN NN O
sensitivity NN NN O
to NN NN O
protein NN NN O
synthesis NN NN O
inhibitors NN NN O
differ NN NN O
considerably NN NN O
. NN NN O
   
Only NN NN O
the NN NN O
activities NN NN O
for NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
require NN NN O
two NN NN O
signals NN NN O
for NN NN O
optimal NN NN O
induction NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
PMA NN NN O
plus NN NN O
either NN NN O
lectin NN NN O
or NN NN O
antibody NN NN O
to NN NN O
the NN NN O
CD3 NN NN O
or NN NN O
CD28 NN NN B-Protein
surface NN NN O
molecules NN NN O
. NN NN O
   
Other NN NN O
factors NN NN O
are NN NN O
induced NN NN O
by NN NN O
lectin NN NN O
, NN NN O
antibody NN NN O
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
PMA NN NN O
alone NN NN O
. NN NN O
   
After NN NN O
appropriate NN NN O
stimulation NN NN O
, NN NN O
both NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
are NN NN O
peculiarly NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
protein NN NN O
synthesis NN NN O
inhibitor NN NN O
anisomycin NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
correlate NN NN O
the NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
gel NN NN O
shift NN NN O
assays NN NN O
with NN NN O
the NN NN O
two NN NN O
signals NN NN O
requirements NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
An NN NN O
erythroid NN NN O
specific NN NN O
enhancer NN NN O
upstream NN NN O
to NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
hemopoietic NN NN O
cells NN NN O
, NN NN O
where NN NN O
it NN NN O
mediates NN NN O
the NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
expression NN NN O
of NN NN O
several NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
cloned NN NN O
the NN NN O
mouse NN NN O
and NN NN O
human NN NN O
GATA NN NN O
- NN NN O
1 NN NN O
genes NN NN O
. NN NN O
   
A NN NN O
region NN NN O
upstream NN NN O
to NN NN O
the NN NN O
first NN NN O
exon NN NN O
, NN NN O
and NN NN O
highly NN NN O
conserved NN NN O
between NN NN O
mouse NN NN O
and NN NN O
man NN NN O
, NN NN O
acts NN NN O
as NN NN O
an NN NN O
erythroid NN NN O
specific NN NN O
enhancer NN NN O
in NN NN O
transient NN NN O
assays NN NN O
, NN NN O
if NN NN O
linked NN NN O
to NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
to NN NN O
the NN NN O
SV40 NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
is NN NN O
almost NN NN O
completely NN NN O
dependent NN NN O
on NN NN O
the NN NN O
integrity NN NN O
of NN NN O
a NN NN O
dimeric NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
Clone NN NN O
pAT NN NN O
133 NN NN O
identifies NN NN O
a NN NN O
gene NN NN O
that NN NN O
encodes NN NN O
another NN NN O
human NN NN O
member NN NN O
of NN NN O
a NN NN O
class NN NN O
of NN NN O
growth NN NN O
factor NN NN O
- NN NN O
induced NN NN O
genes NN NN O
with NN NN O
almost NN NN O
identical NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
domains NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
structure NN NN O
and NN NN O
regulation NN NN O
of NN NN O
a NN NN O
gene NN NN O
represented NN NN O
by NN NN O
clone NN NN O
pAT NN NN O
133 NN NN O
, NN NN O
which NN NN O
is NN NN O
induced NN NN O
upon NN NN O
transition NN NN O
from NN NN O
a NN NN O
resting NN NN O
state NN NN O
( NN NN O
G0 NN NN O
) NN NN O
through NN NN O
the NN NN O
early NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
( NN NN O
G1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
pAT NN NN O
133 NN NN O
gene NN NN O
is NN NN O
immediately NN NN O
induced NN NN O
, NN NN O
with NN NN O
FOS NN NN O
- NN NN O
like NN NN O
kinetics NN NN O
, NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
Primary NN NN O
structure NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
encoded NN NN O
protein NN NN O
contains NN NN O
three NN NN O
tandem NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
sequences NN NN O
of NN NN O
the NN NN O
type NN NN O
Cys2 NN NN O
- NN NN O
Xaa12 NN NN O
- NN NN O
His2 NN NN O
. NN NN O
   
This NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
region NN NN O
, NN NN O
which NN NN O
is NN NN O
thought NN NN O
to NN NN O
bind NN NN O
DNA NN NN O
in NN NN O
a NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
manner NN NN O
, NN NN O
is NN NN O
similar NN NN O
( NN NN O
greater NN NN O
than NN NN O
80 NN NN O
% NN NN O
on NN NN O
the NN NN O
amino NN NN O
acid NN NN O
level NN NN O
) NN NN O
to NN NN O
two NN NN O
previously NN NN O
described NN NN O
transcription NN NN O
factors NN NN O
pAT NN NN O
225 NN NN O
/ NN NN O
EGR1 NN NN B-Protein
and NN NN O
pAT NN NN O
591 NN NN O
/ NN NN O
EGR2 NN NN B-Protein
. NN NN O
   
Except NN NN O
for NN NN O
the NN NN O
conserved NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
domains NN NN O
, NN NN O
the NN NN O
amino NN NN O
acid NN NN O
sequences NN NN O
of NN NN O
the NN NN O
three NN NN O
proteins NN NN O
are NN NN O
distinct NN NN O
. NN NN O
   
This NN NN O
structural NN NN O
similarity NN NN O
suggests NN NN O
that NN NN O
the NN NN O
pAT NN NN O
133 NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
with NN NN O
a NN NN O
specific NN NN O
biological NN NN O
function NN NN O
. NN NN O
   
Comparing NN NN O
the NN NN O
regulation NN NN O
of NN NN O
these NN NN O
related NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
- NN NN O
encoding NN NN O
genes NN NN O
showed NN NN O
coordinate NN NN O
induction NN NN O
upon NN NN O
mitogenic NN NN O
stimulation NN NN O
of NN NN O
resting NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
of NN NN O
resting NN NN O
fibroblasts NN NN O
. NN NN O
   
However NN NN O
, NN NN O
upon NN NN O
transition NN NN O
from NN NN O
a NN NN O
proliferating NN NN O
( NN NN O
G1 NN NN O
) NN NN O
to NN NN O
a NN NN O
resting NN NN O
state NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
the NN NN O
three NN NN O
genes NN NN O
were NN NN O
differently NN NN O
regulated NN NN O
. NN NN O
   
In NN NN O
human NN NN O
histiocytic NN NN O
U937 NN NN O
cells NN NN O
mRNA NN NN O
of NN NN O
clone NN NN O
pAT NN NN O
133 NN NN O
was NN NN O
constitutively NN NN O
expressed NN NN O
, NN NN O
whereas NN NN O
mRNA NN NN O
of NN NN O
pAT NN NN O
225 NN NN O
/ NN NN O
EGR1 NN NN B-Protein
was NN NN O
induced NN NN O
upon NN NN O
induction NN NN O
of NN NN O
terminal NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
mRNA NN NN O
representing NN NN O
pAT NN NN O
591 NN NN O
/ NN NN O
EGR2 NN NN B-Protein
was NN NN O
not NN NN O
expressed NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
in NN NN O
gene NN NN O
regulation NN NN O
suggests NN NN O
distinct NN NN O
biological NN NN O
roles NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
for NN NN O
the NN NN O
respective NN NN O
proteins NN NN O
. NN NN O
   
Every NN NN O
enhancer NN NN O
works NN NN O
with NN NN O
every NN NN O
promoter NN NN O
for NN NN O
all NN NN O
the NN NN O
combinations NN NN O
tested NN NN O
: NN NN O
could NN NN O
new NN NN O
regulatory NN NN O
pathways NN NN O
evolve NN NN O
by NN NN O
enhancer NN NN O
shuffling NN NN O
? NN NN O
   
The NN NN O
promoters NN NN O
and NN NN O
enhancers NN NN O
of NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
genes NN NN O
are NN NN O
often NN NN O
conserved NN NN O
in NN NN O
evolution NN NN O
, NN NN O
and NN NN O
hence NN NN O
one NN NN O
might NN NN O
expect NN NN O
that NN NN O
a NN NN O
given NN NN O
enhancer NN NN O
has NN NN O
evolved NN NN O
to NN NN O
work NN NN O
best NN NN O
with NN NN O
its NN NN O
own NN NN O
promoter NN NN O
. NN NN O
   
While NN NN O
this NN NN O
expectation NN NN O
may NN NN O
be NN NN O
realized NN NN O
in NN NN O
some NN NN O
cases NN NN O
, NN NN O
we NN NN O
have NN NN O
not NN NN O
found NN NN O
evidence NN NN O
for NN NN O
it NN NN O
. NN NN O
   
A NN NN O
total NN NN O
of NN NN O
27 NN NN O
combinations NN NN O
of NN NN O
different NN NN O
promoters NN NN O
and NN NN O
enhancers NN NN O
were NN NN O
tested NN NN O
by NN NN O
transfection NN NN O
into NN NN O
cultured NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
the NN NN O
relative NN NN O
efficiency NN NN O
of NN NN O
the NN NN O
enhancers NN NN O
is NN NN O
approximately NN NN O
the NN NN O
same NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
type NN NN O
of NN NN O
promoter NN NN O
used NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
strong NN NN O
preference NN NN O
for NN NN O
any NN NN O
given NN NN O
enhancer NN NN O
/ NN NN O
promoter NN NN O
combination NN NN O
. NN NN O
   
Notably NN NN O
, NN NN O
we NN NN O
do NN NN O
not NN NN O
see NN NN O
particularly NN NN O
strong NN NN O
transcription NN NN O
when NN NN O
the NN NN O
immunoglobulin NN NN O
kappa NN NN O
enhancer NN NN O
( NN NN O
or NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
) NN NN O
is NN NN O
used NN NN O
to NN NN O
activate NN NN O
a NN NN O
kappa NN NN O
gene NN NN O
promoter NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
a NN NN O
generally NN NN O
permissive NN NN O
enhancer NN NN O
/ NN NN O
promoter NN NN O
interaction NN NN O
is NN NN O
of NN NN O
evolutionary NN NN O
benefit NN NN O
for NN NN O
higher NN NN O
eukaryotes NN NN O
: NN NN O
by NN NN O
enhancer NN NN O
shuffling NN NN O
, NN NN O
genes NN NN O
could NN NN O
be NN NN O
easily NN NN O
brought NN NN O
under NN NN O
a NN NN O
new NN NN O
type NN NN O
of NN NN O
inducibility NN NN O
/ NN NN O
cell NN NN O
type NN NN O
specificity NN NN O
. NN NN O
   
Towards NN NN O
a NN NN O
molecular NN NN O
understanding NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Lymphoid NN NN O
differentiation NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
best NN NN O
studied NN NN O
examples NN NN O
of NN NN O
mammalian NN NN O
development NN NN O
. NN NN O
   
Here NN NN O
Hans NN NN O
Clevers NN NN O
and NN NN O
Michael NN NN O
Owen NN NN O
describe NN NN O
how NN NN O
the NN NN O
cloning NN NN O
of NN NN O
the NN NN O
genes NN NN O
that NN NN O
encode NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
membrane NN NN O
proteins NN NN O
allows NN NN O
the NN NN O
identification NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
control NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
T NN NN O
- NN NN O
cell NN NN O
genes NN NN O
. NN NN O
   
Such NN NN O
transcription NN NN O
factors NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
mature NN NN O
T NN NN O
- NN NN O
cell NN NN O
phenotype NN NN O
by NN NN O
functioning NN NN O
as NN NN O
' NN NN O
master NN NN O
regulators NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
' NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
requirements NN NN O
for NN NN O
U2 NN NN O
snRNA NN NN O
- NN NN O
encoding NN NN O
gene NN NN O
activation NN NN O
in NN NN O
B NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
a NN NN O
human NN NN O
U2 NN NN O
small NN NN O
nuclear NN NN O
RNA NN NN O
( NN NN O
snRNA NN NN O
) NN NN O
- NN NN O
encoding NN NN O
gene NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
requires NN NN O
a NN NN O
distal NN NN O
enhancer NN NN O
element NN NN O
, NN NN O
which NN NN O
is NN NN O
composed NN NN O
of NN NN O
one NN NN O
octamer NN NN O
motif NN NN O
( NN NN O
Oct NN NN O
) NN NN O
and NN NN O
three NN NN O
Sp NN NN B-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
To NN NN O
study NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
requirement NN NN O
in NN NN O
B NN NN O
- NN NN O
cells NN NN O
, NN NN O
different NN NN O
U2 NN NN O
enhancer NN NN O
constructions NN NN O
were NN NN O
transfected NN NN O
into NN NN O
the NN NN O
lymphoid NN NN O
cell NN NN O
line NN NN O
, NN NN O
BJA NN NN O
- NN NN O
B NN NN O
. NN NN O
   
The NN NN O
results NN NN O
showed NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
U2 NN NN O
snRNA NN NN O
transcription NN NN O
in NN NN O
B NN NN O
- NN NN O
cells NN NN O
also NN NN O
requires NN NN O
an NN NN O
enhancer NN NN O
comprising NN NN O
both NN NN O
the NN NN O
Oct NN NN O
and NN NN O
at NN NN O
least NN NN O
one NN NN O
Sp NN NN O
1 NN NN O
- NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
all NN NN O
the NN NN O
Sp NN NN B-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
sites NN NN O
from NN NN O
the NN NN O
enhancer NN NN O
reduces NN NN O
transcription NN NN O
by NN NN O
80 NN NN O
- NN NN O
90 NN NN O
% NN NN O
in NN NN O
HeLa NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
BJA NN NN O
- NN NN O
B NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
the NN NN O
removal NN NN O
of NN NN O
the NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
site NN NN O
reduces NN NN O
transcription NN NN O
to NN NN O
levels NN NN O
below NN NN O
detection NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Enhancers NN NN O
containing NN NN O
a NN NN O
single NN NN O
Oct NN NN O
have NN NN O
, NN NN O
nevertheless NN NN O
, NN NN O
the NN NN O
capacity NN NN O
to NN NN O
partially NN NN O
activate NN NN O
U2 NN NN O
snRNA NN NN O
transcription NN NN O
in NN NN O
both NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
in NN NN O
which NN NN O
only NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
expressed NN NN O
, NN NN O
and NN NN O
in NN NN O
BJA NN NN O
- NN NN O
B NN NN O
cells NN NN O
in NN NN O
which NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
the NN NN O
predominantly NN NN O
expressed NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
most NN NN O
likely NN NN O
interpretation NN NN O
of NN NN O
our NN NN O
results NN NN O
is NN NN O
that NN NN O
both NN NN O
the NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
can NN NN O
activate NN NN O
U2 NN NN O
snRNA NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
results NN NN O
also NN NN O
revealed NN NN O
a NN NN O
similar NN NN O
functional NN NN O
cooperation NN NN O
between NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
bind NN NN O
to NN NN O
the NN NN O
Oct NN NN O
and NN NN O
the NN NN O
adjacent NN NN O
Sp NN NN B-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
BJA NN NN O
- NN NN O
B NN NN O
cells NN NN O
, NN NN O
as NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
since NN NN O
a NN NN O
template NN NN O
which NN NN O
contains NN NN O
a NN NN O
weak NN NN O
binding NN NN O
site NN NN O
for NN NN O
OTFs NN NN O
expresses NN NN O
wild NN NN O
- NN NN O
type NN NN O
levels NN NN O
of NN NN O
U2 NN NN O
snRNA NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
when NN NN O
the NN NN O
weak NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
site NN NN O
is NN NN O
combined NN NN O
with NN NN O
a NN NN O
Sp NN NN B-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
Kappa NN NN O
B NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
differentially NN NN O
inhibited NN NN O
by NN NN O
enhancer NN NN O
mutations NN NN O
and NN NN O
biological NN NN O
oxidation NN NN O
. NN NN O
   
Kappa NN NN O
B NN NN O
( NN NN O
kappa NN NN O
B NN NN O
) NN NN O
enhancer NN NN O
binding NN NN O
proteins NN NN O
isolated NN NN O
from NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
activated NN NN O
human NN NN O
T NN NN O
cells NN NN O
produce NN NN O
two NN NN O
distinct NN NN O
nucleoprotein NN NN O
complexes NN NN O
when NN NN O
incubated NN NN O
with NN NN O
the NN NN O
kappa NN NN O
B NN NN O
element NN NN O
from NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
. NN NN O
   
These NN NN O
two NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
are NN NN O
composed NN NN O
of NN NN O
at NN NN O
least NN NN O
four NN NN O
host NN NN O
proteins NN NN O
( NN NN O
p50 NN NN B-Protein
, NN NN O
p55 NN NN B-Protein
, NN NN O
p75 NN NN B-Protein
, NN NN O
p85 NN NN B-Protein
) NN NN O
, NN NN O
each NN NN O
of NN NN O
which NN NN O
shares NN NN O
structural NN NN O
similarity NN NN O
with NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
oncogene NN NN O
product NN NN O
. NN NN O
   
Nuclear NN NN O
expression NN NN O
of NN NN O
these NN NN O
proteins NN NN O
is NN NN O
induced NN NN O
with NN NN O
distinctly NN NN O
biphasic NN NN O
kinetics NN NN O
following NN NN O
phorbol NN NN O
ester NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
( NN NN O
p55 NN NN B-Protein
/ NN NN O
p75 NN NN B-Protein
early NN NN O
and NN NN O
p50 NN NN B-Protein
/ NN NN O
p85 NN NN B-Protein
late NN NN O
) NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
protein NN NN O
crosslinking NN NN O
studies NN NN O
have NN NN O
revealed NN NN O
that NN NN O
the NN NN O
more NN NN O
rapidly NN NN O
migrating NN NN O
B2 NN NN O
complex NN NN O
contains NN NN O
both NN NN O
p50 NN NN B-Protein
and NN NN O
p55 NN NN B-Protein
while NN NN O
the NN NN O
more NN NN O
slowly NN NN O
migrating NN NN O
B1 NN NN O
complex NN NN O
is NN NN O
composed NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p55 NN NN B-Protein
, NN NN O
p75 NN NN B-Protein
, NN NN O
and NN NN O
p85 NN NN B-Protein
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
kappa NN NN O
B NN NN O
enhancer NN NN O
( NN NN O
GGGGAATCTCCC NN NN O
) NN NN O
has NN NN O
revealed NN NN O
that NN NN O
the NN NN O
binding NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
p55 NN NN B-Protein
( NN NN O
B2 NN NN O
complex NN NN O
) NN NN O
is NN NN O
particularly NN NN O
sensitive NN NN O
to NN NN O
alteration NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
triplet NN NN O
of NN NN O
deoxyguanosine NN NN O
residues NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
formation NN NN O
of NN NN O
the NN NN O
B1 NN NN O
complex NN NN O
, NN NN O
reflecting NN NN O
the NN NN O
binding NN NN O
of NN NN O
p75 NN NN B-Protein
and NN NN O
p85 NN NN B-Protein
, NN NN O
critically NN NN O
depends NN NN O
upon NN NN O
the NN NN O
more NN NN O
3 NN NN O
' NN NN O
sequences NN NN O
of NN NN O
this NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
DNA NN NN O
binding NN NN O
by NN NN O
all NN NN O
four NN NN O
of NN NN O
these NN NN O
Rel NN NN O
- NN NN O
related NN NN O
factors NN NN O
is NN NN O
blocked NN NN O
by NN NN O
selective NN NN O
chemical NN NN O
modification NN NN O
of NN NN O
lysine NN NN O
and NN NN O
arginine NN NN O
residues NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
both NN NN O
of NN NN O
these NN NN O
basic NN NN O
amino NN NN O
acids NN NN O
are NN NN O
required NN NN O
for NN NN O
binding NN NN O
to NN NN O
the NN NN O
kappa NN NN O
B NN NN O
element NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
covalent NN NN O
modification NN NN O
of NN NN O
free NN NN O
sulfhydryl NN NN O
groups NN NN O
with NN NN O
diamide NN NN O
( NN NN O
reversible NN NN O
) NN NN O
or NN NN O
N NN NN O
- NN NN O
ethylmaleimide NN NN O
( NN NN O
irreversible NN NN O
) NN NN O
results NN NN O
in NN NN O
a NN NN O
complete NN NN O
loss NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
mild NN NN O
oxidation NN NN O
with NN NN O
glucose NN NN B-Protein
oxidase NN NN I-Protein
selectively NN NN O
inhibits NN NN O
p75 NN NN B-Protein
and NN NN O
p85 NN NN B-Protein
binding NN NN O
while NN NN O
not NN NN O
blocking NN NN O
p50 NN NN B-Protein
and NN NN O
p55 NN NN B-Protein
interactions NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
reduced NN NN O
cysteine NN NN O
thiols NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
this NN NN O
family NN NN O
of NN NN O
Rel NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Activity NN NN O
of NN NN O
the NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN O
in NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
two NN NN O
nuclear NN NN O
proteins NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
consisting NN NN O
of NN NN O
subunits NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
) NN NN O
by NN NN O
itself NN NN O
, NN NN O
also NN NN O
called NN NN O
KBF1 NN NN B-Protein
, NN NN O
are NN NN O
constitutively NN NN O
expressed NN NN O
and NN NN O
localized NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
IARC NN NN O
301 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
define NN NN O
the NN NN O
roles NN NN O
of NN NN O
these NN NN O
two NN NN O
factors NN NN O
, NN NN O
which NN NN O
bind NN NN O
to NN NN O
the NN NN O
same NN NN O
kappa NN NN O
B NN NN O
enhancers NN NN O
, NN NN O
in NN NN O
transcription NN NN O
activation NN NN O
we NN NN O
have NN NN O
prepared NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
between NN NN O
IARC NN NN O
301 NN NN O
. NN NN O
5 NN NN O
and NN NN O
a NN NN O
murine NN NN O
myeloma NN NN O
. NN NN O
   
Most NN NN O
hybrids NN NN O
express NN NN O
both NN NN O
KBF1 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
their NN NN O
nuclei NN NN O
, NN NN O
but NN NN O
one NN NN O
hybrid NN NN O
expresses NN NN O
only NN NN O
KBF1 NN NN B-Protein
. NN NN O
   
The NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
is NN NN O
functional NN NN O
only NN NN O
in NN NN O
the NN NN O
hybrids NN NN O
expressing NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
show NN NN O
that NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
necessary NN NN O
to NN NN O
activate NN NN O
the NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
, NN NN O
while NN NN O
KBF1 NN NN B-Protein
by NN NN O
itself NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
KBF1 NN NN B-Protein
is NN NN O
a NN NN O
competitive NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
discuss NN NN O
how NN NN O
these NN NN O
factors NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
transient NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
interferon NN NN B-Protein
beta NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
by NN NN O
purified NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
a NN NN O
novel NN NN O
TH NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
human NN NN O
interferon NN NN B-Protein
beta NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
) NN NN O
regulatory NN NN O
element NN NN O
consists NN NN O
of NN NN O
multiple NN NN O
enhanson NN NN O
domains NN NN O
which NN NN O
are NN NN O
targets NN NN O
for NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
To NN NN O
further NN NN O
characterize NN NN O
the NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
interactions NN NN O
mediating NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
induction NN NN O
, NN NN O
positive NN NN O
regulatory NN NN O
domain NN NN O
( NN NN O
PRD NN NN O
) NN NN O
II NN NN O
binding NN NN O
proteins NN NN O
were NN NN O
purified NN NN O
from NN NN O
phorbol NN NN O
ester NN NN O
induced NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
from NN NN O
IFN NN NN O
primed NN NN O
, NN NN O
cycloheximide NN NN O
/ NN NN O
polyinosinic NN NN O
- NN NN O
polycytidylic NN NN O
acid NN NN O
treated NN NN O
HeLa NN NN O
S3 NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
two NN NN O
major NN NN O
proteins NN NN O
of NN NN O
52 NN NN O
and NN NN O
45 NN NN O
kilodaltons NN NN O
( NN NN O
kD NN NN O
) NN NN O
copurified NN NN O
with NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
, NN NN O
whereas NN NN O
from NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
four NN NN O
proteins NN NN O
- NN NN O
- NN NN O
a NN NN O
major NN NN O
protein NN NN O
of NN NN O
52 NN NN O
kD NN NN O
and NN NN O
three NN NN O
minor NN NN O
proteins NN NN O
of NN NN O
82 NN NN O
, NN NN O
67 NN NN O
, NN NN O
and NN NN O
43 NN NN O
- NN NN O
47 NN NN O
kD NN NN O
- NN NN O
- NN NN O
were NN NN O
purified NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
an NN NN O
induction NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
was NN NN O
purified NN NN O
from NN NN O
HeLa NN NN O
cells NN NN O
that NN NN O
interacted NN NN O
with NN NN O
the NN NN O
( NN NN O
AAGTGA NN NN O
) NN NN O
4 NN NN O
tetrahexamer NN NN O
sequence NN NN O
and NN NN O
the NN NN O
PRDI NN NN O
domain NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
is NN NN O
immunologically NN NN O
distinct NN NN O
from NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
ISGF2 NN NN B-Protein
. NN NN O
   
Uninduced NN NN O
or NN NN O
Sendai NN NN O
virus NN NN O
induced NN NN O
HeLa NN NN O
extracts NN NN O
were NN NN O
used NN NN O
to NN NN O
examine NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
using NN NN O
a NN NN O
series NN NN O
of NN NN O
IFN NN NN B-Protein
beta NN NN I-Protein
promoter NN NN O
deletions NN NN O
. NN NN O
   
Deletions NN NN O
upstream NN NN O
of NN NN O
the NN NN O
PRDII NN NN O
element NN NN O
increased NN NN O
transcription NN NN O
in NN NN O
the NN NN O
uninduced NN NN O
extract NN NN O
, NN NN O
indicating NN NN O
predominantly NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
- NN NN O
4 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
promoter NN NN O
transcription NN NN O
was NN NN O
observed NN NN O
in NN NN O
Sendai NN NN O
virus NN NN O
induced NN NN O
extracts NN NN O
, NN NN O
and NN NN O
deletion NN NN O
of NN NN O
PRDI NN NN O
and NN NN O
PRDII NN NN O
elements NN NN O
decreased NN NN O
this NN NN O
induced NN NN O
level NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
When NN NN O
purified NN NN O
PRDII NN NN O
and NN NN O
tetrahexamer NN NN O
binding NN NN O
proteins NN NN O
were NN NN O
added NN NN O
to NN NN O
the NN NN O
induced NN NN O
extract NN NN O
, NN NN O
a NN NN O
4 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
transcription NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
These NN NN O
experiments NN NN O
demonstrate NN NN O
that NN NN O
it NN NN O
is NN NN O
possible NN NN O
to NN NN O
modulate NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
transcription NN NN O
in NN NN O
vitro NN NN O
but NN NN O
indicate NN NN O
that NN NN O
additional NN NN O
proteins NN NN O
may NN NN O
be NN NN O
required NN NN O
to NN NN O
fully NN NN O
activate NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
transcription NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
induced NN NN O
in NN NN O
adherent NN NN O
monocytes NN NN O
that NN NN O
encodes NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
have NN NN O
cloned NN NN O
a NN NN O
group NN NN O
of NN NN O
cDNAs NN NN O
representing NN NN O
mRNAs NN NN O
that NN NN O
are NN NN O
rapidly NN NN O
induced NN NN O
following NN NN O
adherence NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
induced NN NN O
transcripts NN NN O
( NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
of NN NN O
317 NN NN O
amino NN NN O
acids NN NN O
with NN NN O
one NN NN O
domain NN NN O
containing NN NN O
five NN NN O
tandem NN NN O
repeats NN NN O
of NN NN O
the NN NN O
cdc10 NN NN O
/ NN NN O
ankyrin NN NN O
motif NN NN O
, NN NN O
which NN NN O
is NN NN O
60 NN NN O
% NN NN O
similar NN NN O
( NN NN O
46 NN NN O
% NN NN O
identical NN NN O
) NN NN O
to NN NN O
the NN NN O
ankyrin NN NN O
repeat NN NN O
region NN NN O
of NN NN O
the NN NN O
precursor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
KBF1 NN NN B-Protein
p50 NN NN B-Protein
. NN NN O
   
The NN NN O
C NN NN O
- NN NN O
terminus NN NN O
has NN NN O
a NN NN O
putative NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
phosphorylation NN NN O
site NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
translated NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
protein NN NN O
was NN NN O
found NN NN O
to NN NN O
specifically NN NN O
inhibit NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
but NN NN O
not NN NN O
that NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
KBF1 NN NN B-Protein
factor NN NN O
or NN NN O
of NN NN O
other NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
cDNA NN NN O
encodes NN NN O
an NN NN O
I NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
protein NN NN O
that NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
regulation NN NN O
of NN NN O
transcriptional NN NN O
responses NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
including NN NN O
adhesion NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
of NN NN O
monocyte NN NN O
activation NN NN O
. NN NN O
   
Platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
induces NN NN O
phospholipid NN NN O
turnover NN NN O
, NN NN O
calcium NN NN O
flux NN NN O
, NN NN O
arachidonic NN NN O
acid NN NN O
liberation NN NN O
, NN NN O
eicosanoid NN NN O
generation NN NN O
, NN NN O
and NN NN O
oncogene NN NN O
expression NN NN O
in NN NN O
a NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
is NN NN O
a NN NN O
potent NN NN O
mediator NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
the NN NN O
actions NN NN O
of NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
have NN NN O
centered NN NN O
mainly NN NN O
around NN NN O
neutrophils NN NN O
, NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
platelets NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
begin NN NN O
to NN NN O
uncover NN NN O
the NN NN O
influence NN NN O
of NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
on NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Employing NN NN O
the NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
SKW6 NN NN O
. NN NN O
4 NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
significantly NN NN O
alters NN NN O
membrane NN NN O
phospholipid NN NN O
metabolism NN NN O
indicated NN NN O
by NN NN O
the NN NN O
incorporation NN NN O
of NN NN O
32P NN NN O
into NN NN O
phosphatidylcholine NN NN O
, NN NN O
phosphatidylinositol NN NN O
, NN NN O
and NN NN O
phosphatidic NN NN O
acid NN NN O
but NN NN O
not NN NN O
significantly NN NN O
into NN NN O
phosphatidylethanolamine NN NN O
at NN NN O
concentrations NN NN O
ranging NN NN O
from NN NN O
10 NN NN O
( NN NN O
- NN NN O
9 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
. NN NN O
   
The NN NN O
inactive NN NN O
precursor NN NN O
, NN NN O
lyso NN NN O
- NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
, NN NN O
at NN NN O
a NN NN O
concentration NN NN O
as NN NN O
high NN NN O
as NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
M NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
any NN NN O
of NN NN O
the NN NN O
membrane NN NN O
phospholipids NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
from NN NN O
10 NN NN O
( NN NN O
- NN NN O
12 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
induced NN NN O
rapid NN NN O
and NN NN O
significant NN NN O
elevation NN NN O
in NN NN O
intracellular NN NN O
calcium NN NN O
levels NN NN O
, NN NN O
whereas NN NN O
lyso NN NN O
- NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
was NN NN O
again NN NN O
ineffective NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrate NN NN O
the NN NN O
impact NN NN O
of NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
binding NN NN O
to NN NN O
B NN NN O
cells NN NN O
by NN NN O
measuring NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
induced NN NN O
arachidonic NN NN O
acid NN NN O
release NN NN O
and NN NN O
5 NN NN O
- NN NN O
hydroxyeicosatetraenoic NN NN O
acid NN NN O
production NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
was NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
transcription NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
. NN NN O
   
Finally NN NN O
we NN NN O
explored NN NN O
the NN NN O
possible NN NN O
role NN NN O
of NN NN O
5 NN NN O
- NN NN O
hydroxyeicosatetraenoic NN NN O
acid NN NN O
as NN NN O
a NN NN O
regulator NN NN O
of NN NN O
arachidonic NN NN O
acid NN NN O
liberation NN NN O
demonstrating NN NN O
that NN NN O
endogenous NN NN O
5 NN NN B-Protein
- NN NN I-Protein
lipoxygenase NN NN I-Protein
activity NN NN O
modulates NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
induced NN NN O
arachidonic NN NN O
acid NN NN O
release NN NN O
perhaps NN NN O
acting NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
phospholipase NN NN B-Protein
A2 NN NN I-Protein
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
is NN NN O
shown NN NN O
here NN NN O
to NN NN O
have NN NN O
a NN NN O
direct NN NN O
and NN NN O
profound NN NN O
effect NN NN O
on NN NN O
a NN NN O
pure NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
protein NN NN O
phosphatases NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
induces NN NN O
AP1 NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
protein NN NN O
phosphatases NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
Jurkat NN NN O
cells NN NN O
were NN NN O
treated NN NN O
with NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
type NN NN O
1 NN NN O
and NN NN O
2A NN NN O
phosphatases NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
extracts NN NN O
were NN NN O
examined NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
AP1 NN NN O
as NN NN O
a NN NN O
measure NN NN O
of NN NN O
early NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Okadaic NN NN O
acid NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
potent NN NN O
inducer NN NN O
of NN NN O
AP1 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
phorbol NN NN O
esters NN NN O
such NN NN O
as NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
the NN NN O
induction NN NN O
of NN NN O
AP1 NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
occurs NN NN O
predominantly NN NN O
by NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
jun NN NN O
and NN NN O
fos NN NN O
family NN NN O
of NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
while NN NN O
the NN NN O
addition NN NN O
of NN NN O
phytohemagglutinin NN NN B-Protein
further NN NN O
enhanced NN NN O
the NN NN O
induction NN NN O
of NN NN O
AP1 NN NN O
, NN NN O
the NN NN O
addition NN NN O
of NN NN O
PMA NN NN O
inhibited NN NN O
it NN NN O
. NN NN O
   
Okadaic NN NN O
acid NN NN O
treatment NN NN O
was NN NN O
found NN NN O
to NN NN O
dramatically NN NN O
increase NN NN O
mRNA NN NN O
transcripts NN NN O
of NN NN O
the NN NN O
jun NN NN O
family NN NN O
of NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
including NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
junD NN NN B-Protein
, NN NN O
and NN NN O
junB NN NN B-Protein
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
the NN NN O
fos NN NN O
family NN NN O
including NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
fra NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
By NN NN O
comparison NN NN O
, NN NN O
PMA NN NN O
is NN NN O
a NN NN O
very NN NN O
inefficient NN NN O
inducer NN NN O
of NN NN O
the NN NN O
jun NN NN O
gene NN NN O
family NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
its NN NN O
effect NN NN O
on NN NN O
the NN NN O
induction NN NN O
of NN NN O
AP1 NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
PMA NN NN O
inhibits NN NN O
the NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
promoter NN NN O
constructs NN NN O
confirmed NN NN O
the NN NN O
marked NN NN O
difference NN NN O
between NN NN O
PMA NN NN O
and NN NN O
okadaic NN NN O
acid NN NN O
in NN NN O
inducing NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcription NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
AP1 NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
suggests NN NN O
that NN NN O
protein NN NN B-Protein
phosphatases NN NN I-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
( NN NN O
PP1 NN NN O
and NN NN O
PP2A NN NN O
) NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
as NN NN O
important NN NN O
negative NN NN O
regulators NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP1 NN NN O
. NN NN O
   
Transactivation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
promoter NN NN O
by NN NN O
human NN NN O
herpesvirus NN NN O
6 NN NN O
( NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
) NN NN O
strains NN NN O
GS NN NN O
and NN NN O
Z NN NN O
- NN NN O
29 NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
identification NN NN O
of NN NN O
transactivating NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
( NN NN O
GS NN NN O
) NN NN O
gene NN NN O
fragments NN NN O
. NN NN O
   
Human NN NN O
herpesvirus NN NN O
6 NN NN O
( NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
) NN NN O
can NN NN O
activate NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
promoter NN NN O
and NN NN O
accelerate NN NN O
cytopathic NN NN O
effects NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
study NN NN O
examines NN NN O
the NN NN O
regions NN NN O
of NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
required NN NN O
for NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
transactivation NN NN O
in NN NN O
a NN NN O
heterogeneous NN NN O
population NN NN O
of NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
with NN NN O
or NN NN O
without NN NN O
antigenic NN NN O
stimulation NN NN O
. NN NN O
   
Two NN NN O
different NN NN O
strains NN NN O
of NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
, NN NN O
GS NN NN O
and NN NN O
Z29 NN NN O
, NN NN O
transactivated NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
GS NN NN O
strain NN NN O
transactivated NN NN O
the NN NN O
promoter NN NN O
in NN NN O
both NN NN O
stimulated NN NN O
and NN NN O
resting NN NN O
T NN NN O
cells NN NN O
, NN NN O
while NN NN O
the NN NN O
Z29 NN NN O
strain NN NN O
increased NN NN O
HIV NN NN O
promoter NN NN O
activity NN NN O
only NN NN O
in NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Three NN NN O
DNA NN NN O
clones NN NN O
containing NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
( NN NN O
GS NN NN O
) NN NN O
genomic NN NN O
fragments NN NN O
transactivated NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
in NN NN O
cotransfected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
21 NN NN O
. NN NN O
4 NN NN O
- NN NN O
kb NN NN O
DNA NN NN O
clone NN NN O
, NN NN O
pZVB70 NN NN O
, NN NN O
showed NN NN O
the NN NN O
highest NN NN O
transactivating NN NN O
ability NN NN O
, NN NN O
while NN NN O
two NN NN O
other NN NN O
DNA NN NN O
fragments NN NN O
, NN NN O
pZVB10 NN NN O
( NN NN O
6 NN NN O
. NN NN O
2 NN NN O
kb NN NN O
) NN NN O
and NN NN O
pZVH14 NN NN O
( NN NN O
8 NN NN O
. NN NN O
7 NN NN O
kb NN NN O
) NN NN O
, NN NN O
showed NN NN O
lower NN NN O
activity NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
clones NN NN O
, NN NN O
pZVH14 NN NN O
, NN NN O
activated NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
construct NN NN O
containing NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
mutated NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
promoter NN NN O
was NN NN O
not NN NN O
transactivated NN NN O
during NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
( NN NN O
GS NN NN O
) NN NN O
infection NN NN O
or NN NN O
after NN NN O
cotransfection NN NN O
with NN NN O
pZVB70 NN NN O
or NN NN O
pZVB10 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
of NN NN O
the NN NN O
HIV NN NN O
promoter NN NN O
are NN NN O
essential NN NN O
for NN NN O
its NN NN O
transactivation NN NN O
during NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
( NN NN O
GS NN NN O
) NN NN O
infection NN NN O
. NN NN O
   
By NN NN O
increasing NN NN O
HIV NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
may NN NN O
consequently NN NN O
increase NN NN O
HIV NN NN O
replication NN NN O
, NN NN O
leading NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
cytopathic NN NN O
effect NN NN O
on NN NN O
coinfected NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
expression NN NN O
by NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
: NN NN O
role NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
and NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Macrophage NN NN B-Protein
- NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
, NN NN O
also NN NN O
referred NN NN O
to NN NN O
as NN NN O
CSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
regulates NN NN O
the NN NN O
survival NN NN O
, NN NN O
growth NN NN O
, NN NN O
differentiation NN NN O
and NN NN O
functional NN NN O
activity NN NN O
of NN NN O
monocytes NN NN O
by NN NN O
binding NN NN O
to NN NN O
a NN NN O
single NN NN O
class NN NN O
of NN NN O
high NN NN O
- NN NN O
affinity NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
, NN NN O
known NN NN O
to NN NN O
be NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fms NN NN I-Protein
protooncogene NN NN O
. NN NN O
   
The NN NN O
detection NN NN O
of NN NN O
both NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fms NN NN I-Protein
expression NN NN O
by NN NN O
cells NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
lineage NN NN O
has NN NN O
suggested NN NN O
that NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
may NN NN O
act NN NN O
by NN NN O
an NN NN O
autocrine NN NN O
mechanism NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
shown NN NN O
that NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
can NN NN O
induce NN NN O
the NN NN O
expression NN NN O
of NN NN O
its NN NN O
own NN NN O
gene NN NN O
. NN NN O
   
Although NN NN O
sensitivity NN NN O
to NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
can NN NN O
be NN NN O
modulated NN NN O
by NN NN O
regulation NN NN O
of NN NN O
receptor NN NN O
expression NN NN O
and NN NN O
function NN NN O
, NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
responsiveness NN NN O
is NN NN O
largely NN NN O
determined NN NN O
at NN NN O
a NN NN O
postreceptor NN NN O
level NN NN O
. NN NN O
   
To NN NN O
date NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
intracellular NN NN O
pathway NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
signal NN NN O
transduction NN NN O
. NN NN O
   
We NN NN O
have NN NN O
therefore NN NN O
investigated NN NN O
the NN NN O
changes NN NN O
in NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
activity NN NN O
upon NN NN O
exposure NN NN O
of NN NN O
monocytes NN NN O
to NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
activates NN NN O
and NN NN O
translocates NN NN O
PKC NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
PKC NN NN O
by NN NN O
the NN NN O
isoquinoline NN NN O
derivative NN NN O
H7 NN NN O
abolishes NN NN O
induction NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
by NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
activation NN NN O
of NN NN O
PKC NN NN O
was NN NN O
pertussis NN NN O
- NN NN O
toxin NN NN O
- NN NN O
sensitive NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
detection NN NN O
of NN NN O
an NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
- NN NN O
induced NN NN O
blood NN NN O
monocytes NN NN O
but NN NN O
not NN NN O
in NN NN O
monocytes NN NN O
exposed NN NN O
to NN NN O
medium NN NN O
treatment NN NN O
only NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
induction NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
involves NN NN O
G NN NN O
proteins NN NN O
, NN NN O
PKC NN NN O
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
HIV1 NN NN O
infection NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
promotes NN NN O
induction NN NN O
or NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
KB NN NN O
- NN NN O
related NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
1991 NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
, NN NN O
using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
that NN NN O
3 NN NN O
different NN NN O
factors NN NN O
( NN NN O
termed NN NN O
B1 NN NN O
, NN NN O
B2 NN NN O
and NN NN O
B3 NN NN O
) NN NN O
with NN NN O
affinity NN NN O
for NN NN O
the NN NN O
KB NN NN O
- NN NN O
enhancer NN NN O
target NN NN O
sequence NN NN O
were NN NN O
specifically NN NN O
detected NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
HIV1 NN NN O
- NN NN O
infected NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
The NN NN O
B2 NN NN O
factor NN NN O
was NN NN O
induced NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
these NN NN O
cells NN NN O
only NN NN O
upon NN NN O
HIV1 NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
B3 NN NN O
factor NN NN O
was NN NN O
only NN NN O
slightly NN NN O
evident NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
uninfected NN NN O
cells NN NN O
but NN NN O
was NN NN O
readily NN NN O
detectable NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
infected NN NN O
monocytes NN NN O
. NN NN O
   
Its NN NN O
expression NN NN O
remained NN NN O
very NN NN O
low NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
HIV1 NN NN O
- NN NN O
infected NN NN O
macrophages NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
B2 NN NN O
factor NN NN O
is NN NN O
expressed NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
as NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
indicating NN NN O
that NN NN O
it NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
an NN NN O
inhibitor NN NN O
( NN NN O
IKB NN NN O
) NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
remained NN NN O
clustered NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
was NN NN O
translocated NN NN O
to NN NN O
the NN NN O
nuclei NN NN O
only NN NN O
after NN NN O
HIV1 NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
B3 NN NN O
factor NN NN O
is NN NN O
detected NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
only NN NN O
when NN NN O
cells NN NN O
are NN NN O
HIV1 NN NN O
- NN NN O
infected NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
HIV1 NN NN O
infection NN NN O
in NN NN O
the NN NN O
expression NN NN O
and NN NN O
the NN NN O
translocation NN NN O
of NN NN O
these NN NN O
factors NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
during NN NN O
monocyte NN NN O
differentiation NN NN O
is NN NN O
associated NN NN O
with NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Cells NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
- NN NN O
macrophage NN NN O
lineage NN NN O
are NN NN O
important NN NN O
targets NN NN O
of NN NN O
HIV NN NN O
infection NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
phenotypic NN NN O
differentiation NN NN O
of NN NN O
monocyte NN NN O
cell NN NN O
lines NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
or NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
expression NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
with NN NN O
such NN NN O
differentiation NN NN O
, NN NN O
HIV NN NN O
transcription NN NN O
, NN NN O
monitored NN NN O
using NN NN O
an NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
reporter NN NN O
gene NN NN O
construct NN NN O
, NN NN O
is NN NN O
activated NN NN O
in NN NN O
such NN NN O
cells NN NN O
under NN NN O
the NN NN O
influence NN NN O
of NN NN O
enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
in NN NN O
a NN NN O
promonocyte NN NN O
cell NN NN O
line NN NN O
chronically NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
and NN NN O
HIV NN NN O
transcription NN NN O
were NN NN O
enhanced NN NN O
on NN NN O
stimulation NN NN O
with NN NN O
phorbol NN NN O
ester NN NN O
or NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
monocyte NN NN O
cell NN NN O
lines NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
or NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
induces NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
activates NN NN O
HIV NN NN O
transcription NN NN O
. NN NN O
   
Such NN NN O
a NN NN O
process NN NN O
may NN NN O
have NN NN O
fundamental NN NN O
implications NN NN O
in NN NN O
AIDS NN NN O
pathogenesis NN NN O
in NN NN O
vivo NN NN O
and NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
disease NN NN O
progression NN NN O
induced NN NN O
by NN NN O
opportunistic NN NN O
infections NN NN O
directly NN NN O
or NN NN O
indirectly NN NN O
involving NN NN O
macrophages NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
jun NN NN B-Protein
B NN NN I-Protein
and NN NN O
jun NN NN B-Protein
D NN NN I-Protein
proto NN NN O
- NN NN O
oncogenes NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
- NN NN O
blood NN NN O
granulocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
purified NN NN O
human NN NN O
peripheral NN NN O
- NN NN O
blood NN NN O
granulocytes NN NN O
express NN NN O
constitutively NN NN O
significant NN NN O
levels NN NN O
of NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
jun NN NN B-Protein
B NN NN I-Protein
and NN NN O
jun NN NN B-Protein
D NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Upon NN NN O
functional NN NN O
activation NN NN O
of NN NN O
granulocytes NN NN O
by NN NN O
4 NN NN O
beta NN NN O
- NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
the NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
jun NN NN B-Protein
B NN NN I-Protein
and NN NN O
jun NN NN B-Protein
D NN NN I-Protein
transcripts NN NN O
were NN NN O
increased NN NN O
. NN NN O
   
The NN NN O
three NN NN O
jun NN NN O
genes NN NN O
showed NN NN O
a NN NN O
similar NN NN O
time NN NN O
course NN NN O
in NN NN O
their NN NN O
induction NN NN O
by NN NN O
PMA NN NN O
, NN NN O
maximal NN NN O
mRNA NN NN O
levels NN NN O
being NN NN O
reached NN NN O
after NN NN O
60 NN NN O
min NN NN O
of NN NN O
induction NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
jun NN NN B-Protein
B NN NN I-Protein
and NN NN O
jun NN NN B-Protein
D NN NN I-Protein
genes NN NN O
might NN NN O
be NN NN O
involved NN NN O
in NN NN O
terminal NN NN O
granulocyte NN NN O
differentiation NN NN O
or NN NN O
in NN NN O
regulating NN NN O
granulocyte NN NN O
functionality NN NN O
. NN NN O
   
Transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
suppresses NN NN O
human NN NN O
B NN NN O
lymphocyte NN NN O
Ig NN NN O
production NN NN O
by NN NN O
inhibiting NN NN O
synthesis NN NN O
and NN NN O
the NN NN O
switch NN NN O
from NN NN O
the NN NN O
membrane NN NN O
form NN NN O
to NN NN O
the NN NN O
secreted NN NN O
form NN NN O
of NN NN O
Ig NN NN O
mRNA NN NN O
. NN NN O
   
Transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
( NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
) NN NN O
inhibits NN NN O
B NN NN O
cell NN NN O
Ig NN NN O
secretion NN NN O
and NN NN O
reduces NN NN O
B NN NN O
cell NN NN O
membrane NN NN O
Ig NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
to NN NN O
human NN NN O
B NN NN O
lymphocyte NN NN O
cultures NN NN O
stimulated NN NN O
with NN NN O
Staphylococcus NN NN O
aureus NN NN O
Cowan NN NN O
strain NN NN O
I NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
completely NN NN O
inhibited NN NN O
B NN NN O
cell NN NN O
Ig NN NN O
secretion NN NN O
( NN NN O
greater NN NN O
than NN NN O
90 NN NN O
% NN NN O
) NN NN O
and NN NN O
decreased NN NN O
B NN NN O
cell NN NN O
surface NN NN O
IgM NN NN O
, NN NN O
IgD NN NN O
, NN NN O
kappa NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
, NN NN O
and NN NN O
lambda NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
expression NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
had NN NN O
only NN NN O
minimal NN NN O
effects NN NN O
on NN NN O
two NN NN O
other NN NN O
B NN NN O
cell NN NN O
membrane NN NN O
proteins NN NN O
, NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
and NN NN O
CD20 NN NN B-Protein
. NN NN O
   
Internal NN NN O
labeling NN NN O
with NN NN O
[ NN NN O
35S NN NN O
] NN NN O
methionine NN NN O
and NN NN O
immunoprecipitation NN NN O
with NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
, NN NN O
anti NN NN O
- NN NN O
kappa NN NN B-Protein
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
lambda NN NN B-Protein
antibodies NN NN O
revealed NN NN O
a NN NN O
striking NN NN O
reduction NN NN O
in NN NN O
kappa NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
A NN NN O
less NN NN O
pronounced NN NN O
reduction NN NN O
in NN NN O
lambda NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
and NN NN O
microH NN NN O
chain NN NN O
was NN NN O
also NN NN O
noted NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
RNA NN NN O
purified NN NN O
from NN NN O
B NN NN O
cells NN NN O
treated NN NN O
with NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
for NN NN O
varying NN NN O
time NN NN O
intervals NN NN O
revealed NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
steady NN NN O
state NN NN O
kappa NN NN B-Protein
and NN NN O
lambda NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
in NN NN O
the NN NN O
switch NN NN O
from NN NN O
the NN NN O
membrane NN NN O
forms NN NN O
of NN NN O
mu NN NN O
and NN NN O
gamma NN NN O
to NN NN O
their NN NN O
respective NN NN O
secreted NN NN O
forms NN NN O
was NN NN O
noted NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
experiments NN NN O
demonstrated NN NN O
decreased NN NN O
transcription NN NN O
of NN NN O
kappa NN NN B-Protein
L NN NN I-Protein
chain NN NN I-Protein
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
on NN NN O
two NN NN O
transcriptional NN NN O
regulatory NN NN O
factors NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
kappa NN NN O
B NN NN O
, NN NN O
known NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
Ig NN NN O
gene NN NN O
transcription NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
levels NN NN O
and NN NN O
both NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
were NN NN O
not NN NN O
altered NN NN O
by NN NN O
treatment NN NN O
with NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
levels NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
which NN NN O
is NN NN O
not NN NN O
known NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
B NN NN O
cell NN NN O
Ig NN NN O
production NN NN O
, NN NN O
were NN NN O
reduced NN NN O
by NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
decreases NN NN O
B NN NN O
lymphocyte NN NN O
Ig NN NN O
secretion NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
Ig NN NN O
mRNA NN NN O
and NN NN O
inhibiting NN NN O
the NN NN O
switch NN NN O
from NN NN O
the NN NN O
membrane NN NN O
form NN NN O
to NN NN O
the NN NN O
secreted NN NN O
forms NN NN O
of NN NN O
mu NN NN O
and NN NN O
gamma NN NN O
mRNA NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
inhibits NN NN O
Ig NN NN O
chain NN NN O
synthesis NN NN O
is NN NN O
unclear NN NN O
although NN NN O
it NN NN O
does NN NN O
not NN NN O
involve NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
their NN NN O
respective NN NN O
target NN NN O
sequences NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
by NN NN O
cysteine NN NN O
and NN NN O
cysteine NN NN O
derivatives NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
proviral NN NN O
DNA NN NN O
contains NN NN O
two NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
individuals NN NN O
have NN NN O
, NN NN O
on NN NN O
average NN NN O
, NN NN O
abnormally NN NN O
high NN NN O
levels NN NN O
of NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
abnormally NN NN O
low NN NN O
plasma NN NN O
cysteine NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
cysteine NN NN O
and NN NN O
related NN NN O
thiols NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
experiments NN NN O
in NN NN O
this NN NN O
report NN NN O
show NN NN O
that NN NN O
cysteine NN NN O
or NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
raise NN NN O
the NN NN O
intracellular NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
level NN NN O
and NN NN O
inhibit NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
persistently NN NN O
infected NN NN O
Molt NN NN O
- NN NN O
4 NN NN O
and NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
appears NN NN O
not NN NN O
to NN NN O
be NN NN O
directly NN NN O
correlated NN NN O
with NN NN O
GSH NN NN O
levels NN NN O
. NN NN O
   
Cysteine NN NN O
and NN NN O
NAC NN NN O
also NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
as NN NN O
determined NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
- NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
gene NN NN O
expression NN NN O
under NN NN O
control NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sites NN NN O
in NN NN O
uninfected NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
the NN NN O
cysteine NN NN O
deficiency NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
individuals NN NN O
may NN NN O
cause NN NN O
an NN NN O
over NN NN O
- NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
genes NN NN O
and NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
NAC NN NN O
may NN NN O
be NN NN O
considered NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
A NN NN O
nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
that NN NN O
interacts NN NN O
with NN NN O
a NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
essential NN NN O
for NN NN O
its NN NN O
induction NN NN O
in NN NN O
responses NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
: NN NN O
purification NN NN O
from NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
line NN NN O
Jurkat NN NN O
cells NN NN O
and NN NN O
similarity NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
by NN NN O
antigen NN NN O
, NN NN O
lectin NN NN O
, NN NN O
or NN NN O
a NN NN O
combination NN NN O
of NN NN O
phorbol NN NN O
- NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
A23187 NN NN O
) NN NN O
leads NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
genes NN NN O
for NN NN O
a NN NN O
set NN NN O
of NN NN O
lymphokines NN NN O
, NN NN O
including NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
in NN NN O
earlier NN NN O
studies NN NN O
that NN NN O
the NN NN O
upstream NN NN O
region NN NN O
of NN NN O
the NN NN O
mouse NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
at NN NN O
positions NN NN O
between NN NN O
- NN NN O
95 NN NN O
and NN NN O
- NN NN O
73 NN NN O
is NN NN O
essential NN NN O
for NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
. NN NN O
   
This NN NN O
region NN NN O
contains NN NN O
two NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
motifs NN NN O
, NN NN O
GM2 NN NN O
and NN NN O
GC NN NN O
- NN NN O
box NN NN O
. NN NN O
   
The NN NN O
GM2 NN NN O
sequence NN NN O
( NN NN O
GGTAGTTCCC NN NN O
) NN NN O
is NN NN O
recognized NN NN O
by NN NN O
an NN NN O
inducible NN NN O
factor NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
; NN NN O
the NN NN O
other NN NN O
( NN NN O
CCGCCC NN NN O
) NN NN O
by NN NN O
constitutive NN NN O
factors NN NN O
A1 NN NN O
, NN NN O
A2 NN NN O
, NN NN O
and NN NN O
B NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
activation NN NN O
, NN NN O
we NN NN O
have NN NN O
purified NN NN O
the NN NN O
inducible NN NN O
factor NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
from NN NN O
the NN NN O
nuclear NN NN O
extract NN NN O
of NN NN O
stimulated NN NN O
Jurkat NN NN O
cells NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
purified NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
consists NN NN O
of NN NN O
50 NN NN O
( NN NN O
p50 NN NN B-Protein
) NN NN O
and NN NN O
65 NN NN O
kDa NN NN O
( NN NN O
p65 NN NN B-Protein
) NN NN O
polypeptides NN NN O
and NN NN O
has NN NN O
a NN NN O
binding NN NN O
activity NN NN O
specific NN NN O
for NN NN O
both NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
immunoglobulin NN NN O
kappa NN NN O
( NN NN O
GGAAAGTCCC NN NN O
) NN NN O
enhancers NN NN O
. NN NN O
   
Electrophoretically NN NN O
purified NN NN O
p50 NN NN B-Protein
alone NN NN O
can NN NN O
form NN NN O
a NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
, NN NN O
but NN NN O
in NN NN O
the NN NN O
mixture NN NN O
, NN NN O
p50 NN NN B-Protein
associates NN NN O
preferentially NN NN O
with NN NN O
p65 NN NN B-Protein
to NN NN O
form NN NN O
the NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
complex NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
p65 NN NN B-Protein
gave NN NN O
per NN NN O
se NN NN O
, NN NN O
with NN NN O
low NN NN O
affinity NN NN O
, NN NN O
a NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
that NN NN O
migrated NN NN O
more NN NN O
slowly NN NN O
than NN NN O
native NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
complex NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
an NN NN O
antiserum NN NN O
against NN NN O
KBF1 NN NN B-Protein
( NN NN O
identical NN NN O
to NN NN O
50 NN NN O
kDa NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
) NN NN O
reacted NN NN O
with NN NN O
the NN NN O
p50 NN NN B-Protein
of NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
polypeptide NN NN O
cannot NN NN O
be NN NN O
immunologically NN NN O
differentiated NN NN O
from NN NN O
the NN NN O
50 NN NN O
kDa NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
purified NN NN O
NF NN NN O
- NN NN O
GM2 NN NN O
activated NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
from NN NN O
the NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
, NN NN O
while NN NN O
it NN NN O
failed NN NN O
to NN NN O
stimulate NN NN O
transcription NN NN O
from NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
harboring NN NN O
the NN NN O
GM2 NN NN O
sequence NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
the NN NN O
activation NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
through NN NN O
the NN NN O
GM2 NN NN O
/ NN NN O
GC NN NN O
- NN NN O
box NN NN O
sequence NN NN O
is NN NN O
different NN NN O
from NN NN O
that NN NN O
of NN NN O
genes NN NN O
carrying NN NN O
the NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
alone NN NN O
. NN NN O
   
Synergism NN NN O
between NN NN O
two NN NN O
distinct NN NN O
elements NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
during NN NN O
activation NN NN O
by NN NN O
the NN NN O
trans NN NN O
- NN NN O
activator NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
We NN NN O
have NN NN O
conducted NN NN O
functional NN NN O
studies NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
elements NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
using NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
Jurkat NN NN O
and NN NN O
MOLT NN NN O
4 NN NN O
, NN NN O
which NN NN O
are NN NN O
negative NN NN O
for NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
, NN NN O
and NN NN O
MT NN NN O
- NN NN O
2 NN NN O
and NN NN O
TL NN NN O
- NN NN O
Mor NN NN O
, NN NN O
which NN NN O
carry NN NN O
the NN NN O
proviral NN NN O
genome NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
elements NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
function NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
. NN NN O
   
One NN NN O
is NN NN O
the NN NN O
21 NN NN O
- NN NN O
base NN NN O
- NN NN O
pair NN NN O
( NN NN O
bp NN NN O
) NN NN O
core NN NN O
element NN NN O
that NN NN O
is NN NN O
responsible NN NN O
for NN NN O
trans NN NN O
- NN NN O
activation NN NN O
by NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
trans NN NN O
- NN NN O
activator NN NN O
p40tax NN NN B-Protein
and NN NN O
that NN NN O
has NN NN O
the NN NN O
ability NN NN O
to NN NN O
bind NN NN O
to NN NN O
cyclic NN NN B-Protein
- NN NN I-Protein
AMP NN NN I-Protein
responsive NN NN I-Protein
element NN NN I-Protein
binding NN NN I-Protein
factor NN NN I-Protein
( NN NN O
CREB NN NN B-Protein
) NN NN O
- NN NN O
like NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
The NN NN O
other NN NN O
is NN NN O
a NN NN O
region NN NN O
interposed NN NN O
between NN NN O
the NN NN O
21 NN NN O
- NN NN O
bp NN NN O
elements NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
subfragment NN NN O
( NN NN O
C26 NN NN O
) NN NN O
in NN NN O
the NN NN O
region NN NN O
between NN NN O
the NN NN O
21 NN NN O
- NN NN O
bp NN NN O
elements NN NN O
is NN NN O
involved NN NN O
in NN NN O
trans NN NN O
- NN NN O
activation NN NN O
by NN NN O
p40tax NN NN B-Protein
, NN NN O
possibly NN NN O
through NN NN O
binding NN NN O
to NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
nuclear NN NN O
factor NN NN O
or NN NN O
factors NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
the NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
with NN NN O
the NN NN O
C26 NN NN O
subfragment NN NN O
was NN NN O
positively NN NN O
affected NN NN O
by NN NN O
p40tax NN NN B-Protein
. NN NN O
   
The NN NN O
C26 NN NN O
element NN NN O
conferred NN NN O
partial NN NN O
responsiveness NN NN O
to NN NN O
p40tax NN NN B-Protein
when NN NN O
linked NN NN O
to NN NN O
one NN NN O
copy NN NN O
of NN NN O
the NN NN O
21 NN NN O
- NN NN O
bp NN NN O
element NN NN O
that NN NN O
, NN NN O
by NN NN O
itself NN NN O
, NN NN O
showed NN NN O
little NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
p40tax NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
C26 NN NN O
element NN NN O
alone NN NN O
, NN NN O
even NN NN O
when NN NN O
repeated NN NN O
, NN NN O
could NN NN O
not NN NN O
be NN NN O
activated NN NN O
by NN NN O
p40tax NN NN B-Protein
, NN NN O
unlike NN NN O
other NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
elements NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
C26 NN NN O
element NN NN O
itself NN NN O
was NN NN O
profoundly NN NN O
activated NN NN O
upon NN NN O
stimulation NN NN O
with NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
therefore NN NN O
suggest NN NN O
that NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
contains NN NN O
multiple NN NN O
functional NN NN O
elements NN NN O
, NN NN O
including NN NN O
binding NN NN O
sites NN NN O
for NN NN O
at NN NN O
least NN NN O
CREB NN NN B-Protein
- NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
factors NN NN O
, NN NN O
which NN NN O
synergistically NN NN O
cooperate NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
in NN NN O
response NN NN O
to NN NN O
p40tax NN NN B-Protein
. NN NN O
   
Our NN NN O
results NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
TPA NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
may NN NN O
be NN NN O
mediated NN NN O
through NN NN O
the NN NN O
C26 NN NN O
element NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
by NN NN O
dexamethasone NN NN O
is NN NN O
associated NN NN O
with NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
treatment NN NN O
of NN NN O
human NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
with NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
and NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
early NN NN O
response NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
present NN NN O
work NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
glucocorticoid NN NN O
dexamethasone NN NN O
inhibits NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
levels NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
were NN NN O
associated NN NN O
with NN NN O
a NN NN O
block NN NN O
in NN NN O
appearance NN NN O
of NN NN O
the NN NN O
monocytic NN NN O
phenotype NN NN O
, NN NN O
including NN NN O
inhibition NN NN O
of NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
lamin NN NN B-Protein
A NN NN I-Protein
, NN NN O
lamin NN NN B-Protein
C NN NN I-Protein
, NN NN O
and NN NN O
vimentin NN NN B-Protein
transcripts NN NN O
. NN NN O
   
Other NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
and NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
genes NN NN O
in NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
are NN NN O
regulated NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
. NN NN O
   
The NN NN O
finding NN NN O
that NN NN O
dexamethasone NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
PKC NN NN B-Protein
suggests NN NN O
that NN NN O
this NN NN O
glucocorticoid NN NN O
inhibits NN NN O
signals NN NN O
downstream NN NN O
or NN NN O
parallel NN NN O
to NN NN O
this NN NN O
enzyme NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
assays NN NN O
demonstrate NN NN O
that NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
expression NN NN O
by NN NN O
TPA NN NN O
is NN NN O
regulated NN NN O
by NN NN O
transcriptional NN NN O
mechanisms NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
does NN NN O
not NN NN O
require NN NN O
protein NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
both NN NN O
genes NN NN O
is NN NN O
inhibited NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
by NN NN O
dexamethasone NN NN O
. NN NN O
   
To NN NN O
further NN NN O
define NN NN O
the NN NN O
effects NN NN O
of NN NN O
dexamethasone NN NN O
at NN NN O
the NN NN O
molecular NN NN O
level NN NN O
, NN NN O
we NN NN O
prepared NN NN O
a NN NN O
series NN NN O
of NN NN O
deleted NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
promoter NN NN O
fragments NN NN O
linked NN NN O
to NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
gene NN NN O
. NN NN O
   
Increases NN NN O
in NN NN O
CAT NN NN B-Protein
activity NN NN O
during NN NN O
transient NN NN O
expression NN NN O
of NN NN O
these NN NN O
constructs NN NN O
in NN NN O
TPA NN NN O
- NN NN O
treated NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
could NN NN O
be NN NN O
assigned NN NN O
to NN NN O
the NN NN O
region NN NN O
( NN NN O
- NN NN O
97 NN NN O
to NN NN O
- NN NN O
20 NN NN O
) NN NN O
of NN NN O
the NN NN O
promoter NN NN O
that NN NN O
contains NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
of NN NN O
CAT NN NN B-Protein
activity NN NN O
was NN NN O
sensitive NN NN O
to NN NN O
dexamethasone NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
dexamethasone NN NN O
down NN NN O
- NN NN O
regulates NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
transcription NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
by NN NN O
inhibiting NN NN O
activation NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
. NN NN O
   
Evaluation NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
ligand NN NN O
and NN NN O
thermal NN NN O
activation NN NN O
of NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
in NN NN O
vitro NN NN O
synthesized NN NN O
human NN NN O
glucocorticoid NN NN O
receptor NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
/ NN NN O
immunoprecipitation NN NN O
assay NN NN O
to NN NN O
analyze NN NN O
the NN NN O
capacity NN NN O
of NN NN O
human NN NN O
glucocorticoid NN NN O
receptor NN NN O
( NN NN O
hGR NN NN O
) NN NN O
, NN NN O
generated NN NN O
in NN NN O
rabbit NN NN O
reticulocyte NN NN O
lysates NN NN O
, NN NN O
to NN NN O
bind NN NN O
DNA NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
translated NN NN O
hGR NN NN O
was NN NN O
indistinguishable NN NN O
from NN NN O
native NN NN O
hGR NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
migration NN NN O
on NN NN O
sodium NN NN O
dodecyl NN NN O
sulfate NN NN O
- NN NN O
polyacrylamide NN NN O
gels NN NN O
, NN NN O
sedimentation NN NN O
on NN NN O
sucrose NN NN O
density NN NN O
gradients NN NN O
, NN NN O
and NN NN O
reactivity NN NN O
with NN NN O
antipeptide NN NN O
antibodies NN NN O
generated NN NN O
against NN NN O
hGR NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
cell NN NN O
- NN NN O
free NN NN O
synthesized NN NN O
hGR NN NN O
was NN NN O
capable NN NN O
of NN NN O
specific NN NN O
binding NN NN O
to NN NN O
glucocorticoid NN NN O
response NN NN O
element NN NN O
( NN NN O
GRE NN NN O
) NN NN O
- NN NN O
containing NN NN O
DNA NN NN O
fragments NN NN O
. NN NN O
   
Using NN NN O
this NN NN O
assay NN NN O
system NN NN O
, NN NN O
we NN NN O
have NN NN O
evaluated NN NN O
the NN NN O
contributions NN NN O
of NN NN O
ligand NN NN O
binding NN NN O
and NN NN O
heat NN NN O
activation NN NN O
to NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
these NN NN O
glucocorticoid NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
translated NN NN O
hGR NN NN O
was NN NN O
capable NN NN O
of NN NN O
selective NN NN O
DNA NN NN O
binding NN NN O
even NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
glucocorticoid NN NN O
. NN NN O
   
Treatment NN NN O
with NN NN O
dexamethasone NN NN O
or NN NN O
the NN NN O
antiglucocorticoid NN NN O
RU486 NN NN O
had NN NN O
no NN NN O
additional NN NN O
effect NN NN O
on NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
capacity NN NN O
when NN NN O
receptor NN NN O
preparations NN NN O
were NN NN O
maintained NN NN O
at NN NN O
0 NN NN O
C NN NN O
( NN NN O
no NN NN O
activation NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
addition NN NN O
of NN NN O
either NN NN O
ligand NN NN O
or NN NN O
antagonist NN NN O
in NN NN O
combination NN NN O
with NN NN O
a NN NN O
heat NN NN O
activation NN NN O
step NN NN O
promoted NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
approximately NN NN O
3 NN NN O
- NN NN O
fold NN NN O
over NN NN O
that NN NN O
of NN NN O
heat NN NN O
- NN NN O
activated NN NN O
unliganded NN NN O
receptors NN NN O
. NN NN O
   
Agonist NN NN O
( NN NN O
dexamethasone NN NN O
) NN NN O
was NN NN O
slightly NN NN O
more NN NN O
effective NN NN O
in NN NN O
supporting NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
than NN NN O
antagonist NN NN O
( NN NN O
RU486 NN NN O
) NN NN O
. NN NN O
   
DNA NN NN O
binding NN NN O
by NN NN O
in NN NN O
vitro NN NN O
synthesized NN NN O
GR NN NN O
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
sodium NN NN O
molybdate NN NN O
to NN NN O
the NN NN O
receptor NN NN O
preparations NN NN O
before NN NN O
steroid NN NN O
addition NN NN O
and NN NN O
thermal NN NN O
activation NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
KCl NN NN O
resulted NN NN O
in NN NN O
less NN NN O
DNA NN NN O
binding NN NN O
either NN NN O
due NN NN O
to NN NN O
blockage NN NN O
of NN NN O
DNA NN NN O
- NN NN O
receptor NN NN O
complex NN NN O
formation NN NN O
or NN NN O
disruption NN NN O
of NN NN O
the NN NN O
complexes NN NN O
. NN NN O
   
The NN NN O
specificity NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
cell NN NN O
- NN NN O
free NN NN O
synthesized NN NN O
hGR NN NN O
was NN NN O
analyzed NN NN O
further NN NN O
by NN NN O
examining NN NN O
the NN NN O
abilities NN NN O
of NN NN O
various NN NN O
DNAs NN NN O
to NN NN O
compete NN NN O
for NN NN O
binding NN NN O
to NN NN O
a NN NN O
naturally NN NN O
occurring NN NN O
GRE NN NN O
found NN NN O
in NN NN O
the NN NN O
mouse NN NN O
mammary NN NN O
tumor NN NN O
virus NN NN O
- NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
Oligonucleotides NN NN O
containing NN NN O
the NN NN O
consensus NN NN O
GRE NN NN O
were NN NN O
the NN NN O
most NN NN O
efficient NN NN O
competitors NN NN O
, NN NN O
and NN NN O
fragments NN NN O
containing NN NN O
regulatory NN NN O
sequences NN NN O
from NN NN O
glucocorticoid NN NN O
- NN NN O
repressible NN NN O
genes NN NN O
were NN NN O
somewhat NN NN O
competitive NN NN O
, NN NN O
whereas NN NN O
single NN NN O
stranded NN NN O
oligonucleotides NN NN O
were NN NN O
unable NN NN O
to NN NN O
compete NN NN O
for NN NN O
mouse NN NN O
mammary NN NN O
tumor NN NN O
virus NN NN O
- NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
except NN NN O
when NN NN O
competitor NN NN O
was NN NN O
present NN NN O
at NN NN O
extremely NN NN O
high NN NN O
concentrations NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
hGR NN NN O
synthesized NN NN O
in NN NN O
rabbit NN NN O
reticulocyte NN NN O
lysates NN NN O
displays NN NN O
many NN NN O
of NN NN O
the NN NN O
same NN NN O
properties NN NN O
, NN NN O
including NN NN O
GRE NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
observed NN NN O
for NN NN O
glucocorticoid NN NN O
receptor NN NN O
present NN NN O
in NN NN O
cytosolic NN NN O
extracts NN NN O
of NN NN O
mammalian NN NN O
cells NN NN O
and NN NN O
tissues NN NN O
. NN NN O
   
Similarities NN NN O
between NN NN O
the NN NN O
effects NN NN O
of NN NN O
dexamethasone NN NN O
and NN NN O
RU486 NN NN O
suggest NN NN O
that NN NN O
the NN NN O
antiglucocorticoid NN NN O
properties NN NN O
of NN NN O
RU486 NN NN O
do NN NN O
not NN NN O
occur NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
One NN NN O
base NN NN O
pair NN NN O
change NN NN O
abolishes NN NN O
the NN NN O
T NN NN O
cell NN NN O
- NN NN O
restricted NN NN O
activity NN NN O
of NN NN O
a NN NN O
kB NN NN O
- NN NN O
like NN NN O
proto NN NN O
- NN NN O
enhancer NN NN O
element NN NN O
from NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
The NN NN O
inducible NN NN O
, NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancers NN NN O
of NN NN O
murine NN NN O
and NN NN O
human NN NN O
Interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
Il NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
genes NN NN O
contain NN NN O
the NN NN O
kB NN NN O
- NN NN O
like NN NN O
sequence NN NN O
GGGATTTCACC NN NN O
as NN NN O
an NN NN O
essential NN NN O
cis NN NN O
- NN NN O
acting NN NN O
enhancer NN NN O
motif NN NN O
. NN NN O
   
When NN NN O
cloned NN NN O
in NN NN O
multiple NN NN O
copies NN NN O
this NN NN O
so NN NN O
- NN NN O
called NN NN O
TCEd NN NN O
( NN NN O
distal NN NN O
T NN NN O
cell NN NN O
element NN NN O
) NN NN O
acts NN NN O
as NN NN O
an NN NN O
inducible NN NN O
proto NN NN O
- NN NN O
enhancer NN NN O
element NN NN O
in NN NN O
E14 NN NN O
T NN NN O
lymphoma NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
extracts NN NN O
of NN NN O
induced NN NN O
, NN NN O
Il NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secreting NN NN O
El4 NN NN O
cells NN NN O
three NN NN O
individual NN NN O
protein NN NN O
factors NN NN O
bind NN NN O
to NN NN O
TCEd NN NN O
DNA NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
the NN NN O
most NN NN O
prominent NN NN O
factor NN NN O
, NN NN O
named NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
T NN NN B-Protein
cell NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
is NN NN O
correlated NN NN O
with NN NN O
the NN NN O
proto NN NN O
- NN NN O
enhancer NN NN O
activity NN NN O
of NN NN O
TCEd NN NN O
. NN NN O
   
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
consists NN NN O
of NN NN O
two NN NN O
polypeptides NN NN O
of NN NN O
about NN NN O
50 NN NN O
kD NN NN O
and NN NN O
105 NN NN O
kD NN NN O
; NN NN O
the NN NN O
former NN NN O
seems NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
50 NN NN O
kD NN NN O
polypeptide NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
. NN NN O
   
Purified NN NN O
NF NN NN O
- NN NN O
kB NN NN O
is NN NN O
also NN NN O
able NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
TCEd NN NN O
, NN NN O
but NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binds NN NN O
stronger NN NN O
than NN NN O
NF NN NN O
- NN NN O
kB NN NN O
to NN NN O
TCEd NN NN O
DNA NN NN O
. NN NN O
   
The NN NN O
conversion NN NN O
of NN NN O
the NN NN O
TCEd NN NN O
to NN NN O
a NN NN O
' NN NN O
perfect NN NN O
' NN NN O
NF NN NN O
- NN NN O
kB NN NN O
binding NN NN O
site NN NN O
leads NN NN O
to NN NN O
a NN NN O
tighter NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
to NN NN O
TCEd NN NN O
DNA NN NN O
and NN NN O
, NN NN O
as NN NN O
a NN NN O
functional NN NN O
consequence NN NN O
, NN NN O
to NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
' NN NN O
converted NN NN O
' NN NN O
TCEd NN NN O
motifs NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
substitution NN NN O
of NN NN O
the NN NN O
underlined NN NN O
A NN NN O
residue NN NN O
to NN NN O
a NN NN O
C NN NN O
within NN NN O
the NN NN O
GGGATTTCACC NN NN O
motif NN NN O
abolishes NN NN O
its NN NN O
T NN NN O
cell NN NN O
- NN NN O
restricted NN NN O
activity NN NN O
and NN NN O
leads NN NN O
to NN NN O
its NN NN O
functioning NN NN O
in NN NN O
both NN NN O
El4 NN NN O
cells NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
factors NN NN O
binding NN NN O
to NN NN O
the NN NN O
TCEd NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
T NN NN O
cell NN NN O
specific NN NN O
- NN NN O
transcription NN NN O
of NN NN O
the NN NN O
Il NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Negative NN NN O
regulation NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
: NN NN O
role NN NN O
of NN NN O
the NN NN O
65 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
plus NN NN O
50 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
dimer NN NN O
. NN NN O
   
Although NN NN O
monocytic NN NN O
cells NN NN O
can NN NN O
provide NN NN O
a NN NN O
reservoir NN NN O
for NN NN O
viral NN NN O
production NN NN O
in NN NN O
vivo NN NN O
, NN NN O
their NN NN O
regulation NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
transcription NN NN O
can NN NN O
be NN NN O
either NN NN O
latent NN NN O
, NN NN O
restricted NN NN O
, NN NN O
or NN NN O
productive NN NN O
. NN NN O
   
These NN NN O
differences NN NN O
in NN NN O
gene NN NN O
expression NN NN O
have NN NN O
not NN NN O
been NN NN O
molecularly NN NN O
defined NN NN O
. NN NN O
   
In NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
with NN NN O
restricted NN NN O
HIV NN NN O
expression NN NN O
, NN NN O
there NN NN O
is NN NN O
an NN NN O
absence NN NN O
of NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
binding NN NN O
complex NN NN O
formation NN NN O
with NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
- NN NN O
enhancer NN NN O
associated NN NN O
with NN NN O
markedly NN NN O
less NN NN O
viral NN NN O
RNA NN NN O
production NN NN O
. NN NN O
   
This NN NN O
absence NN NN O
of NN NN O
binding NN NN O
was NN NN O
localized NN NN O
to NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
region NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
; NN NN O
the NN NN O
65 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
plus NN NN O
50 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
heterodimer NN NN O
was NN NN O
preferentially NN NN O
lost NN NN O
. NN NN O
   
Adding NN NN O
purified NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
to NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
cells NN NN O
with NN NN O
restricted NN NN O
expression NN NN O
overcomes NN NN O
this NN NN O
lack NN NN O
of NN NN O
binding NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
treatment NN NN O
of NN NN O
these NN NN O
nuclear NN NN O
extracts NN NN O
with NN NN O
sodium NN NN O
deoxycholate NN NN O
restored NN NN O
their NN NN O
ability NN NN O
to NN NN O
form NN NN O
the NN NN O
heterodimer NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
treatment NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
these NN NN O
cells NN NN O
that NN NN O
had NN NN O
restricted NN NN O
expression NN NN O
with NN NN O
lipopolysaccharide NN NN O
increased NN NN O
viral NN NN O
production NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
. NN NN O
   
Antiserum NN NN O
specific NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
but NN NN O
not NN NN O
c NN NN O
- NN NN O
rel NN NN O
- NN NN O
specific NN NN O
antiserum NN NN O
, NN NN O
disrupted NN NN O
heterodimer NN NN O
complex NN NN O
formation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
are NN NN O
needed NN NN O
for NN NN O
optimal NN NN O
viral NN NN O
transcription NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
the NN NN O
65 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
plus NN NN O
50 NN NN B-Protein
- NN NN I-Protein
kDa NN NN I-Protein
heterodimer NN NN O
to NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
can NN NN O
be NN NN O
negatively NN NN O
regulated NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
providing NN NN O
one NN NN O
mechanism NN NN O
restricting NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Isolation NN NN O
of NN NN O
a NN NN O
candidate NN NN O
repressor NN NN O
/ NN NN O
activator NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
( NN NN O
YY NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
delta NN NN B-Protein
) NN NN O
, NN NN O
that NN NN O
binds NN NN O
to NN NN O
the NN NN O
immunoglobulin NN NN O
kappa NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
and NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
mu NN NN O
E1 NN NN O
site NN NN O
. NN NN O
   
We NN NN O
have NN NN O
determined NN NN O
that NN NN O
the NN NN O
developmental NN NN O
control NN NN O
of NN NN O
immunoglobulin NN NN O
kappa NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
( NN NN O
kappa NN NN O
E3 NN NN O
' NN NN O
) NN NN O
activity NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
the NN NN O
combined NN NN O
influence NN NN O
of NN NN O
positive NN NN O
- NN NN O
and NN NN O
negative NN NN O
- NN NN O
acting NN NN O
elements NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
a NN NN O
central NN NN O
core NN NN O
in NN NN O
the NN NN O
kappa NN NN O
E3 NN NN O
' NN NN O
enhancer NN NN O
is NN NN O
active NN NN O
at NN NN O
the NN NN O
pre NN NN O
- NN NN O
B NN NN O
- NN NN O
cell NN NN O
stage NN NN O
but NN NN O
is NN NN O
repressed NN NN O
by NN NN O
flanking NN NN O
negative NN NN O
- NN NN O
acting NN NN O
elements NN NN O
. NN NN O
   
The NN NN O
negative NN NN O
- NN NN O
acting NN NN O
sequences NN NN O
repress NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
a NN NN O
position NN NN O
- NN NN O
and NN NN O
orientation NN NN O
- NN NN O
independent NN NN O
manner NN NN O
at NN NN O
the NN NN O
pre NN NN O
- NN NN O
B NN NN O
- NN NN O
cell NN NN O
stage NN NN O
. NN NN O
   
We NN NN O
have NN NN O
isolated NN NN O
a NN NN O
human NN NN O
cDNA NN NN O
clone NN NN O
encoding NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
protein NN NN O
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
) NN NN O
that NN NN O
binds NN NN O
to NN NN O
the NN NN O
negative NN NN O
- NN NN O
acting NN NN O
segment NN NN O
of NN NN O
the NN NN O
kappa NN NN O
E3 NN NN O
' NN NN O
enhancer NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
also NN NN O
binds NN NN O
to NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
enhancer NN NN O
mu NN NN O
E1 NN NN O
site NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
is NN NN O
encoded NN NN O
by NN NN O
the NN NN O
same NN NN O
gene NN NN O
as NN NN O
the NN NN O
YY NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
the NN NN O
adeno NN NN O
- NN NN O
associated NN NN O
virus NN NN O
P5 NN NN O
promoter NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
is NN NN O
also NN NN O
the NN NN O
human NN NN O
homologue NN NN O
of NN NN O
the NN NN O
mouse NN NN O
delta NN NN B-Protein
protein NN NN O
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
ribosomal NN NN O
protein NN NN O
gene NN NN O
promoters NN NN O
. NN NN O
   
The NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
of NN NN O
this NN NN O
protein NN NN O
contains NN NN O
features NN NN O
characteristic NN NN O
of NN NN O
transcriptional NN NN O
activators NN NN O
as NN NN O
well NN NN O
as NN NN O
transcriptional NN NN O
repressors NN NN O
. NN NN O
   
Cotransfection NN NN O
studies NN NN O
with NN NN O
this NN NN O
cDNA NN NN O
indicate NN NN O
that NN NN O
it NN NN O
can NN NN O
repress NN NN O
basal NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
apparent NN NN O
dual NN NN O
function NN NN O
of NN NN O
this NN NN O
protein NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
production NN NN O
by NN NN O
glucocorticoids NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
: NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
depends NN NN O
on NN NN O
the NN NN O
activation NN NN O
signal NN NN O
. NN NN O
   
Glucocorticoids NN NN O
are NN NN O
known NN NN O
to NN NN O
downregulate NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
production NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
two NN NN O
different NN NN O
mechanims NN NN O
: NN NN O
direct NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
gene NN NN O
transcription NN NN O
and NN NN O
destabilization NN NN O
of NN NN O
the NN NN O
preformed NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Now NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
activating NN NN O
signal NN NN O
on NN NN O
these NN NN O
two NN NN O
inhibitory NN NN O
mechanims NN NN O
. NN NN O
   
When NN NN O
human NN NN O
monocytes NN NN O
were NN NN O
preincubated NN NN O
with NN NN O
dexamethasone NN NN O
for NN NN O
1 NN NN O
hour NN NN O
and NN NN O
then NN NN O
stimulated NN NN O
either NN NN O
with NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
or NN NN O
phorbol NN NN O
myristate NN NN O
, NN NN O
it NN NN O
was NN NN O
found NN NN O
that NN NN O
dexamethasone NN NN O
inhibited NN NN O
the NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
protein NN NN O
production NN NN O
, NN NN O
but NN NN O
the NN NN O
phorbol NN NN O
myristate NN NN O
- NN NN O
induced NN NN O
production NN NN O
was NN NN O
increased NN NN O
3 NN NN O
- NN NN O
10 NN NN O
fold NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
was NN NN O
also NN NN O
seen NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
. NN NN O
   
When NN NN O
dexamethasone NN NN O
was NN NN O
added NN NN O
to NN NN O
the NN NN O
cultures NN NN O
3 NN NN O
hours NN NN O
after NN NN O
the NN NN O
stimulators NN NN O
, NN NN O
it NN NN O
clearly NN NN O
decreased NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
levels NN NN O
regardless NN NN O
of NN NN O
the NN NN O
stimulator NN NN O
used NN NN O
( NN NN O
although NN NN O
the NN NN O
effect NN NN O
was NN NN O
clearly NN NN O
weaker NN NN O
on NN NN O
the NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
mRNA NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
phorbol NN NN O
myristate NN NN O
- NN NN O
induced NN NN O
signal NN NN O
( NN NN O
prolonged NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
activation NN NN O
? NN NN O
) NN NN O
cannot NN NN O
be NN NN O
inhibited NN NN O
by NN NN O
prior NN NN O
incubation NN NN O
with NN NN O
dexamethasone NN NN O
and NN NN O
it NN NN O
also NN NN O
protects NN NN O
the NN NN O
induced NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
degradative NN NN O
action NN NN O
of NN NN O
dexamethasone NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
transcriptional NN NN O
suppressor NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
Two NN NN O
different NN NN O
proteins NN NN O
which NN NN O
independently NN NN O
bound NN NN O
to NN NN O
neighboring NN NN O
sequences NN NN O
within NN NN O
the NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
( NN NN O
NRE NN NN O
) NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
extract NN NN O
of NN NN O
a NN NN O
virus NN NN O
- NN NN O
infected NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
factors NN NN O
bound NN NN O
to NN NN O
a NN NN O
novel NN NN O
dyad NN NN O
symmetrical NN NN O
sequence NN NN O
. NN NN O
   
This NN NN O
sequence NN NN O
is NN NN O
well NN NN O
conserved NN NN O
in NN NN O
various NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
isolates NN NN O
and NN NN O
partial NN NN O
homology NN NN O
was NN NN O
found NN NN O
with NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
retinoblastoma NN NN O
gene NN NN O
. NN NN O
   
Similar NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
detected NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
virus NN NN O
- NN NN O
uninfected NN NN O
human NN NN O
T NN NN O
cell NN NN O
lines NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
The NN NN O
other NN NN O
factor NN NN O
bound NN NN O
to NN NN O
a NN NN O
putative NN NN O
AP NN NN O
- NN NN O
1 NN NN O
recognition NN NN O
sequence NN NN O
predicted NN NN O
for NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
NRE NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
factor NN NN O
did NN NN O
not NN NN O
bind NN NN O
to NN NN O
a NN NN O
typical NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
. NN NN O
   
The NN NN O
insertion NN NN O
of NN NN O
multiple NN NN O
copies NN NN O
of NN NN O
the NN NN O
binding NN NN O
site NN NN O
for NN NN O
the NN NN O
former NN NN O
or NN NN O
latter NN NN O
factor NN NN O
into NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
reduced NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
to NN NN O
one NN NN O
- NN NN O
tenth NN NN O
or NN NN O
one NN NN O
- NN NN O
third NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
each NN NN O
factor NN NN O
may NN NN O
function NN NN O
as NN NN O
a NN NN O
novel NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Constitutive NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
in NN NN O
human NN NN O
thymocytes NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kB NN NN O
is NN NN O
a NN NN O
eukaryotic NN NN O
transcription NN NN O
regulatory NN NN O
factor NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cells NN NN O
and NN NN O
T NN NN O
cell NN NN O
lines NN NN O
, NN NN O
NF NN NN O
- NN NN O
kB NN NN O
is NN NN O
bound NN NN O
to NN NN O
a NN NN O
cytoplasmic NN NN O
proteic NN NN O
inhibitor NN NN O
, NN NN O
the NN NN O
IkB NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
mitogens NN NN O
( NN NN O
phorbol NN NN O
esters NN NN O
) NN NN O
or NN NN O
cytokines NN NN O
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
induces NN NN O
NF NN NN O
- NN NN O
kB NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
the NN NN O
subsequent NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
dependent NN NN O
T NN NN O
cell NN NN O
genes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
examined NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
in NN NN O
human NN NN O
T NN NN O
cell NN NN O
thymic NN NN O
progenitors NN NN O
. NN NN O
   
We NN NN O
report NN NN O
differences NN NN O
in NN NN O
( NN NN O
Ca2 NN NN O
+ NN NN O
) NN NN O
i NN NN O
requirement NN NN O
for NN NN O
NF NN NN O
- NN NN O
kB NN NN O
activation NN NN O
in NN NN O
thymocytes NN NN O
as NN NN O
compared NN NN O
to NN NN O
mature NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
our NN NN O
results NN NN O
indicated NN NN O
that NN NN O
thymocytes NN NN O
have NN NN O
a NN NN O
constitutively NN NN O
active NN NN O
form NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
they NN NN O
are NN NN O
activated NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Suppression NN NN O
of NN NN O
signals NN NN O
required NN NN O
for NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
cells NN NN O
constitutively NN NN O
expressing NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
protein NN NN O
. NN NN O
   
Transient NN NN O
short NN NN O
- NN NN O
term NN NN O
expression NN NN O
of NN NN O
the NN NN O
Tax NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
- NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
leads NN NN O
to NN NN O
activation NN NN O
of NN NN O
the NN NN O
pleiotropic NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
findings NN NN O
obtained NN NN O
with NN NN O
transient NN NN O
expression NN NN O
assays NN NN O
, NN NN O
we NN NN O
observed NN NN O
marked NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
Namalwa NN NN O
B NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
which NN NN O
constitutively NN NN O
express NN NN O
Tax NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
following NN NN O
long NN NN O
- NN NN O
term NN NN O
expression NN NN O
of NN NN O
Tax NN NN B-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
both NN NN O
mitogens NN NN O
and NN NN O
cytokines NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
also NN NN O
blocked NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
constitutively NN NN O
expressing NN NN O
Tax NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
activation NN NN O
of NN NN O
other NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
such NN NN O
as NN NN O
Fos NN NN B-Protein
and NN NN O
Jun NN NN B-Protein
, NN NN O
was NN NN O
unaffected NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
depending NN NN O
on NN NN O
the NN NN O
cellular NN NN O
environment NN NN O
, NN NN O
the NN NN O
short NN NN O
- NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
effects NN NN O
of NN NN O
Tax NN NN B-Protein
expression NN NN O
can NN NN O
be NN NN O
quite NN NN O
different NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
one NN NN O
function NN NN O
of NN NN O
Tax NN NN B-Protein
in NN NN O
cells NN NN O
infected NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
might NN NN O
involve NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
suppression NN NN O
, NN NN O
as NN NN O
opposed NN NN O
to NN NN O
activation NN NN O
, NN NN O
of NN NN O
distinct NN NN O
signal NN NN O
pathways NN NN O
. NN NN O
   
The NN NN O
cells NN NN O
lines NN NN O
described NN NN O
here NN NN O
should NN NN O
be NN NN O
useful NN NN O
for NN NN O
the NN NN O
delineation NN NN O
of NN NN O
signaling NN NN O
pathways NN NN O
utilized NN NN O
in NN NN O
the NN NN O
selective NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
2 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
) NN NN O
gene NN NN O
expression NN NN O
by NN NN O
the NN NN O
cytomegalovirus NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
transactivator NN NN O
gene NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
often NN NN O
causes NN NN O
latent NN NN O
infection NN NN O
. NN NN O
   
Transactivation NN NN O
by NN NN O
some NN NN O
DNA NN NN O
viruses NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
inducing NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
pathogenesis NN NN O
. NN NN O
   
The NN NN O
transactivator NN NN O
( NN NN O
IE NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
of NN NN O
the NN NN O
human NN NN O
cytomegalovirus NN NN O
( NN NN O
CMV NN NN O
) NN NN O
can NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
as NN NN O
well NN NN O
as NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
This NN NN O
inducer NN NN O
can NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
tat NN NN B-Protein
gene NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
in NN NN O
enhancing NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
lymphocytes NN NN O
. NN NN O
   
While NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
tat NN NN B-Protein
genes NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
activators NN NN O
apparently NN NN O
employ NN NN O
independent NN NN O
modes NN NN O
of NN NN O
action NN NN O
, NN NN O
the NN NN O
CMV NN NN O
transactivator NN NN O
in NN NN O
combination NN NN O
with NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
tat NN NN B-Protein
or NN NN O
T NN NN O
- NN NN O
cell NN NN O
activators NN NN O
may NN NN O
employ NN NN O
a NN NN O
gene NN NN O
activation NN NN O
pathway NN NN O
with NN NN O
some NN NN O
common NN NN O
and NN NN O
some NN NN O
distinct NN NN O
components NN NN O
. NN NN O
   
Both NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
and NN NN O
CMV NN NN O
transactivators NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
gene NN NN O
expression NN NN O
by NN NN O
transcriptional NN NN O
activation NN NN O
involving NN NN O
transcript NN NN O
initiation NN NN O
as NN NN O
well NN NN O
as NN NN O
elongation NN NN O
, NN NN O
with NN NN O
CMV NN NN O
transactivator NN NN O
affecting NN NN O
elongation NN NN O
more NN NN O
than NN NN O
the NN NN O
initiation NN NN O
. NN NN O
   
A NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
transcripts NN NN O
appear NN NN O
to NN NN O
terminate NN NN O
prematurely NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
transactivators NN NN O
. NN NN O
   
Deletion NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
suggests NN NN O
that NN NN O
the NN NN O
element NN NN O
that NN NN O
responds NN NN O
to NN NN O
CMV NN NN O
transactivation NN NN O
in NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
lymphocytes NN NN O
is NN NN O
either NN NN O
a NN NN O
diffuse NN NN O
one NN NN O
or NN NN O
located NN NN O
downstream NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
2 NN NN O
gene NN NN O
expression NN NN O
: NN NN O
two NN NN O
enhancers NN NN O
and NN NN O
their NN NN O
activation NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
activators NN NN O
. NN NN O
   
The NN NN O
human NN NN O
immunodeficiency NN NN O
viruses NN NN O
( NN NN O
HIVs NN NN O
) NN NN O
may NN NN O
include NN NN O
a NN NN O
spectrum NN NN O
of NN NN O
retroviruses NN NN O
with NN NN O
varying NN NN O
potential NN NN O
to NN NN O
infect NN NN O
their NN NN O
host NN NN O
, NN NN O
undergo NN NN O
long NN NN O
periods NN NN O
of NN NN O
latent NN NN O
infection NN NN O
, NN NN O
and NN NN O
induce NN NN O
pathology NN NN O
. NN NN O
   
Since NN NN O
expression NN NN O
of NN NN O
the NN NN O
viruses NN NN O
is NN NN O
in NN NN O
large NN NN O
part NN NN O
regulated NN NN O
by NN NN O
the NN NN O
sequence NN NN O
elements NN NN O
in NN NN O
their NN NN O
long NN NN O
terminal NN NN O
repeats NN NN O
( NN NN O
LTRs NN NN O
) NN NN O
, NN NN O
this NN NN O
study NN NN O
was NN NN O
directed NN NN O
to NN NN O
an NN NN O
analysis NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
elements NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
LTR NN NN O
. NN NN O
   
The NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
LTR NN NN O
was NN NN O
found NN NN O
to NN NN O
contain NN NN O
two NN NN O
enhancers NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
enhancers NN NN O
is NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
identical NN NN O
to NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
. NN NN O
   
This NN NN O
enhancer NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
is NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
response NN NN O
element NN NN O
; NN NN O
in NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
, NN NN O
however NN NN O
, NN NN O
it NN NN O
is NN NN O
the NN NN O
second NN NN O
enhancer NN NN O
that NN NN O
is NN NN O
mainly NN NN O
responsible NN NN O
for NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activators NN NN O
. NN NN O
   
The NN NN O
second NN NN O
enhancer NN NN O
interacts NN NN O
with NN NN O
two NN NN O
nuclear NN NN O
binding NN NN O
proteins NN NN O
( NN NN O
85 NN NN O
kD NN NN O
and NN NN O
27 NN NN O
kD NN NN O
mobility NN NN O
) NN NN O
that NN NN O
appear NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
optimal NN NN O
enhancer NN NN O
function NN NN O
and NN NN O
activation NN NN O
. NN NN O
   
Observations NN NN O
such NN NN O
as NN NN O
these NN NN O
encourage NN NN O
the NN NN O
speculation NN NN O
that NN NN O
there NN NN O
may NN NN O
be NN NN O
subtle NN NN O
differences NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
expression NN NN O
that NN NN O
may NN NN O
be NN NN O
relevant NN NN O
to NN NN O
the NN NN O
possible NN NN O
longer NN NN O
latency NN NN O
and NN NN O
reduced NN NN O
pathogenicity NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
KB NN NN O
during NN NN O
monocyte NN NN O
differentiation NN NN O
by NN NN O
HIV NN NN O
type NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
production NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
progeny NN NN O
was NN NN O
followed NN NN O
in NN NN O
the NN NN O
U937 NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
after NN NN O
stimulation NN NN O
either NN NN O
with NN NN O
retinoic NN NN O
acid NN NN O
or NN NN O
PMA NN NN O
, NN NN O
and NN NN O
in NN NN O
purified NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
Southwestern NN NN O
blotting NN NN O
experiments NN NN O
were NN NN O
used NN NN O
to NN NN O
detect NN NN O
the NN NN O
binding NN NN O
of NN NN O
cellular NN NN O
transactivation NN NN O
factor NN NN O
NF NN NN O
- NN NN O
KB NN NN O
to NN NN O
the NN NN O
double NN NN O
repeat NN NN O
- NN NN O
KB NN NN O
enhancer NN NN O
sequence NN NN O
located NN NN O
in NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
PMA NN NN O
treatment NN NN O
, NN NN O
and NN NN O
not NN NN O
retinoic NN NN O
acid NN NN O
treatment NN NN O
of NN NN O
the NN NN O
U937 NN NN O
cells NN NN O
acts NN NN O
in NN NN O
inducing NN NN O
NF NN NN O
- NN NN O
KB NN NN O
expression NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
. NN NN O
   
In NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
monocytes NN NN O
or NN NN O
macrophages NN NN O
, NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
KB NN NN O
occurred NN NN O
only NN NN O
if NN NN O
the NN NN O
cells NN NN O
were NN NN O
previously NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
When NN NN O
U937 NN NN O
cells NN NN O
were NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
no NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
KB NN NN O
factor NN NN O
was NN NN O
detected NN NN O
, NN NN O
whereas NN NN O
high NN NN O
level NN NN O
of NN NN O
progeny NN NN O
virions NN NN O
was NN NN O
produced NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
factor NN NN O
was NN NN O
not NN NN O
required NN NN O
for NN NN O
viral NN NN O
replication NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
in NN NN O
monocytic NN NN O
cell NN NN O
lineage NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
could NN NN O
mimic NN NN O
some NN NN O
differentiation NN NN O
/ NN NN O
activation NN NN O
stimuli NN NN O
allowing NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
KB NN NN O
expression NN NN O
. NN NN O
   
Positive NN NN O
and NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
immunoglobulin NN NN O
gene NN NN O
expression NN NN O
by NN NN O
a NN NN O
novel NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
A NN NN O
new NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
element NN NN O
has NN NN O
been NN NN O
identified NN NN O
3 NN NN O
' NN NN O
of NN NN O
E4 NN NN O
and NN NN O
the NN NN O
octamerlike NN NN O
motifs NN NN O
in NN NN O
the NN NN O
human NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
enhancer NN NN O
. NN NN O
   
Tandem NN NN O
copies NN NN O
of NN NN O
this NN NN O
67 NN NN O
- NN NN O
bp NN NN O
MnlI NN NN O
- NN NN O
AluI NN NN O
fragment NN NN O
, NN NN O
when NN NN O
fused NN NN O
to NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
gene NN NN O
driven NN NN O
by NN NN O
the NN NN O
conalbumin NN NN O
promoter NN NN O
, NN NN O
stimulated NN NN O
transcription NN NN O
in NN NN O
B NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
or NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Footprinting NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
identical NN NN O
sequence NN NN O
CCGAAACTGAAAAGG NN NN O
, NN NN O
designated NN NN O
E6 NN NN B-Protein
, NN NN O
was NN NN O
protected NN NN O
by NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
B NN NN O
cells NN NN O
, NN NN O
T NN NN O
cells NN NN O
, NN NN O
or NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
using NN NN O
a NN NN O
synthetic NN NN O
E6 NN NN O
motif NN NN O
detected NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
complex NN NN O
in NN NN O
addition NN NN O
to NN NN O
a NN NN O
ubiquitous NN NN O
band NN NN O
found NN NN O
also NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
agreement NN NN O
with NN NN O
the NN NN O
results NN NN O
of NN NN O
gel NN NN O
retardation NN NN O
assays NN NN O
, NN NN O
tandem NN NN O
copies NN NN O
of NN NN O
the NN NN O
E6 NN NN B-Protein
motif NN NN O
stimulated NN NN O
transcription NN NN O
in NN NN O
ARH77 NN NN O
and NN NN O
Raji NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
Jurkat NN NN O
or NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
mutant NN NN O
E6 NN NN B-Protein
motif NN NN O
lost NN NN O
both NN NN O
in NN NN O
vitro NN NN O
binding NN NN O
activity NN NN O
and NN NN O
in NN NN O
vivo NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
striking NN NN O
contrast NN NN O
to NN NN O
the NN NN O
mouse NN NN O
Ig NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
enhancer NN NN O
, NN NN O
in NN NN O
which NN NN O
the NN NN O
octamer NN NN O
motif NN NN O
acts NN NN O
as NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
element NN NN O
, NN NN O
the NN NN O
human NN NN O
enhancer NN NN O
contains NN NN O
an NN NN O
octamerlike NN NN O
sequence NN NN O
with NN NN O
one NN NN O
base NN NN O
substitution NN NN O
which NN NN O
bound NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
with NN NN O
only NN NN O
very NN NN O
low NN NN O
affinity NN NN O
and NN NN O
showed NN NN O
no NN NN O
enhancer NN NN O
activity NN NN O
of NN NN O
its NN NN O
own NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
MnlI NN NN O
- NN NN O
AluI NN NN O
fragment NN NN O
could NN NN O
suppress NN NN O
the NN NN O
basal NN NN O
- NN NN O
level NN NN O
activity NN NN O
of NN NN O
the NN NN O
conalbumin NN NN O
promoter NN NN O
in NN NN O
both NN NN O
Jurkat NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
enhancer NN NN O
activity NN NN O
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
MnlI NN NN O
- NN NN O
AluI NN NN O
fragment NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
novel NN NN O
enhancer NN NN O
element NN NN O
identified NN NN O
in NN NN O
this NN NN O
study NN NN O
is NN NN O
probably NN NN O
a NN NN O
target NN NN O
site NN NN O
for NN NN O
both NN NN O
positive NN NN O
and NN NN O
negative NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
independent NN NN O
cis NN NN O
- NN NN O
acting NN NN O
sequences NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
responsive NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
transcription NN NN O
initiation NN NN O
directed NN NN O
by NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
increases NN NN O
in NN NN O
response NN NN O
to NN NN O
mitogenic NN NN O
stimuli NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
may NN NN O
be NN NN O
governed NN NN O
by NN NN O
two NN NN O
independent NN NN O
sequences NN NN O
located NN NN O
5 NN NN O
' NN NN O
to NN NN O
the NN NN O
site NN NN O
of NN NN O
transcription NN NN O
initiation NN NN O
sequences NN NN O
that NN NN O
bind NN NN O
either NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
rate NN NN O
of NN NN O
LTR NN NN O
- NN NN O
directed NN NN O
gene NN NN O
expression NN NN O
increased NN NN O
in NN NN O
response NN NN O
to NN NN O
treatment NN NN O
with NN NN O
either NN NN O
a NN NN O
phorbol NN NN O
ester NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
if NN NN O
either NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sites NN NN O
were NN NN O
deleted NN NN O
, NN NN O
but NN NN O
failed NN NN O
to NN NN O
respond NN NN O
to NN NN O
these NN NN O
mitogenic NN NN O
stimuli NN NN O
if NN NN O
both NN NN O
sequences NN NN O
were NN NN O
absent NN NN O
. NN NN O
   
The NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
mutant NN NN O
virus NN NN O
containing NN NN O
both NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
deletion NN NN O
was NN NN O
able NN NN O
to NN NN O
replicate NN NN O
although NN NN O
at NN NN O
a NN NN O
much NN NN O
decreased NN NN O
growth NN NN O
rate NN NN O
, NN NN O
while NN NN O
the NN NN O
deletion NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alone NN NN O
increased NN NN O
the NN NN O
viral NN NN O
growth NN NN O
rate NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Neither NN NN O
deletion NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
nor NN NN O
deletion NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
decreased NN NN O
activation NN NN O
of NN NN O
viral NN NN O
replication NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
constitutive NN NN O
and NN NN O
inducible NN NN O
transcriptional NN NN O
enhancement NN NN O
mediated NN NN O
by NN NN O
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
sequences NN NN O
: NN NN O
modulation NN NN O
of NN NN O
activity NN NN O
in NN NN O
B NN NN O
cells NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
tax NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
( NN NN O
GGGACTTTCC NN NN O
) NN NN O
binds NN NN O
a NN NN O
factor NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
that NN NN O
is NN NN O
constitutively NN NN O
found NN NN O
in NN NN O
its NN NN O
functional NN NN O
, NN NN O
DNA NN NN O
binding NN NN O
form NN NN O
only NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
A NN NN O
factor NN NN O
with NN NN O
apparently NN NN O
indistinguishable NN NN O
sequence NN NN O
specificity NN NN O
can NN NN O
be NN NN O
induced NN NN O
in NN NN O
many NN NN O
other NN NN O
cell NN NN O
types NN NN O
, NN NN O
where NN NN O
it NN NN O
is NN NN O
used NN NN O
to NN NN O
regulate NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
For NN NN O
example NN NN O
, NN NN O
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
sequences NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
the NN NN O
transcription NN NN O
of NN NN O
a NN NN O
few NN NN O
inducible NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
and NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
interferon NN NN I-Protein
gene NN NN O
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
genes NN NN O
are NN NN O
not NN NN O
constitutively NN NN O
active NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
other NN NN O
regulatory NN NN O
mechanisms NN NN O
must NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
determining NN NN O
the NN NN O
patterns NN NN O
of NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
constitutive NN NN O
and NN NN O
inducible NN NN O
transcriptional NN NN O
activity NN NN O
mediated NN NN O
by NN NN O
five NN NN O
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
sequence NN NN O
elements NN NN O
in NN NN O
two NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
in NN NN O
S194 NN NN O
plasma NN NN O
cells NN NN O
the NN NN O
activity NN NN O
of NN NN O
each NN NN O
element NN NN O
correlates NN NN O
well NN NN O
with NN NN O
the NN NN O
relative NN NN O
affinity NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
derived NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
for NN NN O
that NN NN O
element NN NN O
. NN NN O
   
This NN NN O
leads NN NN O
to NN NN O
significantly NN NN O
lower NN NN O
transcription NN NN O
enhancement NN NN O
by NN NN O
sites NN NN O
derived NN NN O
from NN NN O
the NN NN O
interleukin NN NN O
2 NN NN O
receptor NN NN O
or NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
genes NN NN O
in NN NN O
S194 NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
either NN NN O
EL NN NN O
- NN NN O
4 NN NN O
( NN NN O
T NN NN O
) NN NN O
cells NN NN O
or NN NN O
S194 NN NN O
cells NN NN O
, NN NN O
both NN NN O
lower NN NN O
- NN NN O
affinity NN NN O
sites NN NN O
can NN NN O
be NN NN O
significantly NN NN O
induced NN NN O
by NN NN O
the NN NN O
tax NN NN B-Protein
gene NN NN O
product NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
, NN NN O
showing NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
can NN NN O
be NN NN O
modulated NN NN O
even NN NN O
in NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
that NN NN O
constitutively NN NN O
expresses NN NN O
this NN NN O
factor NN NN O
. NN NN O
   
Isolation NN NN O
of NN NN O
a NN NN O
rel NN NN O
- NN NN O
related NN NN O
human NN NN O
cDNA NN NN O
that NN NN O
potentially NN NN O
encodes NN NN O
the NN NN O
65 NN NN O
- NN NN O
kD NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
Science NN NN O
1991 NN NN O
Oct NN NN O
4 NN NN O
; NN NN O
254 NN NN O
( NN NN O
5028 NN NN O
) NN NN O
: NN NN O
11 NN NN O
] NN NN O
   
A NN NN O
DNA NN NN O
probe NN NN O
that NN NN O
spanned NN NN O
a NN NN O
domain NN NN O
conserved NN NN O
among NN NN O
the NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
the NN NN O
Drosophila NN NN O
morphogen NN NN O
dorsal NN NN O
, NN NN O
and NN NN O
the NN NN O
p50 NN NN B-Protein
DNA NN NN O
binding NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
generated NN NN O
from NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
complementary NN NN O
DNA NN NN O
with NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
and NN NN O
degenerate NN NN O
oligonucleotides NN NN O
. NN NN O
   
This NN NN O
probe NN NN O
was NN NN O
used NN NN O
to NN NN O
identify NN NN O
a NN NN O
rel NN NN O
- NN NN O
related NN NN O
complementary NN NN O
DNA NN NN O
that NN NN O
hybridized NN NN O
to NN NN O
a NN NN O
2 NN NN O
. NN NN O
6 NN NN O
- NN NN O
kilobase NN NN O
messenger NN NN O
RNA NN NN O
present NN NN O
in NN NN O
human NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
transcription NN NN O
and NN NN O
translation NN NN O
of NN NN O
the NN NN O
complementary NN NN O
DNA NN NN O
resulted NN NN O
in NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
protein NN NN O
with NN NN O
an NN NN O
apparent NN NN O
molecular NN NN O
size NN NN O
of NN NN O
65 NN NN O
kilodaltons NN NN O
( NN NN O
kD NN NN O
) NN NN O
. NN NN O
   
The NN NN O
translated NN NN O
protein NN NN O
showed NN NN O
weak NN NN O
DNA NN NN O
binding NN NN O
with NN NN O
a NN NN O
specificity NN NN O
for NN NN O
the NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
motif NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
comigrated NN NN O
with NN NN O
the NN NN O
complex NN NN O
obtained NN NN O
with NN NN O
the NN NN O
purified NN NN O
human NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunit NN NN O
and NN NN O
binding NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
- NN NN B-Protein
beta NN NN I-Protein
proteins NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
65 NN NN O
- NN NN O
kD NN NN O
protein NN NN O
associated NN NN O
with NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
the NN NN O
kappa NN NN O
B NN NN O
probe NN NN O
to NN NN O
form NN NN O
a NN NN O
complex NN NN O
with NN NN O
the NN NN O
same NN NN O
electrophoretic NN NN O
mobility NN NN O
as NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
. NN NN O
   
Therefore NN NN O
the NN NN O
rel NN NN O
- NN NN O
related NN NN O
65 NN NN O
- NN NN O
kD NN NN O
protein NN NN O
may NN NN O
represent NN NN O
the NN NN O
p65 NN NN B-Protein
subunit NN NN O
of NN NN O
the NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
complex NN NN O
. NN NN O
   
Murine NN NN O
and NN NN O
human NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
factors NN NN O
mediate NN NN O
transcription NN NN O
through NN NN O
a NN NN O
cis NN NN O
- NN NN O
regulatory NN NN O
element NN NN O
within NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
delta NN NN O
gene NN NN O
enhancer NN NN O
. NN NN O
   
A NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
activators NN NN O
has NN NN O
recently NN NN O
been NN NN O
identified NN NN O
in NN NN O
chickens NN NN O
; NN NN O
these NN NN O
transcriptional NN NN O
activators NN NN O
recognize NN NN O
a NN NN O
common NN NN O
consensus NN NN O
motif NN NN O
( NN NN O
WGATAR NN NN O
) NN NN O
through NN NN O
a NN NN O
conserved NN NN O
C4 NN NN O
zinc NN NN O
finger NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
members NN NN O
of NN NN O
this NN NN O
multigene NN NN O
family NN NN O
, NN NN O
cGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
is NN NN O
most NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
the NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
lineage NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
human NN NN O
and NN NN O
murine NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
factors NN NN O
shows NN NN O
a NN NN O
striking NN NN O
degree NN NN O
of NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
identity NN NN O
and NN NN O
similar NN NN O
patterns NN NN O
of NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
expression NN NN O
in NN NN O
these NN NN O
three NN NN O
organisms NN NN O
. NN NN O
   
The NN NN O
murine NN NN O
and NN NN O
human NN NN O
factors NN NN O
are NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
human NN NN O
and NN NN O
murine NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
can NN NN O
activate NN NN O
transcription NN NN O
through NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
site NN NN O
identified NN NN O
within NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
delta NN NN O
gene NN NN O
enhancer NN NN O
. NN NN O
   
We NN NN O
infer NN NN O
that NN NN O
the NN NN O
murine NN NN O
and NN NN O
human NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
proteins NN NN O
play NN NN O
a NN NN O
central NN NN O
and NN NN O
highly NN NN O
conserved NN NN O
role NN NN O
in NN NN O
vertebrate NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
regulation NN NN O
. NN NN O
   
Processing NN NN O
of NN NN O
the NN NN O
precursor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
protease NN NN B-Protein
during NN NN O
acute NN NN O
infection NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
genome NN NN O
is NN NN O
regulated NN NN O
in NN NN O
part NN NN O
by NN NN O
cellular NN NN O
factors NN NN O
and NN NN O
is NN NN O
stimulated NN NN O
by NN NN O
activation NN NN O
of NN NN O
latently NN NN O
infected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
also NN NN O
correlates NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
which NN NN O
binds NN NN O
to NN NN O
two NN NN O
adjacent NN NN O
sites NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
consists NN NN O
of NN NN O
two NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
subunits NN NN O
of NN NN O
relative NN NN O
molecular NN NN O
mass NN NN O
50 NN NN O
, NN NN O
000 NN NN O
( NN NN O
50K NN NN O
) NN NN O
associated NN NN O
with NN NN O
two NN NN O
65K NN NN O
subunits NN NN O
. NN NN O
   
It NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
mature NN NN O
B NN NN O
cells NN NN O
, NN NN O
but NN NN O
is NN NN O
present NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
as NN NN O
an NN NN O
inactive NN NN O
cytoplasmic NN NN O
complex NN NN O
. NN NN O
   
External NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
those NN NN O
that NN NN O
activate NN NN O
T NN NN O
cells NN NN O
, NN NN O
result NN NN O
in NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
cloning NN NN O
of NN NN O
the NN NN O
complementary NN NN O
DNA NN NN O
for NN NN O
the NN NN O
50K NN NN B-Protein
subunit NN NN I-Protein
helped NN NN O
to NN NN O
identify NN NN O
an NN NN O
exclusively NN NN O
cytoplasmic NN NN O
105K NN NN O
precursor NN NN O
( NN NN O
p105 NN NN B-Protein
) NN NN O
( NN NN O
V NN NN O
. NN NN O
B NN NN O
. NN NN O
, NN NN O
P NN NN O
. NN NN O
K NN NN O
. NN NN O
and NN NN O
A NN NN O
. NN NN O
I NN NN O
. NN NN O
, NN NN O
manuscript NN NN O
submitted NN NN O
) NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
might NN NN O
therefore NN NN O
also NN NN O
be NN NN O
regulated NN NN O
by NN NN O
the NN NN O
extent NN NN O
of NN NN O
processing NN NN O
of NN NN O
p105 NN NN B-Protein
. NN NN O
   
Because NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
requires NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
for NN NN O
efficient NN NN O
transcription NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
effect NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
on NN NN O
the NN NN O
processing NN NN O
of NN NN O
the NN NN O
human NN NN O
105K NN NN O
precursor NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
protease NN NN B-Protein
can NN NN O
process NN NN O
p105 NN NN B-Protein
and NN NN O
increases NN NN O
levels NN NN O
of NN NN O
active NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
. NN NN O
   
HIV NN NN O
enhancer NN NN O
activity NN NN O
perpetuated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
on NN NN O
infection NN NN O
of NN NN O
monocytes NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
Permissiveness NN NN O
to NN NN O
replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
differs NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
In NN NN O
T NN NN O
cells NN NN O
, NN NN O
HIV NN NN O
transcription NN NN O
is NN NN O
poorly NN NN O
detected NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Cloned NN NN O
, NN NN O
normal NN NN O
T NN NN O
lymphocytes NN NN O
show NN NN O
very NN NN O
little NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
basal NN NN O
activity NN NN O
of NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
and NN NN O
low NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
potent NN NN O
transcriptional NN NN O
activator NN NN O
of NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
fixed NN NN O
tissue NN NN O
macrophages NN NN O
express NN NN O
detectable NN NN O
HIV NN NN O
proteins NN NN O
, NN NN O
indicating NN NN O
permanent NN NN O
virus NN NN O
transcription NN NN O
. NN NN O
   
One NN NN O
explanation NN NN O
for NN NN O
the NN NN O
perpetuation NN NN O
of NN NN O
virus NN NN O
infection NN NN O
in NN NN O
macrophages NN NN O
could NN NN O
be NN NN O
sustained NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
U937 NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
which NN NN O
is NN NN O
fully NN NN O
permissive NN NN O
to NN NN O
HIV NN NN O
replication NN NN O
, NN NN O
is NN NN O
known NN NN O
to NN NN O
express NN NN O
only NN NN O
low NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
chronic NN NN O
HIV NN NN O
infection NN NN O
results NN NN O
in NN NN O
both NN NN O
induction NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
with NN NN O
antigenic NN NN O
properties NN NN O
indistinguishable NN NN O
from NN NN O
those NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
permanently NN NN O
increased NN NN O
HIV NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
phenomenon NN NN O
, NN NN O
which NN NN O
is NN NN O
independent NN NN O
of NN NN O
tumour NN NN O
necrosis NN NN O
factor NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
HIV NN NN O
replication NN NN O
, NN NN O
and NN NN O
is NN NN O
thus NN NN O
likely NN NN O
to NN NN O
explain NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
the NN NN O
perpetuation NN NN O
of NN NN O
HIV NN NN O
infection NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
platelet NN NN O
GPIIb NN NN B-Protein
gene NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
major NN NN O
objectives NN NN O
in NN NN O
the NN NN O
study NN NN O
of NN NN O
thrombogenesis NN NN O
is NN NN O
to NN NN O
determine NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
a NN NN O
hematopoietic NN NN O
progenitor NN NN O
is NN NN O
activated NN NN O
and NN NN O
committed NN NN O
to NN NN O
the NN NN O
megakaryocytic NN NN O
lineage NN NN O
. NN NN O
   
Recent NN NN O
development NN NN O
of NN NN O
primary NN NN O
cultures NN NN O
of NN NN O
human NN NN O
megakaryocytes NN NN O
and NN NN O
the NN NN O
molecular NN NN O
cloning NN NN O
of NN NN O
genes NN NN O
that NN NN O
are NN NN O
specific NN NN O
to NN NN O
this NN NN O
lineage NN NN O
offer NN NN O
the NN NN O
possibility NN NN O
of NN NN O
getting NN NN O
some NN NN O
insights NN NN O
into NN NN O
the NN NN O
genetic NN NN O
mechanisms NN NN O
that NN NN O
control NN NN O
megakaryocytopoiesis NN NN O
. NN NN O
   
One NN NN O
gene NN NN O
of NN NN O
interest NN NN O
is NN NN O
the NN NN O
glycoprotein NN NN B-Protein
IIb NN NN I-Protein
( NN NN O
GPIIb NN NN B-Protein
) NN NN O
gene NN NN O
; NN NN O
GPIIb NN NN B-Protein
, NN NN O
the NN NN O
alpha NN NN O
subunit NN NN O
of NN NN O
the NN NN O
platelet NN NN O
cytoadhesin NN NN O
GPIIb NN NN O
- NN NN O
IIIa NN NN O
, NN NN O
is NN NN O
produced NN NN O
in NN NN O
megakaryocytes NN NN O
at NN NN O
an NN NN O
early NN NN O
stage NN NN O
of NN NN O
the NN NN O
differentiation NN NN O
, NN NN O
whereas NN NN O
the NN NN O
other NN NN O
subunit NN NN O
of NN NN O
this NN NN O
complex NN NN O
, NN NN O
GPIIIa NN NN B-Protein
, NN NN O
is NN NN O
expressed NN NN O
in NN NN O
other NN NN O
cells NN NN O
. NN NN O
   
For NN NN O
these NN NN O
reasons NN NN O
, NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
GPIIb NN NN B-Protein
gene NN NN O
was NN NN O
used NN NN O
to NN NN O
identify NN NN O
the NN NN O
regions NN NN O
that NN NN O
interact NN NN O
with NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
nuclear NN NN O
factors NN NN O
. NN NN O
   
A NN NN O
fragment NN NN O
extending NN NN O
from NN NN O
- NN NN O
643 NN NN O
to NN NN O
+ NN NN O
33 NN NN O
is NN NN O
capable NN NN O
of NN NN O
controlling NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
CAT NN NN B-Protein
gene NN NN O
in NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
Within NN NN O
this NN NN O
region NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
several NN NN O
sequences NN NN O
that NN NN O
are NN NN O
implicated NN NN O
in NN NN O
DNA NN NN O
protein NN NN O
interactions NN NN O
as NN NN O
shown NN NN O
in NN NN O
DNAse NN NN O
I NN NN O
footprints NN NN O
and NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
One NN NN O
region NN NN O
, NN NN O
centered NN NN O
at NN NN O
- NN NN O
54 NN NN O
, NN NN O
is NN NN O
similar NN NN O
to NN NN O
a NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
E1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
, NN NN O
and NN NN O
a NN NN O
region NN NN O
located NN NN O
at NN NN O
position NN NN O
- NN NN O
233 NN NN O
contains NN NN O
a NN NN O
CCAAT NN NN O
motif NN NN O
. NN NN O
   
Two NN NN O
domains NN NN O
centered NN NN O
at NN NN O
positions NN NN O
- NN NN O
345 NN NN O
and NN NN O
- NN NN O
540 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
bind NN NN O
proteins NN NN O
that NN NN O
are NN NN O
present NN NN O
in NN NN O
megakaryocytic NN NN O
cells NN NN O
and NN NN O
nonrelated NN NN O
cells NN NN O
as NN NN O
well NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
two NN NN O
other NN NN O
domains NN NN O
, NN NN O
located NN NN O
at NN NN O
positions NN NN O
- NN NN O
460 NN NN O
and NN NN O
- NN NN O
510 NN NN O
, NN NN O
interact NN NN O
with NN NN O
proteins NN NN O
that NN NN O
are NN NN O
only NN NN O
present NN NN O
in NN NN O
megakaryocytic NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
deletion NN NN O
of NN NN O
the NN NN O
region NN NN O
containing NN NN O
these NN NN O
two NN NN O
domains NN NN O
results NN NN O
in NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
of NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
It NN NN O
is NN NN O
very NN NN O
likely NN NN O
that NN NN O
these NN NN O
domains NN NN O
bind NN NN O
megakaryocyte NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
proteins NN NN O
acting NN NN O
as NN NN O
positive NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Cortivazol NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
messenger NN NN O
ribonucleic NN NN O
acid NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
dexamethasone NN NN O
- NN NN O
resistant NN NN O
human NN NN O
leukemic NN NN O
( NN NN O
CEM NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
Cortivazol NN NN O
is NN NN O
a NN NN O
phenylpyrazolo NN NN O
glucocorticoid NN NN O
of NN NN O
high NN NN O
potency NN NN O
and NN NN O
unusual NN NN O
structure NN NN O
. NN NN O
   
In NN NN O
both NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
highly NN NN O
dexamethasone NN NN O
( NN NN O
dex NN NN O
) NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
of NN NN O
the NN NN O
human NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
CEM NN NN O
, NN NN O
exposure NN NN O
to NN NN O
cortivazol NN NN O
leads NN NN O
to NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
shown NN NN O
recently NN NN O
that NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
CEM NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
a NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
, NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
- NN NN O
defective NN NN O
clone NN NN O
ICR NN NN O
- NN NN O
27 NN NN O
TK NN NN O
- NN NN O
3 NN NN O
, NN NN O
dex NN NN O
induces NN NN O
GR NN NN B-Protein
mRNA NN NN O
. NN NN O
   
To NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
cortivazol NN NN O
acts NN NN O
in NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
by NN NN O
making NN NN O
use NN NN O
of NN NN O
the NN NN O
residual NN NN O
GR NN NN B-Protein
found NN NN O
there NN NN O
, NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
were NN NN O
treated NN NN O
with NN NN O
various NN NN O
concentrations NN NN O
of NN NN O
cortivazol NN NN O
and NN NN O
induction NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
was NN NN O
studied NN NN O
. NN NN O
   
Cortivazol NN NN O
significantly NN NN O
induced NN NN O
GR NN NN B-Protein
mRNA NN NN O
in NN NN O
the NN NN O
normal NN NN O
CEM NN NN O
- NN NN O
C7 NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
two NN NN O
classes NN NN O
of NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
, NN NN O
although NN NN O
the NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
needed NN NN O
at NN NN O
least NN NN O
10 NN NN O
times NN NN O
more NN NN O
cortivazol NN NN O
than NN NN O
the NN NN O
normal NN NN O
cells NN NN O
for NN NN O
significant NN NN O
GR NN NN B-Protein
mRNA NN NN O
induction NN NN O
. NN NN O
   
Increased NN NN O
levels NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
were NN NN O
noticed NN NN O
as NN NN O
early NN NN O
as NN NN O
3 NN NN O
h NN NN O
after NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
general NN NN O
correlation NN NN O
between NN NN O
induction NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
and NN NN O
lysis NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
was NN NN O
found NN NN O
. NN NN O
   
Positive NN NN O
induction NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
might NN NN O
be NN NN O
one NN NN O
of NN NN O
the NN NN O
earliest NN NN O
crucial NN NN O
steps NN NN O
in NN NN O
the NN NN O
lysis NN NN O
of NN NN O
normal NN NN O
and NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
CEM NN NN O
cells NN NN O
, NN NN O
or NN NN O
might NN NN O
serve NN NN O
as NN NN O
a NN NN O
marker NN NN O
for NN NN O
the NN NN O
process NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
lysis NN NN O
pathway NN NN O
in NN NN O
the NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
cells NN NN O
is NN NN O
defective NN NN O
in NN NN O
that NN NN O
dex NN NN O
- NN NN O
resistant NN NN O
clones NN NN O
needed NN NN O
significantly NN NN O
more NN NN O
cortivazol NN NN O
than NN NN O
the NN NN O
normal NN NN O
cells NN NN O
for NN NN O
lysis NN NN O
of NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
regulation NN NN O
in NN NN O
phorbol NN NN O
ester NN NN O
stimulated NN NN O
T NN NN O
and NN NN O
B NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
minimal NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
promoter NN NN O
necessary NN NN O
for NN NN O
its NN NN O
transcriptional NN NN O
induction NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
( NN NN O
PMA NN NN O
) NN NN O
in NN NN O
human NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocyte NN NN O
cell NN NN O
lines NN NN O
has NN NN O
been NN NN O
localized NN NN O
between NN NN O
- NN NN O
52 NN NN O
and NN NN O
+ NN NN O
89 NN NN O
nucleotides NN NN O
( NN NN O
nt NN NN O
) NN NN O
relative NN NN O
to NN NN O
the NN NN O
gene NN NN O
' NN NN O
s NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
these NN NN O
sequences NN NN O
to NN NN O
those NN NN O
required NN NN O
to NN NN O
mediate NN NN O
virus NN NN O
or NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
induction NN NN O
of NN NN O
the NN NN O
gene NN NN O
reveal NN NN O
significant NN NN O
differences NN NN O
, NN NN O
and NN NN O
thus NN NN O
, NN NN O
the NN NN O
sequence NN NN O
requirements NN NN O
for NN NN O
PMA NN NN O
induction NN NN O
are NN NN O
distinct NN NN O
from NN NN O
those NN NN O
that NN NN O
mediate NN NN O
induction NN NN O
by NN NN O
virus NN NN O
or NN NN O
LPS NN NN O
. NN NN O
   
Although NN NN O
three NN NN O
sites NN NN O
in NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
( NN NN O
kappa NN NN O
1 NN NN O
, NN NN O
kappa NN NN O
2 NN NN O
, NN NN O
and NN NN O
kappa NN NN O
3 NN NN O
) NN NN O
specifically NN NN O
bind NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
lymphoid NN NN O
nuclear NN NN O
extracts NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
induction NN NN O
by NN NN O
PMA NN NN O
does NN NN O
not NN NN O
correlate NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activities NN NN O
displayed NN NN O
by NN NN O
different NN NN O
T NN NN O
and NN NN O
B NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
kappa NN NN O
1 NN NN O
- NN NN O
kappa NN NN O
3 NN NN O
can NN NN O
each NN NN O
be NN NN O
deleted NN NN O
from NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
with NN NN O
little NN NN O
effect NN NN O
on NN NN O
the NN NN O
gene NN NN O
' NN NN O
s NN NN O
inducibility NN NN O
by NN NN O
PMA NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
induction NN NN O
by NN NN O
PMA NN NN O
, NN NN O
like NN NN O
its NN NN O
induction NN NN O
by NN NN O
virus NN NN O
and NN NN O
LPS NN NN O
, NN NN O
is NN NN O
not NN NN O
primarily NN NN O
mediated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
but NN NN O
rather NN NN O
is NN NN O
mediated NN NN O
through NN NN O
other NN NN O
sequences NN NN O
and NN NN O
protein NN NN O
factors NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
multimers NN NN O
of NN NN O
kappa NN NN O
1 NN NN O
- NN NN O
kappa NN NN O
3 NN NN O
can NN NN O
confer NN NN O
PMA NN NN O
inducibility NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
in NN NN O
a NN NN O
B NN NN O
( NN NN O
Raji NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
a NN NN O
T NN NN O
( NN NN O
HUT78 NN NN O
) NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
However NN NN O
they NN NN O
are NN NN O
not NN NN O
functional NN NN O
on NN NN O
a NN NN O
truncated NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
, NN NN O
indicating NN NN O
that NN NN O
promoter NN NN O
context NN NN O
and NN NN O
cell NN NN O
type NN NN O
specificity NN NN O
influence NN NN O
the NN NN O
PMA NN NN O
inducible NN NN O
function NN NN O
of NN NN O
these NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
intermediates NN NN O
as NN NN O
apparently NN NN O
widely NN NN O
used NN NN O
messengers NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Hydrogen NN NN O
peroxide NN NN O
and NN NN O
oxygen NN NN O
radicals NN NN O
are NN NN O
agents NN NN O
commonly NN NN O
produced NN NN O
during NN NN O
inflammatory NN NN O
processes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
micromolar NN NN O
concentrations NN NN O
of NN NN O
H2O2 NN NN O
can NN NN O
induce NN NN O
the NN NN O
expression NN NN O
and NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
a NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
is NN NN O
potently NN NN O
and NN NN O
rapidly NN NN O
activated NN NN O
by NN NN O
an NN NN O
H2O2 NN NN O
treatment NN NN O
of NN NN O
cells NN NN O
from NN NN O
its NN NN O
inactive NN NN O
cytoplasmic NN NN O
form NN NN O
. NN NN O
   
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
, NN NN O
a NN NN O
well NN NN O
characterized NN NN O
antioxidant NN NN O
which NN NN O
counteracts NN NN O
the NN NN O
effects NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
( NN NN O
ROI NN NN O
) NN NN O
in NN NN O
living NN NN O
cells NN NN O
, NN NN O
prevented NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
H2O2 NN NN O
. NN NN O
   
NAC NN NN O
and NN NN O
other NN NN O
thiol NN NN O
compounds NN NN O
also NN NN O
blocked NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
cycloheximide NN NN O
, NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
, NN NN O
calcium NN NN O
ionophore NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
active NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
, NN NN O
lipopolysaccharide NN NN O
and NN NN O
lectin NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
diverse NN NN O
agents NN NN O
thought NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
distinct NN NN O
intracellular NN NN O
pathways NN NN O
might NN NN O
all NN NN O
act NN NN O
through NN NN O
a NN NN O
common NN NN O
mechanism NN NN O
involving NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
ROI NN NN O
. NN NN O
   
ROI NN NN O
appear NN NN O
to NN NN O
serve NN NN O
as NN NN O
messengers NN NN O
mediating NN NN O
directly NN NN O
or NN NN O
indirectly NN NN O
the NN NN O
release NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
subunit NN NN O
I NN NN O
kappa NN NN O
B NN NN O
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Contribution NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
motifs NN NN O
to NN NN O
the NN NN O
replicative NN NN O
capacity NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
: NN NN O
distinct NN NN O
patterns NN NN O
of NN NN O
viral NN NN O
growth NN NN O
are NN NN O
determined NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Starting NN NN O
with NN NN O
a NN NN O
replication NN NN O
- NN NN O
incompetent NN NN O
molecular NN NN O
clone NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
, NN NN O
lacking NN NN O
all NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
present NN NN O
in NN NN O
the NN NN O
native NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
, NN NN O
proviruses NN NN O
containing NN NN O
reconstructed NN NN O
LTRs NN NN O
with NN NN O
individual NN NN O
or NN NN O
combinations NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Sp1 NN NN B-Protein
elements NN NN O
were NN NN O
generated NN NN O
and NN NN O
evaluated NN NN O
for NN NN O
their NN NN O
capacity NN NN O
to NN NN O
produce NN NN O
virus NN NN O
progeny NN NN O
following NN NN O
transfection NN NN O
- NN NN O
cocultivation NN NN O
. NN NN O
   
Virus NN NN O
stocks NN NN O
obtained NN NN O
from NN NN O
these NN NN O
experiments NN NN O
exhibited NN NN O
a NN NN O
continuum NN NN O
of NN NN O
replicative NN NN O
capacities NN NN O
in NN NN O
different NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
types NN NN O
depending NN NN O
on NN NN O
which NN NN O
element NN NN O
( NN NN O
s NN NN O
) NN NN O
was NN NN O
present NN NN O
in NN NN O
the NN NN O
LTR NN NN O
. NN NN O
   
For NN NN O
example NN NN O
, NN NN O
in NN NN O
experiments NN NN O
involving NN NN O
proviral NN NN O
clones NN NN O
with NN NN O
LTRs NN NN O
containing NN NN O
one NN NN O
or NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
elements NN NN O
( NN NN O
and NN NN O
no NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
) NN NN O
, NN NN O
a NN NN O
hierarchy NN NN O
of NN NN O
cellular NN NN O
permissivity NN NN O
to NN NN O
virus NN NN O
replication NN NN O
( NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
= NN NN O
MT4 NN NN O
greater NN NN O
than NN NN O
H9 NN NN O
greater NN NN O
than NN NN O
CEM NN NN O
greater NN NN O
than NN NN O
Jurkat NN NN O
) NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Of NN NN O
note NN NN O
was NN NN O
the NN NN O
associated NN NN O
emergence NN NN O
of NN NN O
second NN NN O
- NN NN O
site NN NN O
LTR NN NN O
revertants NN NN O
which NN NN O
involved NN NN O
an NN NN O
alteration NN NN O
of NN NN O
the NN NN O
TATA NN NN O
box NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
LTR NN NN O
possesses NN NN O
functional NN NN O
redundancy NN NN O
which NN NN O
ensures NN NN O
virus NN NN O
replication NN NN O
in NN NN O
different NN NN O
T NN NN O
- NN NN O
cell NN NN O
types NN NN O
and NN NN O
is NN NN O
capable NN NN O
of NN NN O
changing NN NN O
depending NN NN O
on NN NN O
the NN NN O
particular NN NN O
combination NN NN O
of NN NN O
transcriptional NN NN O
factors NN NN O
present NN NN O
. NN NN O
   
Purification NN NN O
of NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
activates NN NN O
the NN NN O
T NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
C NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
enhancer NN NN O
in NN NN O
a NN NN O
context NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
differentiation NN NN O
of NN NN O
T NN NN O
cells NN NN O
into NN NN O
functionally NN NN O
diverse NN NN O
subpopulations NN NN O
is NN NN O
controlled NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
transcriptional NN NN O
activation NN NN O
and NN NN O
silencing NN NN O
; NN NN O
however NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
in NN NN O
detail NN NN O
about NN NN O
the NN NN O
proteins NN NN O
that NN NN O
influence NN NN O
this NN NN O
developmental NN NN O
process NN NN O
. NN NN O
   
We NN NN O
have NN NN O
purified NN NN O
a NN NN O
new NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
that NN NN O
is NN NN O
implicated NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
a NN NN O
major NN NN O
component NN NN O
of NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
. NN NN O
   
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
originally NN NN O
identified NN NN O
and NN NN O
purified NN NN O
through NN NN O
its NN NN O
binding NN NN O
sites NN NN O
on NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
enhancer NN NN O
and NN NN O
to NN NN O
promoters NN NN O
for NN NN O
several NN NN O
genes NN NN O
expressed NN NN O
at NN NN O
significantly NN NN O
earlier NN NN O
stages NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
development NN NN O
than NN NN O
the NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
p56lck NN NN B-Protein
and NN NN O
CD3 NN NN B-Protein
delta NN NN I-Protein
) NN NN O
. NN NN O
   
Sequences NN NN O
related NN NN O
to NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
binding NN NN O
motif NN NN O
( NN NN O
5 NN NN O
' NN NN O
- NN NN O
GGCACCCTTTGA NN NN O
- NN NN O
3 NN NN O
' NN NN O
) NN NN O
are NN NN O
also NN NN O
found NN NN O
in NN NN O
the NN NN O
human NN NN O
TCR NN NN B-Protein
delta NN NN I-Protein
( NN NN O
and NN NN O
possibly NN NN O
TCR NN NN B-Protein
beta NN NN I-Protein
) NN NN O
enhancers NN NN O
. NN NN O
   
Southwestern NN NN O
and NN NN O
gel NN NN O
renaturation NN NN O
experiments NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
purified NN NN O
protein NN NN O
fractions NN NN O
revealed NN NN O
that NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
activity NN NN O
is NN NN O
derived NN NN O
from NN NN O
a NN NN O
family NN NN O
of NN NN O
57 NN NN O
- NN NN O
to NN NN O
53 NN NN O
- NN NN O
kD NN NN O
proteins NN NN O
that NN NN O
are NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
mature NN NN O
and NN NN O
immature NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
( NN NN O
Jurkat NN NN O
, NN NN O
CCRF NN NN O
- NN NN O
CEM NN NN O
) NN NN O
and NN NN O
not NN NN O
in NN NN O
mature NN NN O
B NN NN O
cells NN NN O
( NN NN O
JY NN NN O
, NN NN O
Namalwa NN NN O
) NN NN O
or NN NN O
nonlymphoid NN NN O
( NN NN O
HeLa NN NN O
) NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
A NN NN O
small NN NN O
95 NN NN O
- NN NN O
bp NN NN O
fragment NN NN O
of NN NN O
the NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
control NN NN O
region NN NN O
that NN NN O
contains NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
binding NN NN O
site NN NN O
juxtaposed NN NN O
between NN NN O
a NN NN O
cAMP NN NN O
- NN NN O
response NN NN O
element NN NN O
( NN NN O
the NN NN O
CRE NN NN O
or NN NN O
T NN NN O
alpha NN NN O
1 NN NN O
motif NN NN O
) NN NN O
and NN NN O
the NN NN O
binding NN NN O
site NN NN O
for NN NN O
a NN NN O
distinct NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
protein NN NN O
( NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
behaved NN NN O
as NN NN O
a NN NN O
potent NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Tandem NN NN O
copies NN NN O
of NN NN O
this NN NN O
enhancer NN NN O
functioned NN NN O
synergistically NN NN O
in NN NN O
mature NN NN O
( NN NN O
Jurkat NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
as NN NN O
well NN NN O
as NN NN O
resting NN NN O
and NN NN O
activated NN NN O
immature NN NN O
( NN NN O
CCRF NN NN O
- NN NN O
CEM NN NN O
) NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
binding NN NN O
site NN NN O
diminished NN NN O
enhancer NN NN O
activity NN NN O
and NN NN O
disrupted NN NN O
the NN NN O
synergism NN NN O
observed NN NN O
in NN NN O
vivo NN NN O
between NN NN O
tandem NN NN O
enhancer NN NN O
repeats NN NN O
. NN NN O
   
The NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
binding NN NN O
site NN NN O
was NN NN O
also NN NN O
required NN NN O
for NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
enhancer NN NN O
activity NN NN O
in NN NN O
transcriptionally NN NN O
active NN NN O
extracts NN NN O
from NN NN O
Jurkat NN NN O
but NN NN O
not NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
confirming NN NN O
that NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Curiously NN NN O
, NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
binding NN NN O
element NN NN O
was NN NN O
inactive NN NN O
in NN NN O
vivo NN NN O
when NN NN O
removed NN NN O
from NN NN O
its NN NN O
neighboring NN NN O
elements NN NN O
on NN NN O
the NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
enhancer NN NN O
and NN NN O
positioned NN NN O
in NN NN O
one NN NN O
or NN NN O
more NN NN O
copies NN NN O
upstream NN NN O
of NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
appears NN NN O
to NN NN O
depend NN NN O
on NN NN O
the NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
T NN NN B-Protein
alpha NN NN I-Protein
1 NN NN I-Protein
( NN NN O
CREB NN NN B-Protein
) NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
the NN NN O
context NN NN O
of NN NN O
its NN NN O
binding NN NN O
site NN NN O
within NN NN O
the NN NN O
TCR NN NN B-Protein
alpha NN NN I-Protein
enhancer NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
T NN NN O
- NN NN O
cell NN NN O
trans NN NN O
- NN NN O
activator NN NN O
that NN NN O
recognizes NN NN O
a NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
inducible NN NN O
element NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
The NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
promoter NN NN O
is NN NN O
recognized NN NN O
by NN NN O
several NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
and NN NN O
ubiquitous NN NN O
transcriptional NN NN O
regulators NN NN O
that NN NN O
integrate NN NN O
information NN NN O
transmitted NN NN O
by NN NN O
various NN NN O
signaling NN NN O
systems NN NN O
leading NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
combination NN NN O
of NN NN O
transfection NN NN O
, NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
and NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
methods NN NN O
, NN NN O
we NN NN O
have NN NN O
discovered NN NN O
the NN NN O
novel NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
activator NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
for NN NN O
T NN NN B-Protein
- NN NN I-Protein
Cell NN NN I-Protein
Factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
recognizes NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
response NN NN O
element NN NN O
( NN NN O
TCE NN NN O
) NN NN O
located NN NN O
within NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
TCE NN NN O
is NN NN O
similar NN NN O
in NN NN O
sequence NN NN O
to NN NN O
a NN NN O
consensus NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
site NN NN O
, NN NN O
several NN NN O
criteria NN NN O
indicate NN NN O
that NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
distinct NN NN O
from NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
However NN NN O
, NN NN O
like NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
TCF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
is NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
and NN NN O
other NN NN O
T NN NN O
- NN NN O
cell NN NN O
activators NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
bind NN NN O
the NN NN O
immunoglobulin NN NN O
enhancer NN NN O
microE5 NN NN O
/ NN NN O
kappa NN NN O
2 NN NN O
motif NN NN O
. NN NN O
   
Activity NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
and NN NN O
kappa NN NN O
light NN NN O
chain NN NN O
gene NN NN O
enhancers NN NN O
depends NN NN O
on NN NN O
a NN NN O
complex NN NN O
interplay NN NN O
of NN NN O
ubiquitous NN NN O
and NN NN O
developmentally NN NN O
regulated NN NN O
proteins NN NN O
. NN NN O
   
Two NN NN O
complementary NN NN O
DNAs NN NN O
were NN NN O
isolated NN NN O
that NN NN O
encode NN NN O
proteins NN NN O
, NN NN O
denoted NN NN O
ITF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
ITF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
that NN NN O
are NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
and NN NN O
bind NN NN O
the NN NN O
microE5 NN NN O
/ NN NN O
kappa NN NN O
2 NN NN O
motif NN NN O
found NN NN O
in NN NN O
both NN NN O
heavy NN NN O
and NN NN O
kappa NN NN O
light NN NN O
chain NN NN O
enhancers NN NN O
. NN NN O
   
The NN NN O
complementary NN NN O
DNAs NN NN O
are NN NN O
the NN NN O
products NN NN O
of NN NN O
distinct NN NN O
genes NN NN O
, NN NN O
yet NN NN O
both NN NN O
ITF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
ITF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
structurally NN NN O
and NN NN O
functionally NN NN O
similar NN NN O
. NN NN O
   
The NN NN O
two NN NN O
proteins NN NN O
interact NN NN O
with NN NN O
one NN NN O
another NN NN O
through NN NN O
their NN NN O
putative NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
motifs NN NN O
and NN NN O
each NN NN O
possesses NN NN O
a NN NN O
distinct NN NN O
domain NN NN O
that NN NN O
dictates NN NN O
transcription NN NN O
activation NN NN O
. NN NN O
   
A NN NN O
factor NN NN O
known NN NN O
to NN NN O
bind NN NN O
to NN NN O
endogenous NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
only NN NN O
in NN NN O
lymphocytes NN NN O
is NN NN O
a NN NN O
ubiquitously NN NN O
active NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
enhancer NN NN O
located NN NN O
in NN NN O
the NN NN O
first NN NN O
intron NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
constant NN NN O
region NN NN O
is NN NN O
a NN NN O
major NN NN O
determinant NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
. NN NN O
   
Like NN NN O
other NN NN O
enhancers NN NN O
, NN NN O
the NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
contains NN NN O
several NN NN O
short NN NN O
sequence NN NN O
motifs NN NN O
that NN NN O
bind NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Each NN NN O
binding NN NN O
site NN NN O
contributes NN NN O
to NN NN O
the NN NN O
overall NN NN O
activity NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
, NN NN O
however NN NN O
no NN NN O
single NN NN O
element NN NN O
seems NN NN O
absolutely NN NN O
required NN NN O
for NN NN O
activity NN NN O
. NN NN O
   
For NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
the NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
components NN NN O
, NN NN O
we NN NN O
have NN NN O
cloned NN NN O
and NN NN O
analyzed NN NN O
individual NN NN O
sequence NN NN O
elements NN NN O
. NN NN O
   
We NN NN O
find NN NN O
that NN NN O
the NN NN O
factor NN NN O
that NN NN O
binds NN NN O
to NN NN O
the NN NN O
E3 NN NN O
enhancer NN NN O
motif NN NN O
, NN NN O
CATGTGGC NN NN O
, NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
It NN NN O
is NN NN O
present NN NN O
in NN NN O
an NN NN O
active NN NN O
form NN NN O
in NN NN O
both NN NN O
B NN NN O
cells NN NN O
and NN NN O
non NN NN O
- NN NN O
B NN NN O
cells NN NN O
, NN NN O
where NN NN O
it NN NN O
can NN NN O
mediate NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
However NN NN O
, NN NN O
despite NN NN O
its NN NN O
ability NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
a NN NN O
transfected NN NN O
reporter NN NN O
gene NN NN O
, NN NN O
the NN NN O
factor NN NN O
is NN NN O
apparently NN NN O
unable NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
endogenous NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
in NN NN O
non NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
: NN NN O
In NN NN O
previous NN NN O
experiments NN NN O
by NN NN O
others NN NN O
, NN NN O
the NN NN O
characteristic NN NN O
in NN NN O
vivo NN NN O
footprint NN NN O
of NN NN O
this NN NN O
factor NN NN O
, NN NN O
designated NN NN O
NF NN NN B-Protein
- NN NN I-Protein
muE3 NN NN I-Protein
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
B NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
non NN NN O
- NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
this NN NN O
and NN NN O
other NN NN O
findings NN NN O
the NN NN O
picture NN NN O
emerges NN NN O
that NN NN O
there NN NN O
are NN NN O
at NN NN O
least NN NN O
three NN NN O
categories NN NN O
of NN NN O
factors NN NN O
which NN NN O
mediate NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
: NN NN O
( NN NN O
a NN NN O
) NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factors NN NN O
such NN NN O
as NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2B NN NN I-Protein
that NN NN O
are NN NN O
not NN NN O
expressed NN NN O
in NN NN O
most NN NN O
other NN NN O
cell NN NN O
types NN NN O
: NN NN O
( NN NN O
b NN NN O
) NN NN O
ubiquitous NN NN O
factors NN NN O
such NN NN O
as NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
that NN NN O
are NN NN O
constitutively NN NN O
active NN NN O
in NN NN O
B NN NN O
cells NN NN O
but NN NN O
are NN NN O
sequestered NN NN O
in NN NN O
an NN NN O
inactive NN NN O
form NN NN O
in NN NN O
other NN NN O
cells NN NN O
; NN NN O
( NN NN O
c NN NN O
) NN NN O
ubiquitously NN NN O
active NN NN O
factors NN NN O
, NN NN O
exemplified NN NN O
by NN NN O
the NN NN O
one NN NN O
binding NN NN O
to NN NN O
the NN NN O
E3 NN NN O
sequence NN NN O
motif NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
is NN NN O
present NN NN O
in NN NN O
an NN NN O
active NN NN O
form NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
but NN NN O
is NN NN O
apparently NN NN O
unable NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
endogenous NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
enhancer NN NN O
in NN NN O
non NN NN O
- NN NN O
B NN NN O
cells NN NN O
, NN NN O
perhaps NN NN O
due NN NN O
to NN NN O
a NN NN O
non NN NN O
- NN NN O
permissive NN NN O
chromatin NN NN O
structure NN NN O
of NN NN O
the NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
locus NN NN O
. NN NN O
   
Transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
myeloid NN NN O
leukemic NN NN O
cells NN NN O
. NN NN O
   
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
the NN NN O
polypeptide NN NN O
product NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
recognizes NN NN O
and NN NN O
binds NN NN O
to NN NN O
specific NN NN O
DNA NN NN O
sequences NN NN O
and NN NN O
stimulates NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
responsive NN NN O
to NN NN O
certain NN NN O
growth NN NN O
factors NN NN O
and NN NN O
phorbol NN NN O
esters NN NN O
such NN NN O
as NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
TPA NN NN O
on NN NN O
the NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Low NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcripts NN NN O
were NN NN O
detectable NN NN O
in NN NN O
untreated NN NN O
HL NN NN O
- NN NN O
60 NN NN O
leukemic NN NN O
cells NN NN O
, NN NN O
increased NN NN O
significantly NN NN O
by NN NN O
6 NN NN O
h NN NN O
, NN NN O
and NN NN O
reached NN NN O
near NN NN O
maximal NN NN O
levels NN NN O
by NN NN O
24 NN NN O
h NN NN O
of NN NN O
exposure NN NN O
to NN NN O
32 NN NN O
nM NN NN O
TPA NN NN O
. NN NN O
   
Similar NN NN O
kinetics NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
induction NN NN O
by NN NN O
TPA NN NN O
were NN NN O
observed NN NN O
in NN NN O
human NN NN O
U NN NN O
- NN NN O
937 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocytic NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
Similar NN NN O
findings NN NN O
were NN NN O
obtained NN NN O
with NN NN O
bryostatin NN NN O
1 NN NN O
( NN NN O
10 NN NN O
nM NN NN O
) NN NN O
, NN NN O
another NN NN O
activator NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
and NN NN O
inducer NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
) NN NN O
, NN NN O
a NN NN O
structurally NN NN O
distinct NN NN O
agent NN NN O
which NN NN O
also NN NN O
induces NN NN O
HL NN NN O
- NN NN O
60 NN NN O
monocytic NN NN O
differentiation NN NN O
, NN NN O
increased NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
. NN NN O
   
TPA NN NN O
treatment NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
cycloheximide NN NN O
was NN NN O
associated NN NN O
with NN NN O
superinduction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcripts NN NN O
. NN NN O
   
Run NN NN O
- NN NN O
on NN NN O
analysis NN NN O
demonstrated NN NN O
detectable NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
untreated NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
, NN NN O
and NN NN O
that NN NN O
exposure NN NN O
to NN NN O
TPA NN NN O
increases NN NN O
this NN NN O
rate NN NN O
3 NN NN O
. NN NN O
3 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
with NN NN O
both NN NN O
TPA NN NN O
and NN NN O
cycloheximide NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
rates NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcription NN NN O
. NN NN O
   
The NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
RNA NN NN O
as NN NN O
determined NN NN O
by NN NN O
treating NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
with NN NN O
TPA NN NN O
and NN NN O
actinomycin NN NN O
D NN NN O
was NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
RNA NN NN O
in NN NN O
TPA NN NN O
- NN NN O
treated NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
exposed NN NN O
to NN NN O
cycloheximide NN NN O
and NN NN O
actinomycin NN NN O
D NN NN O
was NN NN O
greater NN NN O
than NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggested NN NN O
that NN NN O
the NN NN O
increase NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
RNA NN NN O
observed NN NN O
during NN NN O
TPA NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
both NN NN O
transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
mechanisms NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
a NN NN O
novel NN NN O
factor NN NN O
that NN NN O
interacts NN NN O
with NN NN O
an NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
promoter NN NN O
and NN NN O
stimulates NN NN O
transcription NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
the NN NN O
lymphoid NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
OTF2 NN NN B-Protein
. NN NN O
   
The NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
MOPC NN NN O
141 NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
was NN NN O
studied NN NN O
by NN NN O
using NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
. NN NN O
   
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
of NN NN O
this NN NN O
gene NN NN O
was NN NN O
dependent NN NN O
on NN NN O
the NN NN O
octamer NN NN O
element NN NN O
5 NN NN O
' NN NN O
- NN NN O
ATGCAAAG NN NN O
- NN NN O
3 NN NN O
' NN NN O
, NN NN O
located NN NN O
in NN NN O
the NN NN O
upstream NN NN O
region NN NN O
of NN NN O
this NN NN O
promoter NN NN O
and NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
all NN NN O
other NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
and NN NN O
light NN NN O
- NN NN O
chain NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
interaction NN NN O
of NN NN O
purified NN NN O
octamer NN NN B-Protein
transcription NN NN I-Protein
factors NN NN I-Protein
1 NN NN I-Protein
and NN NN O
2 NN NN B-Protein
( NN NN O
OTF1 NN NN B-Protein
and NN NN O
OTF2 NN NN B-Protein
) NN NN O
with NN NN O
the NN NN O
MOPC NN NN O
141 NN NN O
promoter NN NN O
was NN NN O
studied NN NN O
by NN NN O
using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
DNase NN NN O
I NN NN O
footprinting NN NN O
. NN NN O
   
Purified NN NN O
OTF1 NN NN B-Protein
from NN NN O
HeLa NN NN O
cells NN NN O
and NN NN O
OTF1 NN NN B-Protein
and NN NN O
OTF2 NN NN B-Protein
from NN NN O
B NN NN O
cells NN NN O
bound NN NN O
to NN NN O
identical NN NN O
sequences NN NN O
within NN NN O
the NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
OTF NN NN O
interactions NN NN O
we NN NN O
observed NN NN O
extended NN NN O
over NN NN O
the NN NN O
heptamer NN NN O
element NN NN O
5 NN NN O
' NN NN O
- NN NN O
CTCAGGA NN NN O
- NN NN O
3 NN NN O
' NN NN O
, NN NN O
and NN NN O
it NN NN O
seems NN NN O
likely NN NN O
that NN NN O
the NN NN O
binding NN NN O
of NN NN O
the NN NN O
purified NN NN O
factors NN NN O
involves NN NN O
cooperation NN NN O
between NN NN O
octamer NN NN O
and NN NN O
heptamer NN NN O
sites NN NN O
in NN NN O
this NN NN O
promoter NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
these NN NN O
elements NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
second NN NN O
regulatory NN NN O
element NN NN O
, NN NN O
the NN NN O
N NN NN O
element NN NN O
with NN NN O
the NN NN O
sequence NN NN O
5 NN NN O
' NN NN O
- NN NN O
GGAACCTCCCCC NN NN O
- NN NN O
3 NN NN O
' NN NN O
. NN NN O
   
The NN NN O
N NN NN O
element NN NN O
could NN NN O
independently NN NN O
mediate NN NN O
low NN NN O
levels NN NN O
of NN NN O
transcription NN NN O
in NN NN O
both NN NN O
B NN NN O
- NN NN O
cell NN NN O
and NN NN O
HeLa NN NN O
- NN NN O
cell NN NN O
extracts NN NN O
, NN NN O
and NN NN O
, NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
the NN NN O
octamer NN NN O
element NN NN O
, NN NN O
it NN NN O
can NN NN O
promote NN NN O
high NN NN O
levels NN NN O
of NN NN O
transcription NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
extracts NN NN O
. NN NN O
   
The NN NN O
N NN NN O
element NN NN O
bound NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NTF NN NN O
, NN NN O
that NN NN O
is NN NN O
ubiquitous NN NN O
in NN NN O
cell NN NN O
- NN NN O
type NN NN O
distribution NN NN O
, NN NN O
and NN NN O
NTF NN NN O
was NN NN O
distinct NN NN O
from NN NN O
any NN NN O
of NN NN O
the NN NN O
previously NN NN O
described NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
to NN NN O
similar NN NN O
sequences NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
NTF NN NN O
and NN NN O
OTF2 NN NN B-Protein
interactions NN NN O
( NN NN O
both NN NN O
with NN NN O
their NN NN O
cognate NN NN O
DNA NN NN O
elements NN NN O
and NN NN O
possibly NN NN O
at NN NN O
the NN NN O
protein NN NN O
- NN NN O
protein NN NN O
level NN NN O
) NN NN O
may NN NN O
be NN NN O
critical NN NN O
to NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
and NN NN O
that NN NN O
these NN NN O
interactions NN NN O
provide NN NN O
additional NN NN O
pathways NN NN O
for NN NN O
regulating NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
a NN NN O
second NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
element NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
enhancer NN NN O
elements NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
highly NN NN O
conserved NN NN O
octamer NN NN O
( NN NN O
OCTA NN NN O
) NN NN O
- NN NN O
nucleotide NN NN O
motif NN NN O
are NN NN O
important NN NN O
for NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
( NN NN O
IgH NN NN O
) NN NN O
gene NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
mutating NN NN O
the NN NN O
binding NN NN O
site NN NN O
for NN NN O
a NN NN O
putative NN NN O
additional NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
designated NN NN O
NF NN NN B-Protein
- NN NN I-Protein
microB NN NN I-Protein
, NN NN O
in NN NN O
the NN NN O
murine NN NN O
IgH NN NN O
enhancer NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
microB NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
IgH NN NN O
enhancer NN NN O
, NN NN O
because NN NN O
mutation NN NN O
of NN NN O
the NN NN O
microB NN NN O
DNA NN NN O
motif NN NN O
decreased NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
IgH NN NN O
enhancer NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
lineage NN NN O
but NN NN O
not NN NN O
in NN NN O
nonlymphoid NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
comparable NN NN O
to NN NN O
or NN NN O
even NN NN O
stronger NN NN O
than NN NN O
the NN NN O
effect NN NN O
of NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
OCTA NN NN O
site NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
combined NN NN O
mutation NN NN O
of NN NN O
both NN NN O
microB NN NN O
and NN NN O
OCTA NN NN O
sites NN NN O
further NN NN O
reduced NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
alteration NN NN O
of NN NN O
either NN NN O
the NN NN O
microB NN NN O
or NN NN O
E3 NN NN O
site NN NN O
in NN NN O
a NN NN O
70 NN NN O
- NN NN O
base NN NN O
- NN NN O
pair NN NN O
fragment NN NN O
of NN NN O
the NN NN O
IgH NN NN O
enhancer NN NN O
that NN NN O
lacks NN NN O
the NN NN O
binding NN NN O
site NN NN O
for NN NN O
OCTA NN NN O
abolished NN NN O
enhancer NN NN O
activity NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
completely NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
a NN NN O
multimer NN NN O
of NN NN O
the NN NN O
microB NN NN O
motif NN NN O
alone NN NN O
showed NN NN O
no NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
DNase NN NN O
footprinting NN NN O
analysis NN NN O
corroborated NN NN O
the NN NN O
functional NN NN O
data NN NN O
showing NN NN O
that NN NN O
a NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
protein NN NN O
binds NN NN O
to NN NN O
the NN NN O
microB NN NN O
DNA NN NN O
motif NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
microB NN NN O
element NN NN O
is NN NN O
a NN NN O
new NN NN O
crucial NN NN O
element NN NN O
important NN NN O
for NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
IgH NN NN O
gene NN NN O
but NN NN O
that NN NN O
interaction NN NN O
with NN NN O
another NN NN O
enhancer NN NN O
element NN NN O
is NN NN O
essential NN NN O
for NN NN O
its NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
genes NN NN O
is NN NN O
regulated NN NN O
by NN NN O
heat NN NN O
shock NN NN O
in NN NN O
human NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
heat NN NN O
shock NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
protooncogenes NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
was NN NN O
studied NN NN O
in NN NN O
human NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Heat NN NN O
shock NN NN O
caused NN NN O
an NN NN O
increase NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
levels NN NN O
and NN NN O
a NN NN O
decrease NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
levels NN NN O
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
( NN NN O
Hyon NN NN O
) NN NN O
and NN NN O
T NN NN O
( NN NN O
DND NN NN O
- NN NN O
41 NN NN O
) NN NN O
cell NN NN O
lines NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
normal NN NN O
human NN NN O
thymocytes NN NN O
. NN NN O
   
The NN NN O
changes NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
these NN NN O
protooncogenes NN NN O
in NN NN O
Hyon NN NN O
cells NN NN O
were NN NN O
most NN NN O
pronounced NN NN O
at NN NN O
42 NN NN O
and NN NN O
43 NN NN O
degrees NN NN O
C NN NN O
; NN NN O
kinetic NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
changes NN NN O
could NN NN O
be NN NN O
detected NN NN O
within NN NN O
30 NN NN O
min NN NN O
of NN NN O
heat NN NN O
shock NN NN O
. NN NN O
   
Altered NN NN O
transcription NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
genes NN NN O
was NN NN O
the NN NN O
primary NN NN O
effect NN NN O
of NN NN O
heat NN NN O
shock NN NN O
. NN NN O
   
Secondarily NN NN O
, NN NN O
heat NN NN O
shock NN NN O
of NN NN O
Hyon NN NN O
cells NN NN O
stabilized NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
level NN NN O
by NN NN O
increasing NN NN O
its NN NN O
half NN NN O
- NN NN O
life NN NN O
from NN NN O
24 NN NN O
to NN NN O
45 NN NN O
min NN NN O
. NN NN O
   
The NN NN O
overall NN NN O
effect NN NN O
of NN NN O
heat NN NN O
shock NN NN O
on NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
level NN NN O
, NN NN O
however NN NN O
, NN NN O
was NN NN O
a NN NN O
marked NN NN O
inhibition NN NN O
of NN NN O
its NN NN O
transcription NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
transcription NN NN O
of NN NN O
nuclear NN NN O
protooncogenes NN NN O
is NN NN O
regulated NN NN O
by NN NN O
heat NN NN O
shock NN NN O
indicating NN NN O
a NN NN O
role NN NN O
for NN NN O
nuclear NN NN O
protooncogenes NN NN O
in NN NN O
the NN NN O
stress NN NN O
response NN NN O
of NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Tandem NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
sites NN NN O
within NN NN O
the NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
dominant NN NN O
control NN NN O
region NN NN O
function NN NN O
as NN NN O
an NN NN O
inducible NN NN O
enhancer NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
powerful NN NN O
enhancer NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
an NN NN O
18 NN NN O
- NN NN O
bp NN NN O
DNA NN NN O
segment NN NN O
located NN NN O
11 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
to NN NN O
the NN NN O
human NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
within NN NN O
the NN NN O
dominant NN NN O
control NN NN O
or NN NN O
locus NN NN O
- NN NN O
activating NN NN O
region NN NN O
. NN NN O
   
This NN NN O
enhancer NN NN O
is NN NN O
inducible NN NN O
in NN NN O
K562 NN NN O
human NN NN O
erythroleukemia NN NN O
cells NN NN O
, NN NN O
increasing NN NN O
linked NN NN O
gamma NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
/ NN NN O
luciferase NN NN B-Protein
gene NN NN O
expression NN NN O
to NN NN O
170 NN NN O
- NN NN O
fold NN NN O
over NN NN O
an NN NN O
enhancerless NN NN O
construct NN NN O
. NN NN O
   
The NN NN O
enhancer NN NN O
consists NN NN O
of NN NN O
tandem NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
phased NN NN O
10 NN NN O
bp NN NN O
apart NN NN O
, NN NN O
which NN NN O
are NN NN O
both NN NN O
required NN NN O
for NN NN O
full NN NN O
activity NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
protein NN NN O
binding NN NN O
assays NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
induced NN NN O
cells NN NN O
demonstrate NN NN O
a NN NN O
high NN NN O
molecular NN NN O
weight NN NN O
complex NN NN O
on NN NN O
the NN NN O
enhancer NN NN O
. NN NN O
   
The NN NN O
formation NN NN O
of NN NN O
this NN NN O
complex NN NN O
also NN NN O
requires NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
and NN NN O
correlates NN NN O
with NN NN O
maximal NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
may NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
increase NN NN O
in NN NN O
globin NN NN O
gene NN NN O
transcription NN NN O
that NN NN O
characterizes NN NN O
erythroid NN NN O
maturation NN NN O
. NN NN O
   
Enhancer NN NN O
activity NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
binding NN NN O
of NN NN O
a NN NN O
complex NN NN O
of NN NN O
proteins NN NN O
from NN NN O
the NN NN O
jun NN NN O
and NN NN O
fos NN NN O
families NN NN O
to NN NN O
tandem NN NN O
AP NN NN O
- NN NN O
1 NN NN O
consensus NN NN O
sequences NN NN O
. NN NN O
   
Adherence NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
human NN NN O
monocyte NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
is NN NN O
associated NN NN O
with NN NN O
increases NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
EGR2 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
Adherence NN NN O
is NN NN O
an NN NN O
important NN NN O
initial NN NN O
step NN NN O
in NN NN O
the NN NN O
transition NN NN O
of NN NN O
a NN NN O
circulating NN NN O
monocyte NN NN O
to NN NN O
a NN NN O
tissue NN NN O
macrophage NN NN O
. NN NN O
   
This NN NN O
differentiation NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
augmented NN NN O
capacity NN NN O
to NN NN O
generate NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
adherence NN NN O
itself NN NN O
might NN NN O
be NN NN O
an NN NN O
important NN NN O
trigger NN NN O
for NN NN O
a NN NN O
sequence NN NN O
of NN NN O
gene NN NN O
activation NN NN O
culminating NN NN O
in NN NN O
cells NN NN O
with NN NN O
increased NN NN O
mRNA NN NN O
encoding NN NN O
profibrotic NN NN O
growth NN NN O
factors NN NN O
such NN NN O
as NN NN O
platelet NN NN B-Protein
- NN NN I-Protein
derived NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
B NN NN I-Protein
subunit NN NN I-Protein
( NN NN O
PDGF NN NN B-Protein
[ NN NN I-Protein
B NN NN I-Protein
] NN NN I-Protein
) NN NN O
and NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
( NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
) NN NN O
. NN NN O
   
After NN NN O
in NN NN O
vitro NN NN O
adherence NN NN O
, NN NN O
human NN NN O
monocytes NN NN O
had NN NN O
a NN NN O
biphasic NN NN O
increase NN NN O
in NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
with NN NN O
peaks NN NN O
at NN NN O
6 NN NN O
h NN NN O
and NN NN O
13 NN NN O
d NN NN O
. NN NN O
   
No NN NN O
increase NN NN O
in NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
6 NN NN O
- NN NN O
h NN NN O
increase NN NN O
in NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
was NN NN O
adherence NN NN O
dependent NN NN O
, NN NN O
and NN NN O
in NN NN O
addition NN NN O
, NN NN O
was NN NN O
abrogated NN NN O
when NN NN O
the NN NN O
cytoskeletal NN NN O
integrity NN NN O
was NN NN O
compromised NN NN O
by NN NN O
cytochalasin NN NN O
D NN NN O
. NN NN O
   
The NN NN O
6 NN NN O
- NN NN O
h NN NN O
increase NN NN O
in NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
was NN NN O
unaltered NN NN O
by NN NN O
adherence NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
stimulus NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Adherence NN NN O
to NN NN O
either NN NN O
fibronectin NN NN B-Protein
or NN NN O
collagen NN NN O
- NN NN O
coated NN NN O
plastic NN NN O
had NN NN O
little NN NN O
consistent NN NN O
effect NN NN O
on NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
. NN NN O
   
The NN NN O
increased NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
observed NN NN O
in NN NN O
adherent NN NN O
monocytes NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
increases NN NN O
in NN NN O
mRNAs NN NN O
of NN NN O
the NN NN O
early NN NN O
growth NN NN O
response NN NN O
genes NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
( NN NN O
maximal NN NN O
at NN NN O
20 NN NN O
min NN NN O
) NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
EGR2 NN NN B-Protein
( NN NN O
maximal NN NN O
at NN NN O
6 NN NN O
- NN NN O
24 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
EGR2 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
mRNA NN NN O
was NN NN O
also NN NN O
abrogated NN NN O
by NN NN O
cytochalasin NN NN O
D NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
adherence NN NN O
results NN NN O
in NN NN O
increases NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
EGR2 NN NN B-Protein
, NN NN O
and NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
increases NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
EGR2 NN NN B-Protein
, NN NN O
and NN NN O
PDGF NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
may NN NN O
depend NN NN O
on NN NN O
cytoskeletal NN NN O
rearrangement NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
these NN NN O
events NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
adherence NN NN O
offers NN NN O
a NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
differential NN NN O
priming NN NN O
of NN NN O
the NN NN O
cells NN NN O
may NN NN O
be NN NN O
accomplished NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
the NN NN O
sexual NN NN O
dimorphism NN NN O
of NN NN O
autoimmunity NN NN O
. NN NN O
   
The NN NN O
sexual NN NN O
difference NN NN O
in NN NN O
the NN NN O
incidence NN NN O
of NN NN O
autoimmune NN NN O
diseases NN NN O
has NN NN O
remained NN NN O
an NN NN O
enigma NN NN O
for NN NN O
many NN NN O
years NN NN O
. NN NN O
   
In NN NN O
the NN NN O
examination NN NN O
of NN NN O
the NN NN O
induction NN NN O
of NN NN O
autoimmunity NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
, NN NN O
evidence NN NN O
has NN NN O
been NN NN O
obtained NN NN O
further NN NN O
implicating NN NN O
the NN NN O
lymphokine NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
the NN NN O
etiology NN NN O
of NN NN O
autoimmunity NN NN O
. NN NN O
   
Sex NN NN O
steroid NN NN O
regulation NN NN O
of NN NN O
the NN NN O
production NN NN O
of NN NN O
this NN NN O
molecule NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
other NN NN O
cytokines NN NN O
, NN NN O
may NN NN O
help NN NN O
explain NN NN O
the NN NN O
gender NN NN O
- NN NN O
specific NN NN O
differences NN NN O
in NN NN O
the NN NN O
immune NN NN O
system NN NN O
, NN NN O
including NN NN O
autoimmunity NN NN O
. NN NN O
   
Single NN NN O
cell NN NN O
assay NN NN O
of NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
reveals NN NN O
a NN NN O
threshold NN NN O
in NN NN O
transcription NN NN O
activated NN NN O
by NN NN O
signals NN NN O
emanating NN NN O
from NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
through NN NN O
their NN NN O
antigen NN NN O
receptor NN NN O
leads NN NN O
to NN NN O
the NN NN O
appearance NN NN O
of NN NN O
several NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
including NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
genes NN NN O
required NN NN O
for NN NN O
immunologic NN NN O
activation NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
single NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
individual NN NN O
viable NN NN O
cells NN NN O
, NN NN O
we NN NN O
have NN NN O
applied NN NN O
an NN NN O
assay NN NN O
that NN NN O
uses NN NN O
the NN NN O
fluorescence NN NN O
- NN NN O
activated NN NN O
cell NN NN O
sorter NN NN O
to NN NN O
quantitate NN NN O
beta NN NN B-Protein
- NN NN I-Protein
galactosidase NN NN I-Protein
( NN NN O
beta NN NN B-Protein
- NN NN I-Protein
gal NN NN I-Protein
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
distribution NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
transcriptional NN NN O
activity NN NN O
among NN NN O
T NN NN O
cells NN NN O
undergoing NN NN O
activation NN NN O
by NN NN O
using NN NN O
a NN NN O
construct NN NN O
in NN NN O
which NN NN O
three NN NN O
tandem NN NN O
copies NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
site NN NN O
directs NN NN O
transcription NN NN O
of NN NN O
the NN NN O
lacZ NN NN B-Protein
gene NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
cloned NN NN O
stably NN NN O
transfected NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
leads NN NN O
to NN NN O
a NN NN O
bimodal NN NN O
pattern NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
gal NN NN I-Protein
expression NN NN O
in NN NN O
which NN NN O
some NN NN O
cells NN NN O
express NN NN O
no NN NN O
beta NN NN B-Protein
- NN NN I-Protein
gal NN NN I-Protein
and NN NN O
others NN NN O
express NN NN O
high NN NN O
levels NN NN O
. NN NN O
   
This NN NN O
expression NN NN O
pattern NN NN O
cannot NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
cell NN NN O
- NN NN O
cycle NN NN O
position NN NN O
or NN NN O
heritable NN NN O
variation NN NN O
. NN NN O
   
Further NN NN O
results NN NN O
, NN NN O
in NN NN O
which NN NN O
beta NN NN B-Protein
- NN NN I-Protein
gal NN NN I-Protein
activity NN NN O
is NN NN O
correlated NN NN O
with NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
activity NN NN O
, NN NN O
indicate NN NN O
that NN NN O
the NN NN O
concentration NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
must NN NN O
exceed NN NN O
a NN NN O
critical NN NN O
threshold NN NN O
before NN NN O
transcription NN NN O
initiates NN NN O
. NN NN O
   
This NN NN O
threshold NN NN O
likely NN NN O
reflects NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
assembly NN NN O
of NN NN O
transcription NN NN O
complexes NN NN O
at NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
Similar NN NN O
constructs NN NN O
controlled NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
the NN NN O
entire NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
show NN NN O
bimodal NN NN O
expression NN NN O
patterns NN NN O
during NN NN O
induction NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
thresholds NN NN O
set NN NN O
by NN NN O
the NN NN O
concentration NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
may NN NN O
be NN NN O
a NN NN O
common NN NN O
property NN NN O
of NN NN O
inducible NN NN O
genes NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
signal NN NN O
transmission NN NN O
pathways NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
are NN NN O
inhibited NN NN O
by NN NN O
complexes NN NN O
formed NN NN O
between NN NN O
an NN NN O
immunophilin NN NN O
and NN NN O
either NN NN O
FK506 NN NN O
or NN NN O
rapamycin NN NN O
. NN NN O
   
Proliferation NN NN O
and NN NN O
immunologic NN NN O
function NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
are NN NN O
initiated NN NN O
by NN NN O
signals NN NN O
from NN NN O
the NN NN O
antigen NN NN O
receptor NN NN O
that NN NN O
are NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
immunosuppressant NN NN O
FK506 NN NN O
but NN NN O
not NN NN O
by NN NN O
its NN NN O
structural NN NN O
analog NN NN O
, NN NN O
rapamycin NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
signals NN NN O
are NN NN O
blocked NN NN O
by NN NN O
rapamycin NN NN O
but NN NN O
not NN NN O
by NN NN O
FK506 NN NN O
. NN NN O
   
Remarkably NN NN O
, NN NN O
these NN NN O
two NN NN O
drugs NN NN O
inhibit NN NN O
each NN NN O
other NN NN O
' NN NN O
s NN NN O
actions NN NN O
, NN NN O
raising NN NN O
the NN NN O
possibility NN NN O
that NN NN O
both NN NN O
act NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
common NN NN O
immunophilin NN NN O
( NN NN O
immunosuppressant NN NN O
binding NN NN O
protein NN NN O
) NN NN O
. NN NN O
   
We NN NN O
find NN NN O
that NN NN O
the NN NN O
dissociation NN NN O
constant NN NN O
of NN NN O
rapamycin NN NN O
to NN NN O
the NN NN O
FK506 NN NN O
binding NN NN O
protein NN NN O
FKBP NN NN O
( NN NN O
Kd NN NN O
= NN NN O
0 NN NN O
. NN NN O
2 NN NN O
nM NN NN O
) NN NN O
is NN NN O
close NN NN O
to NN NN O
the NN NN O
dissociation NN NN O
constant NN NN O
of NN NN O
FK506 NN NN O
to NN NN O
FKBP NN NN O
( NN NN O
Kd NN NN O
= NN NN O
0 NN NN O
. NN NN O
4 NN NN O
nM NN NN O
) NN NN O
and NN NN O
to NN NN O
their NN NN O
effective NN NN O
biologic NN NN O
inhibitory NN NN O
concentrations NN NN O
. NN NN O
   
However NN NN O
, NN NN O
an NN NN O
excess NN NN O
of NN NN O
rapamycin NN NN O
is NN NN O
needed NN NN O
to NN NN O
revert NN NN O
FK506 NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
, NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
necessary NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
activation NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
an NN NN O
excess NN NN O
of NN NN O
FK506 NN NN O
is NN NN O
needed NN NN O
to NN NN O
revert NN NN O
rapamycin NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
proliferation NN NN O
. NN NN O
   
The NN NN O
drug NN NN O
concentrations NN NN O
required NN NN O
for NN NN O
antagonism NN NN O
may NN NN O
be NN NN O
explained NN NN O
by NN NN O
the NN NN O
relative NN NN O
affinity NN NN O
of NN NN O
the NN NN O
drugs NN NN O
to NN NN O
, NN NN O
and NN NN O
by NN NN O
the NN NN O
abundance NN NN O
of NN NN O
, NN NN O
the NN NN O
immunophilin NN NN O
FKBP NN NN O
. NN NN O
   
FKBP NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
catalyze NN NN O
the NN NN O
interconversion NN NN O
of NN NN O
the NN NN O
cis NN NN O
- NN NN O
and NN NN O
trans NN NN O
- NN NN O
rotamers NN NN O
of NN NN O
the NN NN O
peptidyl NN NN O
- NN NN O
prolyl NN NN O
amide NN NN O
bond NN NN O
of NN NN O
peptide NN NN O
substrates NN NN O
; NN NN O
here NN NN O
we NN NN O
show NN NN O
that NN NN O
rapamycin NN NN O
, NN NN O
like NN NN O
FK506 NN NN O
, NN NN O
is NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
the NN NN O
rotamase NN NN O
activity NN NN O
of NN NN O
FKBP NN NN O
( NN NN O
Ki NN NN O
= NN NN O
0 NN NN O
. NN NN O
2 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
Neither NN NN O
FKBP NN NN O
binding NN NN O
nor NN NN O
inhibition NN NN O
of NN NN O
rotamase NN NN O
activity NN NN O
of NN NN O
FKBP NN NN O
alone NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
explain NN NN O
the NN NN O
biologic NN NN O
actions NN NN O
of NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
immunophilin NN NN O
bound NN NN O
to NN NN O
FK506 NN NN O
interferes NN NN O
with NN NN O
antigen NN NN O
receptor NN NN O
- NN NN O
induced NN NN O
signals NN NN O
, NN NN O
while NN NN O
rapamycin NN NN O
bound NN NN O
to NN NN O
the NN NN O
immunophilin NN NN O
interferes NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
signals NN NN O
. NN NN O
   
Transcriptional NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
expression NN NN O
by NN NN O
protein NN NN O
synthesis NN NN O
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
pathways NN NN O
in NN NN O
a NN NN O
human NN NN O
T NN NN O
lymphoblastic NN NN O
tumor NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
in NN NN O
the NN NN O
human NN NN O
T NN NN O
lymphoblastic NN NN O
tumor NN NN O
cell NN NN O
line NN NN O
Molt4 NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
is NN NN O
down NN NN O
- NN NN O
regulated NN NN O
after NN NN O
exposure NN NN O
to NN NN O
dimethyl NN NN O
sulfoxide NN NN O
, NN NN O
to NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
, NN NN O
or NN NN O
to NN NN O
the NN NN O
calcium NN NN O
ionophore NN NN O
A23187 NN NN O
, NN NN O
which NN NN O
raises NN NN O
the NN NN O
intracellular NN NN O
calcium NN NN O
concentration NN NN O
. NN NN O
   
A NN NN O
block NN NN O
to NN NN O
RNA NN NN O
elongation NN NN O
is NN NN O
largely NN NN O
responsible NN NN O
for NN NN O
decreased NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
transcription NN NN O
. NN NN O
   
Although NN NN O
negative NN NN O
regulation NN NN O
by NN NN O
dimethyl NN NN O
sulfoxide NN NN O
takes NN NN O
place NN NN O
even NN NN O
when NN NN O
protein NN NN O
synthesis NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
cycloheximide NN NN O
, NN NN O
the NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
effect NN NN O
is NN NN O
blocked NN NN O
to NN NN O
some NN NN O
extent NN NN O
only NN NN O
by NN NN O
cycloheximide NN NN O
. NN NN O
   
The NN NN O
calcium NN NN O
ionophore NN NN O
- NN NN O
induced NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
suppression NN NN O
, NN NN O
however NN NN O
, NN NN O
strictly NN NN O
requires NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
two NN NN O
different NN NN O
negative NN NN O
regulatory NN NN O
pathways NN NN O
are NN NN O
involved NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
regulation NN NN O
: NN NN O
one NN NN O
which NN NN O
is NN NN O
independent NN NN O
and NN NN O
one NN NN O
which NN NN O
depends NN NN O
on NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
one NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
a NN NN O
rapidly NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
induced NN NN O
gene NN NN O
product NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
immediate NN NN O
early NN NN O
response NN NN O
genes NN NN O
by NN NN O
macrophage NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
A NN NN O
group NN NN O
of NN NN O
coordinately NN NN O
induced NN NN O
protooncogenes NN NN O
, NN NN O
cytoskeletal NN NN O
, NN NN O
and NN NN O
extracellular NN NN O
matrix NN NN O
genes NN NN O
have NN NN O
been NN NN O
termed NN NN O
immediate NN NN O
early NN NN O
response NN NN O
genes NN NN O
, NN NN O
and NN NN O
their NN NN O
induction NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
growth NN NN O
factor NN NN O
- NN NN O
stimulated NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
by NN NN O
macrophage NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
( NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
that NN NN O
do NN NN O
not NN NN O
proliferate NN NN O
in NN NN O
response NN NN O
to NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
but NN NN O
require NN NN O
the NN NN O
factor NN NN O
for NN NN O
optimal NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Normal NN NN O
human NN NN O
monocytes NN NN O
were NN NN O
isolated NN NN O
, NN NN O
carefully NN NN O
washed NN NN O
, NN NN O
and NN NN O
incubated NN NN O
for NN NN O
36 NN NN O
to NN NN O
48 NN NN O
h NN NN O
in NN NN O
fetal NN NN O
bovine NN NN O
serum NN NN O
- NN NN O
containing NN NN O
medium NN NN O
. NN NN O
   
At NN NN O
the NN NN O
end NN NN O
of NN NN O
this NN NN O
incubation NN NN O
the NN NN O
resting NN NN O
cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
and NN NN O
RNA NN NN O
was NN NN O
isolated NN NN O
for NN NN O
analysis NN NN O
by NN NN O
Northern NN NN O
blotting NN NN O
. NN NN O
   
RNA NN NN O
from NN NN O
control NN NN O
resting NN NN O
cells NN NN O
contained NN NN O
low NN NN O
to NN NN O
undetectable NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
fibronectin NN NN O
receptor NN NN O
, NN NN O
and NN NN O
actin NN NN O
mRNA NN NN O
. NN NN O
   
Within NN NN O
15 NN NN O
to NN NN O
30 NN NN O
min NN NN O
of NN NN O
addition NN NN O
of NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
however NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
dramatic NN NN O
coordinate NN NN O
induction NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
gene NN NN O
expression NN NN O
was NN NN O
very NN NN O
transient NN NN O
and NN NN O
was NN NN O
not NN NN O
detectable NN NN O
by NN NN O
60 NN NN O
min NN NN O
after NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
addition NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
actin NN NN O
and NN NN O
fibronectin NN NN O
receptor NN NN O
mRNA NN NN O
was NN NN O
more NN NN O
sustained NN NN O
, NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
remained NN NN O
elevated NN NN O
at NN NN O
24 NN NN O
to NN NN O
48 NN NN O
h NN NN O
after NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
addition NN NN O
. NN NN O
   
We NN NN O
also NN NN O
observed NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
myelomonocytic NN NN O
specific NN NN O
tyrosine NN NN O
kinase NN NN O
hck NN NN B-Protein
gene NN NN O
simultaneously NN NN O
with NN NN O
the NN NN O
other NN NN O
immediate NN NN O
early NN NN O
response NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
protein NN NN O
synthesis NN NN O
inhibitor NN NN O
cycloheximide NN NN O
did NN NN O
not NN NN O
block NN NN O
the NN NN O
induction NN NN O
of NN NN O
any NN NN O
of NN NN O
these NN NN O
genes NN NN O
, NN NN O
and NN NN O
in NN NN O
fact NN NN O
, NN NN O
super NN NN O
- NN NN O
induced NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
hck NN NN B-Protein
. NN NN O
   
Nuclear NN NN O
run NN NN O
on NN NN O
transcription NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
hck NN NN B-Protein
, NN NN O
and NN NN O
actin NN NN O
genes NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
in NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
induces NN NN O
immediate NN NN O
early NN NN O
response NN NN O
genes NN NN O
without NN NN O
inducing NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
These NN NN O
genes NN NN O
may NN NN O
then NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
altering NN NN O
the NN NN O
physiologic NN NN O
status NN NN O
of NN NN O
the NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
CSF NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
clone NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
or NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
induces NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
but NN NN O
not NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
1 NN NN O
enhancer NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
transiently NN NN O
transfected NN NN O
expression NN NN O
vectors NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
or NN NN O
its NN NN O
enhancer NN NN O
sequence NN NN O
and NN NN O
the NN NN O
translocation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
were NN NN O
analyzed NN NN O
in NN NN O
two NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
stimulated NN NN O
through NN NN O
their NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
complex NN NN O
or NN NN O
by NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
or NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
. NN NN O
   
We NN NN O
found NN NN O
a NN NN O
dissociation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
from NN NN O
transactivation NN NN O
of NN NN O
either NN NN O
the NN NN O
HIV NN NN O
LTR NN NN O
or NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
2 NN NN I-Protein
induced NN NN O
proliferation NN NN O
but NN NN O
not NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
or NN NN O
LTR NN NN O
transactivation NN NN O
. NN NN O
   
Phorbol NN NN O
ester NN NN O
or NN NN O
specific NN NN O
antigen NN NN O
recognition NN NN O
induced NN NN O
HIV NN NN O
LTR NN NN O
transactivation NN NN O
, NN NN O
whereas NN NN O
stimulation NN NN O
with NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
or NN NN O
antibody NN NN O
to NN NN O
CD3 NN NN O
did NN NN O
not NN NN O
. NN NN O
   
The NN NN O
two NN NN O
latter NN NN O
signals NN NN O
were NN NN O
nevertheless NN NN O
able NN NN O
to NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
with NN NN O
a NN NN O
pattern NN NN O
in NN NN O
the NN NN O
band NN NN O
- NN NN O
shift NN NN O
assay NN NN O
indistinguishable NN NN O
from NN NN O
that NN NN O
observed NN NN O
using NN NN O
phorbol NN NN O
ester NN NN O
. NN NN O
   
Our NN NN O
finding NN NN O
that NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
or NN NN O
antibody NN NN O
to NN NN O
CD3 NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
induce NN NN O
HIV NN NN O
enhancer NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
in NN NN O
cloned NN NN O
T NN NN O
cells NN NN O
contrasts NN NN O
with NN NN O
results NN NN O
obtained NN NN O
in NN NN O
most NN NN O
lymphoblastoid NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
indicates NN NN O
that NN NN O
normal NN NN O
T NN NN O
lymphocytes NN NN O
differ NN NN O
from NN NN O
tumoral NN NN O
T NN NN O
cells NN NN O
in NN NN O
terms NN NN O
of NN NN O
requirements NN NN O
for NN NN O
HIV NN NN O
LTR NN NN O
activation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
events NN NN O
linked NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
per NN NN O
se NN NN O
, NN NN O
induce NN NN O
functional NN NN O
interactions NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
with NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
. NN NN O
   
Lymphoid NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
of NN NN O
the NN NN O
adenovirus NN NN O
early NN NN O
region NN NN O
3 NN NN O
promoter NN NN O
is NN NN O
mediated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
motifs NN NN O
. NN NN O
   
A NN NN O
primary NN NN O
site NN NN O
of NN NN O
infection NN NN O
by NN NN O
human NN NN O
adenoviruses NN NN O
is NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
analysis NN NN O
of NN NN O
the NN NN O
viral NN NN O
control NN NN O
elements NN NN O
and NN NN O
the NN NN O
cellular NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
adenoviral NN NN O
gene NN NN O
expression NN NN O
in NN NN O
lymphocytes NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
. NN NN O
   
The NN NN O
adenovirus NN NN O
early NN NN O
region NN NN O
3 NN NN O
( NN NN O
ES NN NN O
) NN NN O
gene NN NN O
products NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
viral NN NN O
persistence NN NN O
by NN NN O
complexing NN NN O
with NN NN O
the NN NN O
class NN NN O
I NN NN O
MHC NN NN O
antigens NN NN O
, NN NN O
thus NN NN O
preventing NN NN O
their NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
with NN NN O
a NN NN O
resultant NN NN O
decrease NN NN O
in NN NN O
host NN NN O
immunologic NN NN O
destruction NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
different NN NN O
cellular NN NN O
factors NN NN O
were NN NN O
involved NN NN O
in NN NN O
E3 NN NN O
regulation NN NN O
in NN NN O
lymphocytes NN NN O
as NN NN O
compared NN NN O
with NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
both NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
transfection NN NN O
analysis NN NN O
with NN NN O
the NN NN O
E3 NN NN O
promoter NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
detected NN NN O
two NN NN O
novel NN NN O
domains NN NN O
referred NN NN O
to NN NN O
as NN NN O
L1 NN NN O
and NN NN O
L2 NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
lymphoid NN NN O
but NN NN O
not NN NN O
HeLa NN NN O
extracts NN NN O
. NN NN O
   
Each NN NN O
of NN NN O
these NN NN O
domains NN NN O
possessed NN NN O
strong NN NN O
homology NN NN O
to NN NN O
motifs NN NN O
previously NN NN O
found NN NN O
to NN NN O
bind NN NN O
the NN NN O
cellular NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Transfections NN NN O
of NN NN O
E3 NN NN O
constructs NN NN O
linked NN NN O
to NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
gene NN NN O
revealed NN NN O
that NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
distal NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
motif NN NN O
( NN NN O
L2 NN NN O
) NN NN O
had NN NN O
minimal NN NN O
effects NN NN O
on NN NN O
promoter NN NN O
expression NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
but NN NN O
resulted NN NN O
in NN NN O
dramatic NN NN O
decreases NN NN O
in NN NN O
expression NN NN O
by NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
mutagenesis NN NN O
of NN NN O
proximal NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
motif NN NN O
( NN NN O
L1 NN NN O
) NN NN O
had NN NN O
minimal NN NN O
effects NN NN O
on NN NN O
gene NN NN O
expression NN NN O
in NN NN O
both NN NN O
HeLa NN NN O
cells NN NN O
and NN NN O
lymphoid NN NN O
cells NN NN O
but NN NN O
resulted NN NN O
in NN NN O
a NN NN O
small NN NN O
, NN NN O
but NN NN O
reproducible NN NN O
, NN NN O
increase NN NN O
in NN NN O
gene NN NN O
expression NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
when NN NN O
coupled NN NN O
to NN NN O
the NN NN O
L2 NN NN O
mutation NN NN O
. NN NN O
   
Reversing NN NN O
the NN NN O
position NN NN O
and NN NN O
subsequent NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
L1 NN NN O
and NN NN O
L2 NN NN O
domains NN NN O
indicated NN NN O
that NN NN O
the NN NN O
primary NN NN O
sequence NN NN O
of NN NN O
these NN NN O
motifs NN NN O
rather NN NN O
than NN NN O
their NN NN O
position NN NN O
in NN NN O
the NN NN O
E3 NN NN O
promoter NN NN O
was NN NN O
critical NN NN O
for NN NN O
regulating NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Characterization NN NN O
of NN NN O
defensin NN NN O
resistance NN NN O
phenotypes NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
in NN NN O
the NN NN O
phoP NN NN O
virulence NN NN O
regulon NN NN O
of NN NN O
Salmonella NN NN O
typhimurium NN NN O
. NN NN O
   
The NN NN O
defensin NN NN O
sensitivities NN NN O
of NN NN O
Salmonella NN NN O
typhimurium NN NN O
strains NN NN O
with NN NN O
mutations NN NN O
in NN NN O
the NN NN O
phoP NN NN B-Protein
/ NN NN O
phoQ NN NN B-Protein
two NN NN O
- NN NN O
component NN NN O
virulence NN NN O
regulon NN NN O
were NN NN O
tested NN NN O
by NN NN O
using NN NN O
purified NN NN O
defensins NN NN O
NP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
NP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Strains NN NN O
with NN NN O
mutations NN NN O
in NN NN O
either NN NN O
gene NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
pair NN NN O
( NN NN O
phoP NN NN B-Protein
[ NN NN O
transcriptional NN NN O
activator NN NN O
] NN NN O
or NN NN O
phoQ NN NN B-Protein
[ NN NN O
membrane NN NN O
sensor NN NN O
kinase NN NN O
] NN NN O
) NN NN O
had NN NN O
increased NN NN O
sensitivities NN NN O
to NN NN O
defensin NN NN O
. NN NN O
   
The NN NN O
predicted NN NN O
periplasmic NN NN O
domain NN NN O
of NN NN O
the NN NN O
PhoQ NN NN B-Protein
protein NN NN O
contained NN NN O
a NN NN O
markedly NN NN O
anionic NN NN O
domain NN NN O
that NN NN O
could NN NN O
interact NN NN O
with NN NN O
cationic NN NN O
proteins NN NN O
and NN NN O
that NN NN O
could NN NN O
be NN NN O
responsible NN NN O
for NN NN O
resistance NN NN O
to NN NN O
defensin NN NN O
. NN NN O
   
Because NN NN O
insertion NN NN O
mutations NN NN O
in NN NN O
phoP NN NN B-Protein
are NN NN O
polar NN NN O
on NN NN O
phoQ NN NN B-Protein
, NN NN O
we NN NN O
constructed NN NN O
strains NN NN O
that NN NN O
expressed NN NN O
the NN NN O
PhoQ NN NN B-Protein
protein NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
PhoP NN NN B-Protein
to NN NN O
test NN NN O
whether NN NN O
resistance NN NN O
to NN NN O
defensin NN NN O
requires NN NN O
only NN NN O
the NN NN O
phoQ NN NN B-Protein
gene NN NN O
product NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
resistance NN NN O
to NN NN O
defensin NN NN O
requires NN NN O
the NN NN O
function NN NN O
of NN NN O
both NN NN O
components NN NN O
of NN NN O
this NN NN O
regulatory NN NN O
system NN NN O
, NN NN O
because NN NN O
strains NN NN O
expressing NN NN O
PhoQ NN NN B-Protein
without NN NN O
PhoP NN NN B-Protein
were NN NN O
still NN NN O
markedly NN NN O
sensitive NN NN O
to NN NN O
defensins NN NN O
. NN NN O
   
This NN NN O
implied NN NN O
that NN NN O
a NN NN O
pag NN NN O
( NN NN O
phoP NN NN O
- NN NN O
activated NN NN O
gene NN NN O
) NN NN O
product NN NN O
is NN NN O
responsible NN NN O
for NN NN O
defensin NN NN O
resistance NN NN O
. NN NN O
   
We NN NN O
also NN NN O
tested NN NN O
for NN NN O
the NN NN O
ability NN NN O
of NN NN O
defensins NN NN O
NP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
NP NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
and NN NN O
HNP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
activate NN NN O
pag NN NN O
expression NN NN O
and NN NN O
found NN NN O
that NN NN O
these NN NN O
peptides NN NN O
have NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Defensin NN NN O
resistance NN NN O
is NN NN O
not NN NN O
the NN NN O
only NN NN O
virulence NN NN O
characteristic NN NN O
controlled NN NN O
by NN NN O
the NN NN O
PhoP NN NN B-Protein
- NN NN O
PhoQ NN NN B-Protein
regulon NN NN O
because NN NN O
mutations NN NN O
in NN NN O
pagC NN NN B-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
ones NN NN O
in NN NN O
the NN NN O
phoP NN NN B-Protein
locus NN NN O
that NN NN O
resulted NN NN O
in NN NN O
constitutive NN NN O
pag NN NN O
activation NN NN O
( NN NN O
phenotype NN NN O
PhoPc NN NN O
) NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
defensin NN NN O
resistance NN NN O
, NN NN O
even NN NN O
though NN NN O
they NN NN O
rendered NN NN O
the NN NN O
organism NN NN O
avirulent NN NN O
and NN NN O
deficient NN NN O
in NN NN O
survival NN NN O
within NN NN O
macrophages NN NN O
. NN NN O
   
The NN NN O
virulence NN NN O
defect NN NN O
conferred NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
phoP NN NN B-Protein
- NN NN O
phoQ NN NN B-Protein
two NN NN O
- NN NN O
component NN NN O
regulatory NN NN O
system NN NN O
is NN NN O
not NN NN O
completely NN NN O
explained NN NN O
by NN NN O
alterations NN NN O
in NN NN O
resistance NN NN O
to NN NN O
cationic NN NN O
proteins NN NN O
and NN NN O
involves NN NN O
the NN NN O
control NN NN O
of NN NN O
other NN NN O
proteins NN NN O
necessary NN NN O
for NN NN O
S NN NN O
. NN NN O
typhimurium NN NN O
survival NN NN O
within NN NN O
macrophages NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
cyclic NN NN O
AMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinases NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
for NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Expression NN NN O
of NN NN O
a NN NN O
highly NN NN O
specific NN NN O
protein NN NN O
inhibitor NN NN O
for NN NN O
cyclic NN NN O
AMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinases NN NN O
in NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
- NN NN O
responsive NN NN O
cells NN NN O
blocked NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
induced NN NN O
gene NN NN O
transcription NN NN O
that NN NN O
was NN NN O
driven NN NN O
by NN NN O
the NN NN O
kappa NN NN B-Protein
immunoglobulin NN NN I-Protein
enhancer NN NN O
or NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
This NN NN O
inhibitor NN NN O
did NN NN O
not NN NN O
affect NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
cyclic NN NN O
AMP NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinases NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
a NN NN O
number NN NN O
of NN NN O
responsive NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
is NN NN O
a NN NN O
potent NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
specific NN NN O
stimulator NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
expression NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
potently NN NN O
stimulates NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
- NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
LTR NN NN O
) NN NN O
CAT NN NN B-Protein
constructs NN NN O
transfected NN NN O
into NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cell NN NN O
lines NN NN O
but NN NN O
not NN NN O
a NN NN O
T NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
through NN NN O
the NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrate NN NN O
that NN NN O
LPS NN NN O
induces NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
indistinguishable NN NN O
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
U937 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
LPS NN NN O
is NN NN O
also NN NN O
shown NN NN O
to NN NN O
dramatically NN NN O
increase NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
from NN NN O
a NN NN O
chronically NN NN O
infected NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cloned NN NN O
cell NN NN O
line NN NN O
, NN NN O
U1 NN NN O
, NN NN O
which NN NN O
produces NN NN O
very NN NN O
low NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
at NN NN O
baseline NN NN O
. NN NN O
   
The NN NN O
stimulation NN NN O
of NN NN O
viral NN NN O
production NN NN O
from NN NN O
this NN NN O
cell NN NN O
line NN NN O
occurs NN NN O
only NN NN O
if NN NN O
these NN NN O
cells NN NN O
are NN NN O
treated NN NN O
with NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
before NN NN O
treatment NN NN O
with NN NN O
LPS NN NN O
. NN NN O
   
This NN NN O
stimulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
is NN NN O
correlated NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
RNA NN NN O
and NN NN O
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
LPS NN NN O
is NN NN O
not NN NN O
able NN NN O
to NN NN O
induce NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
in NN NN O
a NN NN O
cloned NN NN O
T NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
LPS NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
occurs NN NN O
at NN NN O
picogram NN NN O
per NN NN O
milliliter NN NN O
concentrations NN NN O
and NN NN O
may NN NN O
be NN NN O
clinically NN NN O
significant NN NN O
in NN NN O
understanding NN NN O
the NN NN O
variability NN NN O
of NN NN O
the NN NN O
natural NN NN O
history NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
Inducible NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
to NN NN O
the NN NN O
kappa NN NN O
B NN NN O
elements NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
enhancer NN NN O
in NN NN O
T NN NN O
cells NN NN O
can NN NN O
be NN NN O
blocked NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
in NN NN O
a NN NN O
signal NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
is NN NN O
thought NN NN O
to NN NN O
exert NN NN O
its NN NN O
immunosuppressive NN NN O
effects NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
distinct NN NN O
set NN NN O
of NN NN O
lymphokine NN NN O
genes NN NN O
which NN NN O
are NN NN O
induced NN NN O
upon NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
among NN NN O
them NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
is NN NN O
partially NN NN O
suppressed NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
suppression NN NN O
by NN NN O
CsA NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
this NN NN O
drug NN NN O
on NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
formation NN NN O
of NN NN O
two NN NN O
distinct NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
, NN NN O
the NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
within NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
and NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
complex NN NN O
within NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
, NN NN O
is NN NN O
inhibited NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
CsA NN NN O
. NN NN O
   
The NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
with NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
is NN NN O
inhibited NN NN O
only NN NN O
if NN NN O
it NN NN O
is NN NN O
activated NN NN O
via NN NN O
the NN NN O
mitogen NN NN O
phytohemagglutinin NN NN O
whereas NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
is NN NN O
completely NN NN O
insensitive NN NN O
to NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
a NN NN O
model NN NN O
in NN NN O
which NN NN O
functionally NN NN O
indistinguishable NN NN O
kappa NN NN O
B NN NN O
complexes NN NN O
can NN NN O
be NN NN O
activated NN NN O
via NN NN O
two NN NN O
separate NN NN O
pathways NN NN O
of NN NN O
signal NN NN O
transduction NN NN O
distinguishable NN NN O
by NN NN O
CsA NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
specific NN NN O
differences NN NN O
in NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
regulatory NN NN O
elements NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
and NN NN O
beta NN NN O
interferon NN NN O
promoters NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
. NN NN O
   
Three NN NN O
aspects NN NN O
of NN NN O
the NN NN O
involvement NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
pathogenesis NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
mRNA NN NN O
production NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
amplification NN NN O
in NN NN O
monocytic NN NN O
U937 NN NN O
cells NN NN O
and NN NN O
in NN NN O
a NN NN O
chronically NN NN O
HIV NN NN O
infected NN NN O
U937 NN NN O
cell NN NN O
line NN NN O
( NN NN O
U9 NN NN O
- NN NN O
IIIB NN NN O
) NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
RNA NN NN O
was NN NN O
undetectable NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
a NN NN O
low NN NN O
constitutive NN NN O
level NN NN O
was NN NN O
detected NN NN O
in NN NN O
U9 NN NN O
- NN NN O
IIIB NN NN O
cells NN NN O
. NN NN O
   
Paramyxovirus NN NN O
infection NN NN O
induced NN NN O
a NN NN O
5 NN NN O
- NN NN O
to NN NN O
10 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
the NN NN O
steady NN NN O
- NN NN O
state NN NN O
level NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
RNA NN NN O
in NN NN O
U9 NN NN O
- NN NN O
IIIB NN NN O
cells NN NN O
compared NN NN O
with NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
monocytic NN NN O
cells NN NN O
produced NN NN O
higher NN NN O
levels NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
than NN NN O
did NN NN O
normal NN NN O
cells NN NN O
after NN NN O
a NN NN O
secondary NN NN O
virus NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
on NN NN O
gene NN NN O
expression NN NN O
were NN NN O
examined NN NN O
by NN NN O
transient NN NN O
expression NN NN O
assays NN NN O
using NN NN O
reporter NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
plasmids NN NN O
linked NN NN O
to NN NN O
regulatory NN NN O
elements NN NN O
from NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
and NN NN O
the NN NN O
beta NN NN B-Protein
interferon NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
U937 NN NN O
and NN NN O
Jurkat NN NN O
T NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
the NN NN O
inducibility NN NN O
of NN NN O
the NN NN O
different NN NN O
hybrid NN NN O
promoters NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
or NN NN O
phorbol NN NN O
ester NN NN O
varied NN NN O
in NN NN O
a NN NN O
cell NN NN O
type NN NN O
- NN NN O
and NN NN O
promoter NN NN O
context NN NN O
- NN NN O
specific NN NN O
manner NN NN O
; NN NN O
the NN NN O
levels NN NN O
of NN NN O
gene NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
containing NN NN O
plasmids NN NN O
correlated NN NN O
directly NN NN O
with NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
intact NN NN O
beta NN NN B-Protein
interferon NN NN I-Protein
promoter NN NN O
was NN NN O
only NN NN O
weakly NN NN O
stimulated NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
or NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
multimers NN NN O
of NN NN O
the NN NN O
PRDII NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
domain NN NN O
were NN NN O
inducible NN NN O
by NN NN O
both NN NN O
agents NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
was NN NN O
able NN NN O
to NN NN O
increase NN NN O
expression NN NN O
of NN NN O
the NN NN O
HIV NN NN O
LTR NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
but NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
did NN NN O
not NN NN O
induce NN NN O
the NN NN O
HIV NN NN O
LTR NN NN O
above NN NN O
a NN NN O
constitutive NN NN O
level NN NN O
of NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
level NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
independent NN NN O
activity NN NN O
appears NN NN O
to NN NN O
be NN NN O
sufficient NN NN O
for NN NN O
virus NN NN O
multiplication NN NN O
, NN NN O
since NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
treatment NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
kinetics NN NN O
of NN NN O
de NN NN O
novo NN NN O
HIV NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
and NN NN O
viral NN NN O
RNA NN NN O
production NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
dramatically NN NN O
enhanced NN NN O
the NN NN O
spread NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
through NN NN O
the NN NN O
cell NN NN O
population NN NN O
and NN NN O
increased NN NN O
viral NN NN O
RNA NN NN O
synthesis NN NN O
, NN NN O
indicating NN NN O
that NN NN O
in NN NN O
T NN NN O
cells NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
multiplication NN NN O
was NN NN O
stimulated NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
treatment NN NN O
. NN NN O
   
Astrocytes NN NN O
and NN NN O
glioblastoma NN NN O
cells NN NN O
express NN NN O
novel NN NN O
octamer NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
distinct NN NN O
from NN NN O
the NN NN O
ubiquitous NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
B NN NN O
cell NN NN O
type NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
proteins NN NN O
. NN NN O
   
The NN NN O
' NN NN O
octamer NN NN O
' NN NN O
sequence NN NN O
, NN NN O
ATGCAAAT NN NN O
or NN NN O
its NN NN O
complement NN NN O
ATTTGCAT NN NN O
, NN NN O
is NN NN O
a NN NN O
key NN NN O
element NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
in NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
number NN NN O
of NN NN O
housekeeping NN NN O
genes NN NN O
in NN NN O
all NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
In NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
and NN NN O
variants NN NN O
thereof NN NN O
are NN NN O
thought NN NN O
to NN NN O
contribute NN NN O
to NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
, NN NN O
while NN NN O
the NN NN O
ubiquitous NN NN O
protein NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
seems NN NN O
to NN NN O
control NN NN O
general NN NN O
octamer NN NN O
site NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
Various NN NN O
other NN NN O
genes NN NN O
, NN NN O
for NN NN O
example NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
and NN NN O
MHC NN NN O
class NN NN O
II NN NN O
genes NN NN O
, NN NN O
contain NN NN O
an NN NN O
octamer NN NN O
sequence NN NN O
in NN NN O
the NN NN O
promoter NN NN O
and NN NN O
are NN NN O
expressed NN NN O
in NN NN O
cells NN NN O
of NN NN O
both NN NN O
the NN NN O
immune NN NN O
and NN NN O
nervous NN NN O
systems NN NN O
. NN NN O
   
This NN NN O
prompted NN NN O
us NN NN O
to NN NN O
analyze NN NN O
the NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
the NN NN O
latter NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
at NN NN O
least NN NN O
six NN NN O
novel NN NN O
octamer NN NN O
binding NN NN O
proteins NN NN O
were NN NN O
detected NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
cultured NN NN O
mouse NN NN O
astrocytes NN NN O
. NN NN O
   
These NN NN O
proteins NN NN O
are NN NN O
differentially NN NN O
expressed NN NN O
in NN NN O
human NN NN O
glioblastoma NN NN O
and NN NN O
neuroblastoma NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
nervous NN NN O
system NN NN O
- NN NN O
derived NN NN O
( NN NN O
N NN NN O
- NN NN O
Oct NN NN O
) NN NN O
proteins NN NN O
bound NN NN O
to NN NN O
the NN NN O
octamer NN NN O
DNA NN NN O
sequence NN NN O
in NN NN O
a NN NN O
manner NN NN O
which NN NN O
is NN NN O
indistinguishable NN NN O
from NN NN O
the NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
proteins NN NN O
. NN NN O
   
The NN NN O
relationship NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
Oct NN NN O
proteins NN NN O
to NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
was NN NN O
analyzed NN NN O
by NN NN O
proteolytic NN NN O
clipping NN NN O
bandshift NN NN O
assays NN NN O
and NN NN O
by NN NN O
their NN NN O
reactivity NN NN O
towards NN NN O
antisera NN NN O
raised NN NN O
against NN NN O
recombinant NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
proteins NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
these NN NN O
assays NN NN O
, NN NN O
all NN NN O
N NN NN O
- NN NN O
Oct NN NN O
- NN NN O
factors NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
distinct NN NN O
from NN NN O
the NN NN O
ubiquitous NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
the NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
proteins NN NN O
. NN NN O
   
In NN NN O
melanoma NN NN O
cells NN NN O
that NN NN O
contain NN NN O
the NN NN O
N NN NN B-Protein
- NN NN I-Protein
Oct NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
factor NN NN O
, NN NN O
a NN NN O
transfected NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
was NN NN O
neither NN NN O
activated NN NN O
nor NN NN O
was NN NN O
it NN NN O
repressed NN NN O
upon NN NN O
contransfection NN NN O
with NN NN O
an NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
expression NN NN O
vector NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
speculate NN NN O
that NN NN O
N NN NN B-Protein
- NN NN I-Protein
Oct NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
other NN NN O
N NN NN O
- NN NN O
Oct NN NN O
factors NN NN O
have NN NN O
a NN NN O
specific NN NN O
role NN NN O
in NN NN O
gene NN NN O
expression NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
Cloning NN NN O
of NN NN O
a NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
with NN NN O
homology NN NN O
to NN NN O
the NN NN O
rel NN NN O
oncogene NN NN O
and NN NN O
to NN NN O
cell NN NN O
- NN NN O
cycle NN NN O
motifs NN NN O
. NN NN O
   
We NN NN O
have NN NN O
cloned NN NN O
and NN NN O
characterized NN NN O
a NN NN O
mitogen NN NN O
- NN NN O
inducible NN NN O
gene NN NN O
isolated NN NN O
from NN NN O
human NN NN O
T NN NN O
cells NN NN O
that NN NN O
predicts NN NN O
a NN NN O
protein NN NN O
of NN NN O
968 NN NN O
amino NN NN O
acids NN NN O
. NN NN O
   
The NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
has NN NN O
regions NN NN O
homologous NN NN O
to NN NN O
the NN NN O
oncogene NN NN O
rel NN NN O
and NN NN O
to NN NN O
the NN NN O
developmentally NN NN O
important NN NN O
gene NN NN O
dorsal NN NN O
of NN NN O
Drosophila NN NN O
. NN NN O
   
The NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
contains NN NN O
repeat NN NN O
structures NN NN O
found NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
proteins NN NN O
that NN NN O
are NN NN O
involved NN NN O
in NN NN O
cell NN NN O
- NN NN O
cycle NN NN O
control NN NN O
of NN NN O
yeast NN NN O
and NN NN O
in NN NN O
tissue NN NN O
differentiation NN NN O
in NN NN O
Drosophila NN NN O
and NN NN O
Ceanorhabditis NN NN O
elegans NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
putative NN NN O
human NN NN O
oncogene NN NN O
bcl NN NN O
- NN NN O
3 NN NN O
and NN NN O
in NN NN O
the NN NN O
ankyrin NN NN O
protein NN NN O
. NN NN O
   
A NN NN O
truncated NN NN O
form NN NN O
of NN NN O
the NN NN O
product NN NN O
of NN NN O
this NN NN O
gene NN NN O
translated NN NN O
in NN NN O
vitro NN NN O
is NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
which NN NN O
interacts NN NN O
specifically NN NN O
with NN NN O
the NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
site NN NN O
found NN NN O
in NN NN O
many NN NN O
inducible NN NN O
genes NN NN O
, NN NN O
including NN NN O
the NN NN O
enhancer NN NN O
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
This NN NN O
gene NN NN O
is NN NN O
yet NN NN O
another NN NN O
in NN NN O
a NN NN O
growing NN NN O
list NN NN O
of NN NN O
important NN NN O
regulatory NN NN O
molecules NN NN O
whose NN NN O
expression NN NN O
is NN NN O
transcriptionally NN NN O
induced NN NN O
upon NN NN O
cellular NN NN O
activation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
with NN NN O
double NN NN O
- NN NN O
stranded NN NN O
phosphorothioate NN NN O
oligonucleotides NN NN O
. NN NN O
   
Alteration NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
specific NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
is NN NN O
necessary NN NN O
for NN NN O
determining NN NN O
how NN NN O
these NN NN O
factors NN NN O
participate NN NN O
in NN NN O
cellular NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
functions NN NN O
of NN NN O
these NN NN O
proteins NN NN O
can NN NN O
be NN NN O
antagonized NN NN O
by NN NN O
several NN NN O
methods NN NN O
, NN NN O
each NN NN O
with NN NN O
specific NN NN O
limitations NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
was NN NN O
achieved NN NN O
with NN NN O
double NN NN O
- NN NN O
stranded NN NN O
( NN NN O
ds NN NN O
) NN NN O
phosphorothioate NN NN O
oligonucleotides NN NN O
that NN NN O
contained NN NN O
octamer NN NN O
or NN NN O
kappa NN NN O
B NN NN O
consensus NN NN O
sequences NN NN O
. NN NN O
   
The NN NN O
phosphorothioate NN NN O
oligonucleotides NN NN O
specifically NN NN O
bound NN NN O
either NN NN O
octamer NN NN O
transcription NN NN O
factor NN NN O
or NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
modified NN NN O
oligonucleotides NN NN O
accumulated NN NN O
in NN NN O
cells NN NN O
more NN NN O
effectively NN NN O
than NN NN O
standard NN NN O
ds NN NN O
oligonucleotides NN NN O
and NN NN O
modulated NN NN O
gene NN NN O
expression NN NN O
in NN NN O
a NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
Octamer NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
plasmid NN NN O
or NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
enhancer NN NN O
was NN NN O
inhibited NN NN O
when NN NN O
the NN NN O
appropriate NN NN O
phosphorothioate NN NN O
oligonucleotide NN NN O
was NN NN O
added NN NN O
to NN NN O
a NN NN O
transiently NN NN O
transfected NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
phosphorothioate NN NN O
oligonucleotides NN NN O
that NN NN O
contained NN NN O
the NN NN O
octamer NN NN O
consensus NN NN O
to NN NN O
Jurkat NN NN O
T NN NN O
leukemia NN NN O
cells NN NN O
inhibited NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
secretion NN NN O
to NN NN O
a NN NN O
degree NN NN O
similar NN NN O
to NN NN O
that NN NN O
observed NN NN O
with NN NN O
a NN NN O
mutated NN NN O
octamer NN NN O
site NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
. NN NN O
   
The NN NN O
ds NN NN O
phosphorothioate NN NN O
oligonucleotides NN NN O
probably NN NN O
compete NN NN O
for NN NN O
binding NN NN O
of NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
may NN NN O
provide NN NN O
anti NN NN O
- NN NN O
viral NN NN O
, NN NN O
immunosuppressive NN NN O
, NN NN O
or NN NN O
other NN NN O
therapeutic NN NN O
effects NN NN O
. NN NN O
   
Differences NN NN O
in NN NN O
transcriptional NN NN O
enhancers NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
Response NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
activation NN NN O
results NN NN O
in NN NN O
high NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
one NN NN O
mechanism NN NN O
leading NN NN O
to NN NN O
the NN NN O
conversion NN NN O
from NN NN O
latent NN NN O
to NN NN O
active NN NN O
viral NN NN O
infection NN NN O
. NN NN O
   
In NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
the NN NN O
sequences NN NN O
that NN NN O
respond NN NN O
to NN NN O
these NN NN O
signaling NN NN O
events NN NN O
are NN NN O
found NN NN O
in NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
and NN NN O
comprise NN NN O
the NN NN O
transcriptional NN NN O
enhancer NN NN O
, NN NN O
which NN NN O
contains NN NN O
two NN NN O
conserved NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
The NN NN O
corresponding NN NN O
region NN NN O
in NN NN O
the NN NN O
second NN NN O
AIDS NN NN O
retrovirus NN NN O
, NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
, NN NN O
contains NN NN O
a NN NN O
conserved NN NN O
and NN NN O
a NN NN O
divergent NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
responds NN NN O
better NN NN O
than NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
LTR NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
These NN NN O
qualitative NN NN O
differences NN NN O
in NN NN O
the NN NN O
response NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
are NN NN O
reproduced NN NN O
not NN NN O
only NN NN O
when NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
or NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancers NN NN O
are NN NN O
placed NN NN O
upstream NN NN O
of NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
but NN NN O
also NN NN O
when NN NN O
these NN NN O
enhancers NN NN O
are NN NN O
switched NN NN O
between NN NN O
their NN NN O
respective NN NN O
LTR NN NN O
. NN NN O
   
In NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
binds NN NN O
to NN NN O
both NN NN O
conserved NN NN O
sites NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
enhancer NN NN O
and NN NN O
only NN NN O
to NN NN O
the NN NN O
single NN NN O
conserved NN NN O
site NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
transcriptional NN NN O
enhancer NN NN O
. NN NN O
   
Instead NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
the NN NN O
activator NN NN B-Protein
protein NN NN I-Protein
3 NN NN I-Protein
binds NN NN O
to NN NN O
the NN NN O
divergent NN NN O
site NN NN O
in NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
are NN NN O
differentially NN NN O
regulated NN NN O
by NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
, NN NN O
and NN NN O
this NN NN O
difference NN NN O
may NN NN O
account NN NN O
for NN NN O
the NN NN O
longer NN NN O
period NN NN O
of NN NN O
viral NN NN O
latency NN NN O
observed NN NN O
with NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
than NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
An NN NN O
in NN NN O
vitro NN NN O
globin NN NN O
gene NN NN O
switching NN NN O
model NN NN O
based NN NN O
on NN NN O
differentiated NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
used NN NN O
mouse NN NN O
embryonic NN NN O
stem NN NN O
( NN NN O
ES NN NN O
) NN NN O
cells NN NN O
to NN NN O
study NN NN O
globin NN NN O
gene NN NN O
expression NN NN O
and NN NN O
switching NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
ES NN NN O
- NN NN O
derived NN NN O
embryoid NN NN O
bodies NN NN O
express NN NN O
the NN NN O
full NN NN O
complement NN NN O
of NN NN O
mouse NN NN O
embryonic NN NN O
globin NN NN O
genes NN NN O
in NN NN O
the NN NN O
correct NN NN O
temporal NN NN O
order NN NN O
and NN NN O
that NN NN O
on NN NN O
further NN NN O
differentiation NN NN O
, NN NN O
a NN NN O
switch NN NN O
occurs NN NN O
to NN NN O
the NN NN O
fetal NN NN O
/ NN NN O
adult NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
expressed NN NN O
coordinately NN NN O
with NN NN O
that NN NN O
of NN NN O
globin NN NN O
in NN NN O
embryoid NN NN O
bodies NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
experiments NN NN O
that NN NN O
the NN NN O
ES NN NN O
cell NN NN O
system NN NN O
provides NN NN O
a NN NN O
good NN NN O
model NN NN O
to NN NN O
study NN NN O
hematopoietic NN NN O
development NN NN O
. NN NN O
   
When NN NN O
the NN NN O
human NN NN O
epsilon NN NN O
- NN NN O
or NN NN O
beta NN NN O
- NN NN O
globin NN NN O
genes NN NN O
driven NN NN O
by NN NN O
the NN NN O
dominant NN NN O
control NN NN O
region NN NN O
( NN NN O
DCR NN NN O
) NN NN O
are NN NN O
introduced NN NN O
into NN NN O
this NN NN O
system NN NN O
, NN NN O
the NN NN O
human NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
, NN NN O
is NN NN O
not NN NN O
deregulated NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
DCR NN NN O
and NN NN O
is NN NN O
expressed NN NN O
strictly NN NN O
as NN NN O
an NN NN O
embryonic NN NN O
gene NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
this NN NN O
that NN NN O
the NN NN O
epsilon NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
is NN NN O
not NN NN O
regulated NN NN O
by NN NN O
competition NN NN O
with NN NN O
other NN NN O
genes NN NN O
in NN NN O
the NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
locus NN NN O
. NN NN O
   
Functional NN NN O
analysis NN NN O
of NN NN O
cis NN NN O
- NN NN O
linked NN NN O
regulatory NN NN O
sequences NN NN O
in NN NN O
the NN NN O
HLA NN NN O
DRA NN NN O
promoter NN NN O
by NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Two NN NN O
consensus NN NN O
sequences NN NN O
, NN NN O
called NN NN O
X NN NN O
and NN NN O
Y NN NN O
boxes NN NN O
, NN NN O
capable NN NN O
of NN NN O
binding NN NN O
nuclear NN NN O
proteins NN NN O
and NN NN O
regulating NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
have NN NN O
been NN NN O
defined NN NN O
within NN NN O
the NN NN O
immediate NN NN O
upstream NN NN O
region NN NN O
of NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
( NN NN O
MHC NN NN O
) NN NN O
class NN NN O
II NN NN O
promoters NN NN O
. NN NN O
   
Unlike NN NN O
other NN NN O
class NN NN O
II NN NN O
promoters NN NN O
, NN NN O
the NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
alpha NN NN O
( NN NN O
DRA NN NN O
) NN NN O
promoter NN NN O
also NN NN O
contains NN NN O
one NN NN O
element NN NN O
identical NN NN O
to NN NN O
the NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
motif NN NN O
of NN NN O
immunoglobulin NN NN O
variable NN NN O
region NN NN O
promoters NN NN O
that NN NN O
is NN NN O
responsible NN NN O
for NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
. NN NN O
   
This NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
DRA NN NN O
appears NN NN O
capable NN NN O
of NN NN O
binding NN NN O
both NN NN O
the NN NN O
ubiquitous NN NN O
( NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
( NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
but NN NN O
at NN NN O
least NN NN O
one NN NN O
other NN NN O
distinct NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
complex NN NN O
was NN NN O
found NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
characterize NN NN O
the NN NN O
function NN NN O
of NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
, NN NN O
we NN NN O
have NN NN O
developed NN NN O
an NN NN O
in NN NN O
vitro NN NN O
system NN NN O
in NN NN O
which NN NN O
a NN NN O
DRA NN NN O
promoter NN NN O
construct NN NN O
is NN NN O
transcribed NN NN O
more NN NN O
efficiently NN NN O
in NN NN O
extracts NN NN O
from NN NN O
B NN NN O
cells NN NN O
than NN NN O
in NN NN O
extracts NN NN O
from NN NN O
class NN NN O
II NN NN O
- NN NN O
negative NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
5 NN NN O
' NN NN O
deletion NN NN O
constructs NN NN O
which NN NN O
lacked NN NN O
the NN NN O
Y NN NN O
box NN NN O
, NN NN O
but NN NN O
retained NN NN O
the NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
motif NN NN O
and NN NN O
TATA NN NN O
box NN NN O
were NN NN O
completely NN NN O
inactive NN NN O
, NN NN O
and NN NN O
internal NN NN O
deletion NN NN O
of NN NN O
the NN NN O
Y NN NN O
box NN NN O
reduced NN NN O
transcription NN NN O
by NN NN O
95 NN NN O
% NN NN O
. NN NN O
   
Using NN NN O
supercoiled NN NN O
, NN NN O
but NN NN O
not NN NN O
linear NN NN O
templates NN NN O
, NN NN O
we NN NN O
observed NN NN O
differences NN NN O
in NN NN O
transcription NN NN O
efficiencies NN NN O
from NN NN O
templates NN NN O
lacking NN NN O
or NN NN O
disrupting NN NN O
the NN NN O
X NN NN O
consensus NN NN O
element NN NN O
that NN NN O
reflect NN NN O
effects NN NN O
of NN NN O
random NN NN O
replacement NN NN O
of NN NN O
X NN NN O
box NN NN O
sequences NN NN O
in NN NN O
transient NN NN O
expression NN NN O
assays NN NN O
. NN NN O
   
Demonstration NN NN O
of NN NN O
the NN NN O
complete NN NN O
dependence NN NN O
on NN NN O
the NN NN O
Y NN NN O
box NN NN O
in NN NN O
this NN NN O
system NN NN O
suggests NN NN O
that NN NN O
, NN NN O
despite NN NN O
its NN NN O
demonstrated NN NN O
importance NN NN O
in NN NN O
the NN NN O
DRA NN NN O
promoter NN NN O
, NN NN O
the NN NN O
DRA NN NN O
"""""""" NN NN O
octamer NN NN O
"""""""" NN NN O
does NN NN O
not NN NN O
utilize NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
a NN NN O
manner NN NN O
analogous NN NN O
to NN NN O
immunoglobulin NN NN O
promoters NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
from NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
cellular NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
. NN NN O
   
Among NN NN O
the NN NN O
protein NN NN O
- NN NN O
binding NN NN O
regions NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
is NN NN O
the NN NN O
transcription NN NN O
- NN NN O
enhancer NN NN O
region NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
at NN NN O
least NN NN O
one NN NN O
inducible NN NN O
, NN NN O
C1 NN NN B-Protein
, NN NN O
and NN NN O
one NN NN O
constitutive NN NN O
, NN NN O
C2 NN NN B-Protein
, NN NN O
protein NN NN O
can NN NN O
bind NN NN O
to NN NN O
the NN NN O
HIV NN NN O
enhancer NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
two NN NN O
proteins NN NN O
differ NN NN O
in NN NN O
their NN NN O
surface NN NN O
charge NN NN O
, NN NN O
since NN NN O
they NN NN O
are NN NN O
separable NN NN O
by NN NN O
anion NN NN O
- NN NN O
exchange NN NN O
chromatography NN NN O
. NN NN O
   
Bivalent NN NN O
cations NN NN O
such NN NN O
as NN NN O
Mg2 NN NN O
+ NN NN O
and NN NN O
Zn2 NN NN O
+ NN NN O
differentially NN NN O
affect NN NN O
their NN NN O
binding NN NN O
to NN NN O
oligonucleotides NN NN O
which NN NN O
contain NN NN O
the NN NN O
HIV NN NN O
- NN NN O
enhancer NN NN O
domain NN NN O
. NN NN O
   
Both NN NN O
C1 NN NN B-Protein
and NN NN O
C2 NN NN B-Protein
proteins NN NN O
also NN NN O
bind NN NN O
to NN NN O
a NN NN O
similar NN NN O
sequence NN NN O
found NN NN O
in NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
subunit NN NN I-Protein
enhancer NN NN O
. NN NN O
   
The NN NN O
inducible NN NN O
C1 NN NN B-Protein
protein NN NN O
was NN NN O
partially NN NN O
purified NN NN O
by NN NN O
three NN NN O
chromatographic NN NN O
steps NN NN O
and NN NN O
characterized NN NN O
by NN NN O
u NN NN O
. NN NN O
v NN NN O
. NN NN O
cross NN NN O
- NN NN O
linking NN NN O
as NN NN O
a NN NN O
47 NN NN O
kDa NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
ubiquitous NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
is NN NN O
sufficient NN NN O
for NN NN O
transcription NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
. NN NN O
   
All NN NN O
immunoglobulin NN NN O
genes NN NN O
contain NN NN O
a NN NN O
conserved NN NN O
octanucleotide NN NN O
promoter NN NN O
element NN NN O
, NN NN O
ATGCAAAT NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
their NN NN O
normal NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
. NN NN O
   
Proteins NN NN O
that NN NN O
bind NN NN O
this NN NN O
octamer NN NN O
have NN NN O
been NN NN O
purified NN NN O
, NN NN O
and NN NN O
cDNAs NN NN O
encoding NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
have NN NN O
been NN NN O
cloned NN NN O
. NN NN O
   
Some NN NN O
of NN NN O
these NN NN O
proteins NN NN O
( NN NN O
referred NN NN O
to NN NN O
as NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
are NN NN O
lymphoid NN NN O
specific NN NN O
, NN NN O
whereas NN NN O
at NN NN O
least NN NN O
one NN NN O
other NN NN O
, NN NN O
and NN NN O
possibly NN NN O
more NN NN O
( NN NN O
referred NN NN O
to NN NN O
as NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
is NN NN O
found NN NN O
ubiquitously NN NN O
in NN NN O
all NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
exact NN NN O
role NN NN O
of NN NN O
these NN NN O
different NN NN O
proteins NN NN O
in NN NN O
directing NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
is NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
two NN NN O
human NN NN O
pre NN NN O
- NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
that NN NN O
contain NN NN O
extremely NN NN O
low NN NN O
levels NN NN O
of NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
yet NN NN O
still NN NN O
express NN NN O
high NN NN O
levels NN NN O
of NN NN O
steady NN NN O
- NN NN O
state NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
mRNA NN NN O
in NN NN O
vivo NN NN O
and NN NN O
efficiently NN NN O
transcribe NN NN O
an NN NN O
immunoglobulin NN NN O
gene NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
a NN NN O
highly NN NN O
enriched NN NN O
preparation NN NN O
of NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
made NN NN O
from NN NN O
one NN NN O
of NN NN O
these NN NN O
pre NN NN O
- NN NN O
B NN NN O
cells NN NN O
or NN NN O
from NN NN O
HeLa NN NN O
cells NN NN O
specifically NN NN O
stimulated NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
of NN NN O
an NN NN O
immunoglobulin NN NN O
gene NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
OFT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
appeared NN NN O
to NN NN O
have NN NN O
approximately NN NN O
the NN NN O
same NN NN O
transactivation NN NN O
ability NN NN O
as NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
when NN NN O
normalized NN NN O
for NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
without NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
is NN NN O
sufficient NN NN O
for NN NN O
transcription NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
and NN NN O
that NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
alone NN NN O
is NN NN O
not NN NN O
responsible NN NN O
for NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
immunoglobulin NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Tax NN NN B-Protein
- NN NN O
independent NN NN O
binding NN NN O
of NN NN O
multiple NN NN O
cellular NN NN O
factors NN NN O
to NN NN O
Tax NN NN B-Protein
- NN NN O
response NN NN O
element NN NN O
DNA NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
. NN NN O
   
The NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
promoter NN NN O
contains NN NN O
three NN NN O
copies NN NN O
of NN NN O
imperfect NN NN O
repeats NN NN O
of NN NN O
a NN NN O
21 NN NN O
- NN NN O
base NN NN O
pair NN NN O
sequence NN NN O
designated NN NN O
here NN NN O
as NN NN O
TRE NN NN O
( NN NN O
Tax NN NN O
- NN NN O
response NN NN O
element NN NN O
) NN NN O
that NN NN O
is NN NN O
responsive NN NN O
to NN NN O
the NN NN O
virally NN NN O
encoded NN NN O
transactivator NN NN O
protein NN NN O
Tax NN NN B-Protein
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
and NN NN O
separated NN NN O
four NN NN O
nuclear NN NN O
proteins NN NN O
from NN NN O
C81 NN NN O
- NN NN O
66 NN NN O
- NN NN O
45 NN NN O
cells NN NN O
, NN NN O
an NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
immortalized NN NN O
Tax NN NN B-Protein
- NN NN O
expressing NN NN O
human NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
line NN NN O
( NN NN O
Salahuddin NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
1983 NN NN O
) NN NN O
, NN NN O
that NN NN O
interact NN NN O
with NN NN O
the NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
, NN NN O
none NN NN O
of NN NN O
which NN NN O
are NN NN O
identical NN NN O
with NN NN O
the NN NN O
Tax NN NN B-Protein
- NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
proteins NN NN O
identified NN NN O
have NN NN O
molecular NN NN O
weights NN NN O
of NN NN O
about NN NN O
32 NN NN O
, NN NN O
36 NN NN O
to NN NN O
42 NN NN O
, NN NN O
50 NN NN O
and NN NN O
110 NN NN O
kD NN NN O
. NN NN O
   
Four NN NN O
different NN NN O
methods NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
the NN NN O
proteins NN NN O
. NN NN O
   
First NN NN O
, NN NN O
from NN NN O
different NN NN O
cell NN NN O
lines NN NN O
three NN NN O
or NN NN O
all NN NN O
four NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
proteins NN NN O
were NN NN O
specifically NN NN O
cross NN NN O
- NN NN O
linked NN NN O
by NN NN O
UV NN NN O
irradiation NN NN O
to NN NN O
the NN NN O
radioactively NN NN O
labeled NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
fragment NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
sedimented NN NN O
through NN NN O
a NN NN O
glycerol NN NN O
density NN NN O
gradient NN NN O
at NN NN O
rates NN NN O
corresponding NN NN O
to NN NN O
proteins NN NN O
of NN NN O
native NN NN O
molecular NN NN O
weights NN NN O
of NN NN O
35 NN NN O
to NN NN O
50 NN NN O
kD NN NN O
and NN NN O
110 NN NN O
kD NN NN O
. NN NN O
   
Third NN NN O
, NN NN O
only NN NN O
the NN NN O
50 NN NN O
kD NN NN O
protein NN NN O
was NN NN O
retained NN NN O
on NN NN O
a NN NN O
biotinylated NN NN O
DNA NN NN O
- NN NN O
streptavidin NN NN O
matrix NN NN O
when NN NN O
the NN NN O
DNA NN NN O
fragment NN NN O
contained NN NN O
the NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
. NN NN O
   
Fourth NN NN O
, NN NN O
extensive NN NN O
purification NN NN O
by NN NN O
several NN NN O
cycles NN NN O
of NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
affinity NN NN O
chromatography NN NN O
resulted NN NN O
in NN NN O
the NN NN O
32 NN NN O
, NN NN O
36 NN NN O
to NN NN O
42 NN NN O
and NN NN O
110 NN NN O
kD NN NN O
proteins NN NN O
and NN NN O
to NN NN O
less NN NN O
extent NN NN O
the NN NN O
50 NN NN O
kD NN NN O
factor NN NN O
. NN NN O
   
Two NN NN O
abundant NN NN O
proteins NN NN O
of NN NN O
75 NN NN O
and NN NN O
80 NN NN O
kD NN NN O
were NN NN O
competed NN NN O
out NN NN O
by NN NN O
poly NN NN O
[ NN NN O
d NN NN O
( NN NN O
I NN NN O
- NN NN O
C NN NN O
) NN NN O
] NN NN O
in NN NN O
all NN NN O
reactions NN NN O
. NN NN O
   
The NN NN O
cAMP NN NN O
- NN NN O
response NN NN O
element NN NN O
CRE NN NN O
, NN NN O
TGACGTCA NN NN O
, NN NN O
present NN NN O
in NN NN O
the NN NN O
21 NN NN O
base NN NN O
- NN NN O
pair NN NN O
sequence NN NN O
, NN NN O
appears NN NN O
to NN NN O
be NN NN O
essential NN NN O
for NN NN O
specific NN NN O
protein NN NN O
- NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
interactions NN NN O
because NN NN O
mutation NN NN O
of NN NN O
the NN NN O
two NN NN O
G NN NN O
' NN NN O
s NN NN O
destroys NN NN O
this NN NN O
complex NN NN O
. NN NN O
   
This NN NN O
result NN NN O
suggests NN NN O
that NN NN O
the NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
binding NN NN O
protein NN NN O
, NN NN O
CREB NN NN B-Protein
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
protein NN NN O
- NN NN O
TRE NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
and NN NN O
in NN NN O
mediating NN NN O
the NN NN O
Tax NN NN B-Protein
response NN NN O
. NN NN O
   
Cell NN NN O
type NN NN O
specificity NN NN O
and NN NN O
activation NN NN O
requirements NN NN O
for NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
- NN NN O
cells NN NN O
) NN NN O
transcriptional NN NN O
activity NN NN O
determined NN NN O
by NN NN O
a NN NN O
new NN NN O
method NN NN O
using NN NN O
transgenic NN NN O
mice NN NN O
to NN NN O
assay NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
an NN NN O
individual NN NN O
nuclear NN NN O
factor NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
- NN NN O
cells NN NN O
( NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
is NN NN O
considered NN NN O
to NN NN O
be NN NN O
an NN NN O
important NN NN O
regulator NN NN O
in NN NN O
early NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
developed NN NN O
a NN NN O
system NN NN O
to NN NN O
monitor NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
at NN NN O
the NN NN O
single NN NN O
cell NN NN O
level NN NN O
in NN NN O
whole NN NN O
animals NN NN O
. NN NN O
   
The NN NN O
system NN NN O
is NN NN O
based NN NN O
on NN NN O
the NN NN O
use NN NN O
of NN NN O
an NN NN O
oligomerized NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
motif NN NN O
that NN NN O
directs NN NN O
transcription NN NN O
of NN NN O
SV40 NN NN O
T NN NN O
- NN NN O
antigen NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
report NN NN O
represents NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
that NN NN O
a NN NN O
multimerized NN NN O
short NN NN O
binding NN NN O
motif NN NN O
can NN NN O
function NN NN O
appropriately NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
had NN NN O
previously NN NN O
been NN NN O
thought NN NN O
to NN NN O
be NN NN O
confined NN NN O
to NN NN O
activated NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
upon NN NN O
release NN NN O
of NN NN O
intracellular NN NN O
calcium NN NN O
. NN NN O
   
By NN NN O
targeting NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
we NN NN O
discovered NN NN O
new NN NN O
sites NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
. NN NN O
   
Besides NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
could NN NN O
also NN NN O
be NN NN O
induced NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
- NN NN O
depleted NN NN O
spleen NN NN O
cells NN NN O
and NN NN O
purified NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
and NN NN O
requires NN NN O
agents NN NN O
that NN NN O
both NN NN O
release NN NN O
intracellular NN NN O
calcium NN NN O
and NN NN O
activate NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
A NN NN O
difference NN NN O
in NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
appearance NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
between NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
and NN NN O
non NN NN O
- NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
was NN NN O
revealed NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
small NN NN O
population NN NN O
of NN NN O
cells NN NN O
in NN NN O
the NN NN O
dermis NN NN O
and NN NN O
some NN NN O
mice NN NN O
have NN NN O
developed NN NN O
skin NN NN O
lesions NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
tissue NN NN O
pattern NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
resembles NN NN O
the NN NN O
expression NN NN O
pattern NN NN O
described NN NN O
for NN NN O
HIV NN NN O
- NN NN O
LTR NN NN O
/ NN NN O
tat NN NN O
transgenic NN NN O
mice NN NN O
( NN NN O
Vogel NN NN O
, NN NN O
J NN NN O
. NN NN O
, NN NN O
Hinrichs NN NN O
, NN NN O
S NN NN O
. NN NN O
H NN NN O
. NN NN O
, NN NN O
Reynolds NN NN O
, NN NN O
R NN NN O
. NN NN O
K NN NN O
. NN NN O
, NN NN O
Luciw NN NN O
, NN NN O
P NN NN O
. NN NN O
A NN NN O
. NN NN O
, NN NN O
and NN NN O
Jay NN NN O
, NN NN O
G NN NN O
. NN NN O
( NN NN O
1988 NN NN O
) NN NN O
Nature NN NN O
335 NN NN O
, NN NN O
606 NN NN O
- NN NN O
611 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
similarity NN NN O
in NN NN O
expression NN NN O
and NN NN O
the NN NN O
fact NN NN O
that NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
bind NN NN O
functional NN NN O
sequences NN NN O
in NN NN O
HIV NN NN O
- NN NN O
LTR NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
dermal NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
LTR NN NN O
. NN NN O
   
Octamer NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
the NN NN O
cell NN NN O
type NN NN O
- NN NN O
specificity NN NN O
of NN NN O
immunoglobulin NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Antibodies NN NN O
are NN NN O
produced NN NN O
exclusively NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
antibody NN NN O
- NN NN O
encoding NN NN O
genes NN NN O
, NN NN O
the NN NN O
immunoglobulin NN NN O
( NN NN O
Ig NN NN O
) NN NN O
genes NN NN O
, NN NN O
is NN NN O
also NN NN O
restricted NN NN O
to NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
octamer NN NN O
sequence NN NN O
ATGCAAAT NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
promoter NN NN O
and NN NN O
the NN NN O
enhancer NN NN O
of NN NN O
Ig NN NN O
genes NN NN O
, NN NN O
and NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
its NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
sequence NN NN O
motif NN NN O
is NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
nuclear NN NN O
proteins NN NN O
, NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
octamer NN NN O
transcription NN NN O
factors NN NN O
( NN NN O
Oct NN NN O
or NN NN O
OTF NN NN O
factors NN NN O
) NN NN O
. NN NN O
   
The NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
is NN NN O
present NN NN O
in NN NN O
all NN NN O
cell NN NN O
types NN NN O
analyzed NN NN O
so NN NN O
far NN NN O
, NN NN O
whereas NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2B NN NN I-Protein
are NN NN O
found NN NN O
mainly NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
All NN NN O
three NN NN O
proteins NN NN O
show NN NN O
the NN NN O
same NN NN O
sequence NN NN O
specificity NN NN O
and NN NN O
binding NN NN O
affinity NN NN O
. NN NN O
   
It NN NN O
appears NN NN O
that NN NN O
the NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
Ig NN NN O
genes NN NN O
is NN NN O
mediated NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
by NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
Oct NN NN O
factors NN NN O
, NN NN O
and NN NN O
that NN NN O
there NN NN O
are NN NN O
both NN NN O
quantitative NN NN O
and NN NN O
qualitative NN NN O
differences NN NN O
between NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
factors NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
a NN NN O
number NN NN O
of NN NN O
other NN NN O
octamer NN NN O
factor NN NN O
variants NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
Many NN NN O
of NN NN O
these NN NN O
may NN NN O
be NN NN O
created NN NN O
by NN NN O
alternative NN NN O
splicing NN NN O
of NN NN O
a NN NN O
primary NN NN O
transcript NN NN O
of NN NN O
one NN NN O
Oct NN NN O
factor NN NN O
gene NN NN O
and NN NN O
may NN NN O
serve NN NN O
a NN NN O
specific NN NN O
function NN NN O
in NN NN O
the NN NN O
fine NN NN O
tuning NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
and NN NN O
thrombin NN NN O
receptor NN NN O
agonist NN NN O
peptide NN NN O
induce NN NN O
early NN NN O
events NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
and NN NN O
synergize NN NN O
with NN NN O
TCR NN NN O
cross NN NN O
- NN NN O
linking NN NN O
for NN NN O
CD69 NN NN B-Protein
expression NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
stimulation NN NN O
of NN NN O
the NN NN O
T NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
induced NN NN O
a NN NN O
transient NN NN O
increase NN NN O
in NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
. NN NN O
   
Proteolytic NN NN O
activity NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
was NN NN O
required NN NN O
for NN NN O
this NN NN O
effect NN NN O
since NN NN O
diisopropyl NN NN O
fluorophosphate NN NN O
- NN NN O
thrombin NN NN B-Protein
failed NN NN O
to NN NN O
increase NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
hirudin NN NN O
and NN NN O
anti NN NN O
- NN NN O
thrombin NN NN B-Protein
III NN NN I-Protein
inhibited NN NN O
the NN NN O
thrombin NN NN B-Protein
- NN NN O
induced NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
rise NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
synthetic NN NN O
thrombin NN NN O
receptor NN NN O
agonist NN NN O
peptide NN NN O
( NN NN O
TRP NN NN O
) NN NN O
of NN NN O
7 NN NN O
residues NN NN O
( NN NN O
SFLLRNP NN NN O
) NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
as NN NN O
effective NN NN O
as NN NN O
thrombin NN NN B-Protein
for NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
mobilization NN NN O
, NN NN O
and NN NN O
both NN NN O
agonists NN NN O
induced NN NN O
Ca2 NN NN O
+ NN NN O
release NN NN O
exclusively NN NN O
from NN NN O
internal NN NN O
stores NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
stimulated NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
several NN NN O
proteins NN NN O
of NN NN O
molecular NN NN O
mass NN NN O
40 NN NN O
, NN NN O
42 NN NN O
, NN NN O
70 NN NN O
, NN NN O
120 NN NN O
, NN NN O
and NN NN O
130 NN NN O
kDa NN NN O
. NN NN O
   
There NN NN O
was NN NN O
a NN NN O
good NN NN O
correlation NN NN O
between NN NN O
thrombin NN NN B-Protein
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
latter NN NN O
three NN NN O
proteins NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
mobilization NN NN O
. NN NN O
   
Thrombin NN NN B-Protein
and NN NN O
TRP NN NN O
also NN NN O
caused NN NN O
translocation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
from NN NN O
the NN NN O
cytosol NN NN O
to NN NN O
the NN NN O
plasma NN NN O
membrane NN NN O
. NN NN O
   
As NN NN O
a NN NN O
likely NN NN O
consequence NN NN O
of NN NN O
these NN NN O
events NN NN O
, NN NN O
thrombin NN NN B-Protein
activated NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kB NN NN O
. NN NN O
   
Several NN NN O
cell NN NN O
lines NN NN O
of NN NN O
hematopoietic NN NN O
origin NN NN O
including NN NN O
the NN NN O
leukemic NN NN O
T NN NN O
cell NN NN O
line NN NN O
HPB NN NN O
. NN NN O
ALL NN NN O
and NN NN O
the NN NN O
erythroleukemic NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
were NN NN O
responsive NN NN O
to NN NN O
thrombin NN NN B-Protein
, NN NN O
whereas NN NN O
others NN NN O
such NN NN O
as NN NN O
THP1 NN NN O
, NN NN O
a NN NN O
myelomonocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
and NN NN O
BL2 NN NN O
, NN NN O
a NN NN O
Burkitt NN NN O
lymphoma NN NN O
were NN NN O
refractory NN NN O
to NN NN O
thrombin NN NN B-Protein
or NN NN O
TRP NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
the NN NN O
thrombin NN NN B-Protein
response NN NN O
in NN NN O
the NN NN O
different NN NN O
cell NN NN O
types NN NN O
paralleled NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
thrombin NN NN B-Protein
receptor NN NN I-Protein
mRNA NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
activation NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
phytohemagglutinin NN NN B-Protein
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
led NN NN O
to NN NN O
a NN NN O
dramatic NN NN O
inhibition NN NN O
of NN NN O
thrombin NN NN B-Protein
receptor NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
to NN NN O
a NN NN O
concomitant NN NN O
loss NN NN O
of NN NN O
the NN NN O
thrombin NN NN B-Protein
response NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
thrombin NN NN B-Protein
and NN NN O
TRP NN NN O
enhanced NN NN O
CD69 NN NN B-Protein
expression NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
production NN NN O
induced NN NN O
by NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
both NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
highlight NN NN O
the NN NN O
role NN NN O
of NN NN O
thrombin NN NN B-Protein
as NN NN O
a NN NN O
potential NN NN O
regulator NN NN O
of NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
Sp1 NN NN B-Protein
is NN NN O
a NN NN O
critical NN NN O
factor NN NN O
for NN NN O
the NN NN O
monocytic NN NN O
specific NN NN O
expression NN NN O
of NN NN O
human NN NN O
CD14 NN NN B-Protein
. NN NN O
   
CD14 NN NN B-Protein
is NN NN O
a NN NN O
membrane NN NN O
glycoprotein NN NN O
expressed NN NN O
specifically NN NN O
on NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
its NN NN O
expression NN NN O
is NN NN O
markedly NN NN O
increased NN NN O
during NN NN O
the NN NN O
process NN NN O
of NN NN O
monocyte NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
study NN NN O
CD14 NN NN B-Protein
gene NN NN O
regulation NN NN O
, NN NN O
the NN NN O
human NN NN O
CD14 NN NN B-Protein
gene NN NN O
was NN NN O
cloned NN NN O
from NN NN O
a NN NN O
partial NN NN O
EcoRI NN NN B-Protein
digested NN NN O
chromosome NN NN O
5 NN NN O
library NN NN O
. NN NN O
   
A NN NN O
5 NN NN O
. NN NN O
5 NN NN O
- NN NN O
kilobase NN NN O
genomic NN NN O
clone NN NN O
contained NN NN O
the NN NN O
full NN NN O
- NN NN O
length NN NN O
CD14 NN NN B-Protein
coding NN NN O
sequence NN NN O
and NN NN O
4 NN NN O
. NN NN O
2 NN NN O
kilobases NN NN O
of NN NN O
5 NN NN O
' NN NN O
- NN NN O
upstream NN NN O
sequence NN NN O
. NN NN O
   
One NN NN O
major NN NN O
and NN NN O
one NN NN O
minor NN NN O
transcription NN NN O
start NN NN O
site NN NN O
were NN NN O
identified NN NN O
101 NN NN O
and NN NN O
130 NN NN O
base NN NN O
pairs NN NN O
( NN NN O
bp NN NN O
) NN NN O
upstream NN NN O
, NN NN O
respectively NN NN O
, NN NN O
from NN NN O
the NN NN O
protein NN NN O
translation NN NN O
start NN NN O
ATG NN NN O
. NN NN O
   
A NN NN O
DNA NN NN O
fragment NN NN O
containing NN NN O
128 NN NN O
bp NN NN O
of NN NN O
upstream NN NN O
sequence NN NN O
had NN NN O
strong NN NN O
, NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
the NN NN O
CD14 NN NN B-Protein
positive NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
nonmonocytic NN NN O
cell NN NN O
lines NN NN O
HeLa NN NN O
and NN NN O
REX NN NN O
. NN NN O
   
Four NN NN O
regions NN NN O
in NN NN O
this NN NN O
DNA NN NN O
fragment NN NN O
interact NN NN O
with NN NN O
nuclear NN NN O
proteins NN NN O
isolated NN NN O
from NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Sp1 NN NN B-Protein
transcription NN NN O
factor NN NN O
bound NN NN O
to NN NN O
three NN NN O
different NN NN O
regions NN NN O
in NN NN O
the NN NN O
CD14 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
major NN NN O
Sp1 NN NN B-Protein
binding NN NN O
site NN NN O
( NN NN O
- NN NN O
110 NN NN O
bp NN NN O
) NN NN O
decreased NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
activity NN NN O
, NN NN O
and NN NN O
these NN NN O
results NN NN O
, NN NN O
together NN NN O
with NN NN O
transactivation NN NN O
experiments NN NN O
, NN NN O
demonstrate NN NN O
that NN NN O
Sp1 NN NN B-Protein
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
CD14 NN NN B-Protein
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
CD14 NN NN B-Protein
Sp1 NN NN B-Protein
site NN NN O
oligonucleotides NN NN O
bound NN NN O
preferentially NN NN O
to NN NN O
a NN NN O
105 NN NN O
- NN NN O
kDa NN NN O
Sp1 NN NN B-Protein
species NN NN O
, NN NN O
which NN NN O
is NN NN O
present NN NN O
in NN NN O
higher NN NN O
relative NN NN O
levels NN NN O
in NN NN O
monocytic NN NN O
than NN NN O
non NN NN O
- NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
modification NN NN O
of NN NN O
Sp1 NN NN B-Protein
, NN NN O
such NN NN O
as NN NN O
phosphorylation NN NN O
, NN NN O
may NN NN O
explain NN NN O
how NN NN O
the NN NN O
Sp1 NN NN B-Protein
site NN NN O
mediates NN NN O
monocytic NN NN O
specific NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Tolerance NN NN O
to NN NN O
lipopolysaccharide NN NN O
involves NN NN O
mobilization NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
with NN NN O
predominance NN NN O
of NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
with NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
leads NN NN O
to NN NN O
rapid NN NN O
and NN NN O
transient NN NN O
expression NN NN O
of NN NN O
cytokines NN NN O
like NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
. NN NN O
   
When NN NN O
such NN NN O
cells NN NN O
are NN NN O
precultured NN NN O
for NN NN O
2 NN NN O
days NN NN O
with NN NN O
a NN NN O
low NN NN O
dose NN NN O
of NN NN O
LPS NN NN O
( NN NN O
20 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
followed NN NN O
by NN NN O
stimulation NN NN O
with NN NN O
a NN NN O
high NN NN O
dose NN NN O
of NN NN O
LPS NN NN O
( NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
TNF NN NN O
gene NN NN O
is NN NN O
minimal NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
the NN NN O
cells NN NN O
are NN NN O
tolerant NN NN O
. NN NN O
   
In NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
analysis NN NN O
, NN NN O
such NN NN O
tolerant NN NN O
cells NN NN O
show NN NN O
only NN NN O
a NN NN O
low NN NN O
degree NN NN O
of NN NN O
transcription NN NN O
, NN NN O
indicating NN NN O
that NN NN O
tolerance NN NN O
operates NN NN O
at NN NN O
or NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
level NN NN O
. NN NN O
   
The NN NN O
CD14 NN NN B-Protein
LPS NN NN O
receptor NN NN O
is NN NN O
, NN NN O
however NN NN O
, NN NN O
up NN NN O
- NN NN O
regulated NN NN O
( NN NN O
not NN NN O
down NN NN O
- NN NN O
regulated NN NN O
) NN NN O
in NN NN O
tolerant NN NN O
cells NN NN O
, NN NN O
and NN NN O
LPS NN NN O
can NN NN O
, NN NN O
in NN NN O
fact NN NN O
, NN NN O
still NN NN O
lead NN NN O
to NN NN O
activation NN NN O
of NN NN O
tolerant NN NN O
cells NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
mobilization NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Resolution NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
in NN NN O
gel NN NN O
shift NN NN O
analysis NN NN O
shows NN NN O
that NN NN O
the NN NN O
binding NN NN O
protein NN NN O
, NN NN O
mobilized NN NN O
in NN NN O
naive NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
cells NN NN O
, NN NN O
consists NN NN O
mainly NN NN O
of NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
, NN NN O
while NN NN O
in NN NN O
tolerant NN NN O
cells NN NN O
, NN NN O
the NN NN O
p50 NN NN B-Protein
homodimer NN NN O
is NN NN O
predominant NN NN O
. NN NN O
   
This NN NN O
increase NN NN O
in NN NN O
p50 NN NN B-Protein
homodimers NN NN O
coincides NN NN O
with NN NN O
an NN NN O
increase NN NN O
in NN NN O
p105 NN NN B-Protein
mRNA NN NN O
, NN NN O
suggestive NN NN O
of NN NN O
a NN NN O
transcriptional NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
p50 NN NN B-Protein
. NN NN O
   
Reporter NN NN O
gene NN NN O
analysis NN NN O
reveals NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
mobilized NN NN O
in NN NN O
tolerant NN NN O
cells NN NN O
is NN NN O
functionally NN NN O
inactive NN NN O
in NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
luciferase NN NN O
constructs NN NN O
containing NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
or NN NN O
the NN NN O
TNF NN NN O
5 NN NN O
' NN NN O
- NN NN O
region NN NN O
show NN NN O
only NN NN O
minimal NN NN O
transactivation NN NN O
after NN NN O
LPS NN NN O
stimulation NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
cells NN NN O
, NN NN O
primary NN NN O
blood NN NN O
monocytes NN NN O
, NN NN O
when NN NN O
precultured NN NN O
with NN NN O
a NN NN O
low NN NN O
dose NN NN O
of NN NN O
LPS NN NN O
, NN NN O
also NN NN O
become NN NN O
tolerant NN NN O
and NN NN O
produce NN NN O
little NN NN O
TNF NN NN O
after NN NN O
LPS NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
tolerant NN NN O
blood NN NN O
monocytes NN NN O
also NN NN O
up NN NN O
- NN NN O
regulate NN NN O
CD14 NN NN B-Protein
, NN NN O
and NN NN O
they NN NN O
mobilize NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
with NN NN O
a NN NN O
predominance NN NN O
of NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
tolerance NN NN O
to NN NN O
LPS NN NN O
is NN NN O
determined NN NN O
by NN NN O
post NN NN O
- NN NN O
receptor NN NN O
mechanisms NN NN O
that NN NN O
involve NN NN O
an NN NN O
altered NN NN O
composition NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
a NN NN O
trans NN NN O
- NN NN O
acting NN NN O
activator NN NN O
function NN NN O
regulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
CD5 NN NN B-Protein
antigen NN NN O
. NN NN O
   
Interspecies NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
were NN NN O
generated NN NN O
by NN NN O
fusing NN NN O
the NN NN O
mouse NN NN O
T NN NN O
- NN NN O
lymphoma NN NN O
cell NN NN O
line NN NN O
, NN NN O
BW5147 NN NN O
, NN NN O
with NN NN O
normal NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
at NN NN O
different NN NN O
stages NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
Thymocytes NN NN O
, NN NN O
activated NN NN O
peripheral NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
or NN NN O
an NN NN O
activated NN NN O
T NN NN O
- NN NN O
cell NN NN O
clone NN NN O
were NN NN O
used NN NN O
as NN NN O
human NN NN O
partners NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
three NN NN O
independent NN NN O
fusions NN NN O
. NN NN O
   
Irrespective NN NN O
of NN NN O
the NN NN O
human NN NN O
cell NN NN O
partner NN NN O
used NN NN O
for NN NN O
fusion NN NN O
, NN NN O
a NN NN O
certain NN NN O
number NN NN O
of NN NN O
hybrids NN NN O
lost NN NN O
CD5 NN NN B-Protein
surface NN NN O
expression NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
time NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
Analysis NN NN O
at NN NN O
the NN NN O
phenotype NN NN O
and NN NN O
genetic NN NN O
level NN NN O
showed NN NN O
that NN NN O
lack NN NN O
of NN NN O
CD5 NN NN B-Protein
expression NN NN O
was NN NN O
due NN NN O
neither NN NN O
to NN NN O
segregation NN NN O
of NN NN O
human NN NN O
autosome NN NN O
11 NN NN O
, NN NN O
on NN NN O
which NN NN O
the NN NN O
CD5 NN NN B-Protein
gene NN NN O
has NN NN O
been NN NN O
mapped NN NN O
, NN NN O
nor NN NN O
to NN NN O
deletion NN NN O
of NN NN O
the NN NN O
CD5 NN NN B-Protein
structural NN NN O
gene NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
loss NN NN O
of NN NN O
CD5 NN NN B-Protein
surface NN NN O
expression NN NN O
correlated NN NN O
with NN NN O
the NN NN O
absence NN NN O
of NN NN O
specific NN NN O
mRNA NN NN O
. NN NN O
   
Since NN NN O
these NN NN O
hybrids NN NN O
preferentially NN NN O
segregate NN NN O
human NN NN O
chromosomes NN NN O
, NN NN O
these NN NN O
results NN NN O
indicate NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
non NN NN O
- NN NN O
syntenic NN NN O
trans NN NN O
- NN NN O
active NN NN O
locus NN NN O
, NN NN O
or NN NN O
loci NN NN O
, NN NN O
positively NN NN O
controlling NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
CD5 NN NN B-Protein
gene NN NN O
. NN NN O
   
Alpha NN NN O
- NN NN O
tocopherol NN NN O
inhibits NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
cultured NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Antioxidants NN NN O
have NN NN O
been NN NN O
proposed NN NN O
to NN NN O
be NN NN O
anti NN NN O
- NN NN O
atherosclerotic NN NN O
agents NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
underlying NN NN O
their NN NN O
beneficial NN NN O
effects NN NN O
are NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
( NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
) NN NN O
on NN NN O
one NN NN O
cellular NN NN O
event NN NN O
in NN NN O
atherosclerotic NN NN O
plaque NN NN O
development NN NN O
, NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
stimulated NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
ECs NN NN O
) NN NN O
. NN NN O
   
Human NN NN O
umbilical NN NN O
vein NN NN O
ECs NN NN O
were NN NN O
pretreated NN NN O
with NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
before NN NN O
stimulation NN NN O
with NN NN O
known NN NN O
agonists NN NN O
of NN NN O
monocyte NN NN O
adhesion NN NN O
: NN NN O
IL NN NN O
- NN NN O
1 NN NN O
( NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
LPS NN NN O
( NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
thrombin NN NN O
( NN NN O
30 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
) NN NN O
, NN NN O
or NN NN O
PMA NN NN O
( NN NN O
10 NN NN O
nM NN NN O
) NN NN O
. NN NN O
   
Agonist NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
, NN NN O
but NN NN O
not NN NN O
basal NN NN O
adhesion NN NN O
, NN NN O
was NN NN O
inhibited NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
by NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
. NN NN O
   
The NN NN O
IC50 NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
on NN NN O
an NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
response NN NN O
was NN NN O
45 NN NN O
microM NN NN O
. NN NN O
   
The NN NN O
inhibition NN NN O
correlated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
steady NN NN O
state NN NN O
levels NN NN O
of NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mRNA NN NN O
and NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
of NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
which NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
ability NN NN O
of NN NN O
a NN NN O
monoclonal NN NN O
antibody NN NN O
to NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
to NN NN O
inhibit NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
in NN NN O
this NN NN O
system NN NN O
. NN NN O
   
Probucol NN NN O
( NN NN O
50 NN NN O
microM NN NN O
) NN NN O
and NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
( NN NN O
20 NN NN O
mM NN NN O
) NN NN O
also NN NN O
inhibited NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
; NN NN O
whereas NN NN O
, NN NN O
several NN NN O
other NN NN O
antioxidants NN NN O
had NN NN O
no NN NN O
significant NN NN O
effect NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
effect NN NN O
since NN NN O
no NN NN O
suppression NN NN O
of NN NN O
phosphorylation NN NN O
of NN NN O
PKC NN NN O
substrates NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
reported NN NN O
to NN NN O
be NN NN O
necessary NN NN O
but NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
expression NN NN O
in NN NN O
EC NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
failed NN NN O
to NN NN O
show NN NN O
an NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
- NN NN O
induced NN NN O
decrease NN NN O
in NN NN O
activation NN NN O
of NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
after NN NN O
cytokine NN NN O
stimulation NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
hypothesized NN NN O
that NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
acts NN NN O
as NN NN O
an NN NN O
anti NN NN O
- NN NN O
atherosclerotic NN NN O
molecule NN NN O
by NN NN O
inhibiting NN NN O
generation NN NN O
of NN NN O
oxidized NN NN O
LDL NN NN O
- NN NN O
- NN NN O
a NN NN O
putative NN NN O
triggering NN NN O
molecule NN NN O
in NN NN O
the NN NN O
atherosclerotic NN NN O
process NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
point NN NN O
to NN NN O
a NN NN O
novel NN NN O
alternative NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tcp NN NN O
. NN NN O
   
Upregulation NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
by NN NN O
the NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
latent NN NN O
membrane NN NN O
protein NN NN O
LMP1 NN NN B-Protein
: NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
response NN NN O
that NN NN O
is NN NN O
delayed NN NN O
relative NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
to NN NN O
induction NN NN O
of NN NN O
cell NN NN O
surface NN NN O
markers NN NN O
. NN NN O
   
An NN NN O
ability NN NN O
of NN NN O
the NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
latent NN NN O
membrane NN NN O
protein NN NN O
LMP1 NN NN B-Protein
to NN NN O
enhance NN NN O
the NN NN O
survival NN NN O
of NN NN O
infected NN NN O
B NN NN O
cells NN NN O
through NN NN O
upregulation NN NN O
of NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
oncogene NN NN O
was NN NN O
first NN NN O
suggested NN NN O
by NN NN O
experiments NN NN O
involving NN NN O
gene NN NN O
transfection NN NN O
and NN NN O
the NN NN O
selection NN NN O
of NN NN O
stable NN NN O
LMP1 NN NN B-Protein
+ NN NN O
clones NN NN O
( NN NN O
S NN NN O
. NN NN O
Henderson NN NN O
, NN NN O
M NN NN O
. NN NN O
Rowe NN NN O
, NN NN O
C NN NN O
. NN NN O
Gregory NN NN O
, NN NN O
F NN NN O
. NN NN O
Wang NN NN O
, NN NN O
E NN NN O
. NN NN O
Kieff NN NN O
, NN NN O
and NN NN O
A NN NN O
. NN NN O
Rickinson NN NN O
, NN NN O
Cell NN NN O
65 NN NN O
: NN NN O
1107 NN NN O
- NN NN O
1115 NN NN O
, NN NN O
1991 NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
was NN NN O
not NN NN O
possible NN NN O
to NN NN O
ascertain NN NN O
whether NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
upregulation NN NN O
was NN NN O
a NN NN O
specific NN NN O
consequence NN NN O
of NN NN O
LMP1 NN NN B-Protein
expression NN NN O
or NN NN O
an NN NN O
artifact NN NN O
of NN NN O
the NN NN O
selection NN NN O
procedure NN NN O
whereby NN NN O
rare NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
+ NN NN O
cells NN NN O
already NN NN O
present NN NN O
in NN NN O
the NN NN O
starting NN NN O
population NN NN O
might NN NN O
best NN NN O
be NN NN O
able NN NN O
to NN NN O
tolerate NN NN O
the NN NN O
potentially NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
LMP1 NN NN B-Protein
. NN NN O
   
We NN NN O
therefore NN NN O
reexamined NN NN O
this NN NN O
issue NN NN O
by NN NN O
using NN NN O
two NN NN O
different NN NN O
experimental NN NN O
approaches NN NN O
that NN NN O
allowed NN NN O
LMP1 NN NN B-Protein
- NN NN O
induced NN NN O
effects NN NN O
to NN NN O
be NN NN O
monitored NN NN O
immediately NN NN O
following NN NN O
expression NN NN O
of NN NN O
the NN NN O
viral NN NN O
protein NN NN O
and NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
selective NN NN O
pressures NN NN O
; NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
upregulation NN NN O
of NN NN O
the NN NN O
cell NN NN O
adhesion NN NN O
molecule NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
were NN NN O
used NN NN O
as NN NN O
early NN NN O
indices NN NN O
of NN NN O
LMP1 NN NN B-Protein
function NN NN O
. NN NN O
   
In NN NN O
the NN NN O
first NN NN O
approach NN NN O
, NN NN O
stable NN NN O
clones NN NN O
of NN NN O
two NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
carrying NN NN O
an NN NN O
LMP1 NN NN B-Protein
gene NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
an NN NN O
inducible NN NN O
metallothionein NN NN O
promoter NN NN O
were NN NN O
induced NN NN O
to NN NN O
express NN NN O
LMP1 NN NN B-Protein
in NN NN O
all NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NK NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
upregulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
occurred NN NN O
within NN NN O
24 NN NN O
h NN NN O
and NN NN O
were NN NN O
followed NN NN O
at NN NN O
48 NN NN O
to NN NN O
72 NN NN O
h NN NN O
by NN NN O
upregulation NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
the NN NN O
second NN NN O
approach NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
generality NN NN O
of NN NN O
this NN NN O
phenomenon NN NN O
by NN NN O
transiently NN NN O
expressing NN NN O
LMP1 NN NN B-Protein
from NN NN O
a NN NN O
strong NN NN O
constitutively NN NN O
active NN NN O
promoter NN NN O
in NN NN O
a NN NN O
range NN NN O
of NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
All NN NN O
six NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
tested NN NN O
showed NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
LMP1 NN NN B-Protein
expression NN NN O
, NN NN O
and NN NN O
this NN NN O
was NN NN O
followed NN NN O
in NN NN O
five NN NN O
of NN NN O
six NN NN O
lines NN NN O
by NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
the NN NN O
same NN NN O
experiments NN NN O
, NN NN O
all NN NN O
three NN NN O
non NN NN O
- NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
showed NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
upregulation NN NN O
but NN NN O
never NN NN O
any NN NN O
effect NN NN O
upon NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
We NN NN O
therefore NN NN O
conclude NN NN O
that NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
upregulation NN NN O
is NN NN O
part NN NN O
of NN NN O
the NN NN O
panoply NN NN O
of NN NN O
cellular NN NN O
changes NN NN O
induced NN NN O
by NN NN O
LMP1 NN NN B-Protein
but NN NN O
that NN NN O
the NN NN O
effect NN NN O
is NN NN O
cell NN NN O
type NN NN O
specific NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
also NN NN O
suggest NN NN O
that NN NN O
whilst NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
be NN NN O
an NN NN O
essential NN NN O
component NN NN O
of NN NN O
LMP1 NN NN B-Protein
signal NN NN O
transduction NN NN O
, NN NN O
other NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factors NN NN O
may NN NN O
be NN NN O
required NN NN O
to NN NN O
effect NN NN O
some NN NN O
functions NN NN O
of NN NN O
the NN NN O
viral NN NN O
protein NN NN O
. NN NN O
   
CD14 NN NN B-Protein
- NN NN O
mediated NN NN O
translocation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induced NN NN O
by NN NN O
lipopolysaccharide NN NN O
does NN NN O
not NN NN O
require NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
. NN NN O
   
During NN NN O
the NN NN O
course NN NN O
of NN NN O
serious NN NN O
bacterial NN NN O
infections NN NN O
, NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
is NN NN O
believed NN NN O
to NN NN O
interact NN NN O
with NN NN O
macrophage NN NN O
receptors NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
and NN NN O
systemic NN NN O
symptoms NN NN O
including NN NN O
hemodynamic NN NN O
instability NN NN O
and NN NN O
shock NN NN O
. NN NN O
   
CD14 NN NN B-Protein
, NN NN O
a NN NN O
glycosylphosphatidylinositol NN NN O
- NN NN O
linked NN NN O
antigen NN NN O
, NN NN O
functions NN NN O
as NN NN O
an NN NN O
LPS NN NN O
signaling NN NN O
receptor NN NN O
. NN NN O
   
A NN NN O
critical NN NN O
issue NN NN O
concerns NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
CD14 NN NN B-Protein
, NN NN O
which NN NN O
has NN NN O
no NN NN O
transmembrane NN NN O
domain NN NN O
, NN NN O
transduces NN NN O
its NN NN O
signal NN NN O
following NN NN O
LPS NN NN O
binding NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
investigators NN NN O
have NN NN O
hypothesized NN NN O
that NN NN O
CD14 NN NN B-Protein
- NN NN O
mediated NN NN O
signaling NN NN O
is NN NN O
effected NN NN O
through NN NN O
a NN NN O
receptor NN NN O
- NN NN O
associated NN NN O
tyrosine NN NN O
kinase NN NN O
( NN NN O
TK NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
multicomponent NN NN O
receptor NN NN O
model NN NN O
of NN NN O
LPS NN NN O
signaling NN NN O
. NN NN O
   
Wild NN NN O
- NN NN O
type NN NN O
Chinese NN NN O
hamster NN NN O
ovary NN NN O
( NN NN O
CHO NN NN O
) NN NN O
- NN NN O
K1 NN NN O
cells NN NN O
can NN NN O
be NN NN O
activated NN NN O
by NN NN O
endotoxin NN NN O
to NN NN O
release NN NN O
arachidonate NN NN O
following NN NN O
transfection NN NN O
with NN NN O
human NN NN O
CD14 NN NN B-Protein
( NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
) NN NN O
. NN NN O
   
Nuclear NN NN O
translocation NN NN O
of NN NN O
cytosolic NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
correlated NN NN O
with NN NN O
a NN NN O
number NN NN O
of NN NN O
LPS NN NN O
- NN NN O
inducible NN NN O
responses NN NN O
. NN NN O
   
We NN NN O
sought NN NN O
to NN NN O
determine NN NN O
if NN NN O
this NN NN O
pathway NN NN O
were NN NN O
present NN NN O
in NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
cells NN NN O
and NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
relationship NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
to NN NN O
the NN NN O
CD14 NN NN B-Protein
receptor NN NN O
system NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
stimulated NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
cells NN NN O
resembled NN NN O
the NN NN O
same NN NN O
response NN NN O
in NN NN O
the NN NN O
murine NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cell NN NN O
line NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
. NN NN O
   
Protein NN NN O
synthesis NN NN O
inhibitors NN NN O
and NN NN O
corticosteroids NN NN O
, NN NN O
which NN NN O
suppress NN NN O
arachidonate NN NN O
release NN NN O
and NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
proinflammatory NN NN O
cytokines NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
or NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
is NN NN O
an NN NN O
early NN NN O
event NN NN O
. NN NN O
   
Although NN NN O
TK NN NN O
activity NN NN O
was NN NN O
consistently NN NN O
observed NN NN O
by NN NN O
immunoblotting NN NN O
extracts NN NN O
from NN NN O
activated NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
, NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
phosphotyrosine NN NN O
residues NN NN O
were NN NN O
not NN NN O
observed NN NN O
from NN NN O
similarly NN NN O
treated NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
TK NN NN O
inhibitors NN NN O
herbimycin NN NN O
A NN NN O
and NN NN O
genistein NN NN O
failed NN NN O
to NN NN O
inhibit NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
CHO NN NN O
/ NN NN O
CD14 NN NN B-Protein
or NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
, NN NN O
although NN NN O
both NN NN O
of NN NN O
these NN NN O
agents NN NN O
inhibited NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TK NN NN O
activity NN NN O
in NN NN O
RAW NN NN O
264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
imply NN NN O
that NN NN O
TK NN NN O
activity NN NN O
is NN NN O
not NN NN O
obligatory NN NN O
for NN NN O
CD14 NN NN B-Protein
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
to NN NN O
occur NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
CD14 NN NN B-Protein
expression NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
induced NN NN O
with NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
. NN NN O
   
CD14 NN NN B-Protein
, NN NN O
a NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
receptor NN NN O
for NN NN O
the NN NN O
complex NN NN O
of NN NN O
LPS NN NN O
and NN NN O
LPS NN NN O
binding NN NN O
protein NN NN O
, NN NN O
is NN NN O
a NN NN O
differentiation NN NN O
marker NN NN O
for NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
regulation NN NN O
of NN NN O
CD14 NN NN B-Protein
expression NN NN O
during NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
VitD3 NN NN O
) NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Using NN NN O
FACS NN NN O
, NN NN O
Northern NN NN O
blotting NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
analyses NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
CD14 NN NN B-Protein
expression NN NN O
during NN NN O
monocytic NN NN O
cell NN NN O
maturation NN NN O
is NN NN O
regulated NN NN O
mainly NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
and NN NN O
that NN NN O
new NN NN O
protein NN NN O
synthesis NN NN O
is NN NN O
required NN NN O
for NN NN O
CD14 NN NN B-Protein
induction NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
cloned NN NN O
the NN NN O
CD14 NN NN B-Protein
5 NN NN O
' NN NN O
upstream NN NN O
sequence NN NN O
and NN NN O
demonstrated NN NN O
its NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Using NN NN O
stable NN NN O
transfection NN NN O
of NN NN O
the NN NN O
monocytoid NN NN O
U937 NN NN O
cell NN NN O
line NN NN O
with NN NN O
a NN NN O
series NN NN O
of NN NN O
deletion NN NN O
mutants NN NN O
of NN NN O
the NN NN O
CD14 NN NN B-Protein
5 NN NN O
' NN NN O
upstream NN NN O
sequence NN NN O
coupled NN NN O
to NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
construct NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
bp NN NN O
- NN NN O
128 NN NN O
to NN NN O
- NN NN O
70 NN NN O
is NN NN O
the NN NN O
critical NN NN O
region NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
CD14 NN NN B-Protein
expression NN NN O
. NN NN O
   
This NN NN O
region NN NN O
contains NN NN O
two NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
Sp1 NN NN B-Protein
transcription NN NN O
factor NN NN O
. NN NN O
   
A NN NN O
3 NN NN O
- NN NN O
bp NN NN O
mutation NN NN O
at NN NN O
the NN NN O
distal NN NN O
Sp1 NN NN B-Protein
- NN NN O
binding NN NN O
site NN NN O
not NN NN O
only NN NN O
eliminates NN NN O
Sp1 NN NN B-Protein
interaction NN NN O
, NN NN O
but NN NN O
also NN NN O
abolishes NN NN O
most NN NN O
of NN NN O
the NN NN O
VitD3 NN NN O
induction NN NN O
of NN NN O
CD14 NN NN B-Protein
expression NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
analysis NN NN O
does NN NN O
not NN NN O
detect NN NN O
a NN NN O
direct NN NN O
interaction NN NN O
of NN NN O
the NN NN O
CD14 NN NN B-Protein
distal NN NN O
Sp1 NN NN B-Protein
- NN NN O
binding NN NN O
site NN NN O
with NN NN O
the NN NN O
vitamin NN NN B-Protein
D3 NN NN I-Protein
receptor NN NN I-Protein
and NN NN O
its NN NN O
partner NN NN O
, NN NN O
the NN NN O
retinoid NN NN O
X NN NN O
receptor NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
VitD3 NN NN O
induces NN NN O
CD14 NN NN B-Protein
indirectly NN NN O
through NN NN O
some NN NN O
intermediary NN NN O
factor NN NN O
, NN NN O
and NN NN O
suggest NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
Sp1 NN NN B-Protein
in NN NN O
this NN NN O
process NN NN O
. NN NN O
   
Calcium NN NN O
signalling NN NN O
in NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
a NN NN O
cyclophilin NN NN B-Protein
B NN NN I-Protein
- NN NN O
binding NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
immunosuppressant NN NN O
drug NN NN O
cyclosporin NN NN O
A NN NN O
blocks NN NN O
a NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
from NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
that NN NN O
normally NN NN O
leads NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
When NN NN O
bound NN NN O
to NN NN O
cyclophilin NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
binds NN NN O
and NN NN O
inactivates NN NN O
the NN NN O
key NN NN O
signalling NN NN O
intermediate NN NN O
calcineurin NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
potential NN NN O
cellular NN NN O
homologues NN NN O
of NN NN O
cyclosporin NN NN O
A NN NN O
that NN NN O
might NN NN O
regulate NN NN O
calcium NN NN O
signalling NN NN O
, NN NN O
we NN NN O
have NN NN O
cloned NN NN O
human NN NN O
genes NN NN O
encoding NN NN O
cyclophilin NN NN B-Protein
B NN NN I-Protein
- NN NN O
binding NN NN O
- NN NN O
proteins NN NN O
using NN NN O
the NN NN O
yeast NN NN O
two NN NN O
- NN NN O
hybrid NN NN O
system NN NN O
. NN NN O
   
One NN NN O
gene NN NN O
product NN NN O
, NN NN O
when NN NN O
overexpressed NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
specifically NN NN O
induced NN NN O
transcription NN NN O
from NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
, NN NN O
by NN NN O
activating NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
NF NN NN O
- NN NN O
IL2A NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
, NN NN O
termed NN NN O
calcium NN NN B-Protein
- NN NN I-Protein
signal NN NN I-Protein
modulating NN NN I-Protein
cyclophilin NN NN I-Protein
ligand NN NN I-Protein
( NN NN O
CAML NN NN B-Protein
) NN NN O
, NN NN O
acts NN NN O
downstream NN NN O
of NN NN O
the NN NN O
TCR NN NN O
and NN NN O
upstream NN NN O
of NN NN O
calcineurin NN NN O
by NN NN O
causing NN NN O
an NN NN O
influx NN NN O
of NN NN O
calcium NN NN O
. NN NN O
   
CAML NN NN B-Protein
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
new NN NN O
participant NN NN O
in NN NN O
the NN NN O
calcium NN NN O
- NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
, NN NN O
implicating NN NN O
cyclophilin NN NN B-Protein
B NN NN I-Protein
in NN NN O
calcium NN NN O
signalling NN NN O
, NN NN O
even NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
cyclosporin NN NN O
. NN NN O
   
Antioxidants NN NN O
inhibit NN NN O
monocyte NN NN O
adhesion NN NN O
by NN NN O
suppressing NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
and NN NN O
induction NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
endothelial NN NN O
cells NN NN O
stimulated NN NN O
to NN NN O
generate NN NN O
radicals NN NN O
. NN NN O
   
Cell NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
is NN NN O
due NN NN O
to NN NN O
induction NN NN O
of NN NN O
surface NN NN O
receptors NN NN O
, NN NN O
such NN NN O
as NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
antioxidant NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
specifically NN NN O
inhibits NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
kappa NN NN O
B NN NN O
motifs NN NN O
are NN NN O
present NN NN O
in NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
promoters NN NN O
, NN NN O
we NN NN O
used NN NN O
PDTC NN NN O
to NN NN O
study NN NN O
the NN NN O
regulatory NN NN O
mechanisms NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
and NN NN O
subsequent NN NN O
monocyte NN NN O
adhesion NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN O
treated NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
. NN NN O
   
PDTC NN NN O
or NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
dose NN NN O
dependently NN NN O
reduced NN NN O
TNF NN NN B-Protein
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
but NN NN O
not NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
surface NN NN O
protein NN NN O
( NN NN O
also NN NN O
in NN NN O
human NN NN O
umbilical NN NN O
arterial NN NN O
endothelial NN NN O
cells NN NN O
) NN NN O
and NN NN O
mRNA NN NN O
expression NN NN O
( NN NN O
by NN NN O
70 NN NN O
% NN NN O
at NN NN O
100 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
PDTC NN NN O
) NN NN O
in NN NN O
HUVECs NN NN O
as NN NN O
assessed NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
and NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O
   
Gel NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
in NN NN O
HUVECs NN NN O
demonstrated NN NN O
that NN NN O
PDTC NN NN O
prevented NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
by NN NN O
TNF NN NN B-Protein
, NN NN O
suggesting NN NN O
that NN NN O
only NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
was NN NN O
controlled NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Since NN NN O
HUVECs NN NN O
released NN NN O
superoxide NN NN O
anions NN NN O
in NN NN O
response NN NN O
to NN NN O
TNF NN NN B-Protein
, NN NN O
and NN NN O
H2O2 NN NN O
induces NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
PDTC NN NN O
may NN NN O
act NN NN O
as NN NN O
a NN NN O
radical NN NN O
scavenger NN NN O
. NN NN O
   
Although NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
was NN NN O
unaffected NN NN O
, NN NN O
inhibitors NN NN O
of NN NN O
NADPH NN NN O
oxidase NN NN O
( NN NN O
apocynin NN NN O
) NN NN O
or NN NN O
cytochrome NN NN O
P NN NN O
- NN NN O
450 NN NN O
( NN NN O
SKF525a NN NN O
) NN NN O
suppressed NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
by NN NN O
TNF NN NN B-Protein
, NN NN O
revealing NN NN O
that NN NN O
several NN NN O
radical NN NN O
- NN NN O
generating NN NN O
systems NN NN O
are NN NN O
involved NN NN O
in NN NN O
its NN NN O
regulation NN NN O
. NN NN O
   
PDTC NN NN O
, NN NN O
apocynin NN NN O
, NN NN O
or NN NN O
SKF525a NN NN O
decreased NN NN O
adhesion NN NN O
of NN NN O
monocytic NN NN O
U937 NN NN O
cells NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN O
treated NN NN O
HUVECs NN NN O
( NN NN O
by NN NN O
75 NN NN O
% NN NN O
at NN NN O
100 NN NN O
mumol NN NN O
/ NN NN O
L NN NN O
PDTC NN NN O
) NN NN O
. NN NN O
   
Inhibition NN NN O
by NN NN O
anti NN NN O
- NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
monoclonal NN NN O
antibody NN NN O
1G11 NN NN O
indicated NN NN O
that NN NN O
U937 NN NN O
adhesion NN NN O
was NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
dependent NN NN O
and NN NN O
suppression NN NN O
by NN NN O
antioxidants NN NN O
was NN NN O
due NN NN O
to NN NN O
reduced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Inducible NN NN O
binding NN NN O
to NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
serum NN NN O
response NN NN O
element NN NN O
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
is NN NN O
regulated NN NN O
by NN NN O
a NN NN O
phosphotyrosine NN NN O
- NN NN O
containing NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
is NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
, NN NN O
and NN NN O
one NN NN O
of NN NN O
the NN NN O
first NN NN O
genes NN NN O
transcribed NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
most NN NN O
cells NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
ligands NN NN O
. NN NN O
   
Fos NN NN B-Protein
expression NN NN O
may NN NN O
be NN NN O
a NN NN O
pivotal NN NN O
event NN NN O
in NN NN O
converting NN NN O
ligand NN NN O
- NN NN O
receptor NN NN O
interactions NN NN O
at NN NN O
the NN NN O
membrane NN NN O
into NN NN O
functional NN NN O
modulation NN NN O
of NN NN O
cell NN NN O
phenotype NN NN O
. NN NN O
   
The NN NN O
serum NN NN O
response NN NN O
element NN NN O
( NN NN O
SRE NN NN O
) NN NN O
in NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
regulatory NN NN O
region NN NN O
participates NN NN O
in NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
by NN NN O
various NN NN O
growth NN NN O
factors NN NN O
and NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
and NN NN O
subsequent NN NN O
squelching NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
an NN NN O
inducible NN NN O
protein NN NN O
complex NN NN O
( NN NN O
Band NN NN O
A NN NN O
) NN NN O
binds NN NN O
to NN NN O
SRE NN NN O
DNA NN NN O
within NN NN O
10 NN NN O
min NN NN O
after NN NN O
mitogenic NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
PBL NN NN O
- NN NN O
T NN NN O
, NN NN O
and NN NN O
becomes NN NN O
nondetectable NN NN O
by NN NN O
60 NN NN O
min NN NN O
. NN NN O
   
Band NN NN O
A NN NN O
contains NN NN O
the NN NN O
serum NN NN O
response NN NN O
factor NN NN O
plus NN NN O
additional NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
A NN NN O
protein NN NN O
that NN NN O
is NN NN O
phosphorylated NN NN O
on NN NN O
a NN NN O
tyrosine NN NN O
residue NN NN O
in NN NN O
resting NN NN O
PBL NN NN O
- NN NN O
T NN NN O
suppresses NN NN O
binding NN NN O
of NN NN O
a NN NN O
component NN NN O
of NN NN O
Band NN NN O
A NN NN O
to NN NN O
the NN NN O
SRE NN NN O
motif NN NN O
. NN NN O
   
Upon NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
cells NN NN O
, NN NN O
this NN NN O
protein NN NN O
no NN NN O
longer NN NN O
prevents NN NN O
binding NN NN O
of NN NN O
DNA NN NN O
by NN NN O
Band NN NN O
A NN NN O
, NN NN O
and NN NN O
suppression NN NN O
of NN NN O
binding NN NN O
is NN NN O
restored NN NN O
within NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
The NN NN O
phosphorylated NN NN O
tyrosine NN NN O
residue NN NN O
itself NN NN O
is NN NN O
important NN NN O
for NN NN O
the NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interaction NN NN O
. NN NN O
   
Steel NN NN B-Protein
factor NN NN I-Protein
affects NN NN O
SCL NN NN B-Protein
expression NN NN O
during NN NN O
normal NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Steel NN NN B-Protein
factor NN NN I-Protein
is NN NN O
one NN NN O
of NN NN O
the NN NN O
growth NN NN O
factors NN NN O
that NN NN O
controls NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
hematopoietic NN NN O
cells NN NN O
and NN NN O
SCL NN NN B-Protein
, NN NN O
also NN NN O
known NN NN O
as NN NN O
Tcl NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
or NN NN O
Tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
erythropoiesis NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
SCL NN NN B-Protein
in NN NN O
the NN NN O
proliferation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
burst NN NN O
- NN NN O
forming NN NN O
unit NN NN O
- NN NN O
erythroid NN NN O
( NN NN O
BFU NN NN O
- NN NN O
E NN NN O
) NN NN O
and NN NN O
the NN NN O
effects NN NN O
of NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
on NN NN O
SCL NN NN B-Protein
expression NN NN O
in NN NN O
proliferating NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
BFU NN NN O
- NN NN O
E NN NN O
- NN NN O
derived NN NN O
colonies NN NN O
increase NN NN O
progressively NN NN O
in NN NN O
size NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
cell NN NN O
number NN NN O
, NN NN O
from NN NN O
day NN NN O
7 NN NN O
to NN NN O
day NN NN O
14 NN NN O
of NN NN O
culture NN NN O
, NN NN O
with NN NN O
the NN NN O
greatest NN NN O
increase NN NN O
in NN NN O
colony NN NN O
size NN NN O
( NN NN O
10 NN NN O
- NN NN O
fold NN NN O
expansion NN NN O
) NN NN O
occurring NN NN O
between NN NN O
day NN NN O
7 NN NN O
and NN NN O
day NN NN O
10 NN NN O
. NN NN O
   
SCL NN NN B-Protein
protein NN NN O
levels NN NN O
in NN NN O
BFU NN NN O
- NN NN O
E NN NN O
- NN NN O
derived NN NN O
cells NN NN O
were NN NN O
highest NN NN O
in NN NN O
day NN NN O
7 NN NN O
cells NN NN O
and NN NN O
decreased NN NN O
progressively NN NN O
from NN NN O
day NN NN O
7 NN NN O
to NN NN O
day NN NN O
14 NN NN O
of NN NN O
culture NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
association NN NN O
of NN NN O
SCL NN NN B-Protein
with NN NN O
erythroid NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
SCL NN NN B-Protein
mRNA NN NN O
levels NN NN O
did NN NN O
not NN NN O
decrease NN NN O
significantly NN NN O
between NN NN O
day NN NN O
7 NN NN O
and NN NN O
day NN NN O
14 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
posttranscriptional NN NN O
mechanisms NN NN O
are NN NN O
largely NN NN O
responsible NN NN O
for NN NN O
the NN NN O
decrease NN NN O
in NN NN O
SCL NN NN B-Protein
protein NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
SCL NN NN B-Protein
in NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
- NN NN O
induced NN NN O
erythroid NN NN O
proliferation NN NN O
was NN NN O
then NN NN O
examined NN NN O
. NN NN O
   
In NN NN O
BFU NN NN O
- NN NN O
E NN NN O
- NN NN O
derived NN NN O
colonies NN NN O
cultured NN NN O
with NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
, NN NN O
colony NN NN O
size NN NN O
was NN NN O
significantly NN NN O
increased NN NN O
compared NN NN O
to NN NN O
control NN NN O
. NN NN O
   
In NN NN O
day NN NN O
7 NN NN O
and NN NN O
day NN NN O
10 NN NN O
erythroid NN NN O
precursors NN NN O
cultured NN NN O
with NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
, NN NN O
SCL NN NN B-Protein
protein NN NN O
was NN NN O
increased NN NN O
significantly NN NN O
compared NN NN O
to NN NN O
control NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
SCL NN NN B-Protein
protein NN NN O
levels NN NN O
in NN NN O
early NN NN O
erythroid NN NN O
precursors NN NN O
stimulated NN NN O
with NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
suggests NN NN O
one NN NN O
mechanism NN NN O
through NN NN O
which NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
may NN NN O
enhance NN NN O
normal NN NN O
erythroid NN NN O
proliferation NN NN O
. NN NN O
   
SCL NN NN B-Protein
mRNA NN NN O
levels NN NN O
assessed NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
in NN NN O
day NN NN O
7 NN NN O
cells NN NN O
did NN NN O
not NN NN O
increase NN NN O
significantly NN NN O
in NN NN O
response NN NN O
to NN NN O
Steel NN NN B-Protein
factor NN NN I-Protein
stimulation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
posttranscriptional NN NN O
mechanisms NN NN O
may NN NN O
also NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
increase NN NN O
in NN NN O
SCL NN NN B-Protein
protein NN NN O
observed NN NN O
in NN NN O
response NN NN O
to NN NN O
Steel NN NN B-Protein
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
CD40 NN NN B-Protein
on NN NN O
B NN NN O
cells NN NN O
rapidly NN NN O
activates NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
B NN NN O
cell NN NN O
- NN NN O
associated NN NN O
surface NN NN O
molecule NN NN O
CD40 NN NN B-Protein
functions NN NN O
to NN NN O
regulate NN NN O
B NN NN O
cell NN NN O
responses NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
CD40 NN NN B-Protein
on NN NN O
B NN NN O
cells NN NN O
can NN NN O
lead NN NN O
to NN NN O
homotypic NN NN O
cell NN NN O
adhesion NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
, NN NN O
and NN NN O
, NN NN O
in NN NN O
combination NN NN O
with NN NN O
cytokines NN NN O
, NN NN O
to NN NN O
Ig NN NN O
isotype NN NN O
switching NN NN O
. NN NN O
   
Tyrosine NN NN O
kinase NN NN O
activity NN NN O
is NN NN O
increased NN NN O
shortly NN NN O
after NN NN O
engagement NN NN O
of NN NN O
this NN NN O
receptor NN NN O
. NN NN O
   
Little NN NN O
is NN NN O
known NN NN O
about NN NN O
how NN NN O
the NN NN O
very NN NN O
early NN NN O
events NN NN O
induced NN NN O
by NN NN O
CD40 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
link NN NN O
to NN NN O
cellular NN NN O
responses NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
activated NN NN O
after NN NN O
cross NN NN O
- NN NN O
linking NN NN O
CD40 NN NN B-Protein
on NN NN O
resting NN NN O
human NN NN O
tonsillar NN NN O
B NN NN O
cells NN NN O
and NN NN O
on NN NN O
B NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
is NN NN O
rapid NN NN O
and NN NN O
is NN NN O
mediated NN NN O
through NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
- NN NN O
dependent NN NN O
pathway NN NN O
. NN NN O
   
The NN NN O
complexes NN NN O
detected NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
contain NN NN O
p50 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
( NN NN O
RelA NN NN B-Protein
) NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
and NN NN O
most NN NN O
likely NN NN O
other NN NN O
components NN NN O
. NN NN O
   
By NN NN O
using NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
cross NN NN O
- NN NN O
linking NN NN O
CD40 NN NN B-Protein
supports NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
define NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
system NN NN O
as NN NN O
an NN NN O
intermediate NN NN O
event NN NN O
in NN NN O
CD40 NN NN B-Protein
signaling NN NN O
and NN NN O
suggest NN NN O
that NN NN O
the NN NN O
CD40 NN NN B-Protein
pathway NN NN O
can NN NN O
influence NN NN O
the NN NN O
expression NN NN O
of NN NN O
B NN NN O
cell NN NN O
- NN NN O
associated NN NN O
genes NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
consensus NN NN O
sites NN NN O
. NN NN O
   
Separation NN NN O
of NN NN O
oxidant NN NN O
- NN NN O
initiated NN NN O
and NN NN O
redox NN NN O
- NN NN O
regulated NN NN O
steps NN NN O
in NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
Studies NN NN O
presented NN NN O
here NN NN O
show NN NN O
that NN NN O
overall NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
signal NN NN O
transduction NN NN O
begins NN NN O
with NN NN O
a NN NN O
parallel NN NN O
series NN NN O
of NN NN O
stimuli NN NN O
- NN NN O
specific NN NN O
pathways NN NN O
through NN NN O
which NN NN O
cytokines NN NN O
( NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
oxidants NN NN O
( NN NN O
hydrogen NN NN O
peroxide NN NN O
and NN NN O
mitomycin NN NN O
C NN NN O
) NN NN O
, NN NN O
and NN NN O
phorbol NN NN O
ester NN NN O
( NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
) NN NN O
individually NN NN O
initiate NN NN O
signaling NN NN O
. NN NN O
   
These NN NN O
initial NN NN O
pathways NN NN O
culminate NN NN O
in NN NN O
a NN NN O
common NN NN O
pathway NN NN O
through NN NN O
which NN NN O
all NN NN O
of NN NN O
the NN NN O
stimulating NN NN O
agents NN NN O
ultimately NN NN O
signal NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
distinguish NN NN O
the NN NN O
stimuli NN NN O
- NN NN O
specific NN NN O
pathways NN NN O
by NN NN O
showing NN NN O
that NN NN O
the NN NN O
oxidative NN NN O
stimuli NN NN O
trigger NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
only NN NN O
one NN NN O
of NN NN O
two NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
( NN NN O
Wurzburg NN NN O
but NN NN O
not NN NN O
Jurkat NN NN O
) NN NN O
, NN NN O
whereas NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
readily NN NN O
stimulate NN NN O
in NN NN O
both NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
the NN NN O
common NN NN O
pathway NN NN O
as NN NN O
the NN NN O
simplest NN NN O
way NN NN O
of NN NN O
accounting NN NN O
for NN NN O
the NN NN O
common NN NN O
requirements NN NN O
and NN NN O
properties NN NN O
of NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
We NN NN O
include NN NN O
a NN NN O
redox NN NN O
- NN NN O
regulatory NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
in NN NN O
this NN NN O
common NN NN O
pathway NN NN O
to NN NN O
account NN NN O
for NN NN O
the NN NN O
previously NN NN O
demonstrated NN NN O
redox NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
( NN NN O
in NN NN O
which NN NN O
oxidants NN NN O
don NN NN O
' NN NN O
t NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
; NN NN O
we NN NN O
put NN NN O
tyrosine NN NN O
phosphorylation NN NN O
in NN NN O
the NN NN O
common NN NN O
pathway NN NN O
by NN NN O
showing NN NN O
that NN NN O
kinase NN NN O
activity NN NN O
( NN NN O
inhibitable NN NN O
by NN NN O
herbimycin NN NN O
A NN NN O
and NN NN O
tyrphostin NN NN O
47 NN NN O
) NN NN O
is NN NN O
required NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
all NN NN O
stimuli NN NN O
tested NN NN O
in NN NN O
both NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Since NN NN O
internal NN NN O
sites NN NN O
of NN NN O
oxidant NN NN O
production NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
cytokine NN NN O
- NN NN O
stimulated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
since NN NN O
tyrosine NN NN O
kinase NN NN O
and NN NN O
phosphatase NN NN O
activities NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
altered NN NN O
by NN NN O
oxidants NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
intracellular NN NN O
redox NN NN O
status NN NN O
controls NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
regulating NN NN O
tyrosine NN NN O
phosphorylation NN NN O
event NN NN O
( NN NN O
s NN NN O
) NN NN O
within NN NN O
the NN NN O
common NN NN O
step NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
Transcription NN NN O
- NN NN O
independent NN NN O
turnover NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
during NN NN O
monocyte NN NN O
adherence NN NN O
: NN NN O
implications NN NN O
for NN NN O
a NN NN O
translational NN NN O
component NN NN O
regulating NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
as NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
that NN NN O
is NN NN O
expressed NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
signals NN NN O
, NN NN O
including NN NN O
adhesion NN NN O
, NN NN O
lipopolysaccharide NN NN O
, NN NN O
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
. NN NN O
   
Within NN NN O
5 NN NN O
min NN NN O
of NN NN O
monocyte NN NN O
adhesion NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
is NN NN O
markedly NN NN O
diminished NN NN O
but NN NN O
is NN NN O
rapidly NN NN O
replaced NN NN O
in NN NN O
a NN NN O
cycloheximide NN NN O
- NN NN O
sensitive NN NN O
manner NN NN O
within NN NN O
20 NN NN O
min NN NN O
. NN NN O
   
Accompanying NN NN O
the NN NN O
rapid NN NN O
turnover NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
is NN NN O
simultaneous NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factors NN NN O
to NN NN O
nuclei NN NN O
of NN NN O
adhered NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
demonstration NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
regulate NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
suggested NN NN O
that NN NN O
the NN NN O
rapid NN NN O
increase NN NN O
in NN NN O
steady NN NN O
- NN NN O
state NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
we NN NN O
observed NN NN O
within NN NN O
30 NN NN O
min NN NN O
of NN NN O
monocyte NN NN O
adherence NN NN O
would NN NN O
result NN NN O
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
analyses NN NN O
indicated NN NN O
that NN NN O
, NN NN O
instead NN NN O
, NN NN O
while NN NN O
several NN NN O
immediate NN NN O
- NN NN O
early NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
interleukin NN NN B-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
) NN NN O
gene NN NN O
, NN NN O
were NN NN O
transcriptionally NN NN O
activated NN NN O
during NN NN O
monocyte NN NN O
adhesion NN NN O
, NN NN O
the NN NN O
rate NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
transcription NN NN O
remained NN NN O
constant NN NN O
. NN NN O
   
The NN NN O
adherence NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
was NN NN O
also NN NN O
not NN NN O
a NN NN O
consequence NN NN O
of NN NN O
mRNA NN NN O
stabilization NN NN O
events NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
while NN NN O
increases NN NN O
in NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
detected NN NN O
in NN NN O
nuclei NN NN O
of NN NN O
adherent NN NN O
monocytes NN NN O
, NN NN O
cytoplasmic NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
mRNA NN NN O
increased NN NN O
during NN NN O
adherence NN NN O
whereas NN NN O
those NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
did NN NN O
not NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
two NN NN O
interactive NN NN O
mechanisms NN NN O
regulate NN NN O
monocytic NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
adherent NN NN O
monocytes NN NN O
regulate NN NN O
nuclear NN NN O
processing NN NN O
( NN NN O
or NN NN O
decay NN NN O
) NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
, NN NN O
thereby NN NN O
increasing NN NN O
mRNA NN NN O
levels NN NN O
without NN NN O
stimulating NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
since NN NN O
inhibition NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
leads NN NN O
to NN NN O
accumulation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
without NN NN O
stimulating NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
transcription NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
low NN NN O
cytoplasmic NN NN O
levels NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
mRNA NN NN O
are NN NN O
maintained NN NN O
by NN NN O
a NN NN O
translation NN NN O
- NN NN O
dependent NN NN O
degradation NN NN O
mechanism NN NN O
. NN NN O
   
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
a NN NN O
cyclin NN NN O
- NN NN O
like NN NN O
DNA NN NN O
repair NN NN O
enzyme NN NN O
, NN NN O
uracil NN NN B-Protein
- NN NN I-Protein
DNA NN NN I-Protein
glycosylase NN NN I-Protein
, NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
an NN NN O
autoregulatory NN NN O
mechanism NN NN O
for NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
cycle NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
regulates NN NN O
the NN NN O
cyclin NN NN O
- NN NN O
like NN NN O
species NN NN O
of NN NN O
the NN NN O
DNA NN NN O
repair NN NN O
enzyme NN NN O
uracil NN NN B-Protein
- NN NN I-Protein
DNA NN NN I-Protein
glycosylase NN NN I-Protein
( NN NN O
UDG NN NN B-Protein
) NN NN O
gene NN NN O
in NN NN O
human NN NN O
osteosarcoma NN NN O
( NN NN O
Saos NN NN O
- NN NN O
2 NN NN O
) NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
, NN NN O
through NN NN O
the NN NN O
deletion NN NN O
of NN NN O
the NN NN O
human NN NN O
UDG NN NN B-Protein
promoter NN NN O
sequences NN NN O
, NN NN O
that NN NN O
expression NN NN O
of NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
the NN NN O
UDG NN NN B-Protein
promoter NN NN O
through NN NN O
several NN NN O
E2F NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
major NN NN O
putative NN NN O
downstream NN NN O
site NN NN O
for NN NN O
E2F NN NN O
, NN NN O
located NN NN O
in NN NN O
the NN NN O
first NN NN O
exon NN NN O
, NN NN O
serves NN NN O
as NN NN O
a NN NN O
target NN NN O
for NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
DP1 NN NN B-Protein
complex NN NN O
binding NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
We NN NN O
also NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
the NN NN O
functional NN NN O
relationship NN NN O
between NN NN O
the NN NN O
cyclin NN NN O
- NN NN O
like NN NN O
UDG NN NN B-Protein
gene NN NN O
product NN NN O
and NN NN O
E2F NN NN O
. NN NN O
   
High NN NN O
levels NN NN O
of NN NN O
UDG NN NN B-Protein
expression NN NN O
in NN NN O
a NN NN O
transient NN NN O
transfection NN NN O
assay NN NN O
result NN NN O
in NN NN O
the NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
transcriptional NN NN O
activity NN NN O
through NN NN O
elements NN NN O
specific NN NN O
for NN NN O
E2F NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
UDG NN NN B-Protein
in NN NN O
Saos NN NN O
2 NN NN O
cells NN NN O
was NN NN O
observed NN NN O
to NN NN O
delay NN NN O
growth NN NN O
late NN NN O
in NN NN O
G1 NN NN O
phase NN NN O
and NN NN O
transiently NN NN O
arrest NN NN O
these NN NN O
cells NN NN O
from NN NN O
progressing NN NN O
into NN NN O
the NN NN O
S NN NN O
phase NN NN O
. NN NN O
   
This NN NN O
hypothetical NN NN O
model NN NN O
integrates NN NN O
one NN NN O
mechanism NN NN O
of NN NN O
DNA NN NN O
repair NN NN O
with NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
control NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
likely NN NN O
through NN NN O
E2F NN NN O
. NN NN O
   
This NN NN O
implicates NN NN O
E2F NN NN O
as NN NN O
a NN NN O
multifunctional NN NN O
target NN NN O
for NN NN O
proteins NN NN O
and NN NN O
enzymes NN NN O
, NN NN O
possibly NN NN O
, NN NN O
responsive NN NN O
to NN NN O
DNA NN NN O
damage NN NN O
through NN NN O
the NN NN O
negative NN NN O
effect NN NN O
of NN NN O
UDG NN NN B-Protein
on NN NN O
E2F NN NN O
- NN NN O
mediated NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
Aspirin NN NN O
inhibits NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
and NN NN O
monocyte NN NN O
adhesion NN NN O
in NN NN O
stimulated NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
The NN NN O
induction NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
is NN NN O
mediated NN NN O
by NN NN O
mobilization NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
salicylates NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
preventing NN NN O
the NN NN O
degradation NN NN O
of NN NN O
its NN NN O
inhibitor NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
we NN NN O
studied NN NN O
a NN NN O
potential NN NN O
inhibition NN NN O
of NN NN O
this NN NN O
pathway NN NN O
by NN NN O
acetylsalicylate NN NN O
( NN NN O
aspirin NN NN O
) NN NN O
in NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Gel NN NN O
- NN NN O
shift NN NN O
analyses NN NN O
demonstrated NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
by NN NN O
aspirin NN NN O
at NN NN O
concentrations NN NN O
ranging NN NN O
from NN NN O
1 NN NN O
to NN NN O
10 NN NN O
mmol NN NN O
/ NN NN O
L NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
surface NN NN O
expression NN NN O
by NN NN O
TNF NN NN B-Protein
was NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
reduced NN NN O
by NN NN O
aspirin NN NN O
over NN NN O
the NN NN O
same NN NN O
range NN NN O
, NN NN O
while NN NN O
induction NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
was NN NN O
hardly NN NN O
affected NN NN O
. NN NN O
   
Aspirin NN NN O
appeared NN NN O
to NN NN O
prevent NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
, NN NN O
since NN NN O
it NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
inhibited NN NN O
induction NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
by NN NN O
TNF NN NN B-Protein
. NN NN O
   
As NN NN O
a NN NN O
functional NN NN O
consequence NN NN O
, NN NN O
adhesion NN NN O
of NN NN O
U937 NN NN O
monocytes NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN O
stimulated NN NN O
HUVECs NN NN O
was NN NN O
markedly NN NN O
reduced NN NN O
by NN NN O
aspirin NN NN O
due NN NN O
to NN NN O
suppression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
upregulation NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
of NN NN O
aspirin NN NN O
were NN NN O
not NN NN O
related NN NN O
to NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
cyclooxygenase NN NN O
activity NN NN O
, NN NN O
since NN NN O
indomethacin NN NN O
was NN NN O
ineffective NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
aspirin NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
, NN NN O
induction NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
and NN NN O
subsequent NN NN O
monocyte NN NN O
adhesion NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
TNF NN NN B-Protein
, NN NN O
thereby NN NN O
providing NN NN O
an NN NN O
additional NN NN O
mechanism NN NN O
for NN NN O
therapeutic NN NN O
effects NN NN O
of NN NN O
aspirin NN NN O
. NN NN O
   
Danazol NN NN O
decreases NN NN O
transcription NN NN O
of NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
danazol NN NN O
for NN NN O
over NN NN O
one NN NN O
month NN NN O
reduced NN NN O
the NN NN O
levels NN NN O
of NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
ER NN NN B-Protein
) NN NN O
and NN NN O
its NN NN O
mRNA NN NN O
to NN NN O
approximately NN NN O
50 NN NN O
and NN NN O
20 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Danazol NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
degradation NN NN O
rate NN NN O
of NN NN O
ER NN NN B-Protein
mRNA NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Danazol NN NN O
decreased NN NN O
the NN NN O
transcription NN NN O
rate NN NN O
of NN NN O
ER NN NN B-Protein
gene NN NN O
to NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
in NN NN O
monocytes NN NN O
in NN NN O
a NN NN O
run NN NN O
- NN NN O
on NN NN O
assay NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
Danazol NN NN O
may NN NN O
release NN NN O
estrogen NN NN O
predominance NN NN O
via NN NN O
the NN NN O
reduction NN NN O
of NN NN O
transcription NN NN O
for NN NN O
ER NN NN B-Protein
gene NN NN O
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
the NN NN O
reduction NN NN O
of NN NN O
ER NN NN B-Protein
mRNA NN NN O
and NN NN O
ER NN NN B-Protein
expressions NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD30 NN NN B-Protein
induces NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
CD30 NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
receptor NN NN O
family NN NN O
, NN NN O
is NN NN O
expressed NN NN O
constitutively NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
the NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
, NN NN O
which NN NN O
is NN NN O
chronically NN NN O
infected NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
) NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
cross NN NN O
- NN NN O
linking NN NN O
CD30 NN NN B-Protein
with NN NN O
an NN NN O
anti NN NN O
- NN NN O
CD30 NN NN B-Protein
- NN NN O
specific NN NN O
monoclonal NN NN O
antibody NN NN O
, NN NN O
which NN NN O
mimics NN NN O
the NN NN O
described NN NN O
biological NN NN O
activities NN NN O
of NN NN O
the NN NN O
CD30 NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
CD30L NN NN B-Protein
) NN NN O
, NN NN O
results NN NN O
in NN NN O
HIV NN NN O
expression NN NN O
. NN NN O
   
CD30 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
does NN NN O
not NN NN O
alter NN NN O
proliferation NN NN O
of NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
cells NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
is NN NN O
not NN NN O
mediated NN NN O
by NN NN O
endogenous NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
/ NN NN O
beta NN NN B-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD30 NN NN B-Protein
leads NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
enhanced NN NN O
HIV NN NN O
transcription NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
CD30 NN NN B-Protein
- NN NN O
CD30L NN NN B-Protein
interactions NN NN O
mediate NN NN O
the NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
by NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
pathway NN NN O
that NN NN O
is NN NN O
independent NN NN O
of NN NN O
TNF NN NN O
. NN NN O
   
This NN NN O
mechanism NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
from NN NN O
latently NN NN O
infected NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
especially NN NN O
in NN NN O
lymphoid NN NN O
organs NN NN O
where NN NN O
cell NN NN O
to NN NN O
cell NN NN O
contact NN NN O
is NN NN O
conducive NN NN O
to NN NN O
receptor NN NN O
- NN NN O
ligand NN NN O
interactions NN NN O
. NN NN O
   
Integrin NN NN O
- NN NN O
mediated NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
cytokine NN NN O
message NN NN O
induction NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
possible NN NN O
signaling NN NN O
role NN NN O
for NN NN O
the NN NN O
Syk NN NN B-Protein
tyrosine NN NN O
kinase NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
cytoplasmic NN NN O
tyrosine NN NN O
kinases NN NN O
is NN NN O
an NN NN O
important NN NN O
aspect NN NN O
of NN NN O
signal NN NN O
transduction NN NN O
mediated NN NN O
by NN NN O
integrins NN NN O
. NN NN O
   
In NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
either NN NN O
integrin NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
fibronectin NN NN O
or NN NN O
ligation NN NN O
of NN NN O
beta NN NN B-Protein
1 NN NN I-Protein
integrins NN NN I-Protein
with NN NN O
antibodies NN NN O
causes NN NN O
a NN NN O
rapid NN NN O
and NN NN O
intense NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
two NN NN O
sets NN NN O
of NN NN O
proteins NN NN O
of NN NN O
about NN NN O
65 NN NN O
- NN NN O
75 NN NN O
and NN NN O
120 NN NN O
- NN NN O
125 NN NN O
kDa NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
integrin NN NN O
ligation NN NN O
leads NN NN O
to NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
subunits NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
to NN NN O
activation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
driven NN NN O
by NN NN O
a NN NN O
promoter NN NN O
containing NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
, NN NN O
and NN NN O
to NN NN O
increased NN NN O
levels NN NN O
of NN NN O
mRNAs NN NN O
for NN NN O
immediate NN NN O
- NN NN O
early NN NN O
genes NN NN O
, NN NN O
including NN NN O
the NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
The NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitors NN NN O
genistein NN NN O
and NN NN O
herbimycin NN NN O
A NN NN O
block NN NN O
both NN NN O
integrin NN NN O
- NN NN O
mediated NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
increases NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
message NN NN O
levels NN NN O
, NN NN O
indicating NN NN O
a NN NN O
causal NN NN O
relationship NN NN O
between NN NN O
the NN NN O
two NN NN O
events NN NN O
. NN NN O
   
The NN NN O
components NN NN O
tyrosine NN NN O
phosphorylated NN NN O
subsequent NN NN O
to NN NN O
cell NN NN O
adhesion NN NN O
include NN NN O
paxillin NN NN B-Protein
, NN NN O
pp125FAK NN NN B-Protein
, NN NN O
and NN NN O
the NN NN O
SH2 NN NN O
domain NN NN O
containing NN NN O
tyrosine NN NN O
kinase NN NN O
Syk NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
integrin NN NN O
ligation NN NN O
with NN NN O
antibodies NN NN O
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Syk NN NN B-Protein
but NN NN O
not NN NN O
of NN NN O
FAK NN NN O
or NN NN O
paxillin NN NN B-Protein
. NN NN O
   
In NN NN O
adhering NN NN O
cells NN NN O
, NN NN O
pre NN NN O
- NN NN O
treatment NN NN O
with NN NN O
cytochalasin NN NN O
D NN NN O
suppresses NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
FAK NN NN O
and NN NN O
paxillin NN NN B-Protein
but NN NN O
not NN NN O
of NN NN O
Syk NN NN B-Protein
, NN NN O
while NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
message NN NN O
induction NN NN O
is NN NN O
unaffected NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
indicate NN NN O
that NN NN O
the NN NN O
Syk NN NN B-Protein
tyrosine NN NN O
kinase NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
component NN NN O
of NN NN O
an NN NN O
integrin NN NN O
signaling NN NN O
pathway NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
leading NN NN O
to NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
to NN NN O
increased NN NN O
levels NN NN O
of NN NN O
cytokine NN NN O
messages NN NN O
. NN NN O
   
Nitric NN NN O
oxide NN NN O
decreases NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
endothelial NN NN O
activation NN NN O
. NN NN O
   
Nitric NN NN O
oxide NN NN O
selectively NN NN O
reduces NN NN O
endothelial NN NN O
expression NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
and NN NN O
proinflammatory NN NN O
cytokines NN NN O
. NN NN O
   
To NN NN O
test NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
limits NN NN O
endothelial NN NN O
activation NN NN O
, NN NN O
we NN NN O
treated NN NN O
cytokine NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
saphenous NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
with NN NN O
several NN NN O
NO NN NN O
donors NN NN O
and NN NN O
assessed NN NN O
their NN NN O
effects NN NN O
on NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
a NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
NO NN NN O
inhibited NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
by NN NN O
35 NN NN O
- NN NN O
55 NN NN O
% NN NN O
as NN NN O
determined NN NN O
by NN NN O
cell NN NN O
surface NN NN O
enzyme NN NN O
immunoassays NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
was NN NN O
paralleled NN NN O
by NN NN O
reduced NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
monolayers NN NN O
in NN NN O
nonstatic NN NN O
assays NN NN O
, NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
cGMP NN NN O
analogues NN NN O
, NN NN O
and NN NN O
was NN NN O
quantitatively NN NN O
similar NN NN O
after NN NN O
stimulation NN NN O
by NN NN O
either NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
or NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
NO NN NN O
also NN NN O
decreased NN NN O
the NN NN O
endothelial NN NN O
expression NN NN O
of NN NN O
other NN NN O
leukocyte NN NN O
adhesion NN NN O
molecules NN NN O
( NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
secretable NN NN O
cytokines NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
endogenous NN NN O
NO NN NN O
production NN NN O
by NN NN O
L NN NN O
- NN NN O
N NN NN O
- NN NN O
monomethyl NN NN O
- NN NN O
arginine NN NN O
also NN NN O
induced NN NN O
the NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
but NN NN O
did NN NN O
not NN NN O
augment NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
assays NN NN O
, NN NN O
transfection NN NN O
studies NN NN O
using NN NN O
various NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
reporter NN NN O
gene NN NN O
constructs NN NN O
, NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
indicated NN NN O
that NN NN O
NO NN NN O
represses NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
transcription NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
inhibiting NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
NO NN NN O
' NN NN O
s NN NN O
ability NN NN O
to NN NN O
limit NN NN O
endothelial NN NN O
activation NN NN O
and NN NN O
inhibit NN NN O
monocyte NN NN O
adhesion NN NN O
may NN NN O
contribute NN NN O
to NN NN O
some NN NN O
of NN NN O
its NN NN O
antiatherogenic NN NN O
and NN NN O
antiinflammatory NN NN O
properties NN NN O
within NN NN O
the NN NN O
vessel NN NN O
wall NN NN O
. NN NN O
   
Distinct NN NN O
signaling NN NN O
properties NN NN O
identify NN NN O
functionally NN NN O
different NN NN O
CD4 NN NN B-Protein
epitopes NN NN O
. NN NN O
   
The NN NN O
CD4 NN NN B-Protein
coreceptor NN NN O
interacts NN NN O
with NN NN O
non NN NN O
- NN NN O
polymorphic NN NN O
regions NN NN O
of NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
class NN NN O
II NN NN O
molecules NN NN O
on NN NN O
antigen NN NN O
- NN NN O
presenting NN NN O
cells NN NN O
and NN NN O
contributes NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
CD4 NN NN B-Protein
triggering NN NN O
on NN NN O
T NN NN O
cell NN NN O
activating NN NN O
signals NN NN O
in NN NN O
a NN NN O
lymphoma NN NN O
model NN NN O
using NN NN O
monoclonal NN NN O
antibodies NN NN O
( NN NN O
mAb NN NN O
) NN NN O
which NN NN O
recognize NN NN O
different NN NN O
CD4 NN NN B-Protein
epitopes NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
CD4 NN NN B-Protein
triggering NN NN O
delivers NN NN O
signals NN NN O
capable NN NN O
of NN NN O
activating NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
is NN NN O
required NN NN O
for NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Whereas NN NN O
different NN NN O
anti NN NN O
- NN NN O
CD4 NN NN B-Protein
mAb NN NN O
or NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gp120 NN NN B-Protein
could NN NN O
all NN NN O
trigger NN NN O
activation NN NN O
of NN NN O
the NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
p56lck NN NN B-Protein
and NN NN O
p59fyn NN NN B-Protein
and NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
Shc NN NN O
adaptor NN NN O
protein NN NN O
, NN NN O
which NN NN O
mediates NN NN O
signals NN NN O
to NN NN O
Ras NN NN O
, NN NN O
they NN NN O
differed NN NN O
significantly NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
Lack NN NN O
of NN NN O
full NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
could NN NN O
be NN NN O
correlated NN NN O
to NN NN O
a NN NN O
dramatically NN NN O
reduced NN NN O
capacity NN NN O
to NN NN O
induce NN NN O
calcium NN NN O
flux NN NN O
and NN NN O
could NN NN O
be NN NN O
complemented NN NN O
with NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
. NN NN O
   
The NN NN O
results NN NN O
identify NN NN O
functionally NN NN O
distinct NN NN O
epitopes NN NN O
on NN NN O
the NN NN O
CD4 NN NN B-Protein
coreceptor NN NN O
involved NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
Ras NN NN O
/ NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
and NN NN O
calcium NN NN O
pathways NN NN O
. NN NN O
   
Lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
expression NN NN O
requires NN NN O
continuous NN NN O
presence NN NN O
of NN NN O
LPS NN NN O
and NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
bactericidal NN NN O
/ NN NN O
permeability NN NN O
- NN NN O
increasing NN NN O
protein NN NN O
. NN NN O
   
Endothelial NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
LPS NN NN O
express NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
which NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
mediating NN NN O
neutrophil NN NN O
adhesion NN NN O
during NN NN O
inflammation NN NN O
. NN NN O
   
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
is NN NN O
induced NN NN O
within NN NN O
1 NN NN O
- NN NN O
2 NN NN O
h NN NN O
, NN NN O
peaks NN NN O
at NN NN O
4 NN NN O
- NN NN O
6 NN NN O
h NN NN O
, NN NN O
and NN NN O
gradually NN NN O
returns NN NN O
to NN NN O
basal NN NN O
level NN NN O
by NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
rBPI21 NN NN O
, NN NN O
a NN NN O
recombinant NN NN O
N NN NN O
- NN NN O
terminal NN NN O
fragment NN NN O
of NN NN O
human NN NN O
bactericidal NN NN B-Protein
/ NN NN I-Protein
permeability NN NN I-Protein
- NN NN I-Protein
increasing NN NN I-Protein
protein NN NN I-Protein
( NN NN O
BPI NN NN B-Protein
) NN NN O
, NN NN O
inhibited NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
expression NN NN O
when NN NN O
added NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
as NN NN O
, NN NN O
and NN NN O
up NN NN O
to NN NN O
6 NN NN O
h NN NN O
after NN NN O
, NN NN O
LPS NN NN O
. NN NN O
   
Delayed NN NN O
administration NN NN O
of NN NN O
rBPI21 NN NN O
also NN NN O
affected NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Two NN NN O
to NN NN O
4 NN NN O
h NN NN O
following NN NN O
LPS NN NN O
addition NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
when NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
already NN NN O
activated NN NN O
, NN NN O
addition NN NN O
of NN NN O
rBPI21 NN NN O
resulted NN NN O
in NN NN O
marked NN NN O
reduction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
detectable NN NN O
at NN NN O
4 NN NN O
or NN NN O
6 NN NN O
h NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
endothelial NN NN O
activation NN NN O
requires NN NN O
continuous NN NN O
presence NN NN O
of NN NN O
LPS NN NN O
, NN NN O
and NN NN O
rBPI21 NN NN O
acts NN NN O
to NN NN O
reverse NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
endothelial NN NN O
activation NN NN O
by NN NN O
interrupting NN NN O
the NN NN O
on NN NN O
- NN NN O
going NN NN O
LPS NN NN O
signal NN NN O
. NN NN O
   
Costimulation NN NN O
of NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
with NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
B7 NN NN B-Protein
induce NN NN O
distinct NN NN O
effects NN NN O
on NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
have NN NN O
earlier NN NN O
shown NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
with NN NN O
SEA NN NN O
presented NN NN O
on NN NN O
Chinese NN NN O
hamster NN NN O
ovary NN NN O
( NN NN O
CHO NN NN O
) NN NN O
- NN NN O
DR NN NN O
transfectants NN NN O
coexpressing NN NN O
either NN NN O
B7 NN NN B-Protein
or NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
resulted NN NN O
in NN NN O
distinct NN NN O
cytokine NN NN O
profiles NN NN O
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
B7 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
strongly NN NN O
costimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
and NN NN O
mRNA NN NN O
expression NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Maximal NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
was NN NN O
recorded NN NN O
with NN NN O
CHO NN NN O
- NN NN O
DR NN NN O
/ NN NN O
B7 NN NN B-Protein
/ NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
suggesting NN NN O
a NN NN O
cooperative NN NN O
effect NN NN O
of NN NN O
B7 NN NN B-Protein
and NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
Gel NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
with NN NN O
CHO NN NN O
- NN NN O
DR NN NN O
and NN NN O
staphylococcal NN NN O
enterotoxin NN NN O
A NN NN O
was NN NN O
sufficient NN NN O
to NN NN O
induce NN NN O
significant NN NN O
amounts NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
whereas NN NN O
induction NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
proteins NN NN O
required NN NN O
costimulation NN NN O
. NN NN O
   
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
induced NN NN O
moderate NN NN O
levels NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
influence NN NN O
the NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
while NN NN O
B7 NN NN B-Protein
costimulation NN NN O
strongly NN NN O
induced NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
substantially NN NN O
enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
CHO NN NN O
- NN NN O
DR NN NN O
/ NN NN O
B7 NN NN B-Protein
/ NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
triple NN NN O
transfectant NN NN O
induced NN NN O
a NN NN O
further NN NN O
increase NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
proteins NN NN O
compared NN NN O
with NN NN O
the NN NN O
double NN NN O
transfectants NN NN O
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
Oct NN NN O
- NN NN O
1 NN NN O
binding NN NN O
proteins NN NN O
remained NN NN O
similar NN NN O
in NN NN O
all NN NN O
samples NN NN O
. NN NN O
   
Super NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
of NN NN O
costimulated NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
contained NN NN O
large NN NN O
amounts NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
substantial NN NN O
amounts NN NN O
of NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
marginal NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
proteins NN NN O
. NN NN O
   
The NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
proteins NN NN O
contained NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
Jun NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
, NN NN O
and NN NN O
Fra NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
but NN NN O
marginal NN NN O
amounts NN NN O
of NN NN O
Jun NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
distinct NN NN O
effects NN NN O
of NN NN O
B7 NN NN B-Protein
and NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
costimulation NN NN O
on NN NN O
the NN NN O
activity NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
These NN NN O
may NN NN O
partly NN NN O
account NN NN O
for NN NN O
the NN NN O
differential NN NN O
effects NN NN O
of NN NN O
B7 NN NN B-Protein
and NN NN O
LFA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
costimulation NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
expression NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
NFAT NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
was NN NN O
originally NN NN O
described NN NN O
as NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
athat NN NN O
supported NN NN O
the NN NN O
activation NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
and NN NN O
mediated NN NN O
the NN NN O
immunoregulatory NN NN O
effects NN NN O
of NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
. NN NN O
   
As NN NN O
we NN NN O
observed NN NN O
that NN NN O
activated NN NN O
endothelial NN NN O
cells NN NN O
also NN NN O
expressed NN NN O
NFAT NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
antiinflammatory NN NN O
properties NN NN O
of NN NN O
CsA NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Significantly NN NN O
, NN NN O
CsA NN NN O
completely NN NN O
suppressed NN NN O
the NN NN O
induction NN NN O
of NN NN O
NFAT NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
inhibited NN NN O
the NN NN O
activity NN NN O
of NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
gene NN NN O
regulatory NN NN O
elements NN NN O
that NN NN O
use NN NN O
NFAT NN NN O
by NN NN O
60 NN NN O
% NN NN O
. NN NN O
   
CsA NN NN O
similarly NN NN O
mediated NN NN O
a NN NN O
reduction NN NN O
of NN NN O
up NN NN O
to NN NN O
65 NN NN O
% NN NN O
in NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
expression NN NN O
in NN NN O
activated NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
CsA NN NN O
also NN NN O
suppressed NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
expression NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
even NN NN O
though NN NN O
the NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
promoter NN NN O
is NN NN O
activated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
rather NN NN O
than NN NN O
NFAT NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
induction NN NN O
of NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
of NN NN O
this NN NN O
leukocyte NN NN O
adhesion NN NN O
molecule NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
was NN NN O
reduced NN NN O
by NN NN O
40 NN NN O
% NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
CsA NN NN O
, NN NN O
and NN NN O
this NN NN O
was NN NN O
reflected NN NN O
by NN NN O
a NN NN O
29 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
neutrophil NN NN O
adhesion NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
CsA NN NN O
on NN NN O
endothelial NN NN O
cells NN NN O
were NN NN O
also NN NN O
detected NN NN O
at NN NN O
the NN NN O
chromatin NN NN O
structure NN NN O
level NN NN O
, NN NN O
as NN NN O
DNasel NN NN B-Protein
hypersensitive NN NN O
sites NN NN O
within NN NN O
both NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
enhancer NN NN O
and NN NN O
the NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
promoter NN NN O
were NN NN O
suppressed NN NN O
by NN NN O
CsA NN NN O
. NN NN O
   
This NN NN O
represents NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
NFAT NN NN O
in NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
suggests NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
CsA NN NN O
could NN NN O
function NN NN O
as NN NN O
an NN NN O
antiinflammatory NN NN O
agent NN NN O
. NN NN O
   
Signalling NN NN O
via NN NN O
CD28 NN NN B-Protein
of NN NN O
human NN NN O
naive NN NN O
neonatal NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Accessory NN NN O
molecules NN NN O
play NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
response NN NN O
to NN NN O
antigenic NN NN O
challenge NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
role NN NN O
of NN NN O
CD28 NN NN B-Protein
in NN NN O
modulating NN NN O
the NN NN O
' NN NN O
naive NN NN O
' NN NN O
neonatal NN NN O
T NN NN O
cell NN NN O
response NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD2 NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
. NN NN O
   
To NN NN O
compare NN NN O
the NN NN O
role NN NN O
of NN NN O
CD28 NN NN B-Protein
, NN NN O
neonatal NN NN O
and NN NN O
adult NN NN O
T NN NN O
cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
a NN NN O
pair NN NN O
of NN NN O
mitogenic NN NN O
anti NN NN O
- NN NN O
CD2 NN NN O
antibodies NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
MoAb NN NN O
. NN NN O
   
With NN NN O
anti NN NN O
- NN NN O
CD2 NN NN O
alone NN NN O
, NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
proliferated NN NN O
slightly NN NN O
but NN NN O
produced NN NN O
no NN NN O
detectable NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
whereas NN NN O
adult NN NN O
T NN NN O
cells NN NN O
proliferated NN NN O
vigorously NN NN O
, NN NN O
with NN NN O
significant NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Costimulation NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
MoAb NN NN O
greatly NN NN O
enhanced NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
of NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
to NN NN O
levels NN NN O
equivalent NN NN O
to NN NN O
those NN NN O
of NN NN O
adult NN NN O
T NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
adult NN NN O
T NN NN O
cells NN NN O
showed NN NN O
only NN NN O
slight NN NN O
increases NN NN O
. NN NN O
   
Although NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
was NN NN O
increased NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
MoAb NN NN O
, NN NN O
neonatal NN NN O
T NN NN O
cell NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
remained NN NN O
lower NN NN O
than NN NN O
in NN NN O
adults NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
enhancement NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
expression NN NN O
in NN NN O
neonates NN NN O
was NN NN O
similar NN NN O
to NN NN O
adult NN NN O
levels NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
CD28 NN NN B-Protein
MoAb NN NN O
costimulation NN NN O
increased NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
levels NN NN O
in NN NN O
neonates NN NN O
, NN NN O
albeit NN NN O
to NN NN O
levels NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
adults NN NN O
. NN NN O
   
The NN NN O
cellular NN NN O
mechanism NN NN O
governing NN NN O
the NN NN O
diminished NN NN O
proliferative NN NN O
response NN NN O
of NN NN O
neonatal NN NN O
T NN NN O
lymphocytes NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD2 NN NN O
may NN NN O
therefore NN NN O
be NN NN O
due NN NN O
to NN NN O
decreased NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
, NN NN O
reduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
deficient NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Although NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
MoAb NN NN O
costimulation NN NN O
enhances NN NN O
all NN NN O
of NN NN O
the NN NN O
above NN NN O
signals NN NN O
, NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
levels NN NN O
remain NN NN O
lower NN NN O
than NN NN O
in NN NN O
adults NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
need NN NN O
for NN NN O
further NN NN O
activation NN NN O
requirements NN NN O
in NN NN O
the NN NN O
neonate NN NN O
. NN NN O
   
N NN NN O
- NN NN O
and NN NN O
C NN NN O
- NN NN O
terminal NN NN O
sequences NN NN O
control NN NN O
degradation NN NN O
of NN NN O
MAD3 NN NN B-Protein
/ NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
inducers NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
proteolytic NN NN O
degradation NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
protein NN NN O
MAD3 NN NN B-Protein
/ NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
extracellular NN NN O
stimulation NN NN O
is NN NN O
a NN NN O
prerequisite NN NN O
step NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
human NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
in NN NN O
stable NN NN O
transfectants NN NN O
of NN NN O
mouse NN NN O
70Z NN NN O
/ NN NN O
3 NN NN O
cells NN NN O
shows NN NN O
that NN NN O
, NN NN O
as NN NN O
for NN NN O
the NN NN O
endogenous NN NN O
murine NN NN O
protein NN NN O
, NN NN O
exogenous NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
degraded NN NN O
in NN NN O
response NN NN O
to NN NN O
inducers NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
, NN NN O
such NN NN O
as NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
or NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
pretreatment NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
the NN NN O
proteasome NN NN O
inhibitor NN NN O
N NN NN O
- NN NN O
Ac NN NN O
- NN NN O
Leu NN NN O
- NN NN O
Leu NN NN O
- NN NN O
norleucinal NN NN O
inhibits NN NN O
this NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
degradation NN NN O
and NN NN O
, NN NN O
in NN NN O
agreement NN NN O
with NN NN O
previous NN NN O
studies NN NN O
, NN NN O
stabilizes NN NN O
a NN NN O
hyperphosphorylated NN NN O
form NN NN O
of NN NN O
the NN NN O
human NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
. NN NN O
   
By NN NN O
expressing NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
the NN NN O
human NN NN O
protein NN NN O
in NN NN O
this NN NN O
cell NN NN O
line NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
able NN NN O
to NN NN O
delineate NN NN O
the NN NN O
sequences NN NN O
responsible NN NN O
for NN NN O
both NN NN O
the NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
and NN NN O
the NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Our NN NN O
results NN NN O
show NN NN O
that NN NN O
deletion NN NN O
of NN NN O
the NN NN O
C NN NN O
terminus NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
molecule NN NN O
up NN NN O
to NN NN O
amino NN NN O
acid NN NN O
279 NN NN O
abolishes NN NN O
constitutive NN NN O
but NN NN O
not NN NN O
ligand NN NN O
- NN NN O
inducible NN NN O
phosphorylation NN NN O
and NN NN O
inhibits NN NN O
ligand NN NN O
- NN NN O
inducible NN NN O
degradation NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
reveals NN NN O
that NN NN O
the NN NN O
inducible NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
maps NN NN O
to NN NN O
two NN NN O
serines NN NN O
in NN NN O
the NN NN O
N NN NN O
terminus NN NN O
of NN NN O
the NN NN O
protein NN NN O
( NN NN O
residues NN NN O
32 NN NN O
and NN NN O
36 NN NN O
) NN NN O
and NN NN O
that NN NN O
the NN NN O
mutation NN NN O
of NN NN O
either NN NN O
residue NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
abolish NN NN O
ligand NN NN O
- NN NN O
induced NN NN O
degradation NN NN O
, NN NN O
whereas NN NN O
both NN NN O
residues NN NN O
must NN NN O
be NN NN O
mutated NN NN O
to NN NN O
abolish NN NN O
inducible NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Transcriptional NN NN O
repression NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
by NN NN O
vitamin NN NN O
D3 NN NN O
: NN NN O
direct NN NN O
inhibition NN NN O
of NN NN O
NFATp NN NN B-Protein
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
formation NN NN O
by NN NN O
a NN NN O
nuclear NN NN O
hormone NN NN O
receptor NN NN O
. NN NN O
   
T NN NN O
- NN NN O
lymphocyte NN NN O
proliferation NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
1 NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
[ NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
] NN NN O
, NN NN O
the NN NN O
active NN NN O
metabolite NN NN O
of NN NN O
vitamin NN NN O
D3 NN NN O
, NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
gamma NN NN O
interferon NN NN O
, NN NN O
and NN NN O
granulocyte NN NN O
- NN NN O
macrophage NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
mediated NN NN O
repression NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
is NN NN O
cycloheximide NN NN O
resistant NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
is NN NN O
a NN NN O
direct NN NN O
transcriptional NN NN O
repressive NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
the NN NN O
vitamin NN NN B-Protein
D3 NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
examined NN NN O
vitamin NN NN O
D3 NN NN O
- NN NN O
mediated NN NN O
repression NN NN O
of NN NN O
activated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
cotransfecting NN NN O
Jurkat NN NN O
cells NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
/ NN NN O
reporter NN NN O
constructs NN NN O
and NN NN O
a NN NN O
VDR NN NN B-Protein
overexpression NN NN O
vector NN NN O
and NN NN O
by NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
We NN NN O
delineated NN NN O
an NN NN O
element NN NN O
conferring NN NN O
both NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
the NN NN O
receptor NN NN O
in NN NN O
vitro NN NN O
and NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
mediated NN NN O
repression NN NN O
in NN NN O
vivo NN NN O
to NN NN O
a NN NN O
short NN NN O
40 NN NN O
- NN NN O
bp NN NN O
region NN NN O
encompassing NN NN O
an NN NN O
important NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
, NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
bound NN NN O
by NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NFATp NN NN B-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
by NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
VDR NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
mutants NN NN O
were NN NN O
unable NN NN O
to NN NN O
either NN NN O
bind NN NN O
to NN NN O
this NN NN O
element NN NN O
in NN NN O
vitro NN NN O
or NN NN O
repress NN NN O
in NN NN O
vivo NN NN O
; NN NN O
the NN NN O
VDR NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
alone NN NN O
, NN NN O
however NN NN O
, NN NN O
bound NN NN O
the NN NN O
element NN NN O
but NN NN O
also NN NN O
could NN NN O
not NN NN O
repress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
VDR NN NN B-Protein
is NN NN O
necessary NN NN O
but NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
mediate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
repression NN NN O
. NN NN O
   
By NN NN O
combining NN NN O
partially NN NN O
purified NN NN O
proteins NN NN O
in NN NN O
vitro NN NN O
, NN NN O
we NN NN O
observed NN NN O
the NN NN O
loss NN NN O
of NN NN O
the NN NN O
bound NN NN O
NFATp NN NN B-Protein
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
upon NN NN O
inclusion NN NN O
of NN NN O
VDR NN NN B-Protein
or NN NN O
VDR NN NN B-Protein
- NN NN O
retinoid NN NN O
X NN NN O
receptor NN NN O
. NN NN O
   
Order NN NN O
of NN NN O
addition NN NN O
and NN NN O
off NN NN O
- NN NN O
rate NN NN O
experiments NN NN O
indicate NN NN O
that NN NN O
the NN NN O
VDR NN NN B-Protein
- NN NN O
retinoid NN NN O
X NN NN O
receptor NN NN O
heterodimer NN NN O
blocks NN NN O
NFATp NN NN B-Protein
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
formation NN NN O
and NN NN O
then NN NN O
stably NN NN O
associates NN NN O
with NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
AT NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
element NN NN O
. NN NN O
   
This NN NN O
direct NN NN O
inhibition NN NN O
by NN NN O
a NN NN O
nuclear NN NN O
hormone NN NN O
receptor NN NN O
of NN NN O
transcriptional NN NN O
activators NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
may NN NN O
provide NN NN O
a NN NN O
mechanistic NN NN O
explanation NN NN O
of NN NN O
how NN NN O
vitamin NN NN O
derivatives NN NN O
can NN NN O
act NN NN O
as NN NN O
potent NN NN O
immunosuppressive NN NN O
agents NN NN O
. NN NN O
   
An NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
sequence NN NN O
mediates NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
IgG NN NN B-Protein
Fc NN NN I-Protein
receptor NN NN I-Protein
type NN NN I-Protein
IC NN NN I-Protein
gene NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
IgG NN NN B-Protein
Fc NN NN I-Protein
receptor NN NN I-Protein
type NN NN I-Protein
I NN NN I-Protein
( NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RI NN NN I-Protein
) NN NN O
on NN NN O
myeloid NN NN O
cells NN NN O
is NN NN O
dramatically NN NN O
increased NN NN O
by NN NN O
treatment NN NN O
with NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
that NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RI NN NN I-Protein
transcript NN NN O
levels NN NN O
in NN NN O
monoblast NN NN O
- NN NN O
like NN NN O
U937 NN NN O
cells NN NN O
were NN NN O
elevated NN NN O
within NN NN O
3 NN NN O
hr NN NN O
and NN NN O
peaked NN NN O
12 NN NN O
hr NN NN O
after NN NN O
exposure NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
Treatment NN NN O
of NN NN O
U937 NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
for NN NN O
9 NN NN O
hr NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
cycloheximide NN NN O
led NN NN O
to NN NN O
super NN NN O
- NN NN O
induction NN NN O
of NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RI NN NN I-Protein
expression NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
rate NN NN O
of NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RI NN NN I-Protein
transcription NN NN O
was NN NN O
increased NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
Genomic NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIC NN NN I-Protein
gene NN NN O
was NN NN O
cloned NN NN O
and NN NN O
subjected NN NN O
to NN NN O
primer NN NN O
extension NN NN O
analysis NN NN O
, NN NN O
which NN NN O
demonstrated NN NN O
a NN NN O
single NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
without NN NN O
a NN NN O
TATA NN NN O
box NN NN O
. NN NN O
   
Transient NN NN O
transfections NN NN O
of NN NN O
CAT NN NN B-Protein
reporter NN NN O
gene NN NN O
constructs NN NN O
containing NN NN O
various NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIC NN NN I-Protein
promoter NN NN O
sequences NN NN O
into NN NN O
U937 NN NN O
cells NN NN O
revealed NN NN O
that NN NN O
a NN NN O
20 NN NN O
- NN NN O
bp NN NN O
region NN NN O
surrounding NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
( NN NN O
- NN NN O
7 NN NN O
to NN NN O
+ NN NN O
13 NN NN O
) NN NN O
was NN NN O
capable NN NN O
of NN NN O
mediating NN NN O
transcription NN NN O
initiation NN NN O
and NN NN O
that NN NN O
an NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
responsive NN NN O
element NN NN O
( NN NN O
GIRE NN NN O
) NN NN O
was NN NN O
present NN NN O
within NN NN O
74 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
A NN NN O
17 NN NN O
- NN NN O
bp NN NN O
sequence NN NN O
between NN NN O
positions NN NN O
- NN NN O
51 NN NN O
and NN NN O
- NN NN O
35 NN NN O
conferred NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
responsiveness NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
Double NN NN O
- NN NN O
stranded NN NN O
GIRE NN NN O
sequence NN NN O
, NN NN O
but NN NN O
not NN NN O
a NN NN O
scrambled NN NN O
sequence NN NN O
, NN NN O
was NN NN O
specifically NN NN O
bound NN NN O
by NN NN O
nuclear NN NN O
proteins NN NN O
from NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
treated NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Gel NN NN O
shift NN NN O
experiments NN NN O
further NN NN O
showed NN NN O
that NN NN O
the NN NN O
STAT1 NN NN B-Protein
alpha NN NN I-Protein
protein NN NN O
bound NN NN O
to NN NN O
the NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIC NN NN I-Protein
GIRE NN NN O
in NN NN O
response NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
treatment NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIC NN NN I-Protein
GIRE NN NN O
is NN NN O
homologous NN NN O
to NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
sequence NN NN O
( NN NN O
GAS NN NN O
) NN NN O
of NN NN O
the NN NN O
guanylate NN NN O
binding NN NN O
protein NN NN O
and NN NN O
to NN NN O
X NN NN O
box NN NN O
elements NN NN O
of NN NN O
class NN NN O
II NN NN O
MHC NN NN O
genes NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIC NN NN I-Protein
gene NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
involves NN NN O
the NN NN O
binding NN NN O
of NN NN O
STAT1 NN NN B-Protein
alpha NN NN I-Protein
to NN NN O
a NN NN O
17 NN NN O
- NN NN O
bp NN NN O
GAS NN NN O
homology NN NN O
in NN NN O
the NN NN O
proximal NN NN O
promoter NN NN O
. NN NN O
   
Immunosuppression NN NN O
by NN NN O
glucocorticoids NN NN O
: NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
through NN NN O
induction NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
synthesis NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
Glucocorticoids NN NN O
are NN NN O
among NN NN O
the NN NN O
most NN NN O
potent NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
and NN NN O
immunosuppressive NN NN O
agents NN NN O
. NN NN O
   
They NN NN O
inhibit NN NN O
synthesis NN NN O
of NN NN O
almost NN NN O
all NN NN O
known NN NN O
cytokines NN NN O
and NN NN O
of NN NN O
several NN NN O
cell NN NN O
surface NN NN O
molecules NN NN O
required NN NN O
for NN NN O
immune NN NN O
function NN NN O
, NN NN O
but NN NN O
the NN NN O
mechanism NN NN O
underlying NN NN O
this NN NN O
activity NN NN O
has NN NN O
been NN NN O
unclear NN NN O
. NN NN O
   
Here NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
glucocorticoids NN NN O
are NN NN O
potent NN NN O
inhibitors NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
in NN NN O
mice NN NN O
and NN NN O
cultured NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
is NN NN O
mediated NN NN O
by NN NN O
induction NN NN O
of NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
inhibitory NN NN O
protein NN NN O
, NN NN O
which NN NN O
traps NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
inactive NN NN O
cytoplasmic NN NN O
complexes NN NN O
. NN NN O
   
Because NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activates NN NN O
many NN NN O
immunoregulatory NN NN O
genes NN NN O
in NN NN O
response NN NN O
to NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
stimuli NN NN O
, NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
its NN NN O
activity NN NN O
can NN NN O
be NN NN O
a NN NN O
major NN NN O
component NN NN O
of NN NN O
the NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
activity NN NN O
of NN NN O
glucocorticoids NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
priming NN NN O
of NN NN O
monocytes NN NN O
enhances NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TNF NN NN O
production NN NN O
by NN NN O
augmenting NN NN O
both NN NN O
transcription NN NN O
and NN NN O
MRNA NN NN O
stability NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
cytokine NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
by NN NN O
bacterial NN NN O
endotoxin NN NN O
or NN NN O
lipopolysaccharide NN NN O
is NN NN O
a NN NN O
critical NN NN O
, NN NN O
highly NN NN O
regulated NN NN O
host NN NN O
defence NN NN O
response NN NN O
. NN NN O
   
The NN NN O
augmentation NN NN O
of NN NN O
LPS NN NN O
responses NN NN O
by NN NN O
interferon NN NN B-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
, NN NN O
referred NN NN O
to NN NN O
as NN NN O
priming NN NN O
, NN NN O
is NN NN O
well NN NN O
established NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
by NN NN O
which NN NN O
priming NN NN O
occurs NN NN O
is NN NN O
poorly NN NN O
defined NN NN O
. NN NN O
   
Using NN NN O
tumour NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
induction NN NN O
as NN NN O
a NN NN O
model NN NN O
, NN NN O
experiments NN NN O
were NN NN O
designed NN NN O
to NN NN O
analyse NN NN O
in NN NN O
detail NN NN O
the NN NN O
priming NN NN O
effect NN NN O
on NN NN O
the NN NN O
LPS NN NN O
response NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Priming NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
was NN NN O
primarily NN NN O
manifested NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
TNF NN NN O
mRNA NN NN O
accumulation NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
pre NN NN O
- NN NN O
treatment NN NN O
affected NN NN O
the NN NN O
magnitude NN NN O
rather NN NN O
than NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
LPS NN NN O
response NN NN O
. NN NN O
   
Priming NN NN O
occurred NN NN O
after NN NN O
several NN NN O
hours NN NN O
of NN NN O
treatment NN NN O
, NN NN O
and NN NN O
the NN NN O
primed NN NN O
state NN NN O
was NN NN O
induced NN NN O
by NN NN O
either NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
or NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
Primed NN NN O
monocytes NN NN O
transcribed NN NN O
TNF NN NN O
mRNA NN NN O
at NN NN O
a NN NN O
higher NN NN O
rate NN NN O
than NN NN O
freshly NN NN O
isolated NN NN O
monocytes NN NN O
upon NN NN O
activation NN NN O
with NN NN O
LPS NN NN O
. NN NN O
   
The NN NN O
increased NN NN O
transcriptional NN NN O
rate NN NN O
correlated NN NN O
with NN NN O
a NN NN O
marked NN NN O
increase NN NN O
in NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
these NN NN O
cells NN NN O
as NN NN O
determined NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
using NN NN O
a NN NN O
consensus NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
oligonucleotide NN NN O
. NN NN O
   
An NN NN O
additional NN NN O
significant NN NN O
finding NN NN O
was NN NN O
than NN NN O
TNF NN NN O
mRNA NN NN O
induced NN NN O
in NN NN O
primed NN NN O
cells NN NN O
was NN NN O
much NN NN O
more NN NN O
stable NN NN O
than NN NN O
in NN NN O
unprimed NN NN O
cells NN NN O
( NN NN O
T1 NN NN O
/ NN NN O
2 NN NN O
increased NN NN O
6 NN NN O
- NN NN O
8 NN NN O
- NN NN O
fold NN NN O
) NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
the NN NN O
increased NN NN O
mRNA NN NN O
stability NN NN O
, NN NN O
the NN NN O
duration NN NN O
of NN NN O
mRNA NN NN O
accumulation NN NN O
was NN NN O
longer NN NN O
following NN NN O
LPS NN NN O
stimulation NN NN O
in NN NN O
primed NN NN O
monocytes NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
being NN NN O
of NN NN O
greater NN NN O
magnitude NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
primed NN NN O
and NN NN O
unprimed NN NN O
cells NN NN O
possessed NN NN O
a NN NN O
differential NN NN O
sensitivity NN NN O
to NN NN O
the NN NN O
kinase NN NN O
inhibitor NN NN O
H NN NN O
- NN NN O
89 NN NN O
. NN NN O
   
H NN NN O
- NN NN O
89 NN NN O
substantially NN NN O
suppressed NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TNF NN NN O
mRNA NN NN O
accumulation NN NN O
in NN NN O
unprimed NN NN O
cells NN NN O
, NN NN O
but NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
primed NN NN O
monocytes NN NN O
following NN NN O
LPS NN NN O
stimulation NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
The NN NN O
myeloid NN NN O
zinc NN NN O
finger NN NN O
gene NN NN O
, NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
regulates NN NN O
the NN NN O
CD34 NN NN B-Protein
promoter NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
C2H2 NN NN O
zinc NN NN O
finger NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
putative NN NN O
transcriptional NN NN O
regulator NN NN O
of NN NN O
myeloid NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
contains NN NN O
13 NN NN O
C2H2 NN NN O
zinc NN NN O
fingers NN NN O
arranged NN NN O
in NN NN O
bipartite NN NN O
DNA NN NN O
binding NN NN O
domains NN NN O
containing NN NN O
zinc NN NN O
fingers NN NN O
through NN NN O
4 NN NN O
and NN NN O
, NN NN O
in NN NN O
the NN NN O
carboxy NN NN O
- NN NN O
terminus NN NN O
, NN NN O
5 NN NN O
through NN NN O
13 NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
identified NN NN O
the NN NN O
DNA NN NN O
consensus NN NN O
binding NN NN O
site NN NN O
recognized NN NN O
by NN NN O
the NN NN O
two NN NN O
DNA NN NN O
binding NN NN O
domains NN NN O
. NN NN O
   
To NN NN O
assess NN NN O
the NN NN O
transcription NN NN O
regulatory NN NN O
function NN NN O
of NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
the NN NN O
full NN NN O
- NN NN O
length NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
coding NN NN O
region NN NN O
was NN NN O
fused NN NN O
to NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
yeast NN NN O
transactivator NN NN O
GAL4 NN NN B-Protein
. NN NN O
   
The NN NN O
expression NN NN O
vector NN NN O
was NN NN O
cotransfected NN NN O
with NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
gene NN NN O
regulated NN NN O
by NN NN O
the NN NN O
thymidine NN NN B-Protein
kinase NN NN I-Protein
promoter NN NN O
containing NN NN O
GAL4 NN NN B-Protein
DNA NN NN O
binding NN NN O
sites NN NN O
into NN NN O
NIH NN NN O
3T3 NN NN O
, NN NN O
293 NN NN O
, NN NN O
K562 NN NN O
, NN NN O
and NN NN O
Jurkat NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
represses NN NN O
CAT NN NN B-Protein
reporter NN NN O
gene NN NN O
expression NN NN O
via NN NN O
GAL4 NN NN B-Protein
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
nonhematopoietic NN NN O
cell NN NN O
lines NN NN O
NIH NN NN O
3T3 NN NN O
and NN NN O
293 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
CAT NN NN B-Protein
reporter NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
K562 NN NN O
and NN NN O
Jurkat NN NN O
. NN NN O
   
The NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
sites NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
several NN NN O
genes NN NN O
expressed NN NN O
during NN NN O
myeloid NN NN O
differentiation NN NN O
, NN NN O
including NN NN O
the NN NN O
CD34 NN NN B-Protein
promoter NN NN O
. NN NN O
   
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcriptional NN NN O
regulation NN NN O
of NN NN O
this NN NN O
physiologically NN NN O
relevant NN NN O
promoter NN NN O
was NN NN O
assessed NN NN O
in NN NN O
both NN NN O
hematopoietic NN NN O
and NN NN O
nonhematopoietic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Recombinant NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
specifically NN NN O
binds NN NN O
to NN NN O
the NN NN O
consensus NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
CD34 NN NN B-Protein
promoter NN NN O
in NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
vectors NN NN O
were NN NN O
cotransfected NN NN O
with NN NN O
the NN NN O
luciferase NN NN O
reporter NN NN O
plasmids NN NN O
regulated NN NN O
by NN NN O
the NN NN O
CD34 NN NN B-Protein
promoter NN NN O
into NN NN O
both NN NN O
nonhematopoietic NN NN O
and NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
As NN NN O
with NN NN O
the NN NN O
heterologous NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
, NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
represses NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
in NN NN O
nonhematopoietic NN NN O
cell NN NN O
lines NN NN O
and NN NN O
activates NN NN O
expression NN NN O
in NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
CD34 NN NN B-Protein
expression NN NN O
in NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
intact NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
the NN NN O
CD34 NN NN B-Protein
promoter NN NN O
by NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
suggests NN NN O
the NN NN O
presence NN NN O
of NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
regulators NN NN O
/ NN NN O
adapters NN NN O
or NN NN O
differential NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
modifications NN NN O
that NN NN O
determine NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcriptional NN NN O
regulatory NN NN O
function NN NN O
. NN NN O
   
The NN NN O
normal NN NN O
cell NN NN O
cycle NN NN O
activation NN NN O
program NN NN O
is NN NN O
exploited NN NN O
during NN NN O
the NN NN O
infection NN NN O
of NN NN O
quiescent NN NN O
B NN NN O
lymphocytes NN NN O
by NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
. NN NN O
   
B NN NN O
lymphocytes NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
circulation NN NN O
are NN NN O
maintained NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
proliferative NN NN O
state NN NN O
. NN NN O
   
Antigen NN NN O
recognition NN NN O
stimulates NN NN O
limited NN NN O
proliferation NN NN O
, NN NN O
whereas NN NN O
infection NN NN O
with NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
results NN NN O
in NN NN O
continual NN NN O
proliferation NN NN O
and NN NN O
the NN NN O
outgrowth NN NN O
of NN NN O
immortal NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Because NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
at NN NN O
which NN NN O
point NN NN O
in NN NN O
cell NN NN O
cycle NN NN O
the NN NN O
peripheral NN NN O
B NN NN O
lymphocytes NN NN O
are NN NN O
arrested NN NN O
, NN NN O
we NN NN O
characterized NN NN O
the NN NN O
expression NN NN O
of NN NN O
several NN NN O
cell NN NN O
cycle NN NN O
- NN NN O
associated NN NN O
genes NN NN O
in NN NN O
quiescent NN NN O
and NN NN O
stimulated NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
four NN NN O
cell NN NN O
genes NN NN O
, NN NN O
cdc NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
cyclin NN NN B-Protein
E NN NN I-Protein
, NN NN O
CD23 NN NN B-Protein
, NN NN O
and NN NN O
cyclin NN NN B-Protein
D2 NN NN I-Protein
, NN NN O
are NN NN O
up NN NN O
- NN NN O
regulated NN NN O
approximately NN NN O
100 NN NN O
- NN NN O
fold NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
EBV NN NN O
- NN NN O
mediated NN NN O
immortalization NN NN O
. NN NN O
   
Because NN NN O
these NN NN O
genes NN NN O
play NN NN O
a NN NN O
positive NN NN O
role NN NN O
in NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
this NN NN O
regulatory NN NN O
switch NN NN O
contributes NN NN O
to NN NN O
controlling NN NN O
entry NN NN O
into NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
Transient NN NN O
stimulation NN NN O
of NN NN O
quiescent NN NN O
B NN NN O
lymphocytes NN NN O
with NN NN O
either NN NN O
a NN NN O
cocktail NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
, NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
, NN NN O
and NN NN O
IL4 NN NN B-Protein
, NN NN O
or NN NN O
EBV NN NN O
results NN NN O
in NN NN O
the NN NN O
rapid NN NN O
expression NN NN O
of NN NN O
the NN NN O
same NN NN O
four NN NN O
genes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
, NN NN O
after NN NN O
infection NN NN O
, NN NN O
EBV NN NN O
exploits NN NN O
the NN NN O
normal NN NN O
program NN NN O
of NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
cell NN NN O
cycle NN NN O
activation NN NN O
. NN NN O
   
CD30 NN NN B-Protein
ligation NN NN O
induces NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
CD30 NN NN B-Protein
is NN NN O
a NN NN O
recently NN NN O
described NN NN O
member NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
/ NN NN O
nerve NN NN O
growth NN NN O
factor NN NN O
receptor NN NN O
superfamily NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
following NN NN O
incubation NN NN O
of NN NN O
L540 NN NN O
cells NN NN O
( NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
disease NN NN O
- NN NN O
derived NN NN O
, NN NN O
T NN NN O
cell NN NN O
- NN NN O
like NN NN O
, NN NN O
CD30 NN NN B-Protein
+ NN NN O
cells NN NN O
) NN NN O
with NN NN O
the NN NN O
agonistic NN NN O
anti NN NN O
- NN NN O
CD30 NN NN B-Protein
monoclonal NN NN O
antibodies NN NN O
( NN NN O
mAb NN NN O
) NN NN O
M44 NN NN O
and NN NN O
M67 NN NN O
, NN NN O
two NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
activities NN NN O
were NN NN O
induced NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
, NN NN O
as NN NN O
determined NN NN O
in NN NN O
gel NN NN O
retardation NN NN O
assays NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
the NN NN O
mAb NN NN O
towards NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
rapid NN NN O
, NN NN O
as NN NN O
it NN NN O
occurred NN NN O
within NN NN O
20 NN NN O
min NN NN O
, NN NN O
and NN NN O
was NN NN O
sustained NN NN O
for NN NN O
up NN NN O
to NN NN O
6 NN NN O
h NN NN O
. NN NN O
   
By NN NN O
comparison NN NN O
, NN NN O
an NN NN O
isotype NN NN O
- NN NN O
matched NN NN O
antibody NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
in NN NN O
human NN NN O
T NN NN O
helper NN NN O
( NN NN O
Th NN NN O
) NN NN O
clones NN NN O
functionally NN NN O
characterized NN NN O
as NN NN O
being NN NN O
of NN NN O
the NN NN O
type NN NN O
0 NN NN O
, NN NN O
type NN NN O
1 NN NN O
and NN NN O
type NN NN O
2 NN NN O
( NN NN O
28 NN NN O
% NN NN O
, NN NN O
< NN NN O
1 NN NN O
% NN NN O
und NN NN O
93 NN NN O
% NN NN O
CD30 NN NN O
+ NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
the NN NN O
extent NN NN O
of NN NN O
CD30 NN NN B-Protein
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
correlated NN NN O
with NN NN O
the NN NN O
proportion NN NN O
of NN NN O
CD30 NN NN B-Protein
+ NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
all NN NN O
cell NN NN O
lines NN NN O
investigated NN NN O
, NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complexes NN NN O
induced NN NN O
following NN NN O
CD30 NN NN B-Protein
engagement NN NN O
were NN NN O
shown NN NN O
to NN NN O
contain NN NN O
p50 NN NN B-Protein
NF NN NN I-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
, NN NN O
p65 NN NN B-Protein
RelA NN NN I-Protein
, NN NN O
and NN NN O
possibly NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Collectively NN NN O
, NN NN O
our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
rank NN NN O
among NN NN O
the NN NN O
short NN NN O
- NN NN O
term NN NN O
cellular NN NN O
responses NN NN O
elicited NN NN O
following NN NN O
CD30 NN NN B-Protein
ligation NN NN O
. NN NN O
   
Constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
enhanced NN NN O
granulopoiesis NN NN O
, NN NN O
and NN NN O
neonatal NN NN O
lethality NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
deficient NN NN O
mice NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
belonging NN NN O
to NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
are NN NN O
controlled NN NN O
by NN NN O
inhibitory NN NN O
I NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
, NN NN O
mainly NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
Apparently NN NN O
normal NN NN O
at NN NN O
birth NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
exhibit NN NN O
severe NN NN O
runting NN NN O
, NN NN O
skin NN NN O
defects NN NN O
, NN NN O
and NN NN O
extensive NN NN O
granulopoiesis NN NN O
postnatally NN NN O
, NN NN O
typically NN NN O
dying NN NN O
by NN NN O
8 NN NN O
days NN NN O
. NN NN O
   
Hematopoietic NN NN O
tissues NN NN O
from NN NN O
these NN NN O
mice NN NN O
display NN NN O
elevated NN NN O
levels NN NN O
of NN NN O
both NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
mRNAs NN NN O
of NN NN O
some NN NN O
, NN NN O
but NN NN O
not NN NN O
all NN NN O
, NN NN O
genes NN NN O
thought NN NN O
to NN NN O
be NN NN O
regulated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
elevation NN NN O
results NN NN O
in NN NN O
these NN NN O
phenotypic NN NN O
abnormalities NN NN O
because NN NN O
mice NN NN O
lacking NN NN O
both NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
show NN NN O
a NN NN O
dramatically NN NN O
delayed NN NN O
onset NN NN O
of NN NN O
abnormalities NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
hematopoietic NN NN O
cells NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
/ NN NN O
- NN NN O
embryonic NN NN O
fibroblasts NN NN O
show NN NN O
minimal NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
normal NN NN O
signal NN NN O
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
that NN NN O
is NN NN O
concomitant NN NN O
with NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
degradation NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
b NN NN I-Protein
beta NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
signal NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
However NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
the NN NN O
postinduction NN NN O
repression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
These NN NN O
results NN NN O
define NN NN O
distinct NN NN O
roles NN NN O
for NN NN O
the NN NN O
two NN NN O
forms NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
and NN NN O
demonstrate NN NN O
the NN NN O
necessity NN NN O
for NN NN O
stringent NN NN O
control NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Vitamin NN NN O
E NN NN O
therapy NN NN O
of NN NN O
acute NN NN O
CCl4 NN NN O
- NN NN O
induced NN NN O
hepatic NN NN O
injury NN NN O
in NN NN O
mice NN NN O
is NN NN O
associated NN NN O
with NN NN O
inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
, NN NN O
with NN NN O
reactive NN NN O
oxygen NN NN O
intermediate NN NN O
formation NN NN O
, NN NN O
may NN NN O
represent NN NN O
a NN NN O
common NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
liver NN NN O
injury NN NN O
is NN NN O
induced NN NN O
by NN NN O
diverse NN NN O
etiologies NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
enhances NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activity NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
enhance NN NN O
the NN NN O
expression NN NN O
of NN NN O
cytotoxic NN NN O
cytokines NN NN O
. NN NN O
   
Acute NN NN O
hepatic NN NN O
injury NN NN O
caused NN NN O
by NN NN O
reactive NN NN O
oxygen NN NN O
intermediate NN NN O
production NN NN O
was NN NN O
induced NN NN O
by NN NN O
an NN NN O
intraperitoneal NN NN O
injection NN NN O
of NN NN O
CCl4 NN NN O
in NN NN O
mice NN NN O
. NN NN O
   
This NN NN O
injury NN NN O
was NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
intravenous NN NN O
pretreatment NN NN O
of NN NN O
the NN NN O
mice NN NN O
with NN NN O
a NN NN O
water NN NN O
- NN NN O
soluble NN NN O
emulsion NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
. NN NN O
   
Alpha NN NN O
- NN NN O
tocopherol NN NN O
treatment NN NN O
of NN NN O
the NN NN O
mice NN NN O
given NN NN O
the NN NN O
CCl4 NN NN O
also NN NN O
reduced NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
to NN NN O
levels NN NN O
approaching NN NN O
those NN NN O
found NN NN O
in NN NN O
normal NN NN O
mice NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
treatment NN NN O
of NN NN O
a NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cell NN NN O
line NN NN O
with NN NN O
CCl4 NN NN O
led NN NN O
to NN NN O
enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
messenger NN NN O
RNA NN NN O
levels NN NN O
. NN NN O
   
Liver NN NN O
specimens NN NN O
taken NN NN O
from NN NN O
patients NN NN O
with NN NN O
acute NN NN O
fulminant NN NN O
hepatitis NN NN O
had NN NN O
markedly NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
in NN NN O
comparison NN NN O
with NN NN O
the NN NN O
binding NN NN O
of NN NN O
normal NN NN O
livers NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
abolishing NN NN O
acute NN NN O
hepatic NN NN O
injury NN NN O
with NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
, NN NN O
a NN NN O
free NN NN O
radical NN NN O
scavenger NN NN O
, NN NN O
also NN NN O
eliminated NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
. NN NN O
   
It NN NN O
is NN NN O
tempting NN NN O
to NN NN O
speculate NN NN O
that NN NN O
enhanced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
caused NN NN O
by NN NN O
free NN NN O
radical NN NN O
production NN NN O
/ NN NN O
oxidative NN NN O
stress NN NN O
may NN NN O
modulate NN NN O
liver NN NN O
injury NN NN O
, NN NN O
perhaps NN NN O
through NN NN O
an NN NN O
effect NN NN O
on NN NN O
cytotoxic NN NN O
cytokine NN NN O
synthesis NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
signaling NN NN O
pathway NN NN O
in NN NN O
a NN NN O
primary NN NN O
T NN NN O
cell NN NN O
response NN NN O
. NN NN O
   
Critical NN NN O
role NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
The NN NN O
T NN NN O
cell NN NN O
activation NN NN O
is NN NN O
initiated NN NN O
by NN NN O
interaction NN NN O
of NN NN O
specific NN NN O
Ags NN NN B-Protein
with NN NN O
TCR NN NN O
, NN NN O
followed NN NN O
by NN NN O
activation NN NN O
of NN NN O
intracellular NN NN O
biochemical NN NN O
events NN NN O
leading NN NN O
to NN NN O
activation NN NN O
of NN NN O
several NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
proteins NN NN O
in NN NN O
a NN NN O
primary NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
have NN NN O
been NN NN O
explored NN NN O
. NN NN O
   
In NN NN O
purified NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
, NN NN O
nuclear NN NN O
STAT NN NN O
proteins NN NN O
were NN NN O
activated NN NN O
approximately NN NN O
3 NN NN O
h NN NN O
after NN NN O
activation NN NN O
by NN NN O
cross NN NN O
- NN NN O
linked NN NN O
anti NN NN O
- NN NN O
CD3 NN NN B-Protein
Abs NN NN O
. NN NN O
   
These NN NN O
STAT NN NN O
proteins NN NN O
were NN NN O
detected NN NN O
by NN NN O
using NN NN O
the NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
- NN NN O
activated NN NN O
sequence NN NN O
( NN NN O
GAS NN NN O
) NN NN O
and NN NN O
related NN NN O
oligonucleotides NN NN O
as NN NN O
probes NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
extracts NN NN O
with NN NN O
anti NN NN O
- NN NN O
STAT NN NN O
Abs NN NN O
indicated NN NN O
that NN NN O
they NN NN O
contained NN NN O
STAT NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
additional NN NN O
proteins NN NN O
crossreactive NN NN O
with NN NN O
the NN NN O
STAT NN NN O
family NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
STAT NN NN O
activity NN NN O
was NN NN O
inhibited NN NN O
completely NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
either NN NN O
cycloheximide NN NN O
or NN NN O
cyclosporin NN NN O
A NN NN O
, NN NN O
thus NN NN O
indicating NN NN O
that NN NN O
the NN NN O
induction NN NN O
was NN NN O
due NN NN O
to NN NN O
a NN NN O
secondary NN NN O
factor NN NN O
produced NN NN O
by NN NN O
the NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
Abs NN NN O
effectively NN NN O
down NN NN O
- NN NN O
regulated NN NN O
the NN NN O
early NN NN O
induction NN NN O
of NN NN O
STAT NN NN O
proteins NN NN O
and NN NN O
as NN NN O
exogenously NN NN O
added NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
rapidly NN NN O
activated NN NN O
DNA NN NN O
binding NN NN O
similar NN NN O
to NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
bindings NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
concluded NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
is NN NN O
the NN NN O
factor NN NN O
responsible NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
STAT NN NN O
proteins NN NN O
in NN NN O
a NN NN O
primary NN NN O
T NN NN O
cell NN NN O
response NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
by NN NN O
PKC NN NN O
- NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
. NN NN O
   
The NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
phosphatase NN NN O
calcineurin NN NN O
, NN NN O
a NN NN O
target NN NN O
of NN NN O
FK506 NN NN O
and NN NN O
CsA NN NN O
, NN NN O
synergizes NN NN O
with NN NN O
PKC NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
whether NN NN O
this NN NN O
synergy NN NN O
is NN NN O
present NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
by NN NN O
which NN NN O
these NN NN O
two NN NN O
pathways NN NN O
lead NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
While NN NN O
this NN NN O
synergy NN NN O
is NN NN O
present NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
, NN NN O
in NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
calcineurin NN NN O
is NN NN O
also NN NN O
sufficient NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Having NN NN O
previously NN NN O
shown NN NN O
that NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
and NN NN O
PKC NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
synergize NN NN O
by NN NN O
accelerating NN NN O
the NN NN O
degradation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
we NN NN O
focused NN NN O
on NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
. NN NN O
   
While NN NN O
PKC NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
sequentially NN NN O
result NN NN O
in NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
in NN NN O
an NN NN O
incomplete NN NN O
degradation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
T NN NN O
cell NN NN O
lines NN NN O
, NN NN O
co NN NN O
- NN NN O
activation NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
accelerates NN NN O
the NN NN O
rate NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
and NN NN O
results NN NN O
in NN NN O
its NN NN O
complete NN NN O
degradation NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
alone NN NN O
do NN NN O
not NN NN O
result NN NN O
in NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
/ NN NN O
or NN NN O
degradation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
or NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
the NN NN O
selective NN NN O
PKC NN NN O
inhibitor NN NN O
GF109203X NN NN O
abrogates NN NN O
the NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
/ NN NN O
degradation NN NN O
irrespective NN NN O
of NN NN O
activation NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
induced NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
a NN NN O
PKC NN NN O
- NN NN O
independent NN NN O
stimulus NN NN O
. NN NN O
   
Contrary NN NN O
to NN NN O
the NN NN O
interaction NN NN O
with NN NN O
PKC NN NN O
, NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
synergize NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
not NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
, NN NN O
but NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
its NN NN O
degradation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathways NN NN O
, NN NN O
including NN NN O
the NN NN O
phosphatase NN NN O
calcineurin NN NN O
, NN NN O
participate NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
a NN NN O
cell NN NN O
specific NN NN O
fashion NN NN O
and NN NN O
synergize NN NN O
with NN NN O
PKC NN NN O
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
pathways NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
IkB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
and NN NN O
degradation NN NN O
. NN NN O
   
Triggering NN NN O
of NN NN O
complement NN NN O
receptors NN NN O
CR1 NN NN B-Protein
( NN NN O
CD35 NN NN B-Protein
) NN NN O
and NN NN O
CR3 NN NN O
( NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
) NN NN O
induces NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
enhances NN NN O
viral NN NN O
replication NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Monocyte NN NN O
/ NN NN O
macrophages NN NN O
may NN NN O
harbor NN NN O
HIV NN NN O
in NN NN O
a NN NN O
nonproductive NN NN O
fashion NN NN O
for NN NN O
prolonged NN NN O
periods NN NN O
of NN NN O
time NN NN O
. NN NN O
   
Viral NN NN O
gene NN NN O
expression NN NN O
may NN NN O
be NN NN O
reactivated NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
LPS NN NN O
or NN NN O
cytokines NN NN O
such NN NN O
as NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
LPS NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
mediated NN NN O
by NN NN O
their NN NN O
ability NN NN O
to NN NN O
induce NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
heterodimer NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
, NN NN O
which NN NN O
binds NN NN O
to NN NN O
a NN NN O
specific NN NN O
sequence NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
triggering NN NN O
of NN NN O
complement NN NN O
receptors NN NN O
CR1 NN NN B-Protein
( NN NN O
CD35 NN NN B-Protein
) NN NN O
and NN NN O
CR3 NN NN O
( NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
) NN NN O
enhances NN NN O
viral NN NN O
replication NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Monocytic NN NN O
cell NN NN O
lines NN NN O
and NN NN O
normal NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
were NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
vitro NN NN O
and NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
F NN NN O
( NN NN O
ab NN NN O
' NN NN O
) NN NN O
2 NN NN O
fragments NN NN O
of NN NN O
monoclonal NN NN O
anti NN NN O
- NN NN O
CR1 NN NN B-Protein
or NN NN O
anti NN NN O
- NN NN O
CR3 NN NN O
Abs NN NN O
or NN NN O
with NN NN O
C3 NN NN O
fragments NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
CR1 NN NN B-Protein
or NN NN O
CR3 NN NN O
induces NN NN O
a NN NN O
two NN NN O
- NN NN O
to NN NN O
fourfold NN NN O
increase NN NN O
in NN NN O
the NN NN O
amount NN NN O
of NN NN O
cell NN NN O
- NN NN O
associated NN NN O
and NN NN O
released NN NN O
p24 NN NN B-Protein
Ag NN NN O
in NN NN O
cell NN NN O
cultures NN NN O
that NN NN O
was NN NN O
equivalent NN NN O
to NN NN O
that NN NN O
observed NN NN O
in NN NN O
control NN NN O
cultures NN NN O
triggered NN NN O
with NN NN O
LPS NN NN O
. NN NN O
   
We NN NN O
further NN NN O
observed NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
CR1 NN NN B-Protein
or NN NN O
CR3 NN NN O
induces NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
in NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
was NN NN O
also NN NN O
observed NN NN O
following NN NN O
stimulation NN NN O
of NN NN O
CR1 NN NN B-Protein
or NN NN O
CR3 NN NN O
of NN NN O
uninfected NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
from NN NN O
HIV NN NN O
- NN NN O
seronegative NN NN O
donors NN NN O
. NN NN O
   
The NN NN O
amount NN NN O
of NN NN O
protein NN NN O
translocated NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
observed NN NN O
when NN NN O
cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
rhTNF NN NN O
- NN NN O
alpha NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
did NN NN O
not NN NN O
mediate NN NN O
the NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
induced NN NN O
by NN NN O
triggering NN NN O
of NN NN O
complement NN NN O
receptors NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
HIV NN NN O
gene NN NN O
expression NN NN O
may NN NN O
be NN NN O
activated NN NN O
in NN NN O
infected NN NN O
monocytes NN NN O
through NN NN O
interaction NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
complement NN NN O
- NN NN O
opsonized NN NN O
particles NN NN O
and NN NN O
that NN NN O
enhanced NN NN O
viral NN NN O
replication NN NN O
is NN NN O
associated NN NN O
with NN NN O
C3 NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
. NN NN O
   
Nuclear NN NN B-Protein
factor NN NN I-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
activates NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Positive NN NN O
regulatory NN NN O
element NN NN O
I NN NN O
( NN NN O
PRE NN NN O
- NN NN O
I NN NN O
) NN NN O
is NN NN O
a NN NN O
strong NN NN O
enhancer NN NN O
element NN NN O
essential NN NN O
for NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
transcription NN NN O
factors NN NN O
binding NN NN O
to NN NN O
PRE NN NN O
- NN NN O
I NN NN O
, NN NN O
we NN NN O
screened NN NN O
a NN NN O
cDNA NN NN O
expression NN NN O
library NN NN O
from NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
isolated NN NN O
a NN NN O
cDNA NN NN O
encoding NN NN O
nuclear NN NN O
factor NN NN O
( NN NN B-Protein
NF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
( NN NN O
also NN NN O
known NN NN O
as NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
) NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
mRNA NN NN O
was NN NN O
found NN NN O
in NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
the NN NN O
mouse NN NN O
Th2 NN NN O
clone NN NN O
D10 NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
Th1 NN NN O
clone NN NN O
29 NN NN O
. NN NN O
   
rNF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
expressed NN NN O
in NN NN O
bacteria NN NN O
was NN NN O
shown NN NN O
to NN NN O
specifically NN NN O
bind NN NN O
to NN NN O
PRE NN NN O
- NN NN O
I NN NN O
. NN NN O
   
PRE NN NN O
- NN NN O
I NN NN O
forms NN NN O
multiple NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Some NN NN O
of NN NN O
these NN NN O
complexes NN NN O
were NN NN O
demonstrated NN NN O
to NN NN O
contain NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
by NN NN O
using NN NN O
anti NN NN O
- NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
beta NN NN I-Protein
Abs NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
enhanced NN NN O
expression NN NN O
of NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
reporter NN NN O
gene NN NN O
linked NN NN O
to NN NN O
the NN NN O
PRE NN NN O
- NN NN O
I NN NN O
- NN NN O
thymidine NN NN O
kinase NN NN O
or NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
more NN NN O
than NN NN O
10 NN NN O
- NN NN O
fold NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Promoter NN NN O
deletion NN NN O
studies NN NN O
revealed NN NN O
two NN NN O
additional NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
binding NN NN O
sites NN NN O
located NN NN O
at NN NN O
positions NN NN O
- NN NN O
44 NN NN O
to NN NN O
- NN NN O
36 NN NN O
( NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proximal NN NN O
) NN NN O
and NN NN O
- NN NN O
87 NN NN O
to NN NN O
- NN NN O
79 NN NN O
( NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
medial NN NN O
) NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
is NN NN O
involved NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
peri NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
mediates NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
2 NN NN O
enhancer NN NN O
activation NN NN O
in NN NN O
monocytes NN NN O
but NN NN O
not NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
2 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
) NN NN O
, NN NN O
like NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
causes NN NN O
AIDS NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
AIDS NN NN O
cases NN NN O
primarily NN NN O
in NN NN O
West NN NN O
Africa NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
display NN NN O
significant NN NN O
differences NN NN O
in NN NN O
nucleic NN NN O
acid NN NN O
sequence NN NN O
and NN NN O
in NN NN O
the NN NN O
natural NN NN O
history NN NN O
of NN NN O
clinical NN NN O
disease NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
differences NN NN O
, NN NN O
we NN NN O
have NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
enhancer NN NN O
/ NN NN O
promoter NN NN O
region NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
functions NN NN O
quite NN NN O
differently NN NN O
from NN NN O
that NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Whereas NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
following NN NN O
T NN NN O
- NN NN O
cell NN NN O
stimulation NN NN O
is NN NN O
mediated NN NN O
largely NN NN O
through NN NN O
binding NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
two NN NN O
adjacent NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
, NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
is NN NN O
dependent NN NN O
on NN NN O
four NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
: NN NN O
a NN NN O
single NN NN O
kappa NN NN O
B NN NN O
site NN NN O
, NN NN O
two NN NN O
purine NN NN O
- NN NN O
rich NN NN O
binding NN NN O
sites NN NN O
, NN NN O
PuB1 NN NN O
and NN NN O
PuB2 NN NN O
, NN NN O
and NN NN O
a NN NN O
pets NN NN O
site NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
identified NN NN O
a NN NN O
novel NN NN O
cis NN NN O
- NN NN O
acting NN NN O
element NN NN O
within NN NN O
the NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
, NN NN O
immediately NN NN O
upstream NN NN O
of NN NN O
the NN NN O
kappa NN NN O
B NN NN O
site NN NN O
, NN NN O
designated NN NN O
peri NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
This NN NN O
site NN NN O
is NN NN O
conserved NN NN O
among NN NN O
isolates NN NN O
of NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
and NN NN O
the NN NN O
closely NN NN O
related NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
, NN NN O
and NN NN O
transfection NN NN O
assays NN NN O
show NN NN O
this NN NN O
site NN NN O
to NN NN O
mediate NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
activation NN NN O
following NN NN O
stimulation NN NN O
of NN NN O
monocytic NN NN O
but NN NN O
not NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
description NN NN O
of NN NN O
an NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancer NN NN O
element NN NN O
which NN NN O
displays NN NN O
such NN NN O
monocyte NN NN O
specificity NN NN O
, NN NN O
and NN NN O
no NN NN O
comparable NN NN O
enhancer NN NN O
element NN NN O
has NN NN O
been NN NN O
clearly NN NN O
defined NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
While NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
from NN NN O
both NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
binds NN NN O
the NN NN O
peri NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
suggest NN NN O
that NN NN O
either NN NN O
a NN NN O
different NN NN O
protein NN NN O
binds NN NN O
to NN NN O
this NN NN O
site NN NN O
in NN NN O
monocytes NN NN O
versus NN NN O
T NN NN O
cells NN NN O
or NN NN O
that NN NN O
the NN NN O
protein NN NN O
recognizing NN NN O
this NN NN O
enhancer NN NN O
element NN NN O
undergoes NN NN O
differential NN NN O
modification NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
, NN NN O
thus NN NN O
supporting NN NN O
the NN NN O
transfection NN NN O
data NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
while NN NN O
specific NN NN O
constitutive NN NN O
binding NN NN O
to NN NN O
the NN NN O
peri NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
is NN NN O
seen NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
stimulation NN NN O
with NN NN O
phorbol NN NN O
esters NN NN O
induces NN NN O
additional NN NN O
, NN NN O
specific NN NN O
binding NN NN O
. NN NN O
   
Understanding NN NN O
the NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
function NN NN O
of NN NN O
the NN NN O
peri NN NN O
- NN NN O
kappa NN NN O
B NN NN O
factor NN NN O
may NN NN O
ultimately NN NN O
provide NN NN O
insight NN NN O
into NN NN O
the NN NN O
different NN NN O
role NN NN O
monocytes NN NN O
and NN NN O
T NN NN O
cells NN NN O
play NN NN O
in NN NN O
HIV NN NN O
pathogenesis NN NN O
. NN NN O
   
Thapsigargin NN NN O
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
in NN NN O
human NN NN O
peripheral NN NN O
and NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
via NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
independent NN NN O
mechanism NN NN O
. NN NN O
   
Thapsigargin NN NN O
( NN NN O
TG NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
, NN NN O
depletes NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
stores NN NN O
and NN NN O
induces NN NN O
a NN NN O
sustained NN NN O
Ca2 NN NN O
+ NN NN O
influx NN NN O
without NN NN O
altering NN NN O
phosphatidyl NN NN O
inositol NN NN O
levels NN NN O
. NN NN O
   
TG NN NN O
plus NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
but NN NN O
not NN NN O
TG NN NN O
alone NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
TG NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
TG NN NN O
induced NN NN O
increases NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
as NN NN O
well NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
by NN NN O
TG NN NN O
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
like NN NN O
PMA NN NN O
, NN NN O
TG NN NN O
markedly NN NN O
induced NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
TG NN NN O
and NN NN O
PMA NN NN O
exhibited NN NN O
a NN NN O
synergistic NN NN O
action NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
TG NN NN O
and NN NN O
PMA NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
through NN NN O
distinct NN NN O
pathways NN NN O
. NN NN O
   
PMA NN NN O
- NN NN O
but NN NN O
not NN NN O
TG NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
PKC NN NN O
inhibitor NN NN O
H7 NN NN O
, NN NN O
whereas NN NN O
TG NN NN O
- NN NN O
but NN NN O
not NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
was NN NN O
inhibited NN NN O
by NN NN O
cholera NN NN O
toxin NN NN O
, NN NN O
forskolin NN NN O
and NN NN O
1 NN NN O
, NN NN O
9 NN NN O
- NN NN O
dideoxy NN NN O
forskolin NN NN O
. NN NN O
   
In NN NN O
toto NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
TG NN NN O
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
through NN NN O
a NN NN O
PKC NN NN O
- NN NN O
independent NN NN O
pathway NN NN O
. NN NN O
   
A NN NN O
functional NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
required NN NN O
for NN NN O
p95vav NN NN B-Protein
activity NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
induces NN NN O
activation NN NN O
of NN NN O
multiple NN NN O
tyrosine NN NN O
kinases NN NN O
, NN NN O
resulting NN NN O
in NN NN O
phosphorylation NN NN O
of NN NN O
numerous NN NN O
intracellular NN NN O
substrates NN NN O
. NN NN O
   
One NN NN O
substrate NN NN O
is NN NN O
p95vav NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
expressed NN NN O
exclusively NN NN O
in NN NN O
hematopoietic NN NN O
and NN NN O
trophoblast NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
contains NN NN O
a NN NN O
number NN NN O
of NN NN O
structural NN NN O
motifs NN NN O
, NN NN O
including NN NN O
Src NN NN O
homology NN NN O
2 NN NN O
, NN NN O
Src NN NN O
homology NN NN O
3 NN NN O
, NN NN O
and NN NN O
pleckstrin NN NN O
homology NN NN O
domains NN NN O
and NN NN O
a NN NN O
putative NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
domain NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
p95vav NN NN B-Protein
in NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
processes NN NN O
is NN NN O
unclear NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
p95vav NN NN B-Protein
alone NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
leads NN NN O
to NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factors NN NN O
, NN NN O
including NN NN O
NFAT NN NN O
, NN NN O
involved NN NN O
in NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
p95vav NN NN B-Protein
synergizes NN NN O
with NN NN O
TCR NN NN O
stimulation NN NN O
in NN NN O
inducing NN NN O
NFAT NN NN O
- NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
NFAT NN NN O
activation NN NN O
by NN NN O
a NN NN O
G NN NN O
- NN NN O
protein NN NN O
- NN NN O
coupled NN NN O
receptor NN NN O
is NN NN O
not NN NN O
modulated NN NN O
by NN NN O
p95vav NN NN B-Protein
overexpression NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
effect NN NN O
is NN NN O
specific NN NN O
to NN NN O
the NN NN O
TCR NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
Although NN NN O
removal NN NN O
of NN NN O
the NN NN O
first NN NN O
67 NN NN O
amino NN NN O
acids NN NN O
of NN NN O
p95vav NN NN B-Protein
activates NN NN O
its NN NN O
transforming NN NN O
potential NN NN O
in NN NN O
NIH NN NN O
3T3 NN NN O
cells NN NN O
, NN NN O
this NN NN O
region NN NN O
appears NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
its NN NN O
function NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
p95vav NN NN B-Protein
- NN NN O
induced NN NN O
NFAT NN NN O
activation NN NN O
is NN NN O
not NN NN O
mimicked NN NN O
by NN NN O
Ras NN NN O
activation NN NN O
, NN NN O
though NN NN O
its NN NN O
function NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
Ras NN NN O
and NN NN O
Raf NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
activating NN NN O
function NN NN O
of NN NN O
p95vav NN NN B-Protein
is NN NN O
blocked NN NN O
by NN NN O
FK506 NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
its NN NN O
activity NN NN O
also NN NN O
depends NN NN O
on NN NN O
calcineurin NN NN B-Protein
. NN NN O
   
To NN NN O
further NN NN O
dissect NN NN O
p95vav NN NN B-Protein
involvement NN NN O
in NN NN O
TCR NN NN O
signaling NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
various NN NN O
Jurkat NN NN O
mutants NN NN O
deficient NN NN O
in NN NN O
TCR NN NN O
signaling NN NN O
function NN NN O
or NN NN O
TCR NN NN O
expression NN NN O
and NN NN O
showed NN NN O
that NN NN O
an NN NN O
intact NN NN O
TCR NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
required NN NN O
for NN NN O
p95vav NN NN B-Protein
to NN NN O
function NN NN O
. NN NN O
   
However NN NN O
, NN NN O
overexpression NN NN O
of NN NN O
p95vav NN NN B-Protein
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
influence NN NN O
TCR NN NN O
- NN NN O
induced NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
or NN NN O
increases NN NN O
in NN NN O
cytoplasmic NN NN O
free NN NN O
calcium NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
p95vav NN NN B-Protein
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
at NN NN O
an NN NN O
yet NN NN O
unidentified NN NN O
proximal NN NN O
position NN NN O
in NN NN O
the NN NN O
TCR NN NN O
signaling NN NN O
cascade NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
phosphatase NN NN O
inhibitors NN NN O
involves NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
at NN NN O
phosphatase NN NN O
2A NN NN O
- NN NN O
sensitive NN NN O
sites NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
various NN NN O
cellular NN NN O
stimuli NN NN O
involves NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
subsequent NN NN O
degradation NN NN O
of NN NN O
its NN NN O
inhibitor NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
although NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
remains NN NN O
unclear NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
phosphatases NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
was NN NN O
investigated NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
incubation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
with NN NN O
low NN NN O
concentrations NN NN O
( NN NN O
approximately NN NN O
1 NN NN O
- NN NN O
5 NN NN O
nM NN NN O
) NN NN O
of NN NN O
calyculin NN NN O
A NN NN O
or NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
potent NN NN O
inhibitors NN NN O
of NN NN O
protein NN NN O
phosphatase NN NN O
type NN NN O
1 NN NN O
( NN NN O
PP NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
type NN NN O
2A NN NN O
( NN NN O
PP NN NN O
- NN NN O
2A NN NN O
) NN NN O
, NN NN O
induces NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
even NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
any NN NN O
cellular NN NN O
stimulus NN NN O
. NN NN O
   
This NN NN O
action NN NN O
of NN NN O
the NN NN O
phosphatase NN NN O
inhibitors NN NN O
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
RelA NN NN B-Protein
. NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
heterodimer NN NN O
, NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
agents NN NN O
that NN NN O
block NN NN O
the NN NN O
induction NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
phosphorylated NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
from NN NN O
calyculin NN NN O
A NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
that NN NN O
from NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
cells NN NN O
, NN NN O
is NN NN O
sensitive NN NN O
to NN NN O
PP NN NN O
- NN NN O
2A NN NN O
in NN NN O
vitro NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
existence NN NN O
of NN NN O
fundamental NN NN O
differences NN NN O
in NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
induced NN NN O
by NN NN O
the NN NN O
two NN NN O
different NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inducers NN NN O
. NN NN O
   
However NN NN O
, NN NN O
induction NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
by NN NN O
both NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
the NN NN O
phosphatase NN NN O
inhibitors NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
subsequent NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
We NN NN O
further NN NN O
demonstrate NN NN O
that NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
and NN NN O
calyculin NN NN O
A NN NN O
- NN NN O
induced NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
exhibits NN NN O
similar NN NN O
but NN NN O
not NN NN O
identical NN NN O
sensitivities NN NN O
to NN NN O
a NN NN O
proteasome NN NN O
inhibitor NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
mediated NN NN O
through NN NN O
both NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
inducible NN NN O
and NN NN O
the NN NN O
PP NN NN O
- NN NN O
2A NN NN O
- NN NN O
opposing NN NN O
kinases NN NN O
, NN NN O
may NN NN O
serve NN NN O
to NN NN O
target NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
for NN NN O
proteasome NN NN O
- NN NN O
mediated NN NN O
degradation NN NN O
. NN NN O
   
Functional NN NN O
roles NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
and NN NN O
the NN NN O
high NN NN O
mobility NN NN O
group NN NN O
protein NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
in NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
gene NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
is NN NN O
expressed NN NN O
in NN NN O
B NN NN O
cells NN NN O
, NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
and NN NN O
in NN NN O
antigen NN NN O
- NN NN O
presenting NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
expression NN NN O
is NN NN O
inducible NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
expression NN NN O
in NN NN O
class NN NN O
II NN NN O
- NN NN O
positive NN NN O
B NN NN O
cell NN NN O
lines NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
high NN NN O
mobility NN NN O
group NN NN O
protein NN NN O
( NN NN O
HMG NN NN O
) NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
binds NN NN O
to NN NN O
multiple NN NN O
sites NN NN O
within NN NN O
the NN NN O
DRA NN NN O
promoter NN NN O
, NN NN O
including NN NN O
the NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
Coexpression NN NN O
of NN NN O
HMG NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
cell NN NN O
lines NN NN O
lacking NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
results NN NN O
in NN NN O
high NN NN O
levels NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
in NN NN O
vitro NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
studies NN NN O
reveal NN NN O
that NN NN O
HMG NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
stimulates NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
binding NN NN O
to NN NN O
the NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
promoter NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
and NN NN O
HMG NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
may NN NN O
synergize NN NN O
to NN NN O
activate NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
is NN NN O
not NN NN O
involved NN NN O
in NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
of NN NN O
the NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
but NN NN O
antisense NN NN O
HMG NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
dramatically NN NN O
decreases NN NN O
the NN NN O
level NN NN O
of NN NN O
induction NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
distinct NN NN O
sets NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
two NN NN O
modes NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
expression NN NN O
, NN NN O
and NN NN O
that NN NN O
HMG NN NN O
I NN NN B-Protein
/ NN NN I-Protein
Y NN NN I-Protein
may NN NN O
be NN NN O
important NN NN O
for NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
, NN NN O
and NN NN O
is NN NN O
essential NN NN O
for NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
4 NN NN I-Protein
activates NN NN O
a NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
Stat NN NN O
) NN NN O
protein NN NN O
which NN NN O
interacts NN NN O
with NN NN O
an NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
site NN NN O
- NN NN O
like NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
I NN NN O
epsilon NN NN O
exon NN NN O
in NN NN O
a NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
the NN NN O
involvement NN NN O
of NN NN O
Janus NN NN B-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
Stat NN NN O
. NN NN O
   
Germ NN NN O
line NN NN O
C NN NN O
transcripts NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
the NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
, NN NN O
BL NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
Utilizing NN NN O
a NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
site NN NN O
- NN NN O
like NN NN O
DNA NN NN O
sequence NN NN O
element NN NN O
located NN NN O
upstream NN NN O
of NN NN O
the NN NN O
I NN NN O
epsilon NN NN O
exon NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
by NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
induced NN NN O
a NN NN O
binding NN NN O
activity NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
nucleus NN NN O
of NN NN O
BL NN NN O
- NN NN O
2 NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
was NN NN O
designated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
NAF NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
nuclear NN NN O
- NN NN O
activating NN NN O
factors NN NN O
) NN NN O
and NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
tyrosine NN NN O
phosphoprotein NN NN O
, NN NN O
which NN NN O
translocates NN NN O
from NN NN O
the NN NN O
cytosol NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
upon NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
treatment NN NN O
. NN NN O
   
Because NN NN O
these NN NN O
are NN NN O
the NN NN O
characteristics NN NN O
of NN NN O
a NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
Stat NN NN O
) NN NN O
protein NN NN O
, NN NN O
we NN NN O
determined NN NN O
whether NN NN O
antibodies NN NN O
to NN NN O
Stat NN NN O
proteins NN NN O
will NN NN O
interfere NN NN O
with NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
and NN NN O
found NN NN O
that NN NN O
antibodies NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
Stat NN NN I-Protein
, NN NN O
also NN NN O
known NN NN O
as NN NN O
Stat6 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
antibodies NN NN O
to NN NN O
other NN NN O
Stat NN NN O
proteins NN NN O
, NN NN O
interfere NN NN O
with NN NN O
the NN NN O
formation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
NAF NN NN O
complex NN NN O
. NN NN O
   
Congruous NN NN O
with NN NN O
the NN NN O
involvement NN NN O
of NN NN O
a NN NN O
Stat NN NN O
protein NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
induced NN NN O
robust NN NN O
Janus NN NN B-Protein
kinase NN NN I-Protein
3 NN NN I-Protein
( NN NN O
JAK3 NN NN B-Protein
) NN NN O
activity NN NN O
in NN NN O
BL NN NN O
- NN NN O
2 NN NN O
cells NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
JAK3 NN NN B-Protein
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
Stat NN NN O
into NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
produced NN NN O
an NN NN O
intracellular NN NN O
activity NN NN O
which NN NN O
bound NN NN O
the NN NN O
same NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
activation NN NN O
site NN NN O
- NN NN O
like NN NN O
sequence NN NN O
and NN NN O
comigrated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
NAF NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
NAF NN NN O
is NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
Stat NN NN O
, NN NN O
which NN NN O
is NN NN O
activated NN NN O
by NN NN O
JAK3 NN NN B-Protein
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
receptor NN NN O
engagement NN NN O
. NN NN O
   
An NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
pathway NN NN O
of NN NN O
DNA NN NN O
damage NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Lymphocytes NN NN O
are NN NN O
particularly NN NN O
susceptible NN NN O
to NN NN O
DNA NN NN O
damage NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
, NN NN O
a NN NN O
response NN NN O
which NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
form NN NN O
of NN NN O
' NN NN O
altruistic NN NN O
suicide NN NN O
' NN NN O
to NN NN O
counter NN NN O
their NN NN O
intrinsic NN NN O
high NN NN O
potential NN NN O
for NN NN O
mutation NN NN O
and NN NN O
clonal NN NN O
expansion NN NN O
. NN NN O
   
The NN NN O
tumour NN NN O
suppressor NN NN O
p53 NN NN B-Protein
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
regulate NN NN O
this NN NN O
type NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
thymocytes NN NN O
, NN NN O
but NN NN O
an NN NN O
as NN NN O
yet NN NN O
unknown NN NN O
, NN NN O
p53 NN NN B-Protein
- NN NN O
independent NN NN O
pathway NN NN O
( NN NN O
s NN NN O
) NN NN O
appears NN NN O
to NN NN O
mediate NN NN O
the NN NN O
same NN NN O
event NN NN O
in NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
mature NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
DNA NN NN O
damage NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
these NN NN O
T NN NN O
lymphocytes NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
antioncogenic NN NN O
transcription NN NN O
factor NN NN O
interferon NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
IRF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Thus NN NN O
two NN NN O
different NN NN O
anti NN NN O
- NN NN O
onco NN NN O
- NN NN O
genic NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
p53 NN NN B-Protein
and NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
are NN NN O
required NN NN O
for NN NN O
distinct NN NN O
apoptotic NN NN O
pathways NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
mitogen NN NN O
induction NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
converting NN NN I-Protein
enzyme NN NN I-Protein
( NN NN O
ICE NN NN B-Protein
) NN NN O
gene NN NN O
, NN NN O
a NN NN O
mammalian NN NN O
homologue NN NN O
of NN NN O
the NN NN O
Caenorhabditis NN NN O
elegans NN NN O
cell NN NN O
death NN NN O
gene NN NN O
ced NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
is NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
. NN NN O
   
Ectopic NN NN O
overexpression NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
results NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
gene NN NN O
for NN NN O
ICE NN NN B-Protein
and NN NN O
enhances NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
cells NN NN O
to NN NN O
radiation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
expression NN NN O
by NN NN O
hydroxyurea NN NN O
in NN NN O
human NN NN O
K562 NN NN O
cells NN NN O
during NN NN O
erythroid NN NN O
differentiation NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
Biochim NN NN O
Biophys NN NN O
Acta NN NN O
1995 NN NN O
Dec NN NN O
27 NN NN O
; NN NN O
1264 NN NN O
( NN NN O
3 NN NN O
) NN NN O
: NN NN O
409 NN NN O
] NN NN O
   
Hydroxyurea NN NN O
( NN NN O
HU NN NN O
) NN NN O
is NN NN O
an NN NN O
antitumor NN NN O
agent NN NN O
which NN NN O
also NN NN O
induces NN NN O
hemoglobinization NN NN O
during NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
HU NN NN O
stimulates NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
fetal NN NN O
hemoglobin NN NN O
in NN NN O
sickle NN NN O
cell NN NN O
anemia NN NN O
patients NN NN O
. NN NN O
   
To NN NN O
further NN NN O
understand NN NN O
its NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
HU NN NN O
on NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
prior NN NN O
to NN NN O
the NN NN O
onset NN NN O
of NN NN O
erythroid NN NN O
differentiation NN NN O
of NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
HU NN NN O
induced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
stimulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
synthesis NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
was NN NN O
elevated NN NN O
4 NN NN O
to NN NN O
7 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
by NN NN O
HU NN NN O
within NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
This NN NN O
was NN NN O
followed NN NN O
by NN NN O
a NN NN O
gradual NN NN O
decline NN NN O
to NN NN O
the NN NN O
basal NN NN O
level NN NN O
by NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Both NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
and NN NN O
actinomycin NN NN O
D NN NN O
pulse NN NN O
experiments NN NN O
strongly NN NN O
indicate NN NN O
that NN NN O
HU NN NN O
regulates NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
expression NN NN O
by NN NN O
increasing NN NN O
the NN NN O
rate NN NN O
of NN NN O
synthesis NN NN O
as NN NN O
well NN NN O
as NN NN O
stabilizing NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
jun NN NN O
protein NN NN O
was NN NN O
elevated NN NN O
by NN NN O
2 NN NN O
to NN NN O
5 NN NN O
- NN NN O
fold NN NN O
within NN NN O
4 NN NN O
h NN NN O
in NN NN O
HU NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
concentrations NN NN O
of NN NN O
HU NN NN O
below NN NN O
250 NN NN O
microM NN NN O
slightly NN NN O
increased NN NN O
the NN NN O
5X NN NN O
AP NN NN O
- NN NN O
1 NN NN O
/ NN NN O
CAT NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
HU NN NN O
induces NN NN O
both NN NN O
transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcription NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
during NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
human NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
. NN NN O
   
Organizational NN NN O
analysis NN NN O
and NN NN O
mapping NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
- NN NN O
responsive NN NN O
elements NN NN O
regulating NN NN O
expression NN NN O
in NN NN O
platelets NN NN O
. NN NN O
   
Platelet NN NN O
thromboxane NN NN B-Protein
receptors NN NN I-Protein
are NN NN O
acutely NN NN O
and NN NN O
reversibly NN NN O
upregulated NN NN O
after NN NN O
acute NN NN O
myocardial NN NN O
infarction NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
if NN NN O
platelet NN NN O
thromboxane NN NN B-Protein
receptors NN NN I-Protein
are NN NN O
under NN NN O
transcriptional NN NN O
control NN NN O
, NN NN O
we NN NN O
isolated NN NN O
and NN NN O
characterized NN NN O
human NN NN O
genomic NN NN O
DNA NN NN O
clones NN NN O
containing NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
exon NN NN O
- NN NN O
intron NN NN O
structure NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
portion NN NN O
of NN NN O
the NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
was NN NN O
determined NN NN O
initially NN NN O
by NN NN O
comparing NN NN O
the NN NN O
nucleotide NN NN O
sequence NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
genomic NN NN O
clone NN NN O
with NN NN O
that NN NN O
of NN NN O
a NN NN O
novel NN NN O
human NN NN O
uterine NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
cDNA NN NN O
that NN NN O
extended NN NN O
the NN NN O
mRNA NN NN O
141 NN NN O
bp NN NN O
further NN NN O
upstream NN NN O
than NN NN O
the NN NN O
previously NN NN O
identified NN NN O
human NN NN O
placental NN NN O
cDNA NN NN O
. NN NN O
   
A NN NN O
major NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
was NN NN O
located NN NN O
in NN NN O
three NN NN O
human NN NN O
tissues NN NN O
approximately NN NN O
560 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
translation NN NN O
initiation NN NN O
codon NN NN O
and NN NN O
380 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
any NN NN O
previously NN NN O
identified NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
The NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
has NN NN O
neither NN NN O
a NN NN O
TATA NN NN O
nor NN NN O
a NN NN O
CAAT NN NN O
consensus NN NN O
site NN NN O
. NN NN O
   
Promoter NN NN O
function NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
was NN NN O
evaluated NN NN O
by NN NN O
transfection NN NN O
of NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
promoter NN NN O
/ NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
chimera NN NN O
plasmids NN NN O
into NN NN O
platelet NN NN O
- NN NN O
like NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
Thromboxane NN NN B-Protein
receptor NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
CAT NN NN B-Protein
expression NN NN O
, NN NN O
was NN NN O
relatively NN NN O
weak NN NN O
but NN NN O
was NN NN O
significantly NN NN O
enhanced NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
treatment NN NN O
. NN NN O
   
Functional NN NN O
analysis NN NN O
of NN NN O
5 NN NN O
' NN NN O
deletion NN NN O
constructs NN NN O
in NN NN O
transfected NN NN O
K562 NN NN O
cells NN NN O
and NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
localized NN NN O
the NN NN O
major NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
responsive NN NN O
motifs NN NN O
in NN NN O
the NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
promoter NN NN O
to NN NN O
a NN NN O
cluster NN NN O
of NN NN O
activator NN NN O
protein NN NN O
- NN NN O
2 NN NN O
( NN NN O
AP NN NN O
- NN NN O
2 NN NN O
) NN NN O
binding NN NN O
consensus NN NN O
sites NN NN O
located NN NN O
approximately NN NN O
1 NN NN O
. NN NN O
8 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
from NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
are NN NN O
the NN NN O
first NN NN O
to NN NN O
determine NN NN O
the NN NN O
structure NN NN O
and NN NN O
organization NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
and NN NN O
demonstrate NN NN O
that NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
expression NN NN O
can NN NN O
be NN NN O
regulated NN NN O
by NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
via NN NN O
induction NN NN O
of NN NN O
an NN NN O
AP NN NN O
- NN NN O
2 NN NN O
- NN NN O
like NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
to NN NN O
upstream NN NN O
promoter NN NN O
elements NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
the NN NN O
mechanism NN NN O
for NN NN O
previously NN NN O
described NN NN O
upregulation NN NN O
of NN NN O
platelet NN NN O
thromboxane NN NN B-Protein
receptors NN NN I-Protein
after NN NN O
acute NN NN O
myocardial NN NN O
infarction NN NN O
is NN NN O
increased NN NN O
thromboxane NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
platelet NN NN O
- NN NN O
progenitor NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
through NN NN O
CD28 NN NN B-Protein
requires NN NN O
reactive NN NN O
oxygen NN NN O
production NN NN O
by NN NN O
5 NN NN O
- NN NN O
lipoxygenase NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
CD28 NN NN B-Protein
surface NN NN O
receptor NN NN O
provides NN NN O
a NN NN O
major NN NN O
costimulatory NN NN O
signal NN NN O
for NN NN O
T NN NN O
cell NN NN O
activation NN NN O
resulting NN NN O
in NN NN O
enhanced NN NN O
production NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
and NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
In NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
we NN NN O
show NN NN O
that NN NN O
CD28 NN NN B-Protein
ligation NN NN O
leads NN NN O
to NN NN O
the NN NN O
rapid NN NN O
intracellular NN NN O
formation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
( NN NN O
ROIs NN NN O
) NN NN O
which NN NN O
are NN NN O
required NN NN O
for NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
CD28 NN NN B-Protein
- NN NN O
responsive NN NN O
complex NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Delineation NN NN O
of NN NN O
the NN NN O
CD28 NN NN B-Protein
signaling NN NN O
cascade NN NN O
was NN NN O
found NN NN O
to NN NN O
involve NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
followed NN NN O
by NN NN O
the NN NN O
activation NN NN O
of NN NN O
phospholipase NN NN O
A2 NN NN O
and NN NN O
5 NN NN O
- NN NN O
lipoxygenase NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
lipoxygenase NN NN O
metabolites NN NN O
activate NN NN O
ROI NN NN O
formation NN NN O
which NN NN O
then NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
should NN NN O
be NN NN O
useful NN NN O
for NN NN O
therapeutic NN NN O
strategies NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
immunosuppressants NN NN O
targeting NN NN O
the NN NN O
CD28 NN NN B-Protein
costimulatory NN NN O
pathway NN NN O
. NN NN O
   
Infection NN NN O
and NN NN O
replication NN NN O
of NN NN O
Tat NN NN B-Protein
- NN NN O
human NN NN O
immunodeficiency NN NN O
viruses NN NN O
: NN NN O
genetic NN NN O
analyses NN NN O
of NN NN O
LTR NN NN O
and NN NN O
tat NN NN B-Protein
mutations NN NN O
in NN NN O
primary NN NN O
and NN NN O
long NN NN O
- NN NN O
term NN NN O
human NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Tat NN NN B-Protein
is NN NN O
an NN NN O
essential NN NN O
regulatory NN NN O
protein NN NN O
for NN NN O
the NN NN O
replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
. NN NN O
   
Mutations NN NN O
in NN NN O
the NN NN O
tat NN NN B-Protein
gene NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
block NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Several NN NN O
studies NN NN O
have NN NN O
established NN NN O
that NN NN O
Tat NN NN B-Protein
releases NN NN O
an NN NN O
elongation NN NN O
block NN NN O
to NN NN O
the NN NN O
transcription NN NN O
of NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
known NN NN O
whether NN NN O
this NN NN O
mechanism NN NN O
alone NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
explain NN NN O
the NN NN O
block NN NN O
to NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
when NN NN O
Tat NN NN B-Protein
is NN NN O
absent NN NN O
. NN NN O
   
It NN NN O
is NN NN O
possible NN NN O
that NN NN O
Tat NN NN B-Protein
is NN NN O
also NN NN O
needed NN NN O
for NN NN O
other NN NN O
functions NN NN O
during NN NN O
HIV NN NN O
replication NN NN O
. NN NN O
   
To NN NN O
test NN NN O
these NN NN O
hypotheses NN NN O
, NN NN O
we NN NN O
studied NN NN O
several NN NN O
tat NN NN B-Protein
mutants NN NN O
, NN NN O
including NN NN O
two NN NN O
stop NN NN O
codon NN NN O
mutants NN NN O
and NN NN O
one NN NN O
deletion NN NN O
mutant NN NN O
using NN NN O
replication NN NN O
- NN NN O
competent NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
constructs NN NN O
carrying NN NN O
wild NN NN O
- NN NN O
type NN NN O
or NN NN O
mutant NN NN O
LTRs NN NN O
with NN NN O
modifications NN NN O
in NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
/ NN NN O
or NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
Tat NN NN B-Protein
- NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
with NN NN O
wild NN NN O
- NN NN O
type NN NN O
LTRs NN NN O
can NN NN O
replicate NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
and NN NN O
the NN NN O
virus NN NN O
produced NN NN O
from NN NN O
HeLa NN NN O
cells NN NN O
can NN NN O
infect NN NN O
primary NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
the NN NN O
propagation NN NN O
of NN NN O
the NN NN O
Tat NN NN B-Protein
mutants NN NN O
containing NN NN O
wild NN NN O
- NN NN O
type NN NN O
LTRs NN NN O
was NN NN O
less NN NN O
efficient NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
LTR NN NN O
- NN NN O
modified NN NN O
Tat NN NN B-Protein
mutants NN NN O
. NN NN O
   
Large NN NN O
amounts NN NN O
of NN NN O
viral NN NN O
RNA NN NN O
and NN NN O
particles NN NN O
were NN NN O
synthesized NN NN O
in NN NN O
infections NN NN O
established NN NN O
using NN NN O
the NN NN O
tat NN NN B-Protein
mutants NN NN O
that NN NN O
contain NN NN O
modified NN NN O
LTRs NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
efficient NN NN O
propagation NN NN O
of NN NN O
the NN NN O
LTR NN NN O
- NN NN O
modified NN NN O
tat NN NN B-Protein
mutants NN NN O
was NN NN O
restricted NN NN O
to NN NN O
some NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
that NN NN O
have NN NN O
been NN NN O
transformed NN NN O
with NN NN O
other NN NN O
viruses NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
despite NN NN O
its NN NN O
essential NN NN O
role NN NN O
for NN NN O
releasing NN NN O
an NN NN O
elongation NN NN O
block NN NN O
, NN NN O
Tat NN NN B-Protein
is NN NN O
not NN NN O
otherwise NN NN O
absolutely NN NN O
required NN NN O
for NN NN O
synthesis NN NN O
of NN NN O
full NN NN O
- NN NN O
length NN NN O
HIV NN NN O
transcripts NN NN O
and NN NN O
assembly NN NN O
of NN NN O
virus NN NN O
particles NN NN O
. NN NN O
   
Direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
viral NN NN O
genomes NN NN O
and NN NN O
reinfection NN NN O
kinetics NN NN O
showed NN NN O
no NN NN O
evidence NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
reversion NN NN O
even NN NN O
after NN NN O
prolonged NN NN O
infection NN NN O
with NN NN O
the NN NN O
Tat NN NN B-Protein
- NN NN O
virus NN NN O
. NN NN O
   
The NN NN O
implications NN NN O
for NN NN O
in NN NN O
vivo NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
potential NN NN O
application NN NN O
of NN NN O
this NN NN O
system NN NN O
to NN NN O
the NN NN O
study NN NN O
of NN NN O
alternative NN NN O
Tat NN NN B-Protein
function NN NN O
are NN NN O
discussed NN NN O
. NN NN O
   
Activation NN NN O
and NN NN O
expression NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factors NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
NFATp NN NN B-Protein
and NN NN O
NFATc NN NN B-Protein
, NN NN O
in NN NN O
human NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
: NN NN O
regulation NN NN O
upon NN NN O
CD16 NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
The NN NN O
putative NN NN O
factors NN NN O
that NN NN O
couple NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
from NN NN O
surface NN NN O
receptors NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
cytokine NN NN O
synthesis NN NN O
in NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cells NN NN O
have NN NN O
not NN NN O
been NN NN O
elucidated NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFATp NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
- NN NN O
sensitive NN NN O
factor NN NN O
that NN NN O
regulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
, NN NN O
mediates NN NN O
CD16 NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
in NN NN O
human NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
CD16 NN NN O
( NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIIIA NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
mRNA NN NN O
in NN NN O
NK NN NN O
cells NN NN O
occurs NN NN O
via NN NN O
a NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
mechanism NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
NK NN NN O
cells NN NN O
with NN NN O
CD16 NN NN O
ligands NN NN O
induces NN NN O
NFAT NN NN O
- NN NN O
like NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
these NN NN O
cells NN NN O
, NN NN O
as NN NN O
detected NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
This NN NN O
occurs NN NN O
with NN NN O
fast NN NN O
kinetics NN NN O
after NN NN O
stimulation NN NN O
, NN NN O
via NN NN O
a NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
and NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
mechanism NN NN O
that NN NN O
does NN NN O
not NN NN O
require NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
NK NN NN O
cell NN NN O
NFAT NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
of NN NN O
nonstimulated NN NN O
cells NN NN O
, NN NN O
migrates NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
upon NN NN O
stimulation NN NN O
, NN NN O
and NN NN O
can NN NN O
associate NN NN O
with NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
molecules NN NN O
, NN NN O
NFATp NN NN B-Protein
and NN NN O
NFATc NN NN B-Protein
, NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
mediate NN NN O
NFAT NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
supershift NN NN O
assays NN NN O
using NN NN O
NFATp NN NN B-Protein
- NN NN O
and NN NN O
NFATc NN NN B-Protein
- NN NN O
specific NN NN O
antibodies NN NN O
indicate NN NN O
that NN NN O
NK NN NN O
cell NN NN O
activation NN NN O
early NN NN O
after NN NN O
CD16 NN NN O
ligand NN NN O
binding NN NN O
involves NN NN O
primarily NN NN O
, NN NN O
if NN NN O
not NN NN O
exclusively NN NN O
, NN NN O
NFATp NN NN B-Protein
, NN NN O
and NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
shows NN NN O
that NN NN O
this NN NN O
has NN NN O
the NN NN O
same NN NN O
electrophoretic NN NN O
mobility NN NN O
( NN NN O
approximately NN NN O
120 NN NN O
kD NN NN O
) NN NN O
as NN NN O
that NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
NK NN NN O
cells NN NN O
do NN NN O
not NN NN O
express NN NN O
NFATc NN NN B-Protein
constitutively NN NN O
, NN NN O
but NN NN O
NFATc NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
is NN NN O
induced NN NN O
in NN NN O
these NN NN O
cells NN NN O
within NN NN O
2 NN NN O
h NN NN O
of NN NN O
stimulation NN NN O
with NN NN O
CD16 NN NN O
ligands NN NN O
. NN NN O
   
However NN NN O
, NN NN O
supershift NN NN O
assays NN NN O
using NN NN O
the NN NN O
available NN NN O
mAb NN NN O
recognizing NN NN O
the NN NN O
T NN NN O
cell NN NN O
NFATc NN NN B-Protein
revealed NN NN O
no NN NN O
detectable NN NN O
NFATc NN NN B-Protein
protein NN NN O
in NN NN O
nuclear NN NN O
and NN NN O
cytoplasmic NN NN O
extracts NN NN O
from NN NN O
CD16 NN NN O
- NN NN O
or NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
at NN NN O
any NN NN O
time NN NN O
tested NN NN O
, NN NN O
up NN NN O
to NN NN O
4 NN NN O
h NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
the NN NN O
first NN NN O
direct NN NN O
evidence NN NN O
that NN NN O
both NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
NFATp NN NN B-Protein
and NN NN O
NFATc NN NN B-Protein
, NN NN O
are NN NN O
expressed NN NN O
in NN NN O
human NN NN O
NK NN NN O
cells NN NN O
, NN NN O
and NN NN O
that NN NN O
their NN NN O
activation NN NN O
and NN NN O
/ NN NN O
or NN NN O
expression NN NN O
can NN NN O
be NN NN O
regulated NN NN O
in NN NN O
primary NN NN O
cells NN NN O
by NN NN O
a NN NN O
single NN NN O
stimulus NN NN O
, NN NN O
that NN NN O
, NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
CD16 NN NN O
in NN NN O
NK NN NN O
cells NN NN O
, NN NN O
results NN NN O
in NN NN O
early NN NN O
activation NN NN O
of NN NN O
NFATp NN NN B-Protein
and NN NN O
subsequently NN NN O
induced NN NN O
expression NN NN O
of NN NN O
NFATc NN NN B-Protein
mRNA NN NN O
. NN NN O
   
Constitutive NN NN O
activation NN NN O
of NN NN O
different NN NN O
Jak NN NN O
tyrosine NN NN O
kinases NN NN O
in NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
tax NN NN B-Protein
protein NN NN O
or NN NN O
virus NN NN O
- NN NN O
transformed NN NN O
cells NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
causes NN NN O
an NN NN O
adult NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
in NN NN O
humans NN NN O
. NN NN O
   
The NN NN O
viral NN NN O
encoded NN NN O
protein NN NN O
tax NN NN B-Protein
, NN NN O
is NN NN O
thought NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
oncogenesis NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
data NN NN O
obtained NN NN O
from NN NN O
a NN NN O
tax NN NN B-Protein
transgenic NN NN O
mouse NN NN O
model NN NN O
revealed NN NN O
that NN NN O
tax NN NN B-Protein
transforms NN NN O
mouse NN NN O
fibroblasts NN NN O
but NN NN O
not NN NN O
thymocytes NN NN O
, NN NN O
despite NN NN O
comparable NN NN O
levels NN NN O
of NN NN O
tax NN NN B-Protein
expression NN NN O
in NN NN O
both NN NN O
tissues NN NN O
. NN NN O
   
Constitutive NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
a NN NN O
130 NN NN O
- NN NN O
kD NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
tax NN NN B-Protein
transformed NN NN O
fibroblast NN NN O
B NN NN O
line NN NN O
and NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
transformed NN NN O
human NN NN O
lymphoid NN NN O
lines NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
thymocytes NN NN O
from NN NN O
Thy NN NN O
- NN NN O
tax NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
Phosphotyrosine NN NN O
immunoprecipitation NN NN O
followed NN NN O
by NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
with NN NN O
a NN NN O
set NN NN O
of NN NN O
Jak NN NN O
kinase NN NN O
specific NN NN O
antibodies NN NN O
, NN NN O
identified NN NN O
p130 NN NN O
as NN NN O
Jak2 NN NN B-Protein
in NN NN O
the NN NN O
tax NN NN B-Protein
transformed NN NN O
mouse NN NN O
fibroblastic NN NN O
cell NN NN O
line NN NN O
and NN NN O
Jak3 NN NN B-Protein
in NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
transformed NN NN O
human NN NN O
T NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Phosphorylation NN NN O
of NN NN O
Jak2 NN NN B-Protein
in NN NN O
tax NN NN B-Protein
transformed NN NN O
cells NN NN O
resulted NN NN O
from NN NN O
high NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
Tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
this NN NN O
protein NN NN O
could NN NN O
also NN NN O
be NN NN O
induced NN NN O
in NN NN O
Balb NN NN O
/ NN NN O
c3T3 NN NN O
cells NN NN O
using NN NN O
a NN NN O
supernatant NN NN O
from NN NN O
the NN NN O
B NN NN O
line NN NN O
, NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
induction NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Both NN NN O
phosphorylation NN NN O
and NN NN O
proliferation NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
neutralizing NN NN O
antibodies NN NN O
. NN NN O
   
Constitutive NN NN O
phosphorylation NN NN O
of NN NN O
Jak NN NN O
kinases NN NN O
may NN NN O
facilitate NN NN O
tumor NN NN O
growth NN NN O
in NN NN O
both NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
infected NN NN O
human NN NN O
T NN NN O
cells NN NN O
and NN NN O
the NN NN O
transgenic NN NN O
mouse NN NN O
model NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
by NN NN O
proteins NN NN O
binding NN NN O
to NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Sp1 NN NN B-Protein
motifs NN NN O
. NN NN O
   
Erythropoietin NN NN B-Protein
( NN NN O
Epo NN NN B-Protein
) NN NN O
, NN NN O
the NN NN O
primary NN NN O
regulator NN NN O
of NN NN O
the NN NN O
production NN NN O
of NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
acts NN NN O
by NN NN O
binding NN NN O
to NN NN O
a NN NN O
cell NN NN O
surface NN NN O
receptor NN NN O
( NN NN O
EpoR NN NN B-Protein
) NN NN O
on NN NN O
erythroid NN NN O
progenitors NN NN O
. NN NN O
   
We NN NN O
used NN NN O
deletion NN NN O
analysis NN NN O
and NN NN O
transfection NN NN O
assays NN NN O
with NN NN O
reporter NN NN O
gene NN NN O
constructs NN NN O
to NN NN O
examine NN NN O
the NN NN O
transcription NN NN O
control NN NN O
elements NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
EpoR NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
erythroid NN NN O
cells NN NN O
most NN NN O
of NN NN O
the NN NN O
transcription NN NN O
activity NN NN O
was NN NN O
contained NN NN O
in NN NN O
a NN NN O
150 NN NN O
bp NN NN O
promoter NN NN O
fragment NN NN O
with NN NN O
binding NN NN O
sites NN NN O
for NN NN O
transcription NN NN O
factors NN NN O
AP2 NN NN O
, NN NN O
Sp1 NN NN B-Protein
and NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
150 NN NN O
bp NN NN O
hEpoR NN NN B-Protein
promoter NN NN O
exhibited NN NN O
high NN NN O
and NN NN O
low NN NN O
activity NN NN O
in NN NN O
erythroid NN NN O
OCIM1 NN NN O
and NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
, NN NN O
reflecting NN NN O
the NN NN O
high NN NN O
and NN NN O
low NN NN O
levels NN NN O
of NN NN O
constitutive NN NN O
hEpoR NN NN B-Protein
expression NN NN O
. NN NN O
   
The NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
in NN NN O
this NN NN O
promoter NN NN O
lacking NN NN O
a NN NN O
TATA NN NN O
sequence NN NN O
were NN NN O
necessary NN NN O
for NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
transcription NN NN O
activation NN NN O
. NN NN O
   
Protein NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
studies NN NN O
suggested NN NN O
that NN NN O
Sp1 NN NN B-Protein
and NN NN O
two NN NN O
other NN NN O
CCGCCC NN NN O
binding NN NN O
proteins NN NN O
from NN NN O
erythroid NN NN O
and NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cells NN NN O
could NN NN O
bind NN NN O
to NN NN O
the NN NN O
Sp1 NN NN B-Protein
binding NN NN O
motif NN NN O
. NN NN O
   
By NN NN O
increasing NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
levels NN NN O
via NN NN O
co NN NN O
- NN NN O
transfection NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
transactivate NN NN O
the NN NN O
hEpoR NN NN B-Protein
promoter NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
and NN NN O
non NN NN O
- NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
highly NN NN O
active NN NN O
OCIM1 NN NN O
cells NN NN O
, NN NN O
although NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
comparable NN NN O
in NN NN O
OCIM1 NN NN O
and NN NN O
K562 NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
when NN NN O
we NN NN O
mutated NN NN O
the NN NN O
Sp1 NN NN B-Protein
site NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
marked NN NN O
decrease NN NN O
in NN NN O
hEpoR NN NN B-Protein
promoter NN NN O
activity NN NN O
, NN NN O
we NN NN O
could NN NN O
restore NN NN O
transactivation NN NN O
by NN NN O
increasing NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
levels NN NN O
in NN NN O
OCIM1 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
while NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
can NN NN O
transactivate NN NN O
the NN NN O
EpoR NN NN B-Protein
promoter NN NN O
, NN NN O
the NN NN O
level NN NN O
of NN NN O
hEpoR NN NN B-Protein
gene NN NN O
expression NN NN O
does NN NN O
not NN NN O
depend NN NN O
on NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alone NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
hEpoR NN NN B-Protein
transcription NN NN O
activity NN NN O
depends NN NN O
on NN NN O
coordination NN NN O
between NN NN O
Sp1 NN NN B-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
with NN NN O
other NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factors NN NN O
, NN NN O
including NN NN O
possibly NN NN O
other NN NN O
Sp1 NN NN B-Protein
- NN NN O
like NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
to NN NN O
provide NN NN O
high NN NN O
level NN NN O
, NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
. NN NN O
   
TCL1 NN NN B-Protein
oncogene NN NN O
activation NN NN O
in NN NN O
preleukemic NN NN O
T NN NN O
cells NN NN O
from NN NN O
a NN NN O
case NN NN O
of NN NN O
ataxia NN NN O
- NN NN O
telangiectasia NN NN O
. NN NN O
   
The NN NN O
TCL1 NN NN B-Protein
oncogene NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
14q32 NN NN O
. NN NN O
1 NN NN O
is NN NN O
involved NN NN O
in NN NN O
chromosome NN NN O
translocations NN NN O
[ NN NN O
t NN NN O
( NN NN O
14 NN NN O
; NN NN O
14 NN NN O
) NN NN O
( NN NN O
q11 NN NN O
; NN NN O
q32 NN NN O
. NN NN O
1 NN NN O
) NN NN O
and NN NN O
t NN NN O
( NN NN O
7 NN NN O
; NN NN O
14 NN NN O
) NN NN O
( NN NN O
q35 NN NN O
; NN NN O
q32 NN NN O
. NN NN O
1 NN NN O
) NN NN O
] NN NN O
and NN NN O
inversions NN NN O
[ NN NN O
inv14 NN NN O
( NN NN O
q11 NN NN O
; NN NN O
q32 NN NN O
. NN NN O
1 NN NN O
) NN NN O
] NN NN O
with NN NN O
TCR NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
loci NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemias NN NN O
, NN NN O
such NN NN O
as NN NN O
T NN NN O
- NN NN O
prolymphocytic NN NN O
( NN NN O
T NN NN O
- NN NN O
PLL NN NN O
) NN NN O
. NN NN O
   
It NN NN O
is NN NN O
also NN NN O
involved NN NN O
in NN NN O
T NN NN O
- NN NN O
acute NN NN O
and NN NN O
- NN NN O
chronic NN NN O
leukemias NN NN O
arising NN NN O
in NN NN O
cases NN NN O
of NN NN O
ataxia NN NN O
- NN NN O
telangiectasia NN NN O
( NN NN O
AT NN NN O
) NN NN O
, NN NN O
an NN NN O
immunodeficiency NN NN O
syndrome NN NN O
. NN NN O
   
Similar NN NN O
chromosomal NN NN O
rearrangements NN NN O
occur NN NN O
also NN NN O
in NN NN O
the NN NN O
clonally NN NN O
expanded NN NN O
T NN NN O
cells NN NN O
in NN NN O
AT NN NN O
patients NN NN O
before NN NN O
the NN NN O
appearance NN NN O
of NN NN O
the NN NN O
overt NN NN O
leukemia NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
of NN NN O
TCL1 NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBLs NN NN O
) NN NN O
from NN NN O
four NN NN O
AT NN NN O
cases NN NN O
and NN NN O
from NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
the NN NN O
TCL1 NN NN B-Protein
gene NN NN O
was NN NN O
overexpressed NN NN O
in NN NN O
the NN NN O
PBLs NN NN O
of NN NN O
an NN NN O
AT NN NN O
patient NN NN O
with NN NN O
a NN NN O
large NN NN O
clonal NN NN O
T NN NN O
- NN NN O
cell NN NN O
population NN NN O
exhibiting NN NN O
the NN NN O
t NN NN O
( NN NN O
14 NN NN O
; NN NN O
14 NN NN O
) NN NN O
translocation NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
lymphocytes NN NN O
of NN NN O
the NN NN O
other NN NN O
cases NN NN O
. NN NN O
   
Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
of NN NN O
the NN NN O
TCL1 NN NN B-Protein
genomic NN NN O
locus NN NN O
to NN NN O
lymphocyte NN NN O
metaphases NN NN O
from NN NN O
the NN NN O
AT NN NN O
patient NN NN O
with NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
clonal NN NN O
expansion NN NN O
showed NN NN O
that NN NN O
the NN NN O
breakpoint NN NN O
of NN NN O
the NN NN O
t NN NN O
( NN NN O
14 NN NN O
; NN NN O
14 NN NN O
) NN NN O
translocation NN NN O
lies NN NN O
within NN NN O
the NN NN O
TCL1 NN NN B-Protein
locus NN NN O
and NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
inverted NN NN O
duplication NN NN O
of NN NN O
the NN NN O
distal NN NN O
part NN NN O
of NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
TCL1 NN NN B-Protein
is NN NN O
activated NN NN O
in NN NN O
preleukemic NN NN O
clonal NN NN O
cells NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
chromosome NN NN O
translocation NN NN O
involving NN NN O
sequences NN NN O
from NN NN O
the NN NN O
TCR NN NN O
locus NN NN O
at NN NN O
14q11 NN NN O
. NN NN O
   
Deregulation NN NN O
of NN NN O
TCL1 NN NN B-Protein
is NN NN O
the NN NN O
first NN NN O
event NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
malignancy NN NN O
in NN NN O
these NN NN O
types NN NN O
of NN NN O
leukemias NN NN O
and NN NN O
represents NN NN O
a NN NN O
potential NN NN O
tool NN NN O
for NN NN O
clinical NN NN O
evaluation NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
transformed NN NN O
B NN NN O
lymphocytes NN NN O
is NN NN O
controlled NN NN O
by NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
chi NN NN O
B NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
has NN NN O
been NN NN O
investigated NN NN O
mainly NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
predominant NN NN O
producers NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
B NN NN O
cells NN NN O
can NN NN O
also NN NN O
synthesize NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
control NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
- NN NN O
transformed NN NN O
B NN NN O
cell NN NN O
clones NN NN O
which NN NN O
are NN NN O
capable NN NN O
of NN NN O
secreting NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
at NN NN O
a NN NN O
low NN NN O
level NN NN O
after NN NN O
stimulation NN NN O
with NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
and NN NN O
the NN NN O
Ca2 NN NN O
+ NN NN O
ionophore NN NN O
ionomycin NN NN O
. NN NN O
   
Transient NN NN O
transfections NN NN O
using NN NN O
reporter NN NN O
constructs NN NN O
with NN NN O
multiples NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
[ NN NN O
distal NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
AT NN NN O
, NN NN O
proximal NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
/ NN NN O
Octamer NN NN O
( NN NN O
UPS NN NN O
) NN NN O
or NN NN O
NF NN NN O
- NN NN O
chi NN NN O
B NN NN O
( NN NN O
TCEd NN NN O
) NN NN O
sites NN NN O
] NN NN O
were NN NN O
performed NN NN O
. NN NN O
   
In NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
B NN NN O
clones NN NN O
, NN NN O
the NN NN O
chi NN NN O
B NN NN O
site NN NN O
exerted NN NN O
the NN NN O
strongest NN NN O
inducible NN NN O
activity NN NN O
; NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
sites NN NN O
showed NN NN O
either NN NN O
no NN NN O
or NN NN O
only NN NN O
weak NN NN O
activity NN NN O
compared NN NN O
to NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
bearing NN NN O
a NN NN O
defective NN NN O
NF NN NN O
- NN NN O
chi NN NN O
B NN NN O
site NN NN O
was NN NN O
completely NN NN O
inactive NN NN O
in NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
B NN NN O
cells NN NN O
, NN NN O
while NN NN O
it NN NN O
still NN NN O
had NN NN O
activity NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
seven NN NN O
EBV NN NN O
- NN NN O
B NN NN O
cell NN NN O
clones NN NN O
or NN NN O
lines NN NN O
differing NN NN O
in NN NN O
their NN NN O
capacity NN NN O
to NN NN O
secrete NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
correlated NN NN O
well NN NN O
with NN NN O
the NN NN O
status NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
a NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
promoter NN NN O
, NN NN O
whose NN NN O
activity NN NN O
is NN NN O
controlled NN NN O
through NN NN O
chi NN NN O
B NN NN O
factors NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
active NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
producing NN NN O
EBV NN NN O
- NN NN O
B NN NN O
cells NN NN O
, NN NN O
but NN NN O
inactive NN NN O
in NN NN O
the NN NN O
non NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
producing NN NN O
cells NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
using NN NN O
protein NN NN O
extracts NN NN O
from NN NN O
EBV NN NN O
- NN NN O
B NN NN O
cells NN NN O
and NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
NF NN NN O
- NN NN O
chi NN NN O
B NN NN O
probe NN NN O
revealed NN NN O
the NN NN O
constitutive NN NN O
generation NN NN O
of NN NN O
chi NN NN O
B NN NN O
complexes NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
secreting NN NN O
cells NN NN O
consisting NN NN O
mainly NN NN O
of NN NN O
heterodimeric NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
complexes NN NN O
. NN NN O
   
A NN NN O
weaker NN NN O
chi NN NN O
B NN NN O
complex NN NN O
formation NN NN O
and NN NN O
faster NN NN O
- NN NN O
migrating NN NN O
complexes NN NN O
were NN NN O
detected NN NN O
in NN NN O
non NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
secreting NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
NF NN NN O
- NN NN O
chi NN NN O
B NN NN O
site NN NN O
is NN NN O
indispensable NN NN O
for NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
B NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
appear NN NN O
to NN NN O
be NN NN O
less NN NN O
important NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Ubiquitin NN NN B-Protein
- NN NN O
mediated NN NN O
processing NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcriptional NN NN O
activator NN NN O
precursor NN NN O
p105 NN NN B-Protein
. NN NN O
   
Reconstitution NN NN O
of NN NN O
a NN NN O
cell NN NN O
- NN NN O
free NN NN O
system NN NN O
and NN NN O
identification NN NN O
of NN NN O
the NN NN O
ubiquitin NN NN B-Protein
- NN NN O
carrier NN NN O
protein NN NN O
, NN NN O
E2 NN NN B-Protein
, NN NN O
and NN NN O
a NN NN O
novel NN NN O
ubiquitin NN NN B-Protein
- NN NN O
protein NN NN O
ligase NN NN O
, NN NN O
E3 NN NN B-Protein
, NN NN O
involved NN NN O
in NN NN O
conjugation NN NN O
. NN NN O
   
In NN NN O
most NN NN O
cases NN NN O
, NN NN O
the NN NN O
transcriptional NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
heterodimer NN NN O
consisting NN NN O
of NN NN O
two NN NN O
subunits NN NN O
, NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
, NN NN O
which NN NN O
are NN NN O
encoded NN NN O
by NN NN O
two NN NN O
distinct NN NN O
genes NN NN O
of NN NN O
the NN NN O
Rel NN NN O
family NN NN O
. NN NN O
   
p50 NN NN B-Protein
is NN NN O
translated NN NN O
as NN NN O
a NN NN O
precursor NN NN O
of NN NN O
105 NN NN O
kDa NN NN O
. NN NN O
   
The NN NN O
C NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
of NN NN O
the NN NN O
precursor NN NN O
is NN NN O
rapidly NN NN O
degraded NN NN O
, NN NN O
forming NN NN O
the NN NN O
mature NN NN O
p50 NN NN B-Protein
subunit NN NN O
consisted NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
the NN NN O
molecule NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
generation NN NN O
of NN NN O
p50 NN NN B-Protein
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
suggested NN NN O
that NN NN O
the NN NN O
ubiquitin NN NN B-Protein
- NN NN O
proteasome NN NN O
system NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
process NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
specific NN NN O
enzymes NN NN O
involved NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
limited NN NN O
proteolysis NN NN O
, NN NN O
in NN NN O
which NN NN O
half NN NN O
of NN NN O
the NN NN O
molecule NN NN O
is NN NN O
spared NN NN O
, NN NN O
have NN NN O
been NN NN O
obscure NN NN O
. NN NN O
   
Palombella NN NN O
and NN NN O
colleagues NN NN O
( NN NN O
Palombella NN NN O
, NN NN O
V NN NN O
. NN NN O
J NN NN O
. NN NN O
, NN NN O
Rando NN NN O
, NN NN O
O NN NN O
. NN NN O
J NN NN O
. NN NN O
, NN NN O
Goldberg NN NN O
, NN NN O
A NN NN O
. NN NN O
L NN NN O
. NN NN O
, NN NN O
and NN NN O
Maniatis NN NN O
, NN NN O
T NN NN O
. NN NN O
( NN NN O
1994 NN NN O
) NN NN O
Cell NN NN O
78 NN NN O
, NN NN O
773 NN NN O
- NN NN O
785 NN NN O
) NN NN O
have NN NN O
shown NN NN O
that NN NN O
ubiquitin NN NN B-Protein
is NN NN O
required NN NN O
for NN NN O
the NN NN O
processing NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
free NN NN O
system NN NN O
of NN NN O
a NN NN O
truncated NN NN O
, NN NN O
artificially NN NN O
constructed NN NN O
, NN NN O
60 NN NN O
- NN NN O
kDa NN NN O
precursor NN NN O
. NN NN O
   
They NN NN O
have NN NN O
also NN NN O
shown NN NN O
that NN NN O
proteasome NN NN O
inhibitors NN NN O
block NN NN O
the NN NN O
processing NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
reconstitution NN NN O
of NN NN O
a NN NN O
cell NN NN O
- NN NN O
free NN NN O
processing NN NN O
system NN NN O
and NN NN O
demonstrate NN NN O
directly NN NN O
that NN NN O
: NN NN O
( NN NN O
a NN NN O
) NN NN O
the NN NN O
ubiquitin NN NN B-Protein
- NN NN O
proteasome NN NN O
system NN NN O
is NN NN O
involved NN NN O
in NN NN O
processing NN NN O
of NN NN O
the NN NN O
intact NN NN O
p105 NN NN B-Protein
precursor NN NN O
, NN NN O
( NN NN O
b NN NN O
) NN NN O
conjugation NN NN O
of NN NN O
ubiquitin NN NN O
to NN NN O
the NN NN O
precursor NN NN O
is NN NN O
an NN NN O
essential NN NN O
intermediate NN NN O
step NN NN O
in NN NN O
the NN NN O
processing NN NN O
, NN NN O
( NN NN O
c NN NN O
) NN NN O
the NN NN O
recently NN NN O
discovered NN NN O
novel NN NN O
species NN NN O
of NN NN O
the NN NN O
ubiquitin NN NN B-Protein
- NN NN O
carrier NN NN O
protein NN NN O
, NN NN O
E2 NN NN B-Protein
- NN NN I-Protein
F1 NN NN I-Protein
, NN NN O
that NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
conjugation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
p53 NN NN B-Protein
, NN NN O
is NN NN O
also NN NN O
required NN NN O
for NN NN O
the NN NN O
limited NN NN O
processing NN NN O
of NN NN O
the NN NN O
p105 NN NN B-Protein
precursor NN NN O
, NN NN O
and NN NN O
( NN NN O
d NN NN O
) NN NN O
a NN NN O
novel NN NN O
, NN NN O
approximately NN NN O
320 NN NN O
- NN NN O
kDa NN NN O
species NN NN O
of NN NN O
ubiquitin NN NN B-Protein
- NN NN O
protein NN NN O
ligase NN NN O
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
process NN NN O
. NN NN O
   
This NN NN O
novel NN NN O
enzyme NN NN O
is NN NN O
distinct NN NN O
from NN NN O
E6 NN NN B-Protein
- NN NN I-Protein
AP NN NN I-Protein
, NN NN O
the NN NN O
p53 NN NN B-Protein
- NN NN O
conjugating NN NN O
ligase NN NN O
, NN NN O
and NN NN O
from NN NN O
E3 NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
the NN NN O
"""""""" NN NN O
N NN NN O
- NN NN O
end NN NN O
rule NN NN O
"""""""" NN NN O
ligase NN NN O
. NN NN O
   
The NN NN O
hematopoietic NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
downregulated NN NN O
in NN NN O
human NN NN O
multiple NN NN O
myeloma NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
hematopoietic NN NN O
transcription NN NN O
factor NN NN O
belonging NN NN O
to NN NN O
the NN NN O
Ets NN NN O
- NN NN O
family NN NN O
. NN NN O
   
It NN NN O
is NN NN O
identical NN NN O
to NN NN O
the NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
oncogene NN NN O
, NN NN O
which NN NN O
is NN NN O
implicated NN NN O
in NN NN O
spleen NN NN O
focus NN NN O
- NN NN O
forming NN NN O
virus NN NN O
- NN NN O
induced NN NN O
murine NN NN O
erythroleukemias NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
seems NN NN O
to NN NN O
be NN NN O
required NN NN O
for NN NN O
early NN NN O
development NN NN O
of NN NN O
multiple NN NN O
hematopoietic NN NN O
lineages NN NN O
, NN NN O
but NN NN O
its NN NN O
expression NN NN O
in NN NN O
mature NN NN O
cells NN NN O
is NN NN O
preferentially NN NN O
observed NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
and NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
differentiation NN NN O
lineage NN NN O
. NN NN O
   
It NN NN O
binds NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
Pu NN NN O
box NN NN O
, NN NN O
an NN NN O
important NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
regulatory NN NN O
DNA NN NN O
element NN NN O
present NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
genes NN NN O
expressed NN NN O
in NN NN O
these NN NN O
cell NN NN O
lineages NN NN O
. NN NN O
   
We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
and NN NN O
activity NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
during NN NN O
human NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
using NN NN O
a NN NN O
panel NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
representing NN NN O
different NN NN O
stages NN NN O
of NN NN O
maturation NN NN O
, NN NN O
from NN NN O
early NN NN O
precursors NN NN O
to NN NN O
differentiated NN NN O
plasma NN NN O
cells NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
, NN NN O
as NN NN O
measured NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
respectively NN NN O
, NN NN O
were NN NN O
evident NN NN O
in NN NN O
cell NN NN O
lines NN NN O
representing NN NN O
pro NN NN O
- NN NN O
B NN NN O
, NN NN O
pre NN NN O
- NN NN O
B NN NN O
, NN NN O
and NN NN O
mature NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
could NN NN O
also NN NN O
show NN NN O
Pu NN NN O
box NN NN O
- NN NN O
dependent NN NN O
transactivation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
in NN NN O
transient NN NN O
transfections NN NN O
in NN NN O
these NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
multiple NN NN O
myeloma NN NN O
cell NN NN O
lines NN NN O
, NN NN O
representing NN NN O
differentiated NN NN O
, NN NN O
plasma NN NN O
cell NN NN O
- NN NN O
like NN NN O
B NN NN O
cells NN NN O
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
, NN NN O
mRNA NN NN O
expression NN NN O
, NN NN O
and NN NN O
Pu NN NN O
box NN NN O
- NN NN O
dependent NN NN O
transactivation NN NN O
were NN NN O
absent NN NN O
or NN NN O
detectable NN NN O
at NN NN O
a NN NN O
very NN NN O
low NN NN O
level NN NN O
. NN NN O
   
In NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
which NN NN O
exemplify NN NN O
an NN NN O
intermediate NN NN O
stage NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
a NN NN O
reduced NN NN O
expression NN NN O
and NN NN O
activity NN NN O
were NN NN O
observed NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
in NN NN O
the NN NN O
human NN NN O
multiple NN NN O
myeloma NN NN O
cell NN NN O
lines NN NN O
represent NN NN O
the NN NN O
first NN NN O
examples NN NN O
of NN NN O
B NN NN O
cells NN NN O
with NN NN O
downregulated NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
apparently NN NN O
contradict NN NN O
observations NN NN O
in NN NN O
the NN NN O
murine NN NN O
system NN NN O
in NN NN O
which NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
expressed NN NN O
and NN NN O
active NN NN O
in NN NN O
plasmacytoma NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
At NN NN O
present NN NN O
, NN NN O
it NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
the NN NN O
lack NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
activity NN NN O
in NN NN O
human NN NN O
multiple NN NN O
myeloma NN NN O
cell NN NN O
lines NN NN O
represents NN NN O
a NN NN O
malignancy NN NN O
- NN NN O
associated NN NN O
defect NN NN O
in NN NN O
these NN NN O
cells NN NN O
or NN NN O
exemplifies NN NN O
a NN NN O
normal NN NN O
developmental NN NN O
regulation NN NN O
in NN NN O
terminally NN NN O
differentiated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
regulatory NN NN O
element NN NN O
in NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
gene NN NN O
promoter NN NN O
is NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
Sp1 NN NN B-Protein
and NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
after NN NN O
antigen NN NN O
recognition NN NN O
is NN NN O
a NN NN O
critical NN NN O
event NN NN O
for NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
effector NN NN O
function NN NN O
. NN NN O
   
Prior NN NN O
studies NN NN O
have NN NN O
identified NN NN O
several NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
contribute NN NN O
to NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
stimulated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
describe NN NN O
a NN NN O
novel NN NN O
regulatory NN NN O
element NN NN O
within NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
located NN NN O
immediately NN NN O
upstream NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cell NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
domain NN NN O
. NN NN O
   
This NN NN O
region NN NN O
( NN NN O
termed NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
protein NN NN O
binding NN NN O
region NN NN O
( NN NN O
ZIP NN NN O
) NN NN O
) NN NN O
serves NN NN O
as NN NN O
binding NN NN O
site NN NN O
for NN NN O
two NN NN O
differently NN NN O
regulated NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
: NN NN O
the NN NN O
constitutively NN NN O
expressed NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN B-Protein
and NN NN O
the NN NN O
inducible NN NN O
early NN NN O
growth NN NN O
response NN NN O
protein NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
In NN NN O
unstimulated NN NN O
cells NN NN O
which NN NN O
do NN NN O
not NN NN O
secrete NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
only NN NN O
Sp1 NN NN B-Protein
binds NN NN O
to NN NN O
this NN NN O
region NN NN O
, NN NN O
while NN NN O
in NN NN O
stimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secreting NN NN O
cells NN NN O
the NN NN O
inducible NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
recognizes NN NN O
this NN NN O
element NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
the NN NN O
ZIP NN NN O
site NN NN O
serves NN NN O
as NN NN O
an NN NN O
activator NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
a NN NN O
combination NN NN O
of NN NN O
ZIP NN NN O
and NN NN O
NFAT NN NN O
binding NN NN O
sites NN NN O
is NN NN O
required NN NN O
for NN NN O
maximal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
critical NN NN O
role NN NN O
of NN NN O
the NN NN O
ZIP NN NN O
site NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Functional NN NN O
antagonism NN NN O
between NN NN O
vitamin NN NN O
D3 NN NN O
and NN NN O
retinoic NN NN O
acid NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
CD14 NN NN B-Protein
and NN NN O
CD23 NN NN B-Protein
expression NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
. NN NN O
   
1 NN NN O
, NN NN O
25 NN NN O
alpha NN NN O
- NN NN O
Dihydroxicholecalciferol NN NN O
( NN NN O
VitD3 NN NN O
) NN NN O
and NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
are NN NN O
important NN NN O
regulators NN NN O
of NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
several NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
describes NN NN O
how NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
- NN NN O
macrophage NN NN O
Ag NN NN O
, NN NN O
CD14 NN NN B-Protein
, NN NN O
and NN NN O
the NN NN O
low NN NN O
affinity NN NN O
Fc NN NN O
receptor NN NN O
for NN NN O
IgE NN NN O
, NN NN O
CD23 NN NN B-Protein
, NN NN O
were NN NN O
inversely NN NN O
regulated NN NN O
during NN NN O
VitD3 NN NN O
- NN NN O
and NN NN O
RA NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
U NN NN O
- NN NN O
937 NN NN O
monoblasts NN NN O
. NN NN O
   
PMA NN NN O
induced NN NN O
the NN NN O
expression NN NN O
of NN NN O
both NN NN O
CD14 NN NN B-Protein
and NN NN O
CD23 NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
. NN NN O
   
Exposure NN NN O
to NN NN O
VitD3 NN NN O
rapidly NN NN O
induced NN NN O
the NN NN O
de NN NN O
novo NN NN O
expression NN NN O
of NN NN O
CD14 NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
cycloheximide NN NN O
completely NN NN O
blocked NN NN O
the NN NN O
VitD3 NN NN O
induction NN NN O
of NN NN O
CD14 NN NN B-Protein
mRNA NN NN O
expression NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
induction NN NN O
was NN NN O
dependent NN NN O
on NN NN O
ongoing NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
While NN NN O
inducing NN NN O
CD14 NN NN B-Protein
expression NN NN O
, NN NN O
VitD3 NN NN O
concomitantly NN NN O
suppressed NN NN O
the NN NN O
basal NN NN O
, NN NN O
PMA NN NN O
- NN NN O
, NN NN O
and NN NN O
RA NN NN O
- NN NN O
inducible NN NN O
CD23 NN NN B-Protein
expression NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
induced NN NN O
by NN NN O
RA NN NN O
strongly NN NN O
increased NN NN O
their NN NN O
expression NN NN O
of NN NN O
CD23 NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
, NN NN O
whereas NN NN O
they NN NN O
completely NN NN O
lacked NN NN O
detectable NN NN O
CD14 NN NN B-Protein
cell NN NN O
surface NN NN O
or NN NN O
mRNA NN NN O
expression NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
VitD3 NN NN O
- NN NN O
and NN NN O
the NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
CD14 NN NN B-Protein
expression NN NN O
was NN NN O
inhibited NN NN O
as NN NN O
a NN NN O
temporal NN NN O
consequence NN NN O
of NN NN O
the NN NN O
RA NN NN O
- NN NN O
induced NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
there NN NN O
exists NN NN O
a NN NN O
functional NN NN O
antagonism NN NN O
between NN NN O
VitD3 NN NN O
and NN NN O
RA NN NN O
that NN NN O
may NN NN O
have NN NN O
important NN NN O
implications NN NN O
for NN NN O
the NN NN O
regulation NN NN O
of NN NN O
certain NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
through NN NN O
their NN NN O
inverse NN NN O
effects NN NN O
on NN NN O
CD14 NN NN B-Protein
and NN NN O
CD23 NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Cytokine NN NN O
modulation NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
. NN NN O
   
Cytokines NN NN O
, NN NN O
the NN NN O
peptide NN NN O
hormones NN NN O
which NN NN O
control NN NN O
the NN NN O
homeostasis NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
and NN NN O
also NN NN O
play NN NN O
a NN NN O
fundamental NN NN O
role NN NN O
in NN NN O
inflammatory NN NN O
and NN NN O
immune NN NN O
mediated NN NN O
reactions NN NN O
, NN NN O
have NN NN O
been NN NN O
involved NN NN O
at NN NN O
multiple NN NN O
levels NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
the NN NN O
acquired NN NN O
immune NN NN O
deficiency NN NN O
syndrome NN NN O
( NN NN O
AIDS NN NN O
) NN NN O
. NN NN O
   
Infection NN NN O
with NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
induce NN NN O
production NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
several NN NN O
cytokines NN NN O
modulate NN NN O
the NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
infected NN NN O
cells NN NN O
of NN NN O
both NN NN O
T NN NN O
lymphocytic NN NN O
and NN NN O
mononuclear NN NN O
phagocytic NN NN O
lineage NN NN O
. NN NN O
   
Activated NN NN O
mononuclear NN NN O
cells NN NN O
, NN NN O
particularly NN NN O
B NN NN O
cells NN NN O
which NN NN O
are NN NN O
in NN NN O
a NN NN O
state NN NN O
of NN NN O
chronic NN NN O
activation NN NN O
in NN NN O
HIV NN NN O
infected NN NN O
individuals NN NN O
, NN NN O
release NN NN O
HIV NN NN O
- NN NN O
inductive NN NN O
cytokines NN NN O
and NN NN O
thus NN NN O
play NN NN O
a NN NN O
potentially NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HIV NN NN O
infection NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
latency NN NN O
reactivation NN NN O
by NN NN O
dehydroepiandrosterone NN NN O
( NN NN O
DHEA NN NN O
) NN NN O
and NN NN O
an NN NN O
analog NN NN O
of NN NN O
DHEA NN NN O
. NN NN O
   
The NN NN O
initial NN NN O
infection NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
in NN NN O
most NN NN O
individuals NN NN O
usually NN NN O
results NN NN O
in NN NN O
the NN NN O
establishment NN NN O
of NN NN O
a NN NN O
latent NN NN O
or NN NN O
chronic NN NN O
infection NN NN O
before NN NN O
eventual NN NN O
progression NN NN O
toward NN NN O
acquired NN NN O
immunodeficiency NN NN O
syndrome NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
can NN NN O
also NN NN O
establish NN NN O
a NN NN O
latent NN NN O
or NN NN O
persistent NN NN O
infection NN NN O
in NN NN O
some NN NN O
T NN NN O
cell NN NN O
lines NN NN O
that NN NN O
show NN NN O
minimal NN NN O
constitutive NN NN O
virus NN NN O
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
activation NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
lines NN NN O
leading NN NN O
to NN NN O
enhanced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
antigens NN NN O
, NN NN O
mitogens NN NN O
, NN NN O
and NN NN O
cytokines NN NN O
( NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
[ NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
] NN NN O
, NN NN O
interleukin NN NN O
1 NN NN O
, NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
. NN NN O
   
Various NN NN O
gene NN NN O
products NN NN O
from NN NN O
other NN NN O
viruses NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
, NN NN O
HSV NN NN O
, NN NN O
EBV NN NN O
, NN NN O
CMV NN NN O
, NN NN O
HBV NN NN O
, NN NN O
and NN NN O
HHV NN NN O
- NN NN O
6 NN NN O
) NN NN O
can NN NN O
also NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
these NN NN O
observations NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
proposed NN NN O
that NN NN O
reactivation NN NN O
of NN NN O
latent NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
harbored NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
monocytes NN NN O
, NN NN O
or NN NN O
macrophages NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
AIDS NN NN O
. NN NN O
   
So NN NN O
far NN NN O
, NN NN O
there NN NN O
are NN NN O
no NN NN O
drugs NN NN O
or NN NN O
therapy NN NN O
available NN NN O
that NN NN O
can NN NN O
provide NN NN O
protection NN NN O
against NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
latency NN NN O
reactivation NN NN O
. NN NN O
   
ACH NN NN O
- NN NN O
2 NN NN O
, NN NN O
derived NN NN O
from NN NN O
a NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
( NN NN O
CEM NN NN O
) NN NN O
, NN NN O
is NN NN O
chronically NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
with NN NN O
low NN NN O
levels NN NN O
of NN NN O
constitutive NN NN O
virus NN NN O
expression NN NN O
. NN NN O
   
ACH NN NN O
- NN NN O
2 NN NN O
can NN NN O
be NN NN O
converted NN NN O
to NN NN O
productive NN NN O
infection NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
, NN NN O
mitogen NN NN O
or NN NN O
cytokines NN NN O
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
or NN NN O
infection NN NN O
with NN NN O
HSV NN NN O
. NN NN O
   
Therefore NN NN O
the NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
cell NN NN O
line NN NN O
is NN NN O
a NN NN O
good NN NN O
candidate NN NN O
for NN NN O
studying NN NN O
the NN NN O
effects NN NN O
of NN NN O
drugs NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
activation NN NN O
. NN NN O
   
Previously NN NN O
, NN NN O
we NN NN O
have NN NN O
reported NN NN O
that NN NN O
DHEA NN NN O
and NN NN O
synthetic NN NN O
analogs NN NN O
of NN NN O
DHEA NN NN O
can NN NN O
be NN NN O
modest NN NN O
inhibitors NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
IIIB NN NN O
replication NN NN O
in NN NN O
phytohemagglutinin NN NN B-Protein
- NN NN O
stimulated NN NN O
peripheral NN NN O
blood NN NN O
lymphocyte NN NN O
cultures NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Nitric NN NN O
oxide NN NN O
- NN NN O
stimulated NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
on NN NN O
p21ras NN NN B-Protein
. NN NN O
   
The NN NN O
protooncogene NN NN O
p21ras NN NN B-Protein
, NN NN O
a NN NN O
monomeric NN NN O
G NN NN O
protein NN NN O
family NN NN O
member NN NN O
, NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
converting NN NN O
extracellular NN NN O
signals NN NN O
into NN NN O
intracellular NN NN O
biochemical NN NN O
events NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
activates NN NN O
p21ras NN NN B-Protein
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
GTP NN NN O
- NN NN O
bound NN NN O
p21ras NN NN B-Protein
. NN NN O
   
In NN NN O
vitro NN NN O
studies NN NN O
using NN NN O
pure NN NN O
recombinant NN NN O
p21ras NN NN B-Protein
demonstrate NN NN O
that NN NN O
the NN NN O
activation NN NN O
is NN NN O
direct NN NN O
and NN NN O
reversible NN NN O
. NN NN O
   
Circular NN NN O
dichroism NN NN O
analysis NN NN O
reveals NN NN O
that NN NN O
NO NN NN O
induces NN NN O
a NN NN O
profound NN NN O
conformational NN NN O
change NN NN O
in NN NN O
p21ras NN NN B-Protein
in NN NN O
association NN NN O
with NN NN O
GDP NN NN O
/ NN NN O
GTP NN NN O
exchange NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
activation NN NN O
is NN NN O
due NN NN O
to NN NN O
S NN NN O
- NN NN O
nitrosylation NN NN O
of NN NN O
a NN NN O
critical NN NN O
cysteine NN NN O
residue NN NN O
which NN NN O
stimulates NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
p21ras NN NN B-Protein
is NN NN O
essential NN NN O
for NN NN O
NO NN NN O
- NN NN O
induced NN NN O
downstream NN NN O
signaling NN NN O
, NN NN O
such NN NN O
as NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
and NN NN O
that NN NN O
endogenous NN NN O
NO NN NN O
can NN NN O
activate NN NN O
p21ras NN NN B-Protein
in NN NN O
the NN NN O
same NN NN O
cell NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
identify NN NN O
p21ras NN NN B-Protein
as NN NN O
a NN NN O
target NN NN O
of NN NN O
the NN NN O
same NN NN O
cell NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
identify NN NN O
p21ras NN NN B-Protein
as NN NN O
a NN NN O
target NN NN O
of NN NN O
NO NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
suggest NN NN O
that NN NN O
NO NN NN O
activates NN NN O
p21ras NN NN B-Protein
by NN NN O
an NN NN O
action NN NN O
which NN NN O
mimics NN NN O
that NN NN O
of NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
factors NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
vacuolar NN NN O
H NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
B2 NN NN B-Protein
subunit NN NN O
gene NN NN O
in NN NN O
differentiating NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Monocyte NN NN O
- NN NN O
macrophage NN NN O
differentiation NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
model NN NN O
system NN NN O
for NN NN O
studying NN NN O
gene NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
vacuolar NN NN O
H NN NN O
( NN NN O
+ NN NN O
) NN NN O
- NN NN O
ATPase NN NN O
( NN NN O
V NN NN O
- NN NN O
ATPase NN NN O
) NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
various NN NN O
V NN NN O
- NN NN O
ATPase NN NN O
subunits NN NN O
during NN NN O
differentiation NN NN O
of NN NN O
both NN NN O
native NN NN O
monocytes NN NN O
and NN NN O
the NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
found NN NN O
that NN NN O
transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
mechanisms NN NN O
could NN NN O
account NN NN O
for NN NN O
increases NN NN O
in NN NN O
cell NN NN O
V NN NN O
- NN NN O
ATPase NN NN O
content NN NN O
. NN NN O
   
From NN NN O
nuclear NN NN O
runoff NN NN O
experiments NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
one NN NN O
subunit NN NN O
in NN NN O
particular NN NN O
, NN NN O
the NN NN O
B2 NN NN B-Protein
isoform NN NN O
( NN NN O
Mr NN NN O
= NN NN O
56 NN NN O
, NN NN O
000 NN NN O
) NN NN O
, NN NN O
was NN NN O
amplified NN NN O
primarily NN NN O
by NN NN O
transcriptional NN NN O
means NN NN O
. NN NN O
   
We NN NN O
have NN NN O
begun NN NN O
to NN NN O
examine NN NN O
the NN NN O
structure NN NN O
of NN NN O
the NN NN O
B2 NN NN B-Protein
subunit NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
Isolation NN NN O
and NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
first NN NN O
exon NN NN O
and NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
this NN NN O
gene NN NN O
reveal NN NN O
a NN NN O
TATA NN NN O
- NN NN O
less NN NN O
promoter NN NN O
with NN NN O
a NN NN O
high NN NN O
G NN NN O
+ NN NN O
C NN NN O
content NN NN O
. NN NN O
   
Primer NN NN O
extension NN NN O
and NN NN O
ribonuclease NN NN O
protection NN NN O
analyses NN NN O
indicate NN NN O
a NN NN O
single NN NN O
major NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
. NN NN O
   
We NN NN O
transfected NN NN O
promoter NN NN O
- NN NN O
luciferase NN NN O
reporter NN NN O
plasmids NN NN O
into NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
to NN NN O
define NN NN O
sequences NN NN O
that NN NN O
mediate NN NN O
transcriptional NN NN O
control NN NN O
during NN NN O
monocyte NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
sequences NN NN O
downstream NN NN O
from NN NN O
the NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
were NN NN O
sufficient NN NN O
to NN NN O
confer NN NN O
increased NN NN O
expression NN NN O
during NN NN O
THP NN NN O
- NN NN O
1 NN NN O
differentiation NN NN O
. NN NN O
   
DNase NN NN B-Protein
I NN NN I-Protein
footprinting NN NN O
and NN NN O
sequence NN NN O
analysis NN NN O
revealed NN NN O
the NN NN O
existence NN NN O
of NN NN O
multiple NN NN O
AP2 NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
untranslated NN NN O
and NN NN O
proximal NN NN O
coding NN NN O
regions NN NN O
. NN NN O
   
Functional NN NN O
characterization NN NN O
of NN NN O
novel NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcriptional NN NN O
inhibitors NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mediated NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
is NN NN O
a NN NN O
critical NN NN O
early NN NN O
event NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
process NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcriptional NN NN O
complex NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
is NN NN O
essential NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
cell NN NN O
line NN NN O
that NN NN O
is NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
a NN NN O
trimer NN NN O
of NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
regulatory NN NN O
element NN NN O
linked NN NN O
to NN NN O
a NN NN O
lac NN NN B-Protein
- NN NN I-Protein
Z NN NN I-Protein
reporter NN NN O
gene NN NN O
, NN NN O
we NN NN O
screened NN NN O
for NN NN O
inhibitors NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
beta NN NN B-Protein
- NN NN I-Protein
galactosidase NN NN I-Protein
activity NN NN O
. NN NN O
   
WIN NN NN O
61058 NN NN O
and NN NN O
WIN NN NN O
53071 NN NN O
were NN NN O
identified NN NN O
as NN NN O
microM NN NN O
inhibitors NN NN O
. NN NN O
   
These NN NN O
compounds NN NN O
also NN NN O
inhibited NN NN O
beta NN NN B-Protein
- NN NN I-Protein
galactosidase NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
Similar NN NN O
inhibition NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
gene NN NN O
expression NN NN O
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
second NN NN O
cell NN NN O
line NN NN O
, NN NN O
which NN NN O
is NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
regulatory NN NN O
elements NN NN O
linked NN NN O
to NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
for NN NN O
sCD8 NN NN O
. NN NN O
   
At NN NN O
10 NN NN O
microM NN NN O
, NN NN O
both NN NN O
compounds NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
levels NN NN O
in NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
linked NN NN O
lac NN NN B-Protein
- NN NN I-Protein
Z NN NN I-Protein
transfectants NN NN O
, NN NN O
and NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
. NN NN O
   
Both NN NN O
compounds NN NN O
inhibited NN NN O
the NN NN O
mixed NN NN O
lymphocyte NN NN O
reaction NN NN O
, NN NN O
and NN NN O
this NN NN O
inhibition NN NN O
was NN NN O
reversed NN NN O
by NN NN O
exogenous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
WIN NN NN O
53071 NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
induced NN NN O
in NN NN O
the NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
PMA NN NN O
and NN NN O
ionomycin NN NN O
pathway NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
calcium NN NN O
- NN NN O
independent NN NN O
anti NN NN O
- NN NN O
CD28 NN NN O
Ab NN NN O
and NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
was NN NN O
resistant NN NN O
. NN NN O
   
Both NN NN O
compounds NN NN O
altered NN NN O
the NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcriptional NN NN O
complex NN NN O
, NN NN O
causing NN NN O
its NN NN O
retarded NN NN O
mobility NN NN O
on NN NN O
gels NN NN O
. NN NN O
   
By NN NN O
these NN NN O
functional NN NN O
criteria NN NN O
, NN NN O
we NN NN O
believe NN NN O
we NN NN O
have NN NN O
identified NN NN O
two NN NN O
structurally NN NN O
distinct NN NN O
, NN NN O
novel NN NN O
inhibitors NN NN O
of NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
transcription NN NN O
. NN NN O
   
cDNA NN NN O
cloning NN NN O
of NN NN O
a NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
/ NN NN O
nur77 NN NN B-Protein
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
from NN NN O
an NN NN O
apoptotic NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
A NN NN O
human NN NN O
T NN NN O
lymphoid NN NN O
cell NN NN O
line NN NN O
, NN NN O
PEER NN NN O
, NN NN O
dies NN NN O
by NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
PMA NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
. NN NN O
   
A NN NN O
new NN NN O
gene NN NN O
, NN NN O
TINUR NN NN B-Protein
, NN NN O
was NN NN O
cloned NN NN O
from NN NN O
apoptotic NN NN O
PEER NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
TINUR NN NN B-Protein
gene NN NN O
is NN NN O
induced NN NN O
within NN NN O
1 NN NN O
h NN NN O
after NN NN O
the NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
Ag NN NN O
receptor NN NN O
complex NN NN O
. NN NN O
   
TINUR NN NN B-Protein
belongs NN NN O
to NN NN O
the NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
/ NN NN O
nur77 NN NN B-Protein
family NN NN O
of NN NN O
the NN NN O
steroid NN NN O
receptor NN NN O
superfamily NN NN O
and NN NN O
is NN NN O
an NN NN O
orphan NN NN O
receptor NN NN O
. NN NN O
   
TINUR NN NN B-Protein
binds NN NN O
to NN NN O
the NN NN O
same NN NN O
DNA NN NN O
sequence NN NN O
as NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
/ NN NN O
nur77 NN NN B-Protein
. NN NN O
   
We NN NN O
also NN NN O
propose NN NN O
that NN NN O
the NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
/ NN NN O
nur77 NN NN B-Protein
family NN NN O
can NN NN O
be NN NN O
classified NN NN O
into NN NN O
two NN NN O
subtypes NN NN O
. NN NN O
   
Platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
stimulates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
heparin NN NN B-Protein
- NN NN I-Protein
binding NN NN I-Protein
epidermal NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
like NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
in NN NN O
monocytes NN NN O
. NN NN O
   
Correlation NN NN O
with NN NN O
an NN NN O
increased NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
responded NN NN O
to NN NN O
stimulation NN NN O
of NN NN O
platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
( NN NN O
PAF NN NN O
) NN NN O
with NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
the NN NN O
transcript NN NN O
for NN NN O
heparin NN NN B-Protein
- NN NN I-Protein
binding NN NN I-Protein
epidermal NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
like NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
( NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
mitogen NN NN O
for NN NN O
vascular NN NN O
smooth NN NN O
muscle NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
function NN NN O
of NN NN O
PAF NN NN O
was NN NN O
observed NN NN O
at NN NN O
nanomolar NN NN O
concentrations NN NN O
of NN NN O
the NN NN O
ligand NN NN O
, NN NN O
starting NN NN O
at NN NN O
30 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
PAF NN NN O
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
mRNA NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
functions NN NN O
of NN NN O
PAF NN NN O
appeared NN NN O
to NN NN O
be NN NN O
mediated NN NN O
through NN NN O
the NN NN O
cell NN NN O
surface NN NN O
PAF NN NN O
receptors NN NN O
, NN NN O
as NN NN O
two NN NN O
PAF NN NN O
receptor NN NN O
antagonists NN NN O
, NN NN O
WEB NN NN O
2086 NN NN O
and NN NN O
L NN NN O
- NN NN O
659 NN NN O
, NN NN O
989 NN NN O
, NN NN O
blocked NN NN O
both NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
mRNA NN NN O
and NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
induced NN NN O
by NN NN O
PAF NN NN O
. NN NN O
   
The NN NN O
antagonists NN NN O
, NN NN O
however NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
mRNA NN NN O
and NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
monocytes NN NN O
with NN NN O
pertussis NN NN O
toxin NN NN O
inhibited NN NN O
these NN NN O
functions NN NN O
of NN NN O
PAF NN NN O
, NN NN O
whereas NN NN O
cholera NN NN O
toxin NN NN O
had NN NN O
no NN NN O
inhibitory NN NN O
effect NN NN O
. NN NN O
   
Pyrrolidine NN NN O
dithiocarbamate NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
markedly NN NN O
reduced NN NN O
PAF NN NN O
- NN NN O
stimulated NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
as NN NN O
well NN NN O
as NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
mRNA NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
potential NN NN O
role NN NN O
of NN NN O
PAF NN NN O
in NN NN O
HB NN NN B-Protein
- NN NN I-Protein
EGF NN NN I-Protein
expression NN NN O
and NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
this NN NN O
stimulation NN NN O
may NN NN O
occur NN NN O
through NN NN O
increased NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
and NN NN O
TCR NN NN O
signals NN NN O
synergize NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
1R NN NN O
) NN NN O
- NN NN O
and NN NN O
TCR NN NN O
- NN NN O
initiated NN NN O
signals NN NN O
can NN NN O
interact NN NN O
synergistically NN NN O
to NN NN O
increase NN NN O
the NN NN O
rate NN NN O
of NN NN O
transcription NN NN O
of NN NN O
several NN NN O
lymphokine NN NN O
and NN NN O
lymphokine NN NN O
receptor NN NN O
genes NN NN O
during NN NN O
the NN NN O
competence NN NN O
phase NN NN O
of NN NN O
the NN NN O
activation NN NN O
program NN NN O
in NN NN O
T NN NN O
helper NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
describe NN NN O
how NN NN O
signals NN NN O
initiated NN NN O
through NN NN O
the NN NN O
type NN NN B-Protein
I NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
1R NN NN I-Protein
interact NN NN O
with NN NN O
signals NN NN O
from NN NN O
the NN NN O
antigen NN NN O
receptor NN NN O
to NN NN O
synergistically NN NN O
augment NN NN O
the NN NN O
transactivating NN NN O
properties NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
synergistic NN NN O
antigen NN NN O
receptor NN NN O
initiated NN NN O
signals NN NN O
are NN NN O
mediated NN NN O
through NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
because NN NN O
they NN NN O
can NN NN O
be NN NN O
mimicked NN NN O
by NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
calcium NN NN O
ionophores NN NN O
; NN NN O
and NN NN O
are NN NN O
staurosporine NN NN O
sensitive NN NN O
but NN NN O
cyclosporine NN NN O
resistant NN NN O
. NN NN O
   
Gel NN NN O
shift NN NN O
analyses NN NN O
demonstrate NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
nuclear NN NN O
translocation NN NN O
is NN NN O
stimulated NN NN O
primarily NN NN O
by NN NN O
IL NN NN O
- NN NN O
1 NN NN O
rather NN NN O
than NN NN O
by NN NN O
antigen NN NN O
receptor NN NN O
signals NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
and NN NN O
phosphorylation NN NN O
analyses NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
synergistic NN NN O
effect NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
functional NN NN O
activity NN NN O
is NN NN O
independent NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD3 NN NN B-Protein
) NN NN O
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
dissociation NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
I NN NN O
kappa NN NN O
B NN NN O
nuclear NN NN O
translocation NN NN O
. NN NN O
   
The NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
nuclear NN NN O
localization NN NN O
is NN NN O
transient NN NN O
and NN NN O
can NN NN O
be NN NN O
prolonged NN NN O
either NN NN O
by NN NN O
an NN NN O
antigen NN NN O
receptor NN NN O
- NN NN O
initiated NN NN O
signal NN NN O
or NN NN O
by NN NN O
inhibiting NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
IL NN NN O
- NN NN O
1 NN NN O
induces NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
responsible NN NN O
for NN NN O
terminating NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
DNA NN NN O
interaction NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Antigen NN NN O
receptor NN NN O
signals NN NN O
prolong NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
DNA NN NN O
interaction NN NN O
, NN NN O
probably NN NN O
by NN NN O
functionally NN NN O
antagonizing NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
responsible NN NN O
for NN NN O
the NN NN O
transient NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
DNA NN NN O
interaction NN NN O
and NN NN O
consequently NN NN O
synergistically NN NN O
enhance NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
aspirin NN NN O
- NN NN O
like NN NN O
drugs NN NN O
. NN NN O
   
Aspirin NN NN O
- NN NN O
like NN NN O
drugs NN NN O
( NN NN O
ALD NN NN O
) NN NN O
induce NN NN O
calcium NN NN O
mobilization NN NN O
, NN NN O
an NN NN O
essential NN NN O
component NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
but NN NN O
do NN NN O
not NN NN O
induce NN NN O
the NN NN O
biosynthesis NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
extent NN NN O
to NN NN O
which NN NN O
ALD NN NN O
may NN NN O
mimic NN NN O
mitogenic NN NN O
stimulation NN NN O
, NN NN O
we NN NN O
studied NN NN O
cytoplasmic NN NN O
and NN NN O
nuclear NN NN O
signaling NN NN O
steps NN NN O
in NN NN O
ALD NN NN O
- NN NN O
treated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
ALD NN NN O
induce NN NN O
a NN NN O
transient NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
PKC NN NN O
) NN NN O
but NN NN O
have NN NN O
no NN NN O
effect NN NN O
( NN NN O
in NN NN O
comparison NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
antibodies NN NN O
) NN NN O
on NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
nor NN NN O
on NN NN O
PCL NN NN B-Protein
gamma NN NN I-Protein
1 NN NN I-Protein
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
ALD NN NN O
- NN NN O
induced NN NN O
calcium NN NN O
mobilization NN NN O
and NN NN O
PKC NN NN O
activation NN NN O
are NN NN O
independent NN NN O
of NN NN O
tyrosine NN NN O
protein NN NN O
kinase NN NN O
activity NN NN O
as NN NN O
shown NN NN O
by NN NN O
the NN NN O
lack NN NN O
of NN NN O
effect NN NN O
of NN NN O
herbimycin NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
- NN NN O
protein NN NN O
kinase NN NN O
- NN NN O
specific NN NN O
inhibitor NN NN O
. NN NN O
   
Although NN NN O
we NN NN O
detected NN NN O
no NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
in NN NN O
ALD NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
these NN NN O
cells NN NN O
contain NN NN O
proteins NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
three NN NN O
regulatory NN NN O
sequences NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
region NN NN O
: NN NN O
NFAT NN NN O
, NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
These NN NN O
binding NN NN O
activities NN NN O
are NN NN O
expressed NN NN O
only NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
depended NN NN O
on NN NN O
calcium NN NN O
mobilization NN NN O
and NN NN O
PKC NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
ALD NN NN O
cause NN NN O
transient NN NN O
but NN NN O
significant NN NN O
changes NN NN O
in NN NN O
T NN NN O
cell NN NN O
transmembrane NN NN O
signaling NN NN O
, NN NN O
although NN NN O
some NN NN O
events NN NN O
induced NN NN O
by NN NN O
stimulation NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
antibodies NN NN O
are NN NN O
not NN NN O
induced NN NN O
by NN NN O
ALD NN NN O
. NN NN O
   
The NN NN O
signal NN NN O
is NN NN O
transmitted NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
induces NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
by NN NN O
several NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
ALD NN NN O
stimulus NN NN O
is NN NN O
not NN NN O
capable NN NN O
of NN NN O
causing NN NN O
complete NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibits NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
suppress NN NN O
cytokine NN NN O
synthesis NN NN O
by NN NN O
different NN NN O
mechanisms NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
studies NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibits NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
stimulated NN NN O
production NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
by NN NN O
blocking NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
, NN NN O
we NN NN O
now NN NN O
show NN NN O
that NN NN O
, NN NN O
in NN NN O
monocytes NN NN O
stimulated NN NN O
with NN NN O
LPS NN NN O
or NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
inhibits NN NN O
nuclear NN NN O
stimulation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
inflammatory NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Several NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
including NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
AP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
AP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
GR NN NN B-Protein
, NN NN O
CREB NN NN B-Protein
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
Sp NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
are NN NN O
not NN NN O
affected NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
. NN NN O
   
This NN NN O
selective NN NN O
inhibition NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
occurs NN NN O
rapidly NN NN O
and NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
and NN NN O
correlates NN NN O
well NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
' NN NN O
s NN NN O
cytokine NN NN O
synthesis NN NN O
inhibitory NN NN O
activity NN NN O
in NN NN O
terms NN NN O
of NN NN O
both NN NN O
kinetics NN NN O
and NN NN O
dose NN NN O
responsiveness NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
compounds NN NN O
such NN NN O
as NN NN O
tosylphenylalanyl NN NN O
chloromethyl NN NN O
ketone NN NN O
and NN NN O
pyrrolidinedithiocarbamate NN NN O
that NN NN O
are NN NN O
known NN NN O
to NN NN O
selectively NN NN O
inhibit NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
block NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
monocytes NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
mechanism NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
suppression NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
another NN NN O
cytokine NN NN O
that NN NN O
inhibits NN NN O
cytokine NN NN O
mRNA NN NN O
accumulation NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
shows NN NN O
little NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Further NN NN O
examination NN NN O
reveals NN NN O
that NN NN O
, NN NN O
unlike NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
enhances NN NN O
mRNA NN NN O
degradation NN NN O
and NN NN O
does NN NN O
not NN NN O
suppress NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inhibit NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
different NN NN O
mechanisms NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
transcription NN NN O
by NN NN O
binding NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
( NN NN O
YY1 NN NN B-Protein
) NN NN O
to NN NN O
a NN NN O
newly NN NN O
identified NN NN O
element NN NN O
in NN NN O
the NN NN O
first NN NN O
exon NN NN O
of NN NN O
the NN NN O
human NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
A NN NN O
previously NN NN O
unrecognized NN NN O
element NN NN O
, NN NN O
located NN NN O
downstream NN NN O
of NN NN O
the NN NN O
start NN NN O
site NN NN O
of NN NN O
transcription NN NN O
in NN NN O
the NN NN O
first NN NN O
exon NN NN O
of NN NN O
the NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
, NN NN O
has NN NN O
been NN NN O
defined NN NN O
that NN NN O
enhances NN NN O
promoter NN NN O
activity NN NN O
up NN NN O
to NN NN O
eightfold NN NN O
in NN NN O
a NN NN O
position NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Mutations NN NN O
in NN NN O
this NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
site NN NN O
abolished NN NN O
binding NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
in NN NN O
human NN NN O
B NN NN O
cell NN NN O
nuclear NN NN O
extract NN NN O
and NN NN O
decreased NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
promoter NN NN O
to NN NN O
a NN NN O
basal NN NN O
level NN NN O
. NN NN O
   
Significant NN NN O
sequence NN NN O
homology NN NN O
of NN NN O
this NN NN O
element NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
DNA NN NN O
of NN NN O
the NN NN O
DR NN NN B-Protein
beta NN NN I-Protein
, NN NN O
DP NN NN O
alpha NN NN O
and NN NN O
- NN NN O
beta NN NN O
, NN NN O
and NN NN O
DQ NN NN B-Protein
alpha NN NN I-Protein
genes NN NN O
, NN NN O
always NN NN O
located NN NN O
downstream NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
binds NN NN O
to NN NN O
the NN NN O
DR NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
DP NN NN B-Protein
alpha NN NN I-Protein
element NN NN O
but NN NN O
not NN NN O
to NN NN O
the NN NN O
element NN NN O
in NN NN O
the NN NN O
DQ NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
It NN NN O
was NN NN O
identified NN NN O
as NN NN O
NF NN NN B-Protein
- NN NN I-Protein
E1 NN NN I-Protein
( NN NN O
YY1 NN NN B-Protein
) NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
, NN NN O
previously NN NN O
identified NN NN O
by NN NN O
its NN NN O
binding NN NN O
to NN NN O
the NN NN O
Ig NN NN O
kappa NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
and NN NN O
the NN NN O
Ig NN NN O
heavy NN NN O
chain NN NN O
mu NN NN O
E1 NN NN O
site NN NN O
, NN NN O
thus NN NN O
also NN NN O
appears NN NN O
to NN NN O
be NN NN O
quite NN NN O
important NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Coupling NN NN O
of NN NN O
a NN NN O
signal NN NN O
response NN NN O
domain NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
to NN NN O
multiple NN NN O
pathways NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
eukaryotic NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
plays NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
the NN NN O
induced NN NN O
expression NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
and NN NN O
in NN NN O
many NN NN O
aspects NN NN O
of NN NN O
the NN NN O
genetic NN NN O
program NN NN O
mediating NN NN O
normal NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
and NN NN O
growth NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
tightly NN NN O
regulated NN NN O
from NN NN O
the NN NN O
cytoplasmic NN NN O
compartment NN NN O
by NN NN O
an NN NN O
inhibitory NN NN O
subunit NN NN O
called NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
This NN NN O
cytoplasmic NN NN O
inhibitor NN NN O
is NN NN O
rapidly NN NN O
phosphorylated NN NN O
and NN NN O
degraded NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
diverse NN NN O
set NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
inducing NN NN O
agents NN NN O
, NN NN O
including NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogens NN NN O
, NN NN O
proinflammatory NN NN O
cytokines NN NN O
, NN NN O
and NN NN O
viral NN NN O
transactivators NN NN O
such NN NN O
as NN NN O
the NN NN O
Tax NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
To NN NN O
explore NN NN O
these NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
dependent NN NN O
mechanisms NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
, NN NN O
we NN NN O
identified NN NN O
novel NN NN O
mutants NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
that NN NN O
uncouple NN NN O
its NN NN O
inhibitory NN NN O
and NN NN O
signal NN NN O
- NN NN O
transducing NN NN O
functions NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Specifically NN NN O
, NN NN O
removal NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
36 NN NN O
amino NN NN O
acids NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
failed NN NN O
to NN NN O
disrupt NN NN O
its NN NN O
ability NN NN O
to NN NN O
form NN NN O
latent NN NN O
complexes NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
deletion NN NN O
mutation NN NN O
prevented NN NN O
the NN NN O
induced NN NN O
phosphorylation NN NN O
, NN NN O
degradative NN NN O
loss NN NN O
, NN NN O
and NN NN O
functional NN NN O
release NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
Tax NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
. NN NN O
   
Alanine NN NN O
substitutions NN NN O
introduced NN NN O
at NN NN O
two NN NN O
serine NN NN O
residues NN NN O
positioned NN NN O
within NN NN O
this NN NN O
N NN NN O
- NN NN O
terminal NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
also NN NN O
yielded NN NN O
constitutive NN NN O
repressors NN NN O
that NN NN O
escaped NN NN O
from NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
turnover NN NN O
and NN NN O
that NN NN O
potently NN NN O
inhibited NN NN O
immune NN NN O
activation NN NN O
pathways NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
, NN NN O
including NN NN O
those NN NN O
initiated NN NN O
from NN NN O
antigen NN NN O
and NN NN O
cytokine NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
introduction NN NN O
of NN NN O
a NN NN O
phosphoserine NN NN O
mimetic NN NN O
at NN NN O
these NN NN O
sites NN NN O
rectified NN NN O
this NN NN O
functional NN NN O
defect NN NN O
, NN NN O
a NN NN O
finding NN NN O
consistent NN NN O
with NN NN O
a NN NN O
causal NN NN O
linkage NN NN O
between NN NN O
the NN NN O
phosphorylation NN NN O
status NN NN O
and NN NN O
proteolytic NN NN O
stability NN NN O
of NN NN O
this NN NN O
cytoplasmic NN NN O
inhibitor NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
in NN NN O
vivo NN NN O
studies NN NN O
define NN NN O
a NN NN O
critical NN NN O
signal NN NN O
response NN NN O
domain NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
that NN NN O
coordinately NN NN O
controls NN NN O
the NN NN O
biologic NN NN O
activities NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
response NN NN O
to NN NN O
viral NN NN O
and NN NN O
immune NN NN O
stimuli NN NN O
. NN NN O
   
HIV NN NN B-Protein
type NN NN I-Protein
1 NN NN I-Protein
protease NN NN I-Protein
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
within NN NN O
T NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
nuclear NN NN O
protein NN NN O
of NN NN O
the NN NN O
rel NN NN O
oncogene NN NN O
family NN NN O
capable NN NN O
of NN NN O
enhancing NN NN O
transcription NN NN O
of NN NN O
several NN NN O
cellular NN NN O
genes NN NN O
, NN NN O
including NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
the NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
, NN NN O
and NN NN O
viral NN NN O
genes NN NN O
transcribed NN NN O
from NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
reported NN NN O
that NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protease NN NN I-Protein
may NN NN O
cleave NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
precursor NN NN O
to NN NN O
its NN NN O
active NN NN O
form NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
the NN NN O
effects NN NN O
of NN NN O
HIV NN NN B-Protein
protease NN NN I-Protein
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
precursor NN NN O
activation NN NN O
were NN NN O
examined NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
by NN NN O
introducing NN NN O
a NN NN O
protease NN NN O
expression NN NN O
vector NN NN O
into NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
was NN NN O
observed NN NN O
and NN NN O
this NN NN O
increased NN NN O
activity NN NN O
was NN NN O
blocked NN NN O
by NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
the NN NN O
viral NN NN O
protease NN NN O
. NN NN O
   
Viral NN NN O
transcription NN NN O
, NN NN O
as NN NN O
measured NN NN O
using NN NN O
LTR NN NN O
- NN NN O
CAT NN NN B-Protein
assays NN NN O
, NN NN O
was NN NN O
only NN NN O
slightly NN NN O
enhanced NN NN O
in NN NN O
the NN NN O
HIV NN NN B-Protein
- NN NN I-Protein
protease NN NN I-Protein
expressing NN NN O
cells NN NN O
, NN NN O
while NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
were NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
The NN NN O
limited NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
HIV NN NN B-Protein
protease NN NN I-Protein
appears NN NN O
unlikely NN NN O
to NN NN O
have NN NN O
a NN NN O
significant NN NN O
effect NN NN O
on NN NN O
virus NN NN O
expression NN NN O
or NN NN O
T NN NN O
cell NN NN O
function NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
TCDD NN NN B-Protein
receptor NN NN I-Protein
) NN NN O
during NN NN O
human NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
found NN NN O
a NN NN O
high NN NN O
expression NN NN O
of NN NN O
human NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
TCDD NN NN B-Protein
receptor NN NN I-Protein
) NN NN O
mRNA NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
of NN NN O
individuals NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
this NN NN O
gene NN NN O
in NN NN O
blood NN NN O
cells NN NN O
was NN NN O
first NN NN O
investigated NN NN O
in NN NN O
fractions NN NN O
of NN NN O
nucleated NN NN O
cells NN NN O
, NN NN O
revealing NN NN O
predominant NN NN O
expression NN NN O
of NN NN O
the NN NN O
Ah NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
in NN NN O
the NN NN O
monocyte NN NN O
fraction NN NN O
. NN NN O
   
Then NN NN O
the NN NN O
expression NN NN O
levels NN NN O
of NN NN O
AhR NN NN B-Protein
mRNA NN NN O
in NN NN O
various NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
were NN NN O
examined NN NN O
together NN NN O
with NN NN O
those NN NN O
of NN NN O
Arnt NN NN O
and NN NN O
P450IA1 NN NN B-Protein
. NN NN O
   
AhR NN NN B-Protein
was NN NN O
expressed NN NN O
at NN NN O
high NN NN O
levels NN NN O
in NN NN O
monocytoid NN NN O
U937 NN NN O
, NN NN O
THP1 NN NN O
, NN NN O
and NN NN O
HEL NN NN O
/ NN NN O
S NN NN O
cells NN NN O
, NN NN O
and NN NN O
at NN NN O
moderate NN NN O
levels NN NN O
in NN NN O
promyelocytic NN NN O
HL60 NN NN O
cells NN NN O
and NN NN O
erythroblastic NN NN O
HEL NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
MOLT4 NN NN O
( NN NN O
T NN NN O
cell NN NN O
) NN NN O
and NN NN O
BALL1 NN NN O
( NN NN O
B NN NN O
cell NN NN O
) NN NN O
, NN NN O
nor NN NN O
in NN NN O
K562 NN NN O
erythroblasts NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
specific NN NN O
induction NN NN O
of NN NN O
AhR NN NN B-Protein
during NN NN O
monocytic NN NN O
differentiation NN NN O
was NN NN O
investigated NN NN O
in NN NN O
HL60 NN NN O
and NN NN O
HEL NN NN O
cells NN NN O
. NN NN O
   
HL60 NN NN O
cells NN NN O
were NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
toward NN NN O
monocytes NN NN O
- NN NN O
macrophages NN NN O
by NN NN O
incubation NN NN O
with NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
showing NN NN O
a NN NN O
5 NN NN O
- NN NN O
to NN NN O
2 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
of NN NN O
AhR NN NN B-Protein
mRNA NN NN O
. NN NN O
   
The NN NN O
incubation NN NN O
with NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
and NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
resulted NN NN O
in NN NN O
a NN NN O
5 NN NN O
- NN NN O
to NN NN O
7 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
of NN NN O
AhR NN NN B-Protein
mRNA NN NN O
. NN NN O
   
The NN NN O
HEL NN NN O
cells NN NN O
also NN NN O
exhibited NN NN O
a NN NN O
similar NN NN O
elevation NN NN O
of NN NN O
AhR NN NN B-Protein
mRNA NN NN O
level NN NN O
, NN NN O
when NN NN O
they NN NN O
had NN NN O
differentiated NN NN O
toward NN NN O
monocyte NN NN O
- NN NN O
macrophage NN NN O
cells NN NN O
by NN NN O
these NN NN O
combined NN NN O
inducers NN NN O
, NN NN O
but NN NN O
little NN NN O
change NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
was NN NN O
observed NN NN O
when NN NN O
the NN NN O
cells NN NN O
were NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
other NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
the NN NN O
differentiated NN NN O
HL60 NN NN O
cells NN NN O
with NN NN O
3 NN NN O
- NN NN O
methylcholanthrene NN NN O
, NN NN O
a NN NN O
ligand NN NN O
of NN NN O
AhR NN NN B-Protein
, NN NN O
induced NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
P450IA1 NN NN B-Protein
gene NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicated NN NN O
that NN NN O
expression NN NN O
of NN NN O
AhR NN NN B-Protein
mRNA NN NN O
was NN NN O
significantly NN NN O
induced NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
and NN NN O
that NN NN O
the NN NN O
differentiated NN NN O
cells NN NN O
were NN NN O
responsive NN NN O
to NN NN O
xenobiotics NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
AhR NN NN B-Protein
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
function NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
also NN NN O
in NN NN O
the NN NN O
eventual NN NN O
activation NN NN O
of NN NN O
environmental NN NN O
carcinogens NN NN O
. NN NN O
   
Platelet NN NN O
- NN NN O
activating NN NN O
factor NN NN O
( NN NN O
PAF NN NN O
) NN NN O
positively NN NN O
auto NN NN O
- NN NN O
regulates NN NN O
the NN NN O
expression NN NN O
of NN NN O
human NN NN O
PAF NN NN B-Protein
receptor NN NN I-Protein
transcript NN NN O
1 NN NN O
( NN NN O
leukocyte NN NN O
- NN NN O
type NN NN O
) NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
human NN NN O
platelet NN NN B-Protein
- NN NN I-Protein
activating NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
PAFR NN NN B-Protein
) NN NN O
gene NN NN O
is NN NN O
transcribed NN NN O
by NN NN O
two NN NN O
distinct NN NN O
promoters NN NN O
( NN NN O
promoter NN NN O
1 NN NN O
and NN NN O
promoter NN NN O
2 NN NN O
) NN NN O
to NN NN O
generate NN NN O
two NN NN O
transcripts NN NN O
( NN NN O
designated NN NN O
as NN NN O
PAFR NN NN B-Protein
transcript NN NN O
1 NN NN O
and NN NN O
PAFR NN NN B-Protein
transcript NN NN O
2 NN NN O
) NN NN O
, NN NN O
though NN NN O
their NN NN O
open NN NN O
reading NN NN O
frames NN NN O
are NN NN O
identical NN NN O
. NN NN O
   
By NN NN O
primer NN NN O
extension NN NN O
analysis NN NN O
to NN NN O
discriminate NN NN O
two NN NN O
transcripts NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
levels NN NN O
of NN NN O
PAFR NN NN B-Protein
transcript NN NN O
1 NN NN O
( NN NN O
leukocyte NN NN O
- NN NN O
type NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
PAFR NN NN B-Protein
transcript NN NN O
2 NN NN O
( NN NN O
tissue NN NN O
- NN NN O
type NN NN O
) NN NN O
, NN NN O
are NN NN O
upregulated NN NN O
by NN NN O
PAF NN NN O
as NN NN O
well NN NN O
as NN NN O
by NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
in NN NN O
the NN NN O
human NN NN O
stomach NN NN O
cancer NN NN O
cell NN NN O
line NN NN O
( NN NN O
JR NN NN O
- NN NN O
St NN NN O
cells NN NN O
) NN NN O
which NN NN O
expresses NN NN O
both NN NN O
functional NN NN O
PAFR NN NN B-Protein
transcript NN NN O
1 NN NN O
and NN NN O
PAFR NN NN B-Protein
transcript NN NN O
2 NN NN O
endogenously NN NN O
. NN NN O
   
Functional NN NN O
analysis NN NN O
of NN NN O
the NN NN O
promoter NN NN O
1 NN NN O
with NN NN O
a NN NN O
transient NN NN O
expression NN NN O
assay NN NN O
using NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
gene NN NN O
as NN NN O
a NN NN O
reporter NN NN O
showed NN NN O
that NN NN O
both NN NN O
PAF NN NN O
and NN NN O
TPA NN NN O
activated NN NN O
the NN NN O
promoter NN NN O
1 NN NN O
but NN NN O
not NN NN O
the NN NN O
deleted NN NN O
promoter NN NN O
lacking NN NN O
the NN NN O
three NN NN O
consensus NN NN O
binding NN NN O
sites NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
located NN NN O
from NN NN O
- NN NN O
571 NN NN O
bp NN NN O
to NN NN O
- NN NN O
459 NN NN O
bp NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
a NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
positive NN NN O
regulation NN NN O
of NN NN O
PAFR NN NN B-Protein
gene NN NN O
expression NN NN O
by NN NN O
PAF NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
possibly NN NN O
by NN NN O
a NN NN O
phosphorylation NN NN O
reaction NN NN O
involving NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
by NN NN O
PAF NN NN O
. NN NN O
   
Distinct NN NN O
roles NN NN O
of NN NN O
the NN NN O
molecular NN NN O
chaperone NN NN O
hsp90 NN NN O
in NN NN O
modulating NN NN O
dioxin NN NN O
receptor NN NN O
function NN NN O
via NN NN O
the NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
and NN NN O
PAS NN NN O
domains NN NN O
. NN NN O
   
The NN NN O
intracellular NN NN O
dioxin NN NN O
receptor NN NN O
mediates NN NN O
signal NN NN O
transduction NN NN O
by NN NN O
dioxin NN NN O
and NN NN O
functions NN NN O
as NN NN O
a NN NN O
ligand NN NN O
- NN NN O
activated NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
It NN NN O
contains NN NN O
a NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
( NN NN O
bHLH NN NN O
) NN NN O
motif NN NN O
contiguous NN NN O
with NN NN O
a NN NN O
Per NN NN O
- NN NN O
Arnt NN NN O
- NN NN O
Sim NN NN O
( NN NN O
PAS NN NN O
) NN NN O
homology NN NN O
region NN NN O
. NN NN O
   
In NN NN O
extracts NN NN O
from NN NN O
nonstimulated NN NN O
cells NN NN O
the NN NN O
receptor NN NN O
is NN NN O
recovered NN NN O
in NN NN O
an NN NN O
inducible NN NN O
cytoplasmic NN NN O
form NN NN O
associated NN NN O
with NN NN O
the NN NN O
90 NN NN O
- NN NN O
kDa NN NN O
heat NN NN O
shock NN NN O
protein NN NN O
( NN NN O
hsp90 NN NN O
) NN NN O
, NN NN O
a NN NN O
molecular NN NN O
chaperone NN NN O
. NN NN O
   
We NN NN O
have NN NN O
reconstituted NN NN O
ligand NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
receptor NN NN O
to NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
form NN NN O
by NN NN O
using NN NN O
the NN NN O
dioxin NN NN O
receptor NN NN O
and NN NN O
its NN NN O
bHLH NN NN O
- NN NN O
PAS NN NN O
partner NN NN O
factor NN NN O
Arnt NN NN O
expressed NN NN O
by NN NN O
in NN NN O
vitro NN NN O
translation NN NN O
in NN NN O
reticulocyte NN NN O
lysate NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
PAS NN NN O
domain NN NN O
of NN NN O
the NN NN O
receptor NN NN O
resulted NN NN O
in NN NN O
constitutive NN NN O
dimerization NN NN O
with NN NN O
Arnt NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
this NN NN O
receptor NN NN O
mutant NN NN O
showed NN NN O
low NN NN O
levels NN NN O
of NN NN O
xenobiotic NN NN O
response NN NN O
element NN NN O
- NN NN O
binding NN NN O
activity NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
PAS NN NN O
domain NN NN O
may NN NN O
be NN NN O
important NN NN O
for NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
affinity NN NN O
and NN NN O
/ NN NN O
or NN NN O
specificity NN NN O
of NN NN O
the NN NN O
receptor NN NN O
. NN NN O
   
It NN NN O
was NN NN O
not NN NN O
possible NN NN O
to NN NN O
reconstitute NN NN O
dioxin NN NN O
receptor NN NN O
function NN NN O
with NN NN O
proteins NN NN O
expressed NN NN O
in NN NN O
wheat NN NN O
germ NN NN O
lysate NN NN O
. NN NN O
   
In NN NN O
line NN NN O
with NN NN O
these NN NN O
observations NN NN O
, NN NN O
reticulocyte NN NN O
lysate NN NN O
but NN NN O
not NN NN O
wheat NN NN O
germ NN NN O
lysate NN NN O
promoted NN NN O
the NN NN O
association NN NN O
of NN NN O
de NN NN O
novo NN NN O
synthesized NN NN O
dioxin NN NN O
receptor NN NN O
with NN NN O
hsp90 NN NN O
. NN NN O
   
At NN NN O
least NN NN O
two NN NN O
distinct NN NN O
domains NN NN O
of NN NN O
the NN NN O
receptor NN NN O
mediated NN NN O
interaction NN NN O
with NN NN O
hsp90 NN NN O
: NN NN O
the NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
domain NN NN O
located NN NN O
within NN NN O
the NN NN O
PAS NN NN O
region NN NN O
and NN NN O
, NN NN O
surprisingly NN NN O
, NN NN O
the NN NN O
bHLH NN NN O
domain NN NN O
. NN NN O
   
Whereas NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
activity NN NN O
correlated NN NN O
with NN NN O
association NN NN O
with NN NN O
hsp90 NN NN O
, NN NN O
bHLH NN NN O
- NN NN O
hsp90 NN NN O
interaction NN NN O
appeared NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
but NN NN O
not NN NN O
for NN NN O
dimerization NN NN O
of NN NN O
the NN NN O
receptor NN NN O
. NN NN O
   
Several NN NN O
distinct NN NN O
roles NN NN O
for NN NN O
hsp90 NN NN O
in NN NN O
modulating NN NN O
dioxin NN NN O
receptor NN NN O
function NN NN O
are NN NN O
therefore NN NN O
likely NN NN O
: NN NN O
correct NN NN O
folding NN NN O
of NN NN O
the NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
domain NN NN O
, NN NN O
interference NN NN O
with NN NN O
Arnt NN NN O
heterodimerization NN NN O
, NN NN O
and NN NN O
folding NN NN O
of NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
conformation NN NN O
of NN NN O
the NN NN O
bHLH NN NN O
domain NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
dioxin NN NN O
receptor NN NN O
system NN NN O
provides NN NN O
a NN NN O
complex NN NN O
and NN NN O
interesting NN NN O
model NN NN O
of NN NN O
the NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
by NN NN O
hsp90 NN NN O
. NN NN O
   
T NN NN O
- NN NN O
cell NN NN O
functional NN NN O
regions NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
proximal NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
expressed NN NN O
almost NN NN O
exclusively NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Its NN NN O
expression NN NN O
is NN NN O
regulated NN NN O
at NN NN O
both NN NN O
the NN NN O
transcriptional NN NN O
and NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
treatment NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
with NN NN O
phytohemaglutinin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
PMA NN NN O
, NN NN O
activated NN NN O
transcription NN NN O
initiation NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
. NN NN O
   
To NN NN O
define NN NN O
the NN NN O
regions NN NN O
of NN NN O
the NN NN O
gene NN NN O
required NN NN O
for NN NN O
transcription NN NN O
activation NN NN O
, NN NN O
we NN NN O
generated NN NN O
a NN NN O
series NN NN O
of NN NN O
reporter NN NN O
constructs NN NN O
containing NN NN O
different NN NN O
regions NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
5 NN NN O
' NN NN O
and NN NN O
3 NN NN O
' NN NN O
flanking NN NN O
sequences NN NN O
. NN NN O
   
Both NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
elements NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
proximal NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
region NN NN O
between NN NN O
- NN NN O
173 NN NN O
and NN NN O
- NN NN O
60 NN NN O
contained NN NN O
the NN NN O
strongest NN NN O
activating NN NN O
elements NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
could NN NN O
bind NN NN O
to NN NN O
this NN NN O
positive NN NN O
activator NN NN O
region NN NN O
of NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
CK NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
CK NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
elements NN NN O
that NN NN O
are NN NN O
present NN NN O
in NN NN O
many NN NN O
cytokine NN NN O
genes NN NN O
and NN NN O
found NN NN O
that NN NN O
they NN NN O
acted NN NN O
as NN NN O
a NN NN O
repressor NN NN O
of NN NN O
basal NN NN O
level NN NN O
expression NN NN O
when NN NN O
cloned NN NN O
upstream NN NN O
of NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
but NN NN O
were NN NN O
also NN NN O
inducible NN NN O
by NN NN O
PMA NN NN O
/ NN NN O
PHA NN NN B-Protein
. NN NN O
   
Two NN NN O
distinct NN NN O
signalling NN NN O
pathways NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
biphasic NN NN O
junB NN NN B-Protein
transcription NN NN O
induced NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
the NN NN O
B NN NN O
cell NN NN O
hybridoma NN NN O
7TD1 NN NN O
. NN NN O
   
We NN NN O
have NN NN O
measured NN NN O
the NN NN O
level NN NN O
of NN NN O
junB NN NN B-Protein
mRNA NN NN O
in NN NN O
the NN NN O
B NN NN O
hybridoma NN NN O
cell NN NN O
line NN NN O
7TD1 NN NN O
, NN NN O
under NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
stimulation NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
increases NN NN O
junB NN NN B-Protein
mRNA NN NN O
in NN NN O
a NN NN O
biphasic NN NN O
fashion NN NN O
. NN NN O
   
The NN NN O
first NN NN O
early NN NN O
- NN NN O
induced NN NN O
peak NN NN O
was NN NN O
transient NN NN O
and NN NN O
likely NN NN O
corresponds NN NN O
to NN NN O
the NN NN O
well NN NN O
documented NN NN O
typical NN NN O
junB NN NN B-Protein
mRNA NN NN O
, NN NN O
stimulated NN NN O
in NN NN O
response NN NN O
to NN NN O
numerous NN NN O
growth NN NN O
factors NN NN O
, NN NN O
including NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
At NN NN O
variance NN NN O
, NN NN O
the NN NN O
second NN NN O
peak NN NN O
which NN NN O
has NN NN O
never NN NN O
been NN NN O
reported NN NN O
previously NN NN O
, NN NN O
lasted NN NN O
several NN NN O
hours NN NN O
. NN NN O
   
As NN NN O
a NN NN O
consequence NN NN O
of NN NN O
its NN NN O
effect NN NN O
on NN NN O
junB NN NN B-Protein
mRNA NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
stimulated NN NN O
, NN NN O
in NN NN O
a NN NN O
biphasic NN NN O
fashion NN NN O
, NN NN O
the NN NN O
nuclear NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
JunB NN NN B-Protein
protein NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
regulation NN NN O
occurred NN NN O
exclusively NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
and NN NN O
that NN NN O
the NN NN O
bimodal NN NN O
increase NN NN O
of NN NN O
junB NN NN B-Protein
mRNA NN NN O
and NN NN O
JunB NN NN B-Protein
protein NN NN O
can NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
a NN NN O
biphasic NN NN O
stimulation NN NN O
of NN NN O
junB NN NN B-Protein
transcription NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
our NN NN O
data NN NN O
point NN NN O
to NN NN O
two NN NN O
major NN NN O
differences NN NN O
between NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
control NN NN O
of NN NN O
the NN NN O
early NN NN O
and NN NN O
the NN NN O
late NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
- NN NN O
induced NN NN O
junB NN NN B-Protein
transcription NN NN O
waves NN NN O
. NN NN O
   
First NN NN O
, NN NN O
cycloheximide NN NN O
strongly NN NN O
potentiated NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
second NN NN O
wave NN NN O
, NN NN O
whereas NN NN O
it NN NN O
failed NN NN O
to NN NN O
affect NN NN O
the NN NN O
early NN NN O
- NN NN O
induced NN NN O
burst NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
tyrphostin NN NN O
, NN NN O
a NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
impaired NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
first NN NN O
but NN NN O
not NN NN O
the NN NN O
second NN NN O
junB NN NN B-Protein
mRNA NN NN O
peak NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
genistein NN NN O
, NN NN O
another NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
totally NN NN O
abolished NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
second NN NN O
peak NN NN O
of NN NN O
junB NN NN B-Protein
mRNA NN NN O
whereas NN NN O
it NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
first NN NN O
peak NN NN O
. NN NN O
   
Altogether NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
, NN NN O
in NN NN O
7TD1 NN NN O
cells NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
controls NN NN O
junB NN NN B-Protein
transcription NN NN O
in NN NN O
a NN NN O
biphasic NN NN O
fashion NN NN O
by NN NN O
means NN NN O
of NN NN O
two NN NN O
separate NN NN O
transduction NN NN O
pathways NN NN O
. NN NN O
   
Biphasic NN NN O
control NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
the NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
complex NN NN O
: NN NN O
role NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
the NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TcR NN NN O
) NN NN O
/ NN NN O
CD3 NN NN O
complex NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
cells NN NN O
has NN NN O
been NN NN O
studied NN NN O
at NN NN O
various NN NN O
times NN NN O
after NN NN O
activation NN NN O
. NN NN O
   
Only NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
bound NN NN O
the NN NN O
kappa NN NN O
B NN NN O
element NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
( NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2R NN NN I-Protein
) NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
promoter NN NN O
on NN NN O
resting NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
immediately NN NN O
after NN NN O
TcR NN NN O
/ NN NN O
CD3 NN NN O
cross NN NN O
- NN NN O
linking NN NN O
( NN NN O
after NN NN O
approximately NN NN O
1 NN NN O
h NN NN O
; NN NN O
immediate NN NN O
) NN NN O
binding NN NN O
of NN NN O
p50 NN NN B-Protein
. NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
p50 NN NN B-Protein
. NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
heterodimers NN NN O
were NN NN O
also NN NN O
detected NN NN O
bound NN NN O
to NN NN O
this NN NN O
sequence NN NN O
at NN NN O
early NN NN O
time NN NN O
points NN NN O
( NN NN O
7 NN NN O
- NN NN O
16 NN NN O
h NN NN O
; NN NN O
early NN NN O
) NN NN O
, NN NN O
and NN NN O
both NN NN O
remained NN NN O
active NN NN O
at NN NN O
later NN NN O
time NN NN O
points NN NN O
( NN NN O
40 NN NN O
h NN NN O
; NN NN O
late NN NN O
) NN NN O
after NN NN O
activation NN NN O
. NN NN O
   
This NN NN O
regulation NN NN O
takes NN NN O
place NN NN O
mainly NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
at NN NN O
immediate NN NN O
and NN NN O
early NN NN O
time NN NN O
points NN NN O
. NN NN O
   
Activation NN NN O
also NN NN O
induced NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
and NN NN O
p105 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
mRNA NN NN O
synthesis NN NN O
, NN NN O
but NN NN O
not NN NN O
p65 NN NN B-Protein
mRNA NN NN O
whose NN NN O
expression NN NN O
was NN NN O
constitutive NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
all NN NN O
those NN NN O
early NN NN O
and NN NN O
late NN NN O
events NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
immediate NN NN O
ones NN NN O
, NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
monoclonal NN NN O
antibody NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
cycloheximide NN NN O
prevented NN NN O
the NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
translocation NN NN O
and NN NN O
consequent NN NN O
formation NN NN O
of NN NN O
active NN NN O
binding NN NN O
heterodimers NN NN O
, NN NN O
at NN NN O
early NN NN O
and NN NN O
late NN NN O
times NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
impaired NN NN O
not NN NN O
only NN NN O
early NN NN O
and NN NN O
late NN NN O
, NN NN O
but NN NN O
also NN NN O
immediate NN NN O
events NN NN O
; NN NN O
however NN NN O
, NN NN O
addition NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
prevented NN NN O
all NN NN O
inhibition NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
by NN NN O
TcR NN NN O
/ NN NN O
CD3 NN NN O
signals NN NN O
is NN NN O
biphasic NN NN O
: NN NN O
TcR NN NN O
/ NN NN O
CD3 NN NN O
triggers NN NN O
its NN NN O
immediate NN NN O
translocation NN NN O
, NN NN O
which NN NN O
is NN NN O
transient NN NN O
if NN NN O
no NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
present NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
therefore NN NN O
, NN NN O
emerges NN NN O
as NN NN O
the NN NN O
main NN NN O
factor NN NN O
responsible NN NN O
for NN NN O
a NN NN O
second NN NN O
phase NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
regulation NN NN O
, NN NN O
controlling NN NN O
both NN NN O
translocation NN NN O
of NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
and NN NN O
new NN NN O
mRNA NN NN O
synthesis NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
and NN NN O
p105 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
is NN NN O
not NN NN O
a NN NN O
downstream NN NN O
effector NN NN O
of NN NN O
p21ras NN NN B-Protein
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
, NN NN O
downstream NN NN O
of NN NN O
p21ras NN NN B-Protein
, NN NN O
in NN NN O
activating NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
reported NN NN O
that NN NN O
PKC NN NN O
is NN NN O
an NN NN O
effector NN NN O
of NN NN O
p21ras NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Data NN NN O
is NN NN O
presented NN NN O
, NN NN O
using NN NN O
the NN NN O
potent NN NN O
and NN NN O
selective NN NN O
PKC NN NN O
inhibitor NN NN O
Ro NN NN O
31 NN NN O
- NN NN O
8425 NN NN O
and NN NN O
transient NN NN O
expression NN NN O
of NN NN O
a NN NN O
constitutively NN NN O
active NN NN O
ras NN NN O
mutant NN NN O
, NN NN O
which NN NN O
clearly NN NN O
shows NN NN O
that NN NN O
PKC NN NN O
is NN NN O
not NN NN O
downstream NN NN O
of NN NN O
p21ras NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
and NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Reporter NN NN O
gene NN NN O
experiments NN NN O
demonstrated NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcriptional NN NN O
activity NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
expression NN NN O
of NN NN O
activated NN NN O
p21ras NN NN B-Protein
. NN NN O
   
The NN NN O
signaling NN NN O
pathways NN NN O
involving NN NN O
PKC NN NN O
activation NN NN O
, NN NN O
calcium NN NN O
mobilization NN NN O
and NN NN O
ras NN NN O
activation NN NN O
combine NN NN O
to NN NN O
provide NN NN O
the NN NN O
necessary NN NN O
components NN NN O
for NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Association NN NN O
of NN NN O
alterations NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
moieties NN NN O
with NN NN O
HIV NN NN O
type NN NN O
1 NN NN O
proviral NN NN O
latency NN NN O
in NN NN O
certain NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
is NN NN O
controlled NN NN O
by NN NN O
a NN NN O
complex NN NN O
array NN NN O
of NN NN O
virally NN NN O
encoded NN NN O
and NN NN O
cellular NN NN O
proteins NN NN O
. NN NN O
   
A NN NN O
wide NN NN O
spectrum NN NN O
of NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
have NN NN O
been NN NN O
demonstrated NN NN O
in NN NN O
various NN NN O
cells NN NN O
, NN NN O
both NN NN O
in NN NN O
cell NN NN O
culture NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Molecular NN NN O
mechanisms NN NN O
leading NN NN O
to NN NN O
restricted NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
may NN NN O
differ NN NN O
between NN NN O
certain NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
It NN NN O
is NN NN O
now NN NN O
demonstrated NN NN O
that NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
proviral NN NN O
latency NN NN O
in NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
U1 NN NN O
, NN NN O
in NN NN O
which NN NN O
only NN NN O
extremely NN NN O
low NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
are NN NN O
detected NN NN O
in NN NN O
the NN NN O
baseline NN NN O
unstimulated NN NN O
state NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
alterations NN NN O
in NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
moieties NN NN O
demonstrated NN NN O
in NN NN O
these NN NN O
cells NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
and NN NN O
in NN NN O
situ NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
studies NN NN O
. NN NN O
   
A NN NN O
predominance NN NN O
of NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
moieties NN NN O
and NN NN O
possibly NN NN O
p50 NN NN B-Protein
homodimers NN NN O
or NN NN O
closely NN NN O
related NN NN O
species NN NN O
, NN NN O
rather NN NN O
than NN NN O
the NN NN O
p50 NN NN B-Protein
- NN NN O
p56 NN NN B-Protein
heterodimer NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
that NN NN O
is NN NN O
the NN NN O
predominant NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
species NN NN O
in NN NN O
most NN NN O
T NN NN O
lymphocytic NN NN O
and NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
is NN NN O
demonstrated NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
U1 NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
pattern NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
related NN NN O
moieties NN NN O
differs NN NN O
from NN NN O
the NN NN O
latently NN NN O
infected NN NN O
T NN NN O
lymphocytic NN NN O
cell NN NN O
line NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
, NN NN O
and NN NN O
from NN NN O
the NN NN O
U937 NN NN O
monocytic NN NN O
line NN NN O
, NN NN O
the NN NN O
parental NN NN O
cell NN NN O
line NN NN O
of NN NN O
the NN NN O
U1 NN NN O
cellular NN NN O
clone NN NN O
. NN NN O
   
As NN NN O
such NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
different NN NN O
proximal NN NN O
mechanisms NN NN O
may NN NN O
lead NN NN O
to NN NN O
restricted NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
various NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
protein NN NN B-Protein
kinase NN NN I-Protein
C NN NN I-Protein
- NN NN I-Protein
zeta NN NN I-Protein
stimulates NN NN O
leukemic NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
A NN NN O
function NN NN O
for NN NN O
protein NN NN B-Protein
kinase NN NN I-Protein
C NN NN I-Protein
- NN NN I-Protein
zeta NN NN I-Protein
( NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
nonresponsive NN NN O
atypical NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
subfamily NN NN O
, NN NN O
in NN NN O
modulating NN NN O
differentiation NN NN O
was NN NN O
examined NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
U937 NN NN O
cell NN NN O
. NN NN O
   
Transfected NN NN O
U937 NN NN O
cells NN NN O
stably NN NN O
overexpressing NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
displayed NN NN O
a NN NN O
longer NN NN O
doubling NN NN O
time NN NN O
, NN NN O
lower NN NN O
saturation NN NN O
density NN NN O
at NN NN O
confluency NN NN O
, NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
adherence NN NN O
to NN NN O
plastic NN NN O
as NN NN O
compared NN NN O
to NN NN O
control NN NN O
cells NN NN O
. NN NN O
   
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
cells NN NN O
expressed NN NN O
a NN NN O
more NN NN O
differentiated NN NN O
phenotype NN NN O
as NN NN O
assessed NN NN O
by NN NN O
changes NN NN O
in NN NN O
morphology NN NN O
, NN NN O
surface NN NN O
antigen NN NN O
expression NN NN O
, NN NN O
and NN NN O
lysosomal NN NN O
enzyme NN NN O
activities NN NN O
and NN NN O
were NN NN O
distinct NN NN O
from NN NN O
parental NN NN O
U937 NN NN O
cells NN NN O
stimulated NN NN O
to NN NN O
differentiate NN NN O
by NN NN O
exposure NN NN O
to NN NN O
phorbol NN NN O
esters NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
parental NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
cells NN NN O
constitutively NN NN O
expressed NN NN O
mRNA NN NN O
transcripts NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
a NN NN O
low NN NN O
mobility NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
overexpression NN NN O
stimulates NN NN O
a NN NN O
type NN NN O
of NN NN O
phenotypic NN NN O
differentiation NN NN O
that NN NN O
differs NN NN O
significantly NN NN O
from NN NN O
maturation NN NN O
occurring NN NN O
upon NN NN O
activation NN NN O
of NN NN O
other NN NN O
PKC NN NN O
subfamilies NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
treatment NN NN O
. NN NN O
   
Increased NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
protooncogene NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
in NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
cells NN NN O
provides NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
for NN NN O
explaining NN NN O
the NN NN O
altered NN NN O
differentiation NN NN O
status NN NN O
of NN NN O
this NN NN O
cell NN NN O
. NN NN O
   
Posttranscriptional NN NN O
regulation NN NN O
of NN NN O
macrophage NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
expression NN NN O
by NN NN O
antioxidants NN NN O
. NN NN O
   
Tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
expression NN NN O
by NN NN O
cells NN NN O
of NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
represents NN NN O
an NN NN O
important NN NN O
mechanism NN NN O
underlying NN NN O
the NN NN O
initiation NN NN O
of NN NN O
fibrin NN NN O
deposition NN NN O
at NN NN O
sites NN NN O
of NN NN O
extravascular NN NN O
inflammation NN NN O
. NN NN O
   
Recent NN NN O
evidence NN NN O
suggests NN NN O
a NN NN O
role NN NN O
for NN NN O
oxidant NN NN O
stress NN NN O
in NN NN O
the NN NN O
signalling NN NN O
pathway NN NN O
of NN NN O
various NN NN O
cell NN NN O
types NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
ability NN NN O
to NN NN O
induce NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
various NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
including NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
antioxidant NN NN O
treatment NN NN O
on NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
induced NN NN O
TF NN NN B-Protein
expression NN NN O
was NN NN O
examined NN NN O
in NN NN O
murine NN NN O
peritoneal NN NN O
macrophages NN NN O
and NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Both NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
, NN NN O
an NN NN O
oxidant NN NN O
scavenger NN NN O
, NN NN O
and NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
cysteine NN NN O
, NN NN O
a NN NN O
precursor NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
antioxidant NN NN O
glutathione NN NN O
, NN NN O
inhibited NN NN O
stimulation NN NN O
of NN NN O
macrophage NN NN O
procoagulant NN NN O
activity NN NN O
by NN NN O
LPS NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
neither NN NN O
of NN NN O
these NN NN O
agents NN NN O
reduced NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
TF NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
, NN NN O
thereby NN NN O
suggesting NN NN O
a NN NN O
posttranscriptional NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
effect NN NN O
. NN NN O
   
Immunofluorescence NN NN O
studies NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
using NN NN O
polyclonal NN NN O
anti NN NN O
- NN NN O
TF NN NN B-Protein
antibody NN NN O
showed NN NN O
that NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
cysteine NN NN O
treatment NN NN O
prevented NN NN O
the NN NN O
characteristic NN NN O
plasmalemmal NN NN O
localization NN NN O
of NN NN O
TF NN NN B-Protein
antigen NN NN O
that NN NN O
occurs NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
cysteine NN NN O
reduced NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
47 NN NN O
- NN NN O
kD NN NN O
mature NN NN O
glycoprotein NN NN O
in NN NN O
LPS NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
a NN NN O
finding NN NN O
consistent NN NN O
with NN NN O
the NN NN O
results NN NN O
of NN NN O
the NN NN O
immunofluorescence NN NN O
studies NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
conditions NN NN O
did NN NN O
not NN NN O
result NN NN O
in NN NN O
an NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
less NN NN O
mature NN NN O
forms NN NN O
of NN NN O
TF NN NN B-Protein
. NN NN O
   
When NN NN O
considered NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
antioxidants NN NN O
exert NN NN O
their NN NN O
effects NN NN O
by NN NN O
impairing NN NN O
translation NN NN O
and NN NN O
/ NN NN O
or NN NN O
by NN NN O
causing NN NN O
degradation NN NN O
of NN NN O
newly NN NN O
translated NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
antioxidants NN NN O
on NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
appeared NN NN O
to NN NN O
be NN NN O
species NN NN O
specific NN NN O
, NN NN O
with NN NN O
no NN NN O
effect NN NN O
on NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
in NN NN O
murine NN NN O
cells NN NN O
, NN NN O
but NN NN O
with NN NN O
inhibition NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
posttranscriptional NN NN O
effect NN NN O
of NN NN O
antioxidants NN NN O
on NN NN O
TF NN NN B-Protein
expression NN NN O
data NN NN O
suggests NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
whereby NN NN O
these NN NN O
agents NN NN O
might NN NN O
modulate NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
activation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
p105 NN NN B-Protein
in NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
persistently NN NN O
infected NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
regulating NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
persistence NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
are NN NN O
partially NN NN O
understood NN NN O
. NN NN O
   
Persistent NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
U937 NN NN O
monocytic NN NN O
cells NN NN O
results NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Whether NN NN O
virus NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
is NN NN O
a NN NN O
mechanism NN NN O
that NN NN O
favors NN NN O
continuous NN NN O
viral NN NN O
replication NN NN O
in NN NN O
macrophages NN NN O
remains NN NN O
unknown NN NN O
. NN NN O
   
To NN NN O
further NN NN O
delineate NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
, NN NN O
we NN NN O
have NN NN O
focused NN NN O
on NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
I NN NN O
kappa NN NN O
B NN NN O
molecules NN NN O
. NN NN O
   
First NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
persistent NN NN O
HIV NN NN O
infection NN NN O
results NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
not NN NN O
only NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
but NN NN O
also NN NN O
in NN NN O
macrophages NN NN O
. NN NN O
   
In NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
cells NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
levels NN NN O
are NN NN O
decreased NN NN O
secondary NN NN O
to NN NN O
enhanced NN NN O
protein NN NN O
degradation NN NN O
. NN NN O
   
This NN NN O
parallels NN NN O
the NN NN O
increased NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
secondary NN NN O
to NN NN O
increased NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
increased NN NN O
RNA NN NN O
and NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
its NN NN O
promoter NN NN O
- NN NN O
enhancer NN NN O
. NN NN O
   
Another NN NN O
protein NN NN O
with NN NN O
I NN NN O
kappa NN NN O
B NN NN O
function NN NN O
, NN NN O
p105 NN NN B-Protein
, NN NN O
is NN NN O
also NN NN O
modified NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
cells NN NN O
: NN NN O
p105 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
steady NN NN O
- NN NN O
state NN NN O
protein NN NN O
levels NN NN O
are NN NN O
increased NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
increased NN NN O
synthesis NN NN O
and NN NN O
proteolytic NN NN O
processing NN NN O
of NN NN O
p105 NN NN B-Protein
. NN NN O
   
Transcriptional NN NN O
activity NN NN O
of NN NN O
p105 NN NN B-Protein
is NN NN O
also NN NN O
increased NN NN O
in NN NN O
infected NN NN O
cells NN NN O
and NN NN O
is NN NN O
also NN NN O
mediated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
through NN NN O
a NN NN O
specific NN NN O
kappa NN NN O
B NN NN O
motif NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
triple NN NN O
autoregulatory NN NN O
loop NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
involving NN NN O
HIV NN NN O
, NN NN O
p105 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
, NN NN O
and NN NN O
MAD3 NN NN B-Protein
, NN NN O
with NN NN O
the NN NN O
end NN NN O
result NN NN O
of NN NN O
persistent NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
viral NN NN O
persistence NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
persistent NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
provides NN NN O
a NN NN O
useful NN NN O
model NN NN O
with NN NN O
which NN NN O
to NN NN O
study NN NN O
concomitant NN NN O
modifications NN NN O
of NN NN O
different NN NN O
I NN NN O
kappa NN NN O
B NN NN O
molecules NN NN O
. NN NN O
   
Expression NN NN O
and NN NN O
genomic NN NN O
configuration NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
C NN NN B-Protein
- NN NN I-Protein
FMS NN NN I-Protein
) NN NN O
, NN NN O
early NN NN B-Protein
growth NN NN I-Protein
response NN NN I-Protein
gene NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
genes NN NN O
in NN NN O
primary NN NN O
myelodysplastic NN NN O
syndromes NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
seventeen NN NN O
patients NN NN O
with NN NN O
primary NN NN O
myelodysplastic NN NN O
syndromes NN NN O
( NN NN O
MDS NN NN O
) NN NN O
in NN NN O
advanced NN NN O
stage NN NN O
were NN NN O
enriched NN NN O
for NN NN O
blasts NN NN O
and NN NN O
tested NN NN O
for NN NN O
( NN NN O
1 NN NN O
) NN NN O
karyotype NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
genomic NN NN O
configuration NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
FMS NN NN B-Protein
and NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
which NN NN O
are NN NN O
all NN NN O
located NN NN O
on NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
, NN NN O
that NN NN O
has NN NN O
been NN NN O
recently NN NN O
reassigned NN NN O
to NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
1 NN NN O
( NN NN O
lp NN NN O
) NN NN O
, NN NN O
was NN NN O
also NN NN O
investigated NN NN O
. NN NN O
   
Aims NN NN O
of NN NN O
the NN NN O
study NN NN O
were NN NN O
to NN NN O
( NN NN O
1 NN NN O
) NN NN O
assess NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
and NN NN O
expansion NN NN O
of NN NN O
the NN NN O
neoplastic NN NN O
clones NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
search NN NN O
for NN NN O
constitutional NN NN O
losses NN NN O
or NN NN O
rearrangements NN NN O
of NN NN O
one NN NN O
allele NN NN O
followed NN NN O
by NN NN O
a NN NN O
deletion NN NN O
of NN NN O
the NN NN O
second NN NN O
allele NN NN O
of NN NN O
the NN NN O
same NN NN O
genes NN NN O
in NN NN O
the NN NN O
leukemic NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
latter NN NN O
issue NN NN O
was NN NN O
investigated NN NN O
by NN NN O
comparing NN NN O
, NN NN O
in NN NN O
8 NN NN O
cases NN NN O
, NN NN O
constitutive NN NN O
DNA NN NN O
from NN NN O
skin NN NN O
fibroblasts NN NN O
with NN NN O
leukemic NN NN O
DNA NN NN O
. NN NN O
   
Eleven NN NN O
of NN NN O
the NN NN O
17 NN NN O
patients NN NN O
had NN NN O
abnormal NN NN O
karyotypes NN NN O
. NN NN O
   
The NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
was NN NN O
expressed NN NN O
in NN NN O
6 NN NN O
cases NN NN O
and NN NN O
the NN NN O
FMS NN NN B-Protein
and NN NN O
the NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
were NN NN O
expressed NN NN O
in NN NN O
2 NN NN O
of NN NN O
the NN NN O
latter NN NN O
cases NN NN O
. NN NN O
   
An NN NN O
autocrine NN NN O
mechanism NN NN O
of NN NN O
growth NN NN O
could NN NN O
be NN NN O
hypothesized NN NN O
only NN NN O
for NN NN O
the NN NN O
2 NN NN O
patients NN NN O
whose NN NN O
cells NN NN O
expressed NN NN O
both NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
FMS NN NN B-Protein
genes NN NN O
. NN NN O
   
No NN NN O
germline NN NN O
changes NN NN O
or NN NN O
rearrangements NN NN O
were NN NN O
observed NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
genes NN NN O
studied NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
deregulation NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
for NN NN O
certain NN NN O
hemopoietic NN NN O
growth NN NN O
factors NN NN O
or NN NN O
receptors NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
represent NN NN O
a NN NN O
major NN NN O
mechanism NN NN O
of NN NN O
MDS NN NN O
progression NN NN O
. NN NN O
   
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
a NN NN O
novel NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
coactivator NN NN O
that NN NN O
stimulates NN NN O
immunoglobulin NN NN O
promoter NN NN O
activity NN NN O
through NN NN O
association NN NN O
with NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
Recent NN NN O
biochemical NN NN O
and NN NN O
genetic NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
other NN NN O
B NN NN O
cell NN NN O
components NN NN O
are NN NN O
required NN NN O
for NN NN O
lymphoid NN NN O
- NN NN O
restricted NN NN O
, NN NN O
octamer NN NN O
site NN NN O
- NN NN O
mediated NN NN O
immunoglobulin NN NN O
gene NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
genetic NN NN O
screen NN NN O
in NN NN O
yeast NN NN O
, NN NN O
we NN NN O
have NN NN O
isolated NN NN O
B NN NN O
cell NN NN O
- NN NN O
derived NN NN O
cDNAs NN NN O
encoding NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
binding NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
( NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
novel NN NN O
protein NN NN O
that NN NN O
specifically NN NN O
associates NN NN O
with NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Biochemical NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
has NN NN O
no NN NN O
intrinsic NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
and NN NN O
recognizes NN NN O
the NN NN O
POU NN NN O
domains NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
those NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
The NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
highly NN NN O
cell NN NN O
- NN NN O
specific NN NN O
manner NN NN O
, NN NN O
being NN NN O
most NN NN O
abundant NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
essentially NN NN O
absent NN NN O
in NN NN O
most NN NN O
of NN NN O
the NN NN O
other NN NN O
cells NN NN O
or NN NN O
tissues NN NN O
tested NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
expression NN NN O
of NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
HeLa NN NN O
cells NN NN O
selectively NN NN O
stimulates NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
natural NN NN O
immunoglobulin NN NN O
promoter NN NN O
in NN NN O
an NN NN O
octamer NN NN O
site NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
has NN NN O
all NN NN O
the NN NN O
properties NN NN O
expected NN NN O
for NN NN O
a NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
coactivator NN NN O
protein NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
human NN NN O
leukemic NN NN O
cells NN NN O
is NN NN O
caused NN NN O
by NN NN O
the NN NN O
repressive NN NN O
function NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
Induction NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
lymphocytes NN NN O
, NN NN O
which NN NN O
may NN NN O
account NN NN O
for NN NN O
the NN NN O
therapeutic NN NN O
effects NN NN O
of NN NN O
glucocorticoids NN NN O
in NN NN O
various NN NN O
diseases NN NN O
including NN NN O
leukemia NN NN O
, NN NN O
depends NN NN O
on NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
events NN NN O
leading NN NN O
from NN NN O
the NN NN O
activated NN NN O
receptor NN NN O
to NN NN O
cell NN NN O
lysis NN NN O
are NN NN O
not NN NN O
understood NN NN O
. NN NN O
   
A NN NN O
prevailing NN NN O
hypothesis NN NN O
postulates NN NN O
induction NN NN O
of NN NN O
so NN NN O
- NN NN O
called NN NN O
' NN NN O
lysis NN NN O
genes NN NN O
' NN NN O
by NN NN O
the NN NN O
activated NN NN O
receptor NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
an NN NN O
activation NN NN O
- NN NN O
deficient NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
mutant NN NN O
is NN NN O
as NN NN O
effective NN NN O
as NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
receptor NN NN O
in NN NN O
repression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
expression NN NN O
and NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
retinoic NN NN O
acid NN NN O
can NN NN O
also NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
these NN NN O
cells NN NN O
through NN NN O
the NN NN O
retinoic NN NN O
acid NN NN O
receptor NN NN O
, NN NN O
whose NN NN O
repressive NN NN O
functions NN NN O
but NN NN O
not NN NN O
target NN NN O
site NN NN O
specificity NN NN O
, NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
primary NN NN O
effect NN NN O
of NN NN O
the NN NN O
receptor NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
mediated NN NN O
apoptosis NN NN O
correlates NN NN O
with NN NN O
transcriptional NN NN O
repression NN NN O
rather NN NN O
than NN NN O
activation NN NN O
and NN NN O
could NN NN O
be NN NN O
mediated NN NN O
by NN NN O
interference NN NN O
with NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
required NN NN O
for NN NN O
cell NN NN O
survival NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
potentiates NN NN O
TNF NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
cytotoxicity NN NN O
by NN NN O
altering NN NN O
the NN NN O
cellular NN NN O
redox NN NN O
state NN NN O
. NN NN O
   
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tat NN NN B-Protein
protein NN NN O
amplifies NN NN O
the NN NN O
activity NN NN O
of NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
, NN NN O
a NN NN O
cytokine NN NN O
that NN NN O
stimulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
through NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
In NN NN O
HeLa NN NN O
cells NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
tat NN NN O
gene NN NN O
( NN NN O
HeLa NN NN O
- NN NN O
tat NN NN O
cells NN NN O
) NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
Tat NN NN B-Protein
protein NN NN O
enhanced NN NN O
both NN NN O
TNF NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
TNF NN NN O
- NN NN O
mediated NN NN O
cytotoxicity NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
potentiation NN NN O
of NN NN O
TNF NN NN O
effects NN NN O
was NN NN O
observed NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
treated NN NN O
with NN NN O
soluble NN NN O
Tat NN NN B-Protein
protein NN NN O
. NN NN O
   
TNF NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
cytotoxicity NN NN O
involves NN NN O
the NN NN O
intracellular NN NN O
formation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
Tat NN NN B-Protein
- NN NN O
mediated NN NN O
effects NN NN O
on NN NN O
the NN NN O
cellular NN NN O
redox NN NN O
state NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
In NN NN O
both NN NN O
T NN NN O
cells NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
suppressed NN NN O
the NN NN O
expression NN NN O
of NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
dependent NN NN I-Protein
superoxide NN NN I-Protein
dismutase NN NN I-Protein
( NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
SOD NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
mitochondrial NN NN O
enzyme NN NN O
that NN NN O
is NN NN O
part NN NN O
of NN NN O
the NN NN O
cellular NN NN O
defense NN NN O
system NN NN O
against NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
SOD NN NN I-Protein
RNA NN NN O
protein NN NN O
levels NN NN O
and NN NN O
activity NN NN O
were NN NN O
markedly NN NN O
reduced NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
Tat NN NN B-Protein
. NN NN O
   
Decreased NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
SOD NN NN I-Protein
expression NN NN O
was NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
glutathione NN NN O
and NN NN O
a NN NN O
lower NN NN O
ratio NN NN O
of NN NN O
reduced NN NN O
: NN NN O
oxidized NN NN O
glutathione NN NN O
. NN NN O
   
A NN NN O
truncated NN NN O
Tat NN NN B-Protein
protein NN NN O
( NN NN O
Tat1 NN NN O
- NN NN O
72 NN NN O
) NN NN O
, NN NN O
known NN NN O
to NN NN O
transactivate NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
, NN NN O
no NN NN O
longer NN NN O
affected NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
SOD NN NN I-Protein
expression NN NN O
, NN NN O
the NN NN O
cellular NN NN O
redox NN NN O
state NN NN O
or NN NN O
TNF NN NN O
- NN NN O
mediated NN NN O
cytotoxicity NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
experiments NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
is NN NN O
required NN NN O
to NN NN O
suppress NN NN O
Mn NN NN B-Protein
- NN NN I-Protein
SOD NN NN I-Protein
expression NN NN O
and NN NN O
to NN NN O
induce NN NN O
pro NN NN O
- NN NN O
oxidative NN NN O
conditions NN NN O
reflected NN NN O
by NN NN O
a NN NN O
drop NN NN O
in NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
and NN NN O
the NN NN O
GSH NN NN O
: NN NN O
oxidized NN NN O
GSH NN NN O
( NN NN O
GSSG NN NN O
) NN NN O
ratio NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
Runt NN NN O
domain NN NN O
- NN NN O
encoding NN NN O
PEBP2 NN NN O
alpha NN NN O
genes NN NN O
in NN NN O
T NN NN O
cells NN NN O
during NN NN O
thymic NN NN O
development NN NN O
. NN NN O
   
The NN NN O
PEBP2 NN NN B-Protein
alpha NN NN I-Protein
A NN NN I-Protein
and NN NN O
PEBP2 NN NN B-Protein
alpha NN NN I-Protein
B NN NN I-Protein
genes NN NN O
encode NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
subunit NN NN O
of NN NN O
a NN NN O
murine NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
PEBP2 NN NN O
, NN NN O
which NN NN O
is NN NN O
implicated NN NN O
as NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
regulator NN NN O
. NN NN O
   
These NN NN O
two NN NN O
related NN NN O
genes NN NN O
share NN NN O
the NN NN O
evolutionarily NN NN O
conserved NN NN O
region NN NN O
encoding NN NN O
the NN NN O
Runt NN NN O
domain NN NN O
. NN NN O
   
PEBP2 NN NN B-Protein
alpha NN NN I-Protein
B NN NN I-Protein
is NN NN O
the NN NN O
murine NN NN O
counterpart NN NN O
of NN NN O
human NN NN O
AML1 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
located NN NN O
at NN NN O
the NN NN O
breakpoints NN NN O
of NN NN O
the NN NN O
8 NN NN O
; NN NN O
21 NN NN O
and NN NN O
3 NN NN O
; NN NN O
21 NN NN O
chromosome NN NN O
translocations NN NN O
associated NN NN O
with NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
. NN NN O
   
Northern NN NN O
( NN NN O
RNA NN NN O
) NN NN O
blots NN NN O
of NN NN O
various NN NN O
adult NN NN O
mouse NN NN O
tissues NN NN O
revealed NN NN O
that NN NN O
the NN NN O
levels NN NN O
of NN NN O
expression NN NN O
of NN NN O
both NN NN O
genes NN NN O
were NN NN O
most NN NN O
prominent NN NN O
in NN NN O
the NN NN O
thymus NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
transcripts NN NN O
of NN NN O
PEBP2 NN NN B-Protein
alpha NN NN I-Protein
A NN NN I-Protein
and NN NN O
mouse NN NN O
AML1 NN NN B-Protein
/ NN NN I-Protein
PEBP2 NN NN I-Protein
alpha NN NN I-Protein
B NN NN I-Protein
were NN NN O
detected NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
the NN NN O
thymuses NN NN O
from NN NN O
day NN NN O
16 NN NN O
embryos NN NN O
and NN NN O
newborns NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
4 NN NN O
- NN NN O
week NN NN O
- NN NN O
old NN NN O
adult NN NN O
mice NN NN O
, NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
genes NN NN O
persisted NN NN O
in NN NN O
peripheral NN NN O
lymph NN NN O
nodes NN NN O
of NN NN O
adult NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
transcripts NN NN O
were NN NN O
detected NN NN O
in NN NN O
all NN NN O
the NN NN O
CD4 NN NN B-Protein
- NN NN O
CD8 NN NN O
- NN NN O
, NN NN O
CD4 NN NN B-Protein
+ NN NN O
CD8 NN NN O
+ NN NN O
, NN NN O
CD4 NN NN B-Protein
+ NN NN O
CD8 NN NN O
- NN NN O
, NN NN O
and NN NN O
CD4 NN NN B-Protein
- NN NN O
CD8 NN NN O
+ NN NN O
cell NN NN O
populations NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicated NN NN O
that NN NN O
both NN NN O
genes NN NN O
are NN NN O
expressed NN NN O
in NN NN O
T NN NN O
cells NN NN O
throughout NN NN O
their NN NN O
development NN NN O
, NN NN O
supporting NN NN O
the NN NN O
notion NN NN O
that NN NN O
PEBP2 NN NN O
is NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Transcripts NN NN O
of NN NN O
mouse NN NN O
AML1 NN NN B-Protein
/ NN NN I-Protein
PEBP2 NN NN I-Protein
alpha NN NN I-Protein
B NN NN I-Protein
were NN NN O
also NN NN O
detected NN NN O
in NN NN O
day NN NN O
12 NN NN O
fetal NN NN O
hematopoietic NN NN O
liver NN NN O
and NN NN O
in NN NN O
the NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
of NN NN O
newborn NN NN O
mice NN NN O
. NN NN O
   
The NN NN O
implication NN NN O
of NN NN O
mouse NN NN O
AML1 NN NN B-Protein
/ NN NN I-Protein
PEBP2 NN NN I-Protein
alpha NN NN I-Protein
B NN NN I-Protein
expression NN NN O
in NN NN O
hematopoietic NN NN O
cells NN NN O
other NN NN O
than NN NN O
those NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
lineage NN NN O
is NN NN O
discussed NN NN O
in NN NN O
relation NN NN O
to NN NN O
myeloid NN NN O
leukemogenesis NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
expression NN NN O
: NN NN O
potential NN NN O
role NN NN O
of NN NN O
physical NN NN O
interactions NN NN O
between NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
( NN NN I-Protein
Y NN NN I-Protein
) NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
rapidly NN NN O
and NN NN O
potently NN NN O
induced NN NN O
in NN NN O
T NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
mitogenic NN NN O
stimuli NN NN O
. NN NN O
   
Previously NN NN O
, NN NN O
an NN NN O
inducible NN NN O
enhancer NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
299 NN NN O
and NN NN O
- NN NN O
228 NN NN O
that NN NN O
contains NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
CArG NN NN O
motifs NN NN O
was NN NN O
identified NN NN O
. NN NN O
   
We NN NN O
now NN NN O
report NN NN O
the NN NN O
characterization NN NN O
of NN NN O
a NN NN O
second NN NN O
essential NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
located NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
137 NN NN O
and NN NN O
- NN NN O
64 NN NN O
that NN NN O
binds NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
( NN NN I-Protein
Y NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
This NN NN O
element NN NN O
had NN NN O
maximal NN NN O
activity NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
paralleling NN NN O
the NN NN O
cell NN NN O
type NN NN O
specificity NN NN O
of NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Transcription NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
was NN NN O
inhibited NN NN O
when NN NN O
either NN NN O
the NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
the NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
( NN NN I-Protein
Y NN NN I-Protein
) NN NN I-Protein
binding NN NN O
site NN NN O
was NN NN O
mutated NN NN O
. NN NN O
   
Coexpression NN NN O
of NN NN O
both NN NN O
proteins NN NN O
activated NN NN O
transcription NN NN O
of NN NN O
the NN NN O
- NN NN O
137 NN NN O
to NN NN O
- NN NN O
64 NN NN O
element NN NN O
in NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
physically NN NN O
associated NN NN O
with NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
and NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
in NN NN O
vitro NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
might NN NN O
functionally NN NN O
coordinate NN NN O
the NN NN O
actions NN NN O
of NN NN O
the NN NN O
upstream NN NN O
and NN NN O
downstream NN NN O
positive NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
a NN NN O
physical NN NN O
interaction NN NN O
between NN NN O
an NN NN O
Ets NN NN O
family NN NN O
member NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
provide NN NN O
significant NN NN O
new NN NN O
insights NN NN O
into NN NN O
the NN NN O
protein NN NN O
- NN NN O
protein NN NN O
and NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
interactions NN NN O
that NN NN O
regulate NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
and NN NN O
inducible NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
and NN NN O
also NN NN O
have NN NN O
implications NN NN O
for NN NN O
other NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
glucocorticoids NN NN O
on NN NN O
transcription NN NN O
factor NN NN O
activation NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Glucocorticoids NN NN O
have NN NN O
an NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
inflammatory NN NN O
and NN NN O
immune NN NN O
responses NN NN O
, NN NN O
and NN NN O
this NN NN O
may NN NN O
be NN NN O
through NN NN O
the NN NN O
modulation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
. NN NN O
   
The NN NN O
interaction NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
and NN NN O
cAMP NN NN O
- NN NN O
responsive NN NN O
element NN NN O
binding NN NN O
protein NN NN O
( NN NN O
CREB NN NN O
) NN NN O
with NN NN O
DNA NN NN O
and NN NN O
glucocorticoid NN NN B-Protein
receptors NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
was NN NN O
analyzed NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
by NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
treatment NN NN O
increased NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
up NN NN O
to NN NN O
200 NN NN O
% NN NN O
but NN NN O
decreased NN NN O
CREB NN NN O
binding NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
over NN NN O
a NN NN O
60 NN NN O
- NN NN O
min NN NN O
time NN NN O
course NN NN O
. NN NN O
   
Dexamethasone NN NN O
produced NN NN O
a NN NN O
rapid NN NN O
and NN NN O
sustained NN NN O
increase NN NN O
in NN NN O
glucocorticoid NN NN O
response NN NN O
element NN NN O
binding NN NN O
and NN NN O
a NN NN O
concomitant NN NN O
40 NN NN O
- NN NN O
50 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
CREB NN NN O
DNA NN NN O
binding NN NN O
that NN NN O
was NN NN O
blocked NN NN O
by NN NN O
combined NN NN O
dexamethasone NN NN O
and NN NN O
cytokine NN NN O
or NN NN O
PMA NN NN O
treatment NN NN O
. NN NN O
   
These NN NN O
latter NN NN O
effects NN NN O
were NN NN O
due NN NN O
to NN NN O
increases NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
GR NN NN B-Protein
, NN NN O
not NN NN O
to NN NN O
reduced NN NN O
amounts NN NN O
of NN NN O
the NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
This NN NN O
suggests NN NN O
that NN NN O
in NN NN O
these NN NN O
cells NN NN O
GR NN NN B-Protein
within NN NN O
the NN NN O
nucleus NN NN O
interacts NN NN O
with NN NN O
cytokine NN NN O
- NN NN O
stimulated NN NN O
transcription NN NN O
factors NN NN O
by NN NN O
the NN NN O
process NN NN O
of NN NN O
cross NN NN O
coupling NN NN O
. NN NN O
   
This NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
molecular NN NN O
site NN NN O
of NN NN O
steroid NN NN O
action NN NN O
. NN NN O
   
Isolation NN NN O
of NN NN O
cDNA NN NN O
clones NN NN O
for NN NN O
42 NN NN O
different NN NN O
Kruppel NN NN O
- NN NN O
related NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
expressed NN NN O
in NN NN O
the NN NN O
human NN NN O
monoblast NN NN O
cell NN NN O
line NN NN O
U NN NN O
- NN NN O
937 NN NN O
. NN NN O
   
To NN NN O
study NN NN O
the NN NN O
complexity NN NN O
and NN NN O
structural NN NN O
characteristics NN NN O
of NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
expressed NN NN O
during NN NN O
human NN NN O
hematopoiesis NN NN O
and NN NN O
to NN NN O
isolate NN NN O
novel NN NN O
regulators NN NN O
of NN NN O
blood NN NN O
cell NN NN O
development NN NN O
, NN NN O
a NN NN O
degenerate NN NN O
oligonucleotide NN NN O
probe NN NN O
specific NN NN O
for NN NN O
a NN NN O
consensus NN NN O
zinc NN NN O
finger NN NN O
peptide NN NN O
domain NN NN O
was NN NN O
used NN NN O
to NN NN O
isolate NN NN O
63 NN NN O
cDNA NN NN O
clones NN NN O
for NN NN O
Kruppel NN NN O
- NN NN O
related NN NN O
zinc NN NN O
finger NN NN O
genes NN NN O
from NN NN O
the NN NN O
human NN NN O
monoblast NN NN O
cell NN NN O
line NN NN O
U NN NN O
- NN NN O
937 NN NN O
. NN NN O
   
By NN NN O
extensive NN NN O
nucleotide NN NN O
sequence NN NN O
and NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
, NN NN O
these NN NN O
cDNA NN NN O
clones NN NN O
were NN NN O
found NN NN O
to NN NN O
originate NN NN O
from NN NN O
approximately NN NN O
42 NN NN O
different NN NN O
genes NN NN O
( NN NN O
HZF NN NN B-Protein
1 NN NN I-Protein
- NN NN O
42 NN NN B-Protein
) NN NN O
of NN NN O
which NN NN O
only NN NN O
8 NN NN O
have NN NN O
previously NN NN O
been NN NN O
described NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
a NN NN O
majority NN NN O
of NN NN O
these NN NN O
genes NN NN O
were NN NN O
expressed NN NN O
at NN NN O
comparable NN NN O
levels NN NN O
in NN NN O
U NN NN O
- NN NN O
937 NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
large NN NN O
number NN NN O
of NN NN O
individual NN NN O
genes NN NN O
represented NN NN O
among NN NN O
the NN NN O
63 NN NN O
clones NN NN O
and NN NN O
their NN NN O
apparent NN NN O
non NN NN O
- NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
expression NN NN O
suggest NN NN O
that NN NN O
the NN NN O
majority NN NN O
of NN NN O
the NN NN O
Kruppel NN NN O
- NN NN O
related NN NN O
zinc NN NN O
finger NN NN O
genes NN NN O
are NN NN O
likely NN NN O
to NN NN O
be NN NN O
expressed NN NN O
in NN NN O
most NN NN O
human NN NN O
tissues NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
some NN NN O
of NN NN O
the NN NN O
genes NN NN O
displayed NN NN O
a NN NN O
restricted NN NN O
expression NN NN O
pattern NN NN O
, NN NN O
indicating NN NN O
that NN NN O
they NN NN O
represent NN NN O
potential NN NN O
regulators NN NN O
of NN NN O
monocyte NN NN O
differentiation NN NN O
or NN NN O
proliferation NN NN O
. NN NN O
   
Detailed NN NN O
structural NN NN O
analysis NN NN O
of NN NN O
the NN NN O
first NN NN O
12 NN NN O
cDNAs NN NN O
( NN NN O
HZF NN NN B-Protein
1 NN NN I-Protein
- NN NN O
10 NN NN B-Protein
) NN NN O
and NN NN O
a NN NN O
partial NN NN O
characterization NN NN O
of NN NN O
HZF NN NN B-Protein
11 NN NN I-Protein
- NN NN O
42 NN NN B-Protein
revealed NN NN O
that NN NN O
a NN NN O
common NN NN O
feature NN NN O
of NN NN O
human NN NN O
Kruppel NN NN O
- NN NN O
related NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
is NN NN O
the NN NN O
presence NN NN O
of NN NN O
tandem NN NN O
arrays NN NN O
of NN NN O
zinc NN NN O
fingers NN NN O
ranging NN NN O
in NN NN O
number NN NN O
from NN NN O
3 NN NN O
to NN NN O
over NN NN O
20 NN NN O
that NN NN O
are NN NN O
preferentially NN NN O
located NN NN O
in NN NN O
the NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
regions NN NN O
of NN NN O
the NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
several NN NN O
novel NN NN O
KRAB NN NN O
- NN NN O
containing NN NN O
zinc NN NN O
finger NN NN O
genes NN NN O
and NN NN O
a NN NN O
novel NN NN O
conserved NN NN O
sequence NN NN O
element NN NN O
were NN NN O
identified NN NN O
. NN NN O
   
Calcium NN NN O
/ NN NN O
calmodulin NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
II NN NN O
downregulates NN NN O
both NN NN O
calcineurin NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
mediated NN NN O
pathways NN NN O
for NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Engagement NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
for NN NN O
antigen NN NN O
activates NN NN O
phospholipase NN NN O
C NN NN O
resulting NN NN O
in NN NN O
an NN NN O
increase NN NN O
in NN NN O
intracellular NN NN O
free NN NN O
calcium NN NN O
concentration NN NN O
( NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
) NN NN O
and NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
. NN NN O
   
Increased NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
activates NN NN O
Ca2 NN NN O
+ NN NN O
/ NN NN O
calmodulin NN NN B-Protein
- NN NN O
dependent NN NN O
kinases NN NN O
including NN NN O
the NN NN O
multifunctional NN NN O
Ca2 NN NN O
+ NN NN O
/ NN NN O
calmodulin NN NN O
- NN NN O
dependent NN NN O
protein NN NN O
kinase NN NN O
II NN NN O
( NN NN O
CaM NN NN O
- NN NN O
K NN NN O
II NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
calcineurin NN NN O
, NN NN O
a NN NN O
type NN NN O
2B NN NN O
protein NN NN O
phosphatase NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
identified NN NN O
calcineurin NN NN O
as NN NN O
a NN NN O
key NN NN O
enzyme NN NN O
for NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
CaM NN NN O
- NN NN O
K NN NN O
II NN NN O
remains NN NN O
unknown NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
mutants NN NN O
of NN NN O
these NN NN O
kinases NN NN O
and NN NN O
phosphatases NN NN O
( NN NN O
gamma NN NN O
B NN NN O
* NN NN O
CaM NN NN O
- NN NN O
K NN NN O
and NN NN O
delta NN NN O
CaM NN NN O
- NN NN O
AI NN NN O
, NN NN O
respectively NN NN O
) NN NN O
to NN NN O
explore NN NN O
their NN NN O
relative NN NN O
role NN NN O
in NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
and NN NN O
their NN NN O
interactions NN NN O
with NN NN O
PKC NN NN O
- NN NN O
dependent NN NN O
signaling NN NN O
systems NN NN O
. NN NN O
gamma NN NN O
B NN NN O
* NN NN O
CaM NN NN O
- NN NN O
K NN NN O
and NN NN O
delta NN NN O
CaM NN NN O
- NN NN O
AI NN NN O
, NN NN O
known NN NN O
to NN NN O
exhibit NN NN O
constitutive NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
independent NN NN O
activity NN NN O
, NN NN O
were NN NN O
cotransfected NN NN O
( NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
) NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
with NN NN O
a NN NN O
plasmid NN NN O
containing NN NN O
the NN NN O
intact NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
driving NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
reporter NN NN O
gene NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
gamma NN NN O
B NN NN O
* NN NN O
CaM NN NN O
- NN NN O
K NN NN O
with NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
construct NN NN O
downregulated NN NN O
its NN NN O
transcription NN NN O
in NN NN O
response NN NN O
to NN NN O
stimulation NN NN O
with NN NN O
ionomycin NN NN O
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
CaM NN NN O
- NN NN O
K NN NN O
II NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
was NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
transcription NN NN O
of NN NN O
its NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
transactivating NN NN O
pathways NN NN O
. NN NN O
   
Under NN NN O
the NN NN O
same NN NN O
conditions NN NN O
, NN NN O
delta NN NN O
CaM NN NN O
- NN NN O
AI NN NN O
superinduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
( NN NN O
approximately NN NN O
twofold NN NN O
increase NN NN O
) NN NN O
. NN NN O
   
When NN NN O
both NN NN O
mutants NN NN O
were NN NN O
used NN NN O
in NN NN O
combination NN NN O
, NN NN O
gamma NN NN O
B NN NN O
* NN NN O
CaM NN NN O
- NN NN O
K NN NN O
inhibited NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
by NN NN O
delta NN NN O
CaM NN NN O
- NN NN O
AI NN NN O
. NN NN O
   
Similar NN NN O
results NN NN O
were NN NN O
obtained NN NN O
when NN NN O
a NN NN O
construct NN NN O
containing NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
also NN NN O
was NN NN O
used NN NN O
. NN NN O
gamma NN NN O
B NN NN O
* NN NN O
CaM NN NN O
- NN NN O
K NN NN O
also NN NN O
downregulated NN NN O
the NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
response NN NN O
to NN NN O
transfection NN NN O
with NN NN O
a NN NN O
constitutively NN NN O
active NN NN O
mutant NN NN O
of NN NN O
PKC NN NN O
or NN NN O
stimulation NN NN O
with NN NN O
PMA NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
CaM NN NN O
- NN NN O
K NN NN O
II NN NN O
may NN NN O
exert NN NN O
negative NN NN O
influences NN NN O
on NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
provide NN NN O
preliminary NN NN O
evidence NN NN O
for NN NN O
negative NN NN O
cross NN NN O
- NN NN O
talk NN NN O
with NN NN O
the NN NN O
calcineurin NN NN O
- NN NN O
and NN NN O
PKC NN NN O
- NN NN O
dependent NN NN O
signaling NN NN O
systems NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
proteolysis NN NN O
by NN NN O
site NN NN O
- NN NN O
specific NN NN O
, NN NN O
signal NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
. NN NN O
   
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
inhibits NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
retaining NN NN O
it NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
Various NN NN O
stimuli NN NN O
, NN NN O
typically NN NN O
those NN NN O
associated NN NN O
with NN NN O
stress NN NN O
or NN NN O
pathogens NN NN O
, NN NN O
rapidly NN NN O
inactivate NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
This NN NN O
liberates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
translocate NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
initiate NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
important NN NN O
for NN NN O
the NN NN O
defense NN NN O
of NN NN O
the NN NN O
organism NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
correlates NN NN O
with NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
requires NN NN O
the NN NN O
proteolysis NN NN O
of NN NN O
this NN NN O
inhibitor NN NN O
. NN NN O
   
When NN NN O
either NN NN O
serine NN NN O
- NN NN O
32 NN NN O
or NN NN O
serine NN NN O
- NN NN O
36 NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
was NN NN O
mutated NN NN O
, NN NN O
the NN NN O
protein NN NN O
did NN NN O
not NN NN O
undergo NN NN O
signal NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
or NN NN O
degradation NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
could NN NN O
not NN NN O
be NN NN O
activated NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
phosphorylation NN NN O
at NN NN O
one NN NN O
or NN NN O
both NN NN O
of NN NN O
these NN NN O
residues NN NN O
is NN NN O
critical NN NN O
for NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
Nef NN NN B-Protein
leads NN NN O
to NN NN O
inhibition NN NN O
or NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
depending NN NN O
on NN NN O
its NN NN O
intracellular NN NN O
localization NN NN O
. NN NN O
   
Nef NN NN B-Protein
of NN NN O
primate NN NN O
lentiviruses NN NN O
is NN NN O
required NN NN O
for NN NN O
viremia NN NN O
and NN NN O
progression NN NN O
to NN NN O
AIDS NN NN O
in NN NN O
monkeys NN NN O
. NN NN O
   
Negative NN NN O
, NN NN O
positive NN NN O
, NN NN O
and NN NN O
no NN NN O
effects NN NN O
of NN NN O
Nef NN NN B-Protein
have NN NN O
also NN NN O
been NN NN O
reported NN NN O
on NN NN O
viral NN NN O
replication NN NN O
in NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
reconcile NN NN O
these NN NN O
observations NN NN O
, NN NN O
we NN NN O
expressed NN NN O
a NN NN O
hybrid NN NN O
CD8 NN NN O
- NN NN O
Nef NN NN B-Protein
protein NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
opposite NN NN O
phenotypes NN NN O
were NN NN O
found NN NN O
, NN NN O
which NN NN O
depended NN NN O
on NN NN O
the NN NN O
intracellular NN NN O
localization NN NN O
of NN NN O
Nef NN NN B-Protein
. NN NN O
   
Expressed NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
or NN NN O
on NN NN O
the NN NN O
cell NN NN O
surface NN NN O
, NN NN O
the NN NN O
chimera NN NN O
inhibited NN NN O
or NN NN O
activated NN NN O
early NN NN O
signaling NN NN O
events NN NN O
from NN NN O
the NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
. NN NN O
   
Activated NN NN O
Jurkat NN NN O
cells NN NN O
died NN NN O
by NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
only NN NN O
cells NN NN O
with NN NN O
mutated NN NN O
nef NN NN B-Protein
genes NN NN O
expressing NN NN O
truncated NN NN O
Nefs NN NN B-Protein
survived NN NN O
, NN NN O
which NN NN O
rendered NN NN O
Nef NN NN B-Protein
nonfunctional NN NN O
. NN NN O
   
These NN NN O
mutations NN NN O
paralleled NN NN O
those NN NN O
in NN NN O
other NN NN O
viral NN NN O
strains NN NN O
passaged NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Not NN NN O
only NN NN O
do NN NN O
these NN NN O
positional NN NN O
effects NN NN O
of NN NN O
Nef NN NN B-Protein
reconcile NN NN O
diverse NN NN O
phenotypes NN NN O
of NN NN O
Nef NN NN B-Protein
and NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
myristylation NN NN O
, NN NN O
but NN NN O
they NN NN O
also NN NN O
explain NN NN O
effects NN NN O
of NN NN O
Nef NN NN B-Protein
in NN NN O
HIV NN NN O
infection NN NN O
and NN NN O
progression NN NN O
to NN NN O
AIDS NN NN O
. NN NN O
   
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
targeting NN NN O
the NN NN O
inhibitory NN NN O
molecule NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
an NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
membrane NN NN O
protein NN NN O
expressed NN NN O
during NN NN O
latent NN NN O
infection NN NN O
, NN NN O
has NN NN O
oncogenic NN NN O
properties NN NN O
, NN NN O
as NN NN O
judged NN NN O
from NN NN O
its NN NN O
ability NN NN O
to NN NN O
transform NN NN O
B NN NN O
lymphocytes NN NN O
and NN NN O
rodent NN NN O
fibroblasts NN NN O
. NN NN O
   
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
bcl2 NN NN B-Protein
, NN NN O
an NN NN O
oncogene NN NN O
which NN NN O
protects NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
other NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
cell NN NN O
regulation NN NN O
and NN NN O
growth NN NN O
control NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
upregulates NN NN O
these NN NN O
proteins NN NN O
is NN NN O
unknown NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
plausible NN NN O
that NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
modifies NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
that NN NN O
result NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
one NN NN O
or NN NN O
more NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
ultimately NN NN O
regulate NN NN O
transcription NN NN O
of NN NN O
oncogenic NN NN O
genes NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
controlling NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
cell NN NN O
activation NN NN O
and NN NN O
growth NN NN O
control NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
activated NN NN O
by NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
regulating NN NN O
this NN NN O
activation NN NN O
remains NN NN O
unknown NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
functional NN NN O
activity NN NN O
are NN NN O
present NN NN O
in NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
stably NN NN O
or NN NN O
transiently NN NN O
expressing NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
selectively NN NN O
modified NN NN O
in NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
expressing NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
phosphorylated NN NN O
form NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
increased NN NN O
protein NN NN O
turnover NN NN O
- NN NN O
degradation NN NN O
correlate NN NN O
with NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
nuclear NN NN O
translocation NN NN O
. NN NN O
   
This NN NN O
results NN NN O
in NN NN O
increased NN NN O
transcription NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
- NN NN O
genes NN NN O
, NN NN O
including NN NN O
those NN NN O
encoding NN NN O
p105 NN NN B-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
MAD3 NN NN B-Protein
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
by NN NN O
targeting NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Identification NN NN O
of NN NN O
the NN NN O
pathways NN NN O
activated NN NN O
by NN NN O
LMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
result NN NN O
in NN NN O
posttranslational NN NN O
modifications NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
will NN NN O
aid NN NN O
in NN NN O
determining NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
virus NN NN O
- NN NN O
host NN NN O
cell NN NN O
protein NN NN O
interaction NN NN O
in NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
mediated NN NN O
oncogenesis NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
by NN NN O
retinoic NN NN O
acid NN NN O
correlates NN NN O
with NN NN O
cellular NN NN O
expression NN NN O
of NN NN O
the NN NN O
retinoic NN NN O
acid NN NN O
receptors NN NN O
. NN NN O
   
OBJECTIVES NN NN O
: NN NN O
To NN NN O
analyze NN NN O
the NN NN O
effect NN NN O
of NN NN O
retinoic NN NN O
acids NN NN O
( NN NN O
RA NN NN O
) NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
and NN NN O
correlate NN NN O
this NN NN O
effect NN NN O
with NN NN O
expression NN NN O
levels NN NN O
of NN NN O
RA NN NN O
receptors NN NN O
( NN NN O
RARs NN NN O
) NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphoid NN NN O
and NN NN O
monocytoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
DESIGN NN NN O
AND NN NN O
METHODS NN NN O
: NN NN O
The NN NN O
effect NN NN O
of NN NN O
all NN NN O
- NN NN O
trans NN NN O
and NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphoid NN NN O
( NN NN O
H9 NN NN O
, NN NN O
CEM NN NN O
) NN NN O
and NN NN O
monocytoid NN NN O
( NN NN O
U937 NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
) NN NN O
cell NN NN O
lines NN NN O
was NN NN O
measured NN NN O
during NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
levels NN NN O
of NN NN O
human NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
( NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
receptor NN NN O
for NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
) NN NN O
and NN NN O
the NN NN O
human NN NN O
retinoid NN NN B-Protein
- NN NN I-Protein
X NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
hRXR NN NN B-Protein
alpha NN NN I-Protein
receptor NN NN O
for NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
) NN NN O
were NN NN O
determined NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Both NN NN O
all NN NN O
- NN NN O
trans NN NN O
and NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
inhibited NN NN O
virus NN NN O
replication NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
IIIB NN NN O
- NN NN O
infected NN NN O
monocytoid NN NN O
cells NN NN O
, NN NN O
in NN NN O
the NN NN O
presence NN NN O
and NN NN O
absence NN NN O
of NN NN O
the NN NN O
co NN NN O
- NN NN O
stimulatory NN NN O
agent NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
. NN NN O
   
The NN NN O
retinoids NN NN O
had NN NN O
weak NN NN O
or NN NN O
no NN NN O
stimulatory NN NN O
effects NN NN O
on NN NN O
HIV NN NN O
production NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
HIV NN NN O
production NN NN O
by NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
these NN NN O
retinoids NN NN O
. NN NN O
   
The NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
was NN NN O
generally NN NN O
more NN NN O
effective NN NN O
than NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
in NN NN O
inhibiting NN NN O
HIV NN NN O
production NN NN O
and NN NN O
in NN NN O
combination NN NN O
generally NN NN O
more NN NN O
effective NN NN O
than NN NN O
the NN NN O
single NN NN O
agents NN NN O
alone NN NN O
. NN NN O
   
Human NN NN O
RAR NN NN O
alpha NN NN O
was NN NN O
expressed NN NN O
in NN NN O
H9 NN NN O
, NN NN O
U937 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
but NN NN O
almost NN NN O
undetectable NN NN O
in NN NN O
CEM NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
RXR NN NN B-Protein
alpha NN NN I-Protein
was NN NN O
significantly NN NN O
expressed NN NN O
in NN NN O
U937 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
weakly NN NN O
expressed NN NN O
in NN NN O
H9 NN NN O
cells NN NN O
and NN NN O
not NN NN O
detectable NN NN O
in NN NN O
CEM NN NN O
cells NN NN O
. NN NN O
   
After NN NN O
stimulation NN NN O
by NN NN O
PMA NN NN O
, NN NN O
RXR NN NN B-Protein
alpha NN NN I-Protein
expression NN NN O
increased NN NN O
in NN NN O
H9 NN NN O
and NN NN O
U937 NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
CEM NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
expression NN NN O
was NN NN O
unchanged NN NN O
in NN NN O
H9 NN NN O
and NN NN O
CEM NN NN O
cells NN NN O
, NN NN O
and NN NN O
elevated NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
after NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
The NN NN O
effect NN NN O
of NN NN O
RA NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
was NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
dependent NN NN O
and NN NN O
partially NN NN O
correlated NN NN O
with NN NN O
cellular NN NN O
expression NN NN O
of NN NN O
RARs NN NN O
. NN NN O
   
Endogenous NN NN O
or NN NN O
exogenously NN NN O
administered NN NN O
RA NN NN O
may NN NN O
have NN NN O
a NN NN O
significant NN NN O
role NN NN O
in NN NN O
HIV NN NN O
regulation NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
human NN NN O
TR2 NN NN O
orphan NN NN O
receptor NN NN O
response NN NN O
element NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
initiation NN NN O
site NN NN O
of NN NN O
the NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
major NN NN O
late NN NN O
promoter NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
J NN NN O
Biol NN NN O
Chem NN NN O
1995 NN NN O
Nov NN NN O
3 NN NN O
; NN NN O
270 NN NN O
( NN NN O
44 NN NN O
) NN NN O
: NN NN O
26721 NN NN O
] NN NN O
   
A NN NN O
DNA NN NN O
response NN NN O
element NN NN O
( NN NN O
TR2RE NN NN O
- NN NN O
SV40 NN NN O
) NN NN O
for NN NN O
the NN NN O
TR2 NN NN O
orphan NN NN O
receptor NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
steroid NN NN O
- NN NN O
thyroid NN NN O
hormone NN NN O
receptor NN NN O
superfamily NN NN O
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
the NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
( NN NN O
SV40 NN NN O
) NN NN O
+ NN NN O
55 NN NN O
region NN NN O
( NN NN O
nucleotide NN NN O
numbers NN NN O
368 NN NN O
- NN NN O
389 NN NN O
, NN NN O
5 NN NN O
' NN NN O
- NN NN O
GTTAAGGTTCGTAGGTCATGGA NN NN O
- NN NN O
3 NN NN O
' NN NN O
) NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
using NN NN O
in NN NN O
vitro NN NN O
translated NN NN O
TR2 NN NN O
orphan NN NN O
receptor NN NN O
with NN NN O
a NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
67 NN NN O
kilodaltons NN NN O
, NN NN O
showed NN NN O
a NN NN O
specific NN NN O
binding NN NN O
with NN NN O
high NN NN O
affinity NN NN O
( NN NN O
dissociation NN NN O
constant NN NN O
= NN NN O
9 NN NN O
nM NN NN O
) NN NN O
for NN NN O
this NN NN O
DNA NN NN O
sequence NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
swap NN NN O
experiments NN NN O
using NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
- NN NN I-Protein
transferase NN NN I-Protein
assay NN NN O
demonstrated NN NN O
that NN NN O
androgen NN NN O
can NN NN O
suppress NN NN O
the NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
SV40 NN NN O
early NN NN O
promoter NN NN O
via NN NN O
the NN NN O
interaction NN NN O
between NN NN O
this NN NN O
TR2RE NN NN O
- NN NN O
SV40 NN NN O
and NN NN O
the NN NN O
chimeric NN NN O
receptor NN NN O
AR NN NN O
/ NN NN O
TR2 NN NN O
/ NN NN O
AR NN NN O
with NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
TR2 NN NN O
orphan NN NN O
receptor NN NN O
flanked NN NN O
by NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
and NN NN O
androgen NN NN O
- NN NN O
binding NN NN O
domains NN NN O
of NN NN O
the NN NN O
androgen NN NN O
receptor NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
this NN NN O
TR2RE NN NN O
- NN NN O
SV40 NN NN O
can NN NN O
function NN NN O
as NN NN O
a NN NN O
repressor NN NN O
to NN NN O
suppress NN NN O
the NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
both NN NN O
SV40 NN NN O
early NN NN O
and NN NN O
late NN NN O
promoters NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
the NN NN O
TR2RE NN NN O
- NN NN O
SV40 NN NN O
may NN NN O
represent NN NN O
the NN NN O
first NN NN O
identified NN NN O
natural NN NN O
DNA NN NN O
response NN NN O
element NN NN O
for NN NN O
the NN NN O
TR2 NN NN O
orphan NN NN O
receptor NN NN O
that NN NN O
may NN NN O
function NN NN O
as NN NN O
a NN NN O
repressor NN NN O
for NN NN O
the NN NN O
SV40 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Mapping NN NN O
of NN NN O
the NN NN O
interaction NN NN O
site NN NN O
of NN NN O
the NN NN O
defective NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
mutant NN NN O
cell NN NN O
line NN NN O
clone NN NN O
- NN NN O
13 NN NN O
to NN NN O
the NN NN O
divergent NN NN O
X2 NN NN O
- NN NN O
box NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
described NN NN O
a NN NN O
mutant NN NN O
B NN NN O
lymphoblastoid NN NN O
cell NN NN O
line NN NN O
, NN NN O
Clone NN NN O
- NN NN O
13 NN NN O
, NN NN O
that NN NN O
expresses NN NN O
HLA NN NN O
- NN NN O
DQ NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
and NN NN O
- NN NN O
DP NN NN O
. NN NN O
   
Several NN NN O
criteria NN NN O
indicated NN NN O
that NN NN O
the NN NN O
defect NN NN O
in NN NN O
this NN NN O
cell NN NN O
line NN NN O
influences NN NN O
the NN NN O
activity NN NN O
of NN NN O
an NN NN O
isotype NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
transient NN NN O
transfection NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
and NN NN O
DQB NN NN O
reporter NN NN O
constructs NN NN O
indicated NN NN O
that NN NN O
the NN NN O
affected NN NN O
factor NN NN O
operates NN NN O
via NN NN O
cis NN NN O
- NN NN O
elements NN NN O
located NN NN O
between NN NN O
- NN NN O
141 NN NN O
base NN NN O
pairs NN NN O
and NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
A NN NN O
series NN NN O
of NN NN O
hybrid NN NN O
DRA NN NN O
/ NN NN O
DQB NN NN O
reporter NN NN O
constructs NN NN O
was NN NN O
generated NN NN O
to NN NN O
further NN NN O
map NN NN O
the NN NN O
relevant NN NN O
cis NN NN O
- NN NN O
elements NN NN O
in NN NN O
this NN NN O
system NN NN O
. NN NN O
   
Insertion NN NN O
of NN NN O
oligonucleotides NN NN O
spanning NN NN O
the NN NN O
DQB NN NN O
X NN NN O
- NN NN O
box NN NN O
( NN NN O
but NN NN O
not NN NN O
the NN NN O
DQB NN NN O
- NN NN O
W NN NN O
region NN NN O
or NN NN O
the NN NN O
DQB NN NN O
Y NN NN O
- NN NN O
box NN NN O
) NN NN O
upstream NN NN O
of NN NN O
- NN NN O
141 NN NN O
in NN NN O
a NN NN O
DRA NN NN O
reporter NN NN O
plasmid NN NN O
rescued NN NN O
expression NN NN O
to NN NN O
nearly NN NN O
wild NN NN O
- NN NN O
type NN NN O
levels NN NN O
. NN NN O
   
Substitution NN NN O
promoters NN NN O
were NN NN O
then NN NN O
generated NN NN O
where NN NN O
the NN NN O
entire NN NN O
X NN NN O
- NN NN O
box NN NN O
, NN NN O
or NN NN O
only NN NN O
the NN NN O
X1 NN NN O
- NN NN O
or NN NN O
X2 NN NN O
- NN NN O
boxes NN NN O
of NN NN O
HLA NN NN B-Protein
- NN NN I-Protein
DRA NN NN I-Protein
were NN NN O
replaced NN NN O
with NN NN O
the NN NN O
analogous NN NN O
regions NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DQB NN NN O
. NN NN O
   
The NN NN O
DQB NN NN O
X2 NN NN O
- NN NN O
box NN NN O
was NN NN O
able NN NN O
to NN NN O
restore NN NN O
expression NN NN O
to NN NN O
the NN NN O
silent NN NN O
DRA NN NN O
reporter NN NN O
construct NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
replacement NN NN O
of NN NN O
the NN NN O
DQB NN NN O
X2 NN NN O
- NN NN O
box NN NN O
with NN NN O
the NN NN O
DRA NN NN O
X2 NN NN O
- NN NN O
box NN NN O
markedly NN NN O
diminished NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
DQB NN NN O
promoter NN NN O
in NN NN O
the NN NN O
mutant NN NN O
cell NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
hybrid NN NN O
reporter NN NN O
constructs NN NN O
were NN NN O
defective NN NN O
when NN NN O
transfected NN NN O
into NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
, NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
/ NN NN O
- NN NN O
DQ NN NN O
positive NN NN O
parental NN NN O
cell NN NN O
line NN NN O
, NN NN O
Jijoye NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
the NN NN O
divergent NN NN O
X2 NN NN O
- NN NN O
box NN NN O
of NN NN O
the NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
promoters NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
influencing NN NN O
differential NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
class NN NN O
II NN NN O
isotypes NN NN O
. NN NN O
   
[ NN NN O
Regulation NN NN O
of NN NN O
transcription NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
in NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
] NN NN O
   
Since NN NN O
most NN NN O
B NN NN O
cell NN NN O
clones NN NN O
immortalized NN NN O
with NN NN O
EBV NN NN O
virus NN NN O
can NN NN O
be NN NN O
induced NN NN O
to NN NN O
produce NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
a NN NN O
typical NN NN O
T NN NN O
cell NN NN O
cytokine NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
different NN NN O
elements NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
such NN NN O
clones NN NN O
by NN NN O
transfection NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
that NN NN O
the NN NN O
element NN NN O
TCEd NN NN O
, NN NN O
which NN NN O
binds NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kB NN NN O
, NN NN O
is NN NN O
very NN NN O
active NN NN O
in NN NN O
all NN NN O
three NN NN O
B NN NN O
clones NN NN O
tested NN NN O
. NN NN O
   
This NN NN O
element NN NN O
has NN NN O
no NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
of NN NN O
the NN NN O
Jurkat NN NN O
line NN NN O
. NN NN O
   
The NN NN O
NFATd NN NN O
element NN NN O
, NN NN O
which NN NN O
binds NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
is NN NN O
very NN NN O
active NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
is NN NN O
only NN NN O
weakly NN NN O
active NN NN O
in NN NN O
one NN NN O
B NN NN O
clone NN NN O
and NN NN O
not NN NN O
at NN NN O
all NN NN O
in NN NN O
another NN NN O
. NN NN O
   
Different NN NN O
elements NN NN O
thus NN NN O
contribute NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
different NN NN O
cells NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
CD45 NN NN B-Protein
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Implications NN NN O
for NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Increased NN NN O
levels NN NN O
of NN NN O
replication NN NN O
of NN NN O
the NN NN O
HIV NN NN O
type NN NN O
1 NN NN O
are NN NN O
observed NN NN O
after NN NN O
the NN NN O
activation NN NN O
of NN NN O
infected NN NN O
T NN NN O
cells NN NN O
through NN NN O
the NN NN O
TCR NN NN O
. NN NN O
   
However NN NN O
, NN NN O
anti NN NN O
- NN NN O
CD45 NN NN B-Protein
antibodies NN NN O
inhibit NN NN O
these NN NN O
effects NN NN O
in NN NN O
cells NN NN O
from NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
interrelationships NN NN O
between NN NN O
CD45 NN NN B-Protein
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
further NN NN O
. NN NN O
   
We NN NN O
measured NN NN O
effects NN NN O
on NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
in NN NN O
T NN NN O
cell NN NN O
lines NN NN O
that NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
antibodies NN NN O
against NN NN O
CD45 NN NN B-Protein
and NN NN O
in NN NN O
those NN NN O
that NN NN O
lacked NN NN O
the NN NN O
expression NN NN O
of NN NN O
CD45 NN NN B-Protein
on NN NN O
their NN NN O
surfaces NN NN O
. NN NN O
   
First NN NN O
, NN NN O
anti NN NN O
- NN NN O
CD45 NN NN B-Protein
antibodies NN NN O
did NN NN O
not NN NN O
affect NN NN O
basal NN NN O
but NN NN O
decreased NN NN O
activated NN NN O
levels NN NN O
of NN NN O
expression NN NN O
from NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
. NN NN O
   
Second NN NN O
, NN NN O
T NN NN O
cells NN NN O
, NN NN O
which NN NN O
lack NN NN O
CD45 NN NN B-Protein
and NN NN O
cannot NN NN O
signal NN NN O
via NN NN O
the NN NN O
TCR NN NN O
, NN NN O
supported NN NN O
higher NN NN O
levels NN NN O
of NN NN O
viral NN NN O
replication NN NN O
and NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
was NN NN O
due NN NN O
to NN NN O
the NN NN O
presence NN NN O
of NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complexes NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
CD45 NN NN B-Protein
- NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
infected NN NN O
T NN NN O
cells NN NN O
displayed NN NN O
lower NN NN O
levels NN NN O
of NN NN O
CD45 NN NN B-Protein
on NN NN O
their NN NN O
surfaces NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
CD45 NN NN B-Protein
plays NN NN O
an NN NN O
active NN NN O
role NN NN O
in NN NN O
the NN NN O
physiology NN NN O
of NN NN O
T NN NN O
cells NN NN O
and NN NN O
in NN NN O
the NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
ERP NN NN B-Protein
, NN NN O
a NN NN O
new NN NN O
member NN NN O
of NN NN O
the NN NN O
ets NN NN O
transcription NN NN O
factor NN NN O
/ NN NN O
oncoprotein NN NN O
family NN NN O
: NN NN O
cloning NN NN O
, NN NN O
characterization NN NN O
, NN NN O
and NN NN O
differential NN NN O
expression NN NN O
during NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
development NN NN O
. NN NN O
   
The NN NN O
ets NN NN O
gene NN NN O
family NN NN O
encodes NN NN O
a NN NN O
group NN NN O
of NN NN O
proteins NN NN O
which NN NN O
function NN NN O
as NN NN O
transcription NN NN O
factors NN NN O
under NN NN O
physiological NN NN O
conditions NN NN O
and NN NN O
, NN NN O
if NN NN O
aberrantly NN NN O
expressed NN NN O
, NN NN O
can NN NN O
cause NN NN O
cellular NN NN O
transformation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
identified NN NN O
two NN NN O
regulatory NN NN O
elements NN NN O
in NN NN O
the NN NN O
murine NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
( NN NN O
IgH NN NN O
) NN NN O
enhancer NN NN O
, NN NN O
pi NN NN O
and NN NN O
microB NN NN O
, NN NN O
which NN NN O
exhibit NN NN O
striking NN NN O
similarity NN NN O
to NN NN O
binding NN NN O
sites NN NN O
for NN NN O
ets NN NN O
- NN NN O
related NN NN O
proteins NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
ets NN NN O
- NN NN O
related NN NN O
transcriptional NN NN O
regulators NN NN O
expressed NN NN O
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
lymphocytes NN NN O
that NN NN O
may NN NN O
interact NN NN O
with NN NN O
either NN NN O
the NN NN O
pi NN NN O
or NN NN O
the NN NN O
microB NN NN O
site NN NN O
, NN NN O
we NN NN O
have NN NN O
used NN NN O
a NN NN O
PCR NN NN O
approach NN NN O
with NN NN O
degenerate NN NN O
oligonucleotides NN NN O
encoding NN NN O
conserved NN NN O
sequences NN NN O
in NN NN O
all NN NN O
members NN NN O
of NN NN O
the NN NN O
ets NN NN O
family NN NN O
. NN NN O
   
We NN NN O
have NN NN O
cloned NN NN O
the NN NN O
gene NN NN O
for NN NN O
a NN NN O
new NN NN O
ets NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
ERP NN NN B-Protein
( NN NN O
ets NN NN B-Protein
- NN NN I-Protein
related NN NN I-Protein
protein NN NN I-Protein
) NN NN O
, NN NN O
from NN NN O
the NN NN O
murine NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
line NN NN O
BASC NN NN O
6C2 NN NN O
and NN NN O
from NN NN O
mouse NN NN O
lung NN NN O
tissue NN NN O
. NN NN O
   
The NN NN O
ERP NN NN B-Protein
protein NN NN O
contains NN NN O
a NN NN O
region NN NN O
of NN NN O
high NN NN O
homology NN NN O
with NN NN O
the NN NN O
ETS NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
common NN NN O
to NN NN O
all NN NN O
members NN NN O
of NN NN O
the NN NN O
ets NN NN O
transcription NN NN O
factor NN NN O
/ NN NN O
oncoprotein NN NN O
family NN NN O
. NN NN O
   
Three NN NN O
additional NN NN O
smaller NN NN O
regions NN NN O
show NN NN O
homology NN NN O
to NN NN O
the NN NN O
ELK NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
SAP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
genes NN NN O
, NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
the NN NN O
ets NN NN O
gene NN NN O
family NN NN O
that NN NN O
interacts NN NN O
with NN NN O
the NN NN O
serum NN NN B-Protein
response NN NN I-Protein
factor NN NN I-Protein
. NN NN O
   
Full NN NN O
- NN NN O
length NN NN O
ERP NN NN B-Protein
expresses NN NN O
only NN NN O
negligible NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
by NN NN O
itself NN NN O
. NN NN O
   
Removal NN NN O
of NN NN O
the NN NN O
carboxy NN NN O
terminus NN NN O
enables NN NN O
ERP NN NN B-Protein
to NN NN O
interact NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
ets NN NN O
- NN NN O
binding NN NN O
sites NN NN O
including NN NN O
the NN NN O
E74 NN NN O
site NN NN O
, NN NN O
the NN NN O
IgH NN NN O
enhancer NN NN O
pi NN NN O
site NN NN O
, NN NN O
and NN NN O
the NN NN O
lck NN NN B-Protein
promoter NN NN O
ets NN NN O
site NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
negative NN NN O
regulatory NN NN O
domain NN NN O
. NN NN O
   
At NN NN O
least NN NN O
three NN NN O
ERP NN NN B-Protein
- NN NN O
related NN NN O
transcripts NN NN O
are NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
tissues NN NN O
. NN NN O
   
However NN NN O
, NN NN O
within NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
lineage NN NN O
, NN NN O
ERP NN NN B-Protein
is NN NN O
highly NN NN O
expressed NN NN O
primarily NN NN O
at NN NN O
early NN NN O
stages NN NN O
of NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
development NN NN O
, NN NN O
and NN NN O
expression NN NN O
declines NN NN O
drastically NN NN O
upon NN NN O
B NN NN O
- NN NN O
cell NN NN O
maturation NN NN O
, NN NN O
correlating NN NN O
with NN NN O
the NN NN O
enhancer NN NN O
activity NN NN O
of NN NN O
the NN NN O
IgH NN NN O
pi NN NN O
site NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
ERP NN NN B-Protein
might NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
and NN NN O
in NN NN O
IgH NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Pentoxifylline NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
infection NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
Cytokine NN NN O
dysregulation NN NN O
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
has NN NN O
been NN NN O
documented NN NN O
in NN NN O
numerous NN NN O
studies NN NN O
and NN NN O
has NN NN O
been NN NN O
cited NN NN O
as NN NN O
an NN NN O
important NN NN O
component NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
this NN NN O
retroviral NN NN O
infection NN NN O
. NN NN O
   
Pharmacological NN NN O
modification NN NN O
of NN NN O
cytokine NN NN O
dysregulation NN NN O
, NN NN O
therefore NN NN O
, NN NN O
has NN NN O
been NN NN O
suggested NN NN O
as NN NN O
a NN NN O
therapeutic NN NN O
modality NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
Dr NN NN O
. NN NN O
Dezube NN NN O
of NN NN O
Beth NN NN O
Israel NN NN O
Hospital NN NN O
( NN NN O
Boston NN NN O
) NN NN O
concisely NN NN O
reviews NN NN O
the NN NN O
state NN NN O
of NN NN O
our NN NN O
knowledge NN NN O
regarding NN NN O
the NN NN O
effects NN NN O
of NN NN O
pentoxifylline NN NN O
on NN NN O
expression NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
a NN NN O
cytokine NN NN O
known NN NN O
to NN NN O
influence NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
to NN NN O
play NN NN O
a NN NN O
possible NN NN O
role NN NN O
in NN NN O
the NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
advanced NN NN O
infection NN NN O
with NN NN O
this NN NN O
virus NN NN O
. NN NN O
   
Pentoxifylline NN NN O
, NN NN O
a NN NN O
trisubstituted NN NN O
xanthine NN NN O
derivative NN NN O
, NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
decrease NN NN O
blood NN NN O
viscosity NN NN O
and NN NN O
is NN NN O
reasonably NN NN O
well NN NN O
tolerated NN NN O
by NN NN O
most NN NN O
recipients NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O
   
Results NN NN O
of NN NN O
preliminary NN NN O
studies NN NN O
, NN NN O
many NN NN O
of NN NN O
which NN NN O
were NN NN O
conducted NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Dezube NN NN O
, NN NN O
suggest NN NN O
that NN NN O
use NN NN O
of NN NN O
this NN NN O
agent NN NN O
in NN NN O
combination NN NN O
with NN NN O
antiretroviral NN NN O
compounds NN NN O
may NN NN O
prove NN NN O
useful NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
Signals NN NN O
transduced NN NN O
through NN NN O
the NN NN O
CD4 NN NN B-Protein
molecule NN NN O
on NN NN O
T NN NN O
lymphocytes NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
native NN NN O
envelope NN NN O
glycoproteins NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
gp160 NN NN B-Protein
can NN NN O
induce NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
stimulatory NN NN O
effects NN NN O
of NN NN O
gp160 NN NN B-Protein
are NN NN O
mediated NN NN O
through NN NN O
the NN NN O
CD4 NN NN B-Protein
molecule NN NN O
, NN NN O
since NN NN O
pretreatment NN NN O
with NN NN O
soluble NN NN O
CD4 NN NN B-Protein
abrogates NN NN O
its NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
gp160 NN NN B-Protein
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
consists NN NN O
of NN NN O
p65 NN NN B-Protein
, NN NN O
p50 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
proteins NN NN O
. NN NN O
   
The NN NN O
stimulatory NN NN O
effect NN NN O
of NN NN O
gp160 NN NN B-Protein
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
is NN NN O
protein NN NN O
synthesis NN NN O
independent NN NN O
, NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
and NN NN O
abrogated NN NN O
by NN NN O
inhibitors NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
The NN NN O
gp160 NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
CD4 NN NN B-Protein
positive NN NN O
T NN NN O
cells NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
biological NN NN O
effects NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
enhanced NN NN O
HIV NN NN O
replication NN NN O
, NN NN O
hypergammaglobulinemia NN NN O
, NN NN O
increased NN NN O
cytokine NN NN O
secretion NN NN O
, NN NN O
hypercellularity NN NN O
in NN NN O
bone NN NN O
marrow NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Nef NN NN B-Protein
expression NN NN O
in NN NN O
activation NN NN O
pathways NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Nef NN NN B-Protein
protein NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
pathways NN NN O
was NN NN O
investigated NN NN O
using NN NN O
a NN NN O
Jurkat NN NN O
CD4 NN NN B-Protein
+ NN NN O
cell NN NN O
line NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
a NN NN O
Nef NN NN B-Protein
expression NN NN O
vector NN NN O
. NN NN O
   
Secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
surface NN NN O
expression NN NN O
of NN NN O
IL NN NN O
- NN NN O
2R NN NN O
, NN NN O
and NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
Fos NN NN B-Protein
/ NN NN O
Jun NN NN B-Protein
) NN NN O
complex NN NN O
in NN NN O
response NN NN O
to NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
or NN NN O
immobilized NN NN O
antibodies NN NN O
to NN NN O
CD3 NN NN O
were NN NN O
monitored NN NN O
. NN NN O
   
These NN NN O
parameters NN NN O
were NN NN O
not NN NN O
modified NN NN O
by NN NN O
Nef NN NN B-Protein
expression NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
stimulation NN NN O
with NN NN O
the NN NN O
same NN NN O
stimuli NN NN O
resulted NN NN O
in NN NN O
partial NN NN O
inhibition NN NN O
of NN NN O
LTR NN NN O
activation NN NN O
in NN NN O
Nef NN NN B-Protein
+ NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
was NN NN O
not NN NN O
mediated NN NN O
through NN NN O
Nef NN NN B-Protein
phosphorylation NN NN O
on NN NN O
Thr NN NN O
- NN NN O
15 NN NN O
or NN NN O
GTP NN NN O
- NN NN O
binding NN NN O
activity NN NN O
because NN NN O
mutations NN NN O
in NN NN O
critical NN NN O
sites NN NN O
did NN NN O
not NN NN O
alter NN NN O
this NN NN O
inhibition NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
truncated NN NN O
LTRs NN NN O
confirmed NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
LTR NN NN O
activation NN NN O
was NN NN O
not NN NN O
mediated NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
but NN NN O
through NN NN O
the NN NN O
region NN NN O
containing NN NN O
the NN NN O
negative NN NN O
responding NN NN O
elements NN NN O
( NN NN O
NREs NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
Nef NN NN B-Protein
downmodulates NN NN O
LTR NN NN O
activation NN NN O
without NN NN O
significantly NN NN O
inhibiting NN NN O
the NN NN O
capacity NN NN O
of NN NN O
T NN NN O
cells NN NN O
to NN NN O
respond NN NN O
to NN NN O
immunological NN NN O
activations NN NN O
. NN NN O
   
A NN NN O
low NN NN O
NM23 NN NN B-Protein
. NN NN I-Protein
H1 NN NN I-Protein
gene NN NN O
expression NN NN O
identifying NN NN O
high NN NN O
malignancy NN NN O
human NN NN O
melanomas NN NN O
. NN NN O
   
The NN NN O
NM23 NN NN O
gene NN NN O
has NN NN O
been NN NN O
proposed NN NN O
as NN NN O
a NN NN O
metastasis NN NN O
- NN NN O
suppressor NN NN O
gene NN NN O
, NN NN O
and NN NN O
its NN NN O
use NN NN O
has NN NN O
been NN NN O
suggested NN NN O
as NN NN O
prognostic NN NN O
factor NN NN O
. NN NN O
   
NM23 NN NN O
was NN NN O
identified NN NN O
in NN NN O
a NN NN O
system NN NN O
of NN NN O
murine NN NN O
melanoma NN NN O
cell NN NN O
lines NN NN O
, NN NN O
in NN NN O
which NN NN O
an NN NN O
inverse NN NN O
relationship NN NN O
was NN NN O
found NN NN O
between NN NN O
NM23 NN NN O
expression NN NN O
and NN NN O
metastatic NN NN O
ability NN NN O
. NN NN O
   
In NN NN O
a NN NN O
human NN NN O
malignant NN NN O
melanoma NN NN O
study NN NN O
NM23 NN NN O
expression NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
metastases NN NN O
that NN NN O
developed NN NN O
less NN NN O
than NN NN O
24 NN NN O
months NN NN O
after NN NN O
diagnosis NN NN O
of NN NN O
the NN NN O
primary NN NN O
tumours NN NN O
. NN NN O
   
The NN NN O
present NN NN O
paper NN NN O
studies NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
NM23 NN NN B-Protein
. NN NN I-Protein
H1 NN NN I-Protein
gene NN NN O
in NN NN O
cell NN NN O
lines NN NN O
which NN NN O
derive NN NN O
from NN NN O
primary NN NN O
or NN NN O
metastatic NN NN O
human NN NN O
malignant NN NN O
melanomas NN NN O
in NN NN O
relation NN NN O
to NN NN O
staging NN NN O
, NN NN O
infiltration NN NN O
degree NN NN O
, NN NN O
lymphocytic NN NN O
infiltration NN NN O
, NN NN O
cell NN NN O
morphology NN NN O
, NN NN O
cell NN NN O
pigmentation NN NN O
, NN NN O
karyotype NN NN O
, NN NN O
and NN NN O
disease NN NN O
- NN NN O
free NN NN O
survival NN NN O
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
the NN NN O
NM23 NN NN O
gene NN NN O
is NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
cell NN NN O
lines NN NN O
that NN NN O
derive NN NN O
from NN NN O
more NN NN O
infiltrating NN NN O
primary NN NN O
melanomas NN NN O
than NN NN O
in NN NN O
cell NN NN O
lines NN NN O
obtained NN NN O
from NN NN O
less NN NN O
infiltrating NN NN O
tumours NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
tumours NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
disease NN NN O
- NN NN O
free NN NN O
survival NN NN O
of NN NN O
more NN NN O
than NN NN O
24 NN NN O
months NN NN O
( NN NN O
24 NN NN O
- NN NN O
58 NN NN O
months NN NN O
) NN NN O
express NN NN O
the NN NN O
NM23 NN NN O
gene NN NN O
at NN NN O
higher NN NN O
levels NN NN O
than NN NN O
cell NN NN O
lines NN NN O
obtained NN NN O
from NN NN O
melanomas NN NN O
of NN NN O
patients NN NN O
with NN NN O
a NN NN O
disease NN NN O
- NN NN O
free NN NN O
survival NN NN O
of NN NN O
less NN NN O
than NN NN O
24 NN NN O
months NN NN O
( NN NN O
6 NN NN O
- NN NN O
15 NN NN O
months NN NN O
) NN NN O
. NN NN O
   
T NN NN O
cells NN NN O
from NN NN O
renal NN NN O
cell NN NN O
carcinoma NN NN O
patients NN NN O
exhibit NN NN O
an NN NN O
abnormal NN NN O
pattern NN NN O
of NN NN O
kappa NN NN O
B NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
: NN NN O
a NN NN O
preliminary NN NN O
report NN NN O
. NN NN O
   
Recent NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
poor NN NN O
induction NN NN O
of NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
response NN NN O
to NN NN O
human NN NN O
renal NN NN O
cell NN NN O
carcinoma NN NN O
( NN NN O
RCC NN NN O
) NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
alterations NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
T NN NN O
cells NN NN O
from NN NN O
RCC NN NN O
patients NN NN O
have NN NN O
two NN NN O
alterations NN NN O
in NN NN O
kappa NN NN O
B NN NN O
motif NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
first NN NN O
alteration NN NN O
involves NN NN O
the NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
substantial NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
, NN NN O
which NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
unstimulated NN NN O
patient NN NN O
T NN NN O
cells NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
observed NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
that NN NN O
had NN NN O
been NN NN O
activated NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
On NN NN O
the NN NN O
basis NN NN O
of NN NN O
Western NN NN O
blotting NN NN O
experiments NN NN O
using NN NN O
antibodies NN NN O
to NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
proteins NN NN O
, NN NN O
the NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
RCC NN NN O
patients NN NN O
is NN NN O
composed NN NN O
mostly NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
( NN NN O
p50 NN NN B-Protein
) NN NN O
subunit NN NN O
. NN NN O
   
The NN NN O
second NN NN O
abnormality NN NN O
in NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
these NN NN O
patients NN NN O
is NN NN O
that NN NN O
RelA NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
Rel NN NN O
homology NN NN O
family NN NN O
which NN NN O
is NN NN O
part NN NN O
of NN NN O
the NN NN O
normal NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
, NN NN O
was NN NN O
not NN NN O
induced NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
following NN NN O
activation NN NN O
. NN NN O
   
Western NN NN O
blotting NN NN O
analysis NN NN O
did NN NN O
not NN NN O
detect NN NN O
any NN NN O
RelA NN NN B-Protein
in NN NN O
nuclear NN NN O
extracts NN NN O
either NN NN O
before NN NN O
or NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
altered NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
RCC NN NN O
patients NN NN O
may NN NN O
impair NN NN O
their NN NN O
capacity NN NN O
to NN NN O
respond NN NN O
normally NN NN O
to NN NN O
various NN NN O
stimuli NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
vivo NN NN O
is NN NN O
regulated NN NN O
by NN NN O
multiple NN NN O
phosphorylations NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
in NN NN O
intact NN NN O
cells NN NN O
is NN NN O
mechanistically NN NN O
not NN NN O
well NN NN O
understood NN NN O
. NN NN O
   
Therefore NN NN O
we NN NN O
investigated NN NN O
the NN NN O
modifications NN NN O
imposed NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
I NN NN O
kappa NN NN O
B NN NN O
components NN NN O
following NN NN O
stimulation NN NN O
and NN NN O
show NN NN O
that NN NN O
the NN NN O
final NN NN O
step NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
in NN NN O
vivo NN NN O
involves NN NN O
phosphorylation NN NN O
of NN NN O
several NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
I NN NN O
kappa NN NN O
B NN NN O
protein NN NN O
families NN NN O
. NN NN O
   
In NN NN O
HeLa NN NN O
cells NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
B NN NN O
cells NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
rapidly NN NN O
induced NN NN O
nuclear NN NN O
translocation NN NN O
primarily NN NN O
of NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
. NN NN O
   
Both NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
precursors NN NN O
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
became NN NN O
strongly NN NN O
phosphorylated NN NN O
with NN NN O
the NN NN O
same NN NN O
kinetics NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
the NN NN O
inducible NN NN O
phosphorylation NN NN O
after NN NN O
stimulation NN NN O
, NN NN O
B NN NN O
lymphocytes NN NN O
containing NN NN O
constitutive NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
revealed NN NN O
constitutively NN NN O
phosphorylated NN NN O
p65 NN NN B-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Phosphorylation NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
induced NN NN O
processing NN NN O
of NN NN O
the NN NN O
precursors NN NN O
p100 NN NN B-Protein
and NN NN O
p105 NN NN B-Protein
and NN NN O
by NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
As NN NN O
an NN NN O
in NN NN O
vitro NN NN O
model NN NN O
we NN NN O
show NN NN O
that NN NN O
phosphorylation NN NN O
of NN NN O
p105 NN NN B-Protein
impedes NN NN O
its NN NN O
ability NN NN O
to NN NN O
interact NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
as NN NN O
has NN NN O
been NN NN O
shown NN NN O
before NN NN O
for NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Surprisingly NN NN O
, NN NN O
even NN NN O
p65 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
, NN NN O
was NN NN O
phosphorylated NN NN O
after NN NN O
induction NN NN O
in NN NN O
vivo NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
selectively NN NN O
activates NN NN O
only NN NN O
specific NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
heteromers NN NN O
and NN NN O
that NN NN O
modifications NN NN O
regulate NN NN O
not NN NN O
only NN NN O
I NN NN O
kappa NN NN O
B NN NN O
molecules NN NN O
but NN NN O
also NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
molecules NN NN O
. NN NN O
   
In NN NN O
fact NN NN O
, NN NN O
cellular NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
was NN NN O
phosphorylation NN NN O
- NN NN O
dependent NN NN O
and NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
p65 NN NN B-Protein
- NN NN O
containing NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
enhanced NN NN O
by NN NN O
phosphorylation NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
induction NN NN O
by NN NN O
hydrogen NN NN O
peroxide NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
which NN NN O
is NN NN O
assumed NN NN O
to NN NN O
be NN NN O
triggered NN NN O
by NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
, NN NN O
also NN NN O
coincided NN NN O
with NN NN O
incorporation NN NN O
of NN NN O
phosphate NN NN O
into NN NN O
the NN NN O
same NN NN O
subunits NN NN O
that NN NN O
were NN NN O
modified NN NN O
after NN NN O
stimulation NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
phosphorylation NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
general NN NN O
mechanism NN NN O
for NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
An NN NN O
active NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
tyrosine NN NN O
kinase NN NN O
blocks NN NN O
immunoglobulin NN NN O
light NN NN O
- NN NN O
chain NN NN O
gene NN NN O
rearrangement NN NN O
. NN NN O
   
Lymphoid NN NN O
cells NN NN O
transformed NN NN O
by NN NN O
Abelson NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
have NN NN O
provided NN NN O
one NN NN O
of NN NN O
the NN NN O
classic NN NN O
models NN NN O
for NN NN O
study NN NN O
of NN NN O
early NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
and NN NN O
immunoglobulin NN NN O
rearrangement NN NN O
. NN NN O
   
Most NN NN O
of NN NN O
these NN NN O
cells NN NN O
have NN NN O
rearranged NN NN O
their NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
locus NN NN O
but NN NN O
not NN NN O
their NN NN O
light NN NN O
chain NN NN O
genes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
an NN NN O
active NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
interferes NN NN O
with NN NN O
this NN NN O
differentiation NN NN O
step NN NN O
. NN NN O
   
To NN NN O
test NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
light NN NN O
- NN NN O
chain NN NN O
gene NN NN O
structure NN NN O
was NN NN O
examined NN NN O
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
cells NN NN O
transformed NN NN O
by NN NN O
temperature NN NN O
- NN NN O
sensitive NN NN O
mutants NN NN O
of NN NN O
the NN NN O
Abelson NN NN O
virus NN NN O
and NN NN O
in NN NN O
derivatives NN NN O
that NN NN O
survive NN NN O
at NN NN O
the NN NN O
nonpermissive NN NN O
temperature NN NN O
because NN NN O
they NN NN O
express NN NN O
a NN NN O
human NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
reveal NN NN O
that NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
tyrosine NN NN O
kinase NN NN O
triggers NN NN O
high NN NN O
- NN NN O
frequency NN NN O
rearrangement NN NN O
of NN NN O
kappa NN NN B-Protein
and NN NN O
lambda NN NN B-Protein
light NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
genes NN NN O
. NN NN O
   
These NN NN O
events NN NN O
are NN NN O
accompanied NN NN O
by NN NN O
marked NN NN O
increases NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
RAG NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
RAG NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
RNAs NN NN O
. NN NN O
   
These NN NN O
increases NN NN O
occur NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
but NN NN O
are NN NN O
dependent NN NN O
on NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
tyrosine NN NN O
kinase NN NN O
. NN NN O
   
As NN NN O
documented NN NN O
in NN NN O
the NN NN O
accompanying NN NN O
paper NN NN O
( NN NN O
Klug NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
this NN NN O
issue NN NN O
) NN NN O
, NN NN O
an NN NN O
active NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
also NN NN O
suppresses NN NN O
the NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
rel NN NN O
and NN NN O
expression NN NN O
controlled NN NN O
by NN NN O
the NN NN O
kappa NN NN O
intron NN NN O
enhancer NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
protein NN NN O
specifically NN NN O
interferes NN NN O
with NN NN O
light NN NN O
- NN NN O
chain NN NN O
gene NN NN O
rearrangement NN NN O
by NN NN O
suppressing NN NN O
at NN NN O
least NN NN O
two NN NN O
pathways NN NN O
essential NN NN O
for NN NN O
this NN NN O
stage NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
suggest NN NN O
that NN NN O
tyrosine NN NN O
phosphorylation NN NN O
is NN NN O
important NN NN O
in NN NN O
regulating NN NN O
RAG NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
[ NN NN O
An NN NN O
overexpression NN NN O
of NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
blocks NN NN O
myeloid NN NN O
cell NN NN O
differentiation NN NN O
at NN NN O
the NN NN O
promyelocyte NN NN O
stage NN NN O
] NN NN O
   
Retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
, NN NN O
a NN NN O
vitamin NN NN O
A NN NN O
derivative NN NN O
, NN NN O
exerts NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
biological NN NN O
effects NN NN O
related NN NN O
to NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
pleiotropic NN NN O
effects NN NN O
of NN NN O
RA NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
mediated NN NN O
through NN NN O
specific NN NN O
nuclear NN NN O
RA NN NN O
receptors NN NN O
( NN NN O
RARs NN NN O
) NN NN O
. NN NN O
   
RARs NN NN O
are NN NN O
members NN NN O
of NN NN O
the NN NN O
steroid NN NN O
/ NN NN O
thyroid NN NN O
hormone NN NN O
receptor NN NN O
superfamily NN NN O
and NN NN O
exhibit NN NN O
a NN NN O
molecular NN NN O
structure NN NN O
that NN NN O
possess NN NN O
discrete NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
and NN NN O
RA NN NN O
( NN NN O
ligand NN NN O
) NN NN O
- NN NN O
binding NN NN O
domains NN NN O
. NN NN O
   
In NN NN O
hematopoietic NN NN O
system NN NN O
, NN NN O
RA NN NN O
and NN NN O
RARs NN NN O
, NN NN O
predominantly NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
may NN NN O
play NN NN O
key NN NN O
roles NN NN O
for NN NN O
the NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
hematopoietic NN NN O
progenitors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
is NN NN O
currently NN NN O
unknown NN NN O
how NN NN O
RA NN NN O
and NN NN O
RARs NN NN O
are NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
normal NN NN O
hematopoietic NN NN O
differentiation NN NN O
. NN NN O
   
To NN NN O
make NN NN O
clear NN NN O
the NN NN O
roles NN NN O
of NN NN O
RA NN NN O
and NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
the NN NN O
normal NN NN O
hematopoiesis NN NN O
, NN NN O
I NN NN O
have NN NN O
introduced NN NN O
the NN NN O
construct NN NN O
of NN NN O
human NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
( NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
into NN NN O
murine NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
with NN NN O
retroviral NN NN O
vector NN NN O
, NN NN O
and NN NN O
selected NN NN O
infected NN NN O
cells NN NN O
with NN NN O
drug NN NN O
resistant NN NN O
marker NN NN O
( NN NN O
Neo NN NN O
( NN NN O
r NN NN O
) NN NN O
) NN NN O
cultured NN NN O
on NN NN O
the NN NN O
stroma NN NN O
cell NN NN O
line NN NN O
( NN NN O
PA6 NN NN O
- NN NN O
neo NN NN O
) NN NN O
, NN NN O
and NN NN O
analyzed NN NN O
the NN NN O
behavior NN NN O
of NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
All NN NN O
of NN NN O
procedure NN NN O
were NN NN O
done NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Most NN NN O
cells NN NN O
infected NN NN O
with NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
exhibited NN NN O
promyelocytic NN NN O
morphology NN NN O
and NN NN O
were NN NN O
thought NN NN O
to NN NN O
be NN NN O
blocked NN NN O
at NN NN O
the NN NN O
promyelocytic NN NN O
stage NN NN O
in NN NN O
their NN NN O
myeloid NN NN O
differentiation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
immature NN NN O
cells NN NN O
differentiated NN NN O
terminally NN NN O
into NN NN O
mature NN NN O
granulocytes NN NN O
by NN NN O
adding NN NN O
with NN NN O
RA NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
M NN NN O
) NN NN O
. NN NN O
   
RAR NN NN B-Protein
alpha NN NN I-Protein
infected NN NN O
cells NN NN O
were NN NN O
also NN NN O
able NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
mature NN NN O
macrophages NN NN O
in NN NN O
the NN NN O
both NN NN O
of NN NN O
long NN NN O
term NN NN O
culture NN NN O
and NN NN O
IL3 NN NN O
colony NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
an NN NN O
overexpression NN NN O
of NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
alone NN NN O
is NN NN O
effective NN NN O
to NN NN O
suppress NN NN O
myeloid NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
terminal NN NN O
differentiation NN NN O
of NN NN O
myeloid NN NN O
precursors NN NN O
. NN NN O
   
The NN NN O
system NN NN O
described NN NN O
here NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
studying NN NN O
the NN NN O
the NN NN O
essential NN NN O
genes NN NN O
for NN NN O
differentiation NN NN O
of NN NN O
normal NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
expression NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
. NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Autocrine NN NN O
role NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
expression NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
activation NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
in NN NN O
resting NN NN O
T NN NN O
cells NN NN O
, NN NN O
has NN NN O
been NN NN O
studied NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
human NN NN O
resting NN NN O
T NN NN O
cells NN NN O
with NN NN O
phorbol NN NN O
esters NN NN O
strongly NN NN O
induced NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
. NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
This NN NN O
activation NN NN O
was NN NN O
due NN NN O
to NN NN O
the NN NN O
translocation NN NN O
of NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
NF NN NN O
. NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
from NN NN O
cytoplasmic NN NN O
stores NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
where NN NN O
they NN NN O
bound NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
either NN NN O
as NN NN O
p50 NN NN B-Protein
. NN NN O
p65 NN NN B-Protein
or NN NN O
as NN NN O
p50 NN NN B-Protein
. NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
heterodimers NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
all NN NN O
of NN NN O
those NN NN O
events NN NN O
were NN NN O
largely NN NN O
indirect NN NN O
and NN NN O
mediated NN NN O
by NN NN O
endogenously NN NN O
secreted NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
as NN NN O
they NN NN O
were NN NN O
strongly NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
monoclonal NN NN O
antibody NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
, NN NN O
which NN NN O
blocked NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
production NN NN O
induced NN NN O
by NN NN O
PKC NN NN O
, NN NN O
strongly NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
NF NN NN O
. NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
either NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
partially NN NN O
recovered NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
inhibition NN NN O
, NN NN O
but NN NN O
only NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
completely NN NN O
recovered NN NN O
NF NN NN O
. NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Those NN NN O
results NN NN O
indicate NN NN O
that NN NN O
, NN NN O
in NN NN O
resting NN NN O
T NN NN O
cells NN NN O
, NN NN O
PKC NN NN O
activation NN NN O
has NN NN O
only NN NN O
a NN NN O
triggering NN NN O
role NN NN O
, NN NN O
whereas NN NN O
the NN NN O
endogenously NN NN O
secreted NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
plays NN NN O
an NN NN O
essential NN NN O
role NN NN O
in NN NN O
the NN NN O
quantitative NN NN O
control NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
or NN NN O
NF NN NN O
. NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Protease NN NN O
inhibitors NN NN O
block NN NN O
lipopolysaccharide NN NN O
induction NN NN O
of NN NN O
tissue NN NN O
factor NN NN O
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
preventing NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
. NN NN O
   
Tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
is NN NN O
expressed NN NN O
rapidly NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
exposed NN NN O
to NN NN O
bacterial NN NN O
endotoxin NN NN O
( NN NN O
lipopolysaccharide NN NN O
, NN NN O
or NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
to NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
site NN NN O
in NN NN O
the NN NN O
TF NN NN B-Protein
promoter NN NN O
. NN NN O
   
Nuclear NN NN O
translocation NN NN O
of NN NN O
cytosolic NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
and NN NN O
other NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
requires NN NN O
dissociation NN NN O
and NN NN O
proteolytic NN NN O
degradation NN NN O
of NN NN O
the NN NN O
inhibitor NN NN O
protein NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
protease NN NN O
inhibitors NN NN O
N NN NN O
alpha NN NN O
- NN NN O
tosylphenylalanyl NN NN O
chloromethyl NN NN O
ketone NN NN O
( NN NN O
TPCK NN NN O
) NN NN O
and NN NN O
N NN NN O
alpha NN NN O
- NN NN O
tosyl NN NN O
- NN NN O
L NN NN O
- NN NN O
lysine NN NN O
chloromethyl NN NN O
ketone NN NN O
( NN NN O
TLCK NN NN O
) NN NN O
block NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
proteins NN NN O
by NN NN O
preventing NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
To NN NN O
determine NN NN O
if NN NN O
TPCK NN NN O
and NN NN O
TLCK NN NN O
inhibited NN NN O
LPS NN NN O
induction NN NN O
of NN NN O
TF NN NN B-Protein
expression NN NN O
, NN NN O
freshly NN NN O
isolated NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
were NN NN O
pretreated NN NN O
with NN NN O
these NN NN O
inhibitors NN NN O
for NN NN O
30 NN NN O
min NN NN O
before NN NN O
LPS NN NN O
stimulation NN NN O
. NN NN O
   
Both NN NN O
TPCK NN NN O
and NN NN O
TLCK NN NN O
inhibited NN NN O
LPS NN NN O
induction NN NN O
of NN NN O
TF NN NN B-Protein
protein NN NN O
, NN NN O
TF NN NN B-Protein
mRNA NN NN O
and NN NN O
TF NN NN B-Protein
promoter NN NN O
activity NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
These NN NN O
inhibitors NN NN O
specifically NN NN O
prevented NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
TPCK NN NN O
and NN NN O
TLCK NN NN O
did NN NN O
not NN NN O
block NN NN O
induction NN NN O
of NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
indicated NN NN O
that NN NN O
inhibiting NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
prevented NN NN O
LPS NN NN O
induction NN NN O
of NN NN O
TF NN NN B-Protein
gene NN NN O
transcription NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
family NN NN O
of NN NN O
serine NN NN O
proteases NN NN O
expressed NN NN O
exclusively NN NN O
in NN NN O
myelo NN NN O
- NN NN O
monocytic NN NN O
cells NN NN O
specifically NN NN O
processes NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunit NN NN O
p65 NN NN B-Protein
in NN NN O
vitro NN NN O
and NN NN O
may NN NN O
impair NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
replication NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
groups NN NN O
of NN NN O
U937 NN NN O
promonocytic NN NN O
cells NN NN O
were NN NN O
obtained NN NN O
by NN NN O
limiting NN NN O
dilution NN NN O
cloning NN NN O
which NN NN O
differed NN NN O
strikingly NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
support NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
. NN NN O
   
"""""""" NN NN O
Plus NN NN O
"""""""" NN NN O
clones NN NN O
replicated NN NN O
the NN NN O
virus NN NN O
efficiently NN NN O
, NN NN O
whereas NN NN O
"""""""" NN NN O
minus NN NN O
"""""""" NN NN O
clones NN NN O
did NN NN O
not NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
these NN NN O
clones NN NN O
for NN NN O
differences NN NN O
in NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
which NN NN O
might NN NN O
account NN NN O
for NN NN O
the NN NN O
observed NN NN O
phenomenon NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
plus NN NN O
clones NN NN O
liberated NN NN O
the NN NN O
classical NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
complex NN NN O
from NN NN O
cytoplasmic NN NN O
pools NN NN O
, NN NN O
whereas NN NN O
minus NN NN O
clones NN NN O
produced NN NN O
an NN NN O
apparently NN NN O
novel NN NN O
, NN NN O
faster NN NN O
- NN NN O
migrating NN NN O
complex NN NN O
, NN NN O
as NN NN O
judged NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
It NN NN O
is NN NN O
surprising NN NN O
that NN NN O
the NN NN O
faster NN NN O
- NN NN O
migrating NN NN O
complex NN NN O
was NN NN O
composed NN NN O
also NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
p65 NN NN B-Protein
subunit NN NN O
was NN NN O
COOH NN NN O
- NN NN O
terminally NN NN O
truncated NN NN O
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
immunoprecipitation NN NN O
. NN NN O
   
The NN NN O
truncation NN NN O
resulted NN NN O
from NN NN O
limited NN NN O
proteolysis NN NN O
of NN NN O
p65 NN NN B-Protein
during NN NN O
cellular NN NN O
extraction NN NN O
which NN NN O
released NN NN O
particular NN NN O
lysosomal NN NN O
serine NN NN O
proteases NN NN O
, NN NN O
such NN NN O
as NN NN O
elastase NN NN O
, NN NN O
cathepsin NN NN B-Protein
G NN NN I-Protein
, NN NN O
and NN NN O
proteinase NN NN B-Protein
3 NN NN I-Protein
. NN NN O
   
These NN NN O
specific NN NN O
proteases NN NN O
are NN NN O
coordinately NN NN O
expressed NN NN O
and NN NN O
were NN NN O
present NN NN O
exclusively NN NN O
in NN NN O
the NN NN O
minus NN NN O
U937 NN NN O
clones NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
plus NN NN O
clones NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
cathepsin NN NN B-Protein
G NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
these NN NN O
proteases NN NN O
were NN NN O
detected NN NN O
in NN NN O
certain NN NN O
subclones NN NN O
of NN NN O
THP NN NN O
- NN NN O
1 NN NN O
and NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
and NN NN O
in NN NN O
primary NN NN O
monocytes NN NN O
, NN NN O
in NN NN O
each NN NN O
case NN NN O
correlating NN NN O
with NN NN O
the NN NN O
truncated NN NN O
from NN NN O
of NN NN O
p65 NN NN B-Protein
. NN NN O
   
We NN NN O
demonstrate NN NN O
in NN NN O
vitro NN NN O
cleavage NN NN O
of NN NN O
p65 NN NN B-Protein
by NN NN O
purified NN NN O
elastase NN NN O
and NN NN O
cathepsin NN NN B-Protein
G NN NN I-Protein
. NN NN O
   
It NN NN O
is NN NN O
possible NN NN O
that NN NN O
particular NN NN O
serine NN NN O
proteases NN NN O
may NN NN O
have NN NN O
inhibiting NN NN O
effects NN NN O
on NN NN O
the NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
myelo NN NN O
- NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
data NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
special NN NN O
precautions NN NN O
must NN NN O
be NN NN O
taken NN NN O
when NN NN O
making NN NN O
extracts NN NN O
from NN NN O
myelo NN NN O
- NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
Tax NN NN B-Protein
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
involves NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
the NN NN O
c NN NN O
- NN NN O
rel NN NN O
gene NN NN O
. NN NN O
   
The NN NN O
tax NN NN B-Protein
gene NN NN O
product NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
is NN NN O
a NN NN O
potent NN NN O
transcriptional NN NN O
activator NN NN O
that NN NN O
both NN NN O
stimulates NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
and NN NN O
activates NN NN O
an NN NN O
array NN NN O
of NN NN O
cellular NN NN O
genes NN NN O
involved NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
growth NN NN O
. NN NN O
   
Tax NN NN B-Protein
acts NN NN O
indirectly NN NN O
by NN NN O
inducing NN NN O
or NN NN O
modifying NN NN O
the NN NN O
action NN NN O
of NN NN O
various NN NN O
host NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
including NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
resting NN NN O
T NN NN O
cells NN NN O
, NN NN O
many NN NN O
of NN NN O
these NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
factors NN NN O
are NN NN O
sequestered NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
by NN NN O
various NN NN O
ankyrin NN NN O
- NN NN O
rich NN NN O
inhibitory NN NN O
proteins NN NN O
, NN NN O
including NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
expression NN NN O
leads NN NN O
to NN NN O
the NN NN O
constitutive NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
biologically NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
complexes NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
biochemical NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
underlying NN NN O
this NN NN O
response NN NN O
remains NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
Tax NN NN B-Protein
- NN NN O
stimulated NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
both NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
infected NN NN O
and NN NN O
Tax NN NN B-Protein
- NN NN O
transfected NN NN O
human NN NN O
T NN NN O
cells NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
rapid NN NN O
proteolytic NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
prior NN NN O
in NN NN O
vitro NN NN O
studies NN NN O
, NN NN O
at NN NN O
least NN NN O
a NN NN O
fraction NN NN O
of NN NN O
the NN NN O
phosphorylated NN NN O
form NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
remains NN NN O
physically NN NN O
associated NN NN O
with NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
in NN NN O
vivo NN NN O
but NN NN O
is NN NN O
subject NN NN O
to NN NN O
rapid NN NN O
degradation NN NN O
, NN NN O
thereby NN NN O
promoting NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrate NN NN O
that NN NN O
Tax NN NN B-Protein
induction NN NN O
of NN NN O
nuclear NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
expression NN NN O
is NN NN O
activated NN NN O
by NN NN O
the NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
activates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
rel NN NN I-Protein
gene NN NN O
through NN NN O
an NN NN O
intrinsic NN NN O
kappa NN NN O
B NN NN O
enhancer NN NN O
element NN NN O
. NN NN O
   
In NN NN O
normal NN NN O
cells NN NN O
, NN NN O
the NN NN O
subsequent NN NN O
accumulation NN NN O
of NN NN O
nuclear NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
acts NN NN O
to NN NN O
inhibit NN NN O
its NN NN O
own NN NN O
continued NN NN O
production NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
autoregulatory NN NN O
loop NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Arrested NN NN O
development NN NN O
: NN NN O
understanding NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
. NN NN O
   
The NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
of NN NN O
the NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
oncogene NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
subvert NN NN O
the NN NN O
normal NN NN O
second NN NN O
messenger NN NN O
systems NN NN O
used NN NN O
by NN NN O
lymphoid NN NN O
cells NN NN O
for NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
Transformation NN NN O
of NN NN O
bone NN NN O
marrow NN NN O
with NN NN O
the NN NN O
Abelson NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
results NN NN O
in NN NN O
the NN NN O
appearance NN NN O
of NN NN O
B NN NN O
cell NN NN O
lineage NN NN O
cells NN NN O
arrested NN NN O
at NN NN O
the NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
stage NN NN O
. NN NN O
   
Recent NN NN O
reports NN NN O
have NN NN O
characterized NN NN O
these NN NN O
cells NN NN O
expressing NN NN O
high NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
kinase NN NN O
activity NN NN O
as NN NN O
deficient NN NN O
in NN NN O
detectable NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
low NN NN O
level NN NN O
RAG NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
v NN NN B-Protein
- NN NN I-Protein
abl NN NN I-Protein
may NN NN O
be NN NN O
inhibiting NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
B NN NN O
cells NN NN O
by NN NN O
blocking NN NN O
these NN NN O
two NN NN O
crucial NN NN O
elements NN NN O
in NN NN O
the NN NN O
maturation NN NN O
pathway NN NN O
. NN NN O
   
Distinct NN NN O
DNase NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
hypersensitive NN NN O
sites NN NN O
are NN NN O
associated NN NN O
with NN NN O
TAL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
in NN NN O
erythroid NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
, NN NN O
frequently NN NN O
activated NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
( NN NN O
T NN NN O
- NN NN O
ALL NN NN O
) NN NN O
, NN NN O
is NN NN O
expressed NN NN O
in NN NN O
the NN NN O
erythroid NN NN O
, NN NN O
megakaryocytic NN NN O
, NN NN O
and NN NN O
mast NN NN O
cell NN NN O
lineages NN NN O
during NN NN O
normal NN NN O
hematopoiesis NN NN O
. NN NN O
   
To NN NN O
gain NN NN O
further NN NN O
insight NN NN O
into NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
control NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
, NN NN O
we NN NN O
investigated NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
chromatin NN NN O
structure NN NN O
in NN NN O
erythroid NN NN O
/ NN NN O
megakaryocytic NN NN O
cell NN NN O
lines NN NN O
and NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
either NN NN O
with NN NN O
or NN NN O
without NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
rearrangements NN NN O
. NN NN O
   
Tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
monoallelic NN NN O
in NN NN O
Jurkat NN NN O
, NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
that NN NN O
expresses NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
apparent NN NN O
genomic NN NN O
alteration NN NN O
of NN NN O
the NN NN O
locus NN NN O
. NN NN O
   
Methylation NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
the NN NN O
tal NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
' NN NN O
GC NN NN O
- NN NN O
rich NN NN O
region NN NN O
behaves NN NN O
like NN NN O
a NN NN O
CpG NN NN O
island NN NN O
, NN NN O
hypomethylated NN NN O
in NN NN O
normal NN NN O
cells NN NN O
, NN NN O
and NN NN O
methylated NN NN O
de NN NN O
novo NN NN O
on NN NN O
transcriptionally NN NN O
inactive NN NN O
alleles NN NN O
in NN NN O
established NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Five NN NN O
major NN NN O
DNase NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
hypersensitive NN NN O
sites NN NN O
( NN NN O
HS NN NN O
) NN NN O
were NN NN O
mapped NN NN O
in NN NN O
the NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
locus NN NN O
. NN NN O
   
HS NN NN O
I NN NN O
, NN NN O
IV NN NN O
, NN NN O
and NN NN O
V NN NN O
were NN NN O
exclusively NN NN O
observed NN NN O
in NN NN O
the NN NN O
erythroid NN NN O
/ NN NN O
megakaryocytic NN NN O
cell NN NN O
lines NN NN O
that NN NN O
express NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
from NN NN O
the NN NN O
promoters NN NN O
1a NN NN O
and NN NN O
1b NN NN O
. NN NN O
   
HS NN NN O
II NN NN O
was NN NN O
weak NN NN O
in NN NN O
hematopoietic NN NN O
cell NN NN O
lines NN NN O
, NN NN O
absent NN NN O
in NN NN O
Hela NN NN O
, NN NN O
and NN NN O
greatly NN NN O
enhanced NN NN O
in NN NN O
Jurkat NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
region NN NN O
might NN NN O
be NN NN O
implicated NN NN O
in NN NN O
the NN NN O
cis NN NN O
- NN NN O
activation NN NN O
of NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
1b NN NN O
in NN NN O
this NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
HS NN NN O
III NN NN O
was NN NN O
weak NN NN O
in NN NN O
HEL NN NN O
and NN NN O
Jurkat NN NN O
, NN NN O
and NN NN O
greatly NN NN O
enhanced NN NN O
in NN NN O
DU528 NN NN O
, NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
that NN NN O
bears NN NN O
a NN NN O
t NN NN O
( NN NN O
1 NN NN O
; NN NN O
14 NN NN O
) NN NN O
and NN NN O
initiates NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
within NN NN O
exon NN NN O
4 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
distinct NN NN O
regulatory NN NN O
elements NN NN O
are NN NN O
associated NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
the NN NN O
different NN NN O
tal NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoters NN NN O
. NN NN O
   
Functions NN NN O
of NN NN O
glutathione NN NN O
and NN NN O
glutathione NN NN O
disulfide NN NN O
in NN NN O
immunology NN NN O
and NN NN O
immunopathology NN NN O
. NN NN O
   
Even NN NN O
a NN NN O
moderate NN NN O
increase NN NN O
in NN NN O
the NN NN O
cellular NN NN O
cysteine NN NN O
supply NN NN O
elevates NN NN O
the NN NN O
intracellular NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
and NN NN O
glutathione NN NN O
disulfide NN NN O
( NN NN O
GSSG NN NN O
) NN NN O
levels NN NN O
and NN NN O
potentiates NN NN O
immunological NN NN O
functions NN NN O
of NN NN O
lymphocytes NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
At NN NN O
low NN NN O
GSSG NN NN O
levels NN NN O
, NN NN O
T NN NN O
cells NN NN O
cannot NN NN O
optimally NN NN O
activate NN NN O
the NN NN O
immunologically NN NN O
important NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
whereas NN NN O
high NN NN O
GSSG NN NN O
levels NN NN O
inhibit NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
GSSG NN NN O
are NN NN O
antagonized NN NN O
by NN NN O
reduced NN NN O
thioredoxin NN NN B-Protein
( NN NN O
TRX NN NN B-Protein
) NN NN O
. NN NN O
   
As NN NN O
the NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activities NN NN O
p56lck NN NN B-Protein
and NN NN O
p59fyn NN NN B-Protein
are NN NN O
activated NN NN O
in NN NN O
intact NN NN O
cells NN NN O
by NN NN O
hydrogen NN NN O
peroxide NN NN O
, NN NN O
they NN NN O
are NN NN O
likely NN NN O
targets NN NN O
for NN NN O
GSSG NN NN O
action NN NN O
. NN NN O
   
These NN NN O
redox NN NN O
- NN NN O
regulated NN NN O
enzymes NN NN O
trigger NN NN O
signal NN NN O
cascades NN NN O
for NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
transduce NN NN O
signals NN NN O
from NN NN O
the NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
, NN NN O
from NN NN O
CD4 NN NN B-Protein
and NN NN O
CD8 NN NN O
molecules NN NN O
, NN NN O
and NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
. NN NN O
   
The NN NN O
effector NN NN O
phase NN NN O
of NN NN O
cytotoxic NN NN O
T NN NN O
cell NN NN O
responses NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
functions NN NN O
are NN NN O
inhibited NN NN O
even NN NN O
by NN NN O
a NN NN O
partial NN NN O
depletion NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
GSH NN NN O
pool NN NN O
. NN NN O
   
As NN NN O
signal NN NN O
transduction NN NN O
is NN NN O
facilitated NN NN O
by NN NN O
prooxidant NN NN O
conditions NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
the NN NN O
well NN NN O
- NN NN O
known NN NN O
immunological NN NN O
consequences NN NN O
of NN NN O
GSH NN NN O
depletion NN NN O
ultimately NN NN O
may NN NN O
be NN NN O
results NN NN O
of NN NN O
the NN NN O
accompanying NN NN O
GSSG NN NN O
deficiency NN NN O
. NN NN O
   
As NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
patients NN NN O
and NN NN O
SIV NN NN O
- NN NN O
infected NN NN O
rhesus NN NN O
macaques NN NN O
have NN NN O
, NN NN O
on NN NN O
the NN NN O
average NN NN O
, NN NN O
significantly NN NN O
decreased NN NN O
plasma NN NN O
cyst NN NN O
( NN NN O
e NN NN O
) NN NN O
ine NN NN O
and NN NN O
intracellular NN NN O
GSH NN NN O
levels NN NN O
, NN NN O
we NN NN O
also NN NN O
hypothesize NN NN O
that NN NN O
AIDS NN NN O
may NN NN O
be NN NN O
the NN NN O
consequence NN NN O
of NN NN O
a NN NN O
GSSG NN NN O
deficiency NN NN O
as NN NN O
well NN NN O
. NN NN O
   
Erythropoietin NN NN B-Protein
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
hemoglobin NN NN O
synthesis NN NN O
in NN NN O
a NN NN O
cytokine NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
line NN NN O
M NN NN O
- NN NN O
TAT NN NN O
. NN NN O
   
M NN NN O
- NN NN O
TAT NN NN O
is NN NN O
a NN NN O
cytokine NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
line NN NN O
with NN NN O
the NN NN O
potential NN NN O
to NN NN O
differentiate NN NN O
along NN NN O
the NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
lineages NN NN O
. NN NN O
   
We NN NN O
cultured NN NN O
M NN NN O
- NN NN O
TAT NN NN O
cells NN NN O
long NN NN O
term NN NN O
( NN NN O
> NN NN O
1 NN NN O
year NN NN O
) NN NN O
in NN NN O
the NN NN O
continuous NN NN O
presence NN NN O
of NN NN O
erythropoietin NN NN B-Protein
( NN NN O
EPO NN NN B-Protein
) NN NN O
, NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
, NN NN O
or NN NN O
stem NN NN B-Protein
cell NN NN I-Protein
factor NN NN I-Protein
( NN NN O
SCF NN NN B-Protein
) NN NN O
. NN NN O
   
These NN NN O
long NN NN O
term NN NN O
cultures NN NN O
are NN NN O
referred NN NN O
to NN NN O
as NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
EPO NN NN O
, NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
GM NN NN O
- NN NN O
CSF NN NN O
, NN NN O
and NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
SCF NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Hemoglobin NN NN O
concentration NN NN O
and NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
and NN NN O
erythroid NN NN B-Protein
delta NN NN I-Protein
- NN NN I-Protein
aminolevulinate NN NN I-Protein
synthase NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
EPO NN NN B-Protein
cells NN NN O
than NN NN O
in NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
cells NN NN O
. NN NN O
   
When NN NN O
the NN NN O
supplemented NN NN O
cytokine NN NN O
was NN NN O
switched NN NN O
from NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
to NN NN O
EPO NN NN B-Protein
, NN NN O
hemoglobin NN NN O
synthesis NN NN O
in NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
cells NN NN O
increased NN NN O
rapidly NN NN O
( NN NN O
within NN NN O
5 NN NN O
h NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
level NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
increased NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
addition NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
to NN NN O
the NN NN O
M NN NN O
- NN NN O
TAT NN NN O
/ NN NN O
EPO NN NN B-Protein
cell NN NN O
culture NN NN O
decreased NN NN O
the NN NN O
amount NN NN O
of NN NN O
hemoglobin NN NN O
, NN NN O
even NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
EPO NN NN B-Protein
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
EPO NN NN B-Protein
signal NN NN O
for NN NN O
erythroid NN NN O
differentiation NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
erythroid NN NN O
development NN NN O
of NN NN O
M NN NN O
- NN NN O
TAT NN NN O
cells NN NN O
is NN NN O
promoted NN NN O
by NN NN O
EPO NN NN B-Protein
and NN NN O
suppressed NN NN O
by NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
These NN NN O
results NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
EPO NN NN B-Protein
actively NN NN O
influences NN NN O
the NN NN O
programming NN NN O
of NN NN O
gene NN NN O
expression NN NN O
required NN NN O
for NN NN O
erythroid NN NN O
progenitor NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
One NN NN O
gene NN NN O
, NN NN O
two NN NN O
transcripts NN NN O
: NN NN O
isolation NN NN O
of NN NN O
an NN NN O
alternative NN NN O
transcript NN NN O
encoding NN NN O
for NN NN O
the NN NN O
autoantigen NN NN B-Protein
La NN NN I-Protein
/ NN NN O
SS NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
from NN NN O
a NN NN O
cDNA NN NN O
library NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
primary NN NN O
Sjogrens NN NN O
' NN NN O
syndrome NN NN O
. NN NN O
   
A NN NN O
cDNA NN NN O
library NN NN O
was NN NN O
prepared NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
of NN NN O
an NN NN O
autoimmune NN NN O
patient NN NN O
with NN NN O
primary NN NN O
Sjogrens NN NN O
' NN NN O
syndrome NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
library NN NN O
was NN NN O
screened NN NN O
with NN NN O
the NN NN O
patients NN NN O
own NN NN O
autoimmune NN NN O
serum NN NN O
being NN NN O
monospecific NN NN O
for NN NN O
the NN NN O
nuclear NN NN O
autoantigen NN NN B-Protein
La NN NN I-Protein
/ NN NN O
SS NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
. NN NN O
   
Thereby NN NN O
an NN NN O
alternative NN NN O
type NN NN O
of NN NN O
La NN NN B-Protein
mRNA NN NN O
was NN NN O
identified NN NN O
that NN NN O
differed NN NN O
from NN NN O
the NN NN O
known NN NN O
La NN NN B-Protein
mRNA NN NN O
due NN NN O
to NN NN O
an NN NN O
exchange NN NN O
of NN NN O
the NN NN O
exon NN NN O
1 NN NN O
. NN NN O
   
Sequencing NN NN O
of NN NN O
the NN NN O
genomic NN NN O
region NN NN O
between NN NN O
the NN NN O
exons NN NN O
1 NN NN O
and NN NN O
2 NN NN O
showed NN NN O
that NN NN O
the NN NN O
alternative NN NN O
5 NN NN O
' NN NN O
- NN NN O
end NN NN O
is NN NN O
a NN NN O
part NN NN O
of NN NN O
the NN NN O
intron NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
alternative NN NN O
promoter NN NN O
site NN NN O
, NN NN O
which NN NN O
exists NN NN O
within NN NN O
the NN NN O
intron NN NN O
downstream NN NN O
of NN NN O
the NN NN O
exon NN NN O
1 NN NN O
, NN NN O
became NN NN O
evident NN NN O
. NN NN O
   
In NN NN O
consequence NN NN O
, NN NN O
the NN NN O
alternative NN NN O
La NN NN B-Protein
mRNA NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
promoter NN NN O
switching NN NN O
combined NN NN O
with NN NN O
an NN NN O
alternative NN NN O
splicing NN NN O
mechanism NN NN O
. NN NN O
   
In NN NN O
the NN NN O
intron NN NN O
, NN NN O
further NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
, NN NN O
including NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
element NN NN O
, NN NN O
were NN NN O
identified NN NN O
leading NN NN O
to NN NN O
the NN NN O
suggestion NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
for NN NN O
the NN NN O
nuclear NN NN O
autoantigen NN NN B-Protein
La NN NN I-Protein
/ NN NN O
SS NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
alters NN NN O
in NN NN O
dependence NN NN O
on NN NN O
disease NN NN O
conditions NN NN O
. NN NN O
   
Functional NN NN O
Myc NN NN B-Protein
- NN NN O
Max NN NN B-Protein
heterodimer NN NN O
is NN NN O
required NN NN O
for NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
T NN NN O
cell NN NN O
hybridomas NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
hybridomas NN NN O
respond NN NN O
to NN NN O
activation NN NN O
signals NN NN O
by NN NN O
undergoing NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
, NN NN O
and NN NN O
this NN NN O
is NN NN O
likely NN NN O
to NN NN O
represent NN NN O
comparable NN NN O
events NN NN O
related NN NN O
to NN NN O
tolerance NN NN O
induction NN NN O
in NN NN O
immature NN NN O
and NN NN O
mature NN NN O
T NN NN O
cells NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
using NN NN O
antisense NN NN O
oligonucleotides NN NN O
implicated NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
protein NN NN O
in NN NN O
the NN NN O
phenomenon NN NN O
of NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
This NN NN O
role NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myc NN NN I-Protein
in NN NN O
apoptosis NN NN O
is NN NN O
now NN NN O
confirmed NN NN O
in NN NN O
studies NN NN O
using NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
form NN NN O
of NN NN O
its NN NN O
heterodimeric NN NN O
binding NN NN O
partner NN NN O
, NN NN O
Max NN NN B-Protein
, NN NN O
which NN NN O
we NN NN O
show NN NN O
here NN NN O
inhibits NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
coexpression NN NN O
of NN NN O
a NN NN O
reciprocally NN NN O
mutant NN NN O
Myc NN NN B-Protein
protein NN NN O
capable NN NN O
of NN NN O
forming NN NN O
functional NN NN O
heterodimers NN NN O
with NN NN O
the NN NN O
mutant NN NN O
Max NN NN B-Protein
can NN NN O
compensate NN NN O
for NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
activity NN NN O
and NN NN O
restore NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
These NN NN O
results NN NN O
imply NN NN O
that NN NN O
Myc NN NN B-Protein
promotes NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
by NN NN O
obligatory NN NN O
heterodimerization NN NN O
with NN NN O
Max NN NN B-Protein
, NN NN O
and NN NN O
therefore NN NN O
, NN NN O
by NN NN O
regulating NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
binding NN NN O
studies NN NN O
of NN NN O
the NN NN O
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
( NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
: NN NN O
evidence NN NN O
for NN NN O
complex NN NN O
formation NN NN O
by NN NN O
latent NN NN O
membrane NN NN O
protein NN NN O
gene NN NN O
promoter NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
positive NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
Epstein NN NN B-Protein
- NN NN I-Protein
Barr NN NN I-Protein
virus NN NN I-Protein
( NN NN I-Protein
EBV NN NN I-Protein
) NN NN I-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
2 NN NN I-Protein
( NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
protein NN NN O
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
immortalization NN NN O
of NN NN O
human NN NN O
primary NN NN O
B NN NN O
cells NN NN O
by NN NN O
EBV NN NN O
. NN NN O
   
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
trans NN NN O
- NN NN O
activates NN NN O
cellular NN NN O
and NN NN O
viral NN NN O
genes NN NN O
like NN NN O
CD23 NN NN B-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
fgr NN NN I-Protein
, NN NN O
latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
and NN NN O
terminal NN NN B-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
TP1 NN NN B-Protein
) NN NN O
. NN NN O
   
Trans NN NN O
- NN NN O
activation NN NN O
of NN NN O
the NN NN O
TP1 NN NN B-Protein
promoter NN NN O
and NN NN O
of NN NN O
the NN NN O
BamHI NN NN B-Protein
C NN NN I-Protein
promoter NN NN O
has NN NN O
already NN NN O
been NN NN O
investigated NN NN O
in NN NN O
detail NN NN O
and NN NN O
appears NN NN O
to NN NN O
be NN NN O
mediated NN NN O
via NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
and NN NN O
not NN NN O
by NN NN O
direct NN NN O
binding NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
type NN NN O
A NN NN O
( NN NN O
of NN NN O
EBV NN NN O
type NN NN O
1 NN NN O
) NN NN O
to NN NN O
the NN NN O
DNA NN NN O
. NN NN O
   
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
able NN NN O
to NN NN O
trans NN NN O
- NN NN O
activate NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
LMP NN NN B-Protein
gene NN NN O
in NN NN O
several NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Various NN NN O
reports NN NN O
have NN NN O
delineated NN NN O
the NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
of NN NN O
the NN NN O
LMP NN NN B-Protein
promoter NN NN O
through NN NN O
which NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mediates NN NN O
trans NN NN O
- NN NN O
activation NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
also NN NN O
trans NN NN O
- NN NN O
activates NN NN O
the NN NN O
LMP NN NN B-Protein
promoter NN NN O
by NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
series NN NN O
of NN NN O
gel NN NN O
retardation NN NN O
assays NN NN O
and NN NN O
competition NN NN O
experiments NN NN O
with NN NN O
LMP NN NN B-Protein
promoter NN NN O
fragments NN NN O
of NN NN O
different NN NN O
sizes NN NN O
. NN NN O
   
We NN NN O
determined NN NN O
that NN NN O
the NN NN O
protein NN NN O
- NN NN O
binding NN NN O
region NN NN O
on NN NN O
the NN NN O
LMP NN NN B-Protein
promoter NN NN O
was NN NN O
within NN NN O
a NN NN O
42 NN NN O
bp NN NN O
fragment NN NN O
encompassing NN NN O
nucleotides NN NN O
- NN NN O
135 NN NN O
to NN NN O
- NN NN O
176 NN NN O
relative NN NN O
to NN NN O
the NN NN O
LMP NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
. NN NN O
   
   O
of NN NN O
the NN NN O
DNA NN NN O
fragments NN NN O
investigated NN NN O
indicated NN NN O
interaction NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
with NN NN O
the NN NN O
DNA NN NN O
via NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
differences NN NN O
between NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
positive NN NN O
and NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
negative NN NN O
nuclear NN NN O
extracts NN NN O
could NN NN O
be NN NN O
seen NN NN O
in NN NN O
the NN NN O
gel NN NN O
retardation NN NN O
assay NN NN O
under NN NN O
conditions NN NN O
that NN NN O
clearly NN NN O
showed NN NN O
binding NN NN O
of NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
to NN NN O
the NN NN O
TP1 NN NN B-Protein
promoter NN NN O
. NN NN O
   
However NN NN O
, NN NN O
analysis NN NN O
of NN NN O
sucrose NN NN O
gradient NN NN O
fractions NN NN O
in NN NN O
the NN NN O
gel NN NN O
retardation NN NN O
assay NN NN O
provided NN NN O
evidence NN NN O
that NN NN O
the NN NN O
LMP NN NN B-Protein
promoter NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
form NN NN O
a NN NN O
complex NN NN O
of NN NN O
higher NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
in NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
positive NN NN O
cell NN NN O
extracts NN NN O
. NN NN O
   
These NN NN O
complexes NN NN O
were NN NN O
destroyed NN NN O
by NN NN O
detergent NN NN O
. NN NN O
   
We NN NN O
deduce NN NN O
from NN NN O
these NN NN O
results NN NN O
that NN NN O
EBNA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
positive NN NN O
cells NN NN O
might NN NN O
indeed NN NN O
contain NN NN O
specific NN NN O
complexes NN NN O
bound NN NN O
to NN NN O
the NN NN O
LMP NN NN B-Protein
promoter NN NN O
which NN NN O
are NN NN O
, NN NN O
however NN NN O
, NN NN O
too NN NN O
labile NN NN O
to NN NN O
be NN NN O
detected NN NN O
in NN NN O
a NN NN O
standard NN NN O
gel NN NN O
retardation NN NN O
assay NN NN O
. NN NN O
   
Enhanced NN NN O
responsiveness NN NN O
to NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
contributes NN NN O
to NN NN O
the NN NN O
unique NN NN O
phenotype NN NN O
of NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
variant NN NN O
SIVsmmPBj14 NN NN O
. NN NN O
   
Infection NN NN O
with NN NN O
a NN NN O
variant NN NN O
of NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
, NN NN O
SIVsmmPBj14 NN NN O
, NN NN O
leads NN NN O
to NN NN O
severe NN NN O
acute NN NN O
disease NN NN O
in NN NN O
macaques NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
investigate NN NN O
the NN NN O
functional NN NN O
significance NN NN O
of NN NN O
previously NN NN O
described NN NN O
mutations NN NN O
in NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
and NN NN O
to NN NN O
elucidate NN NN O
their NN NN O
contribution NN NN O
to NN NN O
the NN NN O
unique NN NN O
phenotype NN NN O
of NN NN O
SIVsmmPBj14 NN NN O
. NN NN O
   
LTR NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
was NN NN O
measured NN NN O
by NN NN O
using NN NN O
luciferase NN NN O
reporter NN NN O
constructs NN NN O
that NN NN O
were NN NN O
transiently NN NN O
transfected NN NN O
into NN NN O
cultured NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
cell NN NN O
types NN NN O
, NN NN O
the NN NN O
basal NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
LTR NN NN O
from NN NN O
SIVsmmPBj14 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
2 NN NN O
- NN NN O
to NN NN O
4 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
higher NN NN O
than NN NN O
that NN NN O
of NN NN O
an NN NN O
LTR NN NN O
from NN NN O
a NN NN O
non NN NN O
- NN NN O
acutely NN NN O
pathogenic NN NN O
strain NN NN O
. NN NN O
   
These NN NN O
LTRs NN NN O
differ NN NN O
by NN NN O
five NN NN O
point NN NN O
mutations NN NN O
and NN NN O
a NN NN O
22 NN NN O
- NN NN O
bp NN NN O
duplication NN NN O
in NN NN O
SIVsmmPBj14 NN NN O
, NN NN O
which NN NN O
includes NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
) NN NN O
site NN NN O
. NN NN O
   
Transcriptional NN NN O
differences NN NN O
between NN NN O
these NN NN O
LTRs NN NN O
were NN NN O
further NN NN O
enhanced NN NN O
by NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
upon NN NN O
treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
phorbol NN NN O
ester NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
or NN NN O
by NN NN O
cotransfection NN NN O
with NN NN O
plasmids NN NN O
expressing NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
. NN NN O
   
Mutagenesis NN NN O
studies NN NN O
, NN NN O
and NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
an NN NN O
enhancerless NN NN O
promoter NN NN O
, NN NN O
indicate NN NN O
that NN NN O
these NN NN O
transcriptional NN NN O
effects NN NN O
are NN NN O
due NN NN O
principally NN NN O
to NN NN O
the NN NN O
22 NN NN O
- NN NN O
bp NN NN O
sequence NN NN O
duplication NN NN O
and NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
site NN NN O
contained NN NN O
within NN NN O
it NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
infectious NN NN O
virus NN NN O
stocks NN NN O
that NN NN O
were NN NN O
isogenic NN NN O
except NN NN O
for NN NN O
the NN NN O
LTR NN NN O
were NN NN O
generated NN NN O
. NN NN O
   
The NN NN O
LTR NN NN O
from NN NN O
SIVsmmPBj14 NN NN O
was NN NN O
found NN NN O
to NN NN O
confer NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
kinetics NN NN O
of NN NN O
virus NN NN O
replication NN NN O
in NN NN O
cultured NN NN O
cells NN NN O
. NN NN O
   
Inclusion NN NN O
of NN NN O
this NN NN O
LTR NN NN O
in NN NN O
recombinant NN NN O
SIVs NN NN O
also NN NN O
resulted NN NN O
in NN NN O
a NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
rise NN NN O
in NN NN O
the NN NN O
extent NN NN O
of NN NN O
cellular NN NN O
proliferation NN NN O
that NN NN O
was NN NN O
induced NN NN O
in NN NN O
quiescent NN NN O
simian NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
LTR NN NN O
mutations NN NN O
assist NN NN O
SIVsmmPBj14 NN NN O
in NN NN O
responding NN NN O
efficiently NN NN O
to NN NN O
cellular NN NN O
stimulation NN NN O
and NN NN O
allow NN NN O
it NN NN O
to NN NN O
replicate NN NN O
to NN NN O
high NN NN O
titers NN NN O
during NN NN O
the NN NN O
acute NN NN O
phase NN NN O
of NN NN O
viral NN NN O
infection NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
a NN NN O
region NN NN O
which NN NN O
directs NN NN O
the NN NN O
monocytic NN NN O
activity NN NN O
of NN NN O
the NN NN O
colony NN NN B-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
( NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
and NN NN O
binds NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
( NN NN O
AML1 NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
receptor NN NN O
for NN NN O
the NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
or NN NN O
colony NN NN B-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
[ NN NN O
CSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
] NN NN O
) NN NN O
is NN NN O
expressed NN NN O
from NN NN O
different NN NN O
promoters NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
and NN NN O
placental NN NN O
trophoblasts NN NN O
. NN NN O
   
We NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
CSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
is NN NN O
regulated NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
by NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
whose NN NN O
activity NN NN O
is NN NN O
stimulated NN NN O
by NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
( NN NN O
D NN NN O
. NN NN O
- NN NN O
E NN NN O
. NN NN O
Zhang NN NN O
, NN NN O
C NN NN O
. NN NN O
J NN NN O
. NN NN O
Hetherington NN NN O
, NN NN O
H NN NN O
. NN NN O
- NN NN O
M NN NN O
. NN NN O
Chen NN NN O
, NN NN O
and NN NN O
D NN NN O
. NN NN O
G NN NN O
. NN NN O
Tenen NN NN O
, NN NN O
Mol NN NN O
. NN NN O
Cell NN NN O
. NN NN O
Biol NN NN O
. NN NN O
14 NN NN O
: NN NN O
373 NN NN O
- NN NN O
381 NN NN O
, NN NN O
1994 NN NN O
) NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
this NN NN O
promoter NN NN O
is NN NN O
also NN NN O
mediated NN NN O
by NN NN O
sequences NN NN O
in NN NN O
a NN NN O
region NN NN O
II NN NN O
( NN NN O
bp NN NN O
- NN NN O
88 NN NN O
to NN NN O
- NN NN O
59 NN NN O
) NN NN O
, NN NN O
which NN NN O
lies NN NN O
10 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
When NN NN O
analyzed NN NN O
by NN NN O
DNase NN NN O
footprinting NN NN O
, NN NN O
region NN NN O
II NN NN O
was NN NN O
protected NN NN O
preferentially NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
confirmed NN NN O
that NN NN O
region NN NN O
II NN NN O
interacts NN NN O
specifically NN NN O
with NN NN O
nuclear NN NN O
proteins NN NN O
from NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
gel NN NN O
shift NN NN O
complexes NN NN O
( NN NN O
Mono NN NN O
A NN NN O
and NN NN O
Mono NN NN O
B NN NN O
) NN NN O
were NN NN O
formed NN NN O
with NN NN O
separate NN NN O
sequence NN NN O
elements NN NN O
within NN NN O
this NN NN O
region NN NN O
. NN NN O
   
Competition NN NN O
and NN NN O
supershift NN NN O
experiments NN NN O
indicate NN NN O
that NN NN O
Mono NN NN O
B NN NN O
contains NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
polyomavirus NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
2 NN NN O
/ NN NN O
core NN NN O
- NN NN O
binding NN NN O
factor NN NN O
( NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
) NN NN O
family NN NN O
, NN NN O
which NN NN O
includes NN NN O
the NN NN O
AML1 NN NN B-Protein
gene NN NN O
product NN NN O
, NN NN O
while NN NN O
Mono NN NN O
A NN NN O
is NN NN O
a NN NN O
distinct NN NN O
complex NN NN O
preferentially NN NN O
expressed NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Promoter NN NN O
constructs NN NN O
with NN NN O
mutations NN NN O
in NN NN O
these NN NN O
sequence NN NN O
elements NN NN O
were NN NN O
no NN NN O
longer NN NN O
expressed NN NN O
specifically NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
multimerized NN NN O
region NN NN O
II NN NN O
sequence NN NN O
elements NN NN O
enhanced NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
heterologous NN NN O
thymidine NN NN O
kinase NN NN O
promoter NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
but NN NN O
not NN NN O
other NN NN O
cell NN NN O
types NN NN O
tested NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
the NN NN O
Mono NN NN O
A NN NN O
and NN NN O
Mono NN NN O
B NN NN O
protein NN NN O
complexes NN NN O
act NN NN O
in NN NN O
concert NN NN O
to NN NN O
regulate NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
of NN NN O
the NN NN O
CSF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
A NN NN O
factor NN NN O
that NN NN O
regulates NN NN O
the NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
gene NN NN O
DPA NN NN B-Protein
is NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
subfamily NN NN O
of NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
that NN NN O
includes NN NN O
a NN NN O
Drosophila NN NN O
developmental NN NN O
control NN NN O
protein NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
DNA NN NN O
sequence NN NN O
element NN NN O
termed NN NN O
the NN NN O
J NN NN O
element NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulated NN NN O
expression NN NN O
of NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
genes NN NN O
was NN NN O
recently NN NN O
described NN NN O
. NN NN O
   
To NN NN O
study NN NN O
this NN NN O
element NN NN O
and NN NN O
its NN NN O
role NN NN O
in NN NN O
class NN NN O
II NN NN O
gene NN NN O
regulation NN NN O
further NN NN O
, NN NN O
a NN NN O
cDNA NN NN O
library NN NN O
was NN NN O
screened NN NN O
with NN NN O
oligonucleotide NN NN O
probes NN NN O
containing NN NN O
both NN NN O
the NN NN O
S NN NN O
element NN NN O
and NN NN O
the NN NN O
nearby NN NN O
J NN NN O
element NN NN O
of NN NN O
the NN NN O
human NN NN O
DPA NN NN B-Protein
gene NN NN O
. NN NN O
   
Several NN NN O
DNA NN NN O
clones NN NN O
were NN NN O
obtained NN NN O
by NN NN O
this NN NN O
procedure NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
, NN NN O
clone NN NN O
18 NN NN O
, NN NN O
is NN NN O
reported NN NN O
and NN NN O
characterized NN NN O
here NN NN O
. NN NN O
   
It NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
predicted NN NN O
to NN NN O
contain NN NN O
688 NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
, NN NN O
including NN NN O
11 NN NN O
zinc NN NN O
finger NN NN O
motifs NN NN O
of NN NN O
the NN NN O
C2H2 NN NN O
type NN NN O
in NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
region NN NN O
, NN NN O
that NN NN O
are NN NN O
Kruppel NN NN O
- NN NN O
like NN NN O
in NN NN O
the NN NN O
conservation NN NN O
of NN NN O
the NN NN O
H NN NN O
/ NN NN O
C NN NN O
link NN NN O
sequence NN NN O
connecting NN NN O
them NN NN O
. NN NN O
   
The NN NN O
160 NN NN O
N NN NN O
- NN NN O
terminal NN NN O
amino NN NN O
acids NN NN O
in NN NN O
the NN NN O
nonfinger NN NN O
region NN NN O
of NN NN O
clone NN NN O
18 NN NN O
are NN NN O
highly NN NN O
homologous NN NN O
with NN NN O
similar NN NN O
regions NN NN O
of NN NN O
several NN NN O
other NN NN O
human NN NN O
, NN NN O
mouse NN NN O
, NN NN O
and NN NN O
Drosophila NN NN O
sequences NN NN O
, NN NN O
defining NN NN O
a NN NN O
subfamily NN NN O
of NN NN O
Kruppel NN NN O
- NN NN O
like NN NN O
zinc NN NN O
finger NN NN O
proteins NN NN O
termed NN NN O
TAB NN NN O
( NN NN O
tramtrack NN NN O
[ NN NN O
ttk NN NN O
] NN NN O
- NN NN O
associated NN NN O
box NN NN O
) NN NN O
here NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
Drosophila NN NN O
sequences NN NN O
, NN NN O
ttk NN NN O
, NN NN O
is NN NN O
a NN NN O
developmental NN NN O
control NN NN O
gene NN NN O
, NN NN O
while NN NN O
a NN NN O
second NN NN O
does NN NN O
not NN NN O
contain NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
region NN NN O
but NN NN O
encodes NN NN O
a NN NN O
structure NN NN O
important NN NN O
in NN NN O
oocyte NN NN O
development NN NN O
. NN NN O
   
An NN NN O
acidic NN NN O
activation NN NN O
domain NN NN O
is NN NN O
located NN NN O
between NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
conserved NN NN O
region NN NN O
of NN NN O
clone NN NN O
18 NN NN O
and NN NN O
its NN NN O
zinc NN NN O
fingers NN NN O
. NN NN O
   
This NN NN O
protein NN NN O
appears NN NN O
to NN NN O
require NN NN O
both NN NN O
the NN NN O
S NN NN O
and NN NN O
J NN NN O
elements NN NN O
, NN NN O
which NN NN O
are NN NN O
separated NN NN O
by NN NN O
10 NN NN O
bp NN NN O
for NN NN O
optimal NN NN O
binding NN NN O
. NN NN O
   
Antisense NN NN O
cDNA NN NN O
to NN NN O
clone NN NN O
18 NN NN O
inhibited NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
the NN NN O
DPA NN NN B-Protein
promoter NN NN O
, NN NN O
indicating NN NN O
its NN NN O
functional NN NN O
importance NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
this NN NN O
class NN NN O
II NN NN O
gene NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
cell NN NN O
death NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
by NN NN O
glucocorticoids NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
earliest NN NN O
and NN NN O
most NN NN O
thoroughly NN NN O
studied NN NN O
models NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
exact NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
apoptosis NN NN O
occurs NN NN O
in NN NN O
lymphocytes NN NN O
is NN NN O
unknown NN NN O
many NN NN O
biochemical NN NN O
and NN NN O
molecular NN NN O
changes NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
occur NN NN O
in NN NN O
these NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
glucocorticoids NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
chromatin NN NN O
degradation NN NN O
and NN NN O
endonucleases NN NN O
in NN NN O
the NN NN O
apoptotic NN NN O
process NN NN O
has NN NN O
been NN NN O
closely NN NN O
studied NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
involvement NN NN O
of NN NN O
several NN NN O
oncogenes NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
cell NN NN O
lysis NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
clinical NN NN O
importance NN NN O
of NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
lymphoid NN NN O
neoplasms NN NN O
has NN NN O
recently NN NN O
received NN NN O
increased NN NN O
attention NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
replication NN NN O
by NN NN O
a NN NN O
Tat NN NN B-Protein
- NN NN O
activated NN NN O
, NN NN O
transduced NN NN O
interferon NN NN O
gene NN NN O
: NN NN O
targeted NN NN O
expression NN NN O
to NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
feasibility NN NN O
of NN NN O
using NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
gene NN NN O
transfer NN NN O
as NN NN O
a NN NN O
novel NN NN O
approach NN NN O
to NN NN O
anti NN NN O
- NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
therapy NN NN O
in NN NN O
this NN NN O
study NN NN O
. NN NN O
   
To NN NN O
limit NN NN O
expression NN NN O
of NN NN O
a NN NN O
transduced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
- NN NN O
IFNA2 NN NN O
( NN NN O
the NN NN O
new NN NN O
approved NN NN O
nomenclature NN NN O
for NN NN O
IFN NN NN O
genes NN NN O
is NN NN O
used NN NN O
throughout NN NN O
this NN NN O
article NN NN O
) NN NN O
hybrid NN NN O
gene NN NN O
to NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
was NN NN O
modified NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
elements NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
significantly NN NN O
inhibited NN NN O
Tat NN NN B-Protein
- NN NN O
mediated NN NN O
transactivation NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
a NN NN O
monocyte NN NN O
line NN NN O
, NN NN O
U937 NN NN O
. NN NN O
   
Replacement NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
elements NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
by NN NN O
a NN NN O
DNA NN NN O
fragment NN NN O
derived NN NN O
from NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
gene NN NN O
15 NN NN O
( NN NN O
ISG15 NN NN O
) NN NN O
, NN NN O
containing NN NN O
the NN NN O
IFN NN NN O
- NN NN O
stimulated NN NN O
response NN NN O
element NN NN O
, NN NN O
partially NN NN O
restored NN NN O
Tat NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
LTR NN NN O
in NN NN O
T NN NN O
cells NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Insertion NN NN O
of NN NN O
this NN NN O
chimeric NN NN O
promoter NN NN O
( NN NN O
ISG15 NN NN O
LTR NN NN O
) NN NN O
upstream NN NN O
of NN NN O
the NN NN O
human NN NN O
IFNA2 NN NN B-Protein
gene NN NN O
directed NN NN O
high NN NN O
levels NN NN O
of NN NN O
IFN NN NN O
synthesis NN NN O
in NN NN O
Tat NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
, NN NN O
while NN NN O
this NN NN O
promoter NN NN O
was NN NN O
not NN NN O
responsive NN NN O
to NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
activation NN NN O
. NN NN O
   
ISG15 NN NN O
- NN NN O
LTR NN NN O
- NN NN O
IFN NN NN O
hybrid NN NN O
gene NN NN O
inserted NN NN O
into NN NN O
the NN NN O
retrovirus NN NN O
vector NN NN O
was NN NN O
transduced NN NN O
into NN NN O
Jurkat NN NN O
and NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Selected NN NN O
transfected NN NN O
clones NN NN O
produced NN NN O
low NN NN O
levels NN NN O
of NN NN O
IFN NN NN B-Protein
A NN NN I-Protein
( NN NN O
IFNA NN NN B-Protein
) NN NN O
constitutively NN NN O
, NN NN O
and NN NN O
their NN NN O
abilities NN NN O
to NN NN O
express NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
upon NN NN O
stimulation NN NN O
with NN NN O
phytohemagglutinin NN NN B-Protein
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
were NN NN O
retained NN NN O
. NN NN O
   
Enhancement NN NN O
of NN NN O
IFNA NN NN B-Protein
synthesis NN NN O
observed NN NN O
upon NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
resulted NN NN O
in NN NN O
significant NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
at NN NN O
least NN NN O
30 NN NN O
days NN NN O
. NN NN O
   
Virus NN NN O
isolated NN NN O
from NN NN O
IFNA NN NN B-Protein
- NN NN O
producing NN NN O
cells NN NN O
was NN NN O
able NN NN O
to NN NN O
replicate NN NN O
in NN NN O
the NN NN O
U937 NN NN O
cells NN NN O
but NN NN O
did NN NN O
not NN NN O
replicate NN NN O
efficiently NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
transduced NN NN O
with NN NN O
the NN NN O
IFNA NN NN B-Protein
gene NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
targeting NN NN O
IFN NN NN O
synthesis NN NN O
to NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cells NN NN O
is NN NN O
an NN NN O
attainable NN NN O
goal NN NN O
and NN NN O
that NN NN O
autocrine NN NN O
IFN NN NN O
synthesis NN NN O
results NN NN O
in NN NN O
a NN NN O
long NN NN O
- NN NN O
lasting NN NN O
and NN NN O
permanent NN NN O
suppression NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Pyrrolidine NN NN O
dithiocarbamate NN NN O
, NN NN O
a NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
, NN NN O
prevents NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
promyelocytic NN NN O
leukemia NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
and NN NN O
thymocytes NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
, NN NN O
which NN NN O
potently NN NN O
blocks NN NN O
the NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
on NN NN O
the NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
by NN NN O
a NN NN O
variety NN NN O
of NN NN O
agents NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
a NN NN O
human NN NN O
promyelocytic NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
, NN NN O
HL NN NN O
- NN NN O
60 NN NN O
, NN NN O
with NN NN O
10 NN NN O
micrograms NN NN O
/ NN NN O
mL NN NN O
etoposide NN NN O
or NN NN O
2 NN NN O
microM NN NN O
1 NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
arabinofuranosylcytosine NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
within NN NN O
1 NN NN O
hr NN NN O
and NN NN O
subsequently NN NN O
caused NN NN O
apoptosis NN NN O
within NN NN O
3 NN NN O
- NN NN O
4 NN NN O
hr NN NN O
. NN NN O
   
The NN NN O
simultaneous NN NN O
addition NN NN O
of NN NN O
50 NN NN O
- NN NN O
500 NN NN O
microM NN NN O
PDTC NN NN O
with NN NN O
these NN NN O
agents NN NN O
blocked NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
completely NN NN O
abrogated NN NN O
both NN NN O
morphologically NN NN O
apoptotic NN NN O
changes NN NN O
and NN NN O
internucleosomal NN NN O
DNA NN NN O
fragmentation NN NN O
for NN NN O
up NN NN O
to NN NN O
6 NN NN O
hr NN NN O
. NN NN O
   
However NN NN O
, NN NN O
PDTC NN NN O
failed NN NN O
to NN NN O
inhibit NN NN O
the NN NN O
endonuclease NN NN O
activity NN NN O
contained NN NN O
in NN NN O
the NN NN O
whole NN NN O
cell NN NN O
lysates NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
PDTC NN NN O
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
etoposide NN NN O
- NN NN O
and NN NN O
dexamethasone NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
thymocytes NN NN O
at NN NN O
a NN NN O
concentration NN NN O
of NN NN O
1 NN NN O
- NN NN O
10 NN NN O
microM NN NN O
. NN NN O
   
Since NN NN O
PDTC NN NN O
has NN NN O
both NN NN O
antioxidant NN NN O
and NN NN O
metal NN NN O
- NN NN O
ion NN NN O
chelating NN NN O
activities NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
effects NN NN O
of NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
( NN NN O
antioxidant NN NN O
) NN NN O
or NN NN O
o NN NN O
- NN NN O
phenanthroline NN NN O
( NN NN O
OP NN NN O
) NN NN O
( NN NN O
metal NN NN O
- NN NN O
ion NN NN O
chelator NN NN O
) NN NN O
on NN NN O
the NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
or NN NN O
thymocytes NN NN O
with NN NN O
100 NN NN O
- NN NN O
500 NN NN O
microM NN NN O
OP NN NN O
for NN NN O
2 NN NN O
hr NN NN O
, NN NN O
but NN NN O
not NN NN O
10 NN NN O
- NN NN O
60 NN NN O
mM NN NN O
NAC NN NN O
, NN NN O
suppressed NN NN O
subsequent NN NN O
occurrence NN NN O
of NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
etoposide NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
apoptotic NN NN O
process NN NN O
of NN NN O
human NN NN O
hematopoietic NN NN O
cells NN NN O
. NN NN O
   
Differential NN NN O
regulation NN NN O
of NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
in NN NN O
T NN NN O
lymphocytes NN NN O
activated NN NN O
through NN NN O
CD28 NN NN B-Protein
. NN NN O
   
The NN NN O
T NN NN O
cell NN NN O
surface NN NN O
molecule NN NN O
CD28 NN NN B-Protein
binds NN NN O
to NN NN O
ligands NN NN O
on NN NN O
accessory NN NN O
cells NN NN O
and NN NN O
APCs NN NN O
, NN NN O
playing NN NN O
an NN NN O
important NN NN O
costimulatory NN NN O
role NN NN O
in NN NN O
the NN NN O
response NN NN O
of NN NN O
T NN NN O
cells NN NN O
to NN NN O
Ags NN NN O
. NN NN O
   
Our NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
signaling NN NN O
pathways NN NN O
coupled NN NN O
to NN NN O
this NN NN O
receptor NN NN O
is NN NN O
incomplete NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
activation NN NN O
of NN NN O
phospholipase NN NN B-Protein
C NN NN I-Protein
gamma NN NN I-Protein
1 NN NN I-Protein
, NN NN O
ligation NN NN O
of NN NN O
this NN NN O
receptor NN NN O
also NN NN O
seems NN NN O
to NN NN O
activate NN NN O
a NN NN O
calcium NN NN O
- NN NN O
independent NN NN O
, NN NN O
CD28 NN NN B-Protein
- NN NN O
specific NN NN O
pathway NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD28 NN NN B-Protein
( NN NN O
but NN NN O
not NN NN O
CD2 NN NN O
, NN NN O
CD5 NN NN B-Protein
, NN NN O
LFA NN NN O
- NN NN O
1 NN NN O
, NN NN O
or NN NN O
CD7 NN NN B-Protein
) NN NN O
leads NN NN O
to NN NN O
an NN NN O
elevation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
, NN NN O
with NN NN O
only NN NN O
minimal NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
expression NN NN O
. NN NN O
   
CD28 NN NN B-Protein
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
requires NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
but NN NN O
does NN NN O
not NN NN O
depend NN NN O
on NN NN O
activation NN NN O
of NN NN O
a NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
responsive NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
or NN NN O
elevation NN NN O
of NN NN O
cytosolic NN NN O
calcium NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
CD28 NN NN B-Protein
- NN NN O
dependent NN NN O
elevation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
mediated NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
mRNA NN NN O
stability NN NN O
. NN NN O
   
A NN NN O
mechanism NN NN O
is NN NN O
suggested NN NN O
whereby NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
junB NN NN B-Protein
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
fos NN NN O
family NN NN O
, NN NN O
can NN NN O
prevent NN NN O
inappropriate NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
caused NN NN O
by NN NN O
ligation NN NN O
of NN NN O
CD28 NN NN B-Protein
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
specific NN NN O
antigenic NN NN O
stimulus NN NN O
. NN NN O
   
Constitutive NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
lineage NN NN O
. NN NN O
   
In NN NN O
monocytes NN NN O
, NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
has NN NN O
been NN NN O
invoked NN NN O
as NN NN O
an NN NN O
important NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
of NN NN O
cell NN NN O
- NN NN O
surface NN NN O
receptors NN NN O
and NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
In NN NN O
such NN NN O
cells NN NN O
, NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
be NN NN O
detected NN NN O
without NN NN O
intentional NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
our NN NN O
studies NN NN O
, NN NN O
cells NN NN O
of NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
line NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
, NN NN O
cultured NN NN O
in NN NN O
medium NN NN O
containing NN NN O
fetal NN NN O
- NN NN O
calf NN NN O
serum NN NN O
and NN NN O
low NN NN O
levels NN NN O
of NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
also NN NN O
exhibit NN NN O
such NN NN O
' NN NN O
constitutive NN NN O
' NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
mobility NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
. NN NN O
   
This NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
still NN NN O
present NN NN O
when NN NN O
contaminant NN NN O
LPS NN NN O
was NN NN O
removed NN NN O
by NN NN O
ultrafiltration NN NN O
and NN NN O
when NN NN O
serum NN NN O
was NN NN O
omitted NN NN O
. NN NN O
   
Protein NN NN O
- NN NN O
DNA NN NN O
complexes NN NN O
of NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
are NN NN O
similar NN NN O
in NN NN O
mobility NN NN O
to NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
both NN NN O
are NN NN O
recognized NN NN O
by NN NN O
an NN NN O
antibody NN NN O
specific NN NN O
to NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN I-Protein
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
will NN NN O
only NN NN O
block NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
constitutive NN NN O
binding NN NN O
protein NN NN O
. NN NN O
   
Using NN NN O
LPS NN NN O
- NN NN O
free NN NN O
and NN NN O
serum NN NN O
- NN NN O
free NN NN O
conditions NN NN O
, NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
be NN NN O
detected NN NN O
in NN NN O
different NN NN O
cell NN NN O
lines NN NN O
of NN NN O
the NN NN O
monocytic NN NN O
lineage NN NN O
( NN NN O
HL60 NN NN O
, NN NN O
U937 NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
Mono NN NN O
Mac NN NN O
1 NN NN O
and NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
Molt NN NN O
4 NN NN O
T NN NN O
cells NN NN O
or NN NN O
K562 NN NN O
stem NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
ordered NN NN O
according NN NN O
to NN NN O
stage NN NN O
of NN NN O
maturation NN NN O
, NN NN O
the NN NN O
amount NN NN O
of NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
not NN NN O
increased NN NN O
in NN NN O
more NN NN O
mature NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
when NN NN O
inducing NN NN O
differentiation NN NN O
in NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
cells NN NN O
, NN NN O
with NN NN O
vitamin NN NN O
D3 NN NN O
, NN NN O
no NN NN O
change NN NN O
in NN NN O
constitutive NN NN O
or NN NN O
inducible NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
be NN NN O
detected NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
primary NN NN O
cells NN NN O
revealed NN NN O
substantial NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
blood NN NN O
monocytes NN NN O
, NN NN O
pleural NN NN O
macrophages NN NN O
and NN NN O
alveolar NN NN O
macrophages NN NN O
. NN NN O
   
The NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
appears NN NN O
to NN NN O
be NN NN O
functionally NN NN O
active NN NN O
, NN NN O
since NN NN O
a NN NN O
low NN NN O
level NN NN O
of NN NN O
tumour NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
transcript NN NN O
is NN NN O
detectable NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
this NN NN O
level NN NN O
can NN NN O
be NN NN O
increased NN NN O
by NN NN O
blocking NN NN O
transcript NN NN O
degradation NN NN O
using NN NN O
cycloheximide NN NN O
. NN NN O
   
The NN NN O
level NN NN O
of NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
these NN NN O
cells NN NN O
is NN NN O
variable NN NN O
and NN NN O
is NN NN O
frequently NN NN O
found NN NN O
to NN NN O
be NN NN O
lower NN NN O
in NN NN O
the NN NN O
more NN NN O
mature NN NN O
macrophages NN NN O
. NN NN O
   
Constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
not NN NN O
maintained NN NN O
by NN NN O
autocrine NN NN O
action NN NN O
of NN NN O
cytokines NN NN O
TNF NN NN O
, NN NN O
interleukin NN NN B-Protein
6 NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
10 NN NN I-Protein
, NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
or NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
, NN NN O
since NN NN O
neutralizing NN NN O
antibodies NN NN O
did NN NN O
not NN NN O
reduce NN NN O
constitutive NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
blockade NN NN O
of NN NN O
prostaglandin NN NN O
or NN NN O
leukotriene NN NN O
biosynthesis NN NN O
did NN NN O
not NN NN O
affect NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
400 NN NN O
WORDS NN NN O
) NN NN O
   
Function NN NN O
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
its NN NN O
properties NN NN O
seem NN NN O
to NN NN O
be NN NN O
most NN NN O
extensively NN NN O
exploited NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
properties NN NN O
are NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
' NN NN O
s NN NN O
rapid NN NN O
posttranslational NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
many NN NN O
pathogenic NN NN O
signals NN NN O
, NN NN O
its NN NN O
direct NN NN O
participation NN NN O
in NN NN O
cytoplasmic NN NN O
/ NN NN O
nuclear NN NN O
signaling NN NN O
, NN NN O
and NN NN O
its NN NN O
potency NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
a NN NN O
great NN NN O
variety NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
immunologically NN NN O
relevant NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
vertebrates NN NN O
, NN NN O
five NN NN O
distinct NN NN O
DNA NN NN O
binding NN NN O
subunits NN NN O
are NN NN O
currently NN NN O
known NN NN O
which NN NN O
might NN NN O
extensively NN NN O
heterodimerize NN NN O
, NN NN O
thereby NN NN O
forming NN NN O
complexes NN NN O
with NN NN O
distinct NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
DNA NN NN O
sequence NN NN O
specificity NN NN O
, NN NN O
and NN NN O
cell NN NN O
type NN NN O
- NN NN O
and NN NN O
cell NN NN O
stage NN NN O
- NN NN O
specific NN NN O
distribution NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
dimers NN NN O
is NN NN O
tightly NN NN O
controlled NN NN O
by NN NN O
accessory NN NN O
proteins NN NN O
called NN NN O
I NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
of NN NN O
which NN NN O
there NN NN O
are NN NN O
also NN NN O
five NN NN O
different NN NN O
species NN NN O
currently NN NN O
known NN NN O
in NN NN O
vertebrates NN NN O
. NN NN O
   
I NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
inhibit NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
prevent NN NN O
nuclear NN NN O
uptake NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complexes NN NN O
. NN NN O
   
An NN NN O
exception NN NN O
is NN NN O
the NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
protein NN NN O
which NN NN O
in NN NN O
addition NN NN O
can NN NN O
function NN NN O
as NN NN O
a NN NN O
transcription NN NN O
activating NN NN O
subunit NN NN O
in NN NN O
th NN NN O
nucleus NN NN O
. NN NN O
   
Other NN NN O
I NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
are NN NN O
rather NN NN O
involved NN NN O
in NN NN O
terminating NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
' NN NN O
s NN NN O
activity NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
The NN NN O
intracellular NN NN O
events NN NN O
that NN NN O
lead NN NN O
to NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
are NN NN O
complex NN NN O
. NN NN O
   
They NN NN O
involve NN NN O
phosphorylation NN NN O
and NN NN O
proteolytic NN NN O
reactions NN NN O
and NN NN O
seem NN NN O
to NN NN O
be NN NN O
controlled NN NN O
by NN NN O
the NN NN O
cells NN NN O
' NN NN O
redox NN NN O
status NN NN O
. NN NN O
   
Interference NN NN O
with NN NN O
the NN NN O
activation NN NN O
or NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
be NN NN O
beneficial NN NN O
in NN NN O
suppressing NN NN O
toxic NN NN O
/ NN NN O
septic NN NN O
shock NN NN O
, NN NN O
graft NN NN O
- NN NN O
vs NN NN O
- NN NN O
host NN NN O
reactions NN NN O
, NN NN O
acute NN NN O
inflammatory NN NN O
reactions NN NN O
, NN NN O
acute NN NN O
phase NN NN O
response NN NN O
, NN NN O
and NN NN O
radiation NN NN O
damage NN NN O
. NN NN O
   
The NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
antioxidants NN NN O
and NN NN O
specific NN NN O
protease NN NN O
inhibitors NN NN O
may NN NN O
provide NN NN O
a NN NN O
pharmacological NN NN O
basis NN NN O
for NN NN O
interfering NN NN O
with NN NN O
these NN NN O
acute NN NN O
processes NN NN O
. NN NN O
   
Increased NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
transcription NN NN O
in NN NN O
murine NN NN O
lymphocytes NN NN O
by NN NN O
ciprofloxacin NN NN O
. NN NN O
   
The NN NN O
fluoroquinolone NN NN O
antibiotic NN NN O
, NN NN O
ciprofloxacin NN NN O
( NN NN O
cipro NN NN O
) NN NN O
, NN NN O
induces NN NN O
hyperproduction NN NN O
of NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
and NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
in NN NN O
stimulated NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
investigation NN NN O
an NN NN O
enhanced NN NN O
and NN NN O
prolonged NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
response NN NN O
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
both NN NN O
stimulated NN NN O
( NN NN O
T NN NN O
cell NN NN O
mitogens NN NN O
or NN NN O
alloantigens NN NN O
) NN NN O
murine NN NN O
splenocytes NN NN O
and NN NN O
in NN NN O
the NN NN O
stimulated NN NN O
murine NN NN O
T NN NN O
cell NN NN O
line NN NN O
EL NN NN O
- NN NN O
4 NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
ciprofloxacin NN NN O
( NN NN O
5 NN NN O
- NN NN O
80 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
) NN NN O
as NN NN O
compared NN NN O
to NN NN O
control NN NN O
cells NN NN O
without NN NN O
antibiotics NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
human NN NN O
lymphocytes NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
was NN NN O
inhibited NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
unaffected NN NN O
at NN NN O
24 NN NN O
h NN NN O
and NN NN O
only NN NN O
slightly NN NN O
upregulated NN NN O
at NN NN O
48 NN NN O
and NN NN O
72 NN NN O
h NN NN O
of NN NN O
culture NN NN O
in NN NN O
murine NN NN O
splenocytes NN NN O
incubated NN NN O
with NN NN O
cipro NN NN O
( NN NN O
20 NN NN O
micrograms NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
were NN NN O
transfected NN NN O
with NN NN O
a NN NN O
plasmid NN NN O
containing NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
enhancer NN NN O
region NN NN O
linked NN NN O
to NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
gene NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
CAT NN NN B-Protein
activity NN NN O
revealed NN NN O
that NN NN O
cipro NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
induction NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
ciprofloxacin NN NN O
showed NN NN O
an NN NN O
early NN NN O
peak NN NN O
and NN NN O
more NN NN O
activated NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
as NN NN O
compared NN NN O
to NN NN O
control NN NN O
cells NN NN O
without NN NN O
antibiotics NN NN O
. NN NN O
   
Cipro NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
or NN NN O
NFIL NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
cipro NN NN O
inhibited NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
synthesis NN NN O
, NN NN O
but NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
murine NN NN O
lymphocytes NN NN O
by NN NN O
means NN NN O
of NN NN O
influencing NN NN O
NFAT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
causing NN NN O
an NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
. NN NN O
   
Multiple NN NN O
prolactin NN NN B-Protein
- NN NN O
responsive NN NN O
elements NN NN O
mediate NN NN O
G1 NN NN O
and NN NN O
S NN NN O
phase NN NN O
expression NN NN O
of NN NN O
the NN NN O
interferon NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
. NN NN O
   
The NN NN O
interferon NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
both NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
G1 NN NN O
phase NN NN O
gene NN NN O
and NN NN O
an NN NN O
S NN NN O
phase NN NN O
gene NN NN O
inducible NN NN O
by NN NN O
PRL NN NN B-Protein
in NN NN O
rat NN NN O
Nb2 NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
PRL NN NN B-Protein
regulates NN NN O
the NN NN O
biphasic NN NN O
expression NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
we NN NN O
cloned NN NN O
the NN NN O
rat NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
and NN NN O
functionally NN NN O
characterized NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Upon NN NN O
transfection NN NN O
into NN NN O
Nb2 NN NN O
T NN NN O
cells NN NN O
, NN NN O
1 NN NN O
. NN NN O
7 NN NN O
kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
DNA NN NN O
linked NN NN O
to NN NN O
a NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
gene NN NN O
mediated NN NN O
a NN NN O
30 NN NN O
- NN NN O
fold NN NN O
induction NN NN O
of NN NN O
CAT NN NN B-Protein
enzyme NN NN O
activity NN NN O
in NN NN O
response NN NN O
to NN NN O
24 NN NN O
h NN NN O
of NN NN O
PRL NN NN B-Protein
stimulation NN NN O
. NN NN O
   
Deletion NN NN O
mutants NN NN O
containing NN NN O
1 NN NN O
. NN NN O
3 NN NN O
, NN NN O
0 NN NN O
. NN NN O
6 NN NN O
, NN NN O
and NN NN O
0 NN NN O
. NN NN O
2 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
DNA NN NN O
were NN NN O
incrementally NN NN O
less NN NN O
transcriptionally NN NN O
active NN NN O
, NN NN O
although NN NN O
0 NN NN O
. NN NN O
2 NN NN O
kb NN NN O
still NN NN O
mediated NN NN O
a NN NN O
12 NN NN O
- NN NN O
fold NN NN O
induction NN NN O
by NN NN O
PRL NN NN B-Protein
. NN NN O
   
The NN NN O
sequence NN NN O
between NN NN O
- NN NN O
1 NN NN O
. NN NN O
7 NN NN O
and NN NN O
- NN NN O
0 NN NN O
. NN NN O
2 NN NN O
kb NN NN O
linked NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
thymidine NN NN O
kinase NN NN O
promoter NN NN O
failed NN NN O
to NN NN O
respond NN NN O
to NN NN O
PRL NN NN B-Protein
stimulation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
activity NN NN O
of NN NN O
upstream NN NN O
PRL NN NN B-Protein
response NN NN O
elements NN NN O
may NN NN O
require NN NN O
an NN NN O
interaction NN NN O
with NN NN O
promoter NN NN O
- NN NN O
proximal NN NN O
elements NN NN O
. NN NN O
   
By NN NN O
assaying NN NN O
CAT NN NN B-Protein
enzyme NN NN O
activity NN NN O
across NN NN O
a NN NN O
24 NN NN O
- NN NN O
h NN NN O
PRL NN NN B-Protein
induction NN NN O
time NN NN O
course NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
assign NN NN O
G1 NN NN O
vs NN NN O
. NN NN O
S NN NN O
phase NN NN O
PRL NN NN B-Protein
responses NN NN O
of NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
to NN NN O
different NN NN O
regions NN NN O
of NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
and NN NN O
promoter NN NN O
DNA NN NN O
. NN NN O
   
The NN NN O
0 NN NN O
. NN NN O
2 NN NN O
- NN NN O
kb NN NN O
IRF NN NN O
- NN NN O
CAT NN NN O
construct NN NN O
was NN NN O
induced NN NN O
by NN NN O
PRL NN NN B-Protein
stimulation NN NN O
during NN NN O
the NN NN O
G1 NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
1 NN NN O
. NN NN O
7 NN NN O
- NN NN O
kb NN NN O
IRF NN NN O
- NN NN O
CAT NN NN O
construct NN NN O
was NN NN O
inducible NN NN O
by NN NN O
PRL NN NN B-Protein
during NN NN O
both NN NN O
G1 NN NN O
and NN NN O
S NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
the NN NN O
PRL NN NN B-Protein
- NN NN O
induced NN NN O
biphasic NN NN O
expression NN NN O
of NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
appears NN NN O
to NN NN O
be NN NN O
controlled NN NN O
by NN NN O
separate NN NN O
PRL NN NN B-Protein
- NN NN O
responsive NN NN O
elements NN NN O
: NN NN O
elements NN NN O
in NN NN O
the NN NN O
first NN NN O
0 NN NN O
. NN NN O
2 NN NN O
kb NN NN O
of NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
region NN NN O
act NN NN O
during NN NN O
early NN NN O
activation NN NN O
, NN NN O
and NN NN O
elements NN NN O
between NN NN O
0 NN NN O
. NN NN O
2 NN NN O
and NN NN O
1 NN NN O
. NN NN O
7 NN NN O
kb NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
the NN NN O
proximal NN NN O
0 NN NN O
. NN NN O
2 NN NN O
- NN NN O
kb NN NN O
region NN NN O
during NN NN O
S NN NN O
phase NN NN O
progression NN NN O
. NN NN O
   
Nonpituitary NN NN O
human NN NN O
prolactin NN NN B-Protein
gene NN NN O
transcription NN NN O
is NN NN O
independent NN NN O
of NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
differentially NN NN O
controlled NN NN O
in NN NN O
lymphocytes NN NN O
and NN NN O
in NN NN O
endometrial NN NN O
stroma NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
human NN NN O
PRL NN NN B-Protein
( NN NN O
hPRL NN NN B-Protein
) NN NN O
gene NN NN O
in NN NN O
extrapituitary NN NN O
sites NN NN O
such NN NN O
as NN NN O
the NN NN O
uterus NN NN O
( NN NN O
decidualized NN NN O
endometrial NN NN O
stroma NN NN O
and NN NN O
myometrium NN NN O
) NN NN O
and NN NN O
cells NN NN O
of NN NN O
the NN NN O
hematopoietic NN NN O
lineage NN NN O
is NN NN O
directed NN NN O
by NN NN O
an NN NN O
alternative NN NN O
promoter NN NN O
which NN NN O
is NN NN O
located NN NN O
approximately NN NN O
6 NN NN O
kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
upstream NN NN O
of NN NN O
the NN NN O
pituitary NN NN O
- NN NN O
specific NN NN O
start NN NN O
site NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
delineate NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
mechanisms NN NN O
governing NN NN O
the NN NN O
control NN NN O
of NN NN O
nonpituitary NN NN O
PRL NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
we NN NN O
have NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
3 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
DNA NN NN O
of NN NN O
the NN NN O
upstream NN NN O
decidual NN NN O
/ NN NN O
lymphoid NN NN O
( NN NN O
dPRL NN NN B-Protein
) NN NN O
promoter NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
sequence NN NN O
homology NN NN O
we NN NN O
identified NN NN O
two NN NN O
binding NN NN O
motifs NN NN O
for NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
seven NN NN O
half NN NN O
- NN NN O
sites NN NN O
for NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
/ NN NN O
progesterone NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
PR NN NN B-Protein
) NN NN O
binding NN NN O
. NN NN O
   
We NN NN O
focused NN NN O
our NN NN O
studies NN NN O
on NN NN O
the NN NN O
role NN NN O
of NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
of NN NN O
PR NN NN B-Protein
as NN NN O
potential NN NN O
transcriptional NN NN O
regulators NN NN O
, NN NN O
since NN NN O
the NN NN O
POU NN NN O
domain NN NN O
protein NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
essential NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
pituitary NN NN O
PRL NN NN B-Protein
expression NN NN O
, NN NN O
and NN NN O
progesterone NN NN O
induces NN NN O
decidual NN NN O
transformation NN NN O
of NN NN O
the NN NN O
endometrial NN NN O
stroma NN NN O
, NN NN O
a NN NN O
differentiation NN NN O
process NN NN O
during NN NN O
which NN NN O
the NN NN O
decidual NN NN O
PRL NN NN B-Protein
gene NN NN O
is NN NN O
activated NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
, NN NN O
including NN NN O
lymphocytes NN NN O
and NN NN O
endometrial NN NN O
stroma NN NN O
, NN NN O
that NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
not NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
dPRL NN NN B-Protein
promoter NN NN O
/ NN NN O
reporter NN NN O
gene NN NN O
constructs NN NN O
carrying NN NN O
3 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
DNA NN NN O
. NN NN O
   
Our NN NN O
experiments NN NN O
also NN NN O
show NN NN O
that NN NN O
activated NN NN O
PR NN NN B-Protein
does NN NN O
not NN NN O
confer NN NN O
direct NN NN O
transcriptional NN NN O
control NN NN O
on NN NN O
the NN NN O
dPRL NN NN B-Protein
promoter NN NN O
. NN NN O
   
When NN NN O
we NN NN O
compared NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
transfected NN NN O
dPRL NN NN B-Protein
promoter NN NN O
in NN NN O
PRL NN NN B-Protein
- NN NN O
secreting NN NN O
and NN NN O
nonsecreting NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
3 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
dPRL NN NN O
promoter NN NN O
did NN NN O
not NN NN O
contain NN NN O
elements NN NN O
restricting NN NN O
expression NN NN O
to NN NN O
only NN NN O
those NN NN O
lymphocytes NN NN O
that NN NN O
produce NN NN O
PRL NN NN B-Protein
but NN NN O
allowed NN NN O
expression NN NN O
of NN NN O
fusion NN NN O
reporter NN NN O
genes NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
status NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
PRL NN NN B-Protein
gene NN NN O
. NN NN O
   
This NN NN O
was NN NN O
in NN NN O
sharp NN NN O
contrast NN NN O
to NN NN O
endometrial NN NN O
cells NN NN O
where NN NN O
3 NN NN O
kb NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
DNA NN NN O
conferred NN NN O
strong NN NN O
transcriptional NN NN O
activation NN NN O
on NN NN O
the NN NN O
dPRL NN NN B-Protein
promoter NN NN O
in NN NN O
decidualized NN NN O
endometrial NN NN O
stromal NN NN O
cells NN NN O
actively NN NN O
secreting NN NN O
PRL NN NN B-Protein
, NN NN O
but NN NN O
did NN NN O
not NN NN O
allow NN NN O
transcription NN NN O
in NN NN O
undifferentiated NN NN O
non NN NN O
- NN NN O
PRL NN NN B-Protein
- NN NN O
secreting NN NN O
endometrial NN NN O
stromal NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
dPRL NN NN B-Protein
promoter NN NN O
construct NN NN O
in NN NN O
these NN NN O
undifferentiated NN NN O
cells NN NN O
could NN NN O
however NN NN O
be NN NN O
induced NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
cAMP NN NN O
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
progesterone NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
a NN NN O
signal NN NN O
transduced NN NN O
through NN NN O
the NN NN O
cAMP NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
a NN NN O
primary NN NN O
inducer NN NN O
of NN NN O
decidual NN NN O
PRL NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
early NN NN B-Protein
growth NN NN I-Protein
response NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
pp90rsk NN NN O
during NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
present NN NN O
work NN NN O
has NN NN O
studied NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
induction NN NN O
of NN NN O
early NN NN B-Protein
growth NN NN I-Protein
response NN NN I-Protein
1 NN NN I-Protein
( NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
during NN NN O
monocytic NN NN O
differentiation NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
Differentiation NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
cells NN NN O
with NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
, NN NN O
an NN NN O
activator NN NN O
of NN NN O
the NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
was NN NN O
associated NN NN O
with NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
- NN NN O
reporter NN NN O
constructs NN NN O
. NN NN O
   
The NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
contains NN NN O
six NN NN O
CC NN NN O
( NN NN O
A NN NN O
/ NN NN O
T NN NN O
) NN NN O
6GG NN NN O
( NN NN O
CArG NN NN O
) NN NN O
motifs NN NN O
. NN NN O
   
The NN NN O
two NN NN O
5 NN NN O
' NN NN O
- NN NN O
most NN NN O
distal NN NN O
CArG NN NN O
sequences NN NN O
conferred NN NN O
TPA NN NN O
inducibility NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
there NN NN O
was NN NN O
little NN NN O
effect NN NN O
of NN NN O
TPA NN NN O
on NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
in NN NN O
a NN NN O
TPA NN NN O
- NN NN O
resistant NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
variant NN NN O
, NN NN O
designated NN NN O
TUR NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
both NN NN O
U NN NN O
- NN NN O
937 NN NN O
and NN NN O
TUR NN NN O
cells NN NN O
with NN NN O
okadaic NN NN O
acid NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
protein NN NN O
phosphatases NN NN O
1 NN NN O
and NN NN O
2A NN NN O
, NN NN O
was NN NN O
associated NN NN O
with NN NN O
induction NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
and NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
through NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
most NN NN O
CArG NN NN O
element NN NN O
. NN NN O
   
Since NN NN O
these NN NN O
findings NN NN O
supported NN NN O
the NN NN O
involvement NN NN O
of NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
protein NN NN O
phosphorylation NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
, NN NN O
we NN NN O
studied NN NN O
activation NN NN O
of NN NN O
the NN NN O
40S NN NN O
ribosomal NN NN O
protein NN NN O
S6 NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
kinases NN NN O
, NN NN O
pp70S6K NN NN O
and NN NN O
pp90rsk NN NN O
. NN NN O
   
Although NN NN O
both NN NN O
kinases NN NN O
participate NN NN O
in NN NN O
regulating NN NN O
cell NN NN O
growth NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
detectable NN NN O
activation NN NN O
of NN NN O
pp70S6K NN NN O
during NN NN O
TPA NN NN O
- NN NN O
or NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
rapamycin NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
pp70S6K NN NN O
activation NN NN O
, NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
induction NN NN O
of NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
analysis NN NN O
of NN NN O
pp90rsk NN NN O
activity NN NN O
by NN NN O
phosphorylation NN NN O
of NN NN O
a NN NN O
peptide NN NN O
derived NN NN O
from NN NN O
S6 NN NN O
protein NN NN O
demonstrated NN NN O
stimulation NN NN O
of NN NN O
this NN NN O
kinase NN NN O
in NN NN O
TPA NN NN O
- NN NN O
treated NN NN O
U NN NN O
- NN NN O
937 NN NN O
, NN NN O
and NN NN O
not NN NN O
TUR NN NN O
, NN NN O
cells NN NN O
. NN NN O
   
Okadaic NN NN O
acid NN NN O
treatment NN NN O
of NN NN O
both NN NN O
cell NN NN O
types NN NN O
was NN NN O
associated NN NN O
with NN NN O
activation NN NN O
of NN NN O
pp90rsk NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
prostaglandin NN NN O
E2 NN NN O
on NN NN O
Th0 NN NN O
- NN NN O
type NN NN O
human NN NN O
T NN NN O
cell NN NN O
clones NN NN O
: NN NN O
modulation NN NN O
of NN NN O
functions NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
cytokine NN NN O
production NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
prostaglandin NN NN O
E2 NN NN O
( NN NN O
PGE2 NN NN O
) NN NN O
on NN NN O
cytokine NN NN O
production NN NN O
and NN NN O
proliferation NN NN O
of NN NN O
the NN NN O
CD4 NN NN B-Protein
+ NN NN O
human NN NN O
helper NN NN O
T NN NN O
cell NN NN O
clone NN NN O
SP NN NN O
- NN NN O
B21 NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
In NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
, NN NN O
PGE2 NN NN O
inhibited NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
the NN NN O
production NN NN O
of NN NN O
all NN NN O
the NN NN O
cytokines NN NN O
examined NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
rIL NN NN O
- NN NN O
2 NN NN O
fully NN NN O
restored NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
and NN NN O
partially NN NN O
restored NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
that NN NN O
of NN NN O
other NN NN O
cytokines NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
/ NN NN O
A23187 NN NN O
, NN NN O
PGE2 NN NN O
enhanced NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
and NN NN O
only NN NN O
partially NN NN O
inhibited NN NN O
the NN NN O
production NN NN O
of NN NN O
other NN NN O
cytokines NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
PGE2 NN NN O
vary NN NN O
depending NN NN O
on NN NN O
the NN NN O
mode NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
and NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
are NN NN O
regulated NN NN O
differently NN NN O
from NN NN O
other NN NN O
cytokines NN NN O
. NN NN O
   
In NN NN O
a NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
only NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
) NN NN O
homodimer NN NN O
was NN NN O
observed NN NN O
in NN NN O
a NN NN O
complex NN NN O
formed NN NN O
with NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
in NN NN O
unstimulated NN NN O
SP NN NN O
- NN NN O
B21 NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
or NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
, NN NN O
a NN NN O
complex NN NN O
formation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimer NN NN O
with NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
was NN NN O
induced NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
PGE2 NN NN O
or NN NN O
di NN NN O
- NN NN O
butyryl NN NN O
( NN NN O
Bt2 NN NN O
) NN NN O
cAMP NN NN O
abolished NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimer NN NN O
to NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sequence NN NN O
in NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
but NN NN O
not NN NN O
with NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
target NN NN O
of NN NN O
PGE2 NN NN O
action NN NN O
is NN NN O
a NN NN O
component NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
by NN NN O
PGE2 NN NN O
is NN NN O
selective NN NN O
. NN NN O
   
PGE2 NN NN O
enhanced NN NN O
the NN NN O
complex NN NN O
formation NN NN O
with NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
CLE0 NN NN O
sequences NN NN O
when NN NN O
the NN NN O
cells NN NN O
were NN NN O
activated NN NN O
by NN NN O
either NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
or NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
stimulation NN NN O
. NN NN O
   
It NN NN O
seems NN NN O
therefore NN NN O
that NN NN O
PGE2 NN NN O
, NN NN O
by NN NN O
elevating NN NN O
cAMP NN NN O
levels NN NN O
, NN NN O
interferes NN NN O
with NN NN O
the NN NN O
activation NN NN O
pathway NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
but NN NN O
not NN NN O
for NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
or NN NN O
CLE0 NN NN O
binding NN NN O
protein NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
down NN NN O
- NN NN O
regulates NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
, NN NN O
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
- NN NN O
induced NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
a NN NN O
product NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
helper NN NN O
0 NN NN O
( NN NN O
Th0 NN NN O
) NN NN O
and NN NN O
2 NN NN O
( NN NN O
Th2 NN NN O
) NN NN O
subset NN NN O
, NN NN O
was NN NN O
originally NN NN O
described NN NN O
as NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
stimulatory NN NN O
factor NN NN O
and NN NN O
has NN NN O
subsequently NN NN O
been NN NN O
found NN NN O
to NN NN O
suppress NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
stimulated NN NN O
with NN NN O
LPS NN NN O
, NN NN O
and NN NN O
to NN NN O
upregulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN I-Protein
( NN NN B-Protein
IL1 NN NN I-Protein
- NN NN I-Protein
RA NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
in NN NN O
monocytes NN NN O
evoked NN NN O
by NN NN O
other NN NN O
T NN NN O
- NN NN O
helper NN NN O
cell NN NN O
cytokines NN NN O
: NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
down NN NN O
- NN NN O
regulated NN NN O
mRNA NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
proinflammatory NN NN O
cytokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
monocytes NN NN O
stimulated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
also NN NN O
suppressed NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Temporal NN NN O
analysis NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
down NN NN O
- NN NN O
regulatory NN NN O
effect NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
, NN NN O
or NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
- NN NN O
induced NN NN O
proinflammatory NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
provided NN NN O
evidence NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
acts NN NN O
predominantly NN NN O
on NN NN O
the NN NN O
post NN NN O
- NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
This NN NN O
was NN NN O
supported NN NN O
by NN NN O
the NN NN O
observation NN NN O
that NN NN O
the NN NN O
down NN NN O
- NN NN O
regulatory NN NN O
capacity NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
appeared NN NN O
to NN NN O
be NN NN O
dependent NN NN O
on NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
did NN NN O
not NN NN O
exert NN NN O
significant NN NN O
influence NN NN O
on NN NN O
the NN NN O
induction NN NN O
of NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN I-Protein
RA NN NN I-Protein
or NN NN O
various NN NN O
CSFs NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Long NN NN O
- NN NN O
term NN NN O
inositol NN NN O
phosphate NN NN O
release NN NN O
, NN NN O
but NN NN O
not NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
correlates NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
induction NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
activated NN NN O
peripheral NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
cascade NN NN O
of NN NN O
events NN NN O
within NN NN O
the NN NN O
first NN NN O
few NN NN O
minutes NN NN O
of NN NN O
T NN NN O
cell NN NN O
stimulation NN NN O
has NN NN O
been NN NN O
well NN NN O
characterized NN NN O
. NN NN O
   
Although NN NN O
many NN NN O
second NN NN O
messengers NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
necessary NN NN O
and NN NN O
sufficient NN NN O
for NN NN O
T NN NN O
cell NN NN O
activation NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
model NN NN O
systems NN NN O
, NN NN O
the NN NN O
rate NN NN O
- NN NN O
limiting NN NN O
step NN NN O
in NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
has NN NN O
not NN NN O
been NN NN O
demonstrated NN NN O
. NN NN O
   
To NN NN O
model NN NN O
effective NN NN O
versus NN NN O
ineffective NN NN O
CD3 NN NN O
- NN NN O
mediated NN NN O
stimulation NN NN O
in NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
used NN NN O
two NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAbs NN NN O
that NN NN O
differ NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
stimulate NN NN O
purified NN NN O
T NN NN O
cells NN NN O
: NN NN O
OKT3 NN NN O
, NN NN O
which NN NN O
causes NN NN O
early NN NN O
second NN NN O
messenger NN NN O
generation NN NN O
but NN NN O
is NN NN O
unable NN NN O
to NN NN O
activate NN NN O
T NN NN O
cells NN NN O
without NN NN O
a NN NN O
second NN NN O
signal NN NN O
, NN NN O
and NN NN O
64 NN NN O
. NN NN O
1 NN NN O
, NN NN O
which NN NN O
stimulates NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
on NN NN O
its NN NN O
own NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
was NN NN O
similar NN NN O
for NN NN O
both NN NN O
mAbs NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
hours NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
inositol NN NN O
phosphate NN NN O
response NN NN O
was NN NN O
stronger NN NN O
for NN NN O
64 NN NN O
. NN NN O
1 NN NN O
than NN NN O
for NN NN O
OKT3 NN NN O
. NN NN O
   
To NN NN O
tie NN NN O
these NN NN O
events NN NN O
to NN NN O
gene NN NN O
activation NN NN O
, NN NN O
we NN NN O
measured NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activity NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
after NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
. NN NN O
   
Both NN NN O
stimuli NN NN O
induced NN NN O
the NN NN O
appearance NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
components NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
p65 NN NN B-Protein
( NN NN O
RelA NN NN B-Protein
) NN NN O
, NN NN O
and NN NN O
p50 NN NN B-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
) NN NN O
) NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
64 NN NN O
. NN NN O
1 NN NN O
induced NN NN O
NF NN NN O
- NN NN O
AT NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
correlating NN NN O
with NN NN O
its NN NN O
ability NN NN O
to NN NN O
activate NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
induction NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
were NN NN O
correlated NN NN O
with NN NN O
the NN NN O
levels NN NN O
of NN NN O
inositol NN NN O
phosphate NN NN O
release NN NN O
but NN NN O
not NN NN O
with NN NN O
gross NN NN O
levels NN NN O
of NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
induced NN NN O
late NN NN O
following NN NN O
the NN NN O
response NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
and NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
occurred NN NN O
even NN NN O
with NN NN O
the NN NN O
smaller NN NN O
second NN NN O
messenger NN NN O
response NN NN O
generated NN NN O
by NN NN O
OKT3 NN NN O
. NN NN O
   
ZAP NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
tyrosine NN NN O
kinase NN NN O
, NN NN O
CD45 NN NN B-Protein
, NN NN O
and NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
involvement NN NN O
in NN NN O
UV NN NN O
- NN NN O
and NN NN O
H2O2 NN NN O
- NN NN O
induced NN NN O
T NN NN O
cell NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
Several NN NN O
mammalian NN NN O
responses NN NN O
to NN NN O
UV NN NN O
irradiation NN NN O
, NN NN O
including NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
are NN NN O
believed NN NN O
to NN NN O
involve NN NN O
tyrosine NN NN O
phosphorylation NN NN O
. NN NN O
   
UV NN NN O
irradiation NN NN O
and NN NN O
H2O2 NN NN O
treatment NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
induce NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
signals NN NN O
similar NN NN O
to NN NN O
those NN NN O
observed NN NN O
following NN NN O
biological NN NN O
stimulation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
role NN NN O
of NN NN O
cell NN NN O
surface NN NN O
molecules NN NN O
in NN NN O
these NN NN O
responses NN NN O
. NN NN O
   
Normal NN NN O
T NN NN O
lymphocytes NN NN O
whose NN NN O
surface NN NN O
expression NN NN O
of NN NN O
CD3 NN NN O
was NN NN O
depleted NN NN O
showed NN NN O
impaired NN NN O
UV NN NN O
- NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
signals NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
lines NN NN O
deficient NN NN O
in NN NN O
CD3 NN NN O
or NN NN O
CD45 NN NN B-Protein
expression NN NN O
also NN NN O
gave NN NN O
impaired NN NN O
UV NN NN O
responses NN NN O
. NN NN O
   
However NN NN O
, NN NN O
all NN NN O
these NN NN O
cell NN NN O
types NN NN O
still NN NN O
gave NN NN O
strong NN NN O
Ca2 NN NN O
+ NN NN O
and NN NN O
tyrosine NN NN O
phosphorylation NN NN O
responses NN NN O
to NN NN O
H2O2 NN NN O
. NN NN O
   
The NN NN O
T NN NN O
cell NN NN O
tyrosine NN NN O
kinase NN NN O
ZAP NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
was NN NN O
found NN NN O
to NN NN O
be NN NN O
highly NN NN O
responsive NN NN O
to NN NN O
UV NN NN O
and NN NN O
H2O2 NN NN O
treatment NN NN O
. NN NN O
   
ZAP NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
responsiveness NN NN O
to NN NN O
UV NN NN O
required NN NN O
expression NN NN O
of NN NN O
both NN NN O
CD3 NN NN O
and NN NN O
CD45 NN NN B-Protein
, NN NN O
whereas NN NN O
only NN NN O
CD3 NN NN O
was NN NN O
required NN NN O
for NN NN O
the NN NN O
response NN NN O
to NN NN O
H2O2 NN NN O
. NN NN O
   
UV NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
blocked NN NN O
by NN NN O
CD3 NN NN O
depletion NN NN O
, NN NN O
indicating NN NN O
the NN NN O
importance NN NN O
of NN NN O
such NN NN O
cell NN NN O
surface NN NN O
molecules NN NN O
in NN NN O
biological NN NN O
responses NN NN O
to NN NN O
UV NN NN O
. NN NN O
   
In NN NN O
nonlymphoid NN NN O
cells NN NN O
, NN NN O
the NN NN O
epidermal NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
displayed NN NN O
increased NN NN O
tyrosine NN NN O
phosphorylation NN NN O
within NN NN O
seconds NN NN O
of NN NN O
UV NN NN O
irradiation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
UV NN NN O
- NN NN O
induced NN NN O
signal NN NN O
transduction NN NN O
is NN NN O
mediated NN NN O
via NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
that NN NN O
normally NN NN O
respond NN NN O
to NN NN O
biological NN NN O
stimulation NN NN O
, NN NN O
whereas NN NN O
H2O2 NN NN O
is NN NN O
able NN NN O
to NN NN O
partially NN NN O
bypass NN NN O
this NN NN O
requirement NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
sodium NN NN O
salicylate NN NN O
and NN NN O
aspirin NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
critical NN NN O
for NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
multiple NN NN O
cellular NN NN O
and NN NN O
viral NN NN O
genes NN NN O
involved NN NN O
in NN NN O
inflammation NN NN O
and NN NN O
infection NN NN O
including NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
The NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
sodium NN NN O
salicylate NN NN O
and NN NN O
aspirin NN NN O
inhibited NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
further NN NN O
explains NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
these NN NN O
drugs NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
prevented NN NN O
the NN NN O
degradation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitor NN NN O
, NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
therefore NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
retained NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
. NN NN O
   
Sodium NN NN O
salicylate NN NN O
and NN NN O
aspirin NN NN O
also NN NN O
inhibited NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
from NN NN O
the NN NN O
Ig NN NN B-Protein
kappa NN NN I-Protein
enhancer NN NN O
and NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
in NN NN O
transfected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Positive NN NN O
and NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
: NN NN O
role NN NN O
of NN NN O
multiple NN NN O
regulatory NN NN O
sites NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
important NN NN O
lymphokine NN NN O
required NN NN O
in NN NN O
the NN NN O
process NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
proliferation NN NN O
, NN NN O
clonal NN NN O
expansion NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
displays NN NN O
both NN NN O
T NN NN O
cell NN NN O
specific NN NN O
and NN NN O
inducible NN NN O
expression NN NN O
: NN NN O
it NN NN O
is NN NN O
only NN NN O
expressed NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
after NN NN O
antigenic NN NN O
or NN NN O
mitogenic NN NN O
stimulation NN NN O
. NN NN O
   
Several NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
sites NN NN O
are NN NN O
required NN NN O
for NN NN O
induction NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
analysed NN NN O
the NN NN O
function NN NN O
of NN NN O
these NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
sites NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
native NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
and NN NN O
promoter NN NN O
sequence NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
suggest NN NN O
that NN NN O
the NN NN O
NFAT NN NN O
( NN NN O
- NN NN O
276 NN NN O
to NN NN O
- NN NN O
261 NN NN O
) NN NN O
, NN NN O
the NN NN O
distal NN NN O
octamer NN NN O
( NN NN O
- NN NN O
256 NN NN O
to NN NN O
- NN NN O
248 NN NN O
) NN NN O
and NN NN O
the NN NN O
proximal NN NN O
octamer NN NN O
( NN NN O
- NN NN O
75 NN NN O
to NN NN O
- NN NN O
66 NN NN O
) NN NN O
sites NN NN O
not NN NN O
only NN NN O
act NN NN O
as NN NN O
enhancers NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
cellular NN NN O
stimulation NN NN O
, NN NN O
but NN NN O
also NN NN O
have NN NN O
a NN NN O
silencing NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
resting NN NN O
cells NN NN O
. NN NN O
   
Two NN NN O
other NN NN O
sites NN NN O
display NN NN O
disparate NN NN O
effects NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
different NN NN O
T NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
: NN NN O
the NN NN O
distal NN NN O
purine NN NN O
box NN NN O
( NN NN O
- NN NN O
291 NN NN O
to NN NN O
- NN NN O
277 NN NN O
) NN NN O
and NN NN O
the NN NN O
proximal NN NN O
purine NN NN O
box NN NN O
sites NN NN O
( NN NN O
- NN NN O
145 NN NN O
to NN NN O
- NN NN O
128 NN NN O
) NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
- NN NN O
186 NN NN O
to NN NN O
- NN NN O
176 NN NN O
) NN NN O
and NN NN O
the NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
( NN NN O
- NN NN O
206 NN NN O
to NN NN O
- NN NN O
195 NN NN O
) NN NN O
respond NN NN O
to NN NN O
different NN NN O
cellular NN NN O
activation NN NN O
in NN NN O
EL4 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
mediated NN NN O
the NN NN O
response NN NN O
to NN NN O
PMA NN NN O
stimulation NN NN O
while NN NN O
the NN NN O
kappa NN NN O
B NN NN O
site NN NN O
responded NN NN O
to NN NN O
IL NN NN O
- NN NN O
1 NN NN O
stimulation NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
is NN NN O
a NN NN O
complex NN NN O
process NN NN O
and NN NN O
multiple NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
sites NN NN O
interact NN NN O
to NN NN O
exert NN NN O
different NN NN O
effects NN NN O
in NN NN O
T NN NN O
cells NN NN O
representative NN NN O
of NN NN O
alternative NN NN O
stages NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
Superantigens NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Binding NN NN O
of NN NN O
superantigens NN NN O
to NN NN O
MHC NN NN O
class NN NN O
II NN NN O
molecules NN NN O
results NN NN O
in NN NN O
transduction NN NN O
of NN NN O
biochemical NN NN O
signals NN NN O
leading NN NN O
to NN NN O
cellular NN NN O
activation NN NN O
and NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
staphylococcal NN NN O
superantigens NN NN O
toxic NN NN B-Protein
shock NN NN I-Protein
syndrome NN NN I-Protein
toxin NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
TSST NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
staphylococcal NN NN B-Protein
enterotoxin NN NN I-Protein
A NN NN I-Protein
( NN NN O
SEA NN NN B-Protein
) NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
of NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
in NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
by NN NN O
superantigens NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Superantigens NN NN O
also NN NN O
increased NN NN O
viral NN NN O
protein NN NN O
secretion NN NN O
from NN NN O
the NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
- NN NN O
pretreated NN NN O
chronically NN NN O
infected NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
U1 NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
superantigens NN NN O
occurred NN NN O
via NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
mechanisms NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
superantigens NN NN O
and NN NN O
other NN NN O
MHC NN NN O
class NN NN O
II NN NN O
ligands NN NN O
may NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
by NN NN O
CD28 NN NN B-Protein
signalling NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
by NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TcR NN NN O
) NN NN O
occupancy NN NN O
and NN NN O
activation NN NN O
of NN NN O
the NN NN O
CD28 NN NN B-Protein
surface NN NN O
molecule NN NN O
results NN NN O
in NN NN O
enhanced NN NN O
proliferation NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
production NN NN O
. NN NN O
   
The NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
triggered NN NN O
by NN NN O
CD28 NN NN B-Protein
involves NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
sequence NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
, NN NN O
called NN NN O
CD28 NN NN B-Protein
- NN NN O
responsive NN NN O
element NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
by NN NN O
agonistic NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
antibodies NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
- NN NN O
or NN NN O
TcR NN NN O
- NN NN O
derived NN NN O
signals NN NN O
induces NN NN O
the NN NN O
enhanced NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
CD28 NN NN B-Protein
engagement NN NN O
, NN NN O
however NN NN O
, NN NN O
exerts NN NN O
opposite NN NN O
effects NN NN O
on NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Whereas NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
together NN NN O
with NN NN O
PMA NN NN O
increased NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
trans NN NN O
- NN NN O
activation NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
significantly NN NN O
suppressed NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effect NN NN O
exerted NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
was NN NN O
observed NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
functional NN NN O
reporter NN NN O
- NN NN O
gene NN NN O
assays NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
two NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
independently NN NN O
regulated NN NN O
and NN NN O
may NN NN O
perform NN NN O
different NN NN O
functions NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
uses NN NN O
the NN NN O
CD28 NN NN B-Protein
costimulatory NN NN O
pathway NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
a NN NN O
potent NN NN O
chemotactic NN NN O
factor NN NN O
for NN NN O
neutrophil NN NN O
granulocytes NN NN O
and NN NN O
lymphocytes NN NN O
, NN NN O
is NN NN O
a NN NN O
proinflammatory NN NN O
cytokine NN NN O
secreted NN NN O
by NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
, NN NN O
including NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
CD28 NN NN B-Protein
cell NN NN O
surface NN NN O
molecule NN NN O
delivers NN NN O
costimulatory NN NN O
signals NN NN O
essential NN NN O
for NN NN O
lymphokine NN NN O
production NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
via NN NN O
a NN NN O
conserved NN NN O
sequence NN NN O
element NN NN O
found NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
several NN NN O
lymphokine NN NN O
genes NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
CD28 NN NN B-Protein
- NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
produced NN NN O
significant NN NN O
amounts NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
; NN NN O
additionally NN NN O
, NN NN O
costimulation NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
Abs NN NN O
resulted NN NN O
in NN NN O
a NN NN O
synergistic NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Sequence NN NN O
homology NN NN O
, NN NN O
single NN NN O
nucleotide NN NN O
mutations NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
Ab NN NN O
stimulation NN NN O
studies NN NN O
established NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
sequence NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
functioned NN NN O
as NN NN O
a NN NN O
CD28 NN NN B-Protein
response NN NN O
element NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
, NN NN O
but NN NN O
not NN NN O
rapamycin NN NN O
, NN NN O
blocked NN NN O
the NN NN O
synergistic NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
achieved NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
costimulation NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
a NN NN O
CD28 NN NN B-Protein
response NN NN O
element NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
expression NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
may NN NN O
provide NN NN O
new NN NN O
insights NN NN O
into NN NN O
the NN NN O
pathogenesis NN NN O
and NN NN O
persistence NN NN O
of NN NN O
immune NN NN O
disorders NN NN O
characterized NN NN O
by NN NN O
increased NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
such NN NN O
as NN NN O
psoriasis NN NN O
and NN NN O
rheumatoid NN NN O
arthritis NN NN O
. NN NN O
   
The NN NN O
severe NN NN O
phenotype NN NN O
of NN NN O
females NN NN O
with NN NN O
tiny NN NN O
ring NN NN O
X NN NN O
chromosomes NN NN O
is NN NN O
associated NN NN O
with NN NN O
inability NN NN O
of NN NN O
these NN NN O
chromosomes NN NN O
to NN NN O
undergo NN NN O
X NN NN O
inactivation NN NN O
. NN NN O
   
Mental NN NN O
retardation NN NN O
and NN NN O
a NN NN O
constellation NN NN O
of NN NN O
congenital NN NN O
malformations NN NN O
not NN NN O
usually NN NN O
associated NN NN O
with NN NN O
Turner NN NN O
syndrome NN NN O
are NN NN O
seen NN NN O
in NN NN O
some NN NN O
females NN NN O
with NN NN O
a NN NN O
mosaic NN NN O
45 NN NN O
, NN NN O
X NN NN O
/ NN NN O
46 NN NN O
, NN NN O
X NN NN O
, NN NN O
r NN NN O
( NN NN O
X NN NN O
) NN NN O
karyotype NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
these NN NN O
females NN NN O
show NN NN O
that NN NN O
the NN NN O
XIST NN NN B-Protein
locus NN NN O
on NN NN O
their NN NN O
tiny NN NN O
ring NN NN O
X NN NN O
chromosomes NN NN O
is NN NN O
either NN NN O
not NN NN O
present NN NN O
or NN NN O
not NN NN O
expressed NN NN O
. NN NN O
   
As NN NN O
XIST NN NN B-Protein
transcription NN NN O
is NN NN O
well NN NN O
correlated NN NN O
with NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
in NN NN O
female NN NN O
somatic NN NN O
cells NN NN O
and NN NN O
spermatogonia NN NN O
, NN NN O
nonexpression NN NN O
of NN NN O
the NN NN O
locus NN NN O
even NN NN O
when NN NN O
it NN NN O
is NN NN O
present NN NN O
suggests NN NN O
that NN NN O
these NN NN O
chromosomes NN NN O
are NN NN O
transcriptionally NN NN O
active NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
ring NN NN O
X NN NN O
chromosomes NN NN O
lacking NN NN O
XIST NN NN B-Protein
expression NN NN O
( NN NN O
XISTE NN NN O
- NN NN O
) NN NN O
, NN NN O
from NN NN O
three NN NN O
females NN NN O
with NN NN O
severe NN NN O
phenotypes NN NN O
. NN NN O
   
The NN NN O
two NN NN O
tiny NN NN O
ring NN NN O
X NN NN O
chromosomes NN NN O
studied NN NN O
with NN NN O
an NN NN O
antibody NN NN O
specific NN NN O
for NN NN O
the NN NN O
acetylated NN NN O
isoforms NN NN O
of NN NN O
histone NN NN B-Protein
H4 NN NN I-Protein
marking NN NN O
transcribed NN NN O
chromatin NN NN O
domains NN NN O
were NN NN O
labeled NN NN O
at NN NN O
a NN NN O
level NN NN O
consistent NN NN O
with NN NN O
their NN NN O
being NN NN O
active NN NN O
. NN NN O
   
We NN NN O
also NN NN O
examined NN NN O
tow NN NN O
of NN NN O
the NN NN O
XISTE NN NN O
- NN NN O
ring NN NN O
chromosomes NN NN O
to NN NN O
determine NN NN O
whether NN NN O
genes NN NN O
that NN NN O
are NN NN O
normally NN NN O
silent NN NN O
on NN NN O
an NN NN O
inactive NN NN O
X NN NN O
are NN NN O
expressed NN NN O
from NN NN O
these NN NN O
chromosomes NN NN O
. NN NN O
   
Analyses NN NN O
of NN NN O
hybrid NN NN O
cells NN NN O
show NN NN O
that NN NN O
TIMP NN NN O
, NN NN O
ZXDA NN NN B-Protein
, NN NN O
and NN NN O
ZXDB NN NN B-Protein
loci NN NN O
on NN NN O
the NN NN O
proximal NN NN O
short NN NN O
arm NN NN O
, NN NN O
and NN NN O
AR NN NN O
and NN NN O
PHKA1 NN NN B-Protein
loci NN NN O
on NN NN O
the NN NN O
long NN NN O
arm NN NN O
, NN NN O
are NN NN O
well NN NN O
expressed NN NN O
from NN NN O
the NN NN O
tiny NN NN O
ring NN NN O
X NN NN O
chromosome NN NN O
lacking NN NN O
XIST NN NN B-Protein
DNA NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
the NN NN O
ring NN NN O
chromosome NN NN O
that NN NN O
has NN NN O
XIST NN NN B-Protein
DNA NN NN O
but NN NN O
does NN NN O
not NN NN O
transcribe NN NN O
it NN NN O
show NN NN O
that NN NN O
its NN NN O
AR NN NN O
allele NN NN O
is NN NN O
transcribed NN NN O
along NN NN O
with NN NN O
the NN NN O
one NN NN O
on NN NN O
the NN NN O
normal NN NN O
X NN NN O
allele NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Signals NN NN O
and NN NN O
nuclear NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
genes NN NN O
in NN NN O
helper NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Mouse NN NN O
thymoma NN NN O
line NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
produce NN NN O
cytokines NN NN O
such NN NN O
as NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
and NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
. NN NN O
   
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
also NN NN O
produce NN NN O
low NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
when NN NN O
stimulated NN NN O
by NN NN O
PMA NN NN O
alone NN NN O
; NN NN O
however NN NN O
, NN NN O
cAMP NN NN O
greatly NN NN O
augments NN NN O
PMA NN NN O
- NN NN O
dependent NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
production NN NN O
. NN NN O
   
A NN NN O
transient NN NN O
transfection NN NN O
assay NN NN O
revealed NN NN O
that NN NN O
two NN NN O
signals NN NN O
, NN NN O
PMA NN NN O
and NN NN O
cAMP NN NN O
, NN NN O
are NN NN O
required NN NN O
for NN NN O
optimal NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
cAMP NN NN O
almost NN NN O
completely NN NN O
inhibited NN NN O
the NN NN O
PMA NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
transfected NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
is NN NN O
positively NN NN O
regulated NN NN O
by NN NN O
cAMP NN NN O
in NN NN O
a NN NN O
manner NN NN O
opposite NN NN O
to NN NN O
that NN NN O
for NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factors NN NN O
( NN NN O
NFs NN NN O
) NN NN O
that NN NN O
regulates NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
to NN NN O
cAMP NN NN O
and NN NN O
PMA NN NN O
has NN NN O
properties NN NN O
similar NN NN O
to NN NN O
NF NN NN O
for NN NN O
activated NN NN O
t NN NN O
cell NN NN O
. NN NN O
   
The NN NN O
P NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
, NN NN O
defined NN NN O
as NN NN O
a NN NN O
responsive NN NN O
element NN NN O
for NN NN O
PMA NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
A23187 NN NN O
) NN NN O
, NN NN O
shares NN NN O
sequence NN NN O
similarity NN NN O
with NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
the NN NN O
NF NN NN O
- NN NN O
activated NN NN O
T NN NN O
cell NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
We NN NN O
attempted NN NN O
to NN NN O
determine NN NN O
whether NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
, NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
specific NN NN O
for NN NN O
the NN NN O
P NN NN O
sequence NN NN O
, NN NN O
is NN NN O
related NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
for NN NN O
activated NN NN O
T NN NN O
cell NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
. NN NN O
   
In NN NN O
electromobility NN NN O
shift NN NN O
assays NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
P65 NN NN B-Protein
or NN NN O
P65 NN NN B-Protein
/ NN NN O
P50 NN NN B-Protein
heterodimer NN NN O
) NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
bound NN NN O
to NN NN O
the NN NN O
P NN NN O
sequence NN NN O
. NN NN O
   
However NN NN O
, NN NN O
sequence NN NN O
specificity NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
was NN NN O
more NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
, NN NN O
and NN NN O
only NN NN O
a NN NN O
small NN NN O
amount NN NN O
of NN NN O
P65 NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
a NN NN O
component NN NN O
or NN NN O
components NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
have NN NN O
the NN NN O
potential NN NN O
to NN NN O
reconstitute NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
, NN NN O
whereas NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
alone NN NN O
does NN NN O
not NN NN O
account NN NN O
for NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
in NN NN O
Jurkat NN NN O
crude NN NN O
extract NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
like NN NN O
factors NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
genes NN NN O
. NN NN O
   
Structure NN NN O
and NN NN O
expression NN NN O
of NN NN O
the NN NN O
human NN NN O
GATA3 NN NN B-Protein
gene NN NN O
. NN NN O
   
GATA3 NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
GATA NN NN O
family NN NN O
that NN NN O
is NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
the NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
lineage NN NN O
, NN NN O
is NN NN O
thought NN NN O
to NN NN O
participate NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
gene NN NN O
activation NN NN O
through NN NN O
binding NN NN O
to NN NN O
enhancers NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
GATA3 NN NN B-Protein
gene NN NN O
regulation NN NN O
, NN NN O
we NN NN O
cloned NN NN O
the NN NN O
human NN NN O
gene NN NN O
and NN NN O
the NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
mouse NN NN O
GATA3 NN NN B-Protein
gene NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
human NN NN O
GATA3 NN NN B-Protein
gene NN NN O
contains NN NN O
six NN NN O
exons NN NN O
distributed NN NN O
over NN NN O
17 NN NN O
kb NN NN O
of NN NN O
DNA NN NN O
. NN NN O
   
The NN NN O
two NN NN O
human NN NN O
GATA3 NN NN B-Protein
zinc NN NN O
fingers NN NN O
are NN NN O
encoded NN NN O
by NN NN O
two NN NN O
separate NN NN O
exons NN NN O
highly NN NN O
conserved NN NN O
with NN NN O
those NN NN O
of NN NN O
GATA1 NN NN B-Protein
, NN NN O
but NN NN O
no NN NN O
other NN NN O
structural NN NN O
homologies NN NN O
between NN NN O
these NN NN O
two NN NN O
genes NN NN O
can NN NN O
be NN NN O
found NN NN O
. NN NN O
   
The NN NN O
human NN NN O
and NN NN O
mouse NN NN O
GATA3 NN NN B-Protein
transcription NN NN O
units NN NN O
start NN NN O
at NN NN O
a NN NN O
major NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
these NN NN O
two NN NN O
genes NN NN O
revealed NN NN O
that NN NN O
they NN NN O
are NN NN O
embedded NN NN O
within NN NN O
a NN NN O
CpG NN NN O
island NN NN O
and NN NN O
share NN NN O
structural NN NN O
features NN NN O
often NN NN O
found NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
housekeeping NN NN O
genes NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
a NN NN O
DNA NN NN O
fragment NN NN O
containing NN NN O
the NN NN O
human NN NN O
GATA3 NN NN B-Protein
transcription NN NN O
unit NN NN O
, NN NN O
3 NN NN O
kb NN NN O
upstream NN NN O
from NN NN O
the NN NN O
initiation NN NN O
site NN NN O
and NN NN O
4 NN NN O
kb NN NN O
downstream NN NN O
from NN NN O
the NN NN O
polyadenylation NN NN O
site NN NN O
, NN NN O
displays NN NN O
T NN NN O
- NN NN O
cell NN NN O
specificity NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
, NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
that NN NN O
interacts NN NN O
with NN NN O
the NN NN O
regulatory NN NN O
P NN NN O
sequence NN NN O
( NN NN O
5 NN NN O
' NN NN O
- NN NN O
CGAAAATTTCC NN NN O
- NN NN O
3 NN NN O
' NN NN O
) NN NN O
of NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
: NN NN O
relationship NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
The NN NN O
P NN NN O
sequence NN NN O
of NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
gene NN NN O
, NN NN O
which NN NN O
was NN NN O
defined NN NN O
as NN NN O
a NN NN O
responsive NN NN O
element NN NN O
for NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
A23187 NN NN O
) NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
shares NN NN O
sequence NN NN O
similarity NN NN O
with NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
whether NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
, NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
specific NN NN O
for NN NN O
the NN NN O
P NN NN O
sequence NN NN O
, NN NN O
is NN NN O
related NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
P65 NN NN B-Protein
or NN NN O
P65 NN NN B-Protein
/ NN NN O
P50 NN NN B-Protein
heterodimer NN NN O
) NN NN O
bound NN NN O
to NN NN O
the NN NN O
P NN NN O
sequence NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
and NN NN O
activated NN NN O
transcription NN NN O
through NN NN O
the NN NN O
P NN NN O
sequence NN NN O
when NN NN O
expression NN NN O
plasmids NN NN O
were NN NN O
cotransfected NN NN O
with NN NN O
P NN NN O
sequence NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
plasmids NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
EMSAs NN NN O
, NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
binding NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
unlabeled NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
site NN NN O
but NN NN O
not NN NN O
by NN NN O
the NN NN O
unlabeled NN NN O
AP1 NN NN O
binding NN NN O
site NN NN O
and NN NN O
purified NN NN O
NF NN NN O
- NN NN O
AT NN NN O
contained NN NN O
an NN NN O
activity NN NN O
that NN NN O
bound NN NN O
to NN NN O
the NN NN O
P NN NN O
sequence NN NN O
. NN NN O
   
Both NN NN O
mobility NN NN O
shift NN NN O
and NN NN O
sequence NN NN O
specificity NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
and NN NN O
only NN NN O
a NN NN O
small NN NN O
amount NN NN O
of NN NN O
P65 NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
in NN NN O
crude NN NN O
nuclear NN NN O
extracts NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
component NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
has NN NN O
the NN NN O
potential NN NN O
to NN NN O
reconstitute NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
whereas NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
alone NN NN O
cannot NN NN O
account NN NN O
for NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
in NN NN O
crude NN NN O
extracts NN NN O
. NN NN O
   
Unlike NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
NF NN NN O
( NN NN O
P NN NN O
) NN NN O
does NN NN O
not NN NN O
contain NN NN O
AP1 NN NN O
as NN NN O
its NN NN O
DNA NN NN O
binding NN NN O
component NN NN O
. NN NN O
   
Hypoxia NN NN O
causes NN NN O
the NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
through NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
on NN NN O
tyrosine NN NN O
residues NN NN O
. NN NN O
   
The NN NN O
response NN NN O
of NN NN O
mammalian NN NN O
cells NN NN O
to NN NN O
stress NN NN O
is NN NN O
controlled NN NN O
by NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
such NN NN O
as NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
to NN NN O
induce NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
early NN NN O
response NN NN O
genes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
exposure NN NN O
of NN NN O
cells NN NN O
to NN NN O
hypoxia NN NN O
( NN NN O
0 NN NN O
. NN NN O
02 NN NN O
% NN NN O
O2 NN NN O
) NN NN O
results NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
, NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
, NN NN O
and NN NN O
transactivation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
construct NN NN O
containing NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitors NN NN O
and NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
allele NN NN O
of NN NN O
c NN NN O
- NN NN O
Raf NN NN O
- NN NN O
1 NN NN O
( NN NN O
Raf NN NN O
301 NN NN O
) NN NN O
inhibited NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
, NN NN O
and NN NN O
transactivation NN NN O
of NN NN O
kappa NN NN O
B NN NN O
reporter NN NN O
constructs NN NN O
by NN NN O
hypoxia NN NN O
. NN NN O
   
To NN NN O
demonstrate NN NN O
a NN NN O
direct NN NN O
link NN NN O
between NN NN O
changes NN NN O
in NN NN O
the NN NN O
phosphorylation NN NN O
pattern NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
we NN NN O
immunoprecipitated NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
after NN NN O
varying NN NN O
times NN NN O
of NN NN O
hypoxic NN NN O
exposure NN NN O
and NN NN O
found NN NN O
that NN NN O
its NN NN O
tyrosine NN NN O
phosphorylation NN NN O
status NN NN O
increased NN NN O
during NN NN O
hypoxic NN NN O
exposure NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
the NN NN O
transfer NN NN O
of NN NN O
tyrosine NN NN O
phosphoryl NN NN O
groups NN NN O
onto NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
prevented NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
to NN NN O
other NN NN O
activators NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
such NN NN O
as NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
or NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
, NN NN O
we NN NN O
did NN NN O
not NN NN O
detect NN NN O
changes NN NN O
in NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
status NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
following NN NN O
treatment NN NN O
with NN NN O
either NN NN O
of NN NN O
these NN NN O
agents NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
during NN NN O
hypoxia NN NN O
is NN NN O
an NN NN O
important NN NN O
proximal NN NN O
step NN NN O
which NN NN O
precedes NN NN O
its NN NN O
dissociation NN NN O
and NN NN O
degradation NN NN O
from NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
A NN NN O
transcriptional NN NN O
regulatory NN NN O
element NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
nuclease NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
in NN NN O
the NN NN O
pol NN NN B-Protein
gene NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
chromatin NN NN O
organization NN NN O
of NN NN O
the NN NN O
integrated NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
genome NN NN O
has NN NN O
previously NN NN O
revealed NN NN O
a NN NN O
major NN NN O
constitutive NN NN O
DNase NN NN O
I NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
associated NN NN O
with NN NN O
the NN NN O
pol NN NN B-Protein
gene NN NN O
( NN NN O
E NN NN O
. NN NN O
Verdin NN NN O
, NN NN O
J NN NN O
. NN NN O
Virol NN NN O
. NN NN O
65 NN NN O
: NN NN O
6790 NN NN O
- NN NN O
6799 NN NN O
, NN NN O
1991 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
high NN NN O
- NN NN O
resolution NN NN O
mapping NN NN O
of NN NN O
this NN NN O
site NN NN O
with NN NN O
DNase NN NN B-Protein
I NN NN I-Protein
and NN NN O
micrococcal NN NN B-Protein
nuclease NN NN I-Protein
identified NN NN O
a NN NN O
nucleosome NN NN O
- NN NN O
free NN NN O
region NN NN O
centered NN NN O
around NN NN O
nucleotides NN NN O
( NN NN O
nt NN NN O
) NN NN O
4490 NN NN O
to NN NN O
4766 NN NN O
. NN NN O
   
A NN NN O
500 NN NN O
- NN NN O
bp NN NN O
fragment NN NN O
encompassing NN NN O
this NN NN O
hypersensitive NN NN O
site NN NN O
( NN NN O
nt NN NN O
4481 NN NN O
to NN NN O
4982 NN NN O
) NN NN O
exhibited NN NN O
transcription NN NN O
- NN NN O
enhancing NN NN O
activity NN NN O
( NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
) NN NN O
when NN NN O
it NN NN O
was NN NN O
cloned NN NN O
in NN NN O
its NN NN O
natural NN NN O
position NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
after NN NN O
transient NN NN O
transfection NN NN O
in NN NN O
U937 NN NN O
and NN NN O
CEM NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
in NN NN O
vitro NN NN O
footprinting NN NN O
and NN NN O
gel NN NN O
shift NN NN O
assays NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
four NN NN O
distinct NN NN O
binding NN NN O
sites NN NN O
for NN NN O
nuclear NN NN O
proteins NN NN O
within NN NN O
this NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
Site NN NN O
B NN NN O
( NN NN O
nt NN NN O
4519 NN NN O
to NN NN O
4545 NN NN O
) NN NN O
specifically NN NN O
bound NN NN O
four NN NN O
distinct NN NN O
nuclear NN NN O
protein NN NN O
complexes NN NN O
: NN NN O
a NN NN O
ubiquitous NN NN O
factor NN NN O
, NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
, NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
, NN NN O
and NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
- NN NN O
and NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
In NN NN O
most NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
isolates NN NN O
in NN NN O
which NN NN O
this NN NN O
PU NN NN O
box NN NN O
was NN NN O
not NN NN O
conserved NN NN O
, NN NN O
it NN NN O
was NN NN O
replaced NN NN O
by NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
the NN NN O
related NN NN O
factor NN NN O
Ets1 NN NN B-Protein
. NN NN O
   
Factors NN NN O
binding NN NN O
to NN NN O
site NN NN O
C NN NN O
( NN NN O
nt NN NN O
4681 NN NN O
to NN NN O
4701 NN NN O
) NN NN O
had NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
specificity NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
factors NN NN O
binding NN NN O
to NN NN O
site NN NN O
B NN NN O
, NN NN O
except NN NN O
for NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
A NN NN O
GC NN NN O
box NN NN O
containing NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
Sp1 NN NN B-Protein
was NN NN O
identified NN NN O
( NN NN O
nt NN NN O
4623 NN NN O
to NN NN O
4631 NN NN O
) NN NN O
. NN NN O
   
Site NN NN O
D NN NN O
( NN NN O
nt NN NN O
4816 NN NN O
to NN NN O
4851 NN NN O
) NN NN O
specifically NN NN O
bound NN NN O
a NN NN O
ubiquitously NN NN O
expressed NN NN O
factor NN NN O
. NN NN O
   
These NN NN O
results NN NN O
identify NN NN O
a NN NN O
transcriptional NN NN O
regulatory NN NN O
element NN NN O
associated NN NN O
with NN NN O
a NN NN O
nuclease NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
in NN NN O
the NN NN O
pol NN NN B-Protein
gene NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
suggest NN NN O
that NN NN O
its NN NN O
activity NN NN O
may NN NN O
be NN NN O
controlled NN NN O
by NN NN O
a NN NN O
complex NN NN O
interplay NN NN O
of NN NN O
cis NN NN O
- NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
v NN NN B-Protein
- NN NN I-Protein
src NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
correlates NN NN O
with NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
rapidly NN NN O
inducible NN NN O
transcriptional NN NN O
activator NN NN O
that NN NN O
responds NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
signals NN NN O
and NN NN O
influences NN NN O
the NN NN O
expression NN NN O
of NN NN O
many NN NN O
genes NN NN O
involved NN NN O
in NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Protein NN NN O
tyrosine NN NN O
kinases NN NN O
transmit NN NN O
signals NN NN O
from NN NN O
cytokine NN NN O
and NN NN O
immune NN NN O
receptors NN NN O
. NN NN O
   
Very NN NN O
little NN NN O
information NN NN O
exists NN NN O
linking NN NN O
these NN NN O
two NN NN O
important NN NN O
classes NN NN O
of NN NN O
signaling NN NN O
molecules NN NN O
. NN NN O
   
We NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
v NN NN B-Protein
- NN NN I-Protein
src NN NN I-Protein
expression NN NN O
correlates NN NN O
with NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
a NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
complex NN NN O
similar NN NN O
to NN NN O
that NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
ester NN NN O
and NN NN O
ionomycin NN NN O
, NN NN O
as NN NN O
detected NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
using NN NN O
a NN NN O
variety NN NN O
of NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
. NN NN O
   
This NN NN O
complex NN NN O
was NN NN O
blocked NN NN O
by NN NN O
the NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
herbimycin NN NN O
A NN NN O
. NN NN O
   
The NN NN O
v NN NN B-Protein
- NN NN I-Protein
src NN NN I-Protein
- NN NN O
induced NN NN O
complex NN NN O
comprised NN NN O
the NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
components NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
supershift NN NN O
and NN NN O
immunoblot NN NN O
analysis NN NN O
. NN NN O
   
As NN NN O
a NN NN O
functional NN NN O
correlate NN NN O
of NN NN O
this NN NN O
finding NN NN O
, NN NN O
transient NN NN O
co NN NN O
- NN NN O
transfection NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
reporter NN NN O
constructs NN NN O
in NN NN O
a NN NN O
different NN NN O
T NN NN O
cell NN NN O
line NN NN O
demonstrated NN NN O
that NN NN O
v NN NN B-Protein
- NN NN I-Protein
src NN NN I-Protein
activated NN NN O
this NN NN O
promoter NN NN O
in NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
by NN NN O
v NN NN B-Protein
- NN NN I-Protein
src NN NN I-Protein
was NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
mutations NN NN O
of NN NN O
the NN NN O
proximal NN NN O
, NN NN O
rather NN NN O
than NN NN O
the NN NN O
distal NN NN O
, NN NN O
kappa NN NN O
B NN NN O
element NN NN O
. NN NN O
   
The NN NN O
implications NN NN O
for NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
signaling NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
are NN NN O
considered NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Nef NN NN B-Protein
protein NN NN O
down NN NN O
- NN NN O
regulates NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
after NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
stimulation NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
negative NN NN B-Protein
factor NN NN I-Protein
( NN NN O
Nef NN NN B-Protein
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
down NN NN O
- NN NN O
regulate NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
To NN NN O
define NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
the NN NN O
Nef NN NN B-Protein
protein NN NN O
, NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
which NN NN O
may NN NN O
be NN NN O
affected NN NN O
in NN NN O
T NN NN O
cells NN NN O
by NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
the NN NN O
nef NN NN B-Protein
gene NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
, NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
, NN NN O
or NN NN O
lipopolysaccharide NN NN O
resulted NN NN O
in NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
transcriptional NN NN O
factors NN NN O
to NN NN O
a NN NN O
similar NN NN O
level NN NN O
whether NN NN O
or NN NN O
not NN NN O
the NN NN O
cells NN NN O
expressed NN NN O
the NN NN O
nef NN NN O
gene NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
by NN NN O
mitogens NN NN O
or NN NN O
antibodies NN NN O
to NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
- NN NN O
CD3 NN NN O
complex NN NN O
resulted NN NN O
in NN NN O
the NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
transcriptional NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
nef NN NN B-Protein
gene NN NN O
compared NN NN O
with NN NN O
cells NN NN O
not NN NN O
expressing NN NN O
the NN NN O
nef NN NN O
gene NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
Nef NN NN B-Protein
protein NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
surface NN NN O
expression NN NN O
of NN NN O
the NN NN O
CD3 NN NN O
- NN NN O
TCR NN NN O
complex NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
Nef NN NN B-Protein
protein NN NN O
down NN NN O
- NN NN O
regulates NN NN O
the NN NN O
transcriptional NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
T NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
through NN NN O
an NN NN O
effect NN NN O
on NN NN O
the NN NN O
TCR NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
neuroblastoma NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
a NN NN O
eukaryotic NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
In NN NN O
B NN NN O
cells NN NN O
and NN NN O
macrophages NN NN O
it NN NN O
is NN NN O
constitutively NN NN O
present NN NN O
in NN NN O
cell NN NN O
nuclei NN NN O
, NN NN O
whereas NN NN O
in NN NN O
many NN NN O
other NN NN O
cell NN NN O
types NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocates NN NN O
from NN NN O
cytosol NN NN O
to NN NN O
nucleus NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
transduction NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
phorbol NN NN O
ester NN NN O
, NN NN O
and NN NN O
other NN NN O
polyclonal NN NN O
signals NN NN O
. NN NN O
   
Using NN NN O
neuroblastoma NN NN O
cell NN NN O
lines NN NN O
as NN NN O
models NN NN O
, NN NN O
we NN NN O
have NN NN O
shown NN NN O
that NN NN O
in NN NN O
neural NN NN O
cells NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
present NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
and NN NN O
translocated NN NN O
into NN NN O
nuclei NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
treatment NN NN O
. NN NN O
   
The NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
- NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
transcriptionally NN NN O
functional NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
by NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
was NN NN O
not NN NN O
correlated NN NN O
with NN NN O
cell NN NN O
differentiation NN NN O
or NN NN O
proliferation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
reagents NN NN O
such NN NN O
as NN NN O
nerve NN NN O
growth NN NN O
factor NN NN O
( NN NN O
NGF NN NN O
) NN NN O
and NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
which NN NN O
induce NN NN O
phenotypical NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
SH NN NN O
- NN NN O
SY5Y NN NN O
neuroblastoma NN NN O
cell NN NN O
line NN NN O
, NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
but NN NN O
only NN NN O
in NN NN O
that NN NN O
particular NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
In NN NN O
a NN NN O
NGF NN NN O
- NN NN O
responsive NN NN O
rat NN NN O
pheochromocytoma NN NN O
cell NN NN O
line NN NN O
, NN NN O
PC12 NN NN O
, NN NN O
PMA NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
whereas NN NN O
NGF NN NN O
did NN NN O
not NN NN O
. NN NN O
   
In NN NN O
other NN NN O
neuroblastoma NN NN O
cell NN NN O
lines NN NN O
, NN NN O
such NN NN O
as NN NN O
SK NN NN O
- NN NN O
N NN NN O
- NN NN O
Be NN NN O
( NN NN O
2 NN NN O
) NN NN O
, NN NN O
the NN NN O
lack NN NN O
of NN NN O
PMA NN NN O
induction NN NN O
of NN NN O
differentiation NN NN O
was NN NN O
correlated NN NN O
with NN NN O
the NN NN O
lack NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
found NN NN O
, NN NN O
moreover NN NN O
, NN NN O
that NN NN O
in NN NN O
SK NN NN O
- NN NN O
N NN NN O
- NN NN O
Be NN NN O
( NN NN O
2 NN NN O
) NN NN O
cells NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
enzymatic NN NN O
activity NN NN O
was NN NN O
much NN NN O
lower NN NN O
compared NN NN O
with NN NN O
that NN NN O
in NN NN O
a NN NN O
control NN NN O
cell NN NN O
line NN NN O
and NN NN O
that NN NN O
the NN NN O
low NN NN O
PKC NN NN O
enzymatic NN NN O
activity NN NN O
was NN NN O
due NN NN O
to NN NN O
low NN NN O
PKC NN NN O
protein NN NN O
expression NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
not NN NN O
activated NN NN O
by NN NN O
retinoic NN NN O
acid NN NN O
, NN NN O
which NN NN O
induced NN NN O
morphological NN NN O
differentiation NN NN O
of NN NN O
all NN NN O
the NN NN O
neuroblastoma NN NN O
cell NN NN O
lines NN NN O
used NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
not NN NN O
required NN NN O
for NN NN O
neuroblastoma NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
results NN NN O
obtained NN NN O
with NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
proved NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
induction NN NN O
of NN NN O
neuroblastoma NN NN O
differentiation NN NN O
. NN NN O
   
Genes NN NN O
encoding NN NN O
general NN NN O
initiation NN NN O
factors NN NN O
for NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
transcription NN NN O
are NN NN O
dispersed NN NN O
in NN NN O
the NN NN O
human NN NN O
genome NN NN O
. NN NN O
   
General NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
required NN NN O
for NN NN O
accurate NN NN O
initiation NN NN O
of NN NN O
transcription NN NN O
by NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
. NN NN O
   
Human NN NN O
cDNAs NN NN O
encoding NN NN O
subunits NN NN O
of NN NN O
these NN NN O
factors NN NN O
have NN NN O
been NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
. NN NN O
   
Using NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
, NN NN O
we NN NN O
show NN NN O
here NN NN O
that NN NN O
the NN NN O
genes NN NN O
encoding NN NN O
the NN NN O
TATA NN NN B-Protein
- NN NN I-Protein
box NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
( NN NN O
TBP NN NN B-Protein
) NN NN O
, NN NN O
TFIIB NN NN B-Protein
, NN NN O
TFIIE NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
TFIIE NN NN B-Protein
beta NN NN I-Protein
, NN NN O
RAP30 NN NN B-Protein
, NN NN O
RAP74 NN NN B-Protein
and NN NN O
the NN NN O
62 NN NN O
kDa NN NN O
subunit NN NN O
, NN NN O
of NN NN O
TFIIH NN NN O
are NN NN O
located NN NN O
at NN NN O
the NN NN O
human NN NN O
chromosomal NN NN O
bands NN NN O
6q26 NN NN O
- NN NN O
27 NN NN O
, NN NN O
1p21 NN NN O
- NN NN O
22 NN NN O
, NN NN O
3q21 NN NN O
- NN NN O
24 NN NN O
, NN NN O
8p12 NN NN O
, NN NN O
13q14 NN NN O
, NN NN O
19p13 NN NN O
. NN NN O
3 NN NN O
and NN NN O
11p14 NN NN O
- NN NN O
15 NN NN O
. NN NN O
1 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
This NN NN O
dispersed NN NN O
localization NN NN O
of NN NN O
a NN NN O
group NN NN O
of NN NN O
functionally NN NN O
related NN NN O
gene NN NN O
provides NN NN O
insights NN NN O
into NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
human NN NN O
genome NN NN O
evolution NN NN O
and NN NN O
their NN NN O
possible NN NN O
involvement NN NN O
in NN NN O
human NN NN O
diseases NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
heterodimerization NN NN O
partner NN NN O
for NN NN O
thyroid NN NN O
hormone NN NN O
receptor NN NN O
. NN NN O
   
Peroxisome NN NN O
proliferator NN NN O
- NN NN O
activated NN NN O
receptor NN NN O
. NN NN O
   
Retinoid NN NN O
- NN NN O
like NN NN O
receptors NN NN O
play NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
hormonal NN NN O
responses NN NN O
by NN NN O
forming NN NN O
heterodimers NN NN O
with NN NN O
other NN NN O
nuclear NN NN O
hormone NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
have NN NN O
identified NN NN O
the NN NN O
peroxisome NN NN O
proliferator NN NN O
- NN NN O
activated NN NN O
receptor NN NN O
( NN NN O
PPAR NN NN O
) NN NN O
as NN NN O
a NN NN O
new NN NN O
thyroid NN NN O
hormone NN NN O
receptor NN NN O
( NN NN O
THR NN NN O
) NN NN O
auxiliary NN NN O
nuclear NN NN O
protein NN NN O
, NN NN O
heterodimerizing NN NN O
with NN NN O
THR NN NN O
in NN NN O
solution NN NN O
. NN NN O
   
Although NN NN O
these NN NN O
heterodimers NN NN O
do NN NN O
not NN NN O
recognize NN NN O
a NN NN O
classical NN NN O
thyroid NN NN O
hormone NN NN O
response NN NN O
element NN NN O
( NN NN O
TRE NN NN O
) NN NN O
characterized NN NN O
by NN NN O
direct NN NN O
repeat NN NN O
separated NN NN O
by NN NN O
four NN NN O
nucleotides NN NN O
( NN NN O
DR NN NN O
+ NN NN O
4 NN NN O
) NN NN O
, NN NN O
PPAR NN NN O
behaves NN NN O
as NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
thyroid NN NN O
hormone NN NN O
( NN NN O
TH NN NN O
) NN NN O
action NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
TH NN NN O
- NN NN O
dependent NN NN O
positive NN NN O
effect NN NN O
is NN NN O
elicited NN NN O
by NN NN O
selective NN NN O
interaction NN NN O
of NN NN O
the NN NN O
THR NN NN O
beta NN NN O
- NN NN O
PPAR NN NN O
but NN NN O
not NN NN O
the NN NN O
THR NN NN O
alpha NN NN O
- NN NN O
PPAR NN NN O
heterodimer NN NN O
with NN NN O
a NN NN O
novel NN NN O
TRE NN NN O
( NN NN O
DR NN NN O
+ NN NN O
2 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
critical NN NN O
region NN NN O
of NN NN O
THR NN NN O
beta NN NN O
was NN NN O
mapped NN NN O
to NN NN O
3 NN NN O
amino NN NN O
acids NN NN O
in NN NN O
the NN NN O
distal NN NN O
box NN NN O
of NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
PPAR NN NN O
can NN NN O
positively NN NN O
or NN NN O
negatively NN NN O
influence NN NN O
TH NN NN O
action NN NN O
depending NN NN O
on NN NN O
TRE NN NN O
structure NN NN O
and NN NN O
THR NN NN O
isotype NN NN O
. NN NN O
   
Hypoxic NN NN O
induction NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Because NN NN O
leukocyte NN NN O
- NN NN O
mediated NN NN O
tissue NN NN O
damage NN NN O
is NN NN O
an NN NN O
important NN NN O
component NN NN O
of NN NN O
the NN NN O
pathologic NN NN O
picture NN NN O
in NN NN O
ischemia NN NN O
/ NN NN O
reperfusion NN NN O
, NN NN O
we NN NN O
have NN NN O
sought NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
PMNs NN NN O
are NN NN O
directed NN NN O
into NN NN O
hypoxic NN NN O
tissue NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
ECs NN NN O
) NN NN O
in NN NN O
hypoxia NN NN O
, NN NN O
PO2 NN NN O
approximately NN NN O
14 NN NN O
- NN NN O
18 NN NN O
Torr NN NN O
, NN NN O
led NN NN O
to NN NN O
time NN NN O
- NN NN O
dependent NN NN O
release NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
antigen NN NN O
into NN NN O
the NN NN O
conditioned NN NN O
medium NN NN O
; NN NN O
this NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
increased NN NN O
chemotactic NN NN O
activity NN NN O
for NN NN O
PMNs NN NN O
, NN NN O
blocked NN NN O
by NN NN O
antibody NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
Production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
by NN NN O
hypoxic NN NN O
ECs NN NN O
occurred NN NN O
concomitantly NN NN O
with NN NN O
both NN NN O
increased NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
mRNA NN NN O
, NN NN O
based NN NN O
on NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
analysis NN NN O
, NN NN O
and NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
transcription NN NN O
, NN NN O
based NN NN O
on NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
assays NN NN O
. NN NN O
   
Northern NN NN O
analysis NN NN O
of NN NN O
mRNA NN NN O
from NN NN O
hypoxic NN NN O
ECs NN NN O
also NN NN O
demonstrated NN NN O
increased NN NN O
levels NN NN O
of NN NN O
mRNA NN NN O
for NN NN O
macrophage NN NN B-Protein
chemotactic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
another NN NN O
member NN NN O
of NN NN O
the NN NN O
chemokine NN NN O
superfamily NN NN O
of NN NN O
proinflammatory NN NN O
cytokines NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
induction NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
increased NN NN O
binding NN NN O
activity NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
hypoxic NN NN O
ECs NN NN O
for NN NN O
the NN NN O
NF NN NN O
- NN NN O
kB NN NN O
site NN NN O
. NN NN O
   
Studies NN NN O
with NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
segments NN NN O
exposed NN NN O
to NN NN O
hypoxia NN NN O
also NN NN O
demonstrated NN NN O
increased NN NN O
elaboration NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
antigen NN NN O
compared NN NN O
with NN NN O
normoxic NN NN O
controls NN NN O
. NN NN O
   
In NN NN O
mice NN NN O
exposed NN NN O
to NN NN O
hypoxia NN NN O
( NN NN O
PO2 NN NN O
approximately NN NN O
30 NN NN O
- NN NN O
40 NN NN O
Torr NN NN O
) NN NN O
, NN NN O
there NN NN O
was NN NN O
increased NN NN O
pulmonary NN NN O
leukostasis NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
increased NN NN O
myeloperoxidase NN NN B-Protein
activity NN NN O
in NN NN O
tissue NN NN O
homogenates NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
, NN NN O
increased NN NN O
levels NN NN O
of NN NN O
transcripts NN NN O
for NN NN O
IP NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
a NN NN O
murine NN NN O
homologue NN NN O
in NN NN O
the NN NN O
chemokine NN NN O
family NN NN O
related NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
were NN NN O
observed NN NN O
in NN NN O
hypoxic NN NN O
lung NN NN O
tissue NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
hypoxia NN NN O
constitutes NN NN O
a NN NN O
stimulus NN NN O
for NN NN O
leukocyte NN NN O
chemotaxis NN NN O
and NN NN O
tissue NN NN O
leukostasis NN NN O
. NN NN O
   
Function NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
major NN NN B-Protein
histocompatibility NN NN I-Protein
complex NN NN I-Protein
class NN NN I-Protein
II NN NN I-Protein
invariant NN NN I-Protein
chain NN NN I-Protein
promoter NN NN O
is NN NN O
dependent NN NN O
on NN NN O
cell NN NN O
- NN NN O
specific NN NN O
binding NN NN O
of NN NN O
different NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
subunits NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
of NN NN O
the NN NN O
human NN NN O
major NN NN O
histocompatibility NN NN B-Protein
complex NN NN I-Protein
class NN NN I-Protein
II NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
invariant NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
( NN NN O
Ii NN NN O
) NN NN O
contains NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
binding NN NN O
sites NN NN O
located NN NN O
at NN NN O
- NN NN O
109 NN NN O
to NN NN O
- NN NN O
118 NN NN O
( NN NN O
Ii NN NN O
kappa NN NN O
B NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
- NN NN O
163 NN NN O
to NN NN O
- NN NN O
172 NN NN O
( NN NN O
Ii NN NN O
kappa NN NN O
B NN NN O
- NN NN O
2 NN NN O
) NN NN O
from NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
differential NN NN O
function NN NN O
of NN NN O
each NN NN O
of NN NN O
these NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
sites NN NN O
in NN NN O
several NN NN O
distinct NN NN O
cell NN NN O
types NN NN O
depends NN NN O
on NN NN O
cell NN NN O
- NN NN O
specific NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Ii NN NN O
kappa NN NN O
B NN NN O
- NN NN O
1 NN NN O
is NN NN O
a NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
in NN NN O
the NN NN O
Ii NN NN O
- NN NN O
expressing NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
, NN NN O
H9 NN NN O
, NN NN O
but NN NN O
acts NN NN O
as NN NN O
a NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
in NN NN O
myelomonocytic NN NN O
and NN NN O
glia NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
contacts NN NN O
are NN NN O
detectable NN NN O
at NN NN O
Ii NN NN O
kappa NN NN O
B NN NN O
- NN NN O
1 NN NN O
in NN NN O
cell NN NN O
lines NN NN O
in NN NN O
which NN NN O
this NN NN O
site NN NN O
is NN NN O
functional NN NN O
as NN NN O
either NN NN O
a NN NN O
positive NN NN O
or NN NN O
negative NN NN O
regulator NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
supershift NN NN O
assays NN NN O
determine NN NN O
that NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
can NN NN O
bind NN NN O
to NN NN O
this NN NN O
site NN NN O
in NN NN O
vitro NN NN O
and NN NN O
that NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
that NN NN O
contain NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
cRel NN NN B-Protein
correlate NN NN O
with NN NN O
positive NN NN O
regulation NN NN O
whereas NN NN O
the NN NN O
presence NN NN O
of NN NN O
p50 NN NN B-Protein
correlates NN NN O
with NN NN O
negative NN NN O
regulation NN NN O
. NN NN O
   
Ii NN NN O
kappa NN NN O
B NN NN O
- NN NN O
2 NN NN O
is NN NN O
a NN NN O
site NN NN O
of NN NN O
positive NN NN O
regulation NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
and NN NN O
a NN NN O
site NN NN O
of NN NN O
negative NN NN O
regulation NN NN O
in NN NN O
H9 NN NN O
T NN NN O
cells NN NN O
, NN NN O
myelomonocytic NN NN O
, NN NN O
and NN NN O
glial NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
occupancy NN NN O
of NN NN O
this NN NN O
site NN NN O
is NN NN O
observed NN NN O
only NN NN O
in NN NN O
the NN NN O
H9 NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Again NN NN O
, NN NN O
in NN NN O
vitro NN NN O
supershift NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
p50 NN NN B-Protein
, NN NN O
p52 NN NN B-Protein
, NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
cRel NN NN B-Protein
correlates NN NN O
with NN NN O
positive NN NN O
function NN NN O
whereas NN NN O
the NN NN O
presence NN NN O
of NN NN O
only NN NN O
p50 NN NN B-Protein
and NN NN O
p52 NN NN B-Protein
correlates NN NN O
with NN NN O
negative NN NN O
function NN NN O
. NN NN O
   
This NN NN O
differential NN NN O
binding NN NN O
of NN NN O
specific NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
subunits NN NN O
is NN NN O
likely NN NN O
to NN NN O
mediate NN NN O
the NN NN O
disparate NN NN O
functions NN NN O
of NN NN O
these NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
Positive NN NN O
regulators NN NN O
of NN NN O
the NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
differentiating NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
major NN NN O
regulator NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
erythroid NN NN O
, NN NN O
megakaryocyte NN NN O
, NN NN O
and NN NN O
mast NN NN O
cell NN NN O
lineages NN NN O
. NN NN O
   
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binds NN NN O
to NN NN O
WGATAR NN NN O
consensus NN NN O
motifs NN NN O
in NN NN O
the NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
virtually NN NN O
all NN NN O
erythroid NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
Analyses NN NN O
with NN NN O
cultured NN NN O
cells NN NN O
and NN NN O
cell NN NN O
- NN NN O
free NN NN O
systems NN NN O
have NN NN O
provided NN NN O
strong NN NN O
evidence NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
involved NN NN O
in NN NN O
control NN NN O
of NN NN O
globin NN NN O
gene NN NN O
expression NN NN O
during NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Targeted NN NN O
mutagenesis NN NN O
of NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
in NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
has NN NN O
demonstrated NN NN O
its NN NN O
requirement NN NN O
in NN NN O
normal NN NN O
erythroid NN NN O
development NN NN O
. NN NN O
   
Efficient NN NN O
rescue NN NN O
of NN NN O
the NN NN O
defect NN NN O
requires NN NN O
an NN NN O
intact NN NN O
GATA NN NN O
element NN NN O
in NN NN O
the NN NN O
distal NN NN O
promoter NN NN O
, NN NN O
suggesting NN NN O
autoregulatory NN NN O
control NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
whether NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
involves NN NN O
additional NN NN O
regulatory NN NN O
factors NN NN O
or NN NN O
is NN NN O
maintained NN NN O
entirely NN NN O
by NN NN O
an NN NN O
autoregulatory NN NN O
loop NN NN O
, NN NN O
we NN NN O
have NN NN O
used NN NN O
a NN NN O
transient NN NN O
heterokaryon NN NN O
system NN NN O
to NN NN O
test NN NN O
the NN NN O
ability NN NN O
of NN NN O
erythroid NN NN O
factors NN NN O
to NN NN O
activate NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
in NN NN O
nonerythroid NN NN O
nuclei NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
proerythroblasts NN NN O
and NN NN O
mature NN NN O
erythroid NN NN O
cells NN NN O
contain NN NN O
a NN NN O
diffusible NN NN O
activity NN NN O
( NN NN O
TAG NN NN O
) NN NN O
capable NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
that NN NN O
this NN NN O
activity NN NN O
decreases NN NN O
during NN NN O
the NN NN O
terminal NN NN O
differentiation NN NN O
of NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
Nuclei NN NN O
from NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mutant NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
can NN NN O
still NN NN O
be NN NN O
reprogrammed NN NN O
to NN NN O
express NN NN O
their NN NN O
globin NN NN O
genes NN NN O
in NN NN O
erythroid NN NN O
heterokaryons NN NN O
, NN NN O
indicating NN NN O
that NN NN O
de NN NN O
novo NN NN O
induction NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
not NN NN O
required NN NN O
for NN NN O
globin NN NN O
gene NN NN O
activation NN NN O
following NN NN O
cell NN NN O
fusion NN NN O
. NN NN O
   
Patterns NN NN O
of NN NN O
Pan NN NN O
expression NN NN O
and NN NN O
role NN NN O
of NN NN O
Pan NN NN O
proteins NN NN O
in NN NN O
endocrine NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
complex NN NN O
formation NN NN O
. NN NN O
   
The NN NN O
Pan NN NN B-Protein
gene NN NN O
encodes NN NN O
at NN NN O
least NN NN O
two NN NN O
distinct NN NN O
transcripts NN NN O
, NN NN O
Pan NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Pan NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
also NN NN O
known NN NN O
as NN NN O
E47 NN NN B-Protein
and NN NN O
E12 NN NN B-Protein
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
by NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
alternative NN NN O
RNA NN NN O
splicing NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analyses NN NN O
performed NN NN O
on NN NN O
rat NN NN O
and NN NN O
mouse NN NN O
tissues NN NN O
have NN NN O
detected NN NN O
ubiquitously NN NN O
expressed NN NN O
Pan NN NN B-Protein
transcripts NN NN O
, NN NN O
but NN NN O
the NN NN O
abundance NN NN O
, NN NN O
distribution NN NN O
, NN NN O
and NN NN O
form NN NN O
of NN NN O
Pan NN NN B-Protein
proteins NN NN O
have NN NN O
not NN NN O
been NN NN O
clearly NN NN O
defined NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
cell NN NN O
lines NN NN O
representing NN NN O
endocrine NN NN O
, NN NN O
fibroblast NN NN O
, NN NN O
and NN NN O
lymphoid NN NN O
lineages NN NN O
using NN NN O
polyclonal NN NN O
antisera NN NN O
to NN NN O
detect NN NN O
E2A NN NN B-Protein
proteins NN NN O
have NN NN O
suggested NN NN O
that NN NN O
significant NN NN O
E2A NN NN B-Protein
protein NN NN O
expression NN NN O
is NN NN O
restricted NN NN O
to NN NN O
B NN NN O
- NN NN O
lymphocytes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
developed NN NN O
a NN NN O
monoclonal NN NN O
antibody NN NN O
, NN NN O
Yae NN NN O
, NN NN O
which NN NN O
is NN NN O
specific NN NN O
for NN NN O
Pan NN NN B-Protein
/ NN NN O
E2A NN NN B-Protein
proteins NN NN O
, NN NN O
and NN NN O
have NN NN O
used NN NN O
the NN NN O
Yae NN NN O
antibody NN NN O
to NN NN O
examine NN NN O
a NN NN O
variety NN NN O
of NN NN O
endocrine NN NN O
and NN NN O
nonendocrine NN NN O
cell NN NN O
lineages NN NN O
for NN NN O
differences NN NN O
in NN NN O
Pan NN NN B-Protein
/ NN NN O
E2A NN NN B-Protein
protein NN NN O
expression NN NN O
, NN NN O
subcellular NN NN O
localization NN NN O
, NN NN O
and NN NN O
heteromeric NN NN O
complex NN NN O
formation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
previous NN NN O
results NN NN O
obtained NN NN O
using NN NN O
polyclonal NN NN O
antiseras NN NN O
to NN NN O
detect NN NN O
Pan NN NN B-Protein
/ NN NN O
E2A NN NN B-Protein
proteins NN NN O
, NN NN O
we NN NN O
report NN NN O
comparable NN NN O
levels NN NN O
of NN NN O
Pan NN NN B-Protein
proteins NN NN O
in NN NN O
GH NN NN B-Protein
/ NN NN O
PRL NN NN O
- NN NN O
and NN NN O
insulin NN NN B-Protein
- NN NN O
producing NN NN O
, NN NN O
B NN NN O
- NN NN O
and NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
cells NN NN O
. NN NN O
   
IEF NN NN O
- NN NN O
1 NN NN O
, NN NN O
a NN NN O
pancreatic NN NN O
beta NN NN O
- NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
complex NN NN O
believed NN NN O
to NN NN O
regulate NN NN O
insulin NN NN B-Protein
expression NN NN O
, NN NN O
is NN NN O
demonstrated NN NN O
to NN NN O
consist NN NN O
of NN NN O
at NN NN O
least NN NN O
two NN NN O
distinct NN NN O
species NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
does NN NN O
not NN NN O
contain NN NN O
Pan NN NN B-Protein
molecules NN NN O
. NN NN O
   
Although NN NN O
it NN NN O
has NN NN O
been NN NN O
postulated NN NN O
that NN NN O
pituitary NN NN O
endocrine NN NN O
cells NN NN O
and NN NN O
pancreatic NN NN O
endocrine NN NN O
beta NN NN O
- NN NN O
cells NN NN O
share NN NN O
identical NN NN O
Pan NN NN B-Protein
/ NN NN O
E2A NN NN B-Protein
complexes NN NN O
, NN NN O
native NN NN O
- NN NN O
Western NN NN O
analyses NN NN O
of NN NN O
pituitary NN NN O
and NN NN O
endocrine NN NN O
beta NN NN O
- NN NN O
cells NN NN O
detect NN NN O
Pan NN NN B-Protein
proteins NN NN O
in NN NN O
distinct NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
complexes NN NN O
. NN NN O
   
Functional NN NN O
block NN NN O
for NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
regulation NN NN O
in NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Elements NN NN O
necessary NN NN O
for NN NN O
the NN NN O
steroid NN NN O
hormone NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
to NN NN O
induce NN NN O
a NN NN O
biological NN NN O
response NN NN O
include NN NN O
the NN NN O
presence NN NN O
of NN NN O
specific NN NN O
intracellular NN NN O
receptors NN NN O
( NN NN O
vitamin NN NN B-Protein
D3 NN NN I-Protein
receptors NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
) NN NN O
and NN NN O
modulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
via NN NN O
hormone NN NN O
- NN NN O
activated NN NN O
receptor NN NN O
binding NN NN O
to NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
These NN NN O
parameters NN NN O
were NN NN O
examined NN NN O
in NN NN O
normal NN NN O
and NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
immortalized NN NN O
human NN NN O
B NN NN O
cells NN NN O
and NN NN O
compared NN NN O
with NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
- NN NN O
responsive NN NN O
cells NN NN O
of NN NN O
the NN NN O
T NN NN O
and NN NN O
monocytic NN NN O
lineages NN NN O
. NN NN O
   
Although NN NN O
resting NN NN O
tonsillar NN NN O
B NN NN O
cells NN NN O
did NN NN O
not NN NN O
express NN NN O
VDR NN NN B-Protein
mRNA NN NN O
, NN NN O
activation NN NN O
of NN NN O
these NN NN O
cells NN NN O
with NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
induced NN NN O
VDR NN NN B-Protein
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
exogenously NN NN O
supplemented NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
As NN NN O
indicators NN NN O
of NN NN O
hormone NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
regulation NN NN O
we NN NN O
analyzed NN NN O
modulation NN NN O
of NN NN O
CD23 NN NN B-Protein
, NN NN O
a NN NN O
common NN NN O
B NN NN O
cell NN NN O
/ NN NN O
monocyte NN NN O
surface NN NN O
antigen NN NN O
, NN NN O
and NN NN O
24 NN NN B-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
. NN NN O
   
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
inhibited NN NN O
CD23 NN NN B-Protein
expression NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
yet NN NN O
failed NN NN O
to NN NN O
modulate NN NN O
CD23 NN NN B-Protein
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
induced NN NN O
24 NN NN B-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
metabolic NN NN O
activity NN NN O
in NN NN O
both NN NN O
U937 NN NN O
cells NN NN O
and NN NN O
lectin NN NN O
- NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
yet NN NN O
failed NN NN O
to NN NN O
induce NN NN O
24 NN NN B-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
mRNA NN NN O
or NN NN O
its NN NN O
metabolic NN NN O
activity NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
although NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
can NN NN O
express NN NN O
VDR NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
, NN NN O
they NN NN O
exhibit NN NN O
a NN NN O
functional NN NN O
block NN NN O
for NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
and NN NN O
dihydrolipoic NN NN O
acid NN NN O
on NN NN O
expression NN NN O
of NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
an NN NN O
important NN NN O
human NN NN O
mediator NN NN O
of NN NN O
the NN NN O
cellular NN NN O
response NN NN O
to NN NN O
serum NN NN O
, NN NN O
growth NN NN O
factors NN NN O
, NN NN O
and NN NN O
phorbol NN NN O
esters NN NN O
such NN NN O
as NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoyl NN NN O
- NN NN O
phorbol NN NN O
- NN NN O
13 NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
. NN NN O
   
The NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
consists NN NN O
of NN NN O
distinct NN NN O
protein NN NN O
heterodimers NN NN O
encoded NN NN O
by NN NN O
the NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
whose NN NN O
gene NN NN O
expression NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
TPA NN NN O
, NN NN O
cyclic NN NN O
AMP NN NN O
and NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
Recent NN NN O
findings NN NN O
suggest NN NN O
an NN NN O
involvement NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
in NN NN O
the NN NN O
pathway NN NN O
of NN NN O
TPA NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
leading NN NN O
to NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
we NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
and NN NN O
dihydrolipoic NN NN O
acid NN NN O
( NN NN O
natural NN NN O
thiol NN NN O
antioxidants NN NN O
) NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
in NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
cells NN NN O
were NN NN O
preincubated NN NN O
with NN NN O
dihydrolipoic NN NN O
acid NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
mM NN NN O
) NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
was NN NN O
suppressed NN NN O
at NN NN O
30 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
of NN NN O
TPA NN NN O
( NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
) NN NN O
whereas NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
preincubation NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoic NN NN O
acid NN NN O
( NN NN O
0 NN NN O
. NN NN O
2 NN NN O
microM NN NN O
) NN NN O
, NN NN O
the NN NN O
expression NN NN O
was NN NN O
enhanced NN NN O
at NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
support NN NN O
the NN NN O
idea NN NN O
that NN NN O
superoxide NN NN O
anion NN NN O
radical NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Alternative NN NN O
splicing NN NN O
of NN NN O
RNA NN NN O
transcripts NN NN O
encoded NN NN O
by NN NN O
the NN NN O
murine NN NN O
p105 NN NN B-Protein
NF NN NN I-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gene NN NN O
generates NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
isoforms NN NN O
with NN NN O
different NN NN O
inhibitory NN NN O
activities NN NN O
. NN NN O
   
The NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
105 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
( NN NN O
p105 NN NN B-Protein
) NN NN O
precursor NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
also NN NN O
encodes NN NN O
a NN NN O
p70 NN NN B-Protein
I NN NN I-Protein
kappa NN NN I-Protein
B NN NN I-Protein
protein NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
identical NN NN O
to NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
607 NN NN O
amino NN NN O
acids NN NN O
of NN NN O
p105 NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
alternative NN NN O
RNA NN NN O
splicing NN NN O
generates NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
isoforms NN NN O
with NN NN O
properties NN NN O
different NN NN O
from NN NN O
those NN NN O
of NN NN O
p70 NN NN O
. NN NN O
   
One NN NN O
63 NN NN O
- NN NN O
kDa NN NN O
isoform NN NN O
, NN NN O
termed NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
which NN NN O
lacks NN NN O
59 NN NN O
amino NN NN O
acids NN NN O
C NN NN O
- NN NN O
terminal NN NN O
to NN NN O
ankyrin NN NN O
repeat NN NN O
7 NN NN O
, NN NN O
has NN NN O
a NN NN O
novel NN NN O
35 NN NN O
- NN NN O
amino NN NN O
acid NN NN O
C NN NN O
terminus NN NN O
encoded NN NN O
by NN NN O
an NN NN O
alternative NN NN O
reading NN NN O
frame NN NN O
of NN NN O
the NN NN O
p105 NN NN B-Protein
gene NN NN O
. NN NN O
   
A NN NN O
55 NN NN O
- NN NN O
kDa NN NN O
isoform NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
lacks NN NN O
the NN NN O
190 NN NN O
C NN NN O
- NN NN O
terminal NN NN O
amino NN NN O
acids NN NN O
of NN NN O
p70I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
p70I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
a NN NN O
cytoplasmic NN NN O
protein NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
found NN NN O
in NN NN O
both NN NN O
the NN NN O
cytoplasm NN NN O
and NN NN O
nucleus NN NN O
, NN NN O
whereas NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
predominantly NN NN O
nuclear NN NN O
. NN NN O
   
The NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
isoforms NN NN O
also NN NN O
display NN NN O
differences NN NN O
in NN NN O
specificity NN NN O
and NN NN O
affinity NN NN O
for NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
. NN NN O
   
While NN NN O
p70I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
inhibits NN NN O
p50 NN NN B-Protein
- NN NN O
, NN NN O
p65 NN NN B-Protein
- NN NN O
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
- NN NN O
mediated NN NN O
transactivation NN NN O
and NN NN O
/ NN NN O
or NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
both NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
specific NN NN O
for NN NN O
p50 NN NN B-Protein
and NN NN O
have NN NN O
different NN NN O
affinities NN NN O
for NN NN O
this NN NN O
subunit NN NN O
. NN NN O
   
The NN NN O
absence NN NN O
in NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
of NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
site NN NN O
whose NN NN O
phosphorylation NN NN O
modulates NN NN O
p70I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
inhibitory NN NN O
activity NN NN O
suggests NN NN O
that NN NN O
alternative NN NN O
RNA NN NN O
splicing NN NN O
may NN NN O
be NN NN O
used NN NN O
to NN NN O
generate NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
isoforms NN NN O
that NN NN O
respond NN NN O
differently NN NN O
to NN NN O
intracellular NN NN O
signals NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
lymphoblastoid NN NN O
cells NN NN O
by NN NN O
low NN NN O
- NN NN O
dose NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
a NN NN O
pleiotropic NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
several NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
Recent NN NN O
reports NN NN O
demonstrated NN NN O
that NN NN O
ionizing NN NN O
radiation NN NN O
in NN NN O
the NN NN O
dose NN NN O
range NN NN O
of NN NN O
2 NN NN O
- NN NN O
50 NN NN O
Gy NN NN O
results NN NN O
in NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
KG NN NN O
- NN NN O
1 NN NN O
myeloid NN NN O
leukemia NN NN O
cells NN NN O
and NN NN O
human NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
precursor NN NN O
cells NN NN O
; NN NN O
the NN NN O
precise NN NN O
mechanism NN NN O
involved NN NN O
and NN NN O
the NN NN O
significance NN NN O
are NN NN O
not NN NN O
yet NN NN O
known NN NN O
. NN NN O
   
The NN NN O
present NN NN O
report NN NN O
demonstrates NN NN O
that NN NN O
even NN NN O
lower NN NN O
doses NN NN O
of NN NN O
ionizing NN NN O
radiation NN NN O
, NN NN O
0 NN NN O
. NN NN O
25 NN NN O
- NN NN O
2 NN NN O
. NN NN O
0 NN NN O
Gy NN NN O
, NN NN O
are NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
EBV NN NN O
- NN NN O
transformed NN NN O
244B NN NN O
human NN NN O
lymphoblastoid NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
in NN NN O
a NN NN O
dose NN NN O
range NN NN O
where NN NN O
the NN NN O
viability NN NN O
of NN NN O
the NN NN O
cells NN NN O
remains NN NN O
very NN NN O
high NN NN O
. NN NN O
   
After NN NN O
exposure NN NN O
to NN NN O
137Cs NN NN O
gamma NN NN O
rays NN NN O
at NN NN O
a NN NN O
dose NN NN O
rate NN NN O
of NN NN O
1 NN NN O
. NN NN O
17 NN NN O
Gy NN NN O
/ NN NN O
min NN NN O
, NN NN O
a NN NN O
maximum NN NN O
in NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
seen NN NN O
at NN NN O
8 NN NN O
h NN NN O
after NN NN O
a NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
Gy NN NN O
exposure NN NN O
. NN NN O
   
Time NN NN O
- NN NN O
course NN NN O
studies NN NN O
revealed NN NN O
a NN NN O
biphasic NN NN O
time NN NN O
- NN NN O
dependent NN NN O
expression NN NN O
after NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
, NN NN O
1 NN NN O
- NN NN O
and NN NN O
2 NN NN O
- NN NN O
Gy NN NN O
exposures NN NN O
. NN NN O
   
However NN NN O
, NN NN O
for NN NN O
each NN NN O
time NN NN O
examined NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
maximum NN NN O
after NN NN O
the NN NN O
0 NN NN O
. NN NN O
5 NN NN O
- NN NN O
Gy NN NN O
exposure NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
was NN NN O
also NN NN O
shown NN NN O
to NN NN O
be NN NN O
regulated NN NN O
differentially NN NN O
after NN NN O
exposures NN NN O
to NN NN O
1 NN NN O
. NN NN O
0 NN NN O
and NN NN O
2 NN NN O
. NN NN O
0 NN NN O
Gy NN NN O
. NN NN O
   
Some NN NN O
antioxidants NN NN O
inhibit NN NN O
, NN NN O
in NN NN O
a NN NN O
co NN NN O
- NN NN O
ordinate NN NN O
fashion NN NN O
, NN NN O
the NN NN O
production NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
by NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Some NN NN O
antioxidants NN NN O
, NN NN O
including NN NN O
butylated NN NN O
hydroxyanisole NN NN O
( NN NN O
BHA NN NN O
) NN NN O
, NN NN O
tetrahydropapaveroline NN NN O
( NN NN O
THP NN NN O
) NN NN O
, NN NN O
nordihydroguiauretic NN NN O
acid NN NN O
, NN NN O
and NN NN O
10 NN NN O
, NN NN O
11 NN NN O
- NN NN O
dihydroxyaporphine NN NN O
( NN NN O
DHA NN NN O
) NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
potent NN NN O
inhibitors NN NN O
of NN NN O
the NN NN O
production NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
by NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
stimulated NN NN O
by NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
( NN NN O
IC50s NN NN O
in NN NN O
the NN NN O
low NN NN O
micromolar NN NN O
range NN NN O
) NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
was NN NN O
gene NN NN O
selective NN NN O
and NN NN O
not NN NN O
due NN NN O
to NN NN O
general NN NN O
effects NN NN O
on NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
PBMC NN NN O
was NN NN O
observed NN NN O
also NN NN O
when NN NN O
other NN NN O
inducers NN NN O
were NN NN O
used NN NN O
( NN NN O
staphylococci NN NN O
, NN NN O
silica NN NN O
, NN NN O
zymosan NN NN O
) NN NN O
. NN NN O
   
Much NN NN O
higher NN NN O
concentrations NN NN O
of NN NN O
other NN NN O
antioxidants NN NN O
- NN NN O
- NN NN O
including NN NN O
ascorbic NN NN O
acid NN NN O
, NN NN O
trolox NN NN O
, NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
, NN NN O
butylated NN NN O
hydroxytoluene NN NN O
, NN NN O
and NN NN O
the NN NN O
5 NN NN O
- NN NN O
lipoxygenase NN NN O
inhibitor NN NN O
zileuton NN NN O
- NN NN O
- NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
production NN NN O
of NN NN O
these NN NN O
cytokines NN NN O
. NN NN O
   
The NN NN O
active NN NN O
compounds NN NN O
did NN NN O
not NN NN O
inhibit NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
fibroblasts NN NN O
, NN NN O
showing NN NN O
the NN NN O
cell NN NN O
selectivity NN NN O
of NN NN O
the NN NN O
effect NN NN O
. NN NN O
   
Antioxidant NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
was NN NN O
correlated NN NN O
with NN NN O
low NN NN O
levels NN NN O
of NN NN O
the NN NN O
corresponding NN NN O
messenger NN NN O
RNAs NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
experiments NN NN O
showed NN NN O
that NN NN O
THP NN NN O
inhibited NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
gene NN NN O
. NN NN O
   
THP NN NN O
decreased NN NN O
the NN NN O
concentration NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
detected NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
PBMC NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
LPS NN NN O
. NN NN O
   
THP NN NN O
and NN NN O
DHA NN NN O
markedly NN NN O
decreased NN NN O
the NN NN O
levels NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
in NN NN O
the NN NN O
circulation NN NN O
of NN NN O
mice NN NN O
following NN NN O
LPS NN NN O
injection NN NN O
. NN NN O
   
Thus NN NN O
antioxidants NN NN O
vary NN NN O
widely NN NN O
in NN NN O
potency NN NN O
as NN NN O
inhibitors NN NN O
of NN NN O
the NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
of NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
for NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
Coordinate NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
for NN NN O
inflammatory NN NN O
cytokines NN NN O
could NN NN O
provide NN NN O
a NN NN O
strategy NN NN O
for NN NN O
therapy NN NN O
of NN NN O
diseases NN NN O
with NN NN O
inflammatory NN NN O
pathogenesis NN NN O
and NN NN O
for NN NN O
septic NN NN O
shock NN NN O
. NN NN O
   
Calcineurin NN NN O
potentiates NN NN O
activation NN NN O
of NN NN O
the NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
gene NN NN O
in NN NN O
T NN NN O
cells NN NN O
: NN NN O
involvement NN NN O
of NN NN O
the NN NN O
conserved NN NN O
lymphokine NN NN O
element NN NN O
0 NN NN O
. NN NN O
   
Granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
are NN NN O
produced NN NN O
by NN NN O
stimulation NN NN O
with NN NN O
phorbol NN NN O
- NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
A23187 NN NN O
) NN NN O
in NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
inhibited NN NN O
by NN NN O
immunosuppressive NN NN O
drugs NN NN O
such NN NN O
as NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
and NN NN O
FK506 NN NN O
. NN NN O
   
Earlier NN NN O
studies NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
showed NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
calcineurin NN NN O
( NN NN O
CN NN NN O
) NN NN O
, NN NN O
a NN NN O
Ca2 NN NN O
+ NN NN O
/ NN NN O
calmodulin NN NN B-Protein
- NN NN O
dependent NN NN O
protein NN NN O
phosphatase NN NN O
, NN NN O
can NN NN O
stimulate NN NN O
transcription NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
through NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
obtained NN NN O
evidence NN NN O
that NN NN O
transfection NN NN O
of NN NN O
the NN NN O
cDNAs NN NN O
for NN NN O
CN NN NN B-Protein
A NN NN I-Protein
( NN NN O
catalytic NN NN O
) NN NN O
and NN NN O
CN NN NN B-Protein
B NN NN I-Protein
( NN NN O
regulatory NN NN O
) NN NN O
subunits NN NN O
also NN NN O
augments NN NN O
transcription NN NN O
from NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
and NN NN O
recovers NN NN O
the NN NN O
transcription NN NN O
inhibited NN NN O
by NN NN O
CsA NN NN O
. NN NN O
   
The NN NN O
constitutively NN NN O
active NN NN O
type NN NN O
of NN NN O
the NN NN O
CN NN NN B-Protein
A NN NN I-Protein
subunit NN NN O
, NN NN O
which NN NN O
lacks NN NN O
the NN NN O
auto NN NN O
- NN NN O
inhibitory NN NN O
and NN NN O
calmodulin NN NN O
- NN NN O
binding NN NN O
domains NN NN O
, NN NN O
acts NN NN O
in NN NN O
synergy NN NN O
with NN NN O
PMA NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
from NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
. NN NN O
   
We NN NN O
also NN NN O
found NN NN O
that NN NN O
the NN NN O
active NN NN O
CN NN NN O
partially NN NN O
replaces NN NN O
calcium NN NN O
ionophore NN NN O
in NN NN O
synergy NN NN O
with NN NN O
PMA NN NN O
to NN NN O
induce NN NN O
expression NN NN O
of NN NN O
endogenous NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
By NN NN O
multimerizing NN NN O
the NN NN O
regulatory NN NN O
elements NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
one NN NN O
of NN NN O
the NN NN O
target NN NN O
sites NN NN O
for NN NN O
the NN NN O
CN NN NN O
action NN NN O
is NN NN O
the NN NN O
conserved NN NN O
lymphokine NN NN O
element NN NN O
0 NN NN O
( NN NN O
CLE0 NN NN O
) NN NN O
, NN NN O
located NN NN O
at NN NN O
positions NN NN O
between NN NN O
- NN NN O
54 NN NN O
and NN NN O
- NN NN O
40 NN NN O
. NN NN O
   
Mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
the NN NN O
CLE0 NN NN O
sequence NN NN O
has NN NN O
an NN NN O
AP1 NN NN O
- NN NN O
binding NN NN O
site NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
like NN NN O
factor NN NN O
, NN NN O
termed NN NN O
NF NN NN B-Protein
- NN NN I-Protein
CLE0 NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
CLE0 NN NN I-Protein
gamma NN NN I-Protein
binding NN NN O
is NN NN O
induced NN NN O
by NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
and NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
treatment NN NN O
with NN NN O
CsA NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
CN NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
coordinated NN NN O
induction NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
genes NN NN O
and NN NN O
that NN NN O
the NN NN O
CLE0 NN NN O
sequence NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
is NN NN O
a NN NN O
functional NN NN O
analogue NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
, NN NN O
which NN NN O
mediates NN NN O
signals NN NN O
downstream NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Central NN NN O
nervous NN NN O
system NN NN O
- NN NN O
derived NN NN O
cells NN NN O
express NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
that NN NN O
enhances NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
transcription NN NN O
in NN NN O
vitro NN NN O
and NN NN O
facilitates NN NN O
TAR NN NN O
- NN NN O
independent NN NN O
transactivation NN NN O
by NN NN O
Tat NN NN B-Protein
. NN NN O
   
The NN NN O
Tat NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
a NN NN O
potent NN NN O
activator NN NN O
of NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
. NN NN O
   
While NN NN O
in NN NN O
most NN NN O
cell NN NN O
types NN NN O
, NN NN O
activation NN NN O
requires NN NN O
interaction NN NN O
of NN NN O
Tat NN NN B-Protein
with NN NN O
the NN NN O
unusual NN NN O
transcription NN NN O
element NN NN O
TAR NN NN O
, NN NN O
astrocytic NN NN O
glial NN NN O
cells NN NN O
support NN NN O
TAR NN NN O
- NN NN O
independent NN NN O
transactivation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
by NN NN O
Tat NN NN B-Protein
. NN NN O
   
This NN NN O
alternative NN NN O
pathway NN NN O
of NN NN O
Tat NN NN B-Protein
activation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
viral NN NN O
enhancer NN NN O
, NN NN O
a NN NN O
kappa NN NN O
B NN NN O
domain NN NN O
capable NN NN O
of NN NN O
binding NN NN O
the NN NN O
prototypical NN NN O
form NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
present NN NN O
in NN NN O
many NN NN O
cell NN NN O
types NN NN O
, NN NN O
including NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Tat NN NN B-Protein
transactivation NN NN O
mediated NN NN O
by NN NN O
the NN NN O
kappa NN NN O
B NN NN O
domain NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
allow NN NN O
replication NN NN O
of NN NN O
TAR NN NN O
- NN NN O
deleted NN NN O
mutant NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
astrocytes NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
demonstrates NN NN O
the NN NN O
existence NN NN O
of NN NN O
kappa NN NN O
B NN NN O
- NN NN O
specific NN NN O
binding NN NN O
factors NN NN O
present NN NN O
in NN NN O
human NN NN O
glial NN NN O
astrocytes NN NN O
that NN NN O
differ NN NN O
from NN NN O
prototypical NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
novel NN NN O
astrocyte NN NN O
- NN NN O
derived NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
is NN NN O
retained NN NN O
on NN NN O
an NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
affinity NN NN O
column NN NN O
, NN NN O
while NN NN O
prototypical NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
from NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
is NN NN O
not NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
transcription NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
astrocyte NN NN O
- NN NN O
derived NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
factors NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
and NN NN O
that NN NN O
this NN NN O
activation NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
kappa NN NN O
B NN NN O
domain NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
TAR NN NN O
- NN NN O
independent NN NN O
transactivation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
is NN NN O
reproduced NN NN O
in NN NN O
vitro NN NN O
in NN NN O
an NN NN O
astrocyte NN NN O
factor NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
which NN NN O
correlates NN NN O
with NN NN O
kappa NN NN O
B NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
- NN NN O
enriched NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
An NN NN O
intricate NN NN O
arrangement NN NN O
of NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
Ets NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
regulates NN NN O
activity NN NN O
of NN NN O
the NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
integrin NN NN I-Protein
gene NN NN O
promoter NN NN O
. NN NN O
   
alpha NN NN B-Protein
4 NN NN I-Protein
integrins NN NN I-Protein
mediate NN NN O
cell NN NN O
- NN NN O
cell NN NN O
and NN NN O
cell NN NN O
- NN NN O
extracellular NN NN O
matrix NN NN O
interactions NN NN O
that NN NN O
are NN NN O
critical NN NN O
for NN NN O
maturation NN NN O
and NN NN O
function NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
as NN NN O
well NN NN O
as NN NN O
differentiation NN NN O
of NN NN O
skeletal NN NN O
muscle NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
examine NN NN O
molecular NN NN O
mechanisms NN NN O
controlling NN NN O
the NN NN O
pattern NN NN O
of NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
expression NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
constructs NN NN O
containing NN NN O
5 NN NN O
' NN NN O
deletion NN NN O
mutants NN NN O
of NN NN O
the NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
gene NN NN O
promoter NN NN O
was NN NN O
compared NN NN O
in NN NN O
transfection NN NN O
assays NN NN O
into NN NN O
cell NN NN O
lines NN NN O
that NN NN O
express NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
and NN NN O
cell NN NN O
lines NN NN O
that NN NN O
do NN NN O
not NN NN O
. NN NN O
   
The NN NN O
sequence NN NN O
between NN NN O
position NN NN O
- NN NN O
42 NN NN O
and NN NN O
- NN NN O
76 NN NN O
base NN NN O
pairs NN NN O
( NN NN O
bp NN NN O
) NN NN O
was NN NN O
required NN NN O
for NN NN O
efficient NN NN O
transcription NN NN O
in NN NN O
cells NN NN O
that NN NN O
express NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
, NN NN O
but NN NN O
it NN NN O
showed NN NN O
no NN NN O
activity NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
which NN NN O
do NN NN O
not NN NN O
express NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
. NN NN O
   
Three NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
Ets NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
found NN NN O
in NN NN O
this NN NN O
region NN NN O
: NN NN O
two NN NN O
adjacent NN NN O
sites NN NN O
at NN NN O
positions NN NN O
- NN NN O
50 NN NN O
and NN NN O
- NN NN O
54 NN NN O
bp NN NN O
and NN NN O
a NN NN O
more NN NN O
5 NN NN O
' NN NN O
site NN NN O
at NN NN O
position NN NN O
- NN NN O
67 NN NN O
bp NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
series NN NN O
of NN NN O
constructs NN NN O
containing NN NN O
deletions NN NN O
and NN NN O
mutations NN NN O
in NN NN O
this NN NN O
region NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
3 NN NN O
' NN NN O
- NN NN O
most NN NN O
site NN NN O
alone NN NN O
was NN NN O
sufficient NN NN O
for NN NN O
binding NN NN O
GA NN NN B-Protein
- NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
GABP NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
/ NN NN O
GABP NN NN O
beta NN NN O
and NN NN O
for NN NN O
a NN NN O
low NN NN O
level NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
When NN NN O
all NN NN O
three NN NN O
sites NN NN O
were NN NN O
present NN NN O
, NN NN O
a NN NN O
second NN NN O
complex NN NN O
"""""""" NN NN O
a NN NN O
"""""""" NN NN O
was NN NN O
detected NN NN O
, NN NN O
which NN NN O
contains NN NN O
an NN NN O
unknown NN NN O
member NN NN O
of NN NN O
the NN NN O
Ets NN NN O
family NN NN O
. NN NN O
   
Formation NN NN O
of NN NN O
complex NN NN O
a NN NN O
was NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
and NN NN O
correlated NN NN O
with NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
most NN NN O
Ets NN NN O
site NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
binding NN NN O
to NN NN O
GABP NN NN B-Protein
alpha NN NN I-Protein
/ NN NN O
GABP NN NN O
beta NN NN O
, NN NN O
but NN NN O
it NN NN O
eliminated NN NN O
a NN NN O
. NN NN O
   
Concomitant NN NN O
with NN NN O
this NN NN O
loss NN NN O
of NN NN O
a NN NN O
, NN NN O
a NN NN O
new NN NN O
Ets NN NN O
- NN NN O
1 NN NN O
- NN NN O
containing NN NN O
complex NN NN O
"""""""" NN NN O
c NN NN O
"""""""" NN NN O
appeared NN NN O
. NN NN O
   
Complex NN NN O
c NN NN O
substituted NN NN O
efficiently NN NN O
for NN NN O
complex NN NN O
a NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
although NN NN O
neither NN NN O
of NN NN O
the NN NN O
two NN NN O
5 NN NN O
' NN NN O
- NN NN O
most NN NN O
Ets NN NN O
sites NN NN O
alone NN NN O
binds NN NN O
nuclear NN NN O
protein NN NN O
, NN NN O
they NN NN O
appear NN NN O
to NN NN O
act NN NN O
as NN NN O
modulators NN NN O
which NN NN O
control NN NN O
the NN NN O
pattern NN NN O
of NN NN O
Ets NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
the NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
gene NN NN O
promoter NN NN O
. NN NN O
   
This NN NN O
arrangement NN NN O
of NN NN O
Ets NN NN O
sites NN NN O
, NN NN O
coupled NN NN O
with NN NN O
the NN NN O
tissue NN NN O
- NN NN O
and NN NN O
developmental NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
Ets NN NN O
members NN NN O
, NN NN O
likely NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
defining NN NN O
the NN NN O
pattern NN NN O
of NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
integrin NN NN I-Protein
. NN NN O
   
Lipopolysaccharide NN NN O
induction NN NN O
of NN NN O
tissue NN NN O
factor NN NN O
gene NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
to NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
site NN NN O
. NN NN O
   
Exposure NN NN O
of NN NN O
monocytic NN NN O
cells NN NN O
to NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
activates NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
proteins NN NN O
and NN NN O
leads NN NN O
to NN NN O
the NN NN O
rapid NN NN O
induction NN NN O
of NN NN O
inflammatory NN NN O
gene NN NN O
products NN NN O
, NN NN O
including NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
. NN NN O
   
TF NN NN B-Protein
is NN NN O
the NN NN O
primary NN NN O
cellular NN NN O
initiator NN NN O
of NN NN O
the NN NN O
coagulation NN NN O
protease NN NN O
cascades NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
the NN NN O
characterization NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
complex NN NN O
from NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
that NN NN O
bound NN NN O
to NN NN O
a NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
site NN NN O
, NN NN O
5 NN NN O
' NN NN O
- NN NN O
CGGAGTTTCC NN NN O
- NN NN O
3 NN NN O
' NN NN O
, NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
TF NN NN B-Protein
gene NN NN O
. NN NN O
   
This NN NN O
nuclear NN NN O
complex NN NN O
was NN NN O
activated NN NN O
by NN NN O
LPS NN NN O
with NN NN O
kinetics NN NN O
that NN NN O
preceded NN NN O
induction NN NN O
of NN NN O
the NN NN O
TF NN NN B-Protein
gene NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
binding NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
TF NN NN B-Protein
site NN NN O
bound NN NN O
translated NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
homodimers NN NN O
but NN NN O
not NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
or NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
Base NN NN O
- NN NN O
pair NN NN O
substitutions NN NN O
in NN NN O
the NN NN O
TF NN NN B-Protein
site NN NN O
indicated NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
cytosine NN NN O
at NN NN O
position NN NN O
1 NN NN O
precluded NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
In NN NN O
fact NN NN O
, NN NN O
under NN NN O
low NN NN O
- NN NN O
ionic NN NN O
- NN NN O
strength NN NN O
conditions NN NN O
, NN NN O
the NN NN O
TF NN NN B-Protein
complex NN NN O
did NN NN O
not NN NN O
migrate NN NN O
with NN NN O
translated NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
dimers NN NN O
but NN NN O
instead NN NN O
comigrated NN NN O
with NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
dimers NN NN O
. NN NN O
   
Antibodies NN NN O
against NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Rel NN NN O
proteins NN NN O
and NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
studies NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
and NN NN O
the NN NN O
absence NN NN O
of NN NN O
p50 NN NN B-Protein
in NN NN O
the NN NN O
TF NN NN B-Protein
complex NN NN O
and NN NN O
further NN NN O
showed NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
selectively NN NN O
bound NN NN O
to NN NN O
the NN NN O
TF NN NN B-Protein
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
site NN NN O
. NN NN O
   
Functional NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
the NN NN O
TF NN NN B-Protein
site NN NN O
conferred NN NN O
LPS NN NN O
inducibility NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
and NN NN O
was NN NN O
transactivated NN NN O
by NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
or NN NN O
p65 NN NN B-Protein
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
binding NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
to NN NN O
a NN NN O
novel NN NN O
kappa NN NN O
B NN NN O
- NN NN O
like NN NN O
site NN NN O
mediated NN NN O
LPS NN NN O
induction NN NN O
of NN NN O
TF NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
by NN NN O
leukemia NN NN B-Protein
inhibitory NN NN I-Protein
factor NN NN I-Protein
. NN NN O
   
This NN NN O
study NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
leukemia NN NN B-Protein
inhibitory NN NN I-Protein
factor NN NN I-Protein
( NN NN O
LIF NN NN B-Protein
) NN NN O
on NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
replication NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
( NN NN O
MNP NN NN O
) NN NN O
. NN NN O
   
LIF NN NN B-Protein
induced NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
p24 NN NN B-Protein
antigen NN NN I-Protein
production NN NN O
in NN NN O
the NN NN O
chronically NN NN O
infected NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
U1 NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
and NN NN O
time NN NN O
kinetics NN NN O
of NN NN O
the NN NN O
LIF NN NN B-Protein
effects NN NN O
were NN NN O
similar NN NN O
to NN NN O
interleukin NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
, NN NN O
other NN NN O
cytokines NN NN O
known NN NN O
to NN NN O
induce NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
this NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
To NN NN O
characterize NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
these NN NN O
LIF NN NN B-Protein
effects NN NN O
, NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
mRNA NN NN O
, NN NN O
activation NN NN O
of NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kB NN NN O
, NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
, NN NN O
and NN NN O
potential NN NN O
interactions NN NN O
with NN NN O
other NN NN O
cytokines NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
LIF NN NN B-Protein
increased NN NN O
steady NN NN O
- NN NN O
state NN NN O
levels NN NN O
of NN NN O
HIV NN NN O
mRNA NN NN O
at NN NN O
2 NN NN O
. NN NN O
0 NN NN O
, NN NN O
4 NN NN O
. NN NN O
3 NN NN O
, NN NN O
and NN NN O
9 NN NN O
. NN NN O
2 NN NN O
kB NN NN O
. NN NN O
   
This NN NN O
was NN NN O
detectable NN NN O
by NN NN O
24 NN NN O
h NN NN O
and NN NN O
persisted NN NN O
until NN NN O
72 NN NN O
h NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
binding NN NN O
protein NN NN O
NF NN NN O
- NN NN O
kB NN NN O
is NN NN O
a NN NN O
central NN NN O
mediator NN NN O
in NN NN O
cytokine NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
transcription NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kB NN NN O
levels NN NN O
were NN NN O
higher NN NN O
in NN NN O
unstimulated NN NN O
U1 NN NN O
cells NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
parent NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
. NN NN O
   
In NN NN O
both NN NN O
cell NN NN O
lines NN NN O
LIF NN NN B-Protein
increased NN NN O
NF NN NN O
- NN NN O
kB NN NN O
activity NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
and NN NN O
HIV NN NN O
replication NN NN O
by NN NN O
cytokines NN NN O
are NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
dependent NN NN O
on NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
. NN NN O
   
The NN NN O
oxygen NN NN O
radical NN NN O
scavenger NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
, NN NN O
but NN NN O
not NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
nitric NN NN O
oxide NN NN O
synthase NN NN O
, NN NN O
inhibited NN NN O
LIF NN NN B-Protein
- NN NN O
induced NN NN O
HIV NN NN O
replication NN NN O
. NN NN O
   
LIF NN NN B-Protein
induces NN NN O
the NN NN O
production NN NN O
of NN NN O
other NN NN O
cytokines NN NN O
in NN NN O
monocytes NN NN O
but NN NN O
its NN NN O
effects NN NN O
on NN NN O
HIV NN NN O
replication NN NN O
were NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
antibodies NN NN O
to NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
TNF NN NN O
, NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
These NN NN O
results NN NN O
identify NN NN O
LIF NN NN B-Protein
as NN NN O
a NN NN O
stimulus NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tat NN NN B-Protein
upregulates NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Dysregulation NN NN O
of NN NN O
cytokines NN NN O
secreted NN NN O
by NN NN O
T NN NN O
cells NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
AIDS NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
effects NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tat NN NN B-Protein
on NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
expression NN NN O
, NN NN O
we NN NN O
used NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
- NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
constructs NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
secreting NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
as NN NN O
a NN NN O
model NN NN O
system NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
induced NN NN O
a NN NN O
five NN NN O
- NN NN O
to NN NN O
eightfold NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
phytohemagglutinin NN NN B-Protein
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
was NN NN O
increased NN NN O
more NN NN O
than NN NN O
twofold NN NN O
in NN NN O
both NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
primary NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
extracellular NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
protein NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
mRNA NN NN O
suggested NN NN O
that NN NN O
Tat NN NN B-Protein
exerts NN NN O
its NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
primarily NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
site NN NN O
at NN NN O
positions NN NN O
- NN NN O
206 NN NN O
to NN NN O
- NN NN O
195 NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
was NN NN O
required NN NN O
but NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
the NN NN O
Tat NN NN B-Protein
effect NN NN O
. NN NN O
   
The NN NN O
Tat NN NN B-Protein
- NN NN O
mediated NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activity NN NN O
could NN NN O
selectively NN NN O
be NN NN O
blocked NN NN O
by NN NN O
antisense NN NN O
tat NN NN B-Protein
or NN NN O
- NN NN O
unlike NN NN O
the NN NN O
analogous NN NN O
effect NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphotropic NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
- NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
. NN NN O
   
The NN NN O
observed NN NN O
increase NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
levels NN NN O
might NN NN O
facilitate NN NN O
virus NN NN O
spread NN NN O
from NN NN O
or NN NN O
to NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
might NN NN O
contribute NN NN O
to NN NN O
the NN NN O
hypergammaglobulinemia NN NN O
or NN NN O
, NN NN O
together NN NN O
with NN NN O
other NN NN O
cytokines NN NN O
found NN NN O
to NN NN O
be NN NN O
dysregulated NN NN O
, NN NN O
the NN NN O
T NN NN O
- NN NN O
helper NN NN O
cell NN NN O
dysfunctions NN NN O
observed NN NN O
in NN NN O
AIDS NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
macrophage NN NN O
transcription NN NN O
factor NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
directs NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
The NN NN O
macrophage NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
M NN NN I-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
from NN NN O
two NN NN O
distinct NN NN O
promoters NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
and NN NN O
the NN NN O
placenta NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
further NN NN O
understand NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
commitment NN NN O
of NN NN O
multipotential NN NN O
progenitors NN NN O
to NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
, NN NN O
we NN NN O
have NN NN O
initiated NN NN O
an NN NN O
investigation NN NN O
of NN NN O
the NN NN O
factors NN NN O
which NN NN O
activate NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
very NN NN O
early NN NN O
during NN NN O
the NN NN O
monocyte NN NN O
differentiation NN NN O
process NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
directs NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
in NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
. NN NN O
   
Since NN NN O
one NN NN O
of NN NN O
the NN NN O
few NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
monocyte NN NN O
genes NN NN O
is NN NN O
the NN NN O
macrophage NN NN O
- NN NN O
and NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factor NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
binds NN NN O
and NN NN O
activates NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
both NN NN O
in NN NN O
vitro NN NN O
- NN NN O
translated NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
from NN NN O
nuclear NN NN O
extracts NN NN O
bind NN NN O
to NN NN O
a NN NN O
specific NN NN O
site NN NN O
in NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
just NN NN O
upstream NN NN O
from NN NN O
the NN NN O
major NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
Mutations NN NN O
in NN NN O
this NN NN O
site NN NN O
which NN NN O
eliminate NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
decrease NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
activity NN NN O
significantly NN NN O
in NN NN O
macrophage NN NN O
cell NN NN O
lines NN NN O
only NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
transactivates NN NN O
the NN NN O
M NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
promoter NN NN O
in NN NN O
nonmacrophage NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
macrophage NN NN O
gene NN NN O
regulation NN NN O
and NN NN O
development NN NN O
by NN NN O
directing NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
receptor NN NN O
for NN NN O
a NN NN O
key NN NN O
macrophage NN NN O
growth NN NN O
factor NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
downmodulates NN NN O
erythroid NN NN O
differentiation NN NN O
and NN NN O
GATA1 NN NN B-Protein
expression NN NN O
in NN NN O
purified NN NN O
adult NN NN O
- NN NN O
progenitor NN NN O
culture NN NN O
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
is NN NN O
an NN NN O
important NN NN O
morphogen NN NN O
in NN NN O
vertebrate NN NN O
development NN NN O
, NN NN O
a NN NN O
normal NN NN O
constituent NN NN O
in NN NN O
human NN NN O
adult NN NN O
blood NN NN O
and NN NN O
is NN NN O
also NN NN O
involved NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
cell NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
in NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
RA NN NN O
on NN NN O
normal NN NN O
hematopoiesis NN NN O
by NN NN O
using NN NN O
early NN NN O
hematopoietic NN NN O
progenitor NN NN O
cells NN NN O
( NN NN O
HPC NN NN O
) NN NN O
stringently NN NN O
purified NN NN O
from NN NN O
adult NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O
   
In NN NN O
clonogenetic NN NN O
fetal NN NN O
calf NN NN O
serum NN NN O
- NN NN O
supplemented NN NN O
( NN NN O
FCS NN NN O
+ NN NN O
) NN NN O
or NN NN O
- NN NN O
nonsupplemented NN NN O
( NN NN O
FCS NN NN O
- NN NN O
) NN NN O
culture NN NN O
treated NN NN O
with NN NN O
saturating NN NN O
levels NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
and NN NN O
erythropoietin NN NN B-Protein
( NN NN O
Ep NN NN B-Protein
) NN NN O
( NN NN O
combined NN NN O
with NN NN O
c NN NN B-Protein
- NN NN I-Protein
kit NN NN I-Protein
ligand NN NN I-Protein
in NN NN O
FCS NN NN O
( NN NN O
- NN NN O
) NN NN O
- NN NN O
culture NN NN O
conditions NN NN O
) NN NN O
, NN NN O
RA NN NN O
induces NN NN O
a NN NN O
dramatic NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
shift NN NN O
from NN NN O
erythroid NN NN O
to NN NN O
granulomonocytic NN NN O
colony NN NN O
formation NN NN O
, NN NN O
the NN NN O
latter NN NN O
colonies NN NN O
being NN NN O
essentially NN NN O
represented NN NN O
by NN NN O
granulocytic NN NN O
clones NN NN O
. NN NN O
   
This NN NN O
shift NN NN O
is NN NN O
apparently NN NN O
not NN NN O
caused NN NN O
by NN NN O
a NN NN O
recruitment NN NN O
phenomenon NN NN O
, NN NN O
because NN NN O
in NN NN O
FCS NN NN O
+ NN NN O
culture NN NN O
, NN NN O
the NN NN O
total NN NN O
number NN NN O
of NN NN O
colonies NN NN O
is NN NN O
not NN NN O
significantly NN NN O
modified NN NN O
by NN NN O
RA NN NN O
addition NN NN O
. NN NN O
   
In NN NN O
FCS NN NN O
- NN NN O
liquid NN NN O
- NN NN O
suspension NN NN O
culture NN NN O
supplemented NN NN O
with NN NN O
saturating NN NN O
Ep NN NN B-Protein
level NN NN O
and NN NN O
low NN NN O
- NN NN O
dose NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
/ NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
, NN NN O
adult NN NN O
HPC NN NN O
undergo NN NN O
unilineage NN NN O
erythropoietic NN NN O
differentiation NN NN O
: NN NN O
Here NN NN O
again NN NN O
, NN NN O
treatment NN NN O
with NN NN O
high NN NN O
- NN NN O
dose NN NN O
RA NN NN O
induces NN NN O
a NN NN O
shift NN NN O
from NN NN O
the NN NN O
erythroid NN NN O
to NN NN O
granulocytic NN NN O
differentiation NN NN O
pathway NN NN O
. NN NN O
   
Studies NN NN O
on NN NN O
RA NN NN O
time NN NN O
- NN NN O
response NN NN O
or NN NN O
pulse NN NN O
treatment NN NN O
in NN NN O
semisolid NN NN O
or NN NN O
liquid NN NN O
culture NN NN O
show NN NN O
that NN NN O
early NN NN O
RA NN NN O
addition NN NN O
is NN NN O
most NN NN O
effective NN NN O
, NN NN O
thus NN NN O
indicating NN NN O
that NN NN O
early NN NN O
but NN NN O
not NN NN O
late NN NN O
HPC NN NN O
are NN NN O
sensitive NN NN O
to NN NN O
its NN NN O
action NN NN O
. NN NN O
   
We NN NN O
then NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
master NN NN O
GATA1 NN NN B-Protein
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
a NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
required NN NN O
for NN NN O
normal NN NN O
erythroid NN NN O
development NN NN O
; NN NN O
addition NN NN O
of NN NN O
RA NN NN O
to NN NN O
HPC NN NN O
stimulated NN NN O
into NN NN O
unilineage NN NN O
erythropoietic NN NN O
differentiation NN NN O
in NN NN O
liquid NN NN O
culture NN NN O
caused NN NN O
a NN NN O
virtually NN NN O
complete NN NN O
inhibition NN NN O
of NN NN O
GATA1 NN NN B-Protein
mRNA NN NN O
induction NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
RA NN NN O
directly NN NN O
inhibits NN NN O
the NN NN O
erythroid NN NN O
differentiation NN NN O
program NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
early NN NN O
adult NN NN O
HPC NN NN O
, NN NN O
and NN NN O
may NN NN O
lead NN NN O
to NN NN O
a NN NN O
shift NN NN O
from NN NN O
the NN NN O
erythroid NN NN O
to NN NN O
granulocytic NN NN O
differentiation NN NN O
pathway NN NN O
. NN NN O
   
This NN NN O
phenomenon NN NN O
is NN NN O
correlated NN NN O
with NN NN O
inhibition NN NN O
of NN NN O
GATA1 NN NN B-Protein
induction NN NN O
in NN NN O
the NN NN O
early NN NN O
stages NN NN O
of NN NN O
erythropoietic NN NN O
differentiation NN NN O
. NN NN O
   
Comparative NN NN O
analysis NN NN O
of NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
) NN NN O
complex NN NN O
in NN NN O
human NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
is NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
that NN NN O
binds NN NN O
to NN NN O
sequences NN NN O
in NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
promoter NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
largely NN NN O
responsible NN NN O
for NN NN O
the NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
inducibility NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
showed NN NN O
that NN NN O
specific NN NN O
NFAT NN NN O
binding NN NN O
activity NN NN O
could NN NN O
also NN NN O
be NN NN O
induced NN NN O
in NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
B NN NN O
cell NN NN O
NFAT NN NN O
complex NN NN O
, NN NN O
however NN NN O
, NN NN O
was NN NN O
not NN NN O
functional NN NN O
, NN NN O
since NN NN O
it NN NN O
failed NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
from NN NN O
an NN NN O
NFAT NN NN O
- NN NN O
driven NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
construct NN NN O
. NN NN O
   
Competition NN NN O
with NN NN O
an NN NN O
AP NN NN O
- NN NN O
1 NN NN O
motif NN NN O
or NN NN O
with NN NN O
anti NN NN O
- NN NN O
Jun NN NN O
and NN NN O
anti NN NN O
- NN NN O
Fos NN NN O
antibodies NN NN O
abolished NN NN O
binding NN NN O
to NN NN O
the NN NN O
NFAT NN NN O
motif NN NN O
in NN NN O
both NN NN O
T NN NN O
and NN NN O
B NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
that NN NN O
Jun NN NN O
and NN NN O
Fos NN NN O
are NN NN O
critical NN NN O
for NN NN O
NFAT NN NN O
complex NN NN O
formation NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Purified NN NN O
recombinant NN NN O
Jun NN NN O
and NN NN O
Fos NN NN O
proteins NN NN O
failed NN NN O
to NN NN O
bind NN NN O
directly NN NN O
to NN NN O
the NN NN O
NFAT NN NN O
motif NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
combined NN NN O
with NN NN O
unstimulated NN NN O
B NN NN O
or NN NN O
T NN NN O
cell NN NN O
extracts NN NN O
, NN NN O
full NN NN O
- NN NN O
length NN NN O
, NN NN O
but NN NN O
not NN NN O
truncated NN NN O
, NN NN O
Jun NN NN O
/ NN NN O
Fos NN NN O
heterodimers NN NN O
were NN NN O
able NN NN O
to NN NN O
form NN NN O
an NN NN O
NFAT NN NN O
complex NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
constitutively NN NN O
expressed NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
necessary NN NN O
for NN NN O
the NN NN O
formation NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
complex NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
An NN NN O
NFAT NN NN O
oligonucleotide NN NN O
carrying NN NN O
mutations NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
purine NN NN O
- NN NN O
rich NN NN O
part NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
sequence NN NN O
failed NN NN O
to NN NN O
form NN NN O
a NN NN O
complex NN NN O
and NN NN O
to NN NN O
compete NN NN O
with NN NN O
the NN NN O
wild NN NN O
type NN NN O
motif NN NN O
for NN NN O
NFAT NN NN O
complex NN NN O
formation NN NN O
in NN NN O
both NN NN O
T NN NN O
and NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
propose NN NN O
a NN NN O
model NN NN O
whereby NN NN O
a NN NN O
core NN NN O
NFAT NN NN O
complex NN NN O
consisting NN NN O
of NN NN O
Jun NN NN O
, NN NN O
Fos NN NN O
, NN NN O
and NN NN O
a NN NN O
constitutive NN NN O
nuclear NN NN O
factor NN NN O
is NN NN O
formed NN NN O
in NN NN O
both NN NN O
T NN NN O
and NN NN O
B NN NN O
cells NN NN O
, NN NN O
but NN NN O
an NN NN O
additional NN NN O
factor NN NN O
and NN NN O
/ NN NN O
or NN NN O
post NN NN O
- NN NN O
translational NN NN O
modification NN NN O
of NN NN O
a NN NN O
factor NN NN O
, NN NN O
missing NN NN O
in NN NN O
B NN NN O
cells NN NN O
, NN NN O
might NN NN O
be NN NN O
required NN NN O
for NN NN O
transactivation NN NN O
by NN NN O
NFAT NN NN O
. NN NN O
   
Differential NN NN O
autoregulation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
expression NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
and NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
expression NN NN O
by NN NN O
its NN NN O
cognate NN NN O
ligand NN NN O
was NN NN O
examined NN NN O
in NN NN O
the NN NN O
glucocorticoid NN NN O
- NN NN O
sensitive NN NN O
human NN NN O
leukemic NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
and NN NN O
in NN NN O
the NN NN O
human NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
IM NN NN O
- NN NN O
9 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
decrease NN NN O
in NN NN O
GR NN NN B-Protein
mRNA NN NN O
seen NN NN O
in NN NN O
IM NN NN O
- NN NN O
9 NN NN O
cells NN NN O
after NN NN O
treatment NN NN O
with NN NN O
1 NN NN O
microM NN NN O
dexamethasone NN NN O
for NN NN O
16 NN NN O
- NN NN O
18 NN NN O
h NN NN O
, NN NN O
treatment NN NN O
of NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
an NN NN O
8 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
GR NN NN B-Protein
mRNA NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
and NN NN O
RNase NN NN O
protection NN NN O
analysis NN NN O
, NN NN O
with NN NN O
a NN NN O
corresponding NN NN O
3 NN NN O
- NN NN O
to NN NN O
4 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
GR NN NN B-Protein
protein NN NN O
. NN NN O
   
Half NN NN O
- NN NN O
maximal NN NN O
induction NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
in NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
was NN NN O
observed NN NN O
between NN NN O
10 NN NN O
- NN NN O
100 NN NN O
nM NN NN O
dexamethasone NN NN O
, NN NN O
and NN NN O
inclusion NN NN O
of NN NN O
1 NN NN O
microM NN NN O
RU NN NN O
38486 NN NN O
completely NN NN O
blocked NN NN O
the NN NN O
effects NN NN O
of NN NN O
100 NN NN O
nM NN NN O
dexamethasone NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
positive NN NN O
autoregulation NN NN O
of NN NN O
GR NN NN B-Protein
expression NN NN O
in NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
is NN NN O
a NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
response NN NN O
. NN NN O
   
Positive NN NN O
autoregulation NN NN O
of NN NN O
GR NN NN B-Protein
expression NN NN O
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
resistant NN NN O
CEM NN NN O
- NN NN O
C1 NN NN O
cells NN NN O
, NN NN O
which NN NN O
contain NN NN O
functional NN NN O
GR NN NN B-Protein
, NN NN O
but NN NN O
whose NN NN O
growth NN NN O
is NN NN O
unaffected NN NN O
by NN NN O
glucocorticoids NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
positive NN NN O
autoregulation NN NN O
is NN NN O
neither NN NN O
a NN NN O
consequence NN NN O
nor NN NN O
the NN NN O
sole NN NN O
cause NN NN O
of NN NN O
growth NN NN O
arrest NN NN O
. NN NN O
   
The NN NN O
degree NN NN O
of NN NN O
negative NN NN O
autoregulation NN NN O
in NN NN O
IM NN NN O
- NN NN O
9 NN NN O
cells NN NN O
and NN NN O
positive NN NN O
autoregulation NN NN O
in NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
with NN NN O
cycloheximide NN NN O
. NN NN O
   
Measurement NN NN O
of NN NN O
GR NN NN B-Protein
mRNA NN NN O
turnover NN NN O
in NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
treated NN NN O
with NN NN O
actinomycin NN NN O
- NN NN O
D NN NN O
revealed NN NN O
a NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
2 NN NN O
. NN NN O
5 NN NN O
h NN NN O
, NN NN O
which NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
dexamethasone NN NN O
treatment NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
half NN NN O
- NN NN O
life NN NN O
was NN NN O
determined NN NN O
in NN NN O
IM NN NN O
- NN NN O
9 NN NN O
cells NN NN O
and NN NN O
was NN NN O
also NN NN O
unaffected NN NN O
by NN NN O
steroid NN NN O
treatment NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
interpretation NN NN O
that NN NN O
glucocorticoid NN NN O
- NN NN O
mediated NN NN O
autoregulation NN NN O
of NN NN O
GR NN NN B-Protein
expression NN NN O
is NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
primary NN NN O
transcriptional NN NN O
response NN NN O
. NN NN O
   
Occurrence NN NN O
of NN NN O
a NN NN O
silencer NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
in NN NN O
naive NN NN O
but NN NN O
not NN NN O
in NN NN O
memory NN NN O
resting NN NN O
T NN NN O
helper NN NN O
lymphocytes NN NN O
. NN NN O
   
In NN NN O
the NN NN O
immune NN NN O
system NN NN O
the NN NN O
first NN NN O
activation NN NN O
of NN NN O
a NN NN O
naive NN NN O
T NN NN O
cell NN NN O
by NN NN O
antigen NN NN O
is NN NN O
a NN NN O
key NN NN O
step NN NN O
in NN NN O
the NN NN O
shaping NN NN O
of NN NN O
the NN NN O
peripheral NN NN O
T NN NN O
cell NN NN O
specificity NN NN O
repertoire NN NN O
and NN NN O
maintenance NN NN O
of NN NN O
self NN NN O
- NN NN O
tolerance NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
analysis NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
activation NN NN O
shows NN NN O
that NN NN O
naive NN NN O
human NN NN O
helper NN NN O
T NN NN O
cells NN NN O
( NN NN O
cord NN NN O
blood NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
adult NN NN O
CD4 NN NN B-Protein
+ NN NN O
CD45RO NN NN B-Protein
- NN NN O
T NN NN O
cells NN NN O
) NN NN O
regulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
by NN NN O
a NN NN O
mechanism NN NN O
involving NN NN O
both NN NN O
a NN NN O
silencer NN NN O
and NN NN O
an NN NN O
activator NN NN O
acting NN NN O
on NN NN O
the NN NN O
purine NN NN O
- NN NN O
rich NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
elements NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
sites NN NN O
) NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
memory NN NN O
cells NN NN O
, NN NN O
either NN NN O
in NN NN O
vitro NN NN O
activated NN NN O
helper NN NN O
T NN NN O
cells NN NN O
reverting NN NN O
to NN NN O
a NN NN O
resting NN NN O
state NN NN O
, NN NN O
or NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
( NN NN O
memory NN NN O
) NN NN O
clones NN NN O
, NN NN O
or NN NN O
CD4 NN NN B-Protein
+ NN NN O
CD45RO NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
isolated NN NN O
ex NN NN O
vivo NN NN O
, NN NN O
no NN NN O
longer NN NN O
have NN NN O
a NN NN O
silencer NN NN O
. NN NN O
   
Their NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
seems NN NN O
to NN NN O
be NN NN O
controlled NN NN O
solely NN NN O
by NN NN O
the NN NN O
transition NN NN O
from NN NN O
inactive NN NN O
to NN NN O
active NN NN O
functional NN NN O
state NN NN O
of NN NN O
a NN NN O
positive NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
to NN NN O
these NN NN O
promoter NN NN O
elements NN NN O
as NN NN O
well NN NN O
as NN NN O
its NN NN O
cytoplasmic NN NN O
or NN NN O
nuclear NN NN O
location NN NN O
: NN NN O
in NN NN O
resting NN NN O
memory NN NN O
T NN NN O
cells NN NN O
the NN NN O
activator NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
and NN NN O
is NN NN O
inactive NN NN O
, NN NN O
whereas NN NN O
in NN NN O
stimulated NN NN O
cells NN NN O
it NN NN O
is NN NN O
functional NN NN O
in NN NN O
promoting NN NN O
transcription NN NN O
and NN NN O
now NN NN O
resides NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
the NN NN O
main NN NN O
T NN NN O
cell NN NN O
growth NN NN O
factor NN NN O
changes NN NN O
irreversibly NN NN O
after NN NN O
the NN NN O
first NN NN O
encounter NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
antigen NN NN O
. NN NN O
   
It NN NN O
is NN NN O
most NN NN O
likely NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
silencer NN NN O
contributes NN NN O
to NN NN O
the NN NN O
more NN NN O
stringent NN NN O
activation NN NN O
requirements NN NN O
of NN NN O
naive NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
production NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
by NN NN O
protein NN NN B-Protein
phosphatase NN NN I-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
inhibitors NN NN O
. NN NN O
   
Protein NN NN B-Protein
phosphatases NN NN I-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
are NN NN O
important NN NN O
in NN NN O
regulating NN NN O
cellular NN NN O
functions NN NN O
by NN NN O
controlling NN NN O
the NN NN O
phosphorylation NN NN O
state NN NN O
of NN NN O
their NN NN O
substrates NN NN O
. NN NN O
   
In NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
the NN NN O
inhibitors NN NN O
of NN NN O
these NN NN O
phosphatases NN NN O
, NN NN O
okadaic NN NN O
acid NN NN O
and NN NN O
calyculin NN NN O
A NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
increase NN NN O
the NN NN O
mRNA NN NN O
accumulation NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
increased NN NN O
mRNA NN NN O
accumulation NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
primarily NN NN O
because NN NN O
of NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
transcription NN NN O
rate NN NN O
of NN NN O
the NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
genes NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
gene NN NN O
transcription NN NN O
may NN NN O
be NN NN O
caused NN NN O
by NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
activities NN NN O
, NN NN O
including NN NN O
those NN NN O
of NN NN O
AP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
by NN NN O
these NN NN O
protein NN NN O
phosphatase NN NN O
inhibitors NN NN O
. NN NN O
   
Okadaic NN NN O
acid NN NN O
increased NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
precursor NN NN O
and NN NN O
mature NN NN O
forms NN NN O
and NN NN O
their NN NN O
secretion NN NN O
. NN NN O
   
This NN NN O
increased NN NN O
processing NN NN O
and NN NN O
secretion NN NN O
correlated NN NN O
with NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
convertase NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
. NN NN O
   
The NN NN O
stimulation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
was NN NN O
more NN NN O
modest NN NN O
than NN NN O
that NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
precursor NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
alpha NN NN I-Protein
cytokine NN NN O
was NN NN O
increased NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
protein NN NN B-Protein
phosphatase NN NN I-Protein
1 NN NN I-Protein
and NN NN O
2A NN NN B-Protein
inhibitors NN NN O
exert NN NN O
multiple NN NN O
effects NN NN O
on NN NN O
cytokine NN NN O
production NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
suggest NN NN O
that NN NN O
these NN NN O
two NN NN O
phosphatases NN NN O
play NN NN O
important NN NN O
roles NN NN O
in NN NN O
regulating NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
production NN NN O
. NN NN O
   
Human NN NN O
CD3 NN NN B-Protein
- NN NN O
CD16 NN NN B-Protein
+ NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
express NN NN O
the NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
T NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
an NN NN O
unrearranged NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
kb NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
transcript NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
T NN NN B-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
( NN NN I-Protein
TcR NN NN I-Protein
) NN NN I-Protein
delta NN NN I-Protein
transcripts NN NN O
expressed NN NN O
by NN NN O
CD3 NN NN B-Protein
- NN NN O
CD16 NN NN B-Protein
+ NN NN O
cells NN NN O
and NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
these NN NN O
cells NN NN O
expressed NN NN O
the NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
T NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
the NN NN O
recombination NN NN B-Protein
- NN NN I-Protein
activating NN NN I-Protein
gene NN NN I-Protein
( NN NN I-Protein
RAG NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Multiple NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
transcripts NN NN O
deriving NN NN O
from NN NN O
an NN NN O
unrearranged NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
gene NN NN O
were NN NN O
detected NN NN O
in NN NN O
both NN NN O
polyclonal NN NN O
and NN NN O
clonal NN NN O
CD3 NN NN B-Protein
- NN NN O
CD16 NN NN B-Protein
+ NN NN O
natural NN NN O
killer NN NN O
( NN NN O
NK NN NN O
) NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Two NN NN O
unrearranged NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
transcripts NN NN O
had NN NN O
a NN NN O
size NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
functional NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
mRNA NN NN O
( NN NN O
2 NN NN O
. NN NN O
3 NN NN O
and NN NN O
1 NN NN O
. NN NN O
3 NN NN O
kb NN NN O
) NN NN O
found NN NN O
in NN NN O
TcR NN NN B-Protein
gamma NN NN I-Protein
/ NN NN O
delta NN NN B-Protein
+ NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
of NN NN O
nine NN NN O
different NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
kb NN NN O
cDNA NN NN O
clones NN NN O
obtained NN NN O
from NN NN O
NK NN NN O
- NN NN O
derived NN NN O
polyA NN NN O
+ NN NN O
RNA NN NN O
confirmed NN NN O
that NN NN O
they NN NN O
corresponded NN NN O
to NN NN O
an NN NN O
unrearranged NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
gene NN NN O
. NN NN O
   
These NN NN O
cDNA NN NN O
were NN NN O
2343 NN NN O
bp NN NN O
long NN NN O
and NN NN O
their NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
was NN NN O
located NN NN O
814 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
J NN NN O
delta NN NN O
1 NN NN O
segment NN NN O
. NN NN O
   
The NN NN O
sequence NN NN O
located NN NN O
upstream NN NN O
of NN NN O
the NN NN O
J NN NN O
delta NN NN O
1 NN NN O
segment NN NN O
corresponded NN NN O
to NN NN O
the NN NN O
previously NN NN O
reported NN NN O
germ NN NN O
- NN NN O
line NN NN O
sequence NN NN O
. NN NN O
   
The NN NN O
J NN NN O
delta NN NN O
1 NN NN O
segment NN NN O
was NN NN O
correctly NN NN O
spliced NN NN O
to NN NN O
C NN NN O
delta NN NN O
; NN NN O
in NN NN O
addition NN NN O
the NN NN O
four NN NN O
C NN NN O
delta NN NN O
exons NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
already NN NN O
assembled NN NN O
. NN NN O
   
Two NN NN O
polyadenylation NN NN O
sites NN NN O
were NN NN O
present NN NN O
in NN NN O
the NN NN O
fourth NN NN O
C NN NN O
delta NN NN O
exon NN NN O
. NN NN O
   
However NN NN O
, NN NN O
only NN NN O
that NN NN O
located NN NN O
at NN NN O
the NN NN O
3 NN NN O
' NN NN O
end NN NN O
appeared NN NN O
to NN NN O
be NN NN O
utilized NN NN O
in NN NN O
the NN NN O
2 NN NN O
. NN NN O
3 NN NN O
- NN NN O
kb NN NN O
cDNA NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
a NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
known NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
of NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
locus NN NN O
, NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
, NN NN O
in NN NN O
cultured NN NN O
NK NN NN O
cell NN NN O
population NN NN O
and NN NN O
clones NN NN O
( NN NN O
but NN NN O
not NN NN O
in NN NN O
freshly NN NN O
derived NN NN O
cell NN NN O
populations NN NN O
) NN NN O
. NN NN O
   
All NN NN O
NK NN NN O
clones NN NN O
and NN NN O
cell NN NN O
lines NN NN O
studied NN NN O
were NN NN O
found NN NN O
to NN NN O
express NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN O
specific NN NN O
mRNA NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
unrearranged NN NN O
TcR NN NN B-Protein
delta NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
no NN NN O
transcription NN NN O
of NN NN O
the NN NN O
RAG NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
could NN NN O
be NN NN O
detected NN NN O
in NN NN O
all NN NN O
NK NN NN O
cell NN NN O
lines NN NN O
or NN NN O
clones NN NN O
analyzed NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
Alu NN NN O
sequences NN NN O
in NN NN O
the NN NN O
cell NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
of NN NN O
the NN NN O
gamma NN NN O
chain NN NN O
of NN NN O
Fc NN NN O
and NN NN O
T NN NN O
cell NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
Fc NN NN B-Protein
epsilon NN NN I-Protein
RI NN NN I-Protein
- NN NN I-Protein
gamma NN NN I-Protein
chains NN NN I-Protein
are NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
hematopoietic NN NN O
cells NN NN O
where NN NN O
they NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
They NN NN O
are NN NN O
part NN NN O
of NN NN O
the NN NN O
high NN NN O
affinity NN NN O
IgE NN NN O
receptor NN NN O
in NN NN O
mast NN NN O
cells NN NN O
, NN NN O
basophils NN NN O
, NN NN O
Langerhans NN NN O
cells NN NN O
, NN NN O
and NN NN O
possibly NN NN O
other NN NN O
cells NN NN O
; NN NN O
a NN NN O
component NN NN O
of NN NN O
the NN NN O
low NN NN O
affinity NN NN O
receptor NN NN O
for NN NN O
IgG NN NN O
( NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RIIIA NN NN I-Protein
or NN NN O
CD16 NN NN B-Protein
) NN NN O
in NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
and NN NN O
macrophages NN NN O
; NN NN O
and NN NN O
part NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
in NN NN O
subsets NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
gamma NN NN O
chain NN NN O
gene NN NN O
by NN NN O
analyzing NN NN O
the NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
kilobase NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
This NN NN O
sequence NN NN O
contains NN NN O
a NN NN O
promoter NN NN O
specific NN NN O
to NN NN O
cells NN NN O
of NN NN O
hematopoietic NN NN O
lineage NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
this NN NN O
promoter NN NN O
is NN NN O
only NN NN O
partial NN NN O
because NN NN O
it NN NN O
is NN NN O
active NN NN O
in NN NN O
all NN NN O
of NN NN O
the NN NN O
hematopoietic NN NN O
cells NN NN O
tested NN NN O
here NN NN O
, NN NN O
regardless NN NN O
of NN NN O
whether NN NN O
they NN NN O
constitutively NN NN O
express NN NN O
Fc NN NN B-Protein
epsilon NN NN I-Protein
RI NN NN I-Protein
- NN NN I-Protein
gamma NN NN I-Protein
chain NN NN I-Protein
transcripts NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
two NN NN O
adjacent NN NN O
cis NN NN O
- NN NN O
acting NN NN O
regulatory NN NN O
elements NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
part NN NN O
of NN NN O
an NN NN O
Alu NN NN O
repeat NN NN O
. NN NN O
   
The NN NN O
first NN NN O
( NN NN O
- NN NN O
445 NN NN O
/ NN NN O
- NN NN O
366 NN NN O
) NN NN O
is NN NN O
a NN NN O
positive NN NN O
element NN NN O
active NN NN O
in NN NN O
both NN NN O
basophils NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
second NN NN O
( NN NN O
- NN NN O
365 NN NN O
/ NN NN O
- NN NN O
264 NN NN O
) NN NN O
binds NN NN O
to NN NN O
nuclear NN NN O
factors NN NN O
, NN NN O
which NN NN O
appear NN NN O
to NN NN O
be NN NN O
different NN NN O
in NN NN O
basophils NN NN O
and NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
acts NN NN O
as NN NN O
a NN NN O
negative NN NN O
element NN NN O
in NN NN O
basophils NN NN O
and NN NN O
as NN NN O
a NN NN O
positive NN NN O
one NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
this NN NN O
Alu NN NN O
repeat NN NN O
( NN NN O
90 NN NN O
% NN NN O
identical NN NN O
to NN NN O
Alu NN NN O
consensus NN NN O
sequences NN NN O
) NN NN O
has NN NN O
evolved NN NN O
to NN NN O
become NN NN O
both NN NN O
a NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulator NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
expression NN NN O
by NN NN O
activated NN NN O
T NN NN O
cells NN NN O
involves NN NN O
an NN NN O
inducible NN NN O
, NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
and NN NN O
an NN NN O
octamer NN NN O
binding NN NN O
protein NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
is NN NN O
exclusively NN NN O
expressed NN NN O
by NN NN O
activated NN NN O
T NN NN O
and NN NN O
natural NN NN O
killer NN NN O
cells NN NN O
, NN NN O
a NN NN O
function NN NN O
that NN NN O
is NN NN O
tightly NN NN O
controlled NN NN O
both NN NN O
in NN NN O
a NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
and NN NN O
in NN NN O
a NN NN O
stimulation NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
protein NN NN O
binding NN NN O
characteristics NN NN O
and NN NN O
functional NN NN O
importance NN NN O
of NN NN O
the NN NN O
ACT NN NN O
- NN NN O
1 NN NN O
- NN NN O
activating NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
. NN NN O
   
This NN NN O
region NN NN O
binds NN NN O
an NN NN O
inducible NN NN O
, NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
over NN NN O
its NN NN O
5 NN NN O
' NN NN O
end NN NN O
, NN NN O
a NN NN O
site NN NN O
that NN NN O
is NN NN O
necessary NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
other NN NN O
upstream NN NN O
elements NN NN O
. NN NN O
   
Over NN NN O
its NN NN O
3 NN NN O
' NN NN O
end NN NN O
, NN NN O
it NN NN O
binds NN NN O
a NN NN O
factor NN NN O
that NN NN O
is NN NN O
ubiquitously NN NN O
and NN NN O
constitutively NN NN O
expressed NN NN O
. NN NN O
   
This NN NN O
factor NN NN O
is NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
an NN NN O
immunologically NN NN O
related NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
and NN NN O
it NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
coordinating NN NN O
the NN NN O
activity NN NN O
of NN NN O
several NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
These NN NN O
characteristics NN NN O
make NN NN O
the NN NN O
ACT NN NN O
- NN NN O
1 NN NN O
site NN NN O
analogous NN NN O
to NN NN O
the NN NN O
activating NN NN O
ARRE NN NN O
- NN NN O
1 NN NN O
site NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
and NN NN O
despite NN NN O
a NN NN O
lack NN NN O
of NN NN O
sequence NN NN O
homology NN NN O
, NN NN O
the NN NN O
promoters NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
share NN NN O
an NN NN O
organizational NN NN O
pattern NN NN O
of NN NN O
regulatory NN NN O
elements NN NN O
that NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
ras NN NN O
protein NN NN O
activity NN NN O
is NN NN O
essential NN NN O
for NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
In NN NN O
a NN NN O
Jurkat NN NN O
cell NN NN O
model NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
an NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
/ NN NN O
reporter NN NN O
gene NN NN O
construct NN NN O
was NN NN O
activated NN NN O
by NN NN O
antigen NN NN O
receptor NN NN O
agonism NN NN O
in NN NN O
combination NN NN O
with NN NN O
the NN NN O
lymphokine NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Antigen NN NN O
receptor NN NN O
signals NN NN O
could NN NN O
be NN NN O
mimicked NN NN O
by NN NN O
suboptimal NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
with NN NN O
phorbol NN NN O
esters NN NN O
in NN NN O
combination NN NN O
with NN NN O
calcium NN NN O
mobilization NN NN O
by NN NN O
an NN NN O
ionophore NN NN O
. NN NN O
   
In NN NN O
cotransfection NN NN O
experiments NN NN O
, NN NN O
oncogenic NN NN O
rats NN NN O
obviated NN NN O
the NN NN O
need NN NN O
for NN NN O
PKC NN NN O
stimulation NN NN O
but NN NN O
did NN NN O
not NN NN O
replace NN NN O
either NN NN O
the NN NN O
calcium NN NN O
signal NN NN O
or NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Activated NN NN O
ras NN NN O
expression NN NN O
also NN NN O
replaced NN NN O
the NN NN O
requirement NN NN O
for NN NN O
PKC NN NN O
stimulation NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
A NN NN O
dominant NN NN O
inhibitory NN NN O
ras NN NN O
mutant NN NN O
specifically NN NN O
blocked NN NN O
antigen NN NN O
receptor NN NN O
agonism NN NN O
, NN NN O
indicating NN NN O
that NN NN O
ras NN NN O
activity NN NN O
is NN NN O
required NN NN O
for NN NN O
antigen NN NN O
receptor NN NN O
signaling NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
PKC NN NN O
blocked NN NN O
both NN NN O
activated NN NN O
ras NN NN O
and NN NN O
phorbol NN NN O
ester NN NN O
stimulation NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
ras NN NN O
upstream NN NN O
of NN NN O
PKC NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
and NN NN O
cytoplasmic NN NN O
components NN NN O
of NN NN O
the NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
complex NN NN O
. NN NN O
   
The NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
complex NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
early NN NN O
gene NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
is NN NN O
assembled NN NN O
from NN NN O
a NN NN O
pre NN NN O
- NN NN O
existing NN NN O
, NN NN O
T NN NN O
cell NN NN O
restricted NN NN O
cytoplasmic NN NN O
factor NN NN O
and NN NN O
an NN NN O
inducible NN NN O
ubiquitous NN NN O
nuclear NN NN O
component NN NN O
within NN NN O
30 NN NN O
min NN NN O
after NN NN O
activation NN NN O
through NN NN O
the NN NN O
antigen NN NN O
receptor NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
implicated NN NN O
the NN NN O
family NN NN O
of NN NN O
AP1 NN NN O
factors NN NN O
as NN NN O
components NN NN O
of NN NN O
the NN NN O
murine NN NN O
NF NN NN O
- NN NN O
AT NN NN O
complex NN NN O
. NN NN O
   
Evidence NN NN O
is NN NN O
provided NN NN O
here NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
component NN NN O
of NN NN O
human NN NN O
NF NN NN O
- NN NN O
AT NN NN O
contains NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
inducible NN NN O
transcription NN NN O
factor NN NN O
AP1 NN NN O
( NN NN O
Jun NN NN O
/ NN NN O
Fos NN NN O
) NN NN O
. NN NN O
   
We NN NN O
further NN NN O
characterize NN NN O
which NN NN O
AP1 NN NN O
family NN NN O
members NN NN O
can NN NN O
assume NN NN O
this NN NN O
role NN NN O
. NN NN O
   
Antisera NN NN O
to NN NN O
Fos NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
AT NN NN O
DNA NN NN O
binding NN NN O
as NN NN O
does NN NN O
an NN NN O
oligonucleotide NN NN O
containing NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
AP1 NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
in NN NN O
vivo NN NN O
of NN NN O
Fos NN NN O
, NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
Fra NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
eliminates NN NN O
the NN NN O
requirement NN NN O
for NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
stimulation NN NN O
, NN NN O
leaving NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
responsive NN NN O
to NN NN O
calcium NN NN O
ionophore NN NN O
alone NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
cJun NN NN B-Protein
or NN NN O
JunD NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
JunB NN NN B-Protein
, NN NN O
also NN NN O
eliminates NN NN O
the NN NN O
requirement NN NN O
for NN NN O
PMA NN NN O
, NN NN O
indicating NN NN O
that NN NN O
many NN NN O
but NN NN O
not NN NN O
all NN NN O
Jun NN NN O
- NN NN O
and NN NN O
Fos NN NN O
- NN NN O
related NN NN O
proteins NN NN O
functionally NN NN O
activate NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
cytoplasmic NN NN O
component NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
AT NN NN O
DNA NN NN O
binding NN NN O
can NN NN O
be NN NN O
reconstituted NN NN O
in NN NN O
vitro NN NN O
using NN NN O
semi NN NN O
- NN NN O
purified NN NN O
AP1 NN NN O
proteins NN NN O
mixed NN NN O
with NN NN O
cytosol NN NN O
from NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Fos NN NN O
proteins NN NN O
are NN NN O
not NN NN O
needed NN NN O
for NN NN O
this NN NN O
reconstitution NN NN O
, NN NN O
and NN NN O
although NN NN O
JunB NN NN B-Protein
is NN NN O
not NN NN O
functional NN NN O
, NN NN O
it NN NN O
can NN NN O
participate NN NN O
in NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
DNA NN NN O
binding NN NN O
complex NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
have NN NN O
partially NN NN O
purified NN NN O
the NN NN O
cytoplasmic NN NN O
component NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
show NN NN O
by NN NN O
elution NN NN O
and NN NN O
renaturation NN NN O
from NN NN O
SDS NN NN O
- NN NN O
polyacrylamide NN NN O
gel NN NN O
electrophoresis NN NN O
gels NN NN O
that NN NN O
it NN NN O
has NN NN O
a NN NN O
molecular NN NN O
mass NN NN O
between NN NN O
94 NN NN O
and NN NN O
116 NN NN O
kDa NN NN O
and NN NN O
may NN NN O
have NN NN O
multiple NN NN O
differentially NN NN O
modified NN NN O
forms NN NN O
. NN NN O
   
Protease NN NN O
treatment NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
distinguishes NN NN O
between NN NN O
class NN NN O
II NN NN O
MHC NN NN O
X1 NN NN O
box NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
class NN NN O
II NN NN O
- NN NN O
deficient NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
X NN NN O
box NN NN O
region NN NN O
is NN NN O
critical NN NN O
for NN NN O
directing NN NN O
the NN NN O
expression NN NN O
of NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
genes NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Although NN NN O
several NN NN O
class NN NN O
II NN NN O
promoter NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
factors NN NN O
have NN NN O
been NN NN O
described NN NN O
, NN NN O
only NN NN O
the NN NN O
X NN NN O
box NN NN O
region NN NN O
factor NN NN O
, NN NN O
RFX NN NN O
, NN NN O
shows NN NN O
a NN NN O
genetic NN NN O
correlation NN NN O
with NN NN O
class NN NN O
II NN NN O
expression NN NN O
, NN NN O
being NN NN O
deficient NN NN O
in NN NN O
some NN NN O
B NN NN O
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
patients NN NN O
with NN NN O
class NN NN O
II NN NN O
- NN NN O
deficient NN NN O
congenital NN NN O
immunodeficiency NN NN O
. NN NN O
   
To NN NN O
further NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
X NN NN O
box NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
, NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
X NN NN O
box NN NN O
region NN NN O
was NN NN O
examined NN NN O
in NN NN O
both NN NN O
class NN NN O
II NN NN O
- NN NN O
positive NN NN O
and NN NN O
- NN NN O
negative NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
B NN NN O
cell NN NN O
line NN NN O
Raji NN NN O
, NN NN O
two NN NN O
class NN NN O
II NN NN O
transcriptional NN NN O
mutant NN NN O
cell NN NN O
lines NN NN O
, NN NN O
SJO NN NN O
and NN NN O
RJ2 NN NN O
. NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
and NN NN O
Jurkat NN NN O
, NN NN O
a NN NN O
class NN NN O
II NN NN O
negative NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
were NN NN O
examined NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
wild NN NN O
- NN NN O
type NN NN O
B NN NN O
cells NN NN O
, NN NN O
neither NN NN O
of NN NN O
the NN NN O
class NN NN O
II NN NN O
mutant NN NN O
cell NN NN O
lines NN NN O
could NN NN O
use NN NN O
the NN NN O
X NN NN O
box NN NN O
region NN NN O
to NN NN O
direct NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
transiently NN NN O
transfected NN NN O
reporter NN NN O
gene NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
X NN NN O
box NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
pathway NN NN O
is NN NN O
defective NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
X1 NN NN O
box NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
RFX NN NN O
was NN NN O
examined NN NN O
and NN NN O
found NN NN O
to NN NN O
be NN NN O
present NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
B NN NN O
cells NN NN O
and NN NN O
the NN NN O
mutant NN NN O
RJ2 NN NN O
. NN NN O
2 NN NN O
. NN NN O
5 NN NN O
but NN NN O
was NN NN O
absent NN NN O
in NN NN O
SJO NN NN O
and NN NN O
Jurkat NN NN O
. NN NN O
   
However NN NN O
, NN NN O
other NN NN O
X1 NN NN O
box NN NN O
- NN NN O
specific NN NN O
activities NN NN O
were NN NN O
detected NN NN O
in NN NN O
all NN NN O
these NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
these NN NN O
different NN NN O
X1 NN NN O
box NN NN O
activities NN NN O
represented NN NN O
distinct NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
or NN NN O
multimeric NN NN O
forms NN NN O
of NN NN O
the NN NN O
same NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
, NN NN O
protease NN NN O
treatment NN NN O
of NN NN O
the NN NN O
crude NN NN O
nuclear NN NN O
extracts NN NN O
followed NN NN O
by NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
assays NN NN O
were NN NN O
carried NN NN O
out NN NN O
and NN NN O
demonstrated NN NN O
that NN NN O
B NN NN O
cell NN NN O
extracts NN NN O
contain NN NN O
at NN NN O
least NN NN O
two NN NN O
X1 NN NN O
- NN NN O
specific NN NN O
factors NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
cleaved NN NN O
products NN NN O
( NN NN O
band NN NN O
1 NN NN O
pk NN NN O
) NN NN O
correlates NN NN O
with NN NN O
RFX NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
similar NN NN O
comparison NN NN O
with NN NN O
protease NN NN O
- NN NN O
treated NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
Jurkat NN NN O
cells NN NN O
demonstrated NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
band NN NN O
1pk NN NN O
activity NN NN O
despite NN NN O
an NN NN O
absence NN NN O
of NN NN O
the NN NN O
native NN NN O
RFX NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
protease NN NN O
treatment NN NN O
and NN NN O
analysis NN NN O
of NN NN O
SJO NN NN O
extracts NN NN O
showed NN NN O
no NN NN O
detectable NN NN O
levels NN NN O
of NN NN O
the NN NN O
band NN NN O
1pk NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
multiple NN NN O
X1 NN NN O
box NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
exist NN NN O
in NN NN O
all NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
but NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
actively NN NN O
binding NN NN O
RFX NN NN O
species NN NN O
correlates NN NN O
with NN NN O
class NN NN O
II NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
human NN NN B-Protein
prointerleukin NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
gene NN NN O
requires NN NN O
DNA NN NN O
sequences NN NN O
both NN NN O
proximal NN NN O
and NN NN O
distal NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
for NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
induction NN NN O
. NN NN O
   
In NN NN O
these NN NN O
studies NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
DNA NN NN O
sequences NN NN O
and NN NN O
specific NN NN O
protein NN NN O
interactions NN NN O
necessary NN NN O
for NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN B-Protein
prointerleukin NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
) NN NN O
gene NN NN O
. NN NN O
   
A NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
independent NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
responsive NN NN O
enhancer NN NN O
element NN NN O
located NN NN O
between NN NN O
- NN NN O
3757 NN NN O
and NN NN O
- NN NN O
2729 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
( NN NN O
cap NN NN O
site NN NN O
) NN NN O
consisted NN NN O
of NN NN O
at NN NN O
least NN NN O
six NN NN O
discrete NN NN O
subregions NN NN O
which NN NN O
were NN NN O
essential NN NN O
to NN NN O
the NN NN O
maximal NN NN O
induction NN NN O
by NN NN O
LPS NN NN O
in NN NN O
transfected NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
enhancer NN NN O
also NN NN O
appeared NN NN O
to NN NN O
mediate NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
induction NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
IL NN NN O
- NN NN O
1 NN NN O
responsiveness NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
Deletion NN NN O
and NN NN O
base NN NN O
substitution NN NN O
mutations NN NN O
along NN NN O
with NN NN O
DNA NN NN O
binding NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
enhancer NN NN O
contained NN NN O
a NN NN O
minimum NN NN O
of NN NN O
three NN NN O
functional NN NN O
protein NN NN O
binding NN NN O
sequences NN NN O
, NN NN O
two NN NN O
of NN NN O
which NN NN O
appeared NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
gene NN NN O
induction NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
essential NN NN O
proteins NN NN O
which NN NN O
bound NN NN O
to NN NN O
the NN NN O
enhancer NN NN O
was NN NN O
similar NN NN O
or NN NN O
identical NN NN O
to NN NN O
members NN NN O
of NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
required NN NN O
for NN NN O
both NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
LPS NN NN O
- NN NN O
specific NN NN O
induction NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
( NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
proteins NN NN O
) NN NN O
. NN NN O
   
When NN NN O
ligated NN NN O
to NN NN O
the NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
cap NN NN O
site NN NN O
- NN NN O
proximal NN NN O
region NN NN O
( NN NN O
located NN NN O
between NN NN O
- NN NN O
131 NN NN O
to NN NN O
+ NN NN O
12 NN NN O
) NN NN O
, NN NN O
both NN NN O
the NN NN O
proIL NN NN O
- NN NN O
1 NN NN O
beta NN NN O
and NN NN O
the NN NN O
simian NN NN O
virus NN NN O
40 NN NN O
enhancer NN NN O
elements NN NN O
functioned NN NN O
more NN NN O
efficiently NN NN O
in NN NN O
monocytes NN NN O
than NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
which NN NN O
are NN NN O
not NN NN O
normally NN NN O
competent NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
expression NN NN O
. NN NN O
   
When NN NN O
ligated NN NN O
to NN NN O
the NN NN O
murine NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
promoter NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
enhancer NN NN O
was NN NN O
inducible NN NN O
in NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
- NN NN O
stimulated NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
proIL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
promoter NN NN O
- NN NN O
proximal NN NN O
requirement NN NN O
for NN NN O
tissue NN NN O
specificity NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
PILOT NN NN B-Protein
, NN NN O
a NN NN O
putative NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
requires NN NN O
two NN NN O
signals NN NN O
and NN NN O
is NN NN O
cyclosporin NN NN O
A NN NN O
sensitive NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Few NN NN O
known NN NN O
genes NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
members NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
8 NN NN O
family NN NN O
, NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
are NN NN O
induced NN NN O
in NN NN O
T NN NN O
cells NN NN O
only NN NN O
through NN NN O
the NN NN O
combined NN NN O
effect NN NN O
of NN NN O
phorbol NN NN O
myristic NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
a NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
ionophore NN NN O
, NN NN O
and NN NN O
expression NN NN O
of NN NN O
only NN NN O
these NN NN O
genes NN NN O
can NN NN O
be NN NN O
fully NN NN O
suppressed NN NN O
by NN NN O
Cyclosporin NN NN O
A NN NN O
( NN NN O
CyA NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
putative NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
designated NN NN O
PILOT NN NN B-Protein
, NN NN O
with NN NN O
an NN NN O
identical NN NN O
dual NN NN O
signal NN NN O
requirement NN NN O
for NN NN O
expression NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
the NN NN O
PILOT NN NN B-Protein
gene NN NN O
is NN NN O
detectable NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
20 NN NN O
min NN NN O
following NN NN O
activation NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
cycloheximide NN NN O
and NN NN O
is NN NN O
fully NN NN O
suppressed NN NN O
by NN NN O
CyA NN NN O
. NN NN O
   
The NN NN O
PILOT NN NN B-Protein
protein NN NN O
has NN NN O
a NN NN O
calculated NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
of NN NN O
42 NN NN O
. NN NN O
6 NN NN O
kDa NN NN O
and NN NN O
contains NN NN O
three NN NN O
zinc NN NN O
fingers NN NN O
of NN NN O
the NN NN O
C2H2 NN NN O
- NN NN O
type NN NN O
at NN NN O
the NN NN O
carboxyl NN NN O
- NN NN O
terminus NN NN O
which NN NN O
are NN NN O
highly NN NN O
homologous NN NN O
to NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
regions NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
EGR1 NN NN B-Protein
, NN NN O
EGR2 NN NN B-Protein
, NN NN O
and NN NN O
pAT NN NN B-Protein
133 NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
T NN NN O
cells NN NN O
, NN NN O
in NN NN O
fibroblasts NN NN O
PILOT NN NN B-Protein
gene NN NN O
expression NN NN O
requires NN NN O
only NN NN O
one NN NN O
signal NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
CyA NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
directly NN NN O
demonstrates NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
Ca2 NN NN O
+ NN NN O
signal NN NN O
- NN NN O
dependent NN NN O
regulatory NN NN O
element NN NN O
obligatory NN NN O
for NN NN O
expression NN NN O
of NN NN O
some NN NN O
genes NN NN O
in NN NN O
T NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
This NN NN O
differential NN NN O
expression NN NN O
model NN NN O
will NN NN O
be NN NN O
valuable NN NN O
in NN NN O
the NN NN O
dissection NN NN O
of NN NN O
the NN NN O
dual NN NN O
signal NN NN O
pathway NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
the NN NN O
effects NN NN O
of NN NN O
CyA NN NN O
upon NN NN O
it NN NN O
. NN NN O
   
Suppression NN NN O
of NN NN O
a NN NN O
cellular NN NN O
differentiation NN NN O
program NN NN O
by NN NN O
phorbol NN NN O
esters NN NN O
coincides NN NN O
with NN NN O
inhibition NN NN O
of NN NN O
binding NN NN O
of NN NN O
a NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
) NN NN O
to NN NN O
an NN NN O
enhancer NN NN O
element NN NN O
required NN NN O
for NN NN O
expression NN NN O
of NN NN O
an NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
. NN NN O
   
Induction NN NN O
by NN NN O
hemin NN NN O
increases NN NN O
, NN NN O
while NN NN O
induction NN NN O
with NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
represses NN NN O
, NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
human NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
. NN NN O
   
We NN NN O
analyzed NN NN O
the NN NN O
effects NN NN O
of NN NN O
hemin NN NN O
or NN NN O
TPA NN NN O
induction NN NN O
on NN NN O
the NN NN O
binding NN NN O
and NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
at NN NN O
a NN NN O
regulatory NN NN O
element NN NN O
found NN NN O
within NN NN O
the NN NN O
transcriptional NN NN O
regulatory NN NN O
sequences NN NN O
of NN NN O
many NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
TPA NN NN O
induction NN NN O
increases NN NN O
the NN NN O
binding NN NN O
of NN NN O
ubiquitous NN NN O
AP NN NN O
- NN NN O
1 NN NN O
factors NN NN O
to NN NN O
this NN NN O
element NN NN O
. NN NN O
   
TPA NN NN O
induction NN NN O
inhibits NN NN O
the NN NN O
binding NN NN O
of NN NN O
the NN NN O
lineage NN NN O
limited NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
to NN NN O
this NN NN O
transcriptional NN NN O
control NN NN O
element NN NN O
. NN NN O
   
Hemin NN NN O
induction NN NN O
of NN NN O
K562 NN NN O
cells NN NN O
does NN NN O
not NN NN O
facilitate NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
to NN NN O
its NN NN O
recognition NN NN O
site NN NN O
. NN NN O
   
Hemin NN NN O
induction NN NN O
appears NN NN O
to NN NN O
nonspecifically NN NN O
increase NN NN O
the NN NN O
expression NN NN O
of NN NN O
transiently NN NN O
transfected NN NN O
genes NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
Beyond NN NN O
this NN NN O
nonspecific NN NN O
increase NN NN O
in NN NN O
gene NN NN O
expression NN NN O
, NN NN O
hemin NN NN O
induction NN NN O
acts NN NN O
to NN NN O
increase NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
lineage NN NN O
limited NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
. NN NN O
   
The NN NN O
divergent NN NN O
effects NN NN O
of NN NN O
hemin NN NN O
and NN NN O
TPA NN NN O
on NN NN O
gene NN NN O
expression NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
are NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
their NN NN O
contrasting NN NN O
effects NN NN O
on NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
pyruvate NN NN O
kinase NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
. NN NN O
   
Mammal NN NN O
pyruvate NN NN O
kinases NN NN O
are NN NN O
encoded NN NN O
by NN NN O
two NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
L NN NN B-Protein
gene NN NN O
produces NN NN O
the NN NN O
erythroid NN NN O
( NN NN O
R NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
) NN NN O
or NN NN O
the NN NN O
hepatic NN NN O
( NN NN O
L NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
) NN NN O
isozymes NN NN O
by NN NN O
the NN NN O
alternative NN NN O
use NN NN O
of NN NN O
two NN NN O
promoters NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
characterization NN NN O
of NN NN O
the NN NN O
cis NN NN O
- NN NN O
and NN NN O
trans NN NN O
- NN NN O
acting NN NN O
elements NN NN O
involved NN NN O
in NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
activity NN NN O
of NN NN O
the NN NN O
L NN NN B-Protein
gene NN NN O
erythroid NN NN O
promoter NN NN O
. NN NN O
   
A NN NN O
R NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
DNA NN NN O
fragment NN NN O
extending NN NN O
from NN NN O
- NN NN O
870 NN NN O
to NN NN O
+ NN NN O
54 NN NN O
relative NN NN O
to NN NN O
the NN NN O
cap NN NN O
site NN NN O
confers NN NN O
erythroid NN NN O
specificity NN NN O
to NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
. NN NN O
   
Within NN NN O
this NN NN O
region NN NN O
, NN NN O
we NN NN O
define NN NN O
a NN NN O
minimal NN NN O
promoter NN NN O
( NN NN O
- NN NN O
62 NN NN O
to NN NN O
+ NN NN O
54 NN NN O
) NN NN O
that NN NN O
displays NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
activity NN NN O
and NN NN O
contains NN NN O
two NN NN O
DNA NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
One NN NN O
, NN NN O
located NN NN O
at NN NN O
- NN NN O
50 NN NN O
, NN NN O
binds NN NN O
members NN NN O
of NN NN O
the NN NN O
CCACC NN NN O
/ NN NN O
Sp1 NN NN O
family NN NN O
and NN NN O
the NN NN O
other NN NN O
, NN NN O
located NN NN O
at NN NN O
- NN NN O
20 NN NN O
, NN NN O
binds NN NN O
the NN NN O
erythroid NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Although NN NN O
the NN NN O
- NN NN O
20 NN NN O
GATA NN NN O
binding NN NN O
site NN NN O
( NN NN O
AGATAA NN NN O
) NN NN O
is NN NN O
also NN NN O
a NN NN O
potential NN NN O
TFIID NN NN O
binding NN NN O
site NN NN O
, NN NN O
it NN NN O
does NN NN O
not NN NN O
bind NN NN O
TFIID NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
substitution NN NN O
of NN NN O
this NN NN O
GATA NN NN O
binding NN NN O
site NN NN O
by NN NN O
a NN NN O
canonical NN NN O
TFIID NN NN O
binding NN NN O
site NN NN O
suppresses NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Mutations NN NN O
and NN NN O
deletions NN NN O
of NN NN O
both NN NN O
sites NN NN O
indicate NN NN O
that NN NN O
only NN NN O
the NN NN O
association NN NN O
of NN NN O
CCACC NN NN O
/ NN NN O
Sp1 NN NN O
and NN NN O
GATA NN NN O
binding NN NN O
sites NN NN O
can NN NN O
drive NN NN O
efficient NN NN O
and NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
this NN NN O
R NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
minimal NN NN O
promoter NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
by NN NN O
co NN NN O
- NN NN O
transfection NN NN O
experiments NN NN O
, NN NN O
we NN NN O
study NN NN O
the NN NN O
elements NN NN O
involved NN NN O
in NN NN O
the NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transactivation NN NN O
of NN NN O
the NN NN O
R NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
promoter NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
interleukin NN NN B-Protein
3 NN NN I-Protein
( NN NN O
IL3 NN NN B-Protein
) NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
control NN NN O
of NN NN O
IL3 NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
molecular NN NN O
and NN NN O
biochemical NN NN O
basis NN NN O
for NN NN O
activation NN NN O
of NN NN O
interleukin NN NN B-Protein
3 NN NN I-Protein
( NN NN O
IL3 NN NN B-Protein
) NN NN O
gene NN NN O
expression NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
following NN NN O
CD3 NN NN O
and NN NN O
CD2 NN NN B-Protein
receptor NN NN O
stimulation NN NN O
or NN NN O
activation NN NN O
by NN NN O
phytohemagglutinin NN NN B-Protein
plus NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
. NN NN O
   
Using NN NN O
transfection NN NN O
and NN NN O
reporter NN NN O
gene NN NN O
assays NN NN O
specifically NN NN O
designed NN NN O
for NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
gel NN NN O
retardation NN NN O
assays NN NN O
, NN NN O
Western NN NN O
blot NN NN O
analyses NN NN O
and NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
studies NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
and NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL3 NN NN B-Protein
gene NN NN O
via NN NN O
their NN NN O
interaction NN NN O
with NN NN O
two NN NN O
specific NN NN O
regions NN NN O
contained NN NN O
within NN NN O
the NN NN O
IL3 NN NN B-Protein
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
sequence NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
the NN NN O
region NN NN O
between NN NN O
bases NN NN O
- NN NN O
107 NN NN O
and NN NN O
- NN NN O
59 NN NN O
of NN NN O
the NN NN O
IL3 NN NN B-Protein
promoter NN NN O
containing NN NN O
putative NN NN O
AP NN NN O
- NN NN O
2 NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
motifs NN NN O
appears NN NN O
necessary NN NN O
for NN NN O
basal NN NN O
level NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL3 NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
data NN NN O
also NN NN O
indicate NN NN O
that NN NN O
CD2 NN NN B-Protein
receptor NN NN O
activation NN NN O
and NN NN O
phytohemagglutinin NN NN B-Protein
plus NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
stimulation NN NN O
augment NN NN O
T NN NN O
cell NN NN O
IL3 NN NN B-Protein
gene NN NN O
expression NN NN O
through NN NN O
the NN NN O
same NN NN O
cis NN NN O
- NN NN O
and NN NN O
trans NN NN O
- NN NN O
activating NN NN O
signals NN NN O
. NN NN O
   
These NN NN O
results NN NN O
should NN NN O
contribute NN NN O
to NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IL3 NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
of NN NN O
human NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
by NN NN O
the NN NN O
alpha NN NN B-Protein
globin NN NN I-Protein
regulatory NN NN O
element NN NN O
( NN NN O
HS NN NN O
- NN NN O
40 NN NN O
) NN NN O
: NN NN O
functional NN NN O
role NN NN O
of NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
DNA NN NN O
complexes NN NN O
. NN NN O
   
We NN NN O
studied NN NN O
the NN NN O
functional NN NN O
interaction NN NN O
between NN NN O
human NN NN O
embryonic NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
and NN NN O
the NN NN O
alpha NN NN B-Protein
globin NN NN I-Protein
regulatory NN NN O
element NN NN O
( NN NN O
HS NN NN O
- NN NN O
40 NN NN O
) NN NN O
located NN NN O
40 NN NN O
kb NN NN O
upstream NN NN O
of NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
. NN NN O
   
It NN NN O
was NN NN O
shown NN NN O
by NN NN O
transient NN NN O
expression NN NN O
assay NN NN O
that NN NN O
HS NN NN O
- NN NN O
40 NN NN O
behaved NN NN O
as NN NN O
an NN NN O
authentic NN NN O
enhancer NN NN O
for NN NN O
high NN NN O
- NN NN O
level NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
an NN NN O
erythroid NN NN O
cell NN NN O
line NN NN O
of NN NN O
embryonic NN NN O
and NN NN O
/ NN NN O
or NN NN O
fetal NN NN O
origin NN NN O
. NN NN O
   
Although NN NN O
sequences NN NN O
located NN NN O
between NN NN O
- NN NN O
559 NN NN O
and NN NN O
- NN NN O
88 NN NN O
of NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
were NN NN O
dispensable NN NN O
for NN NN O
its NN NN O
expression NN NN O
on NN NN O
enhancerless NN NN O
plasmids NN NN O
, NN NN O
they NN NN O
were NN NN O
required NN NN O
for NN NN O
the NN NN O
HS NN NN O
- NN NN O
40 NN NN O
enhancer NN NN O
- NN NN O
mediated NN NN O
activity NN NN O
of NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
HS NN NN O
- NN NN O
40 NN NN O
enhancer NN NN O
- NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
interaction NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
two NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
factor NN NN O
binding NN NN O
motifs NN NN O
located NN NN O
at NN NN O
- NN NN O
230 NN NN O
and NN NN O
- NN NN O
104 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
The NN NN O
functional NN NN O
domains NN NN O
of NN NN O
HS NN NN O
- NN NN O
40 NN NN O
were NN NN O
also NN NN O
mapped NN NN O
. NN NN O
   
Bal NN NN O
31 NN NN O
deletion NN NN O
mapping NN NN O
data NN NN O
suggested NN NN O
that NN NN O
one NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
motif NN NN O
, NN NN O
one NN NN O
GT NN NN O
motif NN NN O
, NN NN O
and NN NN O
two NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
/ NN NN O
AP1 NN NN O
motifs NN NN O
together NN NN O
formed NN NN O
the NN NN O
functional NN NN O
core NN NN O
of NN NN O
HS NN NN O
- NN NN O
40 NN NN O
in NN NN O
the NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
activation NN NN O
of NN NN O
the NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
promoter NN NN O
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
further NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
enhancer NN NN O
function NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
/ NN NN O
AP1 NN NN O
motifs NN NN O
of NN NN O
HS NN NN O
- NN NN O
40 NN NN O
is NN NN O
mediated NN NN O
through NN NN O
its NN NN O
binding NN NN O
to NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
but NN NN O
not NN NN O
AP1 NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
did NN NN O
genomic NN NN O
footprinting NN NN O
of NN NN O
the NN NN O
HS NN NN O
- NN NN O
40 NN NN O
enhancer NN NN O
region NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
adult NN NN O
nucleated NN NN O
erythroblasts NN NN O
, NN NN O
and NN NN O
different NN NN O
nonerythroid NN NN O
cells NN NN O
. NN NN O
   
All NN NN O
sequence NN NN O
motifs NN NN O
within NN NN O
the NN NN O
functional NN NN O
core NN NN O
of NN NN O
HS NN NN O
- NN NN O
40 NN NN O
, NN NN O
as NN NN O
mapped NN NN O
by NN NN O
transient NN NN O
expression NN NN O
analysis NN NN O
, NN NN O
appeared NN NN O
to NN NN O
bind NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
in NN NN O
living NN NN O
K562 NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
nonerythroid NN NN O
cells NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
apparently NN NN O
nonfunctional NN NN O
sequence NN NN O
motifs NN NN O
was NN NN O
bound NN NN O
with NN NN O
factors NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
to NN NN O
K562 NN NN O
, NN NN O
nucleated NN NN O
erythroblasts NN NN O
from NN NN O
adult NN NN O
human NN NN O
bone NN NN O
marrow NN NN O
exhibited NN NN O
a NN NN O
similar NN NN O
but NN NN O
nonidentical NN NN O
pattern NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
in NN NN O
vivo NN NN O
at NN NN O
the NN NN O
HS NN NN O
- NN NN O
40 NN NN O
region NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
human NN NN O
embryonic NN NN O
zeta NN NN B-Protein
2 NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
and NN NN O
the NN NN O
fetal NN NN O
/ NN NN O
adult NN NN O
alpha NN NN B-Protein
globin NN NN I-Protein
genes NN NN O
is NN NN O
mediated NN NN O
by NN NN O
erythroid NN NN O
cell NN NN O
- NN NN O
specific NN NN O
and NN NN O
developmental NN NN O
stage NN NN O
- NN NN O
specific NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
DNA NN NN O
complexes NN NN O
which NN NN O
form NN NN O
at NN NN O
the NN NN O
enhancer NN NN O
( NN NN O
HS NN NN O
- NN NN O
40 NN NN O
) NN NN O
and NN NN O
the NN NN O
globin NN NN O
promoters NN NN O
. NN NN O
   
Costimulation NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cell NN NN O
activation NN NN O
by NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
correlates NN NN O
with NN NN O
increased NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
synthesis NN NN O
and NN NN O
increased NN NN O
Fos NN NN O
content NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Endothelial NN NN O
cells NN NN O
( NN NN O
EC NN NN O
) NN NN O
act NN NN O
as NN NN O
APC NN NN O
for NN NN O
resting NN NN O
PBL NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
may NN NN O
have NN NN O
important NN NN O
roles NN NN O
in NN NN O
vivo NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
allograft NN NN O
rejection NN NN O
and NN NN O
delayed NN NN O
hypersensitivity NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
that NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
EC NN NN O
provide NN NN O
costimulatory NN NN O
signals NN NN O
to NN NN O
PHA NN NN B-Protein
- NN NN O
stimulated NN NN O
PBL NN NN O
via NN NN O
CD2 NN NN B-Protein
: NN NN O
lymphocyte NN NN B-Protein
function NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
Ag NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
an NN NN O
unidentified NN NN O
ligand NN NN O
pair NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
three NN NN O
- NN NN O
to NN NN O
eight NN NN O
- NN NN O
fold NN NN O
enhancement NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
The NN NN O
physiologic NN NN O
relevance NN NN O
of NN NN O
this NN NN O
increase NN NN O
was NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
proliferative NN NN O
advantage NN NN O
provided NN NN O
by NN NN O
EC NN NN O
to NN NN O
PBL NN NN O
suboptimally NN NN O
stimulated NN NN O
with NN NN O
mAb NN NN O
OKT3 NN NN O
. NN NN O
   
We NN NN O
now NN NN O
report NN NN O
that NN NN O
EC NN NN O
costimulation NN NN O
causes NN NN O
increased NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
in NN NN O
PBL NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
EC NN NN O
on NN NN O
T NN NN O
cell NN NN O
nuclear NN NN O
factors NN NN O
known NN NN O
to NN NN O
regulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
, NN NN O
including NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
- NN NN O
two NN NN O
components NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
others NN NN O
. NN NN O
   
PBL NN NN O
constitutively NN NN O
express NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
transcripts NN NN O
, NN NN O
and NN NN O
the NN NN O
level NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
is NN NN O
not NN NN O
altered NN NN O
by NN NN O
PHA NN NN B-Protein
activation NN NN O
in NN NN O
the NN NN O
absence NN NN O
or NN NN O
presence NN NN O
of NN NN O
EC NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
is NN NN O
absent NN NN O
from NN NN O
resting NN NN O
T NN NN O
cells NN NN O
and NN NN O
is NN NN O
induced NN NN O
on NN NN O
PHA NN NN B-Protein
activation NN NN O
. NN NN O
   
EC NN NN O
alone NN NN O
do NN NN O
not NN NN O
induce NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
but NN NN O
augment NN NN O
the NN NN O
level NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
in NN NN O
PHA NN NN B-Protein
- NN NN O
activated NN NN O
T NN NN O
cells NN NN O
by NN NN O
3 NN NN O
- NN NN O
to NN NN O
10 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
is NN NN O
largely NN NN O
independent NN NN O
of NN NN O
the NN NN O
CD2 NN NN B-Protein
: NN NN O
lymphocyte NN NN B-Protein
function NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
Ag NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
pathway NN NN O
. NN NN O
   
Gel NN NN O
- NN NN O
shift NN NN O
analysis NN NN O
reveals NN NN O
the NN NN O
constitutive NN NN O
presence NN NN O
of NN NN O
nuclear NN NN O
factors NN NN O
in NN NN O
resting NN NN O
PBL NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
proximal NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
that NN NN O
contain NN NN O
immunoreactive NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
protein NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
from NN NN O
PHA NN NN B-Protein
- NN NN O
activated NN NN O
cells NN NN O
contains NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
and NN NN O
low NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
. NN NN O
   
Strikingly NN NN O
, NN NN O
costimulation NN NN O
with NN NN O
EC NN NN O
results NN NN O
in NN NN O
a NN NN O
dramatic NN NN O
increase NN NN O
( NN NN O
up NN NN O
to NN NN O
15 NN NN O
- NN NN O
fold NN NN O
) NN NN O
in NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
content NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Levels NN NN O
of NN NN O
other NN NN O
nuclear NN NN O
factors NN NN O
involved NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
regulation NN NN O
were NN NN O
not NN NN O
altered NN NN O
by NN NN O
EC NN NN O
, NN NN O
although NN NN O
NFAT NN NN O
- NN NN O
DNA NN NN O
complexes NN NN O
migrated NN NN O
at NN NN O
a NN NN O
slightly NN NN O
different NN NN O
mobility NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
changes NN NN O
in NN NN O
the NN NN O
composition NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
a NN NN O
key NN NN O
molecular NN NN O
mechanism NN NN O
for NN NN O
increasing NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
and NN NN O
may NN NN O
underlie NN NN O
the NN NN O
phenomenon NN NN O
of NN NN O
costimulation NN NN O
by NN NN O
EC NN NN O
. NN NN O
   
Negative NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
human NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
by NN NN O
glucocorticoids NN NN O
through NN NN O
interference NN NN O
with NN NN O
nuclear NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
is NN NN O
affected NN NN O
by NN NN O
several NN NN O
nuclear NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
asked NN NN O
whether NN NN O
dexamethasone NN NN O
( NN NN O
Dex NN NN O
) NN NN O
and NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
by NN NN O
interfering NN NN O
with NN NN O
the NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
that NN NN O
bind NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Nuclear NN NN O
extracts NN NN O
from NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
electrophoretic NN NN O
DNA NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
Both NN NN O
Dex NN NN O
and NN NN O
CsA NN NN O
inhibited NN NN O
the NN NN O
binding NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
but NN NN O
not NN NN O
of NN NN O
NF NN NN O
- NN NN O
kB NN NN O
and NN NN O
OCT NN NN O
- NN NN O
1 NN NN O
/ NN NN O
OAF NN NN O
, NN NN O
to NN NN O
their NN NN O
corresponding NN NN O
sites NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
promoter NN NN O
. NN NN O
   
To NN NN O
correlate NN NN O
changes NN NN O
in NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
in NN NN O
vitro NN NN O
with NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
vivo NN NN O
and NN NN O
define NN NN O
the NN NN O
structural NN NN O
requirements NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
repression NN NN O
, NN NN O
we NN NN O
used NN NN O
transient NN NN O
DNA NN NN O
transfections NN NN O
. NN NN O
   
Jurkat NN NN O
cells NN NN O
were NN NN O
transfected NN NN O
with NN NN O
plasmids NN NN O
containing NN NN O
either NN NN O
the NN NN O
intact NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
or NN NN O
its NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kB NN NN O
motifs NN NN O
. NN NN O
   
Dex NN NN O
inhibited NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
NF NN NN O
- NN NN O
kB NN NN O
plasmids NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
CsA NN NN O
inhibited NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kB NN NN O
plasmids NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
both NN NN O
Dex NN NN O
and NN NN O
CsA NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
through NN NN O
interference NN NN O
with NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
, NN NN O
while NN NN O
maximum NN NN O
inhibition NN NN O
may NN NN O
involve NN NN O
interaction NN NN O
with NN NN O
both NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
the NN NN O
primary NN NN O
target NN NN O
of NN NN O
Dex NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
transcription NN NN O
factors NN NN O
encoded NN NN O
by NN NN O
the NN NN O
E2A NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
E2A NN NN B-Protein
gene NN NN O
encodes NN NN O
transcription NN NN O
factors NN NN O
of NN NN O
the NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
family NN NN O
that NN NN O
are NN NN O
implicated NN NN O
in NN NN O
cell NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
as NN NN O
part NN NN O
of NN NN O
dimeric NN NN O
complexes NN NN O
that NN NN O
interact NN NN O
with NN NN O
E NN NN O
box NN NN O
enhancer NN NN O
elements NN NN O
. NN NN O
   
It NN NN O
has NN NN O
previously NN NN O
been NN NN O
shown NN NN O
that NN NN O
transcripts NN NN O
of NN NN O
the NN NN O
E2A NN NN B-Protein
gene NN NN O
can NN NN O
be NN NN O
detected NN NN O
in NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
examined NN NN O
expression NN NN O
of NN NN O
the NN NN O
mouse NN NN O
E2A NN NN B-Protein
gene NN NN O
at NN NN O
the NN NN O
protein NN NN O
level NN NN O
using NN NN O
polyclonal NN NN O
antisera NN NN O
directed NN NN O
against NN NN O
distinct NN NN O
portions NN NN O
of NN NN O
the NN NN O
E2A NN NN B-Protein
protein NN NN O
to NN NN O
probe NN NN O
blots NN NN O
of NN NN O
cellular NN NN O
extracts NN NN O
. NN NN O
   
A NN NN O
73 NN NN O
kDa NN NN O
protein NN NN O
was NN NN O
identified NN NN O
by NN NN O
this NN NN O
analysis NN NN O
: NN NN O
this NN NN O
protein NN NN O
is NN NN O
highly NN NN O
enriched NN NN O
in NN NN O
cell NN NN O
lines NN NN O
of NN NN O
B NN NN O
lymphoid NN NN O
origin NN NN O
as NN NN O
compared NN NN O
to NN NN O
pancreatic NN NN O
beta NN NN O
- NN NN O
cells NN NN O
and NN NN O
fibroblast NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
detection NN NN O
of NN NN O
this NN NN O
protein NN NN O
selectively NN NN O
in NN NN O
extracts NN NN O
of NN NN O
lymphoid NN NN O
cells NN NN O
correlates NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
E NN NN O
box NN NN O
- NN NN O
binding NN NN O
activity NN NN O
LEF1 NN NN O
/ NN NN O
BCF1 NN NN O
in NN NN O
these NN NN O
cells NN NN O
; NN NN O
this NN NN O
binding NN NN O
activity NN NN O
was NN NN O
previously NN NN O
shown NN NN O
to NN NN O
be NN NN O
efficiently NN NN O
recognized NN NN O
by NN NN O
antiserum NN NN O
directed NN NN O
against NN NN O
E2A NN NN B-Protein
gene NN NN O
products NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
cells NN NN O
with NN NN O
full NN NN O
length NN NN O
E2A NN NN B-Protein
cDNA NN NN O
leads NN NN O
to NN NN O
appearance NN NN O
of NN NN O
protein NN NN O
co NN NN O
- NN NN O
migrating NN NN O
with NN NN O
the NN NN O
73 NN NN O
kDa NN NN O
protein NN NN O
on NN NN O
SDS NN NN O
gel NN NN O
electrophoresis NN NN O
and NN NN O
co NN NN O
- NN NN O
migrating NN NN O
with NN NN O
LEF1 NN NN O
/ NN NN O
BCF1 NN NN O
on NN NN O
mobility NN NN O
shift NN NN O
analysis NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
view NN NN O
that NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
LEF1 NN NN O
/ NN NN O
BCF1 NN NN O
is NN NN O
a NN NN O
homodimer NN NN O
of NN NN O
E2A NN NN B-Protein
proteins NN NN O
; NN NN O
the NN NN O
selective NN NN O
appearance NN NN O
of NN NN O
this NN NN O
putative NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
B NN NN O
lymphoid NN NN O
cells NN NN O
seems NN NN O
to NN NN O
be NN NN O
attributable NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
the NN NN O
elevated NN NN O
E2A NN NN B-Protein
protein NN NN O
concentrations NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
Nef NN NN B-Protein
protein NN NN O
inhibits NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
LTR NN NN O
, NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
several NN NN O
cellular NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
contribute NN NN O
to NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
studies NN NN O
on NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
encoded NN NN O
Nef NN NN B-Protein
protein NN NN O
suggested NN NN O
that NN NN O
Nef NN NN B-Protein
may NN NN O
be NN NN O
an NN NN O
inhibitor NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
Nef NN NN B-Protein
affects NN NN O
the NN NN O
binding NN NN O
of NN NN O
cellular NN NN O
factors NN NN O
implicated NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
regulation NN NN O
, NN NN O
32P NN NN O
- NN NN O
labeled NN NN O
oligonucleotides NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
binding NN NN O
sites NN NN O
were NN NN O
incubated NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
Nef NN NN B-Protein
- NN NN O
expressing NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
that NN NN O
were NN NN O
not NN NN O
stimulated NN NN O
or NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
T NN NN O
- NN NN O
cell NN NN O
mitogens NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
Nef NN NN B-Protein
inhibited NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
mitogen NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
Nef NN NN B-Protein
expressing NN NN O
cells NN NN O
were NN NN O
transiently NN NN O
transfected NN NN O
with NN NN O
a NN NN O
plasmid NN NN O
in NN NN O
which NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
recognition NN NN O
sequences NN NN O
were NN NN O
cloned NN NN O
downstream NN NN O
of NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
gene NN NN O
. NN NN O
   
Mitogen NN NN O
- NN NN O
mediated NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
CAT NN NN B-Protein
gene NN NN O
in NN NN O
this NN NN O
construct NN NN O
was NN NN O
inhibited NN NN O
in NN NN O
Nef NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
control NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
, NN NN O
by NN NN O
inhibiting NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activation NN NN O
, NN NN O
Nef NN NN B-Protein
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
infected NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Cloning NN NN O
and NN NN O
functional NN NN O
characterization NN NN O
of NN NN O
early NN NN B-Protein
B NN NN I-Protein
- NN NN I-Protein
cell NN NN I-Protein
factor NN NN I-Protein
, NN NN O
a NN NN O
regulator NN NN O
of NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Early NN NN B-Protein
B NN NN I-Protein
- NN NN I-Protein
cell NN NN I-Protein
factor NN NN I-Protein
( NN NN O
EBF NN NN B-Protein
) NN NN O
was NN NN O
identified NN NN O
previously NN NN O
as NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
and NN NN O
differentiation NN NN O
stage NN NN O
- NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
that NN NN O
participates NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
pre NN NN O
- NN NN O
B NN NN O
and NN NN O
B NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
mb NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
. NN NN O
   
Partial NN NN O
amino NN NN O
acid NN NN O
sequences NN NN O
obtained NN NN O
from NN NN O
purified NN NN O
EBF NN NN B-Protein
were NN NN O
used NN NN O
to NN NN O
isolate NN NN O
cDNA NN NN O
clones NN NN O
, NN NN O
which NN NN O
by NN NN O
multiple NN NN O
criteria NN NN O
encode NN NN O
EBF NN NN B-Protein
. NN NN O
   
The NN NN O
recombinant NN NN O
polypeptide NN NN O
formed NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
complexes NN NN O
with NN NN O
the NN NN O
EBF NN NN B-Protein
- NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
mb NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
hybridized NN NN O
to NN NN O
multiple NN NN O
transcripts NN NN O
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
and NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
, NN NN O
but NN NN O
transcripts NN NN O
were NN NN O
not NN NN O
detected NN NN O
at NN NN O
significant NN NN O
levels NN NN O
in NN NN O
plasmacytoma NN NN O
, NN NN O
T NN NN O
- NN NN O
cell NN NN O
, NN NN O
and NN NN O
nonlymphoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
recombinant NN NN O
EBF NN NN B-Protein
in NN NN O
transfected NN NN O
nonlymphoid NN NN O
cells NN NN O
strongly NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
reporter NN NN O
plasmids NN NN O
containing NN NN O
functional NN NN O
EBF NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
by NN NN O
deletion NN NN O
mutants NN NN O
of NN NN O
EBF NN NN B-Protein
identified NN NN O
an NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
lacking NN NN O
obvious NN NN O
sequence NN NN O
similarity NN NN O
to NN NN O
known NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
binding NN NN O
assays NN NN O
with NN NN O
cotranslated NN NN O
wild NN NN O
- NN NN O
type NN NN O
and NN NN O
truncated NN NN O
forms NN NN O
of NN NN O
EBF NN NN B-Protein
indicated NN NN O
that NN NN O
the NN NN O
protein NN NN O
interacts NN NN O
with NN NN O
its NN NN O
site NN NN O
as NN NN O
a NN NN O
homodimer NN NN O
. NN NN O
   
Deletions NN NN O
delineated NN NN O
a NN NN O
carboxy NN NN O
- NN NN O
terminal NN NN O
dimerization NN NN O
region NN NN O
containing NN NN O
two NN NN O
repeats NN NN O
of NN NN O
15 NN NN O
amino NN NN O
acids NN NN O
that NN NN O
show NN NN O
similarity NN NN O
with NN NN O
the NN NN O
dimerization NN NN O
domains NN NN O
of NN NN O
basic NN NN O
- NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
EBF NN NN B-Protein
represents NN NN O
a NN NN O
novel NN NN O
regulator NN NN O
of NN NN O
B NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
Ets NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factor NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
by NN NN O
binding NN NN O
to NN NN O
the NN NN O
retinoblastoma NN NN B-Protein
protein NN NN I-Protein
. NN NN O
   
The NN NN O
retinoblastoma NN NN B-Protein
gene NN NN O
product NN NN O
( NN NN O
Rb NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
nuclear NN NN O
phosphoprotein NN NN O
that NN NN O
regulates NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
Ets NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
regulates NN NN O
inducible NN NN O
gene NN NN O
expression NN NN O
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
it NN NN O
is NN NN O
demonstrated NN NN O
that NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
contains NN NN O
a NN NN O
sequence NN NN O
motif NN NN O
that NN NN O
is NN NN O
highly NN NN O
related NN NN O
to NN NN O
the NN NN O
Rb NN NN B-Protein
binding NN NN O
sites NN NN O
of NN NN O
several NN NN O
viral NN NN O
oncoproteins NN NN O
and NN NN O
binds NN NN O
to NN NN O
the NN NN O
pocket NN NN O
region NN NN O
of NN NN O
Rb NN NN B-Protein
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binds NN NN O
exclusively NN NN O
to NN NN O
the NN NN O
underphosphorylated NN NN O
form NN NN O
of NN NN O
Rb NN NN B-Protein
and NN NN O
fails NN NN O
to NN NN O
bind NN NN O
to NN NN O
Rb NN NN B-Protein
mutants NN NN O
derived NN NN O
from NN NN O
patients NN NN O
with NN NN O
retinoblastoma NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
immunoprecipitation NN NN O
experiments NN NN O
demonstrated NN NN O
an NN NN O
association NN NN O
between NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Rb NN NN B-Protein
in NN NN O
resting NN NN O
normal NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
After NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
Rb NN NN B-Protein
results NN NN O
in NN NN O
the NN NN O
release NN NN O
of NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
correlated NN NN O
temporally NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
transcription NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
a NN NN O
phosphorylation NN NN O
- NN NN O
defective NN NN O
form NN NN O
of NN NN O
Rb NN NN B-Protein
inhibited NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
transcription NN NN O
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
Rb NN NN B-Protein
interacts NN NN O
specifically NN NN O
with NN NN O
a NN NN O
lineage NN NN O
- NN NN O
restricted NN NN O
Ets NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
This NN NN O
regulated NN NN O
interaction NN NN O
may NN NN O
be NN NN O
important NN NN O
for NN NN O
the NN NN O
coordination NN NN O
of NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
effector NN NN O
functions NN NN O
such NN NN O
as NN NN O
lymphokine NN NN O
production NN NN O
with NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Expression NN NN O
levels NN NN O
of NN NN O
the NN NN O
thyrotropin NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
in NN NN O
autoimmune NN NN O
thyroid NN NN O
disease NN NN O
: NN NN O
coregulation NN NN O
with NN NN O
parameters NN NN O
of NN NN O
thyroid NN NN O
function NN NN O
and NN NN O
inverse NN NN O
relation NN NN O
to NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
classes NN NN O
I NN NN O
and NN NN O
II NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
human NN NN O
TSH NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
TSH NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
) NN NN O
cDNA NN NN O
probe NN NN O
, NN NN O
we NN NN O
investigated NN NN O
TSH NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
transcript NN NN O
levels NN NN O
in NN NN O
13 NN NN O
human NN NN O
thyroid NN NN O
fragments NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
; NN NN O
7 NN NN O
Graves NN NN O
' NN NN O
disease NN NN O
, NN NN O
2 NN NN O
Hashimoto NN NN O
' NN NN O
s NN NN O
disease NN NN O
, NN NN O
3 NN NN O
endemic NN NN O
goiter NN NN O
, NN NN O
and NN NN O
1 NN NN O
healthy NN NN O
thyroid NN NN O
gland NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
TSH NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
expression NN NN O
levels NN NN O
were NN NN O
variable NN NN O
, NN NN O
but NN NN O
displayed NN NN O
a NN NN O
close NN NN O
correlation NN NN O
to NN NN O
the NN NN O
expression NN NN O
of NN NN O
thyroid NN NN B-Protein
peroxidase NN NN I-Protein
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
703 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
, NN NN O
thyroglobulin NN NN B-Protein
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
817 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
nuclear NN NN O
oncogene NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
935 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
001 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
. NN NN O
   
Overall NN NN O
, NN NN O
TSH NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
transcript NN NN O
levels NN NN O
were NN NN O
low NN NN O
or NN NN O
absent NN NN O
in NN NN O
those NN NN O
thyroids NN NN O
in NN NN O
which NN NN O
expression NN NN O
of NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
class NN NN O
I NN NN O
or NN NN O
II NN NN O
( NN NN O
MHC NN NN O
I NN NN O
or NN NN O
II NN NN O
) NN NN O
was NN NN O
high NN NN O
, NN NN O
thus NN NN O
establishing NN NN O
an NN NN O
inverse NN NN O
relation NN NN O
( NN NN O
MHC NN NN O
I NN NN O
, NN NN O
r NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
791 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
; NN NN O
MHC NN NN O
II NN NN O
, NN NN O
r NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
784 NN NN O
; NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
situ NN NN O
hybridization NN NN O
showed NN NN O
that NN NN O
apart NN NN O
from NN NN O
lymphocytes NN NN O
, NN NN O
thyroid NN NN O
cells NN NN O
themselves NN NN O
were NN NN O
the NN NN O
source NN NN O
of NN NN O
MHC NN NN O
II NN NN O
transcripts NN NN O
. NN NN O
   
gamma NN NN B-Protein
- NN NN I-Protein
Interferon NN NN I-Protein
expression NN NN O
was NN NN O
only NN NN O
detectable NN NN O
in NN NN O
1 NN NN O
Hashimoto NN NN O
' NN NN O
s NN NN O
goiter NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
next NN NN O
to NN NN O
lymphocyte NN NN O
infiltration NN NN O
, NN NN O
active NN NN O
regulatory NN NN O
events NN NN O
in NN NN O
the NN NN O
thyrocyte NN NN O
are NN NN O
responsible NN NN O
for NN NN O
the NN NN O
inverse NN NN O
relation NN NN O
between NN NN O
functional NN NN O
parameters NN NN O
( NN NN O
TSH NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
, NN NN O
thyroid NN NN B-Protein
peroxidase NN NN I-Protein
, NN NN O
thyroglobulin NN NN B-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
) NN NN O
and NN NN O
immunological NN NN O
markers NN NN O
( NN NN O
MHC NN NN O
I NN NN O
and NN NN O
II NN NN O
) NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
locus NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
the NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
cluster NN NN O
depends NN NN O
upon NN NN O
upstream NN NN O
regulatory NN NN O
sequences NN NN O
, NN NN O
which NN NN O
are NN NN O
collectively NN NN O
termed NN NN O
the NN NN O
locus NN NN O
control NN NN O
region NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
provided NN NN O
new NN NN O
insights NN NN O
into NN NN O
how NN NN O
the NN NN O
individual NN NN O
genes NN NN O
of NN NN O
the NN NN O
cluster NN NN O
are NN NN O
regulated NN NN O
through NN NN O
development NN NN O
. NN NN O
   
The NN NN O
crux NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
is NN NN O
how NN NN O
the NN NN O
locus NN NN O
control NN NN O
region NN NN O
communicates NN NN O
with NN NN O
the NN NN O
gene NN NN O
- NN NN O
proximal NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
Ectopic NN NN O
expression NN NN O
of NN NN O
a NN NN O
conditional NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
/ NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
chimera NN NN O
arrests NN NN O
erythroid NN NN O
differentiation NN NN O
in NN NN O
a NN NN O
hormone NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
The NN NN O
GATA NN NN O
factors NN NN O
are NN NN O
a NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
in NN NN O
eukaryotes NN NN O
that NN NN O
share NN NN O
extensive NN NN O
homology NN NN O
in NN NN O
their NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domains NN NN O
. NN NN O
   
One NN NN O
enigmatic NN NN O
aspect NN NN O
of NN NN O
GATA NN NN O
factor NN NN O
expression NN NN O
is NN NN O
that NN NN O
several NN NN O
GATA NN NN O
proteins NN NN O
, NN NN O
which NN NN O
ostensibly NN NN O
share NN NN O
the NN NN O
same NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
site NN NN O
specificity NN NN O
, NN NN O
are NN NN O
coexpressed NN NN O
in NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
roles NN NN O
of NN NN O
individual NN NN O
GATA NN NN O
factors NN NN O
in NN NN O
erythropoiesis NN NN O
, NN NN O
conditional NN NN O
alleles NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
were NN NN O
prepared NN NN O
by NN NN O
fusing NN NN O
each NN NN O
of NN NN O
the NN NN O
factors NN NN O
to NN NN O
the NN NN O
hormone NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
human NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
ER NN NN B-Protein
) NN NN O
. NN NN O
   
These NN NN O
GATA NN NN O
/ NN NN O
ER NN NN B-Protein
chimeric NN NN O
factors NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
hormone NN NN O
- NN NN O
inducible NN NN O
trans NN NN O
- NN NN O
activating NN NN O
proteins NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
. NN NN O
   
When NN NN O
stably NN NN O
introduced NN NN O
into NN NN O
primary NN NN O
erythroblasts NN NN O
or NN NN O
conditionally NN NN O
transformed NN NN O
erythroid NN NN O
progenitors NN NN O
cells NN NN O
, NN NN O
exogenous NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
/ NN NN O
ER NN NN B-Protein
promoted NN NN O
proliferation NN NN O
and NN NN O
inhibited NN NN O
terminal NN NN O
differentiation NN NN O
in NN NN O
an NN NN O
estrogen NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
These NN NN O
phenotypic NN NN O
effects NN NN O
are NN NN O
specifically NN NN O
attributable NN NN O
to NN NN O
the NN NN O
action NN NN O
of NN NN O
ectopically NN NN O
expressed NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
/ NN NN O
ER NN NN B-Protein
because NN NN O
erythroblasts NN NN O
expressing NN NN O
exogenous NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
constitutively NN NN O
arrested NN NN O
in NN NN O
differentiation NN NN O
and NN NN O
because NN NN O
erythroid NN NN O
progenitors NN NN O
expressing NN NN O
either NN NN O
Gal NN NN O
/ NN NN O
ER NN NN B-Protein
or NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
/ NN NN O
ER NN NN B-Protein
do NN NN O
not NN NN O
display NN NN O
a NN NN O
hormone NN NN O
- NN NN O
responsive NN NN O
block NN NN O
in NN NN O
differentiation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
factor NN NN O
appears NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
self NN NN O
- NN NN O
renewal NN NN O
capacity NN NN O
of NN NN O
early NN NN O
erythroid NN NN O
progenitor NN NN O
cells NN NN O
. NN NN O
   
Molecular NN NN O
basis NN NN O
of NN NN O
a NN NN O
multiple NN NN O
lymphokine NN NN O
deficiency NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
severe NN NN O
combined NN NN O
immunodeficiency NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
reported NN NN O
that NN NN O
the NN NN O
T NN NN O
lymphocytes NN NN O
of NN NN O
a NN NN O
child NN NN O
with NN NN O
severe NN NN O
combined NN NN O
immunodeficiency NN NN O
are NN NN O
defective NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
several NN NN O
lymphokine NN NN O
genes NN NN O
that NN NN O
include NN NN O
IL2 NN NN B-Protein
, NN NN O
IL3 NN NN B-Protein
, NN NN O
IL4 NN NN B-Protein
, NN NN O
and NN NN O
IL5 NN NN B-Protein
, NN NN O
which NN NN O
encode NN NN O
interleukins NN NN B-Protein
2 NN NN I-Protein
, NN NN O
3 NN NN B-Protein
, NN NN O
4 NN NN B-Protein
, NN NN O
and NN NN O
5 NN NN B-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
- NN NN B-Protein
3 NN NN I-Protein
, NN NN O
- NN NN B-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
- NN NN B-Protein
5 NN NN I-Protein
) NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
the NN NN O
defect NN NN O
in NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
T NN NN O
lymphocytes NN NN O
involved NN NN O
a NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factor NN NN O
common NN NN O
to NN NN O
the NN NN O
affected NN NN O
lymphokine NN NN O
genes NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
ability NN NN O
of NN NN O
nuclear NN NN O
factors NN NN O
from NN NN O
the NN NN O
patient NN NN O
' NN NN O
s NN NN O
T NN NN O
lymphocytes NN NN O
to NN NN O
bind NN NN O
response NN NN O
elements NN NN O
present NN NN O
in NN NN O
the NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
IL2 NN NN B-Protein
. NN NN O
   
Nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kB NN NN O
, NN NN O
activation NN NN O
protein NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
IL NN NN O
- NN NN O
2B NN NN O
binding NN NN O
activity NN NN O
were NN NN O
normal NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
binding NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
to NN NN O
its NN NN O
response NN NN O
element NN NN O
in NN NN O
the NN NN O
IL2 NN NN B-Protein
enhancer NN NN O
and NN NN O
to NN NN O
an NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
like NN NN O
response NN NN O
element NN NN O
present NN NN O
in NN NN O
the NN NN O
IL4 NN NN B-Protein
enhancer NN NN O
was NN NN O
abnormal NN NN O
. NN NN O
   
To NN NN O
ascertain NN NN O
whether NN NN O
the NN NN O
abnormal NN NN O
NF NN NN O
- NN NN O
AT NN NN O
binding NN NN O
activity NN NN O
was NN NN O
related NN NN O
to NN NN O
an NN NN O
impaired NN NN O
function NN NN O
, NN NN O
we NN NN O
transfected NN NN O
patient NN NN O
and NN NN O
control NN NN O
T NN NN O
lymphocytes NN NN O
with NN NN O
constructs NN NN O
containing NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
encoding NN NN O
chloramphenicol NN NN B-Protein
acetyl NN NN I-Protein
transferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
entire NN NN O
IL2 NN NN B-Protein
regulatory NN NN O
region NN NN O
or NN NN O
of NN NN O
multimers NN NN O
of NN NN O
individual NN NN O
enhancer NN NN O
sequences NN NN O
. NN NN O
   
CAT NN NN B-Protein
expression NN NN O
directed NN NN O
by NN NN O
the NN NN O
IL2 NN NN B-Protein
regulatory NN NN O
region NN NN O
or NN NN O
by NN NN O
a NN NN O
multimer NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
site NN NN O
was NN NN O
markedly NN NN O
lower NN NN O
in NN NN O
the NN NN O
patient NN NN O
relative NN NN O
to NN NN O
controls NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
CAT NN NN B-Protein
gene NN NN O
expression NN NN O
directed NN NN O
by NN NN O
a NN NN O
multimer NN NN O
of NN NN O
the NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
proximal NN NN O
( NN NN O
OCT NN NN O
- NN NN O
1p NN NN O
) NN NN O
- NN NN O
binding NN NN O
site NN NN O
was NN NN O
equivalent NN NN O
in NN NN O
patient NN NN O
and NN NN O
controls NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
an NN NN O
abnormality NN NN O
of NN NN O
/ NN NN O
or NN NN O
influencing NN NN O
NF NN NN O
- NN NN O
AT NN NN O
may NN NN O
underlie NN NN O
the NN NN O
multiple NN NN O
lymphokine NN NN O
deficiency NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
in NN NN O
human NN NN O
eosinophils NN NN O
and NN NN O
basophils NN NN O
: NN NN O
potential NN NN O
role NN NN O
in NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
the NN NN O
hematopoietic NN NN O
transcription NN NN O
factors NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
studied NN NN O
in NN NN O
eosinophils NN NN O
and NN NN O
basophils NN NN O
. NN NN O
   
Eosinophils NN NN O
express NN NN O
mRNA NN NN O
for NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
Basophils NN NN O
express NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
Treatment NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
eosinophilic NN NN O
sublines NN NN O
with NN NN O
either NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
or NN NN O
butyric NN NN O
acid NN NN O
increased NN NN O
the NN NN O
expression NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
concomitant NN NN O
with NN NN O
the NN NN O
expression NN NN O
of NN NN O
eosinophil NN NN O
- NN NN O
specific NN NN O
genes NN NN O
, NN NN O
whereas NN NN O
levels NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
remained NN NN O
relatively NN NN O
constant NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
mRNA NN NN O
for NN NN O
these NN NN O
proteins NN NN O
in NN NN O
eosinophils NN NN O
and NN NN O
basophils NN NN O
suggests NN NN O
that NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
these NN NN O
lineages NN NN O
may NN NN O
be NN NN O
regulated NN NN O
by NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
Dependence NN NN O
for NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
to NN NN O
erythropoietin NN NN B-Protein
on NN NN O
an NN NN O
established NN NN O
erythroid NN NN O
differentiation NN NN O
program NN NN O
in NN NN O
a NN NN O
human NN NN O
hematopoietic NN NN O
cell NN NN O
line NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
. NN NN O
   
Erythroid NN NN O
differentiation NN NN O
involves NN NN O
the NN NN O
activation NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
, NN NN O
most NN NN O
of NN NN O
which NN NN O
, NN NN O
including NN NN O
the NN NN O
globin NN NN O
genes NN NN O
and NN NN O
the NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
Epo NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
) NN NN O
gene NN NN O
, NN NN O
are NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
regulated NN NN O
by NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
understand NN NN O
the NN NN O
relationship NN NN O
, NN NN O
if NN NN O
any NN NN O
, NN NN O
between NN NN O
expression NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
response NN NN O
to NN NN O
Epo NN NN B-Protein
and NN NN O
erythroid NN NN O
differentiation NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
expression NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Epo NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
and NN NN O
globin NN NN O
genes NN NN O
in NN NN O
an NN NN O
Epo NN NN B-Protein
- NN NN O
dependent NN NN O
human NN NN O
cell NN NN O
line NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
. NN NN O
   
The NN NN O
results NN NN O
were NN NN O
compared NN NN O
to NN NN O
those NN NN O
obtained NN NN O
with NN NN O
the NN NN O
parental NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
- NN NN O
dependent NN NN O
cell NN NN O
line NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
, NN NN O
which NN NN O
has NN NN O
a NN NN O
predominantly NN NN O
megakaryoblastic NN NN O
phenotype NN NN O
and NN NN O
is NN NN O
unable NN NN O
to NN NN O
proliferate NN NN O
continuously NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
Epo NN NN B-Protein
. NN NN O
   
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
and NN NN O
UT NN NN O
- NN NN O
7 NN NN O
expressed NN NN O
similar NN NN O
levels NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
and NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
two NN NN O
lines NN NN O
also NN NN O
expressed NN NN O
comparable NN NN O
levels NN NN O
of NN NN O
Epo NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
mRNA NN NN O
while NN NN O
the NN NN O
number NN NN O
of NN NN O
Epo NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
on NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
cells NN NN O
was NN NN O
one NN NN O
- NN NN O
sixth NN NN O
the NN NN O
number NN NN O
of NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
( NN NN O
2400 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
vs NN NN O
. NN NN O
13 NN NN O
, NN NN O
800 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
300 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
in NN NN O
the NN NN O
number NN NN O
of NN NN O
binding NN NN O
sites NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
differences NN NN O
in NN NN O
cell NN NN O
surface NN NN O
( NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
are NN NN O
20 NN NN O
% NN NN O
smaller NN NN O
than NN NN O
the NN NN O
parental NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
) NN NN O
or NN NN O
in NN NN O
receptor NN NN O
turnover NN NN O
. NN NN O
   
By NN NN O
Northern NN NN O
analysis NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
expressed NN NN O
detectable NN NN O
levels NN NN O
of NN NN O
beta NN NN O
- NN NN O
and NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
but NN NN O
not NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
. NN NN O
   
In NN NN O
comparison NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
cells NN NN O
expressed NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
and NN NN O
higher NN NN O
levels NN NN O
of NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
( NN NN O
5 NN NN O
- NN NN O
fold NN NN O
) NN NN O
and NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
( NN NN O
from NN NN O
barely NN NN O
to NN NN O
clearly NN NN O
detectable NN NN O
) NN NN O
. NN NN O
   
Globin NN NN B-Protein
chains NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
beta NN NN B-Protein
and NN NN O
gamma NN NN B-Protein
) NN NN O
were NN NN O
clearly NN NN O
detectable NN NN O
by NN NN O
affinity NN NN O
chromatography NN NN O
in NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
but NN NN O
not NN NN O
in NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
frequency NN NN O
of NN NN O
the NN NN O
cells NN NN O
which NN NN O
expressed NN NN O
beta NN NN O
- NN NN O
and NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
genes NN NN O
in NN NN O
the NN NN O
two NN NN O
cell NN NN O
populations NN NN O
was NN NN O
measured NN NN O
by NN NN O
immunofluorescence NN NN O
with NN NN O
beta NN NN O
- NN NN O
and NN NN O
gamma NN NN O
- NN NN O
specific NN NN O
antibodies NN NN O
. NN NN O
   
The NN NN O
number NN NN O
of NN NN O
gamma NN NN O
- NN NN O
positive NN NN O
cells NN NN O
and NN NN O
their NN NN O
fluorescence NN NN O
intensity NN NN O
were NN NN O
higher NN NN O
in NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
than NN NN O
in NN NN O
UT NN NN O
- NN NN O
7 NN NN O
cells NN NN O
( NN NN O
0 NN NN O
to NN NN O
17 NN NN O
% NN NN O
barely NN NN O
positive NN NN O
cells NN NN O
and NN NN O
23 NN NN O
to NN NN O
40 NN NN O
% NN NN O
clearly NN NN O
positive NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
increase NN NN O
in NN NN O
globin NN NN O
mRNA NN NN O
observed NN NN O
in NN NN O
UT NN NN O
- NN NN O
7 NN NN O
Epo NN NN O
is NN NN O
due NN NN O
to NN NN O
both NN NN O
an NN NN O
increase NN NN O
of NN NN O
gene NN NN O
expression NN NN O
per NN NN O
cell NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
numbers NN NN O
of NN NN O
cells NN NN O
containing NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
Epo NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
and NN NN O
globin NN NN O
mRNA NN NN O
expressed NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
a NN NN O
24 NN NN O
- NN NN O
hour NN NN O
incubation NN NN O
of NN NN O
either NN NN O
cell NN NN O
line NN NN O
with NN NN O
Epo NN NN B-Protein
, NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
or NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
. NN NN O
   
( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
400 NN NN O
WORDS NN NN O
) NN NN O
   
Protein NN NN B-Protein
kinase NN NN I-Protein
C NN NN I-Protein
- NN NN I-Protein
zeta NN NN I-Protein
mediates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
infected NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
regulating NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
persistence NN NN O
in NN NN O
a NN NN O
major NN NN O
cell NN NN O
reservoir NN NN O
such NN NN O
as NN NN O
the NN NN O
macrophage NN NN O
remain NN NN O
unknown NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
and NN NN O
is NN NN O
selectively NN NN O
activated NN NN O
following NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
human NN NN O
macrophages NN NN O
. NN NN O
   
Although NN NN O
little NN NN O
information NN NN O
as NN NN O
to NN NN O
what NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
mediate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
monocytes NN NN O
- NN NN O
macrophages NN NN O
is NN NN O
available NN NN O
, NN NN O
our NN NN O
previous NN NN O
work NN NN O
indicated NN NN O
that NN NN O
classical NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
isoenzymes NN NN O
were NN NN O
not NN NN O
involved NN NN O
in NN NN O
the NN NN O
HIV NN NN O
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
focused NN NN O
on NN NN O
atypical NN NN O
PKC NN NN O
isoenzymes NN NN O
. NN NN O
   
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
belongs NN NN O
to NN NN O
this NN NN O
family NN NN O
and NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
an NN NN O
important NN NN O
step NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
other NN NN O
cell NN NN O
systems NN NN O
. NN NN O
   
Immunoblotting NN NN O
experiments NN NN O
with NN NN O
U937 NN NN O
cells NN NN O
demonstrate NN NN O
that NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
is NN NN O
present NN NN O
in NN NN O
these NN NN O
cells NN NN O
, NN NN O
and NN NN O
its NN NN O
expression NN NN O
can NN NN O
be NN NN O
downmodulated NN NN O
by NN NN O
antisense NN NN O
oligonucleotides NN NN O
( NN NN O
AO NN NN O
) NN NN O
. NN NN O
   
The NN NN O
HIV NN NN O
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
is NN NN O
selectively NN NN O
reduced NN NN O
by NN NN O
AO NN NN O
to NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
cotransfection NN NN O
of NN NN O
a NN NN O
negative NN NN O
dominant NN NN O
molecule NN NN O
of NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
( NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
mut NN NN O
) NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
genes NN NN O
selectively NN NN O
inhibits NN NN O
the NN NN O
HIV NN NN O
- NN NN O
but NN NN O
not NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
- NN NN O
or NN NN O
lipopolysaccharide NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
That NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
is NN NN O
specific NN NN O
in NN NN O
regulating NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
concluded NN NN O
from NN NN O
the NN NN O
inability NN NN O
of NN NN O
PKC NN NN B-Protein
- NN NN I-Protein
zeta NN NN I-Protein
( NN NN O
mut NN NN O
) NN NN O
to NN NN O
interfere NN NN O
with NN NN O
the NN NN O
basal NN NN O
or NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
- NN NN O
inducible NN NN O
CREB NN NN B-Protein
- NN NN O
or NN NN O
AP1 NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
Lastly NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
a NN NN O
selective NN NN O
inhibition NN NN O
of NN NN O
p24 NN NN O
production NN NN O
by NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
human NN NN O
macrophages NN NN O
when NN NN O
treated NN NN O
with NN NN O
AO NN NN O
to NN NN O
PKC NN NN O
- NN NN O
zeta NN NN O
. NN NN O
   
Altogether NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
atypical NN NN O
PKC NN NN O
isoenzymes NN NN O
, NN NN O
including NN NN O
PKC NN NN O
- NN NN O
zeta NN NN O
, NN NN O
participate NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
by NN NN O
which NN NN O
HIV NN NN O
infection NN NN O
results NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
: NN NN O
implications NN NN O
for NN NN O
differential NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
helper NN NN O
cell NN NN O
subsets NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
individual NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
results NN NN O
in NN NN O
differential NN NN O
lymphokine NN NN O
expression NN NN O
: NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
is NN NN O
preferentially NN NN O
produced NN NN O
by NN NN O
T NN NN O
helper NN NN O
type NN NN O
1 NN NN O
( NN NN O
TH1 NN NN O
) NN NN O
cells NN NN O
, NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
responses NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
is NN NN O
synthesized NN NN O
by NN NN O
TH2 NN NN O
cells NN NN O
, NN NN O
which NN NN O
are NN NN O
essential NN NN O
for NN NN O
humoral NN NN O
immunity NN NN O
. NN NN O
   
The NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
factor NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
inducible NN NN O
transcription NN NN O
of NN NN O
both NN NN O
these NN NN O
lymphokine NN NN O
genes NN NN O
. NN NN O
   
However NN NN O
, NN NN O
while NN NN O
IL2 NN NN B-Protein
expression NN NN O
requires NN NN O
the NN NN O
contribution NN NN O
of NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
- NN NN O
dependent NN NN O
signals NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
activation NN NN O
of NN NN O
human NN NN O
IL4 NN NN B-Protein
transcription NN NN O
through NN NN O
the NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
pathway NN NN O
is NN NN O
diminished NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
stimulation NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
phenomenon NN NN O
is NN NN O
due NN NN O
to NN NN O
mutually NN NN O
exclusive NN NN O
binding NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
the NN NN O
P NN NN O
sequence NN NN O
, NN NN O
an NN NN O
element NN NN O
located NN NN O
69 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
IL4 NN NN B-Protein
transcription NN NN O
initiation NN NN O
site NN NN O
. NN NN O
   
Human NN NN O
IL4 NN NN B-Protein
promoter NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
is NN NN O
downregulated NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
activating NN NN O
cytokine NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
suppressed NN NN O
in NN NN O
RelA NN NN B-Protein
- NN NN O
overexpressing NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
stimulation NN NN O
or NN NN O
RelA NN NN B-Protein
overexpression NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
human NN NN O
IL4 NN NN B-Protein
promoter NN NN O
containing NN NN O
a NN NN O
mouse NN NN O
P NN NN O
sequence NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
higher NN NN O
- NN NN O
affinity NN NN O
site NN NN O
for NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
and NN NN O
a NN NN O
lower NN NN O
- NN NN O
affinity NN NN O
site NN NN O
for NN NN O
RelA NN NN B-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
competition NN NN O
between NN NN O
two NN NN O
general NN NN O
transcriptional NN NN O
activators NN NN O
, NN NN O
RelA NN NN B-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
, NN NN O
mediates NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
stimulation NN NN O
on NN NN O
IL4 NN NN B-Protein
expression NN NN O
and NN NN O
may NN NN O
contribute NN NN O
to NN NN O
differential NN NN O
gene NN NN O
expression NN NN O
in NN NN O
TH NN NN O
cells NN NN O
. NN NN O
   
Functional NN NN O
characterization NN NN O
of NN NN O
the NN NN O
murine NN NN O
homolog NN NN O
of NN NN O
the NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
coactivator NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
promoter NN NN O
activity NN NN O
mediated NN NN O
by NN NN O
the NN NN O
octamer NN NN O
motif NN NN O
requires NN NN O
the NN NN O
Oct1 NN NN B-Protein
or NN NN O
Oct2 NN NN B-Protein
protein NN NN O
and NN NN O
additional NN NN O
B NN NN O
cell NN NN O
- NN NN O
restricted NN NN O
cofactors NN NN O
. NN NN O
   
One NN NN O
such NN NN O
cofactor NN NN O
, NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
was NN NN O
recently NN NN O
isolated NN NN O
from NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
isolation NN NN O
and NN NN O
detailed NN NN O
characterization NN NN O
of NN NN O
the NN NN O
murine NN NN O
homolog NN NN O
. NN NN O
   
Full NN NN O
- NN NN O
length NN NN O
cDNAs NN NN O
and NN NN O
genomic NN NN O
clones NN NN O
were NN NN O
isolated NN NN O
, NN NN O
and NN NN O
the NN NN O
gene NN NN O
structure NN NN O
was NN NN O
determined NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
deduced NN NN O
amino NN NN O
acids NN NN O
shows NN NN O
88 NN NN O
% NN NN O
sequence NN NN O
identity NN NN O
between NN NN O
mouse NN NN O
and NN NN O
human NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
The NN NN O
NH2 NN NN O
- NN NN O
terminal NN NN O
126 NN NN O
amino NN NN O
acids NN NN O
of NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
are NN NN O
both NN NN O
essential NN NN O
and NN NN O
sufficient NN NN O
for NN NN O
interaction NN NN O
with NN NN O
the NN NN O
POU NN NN O
domains NN NN O
of NN NN O
either NN NN O
Oct1 NN NN B-Protein
or NN NN O
Oct2 NN NN B-Protein
. NN NN O
   
This NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interaction NN NN O
does NN NN O
not NN NN O
require NN NN O
the NN NN O
simultaneous NN NN O
binding NN NN O
of NN NN O
Oct NN NN O
proteins NN NN O
to NN NN O
DNA NN NN O
, NN NN O
and NN NN O
high NN NN O
resolution NN NN O
footprinting NN NN O
of NN NN O
the NN NN O
Oct NN NN O
- NN NN O
DNA NN NN O
interaction NN NN O
reveals NN NN O
that NN NN O
binding NN NN O
of NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
to NN NN O
Oct1 NN NN B-Protein
or NN NN O
Oct2 NN NN B-Protein
does NN NN O
not NN NN O
alter NN NN O
the NN NN O
interaction NN NN O
with NN NN O
DNA NN NN O
. NN NN O
   
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
can NN NN O
efficiently NN NN O
activate NN NN O
octamer NN NN O
- NN NN O
dependent NN NN O
promoters NN NN O
in NN NN O
fibroblasts NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
fails NN NN O
to NN NN O
stimulate NN NN O
octamer NN NN O
- NN NN O
dependent NN NN O
enhancer NN NN O
activity NN NN O
. NN NN O
   
Fusion NN NN O
of NN NN O
subdomains NN NN O
of NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
with NN NN O
the NN NN O
GAL4 NN NN B-Protein
DNA NN NN O
binding NN NN O
domain NN NN O
reveals NN NN O
that NN NN O
both NN NN O
NH2 NN NN O
- NN NN O
and NN NN O
COOH NN NN O
- NN NN O
terminal NN NN O
domains NN NN O
of NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
contribute NN NN O
to NN NN O
full NN NN O
transactivation NN NN O
function NN NN O
, NN NN O
the NN NN O
COOH NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
is NN NN O
more NN NN O
efficient NN NN O
in NN NN O
this NN NN O
transactivation NN NN O
assay NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
the NN NN O
failure NN NN O
of NN NN O
full NN NN O
- NN NN O
length NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
to NN NN O
stimulate NN NN O
octamer NN NN O
- NN NN O
dependent NN NN O
enhancer NN NN O
elements NN NN O
in NN NN O
non NN NN O
B NN NN O
cells NN NN O
, NN NN O
the NN NN O
GAL4 NN NN B-Protein
fusions NN NN O
likewise NN NN O
only NN NN O
stimulate NN NN O
from NN NN O
a NN NN O
promoter NN NN O
- NN NN O
proximal NN NN O
position NN NN O
. NN NN O
   
Polymorphic NN NN O
nucleotides NN NN O
within NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
that NN NN O
mediate NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O
   
Atopy NN NN O
, NN NN O
which NN NN O
predisposes NN NN O
individuals NN NN O
to NN NN O
develop NN NN O
asthma NN NN O
, NN NN O
severe NN NN O
systemic NN NN O
anaphylaxis NN NN O
, NN NN O
and NN NN O
atopic NN NN O
dermatitis NN NN O
, NN NN O
is NN NN O
usually NN NN O
associated NN NN O
with NN NN O
dramatically NN NN O
elevated NN NN O
total NN NN O
serum NN NN O
IgE NN NN O
levels NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
controlled NN NN O
by NN NN O
a NN NN O
major NN NN O
susceptibility NN NN O
gene NN NN O
and NN NN O
multiple NN NN O
minor NN NN O
susceptibility NN NN O
genes NN NN O
. NN NN O
   
A NN NN O
recent NN NN O
sib NN NN O
- NN NN O
pair NN NN O
analysis NN NN O
revealed NN NN O
a NN NN O
tight NN NN O
linkage NN NN O
between NN NN O
markers NN NN O
on NN NN O
5q31 NN NN O
. NN NN O
1 NN NN O
and NN NN O
a NN NN O
major NN NN O
susceptibility NN NN O
gene NN NN O
controlling NN NN O
total NN NN O
serum NN NN O
IgE NN NN O
levels NN NN O
. NN NN O
   
Due NN NN O
to NN NN O
its NN NN O
location NN NN O
within NN NN O
this NN NN O
cluster NN NN O
and NN NN O
its NN NN O
biologic NN NN O
role NN NN O
in NN NN O
Ig NN NN O
class NN NN O
switching NN NN O
and NN NN O
Th2 NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
has NN NN O
emerged NN NN O
as NN NN O
one NN NN O
major NN NN O
candidate NN NN O
for NN NN O
the NN NN O
atopy NN NN O
gene NN NN O
. NN NN O
   
In NN NN O
one NN NN O
model NN NN O
, NN NN O
polymorphisms NN NN O
within NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
regulatory NN NN O
elements NN NN O
might NN NN O
result NN NN O
in NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
amplifying NN NN O
Th2 NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
class NN NN O
switching NN NN O
to NN NN O
IgE NN NN O
. NN NN O
   
In NN NN O
support NN NN O
of NN NN O
this NN NN O
model NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
exists NN NN O
in NN NN O
multiple NN NN O
allelic NN NN O
forms NN NN O
that NN NN O
exhibit NN NN O
distinct NN NN O
transcriptional NN NN O
activities NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
positive NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
particular NN NN O
allele NN NN O
has NN NN O
an NN NN O
unusually NN NN O
high NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
nucleotide NN NN O
substitution NN NN O
within NN NN O
a NN NN O
recently NN NN O
described NN NN O
OAP40 NN NN O
element NN NN O
located NN NN O
just NN NN O
upstream NN NN O
of NN NN O
an NN NN O
NF NN NN O
- NN NN O
AT NN NN O
site NN NN O
( NN NN O
P NN NN O
sequence NN NN O
) NN NN O
appears NN NN O
to NN NN O
be NN NN O
largely NN NN O
responsible NN NN O
for NN NN O
the NN NN O
increased NN NN O
promotor NN NN O
strength NN NN O
of NN NN O
this NN NN O
particular NN NN O
allelic NN NN O
form NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
EMSAs NN NN O
, NN NN O
this NN NN O
substitution NN NN O
results NN NN O
in NN NN O
a NN NN O
markedly NN NN O
enhanced NN NN O
affinity NN NN O
for NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
complexes NN NN O
exhibiting NN NN O
an NN NN O
AP NN NN O
- NN NN O
1 NN NN O
specificity NN NN O
. NN NN O
   
The NN NN O
identification NN NN O
of NN NN O
allelic NN NN O
nucleotides NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
, NN NN O
provides NN NN O
specific NN NN O
targets NN NN O
for NN NN O
a NN NN O
comprehensive NN NN O
screening NN NN O
of NN NN O
atopic NN NN O
and NN NN O
nonatopic NN NN O
individuals NN NN O
and NN NN O
may NN NN O
provide NN NN O
a NN NN O
clue NN NN O
for NN NN O
genetic NN NN O
predisposition NN NN O
for NN NN O
atopy NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
cooperates NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
to NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
from NN NN O
latently NN NN O
and NN NN O
acutely NN NN O
infected NN NN O
cells NN NN O
of NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
is NN NN O
elevated NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
individuals NN NN O
and NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
disease NN NN O
progression NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
the NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
from NN NN O
infected NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
Although NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
alone NN NN O
did NN NN O
not NN NN O
induce NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
, NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
markedly NN NN O
enhanced NN NN O
virion NN NN O
production NN NN O
from NN NN O
a NN NN O
chronically NN NN O
infected NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
( NN NN O
U1 NN NN O
) NN NN O
and NN NN O
in NN NN O
acutely NN NN O
infected NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
. NN NN O
   
Neutralizing NN NN O
mAbs NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
indicated NN NN O
that NN NN O
both NN NN O
cytokines NN NN O
were NN NN O
essential NN NN O
for NN NN O
the NN NN O
induction NN NN O
and NN NN O
were NN NN O
required NN NN O
to NN NN O
generate NN NN O
a NN NN O
synergistic NN NN O
increase NN NN O
in NN NN O
virus NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
the NN NN O
two NN NN O
cytokines NN NN O
were NN NN O
distinguishable NN NN O
functionally NN NN O
since NN NN O
pretreatment NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
attenuated NN NN O
the NN NN O
cytokine NN NN O
cooperativity NN NN O
, NN NN O
while NN NN O
pretreatment NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
potentiated NN NN O
their NN NN O
cooperativity NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
play NN NN O
different NN NN O
roles NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
virus NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
as NN NN O
well NN NN O
as NN NN O
Ab NN NN O
blocking NN NN O
and NN NN O
cytokine NN NN O
secretion NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
the NN NN O
induction NN NN O
of NN NN O
either NN NN O
endogenous NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
was NN NN O
not NN NN O
involved NN NN O
in NN NN O
the NN NN O
cooperativity NN NN O
, NN NN O
nor NN NN O
was NN NN O
an NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
TNF NN NN O
- NN NN O
alpha NN NN O
receptors NN NN O
. NN NN O
   
In NN NN O
combination NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
stimulated NN NN O
activating NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activities NN NN O
and NN NN O
cooperated NN NN O
to NN NN O
increase NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
steady NN NN O
- NN NN O
state NN NN O
mRNA NN NN O
levels NN NN O
and NN NN O
enhance NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
through NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sites NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
effect NN NN O
occurs NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
down NN NN O
- NN NN O
regulating NN NN O
the NN NN O
cellular NN NN O
immune NN NN O
response NN NN O
to NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
may NN NN O
also NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
lineage NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
and NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
sequences NN NN O
controlling NN NN O
human NN NN O
B29 NN NN B-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
product NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
B29 NN NN B-Protein
gene NN NN O
( NN NN O
B29 NN NN B-Protein
, NN NN O
Ig NN NN B-Protein
beta NN NN I-Protein
, NN NN O
CD79b NN NN B-Protein
) NN NN O
is NN NN O
essential NN NN O
for NN NN O
Ig NN NN O
- NN NN O
mediated NN NN O
B NN NN O
- NN NN O
cell NN NN O
activation NN NN O
via NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
complex NN NN O
( NN NN O
BCR NN NN O
) NN NN O
on NN NN O
human NN NN O
and NN NN O
murine NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
the NN NN O
regulation NN NN O
of NN NN O
this NN NN O
pivotal NN NN O
gene NN NN O
, NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
human NN NN O
genomic NN NN O
DNA NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
B29 NN NN B-Protein
ATG NN NN O
start NN NN O
codon NN NN O
for NN NN O
transcriptional NN NN O
control NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
human NN NN O
B29 NN NN B-Protein
gene NN NN O
lacks NN NN O
either NN NN O
a NN NN O
TATA NN NN O
or NN NN O
a NN NN O
CAAT NN NN O
box NN NN O
and NN NN O
transcription NN NN O
is NN NN O
initiated NN NN O
at NN NN O
multiple NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
minimal NN NN O
promoter NN NN O
of NN NN O
the NN NN O
human NN NN O
B29 NN NN B-Protein
gene NN NN O
is NN NN O
contained NN NN O
within NN NN O
a NN NN O
193 NN NN O
- NN NN O
bp NN NN O
region NN NN O
5 NN NN O
' NN NN O
of NN NN O
these NN NN O
multiple NN NN O
start NN NN O
sites NN NN O
. NN NN O
   
This NN NN O
minimal NN NN O
promoter NN NN O
exhibits NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
activity NN NN O
and NN NN O
contains NN NN O
SP1 NN NN O
, NN NN O
ETS NN NN O
, NN NN O
OCT NN NN O
, NN NN O
and NN NN O
IKAROS NN NN O
/ NN NN O
LYF NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
motifs NN NN O
. NN NN O
   
All NN NN O
these NN NN O
motifs NN NN O
are NN NN O
strikingly NN NN O
conserved NN NN O
in NN NN O
sequence NN NN O
and NN NN O
placement NN NN O
relative NN NN O
to NN NN O
the NN NN O
previously NN NN O
characterized NN NN O
murine NN NN O
B29 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Additional NN NN O
upstream NN NN O
gene NN NN O
segments NN NN O
dramatically NN NN O
affected NN NN O
B29 NN NN B-Protein
minimal NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
newly NN NN O
identified NN NN O
motif NN NN O
called NN NN O
the NN NN O
B29 NN NN B-Protein
conserved NN NN O
sequence NN NN O
( NN NN O
BCS NN NN O
) NN NN O
, NN NN O
found NN NN O
upstream NN NN O
of NN NN O
both NN NN O
human NN NN O
and NN NN O
murine NN NN O
B29 NN NN B-Protein
promoters NN NN O
, NN NN O
appears NN NN O
to NN NN O
stimulate NN NN O
B29 NN NN B-Protein
transcription NN NN O
through NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
. NN NN O
   
A NN NN O
single NN NN O
BCS NN NN O
had NN NN O
little NN NN O
effect NN NN O
either NN NN O
on NN NN O
the NN NN O
minimal NN NN O
B29 NN NN B-Protein
promoter NN NN O
or NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
Instead NN NN O
, NN NN O
the NN NN O
BCS NN NN O
stimulated NN NN O
transcription NN NN O
by NN NN O
counteracting NN NN O
5 NN NN O
' NN NN O
negative NN NN O
regulatory NN NN O
DNA NN NN O
sequences NN NN O
that NN NN O
block NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
B29 NN NN B-Protein
minimal NN NN O
promoter NN NN O
in NN NN O
its NN NN O
absence NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
B29 NN NN B-Protein
gene NN NN O
expression NN NN O
is NN NN O
controlled NN NN O
by NN NN O
the NN NN O
complex NN NN O
interplay NN NN O
of NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
MEK1 NN NN B-Protein
and NN NN O
the NN NN O
extracellular NN NN O
signal NN NN O
- NN NN O
regulated NN NN O
kinases NN NN O
are NN NN O
required NN NN O
for NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
TCR NN NN O
engagement NN NN O
stimulates NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
protein NN NN O
kinase NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Active NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
phosphorylates NN NN O
and NN NN O
activates NN NN O
the NN NN O
mitogen NN NN B-Protein
- NN NN I-Protein
activated NN NN I-Protein
protein NN NN I-Protein
( NN NN I-Protein
MAP NN NN I-Protein
) NN NN I-Protein
kinase NN NN I-Protein
/ NN NN I-Protein
extracellular NN NN I-Protein
signal NN NN I-Protein
- NN NN I-Protein
regulated NN NN I-Protein
kinase NN NN I-Protein
kinase NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MEK1 NN NN B-Protein
) NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
phosphorylates NN NN O
and NN NN O
activates NN NN O
the NN NN O
MAP NN NN O
kinases NN NN O
/ NN NN O
extracellular NN NN O
signal NN NN O
regulated NN NN O
kinases NN NN O
, NN NN O
ERK1 NN NN B-Protein
and NN NN O
ERK2 NN NN B-Protein
. NN NN O
   
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
activity NN NN O
promotes NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
determine NN NN O
whether NN NN O
MEK1 NN NN B-Protein
and NN NN O
ERK NN NN O
activities NN NN O
also NN NN O
stimulate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
constitutively NN NN O
active NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
MEK1 NN NN B-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
enhanced NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
stimulated NN NN O
by NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
and NN NN O
PMA NN NN O
, NN NN O
and NN NN O
together NN NN O
with NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
the NN NN O
expression NN NN O
of NN NN O
each NN NN O
protein NN NN O
was NN NN O
sufficient NN NN O
to NN NN O
stimulate NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activity NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
MEK1 NN NN B-Protein
- NN NN O
interfering NN NN O
mutants NN NN O
inhibited NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
and NN NN O
blocked NN NN O
the NN NN O
ability NN NN O
of NN NN O
constitutively NN NN O
active NN NN O
Ras NN NN O
and NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
costimulate NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activity NN NN O
with NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
MAP NN NN O
kinase NN NN O
- NN NN O
specific NN NN O
phosphatase NN NN O
, NN NN O
MKP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
which NN NN O
blocks NN NN O
ERK NN NN O
activation NN NN O
, NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
stimulated NN NN O
by NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
and NN NN O
PMA NN NN O
, NN NN O
and NN NN O
in NN NN O
addition NN NN O
, NN NN O
MKP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
neutralized NN NN O
the NN NN O
transcriptional NN NN O
enhancement NN NN O
caused NN NN O
by NN NN O
active NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
MEK1 NN NN B-Protein
expression NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
MAP NN NN O
kinase NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
consisting NN NN O
of NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
MEK1 NN NN B-Protein
, NN NN O
and NN NN O
ERK1 NN NN B-Protein
and NN NN O
ERK2 NN NN B-Protein
functions NN NN O
in NN NN O
the NN NN O
stimulation NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
Fc NN NN O
gamma NN NN O
receptors NN NN O
activates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Elevation NN NN O
of NN NN O
the NN NN O
levels NN NN O
of NN NN O
circulating NN NN O
immune NN NN O
complexes NN NN O
frequently NN NN O
accompanies NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
and NN NN O
is NN NN O
a NN NN O
prognostic NN NN O
indicator NN NN O
of NN NN O
clinical NN NN O
progression NN NN O
from NN NN O
asymptomatic NN NN O
infection NN NN O
to NN NN O
AIDS NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
that NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RI NN NN I-Protein
or NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
RII NN NN I-Protein
by NN NN O
adherent NN NN O
human NN NN O
IgG NN NN O
or NN NN O
by NN NN O
specific NN NN O
anti NN NN O
- NN NN O
Fc NN NN O
gamma NN NN O
R NN NN O
mAb NN NN O
activates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
BF24 NN NN O
and NN NN O
increased NN NN O
HIV NN NN O
RNA NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
from NN NN O
HIV NN NN O
infected NN NN O
patients NN NN O
as NN NN O
assayed NN NN O
by NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
In NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
Fc NN NN O
gamma NN NN O
R NN NN O
cross NN NN O
- NN NN O
linking NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
is NN NN O
known NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
to NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibody NN NN O
but NN NN O
not NN NN O
anti NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
antibody NN NN O
strongly NN NN O
inhibited NN NN O
both NN NN O
the NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
Fc NN NN O
gamma NN NN O
R NN NN O
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Fc NN NN O
gamma NN NN O
R NN NN O
can NN NN O
mediate NN NN O
a NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
transcription NN NN O
and NN NN O
suggest NN NN O
that NN NN O
immune NN NN O
complexes NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
by NN NN O
augmenting NN NN O
viral NN NN O
replication NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
Toremifene NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
some NN NN O
genes NN NN O
in NN NN O
human NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Toremifene NN NN O
exerts NN NN O
multiple NN NN O
and NN NN O
varied NN NN O
effects NN NN O
on NN NN O
the NN NN O
gene NN NN O
expression NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
After NN NN O
short NN NN O
- NN NN O
term NN NN O
, NN NN O
in NN NN O
vitro NN NN O
exposure NN NN O
to NN NN O
therapeutical NN NN O
levels NN NN O
, NN NN O
distinct NN NN O
changes NN NN O
in NN NN O
P NN NN O
- NN NN O
glycoprotein NN NN O
, NN NN O
steroid NN NN O
receptors NN NN O
, NN NN O
p53 NN NN B-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
take NN NN O
place NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
the NN NN O
increasing NN NN O
use NN NN O
of NN NN O
antiestrogens NN NN O
in NN NN O
cancer NN NN O
therapy NN NN O
and NN NN O
prevention NN NN O
, NN NN O
there NN NN O
is NN NN O
obvious NN NN O
merit NN NN O
in NN NN O
long NN NN O
- NN NN O
term NN NN O
in NN NN O
vivo NN NN O
studies NN NN O
to NN NN O
be NN NN O
conducted NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
an NN NN O
ionomycin NN NN O
/ NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
responsive NN NN O
element NN NN O
within NN NN O
the NN NN O
human NN NN O
T NN NN B-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
gamma NN NN I-Protein
enhancer NN NN O
. NN NN O
   
Activation NN NN O
through NN NN O
the NN NN O
Ca2 NN NN O
+ NN NN O
/ NN NN O
calcineurin NN NN O
pathway NN NN O
is NN NN O
essential NN NN O
to NN NN O
the NN NN O
transcription NN NN O
of NN NN O
many NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
conserved NN NN O
cis NN NN O
- NN NN O
acting NN NN O
sequence NN NN O
, NN NN O
GGAAAA NN NN O
, NN NN O
and NN NN O
transcription NN NN O
factors NN NN O
binding NN NN O
to NN NN O
this NN NN O
sequence NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
response NN NN O
to NN NN O
increased NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
concentrations NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
the NN NN O
identification NN NN O
and NN NN O
importance NN NN O
of NN NN O
the NN NN O
same NN NN O
sequence NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
cytokine NN NN O
gene NN NN O
, NN NN O
the NN NN O
human NN NN O
T NN NN B-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
TCRG NN NN B-Protein
) NN NN O
enhancer NN NN O
. NN NN O
   
Results NN NN O
from NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutations NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
this NN NN O
sequence NN NN O
mediates NN NN O
the NN NN O
ionomycin NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
TCRG NN NN B-Protein
enhancer NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
provide NN NN O
an NN NN O
explanation NN NN O
for NN NN O
a NN NN O
previous NN NN O
observation NN NN O
that NN NN O
TCRG NN NN B-Protein
mRNA NN NN O
levels NN NN O
, NN NN O
but NN NN O
not NN NN O
mRNA NN NN O
levels NN NN O
for NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
alpha NN NN O
and NN NN O
- NN NN O
beta NN NN O
, NN NN O
are NN NN O
increased NN NN O
by NN NN O
ionomycin NN NN O
treatment NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
by NN NN O
anetholdithiolthione NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
redox NN NN O
sensitive NN NN O
cytosolic NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Redox NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immuno NN NN O
- NN NN O
deficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
may NN NN O
be NN NN O
an NN NN O
effective NN NN O
strategy NN NN O
for NN NN O
acquired NN NN O
immunodeficiency NN NN O
syndrome NN NN O
therapy NN NN O
. NN NN O
   
Anetholdithiolthione NN NN O
( NN NN O
ADT NN NN O
, NN NN O
5 NN NN O
- NN NN O
[ NN NN O
p NN NN O
- NN NN O
methoxyphenyl NN NN O
] NN NN O
- NN NN O
3H NN NN O
- NN NN O
1 NN NN O
, NN NN O
2 NN NN O
- NN NN O
dithiol NN NN O
- NN NN O
3 NN NN O
- NN NN O
thione NN NN O
) NN NN O
is NN NN O
an NN NN O
antioxidant NN NN O
which NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
protect NN NN O
against NN NN O
acetaminophen NN NN O
- NN NN O
and NN NN O
CCl4 NN NN O
- NN NN O
induced NN NN O
hepatotoxicity NN NN O
, NN NN O
lipid NN NN O
peroxidation NN NN O
, NN NN O
radiation NN NN O
injury NN NN O
, NN NN O
and NN NN O
also NN NN O
has NN NN O
been NN NN O
used NN NN O
clinically NN NN O
as NN NN O
an NN NN O
anti NN NN O
- NN NN O
choleretic NN NN O
agent NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
ADT NN NN O
pretreatment NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
stimuli NN NN O
such NN NN O
as NN NN O
H2O2 NN NN O
, NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
or NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
PMA NN NN O
and NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
induced NN NN O
activation NN NN O
of NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
was NN NN O
partially NN NN O
inhibited NN NN O
by NN NN O
ADT NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mM NN NN O
) NN NN O
pretreatment NN NN O
. NN NN O
   
ADT NN NN O
( NN NN O
0 NN NN O
. NN NN O
1 NN NN O
mM NN NN O
) NN NN O
also NN NN O
inhibited NN NN O
H2O2 NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
peroxide NN NN O
sensitive NN NN O
human NN NN O
Wurzburg NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
ADT NN NN O
treated NN NN O
Wurzburg NN NN O
cells NN NN O
had NN NN O
significantly NN NN O
higher NN NN O
glutathione NN NN O
levels NN NN O
as NN NN O
compared NN NN O
with NN NN O
untreated NN NN O
cells NN NN O
. NN NN O
   
H2O2 NN NN O
induced NN NN O
lipid NN NN O
peroxidation NN NN O
in NN NN O
Wurzburg NN NN O
cells NN NN O
was NN NN O
remarkably NN NN O
inhibited NN NN O
by NN NN O
ADT NN NN O
pretreatment NN NN O
. NN NN O
   
ADT NN NN O
, NN NN O
a NN NN O
pro NN NN O
- NN NN O
glutathione NN NN O
antioxidant NN NN O
, NN NN O
was NN NN O
observed NN NN O
to NN NN O
be NN NN O
capable NN NN O
of NN NN O
modulating NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
anergized NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
express NN NN O
perturbed NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Anergy NN NN O
is NN NN O
a NN NN O
major NN NN O
mechanism NN NN O
to NN NN O
ensure NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
tolerance NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
the NN NN O
adult NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
, NN NN O
anergy NN NN O
has NN NN O
mainly NN NN O
been NN NN O
studied NN NN O
at NN NN O
the NN NN O
cellular NN NN O
level NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
used NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
activating NN NN O
superantigen NN NN O
staphylococcal NN NN B-Protein
enterotoxin NN NN I-Protein
A NN NN I-Protein
( NN NN O
SEA NN NN B-Protein
) NN NN O
to NN NN O
investigate NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
anergy NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Injection NN NN O
of NN NN O
SEA NN NN B-Protein
to NN NN O
adult NN NN O
mice NN NN O
activates NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
expressing NN NN O
certain NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
variable NN NN O
region NN NN O
beta NN NN O
- NN NN O
chain NN NN O
families NN NN O
and NN NN O
induces NN NN O
strong NN NN O
and NN NN O
rapid NN NN O
production NN NN O
of NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
repeated NN NN O
injections NN NN O
of NN NN O
SEA NN NN B-Protein
cause NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
deletion NN NN O
and NN NN O
anergy NN NN O
in NN NN O
the NN NN O
remaining NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
characterized NN NN O
by NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
at NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
levels NN NN O
. NN NN O
   
We NN NN O
analyzed NN NN O
expression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
and NN NN O
octamer NN NN O
binding NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
which NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Large NN NN O
amounts NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
significant NN NN O
quantities NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
were NN NN O
induced NN NN O
in NN NN O
SEA NN NN B-Protein
- NN NN O
activated NN NN O
CD4 NN NN B-Protein
+ NN NN O
spleen NN NN O
T NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
similar NN NN O
in NN NN O
both NN NN O
resting NN NN O
and NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
anergic NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
contained NN NN O
severely NN NN O
reduced NN NN O
levels NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
Fos NN NN B-Protein
/ NN NN O
Jun NN NN B-Protein
- NN NN O
containing NN NN O
NF NN NN O
- NN NN O
AT NN NN O
complexes NN NN O
but NN NN O
expressed NN NN O
significant NN NN O
amounts NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Oct NN NN O
binding NN NN O
proteins NN NN O
after NN NN O
SEA NN NN B-Protein
stimulation NN NN O
. NN NN O
   
Resolution NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
demonstrated NN NN O
predominant NN NN O
expression NN NN O
of NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
heterodimers NN NN O
in NN NN O
activated NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
while NN NN O
anergic NN NN O
cells NN NN O
mainly NN NN O
expressed NN NN O
the NN NN O
transcriptionally NN NN O
inactive NN NN O
p50 NN NN B-Protein
homodimer NN NN O
. NN NN O
   
These NN NN O
alterations NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
likely NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
repression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
anergic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Surfactant NN NN O
suppresses NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
biophysical NN NN O
properties NN NN O
, NN NN O
pulmonary NN NN O
surfactant NN NN O
has NN NN O
immunomodulatory NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
synthetic NN NN O
( NN NN O
Exosurf NN NN O
) NN NN O
and NN NN O
modified NN NN O
natural NN NN O
surfactant NN NN O
( NN NN O
Survanta NN NN O
) NN NN O
downregulated NN NN O
endotoxin NN NN O
- NN NN O
stimulated NN NN O
inflammatory NN NN O
cytokine NN NN O
mRNA NN NN O
levels NN NN O
and NN NN O
protein NN NN O
products NN NN O
( NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
[ NN NN O
TNF NN NN B-Protein
] NN NN O
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
[ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
] NN NN O
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
[ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
] NN NN O
) NN NN O
in NN NN O
human NN NN O
alveolar NN NN O
macrophages NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
both NN NN O
Exosurf NN NN O
and NN NN O
Survanta NN NN O
suppress NN NN O
TNF NN NN B-Protein
mRNA NN NN O
and NN NN O
secretion NN NN O
( NN NN O
85 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
% NN NN O
mean NN NN O
percent NN NN O
inhibition NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SEM NN NN O
by NN NN O
Exosurf NN NN O
; NN NN O
71 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
% NN NN O
by NN NN O
Survanta NN NN O
) NN NN O
by NN NN O
endotoxin NN NN O
- NN NN O
stimulated NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
a NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Because NN NN O
surfactant NN NN O
downregulated NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
similarly NN NN O
in NN NN O
both NN NN O
normal NN NN O
human NN NN O
alveolar NN NN O
macrophages NN NN O
and NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cell NN NN O
line NN NN O
, NN NN O
we NN NN O
used NN NN O
this NN NN O
cell NN NN O
line NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
surfactant NN NN O
affected NN NN O
transcriptional NN NN O
mechanisms NN NN O
. NN NN O
   
Specifically NN NN O
, NN NN O
we NN NN O
examined NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
because NN NN O
it NN NN O
is NN NN O
crucial NN NN O
in NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
many NN NN O
inflammatory NN NN O
cytokine NN NN O
genes NN NN O
including NN NN O
TNF NN NN B-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
showed NN NN O
that NN NN O
both NN NN O
surfactants NN NN O
decreased NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
both NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
components NN NN O
in NN NN O
LPS NN NN O
- NN NN O
activated NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
specific NN NN O
antibody NN NN O
induction NN NN O
of NN NN O
supershifts NN NN O
in NN NN O
mobility NN NN O
assays NN NN O
. NN NN O
   
These NN NN O
results NN NN O
are NN NN O
the NN NN O
first NN NN O
to NN NN O
suggest NN NN O
that NN NN O
surfactant NN NN O
' NN NN O
s NN NN O
suppressive NN NN O
effects NN NN O
on NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
may NN NN O
involve NN NN O
transcriptional NN NN O
regulation NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
A NN NN O
mammalian NN NN O
histone NN NN O
deacetylase NN NN O
related NN NN O
to NN NN O
the NN NN O
yeast NN NN O
transcriptional NN NN O
regulator NN NN O
Rpd3p NN NN B-Protein
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
Trapoxin NN NN O
is NN NN O
a NN NN O
microbially NN NN O
derived NN NN O
cyclotetrapeptide NN NN O
that NN NN O
inhibits NN NN O
histone NN NN O
deacetylation NN NN O
in NN NN O
vivo NN NN O
and NN NN O
causes NN NN O
mammalian NN NN O
cells NN NN O
to NN NN O
arrest NN NN O
in NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
A NN NN O
trapoxin NN NN O
affinity NN NN O
matrix NN NN O
was NN NN O
used NN NN O
to NN NN O
isolate NN NN O
two NN NN O
nuclear NN NN O
proteins NN NN O
that NN NN O
copurified NN NN O
with NN NN O
histone NN NN O
deacetylase NN NN O
activity NN NN O
. NN NN O
   
Both NN NN O
proteins NN NN O
were NN NN O
identified NN NN O
by NN NN O
peptide NN NN O
microsequencing NN NN O
, NN NN O
and NN NN O
a NN NN O
complementary NN NN O
DNA NN NN O
encoding NN NN O
the NN NN O
histone NN NN O
deacetylase NN NN O
catalytic NN NN O
subunit NN NN O
( NN NN O
HD1 NN NN B-Protein
) NN NN O
was NN NN O
cloned NN NN O
from NN NN O
a NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
library NN NN O
. NN NN O
   
As NN NN O
the NN NN O
predicted NN NN O
protein NN NN O
is NN NN O
very NN NN O
similar NN NN O
to NN NN O
the NN NN O
yeast NN NN O
transcriptional NN NN O
regulator NN NN O
Rpd3p NN NN B-Protein
, NN NN O
these NN NN O
results NN NN O
support NN NN O
a NN NN O
role NN NN O
for NN NN O
histone NN NN O
deacetylase NN NN O
as NN NN O
a NN NN O
key NN NN O
regulator NN NN O
of NN NN O
eukaryotic NN NN O
transcription NN NN O
. NN NN O
   
Coexpression NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
genes NN NN O
correlates NN NN O
with NN NN O
their NN NN O
physical NN NN O
linkage NN NN O
in NN NN O
the NN NN O
cytokine NN NN O
gene NN NN O
cluster NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
5q23 NN NN O
- NN NN O
31 NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
) NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
are NN NN O
cytokines NN NN O
produced NN NN O
by NN NN O
T NN NN O
cells NN NN O
that NN NN O
are NN NN O
encoded NN NN O
by NN NN O
the NN NN O
q23 NN NN O
- NN NN O
31 NN NN O
region NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
isolated NN NN O
and NN NN O
sequenced NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
gene NN NN O
, NN NN O
analyzed NN NN O
its NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
for NN NN O
potential NN NN O
transcriptional NN NN O
activation NN NN O
elements NN NN O
, NN NN O
and NN NN O
examined NN NN O
its NN NN O
expression NN NN O
in NN NN O
nontransformed NN NN O
T NN NN O
- NN NN O
lineage NN NN O
cell NN NN O
populations NN NN O
. NN NN O
   
The NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
gene NN NN O
was NN NN O
located NN NN O
12 NN NN O
. NN NN O
5 NN NN O
- NN NN O
kb NN NN O
upstream NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
and NN NN O
2 NN NN O
- NN NN O
kb NN NN O
downstream NN NN O
of NN NN O
a NN NN O
CpG NN NN O
island NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
gene NN NN O
5 NN NN O
' NN NN O
flank NN NN O
region NN NN O
included NN NN O
a NN NN O
segment NN NN O
with NN NN O
sequence NN NN O
homology NN NN O
to NN NN O
P NN NN O
elements NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
involved NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
P NN NN O
element NN NN O
site NN NN O
significantly NN NN O
reduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
response NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Oligonucleotides NN NN O
containing NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
P NN NN O
element NN NN O
sites NN NN O
specifically NN NN O
bound NN NN O
the NN NN O
transcriptional NN NN O
activator NN NN O
protein NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
preformed NN NN O
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
) NN NN O
, NN NN O
when NN NN O
incubated NN NN O
with NN NN O
nuclear NN NN O
protein NN NN O
extracts NN NN O
from NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
mRNA NN NN O
expression NN NN O
was NN NN O
highest NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
populations NN NN O
enriched NN NN O
for NN NN O
cells NN NN O
that NN NN O
had NN NN O
previously NN NN O
been NN NN O
primed NN NN O
in NN NN O
vivo NN NN O
or NN NN O
in NN NN O
vitro NN NN O
, NN NN O
indicating NN NN O
that NN NN O
priming NN NN O
increases NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
genes NN NN O
in NN NN O
a NN NN O
coordinate NN NN O
manner NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
primed NN NN O
T NN NN O
cells NN NN O
contain NN NN O
higher NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
, NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
P NN NN O
elements NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
promoters NN NN O
, NN NN O
than NN NN O
do NN NN O
freshly NN NN O
- NN NN O
isolated NN NN O
T NN NN O
cells NN NN O
, NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
binding NN NN O
P NN NN O
elements NN NN O
are NN NN O
attractive NN NN O
candidates NN NN O
to NN NN O
mediate NN NN O
the NN NN O
coordinate NN NN O
expression NN NN O
of NN NN O
these NN NN O
two NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Transactivation NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
and NN NN O
type NN NN O
II NN NN O
Tax NN NN B-Protein
proteins NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
- NN NN O
infected NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
constitutively NN NN O
produce NN NN O
high NN NN O
levels NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
) NN NN O
. NN NN O
   
To NN NN O
analyze NN NN O
the NN NN O
mechanisms NN NN O
that NN NN O
lead NN NN O
to NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
infected NN NN O
cell NN NN O
lines NN NN O
, NN NN O
we NN NN O
studied NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
involved NN NN O
in NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
constructs NN NN O
drive NN NN O
transcription NN NN O
of NN NN O
the NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
gene NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
positive NN NN O
MT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
, NN NN O
which NN NN O
constitutively NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
. NN NN O
   
In NN NN O
a NN NN O
cotransfection NN NN O
assay NN NN O
, NN NN O
the NN NN O
Tax NN NN B-Protein
protein NN NN O
of NN NN O
both NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
and NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
specifically NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
in NN NN O
an NN NN O
uninfected NN NN O
Jurkat NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
A NN NN O
mutant NN NN O
Tax NN NN B-Protein
protein NN NN O
deficient NN NN O
in NN NN O
transactivation NN NN O
of NN NN O
genes NN NN O
by NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
was NN NN O
unable NN NN O
to NN NN O
induce NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
- NN NN O
CAT NN NN B-Protein
constructs NN NN O
, NN NN O
but NN NN O
was NN NN O
rescued NN NN O
by NN NN O
exogenous NN NN O
provision NN NN O
of NN NN O
p65 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
two NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
kappaB NN NN O
- NN NN O
like NN NN O
sites NN NN O
( NN NN O
positions NN NN O
- NN NN O
1 NN NN O
, NN NN O
065 NN NN O
to NN NN O
- NN NN O
1 NN NN O
, NN NN O
056 NN NN O
and NN NN O
+ NN NN O
646 NN NN O
to NN NN O
+ NN NN O
655 NN NN O
) NN NN O
specifically NN NN O
formed NN NN O
a NN NN O
complex NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
containing NN NN O
nuclear NN NN O
extract NN NN O
from NN NN O
MT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
and NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
bound NN NN O
with NN NN O
higher NN NN O
affinity NN NN O
to NN NN O
the NN NN O
3 NN NN O
' NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
site NN NN O
than NN NN O
to NN NN O
the NN NN O
5 NN NN O
' NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
deletion NN NN O
of NN NN O
either NN NN O
5 NN NN O
' NN NN O
or NN NN O
3 NN NN O
' NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
sites NN NN O
reduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
MT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
and NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
promoter NN NN O
by NN NN O
exogenous NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
Tax NN NN B-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
general NN NN O
role NN NN O
for NN NN O
Tax NN NN B-Protein
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
by NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
by NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
productively NN NN O
infected NN NN O
cells NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
hypercalcemia NN NN O
, NN NN O
osteolytic NN NN O
bone NN NN O
lesions NN NN O
, NN NN O
neutrophilia NN NN O
, NN NN O
elevation NN NN O
of NN NN O
C NN NN O
- NN NN O
reactive NN NN O
protein NN NN O
, NN NN O
and NN NN O
fever NN NN O
frequently NN NN O
seen NN NN O
in NN NN O
patients NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
- NN NN O
induced NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
/ NN NN O
lymphoma NN NN O
. NN NN O
   
Soluble NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
receptors NN NN O
inhibit NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
and NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
chronically NN NN O
infected NN NN O
U1 NN NN O
cells NN NN O
. NN NN O
   
Recombinant NN NN O
human NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
binding NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
r NN NN O
- NN NN O
h NN NN O
TBP NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
recombinant NN NN O
human NN NN O
soluble NN NN O
dimeric NN NN O
TNF NN NN O
receptor NN NN O
( NN NN O
rhu NN NN O
TNFR NN NN O
: NN NN O
Fc NN NN O
) NN NN O
were NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
relative NN NN O
contributions NN NN O
of NN NN O
TNF NN NN O
to NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
promonocytic NN NN O
U1 NN NN O
cells NN NN O
with NN NN O
r NN NN O
- NN NN O
h NN NN O
- NN NN O
TBP NN NN O
- NN NN O
1 NN NN O
or NN NN O
rhu NN NN O
TNFR NN NN O
: NN NN O
Fc NN NN O
reduced NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
p24 NN NN B-Protein
antigen NN NN O
production NN NN O
in NN NN O
a NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
with NN NN O
a NN NN O
maximal NN NN O
inhibition NN NN O
of NN NN O
approximately NN NN O
90 NN NN O
% NN NN O
. NN NN O
   
Maximal NN NN O
inhibition NN NN O
of NN NN O
p24 NN NN B-Protein
antigen NN NN O
production NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphocytic NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
cells NN NN O
was NN NN O
47 NN NN O
% NN NN O
with NN NN O
r NN NN O
- NN NN O
hTBP NN NN O
- NN NN O
1 NN NN O
and NN NN O
42 NN NN O
% NN NN O
with NN NN O
rhu NN NN O
TNFR NN NN O
: NN NN O
Fc NN NN O
. NN NN O
   
r NN NN O
- NN NN O
hTBP NN NN O
- NN NN O
1 NN NN O
and NN NN O
rhu NN NN O
TNFR NN NN O
: NN NN O
Fc NN NN O
also NN NN O
decreased NN NN O
p24 NN NN B-Protein
antigen NN NN O
synthesized NN NN O
by NN NN O
U1 NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
other NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
phytohemagglutinin NN NN O
( NN NN O
PHA NN NN O
) NN NN O
- NN NN O
induced NN NN O
supernatant NN NN O
, NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
TNF NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
r NN NN O
- NN NN O
hTBP NN NN O
- NN NN O
1 NN NN O
to NN NN O
U1 NN NN O
cells NN NN O
during NN NN O
the NN NN O
last NN NN O
4 NN NN O
h NN NN O
of NN NN O
a NN NN O
24 NN NN O
h NN NN O
incubation NN NN O
with NN NN O
PMA NN NN O
still NN NN O
inhibited NN NN O
p24 NN NN B-Protein
antigen NN NN O
production NN NN O
by NN NN O
15 NN NN O
% NN NN O
. NN NN O
   
U1 NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
M NN NN O
PMA NN NN O
released NN NN O
approximately NN NN O
1 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
endogenous NN NN O
TBP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
with NN NN O
an NN NN O
initial NN NN O
peak NN NN O
observed NN NN O
at NN NN O
1 NN NN O
h NN NN O
and NN NN O
a NN NN O
second NN NN O
peak NN NN O
at NN NN O
24 NN NN O
h NN NN O
after NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
r NN NN O
- NN NN O
hTBP NN NN O
- NN NN O
1 NN NN O
also NN NN O
partially NN NN O
reversed NN NN O
inhibition NN NN O
of NN NN O
U1 NN NN O
cellular NN NN O
proliferation NN NN O
caused NN NN O
by NN NN O
PMA NN NN O
. NN NN O
   
Both NN NN O
r NN NN O
- NN NN O
hTBP NN NN O
- NN NN O
1 NN NN O
and NN NN O
rhu NN NN O
TNFR NN NN O
: NN NN O
Fc NN NN O
blocked NN NN O
PMA NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NK NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
U1 NN NN O
cells NN NN O
in NN NN O
association NN NN O
with NN NN O
decreases NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
soluble NN NN O
TNF NN NN O
receptors NN NN O
can NN NN O
inhibit NN NN O
stimuli NN NN O
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
and NN NN O
NK NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
U1 NN NN O
cells NN NN O
. NN NN O
   
AM580 NN NN O
, NN NN O
a NN NN O
stable NN NN O
benzoic NN NN O
derivative NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
, NN NN O
has NN NN O
powerful NN NN O
and NN NN O
selective NN NN O
cyto NN NN O
- NN NN O
differentiating NN NN O
effects NN NN O
on NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
All NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
is NN NN O
successfully NN NN O
used NN NN O
in NN NN O
the NN NN O
cyto NN NN O
- NN NN O
differentiating NN NN O
treatment NN NN O
of NN NN O
acute NN NN O
promyelocytic NN NN O
leukemia NN NN O
( NN NN O
APL NN NN O
) NN NN O
. NN NN O
   
Paradoxically NN NN O
, NN NN O
APL NN NN O
cells NN NN O
express NN NN O
PML NN NN B-Protein
- NN NN I-Protein
RAR NN NN I-Protein
, NN NN O
an NN NN O
aberrant NN NN O
form NN NN O
of NN NN O
the NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
type NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
derived NN NN O
from NN NN O
the NN NN O
leukemia NN NN O
- NN NN O
specific NN NN O
t NN NN O
( NN NN O
15 NN NN O
; NN NN O
17 NN NN O
) NN NN O
chromosomal NN NN O
translocation NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
AM580 NN NN O
, NN NN O
a NN NN O
stable NN NN O
retinobenzoic NN NN O
derivative NN NN O
originally NN NN O
synthesized NN NN O
as NN NN O
a NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
agonist NN NN O
, NN NN O
is NN NN O
a NN NN O
powerful NN NN O
inducer NN NN O
of NN NN O
granulocytic NN NN O
maturation NN NN O
in NN NN O
NB4 NN NN O
, NN NN O
an NN NN O
APL NN NN O
- NN NN O
derived NN NN O
cell NN NN O
line NN NN O
, NN NN O
and NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
APL NN NN O
blasts NN NN O
. NN NN O
   
After NN NN O
treatment NN NN O
of NN NN O
APL NN NN O
cells NN NN O
with NN NN O
AM580 NN NN O
either NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
, NN NN O
the NN NN O
compound NN NN O
induces NN NN O
granulocytic NN NN O
maturation NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
determination NN NN O
of NN NN O
the NN NN O
levels NN NN O
of NN NN O
leukocyte NN NN B-Protein
alkaline NN NN I-Protein
phosphatase NN NN I-Protein
, NN NN O
CD11b NN NN B-Protein
, NN NN O
CD33 NN NN B-Protein
, NN NN O
and NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
receptor NN NN I-Protein
mRNA NN NN O
, NN NN O
at NN NN O
concentrations NN NN O
that NN NN O
are NN NN O
10 NN NN O
- NN NN O
to NN NN O
100 NN NN O
- NN NN O
fold NN NN O
lower NN NN O
than NN NN O
those NN NN O
of NN NN O
ATRA NN NN O
necessary NN NN O
to NN NN O
produce NN NN O
similar NN NN O
effects NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
AM580 NN NN O
is NN NN O
not NN NN O
effective NN NN O
as NN NN O
ATRA NN NN O
in NN NN O
modulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
differentiation NN NN O
markers NN NN O
in NN NN O
the NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cell NN NN O
line NN NN O
and NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
granulocytes NN NN O
obtained NN NN O
from NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
patients NN NN O
during NN NN O
the NN NN O
stable NN NN O
phase NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O
   
In NN NN O
NB4 NN NN O
cells NN NN O
, NN NN O
two NN NN O
other NN NN O
synthetic NN NN O
nonselective NN NN O
RAR NN NN O
ligands NN NN O
are NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
LAP NN NN B-Protein
as NN NN O
much NN NN O
as NN NN O
AM580 NN NN O
, NN NN O
whereas NN NN O
RAR NN NN B-Protein
beta NN NN I-Protein
- NN NN O
or NN NN O
RAR NN NN B-Protein
gamma NN NN I-Protein
- NN NN O
specific NN NN O
ligands NN NN O
are NN NN O
totally NN NN O
ineffective NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
AM580 NN NN O
is NN NN O
more NN NN O
powerful NN NN O
than NN NN O
ATRA NN NN O
in NN NN O
modulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
differentiation NN NN O
antigens NN NN O
only NN NN O
in NN NN O
cells NN NN O
in NN NN O
which NN NN O
PML NN NN B-Protein
- NN NN I-Protein
RAR NN NN I-Protein
is NN NN O
present NN NN O
. NN NN O
   
Binding NN NN O
experiments NN NN O
, NN NN O
using NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
transiently NN NN O
transfected NN NN O
with NN NN O
PML NN NN B-Protein
- NN NN I-Protein
RAR NN NN I-Protein
and NN NN O
the NN NN O
normal NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
show NN NN O
that NN NN O
AM580 NN NN O
has NN NN O
a NN NN O
lower NN NN O
affinity NN NN O
than NN NN O
ATRA NN NN O
for NN NN O
both NN NN O
receptors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
PML NN NN B-Protein
- NN NN I-Protein
RAR NN NN I-Protein
, NN NN O
the NN NN O
synthetic NN NN O
retinoid NN NN O
is NN NN O
a NN NN O
much NN NN O
better NN NN O
transactivator NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
responsive NN NN O
element NN NN O
- NN NN O
containing NN NN O
promoters NN NN O
than NN NN O
the NN NN O
natural NN NN O
retinoid NN NN O
, NN NN O
whereas NN NN O
, NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
AM580 NN NN O
and NN NN O
ATRA NN NN O
have NN NN O
similar NN NN O
activity NN NN O
. NN NN O
   
This NN NN O
may NN NN O
explain NN NN O
the NN NN O
strong NN NN O
cyto NN NN O
- NN NN O
differentiating NN NN O
potential NN NN O
of NN NN O
AM580 NN NN O
in NN NN O
PML NN NN B-Protein
- NN NN I-Protein
RAR NN NN I-Protein
- NN NN O
containing NN NN O
leukemic NN NN O
cells NN NN O
. NN NN O
   
Transcriptional NN NN O
basis NN NN O
for NN NN O
hyporesponsiveness NN NN O
of NN NN O
the NN NN O
human NN NN O
inducible NN NN B-Protein
nitric NN NN I-Protein
oxide NN NN I-Protein
synthase NN NN I-Protein
gene NN NN O
to NN NN O
lipopolysaccharide NN NN O
/ NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
The NN NN O
work NN NN O
reported NN NN O
here NN NN O
resolves NN NN O
, NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
gene NN NN O
regulation NN NN O
, NN NN O
the NN NN O
controversy NN NN O
as NN NN O
to NN NN O
whether NN NN O
or NN NN O
not NN NN O
human NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
can NN NN O
produce NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
when NN NN O
stimulated NN NN O
with NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
with NN NN O
or NN NN O
without NN NN O
co NN NN O
- NN NN O
stimulation NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
. NN NN O
   
Studies NN NN O
included NN NN O
structural NN NN O
comparison NN NN O
of NN NN O
the NN NN O
promoters NN NN O
for NN NN O
human NN NN O
and NN NN O
mouse NN NN O
inducible NN NN B-Protein
NO NN NN I-Protein
synthase NN NN I-Protein
( NN NN O
iNOS NN NN B-Protein
) NN NN O
genes NN NN O
, NN NN O
transfection NN NN O
and NN NN O
assay NN NN O
of NN NN O
human NN NN O
and NN NN O
mouse NN NN O
iNOS NN NN B-Protein
promoter NN NN O
regions NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
+ NN NN O
/ NN NN O
- NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
of NN NN O
kappa NN NN O
B NN NN O
response NN NN O
elements NN NN O
. NN NN O
   
Two NN NN O
explanations NN NN O
for NN NN O
hyporesponsiveness NN NN O
of NN NN O
the NN NN O
human NN NN O
iNOS NN NN B-Protein
promoter NN NN O
to NN NN O
LPS NN NN O
+ NN NN O
/ NN NN O
- NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
were NN NN O
found NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
multiple NN NN O
inactivating NN NN O
nucleotide NN NN O
substitutions NN NN O
in NN NN O
the NN NN O
human NN NN O
counterpart NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
element NN NN O
that NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
regulate NN NN O
LPS NN NN O
/ NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induced NN NN O
expression NN NN O
of NN NN O
the NN NN O
mouse NN NN O
iNOS NN NN B-Protein
gene NN NN O
; NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
and NN NN O
absence NN NN O
of NN NN O
one NN NN O
or NN NN O
more NN NN O
nuclear NN NN O
factors NN NN O
in NN NN O
human NN NN O
macrophages NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
an NN NN O
LPS NN NN O
- NN NN O
inducible NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
complex NN NN O
) NN NN O
, NN NN O
that NN NN O
is NN NN O
( NN NN O
are NN NN O
) NN NN O
required NN NN O
for NN NN O
maximal NN NN O
expression NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
resolution NN NN O
of NN NN O
this NN NN O
controversy NN NN O
is NN NN O
that NN NN O
future NN NN O
research NN NN O
in NN NN O
this NN NN O
area NN NN O
should NN NN O
be NN NN O
directed NN NN O
toward NN NN O
the NN NN O
understanding NN NN O
of NN NN O
alternative NN NN O
mechanisms NN NN O
that NN NN O
can NN NN O
result NN NN O
in NN NN O
the NN NN O
successful NN NN O
production NN NN O
of NN NN O
NO NN NN O
. NN NN O
   
GATA NN NN O
transcription NN NN O
factors NN NN O
associate NN NN O
with NN NN O
a NN NN O
novel NN NN O
class NN NN O
of NN NN O
nuclear NN NN O
bodies NN NN O
in NN NN O
erythroblasts NN NN O
and NN NN O
megakaryocytes NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
distribution NN NN O
of NN NN O
GATA NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
murine NN NN O
haemopoietic NN NN O
cells NN NN O
was NN NN O
examined NN NN O
by NN NN O
indirect NN NN O
immunofluorescence NN NN O
. NN NN O
   
Specific NN NN O
bright NN NN O
foci NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
fluorescence NN NN O
were NN NN O
observed NN NN O
in NN NN O
erythroleukaemia NN NN O
cells NN NN O
and NN NN O
primary NN NN O
murine NN NN O
erythroblasts NN NN O
and NN NN O
megakaryocytes NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
diffuse NN NN O
nucleoplasmic NN NN O
localization NN NN O
. NN NN O
   
These NN NN O
foci NN NN O
, NN NN O
which NN NN O
were NN NN O
preferentially NN NN O
found NN NN O
adjacent NN NN O
to NN NN O
nucleoli NN NN O
or NN NN O
at NN NN O
the NN NN O
nuclear NN NN O
periphery NN NN O
, NN NN O
did NN NN O
not NN NN O
represent NN NN O
sites NN NN O
of NN NN O
active NN NN O
transcription NN NN O
or NN NN O
binding NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
to NN NN O
consensus NN NN O
sites NN NN O
in NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
loci NN NN O
. NN NN O
   
Immunoelectron NN NN O
microscopy NN NN O
demonstrated NN NN O
the NN NN O
presence NN NN O
of NN NN O
intensely NN NN O
labelled NN NN O
structures NN NN O
likely NN NN O
to NN NN O
represent NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
foci NN NN O
seen NN NN O
by NN NN O
immunofluorescence NN NN O
. NN NN O
   
The NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
nuclear NN NN O
bodies NN NN O
differed NN NN O
from NN NN O
previously NN NN O
described NN NN O
nuclear NN NN O
structures NN NN O
and NN NN O
there NN NN O
was NN NN O
no NN NN O
co NN NN O
- NN NN O
localization NN NN O
with NN NN O
nuclear NN NN O
antigens NN NN O
involved NN NN O
in NN NN O
RNA NN NN O
processing NN NN O
or NN NN O
other NN NN O
ubiquitous NN NN O
( NN NN O
Spl NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
and NN NN O
TBP NN NN B-Protein
) NN NN O
or NN NN O
haemopoietic NN NN O
( NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
) NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
proteins NN NN O
also NN NN O
localized NN NN O
to NN NN O
the NN NN O
same NN NN O
nuclear NN NN O
bodies NN NN O
in NN NN O
cell NN NN O
lines NN NN O
co NN NN O
- NN NN O
expressing NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
- NN NN B-Protein
2 NN NN I-Protein
or NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
- NN NN B-Protein
3 NN NN I-Protein
gene NN NN O
products NN NN O
. NN NN O
   
This NN NN O
pattern NN NN O
of NN NN O
distribution NN NN O
is NN NN O
, NN NN O
thus NN NN O
far NN NN O
, NN NN O
unique NN NN O
to NN NN O
the NN NN O
GATA NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
suggests NN NN O
a NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interaction NN NN O
with NN NN O
other NN NN O
components NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
bodies NN NN O
via NN NN O
the NN NN O
GATA NN NN O
zinc NN NN O
finger NN NN O
domain NN NN O
. NN NN O
   
Permanent NN NN O
occupancy NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
enhancer NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
needed NN NN O
for NN NN O
persistent NN NN O
viral NN NN O
replication NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
This NN NN O
work NN NN O
aimed NN NN O
to NN NN O
ascertain NN NN O
the NN NN O
role NN NN O
of NN NN O
kappaB NN NN O
- NN NN O
responsive NN NN O
elements NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
enhancer NN NN O
not NN NN O
only NN NN O
in NN NN O
early NN NN O
initiation NN NN O
but NN NN O
also NN NN O
in NN NN O
long NN NN O
- NN NN O
term NN NN O
maintenance NN NN O
of NN NN O
proviral NN NN O
transcription NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
monocytic NN NN O
lineage NN NN O
. NN NN O
   
For NN NN O
this NN NN O
purpose NN NN O
, NN NN O
we NN NN O
used NN NN O
three NN NN O
main NN NN O
approaches NN NN O
. NN NN O
   
The NN NN O
first NN NN O
was NN NN O
to NN NN O
abruptly NN NN O
terminate NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
to NN NN O
the NN NN O
enhancer NN NN O
sequences NN NN O
in NN NN O
U1 NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
using NN NN O
a NN NN O
short NN NN O
pulse NN NN O
of NN NN O
exogenous NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
. NN NN O
   
This NN NN O
resulted NN NN O
in NN NN O
concomitant NN NN O
decrease NN NN O
in NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
and NN NN O
endogenous NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
second NN NN O
was NN NN O
to NN NN O
suppress NN NN O
the NN NN O
permanent NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
translocation NN NN O
induced NN NN O
by NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
itself NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
using NN NN O
a NN NN O
specific NN NN O
proteasome NN NN O
inhibitor NN NN O
( NN NN O
Z NN NN O
- NN NN O
LLL NN NN O
- NN NN O
H NN NN O
) NN NN O
. NN NN O
   
As NN NN O
early NN NN O
as NN NN O
2 NN NN O
h NN NN O
after NN NN O
addition NN NN O
of NN NN O
the NN NN O
inhibitor NN NN O
to NN NN O
the NN NN O
culture NN NN O
medium NN NN O
, NN NN O
there NN NN O
was NN NN O
an NN NN O
inhibition NN NN O
of NN NN O
both NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
genome NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
third NN NN O
approach NN NN O
was NN NN O
to NN NN O
monitor NN NN O
the NN NN O
replication NN NN O
competence NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
of NN NN O
an NN NN O
infectious NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
provirus NN NN O
carrying NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
kappaB NN NN O
- NN NN O
responsive NN NN O
elements NN NN O
of NN NN O
both NN NN O
long NN NN O
terminal NN NN O
repeats NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
its NN NN O
wild NN NN O
- NN NN O
type NN NN O
counterpart NN NN O
, NN NN O
this NN NN O
mutated NN NN O
provirus NN NN O
showed NN NN O
a NN NN O
profoundly NN NN O
decreased NN NN O
, NN NN O
Z NN NN O
- NN NN O
LLL NN NN O
- NN NN O
H NN NN O
- NN NN O
insensitive NN NN O
transcriptional NN NN O
and NN NN O
replicative NN NN O
activity NN NN O
in NN NN O
U937 NN NN O
monocytes NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
occupancy NN NN O
of NN NN O
the NN NN O
viral NN NN O
enhancer NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimers NN NN O
is NN NN O
required NN NN O
for NN NN O
ongoing NN NN O
transcription NN NN O
of NN NN O
integrated NN NN O
HIV NN NN O
provirus NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
even NN NN O
in NN NN O
cells NN NN O
chronically NN NN O
infected NN NN O
and NN NN O
permanently NN NN O
producing NN NN O
functional NN NN O
HIV NN NN O
Tat NN NN B-Protein
protein NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
ability NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
crucial NN NN O
to NN NN O
the NN NN O
intense NN NN O
self NN NN O
- NN NN O
perpetuated NN NN O
viral NN NN O
transcription NN NN O
observed NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
monocytic NN NN O
lineage NN NN O
. NN NN O
   
Efficient NN NN O
transcription NN NN O
and NN NN O
replication NN NN O
of NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
elements NN NN O
. NN NN O
   
Ten NN NN O
mutants NN NN O
of NN NN O
the NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
SIV NN NN O
) NN NN O
SIVmac239 NN NN O
bearing NN NN O
deletions NN NN O
( NN NN O
delta NN NN O
) NN NN O
or NN NN O
substitutions NN NN O
( NN NN O
subst NN NN O
) NN NN O
in NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
/ NN NN O
or NN NN O
Sp1 NN NN B-Protein
binding NN NN O
elements NN NN O
were NN NN O
created NN NN O
, NN NN O
and NN NN O
the NN NN O
replicative NN NN O
capacities NN NN O
of NN NN O
the NN NN O
mutants NN NN O
were NN NN O
analyzed NN NN O
. NN NN O
   
All NN NN O
mutants NN NN O
, NN NN O
including NN NN O
one NN NN O
extensively NN NN O
mutagenized NN NN O
strain NN NN O
entirely NN NN O
missing NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
four NN NN O
Spl NN NN B-Protein
binding NN NN O
elements NN NN O
, NN NN O
replicated NN NN O
with NN NN O
wild NN NN O
- NN NN O
type NN NN O
kinetics NN NN O
and NN NN O
to NN NN O
a NN NN O
wild NN NN O
- NN NN O
type NN NN O
level NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cell NN NN O
cultures NN NN O
in NN NN O
50 NN NN O
to NN NN O
100 NN NN O
% NN NN O
of NN NN O
the NN NN O
experiments NN NN O
. NN NN O
   
One NN NN O
group NN NN O
of NN NN O
mutants NN NN O
replicated NN NN O
very NN NN O
similarly NN NN O
to NN NN O
SIVmac239 NN NN O
in NN NN O
kinetics NN NN O
and NN NN O
yield NN NN O
in NN NN O
CEMxl74 NN NN O
cells NN NN O
( NN NN O
2xNFKappaB NN NN O
> NN NN O
or NN NN O
= NN NN O
SlVmac239 NN NN O
approximately NN NN O
deltaNFkappaB NN NN O
approximately NN NN O
deltaSpl234 NN NN O
approximately NN NN O
substNFkappaB NN NN O
approximately NN NN O
substSpl2 NN NN O
approximately NN NN O
substSp23 NN NN O
) NN NN O
, NN NN O
while NN NN O
a NN NN O
second NN NN O
group NN NN O
replicated NN NN O
with NN NN O
delayed NN NN O
or NN NN O
slightly NN NN O
delayed NN NN O
kinetics NN NN O
in NN NN O
CEMxl74 NN NN O
cells NN NN O
( NN NN O
SIVmac239 NN NN O
> NN NN O
substSp34 NN NN O
> NN NN O
deltaNFkappaBdeltaSpl234 NN NN O
approximately NN NN O
deltaNFkappaBdeltaSp1 NN NN O
> NN NN O
substSpl234 NN NN O
) NN NN O
. NN NN O
   
Reversions NN NN O
or NN NN O
additional NN NN O
mutations NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
U3 NN NN O
and NN NN O
R NN NN O
regions NN NN O
of NN NN O
proviral NN NN O
DNA NN NN O
from NN NN O
CEMxl74 NN NN O
cells NN NN O
infected NN NN O
with NN NN O
the NN NN O
SIVmac239 NN NN O
mutants NN NN O
. NN NN O
   
Similar NN NN O
results NN NN O
were NN NN O
obtained NN NN O
when NN NN O
mutants NN NN O
of NN NN O
SIVmacMER NN NN O
( NN NN O
a NN NN O
macrophage NN NN O
- NN NN O
competent NN NN O
derivative NN NN O
of NN NN O
SIVmac239 NN NN O
) NN NN O
were NN NN O
tested NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cell NN NN O
and NN NN O
CEMx174 NN NN O
cultures NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
growth NN NN O
of NN NN O
most NN NN O
mutated NN NN O
viruses NN NN O
was NN NN O
suppressed NN NN O
in NN NN O
primary NN NN O
rhesus NN NN O
monkey NN NN O
alveolar NN NN O
macrophages NN NN O
( NN NN O
SIVmacMER NN NN O
approximately NN NN O
2xNFkappaB NN NN O
approximately NN NN O
substNFkappaB NN NN O
> NN NN O
deltaNFkappaB NN NN O
> NN NN O
deltaNFkappaBdeltaSpl234 NN NN O
approximately NN NN O
deltaNFkappaBdeltaSpl NN NN O
> NN NN O
deltaSpl234 NN NN O
approximately NN NN O
substSpl2 NN NN O
> NN NN O
substSp23 NN NN O
approximately NN NN O
substSp34 NN NN O
approximately NN NN O
substSpl234 NN NN O
> NN NN O
or NN NN O
= NN NN O
SIVmac239 NN NN O
) NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
changes NN NN O
in NN NN O
the NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
had NN NN O
the NN NN O
most NN NN O
dramatic NN NN O
effects NN NN O
on NN NN O
SIVmac NN NN O
replication NN NN O
in NN NN O
primary NN NN O
macrophage NN NN O
cultures NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
driven NN NN O
secreted NN NN O
alkaline NN NN O
phosphatase NN NN O
activity NN NN O
in NN NN O
transient NN NN O
assays NN NN O
showed NN NN O
that NN NN O
, NN NN O
unlike NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
, NN NN O
the NN NN O
SIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
possesses NN NN O
an NN NN O
enhancer NN NN O
region NN NN O
just NN NN O
upstream NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
element NN NN O
which NN NN O
maintains NN NN O
significant NN NN O
levels NN NN O
of NN NN O
basal NN NN O
transcription NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
Sp1 NN NN B-Protein
sites NN NN O
. NN NN O
   
This NN NN O
region NN NN O
is NN NN O
responsive NN NN O
to NN NN O
transactivation NN NN O
by NN NN O
Tat NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
SIV NN NN O
TATA NN NN O
box NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
stronger NN NN O
than NN NN O
that NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
surprisingly NN NN O
high NN NN O
replicative NN NN O
capacity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
Sp1 NN NN B-Protein
binding NN NN O
site NN NN O
mutants NN NN O
of NN NN O
SIVmac NN NN O
is NN NN O
due NN NN O
to NN NN O
unique NN NN O
features NN NN O
or NN NN O
the NN NN O
enhancer NN NN O
/ NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
Inactivation NN NN O
of NN NN O
IkappaBbeta NN NN B-Protein
by NN NN O
the NN NN O
tax NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
: NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
for NN NN O
constitutive NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
In NN NN O
resting NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
sequestered NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
via NN NN O
interactions NN NN O
with NN NN O
members NN NN O
of NN NN O
the NN NN O
I NN NN O
kappa NN NN O
B NN NN O
family NN NN O
of NN NN O
inhibitors NN NN O
, NN NN O
including NN NN O
IkappaBalpha NN NN B-Protein
and NN NN O
IkappaBbeta NN NN B-Protein
. NN NN O
   
During NN NN O
normal NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
IkappaBalpha NN NN B-Protein
is NN NN O
rapidly NN NN O
phosphorylated NN NN O
, NN NN O
ubiquitinated NN NN O
, NN NN O
and NN NN O
degraded NN NN O
by NN NN O
the NN NN O
26S NN NN O
proteasome NN NN O
, NN NN O
thus NN NN O
permitting NN NN O
the NN NN O
release NN NN O
of NN NN O
functional NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
its NN NN O
transient NN NN O
pattern NN NN O
of NN NN O
nuclear NN NN O
induction NN NN O
during NN NN O
an NN NN O
immune NN NN O
response NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
constitutively NN NN O
activated NN NN O
in NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
Tax NN NN B-Protein
transforming NN NN O
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
targets NN NN O
IkappaBalpha NN NN B-Protein
to NN NN O
the NN NN O
ubiquitin NN NN O
- NN NN O
proteasome NN NN O
pathway NN NN O
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
remains NN NN O
unclear NN NN O
how NN NN O
this NN NN O
viral NN NN O
protein NN NN O
induces NN NN O
a NN NN O
persistent NN NN O
rather NN NN O
than NN NN O
transient NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
response NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
in NN NN O
addition NN NN O
to NN NN O
acting NN NN O
on NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
Tax NN NN B-Protein
stimulates NN NN O
the NN NN O
turnover NN NN O
Of NN NN O
IkappaBbeta NN NN B-Protein
via NN NN O
a NN NN O
related NN NN O
targeting NN NN O
mechanism NN NN O
. NN NN O
   
Like NN NN O
IkappaBalpha NN NN B-Protein
, NN NN O
Tax NN NN B-Protein
- NN NN O
mediated NN NN O
breakdown NN NN O
of NN NN O
IkappaBbeta NN NN B-Protein
in NN NN O
transfected NN NN O
T NN NN O
lymphocytes NN NN O
is NN NN O
blocked NN NN O
either NN NN O
by NN NN O
cell NN NN O
- NN NN O
permeable NN NN O
proteasome NN NN O
inhibitors NN NN O
or NN NN O
by NN NN O
mutation NN NN O
Of NN NN O
IkappaBbeta NN NN B-Protein
at NN NN O
two NN NN O
serine NN NN O
residues NN NN O
present NN NN O
within NN NN O
its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
region NN NN O
. NN NN O
   
Despite NN NN O
the NN NN O
dual NN NN O
specificity NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
for NN NN O
IkappaBalpha NN NN B-Protein
and NN NN O
IkappaBbeta NN NN B-Protein
at NN NN O
the NN NN O
protein NN NN O
level NN NN O
, NN NN O
Tax NN NN B-Protein
selectively NN NN O
stimulates NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IkappaBalpha NN NN B-Protein
gene NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
IkappaBbeta NN NN B-Protein
protein NN NN O
expression NN NN O
is NN NN O
chronically NN NN O
downregulated NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
with NN NN O
IkappaBbeta NN NN B-Protein
provide NN NN O
a NN NN O
potential NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
Tax NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
EGR1 NN NN B-Protein
in NN NN O
regulation NN NN O
of NN NN O
stimulus NN NN O
- NN NN O
dependent NN NN O
CD44 NN NN B-Protein
transcription NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
encodes NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
EGR1 NN NN B-Protein
) NN NN O
that NN NN O
links NN NN O
B NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
( NN NN O
BCR NN NN O
) NN NN O
signals NN NN O
to NN NN O
downstream NN NN O
activation NN NN O
events NN NN O
through NN NN O
the NN NN O
regulation NN NN O
of NN NN O
previously NN NN O
unidentified NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
identify NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
lymphocyte NN NN O
homing NN NN O
and NN NN O
migration NN NN O
protein NN NN O
CD44 NN NN B-Protein
as NN NN O
a NN NN O
target NN NN O
of NN NN O
EGR1 NN NN B-Protein
regulation NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
BCR NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
CD44 NN NN B-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
transcription NN NN O
levels NN NN O
are NN NN O
shown NN NN O
to NN NN O
occur NN NN O
in NN NN O
EGR1 NN NN B-Protein
- NN NN O
expressing NN NN O
but NN NN O
not NN NN O
in NN NN O
nonexpressing NN NN O
subclones NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
WEHI NN NN O
- NN NN O
231 NN NN O
. NN NN O
   
Kinetics NN NN O
of NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
and NN NN O
the NN NN O
appearance NN NN O
of NN NN O
nuclear NN NN O
EGR1 NN NN B-Protein
protein NN NN O
precede NN NN O
CD44 NN NN B-Protein
induction NN NN O
and NN NN O
occur NN NN O
within NN NN O
30 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
in NN NN O
the NN NN O
EGR1 NN NN B-Protein
- NN NN O
expressing NN NN O
subclone NN NN O
. NN NN O
   
A NN NN O
single NN NN O
EGR1 NN NN B-Protein
binding NN NN O
motif NN NN O
is NN NN O
demonstrated NN NN O
at NN NN O
bp NN NN O
- NN NN O
301 NN NN O
of NN NN O
the NN NN O
human NN NN O
CD44 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
a NN NN O
CD44 NN NN B-Protein
promoter NN NN O
- NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
reporter NN NN O
construct NN NN O
with NN NN O
an NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
vector NN NN O
resulted NN NN O
in NN NN O
a NN NN O
6 NN NN O
. NN NN O
5 NN NN O
- NN NN O
to NN NN O
8 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
induction NN NN O
of NN NN O
transcriptional NN NN O
activity NN NN O
relative NN NN O
to NN NN O
an NN NN O
empty NN NN O
expression NN NN O
vector NN NN O
. NN NN O
   
The NN NN O
EGR1 NN NN B-Protein
binding NN NN O
motif NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
necessary NN NN O
for NN NN O
stimulus NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
a NN NN O
CD44 NN NN B-Protein
promoter NN NN O
- NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
reporter NN NN O
construct NN NN O
in NN NN O
nontransformed NN NN O
B NN NN O
lymphocytes NN NN O
and NN NN O
was NN NN O
required NN NN O
for NN NN O
transactivation NN NN O
by NN NN O
an NN NN O
EGR1 NN NN B-Protein
expression NN NN O
vector NN NN O
in NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
identify NN NN O
EGR1 NN NN B-Protein
as NN NN O
an NN NN O
intermediary NN NN O
linking NN NN O
BCR NN NN O
- NN NN O
derived NN NN O
signals NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
CD44 NN NN B-Protein
. NN NN O
   
The NN NN O
relevance NN NN O
of NN NN O
these NN NN O
molecular NN NN O
events NN NN O
to NN NN O
BCR NN NN O
signal NN NN O
transduction NN NN O
and NN NN O
antigen NN NN O
- NN NN O
stimulated NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
mediated NN NN O
immune NN NN O
responses NN NN O
is NN NN O
discussed NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
an NN NN O
inducible NN NN O
regulator NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Resting NN NN O
T NN NN O
cells NN NN O
express NN NN O
very NN NN O
low NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
protein NN NN O
. NN NN O
   
During NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
is NN NN O
induced NN NN O
and NN NN O
much NN NN O
of NN NN O
the NN NN O
increase NN NN O
in NN NN O
expression NN NN O
occurs NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
region NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
5 NN NN O
' NN NN O
flanking NN NN O
sequence NN NN O
that NN NN O
increased NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
footprinting NN NN O
by NN NN O
ligation NN NN O
- NN NN O
mediated NN NN O
PCR NN NN O
was NN NN O
performed NN NN O
to NN NN O
correlate NN NN O
in NN NN O
vivo NN NN O
protein NN NN O
binding NN NN O
with NN NN O
functional NN NN O
activity NN NN O
. NN NN O
   
A NN NN O
protein NN NN O
footprint NN NN O
was NN NN O
visible NN NN O
over NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
5 NN NN O
' NN NN O
flanking NN NN O
sequence NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
unactivated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
with NN NN O
nuclear NN NN O
extract NN NN O
from NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
an NN NN O
oligonucleotide NN NN O
of NN NN O
this NN NN O
binding NN NN O
site NN NN O
demonstrated NN NN O
a NN NN O
new NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
, NN NN O
referred NN NN O
to NN NN O
as NN NN O
CMAT NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
; NN NN O
this NN NN O
complex NN NN O
was NN NN O
not NN NN O
present NN NN O
in NN NN O
unactivated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
binding NN NN O
site NN NN O
showed NN NN O
some NN NN O
sequence NN NN O
similarity NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
binding NN NN O
site NN NN O
, NN NN O
we NN NN O
compared NN NN O
the NN NN O
kinetics NN NN O
of NN NN O
induction NN NN O
of NN NN O
the NN NN O
two NN NN O
binding NN NN O
complexes NN NN O
and NN NN O
the NN NN O
molecular NN NN O
masses NN NN O
of NN NN O
the NN NN O
two NN NN O
proteins NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
the NN NN O
kinetics NN NN O
of NN NN O
induction NN NN O
showed NN NN O
that NN NN O
the NN NN O
NFAT NN NN O
EMSA NN NN O
binding NN NN O
complex NN NN O
appeared NN NN O
earlier NN NN O
than NN NN O
the NN NN O
CMAT NN NN O
complex NN NN O
. NN NN O
   
The NN NN O
NFAT NN NN O
protein NN NN O
migrated NN NN O
more NN NN O
slowly NN NN O
in NN NN O
a NN NN O
sodium NN NN O
dodecyl NN NN O
sulfate NN NN O
- NN NN O
polyacrylamide NN NN O
gel NN NN O
than NN NN O
the NN NN O
CMAT NN NN O
protein NN NN O
did NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
an NN NN O
antibody NN NN O
against NN NN O
NFAT NN NN O
did NN NN O
not NN NN O
cross NN NN O
- NN NN O
react NN NN O
with NN NN O
the NN NN O
CMAT NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
appearance NN NN O
of NN NN O
the NN NN O
CMAT NN NN O
binding NN NN O
complex NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
both NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
rapamycin NN NN O
. NN NN O
   
The NN NN O
CMAT NN NN O
protein NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
novel NN NN O
inducible NN NN O
protein NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myb NN NN I-Protein
expression NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Structural NN NN O
and NN NN O
functional NN NN O
characterization NN NN O
of NN NN O
the NN NN O
human NN NN O
CD36 NN NN B-Protein
gene NN NN O
promoter NN NN O
: NN NN O
identification NN NN O
of NN NN O
a NN NN O
proximal NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
site NN NN O
. NN NN O
   
CD36 NN NN B-Protein
is NN NN O
a NN NN O
cell NN NN O
surface NN NN O
glycoprotein NN NN O
composed NN NN O
of NN NN O
a NN NN O
single NN NN O
polypeptide NN NN O
chain NN NN O
, NN NN O
which NN NN O
interacts NN NN O
with NN NN O
thrombospondin NN NN O
, NN NN O
collagens NN NN O
type NN NN O
I NN NN O
and NN NN O
IV NN NN O
, NN NN O
oxidized NN NN O
low NN NN O
density NN NN O
lipoprotein NN NN O
, NN NN O
fatty NN NN O
acids NN NN O
, NN NN O
anionic NN NN O
phospholipids NN NN O
, NN NN O
and NN NN O
erythrocytes NN NN O
parasitized NN NN O
with NN NN O
Plasmodium NN NN O
falciparum NN NN O
. NN NN O
   
Its NN NN O
expression NN NN O
is NN NN O
restricted NN NN O
to NN NN O
a NN NN O
few NN NN O
cell NN NN O
types NN NN O
, NN NN O
including NN NN O
monocyte NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
In NN NN O
these NN NN O
cells NN NN O
, NN NN O
CD36 NN NN B-Protein
is NN NN O
involved NN NN O
in NN NN O
phagocytosis NN NN O
of NN NN O
apoptotic NN NN O
cells NN NN O
, NN NN O
and NN NN O
foam NN NN O
cell NN NN O
formation NN NN O
by NN NN O
uptake NN NN O
of NN NN O
oxidized NN NN O
low NN NN O
density NN NN O
lipoprotein NN NN O
. NN NN O
   
To NN NN O
study NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
control NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
CD36 NN NN B-Protein
gene NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
we NN NN O
have NN NN O
isolated NN NN O
and NN NN O
analyzed NN NN O
the NN NN O
CD36 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
experiments NN NN O
of NN NN O
5 NN NN O
' NN NN O
- NN NN O
deletion NN NN O
fragments NN NN O
of NN NN O
the NN NN O
CD36 NN NN B-Protein
promoter NN NN O
coupled NN NN O
to NN NN O
luciferase NN NN O
demonstrated NN NN O
that NN NN O
as NN NN O
few NN NN O
as NN NN O
158 NN NN O
base NN NN O
pairs NN NN O
upstream NN NN O
from NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
were NN NN O
sufficient NN NN O
to NN NN O
direct NN NN O
the NN NN O
monocyte NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
of NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
above NN NN O
region NN NN O
, NN NN O
the NN NN O
fragment NN NN O
spanning NN NN O
nucleotides NN NN O
- NN NN O
158 NN NN O
to NN NN O
- NN NN O
90 NN NN O
was NN NN O
required NN NN O
for NN NN O
optimal NN NN O
transcription NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Biochemical NN NN O
analysis NN NN O
of NN NN O
the NN NN O
region NN NN O
- NN NN O
158 NN NN O
/ NN NN O
- NN NN O
90 NN NN O
revealed NN NN O
a NN NN O
binding NN NN O
site NN NN O
for NN NN O
transcription NN NN O
factors NN NN O
of NN NN O
the NN NN O
polyomavirus NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
2 NN NN O
/ NN NN O
core NN NN O
- NN NN O
binding NN NN O
factor NN NN O
( NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
) NN NN O
family NN NN O
at NN NN O
position NN NN O
- NN NN O
103 NN NN O
. NN NN O
   
Disruption NN NN O
of NN NN O
the NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
site NN NN O
markedly NN NN O
diminished NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
factors NN NN O
in NN NN O
the NN NN O
constitutive NN NN O
transcription NN NN O
of NN NN O
the NN NN O
CD36 NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
family NN NN O
in NN NN O
chromosome NN NN O
translocations NN NN O
associated NN NN O
with NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
myeloid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
encoding NN NN O
for NN NN O
myeloperoxidase NN NN B-Protein
, NN NN O
elastase NN NN O
, NN NN O
and NN NN O
the NN NN O
colony NN NN O
- NN NN O
stimulating NN NN O
factor NN NN O
receptor NN NN O
, NN NN O
highlights NN NN O
the NN NN O
relevance NN NN O
of NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
CD36 NN NN B-Protein
gene NN NN O
promoter NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
members NN NN O
of NN NN O
the NN NN O
PEBP2 NN NN O
/ NN NN O
CBF NN NN O
family NN NN O
. NN NN O
   
CNI NN NN O
- NN NN O
1493 NN NN O
inhibits NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
by NN NN O
suppression NN NN O
of NN NN O
translation NN NN O
efficiency NN NN O
. NN NN O
   
Tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
mediates NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
disease NN NN O
states NN NN O
including NN NN O
septic NN NN O
shock NN NN O
, NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
inflammation NN NN O
, NN NN O
and NN NN O
cachexia NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
a NN NN O
multivalent NN NN O
guanylhydrazone NN NN O
( NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
) NN NN O
developed NN NN O
as NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
macrophage NN NN O
activation NN NN O
was NN NN O
shown NN NN O
to NN NN O
suppress NN NN O
TNF NN NN O
production NN NN O
and NN NN O
protect NN NN O
against NN NN O
tissue NN NN O
inflammation NN NN O
and NN NN O
endotoxin NN NN O
lethality NN NN O
[ NN NN O
Bianchi NN NN O
, NN NN O
M NN NN O
. NN NN O
, NN NN O
Ulrich NN NN O
, NN NN O
P NN NN O
. NN NN O
, NN NN O
Bloom NN NN O
, NN NN O
O NN NN O
. NN NN O
, NN NN O
Meistrell NN NN O
, NN NN O
M NN NN O
. NN NN O
, NN NN O
Zimmerman NN NN O
, NN NN O
G NN NN O
. NN NN O
A NN NN O
. NN NN O
, NN NN O
Schmidtmayerova NN NN O
, NN NN O
H NN NN O
. NN NN O
, NN NN O
Bukrinsky NN NN O
, NN NN O
M NN NN O
. NN NN O
, NN NN O
Donnelley NN NN O
, NN NN O
T NN NN O
. NN NN O
, NN NN O
Bucala NN NN O
, NN NN O
R NN NN O
. NN NN O
, NN NN O
Sherry NN NN O
, NN NN O
B NN NN O
. NN NN O
, NN NN O
Manogue NN NN O
, NN NN O
K NN NN O
. NN NN O
R NN NN O
. NN NN O
, NN NN O
Tortolani NN NN O
, NN NN O
A NN NN O
. NN NN O
J NN NN O
. NN NN O
, NN NN O
Cerami NN NN O
, NN NN O
A NN NN O
. NN NN O
& NN NN O
Tracey NN NN O
, NN NN O
K NN NN O
. NN NN O
J NN NN O
. NN NN O
( NN NN O
1995 NN NN O
) NN NN O
Mol NN NN O
. NN NN O
Med NN NN O
. NN NN O
1 NN NN O
, NN NN O
254 NN NN O
- NN NN O
266 NN NN O
, NN NN O
and NN NN O
Bianchi NN NN O
, NN NN O
M NN NN O
. NN NN O
, NN NN O
Bloom NN NN O
, NN NN O
O NN NN O
. NN NN O
, NN NN O
Raabe NN NN O
, NN NN O
T NN NN O
. NN NN O
, NN NN O
Cohen NN NN O
, NN NN O
P NN NN O
. NN NN O
   
S NN NN O
. NN NN O
, NN NN O
Chesney NN NN O
, NN NN O
J NN NN O
. NN NN O
, NN NN O
Sherry NN NN O
, NN NN O
B NN NN O
. NN NN O
, NN NN O
Schmidtmayerova NN NN O
, NN NN O
H NN NN O
. NN NN O
, NN NN O
Zhang NN NN O
, NN NN O
X NN NN O
. NN NN O
, NN NN O
Bukrinsky NN NN O
, NN NN O
M NN NN O
. NN NN O
, NN NN O
Ulrich NN NN O
, NN NN O
P NN NN O
. NN NN O
, NN NN O
Cerami NN NN O
, NN NN O
A NN NN O
. NN NN O
& NN NN O
Tracey NN NN O
, NN NN O
J NN NN O
. NN NN O
( NN NN O
1996 NN NN O
) NN NN O
J NN NN O
. NN NN O
Exp NN NN O
. NN NN O
Med NN NN O
. NN NN O
, NN NN O
in NN NN O
press NN NN O
] NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
elucidated NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
inhibits NN NN O
macrophage NN NN O
TNF NN NN O
synthesis NN NN O
and NN NN O
show NN NN O
here NN NN O
that NN NN O
it NN NN O
acts NN NN O
through NN NN O
suppression NN NN O
of NN NN O
TNF NN NN O
translation NN NN O
efficiency NN NN O
. NN NN O
   
CNI NN NN O
- NN NN O
1493 NN NN O
blocked NN NN O
neither NN NN O
the NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
induced NN NN O
increases NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
TNF NN NN O
mRNA NN NN O
nor NN NN O
the NN NN O
translocation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
macrophages NN NN O
activated NN NN O
by NN NN O
15 NN NN O
min NN NN O
of NN NN O
LPS NN NN O
stimulation NN NN O
, NN NN O
indicating NN NN O
that NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
does NN NN O
not NN NN O
interfere NN NN O
with NN NN O
early NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
mediated NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
TNF NN NN O
. NN NN O
   
However NN NN O
, NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
26 NN NN O
- NN NN O
kDa NN NN O
membrane NN NN O
form NN NN O
of NN NN O
TNF NN NN O
was NN NN O
effectively NN NN O
blocked NN NN O
by NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
. NN NN O
   
Further NN NN O
evidence NN NN O
for NN NN O
the NN NN O
translational NN NN O
suppression NN NN O
of NN NN O
TNF NN NN O
is NN NN O
given NN NN O
by NN NN O
experiments NN NN O
using NN NN O
chloram NN NN B-Protein
- NN NN I-Protein
phenicol NN NN I-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
constructs NN NN O
containing NN NN O
elements NN NN O
of NN NN O
the NN NN O
TNF NN NN O
gene NN NN O
that NN NN O
are NN NN O
involved NN NN O
in NN NN O
TNF NN NN O
translational NN NN O
regulation NN NN O
. NN NN O
   
Both NN NN O
the NN NN O
5 NN NN O
' NN NN O
and NN NN O
3 NN NN O
' NN NN O
untranslated NN NN O
regions NN NN O
of NN NN O
the NN NN O
TNF NN NN O
gene NN NN O
were NN NN O
required NN NN O
to NN NN O
elicit NN NN O
maximal NN NN O
translational NN NN O
suppression NN NN O
by NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
the NN NN O
molecular NN NN O
target NN NN O
through NN NN O
which NN NN O
CNI NN NN O
- NN NN O
1493 NN NN O
inhibits NN NN O
TNF NN NN O
translation NN NN O
should NN NN O
provide NN NN O
insight NN NN O
into NN NN O
the NN NN O
regulation NN NN O
of NN NN O
macrophage NN NN O
activation NN NN O
and NN NN O
mechanisms NN NN O
of NN NN O
inflammation NN NN O
. NN NN O
   
STAT NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
constitutively NN NN O
activated NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
from NN NN O
acute NN NN O
leukemia NN NN O
patients NN NN O
. NN NN O
   
A NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
activated NN NN O
by NN NN O
many NN NN O
cytokines NN NN O
has NN NN O
recently NN NN O
been NN NN O
elaborated NN NN O
. NN NN O
   
The NN NN O
JAK NN NN O
kinases NN NN O
and NN NN O
the NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
factors NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
essential NN NN O
components NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
presence NN NN O
of NN NN O
constitutively NN NN O
activated NN NN O
STAT NN NN O
factors NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
acute NN NN O
leukemia NN NN O
. NN NN O
   
We NN NN O
used NN NN O
oligonucleotide NN NN O
probes NN NN O
from NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
and NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
promoters NN NN O
and NN NN O
the NN NN O
ISRE NN NN O
probe NN NN O
to NN NN O
detect NN NN O
STAT NN NN O
proteins NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
acute NN NN O
leukemia NN NN O
cells NN NN O
in NN NN O
bandshift NN NN O
assays NN NN O
. NN NN O
   
Specific NN NN O
DNA NN NN O
protein NN NN O
complex NN NN O
formation NN NN O
was NN NN O
observed NN NN O
with NN NN O
the NN NN O
probes NN NN O
from NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
and NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
promoters NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
the NN NN O
ISRE NN NN O
oligonucleotide NN NN O
probe NN NN O
, NN NN O
when NN NN O
cell NN NN O
extracts NN NN O
from NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
( NN NN O
ALL NN NN O
) NN NN O
and NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
( NN NN O
AML NN NN O
) NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
We NN NN O
used NN NN O
nonradioactive NN NN O
oligonucleotides NN NN O
as NN NN O
competitors NN NN O
to NN NN O
show NN NN O
the NN NN O
specificity NN NN O
of NN NN O
the NN NN O
complex NN NN O
formation NN NN O
. NN NN O
   
Specific NN NN O
antibodies NN NN O
directed NN NN O
against NN NN O
the NN NN O
individual NN NN O
STAT NN NN O
proteins NN NN O
were NN NN O
used NN NN O
in NN NN O
supershift NN NN O
experiments NN NN O
. NN NN O
   
STAT5 NN NN B-Protein
- NN NN O
and NN NN O
STAT1 NN NN B-Protein
- NN NN O
related NN NN O
factors NN NN O
were NN NN O
detected NN NN O
in NN NN O
ALL NN NN O
and NN NN O
STAT1 NN NN B-Protein
- NN NN O
, NN NN O
STAT3 NN NN B-Protein
- NN NN O
, NN NN O
and NN NN O
STAT5 NN NN B-Protein
- NN NN O
related NN NN O
proteins NN NN O
were NN NN O
present NN NN O
in NN NN O
nuclear NN NN O
cell NN NN O
extracts NN NN O
from NN NN O
AML NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
cells NN NN O
were NN NN O
not NN NN O
treated NN NN O
with NN NN O
cytokines NN NN O
before NN NN O
the NN NN O
nuclear NN NN O
proteins NN NN O
were NN NN O
extracted NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
these NN NN O
factors NN NN O
are NN NN O
constitutively NN NN O
activated NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
It NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
STAT NN NN O
proteins NN NN O
is NN NN O
a NN NN O
part NN NN O
of NN NN O
the NN NN O
events NN NN O
of NN NN O
leukemogenesis NN NN O
. NN NN O
   
Reversible NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
monoblastic NN NN O
leukemia NN NN O
U937 NN NN O
cells NN NN O
by NN NN O
ML NN NN O
- NN NN O
9 NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
myosin NN NN O
light NN NN O
chain NN NN O
kinase NN NN O
. NN NN O
   
Human NN NN O
monoblastic NN NN O
leukemia NN NN O
U937 NN NN O
cells NN NN O
are NN NN O
induced NN NN O
to NN NN O
differentiate NN NN O
into NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
by NN NN O
various NN NN O
agents NN NN O
. NN NN O
   
We NN NN O
have NN NN O
shown NN NN O
that NN NN O
1 NN NN O
- NN NN O
( NN NN O
5 NN NN O
- NN NN O
chloronaphthalene NN NN O
- NN NN O
1 NN NN O
- NN NN O
sulfonyl NN NN O
) NN NN O
- NN NN O
1H NN NN O
- NN NN O
hexahydro NN NN O
- NN NN O
1 NN NN O
, NN NN O
4 NN NN O
- NN NN O
diazepine NN NN O
hydrochloride NN NN O
( NN NN O
ML NN NN O
- NN NN O
9 NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
myosin NN NN O
light NN NN O
chain NN NN O
kinase NN NN O
, NN NN O
induces NN NN O
differentiation NN NN O
of NN NN O
monocytoid NN NN O
leukemia NN NN O
cell NN NN O
lines NN NN O
U937 NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
but NN NN O
not NN NN O
of NN NN O
myeloblastic NN NN O
leukemic NN NN O
ML NN NN O
- NN NN O
1 NN NN O
cell NN NN O
or NN NN O
erythroleukemia NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
further NN NN O
analyzed NN NN O
the NN NN O
effect NN NN O
of NN NN O
ML NN NN O
- NN NN O
9 NN NN O
in NN NN O
comparison NN NN O
with NN NN O
that NN NN O
of NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
VD3 NN NN O
) NN NN O
a NN NN O
typical NN NN O
inducer NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
ML NN NN O
- NN NN O
9 NN NN O
induced NN NN O
nitroblue NN NN O
tetrazolium NN NN O
( NN NN O
NBT NN NN O
) NN NN O
- NN NN O
reducing NN NN O
activity NN NN O
of NN NN O
U937 NN NN O
cell NN NN O
more NN NN O
rapidly NN NN O
than NN NN O
VD3 NN NN O
: NN NN O
This NN NN O
differentiation NN NN O
marker NN NN O
was NN NN O
induced NN NN O
significantly NN NN O
after NN NN O
incubation NN NN O
with NN NN O
ML NN NN O
- NN NN O
9 NN NN O
and NN NN O
VD3 NN NN O
for NN NN O
4 NN NN O
hours NN NN O
and NN NN O
1 NN NN O
day NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
ML NN NN O
- NN NN O
9 NN NN O
also NN NN O
induced NN NN O
alpha NN NN O
- NN NN O
naphthyl NN NN O
acetate NN NN O
esterase NN NN O
( NN NN O
ANAE NN NN O
) NN NN O
activity NN NN O
, NN NN O
another NN NN O
monocytic NN NN O
differentiation NN NN O
marker NN NN O
, NN NN O
more NN NN O
rapidly NN NN O
than NN NN O
VD3 NN NN O
. NN NN O
   
The NN NN O
maximum NN NN O
levels NN NN O
of NN NN O
these NN NN O
markers NN NN O
induced NN NN O
by NN NN O
ML NN NN O
- NN NN O
9 NN NN O
were NN NN O
comparable NN NN O
to NN NN O
those NN NN O
induced NN NN O
by NN NN O
VD3 NN NN O
, NN NN O
but NN NN O
after NN NN O
removal NN NN O
of NN NN O
ML NN NN O
- NN NN O
9 NN NN O
from NN NN O
the NN NN O
medium NN NN O
by NN NN O
washing NN NN O
the NN NN O
cells NN NN O
, NN NN O
the NN NN O
expressions NN NN O
of NN NN O
theses NN NN O
markers NN NN O
decreased NN NN O
within NN NN O
4 NN NN O
hours NN NN O
and NN NN O
reached NN NN O
basal NN NN O
levels NN NN O
in NN NN O
1 NN NN O
day NN NN O
, NN NN O
indicating NN NN O
that NN NN O
ML NN NN O
- NN NN O
9 NN NN O
' NN NN O
s NN NN O
induction NN NN O
of NN NN O
expression NN NN O
of NN NN O
differentiation NN NN O
- NN NN O
associated NN NN O
phenotypes NN NN O
was NN NN O
reversible NN NN O
. NN NN O
   
The NN NN O
growth NN NN O
inhibition NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
by NN NN O
ML NN NN O
- NN NN O
9 NN NN O
was NN NN O
also NN NN O
reversible NN NN O
. NN NN O
   
Similar NN NN O
effects NN NN O
were NN NN O
observed NN NN O
in NN NN O
another NN NN O
line NN NN O
of NN NN O
human NN NN O
monoblastic NN NN O
cells NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
ML NN NN O
- NN NN O
9 NN NN O
had NN NN O
little NN NN O
or NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
morphology NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
but NN NN O
increased NN NN O
the NN NN O
expression NN NN O
of NN NN O
monocyte NN NN O
- NN NN O
macrophage NN NN O
lineage NN NN O
- NN NN O
associated NN NN O
surface NN NN O
antigen NN NN O
, NN NN O
CD14 NN NN B-Protein
, NN NN O
to NN NN O
some NN NN O
extent NN NN O
. NN NN O
   
Irreversible NN NN O
terminal NN NN O
differentiation NN NN O
induced NN NN O
by NN NN O
VD3 NN NN O
is NN NN O
associated NN NN O
with NN NN O
down NN NN O
regulation NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
and NN NN O
upregulation NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
but NN NN O
ML NN NN O
- NN NN O
9 NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
oncogenes NN NN O
appreciably NN NN O
. NN NN O
   
ML NN NN O
- NN NN O
9 NN NN O
- NN NN O
induced NN NN O
differentiation NN NN O
was NN NN O
also NN NN O
reversible NN NN O
when NN NN O
the NN NN O
cells NN NN O
were NN NN O
cultured NN NN O
with NN NN O
cultured NN NN O
with NN NN O
ML NN NN O
- NN NN O
9 NN NN O
plus NN NN O
an NN NN O
anti NN NN O
- NN NN O
cancer NN NN O
drug NN NN O
such NN NN O
as NN NN O
1 NN NN O
- NN NN O
beta NN NN O
- NN NN O
D NN NN O
- NN NN O
arabino NN NN O
- NN NN O
furanosylcytosine NN NN O
or NN NN O
daunomycin NN NN O
. NN NN O
   
it NN NN O
became NN NN O
irreversible NN NN O
, NN NN O
however NN NN O
, NN NN O
upon NN NN O
simultaneous NN NN O
treatment NN NN O
with NN NN O
dexamethasone NN NN O
and NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
( NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
did NN NN O
not NN NN O
induce NN NN O
differentiation NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
but NN NN O
caused NN NN O
growth NN NN O
arrest NN NN O
of NN NN O
the NN NN O
cells NN NN O
in NN NN O
the NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
ML NN NN O
- NN NN O
9 NN NN O
should NN NN O
be NN NN O
useful NN NN O
for NN NN O
studying NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
modulates NN NN O
the NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
level NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
modulates NN NN O
the NN NN O
expression NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
In NN NN O
view NN NN O
of NN NN O
these NN NN O
findings NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
effects NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
different NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
activated NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Priming NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
resulted NN NN O
in NN NN O
the NN NN O
down NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
in NN NN O
response NN NN O
to NN NN O
stimulation NN NN O
with NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
compared NN NN O
to NN NN O
the NN NN O
effects NN NN O
of NN NN O
LPS NN NN O
alone NN NN O
. NN NN O
   
Not NN NN O
only NN NN O
was NN NN O
this NN NN O
effect NN NN O
observed NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
, NN NN O
but NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
DNA NN NN O
binding NN NN O
capacity NN NN O
was NN NN O
affected NN NN O
as NN NN O
well NN NN O
, NN NN O
A NN NN O
strong NN NN O
reduction NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
LPS NN NN O
- NN NN O
stimulated NN NN O
monocytes NN NN O
showed NN NN O
an NN NN O
increased NN NN O
expression NN NN O
of NN NN O
p105 NN NN B-Protein
mRNA NN NN O
, NN NN O
the NN NN O
precursor NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
while NN NN O
no NN NN O
effect NN NN O
was NN NN O
noticed NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
p65 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
priming NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
expression NN NN O
of NN NN O
p105 NN NN B-Protein
transcripts NN NN O
but NN NN O
enhanced NN NN O
the NN NN O
expression NN NN O
of NN NN O
p65 NN NN B-Protein
mRNA NN NN O
( NN NN O
two NN NN O
- NN NN O
fold NN NN O
) NN NN O
. NN NN O
   
Priming NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
followed NN NN O
by NN NN O
LPS NN NN O
stimulation NN NN O
resulted NN NN O
in NN NN O
a NN NN O
further NN NN O
increase NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
p65 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
This NN NN O
was NN NN O
due NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
p65 NN NN B-Protein
mRNA NN NN O
( NN NN O
75 NN NN O
vs NN NN O
150 NN NN O
minutes NN NN O
) NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
demonstrated NN NN O
that NN NN O
unstimulated NN NN O
monocytes NN NN O
predominantly NN NN O
expressed NN NN O
p50 NN NN B-Protein
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Stimulation NN NN O
with NN NN O
LPS NN NN O
or NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
resulted NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
subunits NN NN O
, NN NN O
while NN NN O
the NN NN O
combination NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
plus NN NN O
LPS NN NN O
caused NN NN O
a NN NN O
further NN NN O
increase NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
With NN NN O
Western NN NN O
blotting NN NN O
, NN NN O
it NN NN O
was NN NN O
shown NN NN O
that NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
monocytes NN NN O
contained NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
protein NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
stimulation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
combined NN NN O
stimulation NN NN O
did NN NN O
not NN NN O
result NN NN O
in NN NN O
enhanced NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
protein NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
were NN NN O
specific NN NN O
, NN NN O
since NN NN O
no NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
or NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
the NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
be NN NN O
important NN NN O
for NN NN O
the NN NN O
modulatory NN NN O
effects NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
the NN NN O
cytokine NN NN O
expression NN NN O
in NN NN O
activated NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
proteins NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
during NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
of NN NN O
HL60 NN NN O
cells NN NN O
and NN NN O
phytohemagglutinin NN NN B-Protein
- NN NN O
stimulated NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
protein NN NN O
products NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
( NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
) NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
( NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
) NN NN O
genes NN NN O
are NN NN O
members NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
and NN NN O
are NN NN O
thought NN NN O
to NN NN O
play NN NN O
important NN NN O
roles NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
during NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
Most NN NN O
studies NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
proteins NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
have NN NN O
been NN NN O
performed NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
, NN NN O
and NN NN O
therefore NN NN O
do NN NN O
not NN NN O
give NN NN O
direct NN NN O
information NN NN O
about NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
proteins NN NN O
during NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
Western NN NN O
blotting NN NN O
to NN NN O
investigate NN NN O
the NN NN O
presence NN NN O
of NN NN O
these NN NN O
proteins NN NN O
during NN NN O
the NN NN O
cell NN NN O
cycles NN NN O
of NN NN O
two NN NN O
different NN NN O
cellular NN NN O
systems NN NN O
: NN NN O
a NN NN O
continuously NN NN O
growing NN NN O
myeloid NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
, NN NN O
HL60 NN NN O
, NN NN O
and NN NN O
normal NN NN O
cells NN NN O
stimulated NN NN O
into NN NN O
cycle NN NN O
, NN NN O
phyto NN NN B-Protein
- NN NN I-Protein
hemagglutinin NN NN I-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
- NN NN O
stimulated NN NN O
normal NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
activity NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
which NN NN O
consists NN NN O
of NN NN O
dimers NN NN O
of NN NN O
Fos NN NN O
and NN NN O
Jun NN NN O
family NN NN O
proteins NN NN O
, NN NN O
was NN NN O
also NN NN O
studied NN NN O
using NN NN O
a NN NN O
gel NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
We NN NN O
found NN NN O
nuclear NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
throughout NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
both NN NN O
in NN NN O
HL60 NN NN O
cells NN NN O
and NN NN O
in NN NN O
PHA NN NN B-Protein
- NN NN O
stimulated NN NN O
PBL NN NN O
, NN NN O
and NN NN O
we NN NN O
postulate NN NN O
that NN NN O
these NN NN O
proteins NN NN O
are NN NN O
required NN NN O
throughout NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
and NN NN O
not NN NN O
transiently NN NN O
in NN NN O
the NN NN O
G0 NN NN O
to NN NN O
G1 NN NN O
transition NN NN O
as NN NN O
previous NN NN O
mRNA NN NN O
studies NN NN O
have NN NN O
indicated NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
an NN NN O
uncoupling NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
from NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
and NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
was NN NN O
expressed NN NN O
more NN NN O
strongly NN NN O
in NN NN O
the NN NN O
G1 NN NN O
- NN NN O
and NN NN O
G2 NN NN O
/ NN NN O
M NN NN O
- NN NN O
phase NN NN O
enriched NN NN O
samples NN NN O
than NN NN O
in NN NN O
the NN NN O
S NN NN O
- NN NN O
phase NN NN O
enriched NN NN O
samples NN NN O
of NN NN O
HL60 NN NN O
cells NN NN O
, NN NN O
while NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
were NN NN O
constant NN NN O
. NN NN O
   
Nuclei NN NN O
of NN NN O
unstimulated NN NN O
PBL NN NN O
from NN NN O
different NN NN O
donors NN NN O
expressed NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
but NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
samples NN NN O
. NN NN O
   
Following NN NN O
PHA NN NN B-Protein
stimulation NN NN O
of NN NN O
PBL NN NN O
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
was NN NN O
delayed NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
augmentation NN NN O
of NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
expression NN NN O
. NN NN O
   
We NN NN O
also NN NN O
observed NN NN O
that NN NN O
cytoplasmic NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
were NN NN O
present NN NN O
in NN NN O
HL60 NN NN O
cells NN NN O
and NN NN O
PHA NN NN B-Protein
- NN NN O
stimulated NN NN O
PBL NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
cytoplasmic NN NN O
p62c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
was NN NN O
detected NN NN O
in NN NN O
unstimulated NN NN O
PBL NN NN O
, NN NN O
although NN NN O
in NN NN O
some NN NN O
cases NN NN O
cytoplasmic NN NN O
p39c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
was NN NN O
detected NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
subcellular NN NN O
compartmentalization NN NN O
of NN NN O
these NN NN O
proteinsmay NN NN O
occur NN NN O
under NN NN O
certain NN NN O
circumstances NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
in NN NN O
oxidant NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
its NN NN O
subclone NN NN O
Wurzburg NN NN O
cells NN NN O
oxidant NN NN O
challenge NN NN O
elevated NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
by NN NN O
mobilizing NN NN O
Ca2 NN NN O
+ NN NN O
from NN NN O
intracellular NN NN O
stores NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
cells NN NN O
this NN NN O
effect NN NN O
was NN NN O
rapid NN NN O
and NN NN O
transient NN NN O
, NN NN O
but NN NN O
in NN NN O
Wurzburg NN NN O
cells NN NN O
the NN NN O
response NN NN O
was NN NN O
slow NN NN O
and NN NN O
sustained NN NN O
. NN NN O
   
H2O2 NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
Wurzburg NN NN O
cells NN NN O
was NN NN O
not NN NN O
influenced NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
extracellular NN NN O
EGTA NN NN O
but NN NN O
was NN NN O
totally NN NN O
inhibited NN NN O
in NN NN O
cells NN NN O
that NN NN O
were NN NN O
loaded NN NN O
with NN NN O
esterified NN NN O
EGTA NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
cells NN NN O
that NN NN O
are NN NN O
not NN NN O
sensitive NN NN O
to NN NN O
H2O2 NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
H2O2 NN NN O
potentiated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
sustained NN NN O
high NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
following NN NN O
thapsigargin NN NN O
treatment NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
regulatory NN NN O
effect NN NN O
of NN NN O
alpha NN NN O
- NN NN O
lipoate NN NN O
and NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
appeared NN NN O
to NN NN O
be NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
due NN NN O
to NN NN O
their NN NN O
ability NN NN O
to NN NN O
stabilize NN NN O
elevation NN NN O
of NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
following NN NN O
oxidant NN NN O
challenge NN NN O
. NN NN O
   
Results NN NN O
of NN NN O
this NN NN O
study NN NN O
indicate NN NN O
that NN NN O
a NN NN O
sustained NN NN O
elevated NN NN O
[ NN NN O
Ca2 NN NN O
+ NN NN O
] NN NN O
i NN NN O
is NN NN O
a NN NN O
significant NN NN O
factor NN NN O
in NN NN O
oxidant NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
A NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
in NN NN O
the NN NN O
human NN NN O
B7 NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
regulated NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
costimulatory NN NN O
molecule NN NN O
B7 NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
provides NN NN O
a NN NN O
second NN NN O
signal NN NN O
critical NN NN O
for NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
distribution NN NN O
of NN NN O
this NN NN O
integral NN NN O
membrane NN NN O
protein NN NN O
is NN NN O
restricted NN NN O
to NN NN O
certain NN NN O
tissues NN NN O
where NN NN O
its NN NN O
level NN NN O
of NN NN O
expression NN NN O
is NN NN O
modulated NN NN O
by NN NN O
multiple NN NN O
exogenous NN NN O
stimuli NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
specificity NN NN O
and NN NN O
inducibility NN NN O
, NN NN O
the NN NN O
chromatin NN NN O
configuration NN NN O
of NN NN O
the NN NN O
human NN NN O
B7 NN NN O
. NN NN O
1 NN NN O
gene NN NN O
was NN NN O
examined NN NN O
in NN NN O
intact NN NN O
nuclei NN NN O
from NN NN O
various NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
identification NN NN O
of NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
deoxyribonuclease NN NN B-Protein
I NN NN I-Protein
hypersensitive NN NN O
site NN NN O
approximately NN NN O
3kb NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
led NN NN O
to NN NN O
the NN NN O
characterization NN NN O
of NN NN O
a NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
region NN NN O
. NN NN O
   
This NN NN O
183 NN NN O
- NN NN O
bp NN NN O
region NN NN O
was NN NN O
both NN NN O
cell NN NN O
type NN NN O
specific NN NN O
and NN NN O
responsive NN NN O
to NN NN O
two NN NN O
distinct NN NN O
stimuli NN NN O
, NN NN O
lipopolysaccharide NN NN O
and NN NN O
dibutyryl NN NN O
cAMP NN NN O
, NN NN O
known NN NN O
to NN NN O
regulate NN NN O
B7 NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Deletional NN NN O
and NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
multiple NN NN O
functionally NN NN O
critical NN NN O
cis NN NN O
elements NN NN O
within NN NN O
this NN NN O
region NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
was NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
consensus NN NN O
sequence NN NN O
. NN NN O
   
In NN NN O
B7 NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
- NN NN O
positive NN NN O
B NN NN O
cells NN NN O
, NN NN O
this NN NN O
element NN NN O
bound NN NN O
several NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
, NN NN O
transcription NN NN O
factors NN NN O
already NN NN O
implicated NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
relevant NN NN O
to NN NN O
B7 NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
description NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
of NN NN O
regulatory NN NN O
elements NN NN O
that NN NN O
control NN NN O
expression NN NN O
of NN NN O
a NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
B7 NN NN O
costimulatory NN NN O
molecule NN NN O
. NN NN O
   
Heat NN NN O
shock NN NN O
induces NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
promyelocyte NN NN O
cell NN NN O
line NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
. NN NN O
   
A NN NN O
long NN NN O
period NN NN O
of NN NN O
clinical NN NN O
latency NN NN O
before NN NN O
development NN NN O
of NN NN O
symptoms NN NN O
is NN NN O
characteristic NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
. NN NN O
   
OM10 NN NN O
. NN NN O
1 NN NN O
, NN NN O
a NN NN O
promyelocyte NN NN O
cell NN NN O
line NN NN O
latently NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
has NN NN O
been NN NN O
developed NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
studying NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
viral NN NN O
latency NN NN O
and NN NN O
the NN NN O
activation NN NN O
of NN NN O
virus NN NN O
expression NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
this NN NN O
latently NN NN O
infected NN NN O
cell NN NN O
line NN NN O
with NN NN O
heat NN NN O
shock NN NN O
at NN NN O
42 NN NN O
degrees NN NN O
C NN NN O
for NN NN O
2 NN NN O
h NN NN O
resulted NN NN O
in NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
without NN NN O
addition NN NN O
of NN NN O
any NN NN O
cytokines NN NN O
. NN NN O
   
The NN NN O
mechanism NN NN O
of NN NN O
activation NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
using NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibody NN NN O
and NN NN O
various NN NN O
inhibitors NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
level NN NN O
in NN NN O
culture NN NN O
supernatants NN NN O
was NN NN O
below NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
an NN NN O
ELISA NN NN O
assay NN NN O
system NN NN O
, NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibody NN NN O
in NN NN O
culture NN NN O
medium NN NN O
could NN NN O
partially NN NN O
suppress NN NN O
the NN NN O
heat NN NN O
shock NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
production NN NN O
. NN NN O
   
Staurosporine NN NN O
( NN NN O
PKC NN NN O
inhibitor NN NN O
) NN NN O
, NN NN O
pentoxifylline NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitor NN NN O
) NN NN O
, NN NN O
and NN NN O
Ro5 NN NN O
- NN NN O
3335 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
inhibitor NN NN O
) NN NN O
also NN NN O
inhibited NN NN O
significantly NN NN O
the NN NN O
heat NN NN O
shock NN NN O
induced NN NN O
virus NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
staurosporine NN NN O
achieved NN NN O
approximately NN NN O
90 NN NN O
% NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
antigen NN NN O
expression NN NN O
in NN NN O
heat NN NN O
shock NN NN O
- NN NN O
treated NN NN O
OM10 NN NN O
. NN NN O
1 NN NN O
at NN NN O
a NN NN O
non NN NN O
- NN NN O
toxic NN NN O
concentration NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
activation NN NN O
with NN NN O
heat NN NN O
shock NN NN O
has NN NN O
not NN NN O
been NN NN O
fully NN NN O
elucidated NN NN O
yet NN NN O
, NN NN O
it NN NN O
is NN NN O
presumed NN NN O
PKC NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
activation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
present NN NN O
observations NN NN O
will NN NN O
provide NN NN O
a NN NN O
further NN NN O
insight NN NN O
into NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infections NN NN O
. NN NN O
   
Abundant NN NN O
expression NN NN O
of NN NN O
erythroid NN NN B-Protein
transcription NN NN I-Protein
factor NN NN I-Protein
P45 NN NN I-Protein
NF NN NN I-Protein
- NN NN I-Protein
E2 NN NN I-Protein
mRNA NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
granurocytes NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
is NN NN O
crucial NN NN O
for NN NN O
regulation NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
p45 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
contains NN NN O
a NN NN O
basic NN NN O
- NN NN O
leucine NN NN O
zipper NN NN O
domain NN NN O
and NN NN O
dimerizes NN NN O
with NN NN O
the NN NN O
small NN NN O
Maf NN NN O
family NN NN O
protein NN NN O
to NN NN O
form NN NN O
functional NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
complex NN NN O
. NN NN O
   
While NN NN O
p45 NN NN B-Protein
expression NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
restricted NN NN O
to NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
megakaryocytes NN NN O
and NN NN O
mast NN NN O
cells NN NN O
in NN NN O
hematopoietic NN NN O
lineage NN NN O
, NN NN O
we NN NN O
found NN NN O
in NN NN O
this NN NN O
study NN NN O
that NN NN O
p45 NN NN B-Protein
mRNA NN NN O
is NN NN O
abundantly NN NN O
transcribed NN NN O
in NN NN O
the NN NN O
granulocyte NN NN O
fraction NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
neutrophils NN NN O
occupy NN NN O
approximately NN NN O
92 NN NN O
% NN NN O
of NN NN O
the NN NN O
cells NN NN O
in NN NN O
granulocyte NN NN O
fraction NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
neutrophils NN NN O
occupy NN NN O
approximately NN NN O
92 NN NN O
% NN NN O
of NN NN O
the NN NN O
cells NN NN O
in NN NN O
this NN NN O
fraction NN NN O
, NN NN O
the NN NN O
cells NN NN O
expressing NN NN O
p45 NN NN B-Protein
is NN NN O
most NN NN O
likely NN NN O
to NN NN O
be NN NN O
neutrophils NN NN O
. NN NN O
   
p45 NN NN B-Protein
mRNA NN NN O
is NN NN O
also NN NN O
expressed NN NN O
in NN NN O
HL NN NN O
- NN NN O
60 NN NN O
promyelocytes NN NN O
, NN NN O
albeit NN NN O
the NN NN O
expression NN NN O
level NN NN O
is NN NN O
much NN NN O
lower NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
granulocyte NN NN O
fraction NN NN O
. NN NN O
   
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
were NN NN O
found NN NN O
to NN NN O
express NN NN O
mafK NN NN B-Protein
mRNA NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
genuine NN NN O
NF NN NN O
- NN NN O
E2 NN NN O
complex NN NN O
in NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
p45 NN NN B-Protein
mRNA NN NN O
is NN NN O
transcribed NN NN O
from NN NN O
two NN NN O
different NN NN O
promoters NN NN O
, NN NN O
aNF NN NN O
- NN NN O
E2 NN NN O
promoter NN NN O
and NN NN O
fNF NN NN O
- NN NN O
E2 NN NN O
promoter NN NN O
, NN NN O
in NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
lineage NN NN O
cells NN NN O
, NN NN O
p45 NN NN B-Protein
mRNA NN NN O
is NN NN O
transcribed NN NN O
only NN NN O
from NN NN O
aNF NN NN O
- NN NN O
E2 NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
p45 NN NN B-Protein
megakaryocytic NN NN O
lineage NN NN O
cells NN NN O
, NN NN O
p45 NN NN B-Protein
mRNA NN NN O
is NN NN O
transcribed NN NN O
only NN NN O
from NN NN O
aNF NN NN O
- NN NN O
E2 NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
p45 NN NN B-Protein
mRNA NN NN O
in NN NN O
the NN NN O
neutrophils NN NN O
declined NN NN O
rapidly NN NN O
after NN NN O
transfer NN NN O
of NN NN O
the NN NN O
cells NN NN O
to NN NN O
in NN NN O
vitro NN NN O
culture NN NN O
and NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
could NN NN O
not NN NN O
sustain NN NN O
the NN NN O
expression NN NN O
from NN NN O
the NN NN O
down NN NN O
- NN NN O
regulation NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
E2 NN NN O
may NN NN O
also NN NN O
participate NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
neutrophil NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
a NN NN O
human NN NN O
LIM NN NN O
- NN NN O
Hox NN NN O
gene NN NN O
, NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
aberrantly NN NN O
expressed NN NN O
in NN NN O
chronic NN NN O
myelogenous NN NN O
leukaemia NN NN O
and NN NN O
located NN NN O
on NN NN O
9q33 NN NN O
- NN NN O
34 NN NN O
. NN NN O
1 NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
the NN NN O
isolation NN NN O
of NN NN O
human NN NN O
LH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
a NN NN O
putative NN NN O
transcription NN NN O
factor NN NN O
containing NN NN O
two NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
regions NN NN O
( NN NN O
LIM NN NN O
domains NN NN O
) NN NN O
and NN NN O
a NN NN O
homeobox NN NN O
( NN NN O
Hox NN NN O
) NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
. NN NN O
   
High NN NN O
levels NN NN O
of NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
were NN NN O
observed NN NN O
in NN NN O
all NN NN O
cases NN NN O
of NN NN O
chronic NN NN O
myelogenous NN NN O
leukaemia NN NN O
( NN NN O
CML NN NN O
) NN NN O
tested NN NN O
, NN NN O
regardless NN NN O
of NN NN O
disease NN NN O
status NN NN O
. NN NN O
   
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
9Q33 NN NN O
- NN NN O
34 NN NN O
. NN NN O
1 NN NN O
, NN NN O
in NN NN O
the NN NN O
same NN NN O
region NN NN O
as NN NN O
the NN NN O
reciprocal NN NN O
translocation NN NN O
that NN NN O
creates NN NN O
the NN NN O
BCR NN NN B-Protein
- NN NN O
ABL NN NN B-Protein
chimera NN NN O
of NN NN O
the NN NN O
Philadelphia NN NN O
chromosome NN NN O
( NN NN O
Ph NN NN O
' NN NN O
) NN NN O
, NN NN O
the NN NN O
hallmark NN NN O
of NN NN O
CML NN NN O
; NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
retained NN NN O
on NN NN O
the NN NN O
derivative NN NN O
9 NN NN O
chromosome NN NN O
and NN NN O
is NN NN O
therefore NN NN O
centromeric NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
ABL NN NN I-Protein
. NN NN O
   
The NN NN O
proximity NN NN O
of NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
to NN NN O
the NN NN O
breakpoint NN NN O
on NN NN O
chromosome NN NN O
9 NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
of NN NN O
cis NN NN O
- NN NN O
activation NN NN O
by NN NN O
the NN NN O
t NN NN O
( NN NN O
9 NN NN O
; NN NN O
22 NN NN O
) NN NN O
( NN NN O
q34 NN NN O
; NN NN O
q11 NN NN O
) NN NN O
translocation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
finding NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
all NN NN O
cases NN NN O
of NN NN O
CML NN NN O
, NN NN O
expression NN NN O
was NN NN O
observed NN NN O
in NN NN O
lymphoid NN NN O
malignancies NN NN O
and NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
primary NN NN O
cases NN NN O
of NN NN O
acute NN NN O
myelogenous NN NN O
leukaemia NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
the NN NN O
development NN NN O
or NN NN O
progression NN NN O
of NN NN O
leukaemia NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
However NN NN O
, NN NN O
hLH NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
may NN NN O
prove NN NN O
useful NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
CML NN NN O
for NN NN O
monitoring NN NN O
residual NN NN O
disease NN NN O
. NN NN O
   
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
during NN NN O
B NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Translocations NN NN O
involving NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
gene NN NN O
are NN NN O
common NN NN O
in NN NN O
the NN NN O
diffuse NN NN O
large NN NN O
cell NN NN O
subtype NN NN O
of NN NN O
non NN NN O
- NN NN O
Hodgkin NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
. NN NN O
   
Invariably NN NN O
, NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
coding NN NN O
region NN NN O
is NN NN O
intact NN NN O
, NN NN O
but NN NN O
its NN NN O
5 NN NN O
' NN NN O
untranslated NN NN O
region NN NN O
is NN NN O
replaced NN NN O
with NN NN O
sequences NN NN O
from NN NN O
the NN NN O
translocation NN NN O
partner NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
shows NN NN O
that NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
is NN NN O
regulated NN NN O
in NN NN O
lymphocytes NN NN O
during NN NN O
mitogenic NN NN O
stimulation NN NN O
. NN NN O
   
Resting NN NN O
B NN NN O
and NN NN O
T NN NN O
lymphocytes NN NN O
contain NN NN O
high NN NN O
levels NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
mouse NN NN O
B NN NN O
cells NN NN O
with NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
or NN NN O
IgD NN NN O
antibodies NN NN O
, NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
, NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
plus NN NN O
ionomycin NN NN O
, NN NN O
or NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
led NN NN O
to NN NN O
a NN NN O
five NN NN O
- NN NN O
fold NN NN O
to NN NN O
35 NN NN O
- NN NN O
fold NN NN O
decrease NN NN O
in NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
Similar NN NN O
downregulation NN NN O
of NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
was NN NN O
seen NN NN O
in NN NN O
human NN NN O
B NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
Staphylococcus NN NN O
aureus NN NN O
plus NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
anti NN NN O
- NN NN O
IgM NN NN O
antibodies NN NN O
and NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
stimulated NN NN O
with NN NN O
phytohemagglutinin NN NN B-Protein
. NN NN O
   
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
levels NN NN O
began NN NN O
to NN NN O
decrease NN NN O
8 NN NN O
to NN NN O
16 NN NN O
hours NN NN O
after NN NN O
stimulation NN NN O
, NN NN O
before NN NN O
cells NN NN O
entered NN NN O
S NN NN O
phase NN NN O
. NN NN O
   
Although NN NN O
polyclonal NN NN O
activation NN NN O
of NN NN O
B NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
invariably NN NN O
decreased NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
MRNA NN NN O
expression NN NN O
, NN NN O
activated NN NN O
B NN NN O
cells NN NN O
from NN NN O
human NN NN O
germinal NN NN O
centers NN NN O
expressed NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
at NN NN O
levels NN NN O
comparable NN NN O
to NN NN O
the NN NN O
levels NN NN O
in NN NN O
resting NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Despite NN NN O
these NN NN O
similar NN NN O
mRNA NN NN O
levels NN NN O
, NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
expression NN NN O
was NN NN O
threefold NN NN O
to NN NN O
34 NN NN O
- NN NN O
fold NN NN O
higher NN NN O
in NN NN O
germinal NN NN O
center NN NN O
B NN NN O
cells NN NN O
than NN NN O
in NN NN O
resting NN NN O
B NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
levels NN NN O
are NN NN O
controlled NN NN O
by NN NN O
translational NN NN O
or NN NN O
posttranslational NN NN O
mechanisms NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
the NN NN O
germinal NN NN O
center NN NN O
reaction NN NN O
provides NN NN O
unique NN NN O
activation NN NN O
signals NN NN O
to NN NN O
B NN NN O
cells NN NN O
that NN NN O
allow NN NN O
for NN NN O
continued NN NN O
, NN NN O
high NN NN O
- NN NN O
level NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
expression NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
interferon NN NN O
regulatory NN NN O
factor NN NN O
family NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
ICSAT NN NN B-Protein
/ NN NN O
Pip NN NN B-Protein
/ NN NN O
LSIRF NN NN B-Protein
, NN NN O
that NN NN O
negatively NN NN O
regulates NN NN O
the NN NN O
activity NN NN O
of NN NN O
interferon NN NN O
- NN NN O
regulated NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
isolated NN NN O
a NN NN O
novel NN NN O
cDNA NN NN O
clone NN NN O
encoding NN NN O
interferon NN NN B-Protein
( NN NN I-Protein
IFN NN NN I-Protein
) NN NN I-Protein
consensus NN NN I-Protein
sequence NN NN I-Protein
- NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
in NN NN I-Protein
adult NN NN I-Protein
T NN NN I-Protein
- NN NN I-Protein
cell NN NN I-Protein
leukemia NN NN I-Protein
cell NN NN I-Protein
line NN NN I-Protein
or NN NN I-Protein
activated NN NN I-Protein
T NN NN I-Protein
cells NN NN I-Protein
( NN NN O
ICSAT NN NN B-Protein
) NN NN O
; NN NN O
this NN NN O
protein NN NN O
is NN NN O
the NN NN O
human NN NN O
homolog NN NN O
of NN NN O
the NN NN O
recently NN NN O
cloned NN NN O
Pip NN NN B-Protein
/ NN NN O
LSIRF NN NN B-Protein
. NN NN O
   
ICSAT NN NN B-Protein
is NN NN O
structurally NN NN O
most NN NN O
closely NN NN O
related NN NN O
to NN NN O
the NN NN O
previously NN NN O
cloned NN NN O
ICSBP NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
IFN NN NN O
regulatory NN NN O
factor NN NN O
( NN NN O
IRF NN NN O
) NN NN O
family NN NN O
of NN NN O
proteins NN NN O
that NN NN O
binds NN NN O
to NN NN O
interferon NN NN O
consensus NN NN O
sequences NN NN O
( NN NN O
ICSs NN NN O
) NN NN O
found NN NN O
in NN NN O
many NN NN O
promoters NN NN O
of NN NN O
the NN NN O
IFN NN NN O
- NN NN O
regulated NN NN O
genes NN NN O
. NN NN O
   
Among NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
investigated NN NN O
, NN NN O
ICSAT NN NN B-Protein
was NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
- NN NN O
infected NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
tax NN NN B-Protein
gene NN NN O
was NN NN O
expressed NN NN O
or NN NN O
phorbol NN NN O
myristake NN NN O
acetate NN NN O
- NN NN O
A23187 NN NN O
stimulation NN NN O
was NN NN O
used NN NN O
, NN NN O
ICSAT NN NN B-Protein
expression NN NN O
was NN NN O
induced NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
which NN NN O
otherwise NN NN O
do NN NN O
not NN NN O
express NN NN O
ICSAT NN NN B-Protein
. NN NN O
   
When NN NN O
the NN NN O
binding NN NN O
of NN NN O
ICSAT NN NN B-Protein
to NN NN O
four NN NN O
different NN NN O
ICSs NN NN O
was NN NN O
tested NN NN O
, NN NN O
the NN NN O
relative NN NN O
differences NN NN O
in NN NN O
binding NN NN O
affinities NN NN O
for NN NN O
those NN NN O
ICSs NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
To NN NN O
study NN NN O
the NN NN O
functional NN NN O
role NN NN O
of NN NN O
ICSAT NN NN B-Protein
, NN NN O
we NN NN O
performed NN NN O
cotransfection NN NN O
experiments NN NN O
with NN NN O
the NN NN O
human NN NN O
embryonal NN NN O
carcinoma NN NN O
cell NN NN O
line NN NN O
N NN NN O
- NN NN O
Tera2 NN NN O
. NN NN O
   
ICSAT NN NN B-Protein
was NN NN O
demonstrated NN NN O
to NN NN O
possess NN NN O
repressive NN NN O
function NN NN O
over NN NN O
the NN NN O
gene NN NN O
activation NN NN O
induced NN NN O
by NN NN O
IFN NN NN O
stimulation NN NN O
or NN NN O
by NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
cotransfection NN NN O
. NN NN O
   
Such NN NN O
repressive NN NN O
function NN NN O
is NN NN O
similar NN NN O
to NN NN O
that NN NN O
seen NN NN O
in NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
ICSBP NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
have NN NN O
found NN NN O
that NN NN O
ICSAT NN NN B-Protein
has NN NN O
a NN NN O
different NN NN O
repressive NN NN O
effect NN NN O
from NN NN O
that NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
ICSBP NN NN B-Protein
in NN NN O
some NN NN O
IFN NN NN O
- NN NN O
responsive NN NN O
reporter NN NN O
constructs NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
of NN NN O
gene NN NN O
regulation NN NN O
by NN NN O
"""""""" NN NN O
differential NN NN O
repression NN NN O
"""""""" NN NN O
is NN NN O
used NN NN O
by NN NN O
multiple NN NN O
members NN NN O
of NN NN O
repressor NN NN O
proteins NN NN O
with NN NN O
different NN NN O
repressive NN NN O
effects NN NN O
on NN NN O
the NN NN O
IFN NN NN O
- NN NN O
responsive NN NN O
genes NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
of NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocytes NN NN O
- NN NN O
- NN NN O
basic NN NN O
research NN NN O
and NN NN O
clinical NN NN O
perspectives NN NN O
for NN NN O
gastroenterology NN NN O
. NN NN O
   
Tissue NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
by NN NN O
transcription NN NN O
factors NN NN O
is NN NN O
a NN NN O
fascinating NN NN O
new NN NN O
field NN NN O
in NN NN O
molecular NN NN O
immunology NN NN O
. NN NN O
   
This NN NN O
review NN NN O
summarizes NN NN O
data NN NN O
on NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
promoters NN NN O
and NN NN O
enhancers NN NN O
by NN NN O
nuclear NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
structural NN NN O
classes NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
described NN NN O
and NN NN O
basic NN NN O
methods NN NN O
for NN NN O
detection NN NN O
and NN NN O
analysis NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
detailed NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
most NN NN O
important NN NN O
trans NN NN O
- NN NN O
acting NN NN O
factors NN NN O
of NN NN O
T NN NN O
and NN NN O
B NN NN O
lymphocytes NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
NF NN NN O
- NN NN O
kB NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
STAT NN NN O
families NN NN O
) NN NN O
and NN NN O
their NN NN O
functional NN NN O
importance NN NN O
are NN NN O
described NN NN O
. NN NN O
   
Several NN NN O
methods NN NN O
for NN NN O
specific NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
shown NN NN O
that NN NN O
may NN NN O
be NN NN O
relevant NN NN O
to NN NN O
treatment NN NN O
of NN NN O
human NN NN O
disease NN NN O
. NN NN O
   
The NN NN O
data NN NN O
are NN NN O
discussed NN NN O
with NN NN O
regard NN NN O
to NN NN O
their NN NN O
potential NN NN O
clinical NN NN O
relevance NN NN O
for NN NN O
gastroenterology NN NN O
. NN NN O
   
DNA NN NN O
triplex NN NN O
formation NN NN O
selectively NN NN O
inhibits NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
hemopoietic NN NN O
growth NN NN O
factor NN NN O
that NN NN O
is NN NN O
expressed NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
fibroblasts NN NN O
, NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
essential NN NN O
for NN NN O
normal NN NN O
hemopoiesis NN NN O
, NN NN O
overexpression NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
some NN NN O
diseases NN NN O
such NN NN O
as NN NN O
myeloid NN NN O
leukemia NN NN O
and NN NN O
chronic NN NN O
inflammation NN NN O
. NN NN O
   
An NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
binding NN NN O
site NN NN O
within NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
, NN NN O
termed NN NN O
the NN NN O
kappaB NN NN O
element NN NN O
appears NN NN O
to NN NN O
be NN NN O
important NN NN O
for NN NN O
controlling NN NN O
expression NN NN O
in NN NN O
reporter NN NN O
gene NN NN O
assays NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
number NN NN O
of NN NN O
stimuli NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
oligonucleotide NN NN O
- NN NN O
directed NN NN O
triple NN NN O
helix NN NN O
formation NN NN O
across NN NN O
this NN NN O
regulatory NN NN O
sequence NN NN O
as NN NN O
a NN NN O
potential NN NN O
tool NN NN O
to NN NN O
inhibit NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
A NN NN O
15 NN NN O
- NN NN O
base NN NN O
oligonucleotide NN NN O
, NN NN O
GM3 NN NN O
, NN NN O
was NN NN O
targeted NN NN O
to NN NN O
a NN NN O
purine NN NN O
- NN NN O
rich NN NN O
region NN NN O
in NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
proximal NN NN O
promoter NN NN O
, NN NN O
which NN NN O
overlaps NN NN O
the NN NN O
kappaB NN NN O
element NN NN O
. NN NN O
   
Gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
and NN NN O
DNase NN NN B-Protein
I NN NN I-Protein
footprinting NN NN O
demonstrated NN NN O
that NN NN O
GM3 NN NN O
formed NN NN O
a NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
collinear NN NN O
triplex NN NN O
with NN NN O
its NN NN O
double NN NN O
- NN NN O
stranded NN NN O
DNA NN NN O
target NN NN O
. NN NN O
   
Triplex NN NN O
formation NN NN O
by NN NN O
GM3 NN NN O
blocked NN NN O
recombinant NN NN O
and NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
binding NN NN O
to NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
element NN NN O
. NN NN O
   
GM3 NN NN O
also NN NN O
caused NN NN O
selective NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphotrophic NN NN O
virus NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
transactivator NN NN O
- NN NN O
induced NN NN O
luciferase NN NN O
activity NN NN O
from NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
driven NN NN O
by NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
GM3 NN NN O
greatly NN NN O
reduced NN NN O
the NN NN O
concentration NN NN O
of NN NN O
endogenous NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
mRNA NN NN O
induced NN NN O
by NN NN O
different NN NN O
stimuli NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
but NN NN O
did NN NN O
not NN NN O
affect NN NN O
interleukin NN NN B-Protein
3 NN NN I-Protein
mRNA NN NN O
levels NN NN O
in NN NN O
the NN NN O
same NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
kappaB NN NN O
element NN NN O
in NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
plays NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
. NN NN O
   
Colinear NN NN O
triplex NN NN O
formation NN NN O
acts NN NN O
as NN NN O
a NN NN O
selective NN NN O
transcriptional NN NN O
repressor NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
and NN NN O
may NN NN O
have NN NN O
potential NN NN O
therapeutic NN NN O
application NN NN O
in NN NN O
cases NN NN O
of NN NN O
undesirable NN NN O
overexpression NN NN O
of NN NN O
this NN NN O
protein NN NN O
. NN NN O
   
Cooperation NN NN O
between NN NN O
core NN NN O
binding NN NN O
factor NN NN O
and NN NN O
adjacent NN NN O
promoter NN NN O
elements NN NN O
contributes NN NN O
to NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
. NN NN O
   
Tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
is NN NN O
mediated NN NN O
via NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
located NN NN O
within NN NN O
315 NN NN O
base NN NN O
pairs NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
. NN NN O
   
This NN NN O
is NN NN O
achieved NN NN O
in NN NN O
part NN NN O
through NN NN O
the NN NN O
positive NN NN O
activities NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
Elf NN NN O
- NN NN O
1 NN NN O
sites NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
. NN NN O
   
The NN NN O
contribution NN NN O
to NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
by NN NN O
other NN NN O
promoter NN NN O
sites NN NN O
was NN NN O
assessed NN NN O
in NN NN O
a NN NN O
transient NN NN O
expression NN NN O
assay NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
constructs NN NN O
linked NN NN O
to NN NN O
a NN NN O
luciferase NN NN O
gene NN NN O
, NN NN O
focusing NN NN O
initially NN NN O
on NN NN O
the NN NN O
core NN NN O
binding NN NN O
factor NN NN O
( NN NN O
CBF NN NN O
) NN NN O
site NN NN O
, NN NN O
which NN NN O
is NN NN O
footprinted NN NN O
in NN NN O
vivo NN NN O
upon NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Activity NN NN O
of NN NN O
the NN NN O
CBF NN NN O
site NN NN O
is NN NN O
shown NN NN O
to NN NN O
be NN NN O
critically NN NN O
dependent NN NN O
on NN NN O
the NN NN O
adjacent NN NN O
activator NN NN O
site NN NN O
Act NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Together NN NN O
the NN NN O
Act NN NN O
- NN NN O
1 NN NN O
and NN NN O
CBF NN NN O
sites NN NN O
form NN NN O
a NN NN O
functional NN NN O
unit NN NN O
( NN NN O
AC NN NN O
unit NN NN O
) NN NN O
with NN NN O
dual NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
AC NN NN O
unit NN NN O
is NN NN O
demonstrated NN NN O
to NN NN O
enhance NN NN O
basal NN NN O
activity NN NN O
of NN NN O
promoters NN NN O
both NN NN O
in NN NN O
fibroblasts NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
activity NN NN O
is NN NN O
further NN NN O
inducible NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
the NN NN O
already NN NN O
identified NN NN O
NIP NN NN O
repressor NN NN O
site NN NN O
, NN NN O
evidence NN NN O
is NN NN O
presented NN NN O
for NN NN O
a NN NN O
second NN NN O
repressor NN NN O
region NN NN O
that NN NN O
restricts NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
a NN NN O
novel NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
has NN NN O
been NN NN O
mapped NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
promoter NN NN O
between NN NN O
nucleotide NN NN O
- NN NN O
180 NN NN O
and NN NN O
- NN NN O
210 NN NN O
that NN NN O
leads NN NN O
to NN NN O
increased NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Together NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
T NN NN O
cell NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
not NN NN O
specified NN NN O
by NN NN O
the NN NN O
activity NN NN O
of NN NN O
a NN NN O
single NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
element NN NN O
, NN NN O
but NN NN O
instead NN NN O
involves NN NN O
multiple NN NN O
interacting NN NN O
elements NN NN O
that NN NN O
provide NN NN O
both NN NN O
specific NN NN O
positive NN NN O
regulation NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
specific NN NN O
negative NN NN O
regulation NN NN O
in NN NN O
fibroblasts NN NN O
. NN NN O
   
Octamer NN NN O
binding NN NN O
factors NN NN O
and NN NN O
their NN NN O
coactivator NN NN O
can NN NN O
activate NN NN O
the NN NN O
murine NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
( NN NN O
spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
promoter NN NN O
. NN NN O
   
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
( NN NN O
spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
Ets NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
, NN NN O
is NN NN O
predominantly NN NN O
expressed NN NN O
in NN NN O
myeloid NN NN O
and NN NN O
B NN NN O
cells NN NN O
, NN NN O
activates NN NN O
many NN NN O
B NN NN O
cell NN NN O
and NN NN O
myeloid NN NN O
genes NN NN O
, NN NN O
and NN NN O
is NN NN O
critical NN NN O
for NN NN O
development NN NN O
of NN NN O
both NN NN O
of NN NN O
these NN NN O
lineages NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
studies NN NN O
( NN NN O
Chen NN NN O
, NN NN O
H NN NN O
. NN NN O
M NN NN O
. NN NN O
, NN NN O
Ray NN NN O
- NN NN O
Gallet NN NN O
, NN NN O
D NN NN O
. NN NN O
, NN NN O
Zhang NN NN O
, NN NN O
P NN NN O
. NN NN O
, NN NN O
Hetherington NN NN O
, NN NN O
C NN NN O
. NN NN O
J NN NN O
. NN NN O
, NN NN O
Gonzalez NN NN O
, NN NN O
D NN NN O
. NN NN O
A NN NN O
. NN NN O
, NN NN O
Zhang NN NN O
, NN NN O
D NN NN O
. NN NN O
- NN NN O
E NN NN O
. NN NN O
, NN NN O
Moreau NN NN O
- NN NN O
Gachelin NN NN O
, NN NN O
F NN NN O
. NN NN O
, NN NN O
and NN NN O
Tenen NN NN O
, NN NN O
D NN NN O
. NN NN O
G NN NN O
. NN NN O
( NN NN O
1995 NN NN O
) NN NN O
Oncogene NN NN O
11 NN NN O
, NN NN O
1549 NN NN O
- NN NN O
1560 NN NN O
) NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
directs NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
in NN NN O
myeloid NN NN O
cell NN NN O
lines NN NN O
, NN NN O
and NN NN O
that NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
its NN NN O
own NN NN O
promoter NN NN O
in NN NN O
an NN NN O
autoregulatory NN NN O
loop NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
murine NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
is NN NN O
also NN NN O
specifically NN NN O
and NN NN O
highly NN NN O
functional NN NN O
in NN NN O
B NN NN O
cell NN NN O
lines NN NN O
as NN NN O
well NN NN O
. NN NN O
   
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
can NN NN O
bind NN NN O
specifically NN NN O
to NN NN O
a NN NN O
site NN NN O
at NN NN O
base NN NN O
pair NN NN O
- NN NN O
55 NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
this NN NN O
site NN NN O
is NN NN O
specifically NN NN O
protected NN NN O
in NN NN O
B NN NN O
cells NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
two NN NN O
other NN NN O
sites NN NN O
contribute NN NN O
to NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
B NN NN O
cells NN NN O
; NN NN O
an NN NN O
Sp1 NN NN B-Protein
binding NN NN O
site NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
octamer NN NN O
site NN NN O
, NN NN O
and NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
autoregulatory NN NN O
site NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
B NN NN O
cell NN NN O
coactivator NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
Bob1 NN NN B-Protein
/ NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
is NN NN O
only NN NN O
expressed NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
not NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
and NN NN O
that NN NN O
OBF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
Bob1 NN NN B-Protein
/ NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
can NN NN O
transactivate NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
in NN NN O
HeLa NN NN O
and NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
B NN NN O
cell NN NN O
restricted NN NN O
coactivator NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
B NN NN O
cell NN NN O
specific NN NN O
expression NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
mediated NN NN O
by NN NN O
the NN NN O
octamer NN NN O
site NN NN O
. NN NN O
   
Tissue NN NN O
- NN NN O
specific NN NN O
activity NN NN O
of NN NN O
the NN NN O
gammac NN NN O
chain NN NN O
gene NN NN O
promoter NN NN O
depends NN NN O
upon NN NN O
an NN NN O
Ets NN NN O
binding NN NN O
site NN NN O
and NN NN O
is NN NN O
regulated NN NN O
by NN NN O
GA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
gammac NN NN B-Protein
chain NN NN O
is NN NN O
a NN NN O
subunit NN NN O
of NN NN O
multiple NN NN O
cytokine NN NN O
receptors NN NN O
( NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
) NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
which NN NN O
is NN NN O
restricted NN NN O
to NN NN O
hematopoietic NN NN O
lineages NN NN O
. NN NN O
   
A NN NN O
defect NN NN O
in NN NN O
gammac NN NN B-Protein
leads NN NN O
to NN NN O
the NN NN O
X NN NN O
- NN NN O
linked NN NN O
severe NN NN O
combined NN NN O
immunodeficiency NN NN O
characterized NN NN O
by NN NN O
a NN NN O
block NN NN O
in NN NN O
T NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
better NN NN O
characterize NN NN O
the NN NN O
human NN NN O
gammac NN NN B-Protein
promoter NN NN O
and NN NN O
define NN NN O
the NN NN O
minimal NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
region NN NN O
, NN NN O
progressive NN NN O
5 NN NN O
' NN NN O
- NN NN O
deletion NN NN O
constructs NN NN O
of NN NN O
a NN NN O
segment NN NN O
extending NN NN O
1053 NN NN O
base NN NN O
pairs NN NN O
upstream NN NN O
of NN NN O
the NN NN O
major NN NN O
transcription NN NN O
start NN NN O
site NN NN O
were NN NN O
generated NN NN O
and NN NN O
tested NN NN O
for NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
various NN NN O
hematopoietic NN NN O
and NN NN O
nonhematopoietic NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
- NN NN O
1053 NN NN O
/ NN NN O
+ NN NN O
34 NN NN O
construct NN NN O
allowed NN NN O
promoter NN NN O
activity NN NN O
only NN NN O
in NN NN O
cells NN NN O
of NN NN O
hematopoietic NN NN O
origin NN NN O
, NN NN O
and NN NN O
tissue NN NN O
specificity NN NN O
was NN NN O
conserved NN NN O
in NN NN O
all NN NN O
other NN NN O
constructs NN NN O
tested NN NN O
. NN NN O
   
The NN NN O
region NN NN O
downstream NN NN O
of NN NN O
- NN NN O
90 NN NN O
appeared NN NN O
critical NN NN O
for NN NN O
basal NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
It NN NN O
contains NN NN O
two NN NN O
potential NN NN O
Ets NN NN O
binding NN NN O
sites NN NN O
conserved NN NN O
in NN NN O
the NN NN O
murine NN NN O
gammac NN NN B-Protein
promoter NN NN O
gene NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
was NN NN O
found NN NN O
essential NN NN O
for NN NN O
functional NN NN O
promoter NN NN O
activity NN NN O
as NN NN O
determined NN NN O
by NN NN O
mutational NN NN O
analysis NN NN O
. NN NN O
   
The NN NN O
functional NN NN O
Ets NN NN O
binding NN NN O
site NN NN O
was NN NN O
found NN NN O
to NN NN O
bind NN NN O
Ets NN NN O
family NN NN O
proteins NN NN O
, NN NN O
principally NN NN O
GA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
and NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
could NN NN O
be NN NN O
transactivated NN NN O
by NN NN O
GABPalpha NN NN O
and NN NN O
- NN NN O
beta NN NN O
synergistically NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
, NN NN O
as NN NN O
already NN NN O
reported NN NN O
for NN NN O
the NN NN O
IL2Rbeta NN NN B-Protein
promoter NN NN O
, NN NN O
GA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
is NN NN O
an NN NN O
essential NN NN O
component NN NN O
of NN NN O
gammac NN NN B-Protein
basal NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Although NN NN O
GABP NN NN B-Protein
expression NN NN O
is NN NN O
not NN NN O
restricted NN NN O
to NN NN O
the NN NN O
hematopoietic NN NN O
lineage NN NN O
, NN NN O
its NN NN O
interaction NN NN O
with NN NN O
other NN NN O
specific NN NN O
factors NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
gammac NN NN B-Protein
gene NN NN O
. NN NN O
   
Multiple NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
required NN NN O
for NN NN O
activation NN NN O
of NN NN O
human NN NN O
interleukin NN NN B-Protein
9 NN NN I-Protein
gene NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
genetic NN NN O
elements NN NN O
and NN NN O
regulatory NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
human NN NN O
interleukin NN NN B-Protein
9 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
in NN NN O
a NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
- NN NN O
transformed NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
C5MJ2 NN NN O
, NN NN O
were NN NN O
investigated NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
expression NN NN O
is NN NN O
controlled NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
of NN NN O
the NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
linked NN NN O
to NN NN O
serially NN NN O
deleted NN NN O
sequences NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
has NN NN O
revealed NN NN O
several NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
elements NN NN O
involved NN NN O
in NN NN O
the NN NN O
basal NN NN O
and NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
in NN NN O
C5MJ2 NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
at NN NN O
- NN NN O
146 NN NN O
to NN NN O
- NN NN O
140 NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
. NN NN O
   
A NN NN O
proximal NN NN O
region NN NN O
between NN NN O
- NN NN O
46 NN NN O
and NN NN O
- NN NN O
80 NN NN O
was NN NN O
identified NN NN O
as NN NN O
the NN NN O
minimum NN NN O
sequence NN NN O
for NN NN O
the NN NN O
basal NN NN O
and NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
in NN NN O
C5MJ2 NN NN O
cells NN NN O
. NN NN O
   
Within NN NN O
this NN NN O
region NN NN O
, NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
at NN NN O
- NN NN O
59 NN NN O
to NN NN O
- NN NN O
50 NN NN O
and NN NN O
its NN NN O
adjacent NN NN O
20 NN NN O
- NN NN O
base NN NN O
pair NN NN O
upstream NN NN O
sequence NN NN O
were NN NN O
demonstrated NN NN O
to NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
protein NN NN O
binding NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
and NN NN O
potentially NN NN O
novel NN NN O
proteins NN NN O
( NN NN O
around NN NN O
35 NN NN O
kDa NN NN O
) NN NN O
can NN NN O
bind NN NN O
to NN NN O
this NN NN O
important NN NN O
sequence NN NN O
. NN NN O
   
Mutations NN NN O
at NN NN O
different NN NN O
sites NN NN O
within NN NN O
this NN NN O
proximal NN NN O
promoter NN NN O
region NN NN O
abolished NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
cooperation NN NN O
of NN NN O
different NN NN O
transcription NN NN O
factors NN NN O
is NN NN O
essential NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
9 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Mapping NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
repression NN NN O
domain NN NN O
of NN NN O
the NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
oct NN NN B-Protein
- NN NN I-Protein
2A NN NN I-Protein
. NN NN O
   
The NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
is NN NN O
implicated NN NN O
in NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
activity NN NN O
via NN NN O
the NN NN O
octamer NN NN O
motif NN NN O
. NN NN O
   
Structure NN NN O
/ NN NN O
function NN NN O
analysis NN NN O
of NN NN O
various NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
effector NN NN O
regions NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
GAL4 NN NN B-Protein
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
revealed NN NN O
that NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
contains NN NN O
two NN NN O
functionally NN NN O
different NN NN O
activation NN NN O
domains NN NN O
at NN NN O
the NN NN O
N NN NN O
and NN NN O
the NN NN O
C NN NN O
termini NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
both NN NN O
domains NN NN O
is NN NN O
strongly NN NN O
potentiated NN NN O
by NN NN O
interactions NN NN O
with NN NN O
distinct NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
coactivators NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
repression NN NN O
domain NN NN O
located NN NN O
within NN NN O
the NN NN O
N NN NN O
terminus NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
( NN NN O
amino NN NN O
acids NN NN O
2 NN NN O
- NN NN O
99 NN NN O
) NN NN O
. NN NN O
   
When NN NN O
this NN NN O
domain NN NN O
was NN NN O
transferred NN NN O
to NN NN O
a NN NN O
potent NN NN O
activator NN NN O
, NN NN O
transcription NN NN O
was NN NN O
strongly NN NN O
inhibited NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
present NN NN O
a NN NN O
deletion NN NN O
analysis NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
to NN NN O
determine NN NN O
the NN NN O
minimal NN NN O
repression NN NN O
domain NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
stretch NN NN O
of NN NN O
23 NN NN O
amino NN NN O
acids NN NN O
, NN NN O
rich NN NN O
in NN NN O
serine NN NN O
and NN NN O
threonine NN NN O
residues NN NN O
, NN NN O
which NN NN O
was NN NN O
responsible NN NN O
for NN NN O
most NN NN O
of NN NN O
the NN NN O
repression NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
repression NN NN O
is NN NN O
strongly NN NN O
dependent NN NN O
on NN NN O
the NN NN O
type NN NN O
of NN NN O
enhancer NN NN O
present NN NN O
in NN NN O
the NN NN O
reporter NN NN O
plasmid NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
the NN NN O
cell NN NN O
line NN NN O
tested NN NN O
. NN NN O
   
The NN NN O
possibility NN NN O
that NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
can NN NN O
act NN NN O
as NN NN O
an NN NN O
activator NN NN O
and NN NN O
/ NN NN O
or NN NN O
a NN NN O
repressor NN NN O
may NN NN O
have NN NN O
important NN NN O
consequences NN NN O
for NN NN O
the NN NN O
function NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2a NN NN I-Protein
in NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
other NN NN O
developmental NN NN O
processes NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
BSAP NN NN B-Protein
( NN NN O
Pax NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
) NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
The NN NN O
hierarchy NN NN O
of NN NN O
transcriptional NN NN O
control NN NN O
in NN NN O
B NN NN O
- NN NN O
cell NN NN O
development NN NN O
has NN NN O
recently NN NN O
been NN NN O
analyzed NN NN O
by NN NN O
targeted NN NN O
gene NN NN O
inactivation NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O
   
In NN NN O
this NN NN O
manner NN NN O
, NN NN O
the NN NN O
paired NN NN O
box NN NN O
containing NN NN O
gene NN NN O
Pax NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
encoding NN NN O
the NN NN O
B NN NN B-Protein
cell NN NN I-Protein
specific NN NN I-Protein
transcription NN NN I-Protein
factor NN NN I-Protein
BSAP NN NN B-Protein
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
early NN NN O
B NN NN O
lymphopoiesis NN NN O
. NN NN O
   
Other NN NN O
experimental NN NN O
strategies NN NN O
have NN NN O
implicated NN NN O
BSAP NN NN B-Protein
in NN NN O
the NN NN O
control NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
isotype NN NN O
switching NN NN O
and NN NN O
transcription NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
at NN NN O
late NN NN O
stages NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
controls NN NN O
responsiveness NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
has NN NN O
potent NN NN O
antiproliferative NN NN O
and NN NN O
apoptotic NN NN O
effects NN NN O
in NN NN O
T NN NN O
cells NN NN O
that NN NN O
are NN NN O
important NN NN O
in NN NN O
determining NN NN O
T NN NN O
cell NN NN O
development NN NN O
and NN NN O
polarized NN NN O
differentiation NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
any NN NN O
event NN NN O
that NN NN O
enables NN NN O
T NN NN O
cells NN NN O
to NN NN O
become NN NN O
less NN NN O
responsive NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
may NN NN O
potentially NN NN O
alter NN NN O
immune NN NN O
responsiveness NN NN O
to NN NN O
Ag NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
that NN NN O
are NN NN O
stimulated NN NN O
through NN NN O
the NN NN O
TCR NN NN O
and NN NN O
expanded NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
are NN NN O
unresponsive NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
a NN NN O
lack NN NN O
of NN NN O
activation NN NN O
of NN NN O
jak NN NN O
kinases NN NN O
and NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
STAT1 NN NN B-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
, NN NN O
a NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
This NN NN O
nonresponsiveness NN NN O
occurs NN NN O
because NN NN O
of NN NN O
a NN NN O
lack NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
chain NN NN O
( NN NN O
accessory NN NN O
factor NN NN O
) NN NN O
of NN NN O
the NN NN O
IFN NN NN O
- NN NN O
gamma NN NN O
receptor NN NN O
, NN NN O
while NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
maintaining NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
expression NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
chain NN NN O
can NN NN O
be NN NN O
restored NN NN O
by NN NN O
secondary NN NN O
TCR NN NN O
ligation NN NN O
or NN NN O
PMA NN NN O
treatment NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
blasts NN NN O
treated NN NN O
with NN NN O
PMA NN NN O
are NN NN O
now NN NN O
responsive NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
When NN NN O
freshly NN NN O
isolated NN NN O
, NN NN O
highly NN NN O
enriched NN NN O
( NN NN O
> NN NN O
98 NN NN O
% NN NN O
) NN NN O
T NN NN O
cells NN NN O
are NN NN O
examined NN NN O
for NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
responsiveness NN NN O
; NN NN O
these NN NN O
cells NN NN O
can NN NN O
respond NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
express NN NN O
beta NN NN O
- NN NN O
chain NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
as NN NN O
T NN NN O
cells NN NN O
progress NN NN O
from NN NN O
primary NN NN O
TCR NN NN O
activation NN NN O
through NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
proliferation NN NN O
, NN NN O
followed NN NN O
by NN NN O
secondary NN NN O
TCR NN NN O
stimulation NN NN O
, NN NN O
their NN NN O
responsiveness NN NN O
to NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
varies NN NN O
, NN NN O
and NN NN O
this NN NN O
may NN NN O
affect NN NN O
their NN NN O
ability NN NN O
to NN NN O
participate NN NN O
in NN NN O
an NN NN O
ongoing NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
CIITA NN NN B-Protein
and NN NN O
modification NN NN O
of NN NN O
in NN NN O
vivo NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
promoter NN NN O
occupancy NN NN O
in NN NN O
normal NN NN O
thymic NN NN O
epithelial NN NN O
cells NN NN O
treated NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
: NN NN O
similarities NN NN O
and NN NN O
distinctions NN NN O
with NN NN O
respect NN NN O
to NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
- NN NN O
constitutive NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
in NN NN O
primary NN NN O
cultures NN NN O
of NN NN O
thymic NN NN O
epithelial NN NN O
cells NN NN O
( NN NN O
TEC NN NN O
) NN NN O
was NN NN O
analyzed NN NN O
. NN NN O
   
This NN NN O
cellular NN NN O
system NN NN O
offers NN NN O
the NN NN O
advantage NN NN O
that NN NN O
MHC NN NN O
class NN NN O
II NN NN O
induction NN NN O
is NN NN O
studied NN NN O
in NN NN O
a NN NN O
"""""""" NN NN O
physiologic NN NN O
"""""""" NN NN O
cell NN NN O
lineage NN NN O
that NN NN O
, NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
this NN NN O
expression NN NN O
within NN NN O
the NN NN O
thymus NN NN O
, NN NN O
is NN NN O
thought NN NN O
to NN NN O
participate NN NN O
to NN NN O
the NN NN O
selection NN NN O
and NN NN O
maturation NN NN O
of NN NN O
the NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
the NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
de NN NN O
novo NN NN O
transcription NN NN O
of NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
CIITA NN NN B-Protein
trans NN NN O
- NN NN O
activator NN NN O
, NN NN O
a NN NN O
crucial NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
regulatory NN NN O
factor NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
anatomy NN NN O
of NN NN O
interaction NN NN O
between NN NN O
the NN NN O
MHC NN NN O
class NN NN O
II NN NN O
DRA NN NN O
promoter NN NN O
and NN NN O
corresponding NN NN O
binding NN NN O
factors NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
in NN NN O
vivo NN NN O
DNAse NN NN O
I NN NN O
footprint NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
treatment NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induces NN NN O
changes NN NN O
in NN NN O
the NN NN O
occupancy NN NN O
of NN NN O
the NN NN O
DRA NN NN O
gene NN NN O
regulatory NN NN O
sequences NN NN O
by NN NN O
nuclear NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
resulting NN NN O
occupancy NN NN O
displays NN NN O
strong NN NN O
similarities NN NN O
with NN NN O
the NN NN O
one NN NN O
observed NN NN O
in NN NN O
the NN NN O
MHC NN NN O
class NN NN O
II NN NN O
- NN NN O
constitutive NN NN O
B NN NN O
cells NN NN O
, NN NN O
represented NN NN O
by NN NN O
both NN NN O
the NN NN O
Burkitt NN NN O
lymphoma NN NN O
line NN NN O
Raji NN NN O
and NN NN O
normal NN NN O
tonsil NN NN O
- NN NN O
derived NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
some NN NN O
peculiar NN NN O
differences NN NN O
were NN NN O
observed NN NN O
between NN NN O
the NN NN O
TEC NN NN O
, NN NN O
either NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
or NN NN O
not NN NN O
, NN NN O
and NN NN O
the NN NN O
constitutive NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
both NN NN O
common NN NN O
mechanisms NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
one NN NN O
mediated NN NN O
by NN NN O
the NN NN O
CIITA NN NN B-Protein
trans NN NN O
- NN NN O
activator NN NN O
, NN NN O
and NN NN O
distinct NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
constraints NN NN O
contribute NN NN O
to NN NN O
the NN NN O
transcriptional NN NN O
control NN NN O
of NN NN O
constitutive NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
MHC NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Recombinant NN NN O
NFAT1 NN NN B-Protein
( NN NN O
NFATp NN NN B-Protein
) NN NN O
is NN NN O
regulated NN NN O
by NN NN O
calcineurin NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
mediates NN NN O
transcription NN NN O
of NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
family NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
and NN NN O
other NN NN O
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
two NN NN O
new NN NN O
isoforms NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NFAT1 NN NN B-Protein
( NN NN O
previously NN NN O
termed NN NN O
NFATp NN NN B-Protein
) NN NN O
that NN NN O
are NN NN O
the NN NN O
predominant NN NN O
isoforms NN NN O
expressed NN NN O
in NN NN O
murine NN NN O
and NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
expressed NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
recombinant NN NN O
NFAT1 NN NN B-Protein
is NN NN O
regulated NN NN O
, NN NN O
as NN NN O
expected NN NN O
, NN NN O
by NN NN O
the NN NN O
calmodulin NN NN B-Protein
- NN NN O
dependent NN NN O
phosphatase NN NN O
calcineurin NN NN O
, NN NN O
and NN NN O
its NN NN O
function NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
immunosuppressive NN NN O
agent NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
. NN NN O
   
Transactivation NN NN O
by NN NN O
recombinant NN NN O
NFAT1 NN NN B-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
requires NN NN O
dual NN NN O
stimulation NN NN O
with NN NN O
ionomycin NN NN O
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
; NN NN O
this NN NN O
activity NN NN O
is NN NN O
potentiated NN NN O
by NN NN O
coexpression NN NN O
of NN NN O
constitutively NN NN O
active NN NN O
calcineurin NN NN O
and NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
CsA NN NN O
. NN NN O
   
Immunocytochemical NN NN O
analysis NN NN O
indicates NN NN O
that NN NN O
recombinant NN NN O
NFAT1 NN NN B-Protein
localizes NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
transiently NN NN O
transfected NN NN O
T NN NN O
cells NN NN O
and NN NN O
translocates NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
a NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
manner NN NN O
following NN NN O
ionomycin NN NN O
stimulation NN NN O
. NN NN O
   
When NN NN O
expressed NN NN O
in NN NN O
COS NN NN O
cells NN NN O
, NN NN O
however NN NN O
, NN NN O
NFAT1 NN NN B-Protein
is NN NN O
capable NN NN O
of NN NN O
transactivation NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
regulated NN NN O
correctly NN NN O
: NN NN O
its NN NN O
subcellular NN NN O
localization NN NN O
and NN NN O
transcriptional NN NN O
function NN NN O
are NN NN O
not NN NN O
affected NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
COS NN NN O
cells NN NN O
with NN NN O
ionomycin NN NN O
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
. NN NN O
   
Recombinant NN NN O
NFAT1 NN NN B-Protein
can NN NN O
mediate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
and NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
promoters NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
NFAT1 NN NN B-Protein
contributes NN NN O
to NN NN O
the NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
transcription NN NN O
of NN NN O
these NN NN O
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
An NN NN O
alternatively NN NN O
spliced NN NN O
isoform NN NN O
of NN NN O
the NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
transcription NN NN O
factor NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
is NN NN O
an NN NN O
Ets NN NN O
transcription NN NN O
factor NN NN O
related NN NN O
to NN NN O
the NN NN O
oncoprotein NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
highly NN NN O
expressed NN NN O
in NN NN O
B NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Ets NN NN O
proteins NN NN O
share NN NN O
a NN NN O
conserved NN NN O
Ets NN NN O
domain NN NN O
that NN NN O
mediates NN NN O
specific NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
binds NN NN O
DNA NN NN O
sequences NN NN O
containing NN NN O
a NN NN O
core NN NN O
5 NN NN O
' NN NN O
- NN NN O
GGAA NN NN O
- NN NN O
3 NN NN O
' NN NN O
and NN NN O
activates NN NN O
transcription NN NN O
through NN NN O
this NN NN O
motif NN NN O
. NN NN O
   
Up NN NN O
to NN NN O
date NN NN O
, NN NN O
the NN NN O
biological NN NN O
function NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
remains NN NN O
unknown NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
characterization NN NN O
of NN NN O
an NN NN O
alternatively NN NN O
spliced NN NN O
variant NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
, NN NN O
named NN NN O
deltaSpi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
, NN NN O
which NN NN O
has NN NN O
lost NN NN O
the NN NN O
Ets NN NN O
domain NN NN O
. NN NN O
   
In NN NN O
B NN NN O
lymphoid NN NN O
cells NN NN O
, NN NN O
deltaspi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
mRNAs NN NN O
were NN NN O
present NN NN O
simultaneously NN NN O
in NN NN O
a NN NN O
ratio NN NN O
of NN NN O
around NN NN O
10 NN NN O
% NN NN O
. NN NN O
   
DeltaSpi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
product NN NN O
was NN NN O
not NN NN O
able NN NN O
to NN NN O
bind NN NN O
DNA NN NN O
and NN NN O
was NN NN O
recovered NN NN O
in NN NN O
cytoplasmic NN NN O
cellular NN NN O
extracts NN NN O
. NN NN O
   
We NN NN O
raise NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
delta NN NN B-Protein
Spi NN NN I-Protein
- NN NN I-Protein
B NN NN I-Protein
might NN NN O
affect NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
function NN NN O
by NN NN O
recruiting NN NN O
factors NN NN O
involved NN NN O
in NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
activity NN NN O
. NN NN O
   
Activation NN NN O
protein NN NN O
1 NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
gene NN NN O
by NN NN O
Ca2 NN NN B-Protein
+ NN NN I-Protein
/ NN NN I-Protein
calmodulin NN NN I-Protein
kinase NN NN I-Protein
type NN NN I-Protein
IV NN NN I-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
. NN NN O
   
The NN NN O
Ca2 NN NN B-Protein
+ NN NN I-Protein
/ NN NN I-Protein
calmodulin NN NN I-Protein
- NN NN I-Protein
dependent NN NN I-Protein
protein NN NN I-Protein
kinase NN NN I-Protein
( NN NN I-Protein
CaMK NN NN I-Protein
) NN NN I-Protein
type NN NN I-Protein
IV NN NN I-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
is NN NN O
selectively NN NN O
expressed NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
is NN NN O
activated NN NN O
after NN NN O
signaling NN NN O
via NN NN O
the NN NN O
T NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
it NN NN O
mediates NN NN O
some NN NN O
of NN NN O
the NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
events NN NN O
that NN NN O
follow NN NN O
TCR NN NN O
engagement NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
CaMKIV NN NN B-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
induces NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
activation NN NN O
protein NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
alone NN NN O
or NN NN O
in NN NN O
synergy NN NN O
with NN NN O
T NN NN O
cell NN NN O
mitogens NN NN O
and NN NN O
with NN NN O
the NN NN O
p21ras NN NN B-Protein
oncoprotein NN NN O
. NN NN O
   
CaMKIV NN NN B-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
signaling NN NN O
is NN NN O
associated NN NN O
with NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
but NN NN O
is NN NN O
independent NN NN O
of NN NN O
p21ras NN NN B-Protein
or NN NN O
calcineurin NN NN O
. NN NN O
   
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
an NN NN O
integral NN NN O
component NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
transcriptional NN NN O
complex NN NN O
, NN NN O
which NN NN O
is NN NN O
required NN NN O
for NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
CaMKIV NN NN B-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
reconstitutes NN NN O
the NN NN O
capacity NN NN O
of NN NN O
the NN NN O
cytosolic NN NN O
component NN NN O
of NN NN O
NFAT NN NN O
to NN NN O
direct NN NN O
transcription NN NN O
from NN NN O
NFAT NN NN O
sites NN NN O
in NN NN O
non NN NN O
- NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
reveal NN NN O
a NN NN O
central NN NN O
role NN NN O
for NN NN O
CaMKIV NN NN B-Protein
/ NN NN I-Protein
Gr NN NN I-Protein
as NN NN O
a NN NN O
Ca NN NN O
( NN NN O
2 NN NN O
+ NN NN O
) NN NN O
- NN NN O
regulated NN NN O
activator NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Mechanisms NN NN O
of NN NN O
transactivation NN NN O
by NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
of NN NN I-Protein
activated NN NN I-Protein
T NN NN I-Protein
cells NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
- NN NN O
family NN NN O
proteins NN NN O
( NN NN O
NFAT1 NN NN B-Protein
/ NN NN O
NFATp NN NN B-Protein
, NN NN O
NFATc NN NN B-Protein
, NN NN O
NFAT3 NN NN B-Protein
, NN NN O
and NN NN O
NFAT4 NN NN B-Protein
/ NN NN O
NFATx NN NN B-Protein
/ NN NN O
NFATc3 NN NN B-Protein
) NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
and NN NN O
other NN NN O
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
We NN NN O
have NN NN O
defined NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
transactivation NN NN O
by NN NN O
NFAT1 NN NN B-Protein
. NN NN O
   
NFAT1 NN NN B-Protein
possesses NN NN O
two NN NN O
transactivation NN NN O
domains NN NN O
whose NN NN O
sequences NN NN O
are NN NN O
not NN NN O
conserved NN NN O
in NN NN O
the NN NN O
other NN NN O
NFAT NN NN O
- NN NN O
family NN NN O
proteins NN NN O
, NN NN O
and NN NN O
a NN NN O
conserved NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
that NN NN O
mediates NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
cooperating NN NN O
nuclear NN NN O
transcription NN NN O
factors NN NN O
even NN NN O
when NN NN O
it NN NN O
is NN NN O
expressed NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
other NN NN O
regions NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
the NN NN O
NH2 NN NN O
- NN NN O
terminal NN NN O
transactivation NN NN O
domain NN NN O
is NN NN O
modulated NN NN O
by NN NN O
an NN NN O
adjacent NN NN O
regulatory NN NN O
region NN NN O
that NN NN O
contains NN NN O
several NN NN O
conserved NN NN O
sequence NN NN O
motifs NN NN O
represented NN NN O
only NN NN O
in NN NN O
the NN NN O
NFAT NN NN O
family NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
emphasize NN NN O
the NN NN O
multiple NN NN O
levels NN NN O
at NN NN O
which NN NN O
NFAT NN NN O
- NN NN O
dependent NN NN O
transactivation NN NN O
is NN NN O
regulated NN NN O
, NN NN O
and NN NN O
predict NN NN O
significant NN NN O
differences NN NN O
in NN NN O
the NN NN O
architecture NN NN O
of NN NN O
cooperative NN NN O
transcription NN NN O
complexes NN NN O
containing NN NN O
different NN NN O
NFAT NN NN O
- NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
a NN NN O
POZ NN NN O
/ NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
protein NN NN O
, NN NN O
is NN NN O
a NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
repressor NN NN O
. NN NN O
   
Approximately NN NN O
40 NN NN O
% NN NN O
of NN NN O
diffuse NN NN O
large NN NN O
cell NN NN O
lymphoma NN NN O
are NN NN O
associated NN NN O
with NN NN O
chromosomal NN NN O
translocations NN NN O
that NN NN O
deregulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
BCL6 NN NN B-Protein
gene NN NN O
by NN NN O
juxtaposing NN NN O
heterologous NN NN O
promoters NN NN O
to NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
coding NN NN O
domain NN NN O
. NN NN O
   
The NN NN O
BCL6 NN NN B-Protein
gene NN NN O
encodes NN NN O
a NN NN O
95 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
containing NN NN O
six NN NN O
C NN NN O
- NN NN O
terminal NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
motifs NN NN O
and NN NN O
an NN NN O
N NN NN O
- NN NN O
terminal NN NN O
POZ NN NN O
domain NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
may NN NN O
function NN NN O
as NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
By NN NN O
using NN NN O
a NN NN O
DNA NN NN O
sequence NN NN O
selected NN NN O
for NN NN O
its NN NN O
ability NN NN O
to NN NN O
bind NN NN O
recombinant NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
vitro NN NN O
, NN NN O
we NN NN O
show NN NN O
here NN NN O
that NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
is NN NN O
present NN NN O
in NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
various NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
transient NN NN O
transfectin NN NN O
experiments NN NN O
, NN NN O
BCL6 NN NN B-Protein
can NN NN O
repress NN NN O
transcription NN NN O
from NN NN O
promoters NN NN O
linked NN NN O
to NN NN O
its NN NN O
DNA NN NN O
target NN NN O
sequence NN NN O
and NN NN O
this NN NN O
activity NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
intact NN NN O
N NN NN O
- NN NN O
terminal NN NN O
half NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
this NN NN O
part NN NN O
of NN NN O
the NN NN O
BCL6 NN NN B-Protein
molecule NN NN O
contains NN NN O
an NN NN O
autonomous NN NN O
transrepressor NN NN O
domain NN NN O
and NN NN O
that NN NN O
two NN NN O
noncontiguous NN NN O
regions NN NN O
, NN NN O
including NN NN O
the NN NN O
POZ NN NN O
motif NN NN O
, NN NN O
mediate NN NN O
maximum NN NN O
transrepressive NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
BCL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
protein NN NN O
can NN NN O
function NN NN O
as NN NN O
a NN NN O
sequence NN NN O
- NN NN O
specific NN NN O
transcriptional NN NN O
repressor NN NN O
and NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
role NN NN O
of NN NN O
BCL6 NN NN B-Protein
in NN NN O
normal NN NN O
lymphoid NN NN O
development NN NN O
and NN NN O
lymphomagenesis NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
of NN NN O
specific NN NN O
interferon NN NN O
isotypes NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
and NN NN O
in NN NN O
promonocytic NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
alpha5 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
was NN NN O
detected NN NN O
in NN NN O
different NN NN O
lymphoid NN NN O
cells NN NN O
including NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
normal NN NN O
individuals NN NN O
following NN NN O
amplification NN NN O
of NN NN O
IFN NN NN O
mRNA NN NN O
by NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
amplified NN NN O
product NN NN O
. NN NN O
   
The NN NN O
activated NN NN O
form NN NN O
of NN NN O
the NN NN O
interferon NN NN O
- NN NN O
induced NN NN O
transcription NN NN O
factor NN NN O
complex NN NN O
ISGF3 NN NN O
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
uninduced NN NN O
cells NN NN O
. NN NN O
   
Culture NN NN O
supernatants NN NN O
from NN NN O
uninduced NN NN O
U937 NN NN O
cells NN NN O
were NN NN O
also NN NN O
found NN NN O
to NN NN O
activate NN NN O
an NN NN O
ISRE NN NN O
cloned NN NN O
upstream NN NN O
of NN NN O
the NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
endogenous NN NN O
IFN NN NN O
activity NN NN O
equivalent NN NN O
to NN NN O
approximately NN NN O
0 NN NN O
. NN NN O
3 NN NN O
to NN NN O
0 NN NN O
. NN NN O
5 NN NN O
IU NN NN O
/ NN NN O
mL NN NN O
. NN NN O
   
This NN NN O
endogenous NN NN O
IFN NN NN O
was NN NN O
also NN NN O
shown NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
maintaining NN NN O
the NN NN O
basal NN NN O
level NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
class NN NN O
I NN NN O
genes NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
alpha5 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
are NN NN O
produced NN NN O
at NN NN O
low NN NN O
levels NN NN O
in NN NN O
normal NN NN O
tissues NN NN O
and NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cell NN NN O
function NN NN O
and NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
homeostasis NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
a NN NN O
new NN NN O
isoform NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
) NN NN O
gene NN NN O
family NN NN O
member NN NN O
NFATc NN NN B-Protein
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
J NN NN O
Biol NN NN O
Chem NN NN O
1996 NN NN O
Dec NN NN O
27 NN NN O
; NN NN O
271 NN NN O
( NN NN O
52 NN NN O
) NN NN O
: NN NN O
33705 NN NN O
] NN NN O
   
The NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
/ NN NN O
FK506 NN NN O
- NN NN O
sensitive NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
NFAT NN NN O
has NN NN O
been NN NN O
recently NN NN O
shown NN NN O
to NN NN O
be NN NN O
inducible NN NN O
in NN NN O
several NN NN O
non NN NN O
- NN NN O
T NN NN O
immune NN NN O
cells NN NN O
, NN NN O
the NN NN O
NFAT NN NN O
gene NN NN O
family NN NN O
members NN NN O
characterized NN NN O
to NN NN O
date NN NN O
have NN NN O
been NN NN O
isolated NN NN O
only NN NN O
from NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
further NN NN O
characterize NN NN O
NFAT NN NN O
function NN NN O
in NN NN O
human NN NN O
B NN NN O
cells NN NN O
and NN NN O
to NN NN O
demonstrate NN NN O
cytokine NN NN O
gene NN NN O
specificity NN NN O
of NN NN O
NFAT NN NN O
proteins NN NN O
, NN NN O
we NN NN O
report NN NN O
here NN NN O
the NN NN O
isolation NN NN O
and NN NN O
characterization NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
clone NN NN O
from NN NN O
the NN NN O
Raji NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
clone NN NN O
encodes NN NN O
a NN NN O
new NN NN O
isoform NN NN O
, NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
beta NN NN I-Protein
, NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
gene NN NN O
family NN NN O
member NN NN O
NFATc NN NN B-Protein
( NN NN O
designated NN NN O
here NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
of NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
beta NN NN I-Protein
differs NN NN O
from NN NN O
that NN NN O
of NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
the NN NN O
first NN NN O
NH2 NN NN O
- NN NN O
terminal NN NN O
29 NN NN O
residues NN NN O
and NN NN O
contains NN NN O
an NN NN O
additional NN NN O
region NN NN O
of NN NN O
142 NN NN O
residues NN NN O
at NN NN O
the NN NN O
COOH NN NN O
terminus NN NN O
. NN NN O
   
Northern NN NN O
analysis NN NN O
using NN NN O
a NN NN O
probe NN NN O
encompassing NN NN O
a NN NN O
common NN NN O
region NN NN O
of NN NN O
both NN NN O
isoforms NN NN O
showed NN NN O
two NN NN O
mRNA NN NN O
species NN NN O
of NN NN O
2 NN NN O
. NN NN O
7 NN NN O
and NN NN O
4 NN NN O
. NN NN O
5 NN NN O
kilobase NN NN O
pairs NN NN O
, NN NN O
while NN NN O
an NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
beta NN NN I-Protein
- NN NN O
specific NN NN O
probe NN NN O
detected NN NN O
only NN NN O
the NN NN O
4 NN NN O
. NN NN O
5 NN NN O
- NN NN O
kilobase NN NN O
pair NN NN O
mRNA NN NN O
which NN NN O
was NN NN O
preferentially NN NN O
expressed NN NN O
in NN NN O
the NN NN O
spleen NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
of NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
beta NN NN I-Protein
was NN NN O
capable NN NN O
of NN NN O
activating NN NN O
an NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
NFAT NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
gene NN NN O
in NN NN O
stimulated NN NN O
Jurkat NN NN O
cells NN NN O
in NN NN O
a NN NN O
CsA NN NN O
- NN NN O
sensitive NN NN O
manner NN NN O
. NN NN O
   
However NN NN O
, NN NN O
NFATc NN NN B-Protein
. NN NN I-Protein
beta NN NN I-Protein
neither NN NN O
bound NN NN O
to NN NN O
the NN NN O
kappa3 NN NN O
element NN NN O
( NN NN O
an NN NN O
NFAT NN NN O
- NN NN O
binding NN NN O
site NN NN O
) NN NN O
in NN NN O
the NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
nor NN NN O
activated NN NN O
the NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
in NN NN O
cotransfection NN NN O
assays NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
different NN NN O
members NN NN O
or NN NN O
isoforms NN NN O
of NN NN O
NFAT NN NN O
gene NN NN O
family NN NN O
may NN NN O
regulate NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
different NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Cytokine NN NN O
- NN NN O
modulating NN NN O
activity NN NN O
of NN NN O
tepoxalin NN NN O
, NN NN O
a NN NN O
new NN NN O
potential NN NN O
antirheumatic NN NN O
. NN NN O
   
Tepoxalin NN NN O
is NN NN O
a NN NN O
new NN NN O
dual NN NN O
cyclooxygenase NN NN O
/ NN NN O
5 NN NN O
- NN NN O
lipoxygenase NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
compound NN NN O
currently NN NN O
under NN NN O
clinical NN NN O
investigation NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
possess NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
activity NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
animal NN NN O
models NN NN O
and NN NN O
more NN NN O
recently NN NN O
to NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induced NN NN O
signal NN NN O
transduction NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
was NN NN O
conducted NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
cytokine NN NN O
modulating NN NN O
activity NN NN O
of NN NN O
tepoxalin NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
iron NN NN O
in NN NN O
these NN NN O
effects NN NN O
. NN NN O
   
In NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
stimulated NN NN O
with NN NN O
OKT3 NN NN O
/ NN NN O
PMA NN NN O
, NN NN O
tepoxalin NN NN O
inhibited NN NN O
lymphocyte NN NN O
proliferation NN NN O
with NN NN O
an NN NN O
IC50 NN NN O
of NN NN O
6 NN NN O
microM NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
it NN NN O
inhibited NN NN O
the NN NN O
production NN NN O
of NN NN O
LTB4 NN NN B-Protein
( NN NN O
IC50 NN NN O
= NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
) NN NN O
and NN NN O
the NN NN O
cytokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
( NN NN O
IC50 NN NN O
= NN NN O
10 NN NN O
- NN NN O
12 NN NN O
microM NN NN O
) NN NN O
. NN NN O
   
Cytotoxicity NN NN O
was NN NN O
not NN NN O
demonstrated NN NN O
at NN NN O
these NN NN O
concentrations NN NN O
. NN NN O
   
Add NN NN O
- NN NN O
back NN NN O
experiments NN NN O
with NN NN O
either NN NN O
cytokines NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
, NN NN O
LTB4 NN NN B-Protein
or NN NN O
conditioned NN NN O
media NN NN O
failed NN NN O
to NN NN O
restore NN NN O
the NN NN O
proliferative NN NN O
response NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
tepoxalin NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
concurrent NN NN O
addition NN NN O
of NN NN O
iron NN NN O
( NN NN O
in NN NN O
the NN NN O
form NN NN O
of NN NN O
ferrous NN NN O
or NN NN O
ferric NN NN O
chloride NN NN O
and NN NN O
other NN NN O
iron NN NN O
salts NN NN O
) NN NN O
reversed NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
proliferation NN NN O
caused NN NN O
by NN NN O
tepoxalin NN NN O
. NN NN O
   
Tepoxalin NN NN O
also NN NN O
inhibits NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
acts NN NN O
on NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Tepoxalin NN NN O
' NN NN O
s NN NN O
effect NN NN O
on NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
is NN NN O
also NN NN O
reversed NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
iron NN NN O
salts NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
action NN NN O
of NN NN O
tepoxalin NN NN O
to NN NN O
inhibit NN NN O
proliferation NN NN O
in NN NN O
PBMC NN NN O
may NN NN O
be NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
due NN NN O
to NN NN O
its NN NN O
ability NN NN O
to NN NN O
reduce NN NN O
the NN NN O
amount NN NN O
of NN NN O
available NN NN O
iron NN NN O
resulting NN NN O
in NN NN O
decreased NN NN O
activation NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
subsequent NN NN O
inhibition NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
. NN NN O
   
oriP NN NN B-Protein
is NN NN O
essential NN NN O
for NN NN O
EBNA NN NN O
gene NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
immortalized NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
During NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
latent NN NN O
infection NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
in NN NN O
vitro NN NN O
, NN NN O
six NN NN O
viral NN NN O
nuclear NN NN O
antigens NN NN O
( NN NN O
EBNAs NN NN O
) NN NN O
are NN NN O
expressed NN NN O
from NN NN O
one NN NN O
of NN NN O
two NN NN O
promoters NN NN O
, NN NN O
Cp NN NN B-Protein
or NN NN O
Wp NN NN B-Protein
, NN NN O
whose NN NN O
activities NN NN O
are NN NN O
mutually NN NN O
exclusive NN NN O
. NN NN O
   
Upon NN NN O
infection NN NN O
, NN NN O
Wp NN NN B-Protein
is NN NN O
initially NN NN O
active NN NN O
, NN NN O
followed NN NN O
by NN NN O
a NN NN O
switch NN NN O
to NN NN O
Cp NN NN B-Protein
for NN NN O
the NN NN O
duration NN NN O
of NN NN O
latency NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
region NN NN O
upstream NN NN O
of NN NN O
Cp NN NN B-Protein
was NN NN O
analyzed NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
cis NN NN O
elements NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
the NN NN O
activities NN NN O
of NN NN O
the NN NN O
EBNA NN NN O
gene NN NN O
promoters NN NN O
in NN NN O
established NN NN O
in NN NN O
vitro NN NN O
immortalized NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
( NN NN O
LCLs NN NN O
) NN NN O
. NN NN O
   
It NN NN O
was NN NN O
determined NN NN O
that NN NN O
oriP NN NN B-Protein
, NN NN O
the NN NN O
origin NN NN O
for NN NN O
episomal NN NN O
maintenance NN NN O
during NN NN O
latency NN NN O
, NN NN O
is NN NN O
essential NN NN O
for NN NN O
efficient NN NN O
transcription NN NN O
initiation NN NN O
from NN NN O
either NN NN O
Cp NN NN B-Protein
or NN NN O
Wp NN NN B-Protein
in NN NN O
LCLs NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
some NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
EBNA2 NN NN B-Protein
- NN NN O
dependent NN NN O
enhancer NN NN O
located NN NN O
upstream NN NN O
of NN NN O
Cp NN NN B-Protein
resulted NN NN O
in NN NN O
a NN NN O
ca NN NN O
. NN NN O
two NN NN O
- NN NN O
to NN NN O
fivefold NN NN O
reduction NN NN O
in NN NN O
Cp NN NN B-Protein
activity NN NN O
in NN NN O
the NN NN O
LCLs NN NN O
assayed NN NN O
. NN NN O
   
More NN NN O
extensive NN NN O
deletion NN NN O
of NN NN O
sequences NN NN O
upstream NN NN O
of NN NN O
Cp NN NN B-Protein
, NN NN O
including NN NN O
the NN NN O
EBNA2 NN NN B-Protein
- NN NN O
dependent NN NN O
enhancer NN NN O
, NN NN O
resulted NN NN O
in NN NN O
nearly NN NN O
complete NN NN O
loss NN NN O
of NN NN O
Cp NN NN B-Protein
activity NN NN O
. NN NN O
   
This NN NN O
loss NN NN O
of NN NN O
activity NN NN O
was NN NN O
shown NN NN O
to NN NN O
correlate NN NN O
with NN NN O
deletion NN NN O
of NN NN O
two NN NN O
CCAAT NN NN O
boxes NN NN O
, NN NN O
a NN NN O
proximal NN NN O
CCAAT NN NN O
box NN NN O
located NN NN O
at NN NN O
bp NN NN O
- NN NN O
61 NN NN O
to NN NN O
- NN NN O
65 NN NN O
and NN NN O
a NN NN O
distal NN NN O
CCAAT NN NN O
box NN NN O
located NN NN O
at NN NN O
bp NN NN O
- NN NN O
253 NN NN O
to NN NN O
- NN NN O
257 NN NN O
, NN NN O
upstream NN NN O
of NN NN O
Cp NN NN B-Protein
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
of NN NN O
these NN NN O
cis NN NN O
elements NN NN O
demonstrated NN NN O
that NN NN O
Cp NN NN B-Protein
activity NN NN O
is NN NN O
highly NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
properly NN NN O
positioned NN NN O
CCAAT NN NN O
box NN NN O
, NN NN O
with NN NN O
the NN NN O
dependence NN NN O
on NN NN O
the NN NN O
distal NN NN O
CCAAT NN NN O
box NN NN O
apparent NN NN O
only NN NN O
when NN NN O
the NN NN O
proximal NN NN O
CCAAT NN NN O
box NN NN O
was NN NN O
deleted NN NN O
or NN NN O
mutated NN NN O
. NN NN O
   
Deletion NN NN O
of NN NN O
the NN NN O
glucocorticoid NN NN O
response NN NN O
elements NN NN O
located NN NN O
at NN NN O
ca NN NN O
. NN NN O
   
bp NN NN O
- NN NN O
850 NN NN O
upstream NN NN O
of NN NN O
Cp NN NN B-Protein
did NN NN O
not NN NN O
result NN NN O
in NN NN O
a NN NN O
significant NN NN O
loss NN NN O
in NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
general NN NN O
, NN NN O
deletions NN NN O
which NN NN O
diminished NN NN O
Cp NN NN B-Protein
activity NN NN O
resulted NN NN O
in NN NN O
induction NN NN O
of NN NN O
Wp NN NN B-Protein
activity NN NN O
, NN NN O
consistent NN NN O
with NN NN O
suppression NN NN O
of NN NN O
Wp NN NN B-Protein
activity NN NN O
by NN NN O
transcriptional NN NN O
interference NN NN O
from NN NN O
Cp NN NN B-Protein
. NN NN O
   
The NN NN O
identification NN NN O
of NN NN O
oriP NN NN B-Protein
and NN NN O
the NN NN O
EBNA2 NN NN B-Protein
- NN NN O
dependent NN NN O
enhancer NN NN O
as NN NN O
the NN NN O
major NN NN O
positive NN NN O
cis NN NN O
elements NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
Cp NN NN B-Protein
activity NN NN O
in NN NN O
LCL NN NN O
suggests NN NN O
that NN NN O
EBNA NN NN O
gene NN NN O
transcription NN NN O
is NN NN O
largely NN NN O
autoregulated NN NN O
by NN NN O
EBNA NN NN B-Protein
1 NN NN I-Protein
and NN NN O
EBNA NN NN B-Protein
2 NN NN I-Protein
. NN NN O
   
Various NN NN O
modes NN NN O
of NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
protein NN NN O
- NN NN O
mediated NN NN O
regulation NN NN O
of NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
transcription NN NN O
in NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
The NN NN O
transcriptionally NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
the NN NN O
lymphomagenic NN NN O
Akv NN NN O
and NN NN O
SL3 NN NN O
- NN NN O
3 NN NN O
murine NN NN O
leukemia NN NN O
retroviruses NN NN O
( NN NN O
MLVs NN NN O
) NN NN O
contain NN NN O
two NN NN O
types NN NN O
of NN NN O
E NN NN O
- NN NN O
box NN NN O
consensus NN NN O
motifs NN NN O
, NN NN O
CAGATG NN NN O
. NN NN O
   
One NN NN O
type NN NN O
, NN NN O
EA NN NN O
/ NN NN O
S NN NN O
, NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
upstream NN NN O
promoter NN NN O
region NN NN O
, NN NN O
and NN NN O
the NN NN O
other NN NN O
, NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
, NN NN O
is NN NN O
located NN NN O
in NN NN O
a NN NN O
tandem NN NN O
repeat NN NN O
with NN NN O
enhancer NN NN O
properties NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
requirements NN NN O
of NN NN O
the NN NN O
individual NN NN O
E NN NN O
- NN NN O
boxes NN NN O
in NN NN O
MLV NN NN O
transcriptional NN NN O
regulation NN NN O
. NN NN O
   
In NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
only NN NN O
, NN NN O
the NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
- NN NN O
binding NN NN O
protein NN NN O
complexes NN NN O
included NN NN O
ALF1 NN NN B-Protein
or NN NN O
HEB NN NN B-Protein
and NN NN O
E2A NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
. NN NN O
   
Ectopic NN NN O
ALF1 NN NN B-Protein
and NN NN O
E2A NN NN O
proteins NN NN O
required NN NN O
intact NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
motifs NN NN O
for NN NN O
mediating NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
ALF1 NN NN B-Protein
transactivated NN NN O
transcription NN NN O
of NN NN O
Akv NN NN O
MLV NN NN O
through NN NN O
the NN NN O
two NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
motifs NN NN O
equally NN NN O
, NN NN O
whereas NN NN O
E2A NN NN O
protein NN NN O
required NN NN O
the NN NN O
promoter NN NN O
- NN NN O
proximal NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
motif NN NN O
. NN NN O
   
In NN NN O
T NN NN O
- NN NN O
and NN NN O
B NN NN O
- NN NN O
cell NN NN O
lines NN NN O
, NN NN O
the NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
motifs NN NN O
were NN NN O
of NN NN O
major NN NN O
importance NN NN O
for NN NN O
Akv NN NN O
MLV NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
while NN NN O
the NN NN O
EA NN NN O
/ NN NN O
S NN NN O
motif NN NN O
had NN NN O
some NN NN O
effect NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
neither NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
nor NN NN O
EA NN NN O
/ NN NN O
S NN NN O
motifs NN NN O
contributed NN NN O
pronouncedly NN NN O
to NN NN O
Akv NN NN O
MLV NN NN O
transcription NN NN O
in NN NN O
NIH NN NN O
3T3 NN NN O
cells NN NN O
lacking NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
ALF1 NN NN B-Protein
or NN NN O
HEB NN NN B-Protein
and NN NN O
E2A NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
Id1 NN NN B-Protein
protein NN NN O
was NN NN O
found NN NN O
to NN NN O
repress NN NN O
ALF1 NN NN O
activity NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
ectopic NN NN O
Id1 NN NN B-Protein
repressed NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
- NN NN O
directed NN NN O
but NN NN O
not NN NN O
EA NN NN O
/ NN NN O
S NN NN O
- NN NN O
directed NN NN O
MLV NN NN O
transcription NN NN O
in NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
E NN NN O
( NN NN O
gre NN NN O
) NN NN O
motifs NN NN O
and NN NN O
interacting NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
are NN NN O
important NN NN O
determinants NN NN O
for NN NN O
MLV NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
lymphocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Gene NN NN O
transcription NN NN O
through NN NN O
activation NN NN O
of NN NN O
G NN NN O
- NN NN O
protein NN NN O
- NN NN O
coupled NN NN O
chemoattractant NN NN O
receptors NN NN O
. NN NN O
   
Receptors NN NN O
for NN NN O
leukocyte NN NN O
chemoattractants NN NN O
, NN NN O
including NN NN O
chemokines NN NN O
, NN NN O
are NN NN O
traditionally NN NN O
considered NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
special NN NN O
leukocyte NN NN O
functions NN NN O
such NN NN O
as NN NN O
chemotaxis NN NN O
, NN NN O
degranulation NN NN O
, NN NN O
and NN NN O
the NN NN O
release NN NN O
of NN NN O
superoxide NN NN O
anions NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
these NN NN O
G NN NN O
- NN NN O
protein NN NN O
- NN NN O
coupled NN NN O
serpentine NN NN O
receptors NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
transduce NN NN O
signals NN NN O
leading NN NN O
to NN NN O
gene NN NN O
transcription NN NN O
and NN NN O
translation NN NN O
in NN NN O
leukocytes NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
, NN NN O
such NN NN O
as NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
are NN NN O
activated NN NN O
upon NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
several NN NN O
chemoattractants NN NN O
at NN NN O
physiologically NN NN O
relevant NN NN O
concentrations NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
through NN NN O
these NN NN O
receptors NN NN O
involves NN NN O
G NN NN O
- NN NN O
protein NN NN O
coupling NN NN O
and NN NN O
the NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinases NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
signaling NN NN O
pathways NN NN O
appear NN NN O
to NN NN O
be NN NN O
different NN NN O
from NN NN O
those NN NN O
utilized NN NN O
by NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
a NN NN O
better NN NN O
characterized NN NN O
cytokine NN NN O
that NN NN O
induces NN NN O
the NN NN O
transcription NN NN O
of NN NN O
immediate NN NN O
- NN NN O
early NN NN O
genes NN NN O
. NN NN O
   
Chemoattractants NN NN O
stimulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
several NN NN O
inflammatory NN NN O
cytokines NN NN O
and NN NN O
chemokines NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
may NN NN O
activate NN NN O
their NN NN O
respective NN NN O
receptors NN NN O
and NN NN O
initiate NN NN O
an NN NN O
autocrine NN NN O
regulatory NN NN O
mechanism NN NN O
for NN NN O
persistent NN NN O
cytokine NN NN O
and NN NN O
chemokine NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
at NN NN O
early NN NN O
stages NN NN O
of NN NN O
B NN NN O
- NN NN O
cell NN NN O
and NN NN O
T NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
distinct NN NN O
sets NN NN O
of NN NN O
genes NN NN O
at NN NN O
different NN NN O
stages NN NN O
of NN NN O
B NN NN O
- NN NN O
lymphocyte NN NN O
and NN NN O
T NN NN O
- NN NN O
lymphocyte NN NN O
differentiation NN NN O
is NN NN O
controlled NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
A NN NN O
number NN NN O
of NN NN O
recent NN NN O
studies NN NN O
have NN NN O
described NN NN O
interactions NN NN O
between NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
lymphocytes NN NN O
that NN NN O
provide NN NN O
new NN NN O
insights NN NN O
into NN NN O
mechanisms NN NN O
regulating NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
mechanisms NN NN O
include NN NN O
the NN NN O
assembly NN NN O
of NN NN O
higher NN NN O
order NN NN O
nucleoprotein NN NN O
complexes NN NN O
and NN NN O
other NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
that NN NN O
enhance NN NN O
the NN NN O
functional NN NN O
specificity NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
tyrosine NN NN O
phosphorylation NN NN O
in NN NN O
endothelial NN NN O
adhesion NN NN O
molecule NN NN O
induction NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
endothelial NN NN O
adhesion NN NN O
molecules NN NN O
by NN NN O
the NN NN O
cytokine NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
can NN NN O
occur NN NN O
independently NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
and NN NN O
activation NN NN O
of NN NN O
a NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
( NN NN O
PTK NN NN O
) NN NN O
has NN NN O
recently NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
on NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
PTK NN NN O
inhibitors NN NN O
herbimycin NN NN O
A NN NN O
or NN NN O
genistein NN NN O
suppress NN NN O
induction NN NN O
of NN NN O
endothelial NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
subsequent NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
TNF NN NN B-Protein
. NN NN O
   
Inhibition NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
specific NN NN O
tyrosine NN NN O
phosphorylation NN NN O
following NN NN O
PTK NN NN O
activation NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
mobilization NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
may NN NN O
have NN NN O
implications NN NN O
for NN NN O
pathophysiological NN NN O
conditions NN NN O
that NN NN O
involve NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
these NN NN O
molecules NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
inflammation NN NN O
and NN NN O
atherosclerosis NN NN O
) NN NN O
. NN NN O
   
Transcription NN NN O
specific NN NN O
differences NN NN O
visualized NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
pattern NN NN O
on NN NN O
interphase NN NN O
nuclei NN NN O
of NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Application NN NN O
of NN NN O
a NN NN O
"""""""" NN NN O
formamide NN NN O
free NN NN O
"""""""" NN NN O
and NN NN O
thus NN NN O
"""""""" NN NN O
material NN NN O
preserving NN NN O
"""""""" NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
technique NN NN O
using NN NN O
the NN NN O
cDNA NN NN O
of NN NN O
the NN NN O
myf3 NN NN B-Protein
gene NN NN O
revealed NN NN O
the NN NN O
following NN NN O
results NN NN O
: NN NN O
Human NN NN O
rhabdomyosarcoma NN NN O
cells NN NN O
, NN NN O
characterized NN NN O
by NN NN O
a NN NN O
high NN NN O
expression NN NN O
of NN NN O
myf3 NN NN B-Protein
show NN NN O
intensive NN NN O
hybridization NN NN O
signals NN NN O
in NN NN O
their NN NN O
interphase NN NN O
. NN NN O
   
RNase NN NN O
treatment NN NN O
prior NN NN O
to NN NN O
hybridization NN NN O
considerably NN NN O
reduces NN NN O
the NN NN O
size NN NN O
of NN NN O
this NN NN O
signals NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
, NN NN O
isolated NN NN O
nuclei NN NN O
of NN NN O
human NN NN O
lymphocytes NN NN O
in NN NN O
which NN NN O
no NN NN O
need NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
this NN NN O
gene NN NN O
exists NN NN O
, NN NN O
show NN NN O
barely NN NN O
hybridization NN NN O
signals NN NN O
. NN NN O
   
Correspondingly NN NN O
, NN NN O
RNase NN NN O
treatment NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
hybridization NN NN O
pattern NN NN O
at NN NN O
all NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
an NN NN O
increased NN NN O
transcription NN NN O
efficiency NN NN O
of NN NN O
a NN NN O
cell NN NN O
type NN NN O
specific NN NN O
gene NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
higher NN NN O
hybridization NN NN O
accessibility NN NN O
in NN NN O
the NN NN O
corresponding NN NN O
cell NN NN O
nuclei NN NN O
. NN NN O
   
Precise NN NN O
alignment NN NN O
of NN NN O
sites NN NN O
required NN NN O
for NN NN O
mu NN NN O
enhancer NN NN O
activation NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
immunoglobulin NN NN O
mu NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
intronic NN NN O
enhancer NN NN O
is NN NN O
regulated NN NN O
by NN NN O
multiple NN NN O
nuclear NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
previously NN NN O
defined NN NN O
minimal NN NN O
enhancer NN NN O
containing NN NN O
the NN NN O
muA NN NN O
, NN NN O
muE3 NN NN O
, NN NN O
and NN NN O
muB NN NN O
sites NN NN O
is NN NN O
transactivated NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
the NN NN O
ETS NN NN O
- NN NN O
domain NN NN O
proteins NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
nonlymphoid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
core NN NN O
GGAAs NN NN O
of NN NN O
the NN NN O
muA NN NN O
and NN NN O
muB NN NN O
sites NN NN O
are NN NN O
separated NN NN O
by NN NN O
30 NN NN O
nucleotides NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
ETS NN NN O
proteins NN NN O
bind NN NN O
to NN NN O
these NN NN O
sites NN NN O
from NN NN O
these NN NN O
same NN NN O
side NN NN O
of NN NN O
the NN NN O
DNA NN NN O
helix NN NN O
. NN NN O
   
We NN NN O
tested NN NN O
the NN NN O
necessity NN NN O
for NN NN O
appropriate NN NN O
spatial NN NN O
alignment NN NN O
of NN NN O
these NN NN O
elements NN NN O
by NN NN O
using NN NN O
mutated NN NN O
enhancers NN NN O
with NN NN O
altered NN NN O
spacings NN NN O
. NN NN O
   
A NN NN O
4 NN NN O
- NN NN O
or NN NN O
10 NN NN O
- NN NN O
bp NN NN O
insertion NN NN O
between NN NN O
muE3 NN NN O
and NN NN O
muB NN NN O
inactivated NN NN O
the NN NN O
mu NN NN O
enhancer NN NN O
in NN NN O
S194 NN NN O
plasma NN NN O
cells NN NN O
but NN NN O
did NN NN O
not NN NN O
affect NN NN O
in NN NN O
vitro NN NN O
binding NN NN O
of NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
, NN NN O
or NN NN O
the NN NN O
muE3 NN NN O
- NN NN O
binding NN NN O
protein NN NN O
TFE3 NN NN B-Protein
, NN NN O
alone NN NN O
or NN NN O
in NN NN O
pairwise NN NN O
combinations NN NN O
. NN NN O
   
Circular NN NN O
permutation NN NN O
and NN NN O
phasing NN NN O
analyses NN NN O
demonstrated NN NN O
that NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
but NN NN O
not NN NN O
TFE3 NN NN B-Protein
or NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
bends NN NN O
mu NN NN O
enhancer NN NN O
DNA NN NN O
toward NN NN O
the NN NN O
major NN NN O
groove NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
the NN NN O
requirement NN NN O
for NN NN O
precise NN NN O
spacing NN NN O
of NN NN O
the NN NN O
muA NN NN O
and NN NN O
muB NN NN O
elements NN NN O
is NN NN O
due NN NN O
in NN NN O
part NN NN O
to NN NN O
a NN NN O
directed NN NN O
DNA NN NN O
bend NN NN O
induced NN NN O
by NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Alpha NN NN B-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
( NN NN I-Protein
CD49d NN NN I-Protein
/ NN NN I-Protein
CD29 NN NN I-Protein
) NN NN I-Protein
integrin NN NN I-Protein
costimulation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
enhances NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
cytokine NN NN O
induction NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
altered NN NN O
sensitivity NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
integrin NN NN B-Protein
alpha NN NN I-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
can NN NN O
provide NN NN O
a NN NN O
costimulus NN NN O
to NN NN O
induce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
expression NN NN O
leading NN NN O
to NN NN O
enhanced NN NN O
proliferation NN NN O
of NN NN O
purified NN NN O
, NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Similar NN NN O
to NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
recombinant NN NN O
vascular NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
when NN NN O
co NN NN O
- NN NN O
immobilized NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
, NN NN O
significantly NN NN O
enhanced NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
as NN NN O
determined NN NN O
by NN NN O
electromobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
ligation NN NN O
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
. NN NN O
   
The NN NN O
requirements NN NN O
for NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
reflected NN NN O
the NN NN O
requirements NN NN O
for NN NN O
the NN NN O
secretion NN NN O
of NN NN O
multiple NN NN O
cytokines NN NN O
, NN NN O
including NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
and NN NN O
granulocyte NN NN B-Protein
macrophage NN NN I-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
freshly NN NN O
isolated NN NN O
T NN NN O
cells NN NN O
, NN NN O
in NN NN O
vitro NN NN O
- NN NN O
cultured NN NN O
T NN NN O
cells NN NN O
did NN NN O
not NN NN O
require NN NN O
costimulation NN NN O
for NN NN O
cytokine NN NN O
secretion NN NN O
in NN NN O
response NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
alone NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
dose NN NN O
response NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
demonstrated NN NN O
that NN NN O
half NN NN O
- NN NN O
maximal NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
achieved NN NN O
using NN NN O
the NN NN O
same NN NN O
dose NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
for NN NN O
both NN NN O
freshly NN NN O
isolated NN NN O
and NN NN O
cultured NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
dose NN NN O
of NN NN O
OKT3 NN NN O
required NN NN O
to NN NN O
achieve NN NN O
half NN NN O
- NN NN O
maximal NN NN O
activation NN NN O
was NN NN O
the NN NN O
same NN NN O
using NN NN O
PMA NN NN O
or NN NN O
different NN NN O
concentrations NN NN O
of NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
ligands NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
costimulation NN NN O
by NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
ligands NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
interaction NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
its NN NN O
substrate NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
, NN NN O
rather NN NN O
, NN NN O
that NN NN O
alpha NN NN B-Protein
4 NN NN I-Protein
beta NN NN I-Protein
1 NN NN I-Protein
in NN NN O
freshly NN NN O
isolated NN NN O
T NN NN O
cells NN NN O
delivers NN NN O
a NN NN O
distinct NN NN O
signal NN NN O
that NN NN O
synergizes NN NN O
early NN NN O
with NN NN O
signals NN NN O
initiated NN NN O
by NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
ligation NN NN O
to NN NN O
induce NN NN O
DNA NN NN O
binding NN NN O
of NN NN O
multiple NN NN O
transcription NN NN O
factors NN NN O
required NN NN O
for NN NN O
cytokine NN NN O
gene NN NN O
induction NN NN O
. NN NN O
   
Defective NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
is NN NN O
associated NN NN O
with NN NN O
impaired NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
FosB NN NN B-Protein
, NN NN O
and NN NN O
JunB NN NN B-Protein
in NN NN O
anergic NN NN O
T NN NN O
helper NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Anergic NN NN O
CD4 NN NN O
+ NN NN O
Th NN NN O
cells NN NN O
do NN NN O
not NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
when NN NN O
challenged NN NN O
with NN NN O
Ag NN NN O
- NN NN O
pulsed NN NN O
accessory NN NN O
cells NN NN O
because NN NN O
of NN NN O
a NN NN O
transcriptional NN NN O
defect NN NN O
. NN NN O
   
In NN NN O
this NN NN O
work NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
these NN NN O
anergic NN NN O
T NN NN O
cells NN NN O
are NN NN O
defective NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
up NN NN O
- NN NN O
regulate NN NN O
protein NN NN O
binding NN NN O
and NN NN O
transactivation NN NN O
at NN NN O
two NN NN O
critical NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
DNA NN NN O
enhancer NN NN O
elements NN NN O
: NN NN O
NF NN NN O
- NN NN O
AT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
; NN NN O
a NN NN O
sequence NN NN O
that NN NN O
binds NN NN O
a NN NN O
heterotrimeric NN NN O
NFATp NN NN B-Protein
, NN NN O
Fos NN NN B-Protein
, NN NN O
and NN NN O
Jun NN NN B-Protein
protein NN NN O
complex NN NN O
) NN NN O
and NN NN O
Activator NN NN O
Protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
( NN NN O
that NN NN O
binds NN NN O
Fos NN NN B-Protein
and NN NN O
Jun NN NN B-Protein
heterodimers NN NN O
) NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
showed NN NN O
that NN NN O
the NN NN O
impaired NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
in NN NN O
anergic NN NN O
T NN NN O
cells NN NN O
were NN NN O
associated NN NN O
with NN NN O
poor NN NN O
expression NN NN O
of NN NN O
the NN NN O
inducible NN NN O
AP NN NN O
- NN NN O
1 NN NN O
family NN NN O
members NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
FosB NN NN B-Protein
, NN NN O
and NN NN O
JunB NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
these NN NN O
proteins NN NN O
was NN NN O
not NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
global NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
- NN NN O
signaling NN NN O
defect NN NN O
because NN NN O
CD3 NN NN O
cross NN NN O
- NN NN O
linking NN NN O
induced NN NN O
an NN NN O
equivalent NN NN O
increase NN NN O
in NN NN O
intracellular NN NN O
- NN NN O
free NN NN O
calcium NN NN O
ions NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
NFATp NN NN B-Protein
dephosphorylation NN NN O
, NN NN O
translocation NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
in NN NN O
both NN NN O
normal NN NN O
and NN NN O
anergic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
defective NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
appears NN NN O
to NN NN O
be NN NN O
due NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
to NN NN O
a NN NN O
selective NN NN O
block NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
Fos NN NN B-Protein
and NN NN O
Jun NN NN B-Protein
family NN NN O
members NN NN O
in NN NN O
anergic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
C NN NN O
/ NN NN O
EBP NN NN O
activators NN NN O
are NN NN O
required NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
proviral NN NN O
induction NN NN O
in NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Previous NN NN O
work NN NN O
has NN NN O
shown NN NN O
that NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
and NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
transcriptional NN NN O
activators NN NN O
are NN NN O
necessary NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
activity NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
role NN NN O
that NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
play NN NN O
in NN NN O
induction NN NN O
and NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Ectopic NN NN O
expression NN NN O
of NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
protein NN NN O
LIP NN NN O
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
mRNA NN NN O
and NN NN O
virus NN NN O
production NN NN O
in NN NN O
activated NN NN O
U1 NN NN O
cells NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
are NN NN O
required NN NN O
for NN NN O
provirus NN NN O
induction NN NN O
. NN NN O
   
U1 NN NN O
lines NN NN O
overexpressing NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
activator NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6 NN NN I-Protein
produced NN NN O
more NN NN O
viral NN NN O
mRNA NN NN O
and NN NN O
virus NN NN O
particles NN NN O
following NN NN O
cellular NN NN O
activation NN NN O
than NN NN O
control NN NN O
lines NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
are NN NN O
limiting NN NN O
for NN NN O
virus NN NN O
transcription NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
harboring NN NN O
mutations NN NN O
within NN NN O
two NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
were NN NN O
crippled NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
replicate NN NN O
in NN NN O
U937 NN NN O
promonocytic NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
that NN NN O
these NN NN O
sites NN NN O
are NN NN O
required NN NN O
for NN NN O
replication NN NN O
. NN NN O
   
These NN NN O
data NN NN O
identify NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
proteins NN NN O
as NN NN O
regulators NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
Stat1 NN NN B-Protein
activity NN NN O
in NN NN O
mononuclear NN NN O
cell NN NN O
cultures NN NN O
and NN NN O
T NN NN O
cells NN NN O
by NN NN O
the NN NN O
cyclic NN NN O
AMP NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
results NN NN O
in NN NN O
a NN NN O
cascade NN NN O
of NN NN O
gene NN NN O
activation NN NN O
and NN NN O
subsequent NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
into NN NN O
effector NN NN O
phenotypes NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
belonging NN NN O
to NN NN O
the NN NN O
signal NN NN O
transducer NN NN O
and NN NN O
activator NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
family NN NN O
was NN NN O
analyzed NN NN O
in NN NN O
PHA NN NN B-Protein
- NN NN O
activated NN NN O
mononuclear NN NN O
cells NN NN O
and NN NN O
in NN NN O
purified NN NN O
T NN NN O
cells NN NN O
activated NN NN O
by NN NN O
cross NN NN O
- NN NN O
linking NN NN O
cell NN NN O
surface NN NN O
CD3 NN NN O
. NN NN O
   
Cell NN NN O
activation NN NN O
resulted NN NN O
in NN NN O
a NN NN O
delayed NN NN O
induction NN NN O
of NN NN O
STAT NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
, NN NN O
which NN NN O
was NN NN O
sustained NN NN O
for NN NN O
several NN NN O
days NN NN O
, NN NN O
was NN NN O
composed NN NN O
predominantly NN NN O
of NN NN O
Stat1 NN NN B-Protein
and NN NN O
Stat3 NN NN B-Protein
, NN NN O
and NN NN O
was NN NN O
blocked NN NN O
by NN NN O
cycloheximide NN NN O
and NN NN O
actinomycin NN NN O
D NN NN O
. NN NN O
   
Increased NN NN O
Stat1 NN NN O
and NN NN O
Stat3 NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
levels NN NN O
were NN NN O
detected NN NN O
, NN NN O
respectively NN NN O
4 NN NN O
and NN NN O
24 NN NN O
h NN NN O
after NN NN O
activation NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
cAMP NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
, NN NN O
which NN NN O
skews NN NN O
cytokine NN NN O
production NN NN O
toward NN NN O
a NN NN O
Th2 NN NN O
pattern NN NN O
, NN NN O
resulted NN NN O
in NN NN O
the NN NN O
preferential NN NN O
suppression NN NN O
of NN NN O
Stat1 NN NN B-Protein
activity NN NN O
. NN NN O
   
cAMP NN NN O
inhibited NN NN O
the NN NN O
induction NN NN O
of NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
components NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
inhibit NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
and NN NN O
CD69 NN NN B-Protein
expression NN NN O
or NN NN O
the NN NN O
induction NN NN O
of NN NN O
activator NN NN O
protein NN NN O
1 NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
cAMP NN NN O
signaling NN NN O
inhibited NN NN O
Stat1 NN NN B-Protein
at NN NN O
several NN NN O
different NN NN O
levels NN NN O
, NN NN O
including NN NN O
suppression NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Stat1 NN NN B-Protein
protein NN NN O
and NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
the NN NN O
regulation NN NN O
of NN NN O
STAT NN NN O
activity NN NN O
by NN NN O
a NN NN O
signaling NN NN O
pathway NN NN O
that NN NN O
regulates NN NN O
the NN NN O
T NN NN O
cell NN NN O
functional NN NN O
phenotype NN NN O
and NN NN O
is NN NN O
distinct NN NN O
from NN NN O
the NN NN O
cytokine NN NN O
- NN NN O
activated NN NN O
Janus NN NN O
kinase NN NN O
- NN NN O
STAT NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
Transcriptional NN NN O
analysis NN NN O
of NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
gene NN NN O
expression NN NN O
in NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
gastric NN NN O
carcinoma NN NN O
: NN NN O
unique NN NN O
viral NN NN O
latency NN NN O
in NN NN O
the NN NN O
tumour NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
case NN NN O
- NN NN O
oriented NN NN O
evidence NN NN O
for NN NN O
an NN NN O
association NN NN O
of NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
with NN NN O
gastric NN NN O
carcinoma NN NN O
has NN NN O
been NN NN O
accumulating NN NN O
recently NN NN O
, NN NN O
the NN NN O
interaction NN NN O
( NN NN O
s NN NN O
) NN NN O
between NN NN O
EBV NN NN O
and NN NN O
gastric NN NN O
epithelial NN NN O
cells NN NN O
is NN NN O
/ NN NN O
are NN NN O
largely NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
seven NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
gastric NN NN O
carcinoma NN NN O
tissues NN NN O
for NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
, NN NN O
from NN NN O
which NN NN O
studies NN NN O
on NN NN O
the NN NN O
EBV NN NN O
oncogenicity NN NN O
in NN NN O
human NN NN O
epithelial NN NN O
cells NN NN O
will NN NN O
benefit NN NN O
. NN NN O
   
Reverse NN NN O
transcription NN NN O
- NN NN O
PCR NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
all NN NN O
seven NN NN O
EBV NN NN O
- NN NN O
positive NN NN O
tumour NN NN O
tissues NN NN O
constitutively NN NN O
expressed NN NN O
EBV NN NN B-Protein
nuclear NN NN I-Protein
antigen NN NN I-Protein
( NN NN I-Protein
EBNA NN NN I-Protein
) NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
, NN NN O
but NN NN O
not NN NN O
EBNA2 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
The NN NN O
EBNA NN NN O
transcription NN NN O
was NN NN O
initiated NN NN O
from NN NN O
one NN NN O
of NN NN O
three NN NN O
EBNA NN NN O
promoters NN NN O
, NN NN O
Qp NN NN O
: NN NN O
by NN NN O
contrast NN NN O
, NN NN O
both NN NN O
Cp NN NN O
and NN NN O
Wp NN NN O
were NN NN O
silent NN NN O
, NN NN O
thus NN NN O
resulting NN NN O
in NN NN O
the NN NN O
lack NN NN O
of NN NN O
EBNA2 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
Latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
( NN NN I-Protein
LMP NN NN I-Protein
) NN NN I-Protein
2A NN NN I-Protein
mRNA NN NN O
was NN NN O
detected NN NN O
in NN NN O
three NN NN O
of NN NN O
seven NN NN O
cases NN NN O
; NN NN O
however NN NN O
, NN NN O
neither NN NN O
LMP1 NN NN B-Protein
nor NN NN O
LMP2B NN NN B-Protein
mRNA NN NN O
was NN NN O
detected NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
tumours NN NN O
tested NN NN O
. NN NN O
   
Transcripts NN NN O
from NN NN O
the NN NN O
BamHI NN NN O
- NN NN O
A NN NN O
region NN NN O
of NN NN O
the NN NN O
viral NN NN O
genome NN NN O
were NN NN O
detectable NN NN O
in NN NN O
all NN NN O
cases NN NN O
. NN NN O
   
BZLF1 NN NN B-Protein
mRNA NN NN O
and NN NN O
the NN NN O
product NN NN O
, NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
for NN NN O
EBV NN NN O
replication NN NN O
, NN NN O
was NN NN O
not NN NN O
expressed NN NN O
in NN NN O
any NN NN O
of NN NN O
them NN NN O
, NN NN O
thereby NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
tumour NN NN O
cells NN NN O
carried NN NN O
EBV NN NN O
genomes NN NN O
in NN NN O
a NN NN O
tightly NN NN O
latent NN NN O
form NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
further NN NN O
extended NN NN O
our NN NN O
previous NN NN O
data NN NN O
regarding NN NN O
EBV NN NN O
latency NN NN O
in NN NN O
gastric NN NN O
carcinoma NN NN O
cells NN NN O
at NN NN O
the NN NN O
protein NN NN O
level NN NN O
, NN NN O
and NN NN O
have NN NN O
affirmed NN NN O
that NN NN O
the NN NN O
programme NN NN O
of NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
tumour NN NN O
more NN NN O
closely NN NN O
resembles NN NN O
' NN NN O
latency NN NN O
I NN NN O
' NN NN O
represented NN NN O
by NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
than NN NN O
' NN NN O
latency NN NN O
II NN NN O
' NN NN O
represented NN NN O
by NN NN O
the NN NN O
majority NN NN O
of NN NN O
nasopharyngeal NN NN O
carcinomas NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
early NN NN B-Protein
growth NN NN I-Protein
response NN NN I-Protein
gene NN NN I-Protein
1 NN NN I-Protein
( NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
in NN NN O
regulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
immediate NN NN O
early NN NN O
genes NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
is NN NN O
critical NN NN O
to NN NN O
determining NN NN O
the NN NN O
ultimate NN NN O
outcome NN NN O
of NN NN O
exposure NN NN O
to NN NN O
antigen NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
many NN NN O
of NN NN O
these NN NN O
genes NN NN O
relates NN NN O
to NN NN O
the NN NN O
role NN NN O
their NN NN O
transcription NN NN O
factor NN NN O
products NN NN O
play NN NN O
in NN NN O
dictating NN NN O
patterns NN NN O
of NN NN O
expression NN NN O
of NN NN O
downstream NN NN O
, NN NN O
function NN NN O
- NN NN O
related NN NN O
genes NN NN O
. NN NN O
   
Evidence NN NN O
from NN NN O
several NN NN O
systems NN NN O
indicates NN NN O
that NN NN O
the NN NN O
immediate NN NN O
early NN NN O
gene NN NN O
, NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
may NN NN O
be NN NN O
of NN NN O
particular NN NN O
importance NN NN O
in NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
the NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
highly NN NN O
responsive NN NN O
to NN NN O
the NN NN O
diverse NN NN O
biochemical NN NN O
signals NN NN O
generated NN NN O
by NN NN O
antigen NN NN O
and NN NN O
cytokines NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
an NN NN O
important NN NN O
role NN NN O
for NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
determining NN NN O
the NN NN O
differentiation NN NN O
pathway NN NN O
of NN NN O
myeloid NN NN O
cell NN NN O
precursors NN NN O
has NN NN O
been NN NN O
recently NN NN O
elaborated NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
potential NN NN O
targets NN NN O
of NN NN O
regulation NN NN O
by NN NN O
the NN NN O
zinc NN NN O
- NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
encoded NN NN O
by NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
include NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
CD44 NN NN B-Protein
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
genes NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
regulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
will NN NN O
be NN NN O
discussed NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
these NN NN O
recent NN NN O
studies NN NN O
. NN NN O
   
Apoptosis NN NN O
mediated NN NN O
by NN NN O
HIV NN NN B-Protein
protease NN NN I-Protein
is NN NN O
preceded NN NN O
by NN NN O
cleavage NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
human NN NN B-Protein
immunodeficiency NN NN I-Protein
virus NN NN I-Protein
type NN NN I-Protein
1 NN NN I-Protein
( NN NN I-Protein
HIV NN NN I-Protein
) NN NN I-Protein
protease NN NN I-Protein
in NN NN O
cultured NN NN O
cells NN NN O
leads NN NN O
to NN NN O
apoptosis NN NN O
, NN NN O
preceded NN NN O
by NN NN O
cleavage NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
a NN NN O
key NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protects NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
from NN NN O
the NN NN O
viral NN NN O
protease NN NN O
and NN NN O
prevents NN NN O
cell NN NN O
death NN NN O
following NN NN O
HIV NN NN O
infection NN NN O
of NN NN O
human NN NN O
lymphocytes NN NN O
, NN NN O
while NN NN O
reducing NN NN O
the NN NN O
yields NN NN O
of NN NN O
viral NN NN O
structural NN NN O
proteins NN NN O
, NN NN O
infectivity NN NN O
, NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
We NN NN O
present NN NN O
a NN NN O
model NN NN O
for NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
which NN NN O
the NN NN O
viral NN NN O
protease NN NN O
depletes NN NN O
the NN NN O
infected NN NN O
cells NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
leading NN NN O
to NN NN O
oxidative NN NN O
stress NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
, NN NN O
a NN NN O
cellular NN NN O
factor NN NN O
required NN NN O
for NN NN O
HIV NN NN O
transcription NN NN O
, NN NN O
and NN NN O
ultimately NN NN O
to NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Purified NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
cleaved NN NN O
by NN NN O
HIV NN NN B-Protein
protease NN NN I-Protein
between NN NN O
phenylalanine NN NN O
112 NN NN O
and NN NN O
alanine NN NN O
113 NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
a NN NN O
new NN NN O
option NN NN O
for NN NN O
HIV NN NN O
gene NN NN O
therapy NN NN O
; NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
muteins NN NN O
that NN NN O
have NN NN O
noncleavable NN NN O
alterations NN NN O
surrounding NN NN O
the NN NN O
HIV NN NN B-Protein
protease NN NN I-Protein
cleavage NN NN O
site NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
Stat NN NN B-Protein
5b NN NN I-Protein
in NN NN O
erythroid NN NN O
progenitors NN NN O
correlates NN NN O
with NN NN O
the NN NN O
ability NN NN O
of NN NN O
ErbB NN NN O
to NN NN O
induce NN NN O
sustained NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Self NN NN O
renewal NN NN O
of NN NN O
normal NN NN O
erythroid NN NN O
progenitors NN NN O
is NN NN O
induced NN NN O
by NN NN O
the NN NN O
receptor NN NN O
tyrosine NN NN O
kinase NN NN O
c NN NN O
- NN NN O
ErbB NN NN O
, NN NN O
whereas NN NN O
other NN NN O
receptors NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Kit NN NN I-Protein
/ NN NN O
Epo NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
) NN NN O
regulate NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
To NN NN O
address NN NN O
possible NN NN O
mechanisms NN NN O
that NN NN O
could NN NN O
explain NN NN O
this NN NN O
selective NN NN O
activity NN NN O
of NN NN O
c NN NN O
- NN NN O
ErbB NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
ability NN NN O
of NN NN O
these NN NN O
receptors NN NN O
to NN NN O
activate NN NN O
the NN NN O
different NN NN O
members NN NN O
of NN NN O
the NN NN O
Stat NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
. NN NN O
   
Ligand NN NN O
activation NN NN O
of NN NN O
c NN NN O
- NN NN O
ErbB NN NN O
induced NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
, NN NN O
and NN NN O
reporter NN NN O
gene NN NN O
transcription NN NN O
of NN NN O
Stat NN NN B-Protein
5b NN NN I-Protein
in NN NN O
erythroblasts NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
ligand NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Kit NN NN I-Protein
was NN NN O
unable NN NN O
to NN NN O
induce NN NN O
any NN NN O
of NN NN O
these NN NN O
effects NN NN O
in NN NN O
the NN NN O
same NN NN O
cells NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
caused NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
of NN NN O
Stat NN NN B-Protein
5b NN NN I-Protein
, NN NN O
but NN NN O
failed NN NN O
to NN NN O
induce NN NN O
reporter NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
These NN NN O
biochemical NN NN O
findings NN NN O
correlate NN NN O
perfectly NN NN O
with NN NN O
the NN NN O
selective NN NN O
ability NN NN O
of NN NN O
c NN NN O
- NN NN O
ErbB NN NN O
to NN NN O
cause NN NN O
sustained NN NN O
self NN NN O
renewal NN NN O
in NN NN O
erythroid NN NN O
progenitors NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
lowered NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
in NN NN O
activated NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
induced NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
young NN NN O
individuals NN NN O
following NN NN O
activation NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
stimuli NN NN O
including NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
, NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
older NN NN O
individuals NN NN O
show NN NN O
a NN NN O
significant NN NN O
reduction NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
same NN NN O
stimuli NN NN O
. NN NN O
   
The NN NN O
age NN NN O
- NN NN O
related NN NN O
decline NN NN O
in NN NN O
induction NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
could NN NN O
not NN NN O
be NN NN O
attributed NN NN O
to NN NN O
alteration NN NN O
in NN NN O
the NN NN O
composition NN NN O
of NN NN O
subunits NN NN O
, NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
were NN NN O
found NN NN O
to NN NN O
be NN NN O
the NN NN O
predominant NN NN O
subunits NN NN O
of NN NN O
induced NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
in NN NN O
T NN NN O
cells NN NN O
from NN NN O
young NN NN O
as NN NN O
well NN NN O
as NN NN O
elderly NN NN O
donors NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
similar NN NN O
levels NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
cytosols NN NN O
of NN NN O
unactivated NN NN O
T NN NN O
cells NN NN O
from NN NN O
both NN NN O
young NN NN O
and NN NN O
elderly NN NN O
donors NN NN O
suggesting NN NN O
that NN NN O
precursor NN NN O
levels NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
remain NN NN O
unaltered NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
an NN NN O
age NN NN O
- NN NN O
associated NN NN O
decline NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
from NN NN O
elderly NN NN O
individuals NN NN O
may NN NN O
be NN NN O
attributable NN NN O
to NN NN O
altered NN NN O
regulation NN NN O
of NN NN O
the NN NN O
inhibitor NN NN O
, NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
immune NN NN O
dysregulation NN NN O
accompanying NN NN O
aging NN NN O
. NN NN O
   
Interaction NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
with NN NN O
the NN NN O
human NN NN O
proteasome NN NN O
: NN NN O
implications NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
induction NN NN O
. NN NN O
   
The NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
has NN NN O
been NN NN O
etiologically NN NN O
associated NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
( NN NN O
ATL NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
degenerative NN NN O
neurologic NN NN O
syndrome NN NN O
termed NN NN O
tropical NN NN O
spastic NN NN O
paraparesis NN NN O
( NN NN O
TSP NN NN O
) NN NN O
. NN NN O
   
HTLV NN NN O
- NN NN O
I NN NN O
encodes NN NN O
a NN NN O
potent NN NN O
transactivator NN NN O
protein NN NN O
termed NN NN O
Tax NN NN B-Protein
that NN NN O
appears NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
process NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
immortalization NN NN O
. NN NN O
   
Even NN NN O
though NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
Tax NN NN B-Protein
induces NN NN O
transformation NN NN O
are NN NN O
still NN NN O
unknown NN NN O
, NN NN O
it NN NN O
seems NN NN O
likely NN NN O
that NN NN O
the NN NN O
ability NN NN O
of NN NN O
Tax NN NN B-Protein
to NN NN O
alter NN NN O
the NN NN O
expression NN NN O
of NN NN O
many NN NN O
cellular NN NN O
genes NN NN O
plays NN NN O
an NN NN O
important NN NN O
part NN NN O
in NN NN O
this NN NN O
process NN NN O
. NN NN O
   
Tax NN NN B-Protein
does NN NN O
not NN NN O
bind NN NN O
directly NN NN O
to NN NN O
DNA NN NN O
but NN NN O
rather NN NN O
deregulates NN NN O
the NN NN O
activity NN NN O
of NN NN O
cellular NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
One NN NN O
family NN NN O
of NN NN O
host NN NN O
transcription NN NN O
factors NN NN O
whose NN NN O
activity NN NN O
is NN NN O
altered NN NN O
by NN NN O
Tax NN NN B-Protein
includes NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
. NN NN O
   
These NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
post NN NN O
- NN NN O
transcriptionally NN NN O
regulated NN NN O
by NN NN O
their NN NN O
assembly NN NN O
with NN NN O
a NN NN O
second NN NN O
family NN NN O
of NN NN O
inhibitory NN NN O
proteins NN NN O
termed NN NN O
I NN NN O
kappa NN NN O
B NN NN O
that NN NN O
serve NN NN O
to NN NN O
sequester NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
complexes NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
Upon NN NN O
cellular NN NN O
activation NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
phosphorylated NN NN O
, NN NN O
polyubiquitinated NN NN O
, NN NN O
and NN NN O
degraded NN NN O
in NN NN O
the NN NN O
proteasome NN NN O
. NN NN O
   
This NN NN O
proteolytic NN NN O
event NN NN O
liberates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
permitting NN NN O
its NN NN O
rapid NN NN O
translocation NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
where NN NN O
it NN NN O
binds NN NN O
to NN NN O
its NN NN O
cognate NN NN O
enhancer NN NN O
elements NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
the NN NN O
p105 NN NN B-Protein
precursor NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
subunit NN NN O
is NN NN O
also NN NN O
post NN NN O
- NN NN O
translationally NN NN O
processed NN NN O
in NN NN O
the NN NN O
proteasome NN NN O
. NN NN O
   
The NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
Tax NN NN B-Protein
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
remain NN NN O
unclear NN NN O
, NN NN O
and NN NN O
findings NN NN O
presented NN NN O
in NN NN O
the NN NN O
literature NN NN O
are NN NN O
often NN NN O
controversial NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
physical NN NN O
interaction NN NN O
between NN NN O
Tax NN NN B-Protein
and NN NN O
the NN NN O
HsN3 NN NN B-Protein
subunit NN NN O
of NN NN O
the NN NN O
human NN NN O
proteasome NN NN O
. NN NN O
   
This NN NN O
raises NN NN O
the NN NN O
intriguing NN NN O
possibility NN NN O
that NN NN O
physical NN NN O
association NN NN O
of NN NN O
the NN NN O
HsN3 NN NN B-Protein
proteasome NN NN O
subunit NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
Tax NN NN B-Protein
coupled NN NN O
with NN NN O
the NN NN O
independent NN NN O
interaction NN NN O
of NN NN O
Tax NN NN B-Protein
with NN NN O
either NN NN O
p100 NN NN B-Protein
or NN NN O
p65 NN NN B-Protein
- NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
targets NN NN O
these NN NN O
cytoplasmic NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
complexes NN NN O
to NN NN O
the NN NN O
proteasome NN NN O
for NN NN O
processing NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
viral NN NN O
latency NN NN O
is NN NN O
disrupted NN NN O
by NN NN O
the NN NN O
immediate NN NN O
- NN NN O
early NN NN O
BRLF1 NN NN B-Protein
protein NN NN O
through NN NN O
a NN NN O
cell NN NN O
- NN NN O
specific NN NN O
mechanism NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
, NN NN O
the NN NN O
causative NN NN O
agent NN NN O
of NN NN O
infectious NN NN O
mononucleosis NN NN O
, NN NN O
is NN NN O
a NN NN O
human NN NN O
herpesvirus NN NN O
associated NN NN O
with NN NN O
epithelial NN NN O
cell NN NN O
malignancies NN NN O
( NN NN O
nasopharyngeal NN NN O
carcinoma NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
B NN NN O
- NN NN O
cell NN NN O
malignancies NN NN O
. NN NN O
   
Understanding NN NN O
how NN NN O
viral NN NN O
latency NN NN O
is NN NN O
disrupted NN NN O
is NN NN O
a NN NN O
central NN NN O
issue NN NN O
in NN NN O
herpesvirus NN NN O
biology NN NN O
. NN NN O
   
Epithelial NN NN O
cells NN NN O
are NN NN O
the NN NN O
major NN NN O
site NN NN O
of NN NN O
lytic NN NN O
EBV NN NN O
replication NN NN O
within NN NN O
the NN NN O
human NN NN O
host NN NN O
, NN NN O
and NN NN O
viral NN NN O
reactivation NN NN O
occurs NN NN O
in NN NN O
EBV NN NN O
- NN NN O
associated NN NN O
nasopharyngeal NN NN O
carcinomas NN NN O
. NN NN O
   
It NN NN O
is NN NN O
known NN NN O
that NN NN O
expression NN NN O
of NN NN O
a NN NN O
single NN NN O
viral NN NN O
immediate NN NN O
- NN NN O
early NN NN O
protein NN NN O
, NN NN O
BZLF1 NN NN B-Protein
, NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
initiate NN NN O
the NN NN O
switch NN NN O
from NN NN O
latent NN NN O
to NN NN O
lytic NN NN O
infection NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Cellular NN NN O
regulation NN NN O
of NN NN O
BZLF1 NN NN B-Protein
transcription NN NN O
is NN NN O
therefore NN NN O
thought NN NN O
to NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
stringency NN NN O
of NN NN O
viral NN NN O
latency NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
, NN NN O
unexpectedly NN NN O
, NN NN O
expression NN NN O
of NN NN O
another NN NN O
viral NN NN O
immediate NN NN O
- NN NN O
early NN NN O
protein NN NN O
, NN NN O
BRLF1 NN NN B-Protein
, NN NN O
can NN NN O
disrupt NN NN O
viral NN NN O
latency NN NN O
in NN NN O
an NN NN O
epithelial NN NN O
cell NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
the NN NN O
mechanisms NN NN O
leading NN NN O
to NN NN O
disruption NN NN O
of NN NN O
EBV NN NN O
latency NN NN O
appear NN NN O
to NN NN O
be NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
. NN NN O
   
Attenuated NN NN O
function NN NN O
of NN NN O
a NN NN O
variant NN NN O
form NN NN O
of NN NN O
the NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
protein NN NN O
, NN NN O
Id NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
generated NN NN O
by NN NN O
an NN NN O
alternative NN NN O
splicing NN NN O
mechanism NN NN O
. NN NN O
   
The NN NN O
Id NN NN O
family NN NN O
of NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
function NN NN O
as NN NN O
negative NN NN O
regulators NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
proteins NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cell NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
on NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
17 NN NN O
kDa NN NN O
variant NN NN O
of NN NN O
the NN NN O
14 NN NN O
kDa NN NN O
Id NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
protein NN NN O
termed NN NN O
Id NN NN O
- NN NN O
3L NN NN O
( NN NN O
long NN NN O
version NN NN O
) NN NN O
which NN NN O
possesses NN NN O
a NN NN O
unique NN NN O
60 NN NN O
amino NN NN O
acid NN NN O
carboxy NN NN O
- NN NN O
terminus NN NN O
generated NN NN O
by NN NN O
read NN NN O
through NN NN O
of NN NN O
a NN NN O
' NN NN O
coding NN NN O
intron NN NN O
' NN NN O
and NN NN O
alternative NN NN O
splicing NN NN O
. NN NN O
   
Northern NN NN O
analysis NN NN O
revealed NN NN O
expression NN NN O
of NN NN O
a NN NN O
minor NN NN O
1 NN NN O
. NN NN O
1 NN NN O
kb NN NN O
Id NN NN O
- NN NN O
3L NN NN O
transcript NN NN O
together NN NN O
with NN NN O
the NN NN O
predominant NN NN O
0 NN NN O
. NN NN O
95 NN NN O
kb NN NN O
Id NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
transcript NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
adult NN NN O
human NN NN O
tissues NN NN O
analysed NN NN O
. NN NN O
   
The NN NN O
variant NN NN O
Id NN NN O
- NN NN O
3L NN NN O
protein NN NN O
is NN NN O
functionally NN NN O
distinguishable NN NN O
from NN NN O
conventional NN NN O
Id NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
since NN NN O
in NN NN O
in NN NN O
vitro NN NN O
DNA NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
it NN NN O
was NN NN O
greatly NN NN O
impaired NN NN O
in NN NN O
its NN NN O
ability NN NN O
to NN NN O
abrogate NN NN O
binding NN NN O
of NN NN O
the NN NN O
basic NN NN O
helix NN NN O
- NN NN O
loop NN NN O
- NN NN O
helix NN NN O
protein NN NN O
, NN NN O
E47 NN NN B-Protein
, NN NN O
to NN NN O
an NN NN O
E NN NN O
box NN NN O
recognition NN NN O
sequence NN NN O
. NN NN O
   
Multifactor NN NN O
cis NN NN O
- NN NN O
dominant NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
anergized NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanism NN NN O
underlying NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcriptional NN NN O
blockade NN NN O
in NN NN O
anergic NN NN O
T NN NN O
cell NN NN O
clones NN NN O
is NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
whether NN NN O
an NN NN O
active NN NN O
negative NN NN O
regulatory NN NN O
process NN NN O
occurs NN NN O
, NN NN O
we NN NN O
created NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
as NN NN O
an NN NN O
enhancer NN NN O
four NN NN O
copies NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
AT NN NN O
site NN NN O
and NN NN O
one NN NN O
copy NN NN O
of NN NN O
the NN NN O
octamer NN NN O
site NN NN O
( NN NN O
4X NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
Oct NN NN O
) NN NN O
. NN NN O
   
This NN NN O
construct NN NN O
was NN NN O
only NN NN O
slightly NN NN O
reduced NN NN O
( NN NN O
1 NN NN O
. NN NN O
3 NN NN O
- NN NN O
fold NN NN O
) NN NN O
in NN NN O
its NN NN O
expression NN NN O
when NN NN O
stimulated NN NN O
under NN NN O
anergic NN NN O
conditions NN NN O
, NN NN O
while NN NN O
a NN NN O
whole NN NN O
mouse NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
construct NN NN O
showed NN NN O
a NN NN O
reduction NN NN O
of NN NN O
4 NN NN O
. NN NN O
3 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
the NN NN O
- NN NN O
176 NN NN O
to NN NN O
- NN NN O
96 NN NN O
sequence NN NN O
to NN NN O
the NN NN O
4X NN NN O
NF NN NN O
- NN NN O
AT NN NN O
- NN NN O
Oct NN NN O
construct NN NN O
did NN NN O
not NN NN O
impart NN NN O
the NN NN O
ability NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
anergy NN NN O
, NN NN O
but NN NN O
addition NN NN O
of NN NN O
the NN NN O
- NN NN O
236 NN NN O
to NN NN O
- NN NN O
96 NN NN O
sequence NN NN O
did NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
anergy NN NN O
is NN NN O
an NN NN O
active NN NN O
inhibitory NN NN O
process NN NN O
and NN NN O
that NN NN O
more NN NN O
than NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
- NN NN O
150 NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
site NN NN O
( NN NN O
- NN NN O
152 NN NN O
to NN NN O
- NN NN O
147 NN NN O
) NN NN O
is NN NN O
required NN NN O
to NN NN O
mediate NN NN O
the NN NN O
effect NN NN O
. NN NN O
   
Mutational NN NN O
studies NN NN O
of NN NN O
the NN NN O
- NN NN O
236 NN NN O
to NN NN O
- NN NN O
96 NN NN O
sequence NN NN O
indicated NN NN O
that NN NN O
the NN NN O
presence NN NN O
of NN NN O
both NN NN O
the NN NN O
- NN NN O
130 NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
like NN NN O
site NN NN O
( NN NN O
- NN NN O
187 NN NN O
to NN NN O
- NN NN O
181 NN NN O
) NN NN O
and NN NN O
the NN NN O
- NN NN O
150 NN NN O
proximal NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
were NN NN O
necessary NN NN O
to NN NN O
observe NN NN O
anergy NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
- NN NN O
180 NN NN O
site NN NN O
is NN NN O
not NN NN O
required NN NN O
for NN NN O
trans NN NN O
- NN NN O
activation NN NN O
, NN NN O
it NN NN O
was NN NN O
possible NN NN O
to NN NN O
confirm NN NN O
by NN NN O
mutation NN NN O
in NN NN O
the NN NN O
normal NN NN O
mouse NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
enhancer NN NN O
that NN NN O
this NN NN O
site NN NN O
is NN NN O
absolutely NN NN O
essential NN NN O
for NN NN O
anergy NN NN O
induction NN NN O
. NN NN O
   
The NN NN O
simplest NN NN O
model NN NN O
to NN NN O
explain NN NN O
these NN NN O
results NN NN O
is NN NN O
that NN NN O
anergy NN NN O
is NN NN O
mediated NN NN O
by NN NN O
a NN NN O
complex NN NN O
of NN NN O
multiple NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
exert NN NN O
a NN NN O
cis NN NN O
- NN NN O
acting NN NN O
dominant NN NN O
negative NN NN O
regulatory NN NN O
effect NN NN O
on NN NN O
the NN NN O
trans NN NN O
- NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
human NN NN O
myeloid NN NN O
cell NN NN O
nuclear NN NN O
differentiation NN NN O
antigen NN NN O
gene NN NN O
promoter NN NN O
. NN NN O
   
MNDA NN NN B-Protein
( NN NN O
myeloid NN NN B-Protein
cell NN NN I-Protein
nuclear NN NN I-Protein
differentiation NN NN I-Protein
antigen NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
interferon NN NN O
alpha NN NN O
regulated NN NN O
nuclear NN NN O
protein NN NN O
expressed NN NN O
only NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
human NN NN O
myelomonocytic NN NN O
lineage NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
this NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
and NN NN O
interferon NN NN O
- NN NN O
regulated NN NN O
expression NN NN O
, NN NN O
the NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
sequence NN NN O
of NN NN O
the NN NN O
gene NN NN O
has NN NN O
been NN NN O
characterized NN NN O
. NN NN O
   
Two NN NN O
interferon NN NN O
- NN NN O
stimulated NN NN O
response NN NN O
elements NN NN O
( NN NN O
ISRE NN NN O
) NN NN O
flank NN NN O
a NN NN O
multiple NN NN O
transcription NN NN O
start NN NN O
site NN NN O
region NN NN O
identifying NN NN O
MNDA NN NN B-Protein
as NN NN O
a NN NN O
TATA NN NN O
- NN NN O
less NN NN O
interferon NN NN O
- NN NN O
regulated NN NN O
gene NN NN O
. NN NN O
   
Other NN NN O
DNA NN NN O
elements NN NN O
present NN NN O
include NN NN O
a NN NN O
cluster NN NN O
of NN NN O
Myb NN NN O
sites NN NN O
, NN NN O
several NN NN O
Ets NN NN O
, NN NN O
an NN NN O
Ets NN NN O
related NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
and NN NN O
an NN NN O
Sp1 NN NN B-Protein
site NN NN O
located NN NN O
within NN NN O
600 NN NN O
bp NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
DNA NN NN O
methylation NN NN O
was NN NN O
revealed NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
possible NN NN O
factors NN NN O
in NN NN O
establishing NN NN O
MNDA NN NN B-Protein
expression NN NN O
. NN NN O
   
The NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
sequence NN NN O
has NN NN O
promoter NN NN O
activity NN NN O
which NN NN O
is NN NN O
elevated NN NN O
by NN NN O
interferon NN NN O
alpha NN NN O
. NN NN O
   
The NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
MNDA NN NN B-Protein
expression NN NN O
is NN NN O
regulated NN NN O
by NN NN O
mechanisms NN NN O
similar NN NN O
to NN NN O
other NN NN O
myelomonocytic NN NN O
cell NN NN O
specific NN NN O
genes NN NN O
and NN NN O
genes NN NN O
up NN NN O
- NN NN O
regulated NN NN O
by NN NN O
interferon NN NN O
alpha NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
transcription NN NN O
by NN NN O
core NN NN O
- NN NN O
binding NN NN O
factor NN NN O
. NN NN O
   
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
is NN NN O
known NN NN O
to NN NN O
involve NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
human NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
and NN NN O
enhancer NN NN O
also NN NN O
encompass NN NN O
binding NN NN O
sites NN NN O
for NN NN O
core NN NN O
- NN NN O
binding NN NN O
factor NN NN O
( NN NN O
CBF NN NN O
) NN NN O
. NN NN O
   
Significantly NN NN O
, NN NN O
the NN NN O
CBF NN NN O
sites NN NN O
are NN NN O
in NN NN O
each NN NN O
case NN NN O
contained NN NN O
within NN NN O
the NN NN O
minimum NN NN O
essential NN NN O
core NN NN O
regions NN NN O
required NN NN O
for NN NN O
inducible NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
core NN NN O
regions NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
and NN NN O
promoter NN NN O
each NN NN O
encompass NN NN O
closely NN NN O
linked NN NN O
binding NN NN O
sites NN NN O
for NN NN O
CBF NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NFATp NN NN B-Protein
. NN NN O
   
The NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
CBF NN NN O
site NN NN O
TGTGGTCA NN NN O
is NN NN O
located NN NN O
51 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
and NN NN O
also NN NN O
overlaps NN NN O
a NN NN O
YY NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
A NN NN O
2 NN NN O
- NN NN O
bp NN NN O
mutation NN NN O
within NN NN O
the NN NN O
CBF NN NN O
site NN NN O
resulted NN NN O
in NN NN O
a NN NN O
2 NN NN O
- NN NN O
3 NN NN O
- NN NN O
fold NN NN O
decrease NN NN O
in NN NN O
the NN NN O
activities NN NN O
of NN NN O
both NN NN O
a NN NN O
69 NN NN O
- NN NN O
bp NN NN O
proximal NN NN O
promoter NN NN O
fragment NN NN O
and NN NN O
a NN NN O
627 NN NN O
- NN NN O
bp NN NN O
full NN NN O
- NN NN O
length NN NN O
promoter NN NN O
fragment NN NN O
. NN NN O
   
Stepwise NN NN O
deletions NN NN O
into NN NN O
the NN NN O
proximal NN NN O
promoter NN NN O
also NN NN O
revealed NN NN O
that NN NN O
the NN NN O
CBF NN NN O
site NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
YY NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
, NN NN O
was NN NN O
required NN NN O
for NN NN O
efficient NN NN O
induction NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
AML1 NN NN B-Protein
and NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
genes NN NN O
that NN NN O
encode NN NN O
CBF NN NN O
each NN NN O
have NN NN O
the NN NN O
ability NN NN O
to NN NN O
influence NN NN O
cell NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
and NN NN O
have NN NN O
been NN NN O
implicated NN NN O
as NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
in NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
. NN NN O
   
This NN NN O
study NN NN O
adds NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
to NN NN O
a NN NN O
growing NN NN O
list NN NN O
of NN NN O
cytokines NN NN O
and NN NN O
receptors NN NN O
that NN NN O
are NN NN O
regulated NN NN O
by NN NN O
CBF NN NN O
and NN NN O
which NN NN O
control NN NN O
the NN NN O
growth NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
activation NN NN O
of NN NN O
hemopoietic NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
locus NN NN O
may NN NN O
represent NN NN O
one NN NN O
of NN NN O
several NN NN O
target NN NN O
genes NN NN O
that NN NN O
are NN NN O
dysregulated NN NN O
in NN NN O
acute NN NN O
myeloid NN NN O
leukemia NN NN O
. NN NN O
   
Requirements NN NN O
for NN NN O
induction NN NN O
of NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
mediated NN NN O
gene NN NN O
regulation NN NN O
in NN NN O
normal NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Mature NN NN O
human NN NN O
lymphocytes NN NN O
are NN NN O
unique NN NN O
targets NN NN O
of NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
- NN NN O
dihydroxyvitamin NN NN O
D3 NN NN O
( NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
) NN NN O
in NN NN O
that NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptors NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
are NN NN O
not NN NN O
constitutively NN NN O
expressed NN NN O
, NN NN O
and NN NN O
specific NN NN O
cellular NN NN O
activation NN NN O
signals NN NN O
are NN NN O
required NN NN O
for NN NN O
both NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
VDR NN NN B-Protein
and NN NN O
establishment NN NN O
of NN NN O
reactivity NN NN O
to NN NN O
the NN NN O
lipophilic NN NN O
ligand NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
with NN NN O
the NN NN O
cytokine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
prior NN NN O
activation NN NN O
, NN NN O
induces NN NN O
a NN NN O
weak NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
VDR NN NN B-Protein
expression NN NN O
but NN NN O
fails NN NN O
to NN NN O
generate NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
responsive NN NN O
element NN NN O
( NN NN O
VDRE NN NN O
) NN NN O
- NN NN O
reactive NN NN O
nuclear NN NN O
protein NN NN O
complexes NN NN O
or NN NN O
to NN NN O
initiate NN NN O
the NN NN O
genomic NN NN O
transcription NN NN O
of NN NN O
25 NN NN B-Protein
- NN NN I-Protein
hydroxyvitamin NN NN I-Protein
D3 NN NN I-Protein
24 NN NN I-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
. NN NN O
   
Stimulation NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
by NN NN O
either NN NN O
ligation NN NN O
of NN NN O
CD40 NN NN B-Protein
Ag NN NN I-Protein
or NN NN O
cross NN NN O
- NN NN O
linking NN NN O
the NN NN O
Ig NN NN O
receptor NN NN O
is NN NN O
also NN NN O
insufficient NN NN O
to NN NN O
render NN NN O
B NN NN O
lymphocytes NN NN O
responsive NN NN O
to NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
apparent NN NN O
lack NN NN O
of NN NN O
response NN NN O
to NN NN O
the NN NN O
secosterol NN NN O
can NN NN O
be NN NN O
overcome NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
with NN NN O
a NN NN O
combination NN NN O
of NN NN O
these NN NN O
cellular NN NN O
activation NN NN O
signals NN NN O
, NN NN O
which NN NN O
are NN NN O
sufficient NN NN O
to NN NN O
lead NN NN O
to NN NN O
G1 NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
In NN NN O
the NN NN O
presence NN NN O
of NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
, NN NN O
cellular NN NN O
activation NN NN O
associated NN NN O
with NN NN O
stimulation NN NN O
of NN NN O
such NN NN O
a NN NN O
progression NN NN O
appears NN NN O
to NN NN O
be NN NN O
sufficient NN NN O
for NN NN O
the NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
VDR NN NN B-Protein
message NN NN O
and NN NN O
protein NN NN O
and NN NN O
necessary NN NN O
for NN NN O
the NN NN O
establishment NN NN O
of NN NN O
VDRE NN NN O
binding NN NN O
complexes NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
24 NN NN B-Protein
- NN NN I-Protein
hydroxylase NN NN I-Protein
message NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
biologic NN NN O
functions NN NN O
are NN NN O
modulated NN NN O
, NN NN O
in NN NN O
that NN NN O
the NN NN O
hormone NN NN O
inhibits NN NN O
proliferation NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
the NN NN O
activated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
reactivity NN NN O
to NN NN O
1 NN NN O
alpha NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
is NN NN O
tightly NN NN O
regulated NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
, NN NN O
requiring NN NN O
specific NN NN O
signals NN NN O
for NN NN O
its NN NN O
initiation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
on NN NN O
rat NN NN O
macrophages NN NN O
. NN NN O
   
Induction NN NN O
by NN NN O
glucocorticoids NN NN O
and NN NN O
enhancement NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Sialoadhesin NN NN B-Protein
is NN NN O
a NN NN O
macrophage NN NN O
- NN NN O
restricted NN NN O
member NN NN O
of NN NN O
the NN NN O
Ig NN NN O
superfamily NN NN O
that NN NN O
mediates NN NN O
adhesion NN NN O
with NN NN O
lymphoid NN NN O
and NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
is NN NN O
expressed NN NN O
on NN NN O
a NN NN O
subpopulation NN NN O
of NN NN O
macrophages NN NN O
in NN NN O
lymphoid NN NN O
tissues NN NN O
and NN NN O
in NN NN O
chronic NN NN O
inflammation NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
during NN NN O
autoimmune NN NN O
diseases NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
studied NN NN O
the NN NN O
regulation NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
in NN NN O
vitro NN NN O
and NN NN O
show NN NN O
that NN NN O
glucocorticoids NN NN O
( NN NN O
GC NN NN O
) NN NN O
induce NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
on NN NN O
freshly NN NN O
isolated NN NN O
rat NN NN O
macrophages NN NN O
and NN NN O
the NN NN O
rat NN NN O
macrophage NN NN O
cell NN NN O
line NN NN O
R2 NN NN O
. NN NN O
   
The NN NN O
cytokines NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
LPS NN NN O
, NN NN O
although NN NN O
unable NN NN O
to NN NN O
induce NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
by NN NN O
themselves NN NN O
, NN NN O
were NN NN O
able NN NN O
to NN NN O
enhance NN NN O
GC NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
. NN NN O
   
Sialoadhesin NN NN B-Protein
expression NN NN O
was NN NN O
functional NN NN O
as NN NN O
shown NN NN O
by NN NN O
cell NN NN O
adhesion NN NN O
assays NN NN O
with NN NN O
human NN NN O
RBCs NN NN O
. NN NN O
   
Northern NN NN O
blotting NN NN O
experiments NN NN O
indicated NN NN O
that NN NN O
regulation NN NN O
predominantly NN NN O
occurred NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
different NN NN O
combinations NN NN O
of NN NN O
GC NN NN O
and NN NN O
cytokines NN NN O
/ NN NN O
LPS NN NN O
revealed NN NN O
differences NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
GC NN NN O
- NN NN O
dependent NN NN O
enhancement NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
, NN NN O
with NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
being NN NN O
more NN NN O
potent NN NN O
than NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
LPS NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
LPS NN NN O
could NN NN O
be NN NN O
reproduced NN NN O
by NN NN O
priming NN NN O
, NN NN O
whereas NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
were NN NN O
required NN NN O
simultaneously NN NN O
with NN NN O
GC NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
was NN NN O
mediated NN NN O
by NN NN O
the NN NN O
GC NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
and NN NN O
not NN NN O
by NN NN O
mineralocorticoid NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
inhibition NN NN O
experiments NN NN O
with NN NN O
specific NN NN O
antagonists NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
it NN NN O
is NN NN O
demonstrated NN NN O
that NN NN O
macrophages NN NN O
in NN NN O
the NN NN O
adrenal NN NN O
gland NN NN O
, NN NN O
the NN NN O
major NN NN O
site NN NN O
of NN NN O
endogenous NN NN O
GC NN NN O
production NN NN O
, NN NN O
express NN NN O
sialoadhesin NN NN B-Protein
. NN NN O
   
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
GC NN NN O
act NN NN O
as NN NN O
a NN NN O
primary NN NN O
inducer NN NN O
of NN NN O
sialoadhesin NN NN B-Protein
expression NN NN O
on NN NN O
rat NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
response NN NN O
can NN NN O
be NN NN O
enhanced NN NN O
by NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
T NN NN O
cell NN NN O
- NN NN O
derived NN NN O
cytokines NN NN O
, NN NN O
or NN NN O
LPS NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
T NN NN O
cells NN NN O
by NN NN O
NFATp NN NN B-Protein
and NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
/ NN NN O
JUN NN NN O
. NN NN O
   
The NN NN O
human NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
earliest NN NN O
genes NN NN O
transcribed NN NN O
after NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
a NN NN O
B NN NN O
cell NN NN O
through NN NN O
its NN NN O
antigen NN NN O
receptor NN NN O
or NN NN O
via NN NN O
the NN NN O
CD NN NN B-Protein
- NN NN I-Protein
40 NN NN I-Protein
pathway NN NN O
. NN NN O
   
In NN NN O
both NN NN O
cases NN NN O
, NN NN O
induction NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
transcription NN NN O
can NN NN O
be NN NN O
blocked NN NN O
by NN NN O
the NN NN O
immunosuppressants NN NN O
cyclosporin NN NN O
A NN NN O
and NN NN O
FK506 NN NN O
, NN NN O
which NN NN O
suggested NN NN O
a NN NN O
role NN NN O
for NN NN O
the NN NN O
NFAT NN NN O
family NN NN O
of NN NN O
proteins NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
gene NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
two NN NN O
molecules NN NN O
of NN NN O
NFATp NN NN B-Protein
bind NN NN O
to NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
element NN NN O
kappa NN NN O
3 NN NN O
in NN NN O
association NN NN O
with NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
Jun NN NN O
proteins NN NN O
bound NN NN O
to NN NN O
an NN NN O
immediately NN NN O
adjacent NN NN O
cyclic NN NN O
AMP NN NN O
response NN NN O
element NN NN O
( NN NN O
CRE NN NN O
) NN NN O
site NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
using NN NN O
the NN NN O
murine NN NN O
B NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
cell NN NN O
line NN NN O
A20 NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
is NN NN O
regulated NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
In NN NN O
A20 NN NN O
B NN NN O
cells NN NN O
, NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
is NN NN O
not NN NN O
regulated NN NN O
by NN NN O
NFATp NN NN B-Protein
bound NN NN O
to NN NN O
the NN NN O
kappa NN NN O
3 NN NN O
element NN NN O
. NN NN O
   
Instead NN NN O
, NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
Jun NN NN O
proteins NN NN O
bind NN NN O
to NN NN O
the NN NN O
composite NN NN O
kappa NN NN O
3 NN NN O
/ NN NN O
CRE NN NN O
site NN NN O
and NN NN O
NFATp NN NN B-Protein
binds NN NN O
to NN NN O
a NN NN O
newly NN NN O
identified NN NN O
second NN NN O
NFAT NN NN O
site NN NN O
centered NN NN O
at NN NN O
- NN NN O
76 NN NN O
nucleotides NN NN O
relative NN NN O
to NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
This NN NN O
new NN NN O
site NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
calcium NN NN O
- NN NN O
mediated NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
induction NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
both NN NN O
A20 NN NN O
B NN NN O
cells NN NN O
and NN NN O
Ar NN NN O
- NN NN O
5 NN NN O
cells NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
results NN NN O
, NN NN O
quantitative NN NN O
DNase NN NN O
footprinting NN NN O
of NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
using NN NN O
increasing NN NN O
amounts NN NN O
of NN NN O
recombinant NN NN O
NFATp NN NN B-Protein
demonstrated NN NN O
that NN NN O
the NN NN O
- NN NN O
76 NN NN O
site NN NN O
binds NN NN O
to NN NN O
NFATp NN NN B-Protein
with NN NN O
a NN NN O
higher NN NN O
affinity NN NN O
than NN NN O
the NN NN O
kappa NN NN O
3 NN NN O
site NN NN O
. NN NN O
   
Two NN NN O
other NN NN O
previously NN NN O
unrecognized NN NN O
NFATp NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
proximal NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
were NN NN O
also NN NN O
identified NN NN O
by NN NN O
this NN NN O
analysis NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
through NN NN O
the NN NN O
differential NN NN O
use NN NN O
of NN NN O
the NN NN O
same NN NN O
promoter NN NN O
element NN NN O
, NN NN O
the NN NN O
composite NN NN O
kappa NN NN O
3 NN NN O
/ NN NN O
CRE NN NN O
site NN NN O
, NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
is NN NN O
regulated NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
manner NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
same NN NN O
extracellular NN NN O
signal NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
human NN NN B-Protein
retinoic NN NN I-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
by NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
. NN NN O
   
Three NN NN O
subtypes NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
receptors NN NN O
( NN NN O
RAR NN NN O
) NN NN O
, NN NN O
termed NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
RAR NN NN B-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
RAR NN NN B-Protein
gamma NN NN I-Protein
, NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O
   
They NN NN O
are NN NN O
composed NN NN O
of NN NN O
different NN NN O
structural NN NN O
domains NN NN O
, NN NN O
including NN NN O
distinct NN NN O
domains NN NN O
for NN NN O
DNA NN NN O
and NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
RARs NN NN O
specifically NN NN O
bind NN NN O
all NN NN O
- NN NN O
trans NN NN O
- NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
, NN NN O
9 NN NN O
- NN NN O
cis NN NN O
- NN NN O
RA NN NN O
, NN NN O
and NN NN O
retinoid NN NN O
analogs NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
functional NN NN O
role NN NN O
of NN NN O
cysteine NN NN O
and NN NN O
arginine NN NN O
residues NN NN O
in NN NN O
the NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
( NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
- NN NN O
LBD NN NN O
, NN NN O
amino NN NN O
acids NN NN O
154 NN NN O
to NN NN O
462 NN NN O
) NN NN O
. NN NN O
   
All NN NN O
conserved NN NN O
cysteine NN NN O
and NN NN O
arginine NN NN O
residues NN NN O
in NN NN O
this NN NN O
domain NN NN O
were NN NN O
mutated NN NN O
by NN NN O
site NN NN O
- NN NN O
directed NN NN O
mutagenesis NN NN O
, NN NN O
and NN NN O
the NN NN O
mutant NN NN O
proteins NN NN O
were NN NN O
characterized NN NN O
by NN NN O
blocking NN NN O
reactions NN NN O
, NN NN O
ligand NN NN O
- NN NN O
binding NN NN O
experiments NN NN O
, NN NN O
transactivation NN NN O
assays NN NN O
, NN NN O
and NN NN O
protease NN NN O
mapping NN NN O
. NN NN O
   
Changes NN NN O
of NN NN O
any NN NN O
cysteine NN NN O
residue NN NN O
of NN NN O
the NN NN O
hRAR NN NN B-Protein
alpha NN NN I-Protein
- NN NN O
LBD NN NN O
had NN NN O
no NN NN O
significant NN NN O
influence NN NN O
on NN NN O
the NN NN O
binding NN NN O
of NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
or NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
residue NN NN O
C NN NN O
- NN NN O
235 NN NN O
is NN NN O
specifically NN NN O
important NN NN O
in NN NN O
antagonist NN NN O
binding NN NN O
. NN NN O
   
With NN NN O
respect NN NN O
to NN NN O
arginine NN NN O
residues NN NN O
, NN NN O
only NN NN O
the NN NN O
two NN NN O
single NN NN O
mutations NN NN O
of NN NN O
R NN NN O
- NN NN O
276 NN NN O
and NN NN O
R NN NN O
- NN NN O
394 NN NN O
to NN NN O
alanine NN NN O
showed NN NN O
a NN NN O
dramatic NN NN O
decrease NN NN O
of NN NN O
agonist NN NN O
and NN NN O
antagonist NN NN O
binding NN NN O
whereas NN NN O
the NN NN O
R272A NN NN O
mutation NN NN O
showed NN NN O
only NN NN O
a NN NN O
slight NN NN O
effect NN NN O
. NN NN O
   
For NN NN O
all NN NN O
other NN NN O
arginine NN NN O
mutations NN NN O
, NN NN O
no NN NN O
differences NN NN O
in NN NN O
affinity NN NN O
were NN NN O
detectable NN NN O
. NN NN O
   
The NN NN O
two NN NN O
mutations NN NN O
R217A NN NN O
and NN NN O
R294A NN NN O
caused NN NN O
an NN NN O
increased NN NN O
binding NN NN O
efficiency NN NN O
for NN NN O
antagonists NN NN O
but NN NN O
no NN NN O
change NN NN O
in NN NN O
agonist NN NN O
binding NN NN O
. NN NN O
   
From NN NN O
these NN NN O
results NN NN O
, NN NN O
we NN NN O
can NN NN O
conclude NN NN O
that NN NN O
electrostatic NN NN O
interactions NN NN O
of NN NN O
retinoids NN NN O
with NN NN O
the NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
- NN NN O
LBD NN NN O
play NN NN O
a NN NN O
significant NN NN O
role NN NN O
in NN NN O
ligand NN NN O
binding NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
antagonists NN NN O
show NN NN O
distinctly NN NN O
different NN NN O
requirements NN NN O
for NN NN O
efficient NN NN O
binding NN NN O
, NN NN O
which NN NN O
may NN NN O
contribute NN NN O
to NN NN O
their NN NN O
interference NN NN O
in NN NN O
the NN NN O
ligand NN NN O
- NN NN O
inducible NN NN O
transactivation NN NN O
function NN NN O
of NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
. NN NN O
   
Cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
the NN NN O
beta NN NN O
subunit NN NN O
of NN NN O
human NN NN O
proximal NN NN O
sequence NN NN O
element NN NN O
- NN NN O
binding NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
its NN NN O
involvement NN NN O
in NN NN O
transcription NN NN O
of NN NN O
small NN NN B-Protein
nuclear NN NN I-Protein
RNA NN NN I-Protein
genes NN NN O
by NN NN O
RNA NN NN O
polymerases NN NN O
II NN NN O
and NN NN O
III NN NN O
. NN NN O
   
The NN NN O
proximal NN NN O
sequence NN NN O
element NN NN O
( NN NN O
PSE NN NN O
) NN NN O
- NN NN O
binding NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
PTF NN NN O
) NN NN O
, NN NN O
which NN NN O
binds NN NN O
the NN NN O
PSE NN NN O
of NN NN O
both NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
- NN NN O
and NN NN O
RNA NN NN O
polymerase NN NN O
III NN NN O
- NN NN O
transcribed NN NN O
mammalian NN NN O
small NN NN B-Protein
nuclear NN NN I-Protein
RNA NN NN I-Protein
( NN NN O
snRNA NN NN B-Protein
) NN NN O
genes NN NN O
, NN NN O
is NN NN O
essential NN NN O
for NN NN O
their NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
the NN NN O
purification NN NN O
of NN NN O
human NN NN O
PTF NN NN O
, NN NN O
a NN NN O
complex NN NN O
of NN NN O
four NN NN O
subunits NN NN O
, NN NN O
and NN NN O
the NN NN O
molecular NN NN O
cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
PTF NN NN B-Protein
gamma NN NN I-Protein
and NN NN O
delta NN NN B-Protein
subunits NN NN I-Protein
. NN NN O
   
Here NN NN O
we NN NN O
describe NN NN O
the NN NN O
isolation NN NN O
and NN NN O
expression NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
encoding NN NN O
PTF NN NN B-Protein
beta NN NN I-Protein
, NN NN O
as NN NN O
well NN NN O
as NN NN O
functional NN NN O
studies NN NN O
using NN NN O
anti NN NN O
- NN NN O
PTF NN NN B-Protein
beta NN NN I-Protein
antibodies NN NN O
. NN NN O
   
Native NN NN O
PTF NN NN B-Protein
beta NN NN I-Protein
, NN NN O
in NN NN O
either NN NN O
protein NN NN O
fractions NN NN O
or NN NN O
a NN NN O
PTF NN NN O
- NN NN O
Oct NN NN O
- NN NN O
1 NN NN O
- NN NN O
DNA NN NN O
complex NN NN O
, NN NN O
can NN NN O
be NN NN O
recognized NN NN O
by NN NN O
polyclonal NN NN O
antibodies NN NN O
raised NN NN O
against NN NN O
recombinant NN NN O
PTF NN NN B-Protein
beta NN NN I-Protein
. NN NN O
   
Immunodepletion NN NN O
studies NN NN O
show NN NN O
that NN NN O
PTF NN NN B-Protein
beta NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
transcription NN NN O
of NN NN O
both NN NN O
classes NN NN O
of NN NN O
snRNA NN NN B-Protein
genes NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
immunoprecipitation NN NN O
analyses NN NN O
demonstrate NN NN O
that NN NN O
substantial NN NN O
and NN NN O
similar NN NN O
molar NN NN O
amounts NN NN O
of NN NN O
TATA NN NN B-Protein
- NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
( NN NN O
TBP NN NN B-Protein
) NN NN O
and NN NN O
TFIIIB90 NN NN B-Protein
can NN NN O
weakly NN NN O
associate NN NN O
with NN NN O
PTF NN NN O
at NN NN O
low NN NN O
salt NN NN O
conditions NN NN O
, NN NN O
but NN NN O
this NN NN O
association NN NN O
is NN NN O
dramatically NN NN O
reduced NN NN O
at NN NN O
high NN NN O
salt NN NN O
concentrations NN NN O
. NN NN O
   
Along NN NN O
with NN NN O
our NN NN O
previous NN NN O
demonstration NN NN O
of NN NN O
both NN NN O
physical NN NN O
interactions NN NN O
between NN NN O
PTF NN NN B-Protein
gamma NN NN I-Protein
/ NN NN O
PTF NN NN B-Protein
delta NN NN I-Protein
and NN NN O
TBP NN NN B-Protein
and NN NN O
the NN NN O
involvement NN NN O
of NN NN O
TFIIIB90 NN NN B-Protein
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
class NN NN O
III NN NN O
snRNA NN NN B-Protein
genes NN NN O
, NN NN O
these NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
notion NN NN O
that NN NN O
a NN NN O
TBP NN NN B-Protein
- NN NN O
containing NN NN O
complex NN NN O
related NN NN O
to NN NN O
TFIIIB NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
transcription NN NN O
of NN NN O
class NN NN O
III NN NN O
snRNA NN NN B-Protein
genes NN NN O
, NN NN O
and NN NN O
acts NN NN O
through NN NN O
weak NN NN O
interaction NN NN O
with NN NN O
the NN NN O
four NN NN O
- NN NN O
subunit NN NN O
PTF NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
phosphorylated NN NN O
CREB NN NN O
proteins NN NN O
during NN NN O
B NN NN O
- NN NN O
cell NN NN O
activation NN NN O
and NN NN O
rescue NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
Engagement NN NN O
of NN NN O
surface NN NN O
immunoglobulin NN NN O
on NN NN O
mature NN NN O
B NN NN O
cells NN NN O
leads NN NN O
to NN NN O
rescue NN NN O
from NN NN O
apoptosis NN NN O
and NN NN O
to NN NN O
proliferation NN NN O
. NN NN O
   
Levels NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
increase NN NN O
with NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
surface NN NN O
immunoglobulin NN NN O
. NN NN O
   
We NN NN O
have NN NN O
located NN NN O
the NN NN O
major NN NN O
positive NN NN O
regulatory NN NN O
region NN NN O
for NN NN O
control NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
. NN NN O
   
The NN NN O
positive NN NN O
region NN NN O
can NN NN O
be NN NN O
divided NN NN O
into NN NN O
an NN NN O
upstream NN NN O
and NN NN O
a NN NN O
downstream NN NN O
regulatory NN NN O
region NN NN O
. NN NN O
   
The NN NN O
downstream NN NN O
regulatory NN NN O
region NN NN O
contains NN NN O
a NN NN O
cyclic NN NN O
AMP NN NN O
- NN NN O
responsive NN NN O
element NN NN O
( NN NN O
CRE NN NN O
) NN NN O
. NN NN O
   
We NN NN O
show NN NN O
by NN NN O
antibody NN NN O
supershift NN NN O
experiments NN NN O
and NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
followed NN NN O
by NN NN O
denaturing NN NN O
polyacrylamide NN NN O
gel NN NN O
electrophoresis NN NN O
that NN NN O
both NN NN O
CREB NN NN O
and NN NN O
ATF NN NN O
family NN NN O
members NN NN O
bind NN NN O
to NN NN O
this NN NN O
region NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Mutations NN NN O
of NN NN O
the NN NN O
CRE NN NN O
site NN NN O
that NN NN O
result NN NN O
in NN NN O
loss NN NN O
of NN NN O
CREB NN NN O
binding NN NN O
also NN NN O
lead NN NN O
to NN NN O
loss NN NN O
of NN NN O
functional NN NN O
activity NN NN O
of NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
transient NN NN O
- NN NN O
transfection NN NN O
assays NN NN O
. NN NN O
   
The NN NN O
presence NN NN O
of NN NN O
an NN NN O
active NN NN O
CRE NN NN O
site NN NN O
in NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
implies NN NN O
that NN NN O
the NN NN O
regulation NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
is NN NN O
linked NN NN O
to NN NN O
a NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
the NN NN O
mature NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
BAL NN NN O
- NN NN O
17 NN NN O
with NN NN O
either NN NN O
anti NN NN O
- NN NN O
immunoglobulin NN NN O
M NN NN O
or NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
leads NN NN O
to NN NN O
an NN NN O
increase NN NN O
in NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
that NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
CRE NN NN O
site NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
the NN NN O
more NN NN O
immature NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
, NN NN O
Ramos NN NN O
, NN NN O
with NN NN O
phorbol NN NN O
esters NN NN O
rescues NN NN O
the NN NN O
cells NN NN O
from NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
apoptosis NN NN O
. NN NN O
   
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
is NN NN O
increased NN NN O
following NN NN O
phorbol NN NN O
ester NN NN O
treatment NN NN O
, NN NN O
and NN NN O
the NN NN O
increased NN NN O
expression NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
CRE NN NN O
site NN NN O
. NN NN O
   
These NN NN O
stimuli NN NN O
result NN NN O
in NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN O
at NN NN O
serine NN NN O
133 NN NN O
. NN NN O
   
The NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN O
that NN NN O
results NN NN O
in NN NN O
activation NN NN O
is NN NN O
mediated NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
rather NN NN O
than NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
CRE NN NN O
site NN NN O
is NN NN O
necessary NN NN O
, NN NN O
optimal NN NN O
induction NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
requires NN NN O
participation NN NN O
of NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
element NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN O
alters NN NN O
its NN NN O
interaction NN NN O
with NN NN O
the NN NN O
upstream NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
The NN NN O
CRE NN NN O
site NN NN O
in NN NN O
the NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
appears NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
during NN NN O
the NN NN O
activation NN NN O
of NN NN O
mature NN NN O
B NN NN O
cells NN NN O
and NN NN O
during NN NN O
the NN NN O
rescue NN NN O
of NN NN O
immature NN NN O
B NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
. NN NN O
   
It NN NN O
is NN NN O
possible NN NN O
that NN NN O
the NN NN O
CRE NN NN O
site NN NN O
is NN NN O
responsible NN NN O
for NN NN O
induction NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
, NN NN O
particularly NN NN O
those NN NN O
in NN NN O
which NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
is NN NN O
involved NN NN O
. NN NN O
   
E3 NN NN B-Protein
, NN NN O
a NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
transcript NN NN O
directly NN NN O
regulated NN NN O
by NN NN O
the NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
- NN NN O
induced NN NN O
maturation NN NN O
mediated NN NN O
by NN NN O
the NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
) NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
myeloid NN NN O
development NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
differential NN NN O
hybridization NN NN O
analysis NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
library NN NN O
constructed NN NN O
from NN NN O
the NN NN O
murine NN NN O
RA NN NN O
- NN NN O
inducible NN NN O
MPRO NN NN O
promyelocyte NN NN O
cell NN NN O
line NN NN O
to NN NN O
identify NN NN O
immediate NN NN O
- NN NN O
early NN NN O
genes NN NN O
induced NN NN O
by NN NN O
RA NN NN O
during NN NN O
granulocytic NN NN O
differentiation NN NN O
. NN NN O
   
E3 NN NN B-Protein
, NN NN O
one NN NN O
of NN NN O
nine NN NN O
sequences NN NN O
identified NN NN O
, NN NN O
was NN NN O
upregulated NN NN O
in NN NN O
an NN NN O
immediate NN NN O
- NN NN O
early NN NN O
manner NN NN O
, NN NN O
with NN NN O
transcript NN NN O
levels NN NN O
peaking NN NN O
after NN NN O
60 NN NN O
minutes NN NN O
exposure NN NN O
to NN NN O
RA NN NN O
. NN NN O
   
E3 NN NN B-Protein
transcripts NN NN O
were NN NN O
RA NN NN O
- NN NN O
inducible NN NN O
in NN NN O
HL60 NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
an NN NN O
RA NN NN O
- NN NN O
resistant NN NN O
subclone NN NN O
, NN NN O
HL60R NN NN O
, NN NN O
that NN NN O
harbors NN NN O
a NN NN O
mutated NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
HL60R NN NN O
cells NN NN O
were NN NN O
transduced NN NN O
with NN NN O
a NN NN O
functional NN NN O
copy NN NN O
of NN NN O
the NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
gene NN NN O
, NN NN O
RA NN NN O
induced NN NN O
a NN NN O
10 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
E3 NN NN B-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
E3 NN NN B-Protein
transcripts NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
myeloid NN NN O
, NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
, NN NN O
and NN NN O
erythroid NN NN O
lineages NN NN O
, NN NN O
absent NN NN O
in NN NN O
nonhematopoietic NN NN O
cells NN NN O
, NN NN O
and NN NN O
encode NN NN O
a NN NN O
highly NN NN O
hydrophobic NN NN O
, NN NN O
potentially NN NN O
phosphorylated NN NN O
polypeptide NN NN O
of NN NN O
unknown NN NN O
function NN NN O
with NN NN O
significant NN NN O
homology NN NN O
to NN NN O
a NN NN O
putative NN NN O
protein NN NN O
expressed NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
murine NN NN O
E3 NN NN B-Protein
promoter NN NN O
harbors NN NN O
a NN NN O
single NN NN O
bipartite NN NN O
retinoic NN NN O
acid NN NN O
response NN NN O
element NN NN O
which NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
assays NN NN O
conferred NN NN O
RA NN NN O
sensitivity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
E3 NN NN B-Protein
is NN NN O
a NN NN O
hematopoietic NN NN O
- NN NN O
specific NN NN O
gene NN NN O
that NN NN O
is NN NN O
an NN NN O
immediate NN NN O
target NN NN O
for NN NN O
the NN NN O
activated NN NN O
RAR NN NN B-Protein
alpha NN NN I-Protein
during NN NN O
myelopoiesis NN NN O
. NN NN O
   
Transcriptional NN NN O
control NN NN O
of NN NN O
steroid NN NN O
- NN NN O
regulated NN NN O
apoptosis NN NN O
in NN NN O
murine NN NN O
thymoma NN NN O
cells NN NN O
. NN NN O
   
Early NN NN O
studies NN NN O
in NN NN O
murine NN NN O
T NN NN O
cell NN NN O
lines NN NN O
indicated NN NN O
that NN NN O
transcriptional NN NN O
transactivation NN NN O
functions NN NN O
encoded NN NN O
in NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
GR NN NN B-Protein
) NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
are NN NN O
required NN NN O
for NN NN O
glucocorticoid NN NN O
- NN NN O
mediated NN NN O
apoptosis NN NN O
. NN NN O
   
However NN NN O
, NN NN O
more NN NN O
recent NN NN O
studies NN NN O
in NN NN O
human NN NN O
T NN NN O
cell NN NN O
lines NN NN O
have NN NN O
suggested NN NN O
that NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
is NN NN O
not NN NN O
necessary NN NN O
for NN NN O
steroid NN NN O
- NN NN O
regulated NN NN O
apoptosis NN NN O
and NN NN O
that NN NN O
GR NN NN B-Protein
- NN NN O
mediated NN NN O
transrepression NN NN O
may NN NN O
be NN NN O
the NN NN O
more NN NN O
critical NN NN O
mechanism NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
the NN NN O
contribution NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
N NN NN O
- NN NN O
terminal NN NN O
transactivation NN NN O
domain NN NN O
in NN NN O
mediating NN NN O
murine NN NN O
thymocyte NN NN O
apoptosis NN NN O
, NN NN O
we NN NN O
stably NN NN O
transfected NN NN O
GR NN NN B-Protein
, NN NN O
GR NN NN B-Protein
variants NN NN O
, NN NN O
and NN NN O
the NN NN O
androgen NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
AR NN NN B-Protein
) NN NN O
into NN NN O
receptor NN NN O
- NN NN O
negative NN NN O
S49 NN NN O
murine NN NN O
thymoma NN NN O
cells NN NN O
. NN NN O
   
GR NN NN B-Protein
expression NN NN O
levels NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
rate NN NN O
- NN NN O
limiting NN NN O
for NN NN O
initiating NN NN O
the NN NN O
apoptotic NN NN O
pathway NN NN O
, NN NN O
and NN NN O
a NN NN O
positive NN NN O
correlation NN NN O
between NN NN O
steroid NN NN O
sensitivity NN NN O
and NN NN O
GR NN NN B-Protein
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
an NN NN O
integrated NN NN O
mouse NN NN O
mammary NN NN O
tumor NN NN O
virus NN NN O
( NN NN O
MMTV NN NN O
) NN NN O
LTR NN NN O
reporter NN NN O
gene NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
GR NN NN B-Protein
chimeric NN NN O
receptors NN NN O
containing NN NN O
the NN NN O
potent NN NN O
VP16 NN NN B-Protein
and NN NN O
E1A NN NN B-Protein
viral NN NN O
transactivation NN NN O
domains NN NN O
in NN NN O
place NN NN O
of NN NN O
the NN NN O
GR NN NN B-Protein
N NN NN O
terminus NN NN O
revealed NN NN O
that NN NN O
even NN NN O
low NN NN O
level NN NN O
expression NN NN O
of NN NN O
these NN NN O
receptors NN NN O
resulted NN NN O
in NN NN O
both NN NN O
enhanced NN NN O
steroid NN NN O
sensitivity NN NN O
and NN NN O
MMTV NN NN O
induction NN NN O
, NN NN O
thus NN NN O
supporting NN NN O
a NN NN O
role NN NN O
for NN NN O
transactivation NN NN O
in NN NN O
apoptosis NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
AR NN NN B-Protein
can NN NN O
initiate NN NN O
apoptosis NN NN O
in NN NN O
S49 NN NN O
cells NN NN O
after NN NN O
treatment NN NN O
with NN NN O
5 NN NN O
alpha NN NN O
- NN NN O
dihydrotestosterone NN NN O
, NN NN O
despite NN NN O
its NN NN O
relative NN NN O
inability NN NN O
to NN NN O
induce NN NN O
high NN NN O
level NN NN O
expression NN NN O
of NN NN O
MMTV NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
this NN NN O
further NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
steroid NN NN O
- NN NN O
regulated NN NN O
expression NN NN O
of NN NN O
an NN NN O
endogenous NN NN O
thymocyte NN NN O
- NN NN O
specific NN NN O
gene NN NN O
called NN NN O
GIG18 NN NN B-Protein
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
GIG18 NN NN B-Protein
was NN NN O
rapidly NN NN O
induced NN NN O
to NN NN O
comparable NN NN O
levels NN NN O
by NN NN O
both NN NN O
AR NN NN B-Protein
and NN NN O
GR NN NN B-Protein
, NN NN O
demonstrating NN NN O
that NN NN O
AR NN NN B-Protein
can NN NN O
indeed NN NN O
function NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
in NN NN O
S49 NN NN O
cells NN NN O
and NN NN O
, NN NN O
moreover NN NN O
, NN NN O
that NN NN O
GIG18 NN NN B-Protein
induction NN NN O
may NN NN O
be NN NN O
a NN NN O
marker NN NN O
of NN NN O
early NN NN O
apoptotic NN NN O
events NN NN O
in NN NN O
steroid NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
support NN NN O
our NN NN O
conclusion NN NN O
that NN NN O
transcriptional NN NN O
transactivation NN NN O
is NN NN O
a NN NN O
necessary NN NN O
signaling NN NN O
component NN NN O
of NN NN O
S49 NN NN O
cell NN NN O
apoptosis NN NN O
, NN NN O
although NN NN O
an NN NN O
additional NN NN O
role NN NN O
for NN NN O
GR NN NN B-Protein
- NN NN O
mediated NN NN O
transrepression NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
Selenium NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
eukaryotic NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
various NN NN O
inflammatory NN NN O
genes NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
induced NN NN O
by NN NN O
prooxidants NN NN O
and NN NN O
several NN NN O
stimuli NN NN O
eliciting NN NN O
oxidative NN NN O
stress NN NN O
, NN NN O
such NN NN O
as NN NN O
cytokines NN NN O
, NN NN O
lipopolysaccharide NN NN O
, NN NN O
UV NN NN O
irradiation NN NN O
and NN NN O
other NN NN O
mediators NN NN O
. NN NN O
   
Various NN NN O
antioxidants NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
these NN NN O
stimuli NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
selenium NN NN O
, NN NN O
an NN NN O
integral NN NN O
component NN NN O
of NN NN O
glutathione NN NN B-Protein
peroxidase NN NN I-Protein
( NN NN O
GPX NN NN B-Protein
) NN NN O
, NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
selenium NN NN O
- NN NN O
deprived NN NN O
Jurkat NN NN O
and NN NN O
ESb NN NN O
- NN NN O
L NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
supplementation NN NN O
of NN NN O
selenium NN NN O
led NN NN O
to NN NN O
a NN NN O
substantial NN NN O
increase NN NN O
of NN NN O
GPX NN NN B-Protein
activity NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
revealed NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
TNF NN NN O
was NN NN O
significantly NN NN O
inhibited NN NN O
under NN NN O
these NN NN O
conditions NN NN O
. NN NN O
   
Likewise NN NN O
, NN NN O
reporter NN NN O
gene NN NN O
assays NN NN O
using NN NN O
luciferase NN NN O
constructs NN NN O
driven NN NN O
by NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
showed NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
controlled NN NN O
gene NN NN O
expression NN NN O
by NN NN O
selenium NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
selenium NN NN O
were NN NN O
specific NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
since NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
not NN NN O
suppressed NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
selenium NN NN O
supplementation NN NN O
may NN NN O
be NN NN O
used NN NN O
to NN NN O
modulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
target NN NN O
genes NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Transcriptional NN NN O
and NN NN O
posttranscriptional NN NN O
regulation NN NN O
of NN NN O
erythroid NN NN O
gene NN NN O
expression NN NN O
in NN NN O
anthracycline NN NN O
- NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
erythroleukemic NN NN O
cells NN NN O
. NN NN O
   
Aclacinomycin NN NN O
( NN NN O
ACLA NN NN O
) NN NN O
and NN NN O
doxorubicin NN NN O
( NN NN O
DOX NN NN O
) NN NN O
were NN NN O
used NN NN O
at NN NN O
subtoxic NN NN O
concentrations NN NN O
to NN NN O
induce NN NN O
erythroid NN NN O
differentiation NN NN O
in NN NN O
the NN NN O
human NN NN O
leukemic NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
. NN NN O
   
Cell NN NN O
hemoglobinization NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
the NN NN O
increased NN NN O
expression NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
and NN NN O
porphobilinogen NN NN B-Protein
deaminase NN NN I-Protein
( NN NN O
PBGD NN NN B-Protein
) NN NN O
, NN NN O
an NN NN O
enzyme NN NN O
of NN NN O
heme NN NN O
synthesis NN NN O
. NN NN O
   
By NN NN O
using NN NN O
run NN NN O
- NN NN O
on NN NN O
assays NN NN O
, NN NN O
ACLA NN NN O
was NN NN O
shown NN NN O
to NN NN O
induce NN NN O
an NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
transcription NN NN O
of NN NN O
erythroid NN NN O
genes NN NN O
, NN NN O
including NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
, NN NN O
PBGD NN NN B-Protein
, NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factor NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
in NN NN O
DOX NN NN O
- NN NN O
treated NN NN O
cells NN NN O
, NN NN O
the NN NN O
transcription NN NN O
rate NN NN O
of NN NN O
these NN NN O
genes NN NN O
was NN NN O
unchanged NN NN O
in NN NN O
comparison NN NN O
with NN NN O
control NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
mRNA NN NN O
synthesis NN NN O
with NN NN O
actinomycin NN NN O
D NN NN O
indicated NN NN O
that NN NN O
DOX NN NN O
induced NN NN O
an NN NN O
increased NN NN O
stability NN NN O
of NN NN O
PBGD NN NN B-Protein
and NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNAs NN NN O
, NN NN O
whereas NN NN O
ACLA NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
half NN NN O
- NN NN O
lives NN NN O
of NN NN O
these NN NN O
mRNAs NN NN O
. NN NN O
   
Because NN NN O
the NN NN O
increase NN NN O
in NN NN O
erythroid NN NN O
mRNA NN NN O
steady NN NN O
- NN NN O
state NN NN O
level NN NN O
in NN NN O
anthracycline NN NN O
- NN NN O
treated NN NN O
cells NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
cycloheximide NN NN O
, NN NN O
this NN NN O
suggests NN NN O
that NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
ACLA NN NN O
- NN NN O
treated NN NN O
cells NN NN O
and NN NN O
mRNA NN NN O
stabilization NN NN O
in NN NN O
DOX NN NN O
- NN NN O
treated NN NN O
cells NN NN O
were NN NN O
dependent NN NN O
on NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
level NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
increased NN NN O
in NN NN O
ACLA NN NN O
- NN NN O
treated NN NN O
but NN NN O
not NN NN O
in NN NN O
DOX NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
two NN NN O
anthracyclines NN NN O
, NN NN O
although NN NN O
closely NN NN O
related NN NN O
in NN NN O
their NN NN O
structures NN NN O
, NN NN O
appeared NN NN O
to NN NN O
act NN NN O
as NN NN O
differentiation NN NN O
inducers NN NN O
by NN NN O
distinct NN NN O
mechanisms NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
erythroid NN NN O
gene NN NN O
expression NN NN O
was NN NN O
demonstrated NN NN O
to NN NN O
be NN NN O
regulated NN NN O
transcriptionally NN NN O
by NN NN O
ACLA NN NN O
and NN NN O
mainly NN NN O
posttranscriptionally NN NN O
by NN NN O
DOX NN NN O
. NN NN O
   
Human NN NN O
TAFII NN NN B-Protein
105 NN NN I-Protein
is NN NN O
a NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
TFIID NN NN O
subunit NN NN O
related NN NN O
to NN NN O
hTAFII130 NN NN B-Protein
. NN NN O
   
We NN NN O
previously NN NN O
characterized NN NN O
Drosophila NN NN O
and NN NN O
human NN NN O
TAF NN NN O
subunits NN NN O
that NN NN O
make NN NN O
up NN NN O
the NN NN O
core NN NN O
TFIID NN NN O
complex NN NN O
found NN NN O
in NN NN O
all NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
differentiated NN NN O
B NN NN O
cells NN NN O
contain NN NN O
a NN NN O
novel NN NN O
substoichiometric NN NN O
TAF NN NN O
of NN NN O
105 NN NN O
kDa NN NN O
not NN NN O
found NN NN O
associated NN NN O
with NN NN O
TFIID NN NN O
isolated NN NN O
from NN NN O
other NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
encoding NN NN O
hTAFII105 NN NN B-Protein
reveals NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
C NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
shared NN NN O
by NN NN O
hTAFII130 NN NN B-Protein
and NN NN O
oTAFII110 NN NN B-Protein
, NN NN O
while NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
coactivator NN NN O
domain NN NN O
has NN NN O
diverged NN NN O
significantly NN NN O
. NN NN O
   
All NN NN O
cells NN NN O
tested NN NN O
express NN NN O
TAFII105 NN NN B-Protein
mRNA NN NN O
, NN NN O
but NN NN O
only NN NN O
B NN NN O
cells NN NN O
contain NN NN O
significant NN NN O
levels NN NN O
of NN NN O
protein NN NN O
associated NN NN O
with NN NN O
TFIID NN NN O
. NN NN O
   
Transient NN NN O
overexpression NN NN O
of NN NN O
hTAFII105 NN NN B-Protein
selectively NN NN O
squelches NN NN O
the NN NN O
transcription NN NN O
of NN NN O
some NN NN O
genes NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
properties NN NN O
suggest NN NN O
that NN NN O
TAFII105 NN NN B-Protein
is NN NN O
a NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
subunit NN NN O
of NN NN O
TFIID NN NN O
that NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
mediating NN NN O
transcription NN NN O
by NN NN O
a NN NN O
subset NN NN O
of NN NN O
activators NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NK NN NN O
and NN NN O
T NN NN O
cells NN NN O
occurs NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
immediate NN NN O
- NN NN O
early NN NN O
activation NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
responses NN NN O
of NN NN O
lymphocytes NN NN O
to NN NN O
IL NN NN O
- NN NN O
2 NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
involving NN NN O
proliferation NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
, NN NN O
are NN NN O
only NN NN O
partially NN NN O
overlapping NN NN O
, NN NN O
and NN NN O
may NN NN O
depend NN NN O
on NN NN O
induced NN NN O
differential NN NN O
expression NN NN O
of NN NN O
specific NN NN O
sets NN NN O
of NN NN O
genes NN NN O
. NN NN O
   
Using NN NN O
reverse NN NN O
- NN NN O
transcription NN NN O
PCR NN NN O
differential NN NN O
display NN NN O
, NN NN O
we NN NN O
isolated NN NN O
an NN NN O
mRNA NN NN O
species NN NN O
expressed NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
but NN NN O
not NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
stimulated NN NN O
NK NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
was NN NN O
identified NN NN O
as NN NN O
the NN NN O
mRNA NN NN O
encoding NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
expressed NN NN O
with NN NN O
fast NN NN O
kinetics NN NN O
in NN NN O
T NN NN O
and NN NN O
NK NN NN O
cells NN NN O
upon NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
stimulation NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
mRNA NN NN O
- NN NN O
encoding NN NN O
members NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
demonstrated NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
junB NN NN B-Protein
are NN NN O
also NN NN O
expressed NN NN O
upon NN NN O
stimulation NN NN O
of NN NN O
NK NN NN O
and NN NN O
T NN NN O
cells NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
whereas NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
junD NN NN B-Protein
is NN NN O
not NN NN O
modified NN NN O
by NN NN O
either NN NN O
cytokine NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
increased NN NN O
AP NN NN O
- NN NN O
1 NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activity NN NN O
were NN NN O
detected NN NN O
exclusively NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
stimulated NN NN O
cells NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
reported NN NN O
to NN NN O
regulate NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
proliferation NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
induce NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
in NN NN O
NK NN NN O
and NN NN O
T NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
only NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
provide NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
that NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
T NN NN O
and NN NN O
NK NN NN O
cells NN NN O
does NN NN O
not NN NN O
involve NN NN O
expression NN NN O
of NN NN O
members NN NN O
of NN NN O
the NN NN O
immediate NN NN O
- NN NN O
early NN NN O
activation NN NN O
genes NN NN O
family NN NN O
( NN NN O
egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
and NN NN O
junB NN NN B-Protein
) NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
, NN NN O
or NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
This NN NN O
indicates NN NN O
that NN NN O
functional NN NN O
differences NN NN O
observed NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
may NN NN O
depend NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
on NN NN O
differential NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
activator NN NN O
protein NN NN O
( NN NN O
AP NN NN O
) NN NN O
- NN NN O
1 NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
CD28 NN NN B-Protein
stimulation NN NN O
involves NN NN O
both NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
and NN NN O
acidic NN NN B-Protein
sphingomyelinase NN NN I-Protein
signals NN NN O
. NN NN O
   
A NN NN O
major NN NN O
obstacle NN NN O
in NN NN O
understanding NN NN O
the NN NN O
signaling NN NN O
events NN NN O
that NN NN O
follow NN NN O
CD28 NN NN B-Protein
receptor NN NN O
ligation NN NN O
arises NN NN O
from NN NN O
the NN NN O
fact NN NN O
that NN NN O
CD28 NN NN B-Protein
acts NN NN O
as NN NN O
a NN NN O
costimulus NN NN O
to NN NN O
TCR NN NN O
engagement NN NN O
, NN NN O
making NN NN O
it NN NN O
difficult NN NN O
to NN NN O
assess NN NN O
the NN NN O
relative NN NN O
contribution NN NN O
of NN NN O
CD28 NN NN B-Protein
signals NN NN O
as NN NN O
distinct NN NN O
from NN NN O
those NN NN O
of NN NN O
the NN NN O
TCR NN NN O
. NN NN O
   
To NN NN O
overcome NN NN O
this NN NN O
problem NN NN O
, NN NN O
we NN NN O
have NN NN O
exploited NN NN O
the NN NN O
observation NN NN O
that NN NN O
activated NN NN O
human NN NN O
T NN NN O
cell NN NN O
blasts NN NN O
can NN NN O
be NN NN O
stimulated NN NN O
via NN NN O
the NN NN O
CD28 NN NN B-Protein
surface NN NN O
molecule NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
antigenic NN NN O
challenge NN NN O
; NN NN O
thus NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
able NN NN O
to NN NN O
observe NN NN O
the NN NN O
response NN NN O
of NN NN O
normal NN NN O
T NN NN O
cells NN NN O
to NN NN O
CD28 NN NN B-Protein
activation NN NN O
in NN NN O
isolation NN NN O
. NN NN O
   
Using NN NN O
this NN NN O
system NN NN O
, NN NN O
we NN NN O
observed NN NN O
that NN NN O
CD28 NN NN B-Protein
stimulation NN NN O
by NN NN O
B7 NN NN B-Protein
- NN NN O
transfected NN NN O
CHO NN NN O
cells NN NN O
induced NN NN O
a NN NN O
proliferative NN NN O
response NN NN O
in NN NN O
T NN NN O
cells NN NN O
that NN NN O
was NN NN O
not NN NN O
accompanied NN NN O
by NN NN O
measurable NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
However NN NN O
, NN NN O
subsequent NN NN O
analysis NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
generation NN NN O
revealed NN NN O
that NN NN O
B7 NN NN B-Protein
stimulation NN NN O
induced NN NN O
both NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
complexes NN NN O
, NN NN O
but NN NN O
not NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
engagement NN NN O
of NN NN O
the NN NN O
TCR NN NN O
by NN NN O
class NN NN O
II NN NN O
MHC NN NN O
/ NN NN O
superantigen NN NN O
, NN NN O
either NN NN O
with NN NN O
or NN NN O
without NN NN O
CD28 NN NN B-Protein
ligation NN NN O
, NN NN O
resulted NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
as NN NN O
well NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
. NN NN O
   
Using NN NN O
selective NN NN O
inhibitors NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
involved NN NN O
in NN NN O
the NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
This NN NN O
revealed NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
generation NN NN O
was NN NN O
sensitive NN NN O
to NN NN O
chloroquine NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
acidic NN NN B-Protein
sphingomyelinase NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
to NN NN O
the NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
inhibitor NN NN O
, NN NN O
wortmannin NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
generation NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
wortmannin NN NN O
and NN NN O
was NN NN O
also NN NN O
variably NN NN O
sensitive NN NN O
to NN NN O
chloroquine NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
in NN NN O
activated NN NN O
normal NN NN O
T NN NN O
cells NN NN O
, NN NN O
CD28 NN NN B-Protein
- NN NN O
derived NN NN O
signals NN NN O
can NN NN O
stimulate NN NN O
proliferation NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
generation NN NN O
, NN NN O
and NN NN O
that NN NN O
this NN NN O
response NN NN O
uses NN NN O
both NN NN O
acidic NN NN B-Protein
sphingomyelinase NN NN I-Protein
and NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
- NN NN O
linked NN NN O
pathways NN NN O
. NN NN O
   
A NN NN O
critical NN NN O
role NN NN O
of NN NN O
Sp1 NN NN B-Protein
- NN NN O
and NN NN O
Ets NN NN O
- NN NN O
related NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
maintaining NN NN O
CTL NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
mouse NN NN O
perforin NN NN B-Protein
gene NN NN O
. NN NN O
   
This NN NN O
study NN NN O
was NN NN O
designed NN NN O
to NN NN O
determine NN NN O
the NN NN O
potential NN NN O
cis NN NN O
- NN NN O
elements NN NN O
involved NN NN O
in NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
mouse NN NN O
perforin NN NN B-Protein
gene NN NN O
. NN NN O
   
DNase NN NN O
I NN NN O
hypersensitive NN NN O
site NN NN O
( NN NN O
DHS NN NN O
) NN NN O
mapping NN NN O
revealed NN NN O
that NN NN O
the NN NN O
perforin NN NN B-Protein
locus NN NN O
contained NN NN O
six NN NN O
DHS NN NN O
within NN NN O
7 NN NN O
. NN NN O
0 NN NN O
kb NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
sequence NN NN O
( NN NN O
- NN NN O
7 NN NN O
. NN NN O
0 NN NN O
kb NN NN O
) NN NN O
and NN NN O
two NN NN O
DHS NN NN O
in NN NN O
intron NN NN O
2 NN NN O
. NN NN O
   
The NN NN O
six NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
and NN NN O
one NN NN O
intronic NN NN O
DHS NN NN O
were NN NN O
detected NN NN O
in NN NN O
only NN NN O
perforin NN NN B-Protein
- NN NN O
expressing NN NN O
lymphocytes NN NN O
. NN NN O
   
Chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
activities NN NN O
directed NN NN O
by NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
promoter NN NN O
were NN NN O
detected NN NN O
preferentially NN NN O
in NN NN O
perforin NN NN O
- NN NN O
expressing NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
A NN NN O
construct NN NN O
termed NN NN O
PFP5a NN NN O
containing NN NN O
- NN NN O
795 NN NN O
bp NN NN O
exhibited NN NN O
the NN NN O
highest NN NN O
CAT NN NN B-Protein
activity NN NN O
, NN NN O
and NN NN O
PFP9a20 NN NN O
containing NN NN O
only NN NN O
- NN NN O
73 NN NN O
bp NN NN O
also NN NN O
produced NN NN O
significantly NN NN O
high NN NN O
CAT NN NN B-Protein
activity NN NN O
in NN NN O
CTLL NN NN O
- NN NN O
R8 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
proximal NN NN O
region NN NN O
in NN NN O
PFP9a20 NN NN O
contained NN NN O
two NN NN O
potential NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
( NN NN O
GC NN NN O
box NN NN O
and NN NN O
GT NN NN O
box NN NN O
) NN NN O
and NN NN O
one NN NN O
Ets NN NN O
binding NN NN O
site NN NN O
( NN NN O
EBS NN NN O
) NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
showed NN NN O
that NN NN O
each NN NN O
of NN NN O
the NN NN O
cis NN NN O
- NN NN O
elements NN NN O
bound NN NN O
specific NN NN O
protein NN NN O
factors NN NN O
. NN NN O
   
When NN NN O
single NN NN O
- NN NN O
point NN NN O
mutation NN NN O
was NN NN O
introduced NN NN O
to NN NN O
each NN NN O
GC NN NN O
box NN NN O
, NN NN O
EBS NN NN O
, NN NN O
and NN NN O
GT NN NN O
box NN NN O
in NN NN O
PFP9a20 NN NN O
, NN NN O
at NN NN O
least NN NN O
3 NN NN O
- NN NN O
fold NN NN O
less NN NN O
CAT NN NN B-Protein
activity NN NN O
was NN NN O
observed NN NN O
in NN NN O
CTLL NN NN O
- NN NN O
R8 NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
confirm NN NN O
the NN NN O
importance NN NN O
of NN NN O
the NN NN O
three NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
in NN NN O
the NN NN O
perforin NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
point NN NN O
mutation NN NN O
was NN NN O
introduced NN NN O
again NN NN O
to NN NN O
each NN NN O
proximal NN NN O
GC NN NN O
box NN NN O
, NN NN O
EBS NN NN O
, NN NN O
and NN NN O
GT NN NN O
box NN NN O
of NN NN O
PFP5a NN NN O
. NN NN O
   
The NN NN O
point NN NN O
mutations NN NN O
resulted NN NN O
in NN NN O
a NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
to NN NN O
3 NN NN O
- NN NN O
fold NN NN O
reduction NN NN O
of NN NN O
CAT NN NN B-Protein
activity NN NN O
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
combination NN NN O
of NN NN O
the NN NN O
three NN NN O
proximal NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
may NN NN O
constitute NN NN O
a NN NN O
minimal NN NN O
region NN NN O
responsible NN NN O
for NN NN O
CTL NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
perforin NN NN B-Protein
. NN NN O
   
Soluble NN NN O
factors NN NN O
secreted NN NN O
by NN NN O
activated NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
modulate NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
immunosuppressive NN NN O
cytokine NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
in NN NN O
glial NN NN O
cells NN NN O
. NN NN O
   
Coordination NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
to NN NN O
injury NN NN O
or NN NN O
disease NN NN O
in NN NN O
the NN NN O
brain NN NN O
is NN NN O
postulated NN NN O
to NN NN O
involve NN NN O
bi NN NN O
- NN NN O
directional NN NN O
discourse NN NN O
between NN NN O
the NN NN O
immune NN NN O
system NN NN O
and NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
This NN NN O
cross NN NN O
communication NN NN O
involves NN NN O
soluble NN NN O
mediators NN NN O
, NN NN O
including NN NN O
various NN NN O
growth NN NN O
factors NN NN O
, NN NN O
cytokines NN NN O
, NN NN O
and NN NN O
neuropeptides NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
supernatant NN NN O
from NN NN O
activated NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
is NN NN O
able NN NN O
to NN NN O
induce NN NN O
the NN NN O
transcription NN NN O
of NN NN O
a NN NN O
potent NN NN O
cytokine NN NN O
, NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
in NN NN O
glial NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
activating NN NN O
stimulus NN NN O
invokes NN NN O
signaling NN NN O
mechanisms NN NN O
distinct NN NN O
from NN NN O
known NN NN O
kinase NN NN O
or NN NN O
protease NN NN O
pathways NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
correlates NN NN O
with NN NN O
the NN NN O
loss NN NN O
of NN NN O
binding NN NN O
activity NN NN O
for NN NN O
an NN NN O
80 NN NN O
kDA NN NN O
glial NN NN O
labile NN NN O
repressor NN NN O
protein NN NN O
, NN NN O
GLRP NN NN B-Protein
, NN NN O
to NN NN O
a NN NN O
responsive NN NN O
region NN NN O
within NN NN O
the NN NN O
TFG NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Although NN NN O
GLRP NN NN B-Protein
shares NN NN O
some NN NN O
characteristics NN NN O
with NN NN O
the NN NN O
inducible NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
it NN NN O
appears NN NN O
to NN NN O
be NN NN O
distinct NN NN O
from NN NN O
known NN NN O
AP NN NN O
- NN NN O
1 NN NN O
family NN NN O
members NN NN O
. NN NN O
   
These NN NN O
data NN NN O
along NN NN O
with NN NN O
previous NN NN O
observations NN NN O
demonstrating NN NN O
the NN NN O
potent NN NN O
immunosuppressive NN NN O
activity NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
, NN NN O
support NN NN O
a NN NN O
model NN NN O
for NN NN O
a NN NN O
feedback NN NN O
mechanism NN NN O
between NN NN O
the NN NN O
activated NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
and NN NN O
astrocytes NN NN O
via NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
2 NN NN I-Protein
to NN NN O
regulate NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
cytokine NN NN O
and NN NN O
cytokine NN NN O
receptor NN NN O
expression NN NN O
by NN NN O
glucocorticoids NN NN O
. NN NN O
   
Glucocorticoids NN NN O
( NN NN O
GCS NN NN O
) NN NN O
profoundly NN NN O
inhibit NN NN O
several NN NN O
aspects NN NN O
of NN NN O
T NN NN O
cell NN NN O
immunity NN NN O
largely NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
cytokine NN NN O
expression NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
and NN NN O
posttranscriptional NN NN O
levels NN NN O
. NN NN O
   
GCS NN NN O
were NN NN O
also NN NN O
reported NN NN O
to NN NN O
act NN NN O
indirectly NN NN O
by NN NN O
inducing NN NN O
transforming NN NN B-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
expression NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
blocks NN NN O
T NN NN O
cell NN NN O
immunity NN NN O
. NN NN O
   
In NN NN O
exerting NN NN O
their NN NN O
antiproliferative NN NN O
effects NN NN O
, NN NN O
GCS NN NN O
diffuse NN NN O
into NN NN O
target NN NN O
cells NN NN O
where NN NN O
they NN NN O
bind NN NN O
their NN NN O
cytoplasmic NN NN O
receptor NN NN O
, NN NN O
which NN NN O
in NN NN O
turn NN NN O
translocates NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
where NN NN O
it NN NN O
inhibits NN NN O
transcription NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
through NN NN O
direct NN NN O
binding NN NN O
to NN NN O
the NN NN O
glucocorticoid NN NN O
response NN NN O
elements NN NN O
( NN NN O
GRE NN NN O
) NN NN O
, NN NN O
which NN NN O
are NN NN O
located NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
or NN NN O
, NN NN O
alternatively NN NN O
, NN NN O
through NN NN O
antagonism NN NN O
of NN NN O
the NN NN O
action NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
required NN NN O
for NN NN O
optimal NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
their NN NN O
inhibitory NN NN O
effects NN NN O
on NN NN O
cytokine NN NN O
expression NN NN O
, NN NN O
GCS NN NN O
up NN NN O
- NN NN O
regulate NN NN O
cytokine NN NN O
receptor NN NN O
expression NN NN O
that NN NN O
correlates NN NN O
with NN NN O
enhanced NN NN O
cytokine NN NN O
effects NN NN O
on NN NN O
target NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
, NN NN O
we NN NN O
summarize NN NN O
the NN NN O
current NN NN O
state NN NN O
of NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
GCS NN NN O
, NN NN O
including NN NN O
the NN NN O
phenomenon NN NN O
of NN NN O
steroid NN NN O
- NN NN O
induced NN NN O
rebound NN NN O
, NN NN O
which NN NN O
ensues NN NN O
upon NN NN O
GCS NN NN O
withdrawal NN NN O
. NN NN O
   
The NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
factor NN NN O
. NN NN O
   
The NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
factor NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
POU NN NN O
( NN NN O
Pit NN NN O
- NN NN O
Oct NN NN O
- NN NN O
Unc NN NN O
) NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
is NN NN O
expressed NN NN O
only NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
and NN NN O
in NN NN O
neuronal NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
RNA NN NN O
transcript NN NN O
of NN NN O
the NN NN O
gene NN NN O
is NN NN O
subject NN NN O
to NN NN O
alternative NN NN O
splicing NN NN O
to NN NN O
yield NN NN O
different NN NN O
variants NN NN O
which NN NN O
can NN NN O
either NN NN O
activate NN NN O
or NN NN O
repress NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
forms NN NN O
produced NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
have NN NN O
a NN NN O
predominantly NN NN O
activating NN NN O
effect NN NN O
on NN NN O
gene NN NN O
expression NN NN O
whereas NN NN O
those NN NN O
produced NN NN O
in NN NN O
neuronal NN NN O
cells NN NN O
have NN NN O
a NN NN O
predominantly NN NN O
inhibitory NN NN O
effect NN NN O
and NN NN O
can NN NN O
repress NN NN O
the NN NN O
expression NN NN O
of NN NN O
both NN NN O
the NN NN O
herpes NN NN O
simplex NN NN O
virus NN NN O
immediate NN NN O
- NN NN O
early NN NN O
genes NN NN O
and NN NN O
the NN NN O
cellular NN NN O
tyrosine NN NN B-Protein
hydroxylase NN NN I-Protein
gene NN NN O
. NN NN O
   
Thus NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cellular NN NN O
gene NN NN O
expression NN NN O
in NN NN O
both NN NN O
B NN NN O
cells NN NN O
and NN NN O
neuronal NN NN O
cells NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
viral NN NN O
latency NN NN O
. NN NN O
   
Tissue NN NN O
and NN NN O
cell NN NN O
- NN NN O
type NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
tuberous NN NN O
sclerosis NN NN O
gene NN NN O
, NN NN O
TSC2 NN NN B-Protein
, NN NN O
in NN NN O
human NN NN O
tissues NN NN O
. NN NN O
   
TSC2 NN NN B-Protein
is NN NN O
a NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
16p13 NN NN O
. NN NN O
3 NN NN O
associated NN NN O
with NN NN O
the NN NN O
autosomal NN NN O
dominant NN NN O
neurocutaneous NN NN O
disorder NN NN O
, NN NN O
tuberous NN NN O
sclerosis NN NN O
complex NN NN O
( NN NN O
TSC NN NN O
) NN NN O
. NN NN O
   
By NN NN O
using NN NN O
a NN NN O
partial NN NN O
nucleotide NN NN O
sequence NN NN O
from NN NN O
the NN NN O
cloned NN NN O
TSC2 NN NN B-Protein
and NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
methodology NN NN O
, NN NN O
we NN NN O
constructed NN NN O
a NN NN O
digoxigenin NN NN O
- NN NN O
labeled NN NN O
complementary NN NN O
DNA NN NN O
probe NN NN O
to NN NN O
examine NN NN O
TSC2 NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
autopsy NN NN O
- NN NN O
or NN NN O
biopsy NN NN O
- NN NN O
derived NN NN O
human NN NN O
tissues NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O
   
TSC2 NN NN B-Protein
messenger NN NN O
RNA NN NN O
was NN NN O
widely NN NN O
expressed NN NN O
in NN NN O
various NN NN O
cell NN NN O
types NN NN O
throughout NN NN O
the NN NN O
body NN NN O
, NN NN O
including NN NN O
epithelia NN NN O
, NN NN O
lymphocytes NN NN O
, NN NN O
and NN NN O
cells NN NN O
with NN NN O
endocrine NN NN O
functions NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
adrenal NN NN O
cortex NN NN O
and NN NN O
anterior NN NN O
pituitary NN NN O
. NN NN O
   
It NN NN O
was NN NN O
prominently NN NN O
and NN NN O
selectively NN NN O
( NN NN O
within NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
) NN NN O
expressed NN NN O
in NN NN O
pyramidal NN NN O
cells NN NN O
of NN NN O
the NN NN O
cerebral NN NN O
cortex NN NN O
and NN NN O
other NN NN O
motor NN NN O
neurons NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
in NN NN O
spinal NN NN O
cord NN NN O
and NN NN O
brainstem NN NN O
nuclei NN NN O
. NN NN O
   
Visceral NN NN O
TSC2 NN NN B-Protein
expression NN NN O
was NN NN O
comparable NN NN O
in NN NN O
autopsy NN NN O
tissues NN NN O
from NN NN O
patients NN NN O
with NN NN O
and NN NN O
without NN NN O
TSC NN NN O
; NN NN O
TSC2 NN NN B-Protein
messenger NN NN O
RNA NN NN O
expression NN NN O
was NN NN O
most NN NN O
prominent NN NN O
in NN NN O
cells NN NN O
with NN NN O
a NN NN O
rapid NN NN O
mitotic NN NN O
rate NN NN O
and NN NN O
turnover NN NN O
, NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
epithelia NN NN O
and NN NN O
lymphocytes NN NN O
, NN NN O
with NN NN O
central NN NN O
nervous NN NN O
system NN NN O
pyramidal NN NN O
cells NN NN O
and NN NN O
other NN NN O
neurons NN NN O
being NN NN O
an NN NN O
obvious NN NN O
exception NN NN O
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
in NN NN O
cells NN NN O
with NN NN O
important NN NN O
secretory NN NN O
/ NN NN O
transport NN NN O
functions NN NN O
. NN NN O
   
This NN NN O
widespread NN NN O
expression NN NN O
of NN NN O
the NN NN O
TSC2 NN NN B-Protein
gene NN NN O
supports NN NN O
the NN NN O
view NN NN O
that NN NN O
it NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
vital NN NN O
to NN NN O
cell NN NN O
growth NN NN O
and NN NN O
metabolism NN NN O
or NN NN O
one NN NN O
that NN NN O
functions NN NN O
as NN NN O
a NN NN O
tumor NN NN O
/ NN NN O
growth NN NN O
suppressor NN NN O
. NN NN O
   
Cell NN NN O
specific NN NN O
expression NN NN O
of NN NN O
human NN NN O
Bruton NN NN B-Protein
' NN NN I-Protein
s NN NN I-Protein
agammaglobulinemia NN NN I-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
gene NN NN O
( NN NN O
Btk NN NN B-Protein
) NN NN O
is NN NN O
regulated NN NN O
by NN NN O
Sp1 NN NN B-Protein
- NN NN O
and NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
- NN NN O
family NN NN O
members NN NN O
. NN NN O
   
Bruton NN NN B-Protein
' NN NN I-Protein
s NN NN I-Protein
agammaglobulinemia NN NN I-Protein
tyrosine NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
Btk NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
cytoplasmic NN NN O
tyrosine NN NN O
kinase NN NN O
involved NN NN O
in NN NN O
the NN NN O
human NN NN O
disease NN NN O
X NN NN O
- NN NN O
linked NN NN O
agammaglobulinemia NN NN O
( NN NN O
XLA NN NN O
) NN NN O
. NN NN O
   
The NN NN O
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
all NN NN O
hematopoietic NN NN O
cells NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
plasma NN NN O
cells NN NN O
. NN NN O
   
For NN NN O
this NN NN O
expression NN NN O
pattern NN NN O
the NN NN O
first NN NN O
280 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
major NN NN O
transcriptional NN NN O
start NN NN O
site NN NN O
seems NN NN O
to NN NN O
be NN NN O
sufficient NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
footprinting NN NN O
analysis NN NN O
within NN NN O
this NN NN O
part NN NN O
of NN NN O
the NN NN O
promoter NN NN O
revealed NN NN O
two NN NN O
Sp1 NN NN B-Protein
binding NN NN O
sites NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
PU NN NN O
- NN NN O
box NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
as NN NN O
well NN NN O
as NN NN O
the NN NN O
closely NN NN O
related NN NN O
factor NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
bound NN NN O
to NN NN O
the NN NN O
PU NN NN O
- NN NN O
box NN NN O
in NN NN O
B NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
erythroleukemia NN NN O
cell NN NN O
line NN NN O
K562 NN NN O
, NN NN O
due NN NN O
to NN NN O
the NN NN O
absence NN NN O
of NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
, NN NN O
only NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
bound NN NN O
to NN NN O
the NN NN O
Btk NN NN B-Protein
promoter NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
either NN NN O
site NN NN O
reduced NN NN O
the NN NN O
expression NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
However NN NN O
, NN NN O
mutation NN NN O
of NN NN O
the NN NN O
PU NN NN O
box NN NN O
had NN NN O
no NN NN O
effect NN NN O
in NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
, NN NN O
where NN NN O
none NN NN O
of NN NN O
the NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
family NN NN O
members NN NN O
is NN NN O
expressed NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
Spi NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
as NN NN O
well NN NN O
as NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
were NN NN O
able NN NN O
to NN NN O
transactivate NN NN O
Btk NN NN B-Protein
expression NN NN O
. NN NN O
   
In NN NN O
fetal NN NN O
liver NN NN O
of NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
, NN NN O
which NN NN O
lack NN NN O
lymphoid NN NN O
and NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
expression NN NN O
of NN NN O
Btk NN NN B-Protein
was NN NN O
reduced NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
but NN NN O
not NN NN O
abolished NN NN O
. NN NN O
   
Collectively NN NN O
this NN NN O
study NN NN O
shows NN NN O
that NN NN O
expression NN NN O
of NN NN O
the NN NN O
Btk NN NN B-Protein
gene NN NN O
is NN NN O
regulated NN NN O
by NN NN O
the NN NN O
combined NN NN O
action NN NN O
of NN NN O
Sp1 NN NN B-Protein
- NN NN O
and NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
- NN NN O
family NN NN O
members NN NN O
. NN NN O
   
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Stat5 NN NN B-Protein
bind NN NN O
to NN NN O
a NN NN O
critical NN NN O
element NN NN O
in NN NN O
a NN NN O
new NN NN O
enhancer NN NN O
of NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
Mol NN NN O
Cell NN NN O
Biol NN NN O
1997 NN NN O
Apr NN NN O
; NN NN O
17 NN NN O
( NN NN O
4 NN NN O
) NN NN O
: NN NN O
2351 NN NN O
] NN NN O
   
The NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
a NN NN O
key NN NN O
regulator NN NN O
of NN NN O
lymphocyte NN NN O
proliferation NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
rapidly NN NN O
and NN NN O
potently NN NN O
induced NN NN O
in NN NN O
T NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
mitogenic NN NN O
stimuli NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
stimulates NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
, NN NN O
thereby NN NN O
amplifying NN NN O
expression NN NN O
of NN NN O
its NN NN O
own NN NN O
high NN NN O
- NN NN O
affinity NN NN O
receptor NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
is NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
controlled NN NN O
by NN NN O
two NN NN O
positive NN NN O
regulatory NN NN O
regions NN NN O
, NN NN O
PRRI NN NN O
and NN NN O
PRRII NN NN O
. NN NN O
   
PRRI NN NN O
is NN NN O
an NN NN O
inducible NN NN O
proximal NN NN O
enhancer NN NN O
, NN NN O
located NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
276 NN NN O
and NN NN O
- NN NN O
244 NN NN O
, NN NN O
which NN NN O
contains NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
SRE NN NN O
/ NN NN O
CArG NN NN O
motifs NN NN O
. NN NN O
   
PRRII NN NN O
is NN NN O
a NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
, NN NN O
located NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
137 NN NN O
and NN NN O
- NN NN O
64 NN NN O
, NN NN O
which NN NN O
binds NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
Ets NN NN O
protein NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
I NN NN I-Protein
( NN NN I-Protein
Y NN NN I-Protein
) NN NN I-Protein
proteins NN NN O
. NN NN O
   
However NN NN O
, NN NN O
none NN NN O
of NN NN O
these NN NN O
proximal NN NN O
regions NN NN O
account NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
To NN NN O
find NN NN O
new NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
, NN NN O
8 NN NN O
. NN NN O
5 NN NN O
kb NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
end NN NN O
noncoding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
have NN NN O
been NN NN O
sequenced NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
an NN NN O
86 NN NN O
- NN NN O
nucleotide NN NN O
fragment NN NN O
that NN NN O
is NN NN O
90 NN NN O
% NN NN O
identical NN NN O
to NN NN O
the NN NN O
recently NN NN O
characterized NN NN O
murine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
responsive NN NN O
element NN NN O
( NN NN O
mIL NN NN O
- NN NN O
2rE NN NN O
) NN NN O
. NN NN O
   
This NN NN O
putative NN NN O
human NN NN O
IL NN NN O
- NN NN O
2rE NN NN O
, NN NN O
designated NN NN O
PRRIII NN NN O
, NN NN O
confers NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
responsiveness NN NN O
on NN NN O
a NN NN O
heterologous NN NN O
promoter NN NN O
. NN NN O
   
PRRIII NN NN O
contains NN NN O
a NN NN O
Stat NN NN O
protein NN NN O
binding NN NN O
site NN NN O
that NN NN O
overlaps NN NN O
with NN NN O
an NN NN O
EBS NN NN O
motif NN NN O
( NN NN O
GASd NN NN O
/ NN NN O
EBSd NN NN O
) NN NN O
. NN NN O
   
These NN NN O
are NN NN O
essential NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
inducibility NN NN O
of NN NN O
PRRIII NN NN O
/ NN NN O
CAT NN NN B-Protein
reporter NN NN O
constructs NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induced NN NN O
the NN NN O
binding NN NN O
of NN NN O
Stat5a NN NN O
and NN NN O
b NN NN O
proteins NN NN O
to NN NN O
the NN NN O
human NN NN O
GASd NN NN O
element NN NN O
. NN NN O
   
To NN NN O
confirm NN NN O
the NN NN O
physiological NN NN O
relevance NN NN O
of NN NN O
these NN NN O
findings NN NN O
, NN NN O
we NN NN O
carried NN NN O
out NN NN O
in NN NN O
vivo NN NN O
footprinting NN NN O
experiments NN NN O
which NN NN O
showed NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
correlated NN NN O
with NN NN O
occupancy NN NN O
of NN NN O
the NN NN O
GASd NN NN O
element NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
demonstrate NN NN O
a NN NN O
major NN NN O
role NN NN O
of NN NN O
the NN NN O
GASd NN NN O
/ NN NN O
EBSd NN NN O
element NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
alpha NN NN I-Protein
regulation NN NN O
and NN NN O
suggest NN NN O
that NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
factor NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
repressor NN NN O
. NN NN O
   
Sterol NN NN O
dependent NN NN O
LDL NN NN B-Protein
- NN NN I-Protein
receptor NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
normal NN NN O
and NN NN O
CML NN NN O
patients NN NN O
. NN NN O
   
Sterol NN NN O
regulatory NN NN O
element NN NN O
( NN NN O
SRE NN NN O
) NN NN O
has NN NN O
been NN NN O
recognized NN NN O
to NN NN O
regulate NN NN O
various NN NN O
key NN NN O
genes NN NN O
coding NN NN O
for NN NN O
especially NN NN O
low NN NN B-Protein
density NN NN I-Protein
lipoprotein NN NN I-Protein
( NN NN I-Protein
LDL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
receptor NN NN I-Protein
, NN NN O
3 NN NN B-Protein
- NN NN I-Protein
hydroxy NN NN I-Protein
- NN NN I-Protein
3 NN NN I-Protein
- NN NN I-Protein
methylglutaryl NN NN I-Protein
coenzyme NN NN I-Protein
A NN NN I-Protein
( NN NN I-Protein
HMG NN NN I-Protein
- NN NN I-Protein
CoA NN NN I-Protein
) NN NN I-Protein
reductase NN NN I-Protein
and NN NN O
HMG NN NN B-Protein
- NN NN I-Protein
CoA NN NN I-Protein
synthase NN NN I-Protein
known NN NN O
to NN NN O
play NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
cholesterol NN NN O
feedback NN NN O
mechanism NN NN O
. NN NN O
   
The NN NN O
deranged NN NN O
cholesterol NN NN O
feedback NN NN O
mechanism NN NN O
has NN NN O
been NN NN O
widely NN NN O
recognised NN NN O
in NN NN O
initiation NN NN O
as NN NN O
well NN NN O
as NN NN O
progression NN NN O
of NN NN O
various NN NN O
types NN NN O
of NN NN O
cancers NN NN O
including NN NN O
chronic NN NN O
myeloid NN NN O
leukaemia NN NN O
( NN NN O
CML NN NN O
) NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
addressed NN NN O
to NN NN O
understand NN NN O
this NN NN O
phenomenon NN NN O
and NN NN O
revealed NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
unique NN NN O
47 NN NN O
kDa NN NN O
protein NN NN O
factor NN NN O
having NN NN O
affinity NN NN O
for NN NN O
this NN NN O
SRE NN NN O
sequence NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
normal NN NN O
subjects NN NN O
as NN NN O
well NN NN O
as NN NN O
its NN NN O
absence NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
untreated NN NN O
CML NN NN O
patients NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
factor NN NN O
appeared NN NN O
when NN NN O
the NN NN O
CML NN NN O
patients NN NN O
achieved NN NN O
complete NN NN O
haematological NN NN O
remission NN NN O
( NN NN O
CHR NN NN O
) NN NN O
through NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
interferon NN NN I-Protein
therapy NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
an NN NN O
inverse NN NN O
relationship NN NN O
was NN NN O
also NN NN O
observed NN NN O
between NN NN O
sterol NN NN O
modulated NN NN O
LDL NN NN B-Protein
- NN NN I-Protein
receptor NN NN I-Protein
gene NN NN O
transcription NN NN O
and NN NN O
the NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
this NN NN O
47 NN NN O
kDa NN NN O
factor NN NN O
to NN NN O
the NN NN O
SRE NN NN O
sequence NN NN O
. NN NN O
   
Based NN NN O
upon NN NN O
these NN NN O
results NN NN O
we NN NN O
propose NN NN O
that NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
interferon NN NN I-Protein
through NN NN O
its NN NN O
receptor NN NN O
initiates NN NN O
phosphatidic NN NN O
acid NN NN O
dependent NN NN O
signalling NN NN O
which NN NN O
in NN NN O
turn NN NN O
regulates NN NN O
the NN NN O
affinity NN NN O
of NN NN O
47 NN NN O
kDa NN NN O
sterol NN NN O
regulatory NN NN O
element NN NN O
binding NN NN O
factor NN NN O
as NN NN O
well NN NN O
as NN NN O
LDL NN NN B-Protein
- NN NN I-Protein
receptor NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
CML NN NN O
patients NN NN O
. NN NN O
   
Lymphocytes NN NN O
from NN NN O
CML NN NN O
patients NN NN O
lack NN NN O
a NN NN O
47 NN NN O
kDa NN NN O
factor NN NN O
having NN NN O
affinity NN NN O
for NN NN O
a NN NN O
genomic NN NN O
sterol NN NN O
regulatory NN NN O
sequence NN NN O
. NN NN O
   
Deranged NN NN O
cellular NN NN O
cholesterol NN NN O
homeostasis NN NN O
has NN NN O
been NN NN O
widely NN NN O
recognized NN NN O
in NN NN O
the NN NN O
initiation NN NN O
as NN NN O
well NN NN O
as NN NN O
progression NN NN O
of NN NN O
various NN NN O
types NN NN O
of NN NN O
cancers NN NN O
including NN NN O
chronic NN NN O
myeloid NN NN O
leukaemia NN NN O
( NN NN O
CML NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
human NN NN O
genomic NN NN O
sterol NN NN O
regulatory NN NN O
element NN NN O
( NN NN O
SRE NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
regulate NN NN O
various NN NN O
key NN NN O
genes NN NN O
involved NN NN O
in NN NN O
this NN NN O
phenomenon NN NN O
, NN NN O
the NN NN O
present NN NN O
study NN NN O
revealed NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
unique NN NN O
47 NN NN O
kDa NN NN O
protein NN NN O
factor NN NN O
having NN NN O
affinity NN NN O
for NN NN O
this NN NN O
SRE NN NN O
sequence NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
normal NN NN O
subjects NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
its NN NN O
absence NN NN O
in NN NN O
lymphocytes NN NN O
from NN NN O
untreated NN NN O
CML NN NN O
patients NN NN O
. NN NN O
   
However NN NN O
, NN NN O
this NN NN O
factor NN NN O
appeared NN NN O
when NN NN O
these NN NN O
CML NN NN O
patients NN NN O
achieved NN NN O
complete NN NN O
haematological NN NN O
remission NN NN O
( NN NN O
CHR NN NN O
) NN NN O
through NN NN O
alpha NN NN O
- NN NN O
interferon NN NN O
therapy NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
an NN NN O
inverse NN NN O
relationship NN NN O
was NN NN O
also NN NN O
observed NN NN O
between NN NN O
the NN NN O
LDL NN NN B-Protein
receptor NN NN I-Protein
gene NN NN O
expression NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
and NN NN O
the NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
this NN NN O
47 NN NN O
kDa NN NN O
protein NN NN O
factor NN NN O
to NN NN O
the NN NN O
SRE NN NN O
sequence NN NN O
. NN NN O
   
Based NN NN O
upon NN NN O
these NN NN O
results NN NN O
we NN NN O
propose NN NN O
that NN NN O
this NN NN O
factor NN NN O
may NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
pathophysiology NN NN O
of NN NN O
chronic NN NN O
myeloid NN NN O
leukaemia NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
immunosuppressive NN NN O
factor NN NN O
in NN NN O
bovine NN NN O
colostrum NN NN O
blocks NN NN O
activation NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
gene NN NN O
enhancer NN NN O
at NN NN O
the NN NN O
NFAT NN NN O
site NN NN O
. NN NN O
   
A NN NN O
factor NN NN O
in NN NN O
bovine NN NN O
colostrum NN NN O
( NN NN O
colostrum NN NN O
inhibitory NN NN O
factor NN NN O
, NN NN O
CIF NN NN O
) NN NN O
inhibits NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL2 NN NN B-Protein
) NN NN O
production NN NN O
in NN NN O
activated NN NN O
T NN NN O
helper NN NN O
cells NN NN O
by NN NN O
blocking NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
IL2 NN NN B-Protein
mRNA NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
CIF NN NN O
blocks NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
IL2 NN NN B-Protein
transcription NN NN O
, NN NN O
we NN NN O
introduced NN NN O
reporter NN NN O
plasmids NN NN O
into NN NN O
the NN NN O
human NN NN O
T NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
by NN NN O
transient NN NN O
transfection NN NN O
. NN NN O
   
These NN NN O
contained NN NN O
the NN NN O
luciferase NN NN O
gene NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
either NN NN O
the NN NN O
human NN NN O
IL2 NN NN B-Protein
upstream NN NN O
enhancer NN NN O
region NN NN O
( NN NN O
segments NN NN O
- NN NN O
326 NN NN O
to NN NN O
+ NN NN O
45 NN NN O
) NN NN O
or NN NN O
three NN NN O
repeats NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
element NN NN O
contained NN NN O
within NN NN O
it NN NN O
( NN NN O
segments NN NN O
- NN NN O
255 NN NN O
to NN NN O
- NN NN O
285 NN NN O
) NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
luciferase NN NN O
in NN NN O
these NN NN O
cells NN NN O
was NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
plus NN NN O
a NN NN O
calcium NN NN O
ionophore NN NN O
. NN NN O
   
CIF NN NN O
inhibited NN NN O
induction NN NN O
of NN NN O
either NN NN O
construct NN NN O
as NN NN O
did NN NN O
cyclosporine NN NN O
, NN NN O
which NN NN O
is NN NN O
known NN NN O
to NN NN O
block NN NN O
activation NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
element NN NN O
. NN NN O
   
CIF NN NN O
failed NN NN O
to NN NN O
inhibit NN NN O
several NN NN O
other NN NN O
enhancer NN NN O
elements NN NN O
. NN NN O
   
The NN NN O
NFAT NN NN O
- NN NN O
controlled NN NN O
luciferase NN NN O
gene NN NN O
system NN NN O
distinguishes NN NN O
CIF NN NN O
from NN NN O
other NN NN O
T NN NN O
cell NN NN O
inhibitory NN NN O
activities NN NN O
present NN NN O
in NN NN O
colostrum NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
TGF NN NN B-Protein
beta NN NN I-Protein
1 NN NN I-Protein
and NN NN O
TGF NN NN B-Protein
beta NN NN I-Protein
2 NN NN I-Protein
and NN NN O
the NN NN O
glucocorticoids NN NN O
. NN NN O
   
Stably NN NN O
transfected NN NN O
Jurkat NN NN O
cells NN NN O
behaved NN NN O
similarly NN NN O
to NN NN O
the NN NN O
transiently NN NN O
transfected NN NN O
ones NN NN O
with NN NN O
respect NN NN O
to NN NN O
inhibition NN NN O
by NN NN O
CIF NN NN O
and NN NN O
cyclosporine NN NN O
. NN NN O
   
The NN NN O
NFAT NN NN O
- NN NN O
luc NN NN O
assay NN NN O
is NN NN O
a NN NN O
useful NN NN O
technique NN NN O
for NN NN O
the NN NN O
rapid NN NN O
, NN NN O
sensitive NN NN O
measurement NN NN O
of NN NN O
CIF NN NN O
or NN NN O
other NN NN O
immunosuppressants NN NN O
with NN NN O
a NN NN O
similar NN NN O
mode NN NN O
of NN NN O
action NN NN O
. NN NN O
   
Octamer NN NN O
independent NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
from NN NN O
the NN NN O
kappa NN NN O
immunoglobulin NN NN O
germline NN NN O
promoter NN NN O
. NN NN O
   
Previous NN NN O
analyses NN NN O
of NN NN O
immunoglobulin NN NN O
V NN NN O
region NN NN O
promoters NN NN O
has NN NN O
led NN NN O
to NN NN O
the NN NN O
discovery NN NN O
of NN NN O
a NN NN O
common NN NN O
octamer NN NN O
motif NN NN O
which NN NN O
is NN NN O
functionally NN NN O
important NN NN O
in NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
and NN NN O
developmentally NN NN O
regulated NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
immunoglobulin NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
germline NN NN O
promoters NN NN O
( NN NN O
Ko NN NN O
) NN NN O
located NN NN O
upstream NN NN O
of NN NN O
the NN NN O
J NN NN O
region NN NN O
gene NN NN O
segments NN NN O
of NN NN O
the NN NN O
kappa NN NN O
locus NN NN O
also NN NN O
contain NN NN O
an NN NN O
octamer NN NN O
motif NN NN O
( NN NN O
containing NN NN O
a NN NN O
single NN NN O
base NN NN O
pair NN NN O
mutation NN NN O
and NN NN O
referred NN NN O
to NN NN O
as NN NN O
the NN NN O
variant NN NN O
octamer NN NN O
) NN NN O
which NN NN O
has NN NN O
been NN NN O
shown NN NN O
previously NN NN O
to NN NN O
bind NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
factors NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
To NN NN O
further NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
variant NN NN O
octamer NN NN O
motif NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
germline NN NN O
transcription NN NN O
from NN NN O
the NN NN O
unrearranged NN NN O
kappa NN NN O
locus NN NN O
, NN NN O
we NN NN O
have NN NN O
quantitated NN NN O
the NN NN O
relative NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
for NN NN O
the NN NN O
variant NN NN O
octamer NN NN O
motif NN NN O
and NN NN O
determined NN NN O
the NN NN O
functional NN NN O
role NN NN O
of NN NN O
this NN NN O
octamer NN NN O
motif NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
find NN NN O
that NN NN O
, NN NN O
although NN NN O
the NN NN O
variant NN NN O
octamer NN NN O
motif NN NN O
binds NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
vitro NN NN O
with NN NN O
5 NN NN O
- NN NN O
fold NN NN O
lower NN NN O
affinity NN NN O
than NN NN O
the NN NN O
consensus NN NN O
octamer NN NN O
motif NN NN O
, NN NN O
mutation NN NN O
of NN NN O
the NN NN O
variant NN NN O
octamer NN NN O
motif NN NN O
to NN NN O
either NN NN O
a NN NN O
consensus NN NN O
octamer NN NN O
or NN NN O
non NN NN O
- NN NN O
octamer NN NN O
motif NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
transcriptional NN NN O
activation NN NN O
from NN NN O
the NN NN O
germline NN NN O
promoter NN NN O
. NN NN O
   
We NN NN O
also NN NN O
find NN NN O
significant NN NN O
differences NN NN O
in NN NN O
activation NN NN O
of NN NN O
germline NN NN O
and NN NN O
V NN NN O
region NN NN O
promoters NN NN O
by NN NN O
kappa NN NN O
enhancers NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
germline NN NN O
promoters NN NN O
and NN NN O
V NN NN O
region NN NN O
promoters NN NN O
differ NN NN O
in NN NN O
their NN NN O
dependence NN NN O
on NN NN O
octamer NN NN O
for NN NN O
activation NN NN O
and NN NN O
respond NN NN O
differently NN NN O
to NN NN O
enhancer NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
have NN NN O
important NN NN O
implications NN NN O
in NN NN O
regulation NN NN O
of NN NN O
germline NN NN O
transcription NN NN O
as NN NN O
well NN NN O
as NN NN O
concomitant NN NN O
activation NN NN O
of NN NN O
the NN NN O
V NN NN O
- NN NN O
J NN NN O
recombination NN NN O
of NN NN O
the NN NN O
kappa NN NN O
light NN NN O
chain NN NN O
locus NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
murine NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
inhibitor NN NN O
gene NN NN O
p27Kip1 NN NN B-Protein
. NN NN O
   
The NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
inhibitor NN NN O
p27Kip1 NN NN B-Protein
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulating NN NN O
cell NN NN O
- NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
p27Kip1 NN NN B-Protein
directly NN NN O
inhibits NN NN O
the NN NN O
catalytic NN NN O
activity NN NN O
of NN NN O
cyclin NN NN O
/ NN NN O
cdks NN NN O
( NN NN O
cyclin NN NN O
- NN NN O
dependent NN NN O
kinase NN NN O
) NN NN O
complexes NN NN O
and NN NN O
/ NN NN O
or NN NN O
interferes NN NN O
physically NN NN O
with NN NN O
cyclin NN NN O
/ NN NN O
cdks NN NN O
activation NN NN O
by NN NN O
CAK NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
expression NN NN O
level NN NN O
of NN NN O
p27Kip1 NN NN B-Protein
mRNA NN NN O
was NN NN O
maximal NN NN O
in NN NN O
resting NN NN O
Go NN NN O
T NN NN O
- NN NN O
cells NN NN O
and NN NN O
rapidly NN NN O
declined NN NN O
following NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
the NN NN O
cloning NN NN O
of NN NN O
p27Kip1 NN NN B-Protein
gene NN NN O
from NN NN O
murine NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
the NN NN O
functional NN NN O
analysis NN NN O
of NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
p27Kip1 NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
gene NN NN O
consists NN NN O
of NN NN O
at NN NN O
least NN NN O
three NN NN O
exons NN NN O
and NN NN O
spans NN NN O
more NN NN O
than NN NN O
5 NN NN O
. NN NN O
6 NN NN O
kb NN NN O
of NN NN O
DNA NN NN O
. NN NN O
   
Primer NN NN O
extension NN NN O
and NN NN O
nuclease NN NN O
S1 NN NN O
protection NN NN O
analysis NN NN O
revealed NN NN O
two NN NN O
major NN NN O
transcription NN NN O
initiation NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
region NN NN O
lacked NN NN O
a NN NN O
TATA NN NN O
box NN NN O
but NN NN O
contained NN NN O
potential NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
factors NN NN O
including NN NN O
two NN NN O
Sp1 NN NN B-Protein
, NN NN O
CRE NN NN O
, NN NN O
Myb NN NN B-Protein
and NN NN O
NFkB NN NN O
located NN NN O
at NN NN O
positions NN NN O
- NN NN O
153 NN NN O
, NN NN O
- NN NN O
178 NN NN O
, NN NN O
- NN NN O
286 NN NN O
, NN NN O
- NN NN O
875 NN NN O
, NN NN O
and NN NN O
- NN NN O
1011 NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
To NN NN O
analyze NN NN O
the NN NN O
regulatory NN NN O
mechanisms NN NN O
controlling NN NN O
p27Kip1 NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
we NN NN O
characterized NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
from NN NN O
nt NN NN O
- NN NN O
1609 NN NN O
to NN NN O
+ NN NN O
178 NN NN O
. NN NN O
   
The NN NN O
- NN NN O
326 NN NN O
to NN NN O
- NN NN O
615 NN NN O
region NN NN O
contained NN NN O
positive NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
The NN NN O
state NN NN O
of NN NN O
maturation NN NN O
of NN NN O
monocytes NN NN O
into NN NN O
macrophages NN NN O
determines NN NN O
the NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
on NN NN O
HIV NN NN O
replication NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
on NN NN O
HIV NN NN O
infection NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
as NN NN O
they NN NN O
matured NN NN O
into NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
over NN NN O
7 NN NN O
days NN NN O
were NN NN O
investigated NN NN O
using NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
( NN NN O
BaL NN NN O
) NN NN O
, NN NN O
and NN NN O
low NN NN O
passage NN NN O
clinical NN NN O
strains NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
up NN NN O
- NN NN O
regulated NN NN O
the NN NN O
expression NN NN O
of NN NN O
both NN NN O
genomic NN NN O
and NN NN O
spliced NN NN O
HIV NN NN O
mRNA NN NN O
in NN NN O
monocytes NN NN O
cultured NN NN O
on NN NN O
Teflon NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
Northern NN NN O
analysis NN NN O
and NN NN O
p24 NN NN B-Protein
Ag NN NN I-Protein
assay NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
nuclear NN NN O
run NN NN O
- NN NN O
on NN NN O
assay NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
stimulation NN NN O
was NN NN O
shown NN NN O
to NN NN O
enhance NN NN O
transcription NN NN O
by NN NN O
two NN NN O
- NN NN O
to NN NN O
threefold NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
stimulated NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
translocation NN NN O
and NN NN O
binding NN NN O
before NN NN O
enhancement NN NN O
of NN NN O
HIV NN NN O
RNA NN NN O
expression NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
markedly NN NN O
and NN NN O
significantly NN NN O
inhibited NN NN O
HIV NN NN O
replication NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
in NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
this NN NN O
occurred NN NN O
whether NN NN O
these NN NN O
cytokines NN NN O
were NN NN O
added NN NN O
before NN NN O
or NN NN O
after NN NN O
HIV NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
reversal NN NN O
from NN NN O
stimulation NN NN O
to NN NN O
inhibition NN NN O
occurred NN NN O
after NN NN O
3 NN NN O
to NN NN O
5 NN NN O
days NN NN O
of NN NN O
adherence NN NN O
to NN NN O
plastic NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
had NN NN O
no NN NN O
significant NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
reverse NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
both NN NN O
cytokines NN NN O
on NN NN O
the NN NN O
monocyte NN NN O
maturation NN NN O
/ NN NN O
differentiation NN NN O
( NN NN O
CD11b NN NN B-Protein
, NN NN O
CD13 NN NN B-Protein
, NN NN O
and NN NN O
CD26 NN NN B-Protein
) NN NN O
and NN NN O
other NN NN O
macrophage NN NN O
markers NN NN O
( NN NN O
CD14 NN NN B-Protein
and NN NN O
CD68 NN NN B-Protein
) NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
enhanced NN NN O
CD11b NN NN B-Protein
, NN NN O
but NN NN O
inhibited NN NN O
CD26 NN NN B-Protein
expression NN NN O
and NN NN O
delayed NN NN O
CD13 NN NN B-Protein
loss NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
13 NN NN I-Protein
had NN NN O
similar NN NN O
effects NN NN O
on NN NN O
CD11b NN NN B-Protein
and NN NN O
CD13 NN NN B-Protein
, NN NN O
but NN NN O
no NN NN O
effect NN NN O
on NN NN O
CD26 NN NN B-Protein
. NN NN O
   
Hence NN NN O
, NN NN O
these NN NN O
cytokines NN NN O
do NN NN O
not NN NN O
simply NN NN O
enhance NN NN O
monocyte NN NN O
differentiation NN NN O
, NN NN O
but NN NN O
have NN NN O
complex NN NN O
and NN NN O
slightly NN NN O
divergent NN NN O
effects NN NN O
that NN NN O
impact NN NN O
on NN NN O
HIV NN NN O
replication NN NN O
probably NN NN O
through NN NN O
cell NN NN O
signaling NN NN O
pathways NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
translocation NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
in NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
promoter NN NN O
confers NN NN O
preferential NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
keratinocytes NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
in NN NN O
non NN NN O
- NN NN O
monocytic NN NN O
cells NN NN O
, NN NN O
we NN NN O
constructed NN NN O
a NN NN O
series NN NN O
of NN NN O
reporter NN NN O
plasmids NN NN O
with NN NN O
the NN NN O
bacterial NN NN O
chloramphenicol NN NN O
acetyltransferase NN NN O
gene NN NN O
linked NN NN O
to NN NN O
various NN NN O
parts NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
promoter NN NN O
and NN NN O
performed NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
promoter NN NN O
segment NN NN O
that NN NN O
activates NN NN O
transcription NN NN O
most NN NN O
efficiently NN NN O
in NN NN O
keratinocytes NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
with NN NN O
a NN NN O
43 NN NN O
- NN NN O
mer NN NN O
oligonucleotide NN NN O
derived NN NN O
from NN NN O
the NN NN O
functionally NN NN O
identified NN NN O
cis NN NN O
- NN NN O
acting NN NN O
element NN NN O
revealed NN NN O
specific NN NN O
complexes NN NN O
. NN NN O
   
By NN NN O
competition NN NN O
analysis NN NN O
with NN NN O
transcription NN NN O
factor NN NN O
consensus NN NN O
sequence NN NN O
oligonucleotides NN NN O
and NN NN O
by NN NN O
immunosupershift NN NN O
, NN NN O
transcription NN NN O
factor NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
or NN NN O
a NN NN O
closely NN NN O
related NN NN O
protein NN NN O
was NN NN O
shown NN NN O
to NN NN O
bind NN NN O
to NN NN O
this NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
The NN NN O
closest NN NN O
match NN NN O
to NN NN O
the NN NN O
known NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
consensus NN NN O
sequence NN NN O
within NN NN O
the NN NN O
respective NN NN O
region NN NN O
is NN NN O
a NN NN O
TCCCCTCCCCT NN NN O
motif NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
this NN NN O
motif NN NN O
almost NN NN O
completely NN NN O
, NN NN O
and NN NN O
specifically NN NN O
, NN NN O
abolished NN NN O
the NN NN O
binding NN NN O
of NN NN O
two NN NN O
low NN NN O
- NN NN O
mobility NN NN O
complexes NN NN O
and NN NN O
led NN NN O
to NN NN O
a NN NN O
95 NN NN O
% NN NN O
decrease NN NN O
of NN NN O
constitutive NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
- NN NN O
170 NN NN O
/ NN NN O
+ NN NN O
108 NN NN O
) NN NN O
. NN NN O
   
Likewise NN NN O
, NN NN O
activation NN NN O
of NN NN O
this NN NN O
reporter NN NN O
construct NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
depended NN NN O
on NN NN O
the NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
a NN NN O
so NN NN O
- NN NN O
far NN NN O
- NN NN O
unrecognized NN NN O
SP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
in NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
promoter NN NN O
may NN NN O
participate NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
this NN NN O
gene NN NN O
in NN NN O
keratinocytes NN NN O
. NN NN O
   
Engagement NN NN O
of NN NN O
the NN NN O
Lewis NN NN O
X NN NN O
antigen NN NN O
( NN NN O
CD15 NN NN O
) NN NN O
results NN NN O
in NN NN O
monocyte NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
reported NN NN O
that NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
- NN NN O
treated NN NN O
endothelial NN NN O
cells NN NN O
increased NN NN O
expression NN NN O
of NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
and NN NN O
CD36 NN NN B-Protein
on NN NN O
monocytes NN NN O
. NN NN O
   
Using NN NN O
immunological NN NN O
cross NN NN O
- NN NN O
linking NN NN O
to NN NN O
mimic NN NN O
receptor NN NN O
engagement NN NN O
by NN NN O
natural NN NN O
ligands NN NN O
, NN NN O
we NN NN O
now NN NN O
show NN NN O
that NN NN O
CD15 NN NN O
( NN NN O
Lewis NN NN O
X NN NN O
) NN NN O
, NN NN O
a NN NN O
monocyte NN NN O
counter NN NN O
- NN NN O
receptor NN NN O
for NN NN O
endothelial NN NN B-Protein
selectins NN NN I-Protein
may NN NN O
participate NN NN O
in NN NN O
this NN NN O
response NN NN O
. NN NN O
   
We NN NN O
used NN NN O
cytokine NN NN O
production NN NN O
as NN NN O
a NN NN O
readout NN NN O
for NN NN O
monocyte NN NN O
activation NN NN O
and NN NN O
found NN NN O
that NN NN O
CD15 NN NN O
cross NN NN O
- NN NN O
linking NN NN O
induced NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
and NN NN O
cells NN NN O
from NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
MM6 NN NN O
. NN NN O
   
Quantitative NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
showed NN NN O
an NN NN O
increase NN NN O
in NN NN O
steady NN NN O
- NN NN O
state NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
after NN NN O
3 NN NN O
to NN NN O
4 NN NN O
hours NN NN O
of NN NN O
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
CD15 NN NN O
cross NN NN O
- NN NN O
linking NN NN O
also NN NN O
concomitantly NN NN O
increased NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
) NN NN O
mRNA NN NN O
, NN NN O
while NN NN O
no NN NN O
apparent NN NN O
change NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
actin NN NN I-Protein
mRNA NN NN O
, NN NN O
indicating NN NN O
specificity NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
by NN NN O
CD15 NN NN O
engagement NN NN O
, NN NN O
a NN NN O
CAT NN NN B-Protein
plasmid NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
sequences NN NN O
was NN NN O
introduced NN NN O
into NN NN O
MM6 NN NN O
. NN NN O
   
Subsequent NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD15 NN NN O
increased NN NN O
CAT NN NN B-Protein
activity NN NN O
. NN NN O
   
CD15 NN NN O
engagement NN NN O
by NN NN O
monoclonal NN NN O
antibody NN NN O
also NN NN O
attenuated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
transcript NN NN O
degradation NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
signaling NN NN O
via NN NN O
CD15 NN NN O
also NN NN O
had NN NN O
posttranscriptional NN NN O
effects NN NN O
. NN NN O
   
Nuclear NN NN O
extracts NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD15 NN NN O
cross NN NN O
- NN NN O
linked NN NN O
cells NN NN O
demonstrated NN NN O
enhanced NN NN O
levels NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
factor NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
, NN NN O
minimally NN NN O
changed NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
did NN NN O
not NN NN O
affect NN NN O
SV40 NN NN B-Protein
promoter NN NN I-Protein
specific NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
engagement NN NN O
of NN NN O
CD15 NN NN O
on NN NN O
monocytes NN NN O
results NN NN O
in NN NN O
monocyte NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
to NN NN O
its NN NN O
well NN NN O
- NN NN O
recognized NN NN O
adhesive NN NN O
role NN NN O
, NN NN O
CD15 NN NN O
may NN NN O
function NN NN O
as NN NN O
an NN NN O
important NN NN O
signaling NN NN O
molecule NN NN O
capable NN NN O
of NN NN O
initiating NN NN O
proinflammatory NN NN O
events NN NN O
in NN NN O
monocytes NN NN O
that NN NN O
come NN NN O
into NN NN O
contact NN NN O
with NN NN O
activated NN NN O
endothelium NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
and NN NN O
expression NN NN O
in NN NN O
cultured NN NN O
lymphocytes NN NN O
of NN NN O
the NN NN O
human NN NN O
FOSB NN NN B-Protein
gene NN NN O
( NN NN O
G0S3 NN NN B-Protein
) NN NN O
. NN NN O
   
G0S3 NN NN B-Protein
is NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
set NN NN O
of NN NN O
putative NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
switch NN NN O
regulatory NN NN O
genes NN NN O
( NN NN O
G0S NN NN O
genes NN NN O
) NN NN O
selected NN NN O
by NN NN O
screening NN NN O
cDNA NN NN O
libraries NN NN O
prepared NN NN O
from NN NN O
human NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
cultured NN NN O
for NN NN O
2 NN NN O
hr NN NN O
with NN NN O
lectin NN NN O
and NN NN O
cycloheximide NN NN O
. NN NN O
   
The NN NN O
sequence NN NN O
shows NN NN O
high NN NN O
homology NN NN O
with NN NN O
the NN NN O
murine NN NN O
FOSB NN NN B-Protein
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
a NN NN O
component NN NN O
of NN NN O
the NN NN O
AP1 NN NN O
transcriptional NN NN O
regulator NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
cDNA NN NN O
and NN NN O
genomic NN NN O
sequences NN NN O
reveals NN NN O
a NN NN O
4 NN NN O
- NN NN O
exon NN NN O
structure NN NN O
characteristic NN NN O
of NN NN O
the NN NN O
FOS NN NN O
family NN NN O
of NN NN O
genes NN NN O
. NN NN O
   
Freshly NN NN O
isolated NN NN O
cells NN NN O
show NN NN O
high NN NN O
levels NN NN O
of NN NN O
FOSB NN NN B-Protein
/ NN NN O
G0S3 NN NN B-Protein
and NN NN O
FOS NN NN B-Protein
/ NN NN O
G0S7 NN NN B-Protein
mRNAs NN NN O
, NN NN O
which NN NN O
decline NN NN O
rapidly NN NN O
during NN NN O
incubation NN NN O
in NN NN O
culture NN NN O
medium NN NN O
. NN NN O
   
The NN NN O
kinetics NN NN O
of NN NN O
expression NN NN O
suggest NN NN O
that NN NN O
the NN NN O
high NN NN O
initial NN NN O
levels NN NN O
are NN NN O
caused NN NN O
by NN NN O
the NN NN O
isolation NN NN O
procedure NN NN O
, NN NN O
and NN NN O
do NN NN O
not NN NN O
reflect NN NN O
constitutive NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
cells NN NN O
preincubated NN NN O
for NN NN O
a NN NN O
day NN NN O
, NN NN O
levels NN NN O
of NN NN O
FOS NN NN B-Protein
mRNA NN NN O
reach NN NN O
a NN NN O
maximum NN NN O
20 NN NN O
min NN NN O
after NN NN O
the NN NN O
addition NN NN O
of NN NN O
lectin NN NN O
and NN NN O
decline NN NN O
to NN NN O
control NN NN O
levels NN NN O
over NN NN O
the NN NN O
next NN NN O
3 NN NN O
hr NN NN O
. NN NN O
   
Levels NN NN O
of NN NN O
FOSB NN NN B-Protein
mRNA NN NN O
reach NN NN O
a NN NN O
maximum NN NN O
40 NN NN O
min NN NN O
after NN NN O
the NN NN O
addition NN NN O
of NN NN O
lectin NN NN O
and NN NN O
decline NN NN O
to NN NN O
control NN NN O
levels NN NN O
over NN NN O
the NN NN O
next NN NN O
6 NN NN O
hr NN NN O
. NN NN O
   
In NN NN O
freshly NN NN O
isolated NN NN O
cells NN NN O
, NN NN O
both NN NN O
FOS NN NN B-Protein
and NN NN O
FOSB NN NN B-Protein
mRNAs NN NN O
increase NN NN O
dramatically NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
protein NN NN O
synthesis NN NN O
inhibitor NN NN O
cycloheximide NN NN O
. NN NN O
   
In NN NN O
preincubated NN NN O
cells NN NN O
, NN NN O
the NN NN O
cycloheximide NN NN O
response NN NN O
is NN NN O
decreased NN NN O
, NN NN O
especially NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
FOSB NN NN B-Protein
. NN NN O
   
These NN NN O
differences NN NN O
in NN NN O
expression NN NN O
of NN NN O
FOS NN NN B-Protein
and NN NN O
FOSB NN NN B-Protein
suggest NN NN O
different NN NN O
roles NN NN O
and NN NN O
regulation NN NN O
. NN NN O
   
Regions NN NN O
of NN NN O
low NN NN O
base NN NN O
order NN NN O
- NN NN O
dependent NN NN O
stem NN NN O
- NN NN O
loop NN NN O
potential NN NN O
in NN NN O
the NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
are NN NN O
defined NN NN O
. NN NN O
   
These NN NN O
indicate NN NN O
where NN NN O
base NN NN O
order NN NN O
has NN NN O
been NN NN O
adapted NN NN O
for NN NN O
purposes NN NN O
other NN NN O
than NN NN O
stem NN NN O
- NN NN O
loop NN NN O
stability NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
, NN NN O
encoding NN NN O
proteins NN NN O
or NN NN O
gene NN NN O
regulation NN NN O
) NN NN O
. NN NN O
   
Regions NN NN O
of NN NN O
low NN NN O
potential NN NN O
in NN NN O
a NN NN O
68 NN NN O
. NN NN O
5 NN NN O
- NN NN O
kb NN NN O
genomic NN NN O
segment NN NN O
containing NN NN O
the NN NN O
FOSB NN NN B-Protein
gene NN NN O
suggest NN NN O
that NN NN O
the NN NN O
potential NN NN O
may NN NN O
help NN NN O
locate NN NN O
genes NN NN O
in NN NN O
uncharted NN NN O
DNA NN NN O
sequences NN NN O
. NN NN O
   
V3 NN NN O
loop NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
suppresses NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
T NN NN O
cell NN NN O
growth NN NN O
[ NN NN O
published NN NN O
erratum NN NN O
appears NN NN O
in NN NN O
AIDS NN NN O
Res NN NN O
Hum NN NN O
Retroviruses NN NN O
1997 NN NN O
May NN NN O
1 NN NN O
; NN NN O
13 NN NN O
( NN NN O
7 NN NN O
) NN NN O
: NN NN O
633 NN NN O
] NN NN O
   
We NN NN O
tested NN NN O
the NN NN O
effect NN NN O
of NN NN O
three NN NN O
linear NN NN O
or NN NN O
two NN NN O
loop NN NN O
peptides NN NN O
derived NN NN O
from NN NN O
the NN NN O
V3 NN NN O
region NN NN O
of NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
III NN NN O
BH10 NN NN O
clone NN NN O
or NN NN O
the NN NN O
SF2 NN NN O
strain NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
driven NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
V3 NN NN O
- NN NN O
BH10 NN NN O
, NN NN O
which NN NN O
consists NN NN O
of NN NN O
42 NN NN O
amino NN NN O
acids NN NN O
and NN NN O
has NN NN O
a NN NN O
loop NN NN O
structure NN NN O
, NN NN O
suppressed NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
driven NN NN O
proliferation NN NN O
of NN NN O
all NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
cells NN NN O
[ NN NN O
Kit225 NN NN O
, NN NN O
ED NN NN O
- NN NN O
40515 NN NN O
( NN NN O
+ NN NN O
) NN NN O
, NN NN O
KT NN NN O
- NN NN O
3 NN NN O
, NN NN O
7 NN NN O
- NN NN O
day NN NN O
PHA NN NN O
- NN NN O
blasts NN NN O
, NN NN O
and NN NN O
fresh NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
] NN NN O
tested NN NN O
, NN NN O
whereas NN NN O
it NN NN O
did NN NN O
not NN NN O
suppress NN NN O
the NN NN O
cell NN NN O
growth NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
cell NN NN O
lines NN NN O
( NN NN O
Hut102 NN NN O
, NN NN O
Molt NN NN O
- NN NN O
4 NN NN O
, NN NN O
and NN NN O
Jurkat NN NN O
) NN NN O
. NN NN O
   
This NN NN O
suppressive NN NN O
effect NN NN O
was NN NN O
also NN NN O
seen NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
driven NN NN O
cell NN NN O
growth NN NN O
of NN NN O
CD8 NN NN O
- NN NN O
positive NN NN O
lymphocytes NN NN O
purified NN NN O
from NN NN O
7 NN NN O
- NN NN O
day NN NN O
PHA NN NN O
- NN NN O
blasts NN NN O
, NN NN O
indicating NN NN O
that NN NN O
CD4 NN NN B-Protein
molecules NN NN O
were NN NN O
not NN NN O
required NN NN O
for NN NN O
the NN NN O
suppression NN NN O
. NN NN O
   
The NN NN O
treatment NN NN O
with NN NN O
anti NN NN O
- NN NN O
V3 NN NN O
loop NN NN O
monoclonal NN NN O
antibody NN NN O
( NN NN O
902 NN NN O
antibody NN NN O
) NN NN O
completely NN NN O
abolished NN NN O
the NN NN O
suppressive NN NN O
effect NN NN O
of NN NN O
V3 NN NN O
- NN NN O
BH10 NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
V3 NN NN O
- NN NN O
BH10 NN NN O
generated NN NN O
the NN NN O
arrest NN NN O
of NN NN O
Kit225 NN NN O
cells NN NN O
and NN NN O
also NN NN O
purified NN NN O
CD8 NN NN O
- NN NN O
positive NN NN O
lymphocytes NN NN O
in NN NN O
G1 NN NN O
phase NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Neither NN NN O
chromatin NN NN O
condensation NN NN O
nor NN NN O
DNA NN NN O
fragmentation NN NN O
was NN NN O
detected NN NN O
in NN NN O
Kit225 NN NN O
cells NN NN O
cultured NN NN O
with NN NN O
V3 NN NN O
- NN NN O
BH10 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
V3 NN NN O
- NN NN O
BH10 NN NN O
neither NN NN O
blocked NN NN O
radiolabeled NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
to NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptors NN NN O
nor NN NN O
affected NN NN O
tyrosyl NN NN O
phosphorylation NN NN O
of NN NN O
several NN NN O
cellular NN NN O
proteins NN NN O
( NN NN O
p120 NN NN B-Protein
, NN NN O
p98 NN NN B-Protein
, NN NN O
p96 NN NN B-Protein
, NN NN O
p54 NN NN B-Protein
, NN NN O
and NN NN O
p38 NN NN B-Protein
) NN NN O
, NN NN O
which NN NN O
is NN NN O
immediately NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
V3 NN NN O
- NN NN O
BH10 NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
or NN NN O
junB NN NN B-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
binding NN NN O
of NN NN O
V3 NN NN O
loop NN NN O
of NN NN O
gp120 NN NN B-Protein
to NN NN O
the NN NN O
cell NN NN O
surface NN NN O
molecule NN NN O
( NN NN O
s NN NN O
) NN NN O
appears NN NN O
to NN NN O
affect NN NN O
intracellular NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
signaling NN NN O
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
the NN NN O
suppression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
T NN NN O
cell NN NN O
growth NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
stimulated NN NN O
with NN NN O
lipopolysaccharide NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
fibroblast NN NN O
conditioned NN NN O
medium NN NN O
and NN NN O
exogenous NN NN O
PGE2 NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
crucially NN NN O
involved NN NN O
in NN NN O
the NN NN O
gene NN NN O
activation NN NN O
of NN NN O
several NN NN O
cytokines NN NN O
, NN NN O
including NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
) NN NN O
. NN NN O
   
Previously NN NN O
, NN NN O
we NN NN O
showed NN NN O
that NN NN O
fibroblast NN NN O
conditioned NN NN O
medium NN NN O
( NN NN O
FCM NN NN O
) NN NN O
is NN NN O
able NN NN O
to NN NN O
inhibit NN NN O
both NN NN O
TNF NN NN B-Protein
mRNA NN NN O
accumulation NN NN O
and NN NN O
protein NN NN O
release NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
- NN NN O
derived NN NN O
human NN NN O
monocytes NN NN O
( NN NN O
PBM NN NN O
) NN NN O
stimulated NN NN O
with NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
FCM NN NN O
on NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
by NN NN O
means NN NN O
of NN NN O
electrophoretic NN NN O
shift NN NN O
assay NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
FCM NN NN O
strongly NN NN O
inhibits NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
PBM NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
exogenous NN NN O
PGE2 NN NN O
mimics NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitory NN NN O
effect NN NN O
of NN NN O
FCM NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
FCM NN NN O
produced NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
indomethacin NN NN O
does NN NN O
not NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
LPS NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
lend NN NN O
further NN NN O
support NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
inflammatory NN NN O
and NN NN O
immune NN NN O
responses NN NN O
of NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
may NN NN O
be NN NN O
modulated NN NN O
at NN NN O
the NN NN O
molecular NN NN O
level NN NN O
by NN NN O
signals NN NN O
originating NN NN O
from NN NN O
tissue NN NN O
structural NN NN O
cells NN NN O
such NN NN O
as NN NN O
fibroblasts NN NN O
. NN NN O
   
Glycation NN NN O
- NN NN O
dependent NN NN O
, NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
- NN NN O
mediated NN NN O
suppression NN NN O
of NN NN O
the NN NN O
insulin NN NN B-Protein
gene NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
HIT NN NN O
cells NN NN O
. NN NN O
   
Prolonged NN NN O
poor NN NN O
glycemic NN NN O
control NN NN O
in NN NN O
non NN NN O
- NN NN O
insulin NN NN B-Protein
- NN NN O
dependent NN NN O
diabetes NN NN O
mellitus NN NN O
patients NN NN O
often NN NN O
leads NN NN O
to NN NN O
a NN NN O
decline NN NN O
in NN NN O
insulin NN NN B-Protein
secretion NN NN O
from NN NN O
pancreatic NN NN O
beta NN NN O
cells NN NN O
, NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
insulin NN NN O
content NN NN O
of NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
As NN NN O
a NN NN O
step NN NN O
toward NN NN O
elucidating NN NN O
the NN NN O
pathophysiological NN NN O
background NN NN O
of NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
glucose NN NN O
toxicity NN NN O
to NN NN O
pancreatic NN NN O
beta NN NN O
cells NN NN O
, NN NN O
we NN NN O
induced NN NN O
glycation NN NN O
in NN NN O
HIT NN NN O
- NN NN O
T15 NN NN O
cells NN NN O
using NN NN O
a NN NN O
sugar NN NN O
with NN NN O
strong NN NN O
deoxidizing NN NN O
activity NN NN O
, NN NN O
D NN NN O
- NN NN O
ribose NN NN O
, NN NN O
and NN NN O
examined NN NN O
the NN NN O
effects NN NN O
on NN NN O
insulin NN NN B-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
results NN NN O
of NN NN O
reporter NN NN O
gene NN NN O
analyses NN NN O
revealed NN NN O
that NN NN O
the NN NN O
insulin NN NN B-Protein
gene NN NN O
promoter NN NN O
is NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
glycation NN NN O
than NN NN O
the NN NN O
control NN NN O
beta NN NN B-Protein
- NN NN I-Protein
actin NN NN I-Protein
gene NN NN O
promoter NN NN O
; NN NN O
approximately NN NN O
50 NN NN O
and NN NN O
80 NN NN O
% NN NN O
of NN NN O
the NN NN O
insulin NN NN B-Protein
gene NN NN O
promoter NN NN O
activity NN NN O
was NN NN O
lost NN NN O
when NN NN O
the NN NN O
cells NN NN O
were NN NN O
kept NN NN O
for NN NN O
3 NN NN O
d NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
40 NN NN O
and NN NN O
60 NN NN O
mM NN NN O
D NN NN O
- NN NN O
ribose NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
agreement NN NN O
with NN NN O
this NN NN O
, NN NN O
decrease NN NN O
in NN NN O
the NN NN O
insulin NN NN B-Protein
mRNA NN NN O
and NN NN O
insulin NN NN B-Protein
content NN NN O
was NN NN O
observed NN NN O
in NN NN O
the NN NN O
glycation NN NN O
- NN NN O
induced NN NN O
cells NN NN O
. NN NN O
   
Also NN NN O
, NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
analyses NN NN O
using NN NN O
specific NN NN O
antiserum NN NN O
revealed NN NN O
decrease NN NN O
in NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
an NN NN O
insulin NN NN B-Protein
gene NN NN I-Protein
transcription NN NN I-Protein
factor NN NN I-Protein
, NN NN O
PDX NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
IPF1 NN NN B-Protein
/ NN NN O
STF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
These NN NN O
effects NN NN O
of NN NN O
D NN NN O
- NN NN O
ribose NN NN O
seemed NN NN O
almost NN NN O
irreversible NN NN O
but NN NN O
could NN NN O
be NN NN O
prevented NN NN O
by NN NN O
addition NN NN O
of NN NN O
1 NN NN O
mM NN NN O
aminoguanidine NN NN O
or NN NN O
10 NN NN O
mM NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
, NN NN O
thus NN NN O
suggesting NN NN O
that NN NN O
glycation NN NN O
and NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
, NN NN O
generated NN NN O
through NN NN O
the NN NN O
glycation NN NN O
reaction NN NN O
, NN NN O
serve NN NN O
as NN NN O
mediators NN NN O
of NN NN O
the NN NN O
phenomena NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
protein NN NN O
glycation NN NN O
in NN NN O
pancreatic NN NN O
beta NN NN O
cells NN NN O
, NN NN O
which NN NN O
occurs NN NN O
in NN NN O
vivo NN NN O
under NN NN O
chronic NN NN O
hyperglycemia NN NN O
, NN NN O
suppresses NN NN O
insulin NN NN B-Protein
gene NN NN O
transcription NN NN O
and NN NN O
thus NN NN O
can NN NN O
explain NN NN O
part NN NN O
of NN NN O
the NN NN O
beta NN NN O
cell NN NN O
glucose NN NN O
toxicity NN NN O
. NN NN O
   
Differential NN NN O
interaction NN NN O
of NN NN O
nuclear NN NN O
factors NN NN O
with NN NN O
the NN NN O
PRE NN NN O
- NN NN O
I NN NN O
enhancer NN NN O
element NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
in NN NN O
different NN NN O
T NN NN O
cell NN NN O
subsets NN NN O
. NN NN O
   
The NN NN O
immunomodulatory NN NN O
cytokine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
affects NN NN O
cells NN NN O
of NN NN O
most NN NN O
hemopoietic NN NN O
lineages NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
is NN NN O
secreted NN NN O
by NN NN O
activated NN NN O
Th2 NN NN O
but NN NN O
not NN NN O
Th1 NN NN O
cells NN NN O
and NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
immune NN NN O
response NN NN O
by NN NN O
modulating NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
naive NN NN O
Th NN NN O
cells NN NN O
toward NN NN O
the NN NN O
Th2 NN NN O
phenotype NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
identified NN NN O
an NN NN O
enhancer NN NN O
element NN NN O
, NN NN O
PRE NN NN O
- NN NN O
I NN NN O
, NN NN O
that NN NN O
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
nuclear NN NN O
factors NN NN O
binding NN NN O
to NN NN O
the NN NN O
PRE NN NN O
- NN NN O
I NN NN O
site NN NN O
and NN NN O
compared NN NN O
the NN NN O
binding NN NN O
activities NN NN O
of NN NN O
these NN NN O
factors NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
of NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
PRE NN NN O
- NN NN O
I NN NN O
interacts NN NN O
with NN NN O
PMA NN NN O
- NN NN O
and NN NN O
PMA NN NN O
/ NN NN O
ionomycin NN NN O
- NN NN O
inducible NN NN O
, NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
nuclear NN NN O
factors NN NN O
. NN NN O
   
Using NN NN O
anti NN NN O
- NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPbeta NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
) NN NN O
, NN NN O
anti NN NN O
- NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBPdelta NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6beta NN NN I-Protein
) NN NN O
, NN NN O
anti NN NN O
- NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATc NN NN I-Protein
, NN NN O
anti NN NN O
- NN NN O
NF NN NN B-Protein
- NN NN I-Protein
ATp NN NN I-Protein
, NN NN O
anti NN NN O
- NN NN O
Fos NN NN O
, NN NN O
and NN NN O
anti NN NN O
- NN NN O
Jun NN NN O
Abs NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
previously NN NN O
identified NN NN O
PRE NN NN O
- NN NN O
I NN NN O
binding NN NN O
factor NN NN O
POS NN NN O
- NN NN O
1 NN NN O
is NN NN O
composed NN NN O
of NN NN O
different NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
different NN NN O
Th NN NN O
cell NN NN O
subsets NN NN O
. NN NN O
   
In NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
producing NN NN O
Th0 NN NN O
- NN NN O
like NN NN O
human NN NN O
Jurkat NN NN O
and NN NN O
mouse NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
, NN NN O
POS NN NN O
- NN NN O
1 NN NN O
( NN NN O
designated NN NN O
POS NN NN O
- NN NN O
1a NN NN O
) NN NN O
contains NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6beta NN NN I-Protein
and NN NN O
Jun NN NN O
. NN NN O
   
In NN NN O
the NN NN O
mouse NN NN O
Th2 NN NN O
D10 NN NN O
cells NN NN O
and NN NN O
in NN NN O
the NN NN O
human NN NN O
Th2 NN NN O
clones NN NN O
, NN NN O
POS NN NN O
- NN NN O
1 NN NN O
( NN NN O
designated NN NN O
POS NN NN O
- NN NN O
1b NN NN O
) NN NN O
contains NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6beta NN NN I-Protein
, NN NN O
Jun NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
/ NN NN O
p NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
POS NN NN O
- NN NN O
1 NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
human NN NN O
Th1 NN NN O
clones NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
PRE NN NN O
- NN NN O
I NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
differential NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
levels NN NN O
. NN NN O
   
Inhibitory NN NN O
effect NN NN O
of NN NN O
growth NN NN O
hormone NN NN O
on NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
translocation NN NN O
in NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Several NN NN O
studies NN NN O
have NN NN O
pointed NN NN O
to NN NN O
a NN NN O
link NN NN O
between NN NN O
immune NN NN O
and NN NN O
endocrine NN NN O
systems NN NN O
, NN NN O
including NN NN O
a NN NN O
regulatory NN NN O
function NN NN O
of NN NN O
GH NN NN O
on NN NN O
monocyte NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
present NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
human NN NN O
THP NN NN O
- NN NN O
1 NN NN O
promonocytic NN NN O
cells NN NN O
, NN NN O
engineered NN NN O
by NN NN O
gene NN NN O
transfer NN NN O
to NN NN O
constitutively NN NN O
produce NN NN O
human NN NN O
growth NN NN O
hormone NN NN O
( NN NN O
hGH NN NN O
) NN NN O
, NN NN O
secreted NN NN O
depressed NN NN O
amounts NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
challenge NN NN O
by NN NN O
LPS NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
GH NN NN O
appears NN NN O
to NN NN O
occur NN NN O
in NN NN O
an NN NN O
autocrine NN NN O
fashion NN NN O
, NN NN O
since NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
on NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
by NN NN O
constitutive NN NN O
GH NN NN O
production NN NN O
could NN NN O
be NN NN O
abolished NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
anti NN NN O
- NN NN O
hGH NN NN O
mAb NN NN O
. NN NN O
   
The NN NN O
GH NN NN O
- NN NN O
induced NN NN O
inhibitory NN NN O
effect NN NN O
was NN NN O
also NN NN O
observed NN NN O
using NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
by NN NN O
THP NN NN O
- NN NN O
1 NN NN O
- NN NN O
hGH NN NN O
- NN NN O
transfected NN NN O
cells NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
LPS NN NN O
is NN NN O
dependent NN NN O
on NN NN O
a NN NN O
selective NN NN O
pathway NN NN O
, NN NN O
since NN NN O
no NN NN O
inhibition NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
was NN NN O
observed NN NN O
when NN NN O
cells NN NN O
were NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
PMA NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
by NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
THP NN NN O
- NN NN O
1 NN NN O
- NN NN O
hGH NN NN O
cells NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
decrease NN NN O
in NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
capacity NN NN O
of NN NN O
GH NN NN O
to NN NN O
inhibit NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
by NN NN O
monocytes NN NN O
without NN NN O
altering NN NN O
other NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
may NN NN O
be NN NN O
of NN NN O
potential NN NN O
relevance NN NN O
in NN NN O
septic NN NN O
shock NN NN O
, NN NN O
since NN NN O
GH NN NN O
is NN NN O
available NN NN O
for NN NN O
clinical NN NN O
use NN NN O
. NN NN O
   
Impaired NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
genes NN NN O
and NN NN O
of NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
binding NN NN O
distinct NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
promoter NN NN O
elements NN NN O
in NN NN O
activated NN NN O
human NN NN O
T NN NN O
cells NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
transcriptional NN NN O
factor NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
T NN NN O
cell NN NN O
responsiveness NN NN O
and NN NN O
is NN NN O
often NN NN O
impaired NN NN O
in NN NN O
T NN NN O
cells NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
aberrancies NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
at NN NN O
the NN NN O
mRNA NN NN O
or NN NN O
protein NN NN O
level NN NN O
might NN NN O
underlie NN NN O
the NN NN O
age NN NN O
- NN NN O
associated NN NN O
impairments NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Whereas NN NN O
T NN NN O
cells NN NN O
from NN NN O
young NN NN O
subjects NN NN O
stimulated NN NN O
with NN NN O
cross NN NN O
- NN NN O
linked NN NN O
anti NN NN O
- NN NN O
CD3epsilon NN NN B-Protein
mAb NN NN O
OKT3 NN NN O
plus NN NN O
PMA NN NN O
or NN NN O
with NN NN O
the NN NN O
lectin NN NN O
PHA NN NN B-Protein
plus NN NN O
PMA NN NN O
demonstrated NN NN O
considerable NN NN O
increases NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
protein NN NN O
expression NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
but NN NN O
not NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
was NN NN O
markedly NN NN O
reduced NN NN O
in NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
from NN NN O
certain NN NN O
elderly NN NN O
subjects NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
RNase NN NN O
protection NN NN O
assays NN NN O
revealed NN NN O
that NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
from NN NN O
a NN NN O
substantial NN NN O
proportion NN NN O
of NN NN O
elderly NN NN O
subjects NN NN O
exhibited NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
/ NN NN O
or NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
mRNA NN NN O
compared NN NN O
to NN NN O
T NN NN O
cells NN NN O
from NN NN O
young NN NN O
subjects NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
the NN NN O
levels NN NN O
of NN NN O
nuclear NN NN O
regulatory NN NN O
proteins NN NN O
recognizing NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
consensus NN NN O
TRE NN NN O
motif NN NN O
, NN NN O
the NN NN O
proximal NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
TRE NN NN O
- NN NN O
like NN NN O
promoter NN NN O
element NN NN O
, NN NN O
and NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
serum NN NN O
response NN NN O
element NN NN O
( NN NN O
SRE NN NN O
) NN NN O
were NN NN O
determined NN NN O
in NN NN O
resting NN NN O
and NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
from NN NN O
young NN NN O
subjects NN NN O
resulted NN NN O
in NN NN O
coordinated NN NN O
increases NN NN O
of NN NN O
nuclear NN NN O
protein NN NN O
complexes NN NN O
binding NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
TRE NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
TRE NN NN O
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
SRE NN NN O
DNA NN NN O
sequence NN NN O
motifs NN NN O
, NN NN O
age NN NN O
- NN NN O
related NN NN O
reductions NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
were NN NN O
accompanied NN NN O
by NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
TRE NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
SRE NN NN O
binding NN NN O
complexes NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
nuclear NN NN O
protein NN NN O
complexes NN NN O
binding NN NN O
the NN NN O
SRE NN NN O
motif NN NN O
induced NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
of NN NN O
young NN NN O
and NN NN O
elderly NN NN O
subjects NN NN O
contained NN NN O
serum NN NN B-Protein
response NN NN I-Protein
factor NN NN I-Protein
and NN NN O
Elk NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
pointing NN NN O
toward NN NN O
age NN NN O
- NN NN O
related NN NN O
defects NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
transcriptional NN NN O
regulatory NN NN O
proteins NN NN O
distinct NN NN O
from NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
underlying NN NN O
aberrancies NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
as NN NN O
well NN NN O
as NN NN O
their NN NN O
nuclear NN NN O
regulatory NN NN O
proteins NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
age NN NN O
- NN NN O
related NN NN O
impairments NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Interaction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
RFX1 NN NN B-Protein
and NN NN O
MIBP1 NN NN B-Protein
with NN NN O
the NN NN O
gamma NN NN O
motif NN NN O
of NN NN O
the NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
the NN NN O
hepatitis NN NN O
B NN NN O
virus NN NN O
core NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
( NN NN O
NRE NN NN O
) NN NN O
of NN NN O
the NN NN O
hepatitis NN NN O
B NN NN O
virus NN NN O
( NN NN O
HBV NN NN O
) NN NN O
core NN NN O
promoter NN NN O
contains NN NN O
three NN NN O
subregions NN NN O
which NN NN O
act NN NN O
synergistically NN NN O
to NN NN O
suppress NN NN O
core NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
subregions NN NN O
, NN NN O
NRE NN NN O
gamma NN NN O
, NN NN O
is NN NN O
active NN NN O
in NN NN O
both NN NN O
HeLa NN NN O
cervical NN NN O
carcinoma NN NN O
cells NN NN O
and NN NN O
Huh7 NN NN O
hepatoma NN NN O
cells NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
bound NN NN O
by NN NN O
a NN NN O
protein NN NN O
factor NN NN O
present NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
RFX1 NN NN B-Protein
can NN NN O
bind NN NN O
to NN NN O
NRE NN NN O
gamma NN NN O
and NN NN O
transactivate NN NN O
the NN NN O
core NN NN O
promoter NN NN O
through NN NN O
this NN NN O
site NN NN O
. NN NN O
   
Mutations NN NN O
which NN NN O
abrogated NN NN O
the NN NN O
gene NN NN O
- NN NN O
suppressive NN NN O
activity NN NN O
of NN NN O
NRE NN NN O
gamma NN NN O
prevented NN NN O
RFX1 NN NN B-Protein
from NN NN O
binding NN NN O
to NN NN O
NRE NN NN O
gamma NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
RFX1 NN NN B-Protein
can NN NN O
bind NN NN O
simultaneously NN NN O
, NN NN O
most NN NN O
likely NN NN O
as NN NN O
a NN NN O
heterodimer NN NN O
, NN NN O
with NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
MIBP1 NN NN B-Protein
to NN NN O
NRE NN NN O
gamma NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
cloned NN NN O
MIBP1 NN NN B-Protein
gene NN NN O
for NN NN O
further NN NN O
studies NN NN O
, NN NN O
we NN NN O
hypothesize NN NN O
that NN NN O
RFX1 NN NN B-Protein
acts NN NN O
with NN NN O
MIBP1 NN NN B-Protein
to NN NN O
negatively NN NN O
regulate NN NN O
the NN NN O
core NN NN O
promoter NN NN O
activity NN NN O
through NN NN O
the NN NN O
NRE NN NN O
gamma NN NN O
site NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
RFX1 NN NN B-Protein
to NN NN O
transactivate NN NN O
the NN NN O
core NN NN O
promoter NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
RFX1 NN NN B-Protein
may NN NN O
play NN NN O
a NN NN O
dual NN NN O
role NN NN O
in NN NN O
regulating NN NN O
HBV NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Differentiation NN NN O
- NN NN O
dependent NN NN O
expression NN NN O
of NN NN O
a NN NN O
human NN NN O
carboxylesterase NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
and NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
to NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
Carboxylesterases NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
defense NN NN O
and NN NN O
clearance NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
system NN NN O
. NN NN O
   
During NN NN O
the NN NN O
differentiation NN NN O
process NN NN O
of NN NN O
cells NN NN O
from NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
we NN NN O
observed NN NN O
a NN NN O
transient NN NN O
transcriptional NN NN O
upregulation NN NN O
of NN NN O
a NN NN O
human NN NN O
carboxylesterase NN NN O
analyzed NN NN O
by NN NN O
means NN NN O
of NN NN O
Northern NN NN O
blots NN NN O
. NN NN O
   
In NN NN O
PMA NN NN O
- NN NN O
treated NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
we NN NN O
could NN NN O
detect NN NN O
three NN NN O
major NN NN O
transcription NN NN O
initiation NN NN O
sites NN NN O
as NN NN O
revealed NN NN O
by NN NN O
Nuclease NN NN O
Protection NN NN O
Assay NN NN O
carried NN NN O
out NN NN O
with NN NN O
two NN NN O
overlapping NN NN O
antisense NN NN O
RNA NN NN O
probes NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
cloned NN NN O
the NN NN O
carboxylesterase NN NN O
upstream NN NN O
sequence NN NN O
and NN NN O
showed NN NN O
its NN NN O
basal NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
CHO NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
analysis NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
promoter NN NN O
region NN NN O
spanning NN NN O
base NN NN O
pairs NN NN O
- NN NN O
1 NN NN O
to NN NN O
- NN NN O
275 NN NN O
, NN NN O
which NN NN O
contains NN NN O
several NN NN O
putative NN NN O
binding NN NN O
sites NN NN O
for NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
is NN NN O
bound NN NN O
by NN NN O
nuclear NN NN O
factors NN NN O
Sp1 NN NN B-Protein
and NN NN O
IRBP NN NN B-Protein
but NN NN O
not NN NN O
by NN NN O
C NN NN O
/ NN NN O
EBPs NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
carboxylesterase NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
starts NN NN O
at NN NN O
multiple NN NN O
initiation NN NN O
sites NN NN O
and NN NN O
that NN NN O
Sp1 NN NN B-Protein
and NN NN O
IRBP NN NN B-Protein
may NN NN O
be NN NN O
critical NN NN O
factors NN NN O
for NN NN O
modulating NN NN O
the NN NN O
differentiation NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
of NN NN O
this NN NN O
human NN NN O
carboxylesterase NN NN O
gene NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
human NN NN O
platelet NN NN B-Protein
/ NN NN I-Protein
endothelial NN NN I-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
: NN NN O
identification NN NN O
of NN NN O
a NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
element NN NN O
required NN NN O
for NN NN O
optimal NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
Platelet NN NN B-Protein
/ NN NN I-Protein
endothelial NN NN I-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
130 NN NN O
- NN NN O
kD NN NN O
member NN NN O
of NN NN O
the NN NN O
Ig NN NN O
gene NN NN O
superfamily NN NN O
that NN NN O
is NN NN O
expressed NN NN O
on NN NN O
platelets NN NN O
, NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
certain NN NN O
leukocyte NN NN O
subsets NN NN O
. NN NN O
   
To NN NN O
examine NN NN O
the NN NN O
factors NN NN O
controlling NN NN O
vascular NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
we NN NN O
cloned NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
flanking NN NN O
region NN NN O
of NN NN O
the NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
and NN NN O
analyzed NN NN O
its NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
5 NN NN O
' NN NN O
- NN NN O
Rapid NN NN O
amplification NN NN O
of NN NN O
cDNA NN NN O
ends NN NN O
( NN NN O
5 NN NN O
' NN NN O
- NN NN O
RACE NN NN O
) NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
transcription NN NN O
initiation NN NN O
occurred NN NN O
at NN NN O
several NN NN O
closely NN NN O
spaced NN NN O
nearby NN NN O
sites NN NN O
originating NN NN O
approximately NN NN O
204 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
translation NN NN O
start NN NN O
site NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
sequence NN NN O
immediately NN NN O
upstream NN NN O
from NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
( NN NN O
TIS NN NN O
) NN NN O
showed NN NN O
no NN NN O
canonical NN NN O
TATA NN NN O
or NN NN O
CAAT NN NN O
elements NN NN O
, NN NN O
however NN NN O
an NN NN O
initiator NN NN O
element NN NN O
commonly NN NN O
found NN NN O
in NN NN O
TATA NN NN O
- NN NN O
less NN NN O
promoters NN NN O
encompassed NN NN O
the NN NN O
TIS NN NN O
. NN NN O
   
5 NN NN O
' NN NN O
- NN NN O
serially NN NN O
truncated NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
segments NN NN O
cloned NN NN O
in NN NN O
front NN NN O
of NN NN O
a NN NN O
luciferase NN NN O
reporter NN NN O
drove NN NN O
transcription NN NN O
in NN NN O
both NN NN O
a NN NN O
lineage NN NN O
- NN NN O
and NN NN O
orientation NN NN O
- NN NN O
specific NN NN O
manner NN NN O
. NN NN O
   
Putative NN NN O
cis NN NN O
- NN NN O
acting NN NN O
control NN NN O
elements NN NN O
present NN NN O
within NN NN O
a NN NN O
300 NN NN O
- NN NN O
bp NN NN O
core NN NN O
promoter NN NN O
included NN NN O
two NN NN O
ets NN NN B-Protein
sites NN NN O
, NN NN O
an NN NN O
Sp1 NN NN B-Protein
site NN NN O
, NN NN O
tandem NN NN O
E NN NN O
- NN NN O
box NN NN O
domains NN NN O
, NN NN O
two NN NN O
GATA NN NN O
- NN NN O
associated NN NN O
sites NN NN O
( NN NN O
CACCC NN NN O
) NN NN O
, NN NN O
an NN NN O
AP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
site NN NN O
, NN NN O
and NN NN O
a NN NN O
GATA NN NN O
element NN NN O
at NN NN O
- NN NN O
24 NN NN O
. NN NN O
   
Mutational NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
optimal NN NN O
transcriptional NN NN O
activity NN NN O
required NN NN O
the NN NN O
GATA NN NN O
sequence NN NN O
at NN NN O
position NN NN O
- NN NN O
24 NN NN O
, NN NN O
and NN NN O
gel NN NN O
- NN NN O
shift NN NN O
assays NN NN O
further NN NN O
showed NN NN O
that NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
transcription NN NN O
factor NN NN O
, NN NN O
but NN NN O
not NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
bound NN NN O
to NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Understanding NN NN O
the NN NN O
cis NN NN O
- NN NN O
and NN NN O
transacting NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
the NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
should NN NN O
increase NN NN O
our NN NN O
understanding NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
vascular NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
is NN NN O
achieved NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
in NN NN O
megakaryoblastic NN NN O
disorders NN NN O
. NN NN O
   
Currently NN NN O
available NN NN O
data NN NN O
indicate NN NN O
that NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
differentiation NN NN O
pathways NN NN O
are NN NN O
closely NN NN O
related NN NN O
to NN NN O
each NN NN O
other NN NN O
, NN NN O
and NN NN O
there NN NN O
may NN NN O
exist NN NN O
progenitor NN NN O
cells NN NN O
common NN NN O
to NN NN O
those NN NN O
two NN NN O
lineages NN NN O
may NN NN O
exist NN NN O
. NN NN O
   
Acute NN NN O
megakaryoblastic NN NN O
leukemia NN NN O
( NN NN O
AML NN NN O
- NN NN O
M7 NN NN O
) NN NN O
and NN NN O
transient NN NN O
myeloproliferative NN NN O
disorder NN NN O
in NN NN O
Down NN NN O
' NN NN O
s NN NN O
syndrome NN NN O
( NN NN O
TMD NN NN O
) NN NN O
are NN NN O
characterized NN NN O
by NN NN O
rapid NN NN O
growth NN NN O
of NN NN O
abnormal NN NN O
blast NN NN O
cells NN NN O
which NN NN O
express NN NN O
megakaryocytic NN NN O
markers NN NN O
. NN NN O
   
These NN NN O
blast NN NN O
cells NN NN O
express NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
such NN NN O
as NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
common NN NN O
to NN NN O
these NN NN O
lineages NN NN O
and NN NN O
frequently NN NN O
express NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
mRNAs NN NN O
such NN NN O
as NN NN O
gamma NN NN O
- NN NN O
globin NN NN O
and NN NN O
erythroid NN NN B-Protein
delta NN NN I-Protein
- NN NN I-Protein
aminolevulinate NN NN I-Protein
synthase NN NN I-Protein
( NN NN O
ALAS NN NN B-Protein
- NN NN I-Protein
E NN NN I-Protein
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
most NN NN O
of NN NN O
the NN NN O
blasts NN NN O
in NN NN O
M7 NN NN O
and NN NN O
TMD NN NN O
cases NN NN O
have NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
phenotypes NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
blasts NN NN O
in NN NN O
M7 NN NN O
and NN NN O
TMD NN NN O
may NN NN O
correspond NN NN O
to NN NN O
progenitors NN NN O
of NN NN O
both NN NN O
erythroid NN NN O
and NN NN O
megakaryocytic NN NN O
lineages NN NN O
. NN NN O
   
Cloning NN NN O
of NN NN O
the NN NN O
novel NN NN O
human NN NN O
myeloid NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
- NN NN O
epsilon NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Chicken NN NN O
NF NN NN B-Protein
- NN NN I-Protein
M NN NN I-Protein
transcription NN NN O
factor NN NN O
, NN NN O
in NN NN O
cooperation NN NN O
with NN NN O
either NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
or NN NN O
v NN NN O
- NN NN O
Myb NN NN O
, NN NN O
is NN NN O
active NN NN O
in NN NN O
the NN NN O
combinatorial NN NN O
activation NN NN O
of NN NN O
myeloid NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
in NN NN O
heterologous NN NN O
cell NN NN O
types NN NN O
, NN NN O
such NN NN O
as NN NN O
embryonic NN NN O
fibroblasts NN NN O
. NN NN O
   
In NN NN O
humans NN NN O
, NN NN O
similar NN NN O
effects NN NN O
were NN NN O
observed NN NN O
with NN NN O
homologous NN NN O
members NN NN O
of NN NN O
the NN NN O
CCAAT NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
) NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
, NN NN O
especially NN NN O
the NN NN O
human NN NN O
homolog NN NN O
of NN NN O
chicken NN NN O
NF NN NN B-Protein
- NN NN I-Protein
M NN NN I-Protein
, NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
) NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
nonmyeloid NN NN O
cell NN NN O
types NN NN O
and NN NN O
is NN NN O
strongly NN NN O
inducible NN NN O
in NN NN O
response NN NN O
to NN NN O
inflammatory NN NN O
stimuli NN NN O
, NN NN O
making NN NN O
it NN NN O
an NN NN O
unlikely NN NN O
candidate NN NN O
to NN NN O
have NN NN O
an NN NN O
exclusive NN NN O
role NN NN O
as NN NN O
a NN NN O
combinatorial NN NN O
differentiation NN NN O
switch NN NN O
during NN NN O
myelopoiesis NN NN O
in NN NN O
human NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
using NN NN O
a NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
PCR NN NN O
- NN NN O
based NN NN O
approach NN NN O
and NN NN O
a NN NN O
set NN NN O
of NN NN O
primers NN NN O
specific NN NN O
for NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domains NN NN O
of NN NN O
highly NN NN O
homologous NN NN O
members NN NN O
of NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
, NN NN O
we NN NN O
have NN NN O
cloned NN NN O
a NN NN O
novel NN NN O
human NN NN O
gene NN NN O
encoding NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
gene NN NN O
family NN NN O
, NN NN O
identified NN NN O
as NN NN O
the NN NN O
human NN NN O
homolog NN NN O
of NN NN O
CRP1 NN NN B-Protein
, NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
. NN NN O
   
A NN NN O
1 NN NN O
. NN NN O
2 NN NN O
- NN NN O
kb NN NN O
cDNA NN NN O
encoding NN NN O
full NN NN O
- NN NN O
length NN NN O
human NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
was NN NN O
cloned NN NN O
from NN NN O
a NN NN O
promyelocyte NN NN O
- NN NN O
late NN NN O
myeloblast NN NN O
- NN NN O
derived NN NN O
lambda NN NN O
gt11 NN NN O
library NN NN O
. NN NN O
   
Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
cDNA NN NN O
and NN NN O
genomic NN NN O
clones NN NN O
indicated NN NN O
the NN NN O
presence NN NN O
of NN NN O
two NN NN O
exons NN NN O
encoding NN NN O
a NN NN O
protein NN NN O
with NN NN O
an NN NN O
apparent NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
32 NN NN O
kDa NN NN O
and NN NN O
a NN NN O
pI NN NN O
of NN NN O
9 NN NN O
. NN NN O
5 NN NN O
. NN NN O
   
Primer NN NN O
extension NN NN O
analysis NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
detected NN NN O
a NN NN O
single NN NN O
major NN NN O
transcription NN NN O
start NN NN O
site NN NN O
approximately NN NN O
200 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
start NN NN O
codon NN NN O
. NN NN O
   
The NN NN O
putative NN NN O
promoter NN NN O
area NN NN O
is NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
several NN NN O
other NN NN O
myeloid NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
in NN NN O
that NN NN O
it NN NN O
contains NN NN O
no NN NN O
TATAAA NN NN O
box NN NN O
but NN NN O
has NN NN O
a NN NN O
number NN NN O
of NN NN O
purine NN NN O
- NN NN O
rich NN NN O
stretches NN NN O
with NN NN O
multiple NN NN O
sites NN NN O
for NN NN O
the NN NN O
factors NN NN O
of NN NN O
the NN NN O
Ets NN NN O
family NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analyses NN NN O
indicated NN NN O
a NN NN O
highly NN NN O
restricted NN NN O
mRNA NN NN O
expression NN NN O
pattern NN NN O
, NN NN O
with NN NN O
the NN NN O
strongest NN NN O
expression NN NN O
occurring NN NN O
in NN NN O
promyelocyte NN NN O
and NN NN O
late NN NN O
- NN NN O
myeloblast NN NN O
- NN NN O
like NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Western NN NN O
blot NN NN O
and NN NN O
immunoprecipitation NN NN O
studies NN NN O
using NN NN O
rabbit NN NN O
anti NN NN O
- NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
antibodies NN NN O
raised NN NN O
against NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
portion NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
( NN NN O
amino NN NN O
acids NN NN O
1 NN NN O
to NN NN O
115 NN NN O
) NN NN O
showed NN NN O
that NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
is NN NN O
a NN NN O
32 NN NN O
- NN NN O
kDa NN NN O
nuclear NN NN O
phosphoprotein NN NN O
. NN NN O
   
The NN NN O
human NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
protein NN NN O
exhibited NN NN O
strong NN NN O
and NN NN O
specific NN NN O
binding NN NN O
to NN NN O
double NN NN O
- NN NN O
stranded NN NN O
DNA NN NN O
containing NN NN O
consensus NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
sites NN NN O
. NN NN O
   
Cotransfection NN NN O
of NN NN O
the NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
sense NN NN O
and NN NN O
antisense NN NN O
expression NN NN O
constructs NN NN O
together NN NN O
with NN NN O
chloramphenicol NN NN O
acetyltransferase NN NN O
reporter NN NN O
vectors NN NN O
containing NN NN O
myeloid NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
c NN NN O
- NN NN O
mim NN NN O
and NN NN O
human NN NN O
myeloperoxidase NN NN O
promoters NN NN O
suggested NN NN O
a NN NN O
role NN NN O
for NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
myeloid NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
Transient NN NN O
tranfection NN NN O
of NN NN O
a NN NN O
promyelocyte NN NN O
cell NN NN O
line NN NN O
( NN NN O
NB4 NN NN O
) NN NN O
with NN NN O
a NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
expression NN NN O
plasmid NN NN O
increased NN NN O
cell NN NN O
growth NN NN O
by NN NN O
sevenfold NN NN O
, NN NN O
while NN NN O
antisense NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
epsilon NN NN I-Protein
caused NN NN O
a NN NN O
fivefold NN NN O
decrease NN NN O
in NN NN O
clonal NN NN O
growth NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
ferritin NN NN O
heavy NN NN O
- NN NN O
chain NN NN O
gene NN NN O
: NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
CCAAT NN NN O
binding NN NN O
factor NN NN O
NF NN NN O
- NN NN O
Y NN NN O
is NN NN O
modulated NN NN O
in NN NN O
heme NN NN O
- NN NN O
treated NN NN O
Friend NN NN O
leukemia NN NN O
cells NN NN O
and NN NN O
during NN NN O
monocyte NN NN O
- NN NN O
to NN NN O
- NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
ferritin NN NN B-Protein
H NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
promoter NN NN O
regulation NN NN O
was NN NN O
analyzed NN NN O
in NN NN O
heme NN NN O
- NN NN O
treated NN NN O
Friend NN NN O
leukemia NN NN O
cells NN NN O
( NN NN O
FLCs NN NN O
) NN NN O
and NN NN O
during NN NN O
monocyte NN NN O
- NN NN O
to NN NN O
- NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
majority NN NN O
of NN NN O
cell NN NN O
lines NN NN O
studied NN NN O
, NN NN O
the NN NN O
regulation NN NN O
of NN NN O
ferritin NN NN O
expression NN NN O
was NN NN O
exerted NN NN O
mostly NN NN O
at NN NN O
the NN NN O
translational NN NN O
level NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
differentiating NN NN O
erythroid NN NN O
cells NN NN O
, NN NN O
which NN NN O
must NN NN O
incorporate NN NN O
high NN NN O
levels NN NN O
of NN NN O
iron NN NN O
to NN NN O
sustain NN NN O
hemoglobin NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
in NN NN O
macrophages NN NN O
, NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
iron NN NN O
storage NN NN O
, NN NN O
transcriptional NN NN O
regulation NN NN O
seemed NN NN O
to NN NN O
be NN NN O
a NN NN O
relevant NN NN O
mechanism NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
the NN NN O
minimum NN NN O
region NN NN O
of NN NN O
the NN NN O
ferritin NN NN B-Protein
H NN NN I-Protein
- NN NN O
gene NN NN O
promoter NN NN O
that NN NN O
is NN NN O
able NN NN O
to NN NN O
confer NN NN O
transcriptional NN NN O
regulation NN NN O
by NN NN O
heme NN NN O
in NN NN O
FLCs NN NN O
to NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
is NN NN O
77 NN NN O
nucleotides NN NN O
upstream NN NN O
of NN NN O
the NN NN O
TATA NN NN O
box NN NN O
. NN NN O
   
This NN NN O
cis NN NN O
element NN NN O
binds NN NN O
a NN NN O
protein NN NN O
complex NN NN O
referred NN NN O
to NN NN O
as NN NN O
HRF NN NN O
( NN NN O
heme NN NN O
- NN NN O
responsive NN NN O
factor NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
greatly NN NN O
enhanced NN NN O
both NN NN O
in NN NN O
heme NN NN O
- NN NN O
treated NN NN O
FLCs NN NN O
and NN NN O
during NN NN O
monocyte NN NN O
- NN NN O
to NN NN O
- NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
The NN NN O
CCAAT NN NN O
element NN NN O
present NN NN O
in NN NN O
reverse NN NN O
orientation NN NN O
in NN NN O
this NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
ferritin NN NN B-Protein
H NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
gene NN NN O
is NN NN O
necessary NN NN O
for NN NN O
binding NN NN O
and NN NN O
for NN NN O
gene NN NN O
activity NN NN O
, NN NN O
since NN NN O
a NN NN O
single NN NN O
point NN NN O
mutation NN NN O
is NN NN O
able NN NN O
to NN NN O
abolish NN NN O
the NN NN O
binding NN NN O
of NN NN O
HRF NN NN O
and NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
transfected NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
competition NN NN O
experiments NN NN O
and NN NN O
supershift NN NN O
assays NN NN O
, NN NN O
we NN NN O
identified NN NN O
the NN NN O
induced NN NN O
HRF NN NN O
as NN NN O
containing NN NN O
at NN NN O
least NN NN O
the NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
Y NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
Y NN NN O
is NN NN O
formed NN NN O
by NN NN O
three NN NN O
subunits NN NN O
, NN NN O
A NN NN O
, NN NN O
B NN NN O
, NN NN O
and NN NN O
C NN NN O
, NN NN O
all NN NN O
of NN NN O
which NN NN O
are NN NN O
necessary NN NN O
for NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
Cotransfection NN NN O
with NN NN O
a NN NN O
transdominant NN NN O
negative NN NN O
mutant NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
YA NN NN O
subunit NN NN O
abolishes NN NN O
the NN NN O
transcriptional NN NN O
activation NN NN O
by NN NN O
heme NN NN O
, NN NN O
indicating NN NN O
that NN NN O
NF NN NN O
- NN NN O
Y NN NN O
plays NN NN O
an NN NN O
essential NN NN O
role NN NN O
in NN NN O
this NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
also NN NN O
observed NN NN O
a NN NN O
differential NN NN O
expression NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
YA NN NN O
subunit NN NN O
in NN NN O
heme NN NN O
- NN NN O
treated NN NN O
and NN NN O
control NN NN O
FLCs NN NN O
and NN NN O
during NN NN O
monocyte NN NN O
- NN NN O
to NN NN O
- NN NN O
macrophage NN NN O
differentiation NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
a NN NN O
mutant NN NN O
cell NN NN O
line NN NN O
that NN NN O
does NN NN O
not NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
response NN NN O
to NN NN O
multiple NN NN O
stimuli NN NN O
. NN NN O
   
Numerous NN NN O
genes NN NN O
required NN NN O
during NN NN O
the NN NN O
immune NN NN O
or NN NN O
inflammation NN NN O
response NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
adhesion NN NN O
process NN NN O
are NN NN O
regulated NN NN O
by NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
. NN NN O
   
Associated NN NN O
with NN NN O
its NN NN O
inhibitor NN NN O
, NN NN O
I NN NN O
kappaB NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
resides NN NN O
as NN NN O
an NN NN O
inactive NN NN O
form NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
. NN NN O
   
Upon NN NN O
stimulation NN NN O
by NN NN O
various NN NN O
agents NN NN O
, NN NN O
I NN NN O
kappaB NN NN O
is NN NN O
proteolyzed NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
translocates NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
where NN NN O
it NN NN O
activates NN NN O
its NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
transduction NN NN O
pathways NN NN O
that NN NN O
lead NN NN O
to NN NN O
I NN NN O
kappaB NN NN O
inactivation NN NN O
remain NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
characterized NN NN O
a NN NN O
cellular NN NN O
mutant NN NN O
, NN NN O
the NN NN O
70 NN NN O
/ NN NN O
Z3 NN NN O
- NN NN O
derived NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
murine NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
line NN NN O
, NN NN O
that NN NN O
does NN NN O
not NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
response NN NN O
to NN NN O
several NN NN O
stimuli NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
upon NN NN O
stimulation NN NN O
by NN NN O
lipopolysaccharide NN NN O
, NN NN O
Taxol NN NN O
, NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
, NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
, NN NN O
or NN NN O
double NN NN O
- NN NN O
stranded NN NN O
RNA NN NN O
, NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
not NN NN O
degraded NN NN O
, NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
an NN NN O
absence NN NN O
of NN NN O
induced NN NN O
phosphorylation NN NN O
on NN NN O
serines NN NN O
32 NN NN O
and NN NN O
36 NN NN O
. NN NN O
   
Neither NN NN O
a NN NN O
mutation NN NN O
in NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
nor NN NN O
a NN NN O
mutation NN NN O
in NN NN O
p50 NN NN B-Protein
or NN NN O
relA NN NN B-Protein
, NN NN O
the NN NN O
two NN NN O
major NN NN O
subunits NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
this NN NN O
cell NN NN O
line NN NN O
, NN NN O
accounts NN NN O
for NN NN O
this NN NN O
phosphorylation NN NN O
defect NN NN O
. NN NN O
   
As NN NN O
well NN NN O
as NN NN O
culminating NN NN O
in NN NN O
the NN NN O
inducible NN NN O
phosphorylation NN NN O
of NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
on NN NN O
serines NN NN O
32 NN NN O
and NN NN O
36 NN NN O
, NN NN O
all NN NN O
the NN NN O
stimuli NN NN O
that NN NN O
are NN NN O
inactive NN NN O
on NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
cells NN NN O
exhibit NN NN O
a NN NN O
sensitivity NN NN O
to NN NN O
the NN NN O
antioxidant NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
stimuli NN NN O
such NN NN O
as NN NN O
hyperosmotic NN NN O
shock NN NN O
or NN NN O
phosphatase NN NN O
inhibitors NN NN O
, NN NN O
which NN NN O
use NN NN O
PDTC NN NN O
- NN NN O
insensitive NN NN O
pathways NN NN O
, NN NN O
induce NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
in NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
redox NN NN O
status NN NN O
of NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
does NN NN O
not NN NN O
reveal NN NN O
any NN NN O
difference NN NN O
from NN NN O
wild NN NN O
- NN NN O
type NN NN O
70Z NN NN O
/ NN NN O
3 NN NN O
. NN NN O
   
We NN NN O
also NN NN O
report NN NN O
that NN NN O
the NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
- NN NN O
derived NN NN O
Tax NN NN B-Protein
trans NN NN O
- NN NN O
activator NN NN O
induces NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
viral NN NN O
protein NN NN O
does NN NN O
not NN NN O
operate NN NN O
via NN NN O
the NN NN O
defective NN NN O
pathway NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
two NN NN O
other NN NN O
I NN NN O
kappaB NN NN O
molecules NN NN O
, NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
beta NN NN I-Protein
and NN NN O
the NN NN O
recently NN NN O
identified NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
epsilon NN NN I-Protein
, NN NN O
are NN NN O
not NN NN O
degraded NN NN O
in NN NN O
the NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
cell NN NN O
line NN NN O
following NN NN O
stimulation NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
1 NN NN O
. NN NN O
3E2 NN NN O
is NN NN O
a NN NN O
cellular NN NN O
transduction NN NN O
mutant NN NN O
exhibiting NN NN O
a NN NN O
defect NN NN O
in NN NN O
a NN NN O
step NN NN O
that NN NN O
is NN NN O
required NN NN O
by NN NN O
several NN NN O
different NN NN O
stimuli NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
this NN NN O
analysis NN NN O
suggests NN NN O
a NN NN O
common NN NN O
step NN NN O
in NN NN O
the NN NN O
signaling NN NN O
pathways NN NN O
that NN NN O
trigger NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
I NN NN B-Protein
kappaB NN NN I-Protein
epsilon NN NN I-Protein
degradation NN NN O
. NN NN O
   
Transcription NN NN O
mediated NN NN O
by NN NN O
NFAT NN NN O
is NN NN O
highly NN NN O
inducible NN NN O
in NN NN O
effector NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
helper NN NN O
2 NN NN O
( NN NN O
Th2 NN NN O
) NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
Th1 NN NN O
cells NN NN O
. NN NN O
   
Transcriptional NN NN O
factors NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
family NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
during NN NN O
the NN NN O
immune NN NN O
response NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
genes NN NN O
for NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
among NN NN O
others NN NN O
. NN NN O
   
Upon NN NN O
antigen NN NN O
stimulation NN NN O
, NN NN O
precursor NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
helper NN NN O
( NN NN O
pTh NN NN O
) NN NN O
cells NN NN O
proliferate NN NN O
and NN NN O
differentiate NN NN O
into NN NN O
two NN NN O
populations NN NN O
of NN NN O
effector NN NN O
cells NN NN O
( NN NN O
eTh1 NN NN O
and NN NN O
eTh2 NN NN O
) NN NN O
, NN NN O
each NN NN O
one NN NN O
expressing NN NN O
a NN NN O
specific NN NN O
pattern NN NN O
of NN NN O
cytokines NN NN O
that NN NN O
distinguishes NN NN O
them NN NN O
from NN NN O
their NN NN O
precursors NN NN O
. NN NN O
   
eTh2 NN NN O
cells NN NN O
are NN NN O
the NN NN O
major NN NN O
source NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
while NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
is NN NN O
produced NN NN O
by NN NN O
eTh1 NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
have NN NN O
used NN NN O
reporter NN NN O
transgenic NN NN O
mice NN NN O
to NN NN O
show NN NN O
that NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
NFAT NN NN O
are NN NN O
transiently NN NN O
induced NN NN O
during NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
pTh NN NN O
cells NN NN O
into NN NN O
either NN NN O
eTh1 NN NN O
or NN NN O
eTh2 NN NN O
cells NN NN O
to NN NN O
mediate NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
as NN NN O
a NN NN O
common NN NN O
growth NN NN O
factor NN NN O
in NN NN O
both NN NN O
pathways NN NN O
. NN NN O
   
However NN NN O
, NN NN O
although NN NN O
NFAT NN NN O
DNA NN NN O
binding NN NN O
is NN NN O
similarly NN NN O
induced NN NN O
in NN NN O
both NN NN O
eTh1 NN NN O
and NN NN O
eTh2 NN NN O
cells NN NN O
upon NN NN O
antigen NN NN O
stimulation NN NN O
, NN NN O
only NN NN O
the NN NN O
NFAT NN NN O
complexes NN NN O
present NN NN O
in NN NN O
eTh2 NN NN O
cells NN NN O
are NN NN O
able NN NN O
to NN NN O
mediate NN NN O
high NN NN O
- NN NN O
level NN NN O
transcription NN NN O
, NN NN O
and NN NN O
relatively NN NN O
little NN NN O
NFAT NN NN O
transcriptional NN NN O
activity NN NN O
was NN NN O
induced NN NN O
in NN NN O
eTh1 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
activated NN NN O
pTh NN NN O
cells NN NN O
, NN NN O
neither NN NN O
eTh1 NN NN O
nor NN NN O
eTh2 NN NN O
cells NN NN O
produced NN NN O
significant NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
upon NN NN O
stimulation NN NN O
, NN NN O
but NN NN O
the NN NN O
high NN NN O
levels NN NN O
of NN NN O
NFAT NN NN O
transcriptional NN NN O
activities NN NN O
directly NN NN O
correlate NN NN O
with NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
production NN NN O
induced NN NN O
in NN NN O
response NN NN O
to NN NN O
antigen NN NN O
stimulation NN NN O
in NN NN O
eTh2 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
activated NN NN O
NFAT NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
effector NN NN O
function NN NN O
of NN NN O
eTh2 NN NN O
cells NN NN O
and NN NN O
that NN NN O
the NN NN O
failure NN NN O
of NN NN O
eTh1 NN NN O
cells NN NN O
to NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
an NN NN O
antigen NN NN O
is NN NN O
due NN NN O
, NN NN O
at NN NN O
least NN NN O
partially NN NN O
, NN NN O
to NN NN O
a NN NN O
failure NN NN O
to NN NN O
induce NN NN O
high NN NN O
- NN NN O
level NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
by NN NN O
NFAT NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
NFAT NN NN O
could NN NN O
be NN NN O
therefore NN NN O
a NN NN O
critical NN NN O
element NN NN O
in NN NN O
the NN NN O
polarization NN NN O
to NN NN O
eTh1 NN NN O
or NN NN O
eTh2 NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
of NN NN O
p50 NN NN B-Protein
homodimer NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
human NN NN O
monocytes NN NN O
decreases NN NN O
with NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
differentiation NN NN O
: NN NN O
a NN NN O
possible NN NN O
mechanism NN NN O
influencing NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
replication NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
mature NN NN O
macrophages NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replicates NN NN O
more NN NN O
efficiently NN NN O
in NN NN O
vitro NN NN O
in NN NN O
differentiated NN NN O
macrophages NN NN O
than NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
monocytes NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
whether NN NN O
this NN NN O
may NN NN O
be NN NN O
partly NN NN O
explained NN NN O
by NN NN O
changes NN NN O
in NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
with NN NN O
monocyte NN NN O
differentiation NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
that NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
primary NN NN O
human NN NN O
monocytes NN NN O
changed NN NN O
significantly NN NN O
with NN NN O
differentiation NN NN O
in NN NN O
vitro NN NN O
to NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
( NN NN O
MDMs NN NN O
) NN NN O
and NN NN O
differentiation NN NN O
in NN NN O
vivo NN NN O
to NN NN O
alveolar NN NN O
macrophages NN NN O
( NN NN O
AMs NN NN O
) NN NN O
. NN NN O
   
Freshly NN NN O
isolated NN NN O
monocytes NN NN O
constitutively NN NN O
expressed NN NN O
high NN NN O
levels NN NN O
of NN NN O
transcriptionally NN NN O
inactive NN NN O
p50 NN NN B-Protein
homodimer NN NN O
which NN NN O
decreased NN NN O
with NN NN O
time NN NN O
in NN NN O
culture NN NN O
in NN NN O
favor NN NN O
of NN NN O
the NN NN O
transcriptionally NN NN O
active NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
/ NN NN O
RelB NN NN B-Protein
heterodimers NN NN O
. NN NN O
   
As NN NN O
in NN NN O
MDMs NN NN O
, NN NN O
AMs NN NN O
constitutively NN NN O
expressed NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
/ NN NN O
RelB NN NN B-Protein
although NN NN O
at NN NN O
lower NN NN O
levels NN NN O
. NN NN O
   
HIV NN NN O
infection NN NN O
of NN NN O
fresh NN NN O
monocytes NN NN O
failed NN NN O
to NN NN O
induce NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
as NN NN O
seen NN NN O
in NN NN O
MDMs NN NN O
. NN NN O
   
The NN NN O
replacement NN NN O
of NN NN O
p50 NN NN B-Protein
homodimers NN NN O
with NN NN O
transcriptionally NN NN O
active NN NN O
heterodimers NN NN O
following NN NN O
time NN NN O
in NN NN O
culture NN NN O
may NN NN O
partially NN NN O
explain NN NN O
the NN NN O
progressive NN NN O
increase NN NN O
in NN NN O
susceptibility NN NN O
of NN NN O
monocytes NN NN O
to NN NN O
HIV NN NN O
infection NN NN O
during NN NN O
in NN NN O
vitro NN NN O
culture NN NN O
. NN NN O
   
The NN NN O
change NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
components NN NN O
with NN NN O
monocyte NN NN O
differentiation NN NN O
in NN NN O
vivo NN NN O
may NN NN O
also NN NN O
explain NN NN O
the NN NN O
different NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
these NN NN O
cell NN NN O
populations NN NN O
in NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
nucleotide NN NN O
sequences NN NN O
that NN NN O
regulate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
MCF13 NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
region NN NN O
downstream NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
( NN NN O
DEN NN NN O
) NN NN O
of NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
of NN NN O
the NN NN O
mink NN NN O
cell NN NN O
focus NN NN O
- NN NN O
forming NN NN O
murine NN NN O
leukemia NN NN O
virus NN NN O
is NN NN O
important NN NN O
for NN NN O
viral NN NN O
pathogenicity NN NN O
. NN NN O
   
Another NN NN O
important NN NN O
activity NN NN O
of NN NN O
DEN NN NN O
is NN NN O
its NN NN O
control NN NN O
of NN NN O
transcription NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
we NN NN O
have NN NN O
determined NN NN O
that NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
is NN NN O
critical NN NN O
for NN NN O
this NN NN O
activity NN NN O
. NN NN O
   
Immune NN NN O
hyperactivation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
T NN NN O
cells NN NN O
mediated NN NN O
by NN NN O
Tat NN NN O
and NN NN O
the NN NN O
CD28 NN NN B-Protein
pathway NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
chronic NN NN O
state NN NN O
of NN NN O
immune NN NN O
hyperactivation NN NN O
in NN NN O
patients NN NN O
. NN NN O
   
Infection NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
vitro NN NN O
resulted NN NN O
in NN NN O
increased NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
secretion NN NN O
in NN NN O
response NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
via NN NN O
the NN NN O
CD3 NN NN O
and NN NN O
CD28 NN NN O
receptors NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transactivator NN NN O
Tat NN NN O
recapitulated NN NN O
this NN NN O
phenotype NN NN O
and NN NN O
was NN NN O
associated NN NN O
with NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
in NN NN O
response NN NN O
to NN NN O
costimulation NN NN O
with NN NN O
CD3 NN NN O
plus NN NN O
CD28 NN NN B-Protein
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
superinduction NN NN O
by NN NN O
Tat NN NN O
occurred NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
, NN NN O
was NN NN O
mediated NN NN O
by NN NN O
the NN NN O
CD28 NN NN B-Protein
- NN NN O
responsive NN NN O
element NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
, NN NN O
and NN NN O
was NN NN O
exclusively NN NN O
dependent NN NN O
on NN NN O
the NN NN O
29 NN NN O
amino NN NN O
acids NN NN O
encoded NN NN O
by NN NN O
the NN NN O
second NN NN O
exon NN NN O
of NN NN O
Tat NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
is NN NN O
a NN NN O
target NN NN O
of NN NN O
pentoxifylline NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
possible NN NN O
clinical NN NN O
use NN NN O
of NN NN O
the NN NN O
methyl NN NN O
xanthine NN NN O
derivative NN NN O
, NN NN O
pentoxifylline NN NN O
( NN NN O
PF NN NN O
) NN NN O
, NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
T NN NN O
cell NN NN O
- NN NN O
dependent NN NN O
diseases NN NN O
is NN NN O
being NN NN O
noted NN NN O
with NN NN O
increasing NN NN O
interest NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
molecular NN NN O
consequences NN NN O
of NN NN O
PF NN NN O
treatment NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
induced NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
expression NN NN O
was NN NN O
blocked NN NN O
by NN NN O
PF NN NN O
, NN NN O
whereas NN NN O
the NN NN O
induction NN NN O
of NN NN O
other NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
members NN NN O
was NN NN O
not NN NN O
significantly NN NN O
affected NN NN O
. NN NN O
   
However NN NN O
, NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
which NN NN O
has NN NN O
the NN NN O
same NN NN O
signaling NN NN O
requirements NN NN O
as NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
induction NN NN O
, NN NN O
was NN NN O
not NN NN O
inhibited NN NN O
by NN NN O
PF NN NN O
. NN NN O
   
Among NN NN O
genes NN NN O
that NN NN O
respond NN NN O
to NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
induction NN NN O
was NN NN O
suppressed NN NN O
by NN NN O
PF NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
( NN NN I-Protein
alpha NN NN I-Protein
) NN NN I-Protein
chain NN NN I-Protein
mRNA NN NN O
induction NN NN O
was NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
implicated NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
as NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
factor NN NN O
, NN NN O
for NN NN O
which NN NN O
experimental NN NN O
support NN NN O
was NN NN O
obtained NN NN O
from NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
with NN NN O
the NN NN O
observation NN NN O
in NN NN O
T NN NN O
cells NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
induction NN NN O
was NN NN O
not NN NN O
blocked NN NN O
by NN NN O
PF NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
greater NN NN O
selectivity NN NN O
of NN NN O
PF NN NN O
, NN NN O
compared NN NN O
with NN NN O
FK506 NN NN O
, NN NN O
at NN NN O
both NN NN O
the NN NN O
molecular NN NN O
and NN NN O
cellular NN NN O
levels NN NN O
may NN NN O
prove NN NN O
advantageous NN NN O
in NN NN O
manipulating NN NN O
T NN NN O
cell NN NN O
responses NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
A NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
in NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
locus NN NN O
is NN NN O
activated NN NN O
cooperatively NN NN O
by NN NN O
Oct NN NN O
and NN NN O
NFAT NN NN O
elements NN NN O
within NN NN O
a NN NN O
DNase NN NN O
I NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
cytokine NN NN O
that NN NN O
is NN NN O
expressed NN NN O
primarily NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
identified NN NN O
an NN NN O
inducible NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
14 NN NN O
kb NN NN O
upstream NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
that NN NN O
responded NN NN O
to NN NN O
activation NN NN O
of NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
enhancer NN NN O
spanned NN NN O
an NN NN O
inducible NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
DNase NN NN O
I NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
found NN NN O
only NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Four NN NN O
NFAT NN NN O
- NN NN O
like NN NN O
elements NN NN O
exist NN NN O
within NN NN O
the NN NN O
enhancer NN NN O
. NN NN O
   
The NN NN O
two NN NN O
most NN NN O
active NN NN O
NFAT NN NN O
- NN NN O
like NN NN O
elements NN NN O
were NN NN O
located NN NN O
at NN NN O
the NN NN O
center NN NN O
of NN NN O
the NN NN O
DNase NN NN O
I NN NN O
- NN NN O
hypersensitive NN NN O
site NN NN O
. NN NN O
   
One NN NN O
of NN NN O
these NN NN O
NFAT NN NN O
- NN NN O
like NN NN O
elements NN NN O
encompassed NN NN O
overlapping NN NN O
Oct NN NN O
- NN NN O
and NN NN O
NFATp NN NN O
/ NN NN O
c NN NN O
- NN NN O
binding NN NN O
sites NN NN O
, NN NN O
which NN NN O
functioned NN NN O
in NN NN O
a NN NN O
highly NN NN O
synergistic NN NN O
manner NN NN O
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
the NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
is NN NN O
partly NN NN O
controlled NN NN O
through NN NN O
the NN NN O
enhancer NN NN O
by NN NN O
cooperation NN NN O
between NN NN O
Oct NN NN O
and NN NN O
NFAT NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
A NN NN O
negative NN NN O
regulatory NN NN O
region NN NN O
containing NN NN O
a NN NN O
glucocorticosteroid NN NN O
response NN NN O
element NN NN O
( NN NN O
nGRE NN NN O
) NN NN O
in NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
important NN NN O
inflammatory NN NN O
mediators NN NN O
in NN NN O
human NN NN O
inflammatory NN NN O
and NN NN O
immunological NN NN O
diseases NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
expression NN NN O
has NN NN O
been NN NN O
studied NN NN O
for NN NN O
several NN NN O
years NN NN O
, NN NN O
and NN NN O
a NN NN O
few NN NN O
regulatory NN NN O
elements NN NN O
have NN NN O
been NN NN O
discovered NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
However NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
negative NN NN O
regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
expression NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
, NN NN O
which NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
and NN NN O
immunosuppressive NN NN O
effects NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
negative NN NN O
regulatory NN NN O
element NN NN O
located NN NN O
in NN NN O
the NN NN O
region NN NN O
between NN NN O
- NN NN O
685 NN NN O
and NN NN O
- NN NN O
395 NN NN O
. NN NN O
   
Within NN NN O
this NN NN O
region NN NN O
, NN NN O
a NN NN O
19 NN NN O
- NN NN O
bp NN NN O
nuclear NN NN O
factor NN NN O
binding NN NN O
site NN NN O
( NN NN O
- NN NN O
570 NN NN O
to NN NN O
- NN NN O
552 NN NN O
) NN NN O
was NN NN O
characterized NN NN O
by NN NN O
DNase NN NN O
I NN NN O
footprinting NN NN O
and NN NN O
electromobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
A NN NN O
consensus NN NN O
sequence NN NN O
for NN NN O
a NN NN O
negative NN NN O
glucocorticoid NN NN O
response NN NN O
element NN NN O
( NN NN O
nGRE NN NN O
) NN NN O
and NN NN O
a NN NN O
transcription NN NN B-Protein
activator NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
binding NN NN O
site NN NN O
were NN NN O
noted NN NN O
within NN NN O
this NN NN O
footprint NN NN O
. NN NN O
   
Functional NN NN O
studies NN NN O
showed NN NN O
a NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
promoter NN NN O
activity NN NN O
when NN NN O
this NN NN O
19 NN NN O
- NN NN O
bp NN NN O
binding NN NN O
site NN NN O
was NN NN O
deleted NN NN O
in NN NN O
the NN NN O
reporter NN NN O
constructs NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
/ NN NN O
CAT NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
/ NN NN O
SV40 NN NN O
promoter NN NN O
/ NN NN O
CAT NN NN B-Protein
. NN NN O
   
Dexamethasone NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
M NN NN O
) NN NN O
repressed NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
production NN NN O
by NN NN O
75 NN NN O
% NN NN O
in NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
fragment NN NN O
but NN NN O
not NN NN O
in NN NN O
a NN NN O
deletion NN NN O
mutant NN NN O
lacking NN NN O
the NN NN O
19 NN NN O
- NN NN O
bp NN NN O
site NN NN O
. NN NN O
   
A NN NN O
protein NN NN O
of NN NN O
about NN NN O
150 NN NN O
kD NN NN O
that NN NN O
bound NN NN O
to NN NN O
this NN NN O
negative NN NN O
regulatory NN NN O
sequence NN NN O
was NN NN O
identified NN NN O
by NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
This NN NN O
is NN NN O
the NN NN O
first NN NN O
description NN NN O
of NN NN O
a NN NN O
negative NN NN O
regulatory NN NN O
region NN NN O
responsive NN NN O
to NN NN O
glucocorticoids NN NN O
in NN NN O
a NN NN O
cytokine NN NN O
gene NN NN O
. NN NN O
   
TRAMP NN NN B-Protein
, NN NN O
a NN NN O
novel NN NN O
apoptosis NN NN O
- NN NN O
mediating NN NN O
receptor NN NN O
with NN NN O
sequence NN NN O
homology NN NN O
to NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Fas NN NN B-Protein
( NN NN O
Apo NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
CD95 NN NN B-Protein
) NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
member NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
receptor NN NN O
family NN NN O
, NN NN O
designated NN NN O
TRAMP NN NN B-Protein
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
. NN NN O
   
The NN NN O
structural NN NN O
organization NN NN O
of NN NN O
the NN NN O
393 NN NN O
amino NN NN O
acid NN NN O
long NN NN O
human NN NN O
TRAMP NN NN B-Protein
is NN NN O
most NN NN O
homologous NN NN O
to NN NN O
TNF NN NN B-Protein
receptor NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
TRAMP NN NN B-Protein
is NN NN O
abundantly NN NN O
expressed NN NN O
on NN NN O
thymocytes NN NN O
and NN NN O
lymphocytes NN NN O
. NN NN O
   
Its NN NN O
extracellular NN NN O
domain NN NN O
is NN NN O
composed NN NN O
of NN NN O
four NN NN O
cysteine NN NN O
- NN NN O
rich NN NN O
domains NN NN O
, NN NN O
and NN NN O
the NN NN O
cytoplasmic NN NN O
region NN NN O
contains NN NN O
a NN NN O
death NN NN O
domain NN NN O
known NN NN O
to NN NN O
signal NN NN O
apoptosis NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
TRAMP NN NN B-Protein
leads NN NN O
to NN NN O
two NN NN O
major NN NN O
responses NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
apoptosis NN NN O
. NN NN O
   
TRAMP NN NN B-Protein
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
ICE NN NN O
- NN NN O
like NN NN O
proteases NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
TRAMP NN NN B-Protein
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
interact NN NN O
with NN NN O
any NN NN O
of NN NN O
the NN NN O
known NN NN O
apoptosis NN NN O
- NN NN O
inducing NN NN O
ligands NN NN O
of NN NN O
the NN NN O
TNF NN NN O
family NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
RelA NN NN B-Protein
synergy NN NN O
in NN NN O
distinguishing NN NN O
T NN NN O
cell NN NN O
activation NN NN O
from NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
transcription NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
an NN NN O
important NN NN O
transcription NN NN O
factor NN NN O
required NN NN O
for NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
other NN NN O
immunological NN NN O
functions NN NN O
. NN NN O
   
The NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B1 NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
105 NN NN O
- NN NN O
kD NN NN O
protein NN NN O
that NN NN O
is NN NN O
the NN NN O
precursor NN NN O
of NN NN O
the NN NN O
p50 NN NN B-Protein
component NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Previously NN NN O
, NN NN O
we NN NN O
and NN NN O
others NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
regulates NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
gene NN NN O
. NN NN O
   
In NN NN O
this NN NN O
manuscript NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
T NN NN O
cell NN NN O
lines NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
phytohemagglutin NN NN B-Protein
( NN NN O
PHA NN NN B-Protein
) NN NN O
display NN NN O
significantly NN NN O
higher NN NN O
levels NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
encoding NN NN O
transcripts NN NN O
than NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
despite NN NN O
the NN NN O
fact NN NN O
that NN NN O
both NN NN O
stimuli NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
promoter NN NN O
identified NN NN O
an NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
site NN NN O
which NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
essential NN NN O
for NN NN O
both NN NN O
the NN NN O
PMA NN NN O
/ NN NN O
PHA NN NN B-Protein
- NN NN O
mediated NN NN O
induction NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
synergistic NN NN O
activation NN NN O
observed NN NN O
after NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
RelA NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
was NN NN O
required NN NN O
for NN NN O
endogenous NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
since NN NN O
PMA NN NN O
/ NN NN O
PHA NN NN B-Protein
- NN NN O
stimulated NN NN O
T NN NN O
cell NN NN O
lines NN NN O
expressing NN NN O
antisense NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
RNA NN NN O
were NN NN O
inhibited NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
upregulate NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
transcription NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
transcriptional NN NN O
synergy NN NN O
mediated NN NN O
by NN NN O
activation NN NN O
of NN NN O
both NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
may NN NN O
have NN NN O
important NN NN O
ramifications NN NN O
in NN NN O
T NN NN O
cell NN NN O
development NN NN O
by NN NN O
upregulating NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Differentiation NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
promonocytic NN NN O
cells NN NN O
by NN NN O
etoposide NN NN O
and NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
, NN NN O
two NN NN O
antitumour NN NN O
DNA NN NN O
topoisomerase NN NN O
II NN NN O
inhibitors NN NN O
with NN NN O
different NN NN O
mechanisms NN NN O
of NN NN O
action NN NN O
. NN NN O
   
We NN NN O
have NN NN O
compared NN NN O
the NN NN O
action NN NN O
on NN NN O
U NN NN O
- NN NN O
937 NN NN O
human NN NN O
promonocytic NN NN O
leukemia NN NN O
cells NN NN O
of NN NN O
two NN NN O
DNA NN NN O
topoisomerase NN NN O
II NN NN O
inhibitors NN NN O
, NN NN O
namely NN NN O
the NN NN O
epipodophyllotoxin NN NN O
etoposide NN NN O
and NN NN O
the NN NN O
bisdioxopiperazine NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
. NN NN O
   
One NN NN O
hour NN NN O
pulse NN NN O
- NN NN O
treatment NN NN O
with NN NN O
3 NN NN O
microM NN NN O
etoposide NN NN O
caused NN NN O
topoisomerase NN NN O
associated NN NN O
, NN NN O
primary NN NN O
DNA NN NN O
breakage NN NN O
, NN NN O
which NN NN O
was NN NN O
rapidly NN NN O
followed NN NN O
by NN NN O
apoptosis NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
these NN NN O
effects NN NN O
were NN NN O
not NN NN O
observed NN NN O
upon NN NN O
pulse NN NN O
- NN NN O
treatment NN NN O
with NN NN O
6 NN NN O
microM NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
. NN NN O
   
However NN NN O
, NN NN O
continuous NN NN O
treatments NN NN O
with NN NN O
subcytotoxic NN NN O
concentrations NN NN O
of NN NN O
etoposide NN NN O
( NN NN O
0 NN NN O
. NN NN O
15 NN NN O
microM NN NN O
) NN NN O
and NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
( NN NN O
0 NN NN O
. NN NN O
3 NN NN O
microM NN NN O
) NN NN O
produced NN NN O
several NN NN O
similar NN NN O
effects NN NN O
, NN NN O
namely NN NN O
decreased NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
accumulation NN NN O
of NN NN O
cells NN NN O
at NN NN O
G2 NN NN O
, NN NN O
increase NN NN O
in NN NN O
cell NN NN O
mass NN NN O
, NN NN O
and NN NN O
induction NN NN O
of NN NN O
differentiation NN NN O
. NN NN O
   
Under NN NN O
these NN NN O
conditions NN NN O
, NN NN O
etoposide NN NN O
produced NN NN O
a NN NN O
biphasic NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
which NN NN O
consisted NN NN O
in NN NN O
an NN NN O
early NN NN O
transient NN NN O
activation NN NN O
( NN NN O
from NN NN O
hours NN NN O
1 NN NN O
to NN NN O
6 NN NN O
) NN NN O
of NN NN O
the NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
enzyme NN NN O
followed NN NN O
by NN NN O
a NN NN O
later NN NN O
activation NN NN O
( NN NN O
hour NN NN O
48 NN NN O
) NN NN O
of NN NN O
the NN NN O
total NN NN O
, NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
and NN NN O
cytosolic NN NN O
enzyme NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
only NN NN O
provoked NN NN O
a NN NN O
late NN NN O
activation NN NN O
( NN NN O
from NN NN O
hours NN NN O
72 NN NN O
to NN NN O
96 NN NN O
) NN NN O
of NN NN O
the NN NN O
total NN NN O
enzyme NN NN O
. NN NN O
   
When NN NN O
used NN NN O
at NN NN O
differentiation NN NN O
- NN NN O
inducing NN NN O
concentrations NN NN O
, NN NN O
both NN NN O
topoisomerase NN NN O
inhibitors NN NN O
caused NN NN O
a NN NN O
great NN NN O
stimulation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
, NN NN O
with NN NN O
maximum NN NN O
value NN NN O
at NN NN O
hour NN NN O
12 NN NN O
in NN NN O
etoposide NN NN O
- NN NN O
treated NN NN O
cells NN NN O
and NN NN O
at NN NN O
hour NN NN O
48 NN NN O
in NN NN O
ICRF NN NN O
- NN NN O
193 NN NN O
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
the NN NN O
binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
( NN NN O
B NN NN O
) NN NN O
and NN NN O
EGR NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factors NN NN O
was NN NN O
little NN NN O
affected NN NN O
. NN NN O
   
It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
topoisomerase NN NN O
II NN NN O
inhibitors NN NN O
may NN NN O
induce NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
promonocytic NN NN O
cells NN NN O
, NN NN O
independently NN NN O
of NN NN O
their NN NN O
capacity NN NN O
to NN NN O
cause NN NN O
DNA NN NN O
strand NN NN O
breaks NN NN O
. NN NN O
   
However NN NN O
, NN NN O
there NN NN O
are NN NN O
other NN NN O
effects NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
early NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
which NN NN O
are NN NN O
probably NN NN O
derived NN NN O
from NN NN O
the NN NN O
production NN NN O
of NN NN O
primary NN NN O
DNA NN NN O
breakage NN NN O
by NN NN O
some NN NN O
anti NN NN O
- NN NN O
topoisomerase NN NN O
drugs NN NN O
. NN NN O
   
Nuclear NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
protein NN NN O
complexes NN NN O
are NN NN O
differentially NN NN O
distributed NN NN O
within NN NN O
human NN NN O
thymocytes NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
/ NN NN O
Rel NN NN O
proteins NN NN O
are NN NN O
inducible NN NN O
transcriptional NN NN O
regulators NN NN O
of NN NN O
numerous NN NN O
cellular NN NN O
genes NN NN O
. NN NN O
   
They NN NN O
are NN NN O
particularly NN NN O
abundant NN NN O
in NN NN O
lymphoid NN NN O
tissues NN NN O
and NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
critical NN NN O
for NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
We NN NN O
have NN NN O
reported NN NN O
previously NN NN O
that NN NN O
a NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
was NN NN O
present NN NN O
in NN NN O
freshly NN NN O
extracted NN NN O
human NN NN O
thymocytes NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
in NN NN O
vitro NN NN O
treatment NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
we NN NN O
identified NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
extracted NN NN O
from NN NN O
human NN NN O
thymocyte NN NN O
nuclei NN NN O
as NN NN O
being NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
complexes NN NN O
. NN NN O
   
Immunochemical NN NN O
and NN NN O
immunofluorescent NN NN O
staining NN NN O
of NN NN O
thymus NN NN O
sections NN NN O
using NN NN O
specific NN NN O
Abs NN NN O
allowed NN NN O
visualization NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
in NN NN O
both NN NN O
thymocytes NN NN O
and NN NN O
nonthymocyte NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
detection NN NN O
suggested NN NN O
a NN NN O
preferential NN NN O
activation NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
in NN NN O
medullary NN NN O
thymocytes NN NN O
, NN NN O
whereas NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
was NN NN O
present NN NN O
in NN NN O
both NN NN O
cortical NN NN O
and NN NN O
medullary NN NN O
regions NN NN O
of NN NN O
human NN NN O
thymus NN NN O
lobules NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
intensity NN NN O
of NN NN O
p65 NN NN B-Protein
labeling NN NN O
was NN NN O
much NN NN O
higher NN NN O
in NN NN O
several NN NN O
thymocytes NN NN O
from NN NN O
the NN NN O
medulla NN NN O
. NN NN O
   
p65 NN NN B-Protein
, NN NN O
p50 NN NN B-Protein
, NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
activities NN NN O
were NN NN O
found NN NN O
in NN NN O
both NN NN O
CD4 NN NN B-Protein
- NN NN O
and NN NN O
CD8 NN NN O
- NN NN O
positive NN NN O
thymocytes NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
p65 NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
complexes NN NN O
play NN NN O
distinct NN NN O
roles NN NN O
in NN NN O
gene NN NN O
expression NN NN O
and NN NN O
that NN NN O
both NN NN O
forms NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
play NN NN O
critical NN NN O
roles NN NN O
during NN NN O
late NN NN O
stages NN NN O
of NN NN O
the NN NN O
intrathymic NN NN O
maturation NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Alteration NN NN O
of NN NN O
a NN NN O
single NN NN O
serine NN NN O
in NN NN O
the NN NN O
basic NN NN O
domain NN NN O
of NN NN O
the NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
ZEBRA NN NN B-Protein
protein NN NN O
separates NN NN O
its NN NN O
functions NN NN O
of NN NN O
transcriptional NN NN O
activation NN NN O
and NN NN O
disruption NN NN O
of NN NN O
latency NN NN O
. NN NN O
   
The NN NN O
ZEBRA NN NN B-Protein
protein NN NN O
from NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
activates NN NN O
a NN NN O
switch NN NN O
from NN NN O
the NN NN O
latent NN NN O
to NN NN O
the NN NN O
lytic NN NN O
expression NN NN O
program NN NN O
of NN NN O
the NN NN O
virus NN NN O
. NN NN O
   
ZEBRA NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
bZIP NN NN O
family NN NN O
of NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
is NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
expression NN NN O
from NN NN O
viral NN NN O
lytic NN NN O
cycle NN NN O
promoters NN NN O
. NN NN O
   
It NN NN O
had NN NN O
previously NN NN O
been NN NN O
thought NN NN O
that NN NN O
ZEBRA NN NN B-Protein
' NN NN O
s NN NN O
capacity NN NN O
to NN NN O
disrupt NN NN O
EBV NN NN O
latency NN NN O
resided NN NN O
primarily NN NN O
in NN NN O
its NN NN O
ability NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
that NN NN O
encode NN NN O
products NN NN O
required NN NN O
for NN NN O
lytic NN NN O
replication NN NN O
. NN NN O
   
We NN NN O
generated NN NN O
a NN NN O
point NN NN O
mutant NN NN O
of NN NN O
ZEBRA NN NN B-Protein
, NN NN O
Z NN NN O
( NN NN O
S186A NN NN O
) NN NN O
, NN NN O
that NN NN O
was NN NN O
not NN NN O
impaired NN NN O
in NN NN O
its NN NN O
ability NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
; NN NN O
however NN NN O
, NN NN O
this NN NN O
mutation NN NN O
abolished NN NN O
its NN NN O
ability NN NN O
to NN NN O
initiate NN NN O
the NN NN O
viral NN NN O
lytic NN NN O
cascade NN NN O
. NN NN O
   
The NN NN O
mutant NN NN O
, NN NN O
containing NN NN O
a NN NN O
serine NN NN O
- NN NN O
to NN NN O
- NN NN O
alanine NN NN O
substitution NN NN O
in NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
protein NN NN O
, NN NN O
bound NN NN O
to NN NN O
several NN NN O
known NN NN O
ZEBRA NN NN B-Protein
- NN NN O
binding NN NN O
sites NN NN O
and NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
reporters NN NN O
bearing NN NN O
known NN NN O
ZEBRA NN NN B-Protein
- NN NN O
responsive NN NN O
promoters NN NN O
but NN NN O
did NN NN O
not NN NN O
disrupt NN NN O
latency NN NN O
in NN NN O
EBV NN NN O
- NN NN O
infected NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
initiation NN NN O
of NN NN O
the NN NN O
EBV NN NN O
lytic NN NN O
cycle NN NN O
by NN NN O
the NN NN O
ZEBRA NN NN B-Protein
protein NN NN O
requires NN NN O
a NN NN O
function NN NN O
in NN NN O
addition NN NN O
to NN NN O
transcriptional NN NN O
activation NN NN O
; NN NN O
a NN NN O
change NN NN O
of NN NN O
serine NN NN O
186 NN NN O
to NN NN O
alanine NN NN O
in NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
of NN NN O
ZEBRA NN NN B-Protein
abolished NN NN O
this NN NN O
additional NN NN O
function NN NN O
and NN NN O
uncovered NN NN O
a NN NN O
new NN NN O
role NN NN O
for NN NN O
the NN NN O
ZEBRA NN NN B-Protein
protein NN NN O
in NN NN O
disruption NN NN O
of NN NN O
EBV NN NN O
latency NN NN O
. NN NN O
   
The NN NN O
additional NN NN O
function NN NN O
that NN NN O
is NN NN O
required NN NN O
for NN NN O
initiation NN NN O
of NN NN O
the NN NN O
lytic NN NN O
viral NN NN O
life NN NN O
cycle NN NN O
is NN NN O
likely NN NN O
to NN NN O
require NN NN O
phosphorylation NN NN O
of NN NN O
serine NN NN O
186 NN NN O
of NN NN O
the NN NN O
ZEBRA NN NN B-Protein
protein NN NN O
, NN NN O
which NN NN O
may NN NN O
influence NN NN O
either NN NN O
DNA NN NN O
recognition NN NN O
or NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
lytic NN NN O
viral NN NN O
promoters NN NN O
in NN NN O
a NN NN O
chromatinized NN NN O
viral NN NN O
episome NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
lipopolysaccharide NN NN O
- NN NN O
stimulated NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
During NN NN O
the NN NN O
course NN NN O
of NN NN O
serious NN NN O
bacterial NN NN O
infections NN NN O
, NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
interacts NN NN O
with NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
receptors NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
crucial NN NN O
in NN NN O
activating NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
proinflammatory NN NN O
cytokines NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
LPS NN NN O
in NN NN O
a NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
( NN NN O
U937 NN NN O
) NN NN O
followed NN NN O
a NN NN O
rather NN NN O
slow NN NN O
kinetics NN NN O
, NN NN O
depending NN NN O
on NN NN O
the NN NN O
rate NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
inhibitor NN NN O
hydrolysis NN NN O
. NN NN O
   
No NN NN O
degradation NN NN O
of NN NN O
p105 NN NN O
and NN NN O
p100 NN NN O
inhibitors NN NN O
was NN NN O
observed NN NN O
under NN NN O
these NN NN O
conditions NN NN O
. NN NN O
   
The NN NN O
transduction NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
involved NN NN O
the NN NN O
intracellular NN NN O
generation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
concomitant NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
antioxidants NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
the NN NN O
emission NN NN O
of NN NN O
a NN NN O
fluorescent NN NN O
probe NN NN O
reacting NN NN O
intracellularly NN NN O
with NN NN O
hydrogen NN NN O
peroxide NN NN O
. NN NN O
   
This NN NN O
ROS NN NN O
pathway NN NN O
was NN NN O
also NN NN O
characterized NN NN O
by NN NN O
the NN NN O
use NN NN O
of NN NN O
other NN NN O
inhibitors NN NN O
. NN NN O
   
This NN NN O
finding NN NN O
indicates NN NN O
that NN NN O
phospholipase NN NN O
A2 NN NN O
and NN NN O
5 NN NN B-Protein
- NN NN I-Protein
lipoxygenase NN NN I-Protein
are NN NN O
also NN NN O
involved NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
pathway NN NN O
involving NN NN O
the NN NN O
acidic NN NN B-Protein
sphingomyelinase NN NN I-Protein
of NN NN O
the NN NN O
endolysosomial NN NN O
membrane NN NN O
did NN NN O
not NN NN O
seem NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Possible NN NN O
role NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
germline NN NN O
C NN NN O
epsilon NN NN O
transcription NN NN O
in NN NN O
a NN NN O
human NN NN O
Burkitt NN NN O
lymphoma NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
plays NN NN O
a NN NN O
broad NN NN O
role NN NN O
in NN NN O
gene NN NN O
regulation NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
evident NN NN O
whether NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
acts NN NN O
as NN NN O
a NN NN O
messenger NN NN O
system NN NN O
for NN NN O
germline NN NN O
C NN NN O
epsilon NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
signaling NN NN O
cascade NN NN O
triggered NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
or NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
monoclonal NN NN O
antibody NN NN O
( NN NN O
mAb NN NN O
) NN NN O
participates NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
responsible NN NN O
for NN NN O
germline NN NN O
C NN NN O
epsilon NN NN O
transcription NN NN O
in NN NN O
a NN NN O
human NN NN O
Burkitt NN NN O
lymphoma NN NN O
B NN NN O
cell NN NN O
line NN NN O
, NN NN O
DND39 NN NN O
. NN NN O
   
Both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
mAb NN NN O
induced NN NN O
activation NN NN O
of NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
( NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
) NN NN O
, NN NN O
translocation NN NN O
of NN NN O
a NN NN O
zeta NN NN O
isoform NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
All NN NN O
such NN NN O
events NN NN O
were NN NN O
abrogated NN NN O
by NN NN O
treatment NN NN O
with NN NN O
LY294002 NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
antioxidant NN NN O
, NN NN O
decreased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
caused NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
mAb NN NN O
, NN NN O
or NN NN O
their NN NN O
combination NN NN O
. NN NN O
   
NAC NN NN O
was NN NN O
also NN NN O
effective NN NN O
in NN NN O
diminishing NN NN O
germline NN NN O
C NN NN O
epsilon NN NN O
transcription NN NN O
, NN NN O
and NN NN O
its NN NN O
potency NN NN O
was NN NN O
higher NN NN O
in NN NN O
cultures NN NN O
costimulated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
mAb NN NN O
than NN NN O
in NN NN O
those NN NN O
stimulated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
alone NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
ligation NN NN O
of NN NN O
CD40 NN NN B-Protein
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
expression NN NN O
via NN NN O
at NN NN O
least NN NN O
a NN NN O
mechanism NN NN O
dependent NN NN O
on NN NN O
the NN NN O
PI3 NN NN O
- NN NN O
kinase NN NN O
pathway NN NN O
and NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
sensitive NN NN O
to NN NN O
NAC NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
germline NN NN O
C NN NN O
epsilon NN NN O
transcription NN NN O
. NN NN O
   
T NN NN O
- NN NN O
lymphocytes NN NN O
from NN NN O
individuals NN NN O
with NN NN O
filarial NN NN O
inflammatory NN NN O
disease NN NN O
have NN NN O
increased NN NN O
transendothelial NN NN O
migration NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
in NN NN O
vitro NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
circulating NN NN O
filarial NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
T NN NN O
- NN NN O
cells NN NN O
was NN NN O
examined NN NN O
in NN NN O
Wuchereria NN NN O
banerofti NN NN O
infection NN NN O
. NN NN O
   
Circulating NN NN O
T NN NN O
- NN NN O
cells NN NN O
from NN NN O
individuals NN NN O
with NN NN O
filaria NN NN O
- NN NN O
induced NN NN O
lymphatic NN NN O
pathology NN NN O
( NN NN O
LP NN NN O
) NN NN O
had NN NN O
significantly NN NN O
greater NN NN O
migration NN NN O
through NN NN O
unstimulated NN NN O
HUVEC NN NN O
monolayers NN NN O
than NN NN O
did NN NN O
T NN NN O
- NN NN O
cells NN NN O
from NN NN O
asymptomatic NN NN O
infected NN NN O
( NN NN O
MF NN NN O
) NN NN O
individuals NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
04 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
MF NN NN O
individuals NN NN O
where NN NN O
no NN NN O
effect NN NN O
was NN NN O
seen NN NN O
, NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
48 NN NN O
- NN NN O
hr NN NN O
filarial NN NN O
antigen NN NN O
stimulated NN NN O
T NN NN O
- NN NN O
cells NN NN O
from NN NN O
LP NN NN O
individuals NN NN O
was NN NN O
significantly NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
greater NN NN O
than NN NN O
migration NN NN O
of NN NN O
48 NN NN O
- NN NN O
hr NN NN O
media NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
six NN NN O
of NN NN O
seven NN NN O
patients NN NN O
examined NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
VLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
/ NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
pathway NN NN O
resulted NN NN O
in NN NN O
greater NN NN O
than NN NN O
50 NN NN O
% NN NN O
inhibition NN NN O
of NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Suppression NN NN O
by NN NN O
azelastine NN NN O
hydrochloride NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
involved NN NN O
in NN NN O
generation NN NN O
of NN NN O
cytokines NN NN O
and NN NN O
nitric NN NN O
oxide NN NN O
. NN NN O
   
The NN NN O
influence NN NN O
of NN NN O
the NN NN O
anti NN NN O
- NN NN O
allergy NN NN O
agent NN NN O
azelastine NN NN O
hydrochloride NN NN O
( NN NN O
Azeptin NN NN O
) NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
associated NN NN O
with NN NN O
the NN NN O
generation NN NN O
of NN NN O
cytokines NN NN O
and NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
NO NN NN O
) NN NN O
was NN NN O
investigated NN NN O
in NN NN O
various NN NN O
kinds NN NN O
of NN NN O
human NN NN O
and NN NN O
mouse NN NN O
cells NN NN O
. NN NN O
   
Azeptin NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
suppressed NN NN O
both NN NN O
DNA NN NN O
and NN NN O
protein NN NN O
synthesis NN NN O
in NN NN O
human NN NN O
gingival NN NN O
fibroblasts NN NN O
( NN NN O
HF NN NN O
) NN NN O
and NN NN O
also NN NN O
suppressed NN NN O
blastogenesis NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
. NN NN O
   
Generation NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
1 NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
from NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
Azeptin NN NN O
- NN NN O
treated NN NN O
PBL NN NN O
and NN NN O
human NN NN O
monocytes NN NN O
( NN NN O
HM NN NN O
) NN NN O
was NN NN O
decreased NN NN O
to NN NN O
approximately NN NN O
1 NN NN O
/ NN NN O
3 NN NN O
to NN NN O
2 NN NN O
/ NN NN O
3 NN NN O
of NN NN O
the NN NN O
control NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
parallel NN NN O
with NN NN O
the NN NN O
decreased NN NN O
cytokine NN NN O
generation NN NN O
, NN NN O
each NN NN O
cytokine NN NN O
mRNA NN NN O
was NN NN O
less NN NN O
expressed NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
Azeptin NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
both NN NN O
inducible NN NN O
nitric NN NN B-Protein
oxide NN NN I-Protein
synthase NN NN I-Protein
- NN NN O
mRNA NN NN O
level NN NN O
and NN NN O
NO NN NN O
generation NN NN O
in NN NN O
mouse NN NN O
peritoneal NN NN O
macrophages NN NN O
were NN NN O
suppressed NN NN O
by NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
Azeptin NN NN O
. NN NN O
   
Being NN NN O
compatible NN NN O
with NN NN O
those NN NN O
results NN NN O
, NN NN O
Azeptin NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
5 NN NN O
) NN NN O
M NN NN O
) NN NN O
suppressed NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
PBL NN NN O
, NN NN O
HM NN NN O
and NN NN O
HF NN NN O
. NN NN O
   
These NN NN O
results NN NN O
appear NN NN O
to NN NN O
indicate NN NN O
that NN NN O
suppression NN NN O
of NN NN O
cytokine NN NN O
and NN NN O
NO NN NN O
generation NN NN O
by NN NN O
Azeptin NN NN O
results NN NN O
at NN NN O
least NN NN O
partially NN NN O
from NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
T NN NN O
cell NN NN O
activation NN NN O
factor NN NN O
NF NN NN O
- NN NN O
ATc NN NN O
positively NN NN O
regulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Clinical NN NN O
deterioration NN NN O
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
infection NN NN O
is NN NN O
associated NN NN O
with NN NN O
increased NN NN O
levels NN NN O
of NN NN O
viral NN NN O
replication NN NN O
and NN NN O
burden NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
and NN NN O
lymphoid NN NN O
organs NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
activation NN NN O
and NN NN O
ensuing NN NN O
cellular NN NN O
gene NN NN O
activation NN NN O
can NN NN O
be NN NN O
critical NN NN O
for NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
The NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
may NN NN O
influence NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
is NN NN O
therefore NN NN O
compelling NN NN O
given NN NN O
the NN NN O
tight NN NN O
correlation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
induction NN NN O
to NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
report NN NN O
that NN NN O
certain NN NN O
NF NN NN O
- NN NN O
AT NN NN O
( NN NN O
Rel NN NN O
) NN NN O
family NN NN O
members NN NN O
productively NN NN O
bind NN NN O
the NN NN O
kappaB NN NN O
regulatory NN NN O
elements NN NN O
, NN NN O
synergize NN NN O
with NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
Tat NN NN B-Protein
in NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
enhance NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
link NN NN O
regulatory NN NN O
factors NN NN O
critical NN NN O
to NN NN O
T NN NN O
cell NN NN O
commitment NN NN O
directly NN NN O
to NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Differentiation NN NN O
of NN NN O
T NN NN O
- NN NN O
helper NN NN O
lymphocytes NN NN O
: NN NN O
selective NN NN O
regulation NN NN O
by NN NN O
members NN NN O
of NN NN O
the NN NN O
STAT NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN O
- NN NN O
12 NN NN O
( NN NN O
IL NN NN O
- NN NN O
12 NN NN O
) NN NN O
control NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
T NN NN O
- NN NN O
helper NN NN O
cells NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
summarize NN NN O
studies NN NN O
which NN NN O
investigate NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
these NN NN O
cytokines NN NN O
selectively NN NN O
reprogramme NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
. NN NN O
   
Cytokine NN NN O
stimulation NN NN O
leads NN NN O
to NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
specific NN NN O
tyrosine NN NN O
residues NN NN O
within NN NN O
the NN NN O
intracellular NN NN O
domain NN NN O
of NN NN O
the NN NN O
corresponding NN NN O
cytokine NN NN O
receptor NN NN O
. NN NN O
   
These NN NN O
phosphotyrosines NN NN O
serve NN NN O
as NN NN O
docking NN NN O
sites NN NN O
for NN NN O
latent NN NN O
, NN NN O
cytoplasmic NN NN O
transcription NN NN O
factors NN NN O
known NN NN O
as NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
Stat NN NN O
) NN NN O
proteins NN NN O
. NN NN O
   
Receptor NN NN O
/ NN NN O
Stat NN NN O
interaction NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
src NN NN O
homology NN NN O
2 NN NN O
( NN NN O
SH2 NN NN O
) NN NN O
domain NN NN O
of NN NN O
the NN NN O
corresponding NN NN O
Stat NN NN O
protein NN NN O
. NN NN O
   
Although NN NN O
Stat NN NN O
binding NN NN O
to NN NN O
the NN NN O
intracellular NN NN O
domain NN NN O
of NN NN O
the NN NN O
cytokine NN NN O
receptor NN NN O
strongly NN NN O
depends NN NN O
on NN NN O
the NN NN O
phosphotyrosine NN NN O
residue NN NN O
, NN NN O
the NN NN O
recruitment NN NN O
of NN NN O
a NN NN O
specific NN NN O
Stat NN NN O
protein NN NN O
is NN NN O
dictated NN NN O
by NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
C NN NN O
- NN NN O
terminal NN NN O
to NN NN O
the NN NN O
phosphotyrosine NN NN O
. NN NN O
   
Specific NN NN O
docking NN NN O
sites NN NN O
within NN NN O
individual NN NN O
cytokine NN NN O
receptors NN NN O
have NN NN O
been NN NN O
identified NN NN O
for NN NN O
almost NN NN O
all NN NN O
Stat NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
direct NN NN O
coupling NN NN O
between NN NN O
cytokine NN NN O
receptor NN NN O
and NN NN O
transcription NN NN O
factor NN NN O
helps NN NN O
to NN NN O
explain NN NN O
how NN NN O
different NN NN O
cytokines NN NN O
elicit NN NN O
distinct NN NN O
patterns NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
the NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
gene NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
proteins NN NN O
in NN NN O
uninduced NN NN O
and NN NN O
lipopolysaccharide NN NN O
- NN NN O
induced NN NN O
expression NN NN O
. NN NN O
   
Tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
expression NN NN O
by NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
during NN NN O
sepsis NN NN O
initiates NN NN O
intravascular NN NN O
thrombosis NN NN O
. NN NN O
   
Bacterial NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
rapidly NN NN O
induces NN NN O
TF NN NN B-Protein
gene NN NN O
transcription NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
human NN NN O
TF NN NN B-Protein
promoter NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
proteins NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
physically NN NN O
interact NN NN O
with NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
Sp1 NN NN B-Protein
proteins NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
role NN NN O
of NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
uninduced NN NN O
and NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TF NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Deletional NN NN O
analysis NN NN O
indicated NN NN O
that NN NN O
five NN NN O
Sp1 NN NN B-Protein
sites NN NN O
mediated NN NN O
basal NN NN O
expression NN NN O
in NN NN O
uninduced NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
two NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
bound NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
heterodimers NN NN O
in NN NN O
both NN NN O
unstimulated NN NN O
and NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
. NN NN O
   
Maximal NN NN O
LPS NN NN O
induction NN NN O
of NN NN O
the NN NN O
TF NN NN B-Protein
promoter NN NN O
required NN NN O
the NN NN O
two NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
and NN NN O
the NN NN O
kappa NN NN O
B NN NN O
site NN NN O
within NN NN O
the NN NN O
LPS NN NN O
response NN NN O
element NN NN O
. NN NN O
   
Disruption NN NN O
of NN NN O
the NN NN O
conserved NN NN O
spacing NN NN O
between NN NN O
the NN NN O
proximal NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
and NN NN O
the NN NN O
kappa NN NN O
B NN NN O
site NN NN O
abolished NN NN O
LPS NN NN O
induction NN NN O
. NN NN O
   
Replacement NN NN O
of NN NN O
the NN NN O
two NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
with NN NN O
intrinsically NN NN O
bent NN NN O
DNA NN NN O
partially NN NN O
restored NN NN O
LPS NN NN O
induction NN NN O
, NN NN O
suggesting NN NN O
an NN NN O
additional NN NN O
structural NN NN O
role NN NN O
for NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
. NN NN O
   
Synergistic NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
LPS NN NN O
response NN NN O
element NN NN O
in NN NN O
Drosophila NN NN O
Schneider NN NN O
cells NN NN O
by NN NN O
coexpression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
and NN NN O
p65 NN NN B-Protein
or NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
required NN NN O
the NN NN O
transactivation NN NN O
domains NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
. NN NN O
   
These NN NN O
data NN NN O
indicated NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
/ NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
/ NN NN O
p65 NN NN B-Protein
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
regulate NN NN O
TF NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Physical NN NN O
interactions NN NN O
between NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
proteins NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
their NN NN O
cooperative NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
enhancer NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
regulatory NN NN O
elements NN NN O
of NN NN O
many NN NN O
inducible NN NN O
T NN NN O
- NN NN O
cell NN NN O
genes NN NN O
contain NN NN O
adjacent NN NN O
or NN NN O
overlapping NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
families NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Similar NN NN O
arrays NN NN O
of NN NN O
functionally NN NN O
important NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
and NN NN O
Ets NN NN O
binding NN NN O
sites NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
enhancers NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
viruses NN NN O
types NN NN O
1 NN NN O
and NN NN O
2 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
) NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
pattern NN NN O
of NN NN O
nuclear NN NN O
protein NN NN O
binding NN NN O
sites NN NN O
reflects NN NN O
an NN NN O
evolutionarily NN NN O
conserved NN NN O
mechanism NN NN O
for NN NN O
regulating NN NN O
inducible NN NN O
T NN NN O
- NN NN O
cell NN NN O
gene NN NN O
expression NN NN O
that NN NN O
has NN NN O
been NN NN O
co NN NN O
- NN NN O
opted NN NN O
during NN NN O
HIV NN NN O
evolution NN NN O
. NN NN O
   
Despite NN NN O
these NN NN O
findings NN NN O
, NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
proteins NN NN O
cooperatively NN NN O
regulate NN NN O
inducible NN NN O
T NN NN O
- NN NN O
cell NN NN O
gene NN NN O
expression NN NN O
remained NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
the NN NN O
studies NN NN O
described NN NN O
in NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
a NN NN O
physical NN NN O
interaction NN NN O
between NN NN O
multiple NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
proteins NN NN O
both NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
activated NN NN O
normal NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
interaction NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
Ets NN NN O
domain NN NN O
of NN NN O
Ets NN NN O
proteins NN NN O
and NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
the NN NN O
Rel NN NN O
homology NN NN O
domains NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
proteins NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
Ets NN NN O
- NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
interaction NN NN O
requires NN NN O
the NN NN O
presence NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
sites NN NN O
for NN NN O
both NN NN O
proteins NN NN O
, NN NN O
as NN NN O
it NN NN O
is NN NN O
abolished NN NN O
by NN NN O
the NN NN O
DNA NN NN O
intercalating NN NN O
agents NN NN O
propidium NN NN O
iodide NN NN O
and NN NN O
ethidium NN NN O
bromide NN NN O
and NN NN O
enhanced NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
synthetic NN NN O
oligonucleotides NN NN O
containing NN NN O
binding NN NN O
sites NN NN O
for NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
. NN NN O
   
A NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
mutant NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
p50 NN NN B-Protein
that NN NN O
binds NN NN O
DNA NN NN O
but NN NN O
fails NN NN O
to NN NN O
interact NN NN O
with NN NN O
Ets NN NN O
proteins NN NN O
inhibits NN NN O
the NN NN O
synergistic NN NN O
activation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancers NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
p50 NN NN B-Protein
+ NN NN O
p65 NN NN B-Protein
) NN NN O
and NN NN O
Ets NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
suggesting NN NN O
that NN NN O
physical NN NN O
interaction NN NN O
between NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
and NN NN O
HIV NN NN O
- NN NN O
2 NN NN O
enhancers NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
evolutionarily NN NN O
conserved NN NN O
physical NN NN O
interactions NN NN O
between NN NN O
Ets NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
NFAT NN NN O
proteins NN NN O
are NN NN O
important NN NN O
in NN NN O
regulating NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
genes NN NN O
and NN NN O
viruses NN NN O
. NN NN O
   
These NN NN O
interactions NN NN O
represent NN NN O
a NN NN O
potential NN NN O
target NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
novel NN NN O
immunosuppressive NN NN O
and NN NN O
antiviral NN NN O
therapies NN NN O
. NN NN O
   
Oxidant NN NN O
- NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
chronically NN NN O
inflamed NN NN O
intestine NN NN O
. NN NN O
   
It NN NN O
is NN NN O
becoming NN NN O
increasingly NN NN O
apparent NN NN O
that NN NN O
the NN NN O
chronic NN NN O
gut NN NN O
inflammation NN NN O
observed NN NN O
in NN NN O
the NN NN O
idiopathic NN NN O
inflammatory NN NN O
bowel NN NN O
diseases NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
ulcerative NN NN O
colitis NN NN O
, NN NN O
Crohn NN NN O
' NN NN O
s NN NN O
disease NN NN O
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
production NN NN O
of NN NN O
leukocyte NN NN O
- NN NN O
derived NN NN O
oxidants NN NN O
. NN NN O
   
Oxidants NN NN O
such NN NN O
as NN NN O
hydrogen NN NN O
peroxide NN NN O
are NN NN O
known NN NN O
to NN NN O
activate NN NN O
certain NN NN O
transcription NN NN O
factors NN NN O
such NN NN O
as NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
kappa NN NN O
beta NN NN O
. NN NN O
   
Nuclear NN NN O
transcription NN NN O
factor NN NN O
kB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
pleiotropic NN NN O
regulator NN NN O
of NN NN O
numerous NN NN O
genes NN NN O
involved NN NN O
in NN NN O
the NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
This NN NN O
transcription NN NN O
factor NN NN O
is NN NN O
activated NN NN O
via NN NN O
the NN NN O
selective NN NN O
phosphorylation NN NN O
, NN NN O
ubiquination NN NN O
and NN NN O
degradation NN NN O
of NN NN O
its NN NN O
inhibitor NN NN O
protein NN NN O
I NN NN O
- NN NN O
kB NN NN O
thereby NN NN O
allowing NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
where NN NN O
it NN NN O
upregulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
cytokines NN NN O
( NN NN O
TNF NN NN O
, NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
) NN NN O
and NN NN O
enzymes NN NN O
( NN NN O
iNOS NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
proteolytic NN NN O
degradation NN NN O
of NN NN O
the NN NN O
post NN NN O
- NN NN O
translationally NN NN O
modified NN NN O
I NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
26S NN NN B-Protein
proteasome NN NN I-Protein
complex NN NN O
. NN NN O
   
Based NN NN O
upon NN NN O
work NN NN O
from NN NN O
our NN NN O
laboratory NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
produces NN NN O
significant NN NN O
anti NN NN O
inflammatory NN NN O
activity NN NN O
which NN NN O
may NN NN O
be NN NN O
mediated NN NN O
by NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
transcription NN NN O
of NN NN O
certain NN NN O
pro NN NN O
- NN NN O
inflammatory NN NN O
mediators NN NN O
and NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
in NN NN O
follicular NN NN O
center NN NN O
( NN NN O
FC NN NN O
) NN NN O
B NN NN O
cells NN NN O
of NN NN O
reactive NN NN O
lymph NN NN O
nodes NN NN O
and NN NN O
FC NN NN O
- NN NN O
derived NN NN O
non NN NN O
- NN NN O
Hodgkin NN NN O
lymphomas NN NN O
. NN NN O
   
Chromosomal NN NN O
translocation NN NN O
resulting NN NN O
in NN NN O
abnormal NN NN O
expression NN NN O
of NN NN O
the NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
gene NN NN O
in NN NN O
B NN NN O
cells NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
tumorigenesis NN NN O
of NN NN O
non NN NN O
- NN NN O
Hodgkin NN NN O
lymphoma NN NN O
( NN NN O
NHL NN NN O
) NN NN O
. NN NN O
   
Therefore NN NN O
we NN NN O
studied NN NN O
the NN NN O
expression NN NN O
pattern NN NN O
of NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
with NN NN O
synthetic NN NN O
oligonucleotide NN NN O
probes NN NN O
in NN NN O
frozen NN NN O
tissue NN NN O
sections NN NN O
from NN NN O
five NN NN O
reactive NN NN O
lymph NN NN O
nodes NN NN O
and NN NN O
38 NN NN O
B NN NN O
cell NN NN O
and NN NN O
non NN NN O
- NN NN O
B NN NN O
NHL NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
expression NN NN O
of NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
on NN NN O
multiple NN NN O
human NN NN O
tissues NN NN O
. NN NN O
   
The NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
transcript NN NN O
was NN NN O
found NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
tissues NN NN O
, NN NN O
including NN NN O
skeletal NN NN O
muscle NN NN O
, NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
, NN NN O
and NN NN O
weakly NN NN O
in NN NN O
normal NN NN O
lymph NN NN O
nodes NN NN O
. NN NN O
   
In NN NN O
the NN NN O
tumor NN NN O
samples NN NN O
, NN NN O
expression NN NN O
of NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
was NN NN O
observed NN NN O
in NN NN O
68 NN NN O
% NN NN O
of NN NN O
all NN NN O
B NN NN O
cell NN NN O
NHL NN NN O
and NN NN O
none NN NN O
of NN NN O
the NN NN O
non NN NN O
- NN NN O
B NN NN O
lymphomas NN NN O
. NN NN O
   
All NN NN O
cases NN NN O
of NN NN O
follicular NN NN O
, NN NN O
mixed NN NN O
small NN NN O
and NN NN O
large NN NN O
cell NN NN O
lymphomas NN NN O
showed NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
expression NN NN O
confined NN NN O
to NN NN O
the NN NN O
neoplastic NN NN O
follicles NN NN O
. NN NN O
   
A NN NN O
follicular NN NN O
expression NN NN O
pattern NN NN O
was NN NN O
also NN NN O
found NN NN O
in NN NN O
all NN NN O
non NN NN O
- NN NN O
malignant NN NN O
reactive NN NN O
lymph NN NN O
nodes NN NN O
. NN NN O
   
Hence NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
LAZ3 NN NN B-Protein
/ NN NN O
BCL6 NN NN B-Protein
does NN NN O
not NN NN O
correlate NN NN O
to NN NN O
malignancy NN NN O
, NN NN O
but NN NN O
reflects NN NN O
the NN NN O
origin NN NN O
of NN NN O
B NN NN O
cells NN NN O
from NN NN O
the NN NN O
germinal NN NN O
centers NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
relA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
subunit NN NN O
expression NN NN O
during NN NN O
differentiation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
to NN NN O
macrophages NN NN O
. NN NN O
   
We NN NN O
evaluated NN NN O
the NN NN O
expression NN NN O
and NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
and NN NN O
in NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
( NN NN O
MDMs NN NN O
) NN NN O
. NN NN O
   
Constitutive NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
consisting NN NN O
of NN NN O
p50 NN NN B-Protein
homodimers NN NN O
was NN NN O
detected NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
An NN NN O
additional NN NN O
complex NN NN O
composed NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimers NN NN O
appeared NN NN O
only NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
7 NN NN O
- NN NN O
day NN NN O
MDMs NN NN O
. NN NN O
   
Immunoblot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
was NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
MDMs NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
subunit NN NN O
was NN NN O
barely NN NN O
detectable NN NN O
in NN NN O
monocytes NN NN O
, NN NN O
but NN NN O
its NN NN O
level NN NN O
increased NN NN O
markedly NN NN O
in NN NN O
MDMs NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
mRNA NN NN O
revealed NN NN O
that NN NN O
the NN NN O
stability NN NN O
of NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
mRNA NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
MDMs NN NN O
, NN NN O
compared NN NN O
with NN NN O
monocytes NN NN O
. NN NN O
   
In NN NN O
MDMs NN NN O
, NN NN O
an NN NN O
upregulation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
appearance NN NN O
of NN NN O
a NN NN O
novel NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
40 NN NN O
, NN NN O
000 NN NN O
form NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
were NN NN O
also NN NN O
observed NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
macrophage NN NN O
differentiation NN NN O
results NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
active NN NN O
p50 NN NN B-Protein
/ NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
heterodimers NN NN O
with NN NN O
the NN NN O
capacity NN NN O
to NN NN O
activate NN NN O
target NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
parallel NN NN O
induction NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
synthesis NN NN O
may NN NN O
allow NN NN O
for NN NN O
the NN NN O
continuous NN NN O
presence NN NN O
of NN NN O
a NN NN O
cytoplasmic NN NN O
reservoir NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
complexes NN NN O
that NN NN O
are NN NN O
readily NN NN O
available NN NN O
for NN NN O
inducer NN NN O
- NN NN O
mediated NN NN O
stimulation NN NN O
. NN NN O
   
Two NN NN O
distinct NN NN O
pathways NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
in NN NN O
allergen NN NN O
- NN NN O
specific NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
are NN NN O
suppressed NN NN O
by NN NN O
glucocorticoids NN NN O
. NN NN O
   
Glucocorticoids NN NN O
( NN NN O
GC NN NN O
) NN NN O
have NN NN O
long NN NN O
been NN NN O
used NN NN O
as NN NN O
the NN NN O
most NN NN O
effective NN NN O
agents NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
allergic NN NN O
diseases NN NN O
accompanied NN NN O
by NN NN O
eosinophilia NN NN O
such NN NN O
as NN NN O
chronic NN NN O
asthma NN NN O
and NN NN O
atopic NN NN O
dermatitis NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
chronic NN NN O
eosinophilic NN NN O
inflammation NN NN O
is NN NN O
dependent NN NN O
on NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
selective NN NN O
eosinophil NN NN O
- NN NN O
activating NN NN O
factor NN NN O
, NN NN O
produced NN NN O
by NN NN O
helper NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
delineate NN NN O
the NN NN O
regulatory NN NN O
mechanisms NN NN O
of NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
, NN NN O
we NN NN O
established NN NN O
allergen NN NN O
- NN NN O
specific NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
from NN NN O
asthmatic NN NN O
patients NN NN O
. NN NN O
   
GC NN NN O
efficiently NN NN O
suppressed NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
activated NN NN O
via NN NN O
either NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
or NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
2R NN NN O
) NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
mRNA NN NN O
upon NN NN O
TCR NN NN O
and NN NN O
IL NN NN O
- NN NN O
2R NN NN O
stimulation NN NN O
was NN NN O
totally NN NN O
inhibited NN NN O
by NN NN O
dexamethasone NN NN O
. NN NN O
   
Human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
luciferase NN NN O
gene NN NN O
construct NN NN O
transfected NN NN O
to NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
was NN NN O
transcribed NN NN O
on NN NN O
either NN NN O
TCR NN NN O
or NN NN O
IL NN NN O
- NN NN O
2R NN NN O
stimulation NN NN O
and NN NN O
was NN NN O
clearly NN NN O
downregulated NN NN O
by NN NN O
dexamethasone NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
approximately NN NN O
500 NN NN O
- NN NN O
bp NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
segment NN NN O
located NN NN O
5 NN NN O
' NN NN O
upstream NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
contains NN NN O
activation NN NN O
- NN NN O
inducible NN NN O
enhancer NN NN O
elements NN NN O
responsible NN NN O
for NN NN O
the NN NN O
regulation NN NN O
by NN NN O
GC NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
analysis NN NN O
suggested NN NN O
that NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
are NN NN O
among NN NN O
the NN NN O
possible NN NN O
targets NN NN O
of NN NN O
GC NN NN O
actions NN NN O
on NN NN O
TCR NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
AT NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
were NN NN O
not NN NN O
significantly NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
stimulation NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
showing NN NN O
that NN NN O
GC NN NN O
suppressed NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
production NN NN O
by NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
activated NN NN O
by NN NN O
two NN NN O
distinct NN NN O
stimuli NN NN O
, NN NN O
TCR NN NN O
and NN NN O
IL NN NN O
- NN NN O
2R NN NN O
stimulation NN NN O
, NN NN O
underscore NN NN O
the NN NN O
efficacy NN NN O
of NN NN O
GC NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
allergic NN NN O
diseases NN NN O
via NN NN O
suppression NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
an NN NN O
SAF NN NN O
- NN NN O
like NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
serum NN NN B-Protein
amyloid NN NN I-Protein
A NN NN I-Protein
gene NN NN O
in NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cells NN NN O
by NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Serum NN NN B-Protein
amyloid NN NN I-Protein
A NN NN I-Protein
( NN NN O
SAA NN NN B-Protein
) NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
atherosclerosis NN NN O
because NN NN O
of NN NN O
its NN NN O
ability NN NN O
to NN NN O
remodel NN NN O
high NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
by NN NN O
the NN NN O
depletion NN NN O
of NN NN O
apolipoprotein NN NN O
A1 NN NN O
, NN NN O
its NN NN O
ability NN NN O
to NN NN O
bind NN NN O
cholesterol NN NN O
, NN NN O
and NN NN O
its NN NN O
presence NN NN O
in NN NN O
the NN NN O
atherosclerotic NN NN O
plaques NN NN O
of NN NN O
coronary NN NN O
and NN NN O
carotid NN NN O
arteries NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
induction NN NN O
mechanism NN NN O
of NN NN O
SAA NN NN B-Protein
gene NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cells NN NN O
which NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
atherosclerotic NN NN O
fatty NN NN O
streak NN NN O
and NN NN O
plaque NN NN O
formation NN NN O
. NN NN O
   
We NN NN O
and NN NN O
others NN NN O
have NN NN O
shown NN NN O
that NN NN O
SAA NN NN B-Protein
gene NN NN O
is NN NN O
induced NN NN O
in NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cells NN NN O
by NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
By NN NN O
promoter NN NN O
function NN NN O
analysis NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
SAA NN NN B-Protein
promoter NN NN O
sequence NN NN O
between NN NN O
- NN NN O
280 NN NN O
and NN NN O
- NN NN O
226 NN NN O
can NN NN O
confer NN NN O
LPS NN NN O
responsiveness NN NN O
. NN NN O
   
Gel NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
detected NN NN O
an NN NN O
induced NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
these NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
by NN NN O
UV NN NN O
cross NN NN O
- NN NN O
linking NN NN O
, NN NN O
Southwestern NN NN O
blot NN NN O
, NN NN O
and NN NN O
antibody NN NN O
ablation NN NN O
/ NN NN O
supershift NN NN O
assays NN NN O
revealed NN NN O
that NN NN O
it NN NN O
is NN NN O
similar NN NN O
to NN NN O
a NN NN O
recently NN NN O
reported NN NN O
nuclear NN NN O
factor NN NN O
designated NN NN O
SAF NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
SAA NN NN B-Protein
gene NN NN O
induction NN NN O
in NN NN O
monocyte NN NN O
/ NN NN O
macrophage NN NN O
cells NN NN O
is NN NN O
primarily NN NN O
due NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
SAF NN NN O
activity NN NN O
. NN NN O
   
Oncogenic NN NN O
forms NN NN O
of NN NN O
NOTCH1 NN NN B-Protein
lacking NN NN O
either NN NN O
the NN NN O
primary NN NN O
binding NN NN O
site NN NN O
for NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
or NN NN O
nuclear NN NN O
localization NN NN O
sequences NN NN O
retain NN NN O
the NN NN O
ability NN NN O
to NN NN O
associate NN NN O
with NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
and NN NN O
activate NN NN O
transcription NN NN O
. NN NN O
   
Truncated NN NN O
forms NN NN O
of NN NN O
the NN NN O
NOTCH1 NN NN B-Protein
transmembrane NN NN O
receptor NN NN O
engineered NN NN O
to NN NN O
resemble NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
NOTCH1 NN NN B-Protein
found NN NN O
in NN NN O
certain NN NN O
cases NN NN O
of NN NN O
human NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
/ NN NN O
lymphoma NN NN O
( NN NN O
T NN NN O
- NN NN O
ALL NN NN O
) NN NN O
efficiently NN NN O
induce NN NN O
T NN NN O
- NN NN O
ALL NN NN O
when NN NN O
expressed NN NN O
in NN NN O
the NN NN O
bone NN NN O
marrow NN NN O
of NN NN O
mice NN NN O
. NN NN O
   
Unlike NN NN O
full NN NN O
- NN NN O
sized NN NN O
NOTCH1 NN NN B-Protein
, NN NN O
two NN NN O
such NN NN O
truncated NN NN O
forms NN NN O
of NN NN O
the NN NN O
protein NN NN O
either NN NN O
lacking NN NN O
a NN NN O
major NN NN O
portion NN NN O
of NN NN O
the NN NN O
extracellular NN NN O
domain NN NN O
( NN NN O
DeltaE NN NN O
) NN NN O
or NN NN O
consisting NN NN O
only NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
domain NN NN O
( NN NN O
ICN NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
activate NN NN O
transcription NN NN O
in NN NN O
cultured NN NN O
cells NN NN O
, NN NN O
presumably NN NN O
through NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
response NN NN O
elements NN NN O
within NN NN O
DNA NN NN O
. NN NN O
   
Both NN NN O
truncated NN NN O
forms NN NN O
also NN NN O
bound NN NN O
to NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
in NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
human NN NN O
and NN NN O
murine NN NN O
T NN NN O
- NN NN O
ALL NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
required NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
weak NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
within NN NN O
the NN NN O
NOTCH1 NN NN B-Protein
ankyrin NN NN O
repeat NN NN O
region NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
domain NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
a NN NN O
second NN NN O
, NN NN O
stronger NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
- NN NN O
binding NN NN O
site NN NN O
, NN NN O
which NN NN O
lies NN NN O
within NN NN O
the NN NN O
intracellular NN NN O
domain NN NN O
close NN NN O
to NN NN O
the NN NN O
transmembrane NN NN O
region NN NN O
and NN NN O
significantly NN NN O
augments NN NN O
association NN NN O
with NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
, NN NN O
was NN NN O
not NN NN O
needed NN NN O
for NN NN O
oncogenesis NN NN O
or NN NN O
for NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
While NN NN O
ICN NN NN O
appeared NN NN O
primarily NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
DeltaE NN NN O
localized NN NN O
to NN NN O
cytoplasmic NN NN O
and NN NN O
nuclear NN NN O
membranes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
intranuclear NN NN O
localization NN NN O
is NN NN O
not NN NN O
essential NN NN O
for NN NN O
oncogenesis NN NN O
or NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
support NN NN O
of NN NN O
this NN NN O
interpretation NN NN O
, NN NN O
mutation NN NN O
of NN NN O
putative NN NN O
nuclear NN NN O
localization NN NN O
sequences NN NN O
decreased NN NN O
nuclear NN NN O
localization NN NN O
and NN NN O
increased NN NN O
transcriptional NN NN O
activation NN NN O
by NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
DeltaE NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
by NN NN O
this NN NN O
mutant NN NN O
form NN NN O
of NN NN O
membrane NN NN O
- NN NN O
bound NN NN O
DeltaE NN NN O
was NN NN O
approximately NN NN O
equivalent NN NN O
to NN NN O
that NN NN O
produced NN NN O
by NN NN O
intranuclear NN NN O
ICN NN NN O
. NN NN O
   
These NN NN O
data NN NN O
are NN NN O
most NN NN O
consistent NN NN O
with NN NN O
NOTCH1 NN NN B-Protein
oncogenesis NN NN O
and NN NN O
transcriptional NN NN O
activation NN NN O
being NN NN O
independent NN NN O
of NN NN O
association NN NN O
with NN NN O
RBP NN NN B-Protein
- NN NN I-Protein
Jkappa NN NN I-Protein
at NN NN O
promoter NN NN O
sites NN NN O
. NN NN O
   
Transcriptional NN NN O
induction NN NN O
of NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
differentiated NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
( NN NN O
U937 NN NN O
) NN NN O
cells NN NN O
is NN NN O
regulated NN NN O
by NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
an NN NN O
upstream NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
site NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
site NN NN O
and NN NN O
a NN NN O
distal NN NN O
promoter NN NN O
element NN NN O
regulate NN NN O
transcriptional NN NN O
induction NN NN O
of NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
during NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O
   
Chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
expression NN NN O
constructs NN NN O
containing NN NN O
regions NN NN O
of NN NN O
the NN NN O
human NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
were NN NN O
stably NN NN O
or NN NN O
transiently NN NN O
transfected NN NN O
into NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
and NN NN O
reporter NN NN O
activity NN NN O
was NN NN O
assessed NN NN O
at NN NN O
various NN NN O
times NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
- NN NN O
mediated NN NN O
differentiation NN NN O
. NN NN O
   
Rapid NN NN O
and NN NN O
strong NN NN O
induction NN NN O
of NN NN O
promoter NN NN O
activity NN NN O
was NN NN O
lost NN NN O
in NN NN O
constructs NN NN O
with NN NN O
a NN NN O
mutant NN NN O
AP NN NN O
- NN NN O
1 NN NN O
element NN NN O
; NN NN O
however NN NN O
, NN NN O
at NN NN O
16 NN NN O
- NN NN O
96 NN NN O
h NN NN O
post NN NN O
- NN NN O
PMA NN NN O
, NN NN O
the NN NN O
mutant NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
displayed NN NN O
AP NN NN O
- NN NN O
1 NN NN O
independent NN NN O
PMA NN NN O
- NN NN O
mediated NN NN O
transactivation NN NN O
. NN NN O
   
The NN NN O
AP NN NN O
- NN NN O
1 NN NN O
mutant NN NN O
constructs NN NN O
also NN NN O
showed NN NN O
delayed NN NN O
transcriptional NN NN O
activation NN NN O
in NN NN O
PMA NN NN O
- NN NN O
treated NN NN O
fibroblasts NN NN O
. NN NN O
   
Western NN NN O
and NN NN O
supershift NN NN O
analyses NN NN O
indicated NN NN O
that NN NN O
functional NN NN O
Jun NN NN O
and NN NN O
Fos NN NN O
proteins NN NN O
were NN NN O
present NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
of NN NN O
PMA NN NN O
- NN NN O
differentiated NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Promoter NN NN O
deletion NN NN O
constructs NN NN O
demonstrated NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
distal NN NN O
promoter NN NN O
sequences NN NN O
in NN NN O
regulating NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
Western NN NN O
, NN NN O
supershift NN NN O
, NN NN O
and NN NN O
promoter NN NN O
deletion NN NN O
analyses NN NN O
suggested NN NN O
a NN NN O
role NN NN O
for NN NN O
CCAAT NN NN B-Protein
/ NN NN I-Protein
enhancer NN NN I-Protein
- NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
( NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
beta NN NN I-Protein
) NN NN O
binding NN NN O
site NN NN O
between NN NN O
- NN NN O
2010 NN NN O
and NN NN O
- NN NN O
1954 NN NN O
in NN NN O
regulating NN NN O
transcription NN NN O
of NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
distinct NN NN O
regulatory NN NN O
elements NN NN O
, NN NN O
acting NN NN O
somewhat NN NN O
independently NN NN O
of NN NN O
each NN NN O
other NN NN O
, NN NN O
control NN NN O
expression NN NN O
of NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
our NN NN O
data NN NN O
suggests NN NN O
that NN NN O
the NN NN O
rapid NN NN O
PMA NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
collagenase NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
is NN NN O
controlled NN NN O
by NN NN O
a NN NN O
mechanism NN NN O
distinct NN NN O
from NN NN O
that NN NN O
regulating NN NN O
the NN NN O
sustained NN NN O
expression NN NN O
of NN NN O
this NN NN O
proteinase NN NN O
in NN NN O
activated NN NN O
macrophages NN NN O
. NN NN O
   
A NN NN O
novel NN NN O
genetic NN NN O
system NN NN O
to NN NN O
isolate NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
effector NN NN O
on NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Recent NN NN O
studies NN NN O
have NN NN O
revealed NN NN O
that NN NN O
interactions NN NN O
between NN NN O
transcription NN NN O
factors NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
eukaryotic NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
isolate NN NN O
cDNA NN NN O
clones NN NN O
that NN NN O
dominantly NN NN O
inhibit NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
chosen NN NN O
as NN NN O
a NN NN O
representative NN NN O
factor NN NN O
, NN NN O
we NN NN O
have NN NN O
developed NN NN O
a NN NN O
novel NN NN O
screening NN NN O
system NN NN O
. NN NN O
   
This NN NN O
employs NN NN O
an NN NN O
Escherichia NN NN O
coli NN NN O
tester NN NN O
strain NN NN O
carrying NN NN O
a NN NN O
modified NN NN O
lac NN NN O
operon NN NN O
as NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
, NN NN O
with NN NN O
the NN NN O
lac NN NN O
operator NN NN O
sequence NN NN O
replaced NN NN O
by NN NN O
an NN NN O
octamer NN NN O
sequence NN NN O
. NN NN O
   
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expressed NN NN O
in NN NN O
this NN NN O
tester NN NN O
strain NN NN O
represses NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
and NN NN O
changes NN NN O
the NN NN O
phenotype NN NN O
of NN NN O
the NN NN O
cell NN NN O
from NN NN O
Lac NN NN O
+ NN NN O
to NN NN O
Lac NN NN O
- NN NN O
. NN NN O
   
Introduction NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
expression NN NN O
library NN NN O
prepared NN NN O
from NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
into NN NN O
the NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
harboring NN NN O
tester NN NN O
strain NN NN O
allowed NN NN O
selection NN NN O
of NN NN O
three NN NN O
Lac NN NN O
+ NN NN O
clones NN NN O
out NN NN O
of NN NN O
1 NN NN O
x NN NN O
10 NN NN O
( NN NN O
5 NN NN O
) NN NN O
transformants NN NN O
. NN NN O
   
One NN NN O
of NN NN O
them NN NN O
, NN NN O
hT86 NN NN O
, NN NN O
encoding NN NN O
a NN NN O
putative NN NN O
zinc NN NN O
finger NN NN O
protein NN NN O
was NN NN O
found NN NN O
to NN NN O
derepress NN NN O
beta NN NN B-Protein
- NN NN I-Protein
galactosidase NN NN I-Protein
activity NN NN O
in NN NN O
the NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
harboring NN NN O
tester NN NN O
strain NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
In NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
hT86 NN NN O
attenuated NN NN O
the NN NN O
intensity NN NN O
of NN NN O
the NN NN O
retarded NN NN O
band NN NN O
composed NN NN O
of NN NN O
the NN NN O
octamer NN NN O
probe NN NN O
and NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
suggesting NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
effect NN NN O
on NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
The NN NN O
strategy NN NN O
described NN NN O
here NN NN O
provides NN NN O
a NN NN O
new NN NN O
approach NN NN O
for NN NN O
studying NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
that NN NN O
govern NN NN O
the NN NN O
complex NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
A NN NN O
negative NN NN O
role NN NN O
for NN NN O
phosphoinositide NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
function NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
A NN NN O
delicate NN NN O
balance NN NN O
between NN NN O
positive NN NN O
and NN NN O
negative NN NN O
regulatory NN NN O
mechanisms NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
determines NN NN O
the NN NN O
specificity NN NN O
and NN NN O
magnitude NN NN O
of NN NN O
an NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Phosphoinositide NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
) NN NN O
is NN NN O
activated NN NN O
by NN NN O
a NN NN O
diverse NN NN O
set NN NN O
of NN NN O
receptors NN NN O
that NN NN O
determine NN NN O
T NN NN O
- NN NN O
cell NN NN O
function NN NN O
, NN NN O
including NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
, NN NN O
the NN NN O
costimulatory NN NN O
receptor NN NN O
CD28 NN NN B-Protein
, NN NN O
and NN NN O
negative NN NN O
regulators NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
such NN NN O
as NN NN O
CTLA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
is NN NN O
also NN NN O
regulated NN NN O
by NN NN O
the NN NN O
haematopoietic NN NN O
cytokines NN NN O
that NN NN O
determine NN NN O
T NN NN O
- NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
lymphocyte NN NN O
proliferation NN NN O
. NN NN O
   
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
can NN NN O
thus NN NN O
dynamically NN NN O
influence NN NN O
the NN NN O
outcome NN NN O
of NN NN O
the NN NN O
immune NN NN O
reactions NN NN O
at NN NN O
various NN NN O
stages NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
importance NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
in NN NN O
TCR NN NN O
- NN NN O
directed NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
using NN NN O
activated NN NN O
or NN NN O
inhibitory NN NN O
versions NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
. NN NN O
   
RESULTS NN NN O
: NN NN O
Certain NN NN O
aspects NN NN O
of NN NN O
TCR NN NN O
responses NN NN O
such NN NN O
as NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
AP1 NN NN O
and NN NN O
serum NN NN O
response NN NN O
factor NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
. NN NN O
   
We NN NN O
found NN NN O
, NN NN O
however NN NN O
, NN NN O
that NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
profoundly NN NN O
influenced NN NN O
the NN NN O
transactivation NN NN O
capacity NN NN O
of NN NN O
' NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
' NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
elicited NN NN O
by NN NN O
the NN NN O
TCR NN NN O
: NN NN O
expression NN NN O
of NN NN O
an NN NN O
activated NN NN O
form NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
inhibited NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
AT NN NN O
responses NN NN O
, NN NN O
whereas NN NN O
expression NN NN O
of NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
mutant NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
potently NN NN O
enhanced NN NN O
TCR NN NN O
- NN NN O
controlled NN NN O
NF NN NN O
- NN NN O
AT NN NN O
induction NN NN O
. NN NN O
   
These NN NN O
effects NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
were NN NN O
not NN NN O
mediated NN NN O
by NN NN O
previously NN NN O
identified NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
effectors NN NN O
, NN NN O
such NN NN O
as NN NN O
protein NN NN O
kinase NN NN O
B NN NN O
, NN NN O
a NN NN O
positive NN NN O
regulator NN NN O
of NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
, NN NN O
or NN NN O
the NN NN O
GTPase NN NN O
Rac NN NN O
, NN NN O
and NN NN O
are NN NN O
therefore NN NN O
likely NN NN O
to NN NN O
involve NN NN O
a NN NN O
novel NN NN O
, NN NN O
as NN NN O
yet NN NN O
unknown NN NN O
, NN NN O
effector NN NN O
molecule NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Our NN NN O
results NN NN O
establish NN NN O
that NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
can NN NN O
both NN NN O
positively NN NN O
and NN NN O
negatively NN NN O
regulate NN NN O
T NN NN O
- NN NN O
cell NN NN O
function NN NN O
, NN NN O
and NN NN O
uncover NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
function NN NN O
for NN NN O
PI NN NN B-Protein
3 NN NN I-Protein
- NN NN I-Protein
kinase NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
as NN NN O
a NN NN O
selective NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
TCR NN NN O
- NN NN O
signalling NN NN O
events NN NN O
and NN NN O
therefore NN NN O
as NN NN O
a NN NN O
determinant NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
homeostasis NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
independent NN NN O
suppression NN NN O
of NN NN O
HIV NN NN O
expression NN NN O
by NN NN O
ascorbic NN NN O
acid NN NN O
. NN NN O
   
Ascorbic NN NN O
acid NN NN O
( NN NN O
ascorbate NN NN O
or NN NN O
vitamin NN NN O
C NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
suppress NN NN O
the NN NN O
induction NN NN O
of NN NN O
HIV NN NN O
in NN NN O
latently NN NN O
infected NN NN O
T NN NN O
lymphocytic NN NN O
cells NN NN O
following NN NN O
stimulation NN NN O
with NN NN O
a NN NN O
tumor NN NN O
promoter NN NN O
( NN NN O
PMA NN NN O
) NN NN O
and NN NN O
inflammatory NN NN O
cytokine NN NN O
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
To NN NN O
assess NN NN O
whether NN NN O
this NN NN O
inhibition NN NN O
was NN NN O
mediated NN NN O
via NN NN O
modulation NN NN O
of NN NN O
the NN NN O
cellular NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
we NN NN O
carried NN NN O
out NN NN O
gel NN NN O
shift NN NN O
analysis NN NN O
on NN NN O
nuclear NN NN O
extracts NN NN O
prepared NN NN O
under NN NN O
different NN NN O
conditions NN NN O
of NN NN O
cell NN NN O
stimulation NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
ascorbate NN NN O
, NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
, NN NN O
or NN NN O
zidovudine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
T NN NN O
cells NN NN O
by NN NN O
NAC NN NN O
followed NN NN O
by NN NN O
stimulation NN NN O
with NN NN O
PMA NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
or NN NN O
hydrogen NN NN O
peroxide NN NN O
( NN NN O
H2O2 NN NN O
) NN NN O
resulted NN NN O
in NN NN O
strong NN NN O
suppression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
neither NN NN O
ascorbate NN NN O
nor NN NN O
AZT NN NN O
affected NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
under NN NN O
all NN NN O
three NN NN O
induction NN NN O
conditions NN NN O
in NN NN O
the NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Ascorbate NN NN O
and NN NN O
AZT NN NN O
also NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
following NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
or NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
stimulation NN NN O
of NN NN O
U1 NN NN O
promonocytic NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
HIV NN NN O
inhibition NN NN O
by NN NN O
ascorbate NN NN O
is NN NN O
not NN NN O
mediated NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibition NN NN O
, NN NN O
unlike NN NN O
that NN NN O
seen NN NN O
with NN NN O
other NN NN O
antioxidants NN NN O
. NN NN O
   
Lineage NN NN O
- NN NN O
and NN NN O
stage NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
runt NN NN B-Protein
box NN NN O
polypeptides NN NN O
in NN NN O
primitive NN NN O
and NN NN O
definitive NN NN O
hematopoiesis NN NN O
. NN NN O
   
Translocations NN NN O
involving NN NN O
the NN NN O
human NN NN O
CBFA2 NN NN B-Protein
locus NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
leukemia NN NN O
. NN NN O
   
This NN NN O
gene NN NN O
, NN NN O
originally NN NN O
named NN NN O
AML1 NN NN B-Protein
, NN NN O
is NN NN O
a NN NN O
human NN NN O
homologue NN NN O
of NN NN O
the NN NN O
Drosophila NN NN O
gene NN NN O
runt NN NN B-Protein
that NN NN O
controls NN NN O
early NN NN O
events NN NN O
in NN NN O
fly NN NN O
embryogenesis NN NN O
. NN NN O
   
To NN NN O
clarify NN NN O
the NN NN O
role NN NN O
of NN NN O
mammalian NN NN O
runt NN NN B-Protein
products NN NN O
in NN NN O
normal NN NN O
and NN NN O
leukemic NN NN O
hematopoiesis NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
their NN NN O
pattern NN NN O
of NN NN O
expression NN NN O
in NN NN O
mouse NN NN O
hematopoietic NN NN O
tissues NN NN O
in NN NN O
the NN NN O
adult NN NN O
and NN NN O
during NN NN O
ontogeny NN NN O
using NN NN O
an NN NN O
anti NN NN O
- NN NN O
runt NN NN O
box NN NN O
antiserum NN NN O
. NN NN O
   
In NN NN O
the NN NN O
adult NN NN O
bone NN NN O
marrow NN NN O
, NN NN O
we NN NN O
found NN NN O
expression NN NN O
of NN NN O
runt NN NN O
polypeptides NN NN O
in NN NN O
differentiating NN NN O
myeloid NN NN O
cells NN NN O
and NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Within NN NN O
the NN NN O
erythroid NN NN O
lineage NN NN O
, NN NN O
runt NN NN B-Protein
expression NN NN O
is NN NN O
biphasic NN NN O
, NN NN O
clearly NN NN O
present NN NN O
in NN NN O
the NN NN O
erythroblasts NN NN O
of NN NN O
early NN NN O
blood NN NN O
islands NN NN O
and NN NN O
of NN NN O
the NN NN O
fetal NN NN O
liver NN NN O
, NN NN O
but NN NN O
absent NN NN O
in NN NN O
the NN NN O
adult NN NN O
. NN NN O
   
Biochemical NN NN O
analysis NN NN O
by NN NN O
Western NN NN O
blotting NN NN O
of NN NN O
fetal NN NN O
and NN NN O
adult NN NN O
hematopoietic NN NN O
populations NN NN O
shows NN NN O
several NN NN O
runt NN NN O
isoforms NN NN O
. NN NN O
   
At NN NN O
least NN NN O
one NN NN O
of NN NN O
them NN NN O
appears NN NN O
to NN NN O
be NN NN O
myeloid NN NN O
specific NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
contact NN NN O
activates NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
1 NN NN O
through NN NN O
its NN NN O
kappaB NN NN O
motif NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
contact NN NN O
between NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
and NN NN O
transfected NN NN O
human NN NN O
colonic NN NN O
carcinoma NN NN O
cell NN NN O
line NN NN O
HT29 NN NN O
activates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeats NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
transcription NN NN O
is NN NN O
controlled NN NN O
by NN NN O
a NN NN O
complex NN NN O
array NN NN O
of NN NN O
virus NN NN O
- NN NN O
encoded NN NN O
and NN NN O
cellular NN NN O
proteins NN NN O
. NN NN O
   
Using NN NN O
various NN NN O
constructs NN NN O
expressing NN NN O
a NN NN O
lacZ NN NN O
reporter NN NN O
gene NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
intact NN NN O
or NN NN O
three NN NN O
deleted NN NN O
forms NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
, NN NN O
we NN NN O
obtained NN NN O
evidence NN NN O
that NN NN O
the NN NN O
kappaB NN NN O
regulatory NN NN O
elements NN NN O
located NN NN O
in NN NN O
the NN NN O
U3 NN NN O
region NN NN O
are NN NN O
involved NN NN O
in NN NN O
cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
contact NN NN O
activates NN NN O
in NN NN O
vitro NN NN O
binding NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimer NN NN O
to NN NN O
an NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
kappaB NN NN O
oligonucleotide NN NN O
. NN NN O
   
Cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
contact NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
was NN NN O
only NN NN O
partially NN NN O
inhibited NN NN O
by NN NN O
100 NN NN O
microM NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
and NN NN O
was NN NN O
not NN NN O
correlated NN NN O
with NN NN O
a NN NN O
significant NN NN O
decrease NN NN O
of NN NN O
cellular NN NN O
inhibitor NN NN B-Protein
kappaB NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
nuclear NN NN O
activation NN NN O
was NN NN O
not NN NN O
detectable NN NN O
before NN NN O
1 NN NN O
h NN NN O
after NN NN O
cell NN NN O
contact NN NN O
and NN NN O
was NN NN O
dependent NN NN O
on NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
HIV NN NN O
does NN NN O
not NN NN O
replicate NN NN O
in NN NN O
naive NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
CD3 NN NN O
/ NN NN O
CD28 NN NN B-Protein
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
T NN NN O
cell NN NN O
tropic NN NN O
strain NN NN O
of NN NN O
HIV NN NN O
, NN NN O
LAI NN NN O
, NN NN O
does NN NN O
not NN NN O
replicate NN NN O
in NN NN O
naive NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
cross NN NN O
- NN NN O
linking NN NN O
CD3 NN NN O
and NN NN O
CD28 NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
LAI NN NN O
replicates NN NN O
well NN NN O
in NN NN O
memory NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
stimulated NN NN O
in NN NN O
the NN NN O
same NN NN O
way NN NN O
. NN NN O
   
Unlike NN NN O
this NN NN O
physiologically NN NN O
relevant NN NN O
stimulation NN NN O
, NN NN O
PHA NN NN B-Protein
stimulates NN NN O
productive NN NN O
LAI NN NN O
replication NN NN O
in NN NN O
both NN NN O
naive NN NN O
and NN NN O
memory NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
were NN NN O
conducted NN NN O
with NN NN O
highly NN NN O
purified NN NN O
( NN NN O
FACS NN NN O
- NN NN O
isolated NN NN O
) NN NN O
subsets NN NN O
of NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
identified NN NN O
by NN NN O
expression NN NN O
of NN NN O
both NN NN O
CD45RA NN NN B-Protein
and NN NN O
CD62L NN NN B-Protein
. NN NN O
   
Remixing NN NN O
of NN NN O
purified NN NN O
T NN NN O
cells NN NN O
showed NN NN O
that NN NN O
naive NN NN O
T NN NN O
cells NN NN O
do NN NN O
not NN NN O
suppress NN NN O
LAI NN NN O
replication NN NN O
in NN NN O
memory NN NN O
T NN NN O
cells NN NN O
and NN NN O
that NN NN O
memory NN NN O
T NN NN O
cells NN NN O
do NN NN O
not NN NN O
restore NN NN O
LAI NN NN O
expression NN NN O
in NN NN O
naive NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
suppression NN NN O
of NN NN O
productive NN NN O
LAI NN NN O
replication NN NN O
in NN NN O
naive NN NN O
T NN NN O
cells NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
differential NN NN O
expression NN NN O
of NN NN O
viral NN NN O
coreceptors NN NN O
, NN NN O
nor NN NN O
is NN NN O
it NN NN O
due NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
activation NN NN O
of NN NN O
the NN NN O
important NN NN O
HIV NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
The NN NN O
inherent NN NN O
resistance NN NN O
of NN NN O
naive NN NN O
T NN NN O
cells NN NN O
to NN NN O
productive NN NN O
HIV NN NN O
infection NN NN O
, NN NN O
coupled NN NN O
with NN NN O
their NN NN O
proliferative NN NN O
advantage NN NN O
as NN NN O
demonstrated NN NN O
here NN NN O
, NN NN O
provides NN NN O
a NN NN O
sound NN NN O
basis NN NN O
for NN NN O
proposed NN NN O
clinical NN NN O
therapies NN NN O
using NN NN O
ex NN NN O
vivo NN NN O
expansion NN NN O
and NN NN O
reinfusion NN NN O
of NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
from NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
adults NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
NFATx1 NN NN B-Protein
nuclear NN NN O
translocation NN NN O
by NN NN O
a NN NN O
calcineurin NN NN O
- NN NN O
regulated NN NN O
inhibitory NN NN O
domain NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
regulates NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
through NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
located NN NN O
in NN NN O
the NN NN O
promoters NN NN O
of NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
NFATx1 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
preferentially NN NN O
expressed NN NN O
in NN NN O
the NN NN O
thymus NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
, NN NN O
is NN NN O
one NN NN O
of NN NN O
four NN NN O
members NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
have NN NN O
performed NN NN O
domain NN NN O
analysis NN NN O
of NN NN O
NFATx1 NN NN B-Protein
by NN NN O
examining NN NN O
the NN NN O
effects NN NN O
of NN NN O
deletion NN NN O
mutations NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
NFATx1 NN NN B-Protein
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
interaction NN NN O
with NN NN O
AP NN NN O
- NN NN O
1 NN NN O
polypeptides NN NN O
were NN NN O
dependent NN NN O
on NN NN O
its NN NN O
central NN NN O
Rel NN NN O
similarity NN NN O
region NN NN O
and NN NN O
that NN NN O
transcriptional NN NN O
activation NN NN O
was NN NN O
reduced NN NN O
by NN NN O
deletions NN NN O
of NN NN O
either NN NN O
its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
or NN NN O
its NN NN O
C NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
presence NN NN O
of NN NN O
intrinsic NN NN O
transcriptional NN NN O
activation NN NN O
motifs NN NN O
in NN NN O
both NN NN O
regions NN NN O
. NN NN O
   
We NN NN O
also NN NN O
identified NN NN O
a NN NN O
potent NN NN O
inhibitory NN NN O
sequence NN NN O
within NN NN O
its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
inhibition NN NN O
was NN NN O
dependent NN NN O
on NN NN O
the NN NN O
activity NN NN O
of NN NN O
calcineurin NN NN O
, NN NN O
a NN NN O
calcium NN NN O
- NN NN O
calmodulin NN NN O
- NN NN O
dependent NN NN O
phosphatase NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
calcineurin NN NN O
associated NN NN O
with NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
of NN NN O
NFATx1 NN NN B-Protein
at NN NN O
multiple NN NN O
docking NN NN O
sites NN NN O
and NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
of NN NN O
size NN NN O
, NN NN O
indicative NN NN O
of NN NN O
dephosphorylation NN NN O
, NN NN O
in NN NN O
NFATx1 NN NN B-Protein
. NN NN O
   
We NN NN O
have NN NN O
mapped NN NN O
the NN NN O
inhibitory NN NN O
activity NN NN O
to NN NN O
less NN NN O
than NN NN O
60 NN NN O
residues NN NN O
, NN NN O
containing NN NN O
motifs NN NN O
that NN NN O
are NN NN O
conserved NN NN O
in NN NN O
all NN NN O
NFAT NN NN O
proteins NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
deletion NN NN O
in NN NN O
NFATx1 NN NN B-Protein
of NN NN O
the NN NN O
mapped NN NN O
60 NN NN O
residues NN NN O
leads NN NN O
to NN NN O
its NN NN O
nuclear NN NN O
translocation NN NN O
independent NN NN O
of NN NN O
calcium NN NN O
signaling NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
support NN NN O
the NN NN O
model NN NN O
proposing NN NN O
that NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
confers NN NN O
calcium NN NN O
- NN NN O
signaling NN NN O
dependence NN NN O
on NN NN O
NFATx1 NN NN B-Protein
transactivation NN NN O
activity NN NN O
by NN NN O
regulating NN NN O
its NN NN O
intracellular NN NN O
localization NN NN O
through NN NN O
a NN NN O
protein NN NN O
module NN NN O
that NN NN O
associates NN NN O
with NN NN O
calcineurin NN NN O
and NN NN O
is NN NN O
a NN NN O
target NN NN O
of NN NN O
its NN NN O
phosphatase NN NN O
activity NN NN O
. NN NN O
   
Neuronal NN NN B-Protein
( NN NN I-Protein
type NN NN I-Protein
I NN NN I-Protein
) NN NN I-Protein
nitric NN NN I-Protein
oxide NN NN I-Protein
synthase NN NN I-Protein
regulates NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
activity NN NN O
and NN NN O
immunologic NN NN B-Protein
( NN NN I-Protein
type NN NN I-Protein
II NN NN I-Protein
) NN NN I-Protein
nitric NN NN I-Protein
oxide NN NN I-Protein
synthase NN NN I-Protein
expression NN NN O
. NN NN O
   
Nitric NN NN O
oxide NN NN O
subserves NN NN O
diverse NN NN O
physiologic NN NN O
roles NN NN O
in NN NN O
the NN NN O
nervous NN NN O
system NN NN O
. NN NN O
   
NO NN NN O
is NN NN O
produced NN NN O
from NN NN O
at NN NN O
least NN NN O
three NN NN O
different NN NN O
NO NN NN O
synthase NN NN O
( NN NN O
NOS NN NN O
) NN NN O
isoforms NN NN O
: NN NN O
neuronal NN NN B-Protein
NOS NN NN I-Protein
( NN NN O
nNOS NN NN B-Protein
) NN NN O
, NN NN O
endothelial NN NN B-Protein
NOS NN NN I-Protein
, NN NN O
and NN NN O
immunologic NN NN B-Protein
NOS NN NN I-Protein
( NN NN O
iNOS NN NN B-Protein
) NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
nNOS NN NN B-Protein
is NN NN O
the NN NN O
predominant NN NN O
isoform NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
glia NN NN O
. NN NN O
   
NO NN NN O
derived NN NN O
from NN NN O
nNOS NN NN B-Protein
in NN NN O
glia NN NN O
inhibits NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
kappaB NN NN O
) NN NN O
as NN NN O
NOS NN NN O
inhibitors NN NN O
enhance NN NN O
basal NN NN O
NF NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
Pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
is NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
kappaB NN NN O
in NN NN O
most NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
PDTC NN NN O
is NN NN O
also NN NN O
a NN NN O
potent NN NN O
scavenger NN NN O
of NN NN O
NO NN NN O
through NN NN O
formation NN NN O
of NN NN O
mononitrosyl NN NN O
iron NN NN O
complexes NN NN O
with NN NN O
PDTC NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
lymphoma NN NN O
cell NN NN O
line NN NN O
, NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
induces NN NN O
NF NN NN O
kappaB NN NN O
activation NN NN O
that NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
PDTC NN NN O
. NN NN O
   
Contrary NN NN O
to NN NN O
the NN NN O
results NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
PDTC NN NN O
did NN NN O
not NN NN O
inhibit NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
NF NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
astrocytes NN NN O
; NN NN O
instead NN NN O
PDTC NN NN O
itself NN NN O
induces NN NN O
NF NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
astrocytes NN NN O
, NN NN O
and NN NN O
this NN NN O
may NN NN O
be NN NN O
related NN NN O
to NN NN O
scavenging NN NN O
of NN NN O
endogenously NN NN O
produced NN NN O
NO NN NN O
by NN NN O
the NN NN O
PDTC NN NN O
iron NN NN O
complex NN NN O
. NN NN O
   
In NN NN O
astrocytes NN NN O
PDTC NN NN O
also NN NN O
dramatically NN NN O
induces NN NN O
the NN NN O
NF NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
enzyme NN NN O
, NN NN O
iNOS NN NN B-Protein
, NN NN O
supporting NN NN O
the NN NN O
physiologic NN NN O
relevance NN NN O
of NN NN O
endogenous NN NN O
NO NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
kappaB NN NN O
. NN NN O
   
NF NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
glia NN NN O
from NN NN O
mice NN NN O
lacking NN NN O
nNOS NN NN B-Protein
responds NN NN O
more NN NN O
rapidly NN NN O
to NN NN O
PDTC NN NN O
compared NN NN O
with NN NN O
astrocytes NN NN O
from NN NN O
wild NN NN O
- NN NN O
type NN NN O
mice NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
nNOS NN NN B-Protein
in NN NN O
astrocytes NN NN O
regulates NN NN O
NF NN NN O
kappaB NN NN O
activity NN NN O
and NN NN O
iNOS NN NN B-Protein
expression NN NN O
, NN NN O
and NN NN O
indicate NN NN O
a NN NN O
novel NN NN O
regulatory NN NN O
role NN NN O
for NN NN O
nNOS NN NN B-Protein
in NN NN O
tonically NN NN O
suppressing NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
NF NN NN O
kappaB NN NN O
- NN NN O
regulated NN NN O
genes NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
human NN NN O
epsilon NN NN O
germline NN NN O
transcription NN NN O
: NN NN O
role NN NN O
of NN NN O
B NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
- NN NN I-Protein
specific NN NN I-Protein
activator NN NN I-Protein
protein NN NN I-Protein
. NN NN O
   
Germline NN NN O
transcripts NN NN O
initiate NN NN O
from NN NN O
promoters NN NN O
upstream NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
switch NN NN O
region NN NN O
, NN NN O
and NN NN O
are NN NN O
necessary NN NN O
to NN NN O
target NN NN O
the NN NN O
appropriate NN NN O
switch NN NN O
region NN NN O
for NN NN O
recombination NN NN O
and NN NN O
switching NN NN O
. NN NN O
   
Different NN NN O
cytokines NN NN O
activate NN NN O
transcription NN NN O
at NN NN O
the NN NN O
appropriate NN NN O
germline NN NN O
promoter NN NN O
. NN NN O
   
Because NN NN O
binding NN NN O
sites NN NN O
for NN NN O
B NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
- NN NN I-Protein
specific NN NN I-Protein
activator NN NN I-Protein
protein NN NN I-Protein
( NN NN O
BSAP NN NN B-Protein
) NN NN O
are NN NN O
located NN NN O
upstream NN NN O
of NN NN O
several NN NN O
switch NN NN O
regions NN NN O
in NN NN O
the NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
gene NN NN O
cluster NN NN O
, NN NN O
BSAP NN NN B-Protein
might NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
germline NN NN O
transcription NN NN O
and NN NN O
isotype NN NN O
switching NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
whether NN NN O
BSAP NN NN B-Protein
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
epsilon NN NN O
germline NN NN O
promoter NN NN O
in NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
showed NN NN O
that NN NN O
BSAP NN NN B-Protein
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
dependent NN NN O
induction NN NN O
and NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
upregulation NN NN O
of NN NN O
human NN NN O
epsilon NN NN O
germline NN NN O
transcription NN NN O
. NN NN O
   
BSAP NN NN B-Protein
is NN NN O
unique NN NN O
among NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
epsilon NN NN O
germline NN NN O
expression NN NN O
, NN NN O
because NN NN O
it NN NN O
is NN NN O
B NN NN O
cell NN NN O
specific NN NN O
, NN NN O
and NN NN O
is NN NN O
at NN NN O
the NN NN O
merging NN NN O
point NN NN O
of NN NN O
two NN NN O
signalling NN NN O
pathways NN NN O
that NN NN O
are NN NN O
critical NN NN O
for NN NN O
IgE NN NN O
switching NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
- NN NN O
induced NN NN O
modulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
production NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
expression NN NN O
on NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
has NN NN O
important NN NN O
immune NN NN O
- NN NN O
modulating NN NN O
effects NN NN O
on NN NN O
both NN NN O
T NN NN O
and NN NN O
B NN NN O
cell NN NN O
function NN NN O
. NN NN O
   
Our NN NN O
laboratory NN NN O
has NN NN O
shown NN NN O
that NN NN O
RA NN NN O
can NN NN O
enhance NN NN O
in NN NN O
vitro NN NN O
polyclonal NN NN O
B NN NN O
cell NN NN O
immunoglobulin NN NN O
( NN NN O
Ig NN NN O
) NN NN O
response NN NN O
. NN NN O
   
Investigating NN NN O
cytokines NN NN O
known NN NN O
to NN NN O
affect NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
, NN NN O
we NN NN O
have NN NN O
recently NN NN O
shown NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
is NN NN O
augmented NN NN O
by NN NN O
RA NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
have NN NN O
examined NN NN O
the NN NN O
immune NN NN O
modulating NN NN O
effects NN NN O
of NN NN O
RA NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
, NN NN O
another NN NN O
important NN NN O
cytokine NN NN O
for NN NN O
B NN NN O
cell NN NN O
immunoglobulin NN NN O
production NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptors NN NN O
on NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
the NN NN O
RA NN NN O
nuclear NN NN O
receptors NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Purified NN NN O
T NN NN O
cells NN NN O
were NN NN O
obtained NN NN O
from NN NN O
adenoidal NN NN O
tissues NN NN O
, NN NN O
and NN NN O
incubated NN NN O
with NN NN O
RA NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
M NN NN O
) NN NN O
or NN NN O
DMSO NN NN O
solvent NN NN O
/ NN NN O
media NN NN O
control NN NN O
for NN NN O
0 NN NN O
, NN NN O
6 NN NN O
- NN NN O
8 NN NN O
, NN NN O
and NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Total NN NN O
mRNA NN NN O
was NN NN O
extracted NN NN O
from NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
using NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
, NN NN O
changes NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN O
- NN NN O
2 NN NN O
and NN NN O
RA NN NN B-Protein
receptors NN NN I-Protein
( NN NN I-Protein
RAR NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
beta NN NN B-Protein
, NN NN O
gamma NN NN B-Protein
mRNA NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
RA NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
receptor NN NN I-Protein
expression NN NN O
was NN NN O
determined NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
on NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
RA NN NN O
can NN NN O
augment NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
production NN NN O
by NN NN O
T NN NN O
cells NN NN O
with NN NN O
a NN NN O
possible NN NN O
paracrine NN NN O
effect NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
expression NN NN O
. NN NN O
   
These NN NN O
changes NN NN O
appear NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
RAR NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Thus NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
may NN NN O
be NN NN O
another NN NN O
important NN NN O
cytokine NN NN O
modulated NN NN O
by NN NN O
RA NN NN O
in NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Itk NN NN B-Protein
, NN NN O
a NN NN O
T NN NN O
cell NN NN O
- NN NN O
specific NN NN O
tyrosine NN NN O
kinase NN NN O
, NN NN O
is NN NN O
required NN NN O
for NN NN O
CD2 NN NN B-Protein
- NN NN O
mediated NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
in NN NN O
the NN NN O
human NN NN O
T NN NN O
cell NN NN O
line NN NN O
Jurkat NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
functional NN NN O
role NN NN O
of NN NN O
Itk NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
cytoplasmic NN NN O
tyrosine NN NN O
kinase NN NN O
Tec NN NN O
family NN NN O
, NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
either NN NN O
CD2 NN NN B-Protein
or NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
/ NN NN O
CD3 NN NN O
on NN NN O
Tcells NN NN O
by NN NN O
monoclonal NN NN O
antibody NN NN O
- NN NN O
mediated NN NN O
cross NN NN O
- NN NN O
linking NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
Itk NN NN B-Protein
, NN NN O
which NN NN O
was NN NN O
maximal NN NN O
as NN NN O
early NN NN O
as NN NN O
1 NN NN O
min NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
The NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
in NN NN O
the NN NN O
anti NN NN O
- NN NN O
Itk NN NN B-Protein
immunoprecipitate NN NN O
was NN NN O
significantly NN NN O
activated NN NN O
upon NN NN O
these NN NN O
stimulations NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
promoter NN NN O
activity NN NN O
stimulated NN NN O
by NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD2 NN NN B-Protein
, NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
, NN NN O
and NN NN O
CD28 NN NN B-Protein
with NN NN O
antibodies NN NN O
was NN NN O
significantly NN NN O
reduced NN NN O
by NN NN O
transient NN NN O
expression NN NN O
of NN NN O
an NN NN O
Itk NN NN B-Protein
mutant NN NN O
lacking NN NN O
the NN NN O
kinase NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
reduction NN NN O
paralleled NN NN O
a NN NN O
decrease NN NN O
in NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
endogenous NN NN O
wild NN NN O
- NN NN O
type NN NN O
Itk NN NN B-Protein
. NN NN O
   
Stimulation NN NN O
of NN NN O
CD2 NN NN B-Protein
or NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
, NN NN O
the NN NN O
binding NN NN O
site NN NN O
of NN NN O
which NN NN O
is NN NN O
included NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
NFAT NN NN O
was NN NN O
also NN NN O
impaired NN NN O
by NN NN O
expression NN NN O
of NN NN O
the NN NN O
Itk NN NN B-Protein
mutant NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
Itk NN NN B-Protein
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
, NN NN O
indicating NN NN O
a NN NN O
critical NN NN O
involvement NN NN O
of NN NN O
Itk NN NN B-Protein
in NN NN O
the NN NN O
initial NN NN O
stage NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
by NN NN O
mediating NN NN O
signals NN NN O
from NN NN O
the NN NN O
TCR NN NN O
/ NN NN O
CD3 NN NN O
complex NN NN O
, NN NN O
CD2 NN NN B-Protein
, NN NN O
and NN NN O
CD28 NN NN B-Protein
. NN NN O
   
Jak3 NN NN B-Protein
is NN NN O
associated NN NN O
with NN NN O
CD40 NN NN B-Protein
and NN NN O
is NN NN O
critical NN NN O
for NN NN O
CD40 NN NN B-Protein
induction NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
CD40 NN NN B-Protein
is NN NN O
a NN NN O
receptor NN NN O
that NN NN O
is NN NN O
critical NN NN O
for NN NN O
the NN NN O
survival NN NN O
, NN NN O
growth NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
isotype NN NN O
switching NN NN O
of NN NN O
B NN NN O
lymphocytes NN NN O
. NN NN O
   
Although NN NN O
CD40 NN NN B-Protein
lacks NN NN O
intrinsic NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
, NN NN O
its NN NN O
ligation NN NN O
induces NN NN O
protein NN NN O
tyrosine NN NN O
phosphorylation NN NN O
, NN NN O
which NN NN O
is NN NN O
necessary NN NN O
for NN NN O
several NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
events NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
engagement NN NN O
of NN NN O
CD40 NN NN B-Protein
induces NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
activation NN NN O
of NN NN O
Jak3 NN NN B-Protein
as NN NN O
well NN NN O
as NN NN O
of NN NN O
STAT3 NN NN B-Protein
. NN NN O
   
Jak3 NN NN B-Protein
is NN NN O
constitutively NN NN O
associated NN NN O
with NN NN O
CD40 NN NN B-Protein
, NN NN O
and NN NN O
this NN NN O
interaction NN NN O
requires NN NN O
a NN NN O
proline NN NN O
- NN NN O
rich NN NN O
sequence NN NN O
in NN NN O
the NN NN O
membrane NN NN O
- NN NN O
proximal NN NN O
region NN NN O
of NN NN O
CD40 NN NN B-Protein
. NN NN O
   
Deletion NN NN O
of NN NN O
this NN NN O
sequence NN NN O
abolishes NN NN O
the NN NN O
capacity NN NN O
of NN NN O
CD40 NN NN B-Protein
to NN NN O
induce NN NN O
expression NN NN O
of NN NN O
CD23 NN NN B-Protein
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
lymphotoxin NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
genes NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
signaling NN NN O
through NN NN O
Jak3 NN NN B-Protein
is NN NN O
activated NN NN O
by NN NN O
CD40 NN NN B-Protein
and NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
functions NN NN O
. NN NN O
   
The NN NN O
tumour NN NN O
associated NN NN O
cell NN NN O
surface NN NN O
antigen NN NN O
A6H NN NN O
is NN NN O
costimulatory NN NN O
for NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
but NN NN O
not NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
A6H NN NN O
monoclonal NN NN O
antibody NN NN O
( NN NN O
mAb NN NN O
) NN NN O
recognizes NN NN O
a NN NN O
120 NN NN O
, NN NN O
000 NN NN O
- NN NN O
140 NN NN O
, NN NN O
000 NN NN O
MW NN NN O
antigen NN NN O
that NN NN O
is NN NN O
expressed NN NN O
at NN NN O
similar NN NN O
densities NN NN O
on NN NN O
85 NN NN O
- NN NN O
90 NN NN O
% NN NN O
of NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
and NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
and NN NN O
on NN NN O
renal NN NN O
cell NN NN O
carcinomas NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
the NN NN O
A6H NN NN O
mAb NN NN O
induced NN NN O
a NN NN O
costimulatory NN NN O
signal NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
A6H NN NN O
costimulated NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
in NN NN O
purified NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
the NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
subpopulation NN NN O
failed NN NN O
to NN NN O
respond NN NN O
. NN NN O
   
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
costimulated NN NN O
with NN NN O
the NN NN O
A6H NN NN O
mAb NN NN O
upregulated NN NN O
CD80 NN NN B-Protein
, NN NN O
CD86 NN NN B-Protein
, NN NN O
CD71 NN NN B-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN I-Protein
R NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
beta NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
while NN NN O
no NN NN O
corresponding NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
these NN NN O
cell NN NN O
surface NN NN O
molecules NN NN O
was NN NN O
seen NN NN O
in NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
A6H NN NN O
mAb NN NN O
costimulus NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
we NN NN O
have NN NN O
examined NN NN O
induction NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
OCT NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
which NN NN O
are NN NN O
known NN NN O
to NN NN O
be NN NN O
transcriptional NN NN O
regulators NN NN O
of NN NN O
several NN NN O
cytokine NN NN O
and NN NN O
cytokine NN NN O
receptor NN NN O
genes NN NN O
, NN NN O
including NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
2R NN NN O
genes NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
ligation NN NN O
of NN NN O
the NN NN O
A6H NN NN O
antigen NN NN O
and NN NN O
the NN NN O
CD3 NN NN O
complex NN NN O
induced NN NN O
expression NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
no NN NN O
increase NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
octamer NN NN O
- NN NN O
binding NN NN O
( NN NN O
Oct NN NN O
) NN NN O
proteins NN NN O
was NN NN O
seen NN NN O
compared NN NN O
to NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
alone NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
no NN NN O
induction NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
was NN NN O
seen NN NN O
in NN NN O
A6H NN NN O
costimulated NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggests NN NN O
that NN NN O
both NN NN O
proximal NN NN O
steps NN NN O
in NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
later NN NN O
phases NN NN O
are NN NN O
unresponsive NN NN O
to NN NN O
A6H NN NN O
ligation NN NN O
. NN NN O
   
Molecular NN NN O
differences NN NN O
of NN NN O
the NN NN O
A6H NN NN O
molecule NN NN O
or NN NN O
distinct NN NN O
regulation NN NN O
of NN NN O
the NN NN O
A6H NN NN O
transduced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activation NN NN O
pathway NN NN O
may NN NN O
exist NN NN O
in NN NN O
CD4 NN NN B-Protein
+ NN NN O
and NN NN O
CD8 NN NN O
+ NN NN O
T NN NN O
cell NN NN O
subpopulations NN NN O
. NN NN O
   
Structure NN NN O
and NN NN O
function NN NN O
analysis NN NN O
of NN NN O
the NN NN O
human NN NN O
myeloid NN NN B-Protein
cell NN NN I-Protein
nuclear NN NN I-Protein
differentiation NN NN I-Protein
antigen NN NN I-Protein
promoter NN NN O
: NN NN O
evidence NN NN O
for NN NN O
the NN NN O
role NN NN O
of NN NN O
Sp1 NN NN B-Protein
and NN NN O
not NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
or NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
in NN NN O
myelomonocytic NN NN O
lineage NN NN O
- NN NN O
specific NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
human NN NN O
myeloid NN NN B-Protein
nuclear NN NN I-Protein
differentiation NN NN I-Protein
antigen NN NN I-Protein
( NN NN O
MNDA NN NN B-Protein
) NN NN O
is NN NN O
expressed NN NN O
specifically NN NN O
in NN NN O
maturing NN NN O
cells NN NN O
of NN NN O
the NN NN O
myelomonocytic NN NN O
lineage NN NN O
and NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
granulocytes NN NN O
. NN NN O
   
Epitope NN NN O
enhancement NN NN O
was NN NN O
used NN NN O
to NN NN O
confirm NN NN O
the NN NN O
strict NN NN O
lineage NN NN O
- NN NN O
and NN NN O
stage NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
MNDA NN NN B-Protein
in NN NN O
bone NN NN O
marrow NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
other NN NN O
paraffin NN NN O
- NN NN O
embedded NN NN O
fixed NN NN O
tissues NN NN O
. NN NN O
   
A NN NN O
1 NN NN O
- NN NN O
kb NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
that NN NN O
includes NN NN O
5 NN NN O
' NN NN O
flanking NN NN O
sequence NN NN O
was NN NN O
reported NN NN O
earlier NN NN O
to NN NN O
contain NN NN O
functional NN NN O
promoter NN NN O
activity NN NN O
and NN NN O
was NN NN O
specifically NN NN O
demethylated NN NN O
in NN NN O
expressing NN NN O
cells NN NN O
in NN NN O
contrast NN NN O
to NN NN O
null NN NN O
cells NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
has NN NN O
revealed NN NN O
that NN NN O
this NN NN O
1 NN NN O
- NN NN O
kb NN NN O
fragment NN NN O
promotes NN NN O
higher NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
in NN NN O
MNDA NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
than NN NN O
non NN NN O
- NN NN O
expressing NN NN O
cells NN NN O
, NN NN O
indicating NN NN O
cell NN NN O
- NN NN O
specific NN NN O
differences NN NN O
in NN NN O
transactivation NN NN O
. NN NN O
   
This NN NN O
sequence NN NN O
contains NN NN O
consensus NN NN O
elements NN NN O
consistent NN NN O
with NN NN O
myeloid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
, NN NN O
including NN NN O
a NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
consensus NN NN O
site NN NN O
near NN NN O
the NN NN O
major NN NN O
transcription NN NN O
start NN NN O
site NN NN O
and NN NN O
a NN NN O
cluster NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
sites NN NN O
located NN NN O
several NN NN O
hundred NN NN O
bases NN NN O
upstream NN NN O
of NN NN O
this NN NN O
region NN NN O
. NN NN O
   
However NN NN O
, NN NN O
analysis NN NN O
of NN NN O
deletion NN NN O
mutants NN NN O
localized NN NN O
nearly NN NN O
all NN NN O
of NN NN O
the NN NN O
promoter NN NN O
activity NN NN O
to NN NN O
a NN NN O
short NN NN O
region NN NN O
( NN NN O
- NN NN O
73 NN NN O
to NN NN O
- NN NN O
16 NN NN O
) NN NN O
that NN NN O
did NN NN O
not NN NN O
include NN NN O
the NN NN O
cluster NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
sites NN NN O
. NN NN O
   
A NN NN O
4 NN NN O
- NN NN O
bp NN NN O
mutation NN NN O
of NN NN O
the NN NN O
core NN NN O
Sp1 NN NN B-Protein
consensus NN NN O
element NN NN O
( NN NN O
GC NN NN O
box NN NN O
) NN NN O
( NN NN O
- NN NN O
20 NN NN O
) NN NN O
reduced NN NN O
overall NN NN O
promoter NN NN O
activity NN NN O
of NN NN O
the NN NN O
1 NN NN O
- NN NN O
kb NN NN O
fragment NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
did NN NN O
not NN NN O
significantly NN NN O
affect NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
Only NN NN O
a NN NN O
small NN NN O
region NN NN O
( NN NN O
- NN NN O
35 NN NN O
to NN NN O
+ NN NN O
22 NN NN O
) NN NN O
including NN NN O
the NN NN O
Sp1 NN NN B-Protein
element NN NN O
and NN NN O
transcription NN NN O
start NN NN O
site NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
PU NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
site NN NN O
was NN NN O
footprinted NN NN O
. NN NN O
   
The NN NN O
4 NN NN O
- NN NN O
bp NN NN O
mutation NN NN O
of NN NN O
the NN NN O
core NN NN O
Sp1 NN NN B-Protein
consensus NN NN O
element NN NN O
abolished NN NN O
footprinting NN NN O
at NN NN O
the NN NN O
site NN NN O
and NN NN O
an NN NN O
antibody NN NN O
super NN NN O
- NN NN O
shift NN NN O
reaction NN NN O
showed NN NN O
that NN NN O
Sp1 NN NN B-Protein
is NN NN O
one NN NN O
of NN NN O
the NN NN O
factors NN NN O
binding NN NN O
the NN NN O
consensus NN NN O
site NN NN O
. NN NN O
   
The NN NN O
Sp1 NN NN B-Protein
site NN NN O
also NN NN O
co NN NN O
- NN NN O
localizes NN NN O
with NN NN O
a NN NN O
DNase NN NN O
I NN NN O
hypersensitive NN NN O
site NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
DNA NN NN O
methylation NN NN O
, NN NN O
chromatin NN NN O
structure NN NN O
, NN NN O
and NN NN O
transactivation NN NN O
at NN NN O
an NN NN O
Sp1 NN NN B-Protein
site NN NN O
contribute NN NN O
to NN NN O
the NN NN O
highly NN NN O
restricted NN NN O
expression NN NN O
of NN NN O
this NN NN O
myelomonocytic NN NN O
lineage NN NN O
specific NN NN O
gene NN NN O
. NN NN O
   
Inhibitor NN NN O
( NN NN O
IK NN NN B-Protein
) NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induced NN NN O
HLA NN NN O
class NN NN O
II NN NN O
antigens NN NN O
expression NN NN O
also NN NN O
inhibits NN NN O
HLA NN NN O
class NN NN O
II NN NN O
constitutive NN NN O
expression NN NN O
in NN NN O
the NN NN O
human NN NN O
Raji NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
( NN NN O
MHC NN NN O
) NN NN O
class NN NN O
II NN NN O
antigens NN NN O
is NN NN O
constitutive NN NN O
in NN NN O
professional NN NN O
antigen NN NN O
presenting NN NN O
cells NN NN O
( NN NN O
APCs NN NN O
) NN NN O
but NN NN O
can NN NN O
also NN NN O
be NN NN O
induced NN NN O
by NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
on NN NN O
the NN NN O
majority NN NN O
of NN NN O
the NN NN O
non NN NN O
professional NN NN O
APCs NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
fibroblasts NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
recently NN NN O
characterised NN NN O
a NN NN O
new NN NN O
factor NN NN O
called NN NN O
IK NN NN B-Protein
which NN NN O
is NN NN O
an NN NN O
efficient NN NN O
inhibitor NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induction NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
antigens NN NN O
expression NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
a NN NN O
novel NN NN O
role NN NN O
for NN NN O
IK NN NN B-Protein
in NN NN O
MHC NN NN O
class NN NN O
II NN NN O
expression NN NN O
since NN NN O
over NN NN O
- NN NN O
expression NN NN O
of NN NN O
this NN NN O
protein NN NN O
by NN NN O
stable NN NN O
transfection NN NN O
into NN NN O
human NN NN O
B NN NN O
cells NN NN O
led NN NN O
to NN NN O
a NN NN O
total NN NN O
disappearance NN NN O
of NN NN O
constitutive NN NN O
MHC NN NN O
class NN NN O
II NN NN O
mRNA NN NN O
expression NN NN O
. NN NN O
   
The NN NN O
class NN NN B-Protein
II NN NN I-Protein
transactivator NN NN I-Protein
( NN NN O
CIITA NN NN B-Protein
) NN NN O
is NN NN O
necessary NN NN O
for NN NN O
both NN NN O
constitutive NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
induced NN NN O
MHC NN NN O
class NN NN O
II NN NN O
expressions NN NN O
. NN NN O
   
Examination NN NN O
of NN NN O
CIITA NN NN B-Protein
mRNA NN NN O
in NN NN O
IK NN NN B-Protein
stably NN NN O
transfected NN NN O
clones NN NN O
revealed NN NN O
a NN NN O
marked NN NN O
reduction NN NN O
of NN NN O
CIITA NN NN B-Protein
mRNA NN NN O
transcription NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
IK NN NN B-Protein
protein NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
MHC NN NN O
class NN NN O
II NN NN O
antigens NN NN O
and NN NN O
that NN NN O
inhibition NN NN O
induced NN NN O
by NN NN O
IK NN NN B-Protein
is NN NN O
upstream NN NN O
of NN NN O
CIITA NN NN B-Protein
in NN NN O
this NN NN O
regulatory NN NN O
pathway NN NN O
. NN NN O
   
An NN NN O
enhancer NN NN O
- NN NN O
blocking NN NN O
element NN NN O
between NN NN O
alpha NN NN O
and NN NN O
delta NN NN O
gene NN NN O
segments NN NN O
within NN NN O
the NN NN O
human NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
alpha NN NN O
/ NN NN O
delta NN NN O
locus NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
alpha NN NN O
and NN NN O
delta NN NN O
gene NN NN O
segments NN NN O
are NN NN O
organized NN NN O
within NN NN O
a NN NN O
single NN NN O
genetic NN NN O
locus NN NN O
but NN NN O
are NN NN O
differentially NN NN O
regulated NN NN O
during NN NN O
T NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
An NN NN O
enhancer NN NN O
- NN NN O
blocking NN NN O
element NN NN O
( NN NN O
BEAD NN NN O
- NN NN O
1 NN NN O
, NN NN O
for NN NN O
blocking NN NN O
element NN NN O
alpha NN NN O
/ NN NN O
delta NN NN O
1 NN NN O
) NN NN O
was NN NN O
localized NN NN O
to NN NN O
a NN NN O
2 NN NN O
. NN NN O
0 NN NN O
- NN NN O
kb NN NN O
region NN NN O
3 NN NN O
' NN NN O
of NN NN O
TCR NN NN O
delta NN NN O
gene NN NN O
segments NN NN O
and NN NN O
5 NN NN O
' NN NN O
of NN NN O
TCR NN NN O
alpha NN NN O
joining NN NN O
gene NN NN O
segments NN NN O
within NN NN O
this NN NN O
locus NN NN O
. NN NN O
   
BEAD NN NN O
- NN NN O
1 NN NN O
blocked NN NN O
the NN NN O
ability NN NN O
of NN NN O
the NN NN O
TCR NN NN O
delta NN NN O
enhancer NN NN O
( NN NN O
Edelta NN NN O
) NN NN O
to NN NN O
activate NN NN O
a NN NN O
promoter NN NN O
when NN NN O
located NN NN O
between NN NN O
the NN NN O
two NN NN O
in NN NN O
a NN NN O
chromatin NN NN O
- NN NN O
integrated NN NN O
construct NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
BEAD NN NN O
- NN NN O
1 NN NN O
functions NN NN O
as NN NN O
a NN NN O
boundary NN NN O
that NN NN O
separates NN NN O
the NN NN O
TCR NN NN O
alpha NN NN O
/ NN NN O
delta NN NN O
locus NN NN O
into NN NN O
distinct NN NN O
regulatory NN NN O
domains NN NN O
controlled NN NN O
by NN NN O
Edelta NN NN O
and NN NN O
the NN NN O
TCR NN NN O
alpha NN NN O
enhancer NN NN O
, NN NN O
and NN NN O
that NN NN O
it NN NN O
prevents NN NN O
Edelta NN NN O
from NN NN O
opening NN NN O
the NN NN O
chromatin NN NN O
of NN NN O
the NN NN O
TCR NN NN O
alpha NN NN O
joining NN NN O
gene NN NN O
segments NN NN O
for NN NN O
VDJ NN NN O
recombination NN NN O
at NN NN O
an NN NN O
early NN NN O
stage NN NN O
of NN NN O
T NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
Quantification NN NN O
of NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
mRNA NN NN O
by NN NN O
competitive NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
in NN NN O
PBMC NN NN O
: NN NN O
lack NN NN O
of NN NN O
correspondence NN NN O
with NN NN O
common NN NN O
allelic NN NN O
variants NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
recently NN NN O
claimed NN NN O
that NN NN O
polymorphism NN NN O
for NN NN O
the NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
influences NN NN O
several NN NN O
aspects NN NN O
of NN NN O
calcium NN NN O
and NN NN O
bone NN NN O
metabolism NN NN O
. NN NN O
   
To NN NN O
evaluate NN NN O
the NN NN O
physiologic NN NN O
plausibility NN NN O
of NN NN O
these NN NN O
claims NN NN O
, NN NN O
we NN NN O
compared NN NN O
the NN NN O
abundance NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
mRNA NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMCs NN NN O
) NN NN O
between NN NN O
different NN NN O
VDR NN NN B-Protein
genotypes NN NN O
using NN NN O
a NN NN O
quantitative NN NN O
reverse NN NN O
transcribed NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
- NN NN O
based NN NN O
method NN NN O
. NN NN O
   
The NN NN O
method NN NN O
is NN NN O
based NN NN O
on NN NN O
the NN NN O
coamplification NN NN O
of NN NN O
VDR NN NN B-Protein
cDNA NN NN O
and NN NN O
an NN NN O
internal NN NN O
standard NN NN O
consisting NN NN O
of NN NN O
known NN NN O
concentrations NN NN O
of NN NN O
a NN NN O
human NN NN O
VDR NN NN B-Protein
CDNA NN NN O
mutated NN NN O
at NN NN O
a NN NN O
BglII NN NN O
restriction NN NN O
site NN NN O
; NN NN O
the NN NN O
interassay NN NN O
coefficient NN NN O
of NN NN O
variation NN NN O
is NN NN O
11 NN NN O
% NN NN O
. NN NN O
   
To NN NN O
validate NN NN O
the NN NN O
method NN NN O
, NN NN O
we NN NN O
made NN NN O
use NN NN O
of NN NN O
earlier NN NN O
receptor NN NN O
binding NN NN O
studies NN NN O
indicating NN NN O
that NN NN O
normal NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
activated NN NN O
, NN NN O
but NN NN O
not NN NN O
resting NN NN O
, NN NN O
lymphocytes NN NN O
expressed NN NN O
the NN NN O
VDR NN NN B-Protein
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
mRNA NN NN O
was NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
g NN NN O
/ NN NN O
g NN NN O
of NN NN O
total NN NN O
RNA NN NN O
in NN NN O
cell NN NN O
- NN NN O
sorted NN NN O
monocytes NN NN O
and NN NN O
in NN NN O
in NN NN O
vitro NN NN O
activated NN NN O
lymphocytes NN NN O
, NN NN O
but NN NN O
only NN NN O
10 NN NN O
( NN NN O
- NN NN O
12 NN NN O
) NN NN O
g NN NN O
/ NN NN O
g NN NN O
of NN NN O
total NN NN O
mRNA NN NN O
in NN NN O
resting NN NN O
lymphocytes NN NN O
, NN NN O
establishing NN NN O
that NN NN O
the NN NN O
VDR NN NN B-Protein
mRNA NN NN O
determined NN NN O
by NN NN O
our NN NN O
method NN NN O
in NN NN O
PBMCs NN NN O
is NN NN O
due NN NN O
to NN NN O
constitutive NN NN O
expression NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Following NN NN O
an NN NN O
initial NN NN O
genotype NN NN O
screening NN NN O
of NN NN O
85 NN NN O
normal NN NN O
volunteers NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
or NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
analysis NN NN O
, NN NN O
14 NN NN O
individuals NN NN O
with NN NN O
the NN NN O
Bb NN NN O
genotype NN NN O
, NN NN O
12 NN NN O
with NN NN O
the NN NN O
bb NN NN O
genotype NN NN O
, NN NN O
and NN NN O
12 NN NN O
with NN NN O
the NN NN O
BB NN NN O
genotype NN NN O
were NN NN O
selected NN NN O
. NN NN O
   
The NN NN O
concentration NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
mRNA NN NN O
, NN NN O
corrected NN NN O
for NN NN O
the NN NN O
number NN NN O
of NN NN O
monocytes NN NN O
, NN NN O
was NN NN O
similar NN NN O
among NN NN O
the NN NN O
three NN NN O
genotype NN NN O
groups NN NN O
, NN NN O
as NN NN O
were NN NN O
the NN NN O
other NN NN O
variables NN NN O
examined NN NN O
: NN NN O
serum NN NN O
calcitriol NN NN O
, NN NN O
serum NN NN B-Protein
osteocalcin NN NN I-Protein
, NN NN O
and NN NN O
vertebral NN NN O
and NN NN O
hip NN NN O
bone NN NN O
density NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
VDR NN NN B-Protein
polymorphism NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
abundance NN NN O
of NN NN O
the NN NN O
VDR NN NN B-Protein
mRNA NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
CD95 NN NN B-Protein
( NN NN I-Protein
Fas NN NN I-Protein
) NN NN I-Protein
ligand NN NN I-Protein
expression NN NN O
by NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
signaling NN NN O
events NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
mature NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
by NN NN O
TCR NN NN O
engagement NN NN O
results NN NN O
in NN NN O
activation NN NN O
of NN NN O
signals NN NN O
that NN NN O
drive NN NN O
induction NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
expression NN NN O
and NN NN O
clonal NN NN O
expansion NN NN O
. NN NN O
   
However NN NN O
, NN NN O
under NN NN O
some NN NN O
conditions NN NN O
, NN NN O
engagement NN NN O
of NN NN O
the NN NN O
TCR NN NN O
leads NN NN O
instead NN NN O
to NN NN O
apoptosis NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
TCR NN NN O
- NN NN O
stimulated NN NN O
apoptosis NN NN O
requires NN NN O
expression NN NN O
of NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
on NN NN O
activated NN NN O
T NN NN O
cells NN NN O
followed NN NN O
by NN NN O
an NN NN O
interaction NN NN O
between NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
and NN NN O
the NN NN O
CD95 NN NN B-Protein
receptor NN NN O
also NN NN O
expressed NN NN O
on NN NN O
this NN NN O
population NN NN O
. NN NN O
   
The NN NN O
experiments NN NN O
reported NN NN O
in NN NN O
this NN NN O
study NN NN O
were NN NN O
designed NN NN O
to NN NN O
address NN NN O
the NN NN O
signaling NN NN O
events NN NN O
triggered NN NN O
by NN NN O
TCR NN NN O
engagement NN NN O
that NN NN O
are NN NN O
important NN NN O
for NN NN O
regulating NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
To NN NN O
approach NN NN O
this NN NN O
, NN NN O
we NN NN O
generated NN NN O
a NN NN O
luciferase NN NN B-Protein
reporter NN NN O
construct NN NN O
containing NN NN O
elements NN NN O
of NN NN O
the NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
promoter NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
previously NN NN O
described NN NN O
mutant NN NN O
of NN NN O
the NN NN O
Jurkat NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
proximal NN NN O
signaling NN NN O
events NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
CD45 NN NN B-Protein
tyrosine NN NN I-Protein
phosphatase NN NN I-Protein
are NN NN O
required NN NN O
for NN NN O
TCR NN NN O
- NN NN O
stimulated NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
expression NN NN O
. NN NN O
   
Transient NN NN O
transfection NN NN O
studies NN NN O
demonstrate NN NN O
further NN NN O
that NN NN O
TCR NN NN O
- NN NN O
stimulated NN NN O
activation NN NN O
of NN NN O
the NN NN O
Ras NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
required NN NN O
for NN NN O
optimal NN NN O
activation NN NN O
of NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
. NN NN O
   
Next NN NN O
, NN NN O
in NN NN O
an NN NN O
effort NN NN O
to NN NN O
determine NN NN O
critical NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
regulate NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
expression NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
a NN NN O
cyclosporin NN NN B-Protein
A NN NN I-Protein
- NN NN O
sensitive NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
AT NN NN O
response NN NN O
element NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
this NN NN O
gene NN NN O
that NN NN O
is NN NN O
critical NN NN O
for NN NN O
optimal NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
reporter NN NN O
activity NN NN O
in NN NN O
stimulated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
studies NN NN O
begin NN NN O
a NN NN O
dissection NN NN O
of NN NN O
the NN NN O
biochemical NN NN O
events NN NN O
that NN NN O
lead NN NN O
to NN NN O
expression NN NN O
of NN NN O
CD95 NN NN B-Protein
ligand NN NN I-Protein
, NN NN O
a NN NN O
required NN NN O
step NN NN O
for NN NN O
TCR NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
CD40 NN NN B-Protein
is NN NN O
a NN NN O
functional NN NN O
activation NN NN O
antigen NN NN O
and NN NN O
B7 NN NN B-Protein
- NN NN O
independent NN NN O
T NN NN O
cell NN NN O
costimulatory NN NN O
molecule NN NN O
on NN NN O
normal NN NN O
human NN NN O
lung NN NN O
fibroblasts NN NN O
. NN NN O
   
CD40 NN NN B-Protein
is NN NN O
an NN NN O
important NN NN O
signaling NN NN O
and NN NN O
activation NN NN O
Ag NN NN O
found NN NN O
on NN NN O
certain NN NN O
bone NN NN O
marrow NN NN O
- NN NN O
derived NN NN O
cells NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
CD40 NN NN B-Protein
also NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
expressed NN NN O
by NN NN O
mesenchymal NN NN O
cells NN NN O
, NN NN O
including NN NN O
human NN NN O
fibroblasts NN NN O
. NN NN O
   
Little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
role NN NN O
of NN NN O
CD40 NN NN B-Protein
in NN NN O
fibroblasts NN NN O
. NN NN O
   
The NN NN O
current NN NN O
study NN NN O
investigates NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
CD40 NN NN B-Protein
expressed NN NN O
on NN NN O
lung NN NN O
fibroblasts NN NN O
is NN NN O
an NN NN O
activation NN NN O
structure NN NN O
and NN NN O
mechanism NN NN O
for NN NN O
interaction NN NN O
with NN NN O
hemopoietic NN NN O
cells NN NN O
. NN NN O
   
Communication NN NN O
between NN NN O
resident NN NN O
tissue NN NN O
fibroblasts NN NN O
and NN NN O
T NN NN O
cells NN NN O
is NN NN O
necessary NN NN O
for NN NN O
normal NN NN O
wound NN NN O
healing NN NN O
, NN NN O
and NN NN O
can NN NN O
be NN NN O
pathologic NN NN O
, NN NN O
resulting NN NN O
in NN NN O
tissue NN NN O
fibrosis NN NN O
. NN NN O
   
Signaling NN NN O
through NN NN O
CD40 NN NN B-Protein
with NN NN O
soluble NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
stimulated NN NN O
fibroblast NN NN O
activation NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
mobilization NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
by NN NN O
induction NN NN O
of NN NN O
the NN NN O
proinflammatory NN NN O
and NN NN O
chemoattractant NN NN O
cytokines NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
primed NN NN O
lung NN NN O
fibroblasts NN NN O
costimulate NN NN O
T NN NN O
lymphocyte NN NN O
proliferation NN NN O
utilizing NN NN O
CD40 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
the NN NN O
well NN NN O
- NN NN O
studied NN NN O
costimulatory NN NN O
molecules NN NN O
B7 NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
B7 NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Data NN NN O
reported NN NN O
herein NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
cognate NN NN O
interactions NN NN O
between NN NN O
tissue NN NN O
fibroblasts NN NN O
and NN NN O
infiltrating NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
via NN NN O
the NN NN O
CD40 NN NN B-Protein
/ NN NN O
CD40L NN NN B-Protein
pathway NN NN O
, NN NN O
augment NN NN O
inflammation NN NN O
and NN NN O
may NN NN O
promote NN NN O
fibrogenesis NN NN O
by NN NN O
activating NN NN O
both NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Tap NN NN O
: NN NN O
a NN NN O
novel NN NN O
cellular NN NN O
protein NN NN O
that NN NN O
interacts NN NN O
with NN NN O
tip NN NN O
of NN NN O
herpesvirus NN NN O
saimiri NN NN O
and NN NN O
induces NN NN O
lymphocyte NN NN O
aggregation NN NN O
. NN NN O
   
Tip NN NN O
of NN NN O
herpesvirus NN NN O
saimiri NN NN O
associates NN NN O
with NN NN O
Lck NN NN B-Protein
and NN NN O
down NN NN O
- NN NN O
regulates NN NN O
Lck NN NN B-Protein
- NN NN O
mediated NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
novel NN NN O
cellular NN NN O
Tip NN NN O
- NN NN O
associated NN NN O
protein NN NN O
( NN NN O
Tap NN NN O
) NN NN O
by NN NN O
a NN NN O
yeast NN NN O
two NN NN O
- NN NN O
hybrid NN NN O
screen NN NN O
. NN NN O
   
Tap NN NN O
associated NN NN O
with NN NN O
Tip NN NN O
following NN NN O
transient NN NN O
expression NN NN O
in NN NN O
COS NN NN O
- NN NN O
1 NN NN O
cells NN NN O
and NN NN O
stable NN NN O
expression NN NN O
in NN NN O
human NN NN O
Jurkat NN NN O
- NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
Tip NN NN O
and NN NN O
Tap NN NN O
in NN NN O
Jurkat NN NN O
- NN NN O
T NN NN O
cells NN NN O
induced NN NN O
dramatic NN NN O
cell NN NN O
aggregation NN NN O
. NN NN O
   
Aggregation NN NN O
was NN NN O
likely NN NN O
caused NN NN O
by NN NN O
the NN NN O
up NN NN O
- NN NN O
regulated NN NN O
surface NN NN O
expression NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
including NN NN O
integrin NN NN O
alpha NN NN O
, NN NN O
L NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
and NN NN O
H NN NN B-Protein
- NN NN I-Protein
CAM NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcriptional NN NN O
factor NN NN O
of NN NN O
aggregated NN NN O
cells NN NN O
had NN NN O
approximately NN NN O
40 NN NN O
- NN NN O
fold NN NN O
higher NN NN O
activity NN NN O
than NN NN O
that NN NN O
of NN NN O
parental NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Tap NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
an NN NN O
important NN NN O
cellular NN NN O
mediator NN NN O
of NN NN O
Tip NN NN O
function NN NN O
in NN NN O
T NN NN O
cell NN NN O
transformation NN NN O
by NN NN O
herpesvirus NN NN O
saimiri NN NN O
. NN NN O
   
Transactivation NN NN O
by NN NN O
CIITA NN NN B-Protein
, NN NN O
the NN NN O
type NN NN O
II NN NN O
bare NN NN O
lymphocyte NN NN O
syndrome NN NN O
- NN NN O
associated NN NN O
factor NN NN O
, NN NN O
requires NN NN O
participation NN NN O
of NN NN O
multiple NN NN O
regions NN NN O
of NN NN O
the NN NN O
TATA NN NN B-Protein
box NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
. NN NN O
   
CIITA NN NN B-Protein
is NN NN O
a NN NN O
positive NN NN O
regulator NN NN O
of NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
gene NN NN O
transcription NN NN O
that NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
defective NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
five NN NN O
complementation NN NN O
groups NN NN O
of NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
- NN NN O
negative NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
region NN NN O
is NN NN O
capable NN NN O
of NN NN O
activating NN NN O
transcription NN NN O
from NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
when NN NN O
fused NN NN O
to NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
transactivation NN NN O
mediated NN NN O
by NN NN O
the NN NN O
CIITA NN NN B-Protein
activation NN NN O
domain NN NN O
by NN NN O
studying NN NN O
its NN NN O
role NN NN O
in NN NN O
the NN NN O
process NN NN O
of NN NN O
transcription NN NN O
initiation NN NN O
and NN NN O
elongation NN NN O
. NN NN O
   
Specifically NN NN O
the NN NN O
altered NN NN O
specificity NN NN O
TBP NN NN B-Protein
( NN NN O
TATA NN NN B-Protein
box NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
) NN NN O
assay NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
analyze NN NN O
the NN NN O
response NN NN O
of NN NN O
the NN NN O
CIITA NN NN B-Protein
activation NN NN O
domain NN NN O
to NN NN O
mutations NN NN O
in NN NN O
TBP NN NN B-Protein
known NN NN O
to NN NN O
disrupt NN NN O
its NN NN O
interaction NN NN O
with NN NN O
its NN NN O
associated NN NN O
general NN NN O
factors NN NN O
. NN NN O
   
Transactivation NN NN O
by NN NN O
CIITA NN NN B-Protein
was NN NN O
extremely NN NN O
sensitive NN NN O
to NN NN O
a NN NN O
mutation NN NN O
in NN NN O
TBP NN NN B-Protein
that NN NN O
in NN NN O
yeast NN NN O
is NN NN O
known NN NN O
to NN NN O
abolish NN NN O
VP16 NN NN B-Protein
- NN NN O
mediated NN NN O
transcription NN NN O
but NN NN O
leaves NN NN O
basal NN NN O
transcription NN NN O
unaffected NN NN O
. NN NN O
   
A NN NN O
TBP NN NN B-Protein
mutant NN NN O
defective NN NN O
in NN NN O
interaction NN NN O
with NN NN O
TBP NN NN B-Protein
- NN NN O
associated NN NN O
factor NN NN O
TAFII250 NN NN B-Protein
also NN NN O
failed NN NN O
to NN NN O
mediate NN NN O
transactivation NN NN O
through NN NN O
the NN NN O
CIITA NN NN B-Protein
activation NN NN O
domain NN NN O
. NN NN O
   
Certain NN NN O
interactions NN NN O
between NN NN O
TBP NN NN B-Protein
and NN NN O
general NN NN O
factors NN NN O
that NN NN O
are NN NN O
specifically NN NN O
required NN NN O
for NN NN O
acidic NN NN O
activation NN NN O
domains NN NN O
were NN NN O
also NN NN O
required NN NN O
for NN NN O
CIITA NN NN B-Protein
- NN NN O
mediated NN NN O
transactivation NN NN O
to NN NN O
reach NN NN O
its NN NN O
full NN NN O
potential NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
like NN NN O
VP16 NN NN B-Protein
, NN NN O
CIITA NN NN B-Protein
was NN NN O
able NN NN O
to NN NN O
stimulate NN NN O
elongation NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Overall NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
transactivation NN NN O
by NN NN O
the NN NN O
human NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
CIITA NN NN B-Protein
is NN NN O
very NN NN O
similar NN NN O
to NN NN O
that NN NN O
mediated NN NN O
by NN NN O
the NN NN O
herpes NN NN O
virus NN NN O
transactivator NN NN O
VP16 NN NN B-Protein
in NN NN O
the NN NN O
ways NN NN O
that NN NN O
have NN NN O
been NN NN O
tested NN NN O
. NN NN O
   
Specific NN NN O
complex NN NN O
formation NN NN O
between NN NN O
the NN NN O
type NN NN O
II NN NN O
bare NN NN O
lymphocyte NN NN O
syndrome NN NN O
- NN NN O
associated NN NN O
transactivators NN NN O
CIITA NN NN B-Protein
and NN NN O
RFX5 NN NN B-Protein
. NN NN O
   
Two NN NN O
of NN NN O
the NN NN O
genes NN NN O
defective NN NN O
in NN NN O
the NN NN O
five NN NN O
complementation NN NN O
groups NN NN O
identified NN NN O
in NN NN O
the NN NN O
class NN NN O
II NN NN O
- NN NN O
negative NN NN O
bare NN NN O
lymphocyte NN NN O
syndrome NN NN O
or NN NN O
corresponding NN NN O
laboratory NN NN O
mutants NN NN O
have NN NN O
been NN NN O
cloned NN NN O
. NN NN O
   
One NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
, NN NN O
RFX5 NN NN B-Protein
, NN NN O
that NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
RFX NN NN O
family NN NN O
of NN NN O
DNA NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
other NN NN O
, NN NN O
CIITA NN NN B-Protein
, NN NN O
encodes NN NN O
a NN NN O
large NN NN O
protein NN NN O
with NN NN O
a NN NN O
defined NN NN O
acidic NN NN O
transcriptional NN NN O
activation NN NN O
domain NN NN O
; NN NN O
this NN NN O
protein NN NN O
does NN NN O
not NN NN O
interact NN NN O
with NN NN O
DNA NN NN O
. NN NN O
   
Expression NN NN O
plasmids NN NN O
encoding NN NN O
regions NN NN O
of NN NN O
RFX5 NN NN B-Protein
fused NN NN O
to NN NN O
the NN NN O
GAL4 NN NN B-Protein
DNA NN NN O
binding NN NN O
domain NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
GAL4 NN NN B-Protein
sites NN NN O
in NN NN O
a NN NN O
cotransfection NN NN O
assay NN NN O
in NN NN O
the NN NN O
Raji NN NN O
human NN NN O
B NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
plasmids NN NN O
produced NN NN O
transcriptional NN NN O
activity NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
only NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
interferon NN NN B-Protein
gamma NN NN I-Protein
stimulation NN NN O
, NN NN O
a NN NN O
condition NN NN O
in NN NN O
which NN NN O
expression NN NN O
of NN NN O
both NN NN O
CIITA NN NN B-Protein
and NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
surface NN NN O
proteins NN NN O
are NN NN O
induced NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
these NN NN O
plasmids NN NN O
were NN NN O
not NN NN O
active NN NN O
in NN NN O
RJ2 NN NN O
. NN NN O
2 NN NN O
. NN NN O
5 NN NN O
, NN NN O
an NN NN O
in NN NN O
vitro NN NN O
mutagenized NN NN O
derivative NN NN O
of NN NN O
Raji NN NN O
in NN NN O
which NN NN O
both NN NN O
copies NN NN O
of NN NN O
CIITA NN NN B-Protein
are NN NN O
defective NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
by NN NN O
the NN NN O
RFX5 NN NN B-Protein
fusion NN NN O
protein NN NN O
could NN NN O
be NN NN O
restored NN NN O
in NN NN O
RJ2 NN NN O
. NN NN O
2 NN NN O
. NN NN O
5 NN NN O
by NN NN O
cotransfection NN NN O
with NN NN O
a NN NN O
CIITA NN NN B-Protein
expression NN NN O
plasmid NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
a NN NN O
direct NN NN O
interaction NN NN O
between NN NN O
RFX5 NN NN B-Protein
and NN NN O
CIITA NN NN B-Protein
was NN NN O
detected NN NN O
with NN NN O
the NN NN O
yeast NN NN O
two NN NN O
- NN NN O
hybrid NN NN O
and NN NN O
far NN NN O
- NN NN O
Western NN NN O
blot NN NN O
assays NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
RFX5 NN NN B-Protein
can NN NN O
activate NN NN O
transcription NN NN O
only NN NN O
in NN NN O
cooperation NN NN O
with NN NN O
CIITA NN NN B-Protein
. NN NN O
   
RFX5 NN NN B-Protein
and NN NN O
CIITA NN NN B-Protein
associate NN NN O
to NN NN O
form NN NN O
a NN NN O
complex NN NN O
capable NN NN O
of NN NN O
activating NN NN O
transcription NN NN O
from NN NN O
class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
promoters NN NN O
. NN NN O
   
In NN NN O
this NN NN O
complex NN NN O
, NN NN O
promoter NN NN O
specificity NN NN O
is NN NN O
determined NN NN O
by NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
of NN NN O
RFX5 NN NN B-Protein
and NN NN O
the NN NN O
general NN NN O
transcription NN NN O
apparatus NN NN O
is NN NN O
recruited NN NN O
by NN NN O
the NN NN O
acidic NN NN O
activation NN NN O
domain NN NN O
of NN NN O
CIITA NN NN B-Protein
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
species NN NN O
and NN NN O
antioxidants NN NN O
in NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
aims NN NN O
to NN NN O
review NN NN O
the NN NN O
role NN NN O
of NN NN O
free NN NN O
radical NN NN O
- NN NN O
induced NN NN O
tissue NN NN O
damage NN NN O
and NN NN O
antioxidant NN NN O
defence NN NN O
mechanisms NN NN O
in NN NN O
inflammatory NN NN O
diseases NN NN O
that NN NN O
involve NN NN O
pathogenic NN NN O
processes NN NN O
similar NN NN O
to NN NN O
the NN NN O
periodontal NN NN O
diseases NN NN O
. NN NN O
   
There NN NN O
is NN NN O
a NN NN O
clearly NN NN O
defined NN NN O
and NN NN O
substantial NN NN O
role NN NN O
for NN NN O
free NN NN O
radicals NN NN O
or NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
in NN NN O
periodontitis NN NN O
, NN NN O
but NN NN O
little NN NN O
research NN NN O
has NN NN O
been NN NN O
performed NN NN O
in NN NN O
this NN NN O
area NN NN O
. NN NN O
   
This NN NN O
paper NN NN O
reviews NN NN O
the NN NN O
considerable NN NN O
data NN NN O
available NN NN O
relating NN NN O
ROS NN NN O
activity NN NN O
and NN NN O
antioxidant NN NN O
defence NN NN O
to NN NN O
inflammatory NN NN O
diseases NN NN O
and NN NN O
attempts NN NN O
to NN NN O
draw NN NN O
parallels NN NN O
with NN NN O
periodontitis NN NN O
, NN NN O
in NN NN O
an NN NN O
effort NN NN O
to NN NN O
stimulate NN NN O
more NN NN O
periodontal NN NN O
research NN NN O
in NN NN O
this NN NN O
important NN NN O
area NN NN O
. NN NN O
   
The NN NN O
recent NN NN O
discovery NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
reviewed NN NN O
and NN NN O
several NN NN O
potential NN NN O
pathways NN NN O
for NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
periodontal NN NN O
tissue NN NN O
damage NN NN O
, NN NN O
mediated NN NN O
by NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
are NN NN O
discussed NN NN O
. NN NN O
   
Emphasis NN NN O
is NN NN O
placed NN NN O
on NN NN O
cytokines NN NN O
that NN NN O
have NN NN O
been NN NN O
studied NN NN O
in NN NN O
periodontitis NN NN O
, NN NN O
principally NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
beta NN NN B-Protein
- NN NN I-Protein
interferon NN NN I-Protein
. NN NN O
   
The NN NN O
link NN NN O
between NN NN O
cellular NN NN O
production NN NN O
of NN NN O
such NN NN O
important NN NN O
mediators NN NN O
of NN NN O
inflammation NN NN O
and NN NN O
the NN NN O
antioxidant NN NN O
( NN NN O
AO NN NN O
) NN NN O
thiols NN NN O
, NN NN O
cysteine NN NN O
and NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
, NN NN O
is NN NN O
discussed NN NN O
and NN NN O
it NN NN O
is NN NN O
hypothesised NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
antagonists NN NN O
may NN NN O
offer NN NN O
important NN NN O
therapeutic NN NN O
benefits NN NN O
. NN NN O
   
Transcriptional NN NN O
activity NN NN O
and NN NN O
constitutive NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
the NN NN O
ETS NN NN O
protein NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
lymphoid NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
belongs NN NN O
to NN NN O
the NN NN O
ETS NN NN O
protein NN NN O
family NN NN O
. NN NN O
   
It NN NN O
can NN NN O
bind NN NN O
to NN NN O
DNA NN NN O
target NN NN O
sequences NN NN O
within NN NN O
a NN NN O
variety NN NN O
of NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
constitutively NN NN O
localized NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
which NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
amino NN NN O
acids NN NN O
86 NN NN O
- NN NN O
265 NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
Gal4 NN NN B-Protein
- NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
fusion NN NN O
proteins NN NN O
revealed NN NN O
that NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
86 NN NN O
amino NN NN O
acids NN NN O
of NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
contain NN NN O
a NN NN O
transcriptional NN NN O
activation NN NN O
domain NN NN O
, NN NN O
the NN NN O
activity NN NN O
of NN NN O
which NN NN O
is NN NN O
attenuated NN NN O
by NN NN O
an NN NN O
internal NN NN O
repression NN NN O
domain NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
interacts NN NN O
specifically NN NN O
with NN NN O
the NN NN O
E74 NN NN O
target NN NN O
sequence NN NN O
and NN NN O
can NN NN O
stimulate NN NN O
transcription NN NN O
driven NN NN O
by NN NN O
the NN NN O
E74 NN NN O
site NN NN O
independent NN NN O
of NN NN O
mitogenic NN NN O
signaling NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Elf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
able NN NN O
to NN NN O
stimulate NN NN O
gene NN NN O
transcription NN NN O
which NN NN O
may NN NN O
be NN NN O
required NN NN O
for NN NN O
the NN NN O
development NN NN O
and NN NN O
activity NN NN O
of NN NN O
lymphocytes NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
inhibits NN NN O
hemin NN NN O
- NN NN O
induced NN NN O
heat NN NN O
shock NN NN O
gene NN NN O
expression NN NN O
and NN NN O
erythroid NN NN O
differentiation NN NN O
in NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
Acquisition NN NN O
of NN NN O
heat NN NN B-Protein
shock NN NN I-Protein
factor NN NN I-Protein
2 NN NN I-Protein
( NN NN O
HSF2 NN NN B-Protein
) NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
induced NN NN O
transcription NN NN O
of NN NN O
heat NN NN O
shock NN NN O
genes NN NN O
in NN NN O
hemin NN NN O
- NN NN O
treated NN NN O
K562 NN NN O
cells NN NN O
undergoing NN NN O
erythroid NN NN O
differentiation NN NN O
. NN NN O
   
Previous NN NN O
studies NN NN O
revealed NN NN O
that NN NN O
HSF2 NN NN B-Protein
consists NN NN O
of NN NN O
two NN NN O
alternatively NN NN O
spliced NN NN O
isoforms NN NN O
, NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
, NN NN O
whose NN NN O
relative NN NN O
abundance NN NN O
is NN NN O
developmentally NN NN O
regulated NN NN O
and NN NN O
varies NN NN O
between NN NN O
different NN NN O
tissues NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
whether NN NN O
the NN NN O
molar NN NN O
ratio NN NN O
of NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
isoforms NN NN O
is NN NN O
crucial NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
HSF2 NN NN B-Protein
and NN NN O
whether NN NN O
the NN NN O
HSF2 NN NN B-Protein
isoforms NN NN O
play NN NN O
functionally NN NN O
distinct NN NN O
roles NN NN O
during NN NN O
the NN NN O
hemin NN NN O
- NN NN O
mediated NN NN O
erythroid NN NN O
differentiation NN NN O
, NN NN O
we NN NN O
generated NN NN O
cell NN NN O
clones NN NN O
expressing NN NN O
different NN NN O
levels NN NN O
of NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
in NN NN O
parental NN NN O
K562 NN NN O
cells NN NN O
, NN NN O
the NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
isoform NN NN O
is NN NN O
predominantly NN NN O
expressed NN NN O
and NN NN O
HSF2 NN NN B-Protein
can NN NN O
be NN NN O
activated NN NN O
upon NN NN O
hemin NN NN O
treatment NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
when NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
is NN NN O
expressed NN NN O
at NN NN O
levels NN NN O
exceeding NN NN O
those NN NN O
of NN NN O
endogenous NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
the NN NN O
hemin NN NN O
- NN NN O
induced NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
transcription NN NN O
of NN NN O
heat NN NN O
shock NN NN O
genes NN NN O
are NN NN O
repressed NN NN O
, NN NN O
whereas NN NN O
overexpression NN NN O
of NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
results NN NN O
in NN NN O
an NN NN O
enhanced NN NN O
hemin NN NN O
response NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
hemin NN NN O
- NN NN O
induced NN NN O
accumulation NN NN O
of NN NN O
globin NN NN O
, NN NN O
known NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
erythroid NN NN O
differentiation NN NN O
, NN NN O
is NN NN O
decreased NN NN O
in NN NN O
cells NN NN O
overexpressing NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
We NN NN O
suggest NN NN O
that NN NN O
HSF2 NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
acts NN NN O
as NN NN O
a NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
HSF2 NN NN B-Protein
activity NN NN O
during NN NN O
hemin NN NN O
- NN NN O
mediated NN NN O
erythroid NN NN O
differentiation NN NN O
of NN NN O
K562 NN NN O
cells NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
mediated NN NN O
repression NN NN O
of NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
human NN NN O
arteritis NN NN O
- NN NN O
SCID NN NN O
chimeras NN NN O
. NN NN O
   
Giant NN NN O
cell NN NN O
arteritis NN NN O
( NN NN O
GCA NN NN O
) NN NN O
is NN NN O
a NN NN O
vasculitic NN NN O
syndrome NN NN O
that NN NN O
preferentially NN NN O
affects NN NN O
medium NN NN O
and NN NN O
large NN NN O
- NN NN O
sized NN NN O
arteries NN NN O
. NN NN O
   
Glucocorticoid NN NN O
therapy NN NN O
resolves NN NN O
clinical NN NN O
symptoms NN NN O
within NN NN O
hours NN NN O
to NN NN O
days NN NN O
, NN NN O
but NN NN O
therapy NN NN O
has NN NN O
to NN NN O
be NN NN O
continued NN NN O
over NN NN O
several NN NN O
years NN NN O
to NN NN O
prevent NN NN O
disease NN NN O
relapses NN NN O
. NN NN O
   
It NN NN O
is NN NN O
not NN NN O
known NN NN O
whether NN NN O
and NN NN O
how NN NN O
glucocorticoids NN NN O
affect NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
infiltrate NN NN O
or NN NN O
why NN NN O
the NN NN O
disease NN NN O
persists NN NN O
subclinically NN NN O
despite NN NN O
chronic NN NN O
treatment NN NN O
. NN NN O
   
GCA NN NN O
is NN NN O
self NN NN O
- NN NN O
sustained NN NN O
in NN NN O
temporal NN NN O
arteries NN NN O
engrafted NN NN O
into NN NN O
SCID NN NN O
mice NN NN O
, NN NN O
providing NN NN O
a NN NN O
model NN NN O
in NN NN O
which NN NN O
the NN NN O
mechanisms NN NN O
of NN NN O
action NN NN O
and NN NN O
limitations NN NN O
of NN NN O
glucocorticoid NN NN O
therapy NN NN O
can NN NN O
be NN NN O
examined NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
dexamethasone NN NN O
to NN NN O
temporal NN NN O
artery NN NN O
- NN NN O
SCID NN NN O
chimeras NN NN O
for NN NN O
1 NN NN O
wk NN NN O
induced NN NN O
a NN NN O
partial NN NN O
suppression NN NN O
of NN NN O
T NN NN O
cell NN NN O
and NN NN O
macrophage NN NN O
function NN NN O
as NN NN O
indicated NN NN O
by NN NN O
the NN NN O
reduced NN NN O
tissue NN NN O
concentrations NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
, NN NN O
and NN NN O
by NN NN O
the NN NN O
diminished NN NN O
expression NN NN O
of NN NN O
inducible NN NN O
NO NN NN O
synthase NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
synthesis NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
mRNA NN NN O
was NN NN O
only NN NN O
slightly NN NN O
decreased NN NN O
, NN NN O
and NN NN O
expression NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
was NN NN O
unaffected NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
correlated NN NN O
with NN NN O
activation NN NN O
of NN NN O
the NN NN O
IkappaBalpha NN NN B-Protein
gene NN NN O
and NN NN O
blockade NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NFkappaB NN NN O
in NN NN O
the NN NN O
xenotransplanted NN NN O
tissue NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
response NN NN O
experiments NN NN O
suggested NN NN O
that NN NN O
steroid NN NN O
doses NN NN O
currently NN NN O
used NN NN O
in NN NN O
clinical NN NN O
medicine NN NN O
are NN NN O
suboptimal NN NN O
in NN NN O
repressing NN NN O
NFkappaB NN NN O
- NN NN O
mediated NN NN O
cytokine NN NN O
production NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
lesions NN NN O
. NN NN O
   
Chronic NN NN O
steroid NN NN O
therapy NN NN O
was NN NN O
able NN NN O
to NN NN O
deplete NN NN O
the NN NN O
T NN NN O
cell NN NN O
products NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
whereas NN NN O
the NN NN O
activation NN NN O
of NN NN O
tissue NN NN O
- NN NN O
infiltrating NN NN O
macrophages NN NN O
was NN NN O
only NN NN O
partially NN NN O
affected NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
transcription NN NN O
was NN NN O
abrogated NN NN O
; NN NN O
in NN NN O
contrast NN NN O
, NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
mRNA NN NN O
synthesis NN NN O
was NN NN O
steroid NN NN O
resistant NN NN O
. NN NN O
   
The NN NN O
persistence NN NN O
of NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
- NN NN O
transcribing NN NN O
macrophages NN NN O
, NN NN O
despite NN NN O
paralysis NN NN O
of NN NN O
T NN NN O
cell NN NN O
function NN NN O
, NN NN O
may NN NN O
provide NN NN O
an NN NN O
explanation NN NN O
for NN NN O
the NN NN O
chronicity NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
and NN NN O
may NN NN O
identify NN NN O
a NN NN O
novel NN NN O
therapeutic NN NN O
target NN NN O
in NN NN O
this NN NN O
inflammatory NN NN O
vasculopathy NN NN O
. NN NN O
   
Histamine NN NN O
modulates NN NN O
the NN NN O
expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
through NN NN O
cyclic NN NN O
AMP NN NN O
production NN NN O
via NN NN O
the NN NN O
H2 NN NN B-Protein
receptor NN NN I-Protein
in NN NN O
the NN NN O
human NN NN O
promonocytic NN NN O
cell NN NN O
line NN NN O
U937 NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
histamine NN NN O
and NN NN O
its NN NN O
agonists NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
proto NN NN O
- NN NN O
oncogenes NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
and NN NN O
translational NN NN O
levels NN NN O
in NN NN O
the NN NN O
human NN NN O
promonocytic NN NN O
U937 NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Histamine NN NN O
transiently NN NN O
increased NN NN O
cAMP NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
expression NN NN O
through NN NN O
H2 NN NN B-Protein
receptors NN NN I-Protein
. NN NN O
   
Dibutyryl NN NN O
cAMP NN NN O
also NN NN O
increased NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNA NN NN O
and NN NN O
protein NN NN O
, NN NN O
and NN NN O
levels NN NN O
remained NN NN O
elevated NN NN O
even NN NN O
after NN NN O
12 NN NN O
hr NN NN O
of NN NN O
treatment NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
dependence NN NN O
studies NN NN O
using NN NN O
histamine NN NN O
and NN NN O
dimaprit NN NN O
showed NN NN O
that NN NN O
the NN NN O
EC50 NN NN O
values NN NN O
for NN NN O
cAMP NN NN O
production NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
increase NN NN O
were NN NN O
similar NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
cAMP NN NN O
might NN NN O
be NN NN O
involved NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
induction NN NN O
via NN NN O
H2 NN NN B-Protein
receptors NN NN I-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
studies NN NN O
carried NN NN O
out NN NN O
using NN NN O
H7 NN NN O
, NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
/ NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
inhibitor NN NN O
, NN NN O
blocked NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
induction NN NN O
, NN NN O
whereas NN NN O
no NN NN O
effect NN NN O
was NN NN O
observed NN NN O
with NN NN O
bisindolylmaleimide NN NN O
, NN NN O
a NN NN O
specific NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
inhibitor NN NN O
. NN NN O
   
No NN NN O
modification NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
expression NN NN O
could NN NN O
be NN NN O
detected NN NN O
on NN NN O
treatment NN NN O
with NN NN O
histamine NN NN O
or NN NN O
its NN NN O
analogues NN NN O
. NN NN O
   
Nevertheless NN NN O
, NN NN O
dibutyryl NN NN O
cAMP NN NN O
induced NN NN O
a NN NN O
down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
the NN NN O
levels NN NN O
of NN NN O
this NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
dibutyryl NN NN O
cAMP NN NN O
inhibited NN NN O
cell NN NN O
growth NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
whereas NN NN O
histamine NN NN O
failed NN NN O
to NN NN O
affect NN NN O
proliferation NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
Cells NN NN O
pretreated NN NN O
with NN NN O
dimaprit NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
cAMP NN NN O
response NN NN O
to NN NN O
subsequent NN NN O
addition NN NN O
of NN NN O
H2 NN NN O
agonists NN NN O
, NN NN O
whereas NN NN O
the NN NN O
cAMP NN NN O
response NN NN O
to NN NN O
prostaglandin NN NN O
E2 NN NN O
remained NN NN O
unaltered NN NN O
. NN NN O
   
This NN NN O
homologous NN NN O
mechanism NN NN O
of NN NN O
H2 NN NN B-Protein
receptor NN NN I-Protein
desensitization NN NN O
was NN NN O
time NN NN O
dependent NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
histamine NN NN O
activates NN NN O
several NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
differentiation NN NN O
, NN NN O
such NN NN O
as NN NN O
cAMP NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
production NN NN O
, NN NN O
but NN NN O
fails NN NN O
to NN NN O
promote NN NN O
differentiation NN NN O
of NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
apparently NN NN O
due NN NN O
to NN NN O
the NN NN O
rapid NN NN O
desensitization NN NN O
of NN NN O
H2 NN NN B-Protein
receptors NN NN I-Protein
. NN NN O
   
Human NN NN O
cytomegalovirus NN NN O
induces NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
by NN NN O
a NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
, NN NN O
through NN NN O
acting NN NN O
concurrently NN NN O
on NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
sites NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
. NN NN O
   
Cytomegalovirus NN NN O
( NN NN O
CMV NN NN O
) NN NN O
infection NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
a NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
, NN NN O
leading NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
secretion NN NN O
. NN NN O
   
The NN NN O
functional NN NN O
analysis NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
revealed NN NN O
that NN NN O
both NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
factor NN NN O
- NN NN O
binding NN NN O
elements NN NN O
were NN NN O
involved NN NN O
in NN NN O
conferring NN NN O
the NN NN O
responsiveness NN NN O
to NN NN O
CMV NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrated NN NN O
that NN NN O
CMV NN NN O
induced NN NN O
the NN NN O
formation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complexes NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
CMV NN NN O
activates NN NN O
these NN NN O
transcriptional NN NN O
factors NN NN O
, NN NN O
resulting NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
gene NN NN O
expression NN NN O
. NN NN O
   
Concomitant NN NN O
downregulation NN NN O
of NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
activity NN NN O
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
expression NN NN O
in NN NN O
a NN NN O
plasmacytoma NN NN O
x NN NN O
fibroblast NN NN O
environment NN NN O
: NN NN O
implications NN NN O
for NN NN O
dysregulation NN NN O
of NN NN O
translocated NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
. NN NN O
   
Regulation NN NN O
of NN NN O
immunoglobulin NN NN O
heavy NN NN O
chain NN NN O
( NN NN O
IgH NN NN O
) NN NN O
gene NN NN O
expression NN NN O
is NN NN O
controlled NN NN O
by NN NN O
a NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
, NN NN O
intronic NN NN O
enhancer NN NN O
and NN NN O
additional NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
enhancer NN NN O
elements NN NN O
identified NN NN O
recently NN NN O
in NN NN O
the NN NN O
3 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
IgH NN NN O
locus NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
latter NN NN O
elements NN NN O
, NN NN O
the NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
, NN NN O
is NN NN O
of NN NN O
particular NN NN O
interest NN NN O
: NN NN O
( NN NN O
1 NN NN O
) NN NN O
it NN NN O
is NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
and NN NN O
active NN NN O
only NN NN O
in NN NN O
late NN NN O
B NN NN O
cell NN NN O
development NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
in NN NN O
rodent NN NN O
plasmacytomas NN NN O
and NN NN O
in NN NN O
some NN NN O
human NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphomas NN NN O
it NN NN O
is NN NN O
part NN NN O
of NN NN O
a NN NN O
locus NN NN O
control NN NN O
region NN NN O
( NN NN O
LCR NN NN O
) NN NN O
that NN NN O
is NN NN O
involved NN NN O
in NN NN O
deregulation NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
oncogene NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
translocation NN NN O
into NN NN O
the NN NN O
IgH NN NN O
locus NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
it NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
mechanisms NN NN O
that NN NN O
control NN NN O
Ig NN NN O
gene NN NN O
class NN NN O
switch NN NN O
recombination NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
a NN NN O
somatic NN NN O
cell NN NN O
hybridization NN NN O
approach NN NN O
to NN NN O
genetically NN NN O
analyse NN NN O
regulation NN NN O
of NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
. NN NN O
   
When NN NN O
mouse NN NN O
MPC11 NN NN O
plasmacytoma NN NN O
cells NN NN O
, NN NN O
in NN NN O
which NN NN O
the NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
is NN NN O
active NN NN O
, NN NN O
are NN NN O
fused NN NN O
with NN NN O
fibroblasts NN NN O
, NN NN O
Ig NN NN O
expression NN NN O
is NN NN O
extinguished NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
in NN NN O
a NN NN O
MPC11 NN NN O
plasmacytoma NN NN O
x NN NN O
fibroblast NN NN O
environment NN NN O
, NN NN O
the NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
is NN NN O
transcriptionally NN NN O
inactive NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
binding NN NN O
of NN NN O
several NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
essential NN NN O
for NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
activity NN NN O
, NN NN O
is NN NN O
lacking NN NN O
, NN NN O
which NN NN O
may NN NN O
explain NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
inactivity NN NN O
, NN NN O
although NN NN O
the NN NN O
binding NN NN O
of NN NN O
repressors NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
high NN NN O
expression NN NN O
level NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
characteristic NN NN O
of NN NN O
the NN NN O
parental NN NN O
MPC11 NN NN O
cells NN NN O
carrying NN NN O
the NN NN O
t NN NN O
( NN NN O
12 NN NN O
; NN NN O
15 NN NN O
) NN NN O
translocation NN NN O
, NN NN O
is NN NN O
down NN NN O
- NN NN O
regulated NN NN O
in NN NN O
the NN NN O
hybrids NN NN O
to NN NN O
that NN NN O
in NN NN O
unfused NN NN O
fibroblasts NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
IgH NN NN O
3 NN NN O
' NN NN O
enhancer NN NN O
is NN NN O
a NN NN O
multifactorial NN NN O
process NN NN O
affecting NN NN O
several NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
control NN NN O
the NN NN O
cell NN NN O
- NN NN O
specific NN NN O
and NN NN O
developmental NN NN O
activity NN NN O
of NN NN O
the NN NN O
enhancer NN NN O
. NN NN O
   
ETS1 NN NN B-Protein
, NN NN O
NFkappaB NN NN O
and NN NN O
AP1 NN NN O
synergistically NN NN O
transactivate NN NN O
the NN NN O
human NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
promoter NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
helper NN NN O
T NN NN O
cells NN NN O
results NN NN O
in NN NN O
coordinate NN NN O
expression NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
cytokines NN NN O
involved NN NN O
in NN NN O
differentiation NN NN O
, NN NN O
proliferation NN NN O
and NN NN O
activation NN NN O
of NN NN O
the NN NN O
haematopoietic NN NN O
system NN NN O
. NN NN O
   
Granulocyte NN NN B-Protein
- NN NN I-Protein
macrophage NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
is NN NN O
one NN NN O
such NN NN O
cytokine NN NN O
, NN NN O
whose NN NN O
increased NN NN O
expression NN NN O
results NN NN O
mostly NN NN O
from NN NN O
increases NN NN O
in NN NN O
transcription NN NN O
. NN NN O
   
Cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
with NN NN O
NFkappaB NN NN O
, NN NN O
AP1 NN NN O
and NN NN O
ETS NN NN O
- NN NN O
like NN NN O
binding NN NN O
motifs NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
, NN NN O
and NN NN O
are NN NN O
important NN NN O
or NN NN O
essential NN NN O
for NN NN O
transcriptional NN NN O
activity NN NN O
following NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
ETS1 NN NN B-Protein
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
of NN NN O
the NN NN O
ETS NN NN O
family NN NN O
that NN NN O
is NN NN O
expressed NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
ETS1 NN NN B-Protein
can NN NN O
transactivate NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
but NN NN O
only NN NN O
after NN NN O
the NN NN O
cells NN NN O
have NN NN O
been NN NN O
stimulated NN NN O
by NN NN O
treatment NN NN O
with NN NN O
PMA NN NN O
and NN NN O
ionomycin NN NN O
, NN NN O
agents NN NN O
that NN NN O
mimic NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Thus NN NN O
we NN NN O
proposed NN NN O
that NN NN O
ETS1 NN NN B-Protein
, NN NN O
which NN NN O
is NN NN O
expressed NN NN O
constitutively NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
may NN NN O
act NN NN O
in NN NN O
concert NN NN O
with NN NN O
PMA NN NN O
/ NN NN O
ionomycin NN NN O
inducible NN NN O
factors NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
ETS1 NN NN B-Protein
can NN NN O
transactivate NN NN O
a NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
reporter NN NN O
construct NN NN O
in NN NN O
unstimulated NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
providing NN NN O
that NN NN O
either NN NN O
NFkappaB NN NN O
or NN NN O
AP1 NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
supplied NN NN O
by NN NN O
co NN NN O
- NN NN O
transfection NN NN O
. NN NN O
   
We NN NN O
confirm NN NN O
that NN NN O
binding NN NN O
of NN NN O
endogenous NN NN O
NFkappaB NN NN O
and NN NN O
AP1 NN NN O
is NN NN O
induced NN NN O
following NN NN O
PMA NN NN O
/ NN NN O
ionomycin NN NN O
treatment NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Transactivation NN NN O
by NN NN O
ETS1 NN NN B-Protein
, NN NN O
NFkappaB NN NN O
and NN NN O
AP1 NN NN O
is NN NN O
synergistic NN NN O
, NN NN O
and NN NN O
mutation NN NN O
of NN NN O
the NN NN O
individual NN NN O
binding NN NN O
sites NN NN O
reveals NN NN O
that NN NN O
the NN NN O
transcriptional NN NN O
activities NN NN O
of NN NN O
these NN NN O
factors NN NN O
are NN NN O
interdependent NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
constitutive NN NN O
ETS1 NN NN B-Protein
, NN NN O
and NN NN O
inducible NN NN O
NFkappaB NN NN O
and NN NN O
AP1 NN NN O
, NN NN O
cooperate NN NN O
as NN NN O
part NN NN O
of NN NN O
a NN NN O
higher NN NN O
order NN NN O
transcriptional NN NN O
complex NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Relief NN NN O
of NN NN O
cyclin NN NN B-Protein
A NN NN I-Protein
gene NN NN O
transcriptional NN NN O
inhibition NN NN O
during NN NN O
activation NN NN O
of NN NN O
human NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
via NN NN O
CD2 NN NN B-Protein
and NN NN O
CD28 NN NN B-Protein
adhesion NN NN O
molecules NN NN O
. NN NN O
   
Cyclin NN NN B-Protein
A NN NN I-Protein
transcription NN NN O
is NN NN O
cell NN NN O
cycle NN NN O
regulated NN NN O
and NN NN O
induced NN NN O
by NN NN O
cell NN NN O
proliferative NN NN O
signals NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
mechanisms NN NN O
underlined NN NN O
in NN NN O
this NN NN O
regulation NN NN O
in NN NN O
normal NN NN O
human NN NN O
cells NN NN O
, NN NN O
we NN NN O
have NN NN O
analysed NN NN O
in NN NN O
vivo NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
interactions NN NN O
at NN NN O
the NN NN O
Cyclin NN NN B-Protein
A NN NN I-Protein
locus NN NN O
in NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
purified NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
monoclonal NN NN O
antibodies NN NN O
directed NN NN O
at NN NN O
CD2 NN NN B-Protein
and NN NN O
CD28 NN NN B-Protein
adhesion NN NN O
molecules NN NN O
gives NN NN O
rise NN NN O
to NN NN O
a NN NN O
long NN NN O
lasting NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
accessory NN NN O
cells NN NN O
. NN NN O
   
Cyclin NN NN B-Protein
A NN NN I-Protein
was NN NN O
observed NN NN O
after NN NN O
4 NN NN O
days NN NN O
of NN NN O
costimulation NN NN O
with NN NN O
anti NN NN O
CD2 NN NN B-Protein
+ NN NN O
CD28 NN NN B-Protein
whereas NN NN O
stimulation NN NN O
by NN NN O
anti NN NN O
CD2 NN NN B-Protein
or NN NN O
anti NN NN O
CD28 NN NN B-Protein
alone NN NN O
was NN NN O
not NN NN O
effective NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
genomic NN NN O
DMS NN NN O
footprinting NN NN O
revealed NN NN O
upstream NN NN O
of NN NN O
the NN NN O
major NN NN O
transcription NN NN O
initiation NN NN O
sites NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
at NN NN O
least NN NN O
three NN NN O
protein NN NN O
binding NN NN O
sites NN NN O
, NN NN O
two NN NN O
of NN NN O
which NN NN O
were NN NN O
constitutively NN NN O
occupied NN NN O
. NN NN O
   
They NN NN O
bind NN NN O
in NN NN O
vitro NN NN O
respectively NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
Y NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
third NN NN O
site NN NN O
was NN NN O
occupied NN NN O
in NN NN O
quiescent NN NN O
cells NN NN O
or NN NN O
in NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
anti NN NN O
CD2 NN NN B-Protein
or NN NN O
anti NN NN O
CD28 NN NN B-Protein
alone NN NN O
. NN NN O
   
The NN NN O
mitogenic NN NN O
combination NN NN O
of NN NN O
anti NN NN O
CD2 NN NN B-Protein
+ NN NN O
anti NN NN O
CD28 NN NN B-Protein
released NN NN O
the NN NN O
footprint NN NN O
as NN NN O
cells NN NN O
were NN NN O
committed NN NN O
to NN NN O
proliferation NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
theses NN NN O
results NN NN O
, NN NN O
nuclear NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
quiescent NN NN O
cells NN NN O
formed NN NN O
a NN NN O
specific NN NN O
complex NN NN O
with NN NN O
this NN NN O
element NN NN O
, NN NN O
whereas NN NN O
extracts NN NN O
prepared NN NN O
from NN NN O
cells NN NN O
treated NN NN O
with NN NN O
anti NN NN O
CD2 NN NN B-Protein
+ NN NN O
anti NN NN O
CD28 NN NN B-Protein
failed NN NN O
to NN NN O
do NN NN O
so NN NN O
after NN NN O
cells NN NN O
entered NN NN O
a NN NN O
proliferative NN NN O
state NN NN O
. NN NN O
   
Biphasic NN NN O
control NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
induced NN NN O
by NN NN O
the NN NN O
triggering NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
antigens NN NN O
expressed NN NN O
on NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
following NN NN O
the NN NN O
triggering NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
antigens NN NN O
by NN NN O
mAb NN NN O
L243 NN NN O
has NN NN O
been NN NN O
studied NN NN O
at NN NN O
various NN NN O
times NN NN O
in NN NN O
Raji NN NN O
cells NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrated NN NN O
a NN NN O
strong NN NN O
increase NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
binding NN NN O
after NN NN O
triggering NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
antigens NN NN O
. NN NN O
   
Using NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
activity NN NN O
neutralizing NN NN O
antibodies NN NN O
, NN NN O
the NN NN O
authors NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
found NN NN O
to NN NN O
depend NN NN O
, NN NN O
at NN NN O
later NN NN O
time NN NN O
point NN NN O
, NN NN O
on NN NN O
an NN NN O
autocrine NN NN O
effect NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secreted NN NN O
following NN NN O
triggering NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
antigens NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
it NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
independent NN NN O
in NN NN O
the NN NN O
early NN NN O
time NN NN O
point NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
is NN NN O
regulated NN NN O
by NN NN O
the NN NN O
triggering NN NN O
of NN NN O
selected NN NN O
epitopes NN NN O
of NN NN O
HLA NN NN O
- NN NN O
DR NN NN O
antigens NN NN O
. NN NN O
   
In NN NN O
fact NN NN O
, NN NN O
mAb NN NN O
L243 NN NN O
but NN NN O
not NN NN O
the NN NN O
staphylococcal NN NN O
superantigens NN NN O
, NN NN O
staphylococcal NN NN O
exotoxin NN NN O
toxic NN NN B-Protein
shock NN NN I-Protein
syndrome NN NN I-Protein
toxin NN NN I-Protein
- NN NN I-Protein
I NN NN I-Protein
or NN NN O
staphylococcal NN NN B-Protein
enterotoxin NN NN I-Protein
B NN NN I-Protein
, NN NN O
regulate NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Comparison NN NN O
of NN NN O
the NN NN O
transactivation NN NN O
domains NN NN O
of NN NN O
Stat5 NN NN B-Protein
and NN NN O
Stat6 NN NN B-Protein
in NN NN O
lymphoid NN NN O
cells NN NN O
and NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
Stat NN NN O
( NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
) NN NN O
and NN NN O
Jak NN NN O
( NN NN O
Janus NN NN O
kinases NN NN O
) NN NN O
proteins NN NN O
are NN NN O
central NN NN O
components NN NN O
in NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
events NN NN O
in NN NN O
hematopoietic NN NN O
and NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
They NN NN O
are NN NN O
rapidly NN NN O
activated NN NN O
by NN NN O
various NN NN O
cytokines NN NN O
, NN NN O
hormones NN NN O
, NN NN O
and NN NN O
growth NN NN O
factors NN NN O
. NN NN O
   
Upon NN NN O
ligand NN NN O
binding NN NN O
and NN NN O
cytokine NN NN O
receptor NN NN O
dimerization NN NN O
, NN NN O
Stat NN NN O
proteins NN NN O
are NN NN O
phosphorylated NN NN O
on NN NN O
tyrosine NN NN O
residues NN NN O
by NN NN O
Jak NN NN O
kinases NN NN O
. NN NN O
   
Activated NN NN O
Stat NN NN O
proteins NN NN O
form NN NN O
homo NN NN O
- NN NN O
or NN NN O
heterodimers NN NN O
, NN NN O
translocate NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
and NN NN O
induce NN NN O
transcription NN NN O
from NN NN O
responsive NN NN O
genes NN NN O
. NN NN O
   
Stat5 NN NN B-Protein
and NN NN O
Stat6 NN NN B-Protein
are NN NN O
transcription NN NN O
factors NN NN O
active NN NN O
in NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
immune NN NN O
cells NN NN O
. NN NN O
   
Prolactin NN NN B-Protein
activates NN NN O
Stat5 NN NN B-Protein
, NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
activates NN NN O
Stat6 NN NN B-Protein
. NN NN O
   
Both NN NN O
cytokines NN NN O
are NN NN O
able NN NN O
to NN NN O
stimulate NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
survival NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
transactivation NN NN O
potential NN NN O
of NN NN O
Stat6 NN NN B-Protein
and NN NN O
found NN NN O
that NN NN O
it NN NN O
is NN NN O
not NN NN O
restricted NN NN O
to NN NN O
lymphocytes NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
Stat6 NN NN B-Protein
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
HC11 NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
these NN NN O
cells NN NN O
, NN NN O
Stat6 NN NN B-Protein
activation NN NN O
led NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
beta NN NN O
- NN NN O
casein NN NN O
gene NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
this NN NN O
promoter NN NN O
was NN NN O
confirmed NN NN O
in NN NN O
COS7 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
was NN NN O
able NN NN O
to NN NN O
further NN NN O
enhance NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
gene NN NN O
transcription NN NN O
through NN NN O
the NN NN O
action NN NN O
of NN NN O
Stat6 NN NN B-Protein
. NN NN O
   
Deletion NN NN O
analysis NN NN O
of NN NN O
the NN NN O
carboxyl NN NN O
- NN NN O
terminal NN NN O
region NN NN O
of NN NN O
Stat6 NN NN B-Protein
and NN NN O
recombination NN NN O
of NN NN O
this NN NN O
region NN NN O
with NN NN O
a NN NN O
heterologous NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
allowed NN NN O
the NN NN O
delimitation NN NN O
and NN NN O
characterization NN NN O
of NN NN O
the NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
Stat6 NN NN B-Protein
. NN NN O
   
The NN NN O
potencies NN NN O
of NN NN O
the NN NN O
transactivation NN NN O
domains NN NN O
of NN NN O
Stat5 NN NN B-Protein
, NN NN O
Stat6 NN NN B-Protein
, NN NN O
and NN NN O
viral NN NN O
protein NN NN O
VP16 NN NN B-Protein
were NN NN O
compared NN NN O
. NN NN O
   
Stat6 NN NN B-Protein
had NN NN O
a NN NN O
transactivation NN NN O
domain NN NN O
which NN NN O
was NN NN O
about NN NN O
10 NN NN O
- NN NN O
fold NN NN O
stronger NN NN O
than NN NN O
that NN NN O
of NN NN O
Stat5 NN NN B-Protein
. NN NN O
   
In NN NN O
pre NN NN O
- NN NN O
B NN NN O
cells NN NN O
( NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
) NN NN O
, NN NN O
the NN NN O
transactivation NN NN O
domain NN NN O
of NN NN O
Stat6 NN NN B-Protein
was NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
regulated NN NN O
, NN NN O
independently NN NN O
from NN NN O
its NN NN O
DNA NN NN O
binding NN NN O
function NN NN O
. NN NN O
   
The NN NN O
immediate NN NN O
- NN NN O
early NN NN O
gene NN NN O
product NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
regulates NN NN O
the NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
promoter NN NN O
through NN NN O
noncanonical NN NN O
Egr NN NN O
and NN NN O
Sp1 NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
The NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
beta NN NN I-Protein
- NN NN I-Protein
chain NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
essential NN NN O
component NN NN O
of NN NN O
the NN NN O
receptors NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
15 NN NN I-Protein
. NN NN O
   
Although NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
is NN NN O
constitutively NN NN O
expressed NN NN O
by NN NN O
lymphocytes NN NN O
, NN NN O
its NN NN O
expression NN NN O
can NN NN O
be NN NN O
further NN NN O
induced NN NN O
by NN NN O
a NN NN O
number NN NN O
of NN NN O
stimuli NN NN O
, NN NN O
including NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
. NN NN O
   
We NN NN O
have NN NN O
now NN NN O
characterized NN NN O
factors NN NN O
that NN NN O
bind NN NN O
to NN NN O
an NN NN O
enhancer NN NN O
region NN NN O
located NN NN O
between NN NN O
nucleotides NN NN O
- NN NN O
170 NN NN O
and NN NN O
- NN NN O
139 NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
promoter NN NN O
. NN NN O
   
Both NN NN O
Sp1 NN NN B-Protein
and NN NN O
Sp3 NN NN B-Protein
bound NN NN O
to NN NN O
the NN NN O
5 NN NN O
' NN NN O
portion NN NN O
of NN NN O
this NN NN O
region NN NN O
, NN NN O
whereas NN NN O
a NN NN O
PMA NN NN O
- NN NN O
inducible NN NN O
factor NN NN O
( NN NN O
PIF NN NN O
) NN NN O
mainly NN NN O
bound NN NN O
to NN NN O
its NN NN O
3 NN NN O
' NN NN O
portion NN NN O
and NN NN O
bound NN NN O
to NN NN O
the NN NN O
Sp NN NN O
binding NN NN O
motifs NN NN O
as NN NN O
well NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
induction NN NN O
of NN NN O
PIF NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
rapidly NN NN O
induced NN NN O
, NN NN O
required NN NN O
de NN NN O
novo NN NN O
protein NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
was NN NN O
sustained NN NN O
at NN NN O
a NN NN O
high NN NN O
level NN NN O
for NN NN O
at NN NN O
least NN NN O
23 NN NN O
h NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
PIF NN NN O
was NN NN O
constitutively NN NN O
activated NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
- NN NN O
transformed NN NN O
MT NN NN O
- NN NN O
2 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
PIF NN NN O
is NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
based NN NN O
on NN NN O
its NN NN O
recognition NN NN O
by NN NN O
anti NN NN O
- NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
antisera NN NN O
in NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
even NN NN O
though NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
DNA NN NN O
binding NN NN O
motif NN NN O
differed NN NN O
substantially NN NN O
from NN NN O
the NN NN O
canonical NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
binding NN NN O
site NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
bound NN NN O
to NN NN O
the NN NN O
Sp NN NN O
binding NN NN O
site NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
both NN NN O
sites NN NN O
were NN NN O
required NN NN O
for NN NN O
maximal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
promoter NN NN O
activity NN NN O
, NN NN O
and NN NN O
in NN NN O
HeLaS3 NN NN O
cells NN NN O
, NN NN O
transfection NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
could NN NN O
drive NN NN O
activity NN NN O
of NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
containing NN NN O
both NN NN O
sites NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
Sp1 NN NN B-Protein
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
could NN NN O
form NN NN O
a NN NN O
complex NN NN O
with NN NN O
kinetics NN NN O
that NN NN O
correlated NN NN O
with NN NN O
the NN NN O
production NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
Jurkat NN NN O
cells NN NN O
upon NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Sp1 NN NN B-Protein
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
physically NN NN O
and NN NN O
functionally NN NN O
cooperate NN NN O
to NN NN O
mediate NN NN O
maximal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2Rbeta NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
Ehrlichia NN NN O
chaffeensis NN NN O
antibody NN NN O
complexed NN NN O
with NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
induces NN NN O
potent NN NN O
proinflammatory NN NN O
cytokine NN NN O
mRNA NN NN O
expression NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
through NN NN O
sustained NN NN O
reduction NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Ehrlichia NN NN O
chaffeensis NN NN O
is NN NN O
an NN NN O
obligatory NN NN O
intracellular NN NN O
bacterium NN NN O
that NN NN O
infects NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
and NN NN O
is NN NN O
the NN NN O
etiologic NN NN O
agent NN NN O
of NN NN O
human NN NN O
ehrlichiosis NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O
   
Our NN NN O
previous NN NN O
studies NN NN O
showed NN NN O
that NN NN O
the NN NN O
exposure NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
to NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
induces NN NN O
the NN NN O
expression NN NN O
of NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
genes NN NN O
in NN NN O
vitro NN NN O
but NN NN O
not NN NN O
the NN NN O
expression NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNAs NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
antibody NN NN O
complexed NN NN O
with NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
on NN NN O
the NN NN O
expression NN NN O
of NN NN O
major NN NN O
proinflammatory NN NN O
cytokines NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
Human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
THP NN NN O
- NN NN O
1 NN NN O
was NN NN O
treated NN NN O
with NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
which NN NN O
had NN NN O
been NN NN O
preincubated NN NN O
with NN NN O
human NN NN O
anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
serum NN NN O
for NN NN O
2 NN NN O
h NN NN O
, NN NN O
and NN NN O
the NN NN O
levels NN NN O
of NN NN O
cytokine NN NN O
mRNAs NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
competitive NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
antibody NN NN O
complexed NN NN O
with NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
significantly NN NN O
enhanced NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNAs NN NN O
was NN NN O
also NN NN O
induced NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
secreted NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
during NN NN O
24 NN NN O
h NN NN O
of NN NN O
stimulation NN NN O
were NN NN O
comparable NN NN O
to NN NN O
those NN NN O
induced NN NN O
by NN NN O
Escherichia NN NN O
coli NN NN O
lipopolysaccharide NN NN O
at NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
. NN NN O
   
Fab NN NN O
fragment NN NN O
of NN NN O
anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
immunoglobulin NN NN O
G NN NN O
complexed NN NN O
with NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
did NN NN O
not NN NN O
induce NN NN O
any NN NN O
of NN NN O
these NN NN O
three NN NN O
cytokines NN NN O
, NN NN O
indicating NN NN O
that NN NN O
ehrlichial NN NN O
binding NN NN O
is NN NN O
required NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
that NN NN O
binding NN NN O
of NN NN O
the NN NN O
immune NN NN O
complex NN NN O
to NN NN O
the NN NN O
Fc NN NN B-Protein
gamma NN NN I-Protein
receptor NN NN I-Protein
is NN NN O
required NN NN O
for NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
prolonged NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
were NN NN O
demonstrated NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
exposed NN NN O
to NN NN O
anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
serum NN NN O
and NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
. NN NN O
   
This NN NN O
result NN NN O
implies NN NN O
that NN NN O
development NN NN O
of NN NN O
anti NN NN O
- NN NN O
E NN NN O
. NN NN O
chaffeensis NN NN O
antibody NN NN O
in NN NN O
patients NN NN O
can NN NN O
result NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
major NN NN O
proinflammatory NN NN O
cytokines NN NN O
, NN NN O
which NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
ehrlichiosis NN NN O
and NN NN O
immune NN NN O
responses NN NN O
to NN NN O
it NN NN O
. NN NN O
   
S NN NN O
- NN NN O
allyl NN NN O
cysteine NN NN O
inhibits NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
in NN NN O
human NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Reactive NN NN O
oxygen NN NN O
species NN NN O
are NN NN O
involved NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
which NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
recently NN NN O
reported NN NN O
that NN NN O
a NN NN O
garlic NN NN O
compound NN NN O
, NN NN O
S NN NN O
- NN NN O
allyl NN NN O
cysteine NN NN O
( NN NN O
SAC NN NN O
) NN NN O
, NN NN O
protects NN NN O
bovine NN NN O
pulmonary NN NN O
artery NN NN O
endothelial NN NN O
cells NN NN O
from NN NN O
oxidant NN NN O
injury NN NN O
induced NN NN O
by NN NN O
hydrogen NN NN O
peroxide NN NN O
( NN NN O
H2O2 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
determined NN NN O
the NN NN O
effects NN NN O
of NN NN O
SAC NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
( NN NN O
Jurkat NN NN O
cells NN NN O
) NN NN O
induced NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
H2O2 NN NN O
. NN NN O
   
Activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
was NN NN O
measured NN NN O
by NN NN O
an NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
using NN NN O
32P NN NN O
- NN NN O
labeled NN NN O
probe NN NN O
. NN NN O
   
SAC NN NN O
consistently NN NN O
exhibited NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
induced NN NN O
by NN NN O
both NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
H2O2 NN NN O
. NN NN O
   
Supershift NN NN O
with NN NN O
specific NN NN O
antibodies NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
subunits NN NN O
confirmed NN NN O
that NN NN O
the NN NN O
inducible NN NN O
retarded NN NN O
bands NN NN O
observed NN NN O
in NN NN O
the NN NN O
EMSA NN NN O
and NN NN O
p65 NN NN B-Protein
- NN NN O
p50 NN NN B-Protein
heterodimer NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
protein NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
SAC NN NN O
may NN NN O
act NN NN O
via NN NN O
antioxidant NN NN O
mechanisms NN NN O
to NN NN O
block NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
Effect NN NN O
of NN NN O
adenovirus NN NN O
2 NN NN O
on NN NN O
cellular NN NN O
gene NN NN O
activation NN NN O
in NN NN O
blood NN NN O
- NN NN O
derived NN NN O
monocytes NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
adenovirus NN NN O
2 NN NN O
( NN NN O
Ad2 NN NN O
) NN NN O
infection NN NN O
on NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
with NN NN O
regard NN NN O
to NN NN O
expression NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
. NN NN O
   
In NN NN O
monocytes NN NN O
, NN NN O
the NN NN O
virus NN NN O
was NN NN O
bound NN NN O
to NN NN O
the NN NN O
surface NN NN O
without NN NN O
being NN NN O
internalized NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
Ad2 NN NN O
was NN NN O
internalized NN NN O
by NN NN O
macrophages NN NN O
. NN NN O
   
No NN NN O
virus NN NN O
replication NN NN O
and NN NN O
no NN NN O
transcription NN NN O
of NN NN O
the NN NN O
Ad2 NN NN O
early NN NN O
genes NN NN O
was NN NN O
observed NN NN O
in NN NN O
either NN NN O
of NN NN O
the NN NN O
cells NN NN O
. NN NN O
   
Ad2 NN NN O
infection NN NN O
induced NN NN O
transient NN NN O
increase NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
levels NN NN O
for NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
in NN NN O
both NN NN O
monocytes NN NN O
and NN NN O
in NN NN O
macrophages NN NN O
, NN NN O
although NN NN O
the NN NN O
kinetics NN NN O
of NN NN O
the NN NN O
transcription NN NN O
was NN NN O
slightly NN NN O
different NN NN O
. NN NN O
   
The NN NN O
production NN NN O
of NN NN O
both NN NN O
cytokines NN NN O
, NN NN O
measured NN NN O
by NN NN O
ELISA NN NN O
tests NN NN O
, NN NN O
was NN NN O
enhanced NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
In NN NN O
macrophages NN NN O
, NN NN O
a NN NN O
slight NN NN O
enhancement NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
was NN NN O
seen NN NN O
, NN NN O
whereas NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
was NN NN O
not NN NN O
detected NN NN O
. NN NN O
   
The NN NN O
data NN NN O
indicate NN NN O
that NN NN O
cellular NN NN O
genes NN NN O
might NN NN O
be NN NN O
activated NN NN O
by NN NN O
Ad2 NN NN O
virus NN NN O
infection NN NN O
in NN NN O
nonpermissive NN NN O
cells NN NN O
where NN NN O
no NN NN O
viral NN NN O
gene NN NN O
products NN NN O
could NN NN O
be NN NN O
detected NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
beta NN NN O
- NN NN O
amyloid NN NN O
peptides NN NN O
and NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
in NN NN O
murine NN NN O
microglia NN NN O
. NN NN O
   
An NN NN O
increasing NN NN O
body NN NN O
of NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
amyloid NN NN O
- NN NN O
beta NN NN O
( NN NN O
A NN NN O
beta NN NN O
) NN NN O
peptides NN NN O
and NN NN O
microglia NN NN O
are NN NN O
crucially NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Alzheimer NN NN O
' NN NN O
s NN NN O
disease NN NN O
. NN NN O
   
In NN NN O
an NN NN O
effort NN NN O
to NN NN O
further NN NN O
elucidate NN NN O
the NN NN O
biological NN NN O
effects NN NN O
of NN NN O
A NN NN O
beta NN NN O
towards NN NN O
microglia NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
ability NN NN O
of NN NN O
A NN NN O
beta NN NN O
peptides NN NN O
to NN NN O
activate NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
N9 NN NN O
murine NN NN O
microglial NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
stimulation NN NN O
of NN NN O
microglia NN NN O
with NN NN O
suboptimal NN NN O
concentrations NN NN O
of NN NN O
A NN NN O
beta NN NN O
( NN NN O
25 NN NN O
- NN NN O
35 NN NN O
) NN NN O
and NN NN O
100 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
IFN NN NN B-Protein
gamma NN NN I-Protein
resulted NN NN O
in NN NN O
the NN NN O
detection NN NN O
of NN NN O
a NN NN O
specific NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
nuclear NN NN O
extracts NN NN O
, NN NN O
as NN NN O
determined NN NN O
in NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
This NN NN O
response NN NN O
required NN NN O
at NN NN O
least NN NN O
120 NN NN O
min NN NN O
to NN NN O
be NN NN O
evident NN NN O
and NN NN O
supershift NN NN O
experiments NN NN O
revealed NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
complex NN NN O
contains NN NN O
both NN NN O
RelA NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
. NN NN O
   
Accordingly NN NN O
, NN NN O
immunoblot NN NN O
experiments NN NN O
showed NN NN O
that NN NN O
amongst NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
proteins NN NN O
, NN NN O
RelA NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
are NN NN O
mobilized NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
following NN NN O
microglial NN NN O
cell NN NN O
stimulation NN NN O
with NN NN O
A NN NN O
beta NN NN O
( NN NN O
25 NN NN O
- NN NN O
35 NN NN O
) NN NN O
plus NN NN O
IFN NN NN B-Protein
gamma NN NN I-Protein
. NN NN O
   
Higher NN NN O
concentrations NN NN O
of NN NN O
A NN NN O
beta NN NN O
( NN NN O
25 NN NN O
- NN NN O
35 NN NN O
) NN NN O
were NN NN O
effective NN NN O
by NN NN O
themselves NN NN O
in NN NN O
inducing NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
both NN NN O
in NN NN O
the NN NN O
N9 NN NN O
microglial NN NN O
cell NN NN O
line NN NN O
and NN NN O
in NN NN O
rat NN NN O
primary NN NN O
microglia NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
For NN NN O
purposes NN NN O
of NN NN O
comparison NN NN O
, NN NN O
microglia NN NN O
were NN NN O
also NN NN O
stimulated NN NN O
with NN NN O
bacterial NN NN O
LPS NN NN O
, NN NN O
a NN NN O
known NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inducer NN NN O
. NN NN O
   
As NN NN O
expected NN NN O
, NN NN O
LPS NN NN O
strongly NN NN O
induced NN NN O
the NN NN O
formation NN NN O
of NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
was NN NN O
identified NN NN O
as NN NN O
RelA NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
. NN NN O
   
The NN NN O
LPS NN NN O
response NN NN O
was NN NN O
also NN NN O
more NN NN O
rapid NN NN O
, NN NN O
as NN NN O
it NN NN O
was NN NN O
already NN NN O
evident NN NN O
by NN NN O
40 NN NN O
min NN NN O
and NN NN O
remained NN NN O
sustained NN NN O
for NN NN O
up NN NN O
to NN NN O
3 NN NN O
h NN NN O
. NN NN O
   
Collectively NN NN O
, NN NN O
these NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
might NN NN O
constitute NN NN O
one NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
genes NN NN O
in NN NN O
microglia NN NN O
stimulated NN NN O
by NN NN O
A NN NN O
beta NN NN O
peptides NN NN O
and NN NN O
IFN NN NN B-Protein
gamma NN NN I-Protein
, NN NN O
or NN NN O
by NN NN O
LPS NN NN O
. NN NN O
   
AP NN NN O
- NN NN O
1 NN NN O
derived NN NN O
from NN NN O
mature NN NN O
monocytes NN NN O
and NN NN O
astrocytes NN NN O
preferentially NN NN O
interacts NN NN O
with NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
promoter NN NN O
central NN NN O
21 NN NN O
bp NN NN O
repeat NN NN O
. NN NN O
   
Characterization NN NN O
of NN NN O
the NN NN O
cellular NN NN O
transcription NN NN O
factors NN NN O
interacting NN NN O
with NN NN O
the NN NN O
human NN NN O
T NN NN O
cell NN NN O
lymphotropic NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
is NN NN O
essential NN NN O
to NN NN O
dissecting NN NN O
the NN NN O
mechanisms NN NN O
involved NN NN O
in NN NN O
viral NN NN O
transcription NN NN O
that NN NN O
may NN NN O
be NN NN O
pertinent NN NN O
to NN NN O
the NN NN O
oncogenic NN NN O
and NN NN O
neuropathogenic NN NN O
processes NN NN O
associated NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
infection NN NN O
in NN NN O
both NN NN O
the NN NN O
immune NN NN O
and NN NN O
nervous NN NN O
systems NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
( NN NN O
EMS NN NN O
) NN NN O
analyses NN NN O
utilizing NN NN O
oligonucleotides NN NN O
homologous NN NN O
to NN NN O
each NN NN O
of NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeat NN NN O
elements NN NN O
reacted NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
derived NN NN O
from NN NN O
cell NN NN O
lines NN NN O
of NN NN O
lymphocytic NN NN O
, NN NN O
monocytic NN NN O
, NN NN O
neuronal NN NN O
, NN NN O
and NN NN O
glial NN NN O
cell NN NN O
origin NN NN O
have NN NN O
demonstrated NN NN O
differential NN NN O
binding NN NN O
of NN NN O
cellular NN NN O
factors NN NN O
to NN NN O
the NN NN O
three NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
( NN NN O
1 NN NN O
- NN NN O
4 NN NN O
) NN NN O
. NN NN O
   
ATF NN NN O
/ NN NN O
CREB NN NN O
and NN NN O
Sp NN NN O
family NN NN O
members NN NN O
interacted NN NN O
with NN NN O
the NN NN O
21 NN NN O
bp NN NN O
repeats NN NN O
to NN NN O
form NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
common NN NN O
to NN NN O
all NN NN O
cell NN NN O
types NN NN O
examined NN NN O
. NN NN O
   
However NN NN O
, NN NN O
a NN NN O
unique NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complex NN NN O
was NN NN O
detected NN NN O
when NN NN O
the NN NN O
promoter NN NN O
central NN NN O
21 NN NN O
bp NN NN O
repeat NN NN O
was NN NN O
reacted NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
derived NN NN O
from NN NN O
either NN NN O
the NN NN O
U NN NN O
- NN NN O
373 NN NN O
MG NN NN O
glioblastoma NN NN O
cell NN NN O
line NN NN O
or NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
mature NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
nucleotide NN NN O
sequence NN NN O
requirements NN NN O
and NN NN O
immunoreactivity NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
this NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complex NN NN O
is NN NN O
comprised NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
components NN NN O
, NN NN O
Fos NN NN O
and NN NN O
Jun NN NN O
. NN NN O
   
Of NN NN O
the NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
only NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
selectively NN NN O
regulates NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
promoter NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
producing NN NN O
cells NN NN O
which NN NN O
express NN NN O
multiple NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
) NN NN O
is NN NN O
produced NN NN O
by NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
known NN NN O
to NN NN O
support NN NN O
B NN NN O
cell NN NN O
growth NN NN O
and NN NN O
eosinophilic NN NN O
differentiation NN NN O
of NN NN O
the NN NN O
progenitor NN NN O
cells NN NN O
. NN NN O
   
Using NN NN O
ATL NN NN O
- NN NN O
16T NN NN O
cells NN NN O
which NN NN O
express NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
mRNA NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
a NN NN O
region NN NN O
, NN NN O
within NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
promoter NN NN O
, NN NN O
that NN NN O
regulates NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
This NN NN O
cis NN NN O
- NN NN O
acting NN NN O
sequence NN NN O
contains NN NN O
the NN NN O
core NN NN O
binding NN NN O
motif NN NN O
, NN NN O
( NN NN O
A NN NN O
/ NN NN O
T NN NN O
) NN NN O
GATA NN NN O
( NN NN O
A NN NN O
/ NN NN O
G NN NN O
) NN NN O
, NN NN O
for NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
family NN NN O
proteins NN NN O
and NN NN O
thus NN NN O
suggests NN NN O
the NN NN O
involvement NN NN O
of NN NN O
these NN NN O
family NN NN O
members NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
cloning NN NN O
of NN NN O
human NN NN B-Protein
GATA NN NN I-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
and NN NN O
show NN NN O
that NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
selectively NN NN O
interacts NN NN O
with NN NN O
the NN NN O
- NN NN O
70 NN NN O
GATA NN NN O
site NN NN O
within NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
proximal NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
By NN NN O
promoter NN NN O
deletion NN NN O
and NN NN O
mutation NN NN O
analyses NN NN O
, NN NN O
we NN NN O
established NN NN O
this NN NN O
region NN NN O
as NN NN O
a NN NN O
positive NN NN O
regulatory NN NN O
element NN NN O
. NN NN O
   
Cotransfection NN NN O
experiments NN NN O
revealed NN NN O
that NN NN O
both NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
PMA NN NN O
/ NN NN O
A23187 NN NN O
stimulation NN NN O
are NN NN O
necessary NN NN O
for NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
requirement NN NN O
of NN NN O
another NN NN O
regulatory NN NN O
element NN NN O
called NN NN O
CLE0 NN NN O
, NN NN O
which NN NN O
lies NN NN O
downstream NN NN O
of NN NN O
the NN NN O
- NN NN O
70 NN NN O
GATA NN NN O
site NN NN O
, NN NN O
was NN NN O
also NN NN O
demonstrated NN NN O
. NN NN O
   
ATL NN NN O
- NN NN O
16T NN NN O
cells NN NN O
express NN NN O
mRNA NN NN O
of NN NN O
three NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
and NN NN O
hGATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
each NN NN O
of NN NN O
them NN NN O
has NN NN O
a NN NN O
potential NN NN O
to NN NN O
bind NN NN O
to NN NN O
the NN NN O
consensus NN NN O
( NN NN O
A NN NN O
/ NN NN O
T NN NN O
) NN NN O
GATA NN NN O
( NN NN O
G NN NN O
/ NN NN O
A NN NN O
) NN NN O
motif NN NN O
. NN NN O
   
However NN NN O
, NN NN O
using NN NN O
ATL NN NN O
- NN NN O
16T NN NN O
nuclear NN NN O
extract NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
is NN NN O
the NN NN O
only NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
protein NN NN O
that NN NN O
forms NN NN O
specific NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complex NN NN O
with NN NN O
the NN NN O
- NN NN O
70 NN NN O
GATA NN NN O
site NN NN O
. NN NN O
   
The NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
with NN NN O
extracts NN NN O
of NN NN O
COS NN NN O
cells NN NN O
expressing NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
showed NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
has NN NN O
the NN NN O
highest NN NN O
binding NN NN O
affinity NN NN O
to NN NN O
the NN NN O
- NN NN O
70 NN NN O
GATA NN NN O
site NN NN O
among NN NN O
the NN NN O
three NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
When NN NN O
the NN NN O
transactivation NN NN O
ability NN NN O
was NN NN O
compared NN NN O
among NN NN O
the NN NN O
three NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
showed NN NN O
the NN NN O
highest NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
the NN NN O
selective NN NN O
role NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
in NN NN O
a NN NN O
circumstance NN NN O
where NN NN O
multiple NN NN O
members NN NN O
of NN NN O
the NN NN O
GATA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
expressed NN NN O
. NN NN O
   
Inducible NN NN O
expression NN NN O
and NN NN O
phosphorylation NN NN O
of NN NN O
coactivator NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
transcriptional NN NN O
coactivator NN NN O
that NN NN O
is NN NN O
constitutively NN NN O
expressed NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
interacts NN NN O
with NN NN O
the NN NN O
Oct1 NN NN B-Protein
and NN NN O
Oct2 NN NN B-Protein
transcription NN NN O
factors NN NN O
. NN NN O
   
Upon NN NN O
activation NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
and NN NN O
primary NN NN O
murine NN NN O
thymocytes NN NN O
with NN NN O
phorbol NN NN O
esters NN NN O
and NN NN O
ionomycin NN NN O
, NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
transactivation NN NN O
function NN NN O
were NN NN O
induced NN NN O
. NN NN O
   
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
was NN NN O
phosphorylated NN NN O
at NN NN O
Ser184 NN NN O
both NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
, NN NN O
and NN NN O
this NN NN O
modification NN NN O
was NN NN O
required NN NN O
for NN NN O
inducible NN NN O
activation NN NN O
. NN NN O
   
Mutation NN NN O
of NN NN O
Ser184 NN NN O
also NN NN O
diminished NN NN O
transactivation NN NN O
function NN NN O
in NN NN O
B NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
activating NN NN O
phosphorylation NN NN O
that NN NN O
is NN NN O
inducible NN NN O
in NN NN O
T NN NN O
cells NN NN O
is NN NN O
constitutively NN NN O
present NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
BOB NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OBF NN NN B-Protein
. NN NN I-Protein
1 NN NN I-Protein
is NN NN O
a NN NN O
transcriptional NN NN O
coactivator NN NN O
that NN NN O
is NN NN O
critically NN NN O
regulated NN NN O
by NN NN O
posttranslational NN NN O
modifications NN NN O
to NN NN O
mediate NN NN O
cell NN NN O
type NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
the NN NN O
X2 NN NN O
box NN NN O
in NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
the NN NN O
DRA NN NN O
promoter NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
evolutionary NN NN O
conserved NN NN O
X2 NN NN O
box NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
HLA NN NN O
- NN NN O
DRA NN NN O
gene NN NN O
from NN NN O
the NN NN O
human NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
( NN NN O
MHC NN NN O
) NN NN O
in NN NN O
resting NN NN O
and NN NN O
activated NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
X2 NN NN O
, NN NN O
which NN NN O
contains NN NN O
members NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
/ NN NN O
ATF NN NN O
/ NN NN O
CREB NN NN O
families NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
interacts NN NN O
with NN NN O
the NN NN O
X2 NN NN O
box NN NN O
( NN NN O
5 NN NN O
' NN NN O
- NN NN O
TGCGTCA NN NN O
- NN NN O
3 NN NN O
' NN NN O
) NN NN O
from NN NN O
positions NN NN O
- NN NN O
97 NN NN O
to NN NN O
- NN NN O
91 NN NN O
in NN NN O
the NN NN O
DRA NN NN O
promoter NN NN O
. NN NN O
   
In NN NN O
resting NN NN O
Raji NN NN O
cells NN NN O
, NN NN O
little NN NN O
to NN NN O
no NN NN O
binding NN NN O
to NN NN O
the NN NN O
X2 NN NN O
box NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
In NN NN O
sharp NN NN O
contrast NN NN O
, NN NN O
in NN NN O
B NN NN O
cells NN NN O
treated NN NN O
with NN NN O
the NN NN O
phorbol NN NN O
ester NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
TPA NN NN O
) NN NN O
, NN NN O
strong NN NN O
interactions NN NN O
between NN NN O
the NN NN O
X2 NN NN O
box NN NN O
and NN NN O
NF NN NN O
- NN NN O
X2 NN NN O
containing NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
were NN NN O
observed NN NN O
. NN NN O
   
As NN NN O
determined NN NN O
by NN NN O
transient NN NN O
expression NN NN O
and NN NN O
RNA NN NN O
analyses NN NN O
, NN NN O
the NN NN O
activation NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
also NN NN O
increased NN NN O
rates NN NN O
of NN NN O
transcription NN NN O
from NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
DRA NN NN O
promoter NN NN O
but NN NN O
not NN NN O
from NN NN O
a NN NN O
DRA NN NN O
promoter NN NN O
bearing NN NN O
clustered NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
X2 NN NN O
box NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
co NN NN O
- NN NN O
expression NN NN O
with NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
abolished NN NN O
the NN NN O
responsiveness NN NN O
to NN NN O
TPA NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
activated NN NN O
transcription NN NN O
of NN NN O
the NN NN O
DRA NN NN O
gene NN NN O
depends NN NN O
on NN NN O
interactions NN NN O
between NN NN O
the NN NN O
X2 NN NN O
box NN NN O
and NN NN O
NF NN NN O
- NN NN O
X2 NN NN O
, NN NN O
which NN NN O
contains NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
. NN NN O
   
Rescue NN NN O
by NN NN O
cytokines NN NN O
of NN NN O
apoptotic NN NN O
cell NN NN O
death NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
of NN NN O
human NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
T NN NN O
cell NN NN O
clones NN NN O
. NN NN O
   
The NN NN O
control NN NN O
of NN NN O
cell NN NN O
survival NN NN O
and NN NN O
cell NN NN O
death NN NN O
is NN NN O
of NN NN O
central NN NN O
importance NN NN O
in NN NN O
tissues NN NN O
with NN NN O
high NN NN O
cell NN NN O
turnover NN NN O
such NN NN O
as NN NN O
the NN NN O
lymphoid NN NN O
system NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
cytokines NN NN O
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
of NN NN O
human NN NN O
antigen NN NN O
- NN NN O
specific NN NN O
T NN NN O
helper NN NN O
clones NN NN O
with NN NN O
different NN NN O
cytokine NN NN O
production NN NN O
profiles NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
interferon NN NN O
- NN NN O
alpha NN NN O
( NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
) NN NN O
, NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
apoptosis NN NN O
in NN NN O
Th0 NN NN O
, NN NN O
Th1 NN NN O
, NN NN O
and NN NN O
Th2 NN NN O
clones NN NN O
. NN NN O
   
We NN NN O
also NN NN O
found NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protects NN NN O
T NN NN O
cell NN NN O
clones NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
deprivation NN NN O
apoptosis NN NN O
accompanying NN NN O
active NN NN O
proliferation NN NN O
and NN NN O
enhanced NN NN O
expression NN NN O
of NN NN O
P53 NN NN B-Protein
, NN NN O
Rb NN NN B-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
proteins NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
rescued NN NN O
T NN NN O
cell NN NN O
clones NN NN O
from NN NN O
apoptosis NN NN O
without NN NN O
active NN NN O
proliferation NN NN O
, NN NN O
and NN NN O
expression NN NN O
of NN NN O
apoptosis NN NN O
- NN NN O
associated NN NN O
proteins NN NN O
tested NN NN O
so NN NN O
far NN NN O
was NN NN O
unaffected NN NN O
. NN NN O
   
This NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
T NN NN O
cells NN NN O
treated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
contained NN NN O
those NN NN O
located NN NN O
in NN NN O
S NN NN O
+ NN NN O
G2 NN NN O
/ NN NN O
M NN NN O
phases NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
whereas NN NN O
the NN NN O
vast NN NN O
majority NN NN O
of NN NN O
T NN NN O
cells NN NN O
treated NN NN O
with NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
were NN NN O
located NN NN O
in NN NN O
G0 NN NN O
/ NN NN O
G1 NN NN O
phase NN NN O
. NN NN O
   
IFN NN NN O
- NN NN O
alpha NN NN O
/ NN NN O
beta NN NN O
specifically NN NN O
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
and NN NN O
translocation NN NN O
into NN NN O
nucleus NN NN O
of NN NN O
signal NN NN B-Protein
transducers NN NN I-Protein
and NN NN I-Protein
activators NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
( NN NN I-Protein
STAT NN NN I-Protein
) NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
in NN NN O
the NN NN O
T NN NN O
cell NN NN O
clones NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
over NN NN O
- NN NN O
expression NN NN O
of NN NN O
STAT2 NN NN B-Protein
by NN NN O
transfection NN NN O
of NN NN O
the NN NN O
cDNA NN NN O
prevented NN NN O
apoptosis NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
clones NN NN O
. NN NN O
   
Our NN NN O
present NN NN O
study NN NN O
shows NN NN O
that NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
and NN NN O
- NN NN O
beta NN NN O
mediate NN NN O
anti NN NN O
- NN NN O
apoptotic NN NN O
effect NN NN O
through NN NN O
other NN NN O
pathways NN NN O
than NN NN O
that NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
growth NN NN O
factor NN NN O
deprivation NN NN O
apoptosis NN NN O
. NN NN O
   
Association NN NN O
between NN NN O
expression NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
integration NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
in NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
cells NN NN O
. NN NN O
   
It NN NN O
is NN NN O
known NN NN O
that NN NN O
the NN NN O
expression NN NN O
levels NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
in NN NN O
adult NN NN O
T NN NN O
cell NN NN O
leukemia NN NN O
( NN NN O
ATL NN NN O
) NN NN O
cells NN NN O
are NN NN O
high NN NN O
, NN NN O
whereas NN NN O
those NN NN O
in NN NN O
T NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
are NN NN O
not NN NN O
. NN NN O
   
In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
factors NN NN O
that NN NN O
influence NN NN O
the NN NN O
induction NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
molecules NN NN O
, NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
to NN NN O
measure NN NN O
the NN NN O
expression NN NN O
level NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNAs NN NN O
and NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
to NN NN O
analyze NN NN O
the NN NN O
integration NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
provirus NN NN O
were NN NN O
done NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
expression NN NN O
of NN NN O
ATL NN NN O
cells NN NN O
were NN NN O
generally NN NN O
higher NN NN O
than NN NN O
those NN NN O
of NN NN O
T NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
ILT NN NN O
- NN NN O
mat NN NN O
cells NN NN O
and NN NN O
ATL16T NN NN O
( NN NN O
- NN NN O
) NN NN O
cells NN NN O
, NN NN O
although NN NN O
they NN NN O
were NN NN O
ATL NN NN O
cells NN NN O
, NN NN O
showed NN NN O
rather NN NN O
low NN NN O
surface NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Southern NN NN O
blot NN NN O
hybridization NN NN O
showed NN NN O
that NN NN O
only NN NN O
two NN NN O
and NN NN O
four NN NN O
bands NN NN O
were NN NN O
found NN NN O
in NN NN O
ILT NN NN O
- NN NN O
mat NN NN O
and NN NN O
ATL16T NN NN O
( NN NN O
- NN NN O
) NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
, NN NN O
whereas NN NN O
> NN NN O
10 NN NN O
bands NN NN O
were NN NN O
detected NN NN O
in NN NN O
other NN NN O
ATL NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
monoclonal NN NN O
integration NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
provirus NN NN O
to NN NN O
the NN NN O
genome NN NN O
of NN NN O
T NN NN O
cell NN NN O
, NN NN O
especially NN NN O
the NN NN O
number NN NN O
of NN NN O
integration NN NN O
sites NN NN O
, NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
factors NN NN O
for NN NN O
induction NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
molecules NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
downstream NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
transcription NN NN O
start NN NN O
site NN NN O
are NN NN O
important NN NN O
for NN NN O
virus NN NN O
infectivity NN NN O
. NN NN O
   
When NN NN O
transcriptionally NN NN O
active NN NN O
, NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
promoter NN NN O
contains NN NN O
a NN NN O
nucleosome NN NN O
- NN NN O
free NN NN O
region NN NN O
encompassing NN NN O
both NN NN O
the NN NN O
promoter NN NN O
/ NN NN O
enhancer NN NN O
region NN NN O
and NN NN O
a NN NN O
large NN NN O
region NN NN O
( NN NN O
255 NN NN O
nucleotides NN NN O
[ NN NN O
nt NN NN O
] NN NN O
) NN NN O
downstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
identified NN NN O
new NN NN O
binding NN NN O
sites NN NN O
for NN NN O
transcription NN NN O
factors NN NN O
downstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
( NN NN O
nt NN NN O
465 NN NN O
to NN NN O
720 NN NN O
) NN NN O
: NN NN O
three NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
( NN NN O
I NN NN O
, NN NN O
II NN NN O
, NN NN O
and NN NN O
III NN NN O
) NN NN O
, NN NN O
an NN NN O
AP3 NN NN O
- NN NN O
like NN NN O
motif NN NN O
( NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
) NN NN O
, NN NN O
a NN NN O
downstream NN NN O
binding NN NN O
factor NN NN O
( NN NN O
DBF NN NN O
) NN NN O
site NN NN O
, NN NN O
and NN NN O
juxtaposed NN NN O
Sp1 NN NN B-Protein
sites NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
DBF NN NN O
site NN NN O
is NN NN O
an NN NN O
interferon NN NN O
- NN NN O
responsive NN NN O
factor NN NN O
( NN NN O
IRF NN NN O
) NN NN O
binding NN NN O
site NN NN O
and NN NN O
that NN NN O
the NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
motif NN NN O
binds NN NN O
the NN NN O
T NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
factor NN NN O
NF NN NN O
- NN NN O
AT NN NN O
. NN NN O
   
Mutations NN NN O
that NN NN O
abolish NN NN O
the NN NN O
binding NN NN O
of NN NN O
each NN NN O
factor NN NN O
to NN NN O
its NN NN O
cognate NN NN O
site NN NN O
are NN NN O
introduced NN NN O
in NN NN O
an NN NN O
infectious NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
molecular NN NN O
clone NN NN O
to NN NN O
study NN NN O
their NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
and NN NN O
replication NN NN O
. NN NN O
   
Individual NN NN O
mutation NN NN O
of NN NN O
the NN NN O
DBF NN NN O
or NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
site NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
double NN NN O
mutation NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
III NN NN O
) NN NN O
/ NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
did NN NN O
not NN NN O
affect NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
compared NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
virus NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
proviruses NN NN O
carrying NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Sp1 NN NN B-Protein
sites NN NN O
were NN NN O
totally NN NN O
defective NN NN O
in NN NN O
terms NN NN O
of NN NN O
replication NN NN O
. NN NN O
   
Virus NN NN O
production NN NN O
occurred NN NN O
with NN NN O
slightly NN NN O
delayed NN NN O
kinetics NN NN O
for NN NN O
viruses NN NN O
containing NN NN O
combined NN NN O
mutations NN NN O
in NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
III NN NN O
) NN NN O
, NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
, NN NN O
and NN NN O
DBF NN NN O
sites NN NN O
and NN NN O
in NN NN O
the NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
and NN NN O
DBF NN NN O
- NN NN O
sites NN NN O
, NN NN O
whereas NN NN O
viruses NN NN O
mutated NN NN O
in NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
I NN NN O
, NN NN O
II NN NN O
, NN NN O
III NN NN O
) NN NN O
and NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
sites NN NN O
and NN NN O
in NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
I NN NN O
, NN NN O
II NN NN O
, NN NN O
III NN NN O
) NN NN O
, NN NN O
AP3 NN NN O
- NN NN O
L NN NN O
, NN NN O
and NN NN O
DBF NN NN O
sites NN NN O
exhibited NN NN O
a NN NN O
severely NN NN O
defective NN NN O
replicative NN NN O
phenotype NN NN O
. NN NN O
   
No NN NN O
RNA NN NN O
- NN NN O
packaging NN NN O
defect NN NN O
could NN NN O
be NN NN O
measured NN NN O
for NN NN O
any NN NN O
of NN NN O
the NN NN O
mutant NN NN O
viruses NN NN O
as NN NN O
determined NN NN O
by NN NN O
quantification NN NN O
of NN NN O
their NN NN O
HIV NN NN O
genomic NN NN O
RNA NN NN O
. NN NN O
   
Measurement NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
after NN NN O
transient NN NN O
transfection NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
provirus NN NN O
DNA NN NN O
or NN NN O
of NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
luciferase NN NN O
constructs NN NN O
showed NN NN O
a NN NN O
positive NN NN O
correlation NN NN O
between NN NN O
the NN NN O
transcriptional NN NN O
and NN NN O
the NN NN O
replication NN NN O
defects NN NN O
for NN NN O
most NN NN O
mutants NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
cytokine NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
are NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
that NN NN O
regulate NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
is NN NN O
a NN NN O
critical NN NN O
transcription NN NN O
factor NN NN O
for NN NN O
maximal NN NN O
expression NN NN O
of NN NN O
many NN NN O
cytokines NN NN O
that NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
inflammatory NN NN O
diseases NN NN O
, NN NN O
such NN NN O
as NN NN O
adult NN NN O
respiratory NN NN O
distress NN NN O
syndrome NN NN O
( NN NN O
ARDS NN NN O
) NN NN O
and NN NN O
sepsis NN NN O
syndrome NN NN O
. NN NN O
   
Activation NN NN O
and NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
are NN NN O
tightly NN NN O
controlled NN NN O
by NN NN O
a NN NN O
group NN NN O
of NN NN O
inhibitory NN NN O
proteins NN NN O
( NN NN O
I NN NN O
kappa NN NN O
B NN NN O
) NN NN O
that NN NN O
sequester NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
immune NN NN O
/ NN NN O
inflammatory NN NN O
effector NN NN O
cells NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
involves NN NN O
signaled NN NN O
phosphorylation NN NN O
, NN NN O
ubiquitination NN NN O
, NN NN O
and NN NN O
proteolysis NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Liberated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
migrates NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
where NN NN O
it NN NN O
binds NN NN O
to NN NN O
specific NN NN O
promoter NN NN O
sites NN NN O
and NN NN O
activates NN NN O
gene NN NN O
transcription NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
initiates NN NN O
both NN NN O
extracellular NN NN O
and NN NN O
intracellular NN NN O
regulatory NN NN O
events NN NN O
that NN NN O
result NN NN O
in NN NN O
autoregulation NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
cascade NN NN O
through NN NN O
modulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Recently NN NN O
, NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
ARDS NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
a NN NN O
critical NN NN O
proximal NN NN O
step NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
neutrophilic NN NN O
inflammation NN NN O
in NN NN O
animal NN NN O
models NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
can NN NN O
be NN NN O
inhibited NN NN O
in NN NN O
vivo NN NN O
by NN NN O
treatment NN NN O
with NN NN O
antioxidants NN NN O
, NN NN O
corticosteroids NN NN O
, NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
endotoxin NN NN O
tolerance NN NN O
. NN NN O
   
Identification NN NN O
of NN NN O
more NN NN O
specific NN NN O
and NN NN O
efficacious NN NN O
inhibitors NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
might NN NN O
prove NN NN O
beneficial NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
cytokine NN NN O
- NN NN O
mediated NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
ascorbate NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
first NN NN O
product NN NN O
of NN NN O
ascorbate NN NN O
oxidation NN NN O
, NN NN O
the NN NN O
ascorbate NN NN O
free NN NN O
radical NN NN O
( NN NN O
AFR NN NN O
) NN NN O
, NN NN O
acts NN NN O
in NN NN O
biological NN NN O
systems NN NN O
mainly NN NN O
as NN NN O
an NN NN O
oxidant NN NN O
, NN NN O
and NN NN O
through NN NN O
its NN NN O
role NN NN O
in NN NN O
the NN NN O
plasma NN NN O
membrane NN NN O
redox NN NN O
system NN NN O
exerts NN NN O
different NN NN O
effects NN NN O
on NN NN O
the NN NN O
cell NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
role NN NN O
of NN NN O
ascorbate NN NN O
, NN NN O
AFR NN NN O
and NN NN O
dehydroascorbate NN NN O
( NN NN O
DHA NN NN O
) NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
tumour NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
, NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
that NN NN O
ascorbate NN NN O
increases NN NN O
the NN NN O
binding NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
to NN NN O
DNA NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
Jurkat NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
ascorbate NN NN O
to NN NN O
enhance NN NN O
cytoplasmic NN NN O
inhibitory NN NN O
IkBalpha NN NN B-Protein
protein NN NN O
degradation NN NN O
correlates NN NN O
completely NN NN O
with NN NN O
its NN NN O
capacity NN NN O
to NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
and NN NN O
to NN NN O
potentiate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
mediated NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
promoter NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
Jurkat NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
PMA NN NN O
plus NN NN O
ionomycin NN NN O
. NN NN O
   
AFR NN NN O
behaves NN NN O
like NN NN O
ascorbate NN NN O
, NN NN O
while NN NN O
DHA NN NN O
and NN NN O
ascorbate NN NN O
phosphate NN NN O
do NN NN O
not NN NN O
affect NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
provide NN NN O
new NN NN O
evidence NN NN O
for NN NN O
a NN NN O
possible NN NN O
relationship NN NN O
between NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
electron NN NN O
- NN NN O
transport NN NN O
system NN NN O
at NN NN O
the NN NN O
plasma NN NN O
membrane NN NN O
by NN NN O
ascorbate NN NN O
or NN NN O
its NN NN O
free NN NN O
radical NN NN O
and NN NN O
redox NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
Pancreatic NN NN O
islet NN NN O
expression NN NN O
studies NN NN O
and NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
in NN NN O
the NN NN O
genes NN NN O
encoding NN NN O
hepatocyte NN NN B-Protein
nuclear NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
3alpha NN NN I-Protein
, NN NN O
- NN NN B-Protein
3beta NN NN I-Protein
, NN NN O
- NN NN B-Protein
3gamma NN NN I-Protein
, NN NN O
- NN NN B-Protein
4gamma NN NN I-Protein
, NN NN O
and NN NN O
- NN NN B-Protein
6 NN NN I-Protein
. NN NN O
   
The NN NN O
genes NN NN O
encoding NN NN O
the NN NN O
functionally NN NN O
related NN NN O
hepatocyte NN NN O
nuclear NN NN O
factors NN NN O
HNF NN NN B-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
and NN NN O
HNF NN NN B-Protein
- NN NN I-Protein
4alpha NN NN I-Protein
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
normal NN NN O
pancreatic NN NN O
beta NN NN O
- NN NN O
cell NN NN O
function NN NN O
. NN NN O
   
Mutations NN NN O
in NN NN O
these NN NN O
liver NN NN O
- NN NN O
enriched NN NN O
transcription NN NN O
factors NN NN O
result NN NN O
in NN NN O
two NN NN O
forms NN NN O
of NN NN O
early NN NN O
- NN NN O
onset NN NN O
type NN NN O
2 NN NN O
diabetes NN NN O
( NN NN O
maturity NN NN O
- NN NN O
onset NN NN O
diabetes NN NN O
of NN NN O
the NN NN O
young NN NN O
[ NN NN O
MODY NN NN O
] NN NN O
) NN NN O
, NN NN O
MODY3 NN NN O
and NN NN O
MODY1 NN NN O
, NN NN O
which NN NN O
are NN NN O
characterized NN NN O
by NN NN O
impaired NN NN O
glucose NN NN O
- NN NN O
stimulated NN NN O
insulin NN NN O
secretion NN NN O
, NN NN O
early NN NN O
disease NN NN O
onset NN NN O
, NN NN O
and NN NN O
autosomal NN NN O
dominant NN NN O
inheritance NN NN O
. NN NN O
   
The NN NN O
transcriptional NN NN O
hierarchy NN NN O
of NN NN O
HNFs NN NN O
suggests NN NN O
that NN NN O
other NN NN O
proteins NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
cascade NN NN O
might NN NN O
be NN NN O
responsible NN NN O
for NN NN O
other NN NN O
forms NN NN O
of NN NN O
MODY NN NN O
and NN NN O
/ NN NN O
or NN NN O
late NN NN O
- NN NN O
onset NN NN O
type NN NN O
2 NN NN O
diabetes NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
HNF NN NN B-Protein
- NN NN I-Protein
3alpha NN NN I-Protein
, NN NN O
- NN NN B-Protein
3beta NN NN I-Protein
, NN NN O
- NN NN B-Protein
3gamma NN NN I-Protein
, NN NN O
- NN NN B-Protein
4gamma NN NN I-Protein
, NN NN O
and NN NN O
- NN NN B-Protein
6 NN NN I-Protein
are NN NN O
expressed NN NN O
in NN NN O
pancreatic NN NN O
beta NN NN O
- NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
report NN NN O
the NN NN O
identification NN NN O
and NN NN O
characterization NN NN O
of NN NN O
simple NN NN O
tandem NN NN O
repeat NN NN O
DNA NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
genes NN NN O
encoding NN NN O
HNF NN NN B-Protein
- NN NN I-Protein
3alpha NN NN I-Protein
, NN NN O
- NN NN B-Protein
3beta NN NN I-Protein
, NN NN O
- NN NN B-Protein
3gamma NN NN I-Protein
, NN NN O
- NN NN B-Protein
4gamma NN NN I-Protein
, NN NN O
and NN NN O
- NN NN B-Protein
6 NN NN I-Protein
and NN NN O
the NN NN O
mapping NN NN O
of NN NN O
HNF NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
to NN NN O
chromosome NN NN O
bands NN NN O
15q21 NN NN O
. NN NN O
1 NN NN O
- NN NN O
21 NN NN O
. NN NN O
2 NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O
   
These NN NN O
markers NN NN O
will NN NN O
be NN NN O
useful NN NN O
to NN NN O
study NN NN O
the NN NN O
role NN NN O
of NN NN O
genetic NN NN O
variation NN NN O
in NN NN O
these NN NN O
genes NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
type NN NN O
2 NN NN O
diabetes NN NN O
. NN NN O
   
RP1 NN NN B-Protein
, NN NN O
a NN NN O
new NN NN O
member NN NN O
of NN NN O
the NN NN O
adenomatous NN NN O
polyposis NN NN O
coli NN NN O
- NN NN O
binding NN NN O
EB1 NN NN O
- NN NN O
like NN NN O
gene NN NN O
family NN NN O
, NN NN O
is NN NN O
differentially NN NN O
expressed NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
the NN NN O
CD3 NN NN O
and NN NN O
CD28 NN NN B-Protein
molecules NN NN O
on NN NN O
T NN NN O
lymphocytes NN NN O
represents NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
effective NN NN O
signals NN NN O
for NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
and NN NN O
triggering NN NN O
of NN NN O
their NN NN O
cytotoxic NN NN O
effector NN NN O
function NN NN O
. NN NN O
   
To NN NN O
identify NN NN O
genes NN NN O
that NN NN O
are NN NN O
expressed NN NN O
in NN NN O
T NN NN O
cells NN NN O
after NN NN O
stimulation NN NN O
, NN NN O
mRNA NN NN O
from NN NN O
T NN NN O
lymphocytes NN NN O
that NN NN O
had NN NN O
been NN NN O
activated NN NN O
by NN NN O
the NN NN O
simultaneous NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
CD3 NN NN O
and NN NN O
CD28 NN NN B-Protein
trigger NN NN O
molecules NN NN O
was NN NN O
transcribed NN NN O
for NN NN O
a NN NN O
differential NN NN O
mRNA NN NN O
display NN NN O
analysis NN NN O
into NN NN O
cDNA NN NN O
and NN NN O
was NN NN O
compared NN NN O
with NN NN O
cDNA NN NN O
from NN NN O
CD28 NN NN B-Protein
- NN NN O
or NN NN O
CD3 NN NN O
- NN NN O
activated NN NN O
or NN NN O
resting NN NN O
lymphocytes NN NN O
. NN NN O
   
Differential NN NN O
expression NN NN O
was NN NN O
confirmed NN NN O
subsequently NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
cDNA NN NN O
fragments NN NN O
expressed NN NN O
specifically NN NN O
in NN NN O
CD3 NN NN O
- NN NN O
and NN NN O
CD28 NN NN B-Protein
- NN NN O
activated NN NN O
T NN NN O
cells NN NN O
was NN NN O
designated NN NN O
RP1 NN NN O
. NN NN O
   
The NN NN O
predictive NN NN O
protein NN NN O
- NN NN O
coding NN NN O
region NN NN O
of NN NN O
RP1 NN NN B-Protein
had NN NN O
a NN NN O
significant NN NN O
homology NN NN O
to NN NN O
members NN NN O
of NN NN O
the NN NN O
recently NN NN O
found NN NN O
adenomatous NN NN B-Protein
polyposis NN NN I-Protein
coli NN NN I-Protein
( NN NN I-Protein
APC NN NN I-Protein
) NN NN I-Protein
protein NN NN I-Protein
- NN NN O
binding NN NN O
EB1 NN NN B-Protein
gene NN NN O
family NN NN O
, NN NN O
which NN NN O
codes NN NN O
for NN NN O
yet NN NN O
unknown NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
Bacterially NN NN O
expressed NN NN O
RP1 NN NN B-Protein
protein NN NN O
revealed NN NN O
specific NN NN O
binding NN NN O
to NN NN O
wild NN NN O
- NN NN O
type NN NN O
but NN NN O
not NN NN O
to NN NN O
mutated NN NN O
APC NN NN B-Protein
protein NN NN O
. NN NN O
   
The NN NN O
rapid NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
RP1 NN NN B-Protein
mRNA NN NN O
in NN NN O
properly NN NN O
activated NN NN O
T NN NN O
cells NN NN O
suggests NN NN O
that NN NN O
this NN NN O
gene NN NN O
might NN NN O
belong NN NN O
to NN NN O
the NN NN O
immediate NN NN O
/ NN NN O
early NN NN O
gene NN NN O
family NN NN O
, NN NN O
which NN NN O
controls NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
cascade NN NN O
downstream NN NN O
of NN NN O
the NN NN O
TCR NN NN O
. NN NN O
   
As NN NN O
the NN NN O
expression NN NN O
level NN NN O
of NN NN O
the NN NN O
RP1 NN NN B-Protein
gene NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
a NN NN O
spectrum NN NN O
of NN NN O
tumor NN NN O
- NN NN O
derived NN NN O
cell NN NN O
lines NN NN O
correlates NN NN O
with NN NN O
the NN NN O
proliferative NN NN O
status NN NN O
of NN NN O
the NN NN O
cells NN NN O
, NN NN O
members NN NN O
of NN NN O
the NN NN O
EB1 NN NN O
- NN NN O
like NN NN O
gene NN NN O
family NN NN O
may NN NN O
not NN NN O
only NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
tumorigenesis NN NN O
of NN NN O
colorectal NN NN O
cancers NN NN O
but NN NN O
may NN NN O
also NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
proliferative NN NN O
control NN NN O
of NN NN O
normal NN NN O
cells NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
by NN NN O
Cryptococcus NN NN O
neoformans NN NN O
and NN NN O
Candida NN NN O
albicans NN NN O
. NN NN O
   
Because NN NN O
candidiasis NN NN O
and NN NN O
cryptococcosis NN NN O
are NN NN O
common NN NN O
in NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
- NN NN O
infected NN NN O
persons NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
Cryptococcus NN NN O
neoformans NN NN O
and NN NN O
Candida NN NN O
albicans NN NN O
on NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
the NN NN O
latently NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
myelomonocytic NN NN O
cell NN NN O
line NN NN O
OM NN NN O
- NN NN O
10 NN NN O
. NN NN O
1 NN NN O
with NN NN O
C NN NN O
. NN NN O
neoformans NN NN O
and NN NN O
C NN NN O
. NN NN O
albicans NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
pooled NN NN O
human NN NN O
serum NN NN O
caused NN NN O
a NN NN O
ratio NN NN O
- NN NN O
dependent NN NN O
increase NN NN O
in NN NN O
HIV NN NN O
production NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
HIV NN NN O
by NN NN O
C NN NN O
. NN NN O
neoformans NN NN O
was NN NN O
enhanced NN NN O
by NN NN O
anti NN NN O
- NN NN O
capsular NN NN O
antibody NN NN O
, NN NN O
while NN NN O
induction NN NN O
by NN NN O
both NN NN O
organisms NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibody NN NN O
. NN NN O
   
In NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
HIV NN NN O
plasmid NN NN O
constructs NN NN O
, NN NN O
both NN NN O
organisms NN NN O
induced NN NN O
transcription NN NN O
from NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
that NN NN O
was NN NN O
dependent NN NN O
on NN NN O
intact NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sequences NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
C NN NN O
. NN NN O
neoformans NN NN O
and NN NN O
C NN NN O
. NN NN O
albicans NN NN O
enhance NN NN O
HIV NN NN O
expression NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
through NN NN O
a NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
mechanism NN NN O
. NN NN O
   
In NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
patients NN NN O
, NN NN O
such NN NN O
enhancement NN NN O
may NN NN O
further NN NN O
impair NN NN O
host NN NN O
immunity NN NN O
and NN NN O
could NN NN O
accelerate NN NN O
the NN NN O
course NN NN O
of NN NN O
HIV NN NN O
disease NN NN O
. NN NN O
   
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
inhibits NN NN O
bufalin NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
activation NN NN O
in NN NN O
human NN NN O
leukemia NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
a NN NN O
previous NN NN O
study NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
bufalin NN NN O
, NN NN O
which NN NN O
is NN NN O
an NN NN O
active NN NN O
principle NN NN O
of NN NN O
Chinese NN NN O
medicine NN NN O
, NN NN O
chan NN NN O
' NN NN O
su NN NN O
, NN NN O
caused NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
leukemia NN NN O
U937 NN NN O
cells NN NN O
by NN NN O
anomalous NN NN O
activation NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
via NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
of NN NN O
Ras NN NN O
, NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
MAPK NN NN B-Protein
kinase NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
effect NN NN O
of NN NN O
overexpression NN NN O
of NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
U937 NN NN O
cells NN NN O
on NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
of NN NN O
apoptosis NN NN O
that NN NN O
is NN NN O
induced NN NN O
by NN NN O
bufalin NN NN O
. NN NN O
   
The NN NN O
results NN NN O
indicated NN NN O
that NN NN O
the NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
bufalin NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
protein NN NN O
. NN NN O
   
No NN NN O
significant NN NN O
difference NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
MAPK NN NN B-Protein
kinase NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
that NN NN O
is NN NN O
induced NN NN O
by NN NN O
bufalin NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
or NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
overexpressed NN NN O
U937 NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
activation NN NN O
of NN NN O
MAPK NN NN O
by NN NN O
bufalin NN NN O
was NN NN O
significantly NN NN O
attenuated NN NN O
in NN NN O
the NN NN O
cells NN NN O
overexpressing NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Bufalin NN NN O
treatment NN NN O
activated NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
; NN NN O
however NN NN O
, NN NN O
this NN NN O
activation NN NN O
was NN NN O
decreased NN NN O
to NN NN O
40 NN NN O
% NN NN O
in NN NN O
bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
overexpressed NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
acts NN NN O
downstream NN NN O
of NN NN O
MAPK NN NN B-Protein
kinase NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
but NN NN O
upstream NN NN O
of NN NN O
MAPK NN NN O
and NN NN O
suggest NN NN O
that NN NN O
, NN NN O
in NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
of NN NN O
the NN NN O
apoptotic NN NN O
process NN NN O
induced NN NN O
by NN NN O
bufalin NN NN O
, NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
may NN NN O
be NN NN O
down NN NN O
- NN NN O
regulated NN NN O
through NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
MAPK NN NN O
activity NN NN O
by NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
A NN NN O
shortened NN NN O
life NN NN O
span NN NN O
of NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
adult NN NN O
erythrocytes NN NN O
, NN NN O
due NN NN O
to NN NN O
a NN NN O
deficiency NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
chains NN NN O
, NN NN O
is NN NN O
ameliorated NN NN O
by NN NN O
human NN NN O
gamma NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
chains NN NN O
. NN NN O
   
Using NN NN O
homologous NN NN O
recombination NN NN O
, NN NN O
both NN NN O
EKLF NN NN B-Protein
alleles NN NN I-Protein
in NN NN O
murine NN NN O
embryonic NN NN O
stem NN NN O
( NN NN O
ES NN NN O
) NN NN O
cells NN NN O
were NN NN O
inactivated NN NN O
. NN NN O
   
These NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
ES NN NN O
cells NN NN O
were NN NN O
capable NN NN O
of NN NN O
undergoing NN NN O
in NN NN O
vitro NN NN O
differentiation NN NN O
to NN NN O
form NN NN O
definitive NN NN O
erythroid NN NN O
colonies NN NN O
that NN NN O
were NN NN O
similar NN NN O
in NN NN O
size NN NN O
and NN NN O
number NN NN O
to NN NN O
those NN NN O
formed NN NN O
by NN NN O
wild NN NN O
- NN NN O
type NN NN O
ES NN NN O
cells NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
colonies NN NN O
were NN NN O
poorly NN NN O
hemoglobinized NN NN O
and NN NN O
enucleated NN NN O
erythrocytes NN NN O
in NN NN O
these NN NN O
colonies NN NN O
contained NN NN O
numerous NN NN O
Heinz NN NN O
bodies NN NN O
. NN NN O
   
Reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
analyses NN NN O
revealed NN NN O
that NN NN O
adult NN NN O
and NN NN O
embryonic NN NN O
globin NN NN O
genes NN NN O
were NN NN O
appropriately NN NN O
regulated NN NN O
, NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
beta NN NN B-Protein
h1 NN NN I-Protein
- NN NN I-Protein
globin NN NN I-Protein
, NN NN O
which NN NN O
continued NN NN O
to NN NN O
be NN NN O
expressed NN NN O
at NN NN O
a NN NN O
very NN NN O
low NN NN O
level NN NN O
. NN NN O
   
The NN NN O
ratio NN NN O
of NN NN O
adult NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
/ NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
mRNA NN NN O
in NN NN O
the NN NN O
mutant NN NN O
ES NN NN O
cells NN NN O
was NN NN O
1 NN NN O
/ NN NN O
15 NN NN O
of NN NN O
that NN NN O
in NN NN O
wild NN NN O
- NN NN O
type NN NN O
ES NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
the NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
cells NN NN O
were NN NN O
injected NN NN O
into NN NN O
blastocysts NN NN O
, NN NN O
they NN NN O
did NN NN O
not NN NN O
contribute NN NN O
at NN NN O
a NN NN O
detectable NN NN O
level NN NN O
to NN NN O
the NN NN O
mature NN NN O
erythrocyte NN NN O
compartment NN NN O
of NN NN O
the NN NN O
chimeric NN NN O
animals NN NN O
, NN NN O
based NN NN O
on NN NN O
analysis NN NN O
of NN NN O
glucose NN NN B-Protein
phosphate NN NN I-Protein
isomerase NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
GPI NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
isozymes NN NN O
and NN NN O
hemoglobins NN NN O
that NN NN O
distinguish NN NN O
ES NN NN O
cell NN NN O
- NN NN O
derived NN NN O
erythrocytes NN NN O
from NN NN O
host NN NN O
blastocyst NN NN O
- NN NN O
derived NN NN O
erythrocytes NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
semiquantitative NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
analysis NN NN O
of NN NN O
RNA NN NN O
from NN NN O
reticulocytes NN NN O
of NN NN O
the NN NN O
same NN NN O
chimeric NN NN O
animals NN NN O
suggested NN NN O
that NN NN O
the NN NN O
ES NN NN O
cell NN NN O
- NN NN O
derived NN NN O
reticulocytes NN NN O
were NN NN O
present NN NN O
at NN NN O
a NN NN O
level NN NN O
of NN NN O
6 NN NN O
% NN NN O
to NN NN O
8 NN NN O
% NN NN O
. NN NN O
   
This NN NN O
indicated NN NN O
that NN NN O
the NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
erythrocytes NN NN O
in NN NN O
adult NN NN O
animals NN NN O
must NN NN O
be NN NN O
short NN NN O
- NN NN O
lived NN NN O
, NN NN O
apparently NN NN O
due NN NN O
to NN NN O
the NN NN O
imbalance NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
versus NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
chains NN NN I-Protein
, NN NN O
leading NN NN O
to NN NN O
the NN NN O
precipitation NN NN O
of NN NN O
excess NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
chains NN NN O
to NN NN O
form NN NN O
Heinz NN NN O
bodies NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
the NN NN O
short NN NN O
life NN NN O
span NN NN O
was NN NN O
ameliorated NN NN O
by NN NN O
introduction NN NN O
into NN NN O
the NN NN O
EKLF NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
ES NN NN O
cells NN NN O
of NN NN O
a NN NN O
human NN NN O
LCR NN NN O
/ NN NN O
gamma NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
ES NN NN O
cell NN NN O
- NN NN O
derived NN NN O
reticulocytes NN NN O
as NN NN O
well NN NN O
as NN NN O
mature NN NN O
erythrocytes NN NN O
in NN NN O
the NN NN O
blood NN NN O
of NN NN O
the NN NN O
chimeric NN NN O
animals NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
nuclear NN NN O
activity NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
anti NN NN O
- NN NN O
HLA NN NN O
class NN NN O
I NN NN O
monoclonal NN NN O
antibodies NN NN O
. NN NN O
   
Monoclonal NN NN O
antibodies NN NN O
against NN NN O
either NN NN O
monomorphic NN NN O
or NN NN O
polymorphic NN NN O
determinants NN NN O
of NN NN O
class NN NN O
I NN NN O
antigen NN NN O
induced NN NN O
in NN NN O
PBMC NN NN O
and NN NN O
highly NN NN O
purified NN NN O
T NN NN O
lymphocytes NN NN O
the NN NN O
nuclear NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
complexes NN NN O
. NN NN O
   
These NN NN O
included NN NN O
both NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
and NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
dimers NN NN O
, NN NN O
recognized NN NN O
by NN NN O
specific NN NN O
antibodies NN NN O
in NN NN O
EMSA NN NN O
. NN NN O
   
The NN NN O
induced NN NN O
complexes NN NN O
were NN NN O
detectable NN NN O
in NN NN O
extracts NN NN O
of NN NN O
cells NN NN O
incubated NN NN O
with NN NN O
anti NN NN O
- NN NN O
class NN NN O
I NN NN O
monoclonal NN NN O
antibody NN NN O
( NN NN O
mAb NN NN O
) NN NN O
for NN NN O
1 NN NN O
. NN NN O
5 NN NN O
h NN NN O
; NN NN O
the NN NN O
induction NN NN O
was NN NN O
maximal NN NN O
at NN NN O
5 NN NN O
h NN NN O
, NN NN O
persistent NN NN O
at NN NN O
16 NN NN O
h NN NN O
and NN NN O
no NN NN O
longer NN NN O
observed NN NN O
at NN NN O
40 NN NN O
h NN NN O
. NN NN O
   
The NN NN O
mAb NN NN O
failed NN NN O
to NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
nuclear NN NN O
activity NN NN O
in NN NN O
cells NN NN O
incubated NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
3 NN NN O
, NN NN O
4 NN NN O
- NN NN O
dichloroisocoumarin NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
class NN NN O
I NN NN O
triggering NN NN O
can NN NN O
induce NN NN O
the NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
nuclear NN NN O
activity NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
thereby NN NN O
modulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
interferes NN NN O
with NN NN O
the NN NN O
inducible NN NN O
degradation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
the NN NN O
processing NN NN O
of NN NN O
p105 NN NN B-Protein
/ NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
controls NN NN O
the NN NN O
induction NN NN O
of NN NN O
numerous NN NN O
cytokine NN NN O
promoters NN NN O
during NN NN O
the NN NN O
activation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
by NN NN O
the NN NN O
immunosuppressants NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
and NN NN O
FK506 NN NN O
exerts NN NN O
a NN NN O
suppressive NN NN O
effect NN NN O
on NN NN O
the NN NN O
induction NN NN O
of NN NN O
these NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
controlled NN NN O
cytokine NN NN O
promoters NN NN O
. NN NN O
   
We NN NN O
show NN NN O
for NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
leukemia NN NN O
cells NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
human NN NN O
and NN NN O
mouse NN NN O
primary NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
that NN NN O
this NN NN O
inhibitory NN NN O
effect NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
impaired NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
Rel NN NN O
proteins NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
RelA NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
/ NN NN O
p50 NN NN B-Protein
, NN NN O
whereas NN NN O
the NN NN O
nuclear NN NN O
appearance NN NN O
of NN NN O
RelB NN NN B-Protein
remains NN NN O
unaffected NN NN O
. NN NN O
   
CsA NN NN O
does NN NN O
not NN NN O
interfere NN NN O
with NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
Rel NN NN O
proteins NN NN O
, NN NN O
but NN NN O
prevents NN NN O
the NN NN O
inducible NN NN O
degradation NN NN O
of NN NN O
cytosolic NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
upon NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
CsA NN NN O
neither NN NN O
inhibits NN NN O
the NN NN O
processing NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
precursor NN NN O
p105 NN NN B-Protein
to NN NN O
p50 NN NN B-Protein
, NN NN O
nor NN NN O
does NN NN O
it NN NN O
"""""""" NN NN O
stabilize NN NN O
"""""""" NN NN O
the NN NN O
C NN NN O
- NN NN O
terminal NN NN O
portion NN NN O
of NN NN O
p105 NN NN B-Protein
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
which NN NN O
is NN NN O
degraded NN NN O
during NN NN O
p105 NN NN B-Protein
processing NN NN O
to NN NN O
mature NN NN O
p50 NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
CsA NN NN O
interferes NN NN O
with NN NN O
a NN NN O
specific NN NN O
event NN NN O
in NN NN O
the NN NN O
signal NN NN O
- NN NN O
induced NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
, NN NN O
but NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
processing NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
/ NN NN O
p105 NN NN B-Protein
to NN NN O
p50 NN NN B-Protein
. NN NN O
   
EBF NN NN B-Protein
and NN NN O
E47 NN NN B-Protein
collaborate NN NN O
to NN NN O
induce NN NN O
expression NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
immunoglobulin NN NN O
surrogate NN NN O
light NN NN O
chain NN NN O
genes NN NN O
. NN NN O
   
Early NN NN B-Protein
B NN NN I-Protein
cell NN NN I-Protein
factor NN NN I-Protein
( NN NN O
EBF NN NN B-Protein
) NN NN O
and NN NN O
E47 NN NN B-Protein
participate NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
control NN NN O
of NN NN O
early NN NN O
B NN NN O
lymphocyte NN NN O
differentiation NN NN O
. NN NN O
   
With NN NN O
the NN NN O
aim NN NN O
of NN NN O
identifying NN NN O
genetic NN NN O
targets NN NN O
for NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
we NN NN O
stably NN NN O
transfected NN NN O
cDNAs NN NN O
encoding NN NN O
EBF NN NN B-Protein
or NN NN O
a NN NN O
covalent NN NN O
homodimer NN NN O
of NN NN O
E47 NN NN B-Protein
, NN NN O
individually NN NN O
or NN NN O
together NN NN O
, NN NN O
into NN NN O
immature NN NN O
hematopoietic NN NN O
Ba NN NN O
/ NN NN O
F3 NN NN O
cells NN NN O
, NN NN O
which NN NN O
lack NN NN O
both NN NN O
factors NN NN O
. NN NN O
   
In NN NN O
combination NN NN O
, NN NN O
EBF NN NN B-Protein
and NN NN O
E47 NN NN B-Protein
induce NN NN O
efficient NN NN O
expression NN NN O
of NN NN O
the NN NN O
endogenous NN NN O
immunoglobulin NN NN O
surrogate NN NN O
light NN NN O
chain NN NN O
genes NN NN O
, NN NN O
lambda5 NN NN B-Protein
and NN NN O
VpreB NN NN B-Protein
, NN NN O
whereas NN NN O
other NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
genes NN NN O
remain NN NN O
silent NN NN O
. NN NN O
   
Multiple NN NN O
functionally NN NN O
important NN NN O
EBF NN NN B-Protein
and NN NN O
E47 NN NN B-Protein
binding NN NN O
sites NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
lambda5 NN NN B-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
region NN NN O
, NN NN O
indicating NN NN O
that NN NN O
lambda5 NN NN B-Protein
is NN NN O
a NN NN O
direct NN NN O
genetic NN NN O
target NN NN O
for NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
EBF NN NN B-Protein
and NN NN O
E47 NN NN B-Protein
synergize NN NN O
to NN NN O
activate NN NN O
expression NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
genes NN NN O
that NN NN O
define NN NN O
an NN NN O
early NN NN O
stage NN NN O
of NN NN O
the NN NN O
B NN NN O
cell NN NN O
lineage NN NN O
. NN NN O
   
Nuclear NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
correlate NN NN O
with NN NN O
syncytium NN NN O
- NN NN O
forming NN NN O
capacity NN NN O
of NN NN O
8e51 NN NN O
cells NN NN O
, NN NN O
expressing NN NN O
a NN NN O
defective NN NN O
HIV NN NN O
virus NN NN O
. NN NN O
   
The NN NN O
double NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
identified NN NN O
in NN NN O
the NN NN O
LTR NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
be NN NN O
necessary NN NN O
for NN NN O
efficient NN NN O
viral NN NN O
transcription NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
we NN NN O
present NN NN O
the NN NN O
characterisation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
engaged NN NN O
in NN NN O
complexes NN NN O
binding NN NN O
to NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
in NN NN O
human NN NN O
8e51 NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
that NN NN O
harbour NN NN O
a NN NN O
defective NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
At NN NN O
least NN NN O
four NN NN O
different NN NN O
specific NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
complexes NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
With NN NN O
the NN NN O
use NN NN O
of NN NN O
specific NN NN O
antibodies NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
composition NN NN O
of NN NN O
each NN NN O
complex NN NN O
using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
The NN NN O
results NN NN O
show NN NN O
the NN NN O
presence NN NN O
of NN NN O
several NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
members NN NN O
, NN NN O
with NN NN O
the NN NN O
transactivating NN NN O
RelA NN NN B-Protein
being NN NN O
engaged NN NN O
in NN NN O
multiple NN NN O
complexes NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
complexes NN NN O
in NN NN O
viral NN NN O
functions NN NN O
has NN NN O
been NN NN O
established NN NN O
comparing NN NN O
the NN NN O
level NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
with NN NN O
syncytia NN NN O
- NN NN O
forming NN NN O
activity NN NN O
of NN NN O
8e51 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
fact NN NN O
, NN NN O
8e51 NN NN O
cells NN NN O
that NN NN O
had NN NN O
almost NN NN O
lost NN NN O
their NN NN O
syncytia NN NN O
- NN NN O
forming NN NN O
capacity NN NN O
were NN NN O
found NN NN O
to NN NN O
contain NN NN O
at NN NN O
least NN NN O
10 NN NN O
times NN NN O
less NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complex NN NN O
than NN NN O
the NN NN O
actively NN NN O
fusing NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
correlation NN NN O
is NN NN O
specific NN NN O
as NN NN O
the NN NN O
level NN NN O
of NN NN O
at NN NN O
least NN NN O
three NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
did NN NN O
not NN NN O
change NN NN O
. NN NN O
   
Differential NN NN O
interaction NN NN O
of NN NN O
nuclear NN NN O
factors NN NN O
with NN NN O
the NN NN O
leukocyte NN NN O
- NN NN O
specific NN NN O
pp52 NN NN B-Protein
promoter NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
leukocyte NN NN O
- NN NN O
specific NN NN O
, NN NN O
cytoskeleton NN NN O
- NN NN O
binding NN NN O
pp52 NN NN B-Protein
( NN NN O
LSP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
WP NN NN B-Protein
- NN NN I-Protein
34 NN NN I-Protein
) NN NN O
protein NN NN O
is NN NN O
widely NN NN O
expressed NN NN O
in NN NN O
multiple NN NN O
leukocyte NN NN O
lineages NN NN O
, NN NN O
including NN NN O
B NN NN O
and NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
granulocytes NN NN O
, NN NN O
and NN NN O
macrophages NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
detected NN NN O
a NN NN O
tissue NN NN O
- NN NN O
specific NN NN O
promoter NN NN O
preceding NN NN O
the NN NN O
exon NN NN O
encoding NN NN O
the NN NN O
N NN NN O
terminus NN NN O
of NN NN O
the NN NN O
pp52 NN NN B-Protein
leukocyte NN NN I-Protein
protein NN NN I-Protein
. NN NN O
   
Here NN NN O
we NN NN O
describe NN NN O
the NN NN O
functional NN NN O
characterization NN NN O
of NN NN O
this NN NN O
promoter NN NN O
and NN NN O
identification NN NN O
of NN NN O
the NN NN O
factors NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
that NN NN O
regulate NN NN O
its NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
pp52 NN NN B-Protein
promoter NN NN O
contains NN NN O
an NN NN O
initiator NN NN O
specifying NN NN O
the NN NN O
unique NN NN O
5 NN NN O
' NN NN O
terminus NN NN O
of NN NN O
pp52 NN NN B-Protein
mRNA NN NN O
, NN NN O
tandem NN NN O
pairs NN NN O
of NN NN O
Ets NN NN O
and NN NN O
SP1 NN NN O
motifs NN NN O
, NN NN O
and NN NN O
a NN NN O
lone NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
motif NN NN O
. NN NN O
   
All NN NN O
these NN NN O
motifs NN NN O
are NN NN O
essential NN NN O
and NN NN O
collectively NN NN O
control NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
DNA NN NN O
binding NN NN O
studies NN NN O
and NN NN O
Ab NN NN O
supershift NN NN O
assays NN NN O
revealed NN NN O
that NN NN O
different NN NN O
combinations NN NN O
of NN NN O
factors NN NN O
interact NN NN O
with NN NN O
these NN NN O
motifs NN NN O
in NN NN O
B NN NN O
cells NN NN O
vs NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Ets NN NN O
motifs NN NN O
are NN NN O
preferentially NN NN O
bound NN NN O
by NN NN O
PU NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
B NN NN O
cell NN NN O
extracts NN NN O
from NN NN O
all NN NN O
stages NN NN O
of NN NN O
development NN NN O
, NN NN O
whereas NN NN O
a NN NN O
different NN NN O
Ets NN NN O
family NN NN O
member NN NN O
reacts NN NN O
with NN NN O
these NN NN O
motifs NN NN O
in NN NN O
T NN NN O
cell NN NN O
extracts NN NN O
. NN NN O
   
The NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
motif NN NN O
is NN NN O
bound NN NN O
by NN NN O
Ig NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
and NN NN O
T NN NN O
cell NN NN O
extracts NN NN O
, NN NN O
but NN NN O
is NN NN O
replaced NN NN O
by NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6beta NN NN I-Protein
or NN NN O
a NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
- NN NN I-Protein
IL NN NN I-Protein
- NN NN I-Protein
6beta NN NN I-Protein
- NN NN O
Ig NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
heterodimer NN NN O
in NN NN O
plasmacytoma NN NN O
cell NN NN O
extracts NN NN O
. NN NN O
   
Despite NN NN O
its NN NN O
reported NN NN O
role NN NN O
as NN NN O
a NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
transcription NN NN O
, NN NN O
Ig NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
appears NN NN O
to NN NN O
exert NN NN O
a NN NN O
stimulatory NN NN O
effect NN NN O
on NN NN O
this NN NN O
promoter NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
reveal NN NN O
the NN NN O
features NN NN O
controlling NN NN O
the NN NN O
pp52 NN NN B-Protein
promoter NN NN O
in NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
and NN NN O
provide NN NN O
the NN NN O
foundation NN NN O
for NN NN O
determining NN NN O
the NN NN O
regulation NN NN O
of NN NN O
this NN NN O
promoter NN NN O
in NN NN O
other NN NN O
leukocyte NN NN O
lineages NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
differentially NN NN O
expressed NN NN O
in NN NN O
murine NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
cells NN NN O
and NN NN O
controls NN NN O
Th2 NN NN O
- NN NN O
specific NN NN O
expression NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
is NN NN O
produced NN NN O
by NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
helper NN NN O
2 NN NN O
( NN NN O
Th2 NN NN O
) NN NN O
cells NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
Th1 NN NN O
cells NN NN O
, NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
eosinophilia NN NN O
in NN NN O
asthma NN NN O
. NN NN O
   
Despite NN NN O
increasing NN NN O
evidence NN NN O
that NN NN O
the NN NN O
outcome NN NN O
of NN NN O
many NN NN O
diseases NN NN O
is NN NN O
determined NN NN O
by NN NN O
the NN NN O
ratio NN NN O
of NN NN O
the NN NN O
two NN NN O
subsets NN NN O
of NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
helper NN NN O
cells NN NN O
, NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
, NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
Th1 NN NN O
- NN NN O
and NN NN O
Th2 NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
established NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
activation NN NN O
in NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
, NN NN O
which NN NN O
express NN NN O
both NN NN O
Th1 NN NN O
- NN NN O
and NN NN O
Th2 NN NN O
- NN NN O
type NN NN O
cytokines NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
reported NN NN O
here NN NN O
demonstrate NN NN O
that NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
is NN NN O
critical NN NN O
for NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
in NN NN O
bona NN NN O
fide NN NN O
Th2 NN NN O
cells NN NN O
. NN NN O
   
Whereas NN NN O
mutations NN NN O
in NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
site NN NN O
abolished NN NN O
antigen NN NN O
- NN NN O
or NN NN O
cAMP NN NN O
- NN NN O
stimulated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
activation NN NN O
in NN NN O
Th2 NN NN O
cells NN NN O
, NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
Th1 NN NN O
cells NN NN O
or NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
lymphoid NN NN O
, NN NN O
non NN NN O
- NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
producing NN NN O
cell NN NN O
line NN NN O
activated NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
. NN NN O
   
During NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
naive NN NN O
CD4 NN NN B-Protein
( NN NN O
+ NN NN O
) NN NN O
T NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
transgenic NN NN O
mice NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
gene NN NN O
expression NN NN O
was NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
developing NN NN O
Th2 NN NN O
cells NN NN O
, NN NN O
but NN NN O
was NN NN O
down NN NN O
- NN NN O
regulated NN NN O
in NN NN O
Th1 NN NN O
cells NN NN O
, NN NN O
and NN NN O
antigen NN NN O
- NN NN O
or NN NN O
cAMP NN NN O
- NN NN O
activated NN NN O
Th2 NN NN O
cells NN NN O
( NN NN O
but NN NN O
not NN NN O
Th1 NN NN O
cells NN NN O
) NN NN O
expressed NN NN O
the NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
protein NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
balance NN NN O
between NN NN O
Th1 NN NN O
and NN NN O
Th2 NN NN O
subsets NN NN O
in NN NN O
immune NN NN O
responses NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
activity NN NN O
has NN NN O
therapeutic NN NN O
potential NN NN O
in NN NN O
the NN NN O
treatment NN NN O
of NN NN O
asthma NN NN O
and NN NN O
other NN NN O
hypereosinophilic NN NN O
diseases NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
replication NN NN O
in NN NN O
vitro NN NN O
by NN NN O
a NN NN O
novel NN NN O
combination NN NN O
of NN NN O
anti NN NN O
- NN NN O
Tat NN NN B-Protein
single NN NN O
- NN NN O
chain NN NN O
intrabodies NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
antagonists NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
Tat NN NN B-Protein
, NN NN O
an NN NN O
early NN NN O
regulatory NN NN O
protein NN NN O
that NN NN O
is NN NN O
critical NN NN O
for NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
and NN NN O
replication NN NN O
, NN NN O
transactivates NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
via NN NN O
its NN NN O
binding NN NN O
to NN NN O
the NN NN O
transactivation NN NN O
response NN NN O
element NN NN O
( NN NN O
TAR NN NN O
) NN NN O
and NN NN O
, NN NN O
along NN NN O
with NN NN O
other NN NN O
cellular NN NN O
factors NN NN O
, NN NN O
increases NN NN O
viral NN NN O
transcription NN NN O
initiation NN NN O
and NN NN O
elongation NN NN O
. NN NN O
   
Tat NN NN B-Protein
also NN NN O
superactivates NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
through NN NN O
a NN NN O
TAR NN NN O
- NN NN O
independent NN NN O
mechanism NN NN O
, NN NN O
including NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
inhibitors NN NN O
of NN NN O
Tat NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
cooperatively NN NN O
down NN NN O
- NN NN O
regulate NN NN O
this NN NN O
Tat NN NN B-Protein
- NN NN O
mediated NN NN O
LTR NN NN O
superactivation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
a NN NN O
combined NN NN O
pharmacologic NN NN O
and NN NN O
genetic NN NN O
strategy NN NN O
using NN NN O
two NN NN O
PKC NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
inhibitors NN NN O
, NN NN O
pentoxifylline NN NN O
( NN NN O
PTX NN NN O
) NN NN O
and NN NN O
Go NN NN O
- NN NN O
6976 NN NN O
, NN NN O
and NN NN O
a NN NN O
stably NN NN O
expressed NN NN O
anti NN NN O
- NN NN O
Tat NN NN B-Protein
single NN NN O
- NN NN O
chain NN NN O
intracellular NN NN O
antibody NN NN O
( NN NN O
sFv NN NN O
intrabody NN NN O
) NN NN O
was NN NN O
employed NN NN O
to NN NN O
obtain NN NN O
cooperative NN NN O
inhibition NN NN O
of NN NN O
both NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
PTX NN NN O
and NN NN O
Go NN NN O
- NN NN O
6976 NN NN O
resulted NN NN O
in NN NN O
cooperative NN NN O
inhibition NN NN O
of NN NN O
both NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
combined NN NN O
use NN NN O
of NN NN O
anti NN NN O
- NN NN O
Tat NN NN B-Protein
sFv NN NN O
intrabodies NN NN O
and NN NN O
the NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
retained NN NN O
the NN NN O
virus NN NN O
in NN NN O
the NN NN O
latent NN NN O
state NN NN O
for NN NN O
as NN NN O
long NN NN O
as NN NN O
45 NN NN O
days NN NN O
. NN NN O
   
The NN NN O
combined NN NN O
treatment NN NN O
resulted NN NN O
in NN NN O
more NN NN O
durable NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
than NN NN O
was NN NN O
seen NN NN O
with NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
alone NN NN O
or NN NN O
the NN NN O
anti NN NN O
- NN NN O
Tat NN NN B-Protein
sFv NN NN O
intrabodies NN NN O
alone NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
in NN NN O
future NN NN O
clinical NN NN O
gene NN NN O
therapy NN NN O
trials NN NN O
, NN NN O
a NN NN O
combined NN NN O
pharmacologic NN NN O
and NN NN O
genetic NN NN O
strategy NN NN O
like NN NN O
the NN NN O
one NN NN O
reported NN NN O
here NN NN O
may NN NN O
improve NN NN O
the NN NN O
survival NN NN O
of NN NN O
transduced NN NN O
cells NN NN O
and NN NN O
prolong NN NN O
clinical NN NN O
benefit NN NN O
. NN NN O
   
Transcription NN NN O
factors NN NN O
in NN NN O
immune NN NN O
- NN NN O
mediated NN NN O
disease NN NN O
. NN NN O
   
A NN NN O
large NN NN O
amount NN NN O
of NN NN O
detailed NN NN O
information NN NN O
about NN NN O
the NN NN O
intracellular NN NN O
proteins NN NN O
regulating NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
the NN NN O
cellular NN NN O
response NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
has NN NN O
emerged NN NN O
recently NN NN O
. NN NN O
   
Several NN NN O
small NN NN O
molecules NN NN O
, NN NN O
an NN NN O
antisense NN NN O
oligonucleotide NN NN O
, NN NN O
and NN NN O
gene NN NN O
therapeutic NN NN O
agents NN NN O
that NN NN O
inhibit NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
b NN NN O
activation NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O
   
Despite NN NN O
this NN NN O
, NN NN O
there NN NN O
are NN NN O
still NN NN O
significant NN NN O
gaps NN NN O
in NN NN O
our NN NN O
understanding NN NN O
of NN NN O
this NN NN O
process NN NN O
and NN NN O
its NN NN O
consequences NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
characterization NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
selectively NN NN O
regulating NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cell NN NN O
subsets NN NN O
is NN NN O
at NN NN O
a NN NN O
very NN NN O
early NN NN O
stage NN NN O
. NN NN O
   
Three NN NN O
interacting NN NN O
proteins NN NN O
have NN NN O
recently NN NN O
been NN NN O
shown NN NN O
to NN NN O
contribute NN NN O
to NN NN O
subset NN NN O
- NN NN O
restricted NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
. NN NN O
   
There NN NN O
are NN NN O
other NN NN O
elements NN NN O
regulating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
however NN NN O
, NN NN O
and NN NN O
the NN NN O
relative NN NN O
importance NN NN O
of NN NN O
these NN NN O
recently NN NN O
identified NN NN O
proteins NN NN O
has NN NN O
yet NN NN O
to NN NN O
be NN NN O
determined NN NN O
. NN NN O
   
CholecystokininB NN NN B-Protein
receptor NN NN I-Protein
from NN NN O
human NN NN O
Jurkat NN NN O
lymphoblastic NN NN O
T NN NN O
cells NN NN O
is NN NN O
involved NN NN O
in NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
- NN NN O
responsive NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
analyze NN NN O
the NN NN O
role NN NN O
of NN NN O
cholecystokinin NN NN O
( NN NN B-Protein
CCK NN NN I-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
in NN NN O
human NN NN O
lymphoblastic NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
trophic NN NN O
effect NN NN O
resulting NN NN O
from NN NN O
activation NN NN O
of NN NN O
such NN NN O
a NN NN O
receptor NN NN O
by NN NN O
using NN NN O
the NN NN O
reporter NN NN O
gene NN NN O
strategy NN NN O
. NN NN O
   
For NN NN O
this NN NN O
purpose NN NN O
, NN NN O
we NN NN O
transiently NN NN O
transfected NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
with NN NN O
the NN NN O
reporter NN NN O
plasmid NN NN O
p NN NN O
[ NN NN O
( NN NN O
TRE NN NN O
) NN NN O
3 NN NN O
- NN NN O
tk NN NN O
- NN NN O
Luc NN NN O
] NN NN O
and NN NN O
found NN NN O
that NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
was NN NN O
able NN NN O
to NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
induce NN NN O
luciferase NN NN B-Protein
expression NN NN O
related NN NN O
to NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
activation NN NN O
with NN NN O
a NN NN O
maximal NN NN O
response NN NN O
identical NN NN O
to NN NN O
that NN NN O
obtained NN NN O
with NN NN O
compounds NN NN O
known NN NN O
to NN NN O
activate NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
( NN NN O
quantitatively NN NN O
, NN NN O
the NN NN O
same NN NN O
level NN NN O
of NN NN O
induction NN NN O
was NN NN O
obtained NN NN O
with NN NN O
1 NN NN O
nM NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
, NN NN O
100 NN NN O
microM NN NN O
diacylglycerol NN NN O
, NN NN O
or NN NN O
4 NN NN O
nM NN NN O
epidermal NN NN O
growth NN NN O
factor NN NN O
) NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
the NN NN O
CCK NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
in NN NN O
such NN NN O
a NN NN O
stimulation NN NN O
was NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
inhibiting NN NN O
effect NN NN O
of NN NN O
the NN NN O
selective NN NN O
CCK NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
antagonist NN NN O
PD NN NN O
- NN NN O
135 NN NN O
, NN NN O
158 NN NN O
. NN NN O
   
This NN NN O
effect NN NN O
was NN NN O
confirmed NN NN O
in NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
the NN NN O
cDNA NN NN O
of NN NN O
CCK NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
cloned NN NN O
from NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
better NN NN O
understand NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
dependent NN NN O
luciferase NN NN B-Protein
expression NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
tested NN NN O
two NN NN O
specific NN NN O
inhibitors NN NN O
of NN NN O
serine NN NN B-Protein
/ NN NN I-Protein
threonine NN NN I-Protein
phosphatases NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
- NN NN B-Protein
2A NN NN I-Protein
: NN NN O
okadaic NN NN O
acid NN NN O
and NN NN O
calyculin NN NN O
A NN NN O
. NN NN O
   
These NN NN O
compounds NN NN O
strongly NN NN O
increased NN NN O
the NN NN O
phorbol NN NN O
- NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
response NN NN O
, NN NN O
whereas NN NN O
we NN NN O
have NN NN O
not NN NN O
observed NN NN O
a NN NN O
contribution NN NN O
of NN NN O
phosphatase NN NN O
inhibitors NN NN O
on NN NN O
a NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
- NN NN O
induced NN NN O
luciferase NN NN B-Protein
activity NN NN O
. NN NN O
   
To NN NN O
confirm NN NN O
that NN NN O
CCK NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
receptors NN NN I-Protein
are NN NN O
involved NN NN O
in NN NN O
AP NN NN O
- NN NN O
1 NN NN O
response NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
effect NN NN O
on NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
, NN NN O
a NN NN O
natural NN NN O
endogenous NN NN O
gene NN NN O
regulated NN NN O
by NN NN O
several NN NN O
factors NN NN O
, NN NN O
including NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
In NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
activated NN NN O
by NN NN O
phorbol NN NN O
- NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
- NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
and NN NN O
phytohemagglutinin NN NN B-Protein
, NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
was NN NN O
abolished NN NN O
by NN NN O
PD NN NN O
- NN NN O
135 NN NN O
, NN NN O
158 NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
CCK NN NN O
- NN NN O
8 NN NN O
exerts NN NN O
a NN NN O
trophic NN NN O
effect NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
through NN NN O
stimulation NN NN O
of NN NN O
CCK NN NN B-Protein
( NN NN I-Protein
B NN NN I-Protein
) NN NN I-Protein
receptors NN NN I-Protein
by NN NN O
modulation NN NN O
of NN NN O
expression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
regulated NN NN O
genes NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
binding NN NN O
to NN NN O
CD21 NN NN B-Protein
activates NN NN O
the NN NN O
initial NN NN O
viral NN NN O
promoter NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
induction NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
, NN NN O
an NN NN O
oncogenic NN NN O
human NN NN O
herpesvirus NN NN O
, NN NN O
binds NN NN O
to NN NN O
and NN NN O
infects NN NN O
normal NN NN O
human NN NN O
B NN NN O
lymphocytes NN NN O
via NN NN O
CD21 NN NN B-Protein
, NN NN O
the NN NN O
CR2 NN NN B-Protein
complement NN NN O
receptor NN NN O
. NN NN O
   
Studies NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
that NN NN O
enable NN NN O
EBV NN NN O
to NN NN O
infect NN NN O
nonactivated NN NN O
, NN NN O
noncycling NN NN O
B NN NN O
cells NN NN O
provide NN NN O
compelling NN NN O
evidence NN NN O
for NN NN O
a NN NN O
sequence NN NN O
of NN NN O
events NN NN O
in NN NN O
which NN NN O
EBV NN NN O
binding NN NN O
to NN NN O
CD21 NN NN B-Protein
on NN NN O
purified NN NN O
resting NN NN O
human NN NN O
B NN NN O
cells NN NN O
rapidly NN NN O
activates NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
which NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
binds NN NN O
to NN NN O
and NN NN O
mediates NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
Wp NN NN O
, NN NN O
the NN NN O
initial NN NN O
viral NN NN O
latent NN NN O
gene NN NN O
promoter NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
EBV NN NN O
binding NN NN O
to NN NN O
its NN NN O
cellular NN NN O
receptor NN NN O
on NN NN O
resting NN NN O
B NN NN O
cells NN NN O
triggers NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
intracellular NN NN O
signaling NN NN O
pathway NN NN O
which NN NN O
is NN NN O
required NN NN O
for NN NN O
infection NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
by NN NN O
phagocytic NN NN O
stimuli NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Phagocytosis NN NN O
represents NN NN O
an NN NN O
important NN NN O
physiological NN NN O
trigger NN NN O
for NN NN O
the NN NN O
inducible NN NN O
expression NN NN O
of NN NN O
several NN NN O
genes NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
a NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
primarily NN NN O
consisting NN NN O
of NN NN O
the NN NN O
classical NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
heterodimer NN NN O
, NN NN O
p50 NN NN B-Protein
/ NN NN O
RelA NN NN B-Protein
, NN NN O
is NN NN O
induced NN NN O
in NN NN O
phagocytosing NN NN O
neutrophils NN NN O
. NN NN O
   
Under NN NN O
these NN NN O
conditions NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
rapid NN NN O
and NN NN O
transient NN NN O
response NN NN O
, NN NN O
reaching NN NN O
a NN NN O
maximum NN NN O
by NN NN O
10 NN NN O
- NN NN O
15 NN NN O
min NN NN O
, NN NN O
and NN NN O
returning NN NN O
to NN NN O
near NN NN O
- NN NN O
basal NN NN O
levels NN NN O
by NN NN O
30 NN NN O
min NN NN O
. NN NN O
   
In NN NN O
neutrophils NN NN O
undergoing NN NN O
the NN NN O
phagocytosis NN NN O
of NN NN O
opsonized NN NN O
yeasts NN NN O
, NN NN O
the NN NN O
onset NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
was NN NN O
paralleled NN NN O
by NN NN O
a NN NN O
decline NN NN O
in NN NN O
immunoreactive NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
levels NN NN O
, NN NN O
and NN NN O
the NN NN O
cellular NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
pool NN NN O
was NN NN O
replenished NN NN O
by NN NN O
30 NN NN O
min NN NN O
, NN NN O
in NN NN O
agreement NN NN O
with NN NN O
our NN NN O
gel NN NN O
shift NN NN O
data NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
could NN NN O
constitute NN NN O
one NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
whereby NN NN O
the NN NN O
expression NN NN O
of NN NN O
kappa NN NN O
B NN NN O
- NN NN O
responsive NN NN O
genes NN NN O
is NN NN O
enhanced NN NN O
in NN NN O
phagocytosing NN NN O
neutrophils NN NN O
. NN NN O
   
To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
this NN NN O
represents NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
that NN NN O
phagocytic NN NN O
stimuli NN NN O
can NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Surfactant NN NN B-Protein
protein NN NN I-Protein
A NN NN I-Protein
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
many NN NN O
genes NN NN O
for NN NN O
which NN NN O
products NN NN O
are NN NN O
involved NN NN O
in NN NN O
inflammation NN NN O
is NN NN O
controlled NN NN O
by NN NN O
the NN NN O
transcriptional NN NN O
regulator NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Because NN NN O
surfactant NN NN O
protein NN NN O
( NN NN O
SP NN NN O
) NN NN O
A NN NN O
is NN NN O
involved NN NN O
in NN NN O
local NN NN O
host NN NN O
defense NN NN O
in NN NN O
the NN NN O
lung NN NN O
and NN NN O
alters NN NN O
immune NN NN O
cell NN NN O
function NN NN O
by NN NN O
modulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
proinflammatory NN NN O
cytokines NN NN O
as NN NN O
well NN NN O
as NN NN O
surface NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
inflammation NN NN O
, NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
SP NN NN O
- NN NN O
A NN NN O
exerts NN NN O
its NN NN O
action NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
via NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
used NN NN O
gel NN NN O
shift NN NN O
assays NN NN O
to NN NN O
determine NN NN O
whether NN NN O
SP NN NN O
- NN NN O
A NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cell NN NN O
line NN NN O
, NN NN O
a NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
by NN NN O
SP NN NN O
- NN NN O
A NN NN O
doses NN NN O
as NN NN O
low NN NN O
as NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
ml NN NN O
occurred NN NN O
within NN NN O
30 NN NN O
min NN NN O
of NN NN O
SP NN NN O
- NN NN O
A NN NN O
treatment NN NN O
, NN NN O
peaked NN NN O
at NN NN O
60 NN NN O
min NN NN O
, NN NN O
and NN NN O
then NN NN O
declined NN NN O
. NN NN O
   
This NN NN O
activation NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
known NN NN O
inhibitors NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
by NN NN O
simultaneous NN NN O
treatment NN NN O
of NN NN O
the NN NN O
cells NN NN O
with NN NN O
surfactant NN NN O
lipids NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
blocked NN NN O
SP NN NN O
- NN NN O
A NN NN O
- NN NN O
dependent NN NN O
increases NN NN O
in NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
a NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
SP NN NN O
- NN NN O
A NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
some NN NN O
lung NN NN O
conditions NN NN O
and NN NN O
point NN NN O
to NN NN O
potential NN NN O
therapeutic NN NN O
measures NN NN O
that NN NN O
could NN NN O
be NN NN O
used NN NN O
to NN NN O
prevent NN NN O
SP NN NN O
- NN NN O
A NN NN O
induced NN NN O
inflammation NN NN O
in NN NN O
the NN NN O
lung NN NN O
. NN NN O
   
alpha NN NN O
- NN NN O
Tocopheryl NN NN O
succinate NN NN O
inhibits NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
by NN NN O
suppressing NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
mobilization NN NN O
. NN NN O
   
The NN NN O
adherence NN NN O
of NN NN O
monocytes NN NN O
to NN NN O
activated NN NN O
endothelium NN NN O
is NN NN O
an NN NN O
early NN NN O
event NN NN O
in NN NN O
atherogenesis NN NN O
. NN NN O
   
Because NN NN O
antioxidants NN NN O
have NN NN O
been NN NN O
considered NN NN O
to NN NN O
be NN NN O
of NN NN O
antiatherosclerotic NN NN O
potential NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
( NN NN O
TCP NN NN O
) NN NN O
and NN NN O
its NN NN O
acetate NN NN O
and NN NN O
succinate NN NN O
esters NN NN O
on NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
cytokine NN NN O
- NN NN O
stimulated NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVEC NN NN O
) NN NN O
. NN NN O
   
Endothelial NN NN O
cells NN NN O
were NN NN O
treated NN NN O
with NN NN O
TCP NN NN O
, NN NN O
alpha NN NN O
- NN NN O
tocopherol NN NN O
acetate NN NN O
( NN NN O
TCP NN NN O
acetate NN NN O
) NN NN O
, NN NN O
or NN NN O
alpha NN NN O
- NN NN O
tocopheryl NN NN O
succinate NN NN O
( NN NN O
TCP NN NN O
succinate NN NN O
) NN NN O
before NN NN O
stimulation NN NN O
with NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
; NN NN O
10 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
, NN NN O
6 NN NN O
h NN NN O
) NN NN O
or NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
; NN NN O
10 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
, NN NN O
6 NN NN O
h NN NN O
) NN NN O
. NN NN O
   
Cytokine NN NN O
- NN NN O
stimulated NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
CD106 NN NN B-Protein
) NN NN O
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
( NN NN O
ELAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
CD62E NN NN B-Protein
) NN NN O
, NN NN O
but NN NN O
not NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
CD54 NN NN B-Protein
) NN NN O
, NN NN O
was NN NN O
time NN NN O
- NN NN O
and NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
inhibited NN NN O
by NN NN O
TCP NN NN O
succinate NN NN O
but NN NN O
not NN NN O
by NN NN O
TCP NN NN O
or NN NN O
TCP NN NN O
acetate NN NN O
. NN NN O
   
TCP NN NN O
succinate NN NN O
( NN NN O
200 NN NN O
microM NN NN O
, NN NN O
24 NN NN O
h NN NN O
) NN NN O
reduced NN NN O
TNF NN NN O
- NN NN O
induced NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
expression NN NN O
from NN NN O
a NN NN O
specific NN NN O
mean NN NN O
fluorescence NN NN O
intensity NN NN O
of NN NN O
151 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
28 NN NN O
to NN NN O
12 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
channels NN NN O
and NN NN O
from NN NN O
225 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
38 NN NN O
to NN NN O
79 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
21 NN NN O
channels NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Succinate NN NN O
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
Decreased NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
reduction NN NN O
of NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
. NN NN O
   
TCP NN NN O
succinate NN NN O
( NN NN O
20 NN NN O
microM NN NN O
, NN NN O
72 NN NN O
h NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
TCP NN NN O
( NN NN O
200 NN NN O
microM NN NN O
, NN NN O
72 NN NN O
h NN NN O
) NN NN O
, NN NN O
reduced NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
( NN NN O
10 NN NN O
U NN NN O
/ NN NN O
ml NN NN O
, NN NN O
6 NN NN O
h NN NN O
) NN NN O
HUVEC NN NN O
by NN NN O
30 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
025 NN NN O
) NN NN O
and NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
- NN NN O
stimulated NN NN O
HUVEC NN NN O
by NN NN O
56 NN NN O
% NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
010 NN NN O
) NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
- NN NN O
shift NN NN O
assays NN NN O
of NN NN O
HUVEC NN NN O
nuclear NN NN O
proteins NN NN O
revealed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
stimulated NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
after NN NN O
pretreatment NN NN O
of NN NN O
HUVEC NN NN O
with NN NN O
TCP NN NN O
succinate NN NN O
but NN NN O
not NN NN O
with NN NN O
TCP NN NN O
, NN NN O
TCP NN NN O
acetate NN NN O
, NN NN O
or NN NN O
succinate NN NN O
alone NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
vitamin NN NN O
E NN NN O
derivative NN NN O
TCP NN NN O
succinate NN NN O
prevents NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
cytokine NN NN O
- NN NN O
stimulated NN NN O
endothelial NN NN O
cells NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
further NN NN O
emphasizing NN NN O
the NN NN O
antiatherosclerotic NN NN O
potential NN NN O
of NN NN O
lipid NN NN O
soluble NN NN O
antioxidants NN NN O
. NN NN O
   
Distinct NN NN O
mechanisms NN NN O
for NN NN O
N NN NN O
- NN NN O
acetylcysteine NN NN O
inhibition NN NN O
of NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
We NN NN O
have NN NN O
examined NN NN O
the NN NN O
effects NN NN O
of NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
, NN NN O
a NN NN O
well NN NN O
- NN NN O
characterized NN NN O
, NN NN O
thiol NN NN O
- NN NN O
containing NN NN O
antioxidant NN NN O
, NN NN O
on NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
EC NN NN O
) NN NN O
. NN NN O
   
NAC NN NN O
inhibited NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
) NN NN O
- NN NN O
induced NN NN O
, NN NN O
but NN NN O
not NN NN O
basal NN NN O
, NN NN O
adhesion NN NN O
with NN NN O
50 NN NN O
% NN NN O
inhibition NN NN O
at NN NN O
approximately NN NN O
20 NN NN O
mM NN NN O
. NN NN O
   
Monocytic NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
EC NN NN O
in NN NN O
response NN NN O
to NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
, NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
alpha NN NN B-Protein
- NN NN I-Protein
thrombin NN NN I-Protein
, NN NN O
or NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
was NN NN O
similarly NN NN O
inhibited NN NN O
by NN NN O
NAC NN NN O
. NN NN O
   
Unlike NN NN O
published NN NN O
studies NN NN O
with NN NN O
pyrrolidinedithiocarbamate NN NN O
, NN NN O
which NN NN O
specifically NN NN O
inhibited NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
NAC NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
- NN NN O
induced NN NN O
mRNA NN NN O
and NN NN O
cell NN NN O
surface NN NN O
expression NN NN O
of NN NN O
both NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
NAC NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
or NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Although NN NN O
NAC NN NN O
reduced NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
in NN NN O
EC NN NN O
as NN NN O
measured NN NN O
by NN NN O
gel NN NN O
- NN NN O
shift NN NN O
assays NN NN O
using NN NN O
an NN NN O
oligonucleotide NN NN O
probe NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
consensus NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
sites NN NN O
of NN NN O
the NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
( NN NN O
VCAM NN NN O
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
the NN NN O
antioxidant NN NN O
had NN NN O
no NN NN O
appreciable NN NN O
effect NN NN O
when NN NN O
an NN NN O
oligomer NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
consensus NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
site NN NN O
of NN NN O
the NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
gene NN NN O
( NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
was NN NN O
used NN NN O
. NN NN O
   
Because NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
redox NN NN O
sensitive NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
effects NN NN O
of NN NN O
NAC NN NN O
on NN NN O
the NN NN O
EC NN NN O
redox NN NN O
environment NN NN O
. NN NN O
   
NAC NN NN O
caused NN NN O
an NN NN O
expected NN NN O
dramatic NN NN O
increase NN NN O
in NN NN O
the NN NN O
reduced NN NN O
glutathione NN NN O
( NN NN O
GSH NN NN O
) NN NN O
levels NN NN O
in NN NN O
EC NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
whereas NN NN O
the NN NN O
binding NN NN O
affinity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
to NN NN O
the NN NN O
VCAM NN NN O
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
oligomer NN NN O
peaked NN NN O
at NN NN O
a NN NN O
GSH NN NN O
- NN NN O
to NN NN O
- NN NN O
oxidized NN NN O
glutathione NN NN O
( NN NN O
GSSG NN NN O
) NN NN O
ratio NN NN O
of NN NN O
approximately NN NN O
200 NN NN O
and NN NN O
decreased NN NN O
at NN NN O
higher NN NN O
ratios NN NN O
, NN NN O
the NN NN O
binding NN NN O
to NN NN O
the NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
oligomer NN NN O
appeared NN NN O
relatively NN NN O
unaffected NN NN O
even NN NN O
at NN NN O
ratios NN NN O
> NN NN O
400 NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
those NN NN O
achieved NN NN O
in NN NN O
EC NN NN O
treated NN NN O
with NN NN O
40 NN NN O
mM NN NN O
NAC NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
to NN NN O
its NN NN O
consensus NN NN O
sequences NN NN O
in NN NN O
the NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
gene NN NN O
exhibits NN NN O
marked NN NN O
differences NN NN O
in NN NN O
redox NN NN O
sensitivity NN NN O
, NN NN O
allowing NN NN O
for NN NN O
differential NN NN O
gene NN NN O
expression NN NN O
regulated NN NN O
by NN NN O
the NN NN O
same NN NN O
transcription NN NN O
factor NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
also NN NN O
demonstrate NN NN O
that NN NN O
NAC NN NN O
increases NN NN O
the NN NN O
GSH NN NN O
- NN NN O
to NN NN O
- NN NN O
GSSG NN NN O
ratio NN NN O
within NN NN O
the NN NN O
EC NN NN O
suggesting NN NN O
one NN NN O
possible NN NN O
mechanism NN NN O
through NN NN O
which NN NN O
this NN NN O
antioxidant NN NN O
inhibits NN NN O
agonist NN NN O
- NN NN O
induced NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
EC NN NN O
. NN NN O
   
Human NN NN O
monocyte NN NN O
binding NN NN O
to NN NN O
fibronectin NN NN B-Protein
enhances NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
early NN NN O
signaling NN NN O
events NN NN O
. NN NN O
   
Leukocyte NN NN O
integrins NN NN O
are NN NN O
fundamentally NN NN O
important NN NN O
in NN NN O
modulating NN NN O
adhesion NN NN O
to NN NN O
extracellular NN NN O
matrix NN NN O
components NN NN O
and NN NN O
to NN NN O
other NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
integrin NN NN O
- NN NN O
mediated NN NN O
adhesion NN NN O
controls NN NN O
leukocyte NN NN O
arrest NN NN O
and NN NN O
extravasation NN NN O
during NN NN O
the NN NN O
onset NN NN O
of NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
integrin NN NN O
- NN NN O
ligand NN NN O
interactions NN NN O
trigger NN NN O
signaling NN NN O
pathways NN NN O
that NN NN O
may NN NN O
influence NN NN O
leukocyte NN NN O
phenotype NN NN O
and NN NN O
function NN NN O
at NN NN O
sites NN NN O
of NN NN O
inflammation NN NN O
. NN NN O
   
In NN NN O
the NN NN O
current NN NN O
studies NN NN O
, NN NN O
we NN NN O
evaluated NN NN O
the NN NN O
combinatorial NN NN O
effects NN NN O
of NN NN O
monocyte NN NN O
adhesion NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
on NN NN O
intracellular NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
triggers NN NN O
a NN NN O
well NN NN O
- NN NN O
defined NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
, NN NN O
which NN NN O
although NN NN O
not NN NN O
directly NN NN O
stimulated NN NN O
by NN NN O
monocyte NN NN O
adherence NN NN O
to NN NN O
fibronectin NN NN B-Protein
or NN NN O
arginine NN NN O
- NN NN O
glycine NN NN O
- NN NN O
aspartate NN NN O
( NN NN O
RGD NN NN O
) NN NN O
- NN NN O
coated NN NN O
substrata NN NN O
, NN NN O
was NN NN O
enhanced NN NN O
significantly NN NN O
in NN NN O
these NN NN O
matrix NN NN O
- NN NN O
adherent NN NN O
cells NN NN O
. NN NN O
   
Compared NN NN O
with NN NN O
monocytes NN NN O
in NN NN O
suspension NN NN O
or NN NN O
adherent NN NN O
on NN NN O
plastic NN NN O
surfaces NN NN O
, NN NN O
monocytes NN NN O
adherent NN NN O
to NN NN O
fibronectin NN NN B-Protein
or NN NN O
RGD NN NN O
exhibited NN NN O
a NN NN O
greater NN NN O
than NN NN O
threefold NN NN O
increase NN NN O
in NN NN O
steady NN NN O
state NN NN O
levels NN NN O
of NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
- NN NN O
induced NN NN O
mRNA NN NN O
for NN NN O
the NN NN O
high NN NN B-Protein
affinity NN NN I-Protein
Fc NN NN I-Protein
gammaRI NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
By NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
this NN NN O
increase NN NN O
in NN NN O
mRNA NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
5 NN NN O
- NN NN O
to NN NN O
10 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
the NN NN O
STAT1 NN NN B-Protein
- NN NN O
containing NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
complex NN NN O
that NN NN O
binds NN NN O
to NN NN O
Fc NN NN O
gammaRI NN NN O
promoter NN NN O
elements NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT1 NN NN B-Protein
and NN NN O
the NN NN O
tyrosine NN NN O
kinases NN NN O
JAK1 NN NN B-Protein
and NN NN O
JAK2 NN NN B-Protein
was NN NN O
enhanced NN NN O
significantly NN NN O
in NN NN O
RGD NN NN O
- NN NN O
adherent NN NN O
monocytes NN NN O
compared NN NN O
with NN NN O
control NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
novel NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
integrin NN NN O
- NN NN O
mediated NN NN O
cell NN NN O
adhesion NN NN O
can NN NN O
modulate NN NN O
the NN NN O
magnitude NN NN O
of NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
, NN NN O
thereby NN NN O
amplifying NN NN O
cellular NN NN O
events NN NN O
leading NN NN O
to NN NN O
monocyte NN NN O
activation NN NN O
and NN NN O
inflammation NN NN O
. NN NN O
   
The NN NN O
carboxyl NN NN O
- NN NN O
terminal NN NN O
cytoplasmic NN NN O
domain NN NN O
of NN NN O
CD36 NN NN B-Protein
is NN NN O
required NN NN O
for NN NN O
oxidized NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
modulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
oxidized NN NN O
low NN NN O
- NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
Ox NN NN O
LDL NN NN O
) NN NN O
by NN NN O
monocyte NN NN O
- NN NN O
macrophages NN NN O
causes NN NN O
pleiotropic NN NN O
effects NN NN O
, NN NN O
including NN NN O
changes NN NN O
in NN NN O
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
represent NN NN O
an NN NN O
early NN NN O
event NN NN O
in NN NN O
atherogenesis NN NN O
. NN NN O
   
The NN NN O
integral NN NN O
membrane NN NN O
glycoprotein NN NN O
CD36 NN NN B-Protein
appears NN NN O
to NN NN O
play NN NN O
a NN NN O
physiological NN NN O
role NN NN O
in NN NN O
binding NN NN O
and NN NN O
uptake NN NN O
of NN NN O
Ox NN NN O
LDL NN NN O
by NN NN O
monocyte NN NN O
- NN NN O
macrophages NN NN O
, NN NN O
although NN NN O
the NN NN O
molecular NN NN O
events NN NN O
associated NN NN O
with NN NN O
CD36 NN NN B-Protein
- NN NN O
Ox NN NN O
LDL NN NN O
interaction NN NN O
are NN NN O
unknown NN NN O
. NN NN O
   
To NN NN O
approach NN NN O
this NN NN O
issue NN NN O
, NN NN O
we NN NN O
used NN NN O
CD36 NN NN B-Protein
transfected NN NN O
Chinese NN NN O
hampster NN NN O
ovary NN NN O
( NN NN O
CHO NN NN O
) NN NN O
cells NN NN O
, NN NN O
exposed NN NN O
them NN NN O
to NN NN O
Ox NN NN O
LDL NN NN O
, NN NN O
and NN NN O
determined NN NN O
changes NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
Ox NN NN O
LDL NN NN O
enhanced NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
to NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
sequence NN NN O
following NN NN O
activation NN NN O
of NN NN O
CD36 NN NN B-Protein
- NN NN O
producing NN NN O
CHO NN NN O
cells NN NN O
with NN NN O
the NN NN O
proinflammatory NN NN O
cytokine NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
This NN NN O
enhanced NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
coincubation NN NN O
of NN NN O
CD36 NN NN B-Protein
transfected NN NN O
cells NN NN O
with NN NN O
the NN NN O
human NN NN O
CD36 NN NN B-Protein
- NN NN O
specific NN NN O
antibody NN NN O
OKM5 NN NN O
. NN NN O
   
We NN NN O
also NN NN O
determined NN NN O
that NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
required NN NN O
an NN NN O
intact NN NN O
carboxyl NN NN O
- NN NN O
terminal NN NN O
cytoplasmic NN NN O
segment NN NN O
on NN NN O
CD36 NN NN B-Protein
. NN NN O
   
Our NN NN O
results NN NN O
support NN NN O
the NN NN O
idea NN NN O
that NN NN O
human NN NN O
CD36 NN NN B-Protein
mediates NN NN O
signal NN NN O
transduction NN NN O
events NN NN O
in NN NN O
response NN NN O
to NN NN O
Ox NN NN O
LDL NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
during NN NN O
myelopoiesis NN NN O
. NN NN O
   
The NN NN O
coordinated NN NN O
production NN NN O
of NN NN O
all NN NN O
blood NN NN O
cells NN NN O
from NN NN O
a NN NN O
common NN NN O
stem NN NN O
cell NN NN O
is NN NN O
a NN NN O
highly NN NN O
regulated NN NN O
process NN NN O
involving NN NN O
successive NN NN O
stages NN NN O
of NN NN O
commitment NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
From NN NN O
analyses NN NN O
of NN NN O
mice NN NN O
deficient NN NN O
in NN NN O
transcription NN NN O
factor NN NN O
genes NN NN O
and NN NN O
from NN NN O
the NN NN O
characterizations NN NN O
of NN NN O
chromosome NN NN O
breakpoints NN NN O
in NN NN O
human NN NN O
leukemias NN NN O
, NN NN O
it NN NN O
has NN NN O
become NN NN O
evident NN NN O
that NN NN O
transcription NN NN O
factors NN NN O
are NN NN O
important NN NN O
regulators NN NN O
of NN NN O
hematopoiesis NN NN O
. NN NN O
   
During NN NN O
myelopoiesis NN NN O
, NN NN O
which NN NN O
includes NN NN O
the NN NN O
development NN NN O
of NN NN O
granulocytic NN NN O
and NN NN O
monocytic NN NN O
lineages NN NN O
, NN NN O
transcription NN NN O
factors NN NN O
from NN NN O
several NN NN O
families NN NN O
are NN NN O
active NN NN O
, NN NN O
including NN NN O
AML1 NN NN B-Protein
/ NN NN O
CBF NN NN B-Protein
beta NN NN I-Protein
, NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
, NN NN O
Ets NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
Myb NN NN I-Protein
, NN NN O
HOX NN NN O
, NN NN O
and NN NN O
MZF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Few NN NN O
of NN NN O
these NN NN O
factors NN NN O
are NN NN O
expressed NN NN O
exclusively NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
; NN NN O
instead NN NN O
it NN NN O
appears NN NN O
that NN NN O
they NN NN O
cooperatively NN NN O
regulate NN NN O
transcription NN NN O
of NN NN O
myeloid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
discuss NN NN O
recent NN NN O
advances NN NN O
in NN NN O
transcriptional NN NN O
regulation NN NN O
during NN NN O
myelopoiesis NN NN O
. NN NN O
   
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
the NN NN O
control NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
process NN NN O
of NN NN O
apoptosis NN NN O
is NN NN O
used NN NN O
to NN NN O
eliminate NN NN O
unwanted NN NN O
cells NN NN O
from NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
organisms NN NN O
. NN NN O
   
Various NN NN O
extracellular NN NN O
signals NN NN O
, NN NN O
often NN NN O
converging NN NN O
in NN NN O
common NN NN O
intracellular NN NN O
pathways NN NN O
, NN NN O
can NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
. NN NN O
   
Recent NN NN O
work NN NN O
from NN NN O
several NN NN O
laboratories NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
regulate NN NN O
apoptosis NN NN O
in NN NN O
many NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
In NN NN O
most NN NN O
cells NN NN O
, NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
appear NN NN O
to NN NN O
mediate NN NN O
survival NN NN O
signals NN NN O
that NN NN O
protect NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
; NN NN O
however NN NN O
, NN NN O
under NN NN O
some NN NN O
circumstances NN NN O
, NN NN O
activation NN NN O
of NN NN O
these NN NN O
factors NN NN O
may NN NN O
also NN NN O
promote NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
proteins NN NN O
in NN NN O
viral NN NN O
oncogenesis NN NN O
and NN NN O
the NN NN O
regulation NN NN O
of NN NN O
viral NN NN O
transcription NN NN O
. NN NN O
   
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
ubiquitous NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
consists NN NN O
of NN NN O
multiple NN NN O
polypeptide NN NN O
subunits NN NN O
, NN NN O
and NN NN O
is NN NN O
subject NN NN O
to NN NN O
complex NN NN O
regulatory NN NN O
mechanisms NN NN O
that NN NN O
involve NN NN O
protein NN NN O
- NN NN O
protein NN NN O
interactions NN NN O
, NN NN O
phosphorylation NN NN O
, NN NN O
ubiquitination NN NN O
, NN NN O
proteolytic NN NN O
degradation NN NN O
, NN NN O
and NN NN O
nucleocytoplasmic NN NN O
translocation NN NN O
. NN NN O
   
The NN NN O
sophisticated NN NN O
control NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
is NN NN O
not NN NN O
surprising NN NN O
since NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
is NN NN O
involved NN NN O
in NN NN O
a NN NN O
wide NN NN O
array NN NN O
of NN NN O
cellular NN NN O
responses NN NN O
to NN NN O
extracellular NN NN O
cues NN NN O
, NN NN O
associated NN NN O
with NN NN O
growth NN NN O
, NN NN O
development NN NN O
, NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
pathogen NN NN O
invasion NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
unexpected NN NN O
that NN NN O
this NN NN O
versatile NN NN O
cellular NN NN O
homeostatic NN NN O
switch NN NN O
would NN NN O
be NN NN O
affected NN NN O
by NN NN O
a NN NN O
variety NN NN O
of NN NN O
viral NN NN O
pathogens NN NN O
, NN NN O
which NN NN O
have NN NN O
evolved NN NN O
mechanisms NN NN O
to NN NN O
utilize NN NN O
various NN NN O
aspects NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
to NN NN O
facilitate NN NN O
their NN NN O
replication NN NN O
, NN NN O
cell NN NN O
survival NN NN O
and NN NN O
possibly NN NN O
evasion NN NN O
of NN NN O
immune NN NN O
responses NN NN O
. NN NN O
   
This NN NN O
review NN NN O
will NN NN O
cover NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
are NN NN O
utilized NN NN O
by NN NN O
mammalian NN NN O
oncogenic NN NN O
viruses NN NN O
to NN NN O
affect NN NN O
the NN NN O
activity NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
viral NN NN O
gene NN NN O
expression NN NN O
and NN NN O
replication NN NN O
. NN NN O
   
Abnormal NN NN O
apoptosis NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
in NN NN O
humans NN NN O
exposed NN NN O
to NN NN O
methyl NN NN O
tertiary NN NN O
- NN NN O
butyl NN NN O
ether NN NN O
and NN NN O
benzene NN NN O
contaminating NN NN O
water NN NN O
. NN NN O
   
1 NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
in NN NN O
individuals NN NN O
with NN NN O
certain NN NN O
genetic NN NN O
makeup NN NN O
, NN NN O
MTBE NN NN O
, NN NN O
benzene NN NN O
or NN NN O
their NN NN O
metabolites NN NN O
act NN NN O
as NN NN O
adducts NN NN O
and NN NN O
may NN NN O
induce NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
2 NN NN O
. NN NN O
   
Our NN NN O
study NN NN O
involved NN NN O
a NN NN O
group NN NN O
of NN NN O
60 NN NN O
male NN NN O
and NN NN O
female NN NN O
subjects NN NN O
who NN NN O
were NN NN O
exposed NN NN O
to NN NN O
MTBE NN NN O
and NN NN O
benzene NN NN O
- NN NN O
contaminated NN NN O
water NN NN O
concentrations NN NN O
up NN NN O
to NN NN O
76 NN NN O
PPB NN NN O
for NN NN O
MTBE NN NN O
and NN NN O
14 NN NN O
PPB NN NN O
for NN NN O
benzene NN NN O
, NN NN O
for NN NN O
a NN NN O
period NN NN O
of NN NN O
5 NN NN O
to NN NN O
8 NN NN O
years NN NN O
. NN NN O
   
For NN NN O
comparison NN NN O
, NN NN O
we NN NN O
recruited NN NN O
a NN NN O
control NN NN O
group NN NN O
consisting NN NN O
of NN NN O
32 NN NN O
healthy NN NN O
males NN NN O
and NN NN O
females NN NN O
with NN NN O
similar NN NN O
age NN NN O
distribution NN NN O
and NN NN O
without NN NN O
a NN NN O
history NN NN O
of NN NN O
exposure NN NN O
to NN NN O
MTBE NN NN O
or NN NN O
benzene NN NN O
. NN NN O
   
3 NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
of NN NN O
both NN NN O
groups NN NN O
were NN NN O
tested NN NN O
for NN NN O
the NN NN O
percentage NN NN O
of NN NN O
apoptotic NN NN O
cells NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
using NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
4 NN NN O
. NN NN O
   
When NN NN O
apoptotic NN NN O
lymphocytes NN NN O
from NN NN O
exposed NN NN O
individuals NN NN O
were NN NN O
compared NN NN O
to NN NN O
apoptotic NN NN O
lymphocytes NN NN O
from NN NN O
the NN NN O
control NN NN O
group NN NN O
, NN NN O
statistically NN NN O
- NN NN O
significant NN NN O
differences NN NN O
between NN NN O
each NN NN O
mean NN NN O
group NN NN O
were NN NN O
detected NN NN O
( NN NN O
26 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
8 NN NN O
and NN NN O
12 NN NN O
. NN NN O
1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
3 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
, NN NN O
indicating NN NN O
an NN NN O
increased NN NN O
rate NN NN O
of NN NN O
apoptosis NN NN O
in NN NN O
80 NN NN O
. NN NN O
5 NN NN O
% NN NN O
of NN NN O
exposed NN NN O
individuals NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
0001 NN NN O
, NN NN O
Mann NN NN O
- NN NN O
Whitney NN NN O
U NN NN O
- NN NN O
Test NN NN O
) NN NN O
. NN NN O
   
MTBE NN NN O
and NN NN O
benzene NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
is NN NN O
attributed NN NN O
to NN NN O
a NN NN O
discrete NN NN O
block NN NN O
within NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
Because NN NN O
cell NN NN O
cycle NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
in NN NN O
PBL NN NN O
from NN NN O
chemically NN NN O
- NN NN O
exposed NN NN O
individuals NN NN O
, NN NN O
between NN NN O
20 NN NN O
- NN NN O
50 NN NN O
% NN NN O
of NN NN O
cells NN NN O
were NN NN O
accumulated NN NN O
at NN NN O
the NN NN O
S NN NN O
- NN NN O
G2 NN NN O
/ NN NN O
M NN NN O
boundaries NN NN O
. NN NN O
   
5 NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
signaling NN NN O
molecules NN NN O
which NN NN O
mediates NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
is NN NN O
nuclear NN NN O
factor NN NN O
Kappa NN NN O
- NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
examined NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
many NN NN O
molecular NN NN O
mechanisms NN NN O
for NN NN O
mediating NN NN O
cell NN NN O
death NN NN O
by NN NN O
MTBE NN NN O
and NN NN O
benzene NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
addition NN NN O
of NN NN O
inhibitors NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
, NN NN O
to NN NN O
the NN NN O
lymphocytes NN NN O
of NN NN O
the NN NN O
chemically NN NN O
- NN NN O
exposed NN NN O
group NN NN O
was NN NN O
capable NN NN O
of NN NN O
inhibiting NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
by NN NN O
40 NN NN O
% NN NN O
. NN NN O
   
This NN NN O
reversal NN NN O
of NN NN O
apoptosis NN NN O
almost NN NN O
to NN NN O
the NN NN O
control NN NN O
level NN NN O
by NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
may NN NN O
indicate NN NN O
involvement NN NN O
of NN NN O
this NN NN O
signaling NN NN O
molecule NN NN O
in NN NN O
MTBE NN NN O
and NN NN O
benzene NN NN O
induction NN NN O
of NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
a NN NN O
novel NN NN O
gene NN NN O
in NN NN O
3q21 NN NN O
and NN NN O
identification NN NN O
of NN NN O
intergenic NN NN O
fusion NN NN O
transcripts NN NN O
with NN NN O
ecotropic NN NN O
viral NN NN O
insertion NN NN O
site NN NN O
I NN NN O
in NN NN O
leukemia NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
novel NN NN O
gene NN NN O
, NN NN O
GR6 NN NN B-Protein
, NN NN O
located NN NN O
within NN NN O
the NN NN O
leukemia NN NN O
breakpoint NN NN O
region NN NN O
of NN NN O
3q21 NN NN O
, NN NN O
that NN NN O
is NN NN O
normally NN NN O
expressed NN NN O
in NN NN O
early NN NN O
fetal NN NN O
development NN NN O
but NN NN O
not NN NN O
in NN NN O
adult NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O
   
GR6 NN NN B-Protein
is NN NN O
activated NN NN O
in NN NN O
the NN NN O
UCSD NN NN O
- NN NN O
AML1 NN NN O
cell NN NN O
line NN NN O
and NN NN O
in NN NN O
a NN NN O
leukemic NN NN O
sample NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
carry NN NN O
a NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
3 NN NN O
) NN NN O
( NN NN O
q21 NN NN O
; NN NN O
q26 NN NN O
) NN NN O
. NN NN O
   
In NN NN O
UCSD NN NN O
- NN NN O
AML1 NN NN O
, NN NN O
we NN NN O
have NN NN O
also NN NN O
identified NN NN O
fusion NN NN O
transcripts NN NN O
between NN NN O
the NN NN O
ecotropic NN NN B-Protein
viral NN NN I-Protein
insertion NN NN I-Protein
site NN NN I-Protein
I NN NN I-Protein
( NN NN O
EVI1 NN NN B-Protein
) NN NN O
gene NN NN O
in NN NN O
3q26 NN NN O
and NN NN O
GR6 NN NN B-Protein
and NN NN O
between NN NN O
EVI1 NN NN B-Protein
and NN NN O
Ribophorin NN NN B-Protein
I NN NN I-Protein
that NN NN O
maps NN NN O
30 NN NN O
kb NN NN O
telomeric NN NN O
to NN NN O
GR6 NN NN B-Protein
in NN NN O
3q21 NN NN O
. NN NN O
   
All NN NN O
fusions NN NN O
splice NN NN O
the NN NN O
5 NN NN O
' NN NN O
ends NN NN O
of NN NN O
the NN NN O
3q21 NN NN O
genes NN NN O
into NN NN O
exon NN NN O
2 NN NN O
of NN NN O
the NN NN O
EVI1 NN NN B-Protein
gene NN NN O
, NN NN O
an NN NN O
event NN NN O
that NN NN O
is NN NN O
similar NN NN O
to NN NN O
the NN NN O
normal NN NN O
intergenic NN NN O
splicing NN NN O
of NN NN O
MDS1 NN NN B-Protein
- NN NN O
EVI1 NN NN B-Protein
and NN NN O
to NN NN O
those NN NN O
previously NN NN O
documented NN NN O
in NN NN O
leukemias NN NN O
with NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
21 NN NN O
) NN NN O
and NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
12 NN NN O
) NN NN O
, NN NN O
in NN NN O
which NN NN O
acute NN NN B-Protein
myelogenous NN NN I-Protein
leukemia NN NN I-Protein
1 NN NN I-Protein
- NN NN O
EVI1 NN NN B-Protein
fusions NN NN O
and NN NN O
ETV6 NN NN B-Protein
- NN NN O
EVI1 NN NN B-Protein
fusions NN NN O
, NN NN O
respectively NN NN O
, NN NN O
occur NN NN O
. NN NN O
   
The NN NN O
Ribophorin NN NN B-Protein
I NN NN I-Protein
- NN NN O
EVI1 NN NN B-Protein
fusion NN NN O
in NN NN O
particular NN NN O
may NN NN O
be NN NN O
a NN NN O
common NN NN O
occurrence NN NN O
in NN NN O
t NN NN O
( NN NN O
3 NN NN O
; NN NN O
3 NN NN O
) NN NN O
. NN NN O
   
Alcohol NN NN O
- NN NN O
induced NN NN O
regulation NN NN O
of NN NN O
nuclear NN NN O
regulatory NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
beta NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Acute NN NN O
ethanol NN NN O
exposure NN NN O
has NN NN O
the NN NN O
capacity NN NN O
to NN NN O
modulate NN NN O
immune NN NN O
functions NN NN O
, NN NN O
particularly NN NN O
, NN NN O
to NN NN O
down NN NN O
regulate NN NN O
monocyte NN NN O
production NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
intracellular NN NN O
mechanisms NN NN O
for NN NN O
these NN NN O
effects NN NN O
of NN NN O
ethanol NN NN O
are NN NN O
yet NN NN O
to NN NN O
be NN NN O
understood NN NN O
. NN NN O
   
Considering NN NN O
that NN NN O
nuclear NN NN O
regulatory NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
beta NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
/ NN NN O
Rel NN NN O
is NN NN O
a NN NN O
common NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
inflammatory NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
herein NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
acute NN NN O
ethanol NN NN O
affects NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Adherence NN NN O
- NN NN O
isolated NN NN O
monocytes NN NN O
showed NN NN O
constitutive NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
A NN NN O
clinically NN NN O
relevant NN NN O
dose NN NN O
( NN NN O
25 NN NN O
mM NN NN O
) NN NN O
of NN NN O
acute NN NN O
ethanol NN NN O
treatment NN NN O
in NN NN O
vitro NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
in NN NN O
monocytes NN NN O
with NN NN O
a NN NN O
preferential NN NN O
induction NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
, NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
homodimer NN NN O
, NN NN O
and NN NN O
resulted NN NN O
in NN NN O
no NN NN O
induction NN NN O
of NN NN O
the NN NN O
p65 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
heterodimer NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
lipopolysaccharide NN NN O
stimulation NN NN O
primarily NN NN O
induced NN NN O
the NN NN O
p65 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
heterodimer NN NN O
that NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
result NN NN O
in NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
such NN NN O
unique NN NN O
activation NN NN O
of NN NN O
the NN NN O
inhibitory NN NN O
p50 NN NN B-Protein
/ NN NN O
p50 NN NN B-Protein
homodimer NN NN O
by NN NN O
acute NN NN O
ethanol NN NN O
treatment NN NN O
may NN NN O
result NN NN O
in NN NN O
inhibition NN NN O
rather NN NN O
than NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
regulated NN NN O
inflammatory NN NN O
cytokine NN NN O
genes NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
these NN NN O
results NN NN O
suggest NN NN O
that NN NN O
physiologically NN NN O
relevant NN NN O
concentrations NN NN O
of NN NN O
ethanol NN NN O
may NN NN O
affect NN NN O
production NN NN O
of NN NN O
inflammatory NN NN O
cytokines NN NN O
, NN NN O
such NN NN O
as NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
and NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
by NN NN O
disrupting NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
signaling NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Four NN NN O
P NN NN O
- NN NN O
like NN NN O
elements NN NN O
are NN NN O
required NN NN O
for NN NN O
optimal NN NN O
transcription NN NN O
of NN NN O
the NN NN O
mouse NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
: NN NN O
involvement NN NN O
of NN NN O
a NN NN O
distinct NN NN O
set NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
family NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
identified NN NN O
the NN NN O
P NN NN O
sequence NN NN O
as NN NN O
a NN NN O
critical NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
the NN NN O
mouse NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
, NN NN O
there NN NN O
are NN NN O
five NN NN O
elements NN NN O
homologous NN NN O
to NN NN O
the NN NN O
human NN NN O
P NN NN O
sequence NN NN O
designated NN NN O
conserved NN NN O
lymphokine NN NN O
element NN NN O
0 NN NN O
( NN NN O
CLE0 NN NN O
) NN NN O
, NN NN O
P NN NN O
, NN NN O
P2 NN NN O
, NN NN O
P3 NN NN O
and NN NN O
P4 NN NN O
. NN NN O
   
To NN NN O
characterize NN NN O
the NN NN O
role NN NN O
of NN NN O
these NN NN O
P NN NN O
- NN NN O
like NN NN O
elements NN NN O
and NN NN O
their NN NN O
binding NN NN O
factors NN NN O
in NN NN O
the NN NN O
native NN NN O
promoter NN NN O
, NN NN O
we NN NN O
did NN NN O
transient NN NN O
transfection NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSA NN NN O
) NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
with NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
- NN NN O
reporter NN NN O
constructs NN NN O
carrying NN NN O
mutated NN NN O
P NN NN O
- NN NN O
like NN NN O
elements NN NN O
showed NN NN O
that NN NN O
four NN NN O
P NN NN O
- NN NN O
like NN NN O
elements NN NN O
, NN NN O
CLE0 NN NN O
, NN NN O
P NN NN O
, NN NN O
P2 NN NN O
and NN NN O
P4 NN NN O
, NN NN O
but NN NN O
not NN NN O
P3 NN NN O
, NN NN O
were NN NN O
required NN NN O
for NN NN O
optimal NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
EMSA NN NN O
showed NN NN O
that NN NN O
both NN NN O
constitutive NN NN O
and NN NN O
inducible NN NN O
complexes NN NN O
bound NN NN O
to NN NN O
CLE0 NN NN O
, NN NN O
P NN NN O
, NN NN O
P2 NN NN O
and NN NN O
P4 NN NN O
, NN NN O
whereas NN NN O
only NN NN O
a NN NN O
constitutive NN NN O
complex NN NN O
bound NN NN O
to NN NN O
P3 NN NN O
. NN NN O
   
In NN NN O
competition NN NN O
and NN NN O
antibody NN NN O
supershift NN NN O
assays NN NN O
in NN NN O
EMSA NN NN O
, NN NN O
complexes NN NN O
formed NN NN O
with NN NN O
P NN NN O
or NN NN O
P2 NN NN O
proved NN NN O
to NN NN O
contain NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
family NN NN O
proteins NN NN O
as NN NN O
major NN NN O
components NN NN O
. NN NN O
   
Activator NN NN O
protein NN NN O
( NN NN O
AP NN NN O
) NN NN O
- NN NN O
1 NN NN O
family NN NN O
proteins NN NN O
interacted NN NN O
with NN NN O
CLE0 NN NN O
, NN NN O
P NN NN O
, NN NN O
P2 NN NN O
and NN NN O
P4 NN NN O
. NN NN O
   
NFAT NN NN O
/ NN NN O
AP NN NN O
- NN NN O
1 NN NN O
complex NN NN O
formed NN NN O
only NN NN O
with NN NN O
P NN NN O
and NN NN O
P2 NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
competition NN NN O
assays NN NN O
among NN NN O
the NN NN O
P NN NN O
- NN NN O
like NN NN O
elements NN NN O
revealed NN NN O
element NN NN O
- NN NN O
specific NN NN O
and NN NN O
common NN NN O
complexes NN NN O
. NN NN O
   
Six NN NN O
tandem NN NN O
repeats NN NN O
of NN NN O
the NN NN O
P NN NN O
element NN NN O
linked NN NN O
to NN NN O
the NN NN O
SV40 NN NN O
promoter NN NN O
responded NN NN O
to NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
, NN NN O
while NN NN O
that NN NN O
of NN NN O
other NN NN O
elements NN NN O
did NN NN O
not NN NN O
. NN NN O
   
It NN NN O
would NN NN O
thus NN NN O
appear NN NN O
that NN NN O
components NN NN O
of NN NN O
each NN NN O
P NN NN O
- NN NN O
like NN NN O
element NN NN O
- NN NN O
binding NN NN O
complexes NN NN O
are NN NN O
not NN NN O
identical NN NN O
and NN NN O
may NN NN O
coordinately NN NN O
contribute NN NN O
to NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
BHRF1 NN NN B-Protein
to NN NN O
inhibit NN NN O
apoptosis NN NN O
is NN NN O
dependent NN NN O
on NN NN O
stimulus NN NN O
and NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
The NN NN O
development NN NN O
of NN NN O
resistance NN NN O
to NN NN O
host NN NN O
defense NN NN O
mechanisms NN NN O
such NN NN O
as NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
- NN NN O
and NN NN O
Fas NN NN B-Protein
- NN NN O
mediated NN NN O
apoptosis NN NN O
of NN NN O
transformed NN NN O
or NN NN O
virus NN NN O
- NN NN O
infected NN NN O
cells NN NN O
may NN NN O
be NN NN O
a NN NN O
critical NN NN O
component NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
disease NN NN O
. NN NN O
   
To NN NN O
find NN NN O
genes NN NN O
that NN NN O
protect NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
, NN NN O
we NN NN O
used NN NN O
an NN NN O
expression NN NN O
cloning NN NN O
strategy NN NN O
and NN NN O
identified NN NN O
BHRF1 NN NN B-Protein
, NN NN O
an NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
early NN NN O
- NN NN O
lytic NN NN O
- NN NN O
cycle NN NN O
protein NN NN O
with NN NN O
distant NN NN O
homology NN NN O
to NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
as NN NN O
an NN NN O
anti NN NN O
- NN NN O
apoptosis NN NN O
protein NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
BHRF1 NN NN B-Protein
in NN NN O
MCF NN NN O
- NN NN O
Fas NN NN O
cells NN NN O
conferred NN NN O
nearly NN NN O
complete NN NN O
resistance NN NN O
against NN NN O
both NN NN O
anti NN NN O
- NN NN O
Fas NN NN B-Protein
antibody NN NN O
and NN NN O
TNF NN NN O
- NN NN O
mediated NN NN O
apoptosis NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
BHRF1 NN NN B-Protein
protected NN NN O
these NN NN O
cells NN NN O
from NN NN O
monocyte NN NN O
- NN NN O
mediated NN NN O
killing NN NN O
but NN NN O
failed NN NN O
to NN NN O
protect NN NN O
them NN NN O
from NN NN O
killing NN NN O
mediated NN NN O
by NN NN O
lymphokine NN NN O
- NN NN O
activated NN NN O
killer NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
BHRF1 NN NN B-Protein
to NN NN O
protect NN NN O
MCF NN NN O
- NN NN O
Fas NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
various NN NN O
stimuli NN NN O
was NN NN O
identical NN NN O
to NN NN O
that NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
. NN NN O
   
Moreover NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
BHRF1 NN NN B-Protein
resembled NN NN O
that NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
xL NN NN I-Protein
as NN NN O
it NN NN O
inhibited NN NN O
TNF NN NN O
- NN NN O
and NN NN O
anti NN NN O
- NN NN O
Fas NN NN B-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
two NN NN O
enzymes NN NN O
participating NN NN O
in NN NN O
the NN NN O
apoptosis NN NN O
pathway NN NN O
, NN NN O
cytosolic NN NN B-Protein
phospholipase NN NN I-Protein
A2 NN NN I-Protein
and NN NN O
caspase NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
/ NN NN O
CPP32 NN NN B-Protein
, NN NN O
but NN NN O
did NN NN O
not NN NN O
interfere NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
like NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
A NN NN O
putative NN NN O
function NN NN O
of NN NN O
BHRF1 NN NN B-Protein
in NN NN O
EBV NN NN O
- NN NN O
infected NN NN O
epithelial NN NN O
cells NN NN O
may NN NN O
be NN NN O
to NN NN O
protect NN NN O
virus NN NN O
- NN NN O
infected NN NN O
cells NN NN O
from NN NN O
TNF NN NN O
- NN NN O
and NN NN O
/ NN NN O
or NN NN O
anti NN NN O
- NN NN O
Fas NN NN B-Protein
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
in NN NN O
order NN NN O
to NN NN O
maximize NN NN O
virus NN NN O
production NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
expression NN NN O
of NN NN O
neither NN NN O
BHRF1 NN NN B-Protein
nor NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
line NN NN O
, NN NN O
BJAB NN NN O
, NN NN O
protected NN NN O
the NN NN O
cells NN NN O
from NN NN O
anti NN NN O
- NN NN O
Fas NN NN B-Protein
- NN NN O
mediated NN NN O
apoptosis NN NN O
even NN NN O
though NN NN O
they NN NN O
increased NN NN O
the NN NN O
survival NN NN O
of NN NN O
serum NN NN O
- NN NN O
starved NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
protective NN NN O
role NN NN O
of NN NN O
BHRF1 NN NN B-Protein
against NN NN O
apoptosis NN NN O
resembles NN NN O
that NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
being NN NN O
cell NN NN O
type NN NN O
specific NN NN O
and NN NN O
dependent NN NN O
on NN NN O
the NN NN O
apoptotic NN NN O
stimulus NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
AT NN NN O
activation NN NN O
induced NN NN O
by NN NN O
a NN NN O
CAML NN NN B-Protein
- NN NN O
interacting NN NN O
member NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
receptor NN NN O
superfamily NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
NF NN NN O
- NN NN O
AT NN NN O
) NN NN O
is NN NN O
a NN NN O
key NN NN O
event NN NN O
underlying NN NN O
lymphocyte NN NN O
action NN NN O
. NN NN O
   
The NN NN O
CAML NN NN B-Protein
( NN NN O
calcium NN NN B-Protein
- NN NN I-Protein
modulator NN NN I-Protein
and NN NN I-Protein
cyclophilin NN NN I-Protein
ligand NN NN I-Protein
) NN NN O
protein NN NN O
is NN NN O
a NN NN O
coinducer NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
activation NN NN O
when NN NN O
overexpressed NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
member NN NN O
of NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
receptor NN NN O
superfamily NN NN O
was NN NN O
isolated NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
affinity NN NN O
for NN NN O
CAML NN NN B-Protein
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
this NN NN O
lymphocyte NN NN O
- NN NN O
specific NN NN O
protein NN NN O
, NN NN O
designated NN NN O
TACI NN NN B-Protein
( NN NN O
transmembrane NN NN B-Protein
activator NN NN I-Protein
and NN NN I-Protein
CAML NN NN I-Protein
- NN NN I-Protein
interactor NN NN I-Protein
) NN NN O
, NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
transfected NN NN O
Jurkat NN NN O
cells NN NN O
with NN NN O
TACI NN NN B-Protein
- NN NN O
specific NN NN O
antibodies NN NN O
led NN NN O
to NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NFkappaB NN NN O
. NN NN O
   
TACI NN NN B-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
AT NN NN O
was NN NN O
specifically NN NN O
blocked NN NN O
by NN NN O
a NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
CAML NN NN B-Protein
mutant NN NN O
, NN NN O
thus NN NN O
implicating NN NN O
CAML NN NN B-Protein
as NN NN O
a NN NN O
signaling NN NN O
intermediate NN NN O
. NN NN O
   
The NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
transcription NN NN O
factor NN NN O
is NN NN O
responsible NN NN O
for NN NN O
its NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
activity NN NN O
and NN NN O
binds NN NN O
to NN NN O
a NN NN O
B NN NN O
cell NN NN O
110 NN NN O
- NN NN O
kDa NN NN O
nuclear NN NN O
protein NN NN O
. NN NN O
   
Expression NN NN O
studies NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
use NN NN O
of NN NN O
transgenic NN NN O
animals NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
transcription NN NN O
factor NN NN O
plays NN NN O
central NN NN O
and NN NN O
specific NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
mature NN NN O
B NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
/ NN NN O
or NN NN O
differentiation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
it NN NN O
is NN NN O
highly NN NN O
expressed NN NN O
in NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
cells NN NN O
and NN NN O
may NN NN O
participate NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
this NN NN O
disease NN NN O
. NN NN O
   
We NN NN O
have NN NN O
therefore NN NN O
investigated NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
and NN NN O
its NN NN O
regulation NN NN O
in NN NN O
several NN NN O
human NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
using NN NN O
co NN NN O
- NN NN O
transfection NN NN O
assays NN NN O
and NN NN O
show NN NN O
that NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
is NN NN O
transcriptionally NN NN O
active NN NN O
in NN NN O
all NN NN O
the NN NN O
B NN NN O
cell NN NN O
lines NN NN O
studied NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
the NN NN O
best NN NN O
responder NN NN O
cell NN NN O
line NN NN O
was NN NN O
the NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
cell NN NN O
line NN NN O
Namalwa NN NN O
. NN NN O
   
The NN NN O
activity NN NN O
of NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
in NN NN O
B NN NN O
and NN NN O
not NN NN O
T NN NN O
cells NN NN O
was NN NN O
observed NN NN O
when NN NN O
either NN NN O
an NN NN O
artificial NN NN O
construct NN NN O
or NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
MYC NN NN I-Protein
promoter NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
reporter NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
functional NN NN O
domains NN NN O
responsible NN NN O
for NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
transactivation NN NN O
, NN NN O
and NN NN O
negative NN NN O
regulation NN NN O
, NN NN O
previously NN NN O
characterized NN NN O
in NN NN O
a NN NN O
fibroblast NN NN O
context NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
similar NN NN O
activity NN NN O
in NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
region NN NN O
of NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
responsible NN NN O
for NN NN O
the NN NN O
B NN NN O
cell NN NN O
specific NN NN O
activity NN NN O
was NN NN O
defined NN NN O
to NN NN O
be NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
218 NN NN O
amino NN NN O
acids NN NN O
containing NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
a NN NN O
110 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
all NN NN O
the NN NN O
B NN NN O
, NN NN O
but NN NN O
not NN NN O
T NN NN O
, NN NN O
cell NN NN O
lines NN NN O
that NN NN O
specifically NN NN O
binds NN NN O
to NN NN O
this NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
this NN NN O
110 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
may NN NN O
be NN NN O
a NN NN O
functionally NN NN O
important NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
co NN NN O
- NN NN O
activator NN NN O
of NN NN O
A NN NN B-Protein
- NN NN I-Protein
MYB NN NN I-Protein
. NN NN O
   
Evidence NN NN O
that NN NN O
calcineurin NN NN O
is NN NN O
rate NN NN O
- NN NN O
limiting NN NN O
for NN NN O
primary NN NN O
human NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O
   
Cyclosporine NN NN O
( NN NN O
CsA NN NN O
) NN NN O
is NN NN O
both NN NN O
a NN NN O
clinical NN NN O
immunosuppressive NN NN O
drug NN NN O
and NN NN O
a NN NN O
probe NN NN O
to NN NN O
dissect NN NN O
intracellular NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
CsA NN NN O
inhibits NN NN O
lymphocyte NN NN O
gene NN NN O
activation NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
phosphatase NN NN O
activity NN NN O
of NN NN O
calcineurin NN NN O
( NN NN O
CN NN NN O
) NN NN O
. NN NN O
   
In NN NN O
clinical NN NN O
use NN NN O
, NN NN O
CsA NN NN O
treatment NN NN O
inhibits NN NN O
50 NN NN O
- NN NN O
75 NN NN O
% NN NN O
of NN NN O
CN NN NN O
activity NN NN O
in NN NN O
circulating NN NN O
leukocytes NN NN O
. NN NN O
   
We NN NN O
modeled NN NN O
this NN NN O
degree NN NN O
of NN NN O
CN NN NN O
inhibition NN NN O
in NN NN O
primary NN NN O
human NN NN O
leukocytes NN NN O
in NN NN O
vitro NN NN O
in NN NN O
order NN NN O
to NN NN O
study NN NN O
the NN NN O
effect NN NN O
of NN NN O
partial NN NN O
CN NN NN O
inhibition NN NN O
on NN NN O
the NN NN O
downstream NN NN O
signaling NN NN O
events NN NN O
that NN NN O
lead NN NN O
to NN NN O
gene NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
CsA NN NN O
- NN NN O
treated NN NN O
leukocytes NN NN O
stimulated NN NN O
by NN NN O
calcium NN NN O
ionophore NN NN O
, NN NN O
the NN NN O
degree NN NN O
of NN NN O
reduction NN NN O
in NN NN O
CN NN NN O
activity NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
similar NN NN O
degree NN NN O
of NN NN O
inhibition NN NN O
of NN NN O
each NN NN O
event NN NN O
tested NN NN O
: NN NN O
dephosphorylation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cell NN NN O
proteins NN NN O
, NN NN O
nuclear NN NN O
DNA NN NN O
binding NN NN O
, NN NN O
activation NN NN O
of NN NN O
a NN NN O
transfected NN NN O
reporter NN NN O
gene NN NN O
construct NN NN O
, NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
, NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
the NN NN O
degree NN NN O
of NN NN O
CN NN NN O
inhibition NN NN O
was NN NN O
reflected NN NN O
by NN NN O
a NN NN O
similar NN NN O
degree NN NN O
of NN NN O
reduction NN NN O
in NN NN O
lymphocyte NN NN O
proliferation NN NN O
and NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
production NN NN O
in NN NN O
the NN NN O
allogeneic NN NN O
mixed NN NN O
lymphocyte NN NN O
cultures NN NN O
. NN NN O
   
These NN NN O
data NN NN O
support NN NN O
the NN NN O
conclusion NN NN O
that NN NN O
CN NN NN O
activity NN NN O
is NN NN O
rate NN NN O
- NN NN O
limiting NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
primary NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
reduction NN NN O
of NN NN O
CN NN NN O
activity NN NN O
observed NN NN O
in NN NN O
CsA NN NN O
- NN NN O
treated NN NN O
patients NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
similar NN NN O
degree NN NN O
of NN NN O
reduction NN NN O
in NN NN O
lymphocyte NN NN O
gene NN NN O
activation NN NN O
, NN NN O
and NN NN O
accounts NN NN O
for NN NN O
the NN NN O
immunosuppression NN NN O
observed NN NN O
. NN NN O
   
Cooperation NN NN O
of NN NN O
binding NN NN O
sites NN NN O
for NN NN O
STAT6 NN NN B-Protein
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
rel NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
IgE NN NN B-Protein
germline NN NN O
promoter NN NN O
. NN NN O
   
Ig NN NN O
heavy NN NN O
chain NN NN O
class NN NN O
switching NN NN O
is NN NN O
directed NN NN O
by NN NN O
cytokines NN NN O
inducing NN NN O
transcription NN NN O
from NN NN O
unrearranged NN NN O
CH NN NN O
genes NN NN O
. NN NN O
   
Subsequently NN NN O
, NN NN O
such NN NN O
primed NN NN O
cells NN NN O
can NN NN O
undergo NN NN O
switch NN NN O
recombination NN NN O
to NN NN O
express NN NN O
the NN NN O
selected NN NN O
new NN NN O
isotype NN NN O
. NN NN O
   
In NN NN O
the NN NN O
case NN NN O
of NN NN O
IgE NN NN O
class NN NN O
switching NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
activates NN NN O
the NN NN O
IgE NN NN O
germline NN NN O
promoter NN NN O
by NN NN O
inducing NN NN O
the NN NN O
interaction NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
STAT6 NN NN B-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4STAT NN NN I-Protein
) NN NN O
with NN NN O
a NN NN O
responsive NN NN O
DNA NN NN O
element NN NN O
in NN NN O
the NN NN O
proximal NN NN O
region NN NN O
of NN NN O
the NN NN O
promoter NN NN O
. NN NN O
   
This NN NN O
study NN NN O
describes NN NN O
the NN NN O
characterization NN NN O
of NN NN O
two NN NN O
additional NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
that NN NN O
interact NN NN O
with NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
rel NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
in NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
independent NN NN O
fashion NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
show NN NN O
that NN NN O
the NN NN O
nucleoprotein NN NN O
complex NN NN O
formed NN NN O
on NN NN O
the NN NN O
upstream NN NN O
site NN NN O
( NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
) NN NN O
contains NN NN O
the NN NN O
classical NN NN O
p50 NN NN B-Protein
/ NN NN O
p65 NN NN B-Protein
heterodimer NN NN O
. NN NN O
   
The NN NN O
complex NN NN O
on NN NN O
the NN NN O
proximal NN NN O
site NN NN O
( NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
) NN NN O
appears NN NN O
to NN NN O
be NN NN O
composed NN NN O
of NN NN O
p50 NN NN B-Protein
and NN NN O
relB NN NN B-Protein
. NN NN O
   
IgE NN NN O
germline NN NN O
promoter NN NN O
reporter NN NN O
gene NN NN O
constructs NN NN O
carrying NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
site NN NN O
were NN NN O
largely NN NN O
unresponsive NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
stimulation NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
, NN NN O
while NN NN O
plasmids NN NN O
with NN NN O
similar NN NN O
mutations NN NN O
in NN NN O
the NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
site NN NN O
responded NN NN O
to NN NN O
cytokine NN NN O
stimulation NN NN O
better NN NN O
than NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
effect NN NN O
was NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
STAT6 NN NN B-Protein
binding NN NN O
site NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
the NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
motif NN NN O
is NN NN O
necessary NN NN O
but NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
mediating NN NN O
cytokine NN NN O
up NN NN O
- NN NN O
regulation NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
combination NN NN O
of NN NN O
a NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
rel NN NN O
binding NN NN O
site NN NN O
and NN NN O
the NN NN O
STAT6 NN NN B-Protein
response NN NN O
element NN NN O
conferred NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
inducibility NN NN O
to NN NN O
a NN NN O
heterologous NN NN O
minimal NN NN O
promoter NN NN O
, NN NN O
while NN NN O
the NN NN O
individual NN NN O
sites NN NN O
had NN NN O
no NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
available NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
NF NN NN B-Protein
kappa NN NN I-Protein
B2 NN NN I-Protein
nucleoprotein NN NN O
complex NN NN O
may NN NN O
cooperate NN NN O
with NN NN O
DNA NN NN O
- NN NN O
bound NN NN O
STAT6 NN NN B-Protein
to NN NN O
achieve NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
IgE NN NN O
germline NN NN O
gene NN NN O
. NN NN O
   
Dual NN NN O
effects NN NN O
of NN NN O
LPS NN NN O
antibodies NN NN O
on NN NN O
cellular NN NN O
uptake NN NN O
of NN NN O
LPS NN NN O
and NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
proinflammatory NN NN O
functions NN NN O
. NN NN O
   
Human NN NN O
phagocytes NN NN O
recognize NN NN O
bacterial NN NN O
LPS NN NN O
( NN NN O
endotoxin NN NN O
) NN NN O
through NN NN O
membrane NN NN O
CD14 NN NN B-Protein
( NN NN O
mCD14 NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
proinflammatory NN NN O
LPS NN NN O
receptor NN NN O
. NN NN O
   
This NN NN O
study NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
anti NN NN O
- NN NN O
LPS NN NN O
Abs NN NN O
neutralize NN NN O
endotoxin NN NN O
by NN NN O
blocking NN NN O
cellular NN NN O
uptake NN NN O
through NN NN O
mCD14 NN NN B-Protein
. NN NN O
   
Ab NN NN O
- NN NN O
associated NN NN O
changes NN NN O
in NN NN O
the NN NN O
uptake NN NN O
and NN NN O
cellular NN NN O
distribution NN NN O
of NN NN O
FITC NN NN O
- NN NN O
LPS NN NN O
were NN NN O
assessed NN NN O
by NN NN O
flow NN NN O
cytometry NN NN O
and NN NN O
laser NN NN O
scanning NN NN O
confocal NN NN O
microscopy NN NN O
in NN NN O
human NN NN O
CD14 NN NN B-Protein
- NN NN O
transfected NN NN O
Chinese NN NN O
hamster NN NN O
ovary NN NN O
fibroblasts NN NN O
( NN NN O
CHO NN NN O
- NN NN O
CD14 NN NN B-Protein
cells NN NN O
) NN NN O
and NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
. NN NN O
   
LPS NN NN O
core NN NN O
- NN NN O
and NN NN O
O NN NN O
- NN NN O
side NN NN O
chain NN NN O
- NN NN O
specific NN NN O
mAbs NN NN O
inhibited NN NN O
mCD14 NN NN B-Protein
- NN NN O
mediated NN NN O
LPS NN NN O
uptake NN NN O
by NN NN O
both NN NN O
cell NN NN O
types NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
serum NN NN O
. NN NN O
   
O NN NN O
- NN NN O
side NN NN O
chain NN NN O
- NN NN O
specific NN NN O
mAb NN NN O
concurrently NN NN O
enhanced NN NN O
complement NN NN O
- NN NN O
dependent NN NN O
LPS NN NN O
uptake NN NN O
by NN NN O
monocytes NN NN O
through NN NN O
complement NN NN B-Protein
receptor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
CR1 NN NN B-Protein
) NN NN O
and NN NN O
uptake NN NN O
by NN NN O
CHO NN NN O
- NN NN O
CD14 NN NN B-Protein
cells NN NN O
involving NN NN O
another NN NN O
heat NN NN O
- NN NN O
labile NN NN O
serum NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
and NN NN O
cell NN NN O
- NN NN O
associated NN NN O
recognition NN NN O
molecule NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O
   
Core NN NN O
- NN NN O
specific NN NN O
mAb NN NN O
inhibited NN NN O
mCD14 NN NN B-Protein
- NN NN O
mediated NN NN O
uptake NN NN O
of NN NN O
homologous NN NN O
and NN NN O
heterologous NN NN O
LPS NN NN O
, NN NN O
while NN NN O
producing NN NN O
less NN NN O
concurrent NN NN O
enhancement NN NN O
of NN NN O
non NN NN O
- NN NN O
mCD14 NN NN B-Protein
- NN NN O
mediated NN NN O
LPS NN NN O
uptake NN NN O
. NN NN O
   
The NN NN O
modulation NN NN O
by NN NN O
anti NN NN O
- NN NN O
LPS NN NN O
mAbs NN NN O
of NN NN O
mCD14 NN NN B-Protein
- NN NN O
mediated NN NN O
LPS NN NN O
uptake NN NN O
was NN NN O
associated NN NN O
with NN NN O
inhibition NN NN O
of NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
translocation NN NN O
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
in NN NN O
CHO NN NN O
- NN NN O
CD14 NN NN B-Protein
cells NN NN O
and NN NN O
monocytes NN NN O
, NN NN O
respectively NN NN O
, NN NN O
while NN NN O
mAb NN NN O
enhancement NN NN O
of NN NN O
non NN NN O
- NN NN O
mCD14 NN NN B-Protein
- NN NN O
mediated NN NN O
LPS NN NN O
uptake NN NN O
stimulated NN NN O
these NN NN O
activities NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
specific NN NN O
Abs NN NN O
thus NN NN O
mediate NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
and NN NN O
proinflammatory NN NN O
functions NN NN O
, NN NN O
respectively NN NN O
, NN NN O
by NN NN O
preventing NN NN O
target NN NN O
cell NN NN O
uptake NN NN O
of NN NN O
LPS NN NN O
through NN NN O
mCD14 NN NN B-Protein
and NN NN O
augmenting NN NN O
uptake NN NN O
through NN NN O
CR1 NN NN B-Protein
or NN NN O
other NN NN O
cell NN NN O
receptors NN NN O
. NN NN O
   
Human NN NN O
neutrophils NN NN O
express NN NN O
GH NN NN B-Protein
- NN NN I-Protein
N NN NN I-Protein
gene NN NN O
transcripts NN NN O
and NN NN O
the NN NN O
pituitary NN NN O
transcription NN NN O
factor NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1b NN NN I-Protein
. NN NN O
   
Since NN NN O
GH NN NN B-Protein
stimulates NN NN O
the NN NN O
development NN NN O
and NN NN O
function NN NN O
of NN NN O
granulocytes NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
expression NN NN O
of NN NN O
GH NN NN B-Protein
in NN NN O
granulocyte NN NN O
subsets NN NN O
. NN NN O
   
By NN NN O
immunocytochemistry NN NN O
, NN NN O
25 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
7 NN NN O
% NN NN O
of NN NN O
the NN NN O
human NN NN O
neutrophils NN NN O
were NN NN O
shown NN NN O
to NN NN O
express NN NN O
immunoreactive NN NN O
GH NN NN B-Protein
, NN NN O
whereas NN NN O
eosinophils NN NN O
were NN NN O
negative NN NN O
. NN NN O
   
Reversed NN NN O
transcription NN NN O
( NN NN O
RT NN NN O
) NN NN O
- NN NN O
PCR NN NN O
analysis NN NN O
demonstrated NN NN O
GH NN NN B-Protein
mRNA NN NN O
in NN NN O
neutrophils NN NN O
. NN NN O
   
Restriction NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
neutrophils NN NN O
express NN NN O
the NN NN O
GH NN NN B-Protein
- NN NN I-Protein
N NN NN I-Protein
gene NN NN O
but NN NN O
not NN NN O
the NN NN O
GH NN NN B-Protein
- NN NN I-Protein
V NN NN I-Protein
gene NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
by NN NN O
western NN NN O
blot NN NN O
analysis NN NN O
that NN NN O
neutrophils NN NN O
express NN NN O
an NN NN O
alternatively NN NN O
spliced NN NN O
variant NN NN O
of NN NN O
the NN NN O
pituitary NN NN O
transcription NN NN O
factor NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
designated NN NN O
Pit NN NN B-Protein
- NN NN I-Protein
1b NN NN I-Protein
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
upregulates NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
gene NN NN O
expression NN NN O
in NN NN O
activated NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
by NN NN O
enhancing NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activities NN NN O
of NN NN O
both NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
stromal NN NN O
- NN NN O
derived NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
) NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
gene NN NN O
regulation NN NN O
in NN NN O
activated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
requires NN NN O
the NN NN O
formation NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
/ NN NN O
CD3 NN NN O
engagement NN NN O
results NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
, NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
CD28 NN NN O
responsive NN NN O
complex NN NN O
( NN NN O
CD28RC NN NN O
) NN NN O
is NN NN O
activated NN NN O
in NN NN O
response NN NN O
to NN NN O
the NN NN O
CD28 NN NN B-Protein
signal NN NN O
. NN NN O
   
Costimulation NN NN O
of NN NN O
phytohemagglutinin NN NN B-Protein
/ NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
activated NN NN O
T NN NN O
lymphocytes NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
induces NN NN O
a NN NN O
fivefold NN NN O
enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mRNA NN NN O
accumulation NN NN O
and NN NN O
a NN NN O
2 NN NN O
. NN NN O
5 NN NN O
- NN NN O
fold NN NN O
enhanced NN NN O
protein NN NN O
secretion NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
gene NN NN O
transcription NN NN O
rate NN NN O
is NN NN O
increased NN NN O
3 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
is NN NN O
in NN NN O
part NN NN O
mediated NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
effect NN NN O
involve NN NN O
the NN NN O
upregulation NN NN O
of NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
NFAT NN NN O
( NN NN O
60 NN NN O
% NN NN O
) NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
( NN NN O
120 NN NN O
% NN NN O
) NN NN O
, NN NN O
without NN NN O
affecting NN NN O
the NN NN O
activities NN NN O
of NN NN O
NFkappaB NN NN O
and NN NN O
CD28RC NN NN O
, NN NN O
which NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
transfection NN NN O
assays NN NN O
. NN NN O
   
We NN NN O
also NN NN O
show NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
induced NN NN O
enhancement NN NN O
of NN NN O
the NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
is NN NN O
not NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
sensitive NN NN O
. NN NN O
   
Since NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
part NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
complex NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
signaling NN NN O
pathway NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
fos NN NN B-Protein
and NN NN O
jun NN NN B-Protein
proteins NN NN O
of NN NN O
which NN NN O
AP NN NN O
- NN NN O
1 NN NN O
consists NN NN O
. NN NN O
   
Monochloramine NN NN O
inhibits NN NN O
phorbol NN NN O
ester NN NN O
- NN NN O
inducible NN NN O
neutrophil NN NN O
respiratory NN NN O
burst NN NN O
activation NN NN O
and NN NN O
T NN NN O
cell NN NN O
interleukin NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
by NN NN O
inhibiting NN NN O
inducible NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
activity NN NN O
. NN NN O
   
Monochloramine NN NN O
derivatives NN NN O
are NN NN O
long NN NN O
lived NN NN O
physiological NN NN O
oxidants NN NN O
produced NN NN O
by NN NN O
neutrophils NN NN O
during NN NN O
the NN NN O
respiratory NN NN O
burst NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
chemically NN NN O
prepared NN NN O
monochloramine NN NN O
( NN NN O
NH2Cl NN NN O
) NN NN O
on NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
and NN NN O
PKC NN NN O
- NN NN O
mediated NN NN O
cellular NN NN O
responses NN NN O
were NN NN O
studied NN NN O
in NN NN O
elicited NN NN O
rat NN NN O
peritoneal NN NN O
neutrophils NN NN O
and NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Neutrophils NN NN O
pretreated NN NN O
with NN NN O
NH2Cl NN NN O
( NN NN O
30 NN NN O
- NN NN O
50 NN NN O
microM NN NN O
) NN NN O
showed NN NN O
a NN NN O
marked NN NN O
decrease NN NN O
in NN NN O
the NN NN O
respiratory NN NN O
burst NN NN O
activity NN NN O
induced NN NN O
by NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
potent NN NN O
PKC NN NN O
activator NN NN O
. NN NN O
   
These NN NN O
cells NN NN O
, NN NN O
however NN NN O
, NN NN O
were NN NN O
viable NN NN O
and NN NN O
showed NN NN O
a NN NN O
complete NN NN O
respiratory NN NN O
burst NN NN O
upon NN NN O
arachidonic NN NN O
acid NN NN O
stimulation NN NN O
, NN NN O
which NN NN O
induces NN NN O
the NN NN O
respiratory NN NN O
burst NN NN O
by NN NN O
a NN NN O
PKC NN NN O
- NN NN O
independent NN NN O
mechanism NN NN O
. NN NN O
   
The NN NN O
NH2Cl NN NN O
- NN NN O
treated NN NN O
neutrophils NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
both NN NN O
PKC NN NN O
activity NN NN O
and NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
phosphorylation NN NN O
of NN NN O
a NN NN O
47 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
, NN NN O
which NN NN O
corresponds NN NN O
to NN NN O
the NN NN O
cytosolic NN NN O
factor NN NN O
of NN NN O
NADPH NN NN O
oxidase NN NN O
, NN NN O
p47 NN NN B-Protein
( NN NN I-Protein
phox NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
Jurkat NN NN O
T NN NN O
cells NN NN O
pretreated NN NN O
with NN NN O
NH2Cl NN NN O
( NN NN O
20 NN NN O
- NN NN O
70 NN NN O
microM NN NN O
) NN NN O
showed NN NN O
a NN NN O
decrease NN NN O
in NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
chain NN NN I-Protein
following NN NN O
PMA NN NN O
stimulation NN NN O
. NN NN O
   
This NN NN O
was NN NN O
also NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
decrease NN NN O
in NN NN O
both NN NN O
PKC NN NN O
activity NN NN O
and NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
also NN NN O
without NN NN O
loss NN NN O
of NN NN O
cell NN NN O
viability NN NN O
. NN NN O
   
These NN NN O
results NN NN O
show NN NN O
that NN NN O
NH2Cl NN NN O
inhibits NN NN O
PKC NN NN O
- NN NN O
mediated NN NN O
cellular NN NN O
responses NN NN O
through NN NN O
inhibition NN NN O
of NN NN O
the NN NN O
inducible NN NN O
PKC NN NN O
activity NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
Vpr NN NN B-Protein
suppresses NN NN O
immune NN NN O
activation NN NN O
and NN NN O
apoptosis NN NN O
through NN NN O
regulation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
The NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
accessory NN NN O
gene NN NN O
product NN NN O
Vpr NN NN B-Protein
can NN NN O
influence NN NN O
viral NN NN O
pathogenesis NN NN O
by NN NN O
affecting NN NN O
viral NN NN O
replication NN NN O
as NN NN O
well NN NN O
as NN NN O
host NN NN O
cell NN NN O
transcription NN NN O
and NN NN O
proliferation NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
Vpr NN NN B-Protein
on NN NN O
host NN NN O
cell NN NN O
activation NN NN O
and NN NN O
confirm NN NN O
that NN NN O
it NN NN O
influences NN NN O
cellular NN NN O
proliferation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
we NN NN O
have NN NN O
also NN NN O
found NN NN O
that NN NN O
Vpr NN NN B-Protein
modulates NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
( NN NN O
TCR NN NN O
) NN NN O
- NN NN O
triggered NN NN O
apoptosis NN NN O
in NN NN O
a NN NN O
manner NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
glucocorticoids NN NN O
. NN NN O
   
In NN NN O
the NN NN O
absence NN NN O
of NN NN O
TCR NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
, NN NN O
Vpr NN NN B-Protein
induces NN NN O
apoptosis NN NN O
whereas NN NN O
in NN NN O
its NN NN O
presence NN NN O
, NN NN O
Vpr NN NN B-Protein
interrupts NN NN O
the NN NN O
expected NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
. NN NN O
   
This NN NN O
regulation NN NN O
of NN NN O
apoptosis NN NN O
is NN NN O
linked NN NN O
to NN NN O
Vpr NN NN B-Protein
suppression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
via NN NN O
the NN NN O
induction NN NN O
of NN NN O
I NN NN O
kappa NN NN O
B NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
Vpr NN NN B-Protein
suppresses NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
, NN NN O
IL NN NN O
- NN NN O
12 NN NN O
, NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
all NN NN O
of NN NN O
which NN NN O
are NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
The NN NN O
effects NN NN O
of NN NN O
Vpr NN NN B-Protein
could NN NN O
be NN NN O
reversed NN NN O
by NN NN O
RU486 NN NN O
. NN NN O
   
Our NN NN O
finding NN NN O
that NN NN O
Vpr NN NN B-Protein
can NN NN O
regulate NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
some NN NN O
aspects NN NN O
of NN NN O
viral NN NN O
pathogenesis NN NN O
are NN NN O
the NN NN O
consequence NN NN O
of NN NN O
cell NN NN O
dysregulation NN NN O
by NN NN O
Vpr NN NN B-Protein
. NN NN O
   
The NN NN O
tax NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
mediates NN NN O
the NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
platelet NN NN B-Protein
- NN NN I-Protein
derived NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
B NN NN I-Protein
promoter NN NN O
through NN NN O
interactions NN NN O
with NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
transcription NN NN O
factors NN NN O
Sp1 NN NN B-Protein
and NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Transcriptional NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
platelet NN NN B-Protein
- NN NN I-Protein
derived NN NN I-Protein
growth NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
B NN NN I-Protein
( NN NN O
PDGF NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
) NN NN O
proto NN NN O
- NN NN O
oncogene NN NN O
by NN NN O
the NN NN O
Tax NN NN B-Protein
protein NN NN O
of NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
one NN NN O
possible NN NN O
mechanism NN NN O
of NN NN O
cellular NN NN O
transformation NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
. NN NN O
   
In NN NN O
previous NN NN O
work NN NN O
, NN NN O
we NN NN O
identified NN NN O
an NN NN O
essential NN NN O
site NN NN O
in NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
PDGF NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
promoter NN NN O
, NN NN O
Tax NN NN B-Protein
- NN NN O
responsive NN NN O
element NN NN O
1 NN NN O
( NN NN O
TRE1 NN NN O
) NN NN O
, NN NN O
necessary NN NN O
for NN NN O
transactivation NN NN O
by NN NN O
Tax NN NN B-Protein
. NN NN O
   
We NN NN O
also NN NN O
identified NN NN O
Sp1 NN NN B-Protein
, NN NN O
Sp3 NN NN B-Protein
, NN NN O
and NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
as NN NN O
the NN NN O
primary NN NN O
nuclear NN NN O
transcription NN NN O
factors NN NN O
binding NN NN O
to NN NN O
TRE1 NN NN O
which NN NN O
mediate NN NN O
Tax NN NN B-Protein
responsiveness NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
work NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
whereby NN NN O
Tax NN NN B-Protein
transactivates NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
PDGF NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
proto NN NN O
- NN NN O
oncogene NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
transcription NN NN O
assays NN NN O
showed NN NN O
that NN NN O
Tax NN NN B-Protein
was NN NN O
able NN NN O
to NN NN O
significantly NN NN O
increase NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
a NN NN O
template NN NN O
containing NN NN O
the NN NN O
- NN NN O
257 NN NN O
to NN NN O
+ NN NN O
74 NN NN O
region NN NN O
of NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
PDGF NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
promoter NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
Tax NN NN B-Protein
increased NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
both NN NN O
Sp1 NN NN B-Protein
and NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
using NN NN O
a NN NN O
TRE1 NN NN O
probe NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
Tax NN NN B-Protein
mutants NN NN O
showed NN NN O
that NN NN O
two NN NN O
mutants NN NN O
, NN NN O
IEXC29S NN NN O
and NN NN O
IEXL320G NN NN O
, NN NN O
were NN NN O
unable NN NN O
to NN NN O
significantly NN NN O
transactivate NN NN O
the NN NN O
c NN NN B-Protein
- NN NN I-Protein
sis NN NN I-Protein
/ NN NN O
PDGF NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
promoter NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
co NN NN O
- NN NN O
immunoprecipitation NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
Tax NN NN B-Protein
is NN NN O
able NN NN O
to NN NN O
stably NN NN O
bind NN NN O
to NN NN O
both NN NN O
Sp1 NN NN B-Protein
and NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Interestingly NN NN O
, NN NN O
co NN NN O
- NN NN O
immunoprecipitation NN NN O
analysis NN NN O
also NN NN O
revealed NN NN O
that NN NN O
Tax NN NN B-Protein
mutant NN NN O
IEXC29S NN NN O
is NN NN O
unable NN NN O
to NN NN O
interact NN NN O
with NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
whereas NN NN O
Tax NN NN B-Protein
mutant NN NN O
IEXL320G NN NN O
is NN NN O
able NN NN O
to NN NN O
interact NN NN O
with NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
/ NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Induction NN NN O
of NN NN O
endothelial NN NN O
cell NN NN O
surface NN NN O
adhesion NN NN O
molecules NN NN O
by NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
is NN NN O
blocked NN NN O
by NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
inhibitors NN NN O
: NN NN O
role NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
from NN NN O
our NN NN O
laboratory NN NN O
have NN NN O
indicated NN NN O
that NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
( NN NN O
PTPase NN NN O
) NN NN O
inhibitors NN NN O
can NN NN O
down NN NN O
- NN NN O
modulate NN NN O
the NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
ML NN NN O
- NN NN O
1a NN NN O
, NN NN O
a NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
( NN NN O
Singh NN NN O
and NN NN O
Aggarwal NN NN O
, NN NN O
J NN NN O
. NN NN O
Biol NN NN O
. NN NN O
Chem NN NN O
. NN NN O
1995 NN NN O
: NN NN O
270 NN NN O
: NN NN O
10631 NN NN O
) NN NN O
. NN NN O
   
Since NN NN O
TNF NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
major NN NN O
inducers NN NN O
of NN NN O
various NN NN O
adhesion NN NN O
molecules NN NN O
in NN NN O
human NN NN O
endothelial NN NN O
cells NN NN O
and NN NN O
their NN NN O
expression NN NN O
is NN NN O
known NN NN O
to NN NN O
require NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
PTPase NN NN O
inhibitors NN NN O
on NN NN O
the NN NN O
TNF NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
intracellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN I-Protein
ICAM NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN I-Protein
VCAM NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
endothelial NN NN B-Protein
leukocyte NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN I-Protein
ELAM NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Like NN NN O
ML NN NN O
- NN NN O
1a NN NN O
, NN NN O
human NN NN O
dermal NN NN O
microvessel NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
MVEC NN NN O
) NN NN O
treated NN NN O
with NN NN O
TNF NN NN O
rapidly NN NN O
activated NN NN O
( NN NN O
within NN NN O
30 NN NN O
min NN NN O
) NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
; NN NN O
this NN NN O
effect NN NN O
was NN NN O
completely NN NN O
abolished NN NN O
by NN NN O
co NN NN O
- NN NN O
treatment NN NN O
with NN NN O
phenylarsine NN NN O
oxide NN NN O
( NN NN O
PAO NN NN O
) NN NN O
, NN NN O
a NN NN O
specific NN NN O
inhibitor NN NN O
of NN NN O
PTPase NN NN O
. NN NN O
   
The NN NN O
induction NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
ELAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
by NN NN O
TNF NN NN O
in NN NN O
MVEC NN NN O
occurred NN NN O
within NN NN O
6 NN NN O
h NN NN O
and NN NN O
was NN NN O
also NN NN O
completely NN NN O
down NN NN O
- NN NN O
regulated NN NN O
by NN NN O
PAO NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
PAO NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
effective NN NN O
even NN NN O
when NN NN O
added NN NN O
3 NN NN O
h NN NN O
after NN NN O
TNF NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
rapid NN NN O
mode NN NN O
of NN NN O
action NN NN O
of NN NN O
this NN NN O
inhibitor NN NN O
. NN NN O
   
Besides NN NN O
PAO NN NN O
, NN NN O
other NN NN O
inhibitors NN NN O
of NN NN O
PTPase NN NN O
, NN NN O
including NN NN O
pervanadate NN NN O
and NN NN O
diamide NN NN O
, NN NN O
also NN NN O
blocked NN NN O
TNF NN NN O
- NN NN O
dependent NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
induction NN NN O
of NN NN O
all NN NN O
the NN NN O
three NN NN O
adhesion NN NN O
proteins NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
these NN NN O
results NN NN O
, NN NN O
the NN NN O
attachment NN NN O
of NN NN O
monocytes NN NN O
to NN NN O
MVEC NN NN O
was NN NN O
also NN NN O
blocked NN NN O
by NN NN O
the NN NN O
PTPase NN NN O
inhibitors NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
overall NN NN O
, NN NN O
our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
PTPase NN NN O
is NN NN O
involved NN NN O
either NN NN O
directly NN NN O
or NN NN O
indirectly NN NN O
in NN NN O
the NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
by NN NN O
TNF NN NN O
. NN NN O
   
Because NN NN O
of NN NN O
their NN NN O
role NN NN O
in NN NN O
cell NN NN O
adhesion NN NN O
, NN NN O
PTPase NN NN O
may NN NN O
provide NN NN O
a NN NN O
novel NN NN O
target NN NN O
of NN NN O
drug NN NN O
development NN NN O
for NN NN O
treatment NN NN O
of NN NN O
inflammation NN NN O
, NN NN O
atherogenesis NN NN O
, NN NN O
and NN NN O
tumor NN NN O
metastasis NN NN O
. NN NN O
   
The NN NN O
spatial NN NN O
distribution NN NN O
of NN NN O
human NN NN O
immunoglobulin NN NN O
genes NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
: NN NN O
evidence NN NN O
for NN NN O
gene NN NN O
topography NN NN O
independent NN NN O
of NN NN O
cell NN NN O
type NN NN O
and NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
The NN NN O
three NN NN O
- NN NN O
dimensional NN NN O
positioning NN NN O
of NN NN O
immunoglobulin NN NN O
( NN NN O
Ig NN NN O
) NN NN O
genes NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
human NN NN O
cells NN NN O
was NN NN O
investigated NN NN O
using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
and NN NN O
confocal NN NN O
microscopy NN NN O
. NN NN O
   
The NN NN O
visualization NN NN O
of NN NN O
heavy NN NN O
and NN NN O
light NN NN O
chain NN NN O
genes NN NN O
in NN NN O
B NN NN O
- NN NN O
lymphoid NN NN O
cells NN NN O
showed NN NN O
that NN NN O
the NN NN O
three NN NN O
Ig NN NN O
genes NN NN O
are NN NN O
differentially NN NN O
and NN NN O
nonrandomly NN NN O
distributed NN NN O
in NN NN O
different NN NN O
nuclear NN NN O
subvolumes NN NN O
: NN NN O
the NN NN O
kappa NN NN O
genes NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
preferentially NN NN O
confined NN NN O
to NN NN O
an NN NN O
outer NN NN O
nuclear NN NN O
volume NN NN O
, NN NN O
whereas NN NN O
the NN NN O
gamma NN NN O
and NN NN O
lambda NN NN O
genes NN NN O
consistently NN NN O
occupied NN NN O
more NN NN O
central NN NN O
positions NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
the NN NN O
lambda NN NN O
genes NN NN O
being NN NN O
more NN NN O
interior NN NN O
when NN NN O
compared NN NN O
with NN NN O
the NN NN O
gamma NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
data NN NN O
further NN NN O
show NN NN O
that NN NN O
these NN NN O
overall NN NN O
topographical NN NN O
distributions NN NN O
are NN NN O
independent NN NN O
of NN NN O
gene NN NN O
transcriptional NN NN O
activity NN NN O
and NN NN O
are NN NN O
conserved NN NN O
in NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Although NN NN O
subtle NN NN O
gene NN NN O
movements NN NN O
within NN NN O
those NN NN O
defined NN NN O
topographical NN NN O
regions NN NN O
cannot NN NN O
be NN NN O
excluded NN NN O
by NN NN O
this NN NN O
study NN NN O
, NN NN O
the NN NN O
results NN NN O
indicate NN NN O
that NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
gene NN NN O
expression NN NN O
is NN NN O
not NN NN O
accompanied NN NN O
by NN NN O
drastic NN NN O
changes NN NN O
in NN NN O
gene NN NN O
nuclear NN NN O
topography NN NN O
, NN NN O
rather NN NN O
suggesting NN NN O
that NN NN O
gene NN NN O
organization NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
may NN NN O
be NN NN O
primarily NN NN O
dependent NN NN O
on NN NN O
structural NN NN O
constraints NN NN O
imposed NN NN O
on NN NN O
the NN NN O
respective NN NN O
chromosomes NN NN O
. NN NN O
   
Transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
expressing NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
protein NN NN O
. NN NN O
   
Recruitment NN NN O
and NN NN O
extravasation NN NN O
of NN NN O
T NN NN O
cells NN NN O
through NN NN O
the NN NN O
blood NN NN O
- NN NN O
brain NN NN O
barrier NN NN O
are NN NN O
favored NN NN O
by NN NN O
adhesion NN NN O
molecule NN NN O
- NN NN O
mediated NN NN O
interactions NN NN O
of NN NN O
circulating NN NN O
T NN NN O
cells NN NN O
with NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
Since NN NN O
a NN NN O
common NN NN O
pathological NN NN O
finding NN NN O
in NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
- NN NN O
associated NN NN O
diseases NN NN O
is NN NN O
the NN NN O
infiltration NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
T NN NN O
lymphocytes NN NN O
into NN NN O
various NN NN O
organs NN NN O
, NN NN O
we NN NN O
have NN NN O
looked NN NN O
for NN NN O
the NN NN O
profile NN NN O
of NN NN O
adhesion NN NN O
molecules NN NN O
expressed NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
transformed NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Flow NN NN O
cytometry NN NN O
analysis NN NN O
indicated NN NN O
that NN NN O
these NN NN O
cells NN NN O
were NN NN O
expressing NN NN O
high NN NN O
levels NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
[ NN NN O
CD106 NN NN B-Protein
] NN NN O
) NN NN O
, NN NN O
a NN NN O
110 NN NN O
- NN NN O
kDa NN NN O
member NN NN O
of NN NN O
the NN NN O
immunoglobulin NN NN O
gene NN NN O
superfamily NN NN O
, NN NN O
first NN NN O
identified NN NN O
on NN NN O
endothelial NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
inflammatory NN NN O
cytokines NN NN O
. NN NN O
   
This NN NN O
adhesion NN NN O
molecule NN NN O
was NN NN O
also NN NN O
expressed NN NN O
by NN NN O
T NN NN O
cells NN NN O
obtained NN NN O
from NN NN O
one NN NN O
patient NN NN O
with NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
associated NN NN O
myelopathy NN NN O
/ NN NN O
tropical NN NN O
spastic NN NN O
paraparesis NN NN O
but NN NN O
not NN NN O
by NN NN O
activated NN NN O
T NN NN O
cells NN NN O
isolated NN NN O
from NN NN O
one NN NN O
normal NN NN O
blood NN NN O
donor NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
the NN NN O
viral NN NN O
trans NN NN O
- NN NN O
activator NN NN O
Tax NN NN B-Protein
protein NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
first NN NN O
indicated NN NN O
by NN NN O
the NN NN O
detection NN NN O
of NN NN O
this NN NN O
adhesion NN NN O
molecule NN NN O
on NN NN O
Jurkat NN NN O
T NN NN O
- NN NN O
cell NN NN O
clones NN NN O
stably NN NN O
expressing NN NN O
the NN NN O
tax NN NN B-Protein
gene NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
Tax NN NN B-Protein
on NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
transcription NN NN O
was NN NN O
next NN NN O
confirmed NN NN O
in NN NN O
JPX NN NN O
- NN NN O
9 NN NN O
cells NN NN O
, NN NN O
a NN NN O
subclone NN NN O
of NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
carrying NN NN O
the NN NN O
tax NN NN B-Protein
sequences NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
an NN NN O
inducible NN NN O
promoter NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
deletion NN NN O
and NN NN O
mutation NN NN O
analyses NN NN O
of NN NN O
the NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
performed NN NN O
with NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
constructs NN NN O
revealed NN NN O
that NN NN O
Tax NN NN B-Protein
was NN NN O
trans NN NN O
activating NN NN O
the NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
via NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
sites NN NN O
present NN NN O
at NN NN O
bp NN NN O
- NN NN O
72 NN NN O
and NN NN O
- NN NN O
57 NN NN O
in NN NN O
the NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
promoter NN NN O
, NN NN O
with NN NN O
both NN NN O
of NN NN O
them NN NN O
being NN NN O
required NN NN O
for NN NN O
the NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
this NN NN O
adhesion NN NN O
molecule NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
gel NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrated NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
proteins NN NN O
specifically NN NN O
bound NN NN O
to NN NN O
these NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
motifs NN NN O
, NN NN O
confirming NN NN O
that NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
induced NN NN O
on NN NN O
Tax NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
in NN NN O
a NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Collectively NN NN O
, NN NN O
these NN NN O
results NN NN O
therefore NN NN O
suggest NN NN O
that NN NN O
the NN NN O
exclusive NN NN O
Tax NN NN B-Protein
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
on NN NN O
T NN NN O
cells NN NN O
may NN NN O
represent NN NN O
a NN NN O
pivotal NN NN O
event NN NN O
in NN NN O
the NN NN O
progression NN NN O
of NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
associated NN NN O
diseases NN NN O
. NN NN O
   
Blockade NN NN O
of NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
by NN NN O
dithiocarbamates NN NN O
involves NN NN O
novel NN NN O
mechanisms NN NN O
of NN NN O
inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Dithiocarbamates NN NN O
( NN NN O
DTCs NN NN O
) NN NN O
have NN NN O
recently NN NN O
been NN NN O
reported NN NN O
as NN NN O
powerful NN NN O
inhibitors NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
role NN NN O
of NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitors NN NN O
have NN NN O
been NN NN O
suggested NN NN O
as NN NN O
potential NN NN O
therapeutic NN NN O
drugs NN NN O
for NN NN O
inflammatory NN NN O
diseases NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
DTCs NN NN O
inhibited NN NN O
both NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
synthesis NN NN O
and NN NN O
membrane NN NN O
expression NN NN O
of NN NN O
antigens NN NN O
which NN NN O
are NN NN O
induced NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
, NN NN O
which NN NN O
occurred NN NN O
with NN NN O
a NN NN O
parallel NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
transactivating NN NN O
functions NN NN O
and NN NN O
expression NN NN O
, NN NN O
was NN NN O
reflected NN NN O
by NN NN O
transfection NN NN O
experiments NN NN O
at NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
level NN NN O
, NN NN O
and NN NN O
involved NN NN O
not NN NN O
only NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
activation NN NN O
but NN NN O
also NN NN O
that NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
( NN NN O
EMSAs NN NN O
) NN NN O
indicated NN NN O
that NN NN O
pyrrolidine NN NN O
DTC NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
prevented NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
and NN NN O
NFAT NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
either NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
plus NN NN O
ionophore NN NN O
or NN NN O
antibodies NN NN O
against NN NN O
the NN NN O
CD3 NN NN O
- NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
complex NN NN O
and NN NN O
simultaneously NN NN O
activated NN NN O
the NN NN O
binding NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
PDTC NN NN O
differentially NN NN O
targeted NN NN O
both NN NN O
NFATp NN NN B-Protein
and NN NN O
NFATc NN NN O
family NN NN O
members NN NN O
, NN NN O
inhibiting NN NN O
the NN NN O
transactivation NN NN O
functions NN NN O
of NN NN O
NFATp NN NN B-Protein
and NN NN O
mRNA NN NN O
induction NN NN O
of NN NN O
NFATc NN NN O
. NN NN O
   
Strikingly NN NN O
, NN NN O
Western NN NN O
blotting NN NN O
and NN NN O
immunocytochemical NN NN O
experiments NN NN O
indicated NN NN O
that NN NN O
PDTC NN NN O
promoted NN NN O
a NN NN O
transient NN NN O
and NN NN O
rapid NN NN O
shuttling NN NN O
of NN NN O
NFATp NN NN B-Protein
and NN NN O
NFATc NN NN O
, NN NN O
leading NN NN O
to NN NN O
their NN NN O
accelerated NN NN O
export NN NN O
from NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
an NN NN O
NFAT NN NN O
kinase NN NN O
by NN NN O
PDTC NN NN O
could NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
rapid NN NN O
shuttling NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
, NN NN O
therefore NN NN O
transiently NN NN O
converting NN NN O
the NN NN O
sustained NN NN O
transactivation NN NN O
of NN NN O
this NN NN O
transcription NN NN O
factor NN NN O
that NN NN O
occurs NN NN O
during NN NN O
lymphocyte NN NN O
activation NN NN O
, NN NN O
and NN NN O
show NN NN O
that NN NN O
c NN NN B-Protein
- NN NN I-Protein
Jun NN NN I-Protein
NH2 NN NN I-Protein
- NN NN I-Protein
terminal NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
JNK NN NN B-Protein
) NN NN O
can NN NN O
act NN NN O
by NN NN O
directly NN NN O
phosphorylating NN NN O
NFATp NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
combined NN NN O
inhibitory NN NN O
effects NN NN O
on NN NN O
NFAT NN NN O
and NN NN O
NF NN NN O
- NN NN O
KB NN NN O
support NN NN O
a NN NN O
potential NN NN O
use NN NN O
of NN NN O
DTCs NN NN O
as NN NN O
immunosuppressants NN NN O
. NN NN O
   
Suppression NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
and NN NN O
CD18 NN NN B-Protein
- NN NN O
mediated NN NN O
leukocyte NN NN O
adhesion NN NN O
to NN NN O
the NN NN O
corneal NN NN O
endothelium NN NN O
by NN NN O
dexamethasone NN NN O
. NN NN O
   
PURPOSE NN NN O
: NN NN O
To NN NN O
demonstrate NN NN O
that NN NN O
leukocyte NN NN O
adhesion NN NN O
to NN NN O
cultured NN NN O
corneal NN NN O
endothelial NN NN O
cells NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
CD18 NN NN B-Protein
antigen NN NN O
, NN NN O
and NN NN O
to NN NN O
determine NN NN O
whether NN NN O
dexamethasone NN NN O
directly NN NN O
suppresses NN NN O
adhesion NN NN O
by NN NN O
inhibiting NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Cultured NN NN O
bovine NN NN O
corneal NN NN O
endothelium NN NN O
was NN NN O
stimulated NN NN O
for NN NN O
6 NN NN O
hours NN NN O
by NN NN O
40 NN NN O
micron NN NN O
/ NN NN O
ml NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
) NN NN O
. NN NN O
   
Dexamethasone NN NN O
was NN NN O
added NN NN O
1 NN NN O
hour NN NN O
before NN NN O
TNFalpha NN NN B-Protein
stimulation NN NN O
in NN NN O
the NN NN O
dexamethasone NN NN O
group NN NN O
. NN NN O
   
After NN NN O
stimulation NN NN O
, NN NN O
neutrophils NN NN O
separated NN NN O
from NN NN O
a NN NN O
healthy NN NN O
human NN NN O
volunteer NN NN O
were NN NN O
added NN NN O
with NN NN O
or NN NN O
without NN NN O
anti NN NN O
- NN NN O
CD18 NN NN B-Protein
antibody NN NN O
. NN NN O
   
The NN NN O
culture NN NN O
plate NN NN O
was NN NN O
settled NN NN O
for NN NN O
15 NN NN O
minutes NN NN O
at NN NN O
37 NN NN O
degrees NN NN O
C NN NN O
, NN NN O
and NN NN O
then NN NN O
neutrophils NN NN O
were NN NN O
activated NN NN O
by NN NN O
N NN NN O
- NN NN O
formyl NN NN O
- NN NN O
methionyl NN NN O
- NN NN O
leucyl NN NN O
- NN NN O
phenylalanine NN NN O
for NN NN O
5 NN NN O
minutes NN NN O
. NN NN O
   
Nonadherent NN NN O
neutrophils NN NN O
were NN NN O
removed NN NN O
by NN NN O
sealing NN NN O
and NN NN O
inverting NN NN O
the NN NN O
culture NN NN O
well NN NN O
. NN NN O
   
The NN NN O
intracellular NN NN O
localization NN NN O
of NN NN O
NFkappaB NN NN O
after NN NN O
TNFalpha NN NN B-Protein
simulation NN NN O
was NN NN O
determined NN NN O
by NN NN O
confocal NN NN O
immunocytochemistry NN NN O
using NN NN O
an NN NN O
anti NN NN O
- NN NN O
p65 NN NN B-Protein
antibody NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Neutrophil NN NN O
adhesion NN NN O
to NN NN O
cultured NN NN O
corneal NN NN O
endothelial NN NN O
cells NN NN O
increased NN NN O
significantly NN NN O
on NN NN O
exposure NN NN O
to NN NN O
TNFalpha NN NN B-Protein
( NN NN O
451 NN NN O
. NN NN O
4 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
45 NN NN O
. NN NN O
4 NN NN O
cells NN NN O
/ NN NN O
mm2 NN NN O
, NN NN O
n NN NN O
= NN NN O
16 NN NN O
) NN NN O
compared NN NN O
to NN NN O
control NN NN O
( NN NN O
156 NN NN O
. NN NN O
7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
27 NN NN O
. NN NN O
3 NN NN O
cells NN NN O
/ NN NN O
mm2 NN NN O
, NN NN O
n NN NN O
= NN NN O
16 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
increased NN NN O
adhesion NN NN O
was NN NN O
suppressed NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD18 NN NN B-Protein
antibody NN NN O
( NN NN O
157 NN NN O
. NN NN O
6 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
25 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
/ NN NN O
mm2 NN NN O
, NN NN O
n NN NN O
= NN NN O
8 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
M NN NN O
dexamethasone NN NN O
( NN NN O
207 NN NN O
. NN NN O
9 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
31 NN NN O
. NN NN O
5 NN NN O
cells NN NN O
/ NN NN O
mm2 NN NN O
, NN NN O
n NN NN O
= NN NN O
10 NN NN O
, NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
Immunocytochemistry NN NN O
60 NN NN O
minutes NN NN O
after NN NN O
stimulation NN NN O
revealed NN NN O
that NN NN O
NFkappaB NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
in NN NN O
unstimulated NN NN O
cells NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
addition NN NN O
of NN NN O
TNFalpha NN NN B-Protein
caused NN NN O
NFkappaB NN NN O
to NN NN O
translocate NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
dexamethasone NN NN O
tapered NN NN O
NFkappaB NN NN O
translocation NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Leukocyte NN NN O
adhesion NN NN O
to NN NN O
the NN NN O
corneal NN NN O
endothelium NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
mediated NN NN O
by NN NN O
CD18 NN NN B-Protein
expressed NN NN O
on NN NN O
activated NN NN O
leukocytes NN NN O
. NN NN O
   
Pretreatment NN NN O
of NN NN O
the NN NN O
endothelium NN NN O
with NN NN O
dexamethasone NN NN O
inhibited NN NN O
leukocyte NN NN O
adhesion NN NN O
; NN NN O
this NN NN O
may NN NN O
be NN NN O
due NN NN O
in NN NN O
part NN NN O
to NN NN O
the NN NN O
suppression NN NN O
of NN NN O
NFkappaB NN NN O
entry NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Helenalin NN NN O
, NN NN O
an NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
sesquiterpene NN NN O
lactone NN NN O
from NN NN O
Arnica NN NN O
, NN NN O
selectively NN NN O
inhibits NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
Alcoholic NN NN O
extracts NN NN O
prepared NN NN O
form NN NN O
Arnicae NN NN O
flos NN NN O
, NN NN O
the NN NN O
collective NN NN O
name NN NN O
for NN NN O
flowerheads NN NN O
from NN NN O
Arnica NN NN O
montana NN NN O
and NN NN O
A NN NN O
. NN NN O
chamissonis NN NN O
ssp NN NN O
. NN NN O
foliosa NN NN O
, NN NN O
are NN NN O
used NN NN O
therapeutically NN NN O
as NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
remedies NN NN O
. NN NN O
   
The NN NN O
active NN NN O
ingredients NN NN O
mediating NN NN O
the NN NN O
pharmacological NN NN O
effect NN NN O
are NN NN O
mainly NN NN O
sesquiterpene NN NN O
lactones NN NN O
, NN NN O
such NN NN O
as NN NN O
helenalin NN NN O
, NN NN O
11alpha NN NN O
, NN NN O
13 NN NN O
- NN NN O
dihydrohelenalin NN NN O
, NN NN O
chamissonolid NN NN O
and NN NN O
their NN NN O
ester NN NN O
derivatives NN NN O
. NN NN O
   
While NN NN O
these NN NN O
compounds NN NN O
affect NN NN O
various NN NN O
cellular NN NN O
processes NN NN O
, NN NN O
current NN NN O
data NN NN O
do NN NN O
not NN NN O
fully NN NN O
explain NN NN O
how NN NN O
sesquiterpene NN NN O
lactones NN NN O
exert NN NN O
their NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
effect NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
helenalin NN NN O
, NN NN O
and NN NN O
, NN NN O
to NN NN O
a NN NN O
much NN NN O
lesser NN NN O
degree NN NN O
, NN NN O
11alpha NN NN O
, NN NN O
13 NN NN O
- NN NN O
dihydrohelenalin NN NN O
and NN NN O
chamissonolid NN NN O
, NN NN O
inhibit NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
This NN NN O
difference NN NN O
in NN NN O
efficacy NN NN O
, NN NN O
which NN NN O
correlates NN NN O
with NN NN O
the NN NN O
compounds NN NN O
' NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
potency NN NN O
in NN NN O
vivo NN NN O
, NN NN O
may NN NN O
be NN NN O
explained NN NN O
by NN NN O
differences NN NN O
in NN NN O
structure NN NN O
and NN NN O
conformation NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
which NN NN O
resides NN NN O
in NN NN O
an NN NN O
inactive NN NN O
, NN NN O
cytoplasmic NN NN O
complex NN NN O
in NN NN O
unstimulated NN NN O
cells NN NN O
, NN NN O
is NN NN O
activated NN NN O
by NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
its NN NN O
inhibitory NN NN O
subunit NN NN O
, NN NN O
IkappaB NN NN O
. NN NN O
   
Helenalin NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
four NN NN O
different NN NN O
stimuli NN NN O
in NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
B NN NN O
- NN NN O
cells NN NN O
and NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
abrogates NN NN O
kappaB NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
is NN NN O
selective NN NN O
, NN NN O
as NN NN O
the NN NN O
activity NN NN O
of NN NN O
four NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
TBP NN NN B-Protein
, NN NN O
Sp1 NN NN B-Protein
and NN NN O
STAT NN NN O
5 NN NN O
was NN NN O
not NN NN O
affected NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
inhibition NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
a NN NN O
direct NN NN O
modification NN NN O
of NN NN O
the NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
heterodimer NN NN O
. NN NN O
   
Rather NN NN O
, NN NN O
helenalin NN NN O
modifies NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
IkappaB NN NN O
complex NN NN O
, NN NN O
preventing NN NN O
the NN NN O
release NN NN O
of NN NN O
IkappaB NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
a NN NN O
molecular NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
effect NN NN O
of NN NN O
sesquiterpene NN NN O
lactones NN NN O
, NN NN O
which NN NN O
differs NN NN O
from NN NN O
that NN NN O
of NN NN O
other NN NN O
nonsteroidal NN NN O
anti NN NN O
- NN NN O
inflammatory NN NN O
drugs NN NN O
( NN NN O
NSAIDs NN NN O
) NN NN O
, NN NN O
indomethacin NN NN O
and NN NN O
acetyl NN NN O
salicylic NN NN O
acid NN NN O
. NN NN O
   
Nuclear NN NN O
accumulation NN NN O
of NN NN O
NFAT4 NN NN B-Protein
opposed NN NN O
by NN NN O
the NN NN O
JNK NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
group NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
is NN NN O
retained NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
quiescent NN NN O
cells NN NN O
. NN NN O
   
NFAT NN NN O
activation NN NN O
is NN NN O
mediated NN NN O
in NN NN O
part NN NN O
by NN NN O
induced NN NN O
nuclear NN NN O
import NN NN O
. NN NN O
   
This NN NN O
process NN NN O
requires NN NN O
calcium NN NN O
- NN NN O
dependent NN NN O
dephosphorylation NN NN O
of NN NN O
NFAT NN NN O
caused NN NN O
by NN NN O
the NN NN O
phosphatase NN NN O
calcineurin NN NN O
. NN NN O
   
The NN NN O
c NN NN O
- NN NN O
Jun NN NN O
amino NN NN O
- NN NN O
terminal NN NN O
kinase NN NN O
( NN NN O
JNK NN NN O
) NN NN O
phosphorylates NN NN O
NFAT4 NN NN B-Protein
on NN NN O
two NN NN O
sites NN NN O
. NN NN O
   
Mutational NN NN O
removal NN NN O
of NN NN O
the NN NN O
JNK NN NN O
phosphorylation NN NN O
sites NN NN O
caused NN NN O
constitutive NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
NFAT4 NN NN B-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
JNK NN NN O
activation NN NN O
in NN NN O
calcineurin NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
caused NN NN O
nuclear NN NN O
exclusion NN NN O
of NN NN O
NFAT4 NN NN B-Protein
. NN NN O
   
These NN NN O
findings NN NN O
show NN NN O
that NN NN O
the NN NN O
nuclear NN NN O
accumulation NN NN O
of NN NN O
NFAT4 NN NN B-Protein
promoted NN NN O
by NN NN O
calcineurin NN NN O
is NN NN O
opposed NN NN O
by NN NN O
the NN NN O
JNK NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
. NN NN O
   
Hypoxia NN NN O
enhances NN NN O
induction NN NN O
of NN NN O
endothelial NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
: NN NN O
role NN NN O
for NN NN O
metabolic NN NN O
acidosis NN NN O
and NN NN O
proteasomes NN NN O
. NN NN O
   
Intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
is NN NN O
an NN NN O
important NN NN O
molecule NN NN O
in NN NN O
promotion NN NN O
of NN NN O
polymorphonuclear NN NN O
neutrophil NN NN O
transendothelial NN NN O
migration NN NN O
during NN NN O
inflammation NN NN O
. NN NN O
   
Coincident NN NN O
with NN NN O
many NN NN O
inflammatory NN NN O
diseases NN NN O
is NN NN O
tissue NN NN O
hypoxia NN NN O
. NN NN O
   
Thus NN NN O
we NN NN O
hypothesized NN NN O
that NN NN O
combinations NN NN O
of NN NN O
hypoxia NN NN O
and NN NN O
inflammatory NN NN O
stimuli NN NN O
may NN NN O
differentially NN NN O
regulate NN NN O
expression NN NN O
of NN NN O
endothelial NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Human NN NN O
endothelial NN NN O
cells NN NN O
were NN NN O
exposed NN NN O
to NN NN O
hypoxia NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
added NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
and NN NN O
examined NN NN O
for NN NN O
expression NN NN O
of NN NN O
functional NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Although NN NN O
hypoxia NN NN O
alone NN NN O
did NN NN O
not NN NN O
induce NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
the NN NN O
combination NN NN O
of NN NN O
LPS NN NN O
and NN NN O
hypoxia NN NN O
enhanced NN NN O
( NN NN O
3 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O
4 NN NN O
- NN NN O
fold NN NN O
over NN NN O
normoxia NN NN O
) NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
. NN NN O
   
Combinations NN NN O
of NN NN O
hypoxia NN NN O
and NN NN O
LPS NN NN O
significantly NN NN O
increased NN NN O
lymphocyte NN NN O
binding NN NN O
, NN NN O
and NN NN O
such NN NN O
increases NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
antibodies NN NN O
or NN NN O
antisense NN NN O
oligonucleotides NN NN O
. NN NN O
   
Hypoxic NN NN O
endothelia NN NN O
showed NN NN O
a NN NN O
> NN NN O
10 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
sensitivity NN NN O
to NN NN O
inhibitors NN NN O
of NN NN O
proteasome NN NN O
activation NN NN O
, NN NN O
and NN NN O
combinations NN NN O
of NN NN O
hypoxia NN NN O
and NN NN O
LPS NN NN O
enhanced NN NN O
proteasome NN NN O
- NN NN O
dependent NN NN O
cytoplasmic NN NN O
- NN NN O
to NN NN O
- NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p65 NN NN B-Protein
( NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
) NN NN O
subunit NN NN O
. NN NN O
   
Such NN NN O
proteasome NN NN O
activation NN NN O
correlated NN NN O
with NN NN O
hypoxia NN NN O
- NN NN O
evoked NN NN O
decreases NN NN O
in NN NN O
both NN NN O
extracellular NN NN O
and NN NN O
intracellular NN NN O
pH NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
studies NN NN O
that NN NN O
endothelial NN NN O
hypoxia NN NN O
provides NN NN O
a NN NN O
novel NN NN O
, NN NN O
proteasome NN NN O
- NN NN O
dependent NN NN O
stimulus NN NN O
for NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
induction NN NN O
. NN NN O
   
Modulation NN NN O
of NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
a NN NN O
novel NN NN O
human NN NN O
myeloid NN NN O
- NN NN O
selective NN NN O
CCAAT NN NN B-Protein
/ NN NN I-Protein
enhancer NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
gene NN NN O
( NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
) NN NN O
. NN NN O
   
Human NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
is NN NN O
a NN NN O
newly NN NN O
cloned NN NN O
gene NN NN O
coding NN NN O
for NN NN O
a NN NN O
CCAAT NN NN B-Protein
/ NN NN I-Protein
enhancer NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
that NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
myeloid NN NN O
differentiation NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
showed NN NN O
that NN NN O
levels NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
were NN NN O
markedly NN NN O
increased NN NN O
in NN NN O
NB4 NN NN O
cells NN NN O
( NN NN O
promyelocytic NN NN O
leukemia NN NN O
line NN NN O
) NN NN O
, NN NN O
because NN NN O
they NN NN O
were NN NN O
induced NN NN O
by NN NN O
9 NN NN O
- NN NN O
cis NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
) NN NN O
to NN NN O
differentiate NN NN O
towards NN NN O
granulocytes NN NN O
. NN NN O
   
Accumulation NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
occurred NN NN O
as NN NN O
early NN NN O
as NN NN O
1 NN NN O
hour NN NN O
after NN NN O
exposure NN NN O
of NN NN O
NB4 NN NN O
cells NN NN O
to NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
( NN NN O
5 NN NN O
x NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
) NN NN O
; NN NN O
and NN NN O
at NN NN O
48 NN NN O
hours NN NN O
, NN NN O
levels NN NN O
were NN NN O
increased NN NN O
by NN NN O
5 NN NN O
. NN NN O
1 NN NN O
- NN NN O
fold NN NN O
. NN NN O
   
Dose NN NN O
- NN NN O
response NN NN O
studies NN NN O
showed NN NN O
that NN NN O
10 NN NN O
( NN NN O
- NN NN O
7 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
( NN NN O
12 NN NN O
hours NN NN O
) NN NN O
resulted NN NN O
in NN NN O
peak NN NN O
levels NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
; NN NN O
but NN NN O
even NN NN O
10 NN NN O
( NN NN O
- NN NN O
10 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
increased NN NN O
levels NN NN O
of NN NN O
these NN NN O
transcripts NN NN O
. NN NN O
   
NB4 NN NN O
cells NN NN O
pulse NN NN O
- NN NN O
exposed NN NN O
( NN NN O
30 NN NN O
minutes NN NN O
) NN NN O
to NN NN O
all NN NN O
- NN NN O
trans NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
ATRA NN NN O
) NN NN O
, NN NN O
washed NN NN O
, NN NN O
and NN NN O
cultured NN NN O
( NN NN O
3 NN NN O
days NN NN O
) NN NN O
with NN NN O
either NN NN O
dimethylsulfoxide NN NN O
( NN NN O
DMSO NN NN O
) NN NN O
or NN NN O
hexamethylene NN NN O
bisacetamide NN NN O
( NN NN O
HMBA NN NN O
) NN NN O
had NN NN O
a NN NN O
prominent NN NN O
increase NN NN O
in NN NN O
levels NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
and NN NN O
an NN NN O
increase NN NN O
in NN NN O
granulocytic NN NN O
differentiation NN NN O
, NN NN O
but NN NN O
exposure NN NN O
to NN NN O
either NN NN O
DMSO NN NN O
or NN NN O
HMBA NN NN O
alone NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
base NN NN O
levels NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
and NN NN O
did NN NN O
not NN NN O
induce NN NN O
differentiation NN NN O
. NN NN O
   
Macrophage NN NN O
- NN NN O
differentiation NN NN O
of NN NN O
NB4 NN NN O
reduced NN NN O
levels NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
. NN NN O
   
Nuclear NN NN O
run NN NN O
- NN NN O
off NN NN O
assays NN NN O
and NN NN O
half NN NN O
- NN NN O
life NN NN O
studies NN NN O
showed NN NN O
that NN NN O
accumulation NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
by NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
was NN NN O
due NN NN O
to NN NN O
enhanced NN NN O
transcription NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
this NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
did NN NN O
not NN NN O
require NN NN O
synthesis NN NN O
of NN NN O
new NN NN O
protein NN NN O
factors NN NN O
because NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
induced NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
new NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
ATRA NN NN O
also NN NN O
induced NN NN O
expression NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
protein NN NN O
in NN NN O
NB4 NN NN O
cells NN NN O
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
Western NN NN O
blotting NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
increase NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
in NN NN O
9 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
- NN NN O
mediated NN NN O
granulocytic NN NN O
differentiation NN NN O
, NN NN O
the NN NN O
DMSO NN NN O
- NN NN O
induced NN NN O
differentiation NN NN O
of NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
down NN NN O
the NN NN O
granulocytic NN NN O
pathway NN NN O
was NN NN O
associated NN NN O
with NN NN O
an NN NN O
initial NN NN O
reduction NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
levels NN NN O
. NN NN O
   
In NN NN O
summary NN NN O
, NN NN O
we NN NN O
have NN NN O
discovered NN NN O
that NN NN O
expression NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
is NN NN O
markedly NN NN O
enhanced NN NN O
as NN NN O
the NN NN O
NB4 NN NN O
promyelocytes NN NN O
are NN NN O
induced NN NN O
by NN NN O
retinoids NN NN O
to NN NN O
differentiate NN NN O
towards NN NN O
granulocytes NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
of NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
mRNA NN NN O
expression NN NN O
is NN NN O
transcriptionally NN NN O
mediated NN NN O
and NN NN O
occurs NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
synthesis NN NN O
of NN NN O
additional NN NN O
protein NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
suspect NN NN O
that NN NN O
the NN NN O
C NN NN B-Protein
/ NN NN I-Protein
EBP NN NN I-Protein
epsilon NN NN I-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
contains NN NN O
a NN NN O
retinoic NN NN O
acid NN NN O
- NN NN O
response NN NN O
element NN NN O
that NN NN O
is NN NN O
directly NN NN O
stimulated NN NN O
by NN NN O
retinoids NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
its NN NN O
inhibitor NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
/ NN NN O
MAD NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
monocytes NN NN O
by NN NN O
Mycobacterium NN NN O
tuberculosis NN NN O
and NN NN O
during NN NN O
human NN NN O
tuberculosis NN NN O
. NN NN O
   
Blood NN NN O
monocytes NN NN O
from NN NN O
patients NN NN O
with NN NN O
active NN NN O
tuberculosis NN NN O
are NN NN O
activated NN NN O
in NN NN O
vivo NN NN O
, NN NN O
as NN NN O
evidenced NN NN O
by NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
stimulated NN NN O
release NN NN O
of NN NN O
proinflammatory NN NN O
cytokines NN NN O
, NN NN O
such NN NN O
as NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
and NN NN O
the NN NN O
spontaneous NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2R NN NN I-Protein
. NN NN O
   
Further NN NN O
, NN NN O
monocytes NN NN O
from NN NN O
patients NN NN O
demonstrate NN NN O
an NN NN O
augmented NN NN O
susceptibility NN NN O
to NN NN O
a NN NN O
productive NN NN O
infection NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Mycobacterium NN NN O
tuberculosis NN NN O
and NN NN O
its NN NN O
components NN NN O
are NN NN O
strong NN NN O
signals NN NN O
to NN NN O
activate NN NN O
monocytes NN NN O
to NN NN O
production NN NN O
of NN NN O
cytokines NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
examined NN NN O
the NN NN O
basis NN NN O
of NN NN O
activation NN NN O
of NN NN O
monocytes NN NN O
during NN NN O
active NN NN O
tuberculosis NN NN O
and NN NN O
by NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
. NN NN O
   
We NN NN O
found NN NN O
a NN NN O
constitutive NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
the NN NN O
major NN NN O
cytoplasmic NN NN O
inhibitor NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
PBMC NN NN O
and NN NN O
monocytes NN NN O
from NN NN O
patients NN NN O
with NN NN O
tuberculosis NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
levels NN NN O
in NN NN O
PBMC NN NN O
and NN NN O
monocytes NN NN O
from NN NN O
healthy NN NN O
subjects NN NN O
or NN NN O
from NN NN O
patients NN NN O
with NN NN O
nontuberculous NN NN O
pulmonary NN NN O
conditions NN NN O
were NN NN O
intact NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
was NN NN O
activated NN NN O
in NN NN O
monocytes NN NN O
from NN NN O
tuberculous NN NN O
patients NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
gene NN NN O
, NN NN O
which NN NN O
is NN NN O
responsive NN NN O
to NN NN O
activation NN NN O
by NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
was NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
PBMC NN NN O
and NN NN O
monocytes NN NN O
from NN NN O
patients NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
healthy NN NN O
subjects NN NN O
or NN NN O
those NN NN O
with NN NN O
nontuberculous NN NN O
lung NN NN O
diseases NN NN O
. NN NN O
   
By NN NN O
contrast NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
other NN NN O
adherence NN NN O
- NN NN O
associated NN NN O
early NN NN O
genes NN NN O
, NN NN O
such NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
beta NN NN I-Protein
, NN NN O
was NN NN O
not NN NN O
up NN NN O
- NN NN O
regulated NN NN O
in NN NN O
PBMC NN NN O
of NN NN O
tuberculous NN NN O
patients NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
and NN NN O
its NN NN O
tuberculin NN NN B-Protein
, NN NN O
purified NN NN O
protein NN NN O
derivative NN NN O
, NN NN O
induced NN NN O
the NN NN O
degradation NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
mRNA NN NN O
, NN NN O
and NN NN O
purified NN NN O
protein NN NN O
derivative NN NN O
induced NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
correlates NN NN O
with NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
responsiveness NN NN O
in NN NN O
Philadelphia NN NN O
chromosome NN NN O
positive NN NN O
chronic NN NN O
myelogenous NN NN O
leukemia NN NN O
. NN NN O
   
This NN NN O
study NN NN O
evaluates NN NN O
( NN NN O
i NN NN O
) NN NN O
constitutive NN NN O
levels NN NN O
of NN NN O
oncogene NN NN O
and NN NN O
p53 NN NN B-Protein
transcripts NN NN O
in NN NN O
chronic NN NN O
phase NN NN O
CML NN NN O
patients NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
their NN NN O
modulations NN NN O
subsequent NN NN O
to NN NN O
in NN NN O
vivo NN NN O
therapy NN NN O
with NN NN O
rIFN NN NN O
- NN NN O
alpha NN NN O
2c NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
pbmc NN NN O
) NN NN O
and NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
of NN NN O
26 NN NN O
patients NN NN O
were NN NN O
examined NN NN O
for NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
, NN NN O
p53 NN NN B-Protein
and NN NN O
the NN NN O
hybrid NN NN O
bcr NN NN O
/ NN NN O
abl NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O
   
Results NN NN O
indicated NN NN O
that NN NN O
( NN NN O
i NN NN O
) NN NN O
constitutive NN NN O
c NN NN O
- NN NN O
fos NN NN O
transcript NN NN O
levels NN NN O
are NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
patients NN NN O
subsequently NN NN O
responding NN NN O
to NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
therapy NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
the NN NN O
proportion NN NN O
of NN NN O
lymphocytes NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O
6895 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
and NN NN O
negatively NN NN O
with NN NN O
the NN NN O
proportion NN NN O
of NN NN O
immature NN NN O
cells NN NN O
( NN NN O
r NN NN O
= NN NN O
- NN NN O
0 NN NN O
. NN NN O
568 NN NN O
, NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
contained NN NN O
in NN NN O
the NN NN O
pbmc NN NN O
preparations NN NN O
tested NN NN O
, NN NN O
( NN NN O
ii NN NN O
) NN NN O
constitutive NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
hybrid NN NN O
bcr NN NN O
/ NN NN O
abl NN NN O
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
and NN NN O
p53 NN NN B-Protein
are NN NN O
positively NN NN O
correlated NN NN O
with NN NN O
each NN NN O
other NN NN O
, NN NN O
but NN NN O
failed NN NN O
to NN NN O
relate NN NN O
to NN NN O
disease NN NN O
parameters NN NN O
, NN NN O
and NN NN O
( NN NN O
iii NN NN O
) NN NN O
acute NN NN O
and NN NN O
chronic NN NN O
in NN NN O
vivo NN NN O
exposure NN NN O
to NN NN O
IFN NN NN O
- NN NN O
alpha NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
upregulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
downregulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
levels NN NN O
in NN NN O
responder NN NN O
patients NN NN O
. NN NN O
   
Molecular NN NN O
cloning NN NN O
and NN NN O
functional NN NN O
characterization NN NN O
of NN NN O
murine NN NN O
cDNA NN NN O
encoding NN NN O
transcription NN NN O
factor NN NN O
NFATc NN NN B-Protein
. NN NN O
   
Transcription NN NN O
factors NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
) NN NN O
family NN NN O
play NN NN O
important NN NN O
roles NN NN O
in NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
by NN NN O
regulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
encoding NN NN O
cytokines NN NN O
and NN NN O
immunoregulatory NN NN O
proteins NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
describe NN NN O
cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
full NN NN O
- NN NN O
length NN NN O
cDNA NN NN O
encoding NN NN O
murine NN NN B-Protein
( NN NN I-Protein
m NN NN I-Protein
) NN NN I-Protein
NFATc NN NN I-Protein
which NN NN O
predicts NN NN O
that NN NN O
the NN NN O
protein NN NN O
has NN NN O
all NN NN O
the NN NN O
conserved NN NN O
structural NN NN O
motifs NN NN O
of NN NN O
NFAT NN NN O
family NN NN O
members NN NN O
, NN NN O
including NN NN O
the NN NN O
rel NN NN O
homology NN NN O
domain NN NN O
, NN NN O
the NN NN O
NFAT NN NN O
homology NN NN O
domain NN NN O
and NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
signals NN NN O
. NN NN O
   
mNFATc NN NN B-Protein
complexed NN NN O
with NN NN O
AP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
bound NN NN O
specifically NN NN O
to NN NN O
the NN NN O
murine NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
NFAT NN NN O
recognition NN NN O
sequence NN NN O
and NN NN O
activated NN NN O
transcription NN NN O
from NN NN O
the NN NN O
co NN NN O
- NN NN O
transfected NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
in NN NN O
COS NN NN O
- NN NN O
7 NN NN O
cells NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
the NN NN O
cDNA NN NN O
probe NN NN O
hybridized NN NN O
with NN NN O
a NN NN O
4 NN NN O
. NN NN O
5 NN NN O
kb NN NN O
transcript NN NN O
which NN NN O
is NN NN O
highly NN NN O
inducible NN NN O
in NN NN O
murine NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
By NN NN O
Northern NN NN O
and NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
mNFATc NN NN B-Protein
transcript NN NN O
was NN NN O
detected NN NN O
from NN NN O
the NN NN O
early NN NN O
stage NN NN O
of NN NN O
development NN NN O
. NN NN O
   
In NN NN O
the NN NN O
mouse NN NN O
embryo NN NN O
, NN NN O
mNFATc NN NN B-Protein
transcript NN NN O
was NN NN O
strongly NN NN O
expressed NN NN O
in NN NN O
thymus NN NN O
, NN NN O
lung NN NN O
and NN NN O
submandibular NN NN O
gland NN NN O
and NN NN O
weakly NN NN O
in NN NN O
skeletal NN NN O
muscle NN NN O
and NN NN O
heart NN NN O
suggesting NN NN O
that NN NN O
mNFATc NN NN B-Protein
may NN NN O
have NN NN O
a NN NN O
role NN NN O
both NN NN O
in NN NN O
embryogenesis NN NN O
and NN NN O
in NN NN O
mature NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
couples NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
receptor NN NN O
to NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
regulator NN NN O
E2F NN NN O
. NN NN O
   
Cell NN NN O
cycle NN NN O
progression NN NN O
initiated NN NN O
by NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
in NN NN O
T NN NN O
cells NN NN O
is NN NN O
critical NN NN O
for NN NN O
lymphoproliferation NN NN O
and NN NN O
an NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Phosphatidyl NN NN O
inositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
( NN NN O
PI3K NN NN O
) NN NN O
is NN NN O
activated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
nuclear NN NN O
targets NN NN O
for NN NN O
PI3K NN NN O
are NN NN O
not NN NN O
known NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
identify NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
regulator NN NN O
E2F NN NN O
as NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
target NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
PI3K NN NN O
as NN NN O
the NN NN O
critical NN NN O
signaling NN NN O
pathway NN NN O
. NN NN O
   
We NN NN O
eliminate NN NN O
both NN NN O
Stat5 NN NN B-Protein
and NN NN O
Raf NN NN O
/ NN NN O
MEK NN NN O
pathways NN NN O
from NN NN O
E2F NN NN O
regulation NN NN O
. NN NN O
   
Protein NN NN B-Protein
kinase NN NN I-Protein
B NN NN I-Protein
( NN NN O
PKB NN NN B-Protein
) NN NN O
is NN NN O
activated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
via NN NN O
PI3K NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
an NN NN O
active NN NN O
PKB NN NN B-Protein
is NN NN O
sufficient NN NN O
to NN NN O
induce NN NN O
E2F NN NN O
activity NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
PI3K NN NN O
inhibits NN NN O
phosphorylation NN NN O
of NN NN O
Rb NN NN B-Protein
, NN NN O
induction NN NN O
of NN NN O
cyclin NN NN O
D3 NN NN O
, NN NN O
and NN NN O
degradation NN NN O
of NN NN O
p27kip1 NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
establish NN NN O
a NN NN O
crucial NN NN O
PI3K NN NN O
/ NN NN O
PKB NN NN B-Protein
- NN NN O
mediated NN NN O
link NN NN O
between NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
teceptor NN NN O
and NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
machinery NN NN O
. NN NN O
   
Thiol NN NN O
modulation NN NN O
inhibits NN NN O
the NN NN O
interleukin NN NN O
( NN NN O
IL NN NN O
) NN NN O
- NN NN O
1 NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
an NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
- NN NN O
associated NN NN O
protein NN NN O
kinase NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
receptor NN NN I-Protein
type NN NN I-Protein
I NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
other NN NN O
proteins NN NN O
thus NN NN O
forming NN NN O
a NN NN O
complex NN NN O
system NN NN O
by NN NN O
which NN NN O
IL NN NN O
- NN NN O
1 NN NN O
exerts NN NN O
its NN NN O
various NN NN O
signals NN NN O
. NN NN O
   
The NN NN O
initiating NN NN O
event NN NN O
is NN NN O
still NN NN O
uncertain NN NN O
, NN NN O
but NN NN O
activation NN NN O
of NN NN O
a NN NN O
recently NN NN O
described NN NN O
receptor NN NN O
- NN NN O
associated NN NN O
protein NN NN O
kinase NN NN O
is NN NN O
one NN NN O
of NN NN O
the NN NN O
earliest NN NN O
events NN NN O
detectable NN NN O
( NN NN O
Martin NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
Eur NN NN O
. NN NN O
J NN NN O
. NN NN O
Immunol NN NN O
. NN NN O
1994 NN NN O
. NN NN O
24 NN NN O
: NN NN O
1566 NN NN O
) NN NN O
. NN NN O
   
IL NN NN O
- NN NN O
1 NN NN O
signaling NN NN O
is NN NN O
commonly NN NN O
accompanied NN NN O
by NN NN O
oxidative NN NN O
processes NN NN O
and NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
subject NN NN O
to NN NN O
redox NN NN O
regulation NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
- NN NN O
associated NN NN O
protein NN NN O
kinase NN NN O
could NN NN O
be NN NN O
a NN NN O
target NN NN O
for NN NN O
redox NN NN O
regulation NN NN O
and NN NN O
whether NN NN O
an NN NN O
altered NN NN O
activity NN NN O
of NN NN O
the NN NN O
kinase NN NN O
could NN NN O
influence NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
A NN NN O
murine NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
EL4 NN NN O
, NN NN O
was NN NN O
stimulated NN NN O
with NN NN O
IL NN NN O
- NN NN O
1 NN NN O
with NN NN O
and NN NN O
without NN NN O
pretreatment NN NN O
with NN NN O
different NN NN O
compounds NN NN O
known NN NN O
to NN NN O
influence NN NN O
the NN NN O
cellular NN NN O
redox NN NN O
status NN NN O
. NN NN O
   
Thiol NN NN O
modifying NN NN O
agents NN NN O
like NN NN O
diamide NN NN O
, NN NN O
menadione NN NN O
, NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
( NN NN O
PDTC NN NN O
) NN NN O
, NN NN O
diethyl NN NN O
dithiocarbamate NN NN O
or NN NN O
phenylarsine NN NN O
oxide NN NN O
inhibited NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
- NN NN O
associated NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
N NN NN O
- NN NN O
Acetylcysteine NN NN O
, NN NN O
alpha NN NN O
, NN NN O
alpha NN NN O
' NN NN O
- NN NN O
dipyridyl NN NN O
, NN NN O
aminotriazole NN NN O
or NN NN O
nitrofurantoin NN NN O
did NN NN O
not NN NN O
show NN NN O
any NN NN O
effect NN NN O
. NN NN O
   
The NN NN O
inhibition NN NN O
by NN NN O
PDTC NN NN O
was NN NN O
reversible NN NN O
unless NN NN O
glutathione NN NN O
synthesis NN NN O
was NN NN O
blocked NN NN O
by NN NN O
buthionine NN NN O
sulfoximine NN NN O
. NN NN O
   
The NN NN O
described NN NN O
conditions NN NN O
which NN NN O
inhibited NN NN O
or NN NN O
prevented NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
- NN NN O
associated NN NN O
kinase NN NN O
similarly NN NN O
impaired NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
EL4 NN NN O
cells NN NN O
. NN NN O
   
From NN NN O
these NN NN O
observations NN NN O
we NN NN O
conclude NN NN O
that NN NN O
free NN NN O
thiols NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
complex NN NN O
are NN NN O
essential NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1RI NN NN I-Protein
- NN NN O
associated NN NN O
protein NN NN O
kinase NN NN O
and NN NN O
that NN NN O
this NN NN O
process NN NN O
is NN NN O
mandatory NN NN O
for NN NN O
IL NN NN O
- NN NN O
1 NN NN O
signaling NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
ATF1 NN NN B-Protein
and NN NN O
CREB NN NN O
trans NN NN O
- NN NN O
activate NN NN O
a NN NN O
cell NN NN O
cycle NN NN O
regulated NN NN O
histone NN NN B-Protein
H4 NN NN I-Protein
gene NN NN O
at NN NN O
a NN NN O
distal NN NN O
nuclear NN NN O
matrix NN NN O
associated NN NN O
promoter NN NN O
element NN NN O
. NN NN O
   
Proteins NN NN O
of NN NN O
the NN NN O
ATF NN NN O
/ NN NN O
CREB NN NN O
class NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
stimulate NN NN O
gene NN NN O
expression NN NN O
of NN NN O
several NN NN O
cell NN NN O
growth NN NN O
- NN NN O
related NN NN O
genes NN NN O
through NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
- NN NN O
related NN NN O
cAMP NN NN O
response NN NN O
elements NN NN O
. NN NN O
   
The NN NN O
promoter NN NN O
activity NN NN O
of NN NN O
cell NN NN O
cycle NN NN O
regulated NN NN O
histone NN NN B-Protein
H4 NN NN I-Protein
genes NN NN O
is NN NN O
regulated NN NN O
by NN NN O
at NN NN O
least NN NN O
four NN NN O
principal NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
which NN NN O
mediate NN NN O
G1 NN NN O
/ NN NN O
S NN NN O
phase NN NN O
control NN NN O
and NN NN O
/ NN NN O
or NN NN O
enhancement NN NN O
of NN NN O
transcription NN NN O
during NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
Using NN NN O
protein NN NN O
- NN NN O
DNA NN NN O
interaction NN NN O
assays NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
H4 NN NN O
promoter NN NN O
contains NN NN O
two NN NN O
ATF NN NN O
/ NN NN O
CREB NN NN O
recognition NN NN O
motifs NN NN O
which NN NN O
interact NN NN O
with NN NN O
CREB NN NN O
, NN NN O
ATF1 NN NN B-Protein
, NN NN O
and NN NN O
ATF2 NN NN B-Protein
but NN NN O
not NN NN O
with NN NN O
ATF4 NN NN B-Protein
/ NN NN O
CREB2 NN NN B-Protein
. NN NN O
   
One NN NN O
ATF NN NN O
/ NN NN O
CRE NN NN O
motif NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
distal NN NN O
promoter NN NN O
at NN NN O
the NN NN O
nuclear NN NN O
matrix NN NN O
- NN NN O
associated NN NN O
Site NN NN O
IV NN NN O
, NN NN O
and NN NN O
the NN NN O
second NN NN O
motif NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
proximal NN NN O
promoter NN NN O
at NN NN O
Site NN NN O
I NN NN O
. NN NN O
Both NN NN O
ATF NN NN O
/ NN NN O
CRE NN NN O
motifs NN NN O
overlap NN NN O
binding NN NN O
sequences NN NN O
for NN NN O
the NN NN O
multifunctional NN NN O
YY1 NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
which NN NN O
has NN NN O
previously NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
nuclear NN NN O
matrix NN NN O
associated NN NN O
. NN NN O
   
Subnuclear NN NN O
fractionation NN NN O
reveals NN NN O
that NN NN O
there NN NN O
are NN NN O
two NN NN O
ATF1 NN NN B-Protein
isoforms NN NN O
which NN NN O
appear NN NN O
to NN NN O
differ NN NN O
with NN NN O
respect NN NN O
to NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
and NN NN O
partition NN NN O
selectively NN NN O
between NN NN O
nuclear NN NN O
matrix NN NN O
and NN NN O
nonmatrix NN NN O
compartments NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
matrix NN NN O
in NN NN O
regulating NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Site NN NN O
- NN NN O
directed NN NN O
mutational NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
Site NN NN O
I NN NN O
and NN NN O
Site NN NN O
IV NN NN O
together NN NN O
support NN NN O
ATF1 NN NN B-Protein
- NN NN O
and NN NN O
CREB NN NN O
- NN NN O
induced NN NN O
trans NN NN O
- NN NN O
activation NN NN O
of NN NN O
the NN NN O
H4 NN NN B-Protein
promoter NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
data NN NN O
establish NN NN O
that NN NN O
ATF NN NN O
/ NN NN O
CREB NN NN O
factors NN NN O
functionally NN NN O
modulate NN NN O
histone NN NN B-Protein
H4 NN NN I-Protein
gene NN NN O
transcription NN NN O
at NN NN O
distal NN NN O
and NN NN O
proximal NN NN O
promoter NN NN O
elements NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
induce NN NN O
heterodimerization NN NN O
of NN NN O
STAT5 NN NN O
isoforms NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphoblasts NN NN O
. NN NN O
   
Despite NN NN O
differences NN NN O
in NN NN O
T NN NN O
cell NN NN O
responses NN NN O
induced NN NN O
by NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
both NN NN O
cytokines NN NN O
modulate NN NN O
T NN NN O
cell NN NN O
functions NN NN O
by NN NN O
activation NN NN O
of NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
proteins NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
contribution NN NN O
of NN NN O
the NN NN O
two NN NN O
isoforms NN NN O
of NN NN O
STAT5 NN NN O
, NN NN O
STAT5A NN NN B-Protein
and NN NN O
STAT5B NN NN B-Protein
, NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphoblasts NN NN O
. NN NN O
   
Both NN NN O
cytokines NN NN O
induced NN NN O
assembly NN NN O
of NN NN O
STAT5A NN NN B-Protein
and NN NN O
STAT5B NN NN B-Protein
containing NN NN O
complexes NN NN O
capable NN NN O
of NN NN O
binding NN NN O
to NN NN O
the NN NN O
interferon NN NN O
- NN NN O
gamma NN NN O
activation NN NN O
sequence NN NN O
( NN NN O
GAS NN NN O
) NN NN O
, NN NN O
and NN NN O
these NN NN O
complexes NN NN O
rapidly NN NN O
translocated NN NN O
( NN NN O
within NN NN O
1 NN NN O
min NN NN O
) NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
kinetics NN NN O
of NN NN O
this NN NN O
translocation NN NN O
were NN NN O
delayed NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
- NN NN O
treated NN NN O
as NN NN O
compared NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
treated NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
were NN NN O
equivalent NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
induce NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
STAT5A NN NN B-Protein
and NN NN O
STAT5B NN NN B-Protein
and NN NN O
to NN NN O
facilitate NN NN O
binding NN NN O
of NN NN O
these NN NN O
STATs NN NN O
to NN NN O
an NN NN O
immobilized NN NN O
GAS NN NN O
element NN NN O
. NN NN O
   
Both NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
induced NN NN O
substantial NN NN O
amounts NN NN O
of NN NN O
STAT5A NN NN B-Protein
/ NN NN O
STAT5B NN NN B-Protein
heterodimerization NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
observed NN NN O
constitutive NN NN O
association NN NN O
of NN NN O
STAT3 NN NN O
with NN NN O
each NN NN O
STAT5 NN NN O
isomer NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
induce NN NN O
assembly NN NN O
of NN NN O
STAT NN NN O
heterodimers NN NN O
in NN NN O
a NN NN O
similar NN NN O
manner NN NN O
and NN NN O
that NN NN O
subsequent NN NN O
cellular NN NN O
responses NN NN O
may NN NN O
be NN NN O
driven NN NN O
by NN NN O
induction NN NN O
of NN NN O
similar NN NN O
sets NN NN O
of NN NN O
genes NN NN O
. NN NN O
   
Molecular NN NN O
mechanisms NN NN O
of NN NN O
anoxia NN NN O
/ NN NN O
reoxygenation NN NN O
- NN NN O
induced NN NN O
neutrophil NN NN O
adherence NN NN O
to NN NN O
cultured NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
objectives NN NN O
of NN NN O
this NN NN O
study NN NN O
were NN NN O
to NN NN O
( NN NN O
1 NN NN O
) NN NN O
determine NN NN O
the NN NN O
time NN NN O
course NN NN O
of NN NN O
neutrophil NN NN O
adhesion NN NN O
to NN NN O
monolayers NN NN O
of NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
that NN NN O
were NN NN O
exposed NN NN O
to NN NN O
60 NN NN O
minutes NN NN O
of NN NN O
anoxia NN NN O
followed NN NN O
by NN NN O
30 NN NN O
to NN NN O
600 NN NN O
minutes NN NN O
of NN NN O
reoxygenation NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
define NN NN O
the NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
both NN NN O
the NN NN O
early NN NN O
( NN NN O
minutes NN NN O
) NN NN O
and NN NN O
late NN NN O
( NN NN O
hours NN NN O
) NN NN O
hyperadhesivity NN NN O
of NN NN O
postanoxic NN NN O
HUVECs NN NN O
to NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
The NN NN O
results NN NN O
clearly NN NN O
demonstrate NN NN O
that NN NN O
anoxia NN NN O
/ NN NN O
reoxygenation NN NN O
( NN NN O
A NN NN O
/ NN NN O
R NN NN O
) NN NN O
leads NN NN O
to NN NN O
a NN NN O
biphasic NN NN O
increase NN NN O
in NN NN O
neutrophil NN NN O
adhesion NN NN O
to NN NN O
HUVECs NN NN O
, NN NN O
with NN NN O
peak NN NN O
responses NN NN O
occurring NN NN O
at NN NN O
30 NN NN O
minutes NN NN O
( NN NN O
phase NN NN O
1 NN NN O
) NN NN O
and NN NN O
240 NN NN O
minutes NN NN O
( NN NN O
phase NN NN O
2 NN NN O
) NN NN O
after NN NN O
reoxygenation NN NN O
. NN NN O
   
Oxypurinol NN NN O
and NN NN O
catalase NN NN B-Protein
inhibited NN NN O
phase NN NN O
- NN NN O
1 NN NN O
adhesion NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
xanthine NN NN B-Protein
oxidase NN NN I-Protein
and NN NN O
H2O2 NN NN O
. NN NN O
   
In NN NN O
comparison NN NN O
, NN NN O
platelet NN NN O
activating NN NN O
factor NN NN O
( NN NN O
PAF NN NN O
) NN NN O
contributed NN NN O
to NN NN O
both NN NN O
phases NN NN O
of NN NN O
neutrophil NN NN O
adhesion NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
anti NN NN O
- NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
antibodies NN NN O
( NN NN O
monoclonal NN NN O
antibodies NN NN O
[ NN NN O
mAbs NN NN O
] NN NN O
) NN NN O
attenuated NN NN O
phase NN NN O
- NN NN O
1 NN NN O
neutrophil NN NN O
adhesion NN NN O
, NN NN O
consistent NN NN O
with NN NN O
roles NN NN O
for NN NN O
constitutively NN NN O
expressed NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
enhanced NN NN O
surface NN NN O
expression NN NN O
of NN NN O
preformed NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
. NN NN O
   
Phase NN NN O
- NN NN O
2 NN NN O
neutrophil NN NN O
adhesion NN NN O
was NN NN O
attenuated NN NN O
by NN NN O
an NN NN O
anti NN NN O
- NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
mAb NN NN O
, NN NN O
indicating NN NN O
a NN NN O
dominant NN NN O
role NN NN O
of NN NN O
this NN NN O
adhesion NN NN O
molecule NN NN O
in NN NN O
the NN NN O
late NN NN O
phase NN NN O
response NN NN O
. NN NN O
   
Pretreatment NN NN O
with NN NN O
actinomycin NN NN O
D NN NN O
and NN NN O
cycloheximide NN NN O
or NN NN O
with NN NN O
competing NN NN O
ds NN NN O
- NN NN O
oligonucleotides NN NN O
containing NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
activator NN NN B-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
cognate NN NN O
DNA NN NN O
sequences NN NN O
significantly NN NN O
attenuated NN NN O
phase NN NN O
- NN NN O
2 NN NN O
response NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
role NN NN O
for NN NN O
de NN NN O
novo NN NN O
macromolecule NN NN O
synthesis NN NN O
. NN NN O
   
Surface NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
P NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
on NN NN O
HUVECs NN NN O
correlated NN NN O
with NN NN O
the NN NN O
phase NN NN O
- NN NN O
1 NN NN O
and NN NN O
- NN NN O
2 NN NN O
neutrophil NN NN O
adhesion NN NN O
responses NN NN O
. NN NN O
   
Collectively NN NN O
, NN NN O
these NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
A NN NN O
/ NN NN O
R NN NN O
elicits NN NN O
a NN NN O
two NN NN O
- NN NN O
phase NN NN O
neutrophil NN NN O
- NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
response NN NN O
that NN NN O
involves NN NN O
transcription NN NN O
- NN NN O
independent NN NN O
and NN NN O
transcription NN NN O
- NN NN O
dependent NN NN O
surface NN NN O
expression NN NN O
of NN NN O
different NN NN O
endothelial NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
. NN NN O
   
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
subunits NN NN O
bind NN NN O
to NN NN O
an NN NN O
upstream NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
in NN NN O
human NN NN O
granulocyte NN NN B-Protein
macrophage NN NN I-Protein
- NN NN I-Protein
colony NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
promoter NN NN O
involved NN NN O
in NN NN O
phorbol NN NN O
ester NN NN O
response NN NN O
in NN NN O
5637 NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
further NN NN O
clarify NN NN O
the NN NN O
complex NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
human NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
gene NN NN O
, NN NN O
which NN NN O
was NN NN O
extensively NN NN O
investigated NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
an NN NN O
upstream NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
like NN NN O
site NN NN O
in NN NN O
the NN NN O
5637 NN NN O
non NN NN O
- NN NN O
lymphoid NN NN O
cell NN NN O
line NN NN O
, NN NN O
which NN NN O
derives NN NN O
from NN NN O
a NN NN O
bladder NN NN O
carcinoma NN NN O
and NN NN O
constitutively NN NN O
produces NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
. NN NN O
   
This NN NN O
sequence NN NN O
, NN NN O
named NN NN O
the NN NN O
A NN NN O
element NN NN O
, NN NN O
has NN NN O
an NN NN O
active NN NN O
role NN NN O
on NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
transcription NN NN O
and NN NN O
is NN NN O
responsive NN NN O
to NN NN O
the NN NN O
tumor NN NN O
promoter NN NN O
PMA NN NN O
in NN NN O
transient NN NN O
transfection NN NN O
experiments NN NN O
. NN NN O
   
We NN NN O
describe NN NN O
here NN NN O
a NN NN O
heterodimeric NN NN O
binding NN NN O
complex NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p65 NN NN B-Protein
) NN NN O
which NN NN O
is NN NN O
identical NN NN O
to NN NN O
the NN NN O
one NN NN O
obtained NN NN O
using NN NN O
the NN NN O
HIV NN NN O
- NN NN O
LTR NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
as NN NN O
recognition NN NN O
sequence NN NN O
and NN NN O
different NN NN O
from NN NN O
the NN NN O
one NN NN O
( NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
p50 NN NN B-Protein
) NN NN O
observed NN NN O
with NN NN O
nuclear NN NN O
extracts NN NN O
from NN NN O
Mo NN NN O
T NN NN O
- NN NN O
lymphoid NN NN O
HTLV NN NN O
- NN NN O
II NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
inhibits NN NN O
monocyte NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
activation NN NN O
in NN NN O
cardiac NN NN O
transplant NN NN O
recipients NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Fibrin NN NN O
deposition NN NN O
and NN NN O
thrombosis NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
both NN NN O
allograft NN NN O
rejection NN NN O
and NN NN O
vasculopathy NN NN O
after NN NN O
cardiac NN NN O
transplantation NN NN O
. NN NN O
   
Because NN NN O
monocytes NN NN O
play NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
intravascular NN NN O
coagulation NN NN O
activation NN NN O
through NN NN O
their NN NN O
ability NN NN O
to NN NN O
synthesize NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
, NN NN O
we NN NN O
asked NN NN O
( NN NN O
1 NN NN O
) NN NN O
whether NN NN O
monocyte NN NN O
TF NN NN B-Protein
activation NN NN O
occurs NN NN O
in NN NN O
cardiac NN NN O
transplant NN NN O
recipients NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
whether NN NN O
monocyte NN NN O
TF NN NN B-Protein
expression NN NN O
is NN NN O
affected NN NN O
by NN NN O
treatment NN NN O
with NN NN O
cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
We NN NN O
measured NN NN O
levels NN NN O
of NN NN O
TF NN NN B-Protein
activity NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
and NN NN O
highly NN NN O
purified NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
from NN NN O
10 NN NN O
consecutive NN NN O
cardiac NN NN O
transplant NN NN O
recipients NN NN O
and NN NN O
10 NN NN O
healthy NN NN O
control NN NN O
subjects NN NN O
. NN NN O
   
TF NN NN B-Protein
activity NN NN O
generated NN NN O
by NN NN O
both NN NN O
unstimulated NN NN O
and NN NN O
endotoxin NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
in NN NN O
transplant NN NN O
recipients NN NN O
than NN NN O
in NN NN O
control NN NN O
subjects NN NN O
( NN NN O
P NN NN O
< NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
Increased NN NN O
monocyte NN NN O
TF NN NN B-Protein
expression NN NN O
in NN NN O
transplant NN NN O
recipients NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
adversely NN NN O
affected NN NN O
by NN NN O
treatment NN NN O
with NN NN O
CsA NN NN O
: NN NN O
TF NN NN B-Protein
induction NN NN O
was NN NN O
markedly NN NN O
reduced NN NN O
by NN NN O
CsA NN NN O
serum NN NN O
concentrations NN NN O
reaching NN NN O
peak NN NN O
CsA NN NN O
drug NN NN O
levels NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
TF NN NN B-Protein
induction NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
high NN NN O
CsA NN NN O
blood NN NN O
concentrations NN NN O
was NN NN O
also NN NN O
observed NN NN O
when NN NN O
stimulation NN NN O
of NN NN O
cells NN NN O
was NN NN O
performed NN NN O
with NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
or NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
. NN NN O
   
As NN NN O
shown NN NN O
by NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
and NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
respectively NN NN O
, NN NN O
treatment NN NN O
with NN NN O
CsA NN NN O
leads NN NN O
to NN NN O
decreased NN NN O
TF NN NN B-Protein
mRNA NN NN O
expression NN NN O
and NN NN O
reduced NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
which NN NN O
is NN NN O
known NN NN O
to NN NN O
contribute NN NN O
to NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
TF NN NN B-Protein
promotor NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
TF NN NN B-Protein
activation NN NN O
, NN NN O
occurring NN NN O
in NN NN O
mononuclear NN NN O
cells NN NN O
of NN NN O
cardiac NN NN O
transplant NN NN O
recipients NN NN O
, NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
treatment NN NN O
with NN NN O
CsA NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
monocyte NN NN O
TF NN NN B-Protein
induction NN NN O
by NN NN O
CsA NN NN O
may NN NN O
contribute NN NN O
to NN NN O
its NN NN O
successful NN NN O
use NN NN O
in NN NN O
cardiac NN NN O
transplant NN NN O
medicine NN NN O
and NN NN O
might NN NN O
be NN NN O
useful NN NN O
in NN NN O
managing NN NN O
further NN NN O
settings NN NN O
of NN NN O
vascular NN NN O
pathology NN NN O
also NN NN O
known NN NN O
to NN NN O
involve NN NN O
TF NN NN B-Protein
expression NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
Agonistic NN NN O
activity NN NN O
of NN NN O
a NN NN O
CD40 NN NN B-Protein
- NN NN O
specific NN NN O
single NN NN O
- NN NN O
chain NN NN O
Fv NN NN O
constructed NN NN O
from NN NN O
the NN NN O
variable NN NN O
regions NN NN O
of NN NN O
mAb NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
. NN NN O
   
A NN NN O
single NN NN O
- NN NN O
chain NN NN O
Fv NN NN O
( NN NN O
sFv NN NN O
) NN NN O
was NN NN O
expressed NN NN O
from NN NN O
the NN NN O
variable NN NN O
regions NN NN O
of NN NN O
the NN NN O
CD40 NN NN B-Protein
- NN NN O
specific NN NN O
mAb NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
. NN NN O
   
The NN NN O
molecule NN NN O
bound NN NN O
CD40 NN NN B-Protein
with NN NN O
a NN NN O
high NN NN O
affinity NN NN O
( NN NN O
2 NN NN O
. NN NN O
2 NN NN O
nM NN NN O
) NN NN O
and NN NN O
was NN NN O
a NN NN O
monomer NN NN O
in NN NN O
solution NN NN O
. NN NN O
   
Surprisingly NN NN O
, NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
sFv NN NN O
was NN NN O
a NN NN O
potent NN NN O
CD40 NN NN B-Protein
agonist NN NN O
that NN NN O
rapidly NN NN O
crosslinked NN NN O
CD40 NN NN B-Protein
on NN NN O
the NN NN O
cell NN NN O
surface NN NN O
but NN NN O
did NN NN O
not NN NN O
crosslink NN NN O
CD40 NN NN B-Protein
- NN NN O
Ig NN NN O
in NN NN O
solution NN NN O
. NN NN O
   
G28 NN NN O
- NN NN O
5 NN NN O
sFv NN NN O
was NN NN O
a NN NN O
more NN NN O
potent NN NN O
agonist NN NN O
than NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
IgG NN NN O
and NN NN O
was NN NN O
able NN NN O
to NN NN O
stimulate NN NN O
CD40 NN NN B-Protein
responses NN NN O
by NN NN O
B NN NN O
cells NN NN O
and NN NN O
monocytes NN NN O
. NN NN O
   
G28 NN NN O
- NN NN O
5 NN NN O
IgG NN NN B-Protein
partially NN NN O
blocked NN NN O
, NN NN O
whereas NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
sFv NN NN O
augmented NN NN O
CD40 NN NN B-Protein
responses NN NN O
during NN NN O
stimulation NN NN O
with NN NN O
natural NN NN O
ligand NN NN O
( NN NN O
gp39 NN NN B-Protein
- NN NN O
CD8 NN NN O
fusion NN NN O
protein NN NN O
) NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
functional NN NN O
activity NN NN O
of NN NN O
ligands NN NN O
built NN NN O
from NN NN O
the NN NN O
binding NN NN O
site NN NN O
of NN NN O
G28 NN NN O
- NN NN O
5 NN NN O
is NN NN O
highly NN NN O
dependent NN NN O
upon NN NN O
the NN NN O
size NN NN O
and NN NN O
physical NN NN O
properties NN NN O
of NN NN O
the NN NN O
molecule NN NN O
both NN NN O
in NN NN O
solution NN NN O
and NN NN O
on NN NN O
the NN NN O
cell NN NN O
surfaces NN NN O
. NN NN O
   
Competent NN NN O
transcription NN NN O
initiation NN NN O
by NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
in NN NN O
cell NN NN O
- NN NN O
free NN NN O
extracts NN NN O
from NN NN O
xeroderma NN NN O
pigmentosum NN NN O
groups NN NN O
B NN NN O
and NN NN O
D NN NN O
in NN NN O
an NN NN O
optimized NN NN O
RNA NN NN O
transcription NN NN O
assay NN NN O
. NN NN O
   
The NN NN O
human NN NN O
autosomal NN NN O
recessive NN NN O
disease NN NN O
, NN NN O
xeroderma NN NN O
pigmentosum NN NN O
( NN NN O
XP NN NN O
) NN NN O
, NN NN O
can NN NN O
result NN NN O
from NN NN O
mutations NN NN O
in NN NN O
any NN NN O
one NN NN O
of NN NN O
seven NN NN O
genes NN NN O
, NN NN O
designated NN NN O
XPA NN NN B-Protein
through NN NN O
XPG NN NN B-Protein
. NN NN O
   
Of NN NN O
these NN NN O
, NN NN O
the NN NN O
XPB NN NN B-Protein
and NN NN O
XPD NN NN B-Protein
genes NN NN O
encode NN NN O
proteins NN NN O
that NN NN O
are NN NN O
subunits NN NN O
of NN NN O
a NN NN O
general NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
TFIIH NN NN O
, NN NN O
involved NN NN O
in NN NN O
both NN NN O
nucleotide NN NN O
excision NN NN O
repair NN NN O
( NN NN O
NER NN NN O
) NN NN O
and NN NN O
initiation NN NN O
of NN NN O
mRNA NN NN O
transcription NN NN O
by NN NN O
RNA NN NN O
polymerase NN NN O
II NN NN O
. NN NN O
   
In NN NN O
humans NN NN O
, NN NN O
mutation NN NN O
of NN NN O
the NN NN O
XPB NN NN B-Protein
or NN NN O
XPD NN NN B-Protein
gene NN NN O
impairs NN NN O
NER NN NN O
, NN NN O
resulting NN NN O
in NN NN O
hyper NN NN O
- NN NN O
sensitivity NN NN O
to NN NN O
sunlight NN NN O
and NN NN O
greatly NN NN O
increased NN NN O
skin NN NN O
tumor NN NN O
formation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
no NN NN O
transcription NN NN O
deficiency NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
in NN NN O
either NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
or NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
. NN NN O
   
We NN NN O
have NN NN O
employed NN NN O
an NN NN O
optimized NN NN O
cell NN NN O
- NN NN O
free NN NN O
RNA NN NN O
transcription NN NN O
assay NN NN O
to NN NN O
analyze NN NN O
transcription NN NN O
activity NN NN O
of NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
. NN NN O
   
Although NN NN O
the NN NN O
growth NN NN O
rate NN NN O
was NN NN O
normal NN NN O
, NN NN O
the NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
cells NN NN O
contained NN NN O
reduced NN NN O
amounts NN NN O
of NN NN O
TFIIH NN NN O
. NN NN O
   
Extracts NN NN O
prepared NN NN O
from NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
lymphoblastoid NN NN O
cells NN NN O
exhibited NN NN O
similar NN NN O
transcription NN NN O
activity NN NN O
from NN NN O
the NN NN O
adenovirus NN NN O
major NN NN O
late NN NN O
promoter NN NN O
when NN NN O
compared NN NN O
to NN NN O
that NN NN O
in NN NN O
extracts NN NN O
from NN NN O
normal NN NN O
cells NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
lymphoblastoid NN NN O
cells NN NN O
do NN NN O
not NN NN O
have NN NN O
impaired NN NN O
RNA NN NN O
transcription NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
consider NN NN O
the NN NN O
possible NN NN O
consequences NN NN O
of NN NN O
the NN NN O
reduced NN NN O
cellular NN NN O
content NN NN O
of NN NN O
TFIIH NN NN O
for NN NN O
the NN NN O
clinical NN NN O
symptoms NN NN O
in NN NN O
XP NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
or NN NN O
XP NN NN B-Protein
- NN NN I-Protein
D NN NN I-Protein
patients NN NN O
, NN NN O
and NN NN O
discuss NN NN O
a NN NN O
' NN NN O
conditional NN NN O
phenotype NN NN O
' NN NN O
that NN NN O
may NN NN O
involve NN NN O
an NN NN O
impairment NN NN O
of NN NN O
cellular NN NN O
function NN NN O
only NN NN O
under NN NN O
certain NN NN O
growth NN NN O
conditions NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
inhibits NN NN O
early NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
G0 NN NN B-Protein
/ NN NN I-Protein
G1 NN NN I-Protein
switch NN NN I-Protein
gene NN NN I-Protein
2 NN NN I-Protein
( NN NN O
G0S2 NN NN B-Protein
) NN NN O
in NN NN O
cultured NN NN O
human NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
( NN NN O
CsA NN NN O
) NN NN O
may NN NN O
achieve NN NN O
its NN NN O
immunosuppressive NN NN O
effects NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
calcium NN NN O
- NN NN O
and NN NN O
calmodulin NN NN O
- NN NN O
dependent NN NN O
phosphatase NN NN O
calcineurin NN NN O
which NN NN O
is NN NN O
required NN NN O
for NN NN O
activation NN NN O
of NN NN O
target NN NN O
genes NN NN O
by NN NN O
members NN NN O
of NN NN O
the NN NN O
NFAT NN NN O
( NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
) NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
. NN NN O
   
Among NN NN O
these NN NN O
target NN NN O
genes NN NN O
is NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL2 NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
cytokine NN NN O
facilitating NN NN O
progression NN NN O
through NN NN O
the NN NN O
G1 NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O
   
However NN NN O
, NN NN O
IL2 NN NN B-Protein
does NN NN O
not NN NN O
reverse NN NN O
CsA NN NN O
inhibition NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
at NN NN O
least NN NN O
one NN NN O
other NN NN O
NFAT NN NN O
- NN NN O
sensitive NN NN O
gene NN NN O
may NN NN O
be NN NN O
involved NN NN O
. NN NN O
   
The NN NN O
human NN NN O
G0 NN NN B-Protein
/ NN NN I-Protein
G1 NN NN I-Protein
switch NN NN I-Protein
gene NN NN I-Protein
, NN NN O
G0S2 NN NN B-Protein
, NN NN O
has NN NN O
potential NN NN O
NFAT NN NN O
- NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
flank NN NN O
and NN NN O
encodes NN NN O
a NN NN O
small NN NN O
basic NN NN O
potential NN NN O
phosphoprotein NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O
   
Using NN NN O
a NN NN O
sensitive NN NN O
, NN NN O
reverse NN NN O
transcription NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
assay NN NN O
, NN NN O
G0S2 NN NN B-Protein
mRNA NN NN O
levels NN NN O
were NN NN O
assayed NN NN O
in NN NN O
cultured NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Freshly NN NN O
isolated NN NN O
cells NN NN O
contain NN NN O
high NN NN O
levels NN NN O
of NN NN O
G0S2 NN NN B-Protein
mRNA NN NN O
which NN NN O
rapidly NN NN O
decline NN NN O
. NN NN O
   
This NN NN O
"""""""" NN NN O
spontaneous NN NN O
stimulation NN NN O
"""""""" NN NN O
is NN NN O
also NN NN O
noted NN NN O
with NN NN O
some NN NN O
other NN NN O
G0S NN NN B-Protein
genes NN NN O
and NN NN O
has NN NN O
been NN NN O
attributed NN NN O
to NN NN O
some NN NN O
aspect NN NN O
of NN NN O
the NN NN O
isolation NN NN O
procedure NN NN O
. NN NN O
   
In NN NN O
cells NN NN O
that NN NN O
have NN NN O
been NN NN O
preincubated NN NN O
to NN NN O
lower NN NN O
mRNA NN NN O
levels NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
transient NN NN O
increase NN NN O
in NN NN O
G0S2 NN NN B-Protein
mRNA NN NN O
, NN NN O
peaking NN NN O
between NN NN O
1 NN NN O
- NN NN O
2 NN NN O
h NN NN O
, NN NN O
in NN NN O
response NN NN O
to NN NN O
Concanavalin NN NN O
- NN NN O
A NN NN O
( NN NN O
ConA NN NN O
) NN NN O
, NN NN O
or NN NN O
to NN NN O
the NN NN O
combination NN NN O
of NN NN O
phorbol NN NN O
ester NN NN O
( NN NN O
TPA NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
calcium NN NN O
ionophore NN NN O
, NN NN O
ionomycin NN NN O
. NN NN O
   
Both NN NN O
these NN NN O
responses NN NN O
are NN NN O
inhibited NN NN O
by NN NN O
CsA NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
G0S2 NN NN B-Protein
expression NN NN O
is NN NN O
required NN NN O
to NN NN O
commit NN NN O
cells NN NN O
to NN NN O
enter NN NN O
the NN NN O
G1 NN NN O
phase NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
, NN NN O
and NN NN O
that NN NN O
, NN NN O
while NN NN O
not NN NN O
excluding NN NN O
other NN NN O
possible NN NN O
targets NN NN O
, NN NN O
early NN NN O
inhibition NN NN O
of NN NN O
G0S2 NN NN B-Protein
expression NN NN O
by NN NN O
CsA NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
achieving NN NN O
immunosuppression NN NN O
. NN NN O
   
G0S2 NN NN B-Protein
may NN NN O
be NN NN O
of NN NN O
value NN NN O
as NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
for NN NN O
analyzing NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
action NN NN O
of NN NN O
CsA NN NN O
and NN NN O
its NN NN O
influence NN NN O
on NN NN O
the NN NN O
positive NN NN O
and NN NN O
negative NN NN O
selection NN NN O
of NN NN O
lymphocytes NN NN O
in NN NN O
response NN NN O
to NN NN O
self NN NN O
and NN NN O
not NN NN O
- NN NN O
self NN NN O
antigens NN NN O
. NN NN O
   
Estrogen NN NN B-Protein
receptor NN NN I-Protein
diminishes NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
of NN NN O
chicken NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CACCC NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
. NN NN O
   
The NN NN O
estrogen NN NN B-Protein
receptor NN NN I-Protein
( NN NN O
ER NN NN B-Protein
) NN NN O
repressed NN NN O
erythroid NN NN O
differentiation NN NN O
and NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effect NN NN O
of NN NN O
ER NN NN B-Protein
alpha NN NN I-Protein
( NN NN O
referred NN NN O
to NN NN O
throughout NN NN O
as NN NN O
ER NN NN B-Protein
) NN NN O
on NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
, NN NN O
and NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
the NN NN O
histone NN NN B-Protein
H5 NN NN I-Protein
gene NN NN O
. NN NN O
   
Using NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
rabbit NN NN O
reticulocyte NN NN O
lysate NN NN O
, NN NN O
human NN NN O
ER NN NN B-Protein
reduced NN NN O
the NN NN O
binding NN NN O
activities NN NN O
of NN NN O
chicken NN NN O
immature NN NN O
erythrocyte NN NN O
nuclear NN NN O
extracted NN NN O
proteins NN NN O
to NN NN O
GATA NN NN O
and NN NN O
CACCC NN NN O
sites NN NN O
in NN NN O
the NN NN O
H5 NN NN O
promoter NN NN O
and NN NN O
enhancer NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
binding NN NN O
activities NN NN O
of NN NN O
NF1 NN NN O
and NN NN O
Sp1 NN NN B-Protein
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
ER NN NN B-Protein
. NN NN O
   
Binding NN NN O
of NN NN O
ER NN NN B-Protein
to NN NN O
an NN NN O
estrogen NN NN O
response NN NN O
element NN NN O
was NN NN O
enhanced NN NN O
by NN NN O
addition NN NN O
of NN NN O
rabbit NN NN O
reticulocyte NN NN O
lysate NN NN O
. NN NN O
   
This NN NN O
lysate NN NN O
was NN NN O
also NN NN O
necessary NN NN O
for NN NN O
ER NN NN B-Protein
to NN NN O
diminish NN NN O
the NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
additional NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
are NN NN O
necessary NN NN O
for NN NN O
full NN NN O
ER NN NN B-Protein
function NN NN O
. NN NN O
   
Both NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CACCC NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
are NN NN O
critical NN NN O
for NN NN O
the NN NN O
developmentally NN NN O
regulated NN NN O
expression NN NN O
of NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
genes NN NN O
. NN NN O
   
We NN NN O
hypothesize NN NN O
that NN NN O
interference NN NN O
in NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
of NN NN O
GATA NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
CACCC NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
is NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
the NN NN O
ER NN NN B-Protein
inhibits NN NN O
regulation NN NN O
of NN NN O
these NN NN O
genes NN NN O
. NN NN O
   
Constitutive NN NN O
expression NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
mRNA NN NN O
is NN NN O
in NN NN O
nucleated NN NN O
fetal NN NN O
blood NN NN O
cells NN NN O
and NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
. NN NN O
   
Fetal NN NN O
and NN NN O
neonatal NN NN O
lymphocytes NN NN O
are NN NN O
relatively NN NN O
resistant NN NN O
to NN NN O
activation NN NN O
and NN NN O
cytokine NN NN O
production NN NN O
when NN NN O
stimulated NN NN O
either NN NN O
via NN NN O
their NN NN O
T NN NN O
- NN NN O
cell NN NN O
antigen NN NN O
receptors NN NN O
or NN NN O
lectins NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
responsible NN NN O
for NN NN O
this NN NN O
phenomenon NN NN O
have NN NN O
not NN NN O
been NN NN O
clearly NN NN O
elucidated NN NN O
. NN NN O
   
We NN NN O
have NN NN O
hypothesized NN NN O
that NN NN O
such NN NN O
defects NN NN O
in NN NN O
fetal NN NN O
/ NN NN O
neonatal NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
lack NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
regulatory NN NN O
elements NN NN O
required NN NN O
for NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
used NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
to NN NN O
examine NN NN O
both NN NN O
fetal NN NN O
and NN NN O
term NN NN O
neonatal NN NN O
cord NN NN O
bloods NN NN O
for NN NN O
mRNA NN NN O
expression NN NN O
of NN NN O
three NN NN O
transcription NN NN O
factors NN NN O
implicated NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
: NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
, NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
( NN NN O
p50 NN NN B-Protein
subunit NN NN O
) NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
mRNAs NN NN O
for NN NN O
all NN NN O
three NN NN O
of NN NN O
these NN NN O
regulatory NN NN O
factors NN NN O
are NN NN O
expressed NN NN O
in NN NN O
fetal NN NN O
blood NN NN O
cells NN NN O
by NN NN O
the NN NN O
27th NN NN O
week NN NN O
of NN NN O
gestation NN NN O
and NN NN O
in NN NN O
term NN NN O
cord NN NN O
bloods NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
term NN NN O
infant NN NN O
cord NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
monoclonal NN NN O
antibodies NN NN O
resulted NN NN O
in NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
both NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
mRNAs NN NN O
within NN NN O
15 NN NN O
min NN NN O
of NN NN O
stimulation NN NN O
. NN NN O
   
However NN NN O
, NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
by NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
stimulated NN NN O
cord NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
was NN NN O
still NN NN O
blunted NN NN O
compared NN NN O
with NN NN O
control NN NN O
cells NN NN O
from NN NN O
adults NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
fetal NN NN O
nucleated NN NN O
blood NN NN O
cells NN NN O
constitutively NN NN O
express NN NN O
important NN NN O
genes NN NN O
for NN NN O
cytokine NN NN O
regulation NN NN O
and NN NN O
are NN NN O
able NN NN O
to NN NN O
increase NN NN O
intracellular NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
mRNAs NN NN O
for NN NN O
these NN NN O
factors NN NN O
in NN NN O
response NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
qualitative NN NN O
differences NN NN O
in NN NN O
the NN NN O
capacity NN NN O
to NN NN O
regulate NN NN O
these NN NN O
factors NN NN O
could NN NN O
not NN NN O
be NN NN O
shown NN NN O
in NN NN O
fetal NN NN O
blood NN NN O
cells NN NN O
. NN NN O
   
Quantitative NN NN O
experiments NN NN O
comparing NN NN O
binding NN NN O
of NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
are NN NN O
currently NN NN O
under NN NN O
investigation NN NN O
. NN NN O
   
Replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
- NN NN O
1 NN NN O
in NN NN O
primary NN NN O
human NN NN O
T NN NN O
cells NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
autocrine NN NN O
secretion NN NN O
of NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
through NN NN O
the NN NN O
control NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
( NN NN I-Protein
TNF NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
controls NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
and NN NN O
is NN NN O
a NN NN O
major NN NN O
inducer NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
cells NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
its NN NN O
role NN NN O
in NN NN O
primary NN NN O
cultures NN NN O
of NN NN O
HIV NN NN O
- NN NN O
infected NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
using NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibodies NN NN O
or NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
Primary NN NN O
resting NN NN O
T NN NN O
lymphocytes NN NN O
produced NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
supported NN NN O
HIV NN NN O
replication NN NN O
after NN NN O
T NN NN O
- NN NN O
cell NN NN O
receptor NN NN O
activation NN NN O
. NN NN O
   
Addition NN NN O
of NN NN O
neutralizing NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
antibodies NN NN O
drastically NN NN O
reduced NN NN O
p24 NN NN B-Protein
antigen NN NN O
release NN NN O
and NN NN O
prevented NN NN O
CD4 NN NN B-Protein
+ NN NN O
cell NN NN O
depletion NN NN O
associated NN NN O
with NN NN O
infection NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
also NN NN O
prevented NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
activation NN NN O
, NN NN O
and NN NN O
a NN NN O
good NN NN O
correlation NN NN O
between NN NN O
this NN NN O
inhibition NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
supplementing NN NN O
the NN NN O
cultures NN NN O
with NN NN O
high NN NN O
doses NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
reverted NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
inhibition NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
but NN NN O
did NN NN O
not NN NN O
affect NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
p24 NN NN B-Protein
antigen NN NN O
release NN NN O
or NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
the NN NN O
same NN NN O
cultures NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
anti NN NN O
- NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
- NN NN O
driven NN NN O
transcription NN NN O
of NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
in NN NN O
primary NN NN O
T NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
activation NN NN O
, NN NN O
either NN NN O
in NN NN O
the NN NN O
presence NN NN O
or NN NN O
the NN NN O
absence NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
. NN NN O
   
Our NN NN O
results NN NN O
support NN NN O
an NN NN O
important NN NN O
role NN NN O
for NN NN O
autocrine NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
in NN NN O
controlling NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
primary NN NN O
T NN NN O
cells NN NN O
because NN NN O
of NN NN O
its NN NN O
ability NN NN O
to NN NN O
maintain NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
elevated NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
thiol NN NN O
antioxidant NN NN O
regulates NN NN O
IgE NN NN O
isotype NN NN O
switching NN NN O
by NN NN O
inhibiting NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
site NN NN O
for NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
is NN NN O
present NN NN O
at NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
germline NN NN O
Cepsilon NN NN O
gene NN NN O
, NN NN O
but NN NN O
there NN NN O
is NN NN O
little NN NN O
information NN NN O
on NN NN O
whether NN NN O
this NN NN O
factor NN NN O
is NN NN O
involved NN NN O
in NN NN O
regulating NN NN O
IgE NN NN O
synthesis NN NN O
by NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Accordingly NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
role NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
by NN NN O
using NN NN O
two NN NN O
human NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
B NN NN O
cell NN NN O
lines NN NN O
, NN NN O
DND39 NN NN O
and NN NN O
DG75 NN NN O
. NN NN O
   
In NN NN O
both NN NN O
cell NN NN O
lines NN NN O
, NN NN O
n NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
cysteine NN NN O
( NN NN O
NAC NN NN O
) NN NN O
, NN NN O
a NN NN O
potent NN NN O
thiol NN NN O
antioxidant NN NN O
, NN NN O
inhibited NN NN O
the NN NN O
triggering NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
monoclonal NN NN O
antibody NN NN O
. NN NN O
   
Although NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
activated NN NN O
signal NN NN B-Protein
transducers NN NN I-Protein
and NN NN I-Protein
activators NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
( NN NN I-Protein
STAT NN NN I-Protein
) NN NN I-Protein
6 NN NN I-Protein
in NN NN O
addition NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
NAC NN NN O
treatment NN NN O
or NN NN O
the NN NN O
transfection NN NN O
of NN NN O
decoy NN NN O
oligodeoxynucleotides NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
or NN NN O
STAT6 NN NN B-Protein
only NN NN O
partly NN NN O
blocked NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
. NN NN O
   
However NN NN O
, NN NN O
these NN NN O
two NN NN O
decoy NN NN O
oligodeoxynucleotides NN NN O
together NN NN O
almost NN NN O
completely NN NN O
abrogated NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
. NN NN O
   
Of NN NN O
note NN NN O
, NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
enhancement NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
driven NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
was NN NN O
markedly NN NN O
decreased NN NN O
by NN NN O
NAC NN NN O
or NN NN O
by NN NN O
a NN NN O
decoy NN NN O
oligodeoxynucleotide NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
NAC NN NN O
was NN NN O
also NN NN O
examined NN NN O
on NN NN O
deletional NN NN O
switch NN NN O
recombination NN NN O
underlying NN NN O
the NN NN O
isotype NN NN O
switch NN NN O
to NN NN O
IgE NN NN O
. NN NN O
   
NAC NN NN O
inhibited NN NN O
the NN NN O
generation NN NN O
of NN NN O
Smu NN NN O
/ NN NN O
Sepsilon NN NN O
switch NN NN O
fragments NN NN O
in NN NN O
normal NN NN O
human NN NN O
B NN NN O
cells NN NN O
costimulated NN NN O
with NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
and NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
monoclonal NN NN O
antibody NN NN O
. NN NN O
   
It NN NN O
also NN NN O
abolished NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
induced NN NN O
upregulation NN NN O
of NN NN O
CD40 NN NN B-Protein
but NN NN O
promoted NN NN O
upregulation NN NN O
of NN NN O
CD23 NN NN B-Protein
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
coordination NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
STAT6 NN NN B-Protein
may NN NN O
be NN NN O
required NN NN O
for NN NN O
induction NN NN O
of NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
and NN NN O
that NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
regulating NN NN O
both NN NN O
enhancement NN NN O
of NN NN O
germline NN NN O
Cepsilon NN NN O
transcription NN NN O
and NN NN O
class NN NN O
switching NN NN O
to NN NN O
IgE NN NN O
. NN NN O
   
Cellular NN NN O
and NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
in NN NN O
atopic NN NN O
diseases NN NN O
: NN NN O
a NN NN O
study NN NN O
with NN NN O
allergen NN NN O
- NN NN O
specific NN NN O
human NN NN O
helper NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
BACKGROUND NN NN O
: NN NN O
Cytokines NN NN O
produced NN NN O
by NN NN O
helper NN NN O
T NN NN O
cells NN NN O
are NN NN O
intimately NN NN O
involved NN NN O
in NN NN O
chronic NN NN O
allergic NN NN O
diseases NN NN O
associated NN NN O
with NN NN O
eosinophilic NN NN O
inflammation NN NN O
. NN NN O
   
OBJECTIVE NN NN O
: NN NN O
We NN NN O
investigated NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
, NN NN O
a NN NN O
potent NN NN O
growth NN NN O
factor NN NN O
and NN NN O
chemotactic NN NN O
factor NN NN O
for NN NN O
eosinophils NN NN O
, NN NN O
by NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
patients NN NN O
with NN NN O
asthma NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
Allergen NN NN O
- NN NN O
specific NN NN O
T NN NN O
cell NN NN O
clones NN NN O
and NN NN O
T NN NN O
cell NN NN O
hybridomas NN NN O
were NN NN O
established NN NN O
from NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
of NN NN O
patients NN NN O
with NN NN O
asthma NN NN O
, NN NN O
and NN NN O
the NN NN O
responses NN NN O
to NN NN O
various NN NN O
stimuli NN NN O
were NN NN O
determined NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
After NN NN O
nonspecific NN NN O
stimulation NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
production NN NN O
by NN NN O
CD4 NN NN O
+ NN NN O
T NN NN O
cells NN NN O
from NN NN O
both NN NN O
atopic NN NN O
and NN NN O
nonatopic NN NN O
subjects NN NN O
with NN NN O
asthma NN NN O
was NN NN O
significantly NN NN O
enhanced NN NN O
compared NN NN O
with NN NN O
that NN NN O
by NN NN O
cells NN NN O
from NN NN O
healthy NN NN O
controls NN NN O
. NN NN O
   
Peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
from NN NN O
atopic NN NN O
asthma NN NN O
patients NN NN O
both NN NN O
proliferated NN NN O
and NN NN O
produced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
after NN NN O
incubation NN NN O
with NN NN O
mite NN NN O
allergen NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
mite NN NN O
- NN NN O
specific NN NN O
helper NN NN O
T NN NN O
cells NN NN O
were NN NN O
involved NN NN O
in NN NN O
the NN NN O
eosinophilic NN NN O
inflammation NN NN O
of NN NN O
atopic NN NN O
asthma NN NN O
. NN NN O
   
A NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
promoter NN NN O
/ NN NN O
enhancer NN NN O
luciferase NN NN O
gene NN NN O
construct NN NN O
transfected NN NN O
into NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
producing NN NN O
T NN NN O
cell NN NN O
clones NN NN O
was NN NN O
clearly NN NN O
transcribed NN NN O
after NN NN O
stimulation NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
515 NN NN O
base NN NN O
pair NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
segment NN NN O
upstream NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
was NN NN O
sufficient NN NN O
to NN NN O
respond NN NN O
to NN NN O
activating NN NN O
signals NN NN O
in NN NN O
human NN NN O
helper NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
same NN NN O
gene NN NN O
segment NN NN O
was NN NN O
not NN NN O
transcribed NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
nonproducing NN NN O
T NN NN O
cell NN NN O
clones NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
human NN NN O
T NN NN O
cell NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
synthesis NN NN O
is NN NN O
regulated NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O
   
Experiments NN NN O
with NN NN O
T NN NN O
cell NN NN O
hybridomas NN NN O
confirmed NN NN O
these NN NN O
findings NN NN O
and NN NN O
suggested NN NN O
that NN NN O
a NN NN O
unique NN NN O
transcription NN NN O
factor NN NN O
may NN NN O
be NN NN O
essential NN NN O
for NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
gene NN NN O
transcription NN NN O
. NN NN O
   
CONCLUSION NN NN O
: NN NN O
Enhanced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
production NN NN O
by NN NN O
helper NN NN O
T NN NN O
cells NN NN O
seems NN NN O
to NN NN O
cause NN NN O
the NN NN O
eosinophilic NN NN O
inflammation NN NN O
of NN NN O
both NN NN O
atopic NN NN O
and NN NN O
nonatopic NN NN O
asthma NN NN O
. NN NN O
   
Elucidation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
5 NN NN I-Protein
- NN NN O
specific NN NN O
regulatory NN NN O
mechanisms NN NN O
may NN NN O
facilitate NN NN O
the NN NN O
development NN NN O
of NN NN O
novel NN NN O
treatments NN NN O
for NN NN O
allergic NN NN O
diseases NN NN O
associated NN NN O
with NN NN O
eosinophilic NN NN O
inflammation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
by NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
stability NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
must NN NN O
be NN NN O
released NN NN O
from NN NN O
cytoplasmic NN NN O
inhibitory NN NN O
molecules NN NN O
( NN NN O
I NN NN O
kappa NN NN O
Bs NN NN O
) NN NN O
in NN NN O
order NN NN O
to NN NN O
move NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
to NN NN O
activate NN NN O
its NN NN O
target NN NN O
genes NN NN O
. NN NN O
   
Little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
mechanisms NN NN O
regulating NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
constitutive NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
some NN NN O
cell NN NN O
- NN NN O
types NN NN O
and NN NN O
of NN NN O
sustained NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
Increased NN NN O
turnover NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
in NN NN O
mature NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
compared NN NN O
the NN NN O
turnover NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
in NN NN O
mature NN NN O
B NN NN O
cells NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
Both NN NN O
proteins NN NN O
display NN NN O
a NN NN O
high NN NN O
turnover NN NN O
in NN NN O
B NN NN O
cells NN NN O
although NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
is NN NN O
considerably NN NN O
more NN NN O
stable NN NN O
than NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
half NN NN O
- NN NN O
life NN NN O
of NN NN O
both NN NN O
inhibitors NN NN O
is NN NN O
increased NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
all NN NN O
other NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
I NN NN O
kappa NN NN O
B NN NN O
molecules NN NN O
tested NN NN O
are NN NN O
relatively NN NN O
stable NN NN O
in NN NN O
both NN NN O
cell NN NN O
- NN NN O
types NN NN O
. NN NN O
   
The NN NN O
elevated NN NN O
turnover NN NN O
of NN NN O
endogenous NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
Namalwa NN NN O
cells NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
proteasome NN NN O
inhibitor NN NN O
and NN NN O
thus NN NN O
seems NN NN O
to NN NN O
be NN NN O
driven NN NN O
by NN NN O
the NN NN O
same NN NN O
degradation NN NN O
machinery NN NN O
as NN NN O
the NN NN O
slower NN NN O
turnover NN NN O
in NN NN O
non NN NN O
- NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
processes NN NN O
involved NN NN O
in NN NN O
persistent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
signaling NN NN O
leads NN NN O
to NN NN O
a NN NN O
rapid NN NN O
depletion NN NN O
of NN NN O
cellular NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
pools NN NN O
. NN NN O
   
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
efficiently NN NN O
resynthesized NN NN O
whereas NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
levels NN NN O
stay NN NN O
low NN NN O
for NN NN O
a NN NN O
prolonged NN NN O
time NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
binding NN NN O
activity NN NN O
can NN NN O
be NN NN O
detected NN NN O
for NN NN O
several NN NN O
hours NN NN O
after NN NN O
stimulation NN NN O
. NN NN O
   
We NN NN O
found NN NN O
that NN NN O
removal NN NN O
of NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
containing NN NN O
medium NN NN O
causes NN NN O
a NN NN O
rapid NN NN O
decrease NN NN O
in NN NN O
nuclear NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
A NN NN O
phosphoform NN NN O
of NN NN O
newly NN NN O
synthesized NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
is NN NN O
visible NN NN O
when NN NN O
degradation NN NN O
by NN NN O
the NN NN O
proteasome NN NN O
is NN NN O
inhibited NN NN O
and NN NN O
new NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
displays NN NN O
the NN NN O
same NN NN O
properties NN NN O
regarding NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
in NN NN O
response NN NN O
to NN NN O
a NN NN O
second NN NN O
inducer NN NN O
. NN NN O
   
There NN NN O
is NN NN O
no NN NN O
significant NN NN O
difference NN NN O
in NN NN O
the NN NN O
turnover NN NN O
of NN NN O
pre NN NN O
- NN NN O
and NN NN O
post NN NN O
- NN NN O
inductive NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
resynthesis NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
removal NN NN O
of NN NN O
the NN NN O
stimulus NN NN O
are NN NN O
obligatory NN NN O
steps NN NN O
for NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
nuclear NN NN O
NF NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Control NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activity NN NN O
by NN NN O
the NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
inhibitor NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
maintained NN NN O
in NN NN O
an NN NN O
inactive NN NN O
cytoplasmic NN NN O
state NN NN O
by NN NN O
I NN NN O
kappa NN NN O
B NN NN O
inhibitors NN NN O
. NN NN O
   
In NN NN O
mammalian NN NN O
cells NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
proteins NN NN O
have NN NN O
been NN NN O
purified NN NN O
and NN NN O
shown NN NN O
to NN NN O
be NN NN O
the NN NN O
inhibitors NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
through NN NN O
their NN NN O
association NN NN O
with NN NN O
the NN NN O
p65 NN NN B-Protein
or NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
subunits NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
we NN NN O
have NN NN O
isolated NN NN O
a NN NN O
third NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
inhibitor NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
epsilon NN NN I-Protein
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
Upon NN NN O
treatment NN NN O
with NN NN O
a NN NN O
large NN NN O
variety NN NN O
of NN NN O
inducers NN NN O
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
are NN NN O
proteolytically NN NN O
degraded NN NN O
, NN NN O
resulting NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
translocation NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
in NN NN O
E29 NN NN O
. NN NN O
1 NN NN O
T NN NN O
cell NN NN O
hybridoma NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
are NN NN O
equally NN NN O
associated NN NN O
with NN NN O
p65 NN NN B-Protein
and NN NN O
that NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
is NN NN O
degraded NN NN O
in NN NN O
response NN NN O
to NN NN O
TNF NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
contrast NN NN O
to NN NN O
what NN NN O
has NN NN O
been NN NN O
originally NN NN O
published NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
also NN NN O
suggest NN NN O
that NN NN O
, NN NN O
unlike NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
is NN NN O
constitutively NN NN O
phosphorylated NN NN O
and NN NN O
resynthesized NN NN O
as NN NN O
a NN NN O
hypophosphorylated NN NN O
form NN NN O
. NN NN O
   
The NN NN O
absence NN NN O
of NN NN O
slow NN NN O
migrating NN NN O
forms NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
beta NN NN I-Protein
following NN NN O
stimulation NN NN O
suggests NN NN O
that NN NN O
the NN NN O
phosphorylation NN NN O
does NN NN O
not NN NN O
necessarily NN NN O
constitute NN NN O
the NN NN O
signal NN NN O
- NN NN O
induced NN NN O
event NN NN O
which NN NN O
targets NN NN O
the NN NN O
molecule NN NN O
for NN NN O
proteolysis NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
members NN NN O
regulating NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
in NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
kappa NN NN O
B NN NN O
- NN NN O
site NN NN O
was NN NN O
identified NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
the NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
gene NN NN O
, NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
regulation NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
by NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
glucocorticoids NN NN O
. NN NN O
   
We NN NN O
now NN NN O
report NN NN O
on NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
which NN NN O
bind NN NN O
and NN NN O
transactivate NN NN O
this NN NN O
enhancer NN NN O
sequence NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
, NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
kappa NN NN O
B NN NN O
site NN NN O
appeared NN NN O
to NN NN O
bind NN NN O
RelA NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
homodimers NN NN O
as NN NN O
well NN NN O
as NN NN O
heterodimers NN NN O
with NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
, NN NN O
but NN NN O
weakly NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
homodimers NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
both NN NN O
RelA NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
, NN NN O
were NN NN O
shown NN NN O
to NN NN O
transactivate NN NN O
an NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
kappa NN NN O
B NN NN O
- NN NN O
reporter NN NN O
construct NN NN O
. NN NN O
   
In NN NN O
monocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
induced NN NN O
two NN NN O
nuclear NN NN O
complexes NN NN O
which NN NN O
in NN NN O
vitro NN NN O
bound NN NN O
to NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
Using NN NN O
antibodies NN NN O
in NN NN O
an NN NN O
electrophoretic NN NN O
mobility NN NN O
supershift NN NN O
assay NN NN O
, NN NN O
one NN NN O
of NN NN O
these NN NN O
complexes NN NN O
was NN NN O
shown NN NN O
to NN NN O
contain NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
and NN NN O
RelA NN NN B-Protein
, NN NN O
and NN NN O
to NN NN O
bind NN NN O
with NN NN O
higher NN NN O
affinity NN NN O
to NN NN O
the NN NN O
consensus NN NN O
kappa NN NN O
B NN NN O
site NN NN O
in NN NN O
the NN NN O
HIV NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
. NN NN O
   
The NN NN O
second NN NN O
complex NN NN O
contained NN NN O
RelA NN NN B-Protein
, NN NN O
and NN NN O
exhibited NN NN O
higher NN NN O
affinity NN NN O
towards NN NN O
the NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
kappa NN NN O
B NN NN O
than NN NN O
to NN NN O
the NN NN O
HIV NN NN O
kappa NN NN O
B NN NN O
site NN NN O
. NN NN O
   
The NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
was NN NN O
shown NN NN O
to NN NN O
repress NN NN O
activity NN NN O
of NN NN O
both NN NN O
the NN NN O
RelA NN NN B-Protein
homodimer NN NN O
and NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappa NN NN I-Protein
B1 NN NN I-Protein
/ NN NN O
RelA NN NN B-Protein
heterodimer NN NN O
. NN NN O
   
We NN NN O
argue NN NN O
that NN NN O
in NN NN O
vivo NN NN O
RelA NN NN B-Protein
homodimers NN NN O
are NN NN O
likely NN NN O
to NN NN O
play NN NN O
a NN NN O
dominant NN NN O
role NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
in NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
LPS NN NN O
tolerance NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
: NN NN O
three NN NN O
3 NN NN O
' NN NN O
cytosins NN NN O
are NN NN O
required NN NN O
in NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
motif NN NN O
for NN NN O
detection NN NN O
of NN NN O
upregulated NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
homodimers NN NN O
. NN NN O
   
When NN NN O
monocytes NN NN O
are NN NN O
stimulated NN NN O
with NN NN O
LPS NN NN O
( NN NN O
lipopolysaccharide NN NN O
) NN NN O
repeatedly NN NN O
then NN NN O
the NN NN O
initially NN NN O
high NN NN O
expression NN NN O
of NN NN O
the NN NN O
TNF NN NN B-Protein
( NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
) NN NN O
gene NN NN O
is NN NN O
only NN NN O
very NN NN O
low NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
the NN NN O
cells NN NN O
are NN NN O
tolerant NN NN O
to NN NN O
LPS NN NN O
. NN NN O
   
Tolerant NN NN O
cells NN NN O
still NN NN O
express NN NN O
the NN NN O
CD14 NN NN B-Protein
receptor NN NN I-Protein
and NN NN O
they NN NN O
can NN NN O
still NN NN O
be NN NN O
activated NN NN O
to NN NN O
mobilize NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
into NN NN O
nucleus NN NN O
. NN NN O
   
Analysis NN NN O
of NN NN O
the NN NN O
binding NN NN O
proteins NN NN O
employing NN NN O
the NN NN O
- NN NN O
605 NN NN O
motif NN NN O
of NN NN O
the NN NN O
human NN NN O
TNF NN NN O
promoter NN NN O
( NN NN O
GGGGCTGTCCC NN NN O
) NN NN O
revealed NN NN O
that NN NN O
in NN NN O
tolerant NN NN O
cells NN NN O
of NN NN O
the NN NN O
human NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
there NN NN O
is NN NN O
a NN NN O
predominance NN NN O
of NN NN O
p50p50 NN NN B-Protein
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
We NN NN O
now NN NN O
show NN NN O
that NN NN O
a NN NN O
mutant NN NN O
motif NN NN O
that NN NN O
exchanges NN NN O
the NN NN O
terminal NN NN O
3 NN NN O
' NN NN O
C NN NN O
for NN NN O
a NN NN O
G NN NN O
fails NN NN O
to NN NN O
bind NN NN O
the NN NN O
p50 NN NN B-Protein
homodimer NN NN O
that NN NN O
is NN NN O
upregulated NN NN O
in NN NN O
LPS NN NN O
toler NN NN O
ant NN NN O
human NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
same NN NN O
is NN NN O
true NN NN O
for NN NN O
nuclear NN NN O
extracts NN NN O
taken NN NN O
from NN NN O
the NN NN O
murine NN NN O
P388D1 NN NN O
macrophage NN NN O
cell NN NN O
line NN NN O
when NN NN O
tested NN NN O
with NN NN O
the NN NN O
- NN NN O
516 NN NN O
motif NN NN O
of NN NN O
the NN NN O
murine NN NN O
TNF NN NN O
promoter NN NN O
( NN NN O
GGGGGCTTTCCC NN NN O
) NN NN O
. NN NN O
   
Here NN NN O
the NN NN O
wild NN NN O
type NN NN O
motif NN NN O
gives NN NN O
efficient NN NN O
binding NN NN O
of NN NN O
p50p50 NN NN B-Protein
that NN NN O
again NN NN O
is NN NN O
upregulated NN NN O
in NN NN O
tolerant NN NN O
cells NN NN O
whereas NN NN O
a NN NN O
mutant NN NN O
with NN NN O
a NN NN O
3 NN NN O
' NN NN O
G NN NN O
shows NN NN O
hardly NN NN O
any NN NN O
binding NN NN O
of NN NN O
p50p50 NN NN B-Protein
. NN NN O
   
Conversely NN NN O
, NN NN O
the NN NN O
murine NN NN O
kappa NN NN B-Protein
light NN NN I-Protein
chain NN NN I-Protein
enhancer NN NN O
motif NN NN O
( NN NN O
GGGGACTTTCCG NN NN O
) NN NN O
does NN NN O
not NN NN O
efficiently NN NN O
bind NN NN O
the NN NN O
nuclear NN NN O
p50p50 NN NN B-Protein
from NN NN O
tolerant NN NN O
murine NN NN O
P388 NN NN O
macrophages NN NN O
. NN NN O
   
Binding NN NN O
is NN NN O
, NN NN O
however NN NN O
, NN NN O
readily NN NN O
detected NN NN O
when NN NN O
the NN NN O
3 NN NN O
' NN NN O
G NN NN O
is NN NN O
replaced NN NN O
by NN NN O
a NN NN O
C NN NN O
. NN NN O
   
These NN NN O
data NN NN O
show NN NN O
that NN NN O
the NN NN O
detection NN NN O
of NN NN O
upregulated NN NN O
p50 NN NN B-Protein
homodimers NN NN O
in NN NN O
LPS NN NN O
tolerant NN NN O
cells NN NN O
is NN NN O
dependent NN NN O
on NN NN O
subtle NN NN O
differences NN NN O
in NN NN O
the NN NN O
sequence NN NN O
of NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
motif NN NN O
. NN NN O
   
Temporal NN NN O
control NN NN O
of NN NN O
IgH NN NN B-Protein
gene NN NN O
expression NN NN O
in NN NN O
developing NN NN O
B NN NN O
cells NN NN O
by NN NN O
the NN NN O
3 NN NN O
' NN NN O
locus NN NN O
control NN NN O
region NN NN O
. NN NN O
   
The NN NN O
suggested NN NN O
roles NN NN O
of NN NN O
the NN NN O
downstream NN NN O
3 NN NN O
' NN NN O
regions NN NN O
acting NN NN O
as NN NN O
a NN NN O
Locus NN NN O
Control NN NN O
Region NN NN O
( NN NN O
LCR NN NN O
) NN NN O
, NN NN O
have NN NN O
allowed NN NN O
comparisons NN NN O
to NN NN O
be NN NN O
made NN NN O
between NN NN O
the NN NN O
regulation NN NN O
of NN NN O
the NN NN O
IgH NN NN B-Protein
locus NN NN O
with NN NN O
other NN NN O
model NN NN O
systems NN NN O
whose NN NN O
gene NN NN O
expression NN NN O
is NN NN O
governed NN NN O
by NN NN O
LCR NN NN O
activity NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
summarize NN NN O
the NN NN O
importance NN NN O
of NN NN O
the NN NN O
IgH NN NN B-Protein
3 NN NN O
' NN NN O
LCR NN NN O
and NN NN O
its NN NN O
putative NN NN O
functional NN NN O
role NN NN O
in NN NN O
IgH NN NN B-Protein
gene NN NN O
expression NN NN O
and NN NN O
compare NN NN O
it NN NN O
with NN NN O
the NN NN O
5 NN NN O
' NN NN O
LCR NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
locus NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
genes NN NN O
after NN NN O
influenza NN NN O
A NN NN O
virus NN NN O
infection NN NN O
. NN NN O
   
Infection NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
with NN NN O
influenza NN NN O
A NN NN O
virus NN NN O
induces NN NN O
a NN NN O
broad NN NN O
range NN NN O
of NN NN O
proinflammatory NN NN O
cytokines NN NN O
and NN NN O
mononuclear NN NN O
cell NN NN O
attracting NN NN O
chemokines NN NN O
before NN NN O
the NN NN O
infected NN NN O
cells NN NN O
undergo NN NN O
apoptosis NN NN O
. NN NN O
   
The NN NN O
underlying NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
the NN NN O
corresponding NN NN O
genes NN NN O
are NN NN O
transcriptionally NN NN O
initiated NN NN O
after NN NN O
virus NN NN O
infection NN NN O
are NN NN O
still NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
seems NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
many NN NN O
proinflammatory NN NN O
cytokine NN NN O
genes NN NN O
, NN NN O
but NN NN O
cannot NN NN O
be NN NN O
the NN NN O
only NN NN O
mechanism NN NN O
, NN NN O
since NN NN O
several NN NN O
cytokine NN NN O
genes NN NN O
lack NN NN O
respective NN NN O
binding NN NN O
sites NN NN O
in NN NN O
their NN NN O
promoter NN NN O
regions NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
additionally NN NN O
investigated NN NN O
other NN NN O
transcription NN NN O
factors NN NN O
of NN NN O
possible NN NN O
importance NN NN O
such NN NN O
as NN NN O
CREB NN NN O
, NN NN O
CTF NN NN B-Protein
, NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
To NN NN O
explore NN NN O
long NN NN O
- NN NN O
term NN NN O
regulatory NN NN O
mechanisms NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
on NN NN O
the NN NN O
gene NN NN O
expression NN NN O
level NN NN O
which NN NN O
may NN NN O
be NN NN O
important NN NN O
to NN NN O
substitute NN NN O
for NN NN O
metabolized NN NN O
transcription NN NN O
factor NN NN O
proteins NN NN O
after NN NN O
their NN NN O
activation NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
a NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
differential NN NN O
response NN NN O
: NN NN O
CREB NN NN O
, NN NN O
CTF NN NN B-Protein
, NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
OFT NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
genes NN NN O
were NN NN O
strongly NN NN O
induced NN NN O
1 NN NN O
to NN NN O
4 NN NN O
hours NN NN O
after NN NN O
influenza NN NN O
A NN NN O
virus NN NN O
infection NN NN O
in NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
Mono NN NN O
Mac NN NN O
6 NN NN O
, NN NN O
while NN NN O
in NN NN O
freshly NN NN O
prepared NN NN O
human NN NN O
monocytes NN NN O
no NN NN O
significant NN NN O
changes NN NN O
were NN NN O
detected NN NN O
. NN NN O
   
In NN NN O
infected NN NN O
monocytes NN NN O
, NN NN O
which NN NN O
die NN NN O
by NN NN O
apoptosis NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
CREB NN NN O
, NN NN O
CTF NN NN B-Protein
, NN NN O
and NN NN O
OTF NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
rather NN NN O
suppressed NN NN O
8 NN NN O
hours NN NN O
after NN NN O
infection NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
the NN NN O
long NN NN O
- NN NN O
term NN NN O
regulation NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
gene NN NN O
expression NN NN O
in NN NN O
non NN NN O
- NN NN O
proliferating NN NN O
cells NN NN O
seems NN NN O
to NN NN O
be NN NN O
of NN NN O
minor NN NN O
importance NN NN O
after NN NN O
influenza NN NN O
infection NN NN O
since NN NN O
in NN NN O
apoptosisprone NN NN O
cells NN NN O
an NN NN O
immediate NN NN O
availability NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
proteins NN NN O
is NN NN O
required NN NN O
. NN NN O
   
[ NN NN O
Molecular NN NN O
- NN NN O
biologic NN NN O
aspects NN NN O
of NN NN O
interaction NN NN O
between NN NN O
nervous NN NN O
and NN NN O
immune NN NN O
systems NN NN O
] NN NN O
   
The NN NN O
problem NN NN O
of NN NN O
the NN NN O
neuro NN NN O
- NN NN O
immuno NN NN O
interactions NN NN O
on NN NN O
the NN NN O
level NN NN O
of NN NN O
the NN NN O
protein NN NN O
trans NN NN O
- NN NN O
factors NN NN O
, NN NN O
stimulating NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
gene NN NN O
expression NN NN O
was NN NN O
discussed NN NN O
. NN NN O
   
The NN NN O
physico NN NN O
- NN NN O
chemical NN NN O
and NN NN O
functional NN NN O
parameters NN NN O
of NN NN O
the NN NN O
low NN NN O
molecular NN NN O
nuclear NN NN O
proteins NN NN O
( NN NN O
SP NN NN O
and NN NN O
BP NN NN O
- NN NN O
14 NN NN O
, NN NN O
18 NN NN O
, NN NN O
19 NN NN O
kDs NN NN O
) NN NN O
isolated NN NN O
from NN NN O
splenic NN NN O
and NN NN O
brain NN NN O
cells NN NN O
of NN NN O
immunized NN NN O
rats NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
these NN NN O
proteins NN NN O
to NN NN O
the NN NN O
regulatory NN NN O
region NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
in NN NN O
vitro NN NN O
and NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2mRNA NN NN I-Protein
synthesis NN NN O
in NN NN O
splenic NN NN O
T NN NN O
- NN NN O
lymphocytes NN NN O
culture NN NN O
in NN NN O
normal NN NN O
conditions NN NN O
were NN NN O
shown NN NN O
. NN NN O
   
The NN NN O
protective NN NN O
effect NN NN O
of NN NN O
SP NN NN O
and NN NN O
BP NN NN O
on NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2mRNA NN NN I-Protein
synthesis NN NN O
in NN NN O
stressful NN NN O
conditions NN NN O
and NN NN O
by NN NN O
the NN NN O
T NN NN O
- NN NN O
cells NN NN O
treatment NN NN O
with NN NN O
the NN NN O
CsA NN NN O
was NN NN O
demonstrated NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
interleukin NN NN O
- NN NN O
12 NN NN O
p40 NN NN B-Protein
transcript NN NN O
by NN NN O
CD40 NN NN B-Protein
ligation NN NN O
via NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Interleukin NN NN O
- NN NN O
12 NN NN O
is NN NN O
produced NN NN O
in NN NN O
response NN NN O
to NN NN O
infection NN NN O
with NN NN O
bacteria NN NN O
or NN NN O
parasites NN NN O
or NN NN O
to NN NN O
bacterial NN NN O
constituents NN NN O
such NN NN O
as NN NN O
LPS NN NN O
in NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
and NN NN O
dendritic NN NN O
cells NN NN O
, NN NN O
and NN NN O
also NN NN O
generated NN NN O
by NN NN O
the NN NN O
interaction NN NN O
between NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
antigen NN NN O
- NN NN O
presenting NN NN O
cells NN NN O
via NN NN O
CD40 NN NN B-Protein
- NN NN O
CD40 NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
CD40L NN NN B-Protein
) NN NN O
. NN NN O
   
So NN NN O
far NN NN O
, NN NN O
transcriptional NN NN O
analyses NN NN O
of NN NN O
p40 NN NN B-Protein
have NN NN O
been NN NN O
carried NN NN O
out NN NN O
only NN NN O
using NN NN O
bacterial NN NN O
constituents NN NN O
such NN NN O
as NN NN O
LPS NN NN O
as NN NN O
stimuli NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
characterized NN NN O
the NN NN O
transcriptional NN NN O
induction NN NN O
of NN NN O
p40 NN NN B-Protein
by NN NN O
CD40 NN NN B-Protein
ligation NN NN O
in NN NN O
a NN NN O
human NN NN O
B NN NN O
lymphoblastoid NN NN O
cell NN NN O
line NN NN O
, NN NN O
Daudi NN NN O
, NN NN O
and NN NN O
a NN NN O
human NN NN O
acute NN NN O
monocytic NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
, NN NN O
THP NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
These NN NN O
cells NN NN O
, NN NN O
stimulated NN NN O
by NN NN O
an NN NN O
agonistic NN NN O
monoclonal NN NN O
antibody NN NN O
against NN NN O
CD40 NN NN B-Protein
or NN NN O
by NN NN O
transfection NN NN O
with NN NN O
a NN NN O
CD40L NN NN B-Protein
expression NN NN O
vector NN NN O
, NN NN O
secreted NN NN O
p40 NN NN B-Protein
and NN NN O
showed NN NN O
enhanced NN NN O
p40 NN NN B-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
of NN NN O
the NN NN O
p40 NN NN B-Protein
promoter NN NN O
region NN NN O
identified NN NN O
two NN NN O
potential NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sites NN NN O
conserved NN NN O
between NN NN O
mouse NN NN O
and NN NN O
human NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
revealed NN NN O
that NN NN O
the NN NN O
potential NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sequence NN NN O
which NN NN O
is NN NN O
located NN NN O
around NN NN O
120 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
in NN NN O
murine NN NN O
and NN NN O
human NN NN O
p40 NN NN B-Protein
genes NN NN O
formed NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
complex NN NN O
with NN NN O
nuclear NN NN O
extract NN NN O
from NN NN O
Daudi NN NN O
cells NN NN O
stimulated NN NN O
by NN NN O
CD40 NN NN B-Protein
ligation NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
transfection NN NN O
of NN NN O
Daudi NN NN O
cells NN NN O
with NN NN O
the NN NN O
polymerized NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sequence NN NN O
ligated NN NN O
to NN NN O
a NN NN O
thymidine NN NN O
kinase NN NN O
/ NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
plasmid NN NN O
greatly NN NN O
induced NN NN O
CAT NN NN B-Protein
activity NN NN O
, NN NN O
but NN NN O
transfection NN NN O
with NN NN O
the NN NN O
polymerized NN NN O
mutated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sequence NN NN O
did NN NN O
not NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
site NN NN O
located NN NN O
around NN NN O
120 NN NN O
bp NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
in NN NN O
murine NN NN O
and NN NN O
human NN NN O
p40 NN NN B-Protein
promoter NN NN O
regions NN NN O
could NN NN O
be NN NN O
important NN NN O
for NN NN O
the NN NN O
p40 NN NN B-Protein
induction NN NN O
by NN NN O
CD40 NN NN B-Protein
ligation NN NN O
via NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Oxidants NN NN O
, NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
and NN NN O
intestinal NN NN O
inflammation NN NN O
. NN NN O
   
It NN NN O
is NN NN O
now NN NN O
well NN NN O
appreciated NN NN O
that NN NN O
chronic NN NN O
gut NN NN O
inflammation NN NN O
is NN NN O
characterized NN NN O
by NN NN O
enhanced NN NN O
production NN NN O
of NN NN O
reactive NN NN O
metabolites NN NN O
of NN NN O
oxygen NN NN O
and NN NN O
nitrogen NN NN O
. NN NN O
   
Some NN NN O
of NN NN O
these NN NN O
oxidants NN NN O
are NN NN O
known NN NN O
to NN NN O
modulate NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
genes NN NN O
that NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
immune NN NN O
and NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
For NN NN O
example NN NN O
, NN NN O
certain NN NN O
oxidants NN NN O
are NN NN O
known NN NN O
to NN NN O
activate NN NN O
the NN NN O
nuclear NN NN O
transcription NN NN O
factor NN NN O
kappa NN NN O
B NN NN O
, NN NN O
which NN NN O
regulates NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
variety NN NN O
of NN NN O
different NN NN O
adhesion NN NN O
molecules NN NN O
, NN NN O
cytokines NN NN O
, NN NN O
and NN NN O
enzymes NN NN O
. NN NN O
   
Oxidants NN NN O
are NN NN O
also NN NN O
known NN NN O
to NN NN O
activate NN NN O
another NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
This NN NN O
transcription NN NN O
factor NN NN O
is NN NN O
composed NN NN O
of NN NN O
products NN NN O
from NN NN O
the NN NN O
fos NN NN B-Protein
and NN NN O
jun NN NN B-Protein
proto NN NN O
- NN NN O
oncogene NN NN O
family NN NN O
and NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
regulating NN NN O
cell NN NN O
growth NN NN O
and NN NN O
proliferation NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
oxidants NN NN O
are NN NN O
believed NN NN O
to NN NN O
promote NN NN O
intestinal NN NN O
epithelial NN NN O
cell NN NN O
apoptosis NN NN O
, NN NN O
and NN NN O
the NN NN O
B NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
lymphoma NN NN I-Protein
/ NN NN I-Protein
leukemia NN NN I-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
product NN NN O
is NN NN O
believed NN NN O
to NN NN O
inhibit NN NN O
this NN NN O
phenomenon NN NN O
in NN NN O
an NN NN O
antioxidant NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
nontoxic NN NN O
concentrations NN NN O
of NN NN O
reactive NN NN O
metabolites NN NN O
of NN NN O
oxygen NN NN O
and NN NN O
nitrogen NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
expression NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
and NN NN O
in NN NN O
modulating NN NN O
apoptosis NN NN O
. NN NN O
   
Differential NN NN O
induction NN NN O
of NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
following NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
human NN NN O
B NN NN O
lineage NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
B NN NN O
cell NN NN O
- NN NN O
specific NN NN O
cell NN NN O
surface NN NN O
molecule NN NN O
CD19 NN NN B-Protein
is NN NN O
expressed NN NN O
at NN NN O
all NN NN O
stages NN NN O
of NN NN O
B NN NN O
cell NN NN O
development NN NN O
, NN NN O
including NN NN O
normal NN NN O
plasma NN NN O
cells NN NN O
, NN NN O
and NN NN O
mediates NN NN O
signal NN NN O
transduction NN NN O
via NN NN O
interaction NN NN O
with NN NN O
cytoplasmic NN NN O
effector NN NN O
proteins NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
CD19 NN NN B-Protein
on NN NN O
early NN NN O
human NN NN O
B NN NN O
lineage NN NN O
cells NN NN O
induces NN NN O
the NN NN O
formation NN NN O
of NN NN O
a NN NN O
CD19 NN NN B-Protein
/ NN NN O
Vav NN NN O
/ NN NN O
phosphatidylinositol NN NN O
- NN NN O
3 NN NN O
kinase NN NN O
complex NN NN O
, NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
CD19 NN NN B-Protein
and NN NN O
Vav NN NN O
, NN NN O
and NN NN O
activation NN NN O
of NN NN O
the NN NN O
Ras NN NN O
pathway NN NN O
. NN NN O
   
To NN NN O
further NN NN O
explore NN NN O
the NN NN O
ramifications NN NN O
of NN NN O
CD19 NN NN B-Protein
signaling NN NN O
, NN NN O
the NN NN O
current NN NN O
study NN NN O
examined NN NN O
whether NN NN O
phosphorylation NN NN O
of NN NN O
Elk NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
activation NN NN O
of NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
or NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
transcription NN NN O
factors NN NN O
occurred NN NN O
following NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
The NN NN O
cells NN NN O
used NN NN O
were NN NN O
the NN NN O
BLIN NN NN O
- NN NN O
1 NN NN O
pre NN NN O
- NN NN O
B NN NN O
cell NN NN O
line NN NN O
expressing NN NN O
low NN NN O
levels NN NN O
of NN NN O
cell NN NN O
surface NN NN O
mu NN NN O
heavy NN NN O
chain NN NN O
associated NN NN O
with NN NN O
surrogate NN NN O
light NN NN O
chain NN NN O
and NN NN O
the NN NN O
1E8 NN NN O
immature NN NN O
B NN NN O
cell NN NN O
line NN NN O
expressing NN NN O
cell NN NN O
surface NN NN O
mu NN NN O
/ NN NN O
kappa NN NN O
. NN NN O
   
Lysates NN NN O
from NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linked NN NN O
1E8 NN NN O
cells NN NN O
induced NN NN O
robust NN NN O
phosphorylation NN NN O
of NN NN O
an NN NN O
Elk NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
fusion NN NN O
protein NN NN O
in NN NN O
vitro NN NN O
, NN NN O
whereas NN NN O
no NN NN O
phosphorylation NN NN O
of NN NN O
Elk NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
fusion NN NN O
protein NN NN O
occurred NN NN O
using NN NN O
lysates NN NN O
from NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linked NN NN O
BLIN NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
An NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
employing NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
consensus NN NN O
oligonucleotides NN NN O
was NN NN O
used NN NN O
to NN NN O
demonstrate NN NN O
that NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
increased NN NN O
, NN NN O
while NN NN O
constitutive NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
binding NN NN O
activity NN NN O
was NN NN O
not NN NN O
enhanced NN NN O
, NN NN O
following NN NN O
2 NN NN O
h NN NN O
of NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
1E8 NN NN O
cells NN NN O
. NN NN O
   
Supershift NN NN O
experiments NN NN O
revealed NN NN O
that NN NN O
JunD NN NN B-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Fos NN NN I-Protein
proteins NN NN O
mediated NN NN O
anti NN NN O
- NN NN O
CD19 NN NN B-Protein
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
in NN NN O
1E8 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
CD19 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
in NN NN O
BLIN NN NN O
- NN NN O
1 NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
but NN NN O
had NN NN O
no NN NN O
apparent NN NN O
effect NN NN O
on NN NN O
AP NN NN O
- NN NN O
1 NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
CD19 NN NN B-Protein
- NN NN O
mediated NN NN O
signal NN NN O
transduction NN NN O
activates NN NN O
different NN NN O
transcription NN NN O
factors NN NN O
at NN NN O
juxtaposed NN NN O
stages NN NN O
of NN NN O
B NN NN O
cell NN NN O
development NN NN O
that NN NN O
may NN NN O
culminate NN NN O
in NN NN O
the NN NN O
activation NN NN O
or NN NN O
suppression NN NN O
of NN NN O
distinct NN NN O
sets NN NN O
of NN NN O
genes NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
quasispecies NN NN O
differ NN NN O
in NN NN O
basal NN NN O
transcription NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
recruitment NN NN O
in NN NN O
human NN NN O
glial NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
generation NN NN O
of NN NN O
genomic NN NN O
diversity NN NN O
during NN NN O
the NN NN O
course NN NN O
of NN NN O
infection NN NN O
has NN NN O
the NN NN O
potential NN NN O
to NN NN O
affect NN NN O
all NN NN O
aspects NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
, NN NN O
including NN NN O
expression NN NN O
of NN NN O
the NN NN O
proviral NN NN O
genome NN NN O
. NN NN O
   
To NN NN O
gain NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
the NN NN O
impact NN NN O
of NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
sequence NN NN O
diversity NN NN O
on NN NN O
LTR NN NN O
- NN NN O
directed NN NN O
gene NN NN O
expression NN NN O
in NN NN O
cells NN NN O
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
and NN NN O
immune NN NN O
system NN NN O
, NN NN O
we NN NN O
amplified NN NN O
and NN NN O
cloned NN NN O
LTRs NN NN O
from NN NN O
proviral NN NN O
DNA NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
peripheral NN NN O
blood NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
of NN NN O
nineteen NN NN O
LTRs NN NN O
cloned NN NN O
from NN NN O
2 NN NN O
adult NN NN O
and NN NN O
3 NN NN O
pediatric NN NN O
patients NN NN O
revealed NN NN O
an NN NN O
average NN NN O
of NN NN O
33 NN NN O
nucleotide NN NN O
changes NN NN O
( NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
sequence NN NN O
of NN NN O
the NN NN O
LAI NN NN O
LTR NN NN O
) NN NN O
within NN NN O
the NN NN O
455 NN NN O
- NN NN O
bp NN NN O
U3 NN NN O
region NN NN O
. NN NN O
   
Transient NN NN O
expression NN NN O
analyses NN NN O
in NN NN O
cells NN NN O
of NN NN O
neuroglial NN NN O
and NN NN O
lymphocytic NN NN O
origin NN NN O
demonstrated NN NN O
that NN NN O
some NN NN O
of NN NN O
these NN NN O
LTRs NN NN O
had NN NN O
activities NN NN O
which NN NN O
varied NN NN O
significantly NN NN O
from NN NN O
the NN NN O
LAI NN NN O
LTR NN NN O
in NN NN O
U NN NN O
- NN NN O
373 NN NN O
MG NN NN O
cells NN NN O
( NN NN O
an NN NN O
astrocytoma NN NN O
cell NN NN O
line NN NN O
) NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
( NN NN O
a NN NN O
CD4 NN NN B-Protein
- NN NN O
positive NN NN O
lymphocyte NN NN O
cell NN NN O
line NN NN O
) NN NN O
. NN NN O
   
While NN NN O
LTRs NN NN O
which NN NN O
demonstrated NN NN O
the NN NN O
highest NN NN O
activities NN NN O
in NN NN O
U NN NN O
- NN NN O
373 NN NN O
MG NN NN O
cells NN NN O
also NN NN O
yielded NN NN O
high NN NN O
activities NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
the NN NN O
LTRs NN NN O
were NN NN O
generally NN NN O
more NN NN O
active NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
when NN NN O
compared NN NN O
to NN NN O
the NN NN O
LAI NN NN O
LTR NN NN O
. NN NN O
   
Differences NN NN O
in NN NN O
LTR NN NN O
sequence NN NN O
also NN NN O
resulted NN NN O
in NN NN O
differences NN NN O
in NN NN O
transcription NN NN O
factor NN NN O
recruitment NN NN O
to NN NN O
cis NN NN O
- NN NN O
acting NN NN O
sites NN NN O
within NN NN O
the NN NN O
U3 NN NN O
region NN NN O
of NN NN O
the NN NN O
LTR NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
In NN NN O
particular NN NN O
, NN NN O
naturally NN NN O
occurring NN NN O
sequence NN NN O
variation NN NN O
impacted NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
to NN NN O
an NN NN O
activating NN NN O
transcription NN NN O
factor NN NN O
/ NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
binding NN NN O
( NN NN O
ATF NN NN O
/ NN NN O
CREB NN NN O
) NN NN O
binding NN NN O
site NN NN O
( NN NN O
located NN NN O
between NN NN O
the NN NN O
LEF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
distal NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
) NN NN O
that NN NN O
we NN NN O
identified NN NN O
in NN NN O
previous NN NN O
studies NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
LTR NN NN O
sequence NN NN O
changes NN NN O
can NN NN O
significantly NN NN O
affect NN NN O
basal NN NN O
LTR NN NN O
function NN NN O
and NN NN O
transcription NN NN O
factor NN NN O
recruitment NN NN O
, NN NN O
which NN NN O
may NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
alter NN NN O
the NN NN O
course NN NN O
of NN NN O
viral NN NN O
replication NN NN O
in NN NN O
cells NN NN O
of NN NN O
CNS NN NN O
and NN NN O
immune NN NN O
system NN NN O
origin NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
activation NN NN O
attenuates NN NN O
apoptosis NN NN O
resistance NN NN O
in NN NN O
lymphoid NN NN O
cells NN NN O
. NN NN O
   
Death NN NN O
- NN NN O
inducing NN NN O
ligands NN NN O
( NN NN O
DILs NN NN O
) NN NN O
such NN NN O
as NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNFalpha NN NN B-Protein
) NN NN O
or NN NN O
the NN NN O
cytotoxic NN NN O
drug NN NN O
doxorubicin NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
activate NN NN O
a NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
- NN NN O
dependent NN NN O
program NN NN O
that NN NN O
may NN NN O
rescue NN NN O
cells NN NN O
from NN NN O
apoptosis NN NN O
induction NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
TRAIL NN NN B-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
related NN NN I-Protein
apoptosis NN NN I-Protein
- NN NN I-Protein
inducing NN NN I-Protein
ligand NN NN I-Protein
) NN NN O
, NN NN O
a NN NN O
recently NN NN O
identified NN NN O
DIL NN NN O
, NN NN O
also NN NN O
activates NN NN O
NFkappaB NN NN O
in NN NN O
lymphoid NN NN O
cell NN NN O
lines NN NN O
in NN NN O
a NN NN O
kinetic NN NN O
similar NN NN O
to NN NN O
TNFalpha NN NN B-Protein
. NN NN O
   
NFkappaB NN NN O
activity NN NN O
is NN NN O
independent NN NN O
from NN NN O
FADD NN NN B-Protein
, NN NN O
caspases NN NN O
, NN NN O
and NN NN O
apoptosis NN NN O
induction NN NN O
. NN NN O
   
To NN NN O
study NN NN O
the NN NN O
influence NN NN O
of NN NN O
NFkappaB NN NN O
activity NN NN O
on NN NN O
apoptosis NN NN O
mediated NN NN O
by NN NN O
TRAIL NN NN B-Protein
, NN NN O
CD95 NN NN B-Protein
, NN NN O
TNFalpha NN NN B-Protein
, NN NN O
or NN NN O
doxorubicin NN NN O
, NN NN O
NFkappaB NN NN O
activation NN NN O
was NN NN O
inhibited NN NN O
using NN NN O
the NN NN O
proteasome NN NN O
inhibitor NN NN O
N NN NN O
- NN NN O
acetyl NN NN O
- NN NN O
L NN NN O
- NN NN O
leucinyl NN NN O
- NN NN O
L NN NN O
- NN NN O
leucinyl NN NN O
- NN NN O
L NN NN O
- NN NN O
norleucinal NN NN O
or NN NN O
transient NN NN O
overexpression NN NN O
of NN NN O
mutant NN NN O
IkappaBalpha NN NN B-Protein
. NN NN O
   
Sensitivity NN NN O
for NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
was NN NN O
markedly NN NN O
increased NN NN O
by NN NN O
these NN NN O
treatments NN NN O
in NN NN O
apoptosis NN NN O
sensitive NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
both NN NN O
in NN NN O
cell NN NN O
lines NN NN O
and NN NN O
in NN NN O
primary NN NN O
leukemia NN NN O
cells NN NN O
that NN NN O
are NN NN O
resistant NN NN O
towards NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
by NN NN O
DILs NN NN O
and NN NN O
doxorubicin NN NN O
, NN NN O
antagonization NN NN O
of NN NN O
NFkappaB NN NN O
activity NN NN O
partially NN NN O
restored NN NN O
apoptosis NN NN O
sensitivity NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
NFkappaB NN NN O
activation NN NN O
may NN NN O
provide NN NN O
a NN NN O
molecular NN NN O
approach NN NN O
to NN NN O
increase NN NN O
apoptosis NN NN O
sensitivity NN NN O
in NN NN O
anticancer NN NN O
treatment NN NN O
. NN NN O
   
The NN NN O
human NN NN O
toll NN NN O
signaling NN NN O
pathway NN NN O
: NN NN O
divergence NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
and NN NN O
JNK NN NN O
/ NN NN O
SAPK NN NN O
activation NN NN O
upstream NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
associated NN NN I-Protein
factor NN NN I-Protein
6 NN NN I-Protein
( NN NN O
TRAF6 NN NN B-Protein
) NN NN O
. NN NN O
   
The NN NN O
human NN NN O
homologue NN NN O
of NN NN O
Drosophila NN NN O
Toll NN NN O
( NN NN O
hToll NN NN O
) NN NN O
is NN NN O
a NN NN O
recently NN NN O
cloned NN NN O
receptor NN NN O
of NN NN O
the NN NN O
interleukin NN NN O
1 NN NN O
receptor NN NN O
( NN NN O
IL NN NN O
- NN NN O
1R NN NN O
) NN NN O
superfamily NN NN O
, NN NN O
and NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
activation NN NN O
of NN NN O
adaptive NN NN O
immunity NN NN O
. NN NN O
   
Signaling NN NN O
by NN NN O
hToll NN NN O
is NN NN O
shown NN NN O
to NN NN O
occur NN NN O
through NN NN O
sequential NN NN O
recruitment NN NN O
of NN NN O
the NN NN O
adapter NN NN O
molecule NN NN O
MyD88 NN NN B-Protein
and NN NN O
the NN NN O
IL NN NN O
- NN NN O
1R NN NN O
- NN NN O
associated NN NN O
kinase NN NN O
. NN NN O
   
Tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
- NN NN I-Protein
activated NN NN I-Protein
factor NN NN I-Protein
6 NN NN I-Protein
( NN NN O
TRAF6 NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
nuclear NN NN B-Protein
factor NN NN I-Protein
kappaB NN NN I-Protein
( NN NN I-Protein
NF NN NN I-Protein
- NN NN I-Protein
kappaB NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
inducing NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
NIK NN NN B-Protein
) NN NN O
are NN NN O
both NN NN O
involved NN NN O
in NN NN O
subsequent NN NN O
steps NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
Conversely NN NN O
, NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
version NN NN O
of NN NN O
TRAF6 NN NN B-Protein
failed NN NN O
to NN NN O
block NN NN O
hToll NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
stress NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
/ NN NN O
c NN NN O
- NN NN O
Jun NN NN O
NH2 NN NN O
- NN NN O
terminal NN NN O
kinases NN NN O
, NN NN O
thus NN NN O
suggesting NN NN O
an NN NN O
early NN NN O
divergence NN NN O
of NN NN O
the NN NN O
two NN NN O
pathways NN NN O
. NN NN O
   
Coactivation NN NN O
by NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
: NN NN O
definition NN NN O
of NN NN O
critical NN NN O
regions NN NN O
and NN NN O
synergism NN NN O
with NN NN O
general NN NN O
cofactors NN NN O
. NN NN O
   
Molecular NN NN O
dissection NN NN O
of NN NN O
the NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
transcription NN NN O
coactivator NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
has NN NN O
revealed NN NN O
distinct NN NN O
regions NN NN O
important NN NN O
, NN NN O
respectively NN NN O
, NN NN O
for NN NN O
recruitment NN NN O
to NN NN O
immunoglobulin NN NN O
promoters NN NN O
through NN NN O
interaction NN NN O
with NN NN O
octamer NN NN O
- NN NN O
bound NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
for NN NN O
subsequent NN NN O
coactivator NN NN O
function NN NN O
. NN NN O
   
Further NN NN O
analysis NN NN O
of NN NN O
general NN NN O
coactivator NN NN O
requirements NN NN O
showed NN NN O
that NN NN O
selective NN NN O
removal NN NN O
of NN NN O
PC4 NN NN B-Protein
from NN NN O
the NN NN O
essential NN NN O
USA NN NN O
fraction NN NN O
severely NN NN O
impairs NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
function NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
free NN NN O
system NN NN O
reconstituted NN NN O
with NN NN O
partially NN NN O
purified NN NN O
factors NN NN O
. NN NN O
   
Full NN NN O
activity NN NN O
can NN NN O
be NN NN O
restored NN NN O
by NN NN O
the NN NN O
combined NN NN O
action NN NN O
of NN NN O
recombinant NN NN O
PC4 NN NN B-Protein
and NN NN O
the NN NN O
PC4 NN NN B-Protein
- NN NN O
depleted NN NN O
USA NN NN O
fraction NN NN O
, NN NN O
thus NN NN O
suggesting NN NN O
a NN NN O
joint NN NN O
requirement NN NN O
for NN NN O
PC4 NN NN B-Protein
and NN NN O
another NN NN O
, NN NN O
USA NN NN O
- NN NN O
derived NN NN O
component NN NN O
( NN NN O
s NN NN O
) NN NN O
for NN NN O
optimal NN NN O
function NN NN O
of NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
/ NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
in NN NN O
the NN NN O
reconstituted NN NN O
system NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
USA NN NN O
- NN NN O
derived NN NN O
PC2 NN NN O
was NN NN O
found NN NN O
to NN NN O
act NN NN O
synergistically NN NN O
with NN NN O
PC4 NN NN O
in NN NN O
reproducing NN NN O
the NN NN O
function NN NN O
of NN NN O
intact NN NN O
USA NN NN O
in NN NN O
the NN NN O
assay NN NN O
system NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
the NN NN O
requirement NN NN O
for NN NN O
PC4 NN NN B-Protein
in NN NN O
the NN NN O
reconstituted NN NN O
system NN NN O
, NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
was NN NN O
found NN NN O
to NN NN O
interact NN NN O
directly NN NN O
with NN NN O
PC4 NN NN B-Protein
. NN NN O
   
Surprisingly NN NN O
, NN NN O
however NN NN O
, NN NN O
removal NN NN O
of NN NN O
PC4 NN NN B-Protein
from NN NN O
the NN NN O
unfractionated NN NN O
nuclear NN NN O
extract NN NN O
has NN NN O
no NN NN O
detrimental NN NN O
effect NN NN O
on NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
/ NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
These NN NN O
results NN NN O
lead NN NN O
to NN NN O
a NN NN O
general NN NN O
model NN NN O
for NN NN O
the NN NN O
synergistic NN NN O
function NN NN O
of NN NN O
activation NN NN O
domains NN NN O
in NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
OCA NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
( NN NN O
mediated NN NN O
by NN NN O
the NN NN O
combined NN NN O
action NN NN O
of NN NN O
the NN NN O
multiple NN NN O
USA NN NN O
components NN NN O
) NN NN O
and NN NN O
, NN NN O
further NN NN O
, NN NN O
suggest NN NN O
a NN NN O
functional NN NN O
redundancy NN NN O
in NN NN O
general NN NN O
coactivators NN NN O
. NN NN O
   
Limited NN NN O
proteolysis NN NN O
for NN NN O
assaying NN NN O
ligand NN NN O
binding NN NN O
affinities NN NN O
of NN NN O
nuclear NN NN O
receptors NN NN O
. NN NN O
   
The NN NN O
binding NN NN O
of NN NN O
natural NN NN O
or NN NN O
synthetic NN NN O
ligands NN NN O
to NN NN O
nuclear NN NN O
receptors NN NN O
is NN NN O
the NN NN O
triggering NN NN O
event NN NN O
leading NN NN O
to NN NN O
gene NN NN O
transcription NN NN O
activation NN NN O
or NN NN O
repression NN NN O
. NN NN O
   
Ligand NN NN O
binding NN NN O
to NN NN O
the NN NN O
ligand NN NN O
binding NN NN O
domain NN NN O
of NN NN O
these NN NN O
receptors NN NN O
induces NN NN O
conformational NN NN O
changes NN NN O
that NN NN O
are NN NN O
evidenced NN NN O
by NN NN O
an NN NN O
increased NN NN O
resistance NN NN O
of NN NN O
this NN NN O
domain NN NN O
to NN NN O
proteases NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
labeled NN NN O
receptors NN NN O
were NN NN O
incubated NN NN O
with NN NN O
various NN NN O
synthetic NN NN O
or NN NN O
natural NN NN O
agonists NN NN O
or NN NN O
antagonists NN NN O
and NN NN O
submitted NN NN O
to NN NN O
trypsin NN NN O
digestion NN NN O
. NN NN O
   
Proteolysis NN NN O
products NN NN O
were NN NN O
separated NN NN O
by NN NN O
SDS NN NN O
- NN NN O
PAGE NN NN O
and NN NN O
quantified NN NN O
. NN NN O
   
The NN NN O
amount NN NN O
of NN NN O
trypsin NN NN O
- NN NN O
resistant NN NN O
fragments NN NN O
was NN NN O
proportional NN NN O
to NN NN O
receptor NN NN O
occupancy NN NN O
by NN NN O
the NN NN O
ligand NN NN O
, NN NN O
and NN NN O
allowed NN NN O
the NN NN O
determination NN NN O
of NN NN O
dissociation NN NN O
constants NN NN O
( NN NN O
kDa NN NN O
) NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
or NN NN O
mutated NN NN O
human NN NN O
retinoic NN NN B-Protein
acid NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
as NN NN O
a NN NN O
model NN NN O
, NN NN O
kDa NN NN O
values NN NN O
determined NN NN O
by NN NN O
classical NN NN O
competition NN NN O
binding NN NN O
assays NN NN O
using NN NN O
tritiated NN NN O
ligands NN NN O
are NN NN O
in NN NN O
agreement NN NN O
with NN NN O
those NN NN O
measured NN NN O
by NN NN O
the NN NN O
proteolytic NN NN O
assay NN NN O
. NN NN O
   
This NN NN O
method NN NN O
was NN NN O
successfully NN NN O
extended NN NN O
to NN NN O
human NN NN O
retinoic NN NN B-Protein
X NN NN I-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
, NN NN O
and NN NN O
progesterone NN NN O
receptor NN NN O
, NN NN O
thus NN NN O
providing NN NN O
a NN NN O
basis NN NN O
for NN NN O
a NN NN O
new NN NN O
, NN NN O
faster NN NN O
assay NN NN O
to NN NN O
determine NN NN O
simultaneously NN NN O
the NN NN O
affinity NN NN O
and NN NN O
conformation NN NN O
of NN NN O
receptors NN NN O
when NN NN O
bound NN NN O
to NN NN O
a NN NN O
given NN NN O
ligand NN NN O
. NN NN O
   
Mycobacterium NN NN O
tuberculosis NN NN O
mannose NN NN O
- NN NN O
capped NN NN O
lipoarabinomannan NN NN O
can NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Tuberculosis NN NN O
has NN NN O
emerged NN NN O
as NN NN O
an NN NN O
epidemic NN NN O
, NN NN O
extended NN NN O
by NN NN O
the NN NN O
large NN NN O
number NN NN O
of NN NN O
individuals NN NN O
infected NN NN O
with NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
major NN NN O
goal NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
mycobacterial NN NN O
cell NN NN O
wall NN NN O
component NN NN O
mannose NN NN O
- NN NN O
capped NN NN O
lipoarabinomannan NN NN O
( NN NN O
ManLAM NN NN O
) NN NN O
of NN NN O
Mycobacterium NN NN O
tuberculosis NN NN O
( NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
) NN NN O
could NN NN O
activate NN NN O
transcription NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
T NN NN O
cells NN NN O
with NN NN O
the NN NN O
use NN NN O
of NN NN O
an NN NN O
in NN NN O
vitro NN NN O
cell NN NN O
culture NN NN O
system NN NN O
. NN NN O
   
These NN NN O
experiments NN NN O
are NN NN O
of NN NN O
prime NN NN O
importance NN NN O
considering NN NN O
that NN NN O
CD4 NN NN B-Protein
- NN NN O
expressing NN NN O
T NN NN O
lymphocytes NN NN O
represent NN NN O
the NN NN O
major NN NN O
virus NN NN O
reservoir NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
infected NN NN O
individuals NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
1G5 NN NN O
cell NN NN O
line NN NN O
harbouring NN NN O
the NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
, NN NN O
it NN NN O
was NN NN O
first NN NN O
found NN NN O
that NN NN O
culture NN NN O
protein NN NN O
filtrates NN NN O
( NN NN O
CFP NN NN O
) NN NN O
from NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
or NN NN O
purified NN NN O
ManLAM NN NN O
could NN NN O
activate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
dependent NN NN O
gene NN NN O
expression NN NN O
unlike NN NN O
similarly NN NN O
prepared NN NN O
CFP NN NN O
extracts NN NN O
devoid NN NN O
of NN NN O
ManLAM NN NN O
. NN NN O
   
The NN NN O
implication NN NN O
of NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
( NN NN O
s NN NN O
) NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
and NN NN O
/ NN NN O
or NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
was NN NN O
highlighted NN NN O
by NN NN O
the NN NN O
abrogation NN NN O
of NN NN O
the NN NN O
ManLAM NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
using NN NN O
herbimycin NN NN O
A NN NN O
and NN NN O
H7 NN NN O
. NN NN O
   
It NN NN O
was NN NN O
also NN NN O
determined NN NN O
, NN NN O
using NN NN O
electrophoresis NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
, NN NN O
that NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
ManLAM NN NN O
led NN NN O
to NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
M NN NN O
. NN NN O
tuberculosis NN NN O
ManLAM NN NN O
resulted NN NN O
in NN NN O
clear NN NN O
induction NN NN O
of NN NN O
the NN NN O
luciferase NN NN O
gene NN NN O
placed NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
kappaB NN NN O
- NN NN O
mutated NN NN O
, NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
region NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
ManLAM NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
transcription NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
independent NN NN O
of NN NN O
the NN NN O
autocrine NN NN O
or NN NN O
paracrine NN NN O
action NN NN O
of NN NN O
endogenous NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
M NN NN O
. NN NN O
tuberculosis NN NN O
can NN NN O
upregulate NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
could NN NN O
thus NN NN O
have NN NN O
the NN NN O
potential NN NN O
to NN NN O
influence NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
Oxidative NN NN O
stress NN NN O
suppresses NN NN O
transcription NN NN O
factor NN NN O
activities NN NN O
in NN NN O
stimulated NN NN O
lymphocytes NN NN O
. NN NN O
   
Effects NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
on NN NN O
stimulation NN NN O
- NN NN O
dependent NN NN O
signal NN NN O
transduction NN NN O
, NN NN O
leading NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
, NN NN O
were NN NN O
studied NN NN O
. NN NN O
   
Purified NN NN O
quiescent NN NN O
human NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
were NN NN O
subjected NN NN O
to NN NN O
: NN NN O
( NN NN O
i NN NN O
) NN NN O
acute NN NN O
exposure NN NN O
to NN NN O
hydrogen NN NN O
peroxide NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
chronic NN NN O
exposure NN NN O
to NN NN O
hydrogen NN NN O
peroxide NN NN O
; NN NN O
and NN NN O
( NN NN O
iii NN NN O
) NN NN O
acute NN NN O
exposure NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O
   
The NN NN O
cells NN NN O
were NN NN O
then NN NN O
stimulated NN NN O
for NN NN O
6 NN NN O
h NN NN O
. NN NN O
   
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
( NN NN O
determined NN NN O
by NN NN O
the NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
) NN NN O
of NN NN O
three NN NN O
transcription NN NN O
factors NN NN O
: NN NN O
NFkappaB NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
and NN NN O
NFAT NN NN O
, NN NN O
were NN NN O
abolished NN NN O
in NN NN O
the NN NN O
lymphocytes NN NN O
by NN NN O
all NN NN O
three NN NN O
modes NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O
   
The NN NN O
lymphocytes NN NN O
exhibited NN NN O
lipid NN NN O
peroxidation NN NN O
only NN NN O
upon NN NN O
exposure NN NN O
to NN NN O
the NN NN O
lowest NN NN O
level NN NN O
of NN NN O
hydrogen NN NN O
peroxide NN NN O
used NN NN O
( NN NN O
20 NN NN O
microM NN NN O
) NN NN O
. NN NN O
   
All NN NN O
three NN NN O
modes NN NN O
of NN NN O
oxidative NN NN O
stress NN NN O
induced NN NN O
catalase NN NN O
activity NN NN O
in NN NN O
the NN NN O
lymphocytes NN NN O
. NN NN O
   
The NN NN O
only NN NN O
exception NN NN O
was NN NN O
hydrogen NN NN O
peroxide NN NN O
at NN NN O
20 NN NN O
microM NN NN O
, NN NN O
which NN NN O
did NN NN O
not NN NN O
induce NN NN O
catalase NN NN O
activity NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
: NN NN O
( NN NN O
i NN NN O
) NN NN O
suppression NN NN O
of NN NN O
specific NN NN O
transcription NN NN O
factor NN NN O
functions NN NN O
can NN NN O
potentially NN NN O
serve NN NN O
as NN NN O
a NN NN O
marker NN NN O
of NN NN O
exposure NN NN O
to NN NN O
oxidative NN NN O
stress NN NN O
and NN NN O
its NN NN O
effects NN NN O
on NN NN O
human NN NN O
lymphocytes NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
lipid NN NN O
peroxidation NN NN O
is NN NN O
only NN NN O
detectable NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
upon NN NN O
exposure NN NN O
to NN NN O
weak NN NN O
oxidative NN NN O
stress NN NN O
which NN NN O
does NN NN O
not NN NN O
induce NN NN O
catalase NN NN O
activity NN NN O
; NN NN O
( NN NN O
iii NN NN O
) NN NN O
therefore NN NN O
, NN NN O
transcription NN NN O
factor NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activities NN NN O
are NN NN O
more NN NN O
sensitive NN NN O
to NN NN O
oxidative NN NN O
stress NN NN O
than NN NN O
lipid NN NN O
peroxidation NN NN O
. NN NN O
   
Thrombopoietin NN NN B-Protein
supports NN NN O
in NN NN O
vitro NN NN O
erythroid NN NN O
differentiation NN NN O
via NN NN O
its NN NN O
specific NN NN O
receptor NN NN O
c NN NN B-Protein
- NN NN I-Protein
Mpl NN NN I-Protein
in NN NN O
a NN NN O
human NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Thrombopoietin NN NN B-Protein
( NN NN O
TPO NN NN B-Protein
) NN NN O
acts NN NN O
on NN NN O
megakaryopoiesis NN NN O
and NN NN O
erythropoiesis NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
isolated NN NN O
a NN NN O
novel NN NN O
subline NN NN O
, NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GMT NN NN O
, NN NN O
from NN NN O
the NN NN O
human NN NN O
leukemia NN NN O
cell NN NN O
line NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GM NN NN O
( NN NN O
N NN NN O
. NN NN O
Komatsu NN NN O
, NN NN O
et NN NN O
al NN NN O
. NN NN O
, NN NN O
Blood NN NN O
, NN NN O
89 NN NN O
: NN NN O
4021 NN NN O
- NN NN O
4033 NN NN O
, NN NN O
1997 NN NN O
) NN NN O
. NN NN O
   
A NN NN O
small NN NN O
population NN NN O
of NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GM NN NN O
cells NN NN O
positively NN NN O
stained NN NN O
for NN NN O
hemoglobin NN NN O
( NN NN O
Hb NN NN O
) NN NN O
after NN NN O
a NN NN O
7 NN NN O
- NN NN O
day NN NN O
exposure NN NN O
to NN NN O
TPO NN NN B-Protein
. NN NN O
   
More NN NN O
than NN NN O
50 NN NN O
% NN NN O
of NN NN O
TPO NN NN B-Protein
- NN NN O
treated NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GMT NN NN O
cells NN NN O
positively NN NN O
stained NN NN O
for NN NN O
Hb NN NN O
. NN NN O
   
Using NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GMT NN NN O
cells NN NN O
, NN NN O
we NN NN O
examined NN NN O
how NN NN O
TPO NN NN B-Protein
promotes NN NN O
hemoglobinization NN NN O
. NN NN O
   
TPO NN NN B-Protein
induced NN NN O
tyrosine NN NN O
phosphorylation NN NN O
of NN NN O
the NN NN O
TPO NN NN B-Protein
receptor NN NN I-Protein
but NN NN O
not NN NN O
the NN NN O
erythropoietin NN NN B-Protein
( NN NN I-Protein
EPO NN NN I-Protein
) NN NN I-Protein
receptor NN NN I-Protein
. NN NN O
   
There NN NN O
was NN NN O
no NN NN O
competition NN NN O
between NN NN O
TPO NN NN B-Protein
and NN NN O
EPO NN NN B-Protein
for NN NN O
binding NN NN O
to NN NN O
EPO NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
TPO NN NN B-Protein
has NN NN O
a NN NN O
direct NN NN O
effect NN NN O
on NN NN O
hemoglobinization NN NN O
via NN NN O
a NN NN O
specific NN NN O
receptor NN NN O
on NN NN O
UT NN NN O
- NN NN O
7 NN NN O
/ NN NN O
GMT NN NN O
cells NN NN O
. NN NN O
   
Isoelectric NN NN O
focusing NN NN O
demonstrated NN NN O
that NN NN O
TPO NN NN B-Protein
induced NN NN O
fetal NN NN O
and NN NN O
adult NN NN O
Hb NN NN O
synthesis NN NN O
, NN NN O
whereas NN NN O
EPO NN NN B-Protein
induced NN NN O
embryonic NN NN O
, NN NN O
fetal NN NN O
, NN NN O
and NN NN O
adult NN NN O
Hb NN NN O
synthesis NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
TPO NN NN B-Protein
has NN NN O
a NN NN O
distinct NN NN O
action NN NN O
on NN NN O
erythropoiesis NN NN O
. NN NN O
   
Redox NN NN O
signals NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Accumulating NN NN O
data NN NN O
from NN NN O
a NN NN O
number NN NN O
of NN NN O
laboratories NN NN O
have NN NN O
recently NN NN O
indicated NN NN O
that NN NN O
the NN NN O
response NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
to NN NN O
alterations NN NN O
in NN NN O
the NN NN O
redox NN NN O
homeostasis NN NN O
of NN NN O
cells NN NN O
may NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
modulating NN NN O
immune NN NN O
function NN NN O
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
has NN NN O
been NN NN O
recognized NN NN O
to NN NN O
regulate NN NN O
a NN NN O
number NN NN O
of NN NN O
genes NN NN O
necessary NN NN O
for NN NN O
normal NN NN O
T NN NN O
cell NN NN O
responses NN NN O
including NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
several NN NN O
T NN NN O
cell NN NN O
surface NN NN O
receptors NN NN O
. NN NN O
   
Diminished NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
occur NN NN O
in NN NN O
T NN NN O
cells NN NN O
with NN NN O
aging NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
impaired NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
might NN NN O
occur NN NN O
during NN NN O
cellular NN NN O
senescence NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
aberrancies NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
immunopathogenesis NN NN O
of NN NN O
diseases NN NN O
involving NN NN O
immune NN NN O
or NN NN O
inflammatory NN NN O
processes NN NN O
such NN NN O
as NN NN O
atherosclerosis NN NN O
and NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
H2O2 NN NN O
and NN NN O
other NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
as NN NN O
an NN NN O
integratory NN NN O
secondary NN NN O
messenger NN NN O
for NN NN O
divergent NN NN O
T NN NN O
cell NN NN O
signals NN NN O
has NN NN O
been NN NN O
complicated NN NN O
by NN NN O
the NN NN O
fact NN NN O
that NN NN O
various NN NN O
T NN NN O
cell NN NN O
lines NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
cells NN NN O
differ NN NN O
markedly NN NN O
in NN NN O
the NN NN O
levels NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
induced NN NN O
by NN NN O
oxidant NN NN O
stress NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
proposed NN NN O
pathways NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
have NN NN O
been NN NN O
based NN NN O
on NN NN O
indirect NN NN O
evidence NN NN O
provided NN NN O
by NN NN O
experiments NN NN O
which NN NN O
used NN NN O
antioxidants NN NN O
to NN NN O
inhibit NN NN O
active NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
formation NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
complete NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
requires NN NN O
at NN NN O
least NN NN O
two NN NN O
signals NN NN O
, NN NN O
one NN NN O
that NN NN O
stimulates NN NN O
an NN NN O
increase NN NN O
in NN NN O
intracellular NN NN O
calcium NN NN O
and NN NN O
one NN NN O
that NN NN O
stimulates NN NN O
enzymatic NN NN O
processes NN NN O
including NN NN O
kinases NN NN O
. NN NN O
   
Similarly NN NN O
, NN NN O
substantial NN NN O
evidence NN NN O
indicates NN NN O
that NN NN O
full NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
requires NN NN O
dual NN NN O
signals NN NN O
. NN NN O
   
The NN NN O
ability NN NN O
of NN NN O
H2O2 NN NN O
or NN NN O
other NN NN O
ROS NN NN O
to NN NN O
induce NN NN O
T NN NN O
cell NN NN O
signals NN NN O
and NN NN O
functional NN NN O
responses NN NN O
by NN NN O
these NN NN O
two NN NN O
mechanisms NN NN O
is NN NN O
reviewed NN NN O
and NN NN O
the NN NN O
specific NN NN O
response NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
to NN NN O
redox NN NN O
changes NN NN O
in NN NN O
T NN NN O
cells NN NN O
is NN NN O
examined NN NN O
. NN NN O
   
Data NN NN O
are NN NN O
also NN NN O
presented NN NN O
to NN NN O
suggest NN NN O
that NN NN O
the NN NN O
redox NN NN O
regulation NN NN O
in NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
may NN NN O
be NN NN O
relevant NN NN O
to NN NN O
immune NN NN O
- NN NN O
related NN NN O
diseases NN NN O
and NN NN O
to NN NN O
aging NN NN O
. NN NN O
   
Fibrinogen NN NN O
activates NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
mononuclear NN NN O
phagocytes NN NN O
. NN NN O
   
Adhesion NN NN O
to NN NN O
extracellular NN NN O
matrices NN NN O
is NN NN O
known NN NN O
to NN NN O
modulate NN NN O
leukocyte NN NN O
activation NN NN O
, NN NN O
although NN NN O
the NN NN O
mechanisms NN NN O
are NN NN O
not NN NN O
fully NN NN O
understood NN NN O
. NN NN O
   
Mononuclear NN NN O
phagocytes NN NN O
are NN NN O
exposed NN NN O
to NN NN O
fibrinous NN NN O
provisional NN NN O
matrix NN NN O
throughout NN NN O
migration NN NN O
into NN NN O
inflammatory NN NN O
foci NN NN O
, NN NN O
so NN NN O
this NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
whether NN NN O
fibrinogen NN NN O
triggers NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
U937 NN NN O
cells NN NN O
differentiated NN NN O
with NN NN O
PMA NN NN O
in NN NN O
nonadherent NN NN O
culture NN NN O
were NN NN O
shown NN NN O
to NN NN O
express NN NN O
two NN NN O
fibrinogen NN NN O
- NN NN O
binding NN NN O
integrins NN NN O
, NN NN O
predominately NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
, NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
, NN NN O
CD11c NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
. NN NN O
   
Cells NN NN O
stimulated NN NN O
with NN NN O
fibrinogen NN NN O
( NN NN O
10 NN NN O
- NN NN O
100 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
/ NN NN O
Mn2 NN NN O
+ NN NN O
( NN NN O
50 NN NN O
microM NN NN O
) NN NN O
for NN NN O
2 NN NN O
h NN NN O
were NN NN O
examined NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
, NN NN O
minimal NN NN O
in NN NN O
unstimulated NN NN O
cells NN NN O
, NN NN O
was NN NN O
substantially NN NN O
up NN NN O
- NN NN O
regulated NN NN O
by NN NN O
fibrinogen NN NN O
. NN NN O
   
Fibrinogen NN NN O
also NN NN O
caused NN NN O
activation NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
but NN NN O
not NN NN O
SP1 NN NN B-Protein
or NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
CREB NN NN O
) NN NN O
factors NN NN O
. NN NN O
   
Blocking NN NN O
mAbs NN NN O
against NN NN O
CD18 NN NN B-Protein
and NN NN O
CD11b NN NN B-Protein
abrogated NN NN O
fibrinogen NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
effects NN NN O
on NN NN O
transcriptional NN NN O
regulation NN NN O
, NN NN O
U937 NN NN O
cells NN NN O
were NN NN O
transfected NN NN O
with NN NN O
a NN NN O
plasmid NN NN O
containing NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
enhancer NN NN O
( NN NN O
bearing NN NN O
two NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
sites NN NN O
) NN NN O
coupled NN NN O
to NN NN O
a NN NN O
chloramphenicol NN NN B-Protein
acetyltransferase NN NN I-Protein
( NN NN O
CAT NN NN B-Protein
) NN NN O
reporter NN NN O
. NN NN O
   
Cells NN NN O
were NN NN O
subsequently NN NN O
stimulated NN NN O
with NN NN O
1 NN NN O
) NN NN O
PMA NN NN O
for NN NN O
24 NN NN O
h NN NN O
, NN NN O
inducing NN NN O
CAT NN NN B-Protein
activity NN NN O
by NN NN O
2 NN NN O
. NN NN O
6 NN NN O
- NN NN O
fold NN NN O
, NN NN O
2 NN NN O
) NN NN O
fibrinogen NN NN O
/ NN NN O
Mn2 NN NN O
+ NN NN O
for NN NN O
2 NN NN O
h NN NN O
, NN NN O
inducing NN NN O
CAT NN NN B-Protein
activity NN NN O
by NN NN O
3 NN NN O
. NN NN O
2 NN NN O
- NN NN O
fold NN NN O
, NN NN O
or NN NN O
3 NN NN O
) NN NN O
costimulation NN NN O
with NN NN O
fibrinogen NN NN O
and NN NN O
PMA NN NN O
, NN NN O
inducing NN NN O
5 NN NN O
. NN NN O
7 NN NN O
- NN NN O
fold NN NN O
the NN NN O
CAT NN NN B-Protein
activity NN NN O
induced NN NN O
by NN NN O
PMA NN NN O
alone NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
contact NN NN O
with NN NN O
fibrinogen NN NN O
- NN NN O
derived NN NN O
proteins NN NN O
may NN NN O
contribute NN NN O
to NN NN O
mononuclear NN NN O
phagocyte NN NN O
activation NN NN O
by NN NN O
signaling NN NN O
through NN NN O
CD11b NN NN B-Protein
/ NN NN O
CD18 NN NN B-Protein
, NN NN O
resulting NN NN O
in NN NN O
selective NN NN O
activation NN NN O
of NN NN O
transcriptional NN NN O
regulatory NN NN O
factors NN NN O
, NN NN O
including NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Ex NN NN O
vivo NN NN O
activation NN NN O
of NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
lymph NN NN O
node NN NN O
T NN NN O
cells NN NN O
reverses NN NN O
defects NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
molecules NN NN O
. NN NN O
   
The NN NN O
adoptive NN NN O
transfer NN NN O
of NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
lymph NN NN O
node NN NN O
( NN NN O
LN NN NN O
) NN NN O
T NN NN O
cells NN NN O
activated NN NN O
ex NN NN O
vivo NN NN O
with NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
interleukin NN NN B-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
mediates NN NN O
the NN NN O
regression NN NN O
of NN NN O
the NN NN O
poorly NN NN O
immunogenic NN NN O
murine NN NN O
melanoma NN NN O
D5 NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
the NN NN O
activated NN NN O
LN NN NN O
cells NN NN O
is NN NN O
augmented NN NN O
when NN NN O
the NN NN O
sensitizing NN NN O
tumor NN NN O
is NN NN O
a NN NN O
genetically NN NN O
modified NN NN O
variant NN NN O
( NN NN O
designated NN NN O
D5G6 NN NN O
) NN NN O
that NN NN O
secretes NN NN O
granulocyte NN NN B-Protein
/ NN NN I-Protein
macrophage NN NN I-Protein
- NN NN I-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
activated NN NN O
LN NN NN O
cells NN NN O
, NN NN O
adoptive NN NN O
transfer NN NN O
of NN NN O
freshly NN NN O
isolated NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
LN NN NN O
T NN NN O
cells NN NN O
has NN NN O
no NN NN O
therapeutic NN NN O
activity NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
whether NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
antitumor NN NN O
function NN NN O
during NN NN O
ex NN NN O
vivo NN NN O
activation NN NN O
is NN NN O
associated NN NN O
with NN NN O
modifications NN NN O
in NN NN O
signal NN NN O
transduction NN NN O
capacity NN NN O
, NN NN O
the NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
p56lck NN NN B-Protein
and NN NN O
p59fyn NN NN B-Protein
and NN NN O
proteins NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
were NN NN O
analyzed NN NN O
in NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
LN NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
levels NN NN O
of NN NN O
p56lck NN NN B-Protein
and NN NN O
p59fyn NN NN B-Protein
were NN NN O
lower NN NN O
in NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
than NN NN O
in NN NN O
normal NN NN O
LN NN NN O
T NN NN O
cells NN NN O
and NN NN O
production NN NN O
of NN NN O
tyrosine NN NN O
- NN NN O
phosphorylated NN NN O
substrates NN NN O
was NN NN O
markedly NN NN O
depressed NN NN O
following NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
. NN NN O
   
After NN NN O
5 NN NN O
- NN NN O
day NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
activation NN NN O
, NN NN O
levels NN NN O
of NN NN O
p56lck NN NN B-Protein
and NN NN O
p59fyn NN NN B-Protein
and NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
increased NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
the NN NN O
levels NN NN O
of NN NN O
p56lck NN NN B-Protein
, NN NN O
p59fyn NN NN B-Protein
, NN NN O
and NN NN O
tyrosine NN NN O
kinase NN NN O
activity NN NN O
were NN NN O
higher NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
derived NN NN O
from NN NN O
LN NN NN O
that NN NN O
drained NN NN O
D5G6 NN NN O
than NN NN O
they NN NN O
were NN NN O
in NN NN O
those NN NN O
from NN NN O
D5 NN NN O
tumors NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
cytoplasmic NN NN O
levels NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
and NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
were NN NN O
normal NN NN O
in NN NN O
freshly NN NN O
isolated NN NN O
tumor NN NN O
- NN NN O
draining NN NN O
LN NN NN O
, NN NN O
as NN NN O
was NN NN O
nuclear NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
induced NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
mAb NN NN O
or NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
activated NN NN O
LN NN NN O
cells NN NN O
with NN NN O
D5 NN NN O
tumor NN NN O
cells NN NN O
induced NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
recovery NN NN O
of NN NN O
proteins NN NN O
mediating NN NN O
signal NN NN O
transduction NN NN O
through NN NN O
the NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
/ NN NN O
CD3 NN NN O
complex NN NN O
in NN NN O
LN NN NN O
T NN NN O
cells NN NN O
activated NN NN O
ex NN NN O
vivo NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
acquisition NN NN O
of NN NN O
antitumor NN NN O
function NN NN O
. NN NN O
   
Targeted NN NN O
disruption NN NN O
of NN NN O
the NN NN O
MyD88 NN NN B-Protein
gene NN NN O
results NN NN O
in NN NN O
loss NN NN O
of NN NN O
IL NN NN O
- NN NN O
1 NN NN O
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
18 NN NN I-Protein
- NN NN O
mediated NN NN O
function NN NN O
. NN NN O
   
MyD88 NN NN B-Protein
, NN NN O
originally NN NN O
isolated NN NN O
as NN NN O
a NN NN O
myeloid NN NN O
differentiation NN NN O
primary NN NN O
response NN NN O
gene NN NN O
, NN NN O
is NN NN O
shown NN NN O
to NN NN O
act NN NN O
as NN NN O
an NN NN O
adaptor NN NN O
in NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
signaling NN NN O
by NN NN O
interacting NN NN O
with NN NN O
both NN NN O
the NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
complex NN NN O
and NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
- NN NN O
associated NN NN O
kinase NN NN O
( NN NN O
IRAK NN NN O
) NN NN O
. NN NN O
   
Mice NN NN O
generated NN NN O
by NN NN O
gene NN NN O
targeting NN NN O
to NN NN O
lack NN NN O
MyD88 NN NN B-Protein
have NN NN O
defects NN NN O
in NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
as NN NN O
well NN NN O
as NN NN O
induction NN NN O
of NN NN O
acute NN NN O
phase NN NN O
proteins NN NN O
and NN NN O
cytokines NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Increases NN NN O
in NN NN O
interferon NN NN O
- NN NN O
gamma NN NN O
production NN NN O
and NN NN O
natural NN NN O
killer NN NN O
cell NN NN O
activity NN NN O
in NN NN O
response NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
18 NN NN I-Protein
are NN NN O
abrogated NN NN O
. NN NN O
   
In NN NN O
vivo NN NN O
Th1 NN NN O
response NN NN O
is NN NN O
also NN NN O
impaired NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
18 NN NN I-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
c NN NN O
- NN NN O
Jun NN NN O
N NN NN O
- NN NN O
terminal NN NN O
kinase NN NN O
( NN NN O
JNK NN NN O
) NN NN O
is NN NN O
blocked NN NN O
in NN NN O
MyD88 NN NN B-Protein
- NN NN O
/ NN NN O
- NN NN O
Th1 NN NN O
- NN NN O
developing NN NN O
cells NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
MyD88 NN NN B-Protein
is NN NN O
a NN NN O
critical NN NN O
component NN NN O
in NN NN O
the NN NN O
signaling NN NN O
cascade NN NN O
that NN NN O
is NN NN O
mediated NN NN O
by NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptor NN NN O
as NN NN O
well NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
18 NN NN I-Protein
receptor NN NN O
. NN NN O
   
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
- NN NN O
transforming NN NN O
protein NN NN O
latent NN NN B-Protein
infection NN NN I-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
activates NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
a NN NN O
pathway NN NN O
that NN NN O
includes NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
inducing NN NN O
kinase NN NN O
and NN NN O
the NN NN O
IkappaB NN NN O
kinases NN NN O
IKKalpha NN NN B-Protein
and NN NN O
IKKbeta NN NN B-Protein
. NN NN O
   
The NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
oncoprotein NN NN O
latent NN NN B-Protein
infection NN NN I-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
is NN NN O
a NN NN O
constitutively NN NN O
aggregated NN NN O
pseudo NN NN O
- NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
receptor NN NN O
( NN NN O
TNFR NN NN O
) NN NN O
that NN NN O
activates NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
two NN NN O
sites NN NN O
in NN NN O
its NN NN O
C NN NN O
- NN NN O
terminal NN NN O
cytoplasmic NN NN O
domain NN NN O
. NN NN O
   
One NN NN O
site NN NN O
is NN NN O
similar NN NN O
to NN NN O
activated NN NN O
TNFRII NN NN B-Protein
in NN NN O
associating NN NN O
with NN NN O
TNFR NN NN O
- NN NN O
associated NN NN O
factors NN NN O
TRAF1 NN NN B-Protein
and NN NN O
TRAF2 NN NN B-Protein
, NN NN O
and NN NN O
the NN NN O
second NN NN O
site NN NN O
is NN NN O
similar NN NN O
to NN NN O
TNFRI NN NN B-Protein
in NN NN O
associating NN NN O
with NN NN O
the NN NN O
TNFRI NN NN B-Protein
death NN NN O
domain NN NN O
interacting NN NN O
protein NN NN O
TRADD NN NN B-Protein
. NN NN O
   
TNFRI NN NN B-Protein
has NN NN O
been NN NN O
recently NN NN O
shown NN NN O
to NN NN O
activate NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
through NN NN O
association NN NN O
with NN NN O
TRADD NN NN B-Protein
, NN NN O
RIP NN NN B-Protein
, NN NN O
and NN NN O
TRAF2 NN NN B-Protein
; NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaB NN NN I-Protein
- NN NN I-Protein
inducing NN NN I-Protein
kinase NN NN I-Protein
( NN NN O
NIK NN NN B-Protein
) NN NN O
; NN NN O
activation NN NN O
of NN NN O
the NN NN O
IkappaB NN NN O
alpha NN NN O
kinases NN NN O
( NN NN O
IKKalpha NN NN B-Protein
and NN NN O
IKKbeta NN NN B-Protein
) NN NN O
; NN NN O
and NN NN O
phosphorylation NN NN O
of NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
. NN NN O
   
IkappaB NN NN B-Protein
alpha NN NN I-Protein
phosphorylation NN NN O
on NN NN O
Ser NN NN O
- NN NN O
32 NN NN O
and NN NN O
Ser NN NN O
- NN NN O
36 NN NN O
is NN NN O
followed NN NN O
by NN NN O
its NN NN O
degradation NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
LMP1 NN NN B-Protein
or NN NN O
by NN NN O
each NN NN O
of NN NN O
its NN NN O
effector NN NN O
sites NN NN O
is NN NN O
mediated NN NN O
by NN NN O
a NN NN O
pathway NN NN O
that NN NN O
includes NN NN O
NIK NN NN B-Protein
, NN NN O
IKKalpha NN NN B-Protein
, NN NN O
and NN NN O
IKKbeta NN NN B-Protein
. NN NN O
   
Dominant NN NN O
negative NN NN O
mutants NN NN O
of NN NN O
NIK NN NN B-Protein
, NN NN O
IKKalpha NN NN B-Protein
, NN NN O
or NN NN O
IKKbeta NN NN B-Protein
substantially NN NN O
inhibited NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
LMP1 NN NN B-Protein
or NN NN O
by NN NN O
each NN NN O
of NN NN O
its NN NN O
effector NN NN O
sites NN NN O
. NN NN O
   
Dimethyldithiocarbamate NN NN O
inhibits NN NN O
in NN NN O
vitro NN NN O
activation NN NN O
of NN NN O
primary NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Dithiocarbamates NN NN O
( NN NN O
DTC NN NN O
) NN NN O
, NN NN O
a NN NN O
diverse NN NN O
group NN NN O
of NN NN O
industrial NN NN O
and NN NN O
therapeutic NN NN O
chemicals NN NN O
, NN NN O
have NN NN O
been NN NN O
reported NN NN O
to NN NN O
inhibit NN NN O
, NN NN O
enhance NN NN O
or NN NN O
have NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O
   
These NN NN O
apparent NN NN O
inconsistencies NN NN O
reflect NN NN O
the NN NN O
complexity NN NN O
of NN NN O
the NN NN O
DTCs NN NN O
biological NN NN O
activities NN NN O
and NN NN O
are NN NN O
probably NN NN O
due NN NN O
in NN NN O
part NN NN O
to NN NN O
differences NN NN O
in NN NN O
dose NN NN O
, NN NN O
route NN NN O
of NN NN O
exposure NN NN O
, NN NN O
animal NN NN O
species NN NN O
used NN NN O
and NN NN O
/ NN NN O
or NN NN O
specific NN NN O
compound NN NN O
tested NN NN O
. NN NN O
   
The NN NN O
studies NN NN O
described NN NN O
herein NN NN O
were NN NN O
undertaken NN NN O
to NN NN O
investigate NN NN O
the NN NN O
immunotoxicity NN NN O
of NN NN O
one NN NN O
member NN NN O
of NN NN O
this NN NN O
family NN NN O
, NN NN O
dimethyldithiocarbamate NN NN O
( NN NN O
DMDTC NN NN O
) NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
DMDTC NN NN O
inhibits NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
primary NN NN O
human NN NN O
CD4 NN NN B-Protein
+ NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
inhibition NN NN O
is NN NN O
not NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
loss NN NN O
in NN NN O
viability NN NN O
, NN NN O
and NN NN O
DMDTC NN NN O
- NN NN O
treated NN NN O
T NN NN O
cells NN NN O
retain NN NN O
other NN NN O
active NN NN O
signaling NN NN O
pathways NN NN O
throughout NN NN O
the NN NN O
exposure NN NN O
duration NN NN O
. NN NN O
   
The NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
apparently NN NN O
permanent NN NN O
as NN NN O
DMDTC NN NN O
- NN NN O
treated NN NN O
T NN NN O
cells NN NN O
did NN NN O
not NN NN O
regain NN NN O
normal NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
activation NN NN O
, NN NN O
even NN NN O
after NN NN O
72 NN NN O
h NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
DMDTC NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
alter NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
directly NN NN O
as NN NN O
pre NN NN O
- NN NN O
incubation NN NN O
of NN NN O
nuclear NN NN O
extracts NN NN O
with NN NN O
DMDTC NN NN O
does NN NN O
not NN NN O
diminish NN NN O
binding NN NN O
activity NN NN O
of NN NN O
this NN NN O
protein NN NN O
. NN NN O
   
We NN NN O
further NN NN O
demonstrate NN NN O
that NN NN O
0 NN NN O
. NN NN O
1 NN NN O
- NN NN O
0 NN NN O
. NN NN O
5 NN NN O
microM NN NN O
DMDTC NN NN O
inhibits NN NN O
intracellular NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
and NN NN O
decreases NN NN O
surface NN NN O
expression NN NN O
of NN NN O
CD25 NN NN B-Protein
( NN NN O
the NN NN O
alpha NN NN O
subunit NN NN O
of NN NN O
the NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
) NN NN O
in NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
phorbol NN NN O
ester NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
DMDTC NN NN O
is NN NN O
a NN NN O
potent NN NN O
immunosuppressive NN NN O
compound NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
The NN NN O
small NN NN O
GTP NN NN O
- NN NN O
binding NN NN O
protein NN NN O
Rho NN NN O
potentiates NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
Rho NN NN O
family NN NN O
of NN NN O
small NN NN O
GTP NN NN O
- NN NN O
binding NN NN O
proteins NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cytoskeletal NN NN O
structure NN NN O
, NN NN O
gene NN NN O
transcription NN NN O
, NN NN O
specific NN NN O
cell NN NN O
fate NN NN O
development NN NN O
, NN NN O
and NN NN O
transformation NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
in NN NN O
this NN NN O
report NN NN O
that NN NN O
overexpression NN NN O
of NN NN O
an NN NN O
activated NN NN O
form NN NN O
of NN NN O
Rho NN NN O
enhances NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
, NN NN O
but NN NN O
activated NN NN O
Rho NN NN O
( NN NN O
V14Rho NN NN O
) NN NN O
has NN NN O
little NN NN O
or NN NN O
no NN NN O
effect NN NN O
on NN NN O
NFAT NN NN O
, NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
enhancer NN NN O
element NN NN O
activities NN NN O
under NN NN O
similar NN NN O
conditions NN NN O
. NN NN O
   
Overexpression NN NN O
of NN NN O
a NN NN O
V14Rho NN NN O
construct NN NN O
incapable NN NN O
of NN NN O
membrane NN NN O
localization NN NN O
( NN NN O
CAAX NN NN O
deleted NN NN O
) NN NN O
abolishes NN NN O
PMA NN NN O
- NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activation NN NN O
. NN NN O
   
The NN NN O
effect NN NN O
of NN NN O
Rho NN NN O
on NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
independent NN NN O
of NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
pathway NN NN O
, NN NN O
as NN NN O
a NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
MEK NN NN O
and NN NN O
a NN NN O
MEK NN NN O
inhibitor NN NN O
( NN NN O
PD98059 NN NN O
) NN NN O
did NN NN O
not NN NN O
affect NN NN O
Rho NN NN O
- NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
. NN NN O
   
V14Rho NN NN O
binds NN NN O
strongly NN NN O
to NN NN O
protein NN NN B-Protein
kinase NN NN I-Protein
Calpha NN NN I-Protein
( NN NN O
PKCalpha NN NN B-Protein
) NN NN O
in NN NN O
vivo NN NN O
; NN NN O
however NN NN O
, NN NN O
deletion NN NN O
of NN NN O
the NN NN O
CAAX NN NN O
site NN NN O
on NN NN O
V14Rho NN NN O
severely NN NN O
diminished NN NN O
this NN NN O
association NN NN O
. NN NN O
   
Evidence NN NN O
for NN NN O
a NN NN O
role NN NN O
for NN NN O
PKCalpha NN NN B-Protein
as NN NN O
an NN NN O
effector NN NN O
of NN NN O
Rho NN NN O
was NN NN O
obtained NN NN O
by NN NN O
the NN NN O
observation NN NN O
that NN NN O
coexpression NN NN O
of NN NN O
the NN NN O
N NN NN O
- NN NN O
terminal NN NN O
domain NN NN O
of NN NN O
PKCalpha NN NN B-Protein
blocked NN NN O
the NN NN O
effects NN NN O
of NN NN O
activated NN NN O
Rho NN NN O
plus NN NN O
PMA NN NN O
on NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
Rho NN NN O
potentiates NN NN O
AP NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
during NN NN O
T NN NN O
- NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
Tax NN NN B-Protein
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
involves NN NN O
activation NN NN O
of NN NN O
the NN NN O
IkappaB NN NN B-Protein
kinase NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
IKKalpha NN NN B-Protein
) NN NN O
and NN NN O
IKKbeta NN NN B-Protein
cellular NN NN O
kinases NN NN O
. NN NN O
   
Tax NN NN B-Protein
corresponds NN NN O
to NN NN O
a NN NN O
40 NN NN O
- NN NN O
kDa NN NN O
transforming NN NN O
protein NN NN O
from NN NN O
the NN NN O
pathogenic NN NN O
retrovirus NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
that NN NN O
activates NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
by NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
. NN NN O
   
Tax NN NN B-Protein
expression NN NN O
promotes NN NN O
N NN NN O
- NN NN O
terminal NN NN O
phosphorylation NN NN O
and NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
a NN NN O
principal NN NN O
cytoplasmic NN NN O
inhibitor NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Our NN NN O
studies NN NN O
now NN NN O
demonstrate NN NN O
that NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
activates NN NN O
the NN NN O
recently NN NN O
identified NN NN O
cellular NN NN O
kinases NN NN O
IkappaB NN NN B-Protein
kinase NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
IKKalpha NN NN B-Protein
) NN NN O
and NN NN O
IKKbeta NN NN B-Protein
, NN NN O
which NN NN O
normally NN NN O
phosphorylate NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
on NN NN O
both NN NN O
of NN NN O
its NN NN O
N NN NN O
- NN NN O
terminal NN NN O
regulatory NN NN O
serines NN NN O
in NN NN O
response NN NN O
to NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
and NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
stimulation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
mutant NN NN O
of NN NN O
Tax NN NN B-Protein
termed NN NN O
M22 NN NN O
, NN NN O
which NN NN O
does NN NN O
not NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
fails NN NN O
to NN NN O
activate NN NN O
either NN NN O
IKKalpha NN NN B-Protein
or NN NN O
IKKbeta NN NN B-Protein
. NN NN O
   
Furthermore NN NN O
, NN NN O
endogenous NN NN O
IKK NN NN O
enzymatic NN NN O
activity NN NN O
was NN NN O
significantly NN NN O
elevated NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
and NN NN O
Tax NN NN B-Protein
- NN NN O
expressing NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Transfection NN NN O
of NN NN O
kinase NN NN O
- NN NN O
deficient NN NN O
mutants NN NN O
of NN NN O
IKKalpha NN NN B-Protein
and NN NN O
IKKbeta NN NN B-Protein
into NN NN O
either NN NN O
human NN NN O
Jurkat NN NN O
T NN NN O
or NN NN O
293 NN NN O
cells NN NN O
also NN NN O
inhibits NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
induced NN NN O
by NN NN O
Tax NN NN B-Protein
. NN NN O
   
Similarly NN NN O
, NN NN O
a NN NN O
kinase NN NN O
- NN NN O
deficient NN NN O
mutant NN NN O
of NN NN O
NIK NN NN B-Protein
( NN NN O
NF NN NN B-Protein
- NN NN I-Protein
kappaB NN NN I-Protein
- NN NN I-Protein
inducing NN NN I-Protein
kinase NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
represents NN NN O
an NN NN O
upstream NN NN O
kinase NN NN O
in NN NN O
the NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
1 NN NN O
signaling NN NN O
pathways NN NN O
leading NN NN O
to NN NN O
IKKalpha NN NN B-Protein
and NN NN O
IKKbeta NN NN B-Protein
activation NN NN O
, NN NN O
blocks NN NN O
Tax NN NN B-Protein
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
However NN NN O
, NN NN O
plasma NN NN O
membrane NN NN O
- NN NN O
proximal NN NN O
elements NN NN O
in NN NN O
these NN NN O
proinflammatory NN NN O
cytokine NN NN O
pathways NN NN O
are NN NN O
apparently NN NN O
not NN NN O
involved NN NN O
since NN NN O
dominant NN NN O
negative NN NN O
mutants NN NN O
of NN NN O
the NN NN O
TRAF2 NN NN B-Protein
and NN NN O
TRAF6 NN NN B-Protein
adaptors NN NN O
, NN NN O
which NN NN O
effectively NN NN O
block NN NN O
signaling NN NN O
through NN NN O
the NN NN O
cytoplasmic NN NN O
tails NN NN O
of NN NN O
the NN NN O
TNF NN NN O
- NN NN O
alpha NN NN O
and NN NN O
IL NN NN O
- NN NN O
1 NN NN O
receptors NN NN O
, NN NN O
respectively NN NN O
, NN NN O
do NN NN O
not NN NN O
inhibit NN NN O
Tax NN NN B-Protein
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
Tax NN NN B-Protein
exploits NN NN O
a NN NN O
distal NN NN O
part NN NN O
of NN NN O
the NN NN O
proinflammatory NN NN O
cytokine NN NN O
signaling NN NN O
cascade NN NN O
leading NN NN O
to NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
pathological NN NN O
alteration NN NN O
of NN NN O
this NN NN O
cytokine NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
by NN NN O
Tax NN NN B-Protein
may NN NN O
play NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
- NN NN O
mediated NN NN O
transformation NN NN O
of NN NN O
human NN NN O
T NN NN O
cells NN NN O
, NN NN O
clinically NN NN O
manifested NN NN O
as NN NN O
the NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
. NN NN O
   
A NN NN O
CD28 NN NN B-Protein
- NN NN O
associated NN NN O
signaling NN NN O
pathway NN NN O
leading NN NN O
to NN NN O
cytokine NN NN O
gene NN NN O
transcription NN NN O
and NN NN O
T NN NN O
cell NN NN O
proliferation NN NN O
without NN NN O
TCR NN NN O
engagement NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
resting NN NN O
human NN NN O
T NN NN O
cells NN NN O
with NN NN O
the NN NN O
CD28 NN NN B-Protein
- NN NN O
specific NN NN O
mAb NN NN O
BW NN NN O
828 NN NN O
induces NN NN O
proliferation NN NN O
and NN NN O
cytokine NN NN O
synthesis NN NN O
without NN NN O
further NN NN O
requirement NN NN O
for NN NN O
TCR NN NN O
coengagement NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
prompted NN NN O
us NN NN O
to NN NN O
postulate NN NN O
that NN NN O
signal NN NN O
2 NN NN O
( NN NN O
costimulatory NN NN O
signal NN NN O
) NN NN O
alone NN NN O
without NN NN O
signal NN NN O
1 NN NN O
( NN NN O
TCR NN NN O
signal NN NN O
) NN NN O
can NN NN O
activate NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
To NN NN O
test NN NN O
whether NN NN O
this NN NN O
putative NN NN O
function NN NN O
of NN NN O
CD28 NN NN B-Protein
is NN NN O
mediated NN NN O
via NN NN O
a NN NN O
particular NN NN O
signaling NN NN O
pathway NN NN O
, NN NN O
we NN NN O
compared NN NN O
early NN NN O
signaling NN NN O
events NN NN O
initiated NN NN O
in NN NN O
resting NN NN O
T NN NN O
cells NN NN O
by NN NN O
the NN NN O
stimulatory NN NN O
mAb NN NN O
BW NN NN O
828 NN NN O
with NN NN O
signals NN NN O
triggered NN NN O
by NN NN O
the NN NN O
nonstimulating NN NN O
CD28 NN NN B-Protein
mAb NN NN O
9 NN NN O
. NN NN O
3 NN NN O
. NN NN O
   
Stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
BW NN NN O
828 NN NN O
induced NN NN O
an NN NN O
increase NN NN O
in NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
lead NN NN O
to NN NN O
detectable NN NN O
activation NN NN O
of NN NN O
the NN NN O
protein NN NN O
kinases NN NN O
p56 NN NN B-Protein
( NN NN I-Protein
lck NN NN I-Protein
) NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Raf NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
This NN NN O
pathway NN NN O
resulted NN NN O
in NN NN O
the NN NN O
induction NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
and NN NN O
proteins NN NN O
binding NN NN O
to NN NN O
the NN NN O
CD28 NN NN B-Protein
response NN NN O
element NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
stimulation NN NN O
of NN NN O
T NN NN O
cells NN NN O
with NN NN O
mAb NN NN O
9 NN NN O
. NN NN O
3 NN NN O
increased NN NN O
the NN NN O
level NN NN O
of NN NN O
intracellular NN NN O
Ca2 NN NN O
+ NN NN O
and NN NN O
triggered NN NN O
the NN NN O
activation NN NN O
of NN NN O
p56 NN NN B-Protein
( NN NN I-Protein
lck NN NN I-Protein
) NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Raf NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
but NN NN O
was NN NN O
unable NN NN O
to NN NN O
induce NN NN O
the NN NN O
binding NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
to NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
the NN NN O
differential NN NN O
signaling NN NN O
of NN NN O
BW NN NN B-Protein
828 NN NN I-Protein
and NN NN O
9 NN NN B-Protein
. NN NN I-Protein
3 NN NN I-Protein
in NN NN O
resting NN NN O
T NN NN O
cells NN NN O
, NN NN O
the NN NN O
two NN NN O
mAbs NN NN O
exhibited NN NN O
a NN NN O
similar NN NN O
pattern NN NN O
of NN NN O
early NN NN O
signaling NN NN O
events NN NN O
in NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
Jurkat NN NN O
cells NN NN O
( NN NN O
p56 NN NN B-Protein
( NN NN I-Protein
lck NN NN I-Protein
) NN NN I-Protein
activation NN NN O
, NN NN O
association NN NN O
of NN NN O
phosphatidylinositol NN NN O
3 NN NN O
- NN NN O
kinase NN NN O
with NN NN O
CD28 NN NN B-Protein
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
signaling NN NN O
capacity NN NN O
of NN NN O
CD28 NN NN B-Protein
changes NN NN O
with NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
data NN NN O
support NN NN O
the NN NN O
view NN NN O
that NN NN O
stimulation NN NN O
through NN NN O
CD28 NN NN B-Protein
can NN NN O
induce NN NN O
some NN NN O
effector NN NN O
functions NN NN O
in NN NN O
T NN NN O
cells NN NN O
and NN NN O
suggest NN NN O
that NN NN O
this NN NN O
capacity NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
particular NN NN O
pattern NN NN O
of NN NN O
early NN NN O
signaling NN NN O
events NN NN O
. NN NN O
   
Cyclosporin NN NN O
A NN NN O
- NN NN O
resistant NN NN O
transactivation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
requires NN NN O
activity NN NN O
of NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
sensitive NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
phosphatases NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
requires NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
through NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
TCR NN NN O
and NN NN O
costimulation NN NN O
through NN NN O
accessory NN NN O
receptors NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
recently NN NN O
that NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
sensitive NN NN O
Ser NN NN O
/ NN NN O
Thr NN NN O
phosphatases NN NN O
are NN NN O
involved NN NN O
in NN NN O
a NN NN O
cyclosporin NN NN O
A NN NN O
- NN NN O
insensitive NN NN O
pathway NN NN O
that NN NN O
selectively NN NN O
transmits NN NN O
costimulatory NN NN O
signals NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
whether NN NN O
activities NN NN O
of NN NN O
these NN NN O
phosphatases NN NN O
are NN NN O
necessary NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
. NN NN O
   
In NN NN O
both NN NN O
activated NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
activated NN NN O
tumorigenic NN NN O
T NN NN O
cell NN NN O
lines NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
was NN NN O
blocked NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
by NN NN O
okadaic NN NN O
acid NN NN O
. NN NN O
   
The NN NN O
transcription NN NN O
factors NN NN O
active NN NN O
at NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
were NN NN O
differentially NN NN O
influenced NN NN O
: NN NN O
upon NN NN O
down NN NN O
- NN NN O
modulation NN NN O
of NN NN O
okadaic NN NN O
acid NN NN O
- NN NN O
sensitive NN NN O
phosphatases NN NN O
, NN NN O
transactivation NN NN O
by NN NN O
octamer NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
and NN NN O
NF NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
proteins NN NN O
was NN NN O
abrogated NN NN O
, NN NN O
while NN NN O
transactivation NN NN O
by NN NN O
AP NN NN O
- NN NN O
1 NN NN O
proteins NN NN O
was NN NN O
even NN NN O
enhanced NN NN O
. NN NN O
   
Inducible NN NN O
nitric NN NN O
oxide NN NN O
: NN NN O
an NN NN O
autoregulatory NN NN O
feedback NN NN O
inhibitor NN NN O
of NN NN O
vascular NN NN O
inflammation NN NN O
. NN NN O
   
Inducible NN NN O
nitric NN NN O
oxide NN NN O
( NN NN O
iNO NN NN O
) NN NN O
is NN NN O
produced NN NN O
at NN NN O
sites NN NN O
of NN NN O
vascular NN NN O
inflammation NN NN O
by NN NN O
resident NN NN O
and NN NN O
nonresident NN NN O
vascular NN NN O
wall NN NN O
cells NN NN O
, NN NN O
but NN NN O
its NN NN O
role NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
process NN NN O
is NN NN O
not NN NN O
known NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
a NN NN O
novel NN NN O
function NN NN O
of NN NN O
iNO NN NN O
is NN NN O
to NN NN O
terminate NN NN O
inflammatory NN NN O
processes NN NN O
. NN NN O
   
We NN NN O
find NN NN O
that NN NN O
iNO NN NN O
produced NN NN O
by NN NN O
murine NN NN O
macrophage NN NN O
- NN NN O
like NN NN O
cells NN NN O
, NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
, NN NN O
can NN NN O
inhibit NN NN O
cytokine NN NN O
- NN NN O
induced NN NN O
endothelial NN NN O
cell NN NN O
activation NN NN O
in NN NN O
a NN NN O
separated NN NN O
and NN NN O
mixed NN NN O
endothelial NN NN O
- NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
coculture NN NN O
system NN NN O
. NN NN O
   
Both NN NN O
iNO NN NN O
production NN NN O
and NN NN O
endothelial NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
were NN NN O
induced NN NN O
simultaneously NN NN O
with NN NN O
bacterial NN NN O
LPS NN NN O
and NN NN O
murine NN NN O
- NN NN O
specific NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
. NN NN O
   
Inhibition NN NN O
of NN NN O
iNO NN NN B-Protein
synthase NN NN I-Protein
( NN NN O
iNOS NN NN B-Protein
) NN NN O
activity NN NN O
with NN NN O
N NN NN O
omega NN NN O
- NN NN O
monomethyl NN NN O
- NN NN O
L NN NN O
- NN NN O
arginine NN NN O
in NN NN O
endothelial NN NN O
- NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
cocultures NN NN O
, NN NN O
stimulated NN NN O
with NN NN O
murine NN NN O
- NN NN O
specific NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
and NN NN O
LPS NN NN O
, NN NN O
decreased NN NN O
iNO NN NN O
production NN NN O
by NN NN O
86 NN NN O
% NN NN O
, NN NN O
augmented NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
iNOS NN NN B-Protein
expression NN NN O
in NN NN O
endothelial NN NN O
and NN NN O
RAW264 NN NN O
. NN NN O
7 NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
, NN NN O
and NN NN O
increased NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
the NN NN O
endothelial NN NN O
cell NN NN O
surface NN NN O
. NN NN O
   
Transient NN NN O
transfection NN NN O
studies NN NN O
using NN NN O
various NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
constructs NN NN O
demonstrated NN NN O
that NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
iNO NN NN O
on NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
transcription NN NN O
were NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
iNO NN NN O
on NN NN O
kappa NN NN O
B NN NN O
cis NN NN O
- NN NN O
acting NN NN O
elements NN NN O
. NN NN O
   
Immunofluorescence NN NN O
studies NN NN O
using NN NN O
an NN NN O
Ab NN NN O
to NN NN O
the NN NN O
RelA NN NN B-Protein
( NN NN O
p65 NN NN B-Protein
) NN NN O
subunit NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
revealed NN NN O
that NN NN O
iNO NN NN O
inhibited NN NN O
the NN NN O
activation NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
indicate NN NN O
that NN NN O
iNO NN NN O
attenuates NN NN O
iNOS NN NN B-Protein
expression NN NN O
in NN NN O
macrophages NN NN O
and NN NN O
inhibits NN NN O
monocyte NN NN O
adhesion NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
suggest NN NN O
that NN NN O
endogenously NN NN O
derived NN NN O
iNO NN NN O
may NN NN O
be NN NN O
an NN NN O
important NN NN O
autoregulatory NN NN O
inhibitor NN NN O
of NN NN O
vascular NN NN O
inflammation NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
by NN NN O
combination NN NN O
of NN NN O
a NN NN O
novel NN NN O
inhibitor NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
with NN NN O
AZT NN NN O
. NN NN O
   
The NN NN O
small NN NN O
molecule NN NN O
S9a NN NN O
was NN NN O
derived NN NN O
from NN NN O
an NN NN O
established NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
inhibitor NN NN O
( NN NN O
Canventol NN NN O
) NN NN O
by NN NN O
replacement NN NN O
of NN NN O
the NN NN O
isopropylidine NN NN O
group NN NN O
with NN NN O
a NN NN O
phenyl NN NN O
ring NN NN O
. NN NN O
   
S9a NN NN O
at NN NN O
10 NN NN O
to NN NN O
100 NN NN O
nM NN NN O
inhibited NN NN O
HIV NN NN O
production NN NN O
as NN NN O
potently NN NN O
as NN NN O
3 NN NN O
' NN NN O
- NN NN O
azido NN NN O
- NN NN O
3 NN NN O
' NN NN O
- NN NN O
deoxythymidine NN NN O
( NN NN O
AZT NN NN O
) NN NN O
, NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
viral NN NN O
reverse NN NN O
transcriptase NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
S9a NN NN O
and NN NN O
AZT NN NN O
in NN NN O
combination NN NN O
, NN NN O
at NN NN O
noncytoxic NN NN O
concentrations NN NN O
strongly NN NN O
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
that NN NN O
was NN NN O
more NN NN O
than NN NN O
additive NN NN O
and NN NN O
substantially NN NN O
prolonged NN NN O
the NN NN O
appearance NN NN O
of NN NN O
virus NN NN O
both NN NN O
in NN NN O
acutely NN NN O
infected NN NN O
CD4 NN NN B-Protein
+ NN NN O
lymphocytes NN NN O
( NN NN O
SupT NN NN O
) NN NN O
in NN NN O
culture NN NN O
and NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMCs NN NN O
) NN NN O
infected NN NN O
with NN NN O
a NN NN O
primary NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
isolate NN NN O
. NN NN O
   
S9a NN NN O
inhibited NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
promoter NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
. NN NN O
   
It NN NN O
was NN NN O
proposed NN NN O
that NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
antiviral NN NN O
action NN NN O
of NN NN O
S9a NN NN O
was NN NN O
on NN NN O
the NN NN O
host NN NN O
cell NN NN O
, NN NN O
by NN NN O
blocking NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
transcription NN NN O
via NN NN O
a NN NN O
Tat NN NN B-Protein
- NN NN O
induced NN NN O
tar NN NN O
- NN NN O
independent NN NN O
loop NN NN O
, NN NN O
which NN NN O
decreases NN NN O
downstream NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
. NN NN O
   
S9a NN NN O
was NN NN O
superior NN NN O
to NN NN O
the NN NN O
first NN NN O
generation NN NN O
compound NN NN O
Canventol NN NN O
, NN NN O
which NN NN O
was NN NN O
superior NN NN O
to NN NN O
the NN NN O
natural NN NN O
compound NN NN O
sarcophytol NN NN O
A NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
further NN NN O
structure NN NN O
- NN NN O
based NN NN O
enhancement NN NN O
of NN NN O
potency NN NN O
of NN NN O
these NN NN O
compounds NN NN O
is NN NN O
feasible NN NN O
. NN NN O
   
This NN NN O
study NN NN O
suggests NN NN O
a NN NN O
therapeutic NN NN O
approach NN NN O
against NN NN O
AIDS NN NN O
by NN NN O
application NN NN O
of NN NN O
two NN NN O
drugs NN NN O
, NN NN O
one NN NN O
against NN NN O
a NN NN O
cellular NN NN O
and NN NN O
the NN NN O
other NN NN O
a NN NN O
viral NN NN O
target NN NN O
, NN NN O
which NN NN O
may NN NN O
provide NN NN O
an NN NN O
approach NN NN O
to NN NN O
the NN NN O
problem NN NN O
of NN NN O
frequent NN NN O
emergence NN NN O
of NN NN O
resistant NN NN O
variants NN NN O
to NN NN O
combinations NN NN O
of NN NN O
drugs NN NN O
that NN NN O
target NN NN O
only NN NN O
HIV NN NN O
genes NN NN O
. NN NN O
   
Retinoic NN NN O
acid NN NN O
inhibits NN NN O
CD40 NN NN B-Protein
+ NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
mediated NN NN O
IgE NN NN O
production NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
To NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
retinoic NN NN O
acid NN NN O
( NN NN O
RA NN NN O
) NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
+ NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
- NN NN O
mediated NN NN O
B NN NN O
- NN NN O
cell NN NN O
activation NN NN O
, NN NN O
the NN NN O
effect NN NN O
of NN NN O
10 NN NN O
( NN NN O
- NN NN O
12 NN NN O
) NN NN O
to NN NN O
10 NN NN O
( NN NN O
- NN NN O
6 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
RA NN NN O
was NN NN O
studied NN NN O
in NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
( NN NN O
1 NN NN O
microgram NN NN O
/ NN NN O
mL NN NN O
) NN NN O
+ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
5 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
- NN NN O
mediated NN NN O
proliferation NN NN O
and NN NN O
Ig NN NN O
synthesis NN NN O
by NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
and NN NN O
B NN NN O
cells NN NN O
in NN NN O
healthy NN NN O
donors NN NN O
. NN NN O
   
Anti NN NN O
- NN NN O
CD40 NN NN B-Protein
+ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
mediated NN NN O
proliferation NN NN O
of NN NN O
PBMC NN NN O
and NN NN O
B NN NN O
cells NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
RA NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
, NN NN O
with NN NN O
maximal NN NN O
inhibition NN NN O
of NN NN O
62 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
5 NN NN O
% NN NN O
in NN NN O
PBMC NN NN O
and NN NN O
55 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
4 NN NN O
% NN NN O
in NN NN O
B NN NN O
cells NN NN O
by NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
, NN NN O
and NN NN O
58 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
6 NN NN O
. NN NN O
7 NN NN O
% NN NN O
and NN NN O
51 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
4 NN NN O
. NN NN O
7 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
by NN NN O
13 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
. NN NN O
   
IgE NN NN O
synthesis NN NN O
was NN NN O
even NN NN O
more NN NN O
markedly NN NN O
inhibited NN NN O
by NN NN O
RA NN NN O
starting NN NN O
at NN NN O
concentrations NN NN O
of NN NN O
> NN NN O
10 NN NN O
( NN NN O
- NN NN O
14 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
for NN NN O
B NN NN O
cells NN NN O
and NN NN O
> NN NN O
10 NN NN O
( NN NN O
- NN NN O
10 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
for NN NN O
PBMC NN NN O
. NN NN O
   
Maximal NN NN O
inhibition NN NN O
of NN NN O
IgE NN NN O
production NN NN O
for NN NN O
B NN NN O
cells NN NN O
was NN NN O
at NN NN O
10 NN NN O
( NN NN O
- NN NN O
8 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
for NN NN O
all NN NN O
- NN NN O
trans NN NN O
RA NN NN O
( NN NN O
94 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O
8 NN NN O
% NN NN O
) NN NN O
and NN NN O
96 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O
2 NN NN O
% NN NN O
for NN NN O
13 NN NN O
- NN NN O
cis NN NN O
RA NN NN O
. NN NN O
   
Low NN NN O
concentrations NN NN O
of NN NN O
RA NN NN O
inhibiting NN NN O
IgE NN NN O
synthesis NN NN O
( NN NN O
10 NN NN O
( NN NN O
- NN NN O
10 NN NN O
) NN NN O
mol NN NN O
/ NN NN O
L NN NN O
) NN NN O
affected NN NN O
neither NN NN O
B NN NN O
- NN NN O
cell NN NN O
proliferation NN NN O
nor NN NN O
the NN NN O
production NN NN O
of NN NN O
IgA NN NN O
, NN NN O
IgG NN NN O
, NN NN O
and NN NN O
IgM NN NN O
. NN NN O
   
Elucidation NN NN O
of NN NN O
the NN NN O
mechanism NN NN O
involved NN NN O
in NN NN O
this NN NN O
inhibition NN NN O
of NN NN O
IgE NN NN O
production NN NN O
shows NN NN O
that NN NN O
epsilon NN NN O
germline NN NN O
transcription NN NN O
is NN NN O
decreased NN NN O
by NN NN O
RA NN NN O
, NN NN O
whereas NN NN O
production NN NN O
of NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
( NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
) NN NN O
was NN NN O
not NN NN O
enhanced NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
RA NN NN O
. NN NN O
   
To NN NN O
differentiate NN NN O
whether NN NN O
the NN NN O
RA NN NN O
effect NN NN O
was NN NN O
mediated NN NN O
by NN NN O
RA NN NN B-Protein
receptors NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
beta NN NN B-Protein
, NN NN O
and NN NN O
gamma NN NN B-Protein
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
retinoic NN NN O
acid NN NN O
receptors NN NN O
( NN NN O
RAR NN NN O
) NN NN O
was NN NN O
examined NN NN O
by NN NN O
reverse NN NN O
transcriptase NN NN O
- NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
) NN NN O
. NN NN O
   
The NN NN O
data NN NN O
show NN NN O
that NN NN O
unstimulated NN NN O
human NN NN O
peripheral NN NN O
B NN NN O
cells NN NN O
express NN NN O
mRNA NN NN O
of NN NN O
the NN NN O
RA NN NN B-Protein
receptor NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
beta NN NN B-Protein
, NN NN O
and NN NN O
gamma NN NN B-Protein
. NN NN O
   
Using NN NN O
retinoids NN NN O
with NN NN O
different NN NN O
receptor NN NN O
binding NN NN O
specificity NN NN O
( NN NN O
CD336 NN NN O
, NN NN O
CD437 NN NN O
, NN NN O
CD2019 NN NN O
, NN NN O
CD367 NN NN O
) NN NN O
, NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
inhibition NN NN O
of NN NN O
IgE NN NN O
synthesis NN NN O
was NN NN O
shown NN NN O
by NN NN O
all NN NN O
four NN NN O
derivates NN NN O
, NN NN O
but NN NN O
was NN NN O
most NN NN O
marked NN NN O
by NN NN O
an NN NN O
RA NN NN O
binding NN NN O
the NN NN O
alpha NN NN O
receptor NN NN O
with NN NN O
high NN NN O
specificity NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
this NN NN O
study NN NN O
shows NN NN O
that NN NN O
RA NN NN O
inhibits NN NN O
IgE NN NN O
production NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD40 NN NN B-Protein
+ NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
stimulated NN NN O
B NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Copyright NN NN O
1998 NN NN O
by NN NN O
The NN NN O
American NN NN O
Society NN NN O
of NN NN O
Hematology NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
induction NN NN O
in NN NN O
CD45RO NN NN B-Protein
+ NN NN O
and NN NN O
CD45RA NN NN B-Protein
+ NN NN O
T NN NN O
cell NN NN O
subsets NN NN O
during NN NN O
aging NN NN O
. NN NN O
   
An NN NN O
increase NN NN O
in NN NN O
the NN NN O
ratio NN NN O
of NN NN O
memory NN NN O
to NN NN O
naive NN NN O
T NN NN O
cells NN NN O
has NN NN O
been NN NN O
postulated NN NN O
to NN NN O
underlie NN NN O
immune NN NN O
hyporesponsiveness NN NN O
accompanying NN NN O
aging NN NN O
. NN NN O
   
Our NN NN O
analyses NN NN O
of NN NN O
the NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NFkappaB NN NN O
) NN NN O
in NN NN O
activated NN NN O
memory NN NN O
( NN NN O
CD45RO NN NN B-Protein
+ NN NN O
) NN NN O
and NN NN O
naive NN NN O
( NN NN O
CD45RA NN NN B-Protein
+ NN NN O
) NN NN O
T NN NN O
cell NN NN O
subsets NN NN O
from NN NN O
young NN NN O
and NN NN O
elderly NN NN O
donors NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
, NN NN O
regardless NN NN O
of NN NN O
donor NN NN O
age NN NN O
, NN NN O
memory NN NN O
T NN NN O
cells NN NN O
are NN NN O
not NN NN O
significantly NN NN O
altered NN NN O
in NN NN O
their NN NN O
responsiveness NN NN O
to NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
NFkappaB NN NN O
. NN NN O
   
Although NN NN O
treatment NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
induced NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
NFkappaB NN NN O
in NN NN O
both NN NN O
memory NN NN O
and NN NN O
naive NN NN O
T NN NN O
cell NN NN O
subsets NN NN O
, NN NN O
irrespective NN NN O
of NN NN O
the NN NN O
age NN NN O
of NN NN O
the NN NN O
donor NN NN O
, NN NN O
the NN NN O
levels NN NN O
of NN NN O
induced NN NN O
NFkappaB NN NN O
were NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
both NN NN O
subsets NN NN O
of NN NN O
T NN NN O
cells NN NN O
obtained NN NN O
from NN NN O
the NN NN O
elderly NN NN O
, NN NN O
when NN NN O
compared NN NN O
to NN NN O
those NN NN O
in NN NN O
young NN NN O
. NN NN O
   
Examination NN NN O
of NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
regulation NN NN O
revealed NN NN O
that NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
mediated NN NN O
degradation NN NN O
of NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
both NN NN O
memory NN NN O
and NN NN O
naive NN NN O
T NN NN O
cells NN NN O
from NN NN O
the NN NN O
elderly NN NN O
was NN NN O
severely NN NN O
impaired NN NN O
, NN NN O
thus NN NN O
contributing NN NN O
to NN NN O
the NN NN O
lowered NN NN O
induction NN NN O
of NN NN O
the NN NN O
observed NN NN O
NFkappaB NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
this NN NN O
age NN NN O
- NN NN O
related NN NN O
decrease NN NN O
in NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
NFkappaB NN NN O
correlated NN NN O
with NN NN O
decrease NN NN O
in NN NN O
intracellular NN NN O
IL NN NN O
- NN NN O
2 NN NN O
receptor NN NN O
expression NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
induced NN NN O
proliferation NN NN O
of NN NN O
both NN NN O
memory NN NN O
and NN NN O
naive NN NN O
T NN NN O
cells NN NN O
subsets NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
age NN NN O
- NN NN O
related NN NN O
hyporesponsiveness NN NN O
cannot NN NN O
be NN NN O
attributed NN NN O
to NN NN O
a NN NN O
skewing NN NN O
of NN NN O
the NN NN O
T NN NN O
cell NN NN O
population NN NN O
towards NN NN O
a NN NN O
memory NN NN O
phenotype NN NN O
in NN NN O
the NN NN O
elderly NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
E2F NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
by NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
Tax NN NN B-Protein
protein NN NN O
in NN NN O
a NN NN O
p16 NN NN B-Protein
( NN NN O
INK4A NN NN B-Protein
) NN NN O
- NN NN O
negative NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
The NN NN O
human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
I NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
) NN NN O
is NN NN O
a NN NN O
causative NN NN O
agent NN NN O
of NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
. NN NN O
   
Although NN NN O
the NN NN O
exact NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
HTLV NN NN O
- NN NN O
I NN NN O
contributes NN NN O
to NN NN O
leukemogenesis NN NN O
is NN NN O
still NN NN O
unclear NN NN O
, NN NN O
the NN NN O
Tax NN NN B-Protein
protein NN NN O
is NN NN O
thought NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
this NN NN O
process NN NN O
. NN NN O
   
This NN NN O
40 NN NN O
- NN NN O
kDa NN NN O
polypeptide NN NN O
is NN NN O
able NN NN O
to NN NN O
interact NN NN O
with NN NN O
the NN NN O
tumor NN NN O
suppressor NN NN O
p16 NN NN B-Protein
( NN NN O
INK4A NN NN B-Protein
) NN NN O
. NN NN O
   
Consequently NN NN O
, NN NN O
Tax NN NN B-Protein
can NN NN O
activate NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
that NN NN O
lead NN NN O
to NN NN O
the NN NN O
release NN NN O
of NN NN O
E2F NN NN O
that NN NN O
in NN NN O
turn NN NN O
induces NN NN O
expression NN NN O
of NN NN O
factors NN NN O
required NN NN O
for NN NN O
cell NN NN O
cycle NN NN O
progression NN NN O
. NN NN O
   
In NN NN O
this NN NN O
paper NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
Tax NN NN B-Protein
can NN NN O
also NN NN O
activate NN NN O
E2F NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
independently NN NN O
of NN NN O
p16 NN NN B-Protein
( NN NN O
INK4A NN NN B-Protein
) NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
when NN NN O
Tax NN NN B-Protein
is NN NN O
coexpressed NN NN O
with NN NN O
the NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
transcription NN NN O
factor NN NN O
in NN NN O
CEM NN NN O
T NN NN O
- NN NN O
cells NN NN O
, NN NN O
which NN NN O
lack NN NN O
expression NN NN O
of NN NN O
p16 NN NN B-Protein
( NN NN O
INK4A NN NN B-Protein
) NN NN O
, NN NN O
it NN NN O
strongly NN NN O
potentiates NN NN O
the NN NN O
E2F NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
a NN NN O
reporter NN NN O
construct NN NN O
driven NN NN O
by NN NN O
a NN NN O
promoter NN NN O
containing NN NN O
E2F NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
This NN NN O
stimulation NN NN O
is NN NN O
abrogated NN NN O
by NN NN O
mutations NN NN O
affecting NN NN O
the NN NN O
E2F NN NN O
- NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
Tax NN NN B-Protein
also NN NN O
stimulates NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gene NN NN O
itself NN NN O
. NN NN O
   
Using NN NN O
Tax NN NN B-Protein
mutants NN NN O
that NN NN O
fail NN NN O
to NN NN O
activate NN NN O
either NN NN O
ATF NN NN O
- NN NN O
or NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
promoters NN NN O
and NN NN O
different NN NN O
5 NN NN O
' NN NN O
truncation NN NN O
mutants NN NN O
of NN NN O
the NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
Tax NN NN B-Protein
- NN NN O
dependent NN NN O
transcriptional NN NN O
control NN NN O
of NN NN O
the NN NN O
E2F1 NN NN B-Protein
gene NN NN O
involves NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
the NN NN O
ATF NN NN O
binding NN NN O
site NN NN O
located NN NN O
in NN NN O
the NN NN O
E2F NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
and NN NN O
regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
human NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
was NN NN O
investigated NN NN O
in NN NN O
glucocorticoid NN NN O
- NN NN O
sensitive NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
and NN NN O
resistant NN NN O
ICR27TK NN NN O
. NN NN O
3 NN NN O
human NN NN O
leukemic NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Following NN NN O
glucocorticoid NN NN O
treatment NN NN O
of NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
, NN NN O
chromatin NN NN O
fragmentation NN NN O
was NN NN O
observed NN NN O
after NN NN O
a NN NN O
delay NN NN O
of NN NN O
24 NN NN O
h NN NN O
. NN NN O
   
Fragmentation NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
ICR27TK NN NN O
. NN NN O
3 NN NN O
cells NN NN O
containing NN NN O
mutant NN NN O
glucocorticoid NN NN O
receptors NN NN O
( NN NN O
L753F NN NN O
) NN NN O
that NN NN O
are NN NN O
activation NN NN O
- NN NN O
deficient NN NN O
but NN NN O
retain NN NN O
the NN NN O
ability NN NN O
to NN NN O
repress NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
. NN NN O
   
Nor NN NN O
was NN NN O
fragmentation NN NN O
observed NN NN O
after NN NN O
treatment NN NN O
with NN NN O
RU38486 NN NN O
, NN NN O
indicating NN NN O
that NN NN O
repression NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
activity NN NN O
is NN NN O
not NN NN O
involved NN NN O
. NN NN O
   
As NN NN O
described NN NN O
in NN NN O
other NN NN O
systems NN NN O
, NN NN O
fragmentation NN NN O
required NN NN O
ongoing NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
However NN NN O
, NN NN O
inhibition NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
with NN NN O
cycloheximide NN NN O
anytime NN NN O
during NN NN O
the NN NN O
first NN NN O
18 NN NN O
h NN NN O
of NN NN O
steroid NN NN O
treatment NN NN O
was NN NN O
as NN NN O
effective NN NN O
in NN NN O
blocking NN NN O
chromatin NN NN O
fragmentation NN NN O
as NN NN O
inhibition NN NN O
for NN NN O
the NN NN O
entire NN NN O
period NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
component NN NN O
with NN NN O
a NN NN O
rapid NN NN O
turnover NN NN O
rate NN NN O
is NN NN O
required NN NN O
. NN NN O
   
Dexamethasone NN NN O
treatment NN NN O
completely NN NN O
blocked NN NN O
12 NN NN O
- NN NN O
O NN NN O
- NN NN O
tetradecanoylphorbol NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
induction NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
activity NN NN O
and NN NN O
elicited NN NN O
an NN NN O
increase NN NN O
in NN NN O
the NN NN O
amount NN NN O
of NN NN O
immunoreactive NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
in NN NN O
sensitive NN NN O
6TG1 NN NN O
. NN NN O
1 NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
resistant NN NN O
ICR27TK NN NN O
. NN NN O
3 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
mild NN NN O
detergent NN NN O
treatment NN NN O
of NN NN O
cell NN NN O
extracts NN NN O
indicated NN NN O
that NN NN O
a NN NN O
substantial NN NN O
amount NN NN O
of NN NN O
cytoplasmic NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
is NN NN O
complexed NN NN O
with NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
or NN NN O
some NN NN O
other NN NN O
inhibitory NN NN O
factor NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
induction NN NN O
of NN NN O
a NN NN O
labile NN NN O
inhibitory NN NN O
factor NN NN O
such NN NN O
as NN NN O
IkappaB NN NN B-Protein
alpha NN NN I-Protein
may NN NN O
contribute NN NN O
to NN NN O
glucocorticoid NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Peripheral NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
women NN NN O
with NN NN O
breast NN NN O
cancer NN NN O
exhibit NN NN O
abnormal NN NN O
protein NN NN O
expression NN NN O
of NN NN O
several NN NN O
signaling NN NN O
molecules NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
signaling NN NN O
molecules NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
obtained NN NN O
from NN NN O
women NN NN O
with NN NN O
breast NN NN O
cancer NN NN O
. NN NN O
   
In NN NN O
6 NN NN O
of NN NN O
14 NN NN O
patients NN NN O
, NN NN O
T NN NN O
lymphocytes NN NN O
displayed NN NN O
an NN NN O
impaired NN NN O
ability NN NN O
to NN NN O
translocate NN NN O
NFeB NN NN O
p65 NN NN B-Protein
( NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
) NN NN O
following NN NN O
activation NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
This NN NN O
observation NN NN O
was NN NN O
made NN NN O
despite NN NN O
normal NN NN O
cytoplasmic NN NN O
levels NN NN O
of NN NN O
the NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
protein NN NN O
. NN NN O
   
We NN NN O
also NN NN O
detected NN NN O
abnormally NN NN O
low NN NN O
levels NN NN O
of NN NN O
the NN NN O
signaling NN NN O
molecules NN NN O
T NN NN B-Protein
- NN NN I-Protein
cell NN NN I-Protein
receptor NN NN I-Protein
( NN NN I-Protein
TCR NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
zeta NN NN I-Protein
, NN NN O
ZAP NN NN B-Protein
- NN NN I-Protein
70 NN NN I-Protein
and NN NN O
p56lck NN NN B-Protein
in NN NN O
4 NN NN O
of NN NN O
14 NN NN O
breast NN NN O
cancer NN NN O
patients NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
, NN NN O
defects NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
signaling NN NN O
molecules NN NN O
. NN NN O
   
T NN NN O
lymphocytes NN NN O
from NN NN O
6 NN NN O
of NN NN O
the NN NN O
14 NN NN O
patients NN NN O
also NN NN O
exhibited NN NN O
an NN NN O
increased NN NN O
expression NN NN O
of NN NN O
the NN NN O
dual NN NN O
specificity NN NN O
phosphatase NN NN O
, NN NN O
map NN NN B-Protein
kinase NN NN I-Protein
phosphatase NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MKP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
. NN NN O
   
MKP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
inactivates NN NN O
MAP NN NN O
kinase NN NN O
and NN NN O
therefore NN NN O
may NN NN O
interfere NN NN O
with NN NN O
the NN NN O
activation NN NN O
of NN NN O
c NN NN B-Protein
- NN NN I-Protein
jun NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
fos NN NN I-Protein
. NN NN O
   
Abnormalities NN NN O
of NN NN O
I NN NN O
or NN NN O
more NN NN O
signaling NN NN O
molecules NN NN O
were NN NN O
found NN NN O
in NN NN O
9 NN NN O
of NN NN O
14 NN NN O
patients NN NN O
; NN NN O
however NN NN O
, NN NN O
only NN NN O
3 NN NN O
patients NN NN O
had NN NN O
T NN NN O
cells NN NN O
that NN NN O
exhibited NN NN O
all NN NN O
5 NN NN O
defects NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
detection NN NN O
of NN NN O
potentially NN NN O
dysfunctional NN NN O
T NN NN O
cells NN NN O
in NN NN O
patients NN NN O
with NN NN O
cancer NN NN O
. NN NN O
   
For NN NN O
example NN NN O
, NN NN O
the NN NN O
analysis NN NN O
of NN NN O
only NN NN O
1 NN NN O
signaling NN NN O
molecule NN NN O
may NN NN O
allow NN NN O
patients NN NN O
with NN NN O
significant NN NN O
defects NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
signaling NN NN O
to NN NN O
go NN NN O
unnoticed NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
despite NN NN O
impaired NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
translocation NN NN O
, NN NN O
T NN NN O
cells NN NN O
were NN NN O
capable NN NN O
of NN NN O
transcribing NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Impairments NN NN O
in NN NN O
the NN NN O
translocation NN NN O
of NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
further NN NN O
suggest NN NN O
that NN NN O
the NN NN O
NFKB NN NN O
family NN NN O
members NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
, NN NN O
Rel NN NN B-Protein
- NN NN I-Protein
B NN NN I-Protein
and NN NN O
c NN NN B-Protein
- NN NN I-Protein
Rel NN NN I-Protein
are NN NN O
not NN NN O
required NN NN O
for NN NN O
the NN NN O
transcription NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
the NN NN O
peripheral NN NN O
T NN NN O
lymphocytes NN NN O
of NN NN O
patients NN NN O
with NN NN O
breast NN NN O
cancer NN NN O
. NN NN O
   
Transcription NN NN O
of NN NN O
a NN NN O
minimal NN NN O
promoter NN NN O
from NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
gene NN NN O
is NN NN O
regulated NN NN O
by NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
and NN NN O
SP1 NN NN B-Protein
proteins NN NN O
in NN NN O
U937 NN NN O
promonocytic NN NN O
cells NN NN O
. NN NN O
   
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
is NN NN O
an NN NN O
important NN NN O
transcriptional NN NN O
regulator NN NN O
of NN NN O
genes NN NN O
induced NN NN O
in NN NN O
activated NN NN O
monocytes NN NN O
/ NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
is NN NN O
the NN NN O
only NN NN O
CCAAT NN NN O
/ NN NN O
enhancer NN NN O
- NN NN O
binding NN NN O
protein NN NN O
( NN NN O
C NN NN O
/ NN NN O
EBP NN NN O
) NN NN O
family NN NN O
member NN NN O
whose NN NN O
steady NN NN O
- NN NN O
state NN NN O
mRNA NN NN O
levels NN NN O
increase NN NN O
upon NN NN O
activation NN NN O
of NN NN O
monocytes NN NN O
( NN NN O
1 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
increased NN NN O
transcription NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
gene NN NN O
is NN NN O
responsible NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
for NN NN O
induction NN NN O
of NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
mRNA NN NN O
following NN NN O
activation NN NN O
of NN NN O
U937 NN NN O
promonocytic NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
identified NN NN O
a NN NN O
104 NN NN O
- NN NN O
bp NN NN O
minimal NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
gene NN NN O
that NN NN O
is NN NN O
sufficient NN NN O
for NN NN O
basal NN NN O
and NN NN O
activation NN NN O
- NN NN O
dependent NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
This NN NN O
region NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
- NN NN O
binding NN NN O
protein NN NN O
/ NN NN O
activation NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
CREB NN NN O
/ NN NN O
ATF NN NN O
) NN NN O
and NN NN O
Sp1 NN NN B-Protein
families NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
Each NN NN O
site NN NN O
is NN NN O
functionally NN NN O
important NN NN O
and NN NN O
contributes NN NN O
independently NN NN O
to NN NN O
transcription NN NN O
of NN NN O
the NN NN O
NF NN NN B-Protein
- NN NN I-Protein
IL6 NN NN I-Protein
gene NN NN O
in NN NN O
U937 NN NN O
cells NN NN O
. NN NN O
   
CD30 NN NN B-Protein
is NN NN O
a NN NN O
CD40 NN NN B-Protein
- NN NN O
inducible NN NN O
molecule NN NN O
that NN NN O
negatively NN NN O
regulates NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
immunoglobulin NN NN O
class NN NN O
switching NN NN O
in NN NN O
non NN NN O
- NN NN O
antigen NN NN O
- NN NN O
selected NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
used NN NN O
our NN NN O
monoclonal NN NN O
model NN NN O
of NN NN O
germinal NN NN O
center NN NN O
maturation NN NN O
, NN NN O
CL NN NN O
- NN NN O
01 NN NN O
B NN NN O
cells NN NN O
, NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
CD30 NN NN B-Protein
in NN NN O
human NN NN O
B NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
CL NN NN O
- NN NN O
01 NN NN O
cells NN NN O
are NN NN O
IgM NN NN O
+ NN NN O
IgD NN NN O
+ NN NN O
CD30 NN NN B-Protein
+ NN NN O
and NN NN O
switch NN NN O
to NN NN O
IgG NN NN O
, NN NN O
IgA NN NN O
, NN NN O
and NN NN O
IgE NN NN O
when NN NN O
exposed NN NN O
to NN NN O
CD40L NN NN B-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
. NN NN O
   
Switching NN NN O
is NN NN O
hampered NN NN O
by NN NN O
CD30 NN NN B-Protein
coengagement NN NN O
, NN NN O
possibly NN NN O
through NN NN O
interference NN NN O
with NN NN O
the NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
downstream NN NN O
C NN NN O
( NN NN O
H NN NN O
) NN NN O
genes NN NN O
. NN NN O
   
The NN NN O
physiological NN NN O
relevance NN NN O
of NN NN O
this NN NN O
phenomenon NN NN O
is NN NN O
emphasized NN NN O
by NN NN O
similar NN NN O
CD30 NN NN B-Protein
- NN NN O
mediated NN NN O
effects NN NN O
in NN NN O
naive NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Expression NN NN O
of NN NN O
CD30 NN NN B-Protein
by NN NN O
these NN NN O
cells NN NN O
is NN NN O
induced NN NN O
by NN NN O
CD40L NN NN B-Protein
but NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
B NN NN O
cell NN NN O
receptor NN NN O
coengagement NN NN O
and NN NN O
/ NN NN O
or NN NN O
exposure NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
. NN NN O
   
Our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
CD30 NN NN B-Protein
critically NN NN O
regulates NN NN O
the NN NN O
CD40 NN NN B-Protein
- NN NN O
mediated NN NN O
differentiation NN NN O
of NN NN O
non NN NN O
- NN NN O
antigen NN NN O
- NN NN O
selected NN NN O
human NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
Mn NN NN B-Protein
SOD NN NN I-Protein
in NN NN O
human NN NN O
monocytes NN NN O
without NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
a NN NN O
mutant NN NN O
endotoxin NN NN O
. NN NN O
   
Endotoxin NN NN O
selectively NN NN O
induces NN NN O
monocyte NN NN O
Mn NN NN B-Protein
superoxide NN NN I-Protein
dismutase NN NN I-Protein
( NN NN O
SOD NN NN O
) NN NN O
without NN NN O
affecting NN NN O
levels NN NN O
of NN NN O
Cu NN NN B-Protein
, NN NN I-Protein
Zn NN NN I-Protein
SOD NN NN I-Protein
, NN NN O
catalase NN NN B-Protein
, NN NN O
or NN NN O
glutathione NN NN O
peroxidase NN NN O
. NN NN O
   
However NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
structure NN NN O
- NN NN O
activity NN NN O
relationship NN NN O
and NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
endotoxin NN NN O
induces NN NN O
Mn NN NN B-Protein
SOD NN NN I-Protein
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
a NN NN O
mutant NN NN O
Escherichia NN NN O
coli NN NN O
endotoxin NN NN O
lacking NN NN O
myristoyl NN NN O
fatty NN NN O
acid NN NN O
at NN NN O
the NN NN O
3 NN NN O
' NN NN O
R NN NN O
- NN NN O
3 NN NN O
- NN NN O
hydroxymyristate NN NN O
position NN NN O
of NN NN O
the NN NN O
lipid NN NN O
A NN NN O
moiety NN NN O
retained NN NN O
its NN NN O
full NN NN O
capacity NN NN O
to NN NN O
coagulate NN NN O
Limulus NN NN O
amoebocyte NN NN O
lysate NN NN O
compared NN NN O
with NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
E NN NN O
. NN NN O
coli NN NN O
endotoxin NN NN O
and NN NN O
markedly NN NN O
stimulated NN NN O
the NN NN O
activation NN NN O
of NN NN O
human NN NN O
monocyte NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
the NN NN O
induction NN NN O
of NN NN O
Mn NN NN B-Protein
SOD NN NN I-Protein
mRNA NN NN O
and NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O
   
However NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
wild NN NN O
- NN NN O
type NN NN O
endotoxin NN NN O
, NN NN O
it NN NN O
failed NN NN O
to NN NN O
induce NN NN O
significant NN NN O
production NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
macrophage NN NN B-Protein
inflammatory NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
by NN NN O
monocytes NN NN O
and NN NN O
did NN NN O
not NN NN O
induce NN NN O
the NN NN O
phosphorylation NN NN O
and NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
1 NN NN O
) NN NN O
lipid NN NN O
A NN NN O
myristoyl NN NN O
fatty NN NN O
acid NN NN O
, NN NN O
although NN NN O
it NN NN O
is NN NN O
important NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
is NN NN O
not NN NN O
necessary NN NN O
for NN NN O
the NN NN O
induction NN NN O
of NN NN O
Mn NN NN B-Protein
SOD NN NN I-Protein
, NN NN O
2 NN NN O
) NN NN O
endotoxin NN NN O
- NN NN O
mediated NN NN O
induction NN NN O
of NN NN O
Mn NN NN B-Protein
SOD NN NN I-Protein
and NN NN O
inflammatory NN NN O
cytokines NN NN O
are NN NN O
regulated NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
through NN NN O
different NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
, NN NN O
and NN NN O
3 NN NN O
) NN NN O
failure NN NN O
of NN NN O
the NN NN O
mutant NN NN O
endotoxin NN NN O
to NN NN O
induce NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
is NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
due NN NN O
to NN NN O
its NN NN O
inability NN NN O
to NN NN O
activate NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
. NN NN O
   
An NN NN O
allosteric NN NN O
drug NN NN O
, NN NN O
o NN NN O
, NN NN O
o NN NN O
' NN NN O
- NN NN O
bismyristoyl NN NN O
thiamine NN NN O
disulfide NN NN O
, NN NN O
suppresses NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
through NN NN O
prevention NN NN O
of NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
both NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
Tat NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
The NN NN O
efficacy NN NN O
of NN NN O
o NN NN O
, NN NN O
o NN NN O
' NN NN O
- NN NN O
bismyristoyl NN NN O
thiamine NN NN O
disulfide NN NN O
( NN NN O
BMT NN NN O
) NN NN O
was NN NN O
examined NN NN O
in NN NN O
detail NN NN O
against NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
laboratory NN NN O
isolates NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
IIIB NN NN O
, NN NN O
JRFL NN NN O
, NN NN O
and NN NN O
MN NN NN O
) NN NN O
, NN NN O
primary NN NN O
isolates NN NN O
( NN NN O
KMT NN NN O
and NN NN O
KMO NN NN O
) NN NN O
, NN NN O
and NN NN O
simian NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
SIVmac251 NN NN O
) NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
BMT NN NN O
inhibited NN NN O
the NN NN O
replication NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
both NN NN O
laboratory NN NN O
and NN NN O
primary NN NN O
isolates NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
BMT NN NN O
exhibited NN NN O
antiviral NN NN O
activity NN NN O
against NN NN O
SIVmac251 NN NN O
. NN NN O
   
Minimizing NN NN O
energy NN NN O
studies NN NN O
of NN NN O
BMT NN NN O
structure NN NN O
reveal NN NN O
that NN NN O
a NN NN O
trans NN NN O
- NN NN O
disulfide NN NN O
of NN NN O
thiamine NN NN O
( NN NN O
holo NN NN O
drug NN NN O
) NN NN O
disulfide NN NN O
( NN NN O
TDS NN NN O
, NN NN O
protodrug NN NN O
) NN NN O
is NN NN O
allosterically NN NN O
transited NN NN O
to NN NN O
the NN NN O
reactive NN NN O
twisted NN NN O
disulfide NN NN O
of NN NN O
BMT NN NN O
( NN NN O
allo NN NN O
drug NN NN O
) NN NN O
by NN NN O
o NN NN O
, NN NN O
o NN NN O
' NN NN O
- NN NN O
bismyristoyl NN NN O
esterification NN NN O
of NN NN O
TDS NN NN O
. NN NN O
   
BMT NN NN O
inhibits NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
both NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transactivator NN NN O
( NN NN O
TAT NN NN B-Protein
) NN NN O
and NN NN O
the NN NN O
cellular NN NN O
transcriptional NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
KB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
) NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
suppression NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
. NN NN O
   
Retinoid NN NN O
X NN NN O
receptor NN NN O
and NN NN O
c NN NN O
- NN NN O
cerbA NN NN O
/ NN NN O
thyroid NN NN O
hormone NN NN O
receptor NN NN O
regulate NN NN O
erythroid NN NN O
cell NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
. NN NN O
   
Nuclear NN NN O
receptors NN NN O
are NN NN O
important NN NN O
regulators NN NN O
of NN NN O
erythroid NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
investigated NN NN O
the NN NN O
impact NN NN O
of NN NN O
retinoid NN NN O
X NN NN O
receptor NN NN O
( NN NN O
RXR NN NN O
) NN NN O
, NN NN O
retinoic NN NN O
acid NN NN O
receptor NN NN O
( NN NN O
RAR NN NN O
) NN NN O
, NN NN O
and NN NN O
of NN NN O
the NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
thyroid NN NN O
hormone NN NN O
( NN NN O
T3 NN NN O
) NN NN O
receptor NN NN O
( NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
) NN NN O
on NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
erythroid NN NN O
cells NN NN O
using NN NN O
an NN NN O
in NN NN O
vitro NN NN O
culture NN NN O
system NN NN O
of NN NN O
stem NN NN B-Protein
cell NN NN I-Protein
factor NN NN I-Protein
- NN NN O
dependent NN NN O
erythroid NN NN O
progenitors NN NN O
. NN NN O
   
RXR NN NN O
, NN NN O
RAR NN NN O
, NN NN O
and NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
- NN NN O
specific NN NN O
ligands NN NN O
were NN NN O
found NN NN O
to NN NN O
induce NN NN O
erythroid NN NN O
- NN NN O
specific NN NN O
gene NN NN O
expression NN NN O
and NN NN O
to NN NN O
accelerate NN NN O
erythroid NN NN O
differentiation NN NN O
in NN NN O
culture NN NN O
, NN NN O
with NN NN O
T3 NN NN O
being NN NN O
most NN NN O
effective NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
while NN NN O
ligand NN NN O
- NN NN O
activated NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
accelerated NN NN O
differentiation NN NN O
, NN NN O
unliganded NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
effectively NN NN O
blocked NN NN O
differentiation NN NN O
and NN NN O
supported NN NN O
sustained NN NN O
progenitor NN NN O
growth NN NN O
in NN NN O
culture NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
appears NN NN O
to NN NN O
act NN NN O
as NN NN O
a NN NN O
binary NN NN O
switch NN NN O
affecting NN NN O
erythroid NN NN O
cell NN NN O
fate NN NN O
: NN NN O
unliganded NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
supports NN NN O
growth NN NN O
while NN NN O
ligand NN NN O
- NN NN O
activated NN NN O
c NN NN O
- NN NN O
erbA NN NN O
/ NN NN O
TR NN NN O
induces NN NN O
differentiation NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
to NN NN O
determine NN NN O
the NN NN O
impact NN NN O
of NN NN O
RXR NN NN O
for NN NN O
erythroid NN NN O
cell NN NN O
development NN NN O
, NN NN O
dominant NN NN O
interfering NN NN O
mutant NN NN O
RXRs NN NN O
, NN NN O
lacking NN NN O
the NN NN O
transcriptional NN NN O
activator NN NN O
functions NN NN O
AF NN NN O
- NN NN O
1 NN NN O
and NN NN O
AF NN NN O
- NN NN O
2 NN NN O
, NN NN O
or NN NN O
AF NN NN O
- NN NN O
2 NN NN O
only NN NN O
, NN NN O
or NN NN O
the NN NN O
entire NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
, NN NN O
were NN NN O
introduced NN NN O
into NN NN O
erythroid NN NN O
progenitor NN NN O
cells NN NN O
via NN NN O
recombinant NN NN O
retrovirus NN NN O
vectors NN NN O
and NN NN O
analyzed NN NN O
for NN NN O
RXR NN NN O
- NN NN O
specific NN NN O
effects NN NN O
. NN NN O
   
It NN NN O
was NN NN O
found NN NN O
that NN NN O
expression NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
RXR NN NN O
and NN NN O
of NN NN O
the NN NN O
RXR NN NN O
mutants NN NN O
devoid NN NN O
of NN NN O
AF NN NN O
- NN NN O
1 NN NN O
and NN NN O
/ NN NN O
or NN NN O
AF NN NN O
- NN NN O
2 NN NN O
supported NN NN O
a NN NN O
transient NN NN O
outgrowth NN NN O
of NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
marked NN NN O
contrast NN NN O
, NN NN O
expression NN NN O
of NN NN O
the NN NN O
dominant NN NN O
interfering NN NN O
deltaDNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
RXR NN NN O
, NN NN O
containing NN NN O
a NN NN O
deletion NN NN O
of NN NN O
the NN NN O
entire NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
, NN NN O
was NN NN O
incompatible NN NN O
with NN NN O
erythroid NN NN O
cell NN NN O
growth NN NN O
in NN NN O
vitro NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
of NN NN O
RXR NN NN O
for NN NN O
erythroid NN NN O
cell NN NN O
development NN NN O
. NN NN O
   
Phosphatidylinositides NN NN O
bind NN NN O
to NN NN O
plasma NN NN O
membrane NN NN O
CD14 NN NN B-Protein
and NN NN O
can NN NN O
prevent NN NN O
monocyte NN NN O
activation NN NN O
by NN NN O
bacterial NN NN O
lipopolysaccharide NN NN O
. NN NN O
   
Although NN NN O
bacterial NN NN O
lipopolysaccharides NN NN O
( NN NN O
LPS NN NN O
) NN NN O
and NN NN O
several NN NN O
other NN NN O
microbial NN NN O
agonists NN NN O
can NN NN O
bind NN NN O
to NN NN O
mCD14 NN NN B-Protein
( NN NN O
membrane NN NN O
CD14 NN NN B-Protein
) NN NN O
, NN NN O
a NN NN O
cell NN NN O
- NN NN O
surface NN NN O
receptor NN NN O
found NN NN O
principally NN NN O
on NN NN O
monocytes NN NN O
and NN NN O
neutrophils NN NN O
, NN NN O
host NN NN O
- NN NN O
derived NN NN O
mCD14 NN NN B-Protein
ligands NN NN O
are NN NN O
poorly NN NN O
defined NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
phosphatidylinositol NN NN O
( NN NN O
PtdIns NN NN O
) NN NN O
, NN NN O
phosphatidylinositol NN NN O
- NN NN O
4 NN NN O
- NN NN O
phosphate NN NN O
, NN NN O
and NN NN O
other NN NN O
phosphatidylinositides NN NN O
can NN NN O
bind NN NN O
to NN NN O
mCD14 NN NN B-Protein
. NN NN O
   
Phosphatidylserine NN NN O
( NN NN O
PS NN NN O
) NN NN O
, NN NN O
another NN NN O
anionic NN NN O
glycerophospholipid NN NN O
, NN NN O
binds NN NN O
to NN NN O
mCD14 NN NN B-Protein
with NN NN O
lower NN NN O
apparent NN NN O
affinity NN NN O
than NN NN O
does NN NN O
PtdIns NN NN O
. NN NN O
   
LPS NN NN O
- NN NN O
binding NN NN O
protein NN NN O
, NN NN O
a NN NN O
lipid NN NN O
transfer NN NN O
protein NN NN O
found NN NN O
in NN NN O
serum NN NN O
, NN NN O
facilitates NN NN O
both NN NN O
PS NN NN O
- NN NN O
and NN NN O
PtdIns NN NN O
- NN NN O
mCD14 NN NN B-Protein
binding NN NN O
. NN NN O
   
PtdIns NN NN O
binding NN NN O
to NN NN O
mCD14 NN NN B-Protein
can NN NN O
be NN NN O
blocked NN NN O
by NN NN O
anti NN NN O
- NN NN O
CD14 NN NN B-Protein
monoclonal NN NN O
antibodies NN NN O
that NN NN O
inhibit NN NN O
LPS NN NN O
- NN NN O
mCD14 NN NN B-Protein
binding NN NN O
, NN NN O
and NN NN O
PtdIns NN NN O
can NN NN O
inhibit NN NN O
both NN NN O
LPS NN NN O
- NN NN O
mCD14 NN NN B-Protein
binding NN NN O
and NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
responses NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Serum NN NN O
- NN NN O
equilibrated NN NN O
PtdIns NN NN O
also NN NN O
binds NN NN O
to NN NN O
mCD14 NN NN B-Protein
- NN NN O
expressing NN NN O
cells NN NN O
, NN NN O
raising NN NN O
the NN NN O
possibility NN NN O
that NN NN O
endogenous NN NN O
PtdIns NN NN O
may NN NN O
modulate NN NN O
cellular NN NN O
responses NN NN O
to NN NN O
LPS NN NN O
and NN NN O
other NN NN O
mCD14 NN NN B-Protein
ligands NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Low NN NN O
CD3 NN NN O
+ NN NN O
CD28 NN NN B-Protein
- NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
correlates NN NN O
with NN NN O
decreased NN NN O
reactive NN NN O
oxygen NN NN O
intermediate NN NN O
formation NN NN O
in NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
capacity NN NN O
of NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
to NN NN O
secrete NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
variable NN NN O
. NN NN O
   
We NN NN O
analysed NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
purified NN NN O
neonatal NN NN O
and NN NN O
adult NN NN O
T NN NN O
cells NN NN O
using NN NN O
polyclonal NN NN O
activator NN NN O
phorbol NN NN O
ester NN NN O
+ NN NN O
calcium NN NN O
ionophore NN NN O
( NN NN O
PDBu NN NN O
+ NN NN O
iono NN NN O
) NN NN O
or NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
/ NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
+ NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
stimulation NN NN O
. NN NN O
   
PDBu NN NN O
+ NN NN O
iono NN NN O
induced NN NN O
equally NN NN O
high NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
levels NN NN O
in NN NN O
both NN NN O
groups NN NN O
and NN NN O
, NN NN O
when NN NN O
stimulated NN NN O
with NN NN O
plate NN NN O
- NN NN O
bound NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
monoclonal NN NN O
antibody NN NN O
( NN NN O
mAb NN NN O
) NN NN O
, NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
by NN NN O
neonatal NN NN O
cells NN NN O
was NN NN O
undetectable NN NN O
and NN NN O
adult NN NN O
cells NN NN O
produced NN NN O
low NN NN O
amounts NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
mean NN NN O
331 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
86 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
mAb NN NN O
to NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
- NN NN O
stimulated NN NN O
cells NN NN O
markedly NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
in NN NN O
both NN NN O
cell NN NN O
types NN NN O
, NN NN O
but NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
remained NN NN O
clearly NN NN O
lower NN NN O
than NN NN O
those NN NN O
of NN NN O
adult NN NN O
T NN NN O
cells NN NN O
( NN NN O
respective NN NN O
mean NN NN O
values NN NN O
: NN NN O
385 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
109 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
and NN NN O
4494 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1199 NN NN O
pg NN NN O
/ NN NN O
ml NN NN O
) NN NN O
. NN NN O
   
As NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
is NN NN O
a NN NN O
critical NN NN O
transcription NN NN O
factor NN NN O
in NN NN O
the NN NN O
control NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
, NN NN O
we NN NN O
next NN NN O
analysed NN NN O
its NN NN O
nuclear NN NN O
translocation NN NN O
in NN NN O
neonatal NN NN O
and NN NN O
adult NN NN O
T NN NN O
cells NN NN O
using NN NN O
the NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
and NN NN O
, NN NN O
because NN NN O
induction NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
intermediates NN NN O
( NN NN O
ROI NN NN O
) NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
we NN NN O
also NN NN O
analysed NN NN O
levels NN NN O
of NN NN O
intracellular NN NN O
ROI NN NN O
in NN NN O
these NN NN O
cells NN NN O
using NN NN O
the NN NN O
ROI NN NN O
- NN NN O
reactive NN NN O
fluorochrome NN NN O
DCFH NN NN O
- NN NN O
DA NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
. NN NN O
   
In NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
and NN NN O
ROI NN NN O
formation NN NN O
after NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
stimulation NN NN O
were NN NN O
low NN NN O
compared NN NN O
with NN NN O
adult NN NN O
T NN NN O
cells NN NN O
and NN NN O
, NN NN O
although NN NN O
addition NN NN O
of NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
mAb NN NN O
increased NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
and NN NN O
ROI NN NN O
formation NN NN O
, NN NN O
levels NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
adults NN NN O
were NN NN O
not NN NN O
achieved NN NN O
. NN NN O
   
After NN NN O
PDBu NN NN O
+ NN NN O
iono NN NN O
stimulation NN NN O
, NN NN O
the NN NN O
cells NN NN O
showed NN NN O
similar NN NN O
ROI NN NN O
formation NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
secretion NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
reduced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
production NN NN O
by NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
is NN NN O
specific NN NN O
for NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
and NN NN O
anti NN NN O
- NN NN O
CD3 NN NN O
+ NN NN O
anti NN NN O
- NN NN O
CD28 NN NN B-Protein
- NN NN O
mediated NN NN O
stimulation NN NN O
and NN NN O
that NN NN O
these NN NN O
activators NN NN O
cannot NN NN O
effectively NN NN O
activate NN NN O
the NN NN O
ROI NN NN O
- NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
signalling NN NN O
pathway NN NN O
in NN NN O
neonatal NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Activated NN NN O
platelets NN NN O
induce NN NN O
monocyte NN NN B-Protein
chemotactic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
secretion NN NN O
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
on NN NN O
endothelial NN NN O
cells NN NN O
[ NN NN O
see NN NN O
comments NN NN O
] NN NN O
   
BACKGROUND NN NN O
: NN NN O
Platelet NN NN O
/ NN NN O
endothelium NN NN O
interaction NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
inflammation NN NN O
and NN NN O
atherosclerosis NN NN O
. NN NN O
   
The NN NN O
role NN NN O
of NN NN O
platelets NN NN O
for NN NN O
monocyte NN NN B-Protein
chemotactic NN NN I-Protein
protein NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
secretion NN NN O
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
on NN NN O
endothelial NN NN O
cells NN NN O
has NN NN O
been NN NN O
assessed NN NN O
. NN NN O
   
METHODS NN NN O
AND NN NN O
RESULTS NN NN O
: NN NN O
Monolayers NN NN O
of NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
were NN NN O
incubated NN NN O
with NN NN O
nonstimulated NN NN O
or NN NN O
ADP NN NN O
- NN NN O
activated NN NN O
platelets NN NN O
for NN NN O
6 NN NN O
hours NN NN O
, NN NN O
and NN NN O
secretion NN NN O
of NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
were NN NN O
determined NN NN O
by NN NN O
ELISA NN NN O
and NN NN O
flow NN NN O
cytometry NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
In NN NN O
the NN NN O
presence NN NN O
of NN NN O
ADP NN NN O
- NN NN O
activated NN NN O
platelets NN NN O
, NN NN O
both NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
secretion NN NN O
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
surface NN NN O
expression NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
compared NN NN O
with NN NN O
nonstimulated NN NN O
platelets NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
02 NN NN O
) NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
determined NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
and NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activity NN NN O
was NN NN O
enhanced NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
activated NN NN O
platelets NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
ADP NN NN O
- NN NN O
activated NN NN O
platelets NN NN O
induced NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
- NN NN O
dependent NN NN O
transcription NN NN O
. NN NN O
   
Liposomal NN NN O
transfection NN NN O
of NN NN O
a NN NN O
double NN NN O
- NN NN O
stranded NN NN O
kappaB NN NN O
phosphorothioate NN NN O
oligonucleotide NN NN O
, NN NN O
but NN NN O
not NN NN O
of NN NN O
the NN NN O
mutated NN NN O
form NN NN O
, NN NN O
inhibited NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
secretion NN NN O
and NN NN O
surface NN NN O
expression NN NN O
of NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
on NN NN O
activated NN NN O
endothelium NN NN O
( NN NN O
P NN NN O
< NN NN O
0 NN NN O
. NN NN O
05 NN NN O
) NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
The NN NN O
present NN NN O
study NN NN O
indicates NN NN O
that NN NN O
activated NN NN O
platelets NN NN O
modulate NN NN O
chemotactic NN NN O
( NN NN O
MCP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
and NN NN O
adhesive NN NN O
( NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
properties NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
via NN NN O
an NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
mechanism NN NN O
. NN NN O
   
Platelet NN NN O
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
system NN NN O
might NN NN O
contribute NN NN O
to NN NN O
early NN NN O
inflammatory NN NN O
events NN NN O
in NN NN O
atherogenesis NN NN O
. NN NN O
   
Altered NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
specificity NN NN O
mutants NN NN O
of NN NN O
EKLF NN NN B-Protein
and NN NN O
Sp1 NN NN B-Protein
show NN NN O
that NN NN O
EKLF NN NN B-Protein
is NN NN O
an NN NN O
activator NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
locus NN NN O
control NN NN O
region NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
The NN NN O
locus NN NN O
control NN NN O
region NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
cluster NN NN O
contains NN NN O
five NN NN O
DNase NN NN O
I NN NN O
hypersensitive NN NN O
sites NN NN O
( NN NN O
5 NN NN O
' NN NN O
HS1 NN NN O
- NN NN O
5 NN NN O
) NN NN O
required NN NN O
for NN NN O
locus NN NN O
activation NN NN O
. NN NN O
   
5 NN NN O
' NN NN O
HS3 NN NN O
contains NN NN O
six NN NN O
G NN NN O
- NN NN O
rich NN NN O
motifs NN NN O
that NN NN O
are NN NN O
essential NN NN O
for NN NN O
its NN NN O
activity NN NN O
. NN NN O
   
Members NN NN O
of NN NN O
a NN NN O
protein NN NN O
family NN NN O
, NN NN O
characterized NN NN O
by NN NN O
three NN NN O
zinc NN NN O
fingers NN NN O
highly NN NN O
homologous NN NN O
to NN NN O
those NN NN O
found NN NN O
in NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN B-Protein
, NN NN O
interact NN NN O
with NN NN O
these NN NN O
motifs NN NN O
. NN NN O
   
Because NN NN O
point NN NN O
mutagenesis NN NN O
cannot NN NN O
distinguish NN NN O
between NN NN O
family NN NN O
members NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
known NN NN O
which NN NN O
protein NN NN O
activates NN NN O
5 NN NN O
' NN NN O
HS3 NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
the NN NN O
function NN NN O
of NN NN O
such NN NN O
closely NN NN O
related NN NN O
proteins NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
in NN NN O
vivo NN NN O
by NN NN O
matching NN NN O
point NN NN O
mutations NN NN O
in NN NN O
5 NN NN O
' NN NN O
HS3 NN NN O
with NN NN O
amino NN NN O
acid NN NN O
changes NN NN O
in NN NN O
the NN NN O
zinc NN NN O
fingers NN NN O
of NN NN O
Sp1 NN NN B-Protein
and NN NN O
EKLF NN NN B-Protein
. NN NN O
   
Testing NN NN O
their NN NN O
activity NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
shows NN NN O
that NN NN O
EKLF NN NN B-Protein
is NN NN O
a NN NN O
direct NN NN O
activator NN NN O
of NN NN O
5 NN NN O
' NN NN O
HS3 NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
distinct NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
neutrophils NN NN O
by NN NN O
bacterial NN NN O
LPS NN NN O
, NN NN O
interferon NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
, NN NN O
and NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
and NN NN O
the NN NN O
necessity NN NN O
to NN NN O
overcome NN NN O
the NN NN O
action NN NN O
of NN NN O
endogenous NN NN O
proteases NN NN O
. NN NN O
   
Human NN NN O
neutrophils NN NN O
can NN NN O
be NN NN O
induced NN NN O
to NN NN O
actively NN NN O
transcribe NN NN O
a NN NN O
number NN NN O
of NN NN O
early NN NN O
- NN NN O
response NN NN O
genes NN NN O
, NN NN O
in NN NN O
particular NN NN O
those NN NN O
encoding NN NN O
cytokines NN NN O
, NN NN O
chemokines NN NN O
, NN NN O
and NN NN O
the NN NN O
high NN NN O
- NN NN O
affinity NN NN O
surface NN NN O
receptor NN NN O
for NN NN O
IgG NN NN O
, NN NN O
FcgammaRI NN NN B-Protein
. NN NN O
   
Although NN NN O
little NN NN O
is NN NN O
known NN NN O
to NN NN O
date NN NN O
about NN NN O
the NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
neutrophils NN NN O
, NN NN O
several NN NN O
indications NN NN O
point NN NN O
to NN NN O
a NN NN O
role NN NN O
for NN NN O
distinct NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
such NN NN O
as NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
STAT NN NN O
families NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
become NN NN O
activated NN NN O
under NN NN O
stimulatory NN NN O
conditions NN NN O
which NN NN O
are NN NN O
known NN NN O
to NN NN O
induce NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
neutrophils NN NN O
. NN NN O
   
Unexpectedly NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
conventional NN NN O
procedures NN NN O
employed NN NN O
to NN NN O
prepare NN NN O
cellular NN NN O
extracts NN NN O
cause NN NN O
the NN NN O
release NN NN O
of NN NN O
proteolytic NN NN O
activities NN NN O
that NN NN O
are NN NN O
normally NN NN O
stored NN NN O
in NN NN O
intracellular NN NN O
granules NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
degradation NN NN O
of NN NN O
various NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
and NN NN O
STAT NN NN O
proteins NN NN O
. NN NN O
   
To NN NN O
circumvent NN NN O
this NN NN O
problem NN NN O
, NN NN O
we NN NN O
developed NN NN O
an NN NN O
alternative NN NN O
procedure NN NN O
which NN NN O
allowed NN NN O
us NN NN O
to NN NN O
show NN NN O
that NN NN O
in NN NN O
neutrophils NN NN O
, NN NN O
LPS NN NN O
and NN NN O
TNFalpha NN NN B-Protein
induce NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
which NN NN O
essentially NN NN O
consists NN NN O
of NN NN O
p50 NN NN B-Protein
/ NN NN O
RelA NN NN B-Protein
dimers NN NN O
, NN NN O
and NN NN O
that NN NN O
IFNgamma NN NN B-Protein
promotes NN NN O
the NN NN O
binding NN NN O
of NN NN O
STAT1 NN NN B-Protein
homodimers NN NN O
to NN NN O
the NN NN O
IFNgamma NN NN B-Protein
response NN NN O
region NN NN O
of NN NN O
the NN NN O
FcgammaRI NN NN B-Protein
promoter NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
neutrophil NN NN O
stimulation NN NN O
with NN NN O
GM NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
results NN NN O
in NN NN O
the NN NN O
formation NN NN O
of NN NN O
a NN NN O
STAT5 NN NN O
- NN NN O
containing NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
Collectively NN NN O
, NN NN O
the NN NN O
current NN NN O
findings NN NN O
open NN NN O
new NN NN O
perspectives NN NN O
about NN NN O
mechanisms NN NN O
that NN NN O
are NN NN O
likely NN NN O
to NN NN O
regulate NN NN O
gene NN NN O
transcription NN NN O
in NN NN O
neutrophils NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
the NN NN O
procedure NN NN O
described NN NN O
herein NN NN O
could NN NN O
prove NN NN O
useful NN NN O
in NN NN O
other NN NN O
cell NN NN O
types NN NN O
that NN NN O
express NN NN O
high NN NN O
levels NN NN O
of NN NN O
endogenous NN NN O
proteases NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
activation NN NN O
in NN NN O
lymphokine NN NN O
activated NN NN O
killer NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
from NN NN O
patients NN NN O
receiving NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
immunotherapy NN NN O
. NN NN O
   
Administration NN NN O
of NN NN O
the NN NN O
cytokine NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
can NN NN O
result NN NN O
in NN NN O
therapeutic NN NN O
benefits NN NN O
for NN NN O
individuals NN NN O
with NN NN O
renal NN NN O
cell NN NN O
carcinoma NN NN O
and NN NN O
melanoma NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
an NN NN O
analysis NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
families NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
Sp1 NN NN B-Protein
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
and NN NN O
signal NN NN O
transducers NN NN O
and NN NN O
activators NN NN O
of NN NN O
transcription NN NN O
( NN NN O
STAT NN NN O
) NN NN O
in NN NN O
cancer NN NN O
patients NN NN O
' NN NN O
lymphocytes NN NN O
before NN NN O
and NN NN O
after NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
immunotherapy NN NN O
, NN NN O
as NN NN O
assessed NN NN O
by NN NN O
a NN NN O
gel NN NN O
- NN NN O
shift NN NN O
assay NN NN O
. NN NN O
   
An NN NN O
in NN NN O
vitro NN NN O
surrogate NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
immunotherapy NN NN O
is NN NN O
the NN NN O
incubation NN NN O
of NN NN O
fresh NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
from NN NN O
healthy NN NN O
individuals NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
for NN NN O
several NN NN O
days NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
lymphokine NN NN O
- NN NN O
activated NN NN O
killer NN NN O
( NN NN O
LAK NN NN O
) NN NN O
activity NN NN O
in NN NN O
these NN NN O
cultures NN NN O
. NN NN O
   
One NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
describe NN NN O
the NN NN O
profile NN NN O
of NN NN O
transcription NN NN O
factor NN NN O
activation NN NN O
in NN NN O
these NN NN O
different NN NN O
populations NN NN O
, NN NN O
and NN NN O
assess NN NN O
whether NN NN O
the NN NN O
patterns NN NN O
observed NN NN O
correlated NN NN O
with NN NN O
functional NN NN O
differences NN NN O
in NN NN O
these NN NN O
cells NN NN O
. NN NN O
   
Prior NN NN O
to NN NN O
in NN NN O
vivo NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
administration NN NN O
, NN NN O
the NN NN O
typical NN NN O
binding NN NN O
pattern NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
in NN NN O
PBMC NN NN O
from NN NN O
patients NN NN O
resembled NN NN O
that NN NN O
seen NN NN O
in NN NN O
fresh NN NN O
PBMC NN NN O
from NN NN O
healthy NN NN O
individuals NN NN O
. NN NN O
   
Over NN NN O
a NN NN O
3 NN NN O
- NN NN O
week NN NN O
course NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
therapy NN NN O
, NN NN O
in NN NN O
most NN NN O
patients NN NN O
the NN NN O
binding NN NN O
patterns NN NN O
of NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
Sp1 NN NN B-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
proteins NN NN O
changed NN NN O
to NN NN O
resemble NN NN O
those NN NN O
seen NN NN O
in NN NN O
PBMC NN NN O
activated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
vitro NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
cells NN NN O
obtained NN NN O
from NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
treated NN NN O
patients NN NN O
did NN NN O
not NN NN O
have NN NN O
low NN NN O
- NN NN O
level NN NN O
constitutive NN NN O
expression NN NN O
of NN NN O
STAT NN NN O
binding NN NN O
factors NN NN O
as NN NN O
did NN NN O
LAK NN NN O
cells NN NN O
. NN NN O
   
When NN NN O
these NN NN O
patient NN NN O
cells NN NN O
were NN NN O
further NN NN O
stimulated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
vitro NN NN O
, NN NN O
additional NN NN O
differences NN NN O
in NN NN O
STAT NN NN O
induction NN NN O
patterns NN NN O
were NN NN O
noted NN NN O
. NN NN O
   
These NN NN O
data NN NN O
provide NN NN O
further NN NN O
information NN NN O
on NN NN O
the NN NN O
molecular NN NN O
events NN NN O
occurring NN NN O
in NN NN O
immune NN NN O
cells NN NN O
generated NN NN O
through NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
administration NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
further NN NN O
document NN NN O
that NN NN O
there NN NN O
is NN NN O
not NN NN O
a NN NN O
precise NN NN O
congruence NN NN O
between NN NN O
PBMC NN NN O
activated NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
A NN NN O
critical NN NN O
role NN NN O
of NN NN O
the NN NN O
p75 NN NN B-Protein
tumor NN NN I-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
p75TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
) NN NN O
in NN NN O
organ NN NN O
inflammation NN NN O
independent NN NN O
of NN NN O
TNF NN NN O
, NN NN O
lymphotoxin NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
or NN NN O
the NN NN O
p55TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
. NN NN O
   
Despite NN NN O
overwhelming NN NN O
evidence NN NN O
that NN NN O
enhanced NN NN O
production NN NN O
of NN NN O
the NN NN O
p75 NN NN B-Protein
tumor NN NN I-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
p75TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
) NN NN O
accompanies NN NN O
development NN NN O
of NN NN O
specific NN NN O
human NN NN O
inflammatory NN NN O
pathologies NN NN O
such NN NN O
as NN NN O
multi NN NN O
- NN NN O
organ NN NN O
failure NN NN O
during NN NN O
sepsis NN NN O
, NN NN O
inflammatory NN NN O
liver NN NN O
disease NN NN O
, NN NN O
pancreatitis NN NN O
, NN NN O
respiratory NN NN O
distress NN NN O
syndrome NN NN O
, NN NN O
or NN NN O
AIDS NN NN O
, NN NN O
the NN NN O
function NN NN O
of NN NN O
this NN NN O
receptor NN NN O
remains NN NN O
poorly NN NN O
defined NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
We NN NN O
show NN NN O
here NN NN O
that NN NN O
at NN NN O
levels NN NN O
relevant NN NN O
to NN NN O
human NN NN O
disease NN NN O
, NN NN O
production NN NN O
of NN NN O
the NN NN O
human NN NN O
p75TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
in NN NN O
transgenic NN NN O
mice NN NN O
results NN NN O
in NN NN O
a NN NN O
severe NN NN O
inflammatory NN NN O
syndrome NN NN O
involving NN NN O
mainly NN NN O
the NN NN O
pancreas NN NN O
, NN NN O
liver NN NN O
, NN NN O
kidney NN NN O
, NN NN O
and NN NN O
lung NN NN O
, NN NN O
and NN NN O
characterized NN NN O
by NN NN O
constitutively NN NN O
increased NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cell NN NN O
compartment NN NN O
. NN NN O
   
This NN NN O
process NN NN O
is NN NN O
shown NN NN O
to NN NN O
evolve NN NN O
independently NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
TNF NN NN O
, NN NN O
lymphotoxin NN NN B-Protein
alpha NN NN I-Protein
, NN NN O
or NN NN O
the NN NN O
p55TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
, NN NN O
although NN NN O
coexpression NN NN O
of NN NN O
a NN NN O
human NN NN O
TNF NN NN O
transgene NN NN O
accelerated NN NN O
pathology NN NN O
. NN NN O
   
These NN NN O
results NN NN O
establish NN NN O
an NN NN O
independent NN NN O
role NN NN O
for NN NN O
enhanced NN NN O
p75TNF NN NN B-Protein
- NN NN I-Protein
R NN NN I-Protein
production NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
inflammatory NN NN O
disease NN NN O
and NN NN O
implicate NN NN O
the NN NN O
direct NN NN O
involvement NN NN O
of NN NN O
this NN NN O
receptor NN NN O
in NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
human NN NN O
inflammatory NN NN O
pathologies NN NN O
. NN NN O
   
Potent NN NN O
inhibition NN NN O
of NN NN O
HIV NN NN O
type NN NN O
1 NN NN O
replication NN NN O
by NN NN O
an NN NN O
antiinflammatory NN NN O
alkaloid NN NN O
, NN NN O
cepharanthine NN NN O
, NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Cepharanthine NN NN O
is NN NN O
a NN NN O
biscoclaurine NN NN O
alkaloid NN NN O
isolated NN NN O
from NN NN O
Stephania NN NN O
cepharantha NN NN O
Hayata NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
have NN NN O
antiinflammatory NN NN O
, NN NN O
antiallergic NN NN O
, NN NN O
and NN NN O
immunomodulatory NN NN O
activities NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
As NN NN O
several NN NN O
inflammatory NN NN O
cytokines NN NN O
and NN NN O
oxidative NN NN O
stresses NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
cepharanthine NN NN O
on NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
- NN NN O
and NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
- NN NN O
induced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
chronically NN NN O
infected NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Two NN NN O
chronically NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
cell NN NN O
lines NN NN O
, NN NN O
U1 NN NN O
( NN NN O
monocytic NN NN O
) NN NN O
and NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
( NN NN O
T NN NN O
lymphocytic NN NN O
) NN NN O
, NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
or NN NN O
PMA NN NN O
and NN NN O
cultured NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
various NN NN O
concentrations NN NN O
of NN NN O
the NN NN O
compound NN NN O
. NN NN O
   
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
was NN NN O
determined NN NN O
by NN NN O
p24 NN NN B-Protein
antigen NN NN I-Protein
level NN NN O
. NN NN O
   
The NN NN O
inhibitory NN NN O
effects NN NN O
of NN NN O
cepharanthine NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
and NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
activation NN NN O
were NN NN O
also NN NN O
examined NN NN O
. NN NN O
   
Cepharanthine NN NN O
dose NN NN O
dependently NN NN O
inhibited NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
- NN NN O
and NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
U1 NN NN O
cells NN NN O
but NN NN O
not NN NN O
in NN NN O
ACH NN NN O
- NN NN O
2 NN NN O
cells NN NN O
. NN NN O
   
Its NN NN O
50 NN NN O
% NN NN O
effective NN NN O
and NN NN O
cytotoxic NN NN O
concentrations NN NN O
were NN NN O
0 NN NN O
. NN NN O
016 NN NN O
and NN NN O
2 NN NN O
. NN NN O
2 NN NN O
microg NN NN O
/ NN NN O
ml NN NN O
in NN NN O
PMA NN NN O
- NN NN O
stimulated NN NN O
U1 NN NN O
cells NN NN O
, NN NN O
respectively NN NN O
. NN NN O
   
Cepharanthine NN NN O
was NN NN O
found NN NN O
to NN NN O
suppress NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
gene NN NN O
expression NN NN O
through NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
cepharanthine NN NN O
is NN NN O
a NN NN O
highly NN NN O
potent NN NN O
inhibitor NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
in NN NN O
a NN NN O
chronically NN NN O
infected NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Since NN NN O
biscoclaurine NN NN O
alkaloids NN NN O
, NN NN O
containing NN NN O
cepharanthine NN NN O
as NN NN O
a NN NN O
major NN NN O
component NN NN O
, NN NN O
are NN NN O
widely NN NN O
used NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
patients NN NN O
with NN NN O
various NN NN O
inflammatory NN NN O
diseases NN NN O
in NN NN O
Japan NN NN O
, NN NN O
cepharanthine NN NN O
should NN NN O
be NN NN O
further NN NN O
pursued NN NN O
for NN NN O
its NN NN O
chemotherapeutic NN NN O
potential NN NN O
in NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
- NN NN O
infected NN NN O
patients NN NN O
. NN NN O
   
Prostaglandin NN NN O
E2 NN NN O
Up NN NN O
- NN NN O
regulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
- NN NN O
driven NN NN O
gene NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
via NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
Replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
highly NN NN O
dependent NN NN O
on NN NN O
the NN NN O
state NN NN O
of NN NN O
activation NN NN O
of NN NN O
the NN NN O
infected NN NN O
cells NN NN O
and NN NN O
is NN NN O
modulated NN NN O
by NN NN O
interactions NN NN O
between NN NN O
viral NN NN O
and NN NN O
host NN NN O
cellular NN NN O
factors NN NN O
. NN NN O
   
Prostaglandin NN NN O
E2 NN NN O
( NN NN O
PGE2 NN NN O
) NN NN O
, NN NN O
a NN NN O
pleiotropic NN NN O
immunomodulatory NN NN O
molecule NN NN O
, NN NN O
is NN NN O
observed NN NN O
at NN NN O
elevated NN NN O
levels NN NN O
during NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
infection NN NN O
as NN NN O
well NN NN O
as NN NN O
during NN NN O
the NN NN O
course NN NN O
of NN NN O
other NN NN O
pathogenic NN NN O
infections NN NN O
. NN NN O
   
In NN NN O
1G5 NN NN O
, NN NN O
a NN NN O
Jurkat NN NN O
- NN NN O
derived NN NN O
T NN NN O
cell NN NN O
line NN NN O
stably NN NN O
transfected NN NN O
with NN NN O
a NN NN O
luciferase NN NN O
gene NN NN O
driven NN NN O
by NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
PGE2 NN NN O
markedly NN NN O
enhanced NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
mediated NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
. NN NN O
   
Experiments NN NN O
have NN NN O
been NN NN O
conducted NN NN O
to NN NN O
identify NN NN O
second NN NN O
messengers NN NN O
involved NN NN O
in NN NN O
this NN NN O
PGE2 NN NN O
- NN NN O
dependent NN NN O
up NN NN O
- NN NN O
regulating NN NN O
effect NN NN O
on NN NN O
the NN NN O
regulatory NN NN O
element NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
present NN NN O
evidence NN NN O
indicating NN NN O
that NN NN O
signal NN NN O
transduction NN NN O
pathways NN NN O
induced NN NN O
by NN NN O
PGE2 NN NN O
necessitate NN NN O
the NN NN O
participation NN NN O
of NN NN O
cyclic NN NN O
AMP NN NN O
, NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
, NN NN O
and NN NN O
Ca2 NN NN O
+ NN NN O
. NN NN O
   
Experiments NN NN O
conducted NN NN O
with NN NN O
different NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
based NN NN O
vectors NN NN O
suggested NN NN O
that NN NN O
PGE2 NN NN O
- NN NN O
mediated NN NN O
activation NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
was NN NN O
transduced NN NN O
via NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
signaling NN NN O
pathways NN NN O
. NN NN O
   
The NN NN O
involvement NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
PGE2 NN NN O
- NN NN O
dependent NN NN O
activating NN NN O
effect NN NN O
on NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
was NN NN O
further NN NN O
confirmed NN NN O
using NN NN O
a NN NN O
kappaB NN NN O
- NN NN O
regulated NN NN O
luciferase NN NN O
encoding NN NN O
vector NN NN O
and NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
Results NN NN O
from NN NN O
Northern NN NN O
blot NN NN O
and NN NN O
flow NN NN O
cytometric NN NN O
analyses NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
selective NN NN O
antagonist NN NN O
indicated NN NN O
that NN NN O
PGE2 NN NN O
modulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
- NN NN O
driven NN NN O
reporter NN NN O
gene NN NN O
activity NN NN O
in NN NN O
studied NN NN O
T NN NN O
lymphoid NN NN O
cells NN NN O
is NN NN O
transduced NN NN O
via NN NN O
the NN NN O
EP4 NN NN B-Protein
receptor NN NN I-Protein
subtype NN NN I-Protein
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
secretion NN NN O
of NN NN O
PGE2 NN NN O
by NN NN O
macrophages NN NN O
in NN NN O
response NN NN O
to NN NN O
infection NN NN O
or NN NN O
inflammatory NN NN O
activators NN NN O
could NN NN O
induce NN NN O
signaling NN NN O
events NN NN O
resulting NN NN O
in NN NN O
activation NN NN O
of NN NN O
proviral NN NN O
DNA NN NN O
present NN NN O
into NN NN O
T NN NN O
cells NN NN O
latently NN NN O
infected NN NN O
with NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Fcgamma NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
activation NN NN O
in NN NN O
monocytes NN NN O
is NN NN O
independent NN NN O
of NN NN O
Ras NN NN O
. NN NN O
   
Receptors NN NN O
for NN NN O
the NN NN O
Fc NN NN O
portion NN NN O
of NN NN O
immunoglobulin NN NN O
molecules NN NN O
( NN NN O
FcR NN NN O
) NN NN O
present NN NN O
on NN NN O
leukocyte NN NN O
cell NN NN O
membranes NN NN O
mediate NN NN O
a NN NN O
large NN NN O
number NN NN O
of NN NN O
cellular NN NN O
responses NN NN O
that NN NN O
are NN NN O
very NN NN O
important NN NN O
in NN NN O
host NN NN O
defense NN NN O
, NN NN O
including NN NN O
phagocytosis NN NN O
, NN NN O
cell NN NN O
cytotoxicity NN NN O
, NN NN O
production NN NN O
and NN NN O
secretion NN NN O
of NN NN O
inflammatory NN NN O
mediators NN NN O
, NN NN O
and NN NN O
modulation NN NN O
of NN NN O
the NN NN O
immune NN NN O
response NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
FcR NN NN O
with NN NN O
immune NN NN O
complexes NN NN O
leads NN NN O
, NN NN O
first NN NN O
to NN NN O
activation NN NN O
of NN NN O
protein NN NN O
- NN NN O
tyrosine NN NN O
kinases NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
events NN NN O
that NN NN O
follow NN NN O
and NN NN O
that NN NN O
transduce NN NN O
signals NN NN O
from NN NN O
these NN NN O
receptors NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
are NN NN O
still NN NN O
poorly NN NN O
defined NN NN O
. NN NN O
   
We NN NN O
have NN NN O
investigated NN NN O
the NN NN O
signal NN NN O
transduction NN NN O
pathway NN NN O
from NN NN O
Fc NN NN O
receptors NN NN O
that NN NN O
leads NN NN O
to NN NN O
gene NN NN O
activation NN NN O
and NN NN O
production NN NN O
of NN NN O
cytokines NN NN O
in NN NN O
monocytes NN NN O
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
FcR NN NN O
, NN NN O
on NN NN O
the NN NN O
THP NN NN O
- NN NN O
1 NN NN O
monocytic NN NN O
cell NN NN O
line NN NN O
, NN NN O
by NN NN O
immune NN NN O
complexes NN NN O
resulted NN NN O
in NN NN O
both NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
interleukin NN NN O
1 NN NN O
production NN NN O
. NN NN O
   
These NN NN O
responses NN NN O
were NN NN O
completely NN NN O
blocked NN NN O
by NN NN O
tyrosine NN NN O
kinase NN NN O
inhibitors NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
expression NN NN O
of NN NN O
dominant NN NN O
negative NN NN O
mutants NN NN O
of NN NN O
Ras NN NN O
and NN NN O
Raf NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
in NN NN O
these NN NN O
cells NN NN O
, NN NN O
did NN NN O
not NN NN O
have NN NN O
any NN NN O
effect NN NN O
on NN NN O
FcR NN NN O
- NN NN O
mediated NN NN O
nuclear NN NN O
factor NN NN O
activation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
signaling NN NN O
pathway NN NN O
was NN NN O
not NN NN O
used NN NN O
by NN NN O
these NN NN O
receptors NN NN O
. NN NN O
   
However NN NN O
, NN NN O
MAPK NN NN O
activation NN NN O
was NN NN O
easily NN NN O
detected NN NN O
by NN NN O
in NN NN O
vitro NN NN O
kinase NN NN O
assays NN NN O
, NN NN O
after NN NN O
FcR NN NN O
cross NN NN O
- NN NN O
linking NN NN O
with NN NN O
immune NN NN O
complexes NN NN O
. NN NN O
   
Using NN NN O
the NN NN O
specific NN NN O
MAPK NN NN O
/ NN NN O
extracellular NN NN O
signal NN NN O
- NN NN O
regulated NN NN O
kinase NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
kinase NN NN O
) NN NN O
inhibitor NN NN O
PD98059 NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
MAPK NN NN O
activation NN NN O
is NN NN O
necessary NN NN O
for NN NN O
FcR NN NN O
- NN NN O
dependent NN NN O
activation NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
the NN NN O
signaling NN NN O
pathway NN NN O
from NN NN O
Fc NN NN O
receptors NN NN O
leading NN NN O
to NN NN O
expression NN NN O
of NN NN O
different NN NN O
genes NN NN O
important NN NN O
to NN NN O
leukocyte NN NN O
biology NN NN O
, NN NN O
initiates NN NN O
with NN NN O
tyrosine NN NN O
kinases NN NN O
and NN NN O
requires NN NN O
MAPK NN NN O
activation NN NN O
; NN NN O
but NN NN O
in NN NN O
contrast NN NN O
to NN NN O
other NN NN O
tyrosine NN NN O
kinase NN NN O
receptors NN NN O
, NN NN O
FcR NN NN O
- NN NN O
mediated NN NN O
MAPK NN NN O
activation NN NN O
does NN NN O
not NN NN O
involve NN NN O
Ras NN NN O
and NN NN O
Raf NN NN O
. NN NN O
   
Differential NN NN O
RNA NN NN O
display NN NN O
identifies NN NN O
novel NN NN O
genes NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
expression NN NN O
. NN NN O
   
To NN NN O
characterize NN NN O
further NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
vitamin NN NN B-Protein
D NN NN I-Protein
receptor NN NN I-Protein
( NN NN O
VDR NN NN B-Protein
) NN NN O
, NN NN O
we NN NN O
have NN NN O
developed NN NN O
stable NN NN O
transfectant NN NN O
variants NN NN O
of NN NN O
a NN NN O
vitamin NN NN O
D NN NN O
- NN NN O
responsive NN NN O
cell NN NN O
line NN NN O
( NN NN O
U937 NN NN O
) NN NN O
which NN NN O
express NN NN O
either NN NN O
decreased NN NN O
or NN NN O
increased NN NN O
numbers NN NN O
of NN NN O
VDR NN NN B-Protein
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
changes NN NN O
in NN NN O
gene NN NN O
expression NN NN O
associated NN NN O
with NN NN O
this NN NN O
variable NN NN O
VDR NN NN B-Protein
expression NN NN O
. NN NN O
   
Initial NN NN O
experiments NN NN O
indicated NN NN O
that NN NN O
a NN NN O
50 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
VDR NN NN B-Protein
levels NN NN O
was NN NN O
associated NN NN O
with NN NN O
a NN NN O
2 NN NN O
- NN NN O
fold NN NN O
increase NN NN O
in NN NN O
cell NN NN O
proliferation NN NN O
and NN NN O
a NN NN O
similar NN NN O
rise NN NN O
in NN NN O
c NN NN B-Protein
- NN NN I-Protein
myc NN NN I-Protein
mRNA NN NN O
expression NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
were NN NN O
carried NN NN O
out NN NN O
using NN NN O
differential NN NN O
RNA NN NN O
display NN NN O
( NN NN O
DD NN NN O
) NN NN O
. NN NN O
   
Sequence NN NN O
analysis NN NN O
of NN NN O
DD NN NN O
products NN NN O
revealed NN NN O
two NN NN O
cDNAs NN NN O
with NN NN O
identity NN NN O
to NN NN O
known NN NN O
gene NN NN O
products NN NN O
: NN NN O
the NN NN O
catalytic NN NN O
sub NN NN O
- NN NN O
unit NN NN O
of NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
DNA NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
( NN NN I-Protein
CS NN NN I-Protein
) NN NN I-Protein
) NN NN O
, NN NN O
and NN NN O
the NN NN O
peroxisomal NN NN O
enzyme NN NN O
17beta NN NN B-Protein
- NN NN I-Protein
hydroxysteroid NN NN I-Protein
dehydrogenase NN NN I-Protein
type NN NN I-Protein
IV NN NN I-Protein
( NN NN O
17beta NN NN B-Protein
- NN NN I-Protein
HSD NN NN I-Protein
IV NN NN I-Protein
) NN NN O
. NN NN O
   
Northern NN NN O
analysis NN NN O
confirmed NN NN O
that NN NN O
expression NN NN O
of NN NN O
both NN NN O
mRNAs NN NN O
was NN NN O
reduced NN NN O
in NN NN O
cells NN NN O
with NN NN O
decreased NN NN O
numbers NN NN O
of NN NN O
VDR NN NN B-Protein
. NN NN O
   
Down NN NN O
- NN NN O
regulation NN NN O
of NN NN O
17beta NN NN B-Protein
- NN NN I-Protein
HSD NN NN I-Protein
IV NN NN I-Protein
mRNA NN NN O
expression NN NN O
was NN NN O
associated NN NN O
with NN NN O
enhanced NN NN O
estradiol NN NN O
inactivation NN NN O
by NN NN O
U937 NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
link NN NN O
between NN NN O
estrogenic NN NN O
pathways NN NN O
and NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
Further NN NN O
Northern NN NN O
analyses NN NN O
indicated NN NN O
that NN NN O
there NN NN O
was NN NN O
no NN NN O
significant NN NN O
change NN NN O
in NN NN O
17beta NN NN B-Protein
- NN NN I-Protein
HSD NN NN I-Protein
IV NN NN I-Protein
or NN NN O
DNA NN NN B-Protein
- NN NN I-Protein
PK NN NN I-Protein
( NN NN I-Protein
CS NN NN I-Protein
) NN NN I-Protein
mRNA NN NN O
levels NN NN O
following NN NN O
treatment NN NN O
with NN NN O
1 NN NN O
, NN NN O
25 NN NN O
( NN NN O
OH NN NN O
) NN NN O
2D3 NN NN O
, NN NN O
although NN NN O
expression NN NN O
of NN NN O
both NN NN O
genes NN NN O
varied NN NN O
with NN NN O
changes NN NN O
in NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O
   
These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
its NN NN O
established NN NN O
role NN NN O
as NN NN O
a NN NN O
hormone NN NN O
- NN NN O
dependent NN NN O
trans NN NN O
- NN NN O
activator NN NN O
, NN NN O
VDR NN NN B-Protein
may NN NN O
influence NN NN O
gene NN NN O
expression NN NN O
by NN NN O
ligand NN NN O
- NN NN O
independent NN NN O
mechanisms NN NN O
. NN NN O
   
Downstream NN NN O
activation NN NN O
of NN NN O
a NN NN O
TATA NN NN O
- NN NN O
less NN NN O
promoter NN NN O
by NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
Bob1 NN NN B-Protein
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
directs NN NN O
expression NN NN O
of NN NN O
the NN NN O
homing NN NN O
receptor NN NN O
BLR1 NN NN B-Protein
to NN NN O
mature NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
chemokine NN NN O
receptor NN NN O
, NN NN O
BLR1 NN NN B-Protein
, NN NN O
is NN NN O
a NN NN O
major NN NN O
regulator NN NN O
of NN NN O
the NN NN O
microenvironmental NN NN O
homing NN NN O
of NN NN O
B NN NN O
cells NN NN O
in NN NN O
lymphoid NN NN O
organs NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
studies NN NN O
identify NN NN O
three NN NN O
essential NN NN O
elements NN NN O
of NN NN O
the NN NN O
TATA NN NN O
- NN NN O
less NN NN O
blr1 NN NN B-Protein
core NN NN O
promoter NN NN O
that NN NN O
confer NN NN O
cell NN NN O
type NN NN O
- NN NN O
and NN NN O
differentiation NN NN O
- NN NN O
specific NN NN O
expression NN NN O
in NN NN O
the NN NN O
B NN NN O
cells NN NN O
of NN NN O
both NN NN O
humans NN NN O
and NN NN O
mice NN NN O
, NN NN O
a NN NN O
functional NN NN O
promoter NN NN O
region NN NN O
( NN NN O
- NN NN O
36 NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
transcription NN NN O
start NN NN O
site NN NN O
) NN NN O
, NN NN O
a NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
motif NN NN O
( NN NN O
+ NN NN O
44 NN NN O
) NN NN O
, NN NN O
and NN NN O
a NN NN O
noncanonical NN NN O
octamer NN NN O
motif NN NN O
( NN NN O
+ NN NN O
157 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
these NN NN O
sites NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
in NN NN O
vivo NN NN O
studies NN NN O
in NN NN O
gene NN NN O
- NN NN O
targeted NN NN O
mice NN NN O
deficient NN NN O
of NN NN O
either NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
Bob1 NN NN B-Protein
, NN NN O
or NN NN O
both NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
subunits NN NN O
p50 NN NN B-Protein
and NN NN O
p52 NN NN B-Protein
. NN NN O
   
In NN NN O
all NN NN O
of NN NN O
these NN NN O
animals NN NN O
, NN NN O
the NN NN O
expression NN NN O
of NN NN O
BLR1 NN NN B-Protein
was NN NN O
reduced NN NN O
or NN NN O
absent NN NN O
. NN NN O
   
In NN NN O
mice NN NN O
deficient NN NN O
only NN NN O
of NN NN O
p52 NN NN B-Protein
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
BLR1 NN NN B-Protein
expression NN NN O
was NN NN O
unaffected NN NN O
. NN NN O
   
Thus NN NN O
our NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
BLR1 NN NN B-Protein
is NN NN O
a NN NN O
target NN NN O
gene NN NN O
for NN NN O
Oct NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
Bob1 NN NN B-Protein
, NN NN O
and NN NN O
members NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
family NN NN O
and NN NN O
provides NN NN O
a NN NN O
link NN NN O
to NN NN O
the NN NN O
impaired NN NN O
B NN NN O
cell NN NN O
functions NN NN O
in NN NN O
mice NN NN O
deficient NN NN O
for NN NN O
these NN NN O
factors NN NN O
. NN NN O
   
Interaction NN NN O
of NN NN O
sickle NN NN O
erythrocytes NN NN O
with NN NN O
endothelial NN NN O
cells NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
endothelial NN NN O
cell NN NN O
conditioned NN NN O
medium NN NN O
induces NN NN O
oxidant NN NN O
stress NN NN O
leading NN NN O
to NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
abnormal NN NN O
adherence NN NN O
of NN NN O
sickle NN NN O
red NN NN O
blood NN NN O
cells NN NN O
( NN NN O
SS NN NN O
RBC NN NN O
) NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
has NN NN O
been NN NN O
thought NN NN O
to NN NN O
contribute NN NN O
to NN NN O
vascular NN NN O
occlusion NN NN O
, NN NN O
a NN NN O
major NN NN O
cause NN NN O
of NN NN O
morbidity NN NN O
in NN NN O
sickle NN NN O
cell NN NN O
disease NN NN O
( NN NN O
SCD NN NN O
) NN NN O
. NN NN O
   
We NN NN O
determined NN NN O
whether NN NN O
the NN NN O
interaction NN NN O
of NN NN O
SS NN NN O
RBC NN NN O
with NN NN O
cultured NN NN O
endothelial NN NN O
cells NN NN O
induced NN NN O
cellular NN NN O
oxidant NN NN O
stress NN NN O
that NN NN O
would NN NN O
culminate NN NN O
in NN NN O
expression NN NN O
of NN NN O
cell NN NN O
adhesion NN NN O
molecules NN NN O
( NN NN O
CAMs NN NN O
) NN NN O
involved NN NN O
in NN NN O
the NN NN O
adhesion NN NN O
and NN NN O
diapedesis NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
the NN NN O
adherence NN NN O
of NN NN O
SS NN NN O
reticulocytes NN NN O
. NN NN O
   
We NN NN O
showed NN NN O
that NN NN O
the NN NN O
interaction NN NN O
of NN NN O
SS NN NN O
RBC NN NN O
at NN NN O
2 NN NN O
% NN NN O
concentration NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
multimers NN NN O
of NN NN O
von NN NN B-Protein
Willebrand NN NN I-Protein
factor NN NN I-Protein
( NN NN O
vWf NN NN B-Protein
) NN NN O
, NN NN O
derived NN NN O
from NN NN O
endothelial NN NN O
cell NN NN O
- NN NN O
derived NN NN O
conditioned NN NN O
medium NN NN O
( NN NN O
E NN NN O
- NN NN O
CM NN NN O
) NN NN O
with NN NN O
cultured NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVEC NN NN O
) NN NN O
, NN NN O
resulted NN NN O
in NN NN O
a NN NN O
fivefold NN NN O
increased NN NN O
formation NN NN O
of NN NN O
thiobarbituric NN NN O
acid NN NN O
- NN NN O
reactive NN NN O
substances NN NN O
( NN NN O
TBARS NN NN O
) NN NN O
and NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kB NN NN O
, NN NN O
both NN NN O
indicators NN NN O
of NN NN O
cellular NN NN O
oxidant NN NN O
stress NN NN O
. NN NN O
   
Normal NN NN O
RBC NN NN O
show NN NN O
none NN NN O
of NN NN O
these NN NN O
phenomena NN NN O
. NN NN O
   
The NN NN O
oxidant NN NN O
stress NN NN O
- NN NN O
induced NN NN O
signaling NN NN O
resulted NN NN O
in NN NN O
an NN NN O
increased NN NN O
surface NN NN O
expression NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
CAMs NN NN O
, NN NN O
ICAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
HUVEC NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
oxygen NN NN O
radical NN NN O
scavenger NN NN O
enzymes NN NN O
( NN NN O
catalase NN NN B-Protein
, NN NN O
superoxide NN NN B-Protein
dismutase NN NN I-Protein
) NN NN O
and NN NN O
antioxidant NN NN O
( NN NN O
probucol NN NN O
) NN NN O
inhibited NN NN O
these NN NN O
events NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
preincubation NN NN O
of NN NN O
HUVEC NN NN O
with NN NN O
a NN NN O
synthetic NN NN O
peptide NN NN O
Arg NN NN O
- NN NN O
Gly NN NN O
- NN NN O
Asp NN NN O
( NN NN O
RGD NN NN O
) NN NN O
that NN NN O
prevents NN NN O
vWf NN NN B-Protein
- NN NN O
mediated NN NN O
adhesion NN NN O
of NN NN O
SS NN NN O
RBC NN NN O
reduced NN NN O
the NN NN O
surface NN NN O
expression NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
NF NN NN O
- NN NN O
kB NN NN O
activation NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
SS NN NN O
RBC NN NN O
- NN NN O
induced NN NN O
oxidant NN NN O
stress NN NN O
resulted NN NN O
in NN NN O
a NN NN O
twofold NN NN O
increase NN NN O
in NN NN O
the NN NN O
transendothelial NN NN O
migration NN NN O
of NN NN O
both NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
HL NN NN O
- NN NN O
60 NN NN O
cells NN NN O
and NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
approximately NN NN O
a NN NN O
sixfold NN NN O
increase NN NN O
in NN NN O
platelet NN NN B-Protein
- NN NN I-Protein
endothelial NN NN I-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
PECAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
phosphorylation NN NN O
, NN NN O
each NN NN O
of NN NN O
which NN NN O
was NN NN O
blocked NN NN O
by NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
inhibitor NN NN O
and NN NN O
antioxidants NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
adherence NN NN O
/ NN NN O
contact NN NN O
of NN NN O
SS NN NN O
RBC NN NN O
to NN NN O
endothelial NN NN O
cells NN NN O
in NN NN O
large NN NN O
vessel NN NN O
can NN NN O
generate NN NN O
enhanced NN NN O
oxidant NN NN O
stress NN NN O
leading NN NN O
to NN NN O
increased NN NN O
adhesion NN NN O
and NN NN O
diapedesis NN NN O
of NN NN O
monocytes NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
heightened NN NN O
adherence NN NN O
of NN NN O
SS NN NN O
reticulocytes NN NN O
, NN NN O
indicating NN NN O
that NN NN O
injury NN NN O
/ NN NN O
activation NN NN O
of NN NN O
endothelium NN NN O
can NN NN O
contribute NN NN O
to NN NN O
vaso NN NN O
- NN NN O
occlusion NN NN O
in NN NN O
SCD NN NN O
. NN NN O
   
Tobacco NN NN O
smoke NN NN O
induces NN NN O
coordinate NN NN O
activation NN NN O
of NN NN O
HSF NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
NFkappaB NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
: NN NN O
effects NN NN O
on NN NN O
TNFalpha NN NN B-Protein
release NN NN O
. NN NN O
   
Tobacco NN NN O
smoke NN NN O
( NN NN O
TS NN NN O
) NN NN O
exposure NN NN O
is NN NN O
a NN NN O
major NN NN O
risk NN NN O
factor NN NN O
for NN NN O
human NN NN O
disease NN NN O
, NN NN O
and NN NN O
macrophages NN NN O
of NN NN O
healthy NN NN O
smokers NN NN O
have NN NN O
a NN NN O
depressed NN NN O
capacity NN NN O
to NN NN O
release NN NN O
cytokines NN NN O
, NN NN O
including NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
alpha NN NN O
. NN NN O
   
TS NN NN O
induces NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
heat NN NN O
shock NN NN O
( NN NN O
HS NN NN O
) NN NN O
/ NN NN O
stress NN NN O
proteins NN NN O
( NN NN O
HSP NN NN O
) NN NN O
, NN NN O
and NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
of NN NN O
Hsp70 NN NN O
. NN NN O
   
We NN NN O
determined NN NN O
whether NN NN O
Hsp70 NN NN O
induction NN NN O
by NN NN O
TS NN NN O
was NN NN O
mediated NN NN O
by NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
HS NN NN O
transcription NN NN O
factor NN NN O
, NN NN O
HSF NN NN O
. NN NN O
   
HSF NN NN O
activation NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
inhibit NN NN O
NFkappaB NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
we NN NN O
also NN NN O
determined NN NN O
the NN NN O
effects NN NN O
of NN NN O
TS NN NN O
on NN NN O
NFkappaB NN NN O
. NN NN O
   
U937 NN NN O
cells NN NN O
and NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
were NN NN O
exposed NN NN O
to NN NN O
TS NN NN O
, NN NN O
binding NN NN O
activities NN NN O
of NN NN O
the NN NN O
respective NN NN O
transcription NN NN O
factors NN NN O
were NN NN O
analyzed NN NN O
, NN NN O
and NN NN O
Hsp70 NN NN O
expression NN NN O
and NN NN O
TNFalpha NN NN B-Protein
release NN NN O
were NN NN O
determined NN NN O
in NN NN O
parallel NN NN O
. NN NN O
   
TS NN NN O
activated NN NN O
HSF NN NN O
, NN NN O
which NN NN O
was NN NN O
associated NN NN O
with NN NN O
Hsp70 NN NN O
overexpression NN NN O
and NN NN O
inhibition NN NN O
of NN NN O
NFkappaB NN NN O
binding NN NN O
activity NN NN O
and NN NN O
TNFalpha NN NN B-Protein
release NN NN O
. NN NN O
   
The NN NN O
altered NN NN O
cytokine NN NN O
profile NN NN O
observed NN NN O
in NN NN O
smokers NN NN O
may NN NN O
relate NN NN O
to NN NN O
an NN NN O
HSF NN NN O
/ NN NN O
Hsp70 NN NN O
- NN NN O
mediated NN NN O
inhibition NN NN O
of NN NN O
NFkappaB NN NN O
activity NN NN O
. NN NN O
   
Copyright NN NN O
1998 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
gene NN NN O
by NN NN O
cytokines NN NN O
: NN NN O
cross NN NN O
- NN NN O
talk NN NN O
between NN NN O
STAT5 NN NN B-Protein
and NN NN O
other NN NN O
signaling NN NN O
molecules NN NN O
. NN NN O
   
The NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
promoter NN NN O
has NN NN O
been NN NN O
widely NN NN O
used NN NN O
to NN NN O
monitor NN NN O
the NN NN O
activation NN NN O
of NN NN O
STAT NN NN B-Protein
( NN NN I-Protein
signal NN NN I-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
) NN NN I-Protein
5 NN NN I-Protein
since NN NN O
STAT5 NN NN B-Protein
was NN NN O
originally NN NN O
found NN NN O
as NN NN O
a NN NN O
mediator NN NN O
of NN NN O
PRL NN NN B-Protein
- NN NN O
inducible NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
expression NN NN O
. NN NN O
   
However NN NN O
, NN NN O
not NN NN O
only NN NN O
is NN NN O
expression NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
gene NN NN O
regulated NN NN O
by NN NN O
STAT5 NN NN B-Protein
but NN NN O
it NN NN O
is NN NN O
also NN NN O
affected NN NN O
by NN NN O
other NN NN O
molecules NN NN O
such NN NN O
as NN NN O
glucocorticoid NN NN O
and NN NN O
Ras NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
gene NN NN O
by NN NN O
cytokines NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
cytotoxic NN NN O
T NN NN O
cell NN NN O
line NN NN O
, NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
, NN NN O
in NN NN O
response NN NN O
to NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
, NN NN O
which NN NN O
activates NN NN O
STAT5 NN NN B-Protein
. NN NN O
   
While NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
does NN NN O
not NN NN O
activate NN NN O
STAT5 NN NN B-Protein
, NN NN O
it NN NN O
induces NN NN O
expression NN NN O
of NN NN O
STAT5 NN NN B-Protein
- NN NN O
regulated NN NN O
genes NN NN O
in NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
, NN NN O
a NN NN O
cytokine NN NN B-Protein
- NN NN I-Protein
inducible NN NN I-Protein
SH2 NN NN I-Protein
- NN NN I-Protein
containing NN NN I-Protein
protein NN NN I-Protein
( NN NN O
CIS NN NN B-Protein
) NN NN O
, NN NN O
and NN NN O
oncostatin NN NN B-Protein
M NN NN I-Protein
( NN NN O
OSM NN NN B-Protein
) NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
STAT6 NN NN B-Protein
activated NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
substitutes NN NN O
for NN NN O
the NN NN O
function NN NN O
of NN NN O
STAT5 NN NN B-Protein
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
expression NN NN O
was NN NN O
enhanced NN NN O
by NN NN O
dexamethasone NN NN O
, NN NN O
and NN NN O
this NN NN O
synergistic NN NN O
effect NN NN O
of NN NN O
Dexamethasone NN NN O
requires NN NN O
the NN NN O
sequence NN NN O
between NN NN O
- NN NN O
155 NN NN O
and NN NN O
- NN NN O
193 NN NN O
in NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
promoter NN NN O
. NN NN O
   
Coincidentally NN NN O
, NN NN O
a NN NN O
deletion NN NN O
of NN NN O
this NN NN O
region NN NN O
enhanced NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
expression NN NN O
of NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
. NN NN O
   
Expression NN NN O
of NN NN O
an NN NN O
active NN NN O
form NN NN O
of NN NN O
Ras NN NN O
, NN NN O
Ras NN NN B-Protein
( NN NN I-Protein
G12V NN NN I-Protein
) NN NN I-Protein
, NN NN O
suppressed NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
and NN NN O
OSM NN NN B-Protein
gene NN NN O
expression NN NN O
, NN NN O
and NN NN O
the NN NN O
negative NN NN O
effect NN NN O
of NN NN O
Ras NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
region NN NN O
between NN NN O
- NN NN O
105 NN NN O
and NN NN O
- NN NN O
193 NN NN O
in NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
promoter NN NN O
. NN NN O
   
In NN NN O
apparent NN NN O
contradiction NN NN O
, NN NN O
expression NN NN O
of NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
form NN NN O
of NN NN O
Ras NN NN O
, NN NN O
RasN17 NN NN B-Protein
, NN NN O
also NN NN O
inhibited NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
induced NN NN O
activation NN NN O
of NN NN O
the NN NN O
promoter NN NN O
containing NN NN O
the NN NN O
minimal NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
STAT5 NN NN B-Protein
element NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
promoters NN NN O
of NN NN O
CIS NN NN B-Protein
and NN NN O
OSM NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
Ras NN NN B-Protein
( NN NN I-Protein
G12V NN NN I-Protein
) NN NN I-Protein
complemented NN NN O
signaling NN NN O
by NN NN O
an NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
mutant NN NN O
defective NN NN O
in NN NN O
Ras NN NN O
activation NN NN O
and NN NN O
augmented NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
beta NN NN B-Protein
- NN NN I-Protein
casein NN NN I-Protein
promoter NN NN O
by NN NN O
the NN NN O
mutant NN NN O
erythropoietin NN NN B-Protein
receptor NN NN I-Protein
signaling NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
possible NN NN O
role NN NN O
of NN NN O
Ras NN NN O
in NN NN O
Stat5 NN NN B-Protein
- NN NN O
mediated NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
These NN NN O
results NN NN O
collectively NN NN O
reveal NN NN O
a NN NN O
complex NN NN O
interaction NN NN O
of NN NN O
STAT5 NN NN B-Protein
with NN NN O
other NN NN O
signaling NN NN O
pathways NN NN O
and NN NN O
illustrate NN NN O
that NN NN O
regulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
requires NN NN O
integration NN NN O
of NN NN O
opposing NN NN O
signals NN NN O
. NN NN O
   
Transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
regulation NN NN O
of NN NN O
renal NN NN O
fibrosis NN NN O
during NN NN O
ureteral NN NN O
obstruction NN NN O
. NN NN O
   
Irrespective NN NN O
of NN NN O
the NN NN O
etiology NN NN O
, NN NN O
many NN NN O
kidney NN NN O
diseases NN NN O
result NN NN O
in NN NN O
inflammation NN NN O
and NN NN O
fibrosis NN NN O
of NN NN O
the NN NN O
tubulointerstitium NN NN O
, NN NN O
with NN NN O
the NN NN O
subsequent NN NN O
loss NN NN O
of NN NN O
renal NN NN O
function NN NN O
. NN NN O
   
To NN NN O
initiate NN NN O
any NN NN O
disease NN NN O
process NN NN O
or NN NN O
for NN NN O
any NN NN O
disease NN NN O
process NN NN O
to NN NN O
progress NN NN O
, NN NN O
there NN NN O
must NN NN O
be NN NN O
changes NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
within NN NN O
the NN NN O
affected NN NN O
tissue NN NN O
. NN NN O
   
The NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
regulates NN NN O
genes NN NN O
involved NN NN O
in NN NN O
inflammation NN NN O
, NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
and NN NN O
cell NN NN O
differentiation NN NN O
. NN NN O
   
This NN NN O
review NN NN O
discusses NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
in NN NN O
general NN NN O
and NN NN O
the NN NN O
association NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
with NN NN O
cellular NN NN O
/ NN NN O
molecular NN NN O
events NN NN O
of NN NN O
renal NN NN O
inflammation NN NN O
and NN NN O
fibrosis NN NN O
. NN NN O
   
TAL1 NN NN B-Protein
and NN NN O
LIM NN NN O
- NN NN O
only NN NN O
proteins NN NN O
synergistically NN NN O
induce NN NN O
retinaldehyde NN NN B-Protein
dehydrogenase NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
by NN NN O
acting NN NN O
as NN NN O
cofactors NN NN O
for NN NN O
GATA3 NN NN B-Protein
. NN NN O
   
Previously NN NN O
, NN NN O
we NN NN O
have NN NN O
shown NN NN O
that NN NN O
TAL1 NN NN B-Protein
and NN NN O
the NN NN O
LIM NN NN O
- NN NN O
only NN NN O
protein NN NN O
gene NN NN O
( NN NN O
LMO NN NN O
) NN NN O
are NN NN O
regularly NN NN O
coactivated NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
acute NN NN O
lymphoblastic NN NN O
leukemia NN NN O
( NN NN O
T NN NN O
- NN NN O
ALL NN NN O
) NN NN O
. NN NN O
   
This NN NN O
observation NN NN O
is NN NN O
likely NN NN O
to NN NN O
relate NN NN O
to NN NN O
the NN NN O
findings NN NN O
that NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
are NN NN O
highly NN NN O
synergistic NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
tumorigenesis NN NN O
in NN NN O
double NN NN O
- NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O
   
To NN NN O
understand NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
functional NN NN O
synergy NN NN O
between NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
in NN NN O
tumorigenesis NN NN O
and NN NN O
transcriptional NN NN O
regulation NN NN O
, NN NN O
we NN NN O
tried NN NN O
to NN NN O
identify NN NN O
downstream NN NN O
target NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
by NN NN O
a NN NN O
subtractive NN NN O
PCR NN NN O
method NN NN O
. NN NN O
   
One NN NN O
of NN NN O
the NN NN O
isolated NN NN O
genes NN NN O
, NN NN O
that NN NN O
for NN NN O
retinaldehyde NN NN B-Protein
dehydrogenase NN NN I-Protein
2 NN NN I-Protein
( NN NN O
RALDH2 NN NN B-Protein
) NN NN O
, NN NN O
was NN NN O
regularly NN NN O
expressed NN NN O
in NN NN O
most NN NN O
of NN NN O
the NN NN O
T NN NN O
- NN NN O
ALL NN NN O
cell NN NN O
lines NN NN O
that NN NN O
coexpressed NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
. NN NN O
   
Exogenously NN NN O
transfected NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
, NN NN O
but NN NN O
not NN NN O
either NN NN O
alone NN NN O
, NN NN O
induced NN NN O
RALDH2 NN NN B-Protein
expression NN NN O
in NN NN O
a NN NN O
T NN NN O
- NN NN O
ALL NN NN O
cell NN NN O
line NN NN O
, NN NN O
HPB NN NN O
- NN NN O
ALL NN NN O
, NN NN O
not NN NN O
expressing NN NN O
endogeneous NN NN O
TAL1 NN NN B-Protein
or NN NN O
LMO NN NN O
. NN NN O
   
The NN NN O
RALDH2 NN NN B-Protein
transcripts NN NN O
in NN NN O
T NN NN O
- NN NN O
ALL NN NN O
were NN NN O
, NN NN O
however NN NN O
, NN NN O
mostly NN NN O
initiated NN NN O
within NN NN O
the NN NN O
second NN NN O
intron NN NN O
. NN NN O
   
Promoter NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
a NN NN O
GATA NN NN O
site NN NN O
in NN NN O
a NN NN O
cryptic NN NN O
promoter NN NN O
in NN NN O
the NN NN O
second NN NN O
intron NN NN O
was NN NN O
essential NN NN O
and NN NN O
sufficient NN NN O
for NN NN O
the NN NN O
TAL1 NN NN B-Protein
- NN NN O
and NN NN O
LMO NN NN O
- NN NN O
dependent NN NN O
transcriptional NN NN O
activation NN NN O
, NN NN O
and NN NN O
GATA3 NN NN B-Protein
binds NN NN O
to NN NN O
this NN NN O
site NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
forced NN NN O
expression NN NN O
of NN NN O
GATA3 NN NN B-Protein
potentiated NN NN O
the NN NN O
induction NN NN O
of NN NN O
RALDH2 NN NN B-Protein
by NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
, NN NN O
and NN NN O
these NN NN O
three NN NN O
factors NN NN O
formed NN NN O
a NN NN O
complex NN NN O
in NN NN O
vivo NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
TAL1 NN NN B-Protein
mutant NN NN O
not NN NN O
binding NN NN O
to NN NN O
DNA NN NN O
also NN NN O
activated NN NN O
the NN NN O
transcription NN NN O
of NN NN O
RALDH2 NN NN B-Protein
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
LMO NN NN O
and NN NN O
GATA3 NN NN B-Protein
. NN NN O
   
Collectively NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
the NN NN O
RALDH2 NN NN B-Protein
gene NN NN O
as NN NN O
a NN NN O
first NN NN O
example NN NN O
of NN NN O
direct NN NN O
transcriptional NN NN O
target NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
in NN NN O
T NN NN O
- NN NN O
ALL NN NN O
. NN NN O
   
In NN NN O
this NN NN O
case NN NN O
, NN NN O
TAL1 NN NN B-Protein
and NN NN O
LMO NN NN O
act NN NN O
as NN NN O
cofactors NN NN O
for NN NN O
GATA3 NN NN B-Protein
to NN NN O
activate NN NN O
the NN NN O
transcription NN NN O
of NN NN O
RALDH2 NN NN B-Protein
. NN NN O
   
Granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
activates NN NN O
a NN NN O
72 NN NN O
- NN NN O
kDa NN NN O
isoform NN NN O
of NN NN O
STAT3 NN NN B-Protein
in NN NN O
human NN NN O
neutrophils NN NN O
. NN NN O
   
Granulocyte NN NN B-Protein
colony NN NN I-Protein
- NN NN I-Protein
stimulating NN NN I-Protein
factor NN NN I-Protein
( NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
) NN NN O
signaling NN NN O
involves NN NN O
activation NN NN O
of NN NN O
STATs NN NN O
, NN NN O
proteins NN NN O
that NN NN O
serve NN NN O
the NN NN O
dual NN NN O
function NN NN O
of NN NN O
signal NN NN O
transduction NN NN O
and NN NN O
activation NN NN O
of NN NN O
transcription NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
activated NN NN O
a NN NN O
distinct NN NN O
Stat3 NN NN B-Protein
- NN NN O
like NN NN O
protein NN NN O
in NN NN O
immature NN NN O
and NN NN O
mature NN NN O
normal NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
StatG NN NN B-Protein
. NN NN O
   
StatG NN NN B-Protein
in NN NN O
normal NN NN O
immature NN NN O
human NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
adult NN NN O
CD34 NN NN B-Protein
+ NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
, NN NN O
was NN NN O
composed NN NN O
of NN NN O
Stat3beta NN NN B-Protein
. NN NN O
   
This NN NN O
investigation NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
determine NN NN O
the NN NN O
composition NN NN O
of NN NN O
StatG NN NN B-Protein
in NN NN O
mature NN NN O
normal NN NN O
human NN NN O
myeloid NN NN O
cells NN NN O
, NN NN O
i NN NN O
. NN NN O
e NN NN O
. NN NN O
polymorphonuclear NN NN O
neutrophilic NN NN O
granulocytes NN NN O
( NN NN O
PMN NN NN O
) NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
revealed NN NN O
that NN NN O
the NN NN O
major NN NN O
protein NN NN O
in NN NN O
extracts NN NN O
of NN NN O
PMN NN NN O
activated NN NN O
by NN NN O
G NN NN B-Protein
- NN NN I-Protein
CSF NN NN I-Protein
to NN NN O
bind NN NN O
the NN NN O
high NN NN O
- NN NN O
affinity NN NN O
serum NN NN O
- NN NN O
inducible NN NN O
element NN NN O
( NN NN O
hSIE NN NN O
) NN NN O
is NN NN O
a NN NN O
72 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
that NN NN O
cross NN NN O
- NN NN O
reacts NN NN O
with NN NN O
Stat3 NN NN B-Protein
monoclonal NN NN O
antibody NN NN O
, NN NN O
which NN NN O
we NN NN O
have NN NN O
designated NN NN O
Stat3gamma NN NN B-Protein
. NN NN O
   
Stat3gamma NN NN B-Protein
is NN NN O
derived NN NN O
from NN NN O
Stat3alpha NN NN B-Protein
by NN NN O
limited NN NN O
proteolysis NN NN O
and NN NN O
lacks NN NN O
the NN NN O
carboxyl NN NN O
- NN NN O
terminal NN NN O
portion NN NN O
of NN NN O
Stat3alpha NN NN B-Protein
. NN NN O
   
Because NN NN O
this NN NN O
region NN NN O
of NN NN O
Stat3alpha NN NN B-Protein
is NN NN O
involved NN NN O
in NN NN O
transcriptional NN NN O
activation NN NN O
, NN NN O
our NN NN O
findings NN NN O
suggest NN NN O
the NN NN O
possibility NN NN O
that NN NN O
Stat3gamma NN NN B-Protein
may NN NN O
be NN NN O
transcriptionally NN NN O
inactive NN NN O
and NN NN O
may NN NN O
compete NN NN O
with NN NN O
Stat3alpha NN NN B-Protein
for NN NN O
Stat3 NN NN B-Protein
binding NN NN O
sites NN NN O
in NN NN O
these NN NN O
terminally NN NN O
differentiated NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O
   
Differential NN NN O
effects NN NN O
of NN NN O
protein NN NN O
kinase NN NN O
C NN NN O
inhibitors NN NN O
on NN NN O
fibronectin NN NN B-Protein
- NN NN O
induced NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
beta NN NN I-Protein
gene NN NN O
transcription NN NN O
, NN NN O
protein NN NN O
synthesis NN NN O
and NN NN O
secretion NN NN O
in NN NN O
human NN NN O
monocytic NN NN O
cells NN NN O
. NN NN O
   
Human NN NN O
monocytic NN NN O
cells NN NN O
express NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
) NN NN O
when NN NN O
stimulated NN NN O
with NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
glycoprotein NN NN O
, NN NN O
fibronectin NN NN B-Protein
( NN NN O
FN NN NN B-Protein
) NN NN O
. NN NN O
   
Protein NN NN O
kinase NN NN O
C NN NN O
( NN NN O
PKC NN NN O
) NN NN O
activation NN NN O
is NN NN O
considered NN NN O
important NN NN O
for NN NN O
this NN NN O
process NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
metabolic NN NN O
steps NN NN O
at NN NN O
which NN NN O
PKC NN NN O
acts NN NN O
upon NN NN O
to NN NN O
mediate NN NN O
the NN NN O
FN NN NN B-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
response NN NN O
remain NN NN O
unclear NN NN O
. NN NN O
   
We NN NN O
performed NN NN O
an NN NN O
analysis NN NN O
of NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
two NN NN O
PKC NN NN O
inhibitors NN NN O
, NN NN O
Calphostin NN NN O
C NN NN O
and NN NN O
Staurosporine NN NN O
, NN NN O
prevent NN NN O
the NN NN O
FN NN NN B-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
response NN NN O
. NN NN O
   
Both NN NN O
inhibitors NN NN O
blocked NN NN O
the NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
protein NN NN O
into NN NN O
the NN NN O
media NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
exposed NN NN O
to NN NN O
FN NN NN B-Protein
. NN NN O
   
Immunoprecipitation NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
under NN NN O
these NN NN O
circumstances NN NN O
, NN NN O
Calphostin NN NN O
C NN NN O
inhibited NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
protein NN NN O
, NN NN O
whereas NN NN O
Staurosporine NN NN O
allowed NN NN O
protein NN NN O
production NN NN O
, NN NN O
but NN NN O
inhibited NN NN O
its NN NN O
secretion NN NN O
. NN NN O
   
To NN NN O
determine NN NN O
the NN NN O
mechanisms NN NN O
responsible NN NN O
for NN NN O
these NN NN O
differences NN NN O
, NN NN O
we NN NN O
turned NN NN O
to NN NN O
human NN NN O
U937 NN NN O
promonocytic NN NN O
cells NN NN O
. NN NN O
   
U937 NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
the NN NN O
human NN NN O
full NN NN O
- NN NN O
length NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
promoter NN NN O
connected NN NN O
to NN NN O
a NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
were NN NN O
submitted NN NN O
to NN NN O
transcription NN NN O
assays NN NN O
, NN NN O
Northern NN NN O
blotting NN NN O
, NN NN O
and NN NN O
DNA NN NN O
electrophoresis NN NN O
mobility NN NN O
gel NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
revealed NN NN O
that NN NN O
Calphostin NN NN O
C NN NN O
inhibited NN NN O
the NN NN O
nuclear NN NN O
translocation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
activator NN NN O
protein NN NN O
- NN NN O
1 NN NN O
( NN NN O
AP NN NN O
- NN NN O
1 NN NN O
) NN NN O
which NN NN O
is NN NN O
considered NN NN O
necessary NN NN O
for NN NN O
FN NN NN B-Protein
induction NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
transcription NN NN O
, NN NN O
and NN NN O
prevented NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
Staurosporine NN NN O
alone NN NN O
induced NN NN O
AP NN NN O
- NN NN O
1 NN NN O
translocation NN NN O
and NN NN O
stimulation NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O
   
Overall NN NN O
, NN NN O
our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
Calphostin NN NN O
C NN NN O
prevents NN NN O
the NN NN O
transcription NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
gene NN NN O
thereby NN NN O
inhibiting NN NN O
protein NN NN O
synthesis NN NN O
. NN NN O
   
Based NN NN O
on NN NN O
the NN NN O
high NN NN O
specificity NN NN O
of NN NN O
this NN NN O
compound NN NN O
for NN NN O
PKC NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
PKC NN NN O
is NN NN O
necessary NN NN O
for NN NN O
FN NN NN B-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
protein NN NN O
production NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
Staurosporine NN NN O
prevented NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
by NN NN O
unknown NN NN O
mechanisms NN NN O
. NN NN O
   
Cloning NN NN O
of NN NN O
ARE NN NN O
- NN NN O
containing NN NN O
genes NN NN O
by NN NN O
AU NN NN O
- NN NN O
motif NN NN O
- NN NN O
directed NN NN O
display NN NN O
. NN NN O
   
A NN NN O
procedure NN NN O
suitable NN NN O
for NN NN O
cloning NN NN O
labile NN NN O
mRNAs NN NN O
that NN NN O
contain NN NN O
AU NN NN O
motifs NN NN O
is NN NN O
presented NN NN O
( NN NN O
AU NN NN O
- NN NN O
DD NN NN O
) NN NN O
. NN NN O
   
These NN NN O
motifs NN NN O
are NN NN O
regulatory NN NN O
sequences NN NN O
within NN NN O
the NN NN O
so NN NN O
- NN NN O
called NN NN O
AU NN NN O
- NN NN O
rich NN NN O
elements NN NN O
( NN NN O
AREs NN NN O
) NN NN O
often NN NN O
found NN NN O
in NN NN O
3 NN NN O
' NN NN O
untranslated NN NN O
regions NN NN O
of NN NN O
genes NN NN O
such NN NN O
as NN NN O
cytokines NN NN O
, NN NN O
proto NN NN O
- NN NN O
oncogenes NN NN O
, NN NN O
and NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
AU NN NN O
- NN NN O
DD NN NN O
is NN NN O
an NN NN O
AU NN NN O
- NN NN O
motif NN NN O
- NN NN O
directed NN NN O
differential NN NN O
display NN NN O
that NN NN O
permits NN NN O
the NN NN O
identification NN NN O
of NN NN O
ARE NN NN O
- NN NN O
containing NN NN O
genes NN NN O
differentially NN NN O
expressed NN NN O
after NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
It NN NN O
has NN NN O
been NN NN O
applied NN NN O
to NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
and NN NN O
a NN NN O
T NN NN O
cell NN NN O
clone NN NN O
to NN NN O
isolate NN NN O
59 NN NN O
cDNA NN NN O
fragments NN NN O
associated NN NN O
to NN NN O
activation NN NN O
. NN NN O
   
Fourteen NN NN O
percent NN NN O
of NN NN O
isolated NN NN O
fragments NN NN O
belong NN NN O
to NN NN O
already NN NN O
known NN NN O
genes NN NN O
that NN NN O
certainly NN NN O
are NN NN O
cytokines NN NN O
and NN NN O
transduction NN NN O
/ NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
The NN NN O
remaining NN NN O
86 NN NN O
% NN NN O
correspond NN NN O
to NN NN O
unknown NN NN O
genes NN NN O
of NN NN O
which NN NN O
92 NN NN O
% NN NN O
have NN NN O
been NN NN O
confirmed NN NN O
to NN NN O
be NN NN O
differentially NN NN O
expressed NN NN O
. NN NN O
   
These NN NN O
data NN NN O
demonstrate NN NN O
the NN NN O
efficiency NN NN O
of NN NN O
the NN NN O
system NN NN O
and NN NN O
support NN NN O
the NN NN O
notion NN NN O
that NN NN O
numerous NN NN O
genes NN NN O
falling NN NN O
into NN NN O
those NN NN O
categories NN NN O
remain NN NN O
unidentified NN NN O
and NN NN O
that NN NN O
they NN NN O
can NN NN O
be NN NN O
cloned NN NN O
by NN NN O
this NN NN O
method NN NN O
. NN NN O
   
Copyright NN NN O
1998 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Signaling NN NN O
pathways NN NN O
mediated NN NN O
by NN NN O
the NN NN O
TNF NN NN O
- NN NN O
and NN NN O
cytokine NN NN O
- NN NN O
receptor NN NN O
families NN NN O
target NN NN O
a NN NN O
common NN NN O
cis NN NN O
- NN NN O
element NN NN O
of NN NN O
the NN NN O
IFN NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
promoter NN NN O
. NN NN O
   
CD40 NN NN B-Protein
activation NN NN O
of NN NN O
B NN NN O
cells NN NN O
is NN NN O
strongly NN NN O
influenced NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
cytokines NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
interplay NN NN O
between NN NN O
these NN NN O
distinct NN NN O
stimuli NN NN O
is NN NN O
not NN NN O
clearly NN NN O
delineated NN NN O
. NN NN O
   
IFN NN NN B-Protein
regulatory NN NN I-Protein
factor NN NN I-Protein
1 NN NN I-Protein
( NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
transcription NN NN O
factor NN NN O
activated NN NN O
by NN NN O
either NN NN O
CD40 NN NN B-Protein
or NN NN O
cytokines NN NN O
. NN NN O
   
We NN NN O
have NN NN O
found NN NN O
that NN NN O
these NN NN O
different NN NN O
sets NN NN O
of NN NN O
signals NN NN O
target NN NN O
a NN NN O
common NN NN O
cis NN NN O
- NN NN O
acting NN NN O
element NN NN O
in NN NN O
the NN NN O
promoter NN NN O
of NN NN O
this NN NN O
gene NN NN O
, NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
gamma NN NN O
- NN NN O
activated NN NN O
site NN NN O
( NN NN O
GAS NN NN O
) NN NN O
. NN NN O
   
Targeting NN NN O
of NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
GAS NN NN O
is NN NN O
not NN NN O
confined NN NN O
to NN NN O
activation NN NN O
via NN NN O
CD40 NN NN B-Protein
but NN NN O
extends NN NN O
to NN NN O
other NN NN O
stimuli NN NN O
that NN NN O
mimic NN NN O
the NN NN O
CD40 NN NN B-Protein
signaling NN NN O
cascade NN NN O
, NN NN O
like NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
EBV NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
to NN NN O
induction NN NN O
of NN NN O
STATs NN NN O
by NN NN O
cytokines NN NN O
, NN NN O
the NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
GAS NN NN O
- NN NN O
binding NN NN O
complex NN NN O
activated NN NN O
by NN NN O
CD40 NN NN B-Protein
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
or NN NN O
EBV NN NN O
contains NN NN O
Rel NN NN O
proteins NN NN O
, NN NN O
specifically NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
. NN NN O
   
In NN NN O
this NN NN O
system NN NN O
, NN NN O
simultaneous NN NN O
exposure NN NN O
to NN NN O
CD40L NN NN B-Protein
together NN NN O
with NN NN O
either NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
or NN NN O
IFN NN NN B-Protein
- NN NN I-Protein
gamma NN NN I-Protein
does NN NN O
not NN NN O
lead NN NN O
to NN NN O
the NN NN O
activation NN NN O
of NN NN O
novel NN NN O
Rel NN NN O
/ NN NN O
STAT NN NN O
complexes NN NN O
. NN NN O
   
Given NN NN O
the NN NN O
importance NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
biologic NN NN O
functions NN NN O
from NN NN O
proliferation NN NN O
to NN NN O
apoptosis NN NN O
, NN NN O
our NN NN O
findings NN NN O
support NN NN O
the NN NN O
notion NN NN O
that NN NN O
modulation NN NN O
of NN NN O
IRF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
levels NN NN O
may NN NN O
be NN NN O
a NN NN O
critical NN NN O
control NN NN O
point NN NN O
in NN NN O
B NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
STAT1 NN NN B-Protein
nuclear NN NN O
import NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
noninvasive NN NN O
delivery NN NN O
of NN NN O
peptide NN NN O
carrying NN NN O
the NN NN O
nuclear NN NN O
localization NN NN O
sequence NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
. NN NN O
   
Activation NN NN O
of NN NN O
T NN NN O
lymphocytes NN NN O
by NN NN O
Ags NN NN O
or NN NN O
cytokines NN NN O
results NN NN O
in NN NN O
translocation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
STAT NN NN O
from NN NN O
the NN NN O
cytoplasm NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
. NN NN O
   
The NN NN O
first NN NN O
step NN NN O
in NN NN O
the NN NN O
nuclear NN NN O
import NN NN O
process NN NN O
is NN NN O
recognition NN NN O
of NN NN O
a NN NN O
nuclear NN NN O
localization NN NN O
sequence NN NN O
( NN NN O
NLS NN NN O
) NN NN O
within NN NN O
the NN NN O
karyophilic NN NN O
protein NN NN O
by NN NN O
a NN NN O
cytoplasmic NN NN O
receptor NN NN O
such NN NN O
as NN NN O
the NN NN O
importin NN NN O
( NN NN O
karyopherin NN NN O
) NN NN O
- NN NN O
alpha NN NN O
subunit NN NN O
. NN NN O
   
The NN NN O
NLSs NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NFAT NN NN O
differ NN NN O
and NN NN O
the NN NN O
NLS NN NN O
of NN NN O
STAT1 NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
identified NN NN O
. NN NN O
   
Herein NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
inducible NN NN O
nuclear NN NN O
import NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
STAT1 NN NN B-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
lymphocytes NN NN O
is NN NN O
significantly NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
cell NN NN O
- NN NN O
permeable NN NN O
peptide NN NN O
carrying NN NN O
the NN NN O
NLS NN NN O
of NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
p50 NN NN B-Protein
subunit NN NN O
. NN NN O
   
NLS NN NN O
peptide NN NN O
- NN NN O
mediated NN NN O
disruption NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
import NN NN O
of NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
results NN NN O
in NN NN O
inhibition NN NN O
of NN NN O
I NN NN B-Protein
kappa NN NN I-Protein
B NN NN I-Protein
alpha NN NN I-Protein
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
expression NN NN O
, NN NN O
processes NN NN O
dependent NN NN O
on NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
or NN NN O
the NN NN O
combination NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
NFAT NN NN O
. NN NN O
   
Further NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
inhibitory NN NN O
NLS NN NN O
peptide NN NN O
interacts NN NN O
in NN NN O
vitro NN NN O
with NN NN O
a NN NN O
cytoplasmic NN NN O
NLS NN NN O
receptor NN NN O
complex NN NN O
comprised NN NN O
of NN NN O
the NN NN O
Rch1 NN NN B-Protein
/ NN NN O
importin NN NN O
( NN NN O
karyopherin NN NN O
) NN NN O
- NN NN O
beta NN NN O
heterodimer NN NN O
expressed NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
inducible NN NN O
nuclear NN NN O
import NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
, NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NFAT NN NN O
, NN NN O
and NN NN O
STAT1 NN NN B-Protein
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
can NN NN O
be NN NN O
regulated NN NN O
by NN NN O
NLS NN NN O
peptide NN NN O
delivered NN NN O
noninvasively NN NN O
to NN NN O
the NN NN O
cytoplasm NN NN O
of NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
to NN NN O
target NN NN O
members NN NN O
of NN NN O
the NN NN O
importin NN NN O
( NN NN O
karyopherin NN NN O
) NN NN O
- NN NN O
alpha NN NN O
beta NN NN O
NLS NN NN O
receptor NN NN O
complex NN NN O
. NN NN O
   
Epithelial NN NN O
cell NN NN O
- NN NN O
initiated NN NN O
inflammation NN NN O
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
early NN NN O
tissue NN NN O
damage NN NN O
in NN NN O
amebic NN NN O
infection NN NN O
of NN NN O
human NN NN O
intestine NN NN O
. NN NN O
   
BACKGROUND NN NN O
& NN NN O
AIMS NN NN O
: NN NN O
Entamoeba NN NN O
histolytica NN NN O
infection NN NN O
of NN NN O
the NN NN O
intestine NN NN O
can NN NN O
induce NN NN O
severe NN NN O
gut NN NN O
inflammation NN NN O
. NN NN O
   
The NN NN O
aims NN NN O
of NN NN O
this NN NN O
study NN NN O
were NN NN O
to NN NN O
assess NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
host NN NN O
inflammatory NN NN O
response NN NN O
in NN NN O
the NN NN O
tissue NN NN O
damage NN NN O
observed NN NN O
with NN NN O
amebiasis NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
intestinal NN NN O
epithelial NN NN O
cell NN NN O
in NN NN O
initiating NN NN O
that NN NN O
response NN NN O
. NN NN O
   
METHODS NN NN O
: NN NN O
E NN NN O
. NN NN O
histolytica NN NN O
infection NN NN O
was NN NN O
established NN NN O
in NN NN O
human NN NN O
intestinal NN NN O
xenografts NN NN O
in NN NN O
severe NN NN O
combined NN NN O
immunodeficient NN NN O
( NN NN O
SCID NN NN O
- NN NN O
HU NN NN O
- NN NN O
INT NN NN O
) NN NN O
mice NN NN O
. NN NN O
   
Human NN NN O
intestinal NN NN O
epithelial NN NN O
cell NN NN O
inflammatory NN NN O
responses NN NN O
to NN NN O
amebic NN NN O
infection NN NN O
were NN NN O
inhibited NN NN O
by NN NN O
the NN NN O
intraluminal NN NN O
administration NN NN O
of NN NN O
an NN NN O
antisense NN NN O
oligonucleotide NN NN O
to NN NN O
the NN NN O
human NN NN O
p65 NN NN B-Protein
subunit NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
, NN NN O
and NN NN O
the NN NN O
role NN NN O
of NN NN O
neutrophils NN NN O
in NN NN O
tissue NN NN O
damage NN NN O
observed NN NN O
with NN NN O
amebiasis NN NN O
was NN NN O
studied NN NN O
by NN NN O
depleting NN NN O
neutrophils NN NN O
from NN NN O
SCID NN NN O
- NN NN O
HU NN NN O
- NN NN O
INT NN NN O
mice NN NN O
. NN NN O
   
RESULTS NN NN O
: NN NN O
Administration NN NN O
of NN NN O
the NN NN O
antisense NN NN O
oligonucleotide NN NN O
blocked NN NN O
the NN NN O
production NN NN O
of NN NN O
human NN NN O
interleukin NN NN B-Protein
1beta NN NN I-Protein
and NN NN O
interleukin NN NN B-Protein
8 NN NN I-Protein
by NN NN O
intestinal NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
inhibited NN NN O
neutrophil NN NN O
influx NN NN O
into NN NN O
the NN NN O
E NN NN O
. NN NN O
histolytica NN NN O
- NN NN O
infected NN NN O
intestinal NN NN O
xenografts NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
the NN NN O
gut NN NN O
inflammatory NN NN O
response NN NN O
by NN NN O
the NN NN O
antisense NN NN O
oligonucleotide NN NN O
or NN NN O
the NN NN O
depletion NN NN O
of NN NN O
neutrophils NN NN O
from NN NN O
SCID NN NN O
- NN NN O
HU NN NN O
- NN NN O
INT NN NN O
mice NN NN O
blocked NN NN O
the NN NN O
increase NN NN O
in NN NN O
intestinal NN NN O
permeability NN NN O
observed NN NN O
with NN NN O
amebic NN NN O
infection NN NN O
. NN NN O
   
CONCLUSIONS NN NN O
: NN NN O
Intestinal NN NN O
epithelial NN NN O
cells NN NN O
initiate NN NN O
an NN NN O
inflammatory NN NN O
response NN NN O
with NN NN O
resulting NN NN O
neutrophil NN NN O
- NN NN O
mediated NN NN O
tissue NN NN O
damage NN NN O
in NN NN O
response NN NN O
to NN NN O
E NN NN O
. NN NN O
histolytica NN NN O
infection NN NN O
; NN NN O
this NN NN O
inflammatory NN NN O
cascade NN NN O
can NN NN O
be NN NN O
blocked NN NN O
by NN NN O
inhibiting NN NN O
the NN NN O
transcription NN NN O
of NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
. NN NN O
   
In NN NN O
vitro NN NN O
suppression NN NN O
of NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
of NN NN O
B NN NN O
cells NN NN O
by NN NN O
tissue NN NN B-Protein
inhibitor NN NN I-Protein
of NN NN I-Protein
metalloproteinases NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Cellular NN NN O
pathways NN NN O
for NN NN O
induction NN NN O
of NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
( NN NN O
PCD NN NN O
) NN NN O
have NN NN O
been NN NN O
identified NN NN O
, NN NN O
but NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
specific NN NN O
extracellular NN NN O
matrix NN NN O
processes NN NN O
that NN NN O
may NN NN O
affect NN NN O
apoptosis NN NN O
along NN NN O
those NN NN O
pathways NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
a NN NN O
series NN NN O
of NN NN O
Burkitt NN NN O
' NN NN O
s NN NN O
lymphoma NN NN O
( NN NN O
BL NN NN O
) NN NN O
cell NN NN O
lines NN NN O
were NN NN O
assayed NN NN O
for NN NN O
their NN NN O
expression NN NN O
of NN NN O
tissue NN NN B-Protein
inhibitor NN NN I-Protein
of NN NN I-Protein
metalloproteinases NN NN I-Protein
( NN NN I-Protein
TIMP NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Results NN NN O
indicate NN NN O
that NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
positive NN NN O
BL NN NN O
lines NN NN O
show NN NN O
resistance NN NN O
to NN NN O
cold NN NN O
- NN NN O
shock NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
recombinant NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
a NN NN O
synthetic NN NN O
metalloproteinase NN NN O
inhibitor NN NN O
( NN NN O
BB NN NN O
- NN NN O
94 NN NN O
) NN NN O
, NN NN O
confers NN NN O
resistance NN NN O
to NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
both NN NN O
CD95 NN NN B-Protein
- NN NN O
dependent NN NN O
and NN NN O
- NN NN O
independent NN NN O
( NN NN O
cold NN NN O
shock NN NN O
, NN NN O
serum NN NN O
deprivation NN NN O
, NN NN O
and NN NN O
gamma NN NN O
- NN NN O
radiation NN NN O
) NN NN O
pathways NN NN O
in NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
negative NN NN O
BL NN NN O
lines NN NN O
. NN NN O
   
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
suppression NN NN O
of NN NN O
PCD NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
metalloproteinase NN NN O
inhibition NN NN O
, NN NN O
as NN NN O
reduction NN NN O
and NN NN O
alkylation NN NN O
of NN NN O
the NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
did NN NN O
not NN NN O
abolish NN NN O
this NN NN O
activity NN NN O
. NN NN O
   
Retroviral NN NN O
induction NN NN O
of NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
not NN NN O
only NN NN O
resulted NN NN O
in NN NN O
cell NN NN O
survival NN NN O
but NN NN O
also NN NN O
in NN NN O
continued NN NN O
DNA NN NN O
synthesis NN NN O
for NN NN O
up NN NN O
to NN NN O
5 NN NN O
d NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
serum NN NN O
, NN NN O
while NN NN O
controls NN NN O
underwent NN NN O
apoptosis NN NN O
. NN NN O
   
This NN NN O
resistance NN NN O
to NN NN O
apoptosis NN NN O
is NN NN O
reversed NN NN O
by NN NN O
anti NN NN O
- NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
antibodies NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
secreted NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
is NN NN O
active NN NN O
in NN NN O
blocking NN NN O
apoptosis NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
upregulation NN NN O
induced NN NN O
expression NN NN O
of NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
XL NN NN I-Protein
but NN NN O
not NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
as NN NN O
well NN NN O
as NN NN O
decreased NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
as NN NN O
compared NN NN O
with NN NN O
controls NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
suppresses NN NN O
apoptosis NN NN O
in NN NN O
B NN NN O
cells NN NN O
and NN NN O
suggests NN NN O
a NN NN O
novel NN NN O
activity NN NN O
for NN NN O
TIMP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
in NN NN O
tissue NN NN O
homeostasis NN NN O
. NN NN O
   
Interleukin NN NN O
- NN NN O
12 NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
by NN NN O
transformation NN NN O
with NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
. NN NN O
   
Although NN NN O
interleukin NN NN O
( NN NN O
IL NN NN O
) NN NN O
- NN NN O
12 NN NN O
was NN NN O
originally NN NN O
purified NN NN O
from NN NN O
an NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
( NN NN O
EBV NN NN O
) NN NN O
- NN NN O
transformed NN NN O
B NN NN O
cell NN NN O
line NN NN O
and NN NN O
the NN NN O
high NN NN O
correlation NN NN O
of NN NN O
EBV NN NN O
infection NN NN O
and NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
has NN NN O
been NN NN O
suggested NN NN O
, NN NN O
no NN NN O
study NN NN O
has NN NN O
reported NN NN O
whether NN NN O
EBV NN NN O
infection NN NN O
is NN NN O
directly NN NN O
linked NN NN O
to NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
. NN NN O
   
To NN NN O
address NN NN O
this NN NN O
issue NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
in NN NN O
B NN NN O
cells NN NN O
during NN NN O
in NN NN O
vitro NN NN O
transformation NN NN O
with NN NN O
EBV NN NN O
. NN NN O
   
Human NN NN O
peripheral NN NN O
B NN NN O
cells NN NN O
became NN NN O
capable NN NN O
of NN NN O
constitutively NN NN O
producing NN NN O
p40 NN NN B-Protein
by NN NN O
in NN NN O
vitro NN NN O
transformation NN NN O
with NN NN O
EBV NN NN O
, NN NN O
coincident NN NN O
with NN NN O
the NN NN O
expression NN NN O
of NN NN O
latent NN NN B-Protein
membrane NN NN I-Protein
protein NN NN I-Protein
1 NN NN I-Protein
( NN NN O
LMP1 NN NN B-Protein
) NN NN O
of NN NN O
EBV NN NN O
. NN NN O
   
These NN NN O
B NN NN O
cells NN NN O
expressed NN NN O
p40 NN NN B-Protein
and NN NN O
p35 NN NN B-Protein
mRNA NN NN O
, NN NN O
and NN NN O
phorbol NN NN O
myristate NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
stimulation NN NN O
strongly NN NN O
enhanced NN NN O
p40 NN NN B-Protein
and NN NN O
p70 NN NN O
production NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
transfection NN NN O
with NN NN O
LMP1 NN NN B-Protein
expression NN NN O
vector NN NN O
into NN NN O
a NN NN O
human NN NN O
B NN NN O
lymphoma NN NN O
cell NN NN O
line NN NN O
, NN NN O
Daudi NN NN O
, NN NN O
led NN NN O
to NN NN O
p40 NN NN B-Protein
production NN NN O
with NN NN O
nuclear NN NN O
factor NN NN O
( NN NN O
NF NN NN O
) NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
. NN NN O
   
These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
transformation NN NN O
of NN NN O
primary NN NN O
B NN NN O
cells NN NN O
with NN NN O
EBV NN NN O
induces NN NN O
IL NN NN O
- NN NN O
12 NN NN O
expression NN NN O
potentially NN NN O
through NN NN O
LMP1 NN NN B-Protein
expression NN NN O
. NN NN O
   
Copyright NN NN O
1998 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Anaphylatoxins NN NN O
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
induce NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
. NN NN O
   
The NN NN O
anaphylatoxins NN NN O
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cytokine NN NN O
production NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
the NN NN O
capability NN NN O
of NN NN O
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
to NN NN O
induce NN NN O
transcription NN NN O
factor NN NN O
activation NN NN O
was NN NN O
examined NN NN O
. NN NN O
   
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
stimulation NN NN O
of NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
monocytes NN NN O
resulted NN NN O
in NN NN O
nuclear NN NN O
expression NN NN O
of NN NN O
a NN NN O
DNA NN NN O
binding NN NN O
activity NN NN O
with NN NN O
specificity NN NN O
to NN NN O
the NN NN O
kappaB NN NN O
sequence NN NN O
. NN NN O
   
The NN NN O
p50 NN NN B-Protein
and NN NN O
p65 NN NN B-Protein
proteins NN NN O
, NN NN O
constituents NN NN O
of NN NN O
the NN NN O
prototypic NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
, NN NN O
were NN NN O
identified NN NN O
as NN NN O
components NN NN O
of NN NN O
the NN NN O
DNA NN NN O
- NN NN O
protein NN NN O
complexes NN NN O
by NN NN O
anti NN NN O
- NN NN O
peptide NN NN O
antibodies NN NN O
in NN NN O
gel NN NN O
supershift NN NN O
assays NN NN O
. NN NN O
   
C5a NN NN B-Protein
induced NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
was NN NN O
detected NN NN O
15 NN NN O
min NN NN O
after NN NN O
agonist NN NN O
stimulation NN NN O
, NN NN O
peaked NN NN O
at NN NN O
30 NN NN O
- NN NN O
40 NN NN O
min NN NN O
, NN NN O
and NN NN O
remained NN NN O
detectable NN NN O
at NN NN O
2 NN NN O
h NN NN O
. NN NN O
   
Binding NN NN O
to NN NN O
kappaB NN NN O
sequence NN NN O
was NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
initial NN NN O
decrease NN NN O
and NN NN O
subsequent NN NN O
increase NN NN O
in NN NN O
the NN NN O
cytoplasmic NN NN O
IkappaBalpha NN NN B-Protein
levels NN NN O
, NN NN O
as NN NN O
detected NN NN O
by NN NN O
Western NN NN O
blotting NN NN O
using NN NN O
an NN NN O
anti NN NN O
- NN NN O
IkappaBalpha NN NN B-Protein
antibody NN NN O
. NN NN O
   
Pertussis NN NN O
toxin NN NN O
treatment NN NN O
markedly NN NN O
decreased NN NN O
kappaB NN NN O
binding NN NN O
activities NN NN O
induced NN NN O
by NN NN O
both NN NN O
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
, NN NN O
whereas NN NN O
cholera NN NN O
toxin NN NN O
displayed NN NN O
no NN NN O
inhibitory NN NN O
effect NN NN O
. NN NN O
   
Neither NN NN O
of NN NN O
the NN NN O
two NN NN O
toxins NN NN O
affected NN NN O
kappaB NN NN O
binding NN NN O
activity NN NN O
induced NN NN O
by NN NN O
TNFalpha NN NN B-Protein
in NN NN O
the NN NN O
same NN NN O
cells NN NN O
. NN NN O
   
These NN NN O
results NN NN O
imply NN NN O
a NN NN O
potential NN NN O
role NN NN O
of NN NN O
the NN NN O
anaphylatoxins NN NN O
C5a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
in NN NN O
regulating NN NN O
leukocytes NN NN O
gene NN NN O
expression NN NN O
through NN NN O
G NN NN O
protein NN NN O
- NN NN O
coupled NN NN O
transcription NN NN O
factor NN NN O
activation NN NN O
. NN NN O
   
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
by NN NN O
triggering NN NN O
multiple NN NN O
signaling NN NN O
pathways NN NN O
that NN NN O
activate NN NN O
NFAT NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
The NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
kinase NN NN O
activates NN NN O
the NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
and NN NN O
induces NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
in NN NN O
T NN NN O
- NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
inhibited NN NN O
by NN NN O
mutant NN NN O
signaling NN NN O
molecules NN NN O
that NN NN O
inhibit NN NN O
the NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
MAPK NN NN O
) NN NN O
or NN NN O
the NN NN O
calcineurin NN NN O
/ NN NN O
NFAT NN NN O
pathways NN NN O
and NN NN O
is NN NN O
promoted NN NN O
by NN NN O
combinations NN NN O
of NN NN O
signaling NN NN O
molecules NN NN O
that NN NN O
activate NN NN O
these NN NN O
pathways NN NN O
. NN NN O
   
We NN NN O
, NN NN O
therefore NN NN O
, NN NN O
conclude NN NN O
that NN NN O
signals NN NN O
generated NN NN O
by NN NN O
the NN NN O
convergence NN NN O
of NN NN O
the NN NN O
MAPK NN NN O
and NN NN O
the NN NN O
calcineurin NN NN O
/ NN NN O
NFAT NN NN O
pathway NN NN O
are NN NN O
necessary NN NN O
and NN NN O
sufficient NN NN O
for NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
The NN NN O
activation NN NN O
of NN NN O
both NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
an NN NN O
NFAT NN NN O
- NN NN O
driven NN NN O
minimal NN NN O
promoter NN NN O
were NN NN O
shown NN NN O
to NN NN O
depend NN NN O
on NN NN O
signals NN NN O
transduced NN NN O
by NN NN O
Raf1 NN NN B-Protein
. NN NN O
   
However NN NN O
, NN NN O
it NN NN O
was NN NN O
only NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
whose NN NN O
activation NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
fully NN NN O
blocked NN NN O
by NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
mutant NN NN O
MEK1S218 NN NN O
/ NN NN O
222A NN NN O
and NN NN O
the NN NN O
MEK1 NN NN B-Protein
/ NN NN O
MEK2 NN NN B-Protein
inhibitor NN NN O
PD098059 NN NN O
. NN NN O
   
Since NN NN O
the NN NN O
activation NN NN O
of NN NN O
NFAT NN NN O
is NN NN O
MAPK NN NN O
- NN NN O
dependent NN NN O
these NN NN O
findings NN NN O
suggested NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
MAPK NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
either NN NN O
independent NN NN O
or NN NN O
only NN NN O
partially NN NN O
dependent NN NN O
on NN NN O
MEK1 NN NN B-Protein
and NN NN O
MEK2 NN NN B-Protein
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
they NN NN O
suggested NN NN O
that NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
is NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
not NN NN O
only NN NN O
NFAT NN NN O
but NN NN O
also NN NN O
a NN NN O
second NN NN O
factor NN NN O
whose NN NN O
activation NN NN O
is NN NN O
MEK NN NN O
- NN NN O
dependent NN NN O
. NN NN O
   
Experiments NN NN O
in NN NN O
COS NN NN O
- NN NN O
1 NN NN O
and NN NN O
EL NN NN O
- NN NN O
4 NN NN O
cells NN NN O
confirmed NN NN O
both NN NN O
hypotheses NN NN O
and NN NN O
revealed NN NN O
that NN NN O
the NN NN O
second NN NN O
factor NN NN O
activated NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
While NN NN O
the NN NN O
activation NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
and NN NN O
an NN NN O
NFAT NN NN O
- NN NN O
driven NN NN O
minimal NN NN O
promoter NN NN O
by NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
fully NN NN O
blocked NN NN O
by NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
mutant NN NN O
NFAT NN NN O
delta418 NN NN O
, NN NN O
it NN NN O
was NN NN O
only NN NN O
partially NN NN O
blocked NN NN O
by NN NN O
the NN NN O
calcineurin NN NN O
inhibitor NN NN O
cyclosporin NN NN O
A NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
Tpl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
mediated NN NN O
NFAT NN NN O
activation NN NN O
is NN NN O
under NN NN O
the NN NN O
control NN NN O
of NN NN O
a NN NN O
combination NN NN O
of NN NN O
calcineurin NN NN O
- NN NN O
dependent NN NN O
and NN NN O
independent NN NN O
pathways NN NN O
. NN NN O
   
Both NN NN O
pathways NN NN O
were NN NN O
fully NN NN O
blocked NN NN O
by NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
or NN NN O
Bcl NN NN B-Protein
- NN NN I-Protein
X NN NN I-Protein
( NN NN I-Protein
L NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
Activation NN NN O
of NN NN O
human NN NN O
macrophages NN NN O
by NN NN O
mechanical NN NN O
ventilation NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Positive NN NN O
- NN NN O
pressure NN NN O
mechanical NN NN O
ventilation NN NN O
supports NN NN O
gas NN NN O
exchange NN NN O
in NN NN O
patients NN NN O
with NN NN O
respiratory NN NN O
failure NN NN O
but NN NN O
is NN NN O
also NN NN O
responsible NN NN O
for NN NN O
significant NN NN O
lung NN NN O
injury NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
developed NN NN O
an NN NN O
in NN NN O
vitro NN NN O
model NN NN O
in NN NN O
which NN NN O
isolated NN NN O
lung NN NN O
cells NN NN O
can NN NN O
be NN NN O
submitted NN NN O
to NN NN O
a NN NN O
prolonged NN NN O
cyclic NN NN O
pressure NN NN O
- NN NN O
stretching NN NN O
strain NN NN O
resembling NN NN O
that NN NN O
of NN NN O
conventional NN NN O
mechanical NN NN O
ventilation NN NN O
. NN NN O
   
In NN NN O
this NN NN O
model NN NN O
, NN NN O
cells NN NN O
cultured NN NN O
on NN NN O
a NN NN O
Silastic NN NN O
membrane NN NN O
were NN NN O
elongated NN NN O
up NN NN O
to NN NN O
7 NN NN O
% NN NN O
of NN NN O
their NN NN O
initial NN NN O
diameter NN NN O
, NN NN O
corresponding NN NN O
to NN NN O
a NN NN O
12 NN NN O
% NN NN O
increase NN NN O
in NN NN O
cell NN NN O
surface NN NN O
. NN NN O
   
The NN NN O
lung NN NN O
macrophage NN NN O
was NN NN O
identified NN NN O
as NN NN O
the NN NN O
main NN NN O
cellular NN NN O
source NN NN O
for NN NN O
critical NN NN O
inflammatory NN NN O
mediators NN NN O
such NN NN O
as NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
, NN NN O
the NN NN O
chemokines NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
- NN NN B-Protein
6 NN NN I-Protein
, NN NN O
and NN NN O
matrix NN NN B-Protein
metalloproteinase NN NN I-Protein
- NN NN I-Protein
9 NN NN I-Protein
in NN NN O
this NN NN O
model NN NN O
system NN NN O
of NN NN O
mechanical NN NN O
ventilation NN NN O
. NN NN O
   
These NN NN O
mediators NN NN O
were NN NN O
measured NN NN O
in NN NN O
supernatants NN NN O
from NN NN O
ventilated NN NN O
alveolar NN NN O
macrophages NN NN O
, NN NN O
monocyte NN NN O
- NN NN O
derived NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
promonocytic NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
activated NN NN O
in NN NN O
ventilated NN NN O
macrophages NN NN O
. NN NN O
   
Synergistic NN NN O
proinflammatory NN NN O
effects NN NN O
of NN NN O
mechanical NN NN O
stress NN NN O
and NN NN O
molecules NN NN O
such NN NN O
as NN NN O
bacterial NN NN O
endotoxin NN NN O
were NN NN O
observed NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
mechanical NN NN O
ventilation NN NN O
might NN NN O
be NN NN O
particularly NN NN O
deleterious NN NN O
in NN NN O
preinjured NN NN O
or NN NN O
infected NN NN O
lungs NN NN O
. NN NN O
   
Dexamethasone NN NN O
prevented NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
and NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
secretion NN NN O
in NN NN O
ventilated NN NN O
macrophages NN NN O
. NN NN O
   
Mechanical NN NN O
ventilation NN NN O
induced NN NN O
low NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
secretion NN NN O
by NN NN O
alveolar NN NN O
type NN NN O
II NN NN O
- NN NN O
like NN NN O
cells NN NN O
. NN NN O
   
Other NN NN O
lung NN NN O
cell NN NN O
types NN NN O
such NN NN O
as NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
bronchial NN NN O
cells NN NN O
, NN NN O
and NN NN O
fibroblasts NN NN O
failed NN NN O
to NN NN O
produce NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
in NN NN O
response NN NN O
to NN NN O
a NN NN O
prolonged NN NN O
cyclic NN NN O
pressure NN NN O
- NN NN O
stretching NN NN O
load NN NN O
. NN NN O
   
This NN NN O
model NN NN O
is NN NN O
of NN NN O
particular NN NN O
value NN NN O
for NN NN O
exploring NN NN O
physical NN NN O
stress NN NN O
- NN NN O
induced NN NN O
signaling NN NN O
pathways NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
testing NN NN O
the NN NN O
effects NN NN O
of NN NN O
novel NN NN O
ventilatory NN NN O
strategies NN NN O
or NN NN O
adjunctive NN NN O
substances NN NN O
aimed NN NN O
at NN NN O
modulating NN NN O
cell NN NN O
activation NN NN O
induced NN NN O
by NN NN O
mechanical NN NN O
ventilation NN NN O
. NN NN O
   
Stat6 NN NN B-Protein
inhibits NN NN O
human NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
differentiation NN NN O
of NN NN O
naive NN NN O
T NN NN O
- NN NN O
helper NN NN O
( NN NN O
Th NN NN O
) NN NN O
cells NN NN O
into NN NN O
cytokine NN NN O
- NN NN O
secreting NN NN O
effector NN NN O
Th NN NN O
cells NN NN O
requires NN NN O
exposure NN NN O
to NN NN O
multiple NN NN O
signals NN NN O
, NN NN O
including NN NN O
exogenous NN NN O
cytokines NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
) NN NN O
plays NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
this NN NN O
process NN NN O
by NN NN O
promoting NN NN O
the NN NN O
differentiation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
secreting NN NN O
Th2 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
Th2 NN NN O
cells NN NN O
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
is NN NN O
tightly NN NN O
controlled NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
transcription NN NN O
by NN NN O
the NN NN O
coordinated NN NN O
binding NN NN O
of NN NN O
multiple NN NN O
transcription NN NN O
factors NN NN O
to NN NN O
regulatory NN NN O
elements NN NN O
in NN NN O
the NN NN O
proximal NN NN O
promoter NN NN O
region NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cell NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
family NN NN O
members NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
regulating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
transcription NN NN O
and NN NN O
interact NN NN O
with NN NN O
up NN NN O
to NN NN O
five NN NN O
sequences NN NN O
( NN NN O
termed NN NN O
P0 NN NN O
through NN NN O
P4 NN NN O
) NN NN O
in NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
The NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
induces NN NN O
expression NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
are NN NN O
not NN NN O
known NN NN O
, NN NN O
although NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
- NN NN O
activated NN NN O
transcription NN NN O
factor NN NN O
signal NN NN B-Protein
transducer NN NN I-Protein
and NN NN I-Protein
activator NN NN I-Protein
of NN NN I-Protein
transcription NN NN I-Protein
6 NN NN I-Protein
( NN NN O
Stat6 NN NN B-Protein
) NN NN O
is NN NN O
required NN NN O
for NN NN O
this NN NN O
effect NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
Stat6 NN NN B-Protein
interacts NN NN O
with NN NN O
three NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
These NN NN O
sites NN NN O
overlap NN NN O
the NN NN O
P1 NN NN O
, NN NN O
P2 NN NN O
, NN NN O
and NN NN O
P4 NN NN O
NFAT NN NN O
elements NN NN O
. NN NN O
   
To NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
Stat6 NN NN B-Protein
in NN NN O
regulating NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
transcription NN NN O
, NN NN O
we NN NN O
used NN NN O
Stat6 NN NN B-Protein
- NN NN O
deficient NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
with NN NN O
different NN NN O
intact NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
constructs NN NN O
in NN NN O
cotransfection NN NN O
assays NN NN O
. NN NN O
   
We NN NN O
show NN NN O
that NN NN O
, NN NN O
whereas NN NN O
a NN NN O
multimerized NN NN O
response NN NN O
element NN NN O
from NN NN O
the NN NN O
germline NN NN O
IgE NN NN O
promoter NN NN O
was NN NN O
highly NN NN O
induced NN NN O
by NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
in NN NN O
Stat6 NN NN B-Protein
- NN NN O
expressing NN NN O
Jurkat NN NN O
cells NN NN O
, NN NN O
the NN NN O
intact NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
was NN NN O
repressed NN NN O
under NN NN O
similar NN NN O
conditions NN NN O
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
function NN NN O
of NN NN O
Stat6 NN NN B-Protein
is NN NN O
highly NN NN O
dependent NN NN O
on NN NN O
promoter NN NN O
context NN NN O
and NN NN O
that NN NN O
this NN NN O
factor NN NN O
promotes NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
an NN NN O
indirect NN NN O
manner NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
- NN NN O
beta NN NN O
promoter NN NN O
polymorphisms NN NN O
in NN NN O
allergies NN NN O
and NN NN O
asthma NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
and NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
beta NN NN O
( NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
) NN NN O
are NN NN O
inhibitory NN NN O
for NN NN O
B NN NN O
and NN NN O
T NN NN O
cells NN NN O
, NN NN O
IgE NN NN O
production NN NN O
, NN NN O
and NN NN O
mast NN NN O
cell NN NN O
proliferation NN NN O
, NN NN O
and NN NN O
they NN NN O
induce NN NN O
apoptosis NN NN O
in NN NN O
eosinophils NN NN O
. NN NN O
   
These NN NN O
cytokines NN NN O
are NN NN O
therefore NN NN O
candidate NN NN O
genes NN NN O
which NN NN O
could NN NN O
contribute NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
asthma NN NN O
or NN NN O
allergies NN NN O
. NN NN O
   
We NN NN O
investigated NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
polymorphic NN NN O
nucleotides NN NN O
within NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
and NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
gene NN NN O
promoters NN NN O
would NN NN O
link NN NN O
to NN NN O
the NN NN O
expression NN NN O
of NN NN O
allergies NN NN O
and NN NN O
asthma NN NN O
. NN NN O
   
DNA NN NN O
taken NN NN O
from NN NN O
families NN NN O
with NN NN O
an NN NN O
asthmatic NN NN O
proband NN NN O
was NN NN O
examined NN NN O
for NN NN O
base NN NN O
exchanges NN NN O
by NN NN O
single NN NN O
- NN NN O
stranded NN NN O
conformational NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
. NN NN O
   
We NN NN O
demonstrated NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
gene NN NN O
and NN NN O
four NN NN O
in NN NN O
the NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
gene NN NN O
promoters NN NN O
( NN NN O
3 NN NN O
in NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta1 NN NN I-Protein
and NN NN O
1 NN NN O
in NN NN O
TGF NN NN B-Protein
- NN NN I-Protein
beta2 NN NN I-Protein
) NN NN O
. NN NN O
   
The NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
gene NN NN O
polymorphism NN NN O
was NN NN O
a NN NN O
C NN NN O
- NN NN O
to NN NN O
- NN NN O
A NN NN O
exchange NN NN O
571 NN NN O
base NN NN O
pairs NN NN O
upstream NN NN O
from NN NN O
the NN NN O
translation NN NN O
start NN NN O
site NN NN O
and NN NN O
was NN NN O
present NN NN O
between NN NN O
consensus NN NN O
binding NN NN O
sequences NN NN O
for NN NN O
Sp1 NN NN B-Protein
and NN NN O
elevated NN NN O
total NN NN O
serum NN NN O
. NN NN O
   
This NN NN O
polymorphism NN NN O
was NN NN O
associated NN NN O
with NN NN O
elevated NN NN O
total NN NN O
serum NN NN O
IgE NN NN O
in NN NN O
subjects NN NN O
heterozygotic NN NN O
or NN NN O
homozygotic NN NN O
for NN NN O
this NN NN O
base NN NN O
exchange NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
009 NN NN O
) NN NN O
. NN NN O
   
The NN NN O
base NN NN O
exchange NN NN O
at NN NN O
- NN NN O
509 NN NN O
( NN NN O
from NN NN O
the NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
) NN NN O
in NN NN O
the NN NN O
TGF NN NN O
- NN NN O
beta NN NN O
promoter NN NN O
also NN NN O
linked NN NN O
to NN NN O
elevated NN NN O
total NN NN O
IgE NN NN O
( NN NN O
p NN NN O
< NN NN O
0 NN NN O
. NN NN O
01 NN NN O
) NN NN O
. NN NN O
   
This NN NN O
polymorphism NN NN O
represented NN NN O
a NN NN O
C NN NN O
- NN NN O
to NN NN O
- NN NN O
T NN NN O
base NN NN O
exchange NN NN O
which NN NN O
induced NN NN O
a NN NN O
YY1 NN NN O
consensus NN NN O
sequence NN NN O
and NN NN O
is NN NN O
present NN NN O
in NN NN O
a NN NN O
region NN NN O
of NN NN O
the NN NN O
promoter NN NN O
associated NN NN O
with NN NN O
negative NN NN O
transcription NN NN O
regulation NN NN O
. NN NN O
   
The NN NN O
control NN NN O
of NN NN O
lytic NN NN O
replication NN NN O
of NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
in NN NN O
B NN NN O
lymphocytes NN NN O
( NN NN O
Review NN NN O
) NN NN O
. NN NN O
   
Uncontrolled NN NN O
replication NN NN O
of NN NN O
a NN NN O
virus NN NN O
, NN NN O
which NN NN O
is NN NN O
harmful NN NN O
to NN NN O
the NN NN O
host NN NN O
is NN NN O
also NN NN O
disadvantageous NN NN O
to NN NN O
the NN NN O
virus NN NN O
. NN NN O
   
Most NN NN O
viruses NN NN O
cannot NN NN O
compete NN NN O
with NN NN O
the NN NN O
various NN NN O
immune NN NN O
mechanisms NN NN O
and NN NN O
become NN NN O
eliminated NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
infection NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
only NN NN O
the NN NN O
time NN NN O
between NN NN O
infection NN NN O
and NN NN O
eradication NN NN O
remains NN NN O
for NN NN O
these NN NN O
viruses NN NN O
to NN NN O
proliferate NN NN O
. NN NN O
   
A NN NN O
few NN NN O
viruses NN NN O
, NN NN O
like NN NN O
the NN NN O
Herpesviruses NN NN O
or NN NN O
the NN NN O
papillomaviruses NN NN O
, NN NN O
however NN NN O
, NN NN O
have NN NN O
developed NN NN O
a NN NN O
sophisticated NN NN O
strategy NN NN O
for NN NN O
persisting NN NN O
lifelong NN NN O
, NN NN O
usually NN NN O
asymptomatically NN NN O
in NN NN O
the NN NN O
host NN NN O
, NN NN O
hiding NN NN O
from NN NN O
the NN NN O
immune NN NN O
system NN NN O
and NN NN O
producing NN NN O
infectious NN NN O
progeny NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
. NN NN O
   
This NN NN O
strategy NN NN O
depends NN NN O
on NN NN O
a NN NN O
separation NN NN O
of NN NN O
latency NN NN O
and NN NN O
the NN NN O
lytic NN NN O
replication NN NN O
, NN NN O
either NN NN O
by NN NN O
time NN NN O
due NN NN O
to NN NN O
differentiation NN NN O
- NN NN O
dependent NN NN O
mechanisms NN NN O
or NN NN O
by NN NN O
spatial NN NN O
separation NN NN O
as NN NN O
the NN NN O
result NN NN O
of NN NN O
different NN NN O
host NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
Both NN NN O
are NN NN O
true NN NN O
for NN NN O
the NN NN O
Epstein NN NN O
- NN NN O
Barr NN NN O
virus NN NN O
( NN NN O
EBV NN NN O
) NN NN O
. NN NN O
   
B NN NN O
cells NN NN O
and NN NN O
epithelial NN NN O
cells NN NN O
have NN NN O
a NN NN O
pivotal NN NN O
role NN NN O
in NN NN O
the NN NN O
life NN NN O
cycle NN NN O
of NN NN O
the NN NN O
virus NN NN O
. NN NN O
   
The NN NN O
former NN NN O
can NN NN O
become NN NN O
latently NN NN O
infected NN NN O
and NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
the NN NN O
virus NN NN O
reservoir NN NN O
in NN NN O
vivo NN NN O
, NN NN O
whereas NN NN O
the NN NN O
latter NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
permissive NN NN O
for NN NN O
lytic NN NN O
replication NN NN O
. NN NN O
   
However NN NN O
, NN NN O
replication NN NN O
of NN NN O
EBV NN NN O
in NN NN O
vivo NN NN O
is NN NN O
controlled NN NN O
primarily NN NN O
by NN NN O
host NN NN O
immune NN NN O
mechanisms NN NN O
selecting NN NN O
for NN NN O
cells NN NN O
that NN NN O
are NN NN O
not NN NN O
permissive NN NN O
for NN NN O
viral NN NN O
replication NN NN O
as NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
particular NN NN O
set NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
These NN NN O
factors NN NN O
control NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
regulatory NN NN O
immediate NN NN O
- NN NN O
early NN NN O
genes NN NN O
and NN NN O
, NN NN O
in NN NN O
addition NN NN O
, NN NN O
lytic NN NN O
and NN NN O
latent NN NN O
cycle NN NN O
regulatory NN NN O
genes NN NN O
negatively NN NN O
interfere NN NN O
with NN NN O
each NN NN O
other NN NN O
and NN NN O
thus NN NN O
link NN NN O
cellular NN NN O
and NN NN O
viral NN NN O
gene NN NN O
regulatory NN NN O
mechanisms NN NN O
. NN NN O
   
Disturbance NN NN O
of NN NN O
both NN NN O
the NN NN O
immune NN NN O
surveillance NN NN O
as NN NN O
well NN NN O
as NN NN O
viral NN NN O
gene NN NN O
regulation NN NN O
may NN NN O
result NN NN O
in NN NN O
EBV NN NN O
- NN NN O
associated NN NN O
disease NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
: NN NN O
role NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
untranslated NN NN O
leader NN NN O
region NN NN O
( NN NN O
review NN NN O
) NN NN O
. NN NN O
   
Human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
- NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
transcription NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
interaction NN NN O
of NN NN O
host NN NN O
- NN NN O
cell NN NN O
transcription NN NN O
factors NN NN O
with NN NN O
cis NN NN O
- NN NN O
regulatory NN NN O
DNA NN NN O
elements NN NN O
within NN NN O
the NN NN O
viral NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
. NN NN O
   
Much NN NN O
attention NN NN O
has NN NN O
focused NN NN O
on NN NN O
the NN NN O
series NN NN O
of NN NN O
sequence NN NN O
elements NN NN O
upstream NN NN O
of NN NN O
the NN NN O
transcriptional NN NN O
initiation NN NN O
site NN NN O
in NN NN O
the NN NN O
U3 NN NN O
region NN NN O
of NN NN O
the NN NN O
LTR NN NN O
including NN NN O
the NN NN O
Sp1 NN NN B-Protein
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sites NN NN O
. NN NN O
   
Recent NN NN O
studies NN NN O
, NN NN O
however NN NN O
, NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
transcribed NN NN O
5 NN NN O
' NN NN O
- NN NN O
untranslated NN NN O
leader NN NN O
region NN NN O
( NN NN O
5 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
) NN NN O
also NN NN O
contains NN NN O
important NN NN O
transcriptional NN NN O
elements NN NN O
. NN NN O
   
These NN NN O
regulatory NN NN O
elements NN NN O
situated NN NN O
downstream NN NN O
of NN NN O
transcription NN NN O
interact NN NN O
with NN NN O
constitutive NN NN O
and NN NN O
inducible NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
mediate NN NN O
transmission NN NN O
of NN NN O
cellular NN NN O
activation NN NN O
signals NN NN O
, NN NN O
and NN NN O
are NN NN O
important NN NN O
for NN NN O
efficient NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
and NN NN O
replication NN NN O
. NN NN O
   
The NN NN O
5 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
contains NN NN O
binding NN NN O
sites NN NN O
for NN NN O
the NN NN O
transcription NN NN O
factors NN NN O
AP NN NN O
- NN NN O
1 NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
NF NN NN O
- NN NN O
AT NN NN O
, NN NN O
IRF NN NN O
, NN NN O
and NN NN O
Sp1 NN NN B-Protein
. NN NN O
   
Mutations NN NN O
in NN NN O
these NN NN O
binding NN NN O
sites NN NN O
can NN NN O
interfere NN NN O
with NN NN O
the NN NN O
viral NN NN O
response NN NN O
to NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
, NN NN O
decrease NN NN O
LTR NN NN O
transcription NN NN O
, NN NN O
and NN NN O
inhibit NN NN O
viral NN NN O
replication NN NN O
. NN NN O
   
The NN NN O
5 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
also NN NN O
interacts NN NN O
with NN NN O
a NN NN O
specific NN NN O
nucleosome NN NN O
that NN NN O
is NN NN O
rapidly NN NN O
displaced NN NN O
during NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
the NN NN O
latent NN NN O
provirus NN NN O
. NN NN O
   
We NN NN O
propose NN NN O
that NN NN O
the NN NN O
inducible NN NN O
transcription NN NN O
factor NN NN O
binding NN NN O
sites NN NN O
in NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
comprise NN NN O
a NN NN O
downstream NN NN O
enhancer NN NN O
domain NN NN O
that NN NN O
can NN NN O
function NN NN O
independent NN NN O
of NN NN O
, NN NN O
or NN NN O
in NN NN O
concert NN NN O
with NN NN O
, NN NN O
the NN NN O
LTR NN NN O
promoter NN NN O
to NN NN O
rapidly NN NN O
increase NN NN O
latent NN NN O
proviral NN NN O
transcription NN NN O
in NN NN O
response NN NN O
to NN NN O
cell NN NN O
activation NN NN O
signals NN NN O
. NN NN O
   
In NN NN O
this NN NN O
review NN NN O
, NN NN O
we NN NN O
describe NN NN O
the NN NN O
host NN NN O
- NN NN O
cell NN NN O
transcription NN NN O
factors NN NN O
that NN NN O
interact NN NN O
with NN NN O
the NN NN O
5 NN NN O
' NN NN O
- NN NN O
UTR NN NN O
and NN NN O
discuss NN NN O
their NN NN O
role NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
Molecular NN NN O
cloning NN NN O
of NN NN O
FKHRL1P2 NN NN B-Protein
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
developmentally NN NN O
regulated NN NN O
fork NN NN O
head NN NN O
domain NN NN O
transcription NN NN O
factor NN NN O
family NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
report NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
fork NN NN O
head NN NN O
domain NN NN O
protein NN NN O
in NN NN O
human NN NN O
T NN NN O
helper NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
cloned NN NN O
and NN NN O
characterized NN NN O
a NN NN O
fork NN NN O
head NN NN O
cDNA NN NN O
from NN NN O
human NN NN O
T NN NN O
helper NN NN O
cell NN NN O
mRNA NN NN O
using NN NN O
differential NN NN O
display NN NN O
RT NN NN O
- NN NN O
PCR NN NN O
. NN NN O
   
The NN NN O
cDNA NN NN O
contains NN NN O
a NN NN O
546 NN NN O
- NN NN O
nucleotide NN NN O
( NN NN O
nt NN NN O
) NN NN O
open NN NN O
reading NN NN O
frame NN NN O
( NN NN O
ORF NN NN O
) NN NN O
that NN NN O
codes NN NN O
for NN NN O
the NN NN O
carboxyl NN NN O
- NN NN O
terminal NN NN O
180 NN NN O
amino NN NN O
acids NN NN O
( NN NN O
aa NN NN O
) NN NN O
of NN NN O
the NN NN O
recently NN NN O
identified NN NN O
fkhrl1 NN NN B-Protein
gene NN NN O
. NN NN O
   
This NN NN O
ORF NN NN O
does NN NN O
not NN NN O
contain NN NN O
the NN NN O
characteristic NN NN O
DNA NN NN O
- NN NN O
binding NN NN O
domain NN NN O
found NN NN O
in NN NN O
members NN NN O
of NN NN O
the NN NN O
forkhead NN NN O
protein NN NN O
family NN NN O
. NN NN O
   
In NN NN O
- NN NN O
vitro NN NN O
transcription NN NN O
/ NN NN O
translation NN NN O
of NN NN O
this NN NN O
cDNA NN NN O
expressed NN NN O
a NN NN O
protein NN NN O
of NN NN O
approximately NN NN O
20 NN NN O
kDa NN NN O
. NN NN O
   
We NN NN O
have NN NN O
generated NN NN O
antibodies NN NN O
that NN NN O
specifically NN NN O
immunoprecipitated NN NN O
the NN NN O
in NN NN O
- NN NN O
vitro NN NN O
- NN NN O
translated NN NN O
20 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
. NN NN O
   
This NN NN O
antibody NN NN O
also NN NN O
recognizes NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocytes NN NN O
a NN NN O
70 NN NN O
- NN NN O
kDa NN NN O
protein NN NN O
corresponding NN NN O
in NN NN O
size NN NN O
to NN NN O
that NN NN O
predicted NN NN O
for NN NN O
the NN NN O
fkhrl1 NN NN B-Protein
gene NN NN O
product NN NN O
. NN NN O
   
The NN NN O
mRNA NN NN O
levels NN NN O
for NN NN O
fkhrl1 NN NN B-Protein
is NN NN O
elevated NN NN O
in NN NN O
T NN NN O
helper NN NN O
- NN NN O
induced NN NN O
lymphocytes NN NN O
in NN NN O
comparison NN NN O
to NN NN O
PHA NN NN O
- NN NN O
stimulated NN NN O
T NN NN O
lymphocytes NN NN O
. NN NN O
   
Further NN NN O
characterization NN NN O
of NN NN O
FKHRL1 NN NN B-Protein
and NN NN O
its NN NN O
related NN NN O
family NN NN O
members NN NN O
should NN NN O
shed NN NN O
light NN NN O
on NN NN O
the NN NN O
transcriptional NN NN O
mechanisms NN NN O
of NN NN O
this NN NN O
fork NN NN O
head NN NN O
gene NN NN O
subfamily NN NN O
and NN NN O
their NN NN O
role NN NN O
in NN NN O
T NN NN O
helper NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
regulation NN NN O
of NN NN O
cell NN NN O
growth NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
human NN NN O
delta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
gene NN NN O
promoter NN NN O
in NN NN O
primary NN NN O
adult NN NN O
erythroid NN NN O
cells NN NN O
. NN NN O
   
Restoration NN NN O
of NN NN O
the NN NN O
CCAAT NN NN O
box NN NN O
or NN NN O
insertion NN NN O
of NN NN O
an NN NN O
erythroid NN NN B-Protein
Kruppel NN NN I-Protein
- NN NN I-Protein
like NN NN I-Protein
factor NN NN I-Protein
( NN NN O
EKLF NN NN B-Protein
) NN NN O
binding NN NN O
site NN NN O
in NN NN O
the NN NN O
delta NN NN O
promoter NN NN O
activates NN NN O
its NN NN O
expression NN NN O
in NN NN O
several NN NN O
erythroid NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
We NN NN O
extended NN NN O
these NN NN O
studies NN NN O
using NN NN O
a NN NN O
novel NN NN O
primary NN NN O
human NN NN O
adult NN NN O
erythroid NN NN O
cell NN NN O
( NN NN O
hAEC NN NN O
) NN NN O
system NN NN O
to NN NN O
investigate NN NN O
these NN NN O
effects NN NN O
at NN NN O
the NN NN O
late NN NN O
erythroblast NN NN O
stage NN NN O
. NN NN O
   
Restoration NN NN O
of NN NN O
the NN NN O
CCAAT NN NN O
box NN NN O
at NN NN O
- NN NN O
70 NN NN O
bp NN NN O
, NN NN O
or NN NN O
insertion NN NN O
of NN NN O
an NN NN O
EKLF NN NN B-Protein
binding NN NN O
site NN NN O
at NN NN O
- NN NN O
85 NN NN O
bp NN NN O
or NN NN O
- NN NN O
95 NN NN O
bp NN NN O
in NN NN O
the NN NN O
promoter NN NN O
significantly NN NN O
increased NN NN O
delta NN NN B-Protein
globin NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
hAEC NN NN O
. NN NN O
   
Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
altered NN NN O
CCAAT NN NN O
box NN NN O
( NN NN O
CCAAC NN NN O
) NN NN O
and NN NN O
the NN NN O
lack NN NN O
of NN NN O
an NN NN O
EKLF NN NN B-Protein
binding NN NN O
site NN NN O
in NN NN O
delta NN NN B-Protein
- NN NN I-Protein
globin NN NN I-Protein
contribute NN NN O
to NN NN O
its NN NN O
low NN NN O
level NN NN O
of NN NN O
expression NN NN O
in NN NN O
the NN NN O
hAEC NN NN O
model NN NN O
as NN NN O
well NN NN O
. NN NN O
   
Interactions NN NN O
between NN NN O
the NN NN O
class NN NN B-Protein
II NN NN I-Protein
transactivator NN NN I-Protein
and NN NN O
CREB NN NN B-Protein
binding NN NN I-Protein
protein NN NN I-Protein
increase NN NN O
transcription NN NN O
of NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
class NN NN O
II NN NN O
genes NN NN O
. NN NN O
   
Class NN NN O
II NN NN O
major NN NN O
histocompatibility NN NN O
( NN NN O
class NN NN O
II NN NN O
) NN NN O
genes NN NN O
are NN NN O
regulated NN NN O
in NN NN O
a NN NN O
B NN NN O
- NN NN O
cell NN NN O
- NN NN O
specific NN NN O
and NN NN O
gamma NN NN B-Protein
interferon NN NN I-Protein
- NN NN O
inducible NN NN O
fashion NN NN O
. NN NN O
   
The NN NN O
master NN NN O
switch NN NN O
for NN NN O
the NN NN O
expression NN NN O
of NN NN O
these NN NN O
genes NN NN O
is NN NN O
the NN NN O
class NN NN B-Protein
II NN NN I-Protein
transactivator NN NN I-Protein
( NN NN O
CIITA NN NN B-Protein
) NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
one NN NN O
of NN NN O
the NN NN O
functions NN NN O
of NN NN O
CIITA NN NN B-Protein
is NN NN O
to NN NN O
recruit NN NN O
the NN NN O
CREB NN NN B-Protein
binding NN NN I-Protein
protein NN NN I-Protein
( NN NN O
CBP NN NN B-Protein
) NN NN O
to NN NN O
class NN NN O
II NN NN O
promoters NN NN O
. NN NN O
   
Not NN NN O
only NN NN O
functional NN NN O
but NN NN O
also NN NN O
specific NN NN O
binding NN NN O
interactions NN NN O
between NN NN O
CIITA NN NN B-Protein
and NN NN O
CBP NN NN B-Protein
were NN NN O
demonstrated NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
form NN NN O
of NN NN O
CBP NN NN B-Protein
decreased NN NN O
the NN NN O
activity NN NN O
of NN NN O
class NN NN O
II NN NN O
promoters NN NN O
and NN NN O
levels NN NN O
of NN NN O
class NN NN O
II NN NN O
determinants NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
cells NN NN O
. NN NN O
   
Finally NN NN O
, NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
class NN NN O
II NN NN O
gene NN NN O
expression NN NN O
by NN NN O
the NN NN O
glucocorticoid NN NN O
hormone NN NN O
could NN NN O
be NN NN O
attributed NN NN O
to NN NN O
the NN NN O
squelching NN NN O
of NN NN O
CBP NN NN B-Protein
by NN NN O
the NN NN O
glucocorticoid NN NN B-Protein
receptor NN NN I-Protein
. NN NN O
   
We NN NN O
conclude NN NN O
that NN NN O
CBP NN NN B-Protein
, NN NN O
a NN NN O
histone NN NN O
acetyltransferase NN NN O
, NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
transcription NN NN O
of NN NN O
class NN NN O
II NN NN O
genes NN NN O
. NN NN O
   
Nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
are NN NN O
insufficient NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
: NN NN O
requirement NN NN O
for NN NN O
CD28 NN NN B-Protein
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
RE NN NN O
/ NN NN O
AP NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
gene NN NN O
transcription NN NN O
in NN NN O
T NN NN O
cells NN NN O
requires NN NN O
both NN NN O
TCR NN NN O
and NN NN O
costimulatory NN NN O
signals NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
in NN NN O
Jurkat NN NN O
T NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
superantigen NN NN O
presented NN NN O
by NN NN O
Raji NN NN O
B NN NN O
cells NN NN O
requires NN NN O
CD28 NN NN B-Protein
activation NN NN O
. NN NN O
   
The NN NN O
addition NN NN O
of NN NN O
rCTLA4Ig NN NN O
, NN NN O
which NN NN O
blocks NN NN O
CD28 NN NN B-Protein
binding NN NN O
to NN NN O
its NN NN O
ligand NN NN O
, NN NN O
to NN NN O
the NN NN O
cultures NN NN O
decreased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
by NN NN O
> NN NN O
80 NN NN O
% NN NN O
. NN NN O
   
Interestingly NN NN O
, NN NN O
CTLA4Ig NN NN O
did NN NN O
not NN NN O
significantly NN NN O
inhibit NN NN O
the NN NN O
activation NN NN O
of NN NN O
either NN NN O
NF NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
or NN NN O
AP NN NN O
- NN NN O
1 NN NN O
reporters NN NN O
. NN NN O
   
Therefore NN NN O
, NN NN O
activation NN NN O
of NN NN O
NFAT NN NN O
and NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
insufficient NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
an NN NN O
RE NN NN O
/ NN NN O
AP NN NN O
reporter NN NN O
was NN NN O
blocked NN NN O
by NN NN O
CTLA4Ig NN NN O
by NN NN O
> NN NN O
90 NN NN O
% NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
the NN NN O
requirement NN NN O
for NN NN O
CD28 NN NN B-Protein
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
promoter NN NN O
activation NN NN O
appears NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
RE NN NN O
/ NN NN O
AP NN NN O
and NN NN O
not NN NN O
the NN NN O
NFAT NN NN O
or NN NN O
AP NN NN O
- NN NN O
1 NN NN O
sites NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
transcriptional NN NN O
activation NN NN O
of NN NN O
RE NN NN O
/ NN NN O
AP NN NN O
is NN NN O
not NN NN O
mediated NN NN O
by NN NN O
NFAT NN NN O
, NN NN O
because NN NN O
activation NN NN O
of NN NN O
a NN NN O
NFAT NN NN O
reporter NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
CTLA4Ig NN NN O
. NN NN O
   
Phenylarsine NN NN O
oxide NN NN O
inhibits NN NN O
ex NN NN O
vivo NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
expression NN NN O
. NN NN O
   
Phenylarsine NN NN O
oxide NN NN O
( NN NN O
PAO NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
described NN NN O
as NN NN O
an NN NN O
inhibitor NN NN O
of NN NN O
tyrosine NN NN O
phosphatase NN NN O
activity NN NN O
, NN NN O
inhibits NN NN O
H2O2 NN NN O
release NN NN O
from NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMCs NN NN O
) NN NN O
as NN NN O
measured NN NN O
by NN NN O
electrochemistry NN NN O
. NN NN O
   
Since NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
favored NN NN O
under NN NN O
oxidative NN NN O
stress NN NN O
conditions NN NN O
, NN NN O
ex NN NN O
vivo NN NN O
experiments NN NN O
using NN NN O
uninfected NN NN O
PBMCs NN NN O
, NN NN O
primary NN NN O
monocytes NN NN O
or NN NN O
a NN NN O
latently NN NN O
infected NN NN O
promonocytic NN NN O
U1 NN NN O
cell NN NN O
line NN NN O
show NN NN O
that NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
replication NN NN O
and NN NN O
reactivation NN NN O
, NN NN O
monitored NN NN O
by NN NN O
p24 NN NN B-Protein
antigen NN NN I-Protein
measurement NN NN O
, NN NN O
are NN NN O
inhibited NN NN O
by NN NN O
PAO NN NN O
in NN NN O
a NN NN O
time NN NN O
- NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
These NN NN O
observations NN NN O
can NN NN O
be NN NN O
linked NN NN O
with NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
when NN NN O
uninfected NN NN O
monocytes NN NN O
are NN NN O
induced NN NN O
by NN NN O
either NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
( NN NN O
PMA NN NN O
) NN NN O
or NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
stabilizes NN NN O
inhibitory NN NN B-Protein
kappaB NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
in NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
) NN NN O
protects NN NN O
animals NN NN O
from NN NN O
lethal NN NN O
endotoxemia NN NN O
. NN NN O
   
This NN NN O
beneficial NN NN O
effect NN NN O
is NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
by NN NN O
inhibition NN NN O
of NN NN O
inflammatory NN NN O
cytokine NN NN O
production NN NN O
, NN NN O
including NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
Evidence NN NN O
suggests NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
may NN NN O
inhibit NN NN O
activation NN NN O
of NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
through NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
in NN NN O
response NN NN O
to NN NN O
inflammatory NN NN O
signals NN NN O
is NN NN O
dependent NN NN O
upon NN NN O
degradation NN NN O
of NN NN O
its NN NN O
associated NN NN O
inhibitory NN NN O
peptide NN NN O
, NN NN O
inhibitory NN NN B-Protein
kappaB NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
prevents NN NN O
human NN NN O
monocyte NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
and NN NN O
resultant NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
by NN NN O
stabilization NN NN O
of NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
The NN NN O
purpose NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
the NN NN O
effect NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
on NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
- NN NN O
induced NN NN O
human NN NN O
monocyte NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
and NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
degradation NN NN O
. NN NN O
   
Monocytes NN NN O
were NN NN O
isolated NN NN O
from NN NN O
human NN NN O
donors NN NN O
. NN NN O
   
Cells NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
endotoxin NN NN O
( NN NN O
LPS NN NN O
, NN NN O
100 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
with NN NN O
and NN NN O
without NN NN O
human NN NN O
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
( NN NN O
10 NN NN O
ng NN NN O
/ NN NN O
mL NN NN O
) NN NN O
. NN NN O
   
Following NN NN O
stimulation NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
was NN NN O
measured NN NN O
in NN NN O
cell NN NN O
supernatants NN NN O
by NN NN O
ELISA NN NN O
, NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
by NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assay NN NN O
, NN NN O
and NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
levels NN NN O
by NN NN O
Western NN NN O
blot NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
that NN NN O
after NN NN O
LPS NN NN O
stimulation NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
increased NN NN O
to NN NN O
798 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
67 NN NN O
pg NN NN O
/ NN NN O
mL NN NN O
( NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
versus NN NN O
control NN NN O
) NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
attenuated NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
production NN NN O
( NN NN O
297 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
54 NN NN O
; NN NN O
p NN NN O
< NN NN O
. NN NN O
001 NN NN O
versus NN NN O
LPS NN NN O
alone NN NN O
) NN NN O
. NN NN O
   
After NN NN O
LPS NN NN O
stimulation NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
levels NN NN O
decreased NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
increased NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
pretreatment NN NN O
prevented NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
decreases NN NN O
in NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
levels NN NN O
and NN NN O
attenuated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
DNA NN NN O
binding NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
10 NN NN I-Protein
appears NN NN O
to NN NN O
prevent NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
preserving NN NN O
IkappaB NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
protein NN NN O
levels NN NN O
, NN NN O
leading NN NN O
to NN NN O
a NN NN O
reduction NN NN O
in NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
release NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
fas NN NN B-Protein
- NN NN I-Protein
ligand NN NN I-Protein
expression NN NN O
during NN NN O
activation NN NN O
- NN NN O
induced NN NN O
cell NN NN O
death NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
via NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
receptor NN NN O
engagement NN NN O
activates NN NN O
transcription NN NN O
factors NN NN O
important NN NN O
for NN NN O
cytokine NN NN O
gene NN NN O
regulation NN NN O
. NN NN O
   
Additionally NN NN O
, NN NN O
this NN NN O
signaling NN NN O
pathway NN NN O
also NN NN O
leads NN NN O
to NN NN O
activation NN NN O
- NN NN O
induced NN NN O
apoptosis NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
that NN NN O
is NN NN O
dependent NN NN O
on NN NN O
FasL NN NN B-Protein
transcription NN NN O
and NN NN O
expression NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
many NN NN O
cytokine NN NN O
genes NN NN O
expressed NN NN O
in NN NN O
activated NN NN O
lymphocytes NN NN O
, NN NN O
also NN NN O
plays NN NN O
a NN NN O
role NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
- NN NN O
induced NN NN O
FasL NN NN B-Protein
expression NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
in NN NN O
a NN NN O
T NN NN O
cell NN NN O
hybridoma NN NN O
leads NN NN O
to NN NN O
decreased NN NN O
FasL NN NN B-Protein
expression NN NN O
and NN NN O
apoptosis NN NN O
upon NN NN O
T NN NN O
cell NN NN O
receptor NN NN O
stimulation NN NN O
. NN NN O
   
We NN NN O
identified NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
site NN NN O
in NN NN O
the NN NN O
FasL NN NN B-Protein
promoter NN NN O
that NN NN O
contributes NN NN O
to NN NN O
such NN NN O
regulation NN NN O
. NN NN O
   
Co NN NN O
- NN NN O
expression NN NN O
of NN NN O
p65 NN NN B-Protein
( NN NN O
Rel NN NN B-Protein
A NN NN I-Protein
) NN NN O
with NN NN O
the NN NN O
FasL NN NN B-Protein
promoter NN NN O
enhanced NN NN O
its NN NN O
activity NN NN O
, NN NN O
and NN NN O
co NN NN O
- NN NN O
expression NN NN O
of NN NN O
IkappaB NN NN O
dramatically NN NN O
inhibited NN NN O
the NN NN O
inducible NN NN O
promoter NN NN O
activity NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN O
- NN NN O
1 NN NN O
is NN NN O
not NN NN O
required NN NN O
for NN NN O
activation NN NN O
- NN NN O
induced NN NN O
FasL NN NN B-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
define NN NN O
a NN NN O
role NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
mediating NN NN O
FasL NN NN B-Protein
expression NN NN O
during NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O
   
X NN NN O
- NN NN O
rays NN NN O
- NN NN O
induced NN NN O
secretion NN NN O
of NN NN O
cellular NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
that NN NN O
enhance NN NN O
( NN NN O
s NN NN O
) NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
transcription NN NN O
in NN NN O
various NN NN O
non NN NN O
- NN NN O
irradiated NN NN O
transfected NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Various NN NN O
cellular NN NN O
stress NN NN O
agents NN NN O
like NN NN O
ionizing NN NN O
radiation NN NN O
exposure NN NN O
could NN NN O
activate NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
or NN NN O
reporter NN NN O
gene NN NN O
expression NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
extracellular NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
released NN NN O
by NN NN O
X NN NN O
- NN NN O
ray NN NN O
- NN NN O
treated NN NN O
human NN NN O
colonic NN NN O
carcinoma NN NN O
cell NN NN O
line NN NN O
( NN NN O
HT29 NN NN O
) NN NN O
might NN NN O
activate NN NN O
the NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
in NN NN O
non NN NN O
- NN NN O
irradiated NN NN O
HT29 NN NN O
cells NN NN O
. NN NN O
   
In NN NN O
the NN NN O
present NN NN O
report NN NN O
we NN NN O
show NN NN O
that NN NN O
in NN NN O
various NN NN O
transiently NN NN O
or NN NN O
stably NN NN O
transfected NN NN O
cell NN NN O
lines NN NN O
, NN NN O
X NN NN O
- NN NN O
ray NN NN O
irradiation NN NN O
up NN NN O
- NN NN O
regulates NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
transcription NN NN O
through NN NN O
the NN NN O
kappaB NN NN O
regulatory NN NN O
elements NN NN O
. NN NN O
   
A NN NN O
factor NN NN O
( NN NN O
s NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
processed NN NN O
by NN NN O
and NN NN O
acts NN NN O
upon NN NN O
a NN NN O
variety NN NN O
of NN NN O
cell NN NN O
types NN NN O
, NN NN O
was NN NN O
detected NN NN O
by NN NN O
addition NN NN O
to NN NN O
non NN NN O
- NN NN O
irradiated NN NN O
cells NN NN O
of NN NN O
either NN NN O
X NN NN O
- NN NN O
ray NN NN O
- NN NN O
treated NN NN O
cells NN NN O
or NN NN O
a NN NN O
conditioned NN NN O
medium NN NN O
taken NN NN O
from NN NN O
irradiated NN NN O
cultures NN NN O
. NN NN O
   
The NN NN O
magnitude NN NN O
of NN NN O
responsiveness NN NN O
is NN NN O
cell NN NN O
type NN NN O
dependent NN NN O
. NN NN O
   
In NN NN O
addition NN NN O
, NN NN O
X NN NN O
- NN NN O
ray NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
in NN NN O
transiently NN NN O
or NN NN O
stably NN NN O
transfected NN NN O
cell NN NN O
lines NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
potent NN NN O
antioxidant NN NN O
drug NN NN O
, NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
and NN NN O
by NN NN O
another NN NN O
drug NN NN O
, NN NN O
known NN NN O
for NN NN O
its NN NN O
role NN NN O
in NN NN O
the NN NN O
trapping NN NN O
of NN NN O
growth NN NN O
factors NN NN O
, NN NN O
suramin NN NN O
. NN NN O
   
The NN NN O
importance NN NN O
of NN NN O
these NN NN O
observations NN NN O
in NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
patients NN NN O
with NN NN O
AIDS NN NN O
- NN NN O
related NN NN O
cancers NN NN O
treated NN NN O
by NN NN O
radiotherapy NN NN O
remains NN NN O
to NN NN O
be NN NN O
established NN NN O
. NN NN O
   
Reactivation NN NN O
of NN NN O
Kaposi NN NN O
' NN NN O
s NN NN O
sarcoma NN NN O
- NN NN O
associated NN NN O
herpesvirus NN NN O
infection NN NN O
from NN NN O
latency NN NN O
by NN NN O
expression NN NN O
of NN NN O
the NN NN O
ORF NN NN B-Protein
50 NN NN I-Protein
transactivator NN NN I-Protein
, NN NN O
a NN NN O
homolog NN NN O
of NN NN O
the NN NN O
EBV NN NN B-Protein
R NN NN I-Protein
protein NN NN O
. NN NN O
   
Kaposi NN NN O
' NN NN O
s NN NN O
sarcoma NN NN O
( NN NN O
KS NN NN O
) NN NN O
- NN NN O
associated NN NN O
herpesvirus NN NN O
( NN NN O
KSHV NN NN O
) NN NN O
, NN NN O
or NN NN O
human NN NN O
herpesvirus NN NN O
8 NN NN O
, NN NN O
is NN NN O
a NN NN O
lymphotropic NN NN O
virus NN NN O
strongly NN NN O
linked NN NN O
to NN NN O
several NN NN O
AIDS NN NN O
- NN NN O
related NN NN O
neoplasms NN NN O
. NN NN O
   
The NN NN O
primary NN NN O
reservoir NN NN O
of NN NN O
infection NN NN O
consists NN NN O
of NN NN O
latently NN NN O
infected NN NN O
B NN NN O
lymphocytes NN NN O
and NN NN O
possibly NN NN O
other NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O
   
Viral NN NN O
reactivation NN NN O
from NN NN O
latency NN NN O
and NN NN O
spread NN NN O
from NN NN O
this NN NN O
lymphoid NN NN O
reservoir NN NN O
is NN NN O
presumably NN NN O
required NN NN O
for NN NN O
development NN NN O
of NN NN O
nonlymphoid NN NN O
tumors NN NN O
like NN NN O
KS NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
deregulated NN NN O
expression NN NN O
of NN NN O
a NN NN O
single NN NN O
viral NN NN O
gene NN NN O
, NN NN O
ORF NN NN B-Protein
50 NN NN I-Protein
, NN NN O
which NN NN O
encodes NN NN O
a NN NN O
transactivator NN NN O
able NN NN O
to NN NN O
selectively NN NN O
upregulate NN NN O
delayed NN NN O
- NN NN O
early NN NN O
viral NN NN O
genes NN NN O
, NN NN O
suffices NN NN O
to NN NN O
disrupt NN NN O
latency NN NN O
and NN NN O
induce NN NN O
the NN NN O
lytic NN NN O
gene NN NN O
cascade NN NN O
in NN NN O
latently NN NN O
infected NN NN O
B NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
identification NN NN O
of NN NN O
this NN NN O
gene NN NN O
opens NN NN O
the NN NN O
way NN NN O
to NN NN O
studies NN NN O
of NN NN O
the NN NN O
physiologic NN NN O
mechanisms NN NN O
controlling NN NN O
reactvation NN NN O
of NN NN O
KSHV NN NN O
from NN NN O
latency NN NN O
. NN NN O
   
Copyright NN NN O
1998 NN NN O
Academic NN NN O
Press NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
tax NN NN B-Protein
protein NN NN O
abrogates NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
dependence NN NN O
in NN NN O
a NN NN O
mouse NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
. NN NN O
   
Human NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
is NN NN O
the NN NN O
etiologic NN NN O
agent NN NN O
of NN NN O
adult NN NN O
T NN NN O
- NN NN O
cell NN NN O
leukemia NN NN O
. NN NN O
   
Tax NN NN B-Protein
, NN NN O
the NN NN O
viral NN NN O
protein NN NN O
, NN NN O
is NN NN O
thought NN NN O
to NN NN O
be NN NN O
crucial NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
since NN NN O
it NN NN O
transforms NN NN O
healthy NN NN O
T NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
and NN NN O
induces NN NN O
tumors NN NN O
in NN NN O
transgenic NN NN O
animals NN NN O
. NN NN O
   
We NN NN O
examined NN NN O
the NN NN O
effect NN NN O
of NN NN O
Tax NN NN B-Protein
activity NN NN O
on NN NN O
the NN NN O
growth NN NN O
of NN NN O
the NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
) NN NN O
- NN NN O
dependent NN NN O
T NN NN O
- NN NN O
cell NN NN O
line NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
. NN NN O
   
Stable NN NN O
expression NN NN O
of NN NN O
Tax NN NN B-Protein
in NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
transformed NN NN O
cell NN NN O
growth NN NN O
from NN NN O
being NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
dependent NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
independent NN NN O
. NN NN O
   
Tax NN NN B-Protein
stimulated NN NN O
transcription NN NN O
through NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
the NN NN O
cyclic NN NN O
AMP NN NN O
- NN NN O
responsive NN NN O
element NN NN O
- NN NN O
like NN NN O
sequence NN NN O
in NN NN O
the NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
promoter NN NN O
. NN NN O
   
The NN NN O
finding NN NN O
of NN NN O
Tax NN NN B-Protein
mutants NN NN O
segregating NN NN O
these NN NN O
two NN NN O
pathways NN NN O
suggested NN NN O
that NN NN O
the NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
pathway NN NN O
was NN NN O
essential NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
growth NN NN O
of NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
cells NN NN O
while NN NN O
the NN NN O
CRE NN NN O
pathway NN NN O
was NN NN O
unnecessary NN NN O
. NN NN O
   
However NN NN O
, NN NN O
both NN NN O
pathways NN NN O
were NN NN O
necessary NN NN O
for NN NN O
another NN NN O
transformation NN NN O
- NN NN O
related NN NN O
activity NN NN O
( NN NN O
colony NN NN O
formation NN NN O
in NN NN O
soft NN NN O
agar NN NN O
) NN NN O
of NN NN O
CTLL NN NN O
- NN NN O
2 NN NN O
/ NN NN O
Tax NN NN B-Protein
. NN NN O
   
Our NN NN O
results NN NN O
show NN NN O
that NN NN O
Tax NN NN B-Protein
has NN NN O
at NN NN O
least NN NN O
two NN NN O
distinct NN NN O
activities NN NN O
on NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
suggest NN NN O
that NN NN O
Tax NN NN B-Protein
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
independent NN NN O
T NN NN O
- NN NN O
cell NN NN O
transformation NN NN O
induced NN NN O
by NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
its NN NN O
well NN NN O
- NN NN O
known NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
- NN NN O
dependent NN NN O
cell NN NN O
transformation NN NN O
. NN NN O
   
Regulation NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
synthesis NN NN O
in NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
by NN NN O
C3a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
. NN NN O
   
The NN NN O
anaphylatoxin NN NN O
C3a NN NN B-Protein
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
have NN NN O
immunomodulatory NN NN O
effects NN NN O
on NN NN O
a NN NN O
number NN NN O
of NN NN O
different NN NN O
cell NN NN O
types NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
C3a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
on NN NN O
gene NN NN O
expression NN NN O
and NN NN O
protein NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
in NN NN O
human NN NN O
PBMCs NN NN O
, NN NN O
either NN NN O
alone NN NN O
or NN NN O
in NN NN O
combination NN NN O
with NN NN O
LPS NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
. NN NN O
   
C3a NN NN B-Protein
or NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
alone NN NN O
exhibited NN NN O
no NN NN O
effect NN NN O
on NN NN O
the NN NN O
expression NN NN O
or NN NN O
secretion NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
However NN NN O
, NN NN O
when NN NN O
PBMC NN NN O
were NN NN O
stimulated NN NN O
with NN NN O
LPS NN NN O
or NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
both NN NN O
C3a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
were NN NN O
found NN NN O
to NN NN O
enhance NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
release NN NN O
by NN NN O
PBMC NN NN O
in NN NN O
a NN NN O
dose NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
. NN NN O
   
Since NN NN O
C3a NN NN B-Protein
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
induce NN NN O
PGE2 NN NN O
production NN NN O
by NN NN O
monocytes NN NN O
, NN NN O
and NN NN O
PGE2 NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
influence NN NN O
cytokine NN NN O
production NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
PGE2 NN NN O
in NN NN O
C3a NN NN B-Protein
- NN NN O
mediated NN NN O
enhancement NN NN O
of NN NN O
LPS NN NN O
- NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
- NN NN O
induced NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
. NN NN O
   
Indomethacin NN NN O
blocked NN NN O
PGE2 NN NN O
release NN NN O
, NN NN O
but NN NN O
had NN NN O
no NN NN O
influence NN NN O
on NN NN O
the NN NN O
observed NN NN O
effects NN NN O
of NN NN O
C3a NN NN B-Protein
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
effects NN NN O
of NN NN O
C3a NN NN B-Protein
on NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
production NN NN O
are NN NN O
independent NN NN O
of NN NN O
PGE2 NN NN O
formation NN NN O
by NN NN O
monocytes NN NN O
. NN NN O
   
Northern NN NN O
blot NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
C3a NN NN B-Protein
as NN NN O
well NN NN O
as NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
enhanced NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
mRNA NN NN O
levels NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
6 NN NN I-Protein
. NN NN O
   
Pretreatment NN NN O
of NN NN O
PBMCs NN NN O
with NN NN O
pertussis NN NN O
toxin NN NN O
blocked NN NN O
the NN NN O
functions NN NN O
of NN NN O
C3a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
actions NN NN O
of NN NN O
these NN NN O
two NN NN O
molecules NN NN O
are NN NN O
mediated NN NN O
by NN NN O
a NN NN O
G NN NN O
protein NN NN O
- NN NN O
coupled NN NN O
pathway NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
we NN NN O
investigated NN NN O
the NN NN O
effects NN NN O
of NN NN O
C3a NN NN B-Protein
and NN NN O
C3a NN NN B-Protein
( NN NN I-Protein
desArg NN NN I-Protein
) NN NN I-Protein
on NN NN O
induction NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
activating NN NN O
protein NN NN O
- NN NN O
1 NN NN O
binding NN NN O
. NN NN O
   
Both NN NN O
molecules NN NN O
enhanced NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
activating NN NN O
protein NN NN O
- NN NN O
1 NN NN O
binding NN NN O
activity NN NN O
. NN NN O
   
These NN NN O
results NN NN O
demonstrate NN NN O
the NN NN O
capacity NN NN O
of NN NN O
intact NN NN O
C3a NN NN B-Protein
and NN NN O
its NN NN O
circulating NN NN O
des NN NN O
- NN NN O
Arg NN NN O
form NN NN O
to NN NN O
exert NN NN O
immunmodulatory NN NN O
effects NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
Differential NN NN O
monocyte NN NN O
adhesion NN NN O
and NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
in NN NN O
venous NN NN O
and NN NN O
arterial NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
compared NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
adhesion NN NN O
and NN NN O
adhesion NN NN O
molecule NN NN O
expression NN NN O
in NN NN O
human NN NN O
umbilical NN NN O
venous NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
and NN NN O
arterial NN NN O
( NN NN O
HUAECs NN NN O
) NN NN O
endothelial NN NN O
cells NN NN O
exposed NN NN O
to NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
, NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
TNF NN NN O
and NN NN O
LPS NN NN O
stimulated NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
( NN NN I-Protein
VCAM NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
surface NN NN O
expression NN NN O
and NN NN O
adhesion NN NN O
of NN NN O
U NN NN O
- NN NN O
937 NN NN O
monocyte NN NN O
- NN NN O
like NN NN O
cells NN NN O
to NN NN O
HUVECs NN NN O
but NN NN O
not NN NN O
to NN NN O
HUAECs NN NN O
. NN NN O
   
Antibody NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
in NN NN O
HUVECs NN NN O
at NN NN O
least NN NN O
75 NN NN O
% NN NN O
of NN NN O
the NN NN O
adhesion NN NN O
response NN NN O
is NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mediated NN NN O
. NN NN O
   
Interleukin NN NN O
- NN NN O
1 NN NN O
stimulated NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
surface NN NN O
expression NN NN O
in NN NN O
both NN NN O
HUVECs NN NN O
and NN NN O
HUAECs NN NN O
. NN NN O
   
Pyrrolidinedithiocarbamate NN NN O
and NN NN O
the NN NN O
proteasome NN NN O
inhibitor NN NN O
MG NN NN O
- NN NN O
132 NN NN O
blocked NN NN O
TNF NN NN O
- NN NN O
and NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
U NN NN O
- NN NN O
937 NN NN O
cell NN NN O
adhesion NN NN O
to NN NN O
HUVECs NN NN O
. NN NN O
   
These NN NN O
agents NN NN O
also NN NN O
significantly NN NN O
decreased NN NN O
TNF NN NN O
- NN NN O
and NN NN O
LPS NN NN O
- NN NN O
stimulated NN NN O
increases NN NN O
in NN NN O
HUVEC NN NN O
surface NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
TNF NN NN O
increased NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
protein NN NN O
and NN NN O
mRNA NN NN O
in NN NN O
HUVECs NN NN O
that NN NN O
was NN NN O
blocked NN NN O
by NN NN O
pyrrolidinedithiocarbamate NN NN O
. NN NN O
   
However NN NN O
, NN NN O
neither NN NN O
TNF NN NN O
or NN NN O
LPS NN NN O
stimulated NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
in NN NN O
HUAECs NN NN O
. NN NN O
   
TNF NN NN O
stimulated NN NN O
expression NN NN O
of NN NN O
both NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
in NN NN O
HUVECs NN NN O
, NN NN O
but NN NN O
in NN NN O
HUAECs NN NN O
, NN NN O
only NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
increased NN NN O
. NN NN O
   
Electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
demonstrated NN NN O
no NN NN O
difference NN NN O
in NN NN O
the NN NN O
pattern NN NN O
of NN NN O
TNF NN NN O
- NN NN O
stimulated NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
between NN NN O
HUVECs NN NN O
and NN NN O
HUAECs NN NN O
. NN NN O
   
These NN NN O
studies NN NN O
demonstrate NN NN O
a NN NN O
novel NN NN O
and NN NN O
striking NN NN O
insensitivity NN NN O
of NN NN O
arterial NN NN O
endothelium NN NN O
to NN NN O
the NN NN O
effects NN NN O
of NN NN O
TNF NN NN O
and NN NN O
LPS NN NN O
and NN NN O
indicate NN NN O
a NN NN O
dissociation NN NN O
between NN NN O
the NN NN O
ability NN NN O
of NN NN O
HUAECs NN NN O
to NN NN O
upregulate NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
Tissue NN NN B-Protein
factor NN NN I-Protein
expression NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
is NN NN O
suppressed NN NN O
by NN NN O
lysophosphatidylcholine NN NN O
. NN NN O
   
The NN NN O
expression NN NN O
of NN NN O
tissue NN NN B-Protein
factor NN NN I-Protein
( NN NN O
TF NN NN B-Protein
) NN NN O
, NN NN O
the NN NN O
principal NN NN O
initiator NN NN O
of NN NN O
coagulation NN NN O
, NN NN O
is NN NN O
increased NN NN O
during NN NN O
inflammation NN NN O
and NN NN O
atherosclerosis NN NN O
. NN NN O
   
Both NN NN O
conditions NN NN O
are NN NN O
promoted NN NN O
by NN NN O
lysophosphatidylcholine NN NN O
( NN NN O
lysoPC NN NN O
) NN NN O
. NN NN O
   
We NN NN O
observed NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
that NN NN O
lysoPC NN NN O
( NN NN O
1 NN NN O
to NN NN O
10 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
) NN NN O
dose NN NN O
- NN NN O
dependently NN NN O
reduced NN NN O
TF NN NN B-Protein
activity NN NN O
in NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
as NN NN O
elicited NN NN O
by NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
. NN NN O
   
Lysophosphatidylethanolamine NN NN O
( NN NN O
lysoPE NN NN O
) NN NN O
and NN NN O
other NN NN O
lysophospholipids NN NN O
did NN NN O
not NN NN O
affect NN NN O
LPS NN NN O
- NN NN O
induced NN NN O
TF NN NN B-Protein
activity NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
TF NN NN B-Protein
antigen NN NN O
expression NN NN O
as NN NN O
elicited NN NN O
by NN NN O
LPS NN NN O
was NN NN O
also NN NN O
lowered NN NN O
by NN NN O
lysoPC NN NN O
. NN NN O
   
Phospholipid NN NN O
analyses NN NN O
indicated NN NN O
a NN NN O
selective NN NN O
increase NN NN O
in NN NN O
the NN NN O
lysoPC NN NN O
content NN NN O
of NN NN O
the NN NN O
monocytes NN NN O
after NN NN O
preincubation NN NN O
with NN NN O
the NN NN O
lysophospholipid NN NN O
. NN NN O
   
LysoPC NN NN O
inhibited NN NN O
the NN NN O
TF NN NN B-Protein
activity NN NN O
of NN NN O
Mono NN NN O
Mac NN NN O
- NN NN O
6 NN NN O
cells NN NN O
to NN NN O
a NN NN O
similar NN NN O
extent NN NN O
as NN NN O
in NN NN O
the NN NN O
monocytes NN NN O
. NN NN O
   
LPS NN NN O
binding NN NN O
to NN NN O
plasma NN NN O
membrane NN NN O
receptors NN NN O
and NN NN O
internalization NN NN O
of NN NN O
LPS NN NN O
into NN NN O
monocytes NN NN O
were NN NN O
not NN NN O
affected NN NN O
by NN NN O
lysoPC NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
nuclear NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
/ NN NN O
Rel NN NN O
to NN NN O
a NN NN O
TF NN NN B-Protein
- NN NN O
specific NN NN O
kappaB NN NN O
site NN NN O
was NN NN O
inhibited NN NN O
by NN NN O
lysoPC NN NN O
. NN NN O
   
Induction NN NN O
of NN NN O
TF NN NN B-Protein
mRNA NN NN O
expression NN NN O
by NN NN O
LPS NN NN O
tended NN NN O
to NN NN O
be NN NN O
partially NN NN O
reduced NN NN O
by NN NN O
the NN NN O
lysophospholipid NN NN O
. NN NN O
   
Preincubation NN NN O
with NN NN O
lysoPC NN NN O
increased NN NN O
monocytic NN NN O
cAMP NN NN O
levels NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
adenylyl NN NN O
cyclase NN NN O
by NN NN O
pretreatment NN NN O
with NN NN O
2 NN NN O
' NN NN O
- NN NN O
deoxy NN NN O
- NN NN O
3 NN NN O
' NN NN O
- NN NN O
adenosine NN NN O
monophosphate NN NN O
partially NN NN O
reversed NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
TF NN NN B-Protein
activity NN NN O
promoted NN NN O
by NN NN O
lysoPC NN NN O
. NN NN O
   
In NN NN O
conclusion NN NN O
, NN NN O
lysoPC NN NN O
markedly NN NN O
decreases NN NN O
LPS NN NN O
- NN NN O
mediated NN NN O
TF NN NN B-Protein
expression NN NN O
of NN NN O
human NN NN O
monocytes NN NN O
, NN NN O
the NN NN O
effect NN NN O
probably NN NN O
being NN NN O
mediated NN NN O
by NN NN O
both NN NN O
transcriptional NN NN O
and NN NN O
posttranscriptional NN NN O
mechanisms NN NN O
. NN NN O
   
LysoPC NN NN O
may NN NN O
thus NN NN O
attenuate NN NN O
activation NN NN O
of NN NN O
coagulation NN NN O
during NN NN O
inflammation NN NN O
and NN NN O
atherosclerosis NN NN O
. NN NN O
   
Intranuclear NN NN O
targeted NN NN O
delivery NN NN O
of NN NN O
functional NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
by NN NN O
70 NN NN O
kDa NN NN O
heat NN NN O
shock NN NN O
protein NN NN O
. NN NN O
   
The NN NN O
70 NN NN O
kDa NN NN O
heat NN NN O
shock NN NN O
protein NN NN O
( NN NN O
Hsp70 NN NN O
) NN NN O
is NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
, NN NN O
ubiquitous NN NN O
protein NN NN O
involved NN NN O
in NN NN O
chaperoning NN NN O
proteins NN NN O
to NN NN O
various NN NN O
cellular NN NN O
organelles NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
when NN NN O
added NN NN O
exogenously NN NN O
to NN NN O
cells NN NN O
, NN NN O
Hsp70 NN NN O
is NN NN O
readily NN NN O
imported NN NN O
into NN NN O
both NN NN O
cytoplasmic NN NN O
and NN NN O
nuclear NN NN O
compartments NN NN O
in NN NN O
a NN NN O
cell NN NN O
- NN NN O
type NN NN O
- NN NN O
specific NN NN O
fashion NN NN O
. NN NN O
   
We NN NN O
exploited NN NN O
this NN NN O
ability NN NN O
of NN NN O
Hsp70 NN NN O
to NN NN O
deliver NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
a NN NN O
key NN NN O
transcriptional NN NN O
regulator NN NN O
of NN NN O
inflammatory NN NN O
responses NN NN O
. NN NN O
   
We NN NN O
demonstrate NN NN O
that NN NN O
a NN NN O
fusion NN NN O
protein NN NN O
composed NN NN O
of NN NN O
a NN NN O
C NN NN O
- NN NN O
terminal NN NN O
Hsp70 NN NN O
peptide NN NN O
and NN NN O
the NN NN O
p50 NN NN B-Protein
subunit NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
was NN NN O
directed NN NN O
into NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
cells NN NN O
, NN NN O
could NN NN O
bind NN NN O
DNA NN NN O
specifically NN NN O
, NN NN O
and NN NN O
activated NN NN O
Igkappa NN NN B-Protein
expression NN NN O
and NN NN O
TNFalpha NN NN B-Protein
production NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
propose NN NN O
that NN NN O
Hsp70 NN NN O
can NN NN O
be NN NN O
used NN NN O
as NN NN O
a NN NN O
vehicle NN NN O
for NN NN O
intracytoplasmic NN NN O
and NN NN O
intranuclear NN NN O
delivery NN NN O
of NN NN O
proteins NN NN O
or NN NN O
DNA NN NN O
to NN NN O
modulate NN NN O
gene NN NN O
expression NN NN O
and NN NN O
thereby NN NN O
control NN NN O
immune NN NN O
responses NN NN O
. NN NN O
   
CD2 NN NN O
signalling NN NN O
induces NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN B-Protein
in NN NN O
primary NN NN O
lymphocytes NN NN O
. NN NN O
   
Promoter NN NN O
sequences NN NN O
responsive NN NN O
to NN NN O
cyclic NN NN O
AMP NN NN O
( NN NN O
cAMP NN NN O
) NN NN O
are NN NN O
found NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
cellular NN NN O
genes NN NN O
, NN NN O
and NN NN O
bind NN NN O
transcription NN NN O
factors NN NN O
of NN NN O
the NN NN O
cAMP NN NN B-Protein
response NN NN I-Protein
element NN NN I-Protein
binding NN NN I-Protein
protein NN NN I-Protein
( NN NN O
CREB NN NN B-Protein
) NN NN O
/ NN NN O
activating NN NN B-Protein
transcription NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
family NN NN O
. NN NN O
   
We NN NN O
have NN NN O
used NN NN O
a NN NN O
human NN NN O
T NN NN O
- NN NN O
lymphotropic NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
) NN NN O
model NN NN O
of NN NN O
cAMP NN NN O
response NN NN O
element NN NN O
( NN NN O
CRE NN NN O
) NN NN O
transcription NN NN O
to NN NN O
investigate NN NN O
the NN NN O
influence NN NN O
of NN NN O
lymphocyte NN NN O
activation NN NN O
on NN NN O
transcription NN NN O
from NN NN O
homologous NN NN O
regions NN NN O
in NN NN O
the NN NN O
viral NN NN O
promoter NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
demonstrated NN NN O
increased NN NN O
HTLV NN NN O
- NN NN O
1 NN NN O
transcription NN NN O
following NN NN O
CD2 NN NN B-Protein
but NN NN O
not NN NN O
CD3 NN NN O
receptor NN NN O
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
We NN NN O
hypothesized NN NN O
that NN NN O
this NN NN O
increased NN NN O
viral NN NN O
transcription NN NN O
was NN NN O
mediated NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
through NN NN O
the NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN B-Protein
. NN NN O
   
Therefore NN NN O
, NN NN O
we NN NN O
investigated NN NN O
CD2 NN NN B-Protein
and NN NN O
CD3 NN NN O
receptor NN NN O
- NN NN O
mediated NN NN O
signalling NN NN O
in NN NN O
primary NN NN O
human NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
( NN NN O
PBMC NN NN O
) NN NN O
. NN NN O
   
CD2 NN NN B-Protein
, NN NN O
but NN NN O
not NN NN O
CD3 NN NN O
, NN NN O
cross NN NN O
- NN NN O
linking NN NN O
increased NN NN O
cAMP NN NN O
detected NN NN O
by NN NN O
competitive NN NN O
enzyme NN NN O
- NN NN O
linked NN NN O
immunosorbent NN NN O
assay NN NN O
( NN NN O
ELISA NN NN O
) NN NN O
approximately NN NN O
fourfold NN NN O
. NN NN O
   
CD2 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
concurrently NN NN O
increased NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN B-Protein
detected NN NN O
by NN NN O
immunoblot NN NN O
assay NN NN O
eightfold NN NN O
. NN NN O
   
Consistent NN NN O
with NN NN O
post NN NN O
- NN NN O
translational NN NN O
regulation NN NN O
, NN NN O
no NN NN O
change NN NN O
in NN NN O
total NN NN O
level NN NN O
of NN NN O
CREB NN NN B-Protein
protein NN NN O
was NN NN O
observed NN NN O
. NN NN O
   
Phosphorylation NN NN O
of NN NN O
CREB NN NN B-Protein
occurred NN NN O
through NN NN O
a NN NN O
herbimycin NN NN O
A NN NN O
and NN NN O
Rp NN NN O
- NN NN O
cAMP NN NN O
- NN NN O
sensitive NN NN O
pathway NN NN O
, NN NN O
suggesting NN NN O
phosphorylation NN NN O
required NN NN O
antecedent NN NN O
activation NN NN O
of NN NN O
both NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
( NN NN O
PTK NN NN O
) NN NN O
and NN NN O
protein NN NN O
kinase NN NN O
A NN NN O
( NN NN O
PKA NN NN O
) NN NN O
. NN NN O
   
Both NN NN O
CD2 NN NN B-Protein
and NN NN O
CD3 NN NN O
cross NN NN O
- NN NN O
linking NN NN O
increased NN NN O
binding NN NN O
of NN NN O
nuclear NN NN O
proteins NN NN O
to NN NN O
a NN NN O
radiolabelled NN NN O
CRE NN NN O
oligonucleotide NN NN O
probe NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
suggesting NN NN O
that NN NN O
lymphocyte NN NN O
activation NN NN O
enhances NN NN O
binding NN NN O
independently NN NN O
of NN NN O
phosphorylation NN NN O
of NN NN O
CREB NN NN B-Protein
at NN NN O
serine NN NN O
133 NN NN O
. NN NN O
   
These NN NN O
data NN NN O
indicate NN NN O
specific NN NN O
modulation NN NN O
of NN NN O
the NN NN O
CREB NN NN B-Protein
/ NN NN O
ATF NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
by NN NN O
the NN NN O
CD2 NN NN B-Protein
signalling NN NN O
pathway NN NN O
and NN NN O
suggest NN NN O
CD2 NN NN B-Protein
receptor NN NN I-Protein
modulation NN NN O
of NN NN O
CRE NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
following NN NN O
ligand NN NN O
engagement NN NN O
( NN NN O
e NN NN O
. NN NN O
g NN NN O
. NN NN O
cell NN NN O
- NN NN O
to NN NN O
- NN NN O
cell NN NN O
contact NN NN O
) NN NN O
. NN NN O
   
Anoxia NN NN O
/ NN NN O
reoxygenation NN NN O
- NN NN O
induced NN NN O
tolerance NN NN O
with NN NN O
respect NN NN O
to NN NN O
polymorphonuclear NN NN O
leukocyte NN NN O
adhesion NN NN O
to NN NN O
cultured NN NN O
endothelial NN NN O
cells NN NN O
. NN NN O
   
A NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
- NN NN O
mediated NN NN O
phenomenon NN NN O
. NN NN O
   
Exposing NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
( NN NN O
HUVECs NN NN O
) NN NN O
to NN NN O
anoxia NN NN O
/ NN NN O
reoxygenation NN NN O
( NN NN O
A NN NN O
/ NN NN O
R NN NN O
) NN NN O
results NN NN O
in NN NN O
an NN NN O
increase NN NN O
in NN NN O
polymorphonuclear NN NN O
leukocyte NN NN O
( NN NN O
PMN NN NN O
) NN NN O
adhesion NN NN O
to NN NN O
HUVECs NN NN O
. NN NN O
   
This NN NN O
A NN NN O
/ NN NN O
R NN NN O
- NN NN O
induced NN NN O
hyperadhesion NN NN O
is NN NN O
completely NN NN O
prevented NN NN O
by NN NN O
a NN NN O
previous NN NN O
( NN NN O
24 NN NN O
hours NN NN O
earlier NN NN O
) NN NN O
exposure NN NN O
of NN NN O
HUVECs NN NN O
to NN NN O
A NN NN O
/ NN NN O
R NN NN O
. NN NN O
   
This NN NN O
phenomenon NN NN O
has NN NN O
been NN NN O
termed NN NN O
"""""""" NN NN O
A NN NN O
/ NN NN O
R NN NN O
tolerance NN NN O
. NN NN O
"""""""" NN NN O
Exposing NN NN O
HUVECs NN NN O
to NN NN O
A NN NN O
/ NN NN O
R NN NN O
induces NN NN O
an NN NN O
increase NN NN O
in NN NN O
nuclear NN NN O
factor NN NN O
kappaB NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
in NN NN O
HUVEC NN NN O
nuclei NN NN O
within NN NN O
4 NN NN O
hours NN NN O
. NN NN O
   
Interfering NN NN O
with NN NN O
either NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
( NN NN O
proteasome NN NN O
inhibitor NN NN O
) NN NN O
or NN NN O
translocation NN NN O
( NN NN O
double NN NN O
- NN NN O
stranded NN NN O
oligonucleotides NN NN O
containing NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
binding NN NN O
sequence NN NN O
) NN NN O
prevents NN NN O
the NN NN O
development NN NN O
of NN NN O
A NN NN O
/ NN NN O
R NN NN O
tolerance NN NN O
( NN NN O
ie NN NN O
, NN NN O
the NN NN O
increase NN NN O
in NN NN O
A NN NN O
/ NN NN O
R NN NN O
- NN NN O
induced NN NN O
PMN NN NN O
adhesion NN NN O
to NN NN O
HUVECs NN NN O
is NN NN O
the NN NN O
same NN NN O
after NN NN O
the NN NN O
first NN NN O
and NN NN O
second NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenges NN NN O
) NN NN O
. NN NN O
   
NO NN NN O
production NN NN O
by NN NN O
HUVECs NN NN O
is NN NN O
increased NN NN O
after NN NN O
the NN NN O
second NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenge NN NN O
, NN NN O
but NN NN O
not NN NN O
after NN NN O
the NN NN O
first NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenge NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NO NN NN B-Protein
synthase NN NN I-Protein
( NN NN O
NOS NN NN B-Protein
) NN NN O
during NN NN O
the NN NN O
second NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenge NN NN O
prevents NN NN O
the NN NN O
development NN NN O
of NN NN O
A NN NN O
/ NN NN O
R NN NN O
tolerance NN NN O
with NN NN O
respect NN NN O
to NN NN O
PMN NN NN O
adhesion NN NN O
. NN NN O
   
However NN NN O
, NN NN O
while NN NN O
HUVECs NN NN O
contained NN NN O
endothelial NN NN O
NOS NN NN B-Protein
protein NN NN O
, NN NN O
no NN NN O
inducible NN NN O
NOS NN NN B-Protein
was NN NN O
detected NN NN O
in NN NN O
either NN NN O
tolerant NN NN O
or NN NN O
nontolerant NN NN O
cells NN NN O
. NN NN O
   
Further NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
inhibition NN NN O
of NN NN O
GTP NN NN B-Protein
- NN NN I-Protein
cyclohydrolase NN NN I-Protein
I NN NN I-Protein
( NN NN O
an NN NN O
enzyme NN NN O
involved NN NN O
in NN NN O
de NN NN O
novo NN NN O
synthesis NN NN O
of NN NN O
an NN NN O
important NN NN O
cofactor NN NN O
for NN NN O
NOS NN NN B-Protein
activity NN NN O
, NN NN O
tetrahydrobiopterin NN NN O
) NN NN O
prevented NN NN O
the NN NN O
generation NN NN O
of NN NN O
NO NN NN O
in NN NN O
A NN NN O
/ NN NN O
R NN NN O
- NN NN O
tolerant NN NN O
cells NN NN O
. NN NN O
   
Extracellular NN NN O
generation NN NN O
of NN NN O
NO NN NN O
( NN NN O
NO NN NN O
donor NN NN O
) NN NN O
did NN NN O
not NN NN O
effect NN NN O
the NN NN O
hyperadhesion NN NN O
response NN NN O
induced NN NN O
by NN NN O
the NN NN O
initial NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenge NN NN O
. NN NN O
   
A NN NN O
/ NN NN O
R NN NN O
also NN NN O
induced NN NN O
an NN NN O
oxidant NN NN O
stress NN NN O
in NN NN O
naive NN NN O
HUVECs NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
A NN NN O
/ NN NN O
R NN NN O
- NN NN O
tolerant NN NN O
HUVECs NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NOS NN NN B-Protein
during NN NN O
the NN NN O
second NN NN O
A NN NN O
/ NN NN O
R NN NN O
insult NN NN O
results NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
an NN NN O
oxidant NN NN O
stress NN NN O
similar NN NN O
to NN NN O
that NN NN O
observed NN NN O
after NN NN O
the NN NN O
first NN NN O
A NN NN O
/ NN NN O
R NN NN O
challenge NN NN O
. NN NN O
   
Taken NN NN O
together NN NN O
, NN NN O
the NN NN O
findings NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
A NN NN O
/ NN NN O
R NN NN O
tolerance NN NN O
( NN NN O
with NN NN O
respect NN NN O
to NN NN O
PMN NN NN O
adhesion NN NN O
) NN NN O
, NN NN O
perhaps NN NN O
by NN NN O
transcriptional NN NN O
regulation NN NN O
of NN NN O
GTP NN NN B-Protein
- NN NN I-Protein
cyclohydrolase NN NN I-Protein
. NN NN O
   
The NN NN O
increased NN NN O
NO NN NN O
production NN NN O
during NN NN O
the NN NN O
second NN NN O
A NN NN O
/ NN NN O
R NN NN O
insult NN NN O
reduces NN NN O
PMN NN NN O
adhesion NN NN O
most NN NN O
likely NN NN O
by NN NN O
reducing NN NN O
the NN NN O
intracellular NN NN O
oxidant NN NN O
stress NN NN O
induced NN NN O
by NN NN O
A NN NN O
/ NN NN O
R NN NN O
. NN NN O
   
Role NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
in NN NN O
up NN NN O
- NN NN O
regulation NN NN O
of NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
in NN NN O
normal NN NN O
T NN NN O
cells NN NN O
and NN NN O
aberrant NN NN O
double NN NN O
- NN NN O
negative NN NN O
lpr NN NN O
and NN NN O
gld NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
previously NN NN O
identified NN NN O
a NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
regulatory NN NN O
element NN NN O
( NN NN O
FLRE NN NN O
) NN NN O
in NN NN O
the NN NN O
Fas NN NN B-Protein
ligand NN NN I-Protein
( NN NN O
fasL NN NN B-Protein
) NN NN O
promoter NN NN O
that NN NN O
binds NN NN O
Egr NN NN O
family NN NN O
proteins NN NN O
and NN NN O
demonstrated NN NN O
that NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
( NN NN O
PILOT NN NN B-Protein
) NN NN O
but NN NN O
not NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
NGFI NN NN B-Protein
- NN NN I-Protein
A NN NN I-Protein
, NN NN O
Krox NN NN B-Protein
- NN NN I-Protein
24 NN NN I-Protein
, NN NN O
Tis NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
, NN NN O
and NN NN O
Zif NN NN B-Protein
- NN NN I-Protein
268 NN NN I-Protein
) NN NN O
induces NN NN O
transcription NN NN O
of NN NN O
fasL NN NN B-Protein
. NN NN O
   
The NN NN O
aberrant NN NN O
CD4 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
T NN NN O
cells NN NN O
from NN NN O
lpr NN NN O
/ NN NN O
lpr NN NN O
and NN NN O
gld NN NN O
/ NN NN O
gld NN NN O
mice NN NN O
, NN NN O
which NN NN O
have NN NN O
mutations NN NN O
in NN NN O
the NN NN O
genes NN NN O
encoding NN NN O
Fas NN NN B-Protein
and NN NN O
FasL NN NN B-Protein
, NN NN O
respectively NN NN O
, NN NN O
have NN NN O
an NN NN O
activated NN NN O
phenotype NN NN O
and NN NN O
constitutively NN NN O
express NN NN O
high NN NN O
levels NN NN O
of NN NN O
fasL NN NN B-Protein
mRNA NN NN O
, NN NN O
prompting NN NN O
us NN NN O
to NN NN O
ask NN NN O
what NN NN O
role NN NN O
if NN NN O
any NN NN O
the NN NN O
FLRE NN NN O
and NN NN O
Egr NN NN O
family NN NN O
proteins NN NN O
have NN NN O
in NN NN O
this NN NN O
aberrant NN NN O
expression NN NN O
of NN NN O
fasL NN NN B-Protein
. NN NN O
   
Unstimulated NN NN O
MRL NN NN O
- NN NN O
lpr NN NN O
/ NN NN O
lpr NN NN O
and NN NN O
C3H NN NN O
- NN NN O
gld NN NN O
/ NN NN O
gld NN NN O
CD4 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
T NN NN O
cells NN NN O
constitutively NN NN O
contained NN NN O
high NN NN O
levels NN NN O
of NN NN O
two NN NN O
proteins NN NN O
that NN NN O
bound NN NN O
to NN NN O
the NN NN O
FLRE NN NN O
. NN NN O
   
Supershift NN NN O
analysis NN NN O
revealed NN NN O
these NN NN O
proteins NN NN O
to NN NN O
be NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
( NN NN O
Krox NN NN B-Protein
- NN NN I-Protein
20 NN NN I-Protein
) NN NN O
; NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
was NN NN O
not NN NN O
detected NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
normal NN NN O
lymph NN NN O
node NN NN O
cells NN NN O
resulted NN NN O
in NN NN O
increased NN NN O
expression NN NN O
of NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
, NN NN O
- NN NN B-Protein
2 NN NN I-Protein
, NN NN O
and NN NN O
- NN NN B-Protein
3 NN NN I-Protein
. NN NN O
   
As NN NN O
with NN NN O
egr NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
expression NN NN O
of NN NN O
egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
blocked NN NN O
by NN NN O
cyclosporin NN NN O
A NN NN O
. NN NN O
   
Although NN NN O
overexpressed NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
ineffective NN NN O
, NN NN O
overexpressed NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
was NN NN O
as NN NN O
potent NN NN O
as NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
in NN NN O
inducing NN NN O
fasL NN NN B-Protein
promoter NN NN O
- NN NN O
dependent NN NN O
reporter NN NN O
constructs NN NN O
in NN NN O
T NN NN O
cell NN NN O
hybridomas NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
and NN NN O
both NN NN O
up NN NN O
- NN NN O
regulated NN NN O
endogenous NN NN O
fasL NN NN B-Protein
mRNA NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O
   
FasL NN NN B-Protein
- NN NN O
dependent NN NN O
reporter NN NN O
constructs NN NN O
in NN NN O
MRL NN NN O
- NN NN O
lpr NN NN O
/ NN NN O
lpr NN NN O
and NN NN O
C3H NN NN O
- NN NN O
gld NN NN O
/ NN NN O
gld NN NN O
CD4 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
T NN NN O
cells NN NN O
were NN NN O
constitutively NN NN O
active NN NN O
, NN NN O
and NN NN O
this NN NN O
activity NN NN O
was NN NN O
largely NN NN O
prevented NN NN O
by NN NN O
mutation NN NN O
of NN NN O
the NN NN O
critical NN NN O
Egr NN NN O
family NN NN O
binding NN NN O
element NN NN O
. NN NN O
   
Thus NN NN O
, NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
3 NN NN I-Protein
, NN NN O
regulates NN NN O
FasL NN NN B-Protein
expression NN NN O
in NN NN O
activated NN NN O
normal NN NN O
T NN NN O
cells NN NN O
, NN NN O
and NN NN O
Egr NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
is NN NN O
likely NN NN O
to NN NN O
play NN NN O
a NN NN O
direct NN NN O
role NN NN O
in NN NN O
aberrant NN NN O
fasL NN NN B-Protein
up NN NN O
- NN NN O
regulation NN NN O
in NN NN O
lpr NN NN O
/ NN NN O
lpr NN NN O
and NN NN O
gld NN NN O
/ NN NN O
gld NN NN O
CD4 NN NN B-Protein
( NN NN O
- NN NN O
) NN NN O
CD8 NN NN O
( NN NN O
- NN NN O
) NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
Involvement NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
pathways NN NN O
in NN NN O
interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
production NN NN O
by NN NN O
human NN NN O
monocytes NN NN O
and NN NN O
polymorphonuclear NN NN O
cells NN NN O
stimulated NN NN O
with NN NN O
lipopolysaccharide NN NN O
or NN NN O
Mycoplasma NN NN O
fermentans NN NN O
membrane NN NN O
lipoproteins NN NN O
. NN NN O
   
Interleukin NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
( NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
) NN NN O
is NN NN O
a NN NN O
chemokine NN NN O
that NN NN O
belongs NN NN O
to NN NN O
the NN NN O
alpha NN NN O
- NN NN O
chemokine NN NN O
or NN NN O
CXC NN NN O
subfamily NN NN O
and NN NN O
is NN NN O
produced NN NN O
by NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
human NN NN O
cells NN NN O
, NN NN O
including NN NN O
monocytes NN NN O
and NN NN O
polymorphonuclear NN NN O
cells NN NN O
( NN NN O
PMN NN NN O
) NN NN O
. NN NN O
   
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
is NN NN O
secreted NN NN O
in NN NN O
response NN NN O
to NN NN O
inflammatory NN NN O
stimuli NN NN O
, NN NN O
notably NN NN O
bacterial NN NN O
products NN NN O
such NN NN O
as NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
but NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
these NN NN O
agents NN NN O
mediate NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
induction NN NN O
. NN NN O
   
In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
Mycoplasma NN NN O
fermentans NN NN O
lipid NN NN O
- NN NN O
associated NN NN O
membrane NN NN O
proteins NN NN O
( NN NN O
LAMPf NN NN O
) NN NN O
induce NN NN O
the NN NN O
production NN NN O
of NN NN O
high NN NN O
levels NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
by NN NN O
THP NN NN O
- NN NN O
1 NN NN O
( NN NN O
human NN NN O
monocyte NN NN O
) NN NN O
cells NN NN O
and NN NN O
PMN NN NN O
at NN NN O
the NN NN O
same NN NN O
extent NN NN O
as NN NN O
LPS NN NN O
. NN NN O
   
It NN NN O
was NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
stimulation NN NN O
of NN NN O
monocytic NN NN O
cells NN NN O
with NN NN O
either NN NN O
LPS NN NN O
or NN NN O
LAMPf NN NN O
led NN NN O
to NN NN O
a NN NN O
series NN NN O
of NN NN O
common NN NN O
downstream NN NN O
signaling NN NN O
events NN NN O
, NN NN O
including NN NN O
the NN NN O
activation NN NN O
of NN NN O
protein NN NN O
tyrosine NN NN O
kinase NN NN O
and NN NN O
of NN NN O
mitogen NN NN O
- NN NN O
activated NN NN O
protein NN NN O
kinase NN NN O
cascades NN NN O
. NN NN O
   
By NN NN O
using NN NN O
PD NN NN O
- NN NN O
98059 NN NN O
and NN NN O
SB203580 NN NN O
, NN NN O
two NN NN O
potent NN NN O
and NN NN O
selective NN NN O
inhibitors NN NN O
of NN NN O
MEK1 NN NN B-Protein
( NN NN O
a NN NN O
kinase NN NN O
upstream NN NN O
of NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
and NN NN O
p38 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
we NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
both NN NN O
ERK1 NN NN O
/ NN NN O
2 NN NN O
and NN NN O
p38 NN NN O
cascades NN NN O
play NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
the NN NN O
production NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
8 NN NN I-Protein
by NN NN O
monocytes NN NN O
and NN NN O
PMN NN NN O
stimulated NN NN O
with NN NN O
bacterial NN NN O
fractions NN NN O
. NN NN O
   
T NN NN O
cell NN NN O
priming NN NN O
enhances NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
increasing NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
The NN NN O
repetitive NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
( NN NN O
priming NN NN O
) NN NN O
enhances NN NN O
the NN NN O
expression NN NN O
of NN NN O
many NN NN O
cytokines NN NN O
, NN NN O
such NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
but NN NN O
not NN NN O
others NN NN O
, NN NN O
such NN NN O
as NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
. NN NN O
   
Molecular NN NN O
mechanisms NN NN O
underlying NN NN O
selective NN NN O
expression NN NN O
of NN NN O
cytokines NN NN O
by NN NN O
T NN NN O
cells NN NN O
remain NN NN O
poorly NN NN O
understood NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
priming NN NN O
of NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
selectively NN NN O
enhances NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
expression NN NN O
relative NN NN O
to NN NN O
IL NN NN B-Protein
- NN NN I-Protein
2 NN NN I-Protein
expression NN NN O
by NN NN O
a NN NN O
transcriptional NN NN O
mechanism NN NN O
involving NN NN O
nuclear NN NN O
factor NN NN O
of NN NN O
activated NN NN O
T NN NN O
cells NN NN O
( NN NN O
NFAT NN NN O
) NN NN O
proteins NN NN O
. NN NN O
   
As NN NN O
detected NN NN O
by NN NN O
in NN NN O
vivo NN NN O
footprinting NN NN O
, NN NN O
priming NN NN O
markedly NN NN O
increases NN NN O
the NN NN O
activation NN NN O
- NN NN O
dependent NN NN O
engagement NN NN O
of NN NN O
the NN NN O
P0 NN NN O
and NN NN O
P1 NN NN O
NFAT NN NN O
- NN NN O
binding NN NN O
elements NN NN O
of NN NN O
the NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
. NN NN O
   
Moreover NN NN O
, NN NN O
each NN NN O
proximal NN NN O
P NN NN O
element NN NN O
is NN NN O
essential NN NN O
for NN NN O
optimal NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activity NN NN O
. NN NN O
   
Activated NN NN O
primed NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
contain NN NN O
more NN NN O
NFAT1 NN NN B-Protein
and NN NN O
support NN NN O
greater NN NN O
NFAT NN NN O
- NN NN O
directed NN NN O
transcription NN NN O
than NN NN O
unprimed NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
, NN NN O
while NN NN O
activator NN NN O
protein NN NN O
1 NN NN O
binding NN NN O
and NN NN O
activator NN NN O
protein NN NN O
1 NN NN O
- NN NN O
mediated NN NN O
transcription NN NN O
by NN NN O
both NN NN O
cell NN NN O
types NN NN O
is NN NN O
similar NN NN O
. NN NN O
   
Increased NN NN O
expression NN NN O
of NN NN O
wild NN NN O
- NN NN O
type NN NN O
NFAT1 NN NN B-Protein
substantially NN NN O
increases NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
unprimed NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
, NN NN O
suggesting NN NN O
NFAT1 NN NN B-Protein
may NN NN O
be NN NN O
limiting NN NN O
for NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
in NN NN O
this NN NN O
cell NN NN O
type NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
a NN NN O
truncated NN NN O
form NN NN O
of NN NN O
NFAT1 NN NN B-Protein
acts NN NN O
as NN NN O
a NN NN O
dominant NN NN O
- NN NN O
negative NN NN O
, NN NN O
reducing NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
promoter NN NN O
activity NN NN O
in NN NN O
primed NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
and NN NN O
confirming NN NN O
the NN NN O
importance NN NN O
of NN NN O
endogenous NN NN O
NFAT NN NN O
to NN NN O
increased NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
gene NN NN O
expression NN NN O
by NN NN O
effector NN NN O
T NN NN O
cells NN NN O
. NN NN O
   
NFAT1 NN NN B-Protein
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
major NN NN O
NFAT NN NN O
family NN NN O
member NN NN O
responsible NN NN O
for NN NN O
the NN NN O
initial NN NN O
increased NN NN O
expression NN NN O
of NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
by NN NN O
primed NN NN O
CD4 NN NN B-Protein
T NN NN O
cells NN NN O
. NN NN O
   
Inhibition NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
activation NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
: NN NN O
role NN NN O
of NN NN O
26S NN NN O
proteasome NN NN O
. NN NN O
   
It NN NN O
is NN NN O
becoming NN NN O
increasingly NN NN O
apparent NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
plays NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
inflammatory NN NN O
response NN NN O
. NN NN O
   
Data NN NN O
obtained NN NN O
from NN NN O
studies NN NN O
in NN NN O
our NN NN O
laboratories NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
proteasome NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
inflammatory NN NN O
cascade NN NN O
by NN NN O
regulating NN NN O
the NN NN O
activation NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
. NN NN O
   
Indeed NN NN O
, NN NN O
the NN NN O
availability NN NN O
of NN NN O
selective NN NN O
and NN NN O
orally NN NN O
active NN NN O
proteasome NN NN O
inhibitors NN NN O
should NN NN O
prove NN NN O
useful NN NN O
in NN NN O
delineating NN NN O
the NN NN O
roles NN NN O
of NN NN O
the NN NN O
proteasome NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappa NN NN O
B NN NN O
in NN NN O
other NN NN O
pathophysiological NN NN O
conditions NN NN O
such NN NN O
as NN NN O
cancer NN NN O
and NN NN O
heart NN NN O
disease NN NN O
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
is NN NN O
a NN NN O
critical NN NN O
regulator NN NN O
of NN NN O
human NN NN O
granulocyte NN NN O
apoptosis NN NN O
in NN NN O
vitro NN NN O
. NN NN O
   
During NN NN O
beneficial NN NN O
inflammation NN NN O
, NN NN O
potentially NN NN O
tissue NN NN O
- NN NN O
damaging NN NN O
granulocytes NN NN O
undergo NN NN O
apoptosis NN NN O
before NN NN O
being NN NN O
cleared NN NN O
by NN NN O
phagocytes NN NN O
in NN NN O
a NN NN O
non NN NN O
- NN NN O
phlogistic NN NN O
manner NN NN O
. NN NN O
   
Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
rate NN NN O
of NN NN O
constitutive NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
neutrophils NN NN O
and NN NN O
eosinophils NN NN O
is NN NN O
greatly NN NN O
accelerated NN NN O
in NN NN O
both NN NN O
a NN NN O
rapid NN NN O
and NN NN O
concentration NN NN O
- NN NN O
dependent NN NN O
manner NN NN O
by NN NN O
the NN NN O
fungal NN NN O
metabolite NN NN O
gliotoxin NN NN O
, NN NN O
but NN NN O
not NN NN O
by NN NN O
its NN NN O
inactive NN NN O
analog NN NN O
methylthiogliotoxin NN NN O
. NN NN O
   
This NN NN O
induction NN NN O
of NN NN O
apoptosis NN NN O
was NN NN O
abolished NN NN O
by NN NN O
the NN NN O
caspase NN NN O
inhibitor NN NN O
zVAD NN NN O
- NN NN O
fmk NN NN O
, NN NN O
correlated NN NN O
with NN NN O
the NN NN O
inhibition NN NN O
of NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappa NN NN O
B NN NN O
( NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
) NN NN O
, NN NN O
and NN NN O
was NN NN O
mimicked NN NN O
by NN NN O
a NN NN O
cell NN NN O
permeable NN NN O
inhibitory NN NN O
peptide NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
SN NN NN O
- NN NN O
50 NN NN O
; NN NN O
other NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
inhibitors NN NN O
, NN NN O
curcumin NN NN O
and NN NN O
pyrrolidine NN NN O
dithiocarbamate NN NN O
; NN NN O
and NN NN O
the NN NN O
proteasome NN NN O
inhibitor NN NN O
, NN NN O
MG NN NN O
- NN NN O
132 NN NN O
. NN NN O
   
Gliotoxin NN NN O
also NN NN O
augmented NN NN O
dramatically NN NN O
the NN NN O
early NN NN O
( NN NN O
2 NN NN O
- NN NN O
6 NN NN O
h NN NN O
) NN NN O
pro NN NN O
- NN NN O
apoptotic NN NN O
effects NN NN O
of NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alpha NN NN I-Protein
( NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
) NN NN O
in NN NN O
neutrophils NN NN O
and NN NN O
unmasked NN NN O
the NN NN O
ability NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
to NN NN O
induce NN NN O
eosinophil NN NN O
apoptosis NN NN O
. NN NN O
   
In NN NN O
neutrophils NN NN O
, NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
caused NN NN O
a NN NN O
gliotoxin NN NN O
- NN NN O
inhibitable NN NN O
activation NN NN O
of NN NN O
an NN NN O
inducible NN NN O
form NN NN O
of NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
, NN NN O
a NN NN O
response NN NN O
that NN NN O
may NN NN O
underlie NN NN O
the NN NN O
ability NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
to NN NN O
delay NN NN O
apoptosis NN NN O
at NN NN O
later NN NN O
times NN NN O
( NN NN O
12 NN NN O
- NN NN O
24 NN NN O
h NN NN O
) NN NN O
and NN NN O
limit NN NN O
its NN NN O
early NN NN O
killing NN NN O
effect NN NN O
. NN NN O
   
Furthermore NN NN O
, NN NN O
cycloheximide NN NN O
displayed NN NN O
a NN NN O
similar NN NN O
capacity NN NN O
to NN NN O
enhance NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
induced NN NN O
neutrophil NN NN O
apoptosis NN NN O
even NN NN O
at NN NN O
time NN NN O
points NN NN O
when NN NN O
cycloheximide NN NN O
alone NN NN O
had NN NN O
no NN NN O
pro NN NN O
- NN NN O
apoptotic NN NN O
effect NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
may NN NN O
regulate NN NN O
the NN NN O
production NN NN O
of NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
which NN NN O
protect NN NN O
neutrophils NN NN O
from NN NN O
the NN NN O
cytotoxic NN NN O
effects NN NN O
of NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
. NN NN O
   
These NN NN O
data NN NN O
shed NN NN O
light NN NN O
on NN NN O
the NN NN O
biochemical NN NN O
and NN NN O
molecular NN NN O
mechanisms NN NN O
regulating NN NN O
human NN NN O
granulocyte NN NN O
apoptosis NN NN O
and NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
indicate NN NN O
that NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
regulating NN NN O
the NN NN O
physiological NN NN O
cell NN NN O
death NN NN O
pathway NN NN O
in NN NN O
granulocytes NN NN O
. NN NN O
   
Lactobacilli NN NN O
and NN NN O
vaginal NN NN O
host NN NN O
defense NN NN O
: NN NN O
activation NN NN O
of NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
, NN NN O
cytokine NN NN O
production NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
. NN NN O
   
Lactobacilli NN NN O
, NN NN O
a NN NN O
component NN NN O
of NN NN O
the NN NN O
normal NN NN O
vaginal NN NN O
flora NN NN O
, NN NN O
can NN NN O
activate NN NN O
the NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
( NN NN O
HIV NN NN O
) NN NN O
- NN NN O
1 NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
in NN NN O
the NN NN O
Jurkat NN NN O
T NN NN O
lymphocyte NN NN O
and NN NN O
THP NN NN O
- NN NN O
1 NN NN O
macrophage NN NN O
cell NN NN O
lines NN NN O
. NN NN O
   
Activation NN NN O
of NN NN O
the NN NN O
LTR NN NN O
in NN NN O
Jurkat NN NN O
cells NN NN O
was NN NN O
strongly NN NN O
enhanced NN NN O
by NN NN O
vanadate NN NN O
and NN NN O
inhibited NN NN O
by NN NN O
catalase NN NN B-Protein
, NN NN O
implicating NN NN O
H2O2 NN NN O
. NN NN O
   
In NN NN O
contrast NN NN O
, NN NN O
activation NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
occurred NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
vanadate NN NN O
and NN NN O
was NN NN O
unaffected NN NN O
by NN NN O
catalase NN NN B-Protein
. NN NN O
   
The NN NN O
active NN NN O
material NN NN O
partitioned NN NN O
into NN NN O
the NN NN O
phenol NN NN O
layer NN NN O
on NN NN O
hot NN NN O
aqueous NN NN O
phenol NN NN O
extraction NN NN O
. NN NN O
   
Lactobacilli NN NN O
also NN NN O
increased NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alphaand NN NN I-Protein
interleukin NN NN B-Protein
- NN NN I-Protein
1betaproduction NN NN I-Protein
and NN NN O
activated NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
THP NN NN O
- NN NN O
1 NN NN O
cells NN NN O
and NN NN O
increased NN NN O
tumor NN NN B-Protein
necrosis NN NN I-Protein
factor NN NN I-Protein
- NN NN I-Protein
alphaproduction NN NN I-Protein
by NN NN O
human NN NN O
monocytes NN NN O
. NN NN O
   
Human NN NN O
vaginal NN NN O
fluid NN NN O
specimens NN NN O
had NN NN O
comparable NN NN O
properties NN NN O
, NN NN O
which NN NN O
correlated NN NN O
with NN NN O
their NN NN O
bacterial NN NN O
content NN NN O
. NN NN O
   
These NN NN O
findings NN NN O
suggest NN NN O
the NN NN O
presence NN NN O
in NN NN O
vaginal NN NN O
fluid NN NN O
of NN NN O
agent NN NN O
( NN NN O
s NN NN O
) NN NN O
derived NN NN O
from NN NN O
indigenous NN NN O
bacteria NN NN O
that NN NN O
can NN NN O
activate NN NN O
the NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
LTR NN NN O
, NN NN O
cytokine NN NN O
production NN NN O
, NN NN O
and NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
in NN NN O
cells NN NN O
of NN NN O
macrophage NN NN O
lineage NN NN O
, NN NN O
with NN NN O
possible NN NN O
influence NN NN O
on NN NN O
vaginal NN NN O
physiology NN NN O
and NN NN O
host NN NN O
defense NN NN O
. NN NN O
   
High NN NN O
- NN NN O
level NN NN O
replication NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
in NN NN O
thymocytes NN NN O
requires NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
through NN NN O
interaction NN NN O
with NN NN O
thymic NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O
   
We NN NN O
have NN NN O
previously NN NN O
demonstrated NN NN O
that NN NN O
interaction NN NN O
of NN NN O
infected NN NN O
thymocytes NN NN O
with NN NN O
autologous NN NN O
thymic NN NN O
epithelial NN NN O
cells NN NN O
( NN NN O
TEC NN NN O
) NN NN O
is NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
human NN NN O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 NN NN O
( NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
) NN NN O
replication NN NN O
in NN NN O
thymocytes NN NN O
( NN NN O
M NN NN O
. NN NN O
Rothe NN NN O
, NN NN O
L NN NN O
. NN NN O
Chene NN NN O
, NN NN O
M NN NN O
. NN NN O
Nugeyre NN NN O
, NN NN O
F NN NN O
. NN NN O
Barre NN NN O
- NN NN O
Sinoussi NN NN O
, NN NN O
and NN NN O
N NN NN O
. NN NN O
Israel NN NN O
, NN NN O
J NN NN O
. NN NN O
Virol NN NN O
. NN NN O
72 NN NN O
: NN NN O
5852 NN NN O
- NN NN O
5861 NN NN O
, NN NN O
1998 NN NN O
) NN NN O
. NN NN O
   
We NN NN O
report NN NN O
here NN NN O
that NN NN O
this NN NN O
activation NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
takes NN NN O
place NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
through NN NN O
activation NN NN O
of NN NN O
the NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
transcription NN NN O
factors NN NN O
. NN NN O
   
We NN NN O
first NN NN O
demonstrate NN NN O
that NN NN O
an NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
provirus NN NN O
( NN NN O
SF NN NN O
- NN NN O
2 NN NN O
strain NN NN O
) NN NN O
very NN NN O
effectively NN NN O
replicates NN NN O
in NN NN O
thymocytes NN NN O
cocultured NN NN O
with NN NN O
TEC NN NN O
whereas NN NN O
this NN NN O
provirus NN NN O
, NN NN O
with NN NN O
kappaB NN NN O
sites NN NN O
deleted NN NN O
, NN NN O
fails NN NN O
to NN NN O
replicate NN NN O
. NN NN O
   
We NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
several NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
complexes NN NN O
are NN NN O
constitutively NN NN O
found NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
thymocytes NN NN O
either NN NN O
freshly NN NN O
isolated NN NN O
from NN NN O
the NN NN O
thymus NN NN O
or NN NN O
maintained NN NN O
in NN NN O
coculture NN NN O
with NN NN O
autologous NN NN O
or NN NN O
heterologous NN NN O
TEC NN NN O
. NN NN O
   
The NN NN O
prevalent NN NN O
complex NN NN O
is NN NN O
the NN NN O
heterodimer NN NN O
p50 NN NN B-Protein
- NN NN O
p65 NN NN B-Protein
. NN NN O
   
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
is NN NN O
tightly NN NN O
correlated NN NN O
with NN NN O
the NN NN O
transcriptional NN NN O
activity NN NN O
of NN NN O
a NN NN O
long NN NN O
terminal NN NN O
repeat NN NN O
( NN NN O
LTR NN NN O
) NN NN O
of NN NN O
HIV NN NN O
- NN NN O
1 NN NN O
transfected NN NN O
in NN NN O
thymocytes NN NN O
. NN NN O
   
The NN NN O
cotransfection NN NN O
of NN NN O
this NN NN O
LTR NN NN O
with NN NN O
a NN NN O
mutated NN NN O
IkappaBalpha NN NN B-Protein
molecule NN NN O
formally NN NN O
demonstrates NN NN O
that NN NN O
LTR NN NN O
transactivation NN NN O
is NN NN O
regulated NN NN O
by NN NN O
members NN NN O
of NN NN O
the NN NN O
Rel NN NN O
/ NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
family NN NN O
in NN NN O
thymocytes NN NN O
. NN NN O
   
We NN NN O
also NN NN O
showed NN NN O
that NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
( NN NN O
TNF NN NN O
) NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
interleukin NN NN O
- NN NN O
1 NN NN O
( NN NN O
IL NN NN O
- NN NN O
1 NN NN O
) NN NN O
, NN NN O
secreted NN NN O
within NN NN O
the NN NN O
coculture NN NN O
, NN NN O
induce NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activity NN NN O
and NN NN O
a NN NN O
correlative NN NN O
LTR NN NN O
transactivation NN NN O
. NN NN O
   
However NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
, NN NN O
a NN NN O
crucial NN NN O
factor NN NN O
for NN NN O
thymopoiesis NN NN O
that NN NN O
is NN NN O
secreted NN NN O
mainly NN NN O
by NN NN O
TEC NN NN O
, NN NN O
is NN NN O
a NN NN O
necessary NN NN O
cofactor NN NN O
for NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
elicited NN NN O
by NN NN O
TNF NN NN O
or NN NN O
IL NN NN O
- NN NN O
1 NN NN O
. NN NN O
   
Together NN NN O
, NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
NF NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
, NN NN O
required NN NN O
for NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
HIV NN NN O
replication NN NN O
in NN NN O
thymocytes NN NN O
, NN NN O
is NN NN O
regulated NN NN O
in NN NN O
a NN NN O
specific NN NN O
manner NN NN O
in NN NN O
the NN NN O
thymic NN NN O
microenvironment NN NN O
which NN NN O
provides NN NN O
the NN NN O
necessary NN NN O
cytokines NN NN O
: NN NN O
TNF NN NN O
, NN NN O
IL NN NN O
- NN NN O
1 NN NN O
, NN NN O
and NN NN O
IL NN NN B-Protein
- NN NN I-Protein
7 NN NN I-Protein
. NN NN O
   
Cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD44 NN NN B-Protein
on NN NN O
rheumatoid NN NN O
synovial NN NN O
cells NN NN O
up NN NN O
- NN NN O
regulates NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
. NN NN O
   
CD44 NN NN B-Protein
is NN NN O
a NN NN O
ubiquitous NN NN O
molecule NN NN O
also NN NN O
known NN NN O
as NN NN O
hyaluronic NN NN O
acid NN NN O
or NN NN O
homing NN NN O
receptor NN NN O
. NN NN O
   
However NN NN O
, NN NN O
the NN NN O
cellular NN NN O
functions NN NN O
and NN NN O
its NN NN O
role NN NN O
in NN NN O
inflammation NN NN O
, NN NN O
for NN NN O
example NN NN O
, NN NN O
rheumatoid NN NN O
synovitis NN NN O
, NN NN O
are NN NN O
currently NN NN O
unknown NN NN O
. NN NN O
   
In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
propose NN NN O
a NN NN O
novel NN NN O
function NN NN O
for NN NN O
CD44 NN NN B-Protein
. NN NN O
   
Using NN NN O
synovial NN NN O
cells NN NN O
from NN NN O
rheumatoid NN NN O
arthritis NN NN O
( NN NN O
RA NN NN O
) NN NN O
patients NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
CD44 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
and NN NN O
binding NN NN O
to NN NN O
hyaluronan NN NN O
augmented NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
subsequently NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
cell NN NN O
adhesion NN NN O
. NN NN O
   
Briefly NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
1 NN NN O
) NN NN O
rheumatoid NN NN O
synovial NN NN O
cells NN NN O
highly NN NN O
expressed NN NN O
CD44 NN NN B-Protein
; NN NN O
2 NN NN O
) NN NN O
cross NN NN O
- NN NN O
linking NN NN O
of NN NN O
CD44 NN NN B-Protein
markedly NN NN O
but NN NN O
transiently NN NN O
augmented NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
its NN NN O
mRNA NN NN O
transcription NN NN O
much NN NN O
more NN NN O
than NN NN O
did NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
and NN NN O
TNF NN NN B-Protein
- NN NN I-Protein
alpha NN NN I-Protein
; NN NN O
3 NN NN O
) NN NN O
hyaluronan NN NN O
, NN NN O
especially NN NN O
when NN NN O
fragmented NN NN O
, NN NN O
also NN NN O
up NN NN O
- NN NN O
regulated NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
; NN NN O
4 NN NN O
) NN NN O
CD44 NN NN B-Protein
activated NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
AP NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
; NN NN O
and NN NN O
5 NN NN O
) NN NN O
the NN NN O
integrin NN NN O
- NN NN O
dependent NN NN O
adhesive NN NN O
function NN NN O
of NN NN O
RA NN NN O
synovial NN NN O
cells NN NN O
to NN NN O
T NN NN O
cells NN NN O
was NN NN O
also NN NN O
amplified NN NN O
by NN NN O
CD44 NN NN B-Protein
cross NN NN O
- NN NN O
linking NN NN O
. NN NN O
   
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
adhesion NN NN O
of NN NN O
RA NN NN O
synovial NN NN O
cells NN NN O
to NN NN O
matrices NN NN O
such NN NN O
as NN NN O
hyaluronic NN NN O
acid NN NN O
through NN NN O
CD44 NN NN B-Protein
could NN NN O
up NN NN O
- NN NN O
regulate NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
and NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
- NN NN O
mediated NN NN O
adhesion NN NN O
to NN NN O
T NN NN O
cells NN NN O
, NN NN O
which NN NN O
might NN NN O
in NN NN O
turn NN NN O
cause NN NN O
activation NN NN O
of NN NN O
T NN NN O
cells NN NN O
and NN NN O
synovial NN NN O
cells NN NN O
in NN NN O
RA NN NN O
synovitis NN NN O
. NN NN O
   
We NN NN O
therefore NN NN O
propose NN NN O
that NN NN O
such NN NN O
cross NN NN O
- NN NN O
talking NN NN O
among NN NN O
distinct NN NN O
adhesion NN NN O
molecules NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
inflammation NN NN O
, NN NN O
including NN NN O
RA NN NN O
synovitis NN NN O
. NN NN O
   
Oleic NN NN O
acid NN NN O
inhibits NN NN O
endothelial NN NN O
activation NN NN O
: NN NN O
A NN NN O
direct NN NN O
vascular NN NN O
antiatherogenic NN NN O
mechanism NN NN O
of NN NN O
a NN NN O
nutritional NN NN O
component NN NN O
in NN NN O
the NN NN O
mediterranean NN NN O
diet NN NN O
. NN NN O
   
Because NN NN O
oleic NN NN O
acid NN NN O
is NN NN O
implicated NN NN O
in NN NN O
the NN NN O
antiatherogenic NN NN O
effects NN NN O
attributed NN NN O
to NN NN O
the NN NN O
Mediterranean NN NN O
diet NN NN O
, NN NN O
we NN NN O
investigated NN NN O
whether NN NN O
this NN NN O
fatty NN NN O
acid NN NN O
can NN NN O
modulate NN NN O
endothelial NN NN O
activation NN NN O
, NN NN O
ie NN NN O
, NN NN O
the NN NN O
concerted NN NN O
expression NN NN O
of NN NN O
gene NN NN O
products NN NN O
involved NN NN O
in NN NN O
leukocyte NN NN O
recruitment NN NN O
and NN NN O
early NN NN O
atherogenesis NN NN O
. NN NN O
   
We NN NN O
incubated NN NN O
sodium NN NN O
oleate NN NN O
with NN NN O
human NN NN O
umbilical NN NN O
vein NN NN O
endothelial NN NN O
cells NN NN O
for NN NN O
0 NN NN O
to NN NN O
72 NN NN O
hours NN NN O
, NN NN O
followed NN NN O
by NN NN O
coincubation NN NN O
of NN NN O
oleate NN NN O
with NN NN O
human NN NN O
recombinant NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
, NN NN O
interleukin NN NN B-Protein
( NN NN I-Protein
IL NN NN I-Protein
) NN NN I-Protein
- NN NN I-Protein
1alpha NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
1beta NN NN I-Protein
, NN NN O
IL NN NN B-Protein
- NN NN I-Protein
4 NN NN I-Protein
, NN NN O
Escherichia NN NN O
coli NN NN O
lipopolysaccharide NN NN O
( NN NN O
LPS NN NN O
) NN NN O
, NN NN O
or NN NN O
phorbol NN NN O
12 NN NN O
- NN NN O
myristate NN NN O
13 NN NN O
- NN NN O
acetate NN NN O
for NN NN O
a NN NN O
further NN NN O
6 NN NN O
to NN NN O
24 NN NN O
hours NN NN O
. NN NN O
   
The NN NN O
endothelial NN NN O
expression NN NN O
of NN NN O
vascular NN NN B-Protein
cell NN NN I-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
( NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
) NN NN O
, NN NN O
E NN NN B-Protein
- NN NN I-Protein
selectin NN NN I-Protein
, NN NN O
and NN NN O
intercellular NN NN B-Protein
adhesion NN NN I-Protein
molecule NN NN I-Protein
- NN NN I-Protein
1 NN NN I-Protein
was NN NN O
monitored NN NN O
by NN NN O
cell NN NN O
surface NN NN O
enzyme NN NN O
immunoassays NN NN O
or NN NN O
flow NN NN O
cytometry NN NN O
, NN NN O
and NN NN O
steady NN NN O
- NN NN O
state NN NN O
levels NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
were NN NN O
assessed NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O
   
At NN NN O
10 NN NN O
to NN NN O
100 NN NN O
micromol NN NN O
/ NN NN O
L NN NN O
for NN NN O
> NN NN O
24 NN NN O
hours NN NN O
, NN NN O
oleate NN NN O
inhibited NN NN O
the NN NN O
expression NN NN O
of NN NN O
all NN NN O
adhesion NN NN O
molecules NN NN O
tested NN NN O
. NN NN O
   
After NN NN O
a NN NN O
72 NN NN O
- NN NN O
hour NN NN O
incubation NN NN O
with NN NN O
oleate NN NN O
and NN NN O
a NN NN O
further NN NN O
16 NN NN O
- NN NN O
hour NN NN O
incubation NN NN O
with NN NN O
oleate NN NN O
plus NN NN O
1 NN NN O
microg NN NN O
/ NN NN O
mL NN NN O
LPS NN NN O
, NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
expression NN NN O
was NN NN O
reduced NN NN O
by NN NN O
> NN NN O
40 NN NN O
% NN NN O
compared NN NN O
with NN NN O
control NN NN O
. NN NN O
   
Adhesion NN NN O
of NN NN O
monocytoid NN NN O
U937 NN NN O
cells NN NN O
to NN NN O
LPS NN NN O
- NN NN O
treated NN NN O
endothelial NN NN O
cells NN NN O
was NN NN O
reduced NN NN O
concomitantly NN NN O
. NN NN O
   
Oleate NN NN O
also NN NN O
produced NN NN O
a NN NN O
quantitatively NN NN O
similar NN NN O
reduction NN NN O
of NN NN O
VCAM NN NN B-Protein
- NN NN I-Protein
1 NN NN I-Protein
mRNA NN NN O
levels NN NN O
on NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
and NN NN O
inhibited NN NN O
nuclear NN NN O
factor NN NN O
- NN NN O
kappaB NN NN O
activation NN NN O
on NN NN O
electrophoretic NN NN O
mobility NN NN O
shift NN NN O
assays NN NN O
. NN NN O
   
Incubation NN NN O
of NN NN O
endothelial NN NN O
cells NN NN O
with NN NN O
oleate NN NN O
for NN NN O
72 NN NN O
hours NN NN O
decreased NN NN O
the NN NN O
relative NN NN O
proportions NN NN O
of NN NN O
saturated NN NN O
( NN NN O
palmitic NN NN O
and NN NN O
stearic NN NN O
) NN NN O
acids NN NN O
in NN NN O
total NN NN O
cell NN NN O
lipids NN NN O
and NN NN O
increased NN NN O
the NN NN O
proportions NN NN O
of NN NN O
oleate NN NN O
in NN NN O
total NN NN O
cell NN NN O
lipids NN NN O
without NN NN O
significantly NN NN O
changing NN NN O
the NN NN O
relative NN NN O
proportions NN NN O
of NN NN O
polyunsaturated NN NN O
fatty NN NN O
acids NN NN O
. NN NN O
   
Although NN NN O
less NN NN O
potent NN NN O
than NN NN O
polyunsaturated NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
inhibiting NN NN O
endothelial NN NN O
activation NN NN O
, NN NN O
oleic NN NN O
acid NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
prevention NN NN O
of NN NN O
atherogenesis NN NN O
through NN NN O
selective NN NN O
displacement NN NN O
of NN NN O
saturated NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
cell NN NN O
membrane NN NN O
phospholipids NN NN O
and NN NN O
a NN NN O
consequent NN NN O
modulation NN NN O
of NN NN O
gene NN NN O
expression NN NN O
for NN NN O
molecules NN NN O
involved NN NN O
in NN NN O
monocyte NN NN O
recruitment NN NN O
. NN NN O
   
   
